<SEC-DOCUMENT>0001564590-21-013584.txt : 20210316
<SEC-HEADER>0001564590-21-013584.hdr.sgml : 20210316
<ACCEPTANCE-DATETIME>20210316162213
ACCESSION NUMBER:		0001564590-21-013584
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210316
DATE AS OF CHANGE:		20210316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merus N.V.
		CENTRAL INDEX KEY:			0001651311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37773
		FILM NUMBER:		21746008

	BUSINESS ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			3584 CM UTRECHT
		STATE:			P7
		ZIP:			3584 CM
		BUSINESS PHONE:		31 030 253 8800

	MAIL ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			3584 CM UTRECHT
		STATE:			P7
		ZIP:			3584 CM

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merus B.V.
		DATE OF NAME CHANGE:	20150819
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrus-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T01:02:00.9496874+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 86139572bfd14d72a654e4791bd938db -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mrus="http://www.merus.nl/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
mrus-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001651311_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003_2" name="dei:DocumentFiscalYearFocus" contextRef="C_0001651311_20200101_20201231">2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001651311_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001651311_20200101_20201231">Merus N.V.</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001651311_20200101_20201231">0001651311</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001651311_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000023" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001651311_20200101_20201231">00-0000000</ix:nonNumeric>
			<ix:nonNumeric id="F_000566" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001651311_20200101_20201231">2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000777" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000783" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000793" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000806" name="mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000784" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000794" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000802" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000807" name="mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">P4Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001651311_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001651311_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000593" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001651311_20201231">P4Y2M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000594" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001651311_20191231">P4Y9M18D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3">0</ix:nonFraction>
			<ix:nonNumeric id="F_000819" name="mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000820" name="mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000821" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P6Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000839" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001651311_20200101_20201231">P5Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000840" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001651311_20200101_20201231">P4Y1M6D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="mrus-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001651311_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217EUR_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:EUR</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:GrantRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:GrantRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_mrusCollaborationAndSharePurchaseAgreementsMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrus:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusFollowOnPublicOfferingMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:FollowOnPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeFurnitureAndEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_mrusSegment">
				<xbrli:measure>mrus:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtStatementGeographicalAxis_countryNL_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtStatementGeographicalAxis_countryNL_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2024Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2025Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2026Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2027Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2024Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2025Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2026Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2027Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrus:MerusUSIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrus:MerusUSIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqm">
				<xbrli:measure>utr:sqm</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrus:KadansSciencePartnerXIIBVMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeAndLaboratoryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrus:KadansSciencePartnerXIIBVMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeAndLaboratoryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_mrusRenewalTerm">
				<xbrli:measure>mrus:RenewalTerm</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_iso4217EUR">
				<xbrli:measure>iso4217:EUR</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtRangeAxis_srtMinimumMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrus:KadansSciencePartnerXIIBVMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeAndLaboratoryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-07</xbrli:startDate>
					<xbrli:endDate>2019-11-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-11-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123_20201123">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-23</xbrli:startDate>
					<xbrli:endDate>2020-11-23</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124_20201124">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-24</xbrli:startDate>
					<xbrli:endDate>2020-11-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-24</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203_20201203">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-03</xbrli:startDate>
					<xbrli:endDate>2020-12-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapPlanNameAxis_mrusTwoThousandSixteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenIncentiveAwardPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:IncyteCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:IncyteCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-12-01</xbrli:startDate>
					<xbrli:endDate>2016-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndRelatedActivitiesMember_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:IncyteCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:LicenseAndRelatedActivitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-12-01</xbrli:startDate>
					<xbrli:endDate>2016-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_mrusAntibody">
				<xbrli:measure>mrus:Antibody</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SecondONOResearchAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-14</xbrli:startDate>
					<xbrli:endDate>2018-03-14</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SecondONOResearchAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-03-14</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SecondONOResearchAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-14</xbrli:startDate>
					<xbrli:endDate>2018-03-14</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_mrusPerformanceObligation">
				<xbrli:measure>mrus:PerformanceObligation</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndPerformanceMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentArrangementMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:LicenseAndPerformanceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_mrusMilestone">
				<xbrli:measure>mrus:Milestone</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200701_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrusSecondBispecificAntibodyResearchProgramMember_20200701_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrus:SecondBispecificAntibodyResearchProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:BettaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:BettaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:BettaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">mrus:SubsequentAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">mrus:SubsequentAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">mrus:FourZeroOnePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">mrus:FourZeroOnePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">mrus:FourZeroOnePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">mrus:MerusNVMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">mrus:MerusNVMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-18</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-18</xbrli:startDate>
					<xbrli:endDate>2021-01-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-18</xbrli:startDate>
					<xbrli:endDate>2021-01-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwritersMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-21</xbrli:startDate>
					<xbrli:endDate>2021-01-21</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwritersMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-21</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001651311</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwritersMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-21</xbrli:startDate>
					<xbrli:endDate>2021-01-21</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001651311_20200101_20201231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:DocumentAnnualReport" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;"></span>ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001651311_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31, 2020</ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentTransitionReport" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;"></span>TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number<span style="font-weight:bold;">&#160;<ix:nonNumeric id="F_000021" name="dei:EntityFileNumber" contextRef="C_0001651311_20200101_20201231">001-37773</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000022" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:edgarprovcountryen">Netherlands</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityAddressAddressLine1" contextRef="C_0001651311_20200101_20201231">Yalelaan 62</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityAddressPostalZipCode" contextRef="C_0001651311_20200101_20201231">3584 CM</ix:nonNumeric> <ix:nonNumeric id="F_000025" name="dei:EntityAddressCityOrTown" contextRef="C_0001651311_20200101_20201231">Utrecht</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000027" name="dei:EntityAddressCountry" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:countrynameen">Netherlands</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code:</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:CityAreaCode" contextRef="C_0001651311_20200101_20201231">+31 30</ix:nonNumeric> <ix:nonNumeric id="F_000029" name="dei:LocalPhoneNumber" contextRef="C_0001651311_20200101_20201231">253 8800</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:40%;"><ix:nonNumeric id="F_000032" name="dei:Security12bTitle" contextRef="C_0001651311_20200101_20201231"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Common shares, </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">nominal value &#8364;0.09 per share</span></p></ix:nonNumeric></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:TradingSymbol" contextRef="C_0001651311_20200101_20201231">MRUS</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:SecurityExchangeName" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Nasdaq Global Market)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: </p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001651311_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001651311_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0001651311_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000018" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001651311_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;<span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:69.26%;">
<tr style="height:19.35pt;">
<td valign="top" style="width:27.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:36.24%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.52%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:29.6%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:3.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:2.25pt;">
<td valign="top" style="width:27.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:31.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:3.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:27.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:36.24%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.52%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:29.6%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:3.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntitySmallBusiness" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:2.25pt;">
<td valign="top" style="width:27.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:29.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:27.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.24%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.52%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:29.6%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.86%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000016" name="dei:EntityExTransitionPeriod" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000017" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001651311_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;<span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2020, was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000020" name="dei:EntityPublicFloat" contextRef="C_0001651311_20200630" decimals="-5" scale="6">464.9</ix:nonFraction> million. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of registrant&#8217;s Common Shares outstanding as of February 28, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000019" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001651311_20210228" decimals="INF" format="ixt:numdotdecimal">38,126,976</ix:nonFraction>.</p><ix:nonNumeric id="F_000280" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2021 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS_MERUS_20F"><span style="text-decoration:underline;">Risk Factors</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES_MERUS_20F"><span style="text-decoration:underline;">Properties</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS_MERUS_20F"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Selected Financial Data</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this Annual Report on Form 10-K, include without limitation statements regarding our plans to develop and commercialize our product candidates, the timing of our ongoing or planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations surrounding our collaborations, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency of our cash, cash equivalents and investments, and the plans and objectives of management for future operations and capital expenditures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions and other important factors, including those described under the sections in this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Annual Report on Form 10-K to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY RISK FACTORS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common shares. The principal risks and uncertainties affecting our business include the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The clinical trial and regulatory approval processes are lengthy, time consuming and inherently unpredictable, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our antibody candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of our antibody candidates or following approval, if any, we may need to abandon our development of such antibody candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any </span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We depend on enrollment of patients in our clinical trials for our antibody candidates, including patients having NRG1</span><span style="color:#000000;"> </span><span style="color:#000000;">fusion positive tumors, which are rare, tumorigenic genomic events. If we are unable to enroll patients in our clinical trials, including those having these rar</span><span style="color:#000000;">e</span><span style="color:#000000;"> tumorigenic events, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations or CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our antibody candidates and our business could be substantially harmed.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, we may not be able to sustain or grow our business.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We operate in highly competitive and rapidly changing industries, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our success depends on our ability to protect our intellectual property and our proprietary technologies. If we are unable to adequately protect our intellectual property and our proprietary technologies, or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our existing collaborations are important to our business and future licenses may also be important to us, and if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The COVID-19 pandemic caused by the novel coronavirus has and may continue to adversely impact our business, including our pre-clinical studies and clinical trials, financial condition and results of operations.</span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage oncology company developing innovative antibody therapeutics. Our pipeline of full-length human multispecific antibody candidates are generated from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains, or Fabs, against virtually any target. Each antibody binding domain consists of a target-specific heavy chain paired with a common light chain. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies that bind to a wide range of targets and display novel and innovative biology. These platforms, referred to as Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, allow us to generate large numbers of diverse panels of bispecific and trispecific antibodies, respectively, which can then be functionally screened in large-scale cell-based assays to identify those unique molecules that possess novel biology, which we believe are best suited for a given therapeutic application. Further, by binding to multiple targets, Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> may be designed to provide a variety of mechanisms of action, including simultaneously blocking receptors that drive tumor cell growth and survival and mobilizing the patient&#8217;s immune response by engaging T cells, and/or activating various killer cells to eradicate tumors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology platforms employ an assortment of patented technologies and techniques to generate human antibodies. We utilize our patented MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> mouse to produce a host of antibodies with diverse heavy chains and a common light chain that are capable of binding to virtually any antigen target. We use our patented heavy chain and CH3 domain dimerization technology to generate substantially pure bispecific and trispecific antibodies. We also employ our patented Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology to efficiently screen panels of diverse heavy chains, designed to allow us to more rapidly identify Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> therapeutic candidates with differentiated modes of action for pre-clinical and clinical testing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform we have produced, and are currently developing, the following candidates: MCLA-128 (zenocutuzumab) for the potential treatment of solid tumors that harbor Neuregulin 1 (NRG1) gene fusions&#59; MCLA-158 for the potential treatment of solid tumors&#59; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors. In 2021, we are planning to commence a clinical trial in the United States for MCLA-129, for the potential treatment of solid tumors, which is also the subject to collaboration and license agreement, which permits Betta Pharmaceuticals Co. Ltd. (Betta) to exclusively develop MCLA-129 in China, while Merus retains full ex-China rights. Furthermore, we have a pipeline of proprietary antibody candidates in pre-clinical development and intend to further leverage our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>technology platforms to identify multiple additional antibody candidates and advance them to clinical development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to become a leading oncology company developing innovative multispecific antibodies to treat various types of cancer. Our business strategy comprises the following components:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Successfully develop our most advanced bispecific antibody candidate, zenocutuzumab, for the treatment of NRG1 fusion solid tumors.</span><span style="color:#000000;"> We are developing our most advanced bispecific antibody candidate, zenocutuzumab, for the potential treatment of solid tumors that contain NRG1 gene fusions. The NRG1 protein is the ligand for the HER3 receptor&#8212;a known cause of cancer cell growth. The gene encoding NRG1 can form genetic rearrangements referred to as NRG1 gene fusions. The protein product of the NRG1 gene fusion can drive signaling through the HER3 receptor and thus drive cancer cell growth. NRG1 gene fusions occur infrequently in a wide range of different cancer types. Zenocutuzumab has been shown pre-clinically to potently disrupt binding of NRG1 (and NRG1-fusion proteins) to HER3 and halt NRG1-stimulated tumor cell growth. In October 2019, we reported on the 9 patients with NRG1 gene fusion cancers who had received zenocutuzumab as of that date, either while participating in the clinical trial or in connection with an Early Access Program (EAP), including, for several patients, clinical responses and stable disease with tumor reduction and reductions in serum tumor markers. We expect to present data from our Phase 1/2 NRG1 fusion-positive solid tumor trial, </span><span style="font-style:italic;color:#000000;">eNRGy</span><span style="color:#000000;">, at a medical conference in the second quarter of 2021. We believe that if zenocutuzumab is successfully developed and obtains regulatory approval, it has the potential to address an important unmet medical need that is not currently being met by existing therapies. In July 2020, the U.S. Food and Drug Administration (FDA) granted zenocutuzumab Orphan Drug Designation for pancreatic cancer and in January 2021, the FDA granted Fast Track Designation to zenocutuzumab for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions that have progressed on standard-of-care therapy. </span></p></td>
<td valign="top" style="width:1.3%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:12pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Successfully develop our bispecific antibody candidate MCLA-158. </span><span style="font-size:10pt;color:#000000;">We are developing MCLA-158 for a potential dual EGFR/LRG5 blockade for the treatment of solid tumors. Our Phase 1 clinical trial of MCLA-158 is ongoing in the dose expansion phase. On January 15, 2021, we presented in a poster session interim clinical data from the phase 1 dose escalation of MCLA-158 at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium. As of a data cut-off of September 2020, MCLA-158 was administered to 33 patients over 11 dose levels (5-1500 mg, flat dose), a heavily pretreated population with a median of four lines of prior therapy. As of the cut-off date, MCLA-158 was observed to be well tolerated, and no dose limiting toxicities occurred. The recommended Phase 2 dose was established at 1500 mg </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">administered intravenously once every two weeks. Enrollment of patients with gastro-esophageal and head-and-neck cancers continues at this dose in the expansion phase of the open-label, multicenter trial, </span><span style="font-size:10pt;color:#000000;">and</span><span style="font-size:10pt;color:#000000;"> preliminary evidence of antitumor activity ha</span><span style="font-size:10pt;color:#000000;">s</span><span style="font-size:10pt;color:#000000;"> been observed.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Successfully develop our bispecific antibody candidate MCLA-145. </span><span style="font-size:10pt;color:#000000;">We are developing MCLA-145, in collaboration with Incyte Corporation (Incyte), in an ongoing Phase 1 trial for the potential treatment of solid tumors. MCLA-145 is designed to recruit, activate and prevent the exhaustion of tumor-infiltrating T-cells, and we believe has the potential to avoid the known side effects experienced with CD137 agonists that have been tested in the clinic. We plan to present a clinical update at a major medical conference in the second half of 2021.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Successfully develop our bispecific antibody candidate</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">MCLA-129</span><span style="font-weight:bold;font-size:10pt;color:#000000;">.</span><span style="font-size:10pt;color:#000000;"> We are developing MCLA-129, in collaboration with Betta, and are planning to commence a Phase 1 trial in 2021 to investigate MCLA-129 as a potential treatment for solid tumors, including non-small cell lung cancer (NSCLC). We presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2019 pre-clinical data showing that MCLA-129 inhibited tyrosine kinase inhibitor-resistant NSCLC in pre-clinical xenograft mouse models. We plan to dose the first patient in a clinical trial in the US in 2021.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Accelerate the discovery and development of additional internal and collaboration-related bispecific antibody candidates and internal trispecific antibody candidates</span><span style="font-weight:bold;font-size:10pt;color:#000000;">.</span><span style="font-size:10pt;color:#000000;">&#160;We believe we are well positioned to expand our pipeline of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> molecules for the potential treatment of cancer and potentially other forms of disease. We are conducting pre-clinical studies for our internal proprietary bispecific and trispecific pipeline as well as leveraging our bispecific platform with our collaborators including Incyte, Eli Lilly and Company (Eli Lilly), Simcere Pharmaceutical Group (Simcere), and Betta.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Seek strategic collaborations</span><span style="font-size:10pt;color:#000000;">.&#160;We intend to seek strategic collaborations to facilitate the capital-efficient development of our pipeline and to maximize the value of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms and to access unique partner capabilities and capacity. We have entered into collaborations with Incyte, Eli Lilly, Simcere, and Betta to develop bispecific antibody candidates based on our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. We plan to work with other potential future collaborators to further validate and expand the use of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>platforms in developing bispecific and trispecific antibody candidates. We have also worked with ONO Pharmaceutical Co., Ltd., under a research license agreement to generate bispecific antibodies for indications outside oncology, which further underscore the breadth of the Merus platform. We believe these collaborations, license and future agreements could potentially provide significant funding to advance our pipeline and allow us to benefit from the additional resources, development and commercialization expertise of our collaborators. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Candidate Portfolio </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have bispecific candidates in clinical development, with a variety bispecific and trispecific candidates in pre-clinical development. The following table summarizes our development candidate pipeline: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000001.jpg" title="" alt="" style="width:720px;height:336px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cancer Immunotherapeutics </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immunotherapy is relatively a new class of cancer treatment that works to harness a patient&#8217;s own immune system to attack the cancer cells. There are a number of immunotherapies that are designed to engage various aspects of the immune system, for example: (1) adaptive immunity, specifically directing genetically modified T cells to the tumor with chimeric antigen receptor, or CAR T cells or T-cell receptor modification&#59; or modulating T-cell activity through co-stimulation or checkpoint signals&#59; (2) innate immunity, including antibody-dependent cellular cytotoxicity (ADCC), cellular-dependent cytotoxicity (CDC), monocyte/macrophage cytotoxicity, natural killer (NK) cell cytotoxicity, or other forms of T-cell cytotoxicity&#59; all directed at the cancer cells. While these therapies vary in mechanism of action, they rely on specific components of the innate or adaptive immune system to kill tumor cells or counteract signals produced by cancer cells that suppress immune responses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While these approaches have advanced the field of oncology, each also have limitations. For example, the enhanced ADCC of monoclonal antibodies that bind to a single target expressed by tumor cells can potentially induce an autoimmune &#8220;on-target, off-tumor&#8221; toxicity to normal non-tumor tissues that may also express the same target antigen. Cell-based therapies such as genetically modified CAR-T cells can be difficult and expensive to manufacture, can persist in patients for many months, can be associated with a toxic cytokine release syndrome as safety concerns, or can become ineffective if the tumor loses expression of the single antigen against which the CAR-T cells are directed. We believe bispecific and trispecific antibody candidates developed from our novel platforms offer the potential to overcome these limitations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Background on Antibodies </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conventional antibody in full length immunoglobulin G (IgG) format is a Y-shaped molecule that consists of two identical heavy chains and two identical light chains, as shown in the figure below. Each heavy chain pairs with the light chain to form two variable regions, or antigen binding fragment, Fab, that bind to antigens, or targets, and a constant region, which includes a region known as the fragment crystallizable (Fc) that binds to receptors present on effector cells in the immune system. In conventional full-length IgG, the variable regions are identical and bind to the same targets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000002.jpg" title="" alt="" style="width:532px;height:280px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In bispecific antibodies, the two variable regions bind to two different targets. To achieve this in the full-length IgG format, two different heavy chain variable regions that can both use a common light chain are combined. In addition, modifications of the heavy chain Fc regions are engineered to drive the formation of full-length IgG that use two different heavy chains rather that two copies of the same heavy chain, which make a monospecific antibody.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In both conventional monoclonal antibodies (mAbs) and IgG bispecific antibodies, the Fc region can bind to Fc receptors present on effector cells. This binding results in the recruitment and activation of immune effector cells and amplifies the immune system&#8217;s response to antigens bound by the variable region of the antibody. This process is called ADCC. The Fc region can be modified to enhance ADCC so as to generate a more potent immune response against a particular target. The Fc region can also be silenced to block interactions with the immune system.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<span style="font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> Platforms </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our two technology platforms use large-scale functional screening in molecular and cell-based assays to identify novel, innovative Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> with the specific characteristics desired for further development.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platforms allow us to approach cancer treatment through multiple innovative modes of action:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Blocking oncogenic growth factor signaling by disrupting the signaling pathways that drive tumor cell growth or resistance to monoclonal antibody therapy. </span><span style="color:#000000;">This includes, for example tumor cell growth driven by NRG1 fusions interacting with the HER3 receptor. Hard-to-target receptors that may drive tumor growth or escape can be targeted by our Dock and Block<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> mechanism whereby the binding a tumor associated target prevalent on cancer cells facilitates a second domain to bind and block lesser expressed targets that are critical for cancer growth.</span><span style="font-weight:bold;font-style:italic;color:#000000;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Engaging an adaptive immune response by recruiting T-cells and/or modulating co-stimulation or checkpoint inhibition. </span><span style="color:#000000;">We can produce multispecific antibodies that are designed to</span><span style="font-weight:bold;font-style:italic;color:#000000;"> </span><span style="color:#000000;">simultaneously</span><span style="font-weight:bold;font-style:italic;color:#000000;"> </span><span style="color:#000000;">bind to the T-cell antigen CD3 or other effector cell engaging antigens, and/or tumor-associated targets, for a potentially potent T cell or other effector cell recruitment and engagement to selectively kill tumor cells. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Engaging the innate immune response through multiple mechanisms. </span><span style="color:#000000;">We can produce enhanced ADCC modifications in the Fc region of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> or Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> designed to facilitate the recruitment of immune effector cells, such as natural killer cells, or NK cells, and macrophages, to directly kill tumor cells. Specific binding domains engineered in multispecific antibodies can directly bind to macrophages and monocytes&#59; NK cells, each providing specific immune cell function to attack cancer cells. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Employing combinations of the above mechanisms. </span><span style="color:#000000;">Using our platforms, we can design antibodies to simultaneously target</span><span style="font-weight:bold;font-style:italic;color:#000000;"> </span><span style="color:#000000;">a growth factor receptor expressed by tumor cells and an immunomodulatory molecule involved in blocking and/or reactivating tumor-specific T cells. Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> can be designed to target growth factor receptors, like epidermal growth factor receptors (EGFR) and HER2 that are expressed on many tumors, while delivering an activation signal or checkpoint blockade to T cells. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our process to select lead Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for clinical development is illustrated below. We use our patented MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> human antibody generation and Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> production technologies to rapidly build large collections of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> or Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> directed against particular target combinations. We then test these collections in cell-based functional assays to identify multispecific antibodies that have the potential for novel and innovative modes of action. We select the most potent or efficacious and evaluate them in multiple<span style="font-style:italic;"> in vitro</span> and<span style="font-style:italic;"> in vivo</span> assays to identify lead candidates for clinical development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Selection of Lead Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000003.jpg" title="" alt="" style="width:578px;height:258px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Human antibody generation.<span style="font-weight:normal;font-style:normal;">&#160;Our platform for generating human antibodies employs our patented transgenic murine technology, which we refer to as MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, which harbors human heavy chain variable regions and a human common light chain in its germline. MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> harnesses the power of the</span><span style="font-weight:normal;"> in vivo</span><span style="font-weight:normal;font-style:normal;"> immune system to yield human antibodies with the potential for high affinity, specificity, optimal biophysical characteristics and low immunogenicity. Upon immunization, MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is capable of generating large and diverse panels of human common light chain antibodies against a broad variety of targets. These human common light chain antibodies are then used to generate large and diverse panels of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, human multispecific antibodies capable of binding different targets of virtually any combination.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Patented dimerization technology and the full-length Immunoglobulin G format.</span><span style="color:#000000;">&#160;Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> consist of two different heavy chains that need to stably form, or heterodimerize, inside a manufacturing cell line. Using our patented dimerization technology, we employ amino acid residues with opposite charges in the CH3 domains of these heavy chains to efficiently drive the formation of the heterodimer bispecific antibody rather than the homodimer antibody consisting of two copies of the same heavy chain. In addition, the use of a single, or common, light chain in our human Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> antibodies ensures that each heavy chain pairs with the correct, common light chain to efficiently form the intended functional antigen binding regions. The combination of these approaches prevents the need for additional, more artificial techniques, such as the use of linkers or chemical reactions, to force the pairing of different parts of the bispecific antibody. In addition, the format is designed to retain favorable attributes of conventional human IgG mAbs, including their stability and predictability during manufacturing as well as their long half-life and low immunogenicity during treatment of patients. The resulting Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> are bispecific heterodimeric IgG antibodies that are designed to closely mimic IgG antibodies that are produced naturally by the immune system. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> format also permits us to make modifications to the Fc region of the IgG antibody in order to enhance or limit effector functions associated with this part of the molecule. This strategy has been successfully executed with conventional therapeutic mAbs. In order to enhance efficacy and promote immunotherapeutic activity, we can use glycoengineered cell lines used in production to generate Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> that are enhanced for ADCC, resulting in the improved ability to recruit NK cells and macrophages. This ADCC enhancement has been made to our most advanced bispecific antibody candidate, zenocutuzumab, and other of our antibody candidates, MCLA-158 and MCLA-129. In order to improve safety and tolerability, we can modify our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> to prevent the excessive release of signaling proteins called cytokines, which can overstimulate the immune system. This process is called Fc-silencing as it blocks the ability of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> to bind to certain protein receptors on cells, known as Fc receptors, which are associated with cytokine release. We utilize Fc silencing in the design of our bispecific antibody candidate MCLA-145. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">High-throughput functional screening.</span><span style="color:#000000;">&#160;We employ our patented Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology to rapidly screen panels of new target-specific heavy chains that form common light chain binding domains, or we employ our already established panels of common light chain antibodies. To date we have discovered over 10,000 unique common light chain antibodies directed at more than 40 different antigens, including tumor-associated antigens such as EGFR and cMET&#59; T-cell binding, stimulating or co-stimulating proteins such as CD3 and CD137 (also called 4-1BB)&#59; and other immune-cell engaging antigens. For example, we have an established a panel of more than 175 unique and novel anti-CD3 common light chain antibodies from which to discover and develop the next generation of T-cell engaging bispecific and trispecific antibodies. We then generate DNA constructs that encode target-specific human antibodies and express them in mammalian cells. The common light chain format and proprietary dimerization modifications to the CH3 domain of the IgG promote the secretion of virtually pure Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> into the cell culture medium. The medium of thousands of cell cultures that each express a different Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is harvested and individually used in high throughput molecular and cell-based functional assays to identify Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> with specific novel characteristics for further development. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the chart below shows the results of a pre-clinical study in which hundreds of different Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> targeting HER2 and HER3 were functionally screened for cell growth inhibition of tumor cell samples in the presence or absence of the HER3 ligand NRG1. Forty of the Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> depicted in the chart exhibited superior inhibition of cell growth compared to trastuzumab, a drug commonly prescribed for the treatment of breast cancer, and were selected in the process leading to identification of zenocutuzumab. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000004.jpg" title="" alt="" style="width:510px;height:282px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advantages of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform provides the following advantages:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Rapid generation of human IgG antibodies having diversity at the heavy chain targeting an array of antigens, that are ready to be paired to produce our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, bispecific antibodies.</span><span style="color:#000000;"> Use of our patented MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, heterodimerization and Fc modification technologies, permits us to rapidly generate a large amount of diverse bispecific antibodies capable of targeting an array of antigen combinations. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;are stable, bispecific, full-length human IgG antibodies with no linkers or fusion proteins.</span><span style="color:#000000;">&#160;Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> retain the IgG format of antibodies that are produced naturally by the immune system. Additionally, in contrast to many other bispecific antibody formats, Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> do not require linkers or modifications to force the correct pairing of heavy and light chain variable regions or exploit fusion proteins to add functionality to the molecule. These qualities minimize time-consuming engineering efforts and allow us to create Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> with predictable behavior during pre-clinical development. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform allows for functional evaluation of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;in the relevant therapeutic format leading to the discovery of therapeutic candidates with novel and innovative properties.</span><span style="color:#000000;"> Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform permits rapid functional screening of large collections of bispecific antibodies which allows us to identify lead candidates with multiple mechanisms of action that have the potential to effectively kill tumor cells with high potency. This is an important step in the identification of lead bispecific antibody candidates with functionalities that compare favorably against other forms of therapeutics, such as conventional mAbs as well as their combinations.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> preserve the stability, behavior and adaptability of normal IgG antibodies.</span><span style="color:#000000;">&#160;Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;are based on the robust and commonly used IgG format to yield the favorable</span><span style="font-style:italic;color:#000000;"> in vivo</span><span style="color:#000000;">&#160;qualities associated with conventional mAbs, such as stability, long half-life and low immunogenicity. As a result, our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> format provides attractive options for dosage schedules and methods of administration, rendering them compatible with multiple modes of action for the efficient killing of tumor cells. Further, the IgG format allows us to apply previously established technologies to further optimize our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for therapeutic use. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> can be reliably manufactured with high yields.</span><span style="color:#000000;">&#160;Because our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> retain the IgG format of antibodies, our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> are manufactured using the large-scale industry-standard processes that are also used for the production of conventional mAbs, and the yields of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> we obtain are comparable to those of normal IgG antibodies. In stable cell lines, we are able to obtain over 90% of bispecific antibody formation using these processes and the IgG-based purification process results in up to greater than 98% purity for our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Triclonics<span style="font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> Platform </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next generation proprietary Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology is covered by existing Merus patents and other pending applications. This new format and the suite of technologies that underpin it permit the development of therapeutic candidates designed to bind three targets with a single multivalent molecule. In pre-clinical studies and modeling, Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> have shown similar qualities of a natural IgG antibody, including favorable half-life, stability, low immunogenicity and favorable developability characteristics. We believe Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> have the potential to produce tumor cell-killing activity and/or to modulate the immune system to promote more robust anti-tumor immune responses, and have the potential for less on-target off-tumor toxicity. This format allows us to leverage our proprietary genetically modified MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> mice, which as described above, harbors human heavy chain variable region gene segments and a human common light chain in its germline. MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> harnesses the power of the <span style="font-style:italic;">in vivo</span> immune system to yield human antibodies with the potential for high affinity, specificity, optimal biophysical characteristics and low immunogenicity, which can be combined into a single trispecific antibody produced with relative high purity. The Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform employs our proprietary technologies to produce large panels of substantially pure trispecific antibodies. In addition, we have engineered a panel of novel linkers that attach a third binding domain to the antibody. This panel of linkers vary in properties such as length and flexibility, and are empirically selected for stability and other drug-like properties, while remaining stable and are predicted to have low immunogenicity. The linker panel provides another lever of flexibility in optimizing functional characteristics in our high-throughput screening while maintaining high quality, stability and limiting risk of immunogenicity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000005.jpg" title="" alt="" style="width:498px;height:216px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One application of the Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform is as a T-cell engager for solid tumors. By binding to three targets, we can generate Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> designed to specifically engage a combination of two tumor antigens for enhanced specificity, binding preferentially to tumor cells expressing both antigens, over normal tissues that may express either antigen, but not both or both at lower expression levels. In this construct, the third binding domain can for example engage an innate or adaptive immune effector cell protein, to stimulate killing of the tumor cell. We believe our Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform will permit us to develop molecules with enhanced on target, on tumor specificity, while optimally engaging the immune system mechanisms.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000006.jpg" title="" alt="" style="width:276px;height:204px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our process to select lead Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> leverages our patented MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> human antibody generation and heterodimerization technologies, along with our proprietary linkers based on natural structures to undertake high throughput unbiased functional screening of Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. With this approach, we have been able to evaluate up to 1,800 different trispecific antibodies targeting three different antigens to identify those unique combinations that pre-clinically have been observed to have desired characteristics for further development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Bispecific and Trispecific Antibody Candidate Portfolio </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have four bispecific antibody candidates in clinical development, with additional bispecific and trispecific programs in pre-clinical development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Zenocutuzumab (MCLA-128, HER3 x HER2 Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zenocutuzumab is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> that utilizes Merus&#8217; Dock &#38; Block<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> mechanism to bind to HER2, and bind to and disrupt the interaction between HER3 and ligand, NRG1, in solid tumors. HER2, or human epidermal growth factor receptor 2, is amplified in many solid tumors and is associated with poor prognosis, and the activation of HER3, or human epidermal growth factor receptor 3, is associated with tumor progression and treatment resistance. On the surface of tumor cells, HER2 pairs, or dimerizes, with HER3, and the resulting pair drives malignant progression of HER2-expressing cancer cells. NRG1, which is the ligand for HER3, causes cancer cells to grow and become resistant to treatment with HER2-targeted therapies. Zenocutuzumab is believed to target the HER3 signaling pathway by disrupting the interaction of Her3 with its ligand NRG1 and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment, and ADCC enhanced elimination of the tumor via effector cells. In addition, we have identified a rare, genetically defined patient population whose cancers harbor NRG1 fusions. The NRG1 gene encodes for neuregulin, the ligand for HER3. Fusions between NRG1 and other genes in the genome are rare genetic events occurring in lung, pancreatic and other solid tumors, and are associated with activation of HER2/HER3 signaling and growth of cancer cells. Overall estimates of the incidence of NRG1 fusions&#8217; occurrence are based on limited published information. Based on available literature, we estimate NRG1 fusions occur at a rate of approximately 0.3% &#8211; 3.0% in non-small cell lung cancer (NSCLC) 0.5% - 1.5% in pancreatic ductal adenocarcinoma (PDAC), and less than 1% in all other tumor types. Importantly, we believe NRG1 fusions occur more frequently in the invasive mucinous adenocarcinoma subtype of lung cancer, and in the subset of patients with PDAC lacking a mutation in the K-RAS gene. The NRG1 fusion is a powerful driver of cancer cell growth. We believe that pre-clinical studies and early clinical evaluation suggest zenocutuzumab (binding to HER2 and blocking NRG1 fusion protein interaction with HER3) has the potential to be particularly effective against tumors harboring NRG1 fusions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000007.jpg" title="" alt="" style="width:436px;height:310px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our pre-clinical studies, the administration of zenocutuzumab resulted in the inhibition of NRG-induced growth in cultures of cancer cells. Zenocutuzumab also blocked activation of two key signaling pathways for the growth and survival of tumor cells more than Herceptin (trastuzumab) or the combination of Herceptin and Perjeta (pertuzumab) (shown in red below) or experimental anti-HER3 mAbs (shown in green below). <span style="font-style:italic;">See</span> Geuijen et al. Cancer Cell (2018). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000008.jpg" title="" alt="" style="width:466px;height:248px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* indicates analog antibodies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a patient-derived tumor xenograph mouse model (PDX model) zenocutuzumab significantly blocked tumor growth of a cancer containing an NRG1 gene fusion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000009.jpg" title="" alt="" style="width:308px;height:292px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on encouraging pre-clinical results, we initiated a Phase 1/2 study of zenocutuzumab in solid tumors. As of January 2019, zenocutuzumab administered as a single-agent had been evaluated in 117 patients, who received the recommended Phase 2 doses. Zenocutuzumab was well-tolerated as a single agent, with low observed immunogenicity, and most reported adverse events (AEs) were mild to moderate. Also as of January 2019, the incidence of grade 3 and 4 AEs irrespective of causality was 37% and 3%, respectively, with the incidence of suspected drug-related grade 3 AEs of about 4%, no suspected drug-related grade 4 adverse events, and one patient experienced a grade 5 hypersensitivity reaction. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">NRG1 Fusions</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we opened a zenocutuzumab EAP and amended the Phase 1/2 trial to focus on patients with solid tumors harboring an NRG1 fusion (the eNRGy trial). Patients treated under EAP and the protocol amendment receive zenocutuzumab at 750 mg administered intravenously every other week. As of October&#160;27, 2019, nine patients identified with cancers harboring NRG1 fusions (three pancreatic ductal adenocarcinoma (PDAC) and six NSCLC) who had previously progressed through standard of care, had been enrolled and treated with zenocutuzumab across the EAP under single patient investigational new drug applications, and the eNRGy trial. Of the nine patients treated, six had at least one evaluation and thus were considered evaluable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;27, 2019, investigators from the Memorial Sloan Kettering Cancer Center (MSKCC) provided an oral presentation at the<span style="color:#000000;"> </span>AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, in Boston, Massachusetts, entitled &#8220;Clinical proof-of-concept for zenocutuzumab, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers&#8221;, reporting a summary and initial data concerning the treatment of three cancer patients harboring NRG1 fusions (NRG1+) with zenocutuzumab at 750 mg administered intravenously every other week. Assessments of these patients were conducted locally at MSKCC. All three patients, two having PDAC and one having NSCLC, exhibited tumor shrinkage, symptomatic improvement and durability up to the then most recent assessment. All three patients remained on treatment as of October&#160;29, 2019. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the two patients having PDAC reported by MSKCC on October 27, 2019, one exhibited a 54% reduction in tumor diameter at a confirmatory 5 months scan (partial response (PR) by RECIST v1.1).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000010.jpg" title="" alt="" style="width:568px;height:282px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The other PDAC patient exhibited a 25% reduction in tumor diameter at a confirmatory 5 months scan (stable disease (SD) by RECIST v1.1). Both patients remained on treatment for over 7 months as of October&#160;29, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third patient reported by MSKCC on October 27, 2019 has NSCLC and exhibited a 41% reduction in tumor diameter at a confirmatory scan (PR by RECIST v1.1) and improvement in brain metastases. Prior to zenocutuzumab treatment the patient progressed on six lines of therapy, including the tyrosine kinase inhibitor afatinib. The patient remained on treatment for approximately 5 months as of October&#160;29, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also reported that as of October 29, 2019, we had previously treated six additional patients with NRG1+ cancers, one having PDAC and five having NSCLC. The one patient with PDAC, who was enrolled under a single patient IND outside of MSKCC, had received two treatments with zenocutuzumab, at a four-week non-standard interval due to the severity of the patient&#8217;s illness, and was non-evaluable, passing away due to complications related to the underlying disease prior to a first tumor evaluation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the five of these additional six patients, each with NRG1+ NSCLC enrolled in the eNRGy clinical trial that received treatment with zenocutuzumab, one patient had SD for greater than 7 months but discontinued the trial due to poor adherence to the treatment protocol (unrelated to any AE or lack of efficacy)&#59; two patients had progressive disease and are no longer on the trial&#59; and two patients as of October 29, 2019, had only recently started treatment and had not yet undergone initial assessment for tumor response.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reported in October 2019 that the safety results observed for zenocutuzumab in patients with cancers harboring NRG1 gene fusions was observed to be well tolerated, consistent with what has been previously reported in the overall patient population treated with zenocutuzumab.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently enrolling patients for the Phase 1/2 eNRGy trial to assess the anti-tumor activity of monotherapy zenocutuzumab in NRG1+ cancers. The eNRGy trial enrolls patients with NRG1+ pancreatic cancer, non-small cell lung cancer and other solid tumors. Enrolled patients will receive 750mg of zenocutuzumab every two weeks. We expect to present data at a medical conference in the second quarter of 2021. In January of 2021 the FDA granted Fast Track designation of zenocutuzumab for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions that have progressed on standard-of-care therapy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Her2 Amplified Metastatic Breast Cancer (mBC)</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced that we had completed enrollment of a Phase 2 trial of zenocutuzumab (zeno) in metastatic breast cancer, and would be presenting data at Annual Meeting of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program. These data presented at that program showed that zeno in combination with trastuzumab and vinorelbine was active in heavily pretreated HER2+ metastatic breast cancer patients who have progressed on multiple lines of anti-HER2 therapies and that zeno was well tolerated. With a safety cut-off (sample size 28) of November 2019, and an efficacy data cut-off (sample size 39) of March 31, 2020, 39 patients were treated with the triplet combination &#8211; among the 39 patients, 12 were ongoing on study treatment, and the median numbers of prior therapies and prior anti-HER2 lines were 5 and 3, respectively. The most common severe adverse event (AE) reported with the triplet therapy was neutropenia considered related to vinorelbine, with few patients discontinuing due to AEs. As of March 31, 2020, anti-tumor activity was evaluated in 37 evaluable patients with locally confirmed Her2 amplification (3+ immunohistochemistry (IHC) or 2+ IHC confirmed by fluorescent in situ hybridization (FISH)) with a the clinical benefit rate (compete response (CR)+ partial response (PR)+ [stable disease (SD) at 24 weeks]) of 35.1% [90%CI 22.2-50.0], with one patent having a CR lasting 19.3 weeks, 6 patients having a PR (lasting from 5.3+ to 12.3 weeks), and 22 having SD (lasting from 5.9+ to 59.1+ weeks).&#160;&#160;As of the efficacy cut-off, among those with a best response of SD, 5 patients had an unconfirmed PR, 2 of which were </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing as of the presentation. Currently, certain patients remain on treatment in the Phase 2 trial. We plan to present data from the Phase 2 trial in a future medical conference when the studies are completed.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, we previously disclosed that we plan to advance development in metastatic breast cancer only with a partner and intend to focus our efforts on the eNRGy trial of zeno in NRG1 fusion cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MCLA-158 (Lgr5 x EGFR Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-158 is an investigational antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;for the potential treatment of solid tumors that is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptor (EGFR). Lgr5 is a WNT target gene expressed in cancer cells with aberrations in the WNT signaling pathway, while EGFR is a member of the HER family of receptor tyrosine kinases and is important for growth and survival of cancer stem cells, including those with RAS mutations. MCLA-158 is designed to use two different mechanisms of action. The first is intended to block growth and survival pathways in cancer stem cells. The second involves the recruitment and enhancement of immune effector cells in an effort to directly kill cancer stem cells that persist in solid tumors and cause relapse and metastasis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our pre-clinical studies, MCLA-158 demonstrated superior growth inhibition and selectivity versus the EGFR-targeting mAb, cetuximab. MCLA-158 was significantly more potent than cetuximab in inhibiting the growth of patient-derived colorectal cancer organoids. Additionally, MCLA-158 was observed to be selectively more active in human tumor-derived organoids than in organoids derived from normal human colon. The activity of MCLA-158 on the tumor organoid size was more than 100 times greater than on the normal colon organoids. In contrast, the activity of cetuximab was similar to the activity of MCLA-158 on normal colon organoids and 20 to 100 times less than the activity of MCLA-158 on tumor organoids. These ex-vivo observations of MCLA-158 with organoid models were further observed <span style="font-style:italic;">in vivo</span> in xenograft models generated from the same patient-derived organoids.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000011.jpg" title="" alt="" style="width:522px;height:274px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Solid Tumors</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-158 is currently being evaluated in a Phase 1 open-label, multicenter study, currently in the expansion phase, in patients with solid tumors. The primary endpoint is safety and tolerability of the defined dose&#59; secondary endpoints include single-agent preliminary anti-tumor activity. On January 15, 2021, we presented in a poster session interim clinical data from our Phase 1 dose escalation of MCLA-158 at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium. As of a data cut-off of September 2020, MCLA-158 was administered to 33 patients over 11 dose levels (5-1500 mg, flat dose), a heavily pretreated population with a median of four lines of prior therapy. As of the cut-off date, MCLA-158 was observed to be well tolerated, and no dose limiting toxicities occurred. The recommended Phase 2 dose was established at 1500 mg administered intravenously once every two weeks. Enrollment of patients with gastro-esophageal and head-and-neck cancers continues at this dose in the expansion phase of the open-label, multicenter trial, and preliminary evidence of antitumor activity has been observed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MCLA-145 (CD137 x PD-L1 Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-145 is a Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> T-cell engager that binds to human programmed death-ligand 1 (PD-L1) and CD137. MCLA-145 is designed to recruit, activate and prevent the exhaustion of tumor-infiltrating T cells, and to cause a potent and durable T-cell activation in the tumor microenvironment. MCLA-145&#8217;s binding to a cell is predicted to lead to clustering of CD137 on T cells when PD-L1 is expressed on adjacent cells, and block the T-cell inhibitory PD-1/PD-L1 interactions in the tumor. Because T-cell activation in our pre-clinical studies was shown to be context-dependent, requiring PD-L1 expression in the tumor microenvironment, we believe MCLA-145 has the potential to overcome the known side effects experienced with CD137 agonists that have been tested in the clinic</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-145 is the first drug candidate co-developed under our global research and collaboration with Incyte Corporation (Incyte), which permits the development and commercialization of up to 11 bispecific and monospecific antibodies from our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform. Under the terms of the collaboration, Merus retains all rights to develop and commercialize MCLA-145, if approved, in the United States, while Incyte has rights to develop and commercialize MCLA-145, if approved, outside the United States.&#160;&#160;We plan to present a clinical update on MCLA-145 at a major medical conference in the second half of 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our pre-clinical studies, MCLA-145 showed binding to PD-L1 and CD137, recruitment of T cells into the tumor, blocking of inhibitory PD-1/PD-L1 axis and potent T-cell activation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000012.jpg" title="" alt="" style="width:446px;height:310px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, MCLA-145 demonstrated superior tumor cell killing as compared to the administration of a combination of monospecific anti-PD-L1 and anti-CD137 antibodies in PDX models. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000013.jpg" title="" alt="" style="width:624px;height:328px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Solid Tumors </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we commenced a Phase 1 open-label, single-agent clinical trial of MCLA-145, consisting of dose escalation followed by dose expansion, for the potential treatment of patients with advanced solid tumors. The primary objectives of the Phase 1 trial are dose finding and evaluation of safety and tolerability in patients. The trial will also examine potential preliminary antitumor activity and functional target engagement of single-agent MCLA-145.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MCLA-129 (EGFR x c-MET Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-129 is an investigational Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, designed to bind EGFR and c-MET, for the potential treatment of solid tumors. EGFR is an important oncogenic driver in many cancers. The upregulation of c-MET signaling has been associated with resistance to EGFR inhibition. MCLA-129 has two distinct mechanisms of action. First, MCLA-129 is designed to block the signaling of EGFR as well as c-MET, in an effort to inhibit tumor growth and survival. Second, MCLA-129 utilizes ADCC-enhancement technology, which is designed for greater cell-killing potential. Because both mechanisms of action are dependent on the co-expression of EGFR and c-MET, we believe MCLA-129 has the potential for less toxicity compared to agents targeting EGFR alone. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-129 is being developed in collaboration with Betta Pharmaceuticals Co. Ltd. (Betta). Under the terms of the collaboration, Betta is responsible for the clinical development and commercialization of MCLA-129, if approved, in China and we retain all rights to MCLA-129 outside of China. In January 2021, Betta announced that the Chinese National Medical Products Administration had accepted its IND for MCLA-129 injection. We have also announced we plan to dose the first patient in a clinical trial in the US in 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-clinical data on MCLA-129 were presented in October 2019, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The poster, entitled &#8220;Pre-clinical evaluation of MCLA-129: a bispecific antibody targeting c-MET and EGFR,&#8221; showed that MCLA-129 inhibited and reversed resistance to tyrosine kinase resistant non-small cell lung cancer (NSCLC), cell lines resulting in tumor growth inhibition in xenograft models of NSCLC. In these xenograft models, MCLA-129 showed tumor shrinkage in mice whose tumors are resistant to the EGFR small molecule inhibitor erlotinib. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-129 Inhibited TKI Resistant NSCLC<span style="margin-left:36pt;"> </span><span style="font-weight:bold;"> |</span><span style="margin-left:36pt;">MCLA-129 Reversed Acquired TKI Resistance</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><p>&#160;
</p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtqsgrqcdg4e000014.jpg" title="" alt="" style="width:306px;height:172px;" />&#160;<img src="gtqsgrqcdg4e000015.jpg" title="" alt="" style="width:306px;height:172px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These pre-clinical data suggest MCLA-129, if successfully developed and approved, could benefit patients having NSCLC that become resistant to EGFR targeted therapies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pre-clinical Discovery Programs</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to further leverage our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms to identify multiple additional antibody candidates and advance them to clinical development. Each of these antibody candidates are designed to bind to targets believed to be useful in the treatment of cancer with an intention to establish efficacy and obtain information for submission to the FDA. Using our platform, we will continue to evaluate new targets and combinations to identify potential candidates with the highest therapeutic potential and select those candidates to be advanced into clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we collaborate with a range of partners, including pharmaceutical, biotechnology, and diagnostic companies as well as academic institutions. We intend to continue to seek collaborations and license agreements to develop and commercialize therapeutics in order to exploit the potential of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platforms. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Incyte Corporation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into a collaboration and license agreement (Collaboration Agreement) with Incyte Corporation (Incyte). Under the terms of the Collaboration Agreement, we and Incyte have agreed to collaborate with respect to the research, discovery and development of monospecific or bispecific antibodies utilizing our proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. The collaboration encompasses up to 11 independent programs, including some of our current pre-clinical immuno-oncology discovery programs. For one of the current clinical programs, concerning MCLA-145, we retain the exclusive right to develop and commercialize the product candidate in the United States, while Incyte has the exclusive right to develop and commercialize the product candidate outside the United States. For MCLA-145, we and Incyte will conduct and share equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in our respective territories. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the option to co-fund development of products, if any, arising from one specified program, and subject to certain conditions, to a second specified program, in each case in exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of detailing activities in the United States for one of such programs. If we exercise our co-funding option for a program, we would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing Incyte for certain development costs incurred prior to the option exercise. All products as to which we have exercised our option to co-fund development would be subject to joint development plans and overseen by a joint development committee, with Incyte having final determination as to such plans in cases of dispute. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each program other than MCLA-145, where we have not elected to co-fund development or where we do not have such a co-funding option, Incyte is solely responsible for all costs of global development and commercialization activities. We retain the rights </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to, among other things, our Biclonics</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technology platform as well as clinical and pre-clinical candidates and future programs emerging from our platform that are outside the scope of the Collaboration Agreement. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, upon the Collaboration Agreement becoming effective, Incyte made an upfront non-refundable payment to us of $120&#160;million for the rights granted under the Collaboration Agreement. For each program as to which we do not have commercialization or co-development rights, we are eligible to receive up to $100&#160;million in future contingent development and regulatory milestones and up to $250&#160;million in commercialization milestones, as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which we have exercised our option to co-fund development, we are eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. If we opt to cease co-funding a program as to which we exercised our co-development option, then we will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to non-co-developed programs and, depending on the stage at which we choose to cease co-funding development costs, additional royalties ranging up to 4% of net sales in the United States. For MCLA-145, for which we retain all commercial rights in the United States, we and Incyte are each eligible to receive tiered royalties on net sales in the other&#8217;s territory at rates ranging from 6% to 10%. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Collaboration Agreement will continue on a program-by-program basis until neither party has any royalty payment obligations with respect to such program or, if earlier, the termination of the Collaboration Agreement or any program in accordance with the terms of the Collaboration Agreement. The Collaboration Agreement may be terminated in its entirety, or on a program-by-program basis, by Incyte for convenience. The Collaboration Agreement may also be terminated by either party under certain other circumstances, including material breach, or on a program-by-program basis for patent challenge of patents under the applicable program, in each case as set forth in the Collaboration Agreement. If the Collaboration Agreement is terminated in its entirety or with respect to one or more programs, all rights in the terminated programs revert to us, subject to payment to Incyte of a reverse royalty of up to 4% on sales of future products, if we elect to pursue development and commercialization of products arising from the terminated programs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which, in January 2017, we issued and sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Eli Lilly and Company (Eli Lilly)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, we entered into a collaboration and license agreement (the &#8220;Lilly Collaboration Agreement&#8221;) and share subscription agreement (the &#8220;Lilly Subscription Agreement&#8221;) with Eli Lilly and Company, an Indiana corporation (&#8220;Eli Lilly&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Lilly Collaboration Agreement, we and Eli Lilly agreed to collaborate with respect to the discovery and research of bispecific antibodies utilizing our proprietary Biclonics&#174; bispecific technology platform. The collaboration encompasses up to three (3) independent programs directed to the generation of T-cell re-directing bispecific antibodies that bind CD3 and a tumor associated antigen target selected by Eli Lilly (&#8220;Target&#8221;) to be the subject of each such program.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We granted to Eli Lilly an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights and know-how to exploit certain compounds and products directed to designated Targets in combination with CD3, or directed to such designated Target(s) alone as a monospecific antibody or monospecific antibody drug conjugate, subject to rights granted by us to third parties under one or more existing third party agreements. We also retain all rights not granted to Eli Lilly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in the case of a change of control that may adversely impact certain rights and obligations of us and Eli Lilly under the Lilly Collaboration Agreement, (a) we have agreed to terminate or transfer its rights to third parties under certain research programs and (b) Eli Lilly has the option to take over certain of our research obligations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eli Lilly paid an upfront, non-refundable payment of $40 million for the rights granted under the Lilly Collaboration Agreement. Eli Lilly agreed to fund the research and development activities we conduct for each program under an agreed research plan and budget. With respect to each product arising from each program, we are eligible to receive up to $290 million in future contingent development and regulatory milestones and up to $250 million in commercial sales milestones, for a total of up to approximately $1.6 billion for a single product generated from all three programs. We are further eligible to receive, on a product-by-product and country-by-country basis, tiered royalties based on the level of worldwide aggregate annual net sales at percentages ranging from the mid-single digits to low double digits until the royalty term expires.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lilly Collaboration Agreement includes a three-year research term for us to perform research and development activities, subject to two extension terms of six months at Eli Lilly&#8217;s discretion. The Lilly Collaboration Agreement will continue on a product-by-product basis until Eli Lilly has no royalty payment obligations with respect to such product or, if earlier, the termination of the Lilly Collaboration Agreement or any program in accordance with the terms of the Lilly Collaboration Agreement. The Lilly Collaboration Agreement may be terminated in its entirety or on a program-by-program basis at will by Eli Lilly. The Lilly Collaboration Agreement may also be terminated by either us or Eli Lilly under certain other circumstances, including material breach, as set forth in the Lilly Collaboration Agreement. If the Lilly Collaboration Agreement is terminated with respect to one or more programs, depending on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage of development, certain rights in the terminated programs revert to us, in accordance with the terms of the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lilly </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in January 2021, in connection with entering into the Lilly Collaboration Agreement, pursuant to the Lilly Subscription Agreement, Eli Lilly agreed to purchase 706,834 common shares of the Company at a price per share of $28.295 for aggregate gross proceeds to us of approximately $20 million (the &#8220;Private Placement&#8221;). Eli Lilly agreed not to transfer, sell, or otherwise dispose of the shares purchased in the private placement for a period of time following the closing date, subject to certain customary exceptions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONO Pharmaceutical </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, we entered into a strategic research and license agreement with ONO, under which we granted ONO an exclusive, worldwide, royalty-bearing license to research, test, make, use and market a limited set of bispecific antibody candidates, if approved, based on our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, directed to two undisclosed targets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONO paid us a non-refundable upfront fee of &#8364;1.0&#160;million, and we are eligible to receive up to an aggregate of &#8364;57.0&#160;million in milestone payments upon achievement of specified research and clinical development milestones. To date, we have achieved four of the specified pre-clinical milestones under this research and license agreement and have received an aggregate of &#8364;2.7&#160;million in milestone payments. For products commercialized under this agreement, if any, we are also eligible to receive a mid-single digit royalty on net sales. For a designated period, which may include limited time periods following termination of this agreement, in certain circumstances we and our affiliates are prohibited from researching, developing or commercializing bispecific antibodies against the target combination that are the subject of this agreement. ONO also provides funding for our research and development activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. We retain all rights to use and commercialize any antibodies directed to one target utilized under the collaborative research program, and any antibodies directed to the second target developed under the collaborative research program, excluding the up to five lead and/or selected antibodies against the second target ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;14, 2018, we entered into a second contract research and license agreement with ONO. Pursuant to an exclusive option granted to ONO in the prior agreement executed in April 2014, ONO exercised its option to enter into the March 2018 agreement. We granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market bispecific antibody candidates based on our Biclonics<span style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> technology platform against two undisclosed targets directed to a particular undisclosed target combination. ONO identifies and selects the licensed bispecific antibodies for which it is responsible for conducting further non-clinical and clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development. ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has agreed to fund our research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually agreed upon research plan. We retain all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONO has agreed to pay an upfront non-refundable payment of &#8364;700,000 for the rights granted and we are also eligible to receive an aggregate of &#8364;57.0&#160;million in milestone payments upon achievement of specified research and clinical development milestones. To date, we have achieved four of the specified pre-clinical milestones under this research and license agreement and have received an aggregate of &#8364;3.7&#160;million in milestone payments. For products commercialized under the License Agreement, if any, the Company is eligible to receive a mid-single digit royalty on net sales. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a designated period, which may include limited time periods following termination of this agreement, in certain circumstances we are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of this agreement. ONO also provides funding for our research and development activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Simcere Pharmaceutical Group </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;8, 2018, we entered into an agreement with Simcere Pharmaceutical Group (Simcere) granting Simcere an exclusive license to develop and commercialize in China up to three bispecific antibodies to be produced by Merus utilizing our proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. We retain all rights outside of China.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to lead research and discovery activities while Simcere has agreed to be responsible for the IND-enabling studies, clinical development, regulatory filings and commercialization of these product candidates in China. Under the terms of the agreement, for a program achieving development candidate nomination, Simcere will retain a contract manufacturing organization with experience in filing IND applications with U.S. authorities and clinical trial agreements (CTAs) with European regulatory authorities in order to produce clinical trial materials. We received an upfront payment, and are eligible to receive milestone payments contingent upon Simcere achieving certain specified development and commercial goals. To date, we have achieved two undisclosed milestone payments under this agreement. We are eligible to receive tiered royalty payments on sales of any products resulting from the collaboration in China from Simcere. Simcere is eligible to receive tiered royalty payments on sales outside of China from us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Betta Pharmaceuticals Co. Ltd. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;10, 2018, we entered into a collaboration and license agreement with Betta Pharmaceuticals Co. Ltd. (Betta) where we granted Betta an exclusive license to develop and commercialize in China MCLA-129, a Merus proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> produced by our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. We retain all rights outside of China. Under the terms of the agreement, Betta retained a contract manufacturing organization with experience in filing IND applications with U.S. authorities and CTAs with European regulatory authorities in order to produce clinical trial materials for the Chinese market and the rest of the world. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to a non-refundable upfront payment, we and Betta will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. We are also eligible to receive milestone payments contingent upon Betta achieving certain specified development and commercial goals as well as tiered royalty payments of net sales of any products resulting from the collaboration in China. Betta is eligible to receive milestone payments contingent upon us achieving certain specified development and commercial goals, and is eligible to receive tiered royalty payments of net sales outside of China. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform relies on third parties for biological materials. We rely on and expect to continue to rely on third-party contract manufacturing organizations (CMOs) for the supply of current good manufacturing practice-grade (cGMP-grade) clinical trial materials and commercial quantities of our antibody candidates and products, if approved. We currently do not have any agreements for the commercial production of product candidates, but we have contracted several biopharmaceutical CMOs for the clinical manufacture of zenocutuzumab, MCLA-158, MCLA-145, and MCLA-129. We believe that the standardized Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> manufacturing process can be transferred to additional CMOs and potential future co-development or co-commercialization collaborations or partnerships for the production of clinical and commercial supplies of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the ordinary course of business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales and Marketing </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet defined our sales, marketing or product distribution strategy for zenocutuzumab, MCLA-158, MCLA-145, MCLA-129 or any of our other antibody candidates because our antibody candidates are still in pre-clinical or early-to-middle-stage clinical development. Our commercial strategy may include the use of strategic partners, distributors, a contract sales force, or the establishment of our own commercial and specialty sales force. We plan to further evaluate these alternatives as we approach approval, if any, for one of our antibody candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We compete directly with companies that focus on oncology and companies dedicating their resources to cancer therapies. We also face competition from academic research institutions, governmental agencies and other various public and private research institutions. With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available and new therapeutic candidates are clinically developed or approved therapies are explored for new indications. Any antibody candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, manufacturer&#8217;s production capacity, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key competitive factors affecting the success of all of our therapeutic antibody candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe effects than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our antibody candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to currently marketed therapies, there are also a number of products in late-stage clinical development to treat cancer, including other bispecific antibodies or similar molecules. Our closest competitors in this area include Affimed N.V., Zymeworks Inc., Genmab A/S, EpimAb Biotherapeutics, MacroGenics, Inc., NuMab Therapeutics, Elevation Oncology, Rain Therapeutics, Hummingbird Bioscience, Regeneron Pharmaceuticals, Inc. and Xencor, Inc. The antibody candidates in development by competitors may provide efficacy, safety, dosing convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our antibody candidates for which we obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technologies, inventions, and improvements that we believe are important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and antibody candidates that are important to the development and implementation of our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to our bispecific antibody candidate zenocutuzumab consists of one application filed under the Patent Cooperation Treaty (PCT) application, filed on February&#160;27, 2015 with two issued patents in Europe and applications</span><span style="color:#00B0F0;font-size:10pt;"> </span><span style="font-size:10pt;color:#000000;">pending in the United States, Europe and 16&#160;other foreign jurisdictions with an expected expiry not earlier than February, 2035. Claims are directed to the zenocutuzumab composition of matter and methods of using zenocutuzumab to treat subjects having or at risk of having an ErbB-2 and/or ErbB3 positive tumor. In addition, our portfolio includes four PCT patent applications covering further methods of using zenocutuzumab, including in combination therapies to treat patients, concerning methods of treating patients with cancer harbor NRG1 gene fusions, three of which were filed on April&#160;3, 2018, and one filed on May&#160;17, 2018. Three of these four PCT patent applications entered national phases in the United States, Europe and 17 other foreign jurisdictions. One of these four PCT patent applications entered national phases in the United States, Europe and four other foreign jurisdictions. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to our CD3 technology consists of a first PCT application, filed on July 8, 2016, with issued patents in the United States and Europe and applications pending in the United States, Europe and 13</span><span style="color:#FF0000;font-size:10pt;"> </span><span style="font-size:10pt;color:#000000;">foreign jurisdictions with an expected expiry not earlier than July 2036. A second PCT application was filed on March 27, 2020, as well as in two foreign jurisdictions with an expected expiry not earlier than March, 2040. Claims are related to the anti-CD3 binding domains, antibodies, their use, among other subject matter.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to our bispecific antibody candidate MCLA-158 consists of one PCT filed on October&#160;21, 2016, with two issued patents in foreign jurisdictions and applications pending in the United States, Europe and 14 other foreign jurisdictions with an expiry no earlier than October, 2036. Claims are directed to the MCLA-158 composition of matter and methods of using MCLA-158 in the treatment or prevention of various solid tumors. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related our bispecific antibody candidate MCLA-145 consists of one PCT filed on September&#160;22, 2017, with application pending in the United States, Europe and 19 other foreign jurisdictions with an expiry no earlier than September 2037. Claims are directed to the MCLA-145 composition of matter and methods of using MCLA-145 in the treatment or prevention of various solid tumors. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related our bispecific antibody candidate MCLA-129 consists of one PCT filed on August&#160;9, 2018, with applications pending in the United States, Europe and 19 other foreign jurisdictions with an expiry of no earlier than August 2038. Claims are directed to the MCLA-129 composition of matter and methods of using MCLA-129 in the treatment or prevention of various solid tumors. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to our MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> transgenic animal consists of four issued U.S. patents, nine pending U.S. applications, two issued European patents that have been validated in many countries, and four pending European applications, 16 issued foreign patents and 15 pending foreign applications, all with an expected expiry not earlier than June </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">2029. Claims are directed to a common light chain animal and methods of producing hybridomas, host cells, and antibodies relating to the use of a common light chain and by exposing the animal to an antigen. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to our Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology consists of three issued U.S. patents, one pending U.S. application, one issued European Patent, which was revoked in opposition and currently subject to appeal before the Technical Board of Appeals, one pending European application and three issued foreign patents, with three foreign pending applications, all with an expected expiry not earlier than September 2032. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-3.4%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to recombinant production of mixtures of antibodies includes claims directed to host cells generating multispecific antibodies and consists of five issued U.S. patents, and three pending U.S. applications, two issued European patents, 16 issued foreign patents, and four pending foreign applications, all with an expected expiry not earlier than July, 2023. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to efficient dimerization of heavy chains promoting efficient production of Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>and mixtures of antibodies, methods and host cells for recombinant production thereof, and consists of two PCT applications filed on April 19, 2013, which resulted in seven issued U.S. patents, one pending U.S. application, two issued European patents, 2 pending European applications, 25 issued foreign patents, and twenty-one pending foreign applications, all with an expected expiry not earlier than April, 2033.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our patent portfolio related to our trispecific antibody technology consists of one PCT application, filed on March&#160;29, 2019, with pending applications in the United States, Europe, and 19 foreign jurisdictions, having with an expiry no earlier than March 2039. Claims are directed to a multivalent antibody format, including the Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> format.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment and additional compositions created or identified from our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, improvements to our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, our next generation Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform and ongoing development of our antibody candidates. Specifically, we seek patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing these molecules and the use of these molecules in a variety of therapies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio is intended to cover, but is not limited to, the composition of matter of our bispecific antibody candidates, their methods of use, the Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business, including our MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> mouse, Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology, and recombinant host cells capable of producing our antibody candidates, methods of purification, and heterodimerization, among other proprietary technology. We also rely on trademarks, trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary positions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable patents and other proprietary rights of third parties. For important factors related to our proprietary technology, inventions, improvements, platforms and antibody candidates, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Intellectual Property and Information Technology.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to extensive regulation. We expect our antibody candidates to be regulated as biologics. Biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (FD&#38;C Act) and the Public Health Service Act (PHS Act) and other federal, state, local and foreign statutes and regulations. Both the FD&#38;C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Biological Products Development Process</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, and pre-clinical animal trials and applicable requirements for the humane use of laboratory animals and formulation studies in accordance with applicable regulations, including good laboratory practices (GLPs)&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations, commonly referred to as good clinical practice (GCP), regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of a Biologics License Application (BLA) that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical trials&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with current Good Manufacturing Practice (cGMP) requirements to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA&#59; and </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA review and approval, or licensure, of the BLA.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any antibody candidate in humans, the antibody candidate enters the pre-clinical testing stage. Pre-clinical tests, also referred to as nonclinical trials, generally include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the antibody candidate. The conduct of the pre-clinical tests must comply with federal regulations and requirements including GLPs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds, at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the biological antibody candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board (IRB) at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase 1. The biological antibody candidate is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase 2. The biological antibody candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or<span style="font-style:italic;"> in vitro</span> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological antibody candidate has been associated with unexpected serious harm to patients.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the physical characteristics of the biological antibody candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the biological antibody candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological antibody candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological antibody candidate, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal trials, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act (PREA) a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological antibody candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. A sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, and whether the product is being manufactured in accordance with cGMP requirements to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure the safe use of the biological antibody candidate. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS&#59; the FDA will not approve the BLA without a REMS, if required.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. If the FDA decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase IV clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of the performance goals agreed to by the FDA under the PDUFA is to review 90% of standard BLAs in 10 months from the filing date and 90% of priority BLAs in six months from the filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and marketing the drug for this type of disease or condition will be recovered from sales in the United States. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven&#160;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer with orphan exclusivity is unable to assure sufficient quantities of the approved orphan designated product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our antibody candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new biological products that meet certain criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a Fast Track product at any time during the clinical development of the product. With regard to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it is intended to treat a serious disease or condition, if approved, would provide a significant improvement in safety or effectiveness compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product subject to accelerated approval perform adequate and well-controlled post-marketing clinical trials. Biological products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">post-market clinical trials or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the provisions of the Food and Drug Administration Safety and Innovation Act (FDASIA) enacted in 2012, the FDA established a Breakthrough Therapy designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases or conditions. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of Fast Track designation, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, but these can also be granted to the same antibody candidate if the relevant criteria are met. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. All requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and FDA will either grant or deny the request. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, priority review and Breakthrough Therapy designation do not change the standards for approval but may expedite the development or approval process. Even if we receive one of these designations for our antibody candidates, the FDA may later decide that our antibody candidates no longer meet the conditions for qualification. In addition, these designations may not provide us with a material commercial advantage. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements. Manufacturers of approved biologics are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products include record-keeping requirements, reporting of adverse effects, and reporting updated safety and efficacy information. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biosimilars and Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approve biosimilars. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. Certain aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and meaning of the BPCIA remain subject to significant uncertainty. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA Regulation of Companion Diagnostics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our antibody candidates may require use of an<span style="font-style:italic;"> in vitro</span> diagnostic to identify appropriate patient populations for our products. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FD&#38;C Act and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (PMA) approval. We expect that any companion diagnostic developed for use with our antibody candidates may utilize the PMA pathway.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If use of a companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&#160;6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;<span style="font-style:italic;"> In Vitro</span> Companion Diagnostic Devices.&#8221; According to the guidance, for novel candidates such as our antibody candidates, a companion diagnostic device and its corresponding drug or biologic candidate may be required to be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product labeling, although the FDA may decide that it is appropriate to approve a therapeutic product even though a companion diagnostic device is not approved or cleared contemporaneously. In general, the FDA expects that a companion diagnostic that is intended for use with the therapeutic product will be later approved or cleared through an appropriate submission and the therapeutic product labeling will be revised to stipulate the use of the companion diagnostic. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (IDE) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of<span style="font-style:italic;"> in vitro</span> companion diagnostic devices on issues related to co-development of these products, and in December 2018, the FDA issued a draft guidance describing considerations for the development and labeling of <span style="font-style:italic;">in vitro</span> companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these<span style="font-style:italic;"> in vitro</span> companion diagnostics in conjunction with the review of a cancer therapeutic involves coordination of review by the FDA&#8217;s Center for Biologics Evaluation and Research and by the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation (QSR) which imposes elaborate testing, control, documentation and other quality assurance requirements. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data is submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trials or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Regulation Outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. In addition, ethical, social and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application (CTA) much like the IND prior to the commencement of human clinical trials. In the European Economic Area (EEA) (which is comprised of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein), for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved by the national health authority and the Ethics Committee has granted a positive opinion in relation to the conduct of the trial in the relevant Member State(s), in accordance with a country&#8217;s requirements, clinical trial development may proceed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization (ICH), guidelines on Good Clinical Practices (GCP) as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing a clinical trial, the sponsor must obtain a CTA from the Competent Authority, and a positive opinion from an independent Ethics Committee. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, CTAs must be submitted to the Competent Authority in each EU Member State in which the trial will be conducted.&#160;&#160;Under the new Regulation on Clinical Trials, which is currently expected to take effect by early 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement.&#160;&#160;Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant Competent Authorities and Ethics Committees.&#160;&#160;Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practices (GMP). Other national and European Union-wide regulatory requirements may also apply.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a medicinal product, the European Medicines Agency (EMA) and national regulators provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use (CHMP). A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical trials, and pharmacovigilance plans and risk-management programs.&#160;&#160;Advice is not legally binding with regard to any future marketing authorization application of the product concerned.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorizations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, medicinal products can only be placed on the market after obtaining a Marketing Authorization (MA). To obtain regulatory approval of an investigational biological product in the EEA, we must submit a marketing authorization application (MAA). The application used to file the BLA in the United States is similar to that required in the EEA, with the exception of, among other things, country-specific document requirements. The European Union also provides opportunities for market exclusivity. The process for doing this depends, among other things, on the nature of the medicinal product.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure results in a single MA, issued by the European Commission, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA which is valid across the entire territory of the EEA. The centralized procedure is compulsory for human drugs that are: (i)&#160;derived from biotechnology processes, such as genetic engineering, (ii)&#160;contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii)&#160;designated orphan medicines and (iv)&#160;advanced-therapy medicines, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days.&#160;&#160;This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP.&#160;&#160;At the end of the review period, the CHMP provides an opinion to the European Commission.&#160;&#160;If this opinion is favorable, the Commission may then adopt a decision to grant an MA.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the national Competent Authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exceptional cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is however not guaranteed. The benefits of a PRIME designation includes the appointment of a rapporteur from the CHMP before submission of an MAA, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Data and Marketing Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EEA also provides opportunities for market exclusivity.&#160;&#160;For example, in the European Union, upon receiving marketing authorization, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. The overall ten-year market exclusivity period may be extended to a maximum of eleven years if, during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. If granted, data exclusivity prevents regulatory authorities in the EEA from referencing the innovator&#8217;s data to assess a generic or biosimilar application. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the EEA&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Medicinal</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> Products</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EEA are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers. During this period, the EMA cannot accept another application for a MA, or grant a MA or accept an application to extend an existing MA for the same indication, in respect of a similar medicinal product. An orphan medicinal product can also obtain an additional two years of market exclusivity in the EEA for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. The application for orphan drug designation must be submitted before the MAA. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the applicant consents to a second orphan medicinal product application&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the applicant cannot supply enough orphan medicinal product. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the Member States. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All new MAAs must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited.&#160;&#160;Direct-to-consumer advertising of prescription medicines is also prohibited in the EEA. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each Member State and can differ from one country to another.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with EU and Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Approval and Regulation of Companion Diagnostics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, <span style="font-style:italic;">in vitro</span> diagnostic medical devices are regulated by Directive 98/79/EC which regulates the placing on the market, the CE-marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufactures and devices as well as the vigilance procedure. <span style="font-style:italic;">In vitro</span> diagnostic medical devices must comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be). </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companion diagnostics can also be considered &#8220;combination products&#8221; which are governed by a different regulatory pathway depending on the mode of action of the products. A combination medicine/device product could either be regulated as a medicinal product or a medical device based on its primary mode of action. In principle, if a medical device incorporates a substance which, if used separately, is likely to be considered as a medicinal product and act on the human body by an action ancillary to that of the device, the device must be evaluated and authorized in accordance with the medical device regulations. However, if the medicinal substance constitutes the main function of the product then the product is considered as a medicinal product. Currently, for such combination products, the manufacturer will have to consult, prior to obtaining the CE marking of the device, the EMA or national Competent Authorities to obtain scientific advice on the quality and safety of the medicinal substance, including the benefit/risk profile of its incorporation into the device.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulation of companion diagnostics will be subject to further requirements as of the entry into force of the <span style="font-style:italic;">in-vitro</span> diagnostic devices Regulation (No 2017/746) which introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national Competent Authorities or the EMA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the United Kingdom, the transition period, during which EU pharmaceutical laws continued to apply to the United Kingdom, has expired on December 31, 2020. However, the EU and the United Kingdom have concluded a trade and cooperation agreement, or TCA, which is provisionally applicable since January 1, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of Good Manufacturing Practice, or GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to FDA restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory laws restrict business practices in the biopharmaceutical industry, which include, but are not limited to, state and federal anti-kickback, false claims, data privacy and security, and physician payment and drug pricing transparency laws. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal false claims laws, including the civil False Claims Act, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the civil False Claims Act can result in very significant monetary penalties and treble damages. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved (</span><span style="font-style:italic;"> e.g.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> , off-label) uses. In addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Given the significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The ACA imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians, as defined by statute, and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties. Covered manufacturers must submit reports by the 90th&#160;day of each subsequent calendar year. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of pricing and marketing information as well as gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. We are not currently a covered manufacturer under the ACA, but may become one if successful in obtaining approval of one of our antibody candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their respective implementing regulations, impose specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act (CCPA) effective January 1, 2020, which gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability.<span style="font-size:12pt;"> </span>Additionally, the California Privacy Rights Act (CPRA), recently passed in California. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on January 1, 2023, and become enforceable on July 1, 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement, and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any of our antibody candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Privacy and Data Protection Laws in Europe </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to European laws relating to our and our suppliers&#8217;, collaborators&#8217; and subcontractors&#8217; (where they act as processors) collection, control, processing and other use of personal data (i.e., any data relating to an identifiable living individual, whether that individual can be identified directly or indirectly). We are subject to the supervision of local data protection authorities in those jurisdictions where we are established, and where we process personal data in the context of the activities of that establishment (e.g., undertaking clinical trials). We and our suppliers, collaborators and subcontractors process personal data including in relation to our employees, employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health and medical information. The data privacy regime in the EU includes the General Data Protection Regulation (GDPR) and national laws and regulations implementing or supplementing it. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and the data may then only be processed in a manner compatible with those purposes. The personal data collected and processed must be adequate, relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the European Economic Area (EEA) unless certain steps are taken to ensure an adequate level of protection, and must not be retained for longer than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure, and to be able to demonstrate, protection. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, may require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a sufficiently large scale, introduces mandatory data breach notification throughout the EU and imposes additional obligations on us when we are contracting with certain service providers. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to the extent a company processes, controls or otherwise uses &#8220;special category&#8221; personal data (including patients&#8217; health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner in which a company is legally permitted to process that data. The GDPR provides a broad right for EU and EEA member states to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating model or standard operating procedures. Such laws, for example, may relate to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to EU laws on personal data export, as we may transfer personal data from the EEA to other jurisdictions which are not considered by the European Commission to offer &#8220;adequate&#8221; protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. From January 1, 2021, we are subject to the GDPR and also the United Kingdom (UK) GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and UK Trade and Cooperation Agreement, ending 30 June 2021 at the latest, whilst the parties discuss an adequacy decision. Further, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For example, on July 16, 2020, the Court of Justice of the European Union (CJEU) invalidated the EU-US Privacy Shield Framework (Privacy Shield) under which personal data could be transferred from the EEA to United States entities who had self-certified under the Privacy Shield scheme. It is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&#8217; national laws. Any failure or perceived failure to comply with global privacy laws carries with it the risk of significant penalties and sanctions of up to &#8364;20&#160;million or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">up to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4% of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">total worldwide annual </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">turnover</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the preceding financial year</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Additionally, following the United Kingdom&#8217;s withdrawal from the EEA and the EU, and the expiry of the transition period, companies have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;20 million (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#163;17.5 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or 4% of global turnover. These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional operational requirements on our business, could affect the manner in which we use and transmit patient information and could increase our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States. Most recently, on July 16, 2020, the Court of Justice of the European Union (CJEU) invalidated the EU-US Privacy Shield Framework (Privacy Shield), under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the standard contractual clauses cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.56%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These recent developments may require us to review and amend the legal mechanisms by which we make and/ or receive personal data transfers to/ in the U.S.&#160;&#160;As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. A decision by a third-party payor not to cover our bispecific antibody candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for new products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, governments influence the price of products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Member States are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member States may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or biological products have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program&#59; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans&#59; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part D&#59; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs&#59; and created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the law. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria and lower reimbursement, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical and biological products. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on August&#160;2, 2011, the Budget Control Act of 2011 was enacted, which, among other things, included aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 31, 2021, we had 93 full-time employees and 48 part-time employees, including 60 employees with M.D. or Ph.D. degrees. Of these employees, 93 were primarily engaged in research and development activities and 48 were primarily engaged in general and administrative activities. None of our employees are represented by a labor union, and we consider our employee relations to be good.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated as Merus B.V. under the laws of the Netherlands on June 16, 2003. Our principal executive offices are located at Yalelaan 62, 3584 CM Utrecht, The Netherlands. Our telephone number at the Utrecht address is +31 30 253 8800. Our website address is www.merus.nl. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. We make available on our website at&#160;www.merus.nl, under &#8220;Investors &#38; Media,&#8221; free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS_MERUS_20F">Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RISK FACTORS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business and Industry </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the other information included or incorporated by reference in this Annual Report on Form 10-K. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a clinical-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage oncology company with a limited operating history. We have incurred net losses of $85.5 million, and $55.2 million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated loss of $400.1 million.&#160;Our losses have resulted principally from expenses incurred in research and development of our antibody candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect to continue to incur significant operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our antibody candidates. We anticipate that our expenses will increase substantially as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conduct our ongoing, single agent, Phase 1/2 eNRGy clinical trial of zenocutuzumab, our most advanced bispecific antibody candidate, for the treatment of solid tumors harboring neuregulin 1 (NRG1) gene fusions and conclude our ongoing Phase 2 clinical trial for the treatment of metastatic breast cancer in combination with other therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conclude our ongoing dose-escalation portion of our Phase 1 clinical trial of MCLA-117, our bispecific antibody candidate, for the treatment of acute myeloid leukemia (AML)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conduct our ongoing Phase 1 clinical trial of MCLA-158 for the treatment of solid tumors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conduct our ongoing Phase 1 clinical trial for MCLA-145 for the treatment of advanced solid tumors and B-cell lymphomas, which is being co-developed with Incyte Corporation (Incyte)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">commence our Phase 1 clinical trial for MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd. (Betta)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue the research and development of our other pre-clinical antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expand our clinical programs to explore new potential combination therapies or indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expand and enhance our technology platforms, including our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform which generates our pipeline of bispecific product candidates, our Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, which generates pre-clinical trispecific candidates and generate and develop additional multispecific antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek regulatory approvals for any antibody candidates that successfully complete clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain, expand and protect our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">secure, maintain and/or obtain freedom to operate for our technologies and products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">add clinical, scientific, operational, financial, information technology and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operation as a public company&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, manufacturing challenges, safety issues or other regulatory challenges.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed our operations primarily through public offerings and private placements of our common shares and our collaboration and license agreement with Incyte and Eli Lilly. We have devoted a significant portion of our financial resources and efforts to developing our full-length bispecific antibody therapeutics, which we refer to as Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, our technology platforms, identifying potential antibody candidates, conducting pre-clinical studies of a variety of candidates, and conducting our clinical trials of zenocutuzumab, MCLA-158, and MCLA-145, concluding MCLA-117 and expected commencement of a clinical trial of MCLA-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We are in the early stages of development of our antibody candidates, and we have not completed development of any Biclonics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;or any other drugs or biologics.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing pre-clinical testing and clinical trials of our bispecific antibody candidates, discovering and developing additional bispecific and trispecific antibody candidates, obtaining regulatory approval for any antibody candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with pharmaceutical product and biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration (FDA), or the European Medicines Agency (EMA), or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our antibody candidates, our expenses could increase and commercial revenue could be further delayed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we do generate product royalties or product sales, we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain profitability could depress the market price of our common shares and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need additional funding in order to complete development of our antibody candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing clinical trials of zenocutuzumab, MCLA-158, and MCLA-145, conclude our trial of MCLA-117, commence our clinical trial for MCLA-129 and continue to research, develop and conduct pre-clinical studies of our other antibody candidates. In addition, if we obtain regulatory approval for any of our antibody candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. For example, the trading prices for our and other biopharmaceutical companies&#8217; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, we expect that our existing cash, cash equivalents and investments as of December&#160;31, 2020 will be sufficient to fund our operations into at least the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost, progress and results of our ongoing clinical trials of zenocutuzumab and the Phase 1 clinical trials of MCLA-117, MCLA-158, and MCLA-145&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of our collaboration with Incyte to develop monospecific and bispecific antibodies candidates, including our ongoing Phase 1 clinical trial for MCLA-145&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost, progress and results of our anticipated clinical trial for MCLA-129&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of manufacturing clinical supplies of our bispecific antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for our other bispecific and multi-specific antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs, timing and outcome of regulatory review of any of our antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our antibody candidates to the extent any receive marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any potential future claims by third parties that we are alleged to be infringing upon their intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of securing, maintaining and/or obtaining freedom to operate for our technologies and products&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the revenue, if any, received from commercial sales of our antibody candidates to the extent any receive marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effect of competing technological and market developments&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which we acquire or invest in businesses, products and technologies, including our existing collaborations and any other future licensing or collaboration arrangements for any of our antibody candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend heavily on the success of our antibody candidates, and we cannot give any assurance that any of our antibody candidates will receive regulatory approval, which is necessary before they can be commercialized. If we, any of our collaborators, or any other strategic partners we may enter into collaboration agreements with for the development and commercialization of our antibody candidates, are unable to commercialize our antibody candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested a significant portion of our efforts and financial resources in the development of bispecific antibody candidates using our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform and in development of multi-specific antibody candidates using our Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. Our ability to generate royalty and product revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of these antibody candidates, which may never occur. We currently generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. Each of our bispecific antibody candidates and pre-clinical trispecific antibody candidates will require additional clinical development, management of clinical, pre-clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, including commercial manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our antibody candidates before we receive regulatory approval from the FDA, the EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our antibody candidates. The success of our antibody candidates will depend on several factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">for antibody candidates which we may license to others, such as to our collaborators, the successful efforts of those parties in completing clinical trials of, receipt of regulatory approval for and commercialization of such antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">for the antibody candidates to which we retain rights, completion of pre-clinical studies and clinical trials of, receipt of marketing approvals for, establishment of commercial manufacturing supplies of and successful commercialization of such antibody candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">for all of our antibody candidates, if approved, acceptance of our antibody candidates by patients, the medical community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators, as applicable, do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our antibody candidates, which would materially adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not previously submitted a Biologics License Application (BLA), to the FDA, a Marketing Authorisation Application (MAA) to the EMA, or similar regulatory approval filings to comparable foreign authorities, for any antibody candidate, and we cannot be certain that any of our antibody candidates will be successful in clinical trials or receive regulatory approval. Further, our antibody candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our antibody candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our antibody candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to seek regulatory approval to commercialize our antibody candidates both in the United States and the EU, and potentially in additional foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with the numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our antibody candidates, and we cannot predict success in these jurisdictions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform and Triclonics<span style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> technology platform are unproven, novel approaches to the production of molecules for therapeutic intervention.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not received regulatory approval for a therapeutic based on a full-length human bispecific or trispecific IgG approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> may have different effectiveness rates in various indications and in different geographical areas. Finally, the FDA, the EMA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on Biclonics&#174;&#160;and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Triclonics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our antibody candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms rely on third parties for biological materials. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these biological materials could materially adversely affect our business. Although we have control processes and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our biological raw materials or antibody candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could harm our development strategy.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to identify patient subsets within a disease category that may derive selective and meaningful benefit from the antibody candidates we are developing. Through collaborations or license agreements, we may develop companion diagnostics to help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our antibody candidates, if approved. Companion diagnostics are subject to regulation by the FDA, and comparable foreign regulatory authorities as medical devices and typically require separate regulatory approval (or clearance, or certification) prior to commercialization. If needed, we intend to develop companion diagnostics in collaboration with or via license agreements with third parties and are dependent on the scientific insights and sustained cooperation and effort of any third-party collaborators in developing and obtaining approval (or clearance, or certification) for companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for any companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility or clinical validation. Any delay or failure by us or our collaborators to develop or obtain regulatory approval (or clearance, or certification) of companion diagnostics could delay or prevent approval of our antibody candidates. In addition, our collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our products. In addition, the diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our antibody candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative companion diagnostic test for use in connection with the development and commercialization of our antibody candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our antibody candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2003, we have devoted a significant portion of our resources to developing zenocutuzumab, MCLA-117, MCLA-158, MCLA-145, MCLA-129 and our other antibody candidates, building our intellectual property portfolio, developing our clinical manufacturing supply chain, generating and enhancing our Biclonics&#174; technology platform, generating our Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, planning our business, raising capital and providing general and administrative support for these operations. While we have ongoing clinical trials for zenocutuzumab, MCLA-158, and MCLA-145, concluding the MCLA-117 trial and anticipate commencing a clinical trial for MCLA-129, we have not successfully completed any clinical trials for any antibody candidate. We have not yet demonstrated our ability to successfully complete any Phase 2 clinical trial or any Phase&#160;3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our holders, restrict our operations or require us to relinquish rights to our technologies or antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity or debt financings and upfront and milestone payments, if any, received under our existing collaborations and any other future licenses or collaborations, together with our existing cash and cash equivalents. In order to accomplish our business objectives and further develop our product pipeline, we will, however, need to seek additional funds. If we raise additional capital through the sale of equity or convertible debt securities, our existing shareholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing shareholders&#8217; rights as holders of our common shares. In addition, the possibility of such issuance may cause the market price of our common shares to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, or acquiring, selling or licensing intellectual property rights, which could adversely impact our ability to conduct our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or antibody candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our antibody candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. For example, the trading prices for our and other biopharmaceutical companies&#8217; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any of our antibody candidates, if approved, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business may become subject to economic, political, regulatory and other risks associated with international operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company based in the Netherlands, our business is subject to risks associated with conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">economic weakness, including inflation, or political instability, in particular, in non-U.S. economies and markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing regulatory requirements for drug approvals in non-U.S. countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing jurisdictions could present different issues for securing, maintaining and/or obtaining freedom to operate in such jurisdictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potentially reduced protection for intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in compliance with non-U.S. laws and regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in non-U.S. regulations and customs, tariffs and trade barriers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in non-U.S. currency exchange rates of the euro and currency controls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in a specific country&#8217;s or region&#8217;s political or economic environment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing reimbursement regimes and price controls in certain non-U.S. markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negative consequences from changes in tax laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with international privacy regulations, including the General Data Protection Regulation (GDPR)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negative consequences from the United Kingdom&#8217;s withdrawal from the EU, and its potential impact on supply-chain and our personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties associated with staffing and managing international operations, including differing labor relations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geo-political actions, including war, riots and terrorism, or natural disasters including earthquakes, typhoons, floods, fires, epidemics or public health emergencies and U.S. or non-U.S. governmental actions or restrictions related thereto.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Exchange rate fluctuations or abandonment of the euro currency may materially affect our results of operations and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the international scope of our operations, fluctuations in exchange rates, particularly between the euro and the U.S. dollar, may adversely affect us. Although we are based in the Netherlands, we source research and development, manufacturing, consulting and other services from several countries. Further, potential future revenue may be derived from abroad, particularly from the United States. Additionally, our funding has mainly come from investors and collaborators mainly in the United States. As a result, our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business and share price may be affected by fluctuations in foreign exchange rates between the euro and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the possible abandonment of the euro by one or more members of the EU could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks from improper conduct by our employees, agents, contractors, or collaborators could adversely affect our reputation, business, prospects, operating results, and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, health care, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, import and export requirements, competition, patient privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a number of anti-corruption laws, including the Foreign Corrupt Practices Act (FCPA) in the United States, the Bribery Act in the United Kingdom and the anti-corruption provisions of the Dutch Criminal Code in the Netherlands. Our failure to comply with anti-corruption laws applicable to us could result in penalties, which could harm our reputation and harm our business, financial condition, results of operations, cash flows or prospects. The FCPA generally prohibits companies and their intermediaries from making improper payments to foreign officials for the purpose of improperly or corruptly obtaining or keeping business, obtaining preferential treatment and/or other undue benefits or advantages. The FCPA also requires public companies to maintain accurate books and records and devise a system of sufficient internal accounting controls. We regularly review and update our policies and procedures and internal controls designed to provide reasonable assurance that we, our employees, distributors and other intermediaries comply with the anti-corruption laws to which we are subject. However, there are inherent limitations to the effectiveness of any policies, procedures and internal controls, including the possibility of human error and the circumvention or overriding of the policies, procedures and internal controls. There can be no assurance that such policies or procedures or internal controls will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, distributors and other intermediaries with respect to our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Securities and Exchange Commission (SEC) and Department of Justice continue to view FCPA enforcement activities as a high priority. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could materially damage our reputation, our brand, our international operations, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions and financial markets, which could materially affect our financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the EU on January 31, 2020 and entered into a transition period. On December 24, 2020, the United Kingdom and the EU announced that they had agreed to the terms of their future trading relationship in the EU&#8212;UK Trade and Cooperation Agreement (&#8220;TCA&#8221;), which became binding on both the EU and the United Kingdom on January 1, 2021, and awaits the final agreement of the remaining 27 EU Member States. While agreement on the terms of the TCA has avoided a &#8220;no deal&#8221; Brexit scenario, and provides in principle for quota- and tariff-free trading of goods, it is nevertheless expected that the TCA will result in the creation of non-tariff barriers (such as increased shipping and regulatory costs and complexities) to the trade in goods between the United Kingdom and the EU. Further, the TCA does not provide for the continued free movement of services between the UK and the EU and imposes additional restrictions on the free movement of people between the UK and the EU. The TCA includes provisions affecting pharmaceutical businesses (including on customs and tariffs). In addition, there are some specific provisions concerning pharmaceuticals. These include the mutual recognition of Good Manufacturing Practice (GMP) inspections of manufacturing facilities for medicinal products and GMP documents issued. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards. Significant political and economic uncertainty remains about how much the relationship between the United Kingdom and EU will differ as a result of the United Kingdom&#8217;s withdrawal.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United Kingdom&#8217;s withdrawal from the EU and the associated uncertainty has</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had and may continue to have a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Asset valuations, currency exchange rates and credit ratings may be especially subject to increased market volatility. Any of these factors could have a significant adverse effect on our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the United Kingdom&#8217;s withdrawal from the EU has resulted in the relocation of the EMA from the United Kingdom to the Netherlands. This relocation has caused, and may continue to cause, disruption in the administrative and medical scientific links between the EMA and the U.K. Medicines and Healthcare products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the EU and/or the United Kingdom.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic caused by the novel coronavirus has and may continue to adversely impact our business, including our pre-clinical studies and clinical trials, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a strain of novel coronavirus causing the COVID-19 disease was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread throughout the world, including the Netherlands and the United States. In March 2020, the World Health Organization (WHO) characterized COVID-19 as a pandemic. To date, the COVID-19 pandemic has interfered with the normal function of businesses worldwide, including in the form of travel restrictions, shelter-in-place orders and quarantines, office and school closures, bans on public gatherings and employees being encouraged or required to work from home pursuant to guidance provided by national, state and local officials including the U.S. Center for Disease Control and Prevention (CDC) and European local health agencies, including the Dutch National Institute for Health and Environment or Het Rijksinstituut voor Volksgezondheid en Milieu (RIVM). For example, most of our employees located in the Netherlands restricted from traveling to the U.S., where certain of our collaborators and employees are located, which could have an adverse impact on our ability to conduct our business. Similarly, employees located in the U.S. are restricted from travel to the Netherlands under current guidelines. Additionally, <span style="color:#000000;">on March 18, 2020, we temporarily suspended our laboratory research activities at our facilities in Utrecht, the Netherlands to help secure the safety of our employees and to adhere to government recommendations of social distancing and limited public exposure in connection with the COVID-19 pandemic. We have since re-opened our offices and laboratory in Utrecht, maintaining social distancing and imposing other requirements consistent with government guidance. Further, </span>we have recommended our employees in the Netherlands and employees of our subsidiary Merus US, Inc., in the U.S. work from home when possible.&#160;&#160;For those employees working at our offices and laboratory in Utrecht, and offices of our subsidiary in Cambridge Ma., they are required to maintain social distancing and follow requirements consistent with the guidance provided by the CDC, Federal, state and local regulations for the U.S. and RIVM for the Netherlands. While we use reasonable business practices to mitigate the risk of exposure to COVID-19 while on Company-operated premises, we cannot guarantee that traveling to and from and visiting the office will not expose employees to infectious agents or eliminate inherent risks to our workforce and our business operations resulting from COVID-19. Given the uncertainty caused by the COVID-19 pandemic we cannot be certain that we will not suspend our laboratory research activities at our facilities or suspend use of our offices in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the COVID-19 pandemic, certain of our contract research organizations (CROs) and third-party suppliers, as well as collaborators in the U.S. and China that are developing or collaborating with us to develop certain of our pre-clinical and clinical-stage antibody candidates have been affected. As a result of such impact, we may face difficulties with and delays in performance of certain chemistry manufacturing and controls associated with our clinical candidates, including as it relates to sourcing materials required for such manufacture that may be diverted for other purposes associated with COVID-19, or difficulties or delays associated with testing of our pre-clinical antibody candidates associated with our collaborations with Incyte, Eli Lilly and Simcere, which may delay or prevent their potential clinical development. Additionally, our collaborators, CROs and third-party suppliers may in the future experience closures and labor shortages, which may delay or prevent our development of our antibody candidates, including zenocutuzumab, MCLA-158 and MCLA-145 and MCLA-129. Moreover, although our collaborators based in China and elsewhere have resumed operations, we may experience labor shortages associated with these chemistry manufacturing and controls, or pre-clinical development activities due to the current restrictions on travel and work globally, which may force us to reduce related workflows until such work and travel restrictions are lifted. Also, there can be no assurances that the applicable governments will not renew or extend these closures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our clinical trials, the COVID-19 pandemic and related precautions have directly or indirectly impacted enrollment, new, planned clinical trial site openings, patient visits, and on-site monitoring of our clinical trials and source verification of clinical data required for presentation of clinical data for zenocutuzumab, MCLA-158 and MCLA-145, and anticipated commencement of the clinical trial for MCLA-129. To date, we have observed a moderate to high impact on clinical trial enrollment and operations as a consequence of the COVID-19 pandemic, particularly at sites in countries not yet open to recruitment, and to a lesser extent in countries where COVID-19 related restrictions have been eased, with adjustments made to allow remote visits for some patient follow-up, and reduced onsite monitoring by the sponsor or CRO and insufficient source verification of clinical data required for presentation of clinical data. The extent of the impact to our overall clinical development timeline is uncertain at this time and we </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to monitor this impact on a regular basis. As a result of the COVID-19 pandemic, we may experience further disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in enrolling patients in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of key clinical trial activities, operations, source data verification, and other clinical trial activities such as clinical trial site patient visits, patient and data monitoring, due to limitations on travel imposed or recommended by national, state or local governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption or delays in the operations of the FDA or EMA or comparable foreign regulatory authorities, which may impact approval timelines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns, global shipping delays or stoppages and disruptions in delivery systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal of the FDA or EMA or comparable foreign regulatory authorities to accept data from clinical trials in affected geographies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption or delays in our collaborations, including with Incyte, Eli Lilly, Betta Pharma, Simcere, and our license agreements with Ono and our academic collaborators, which may experience laboratory closures causing delays in preclinical, translational and development studies that support our clinical programs and IND-enabling studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties with equity offerings due to disruptions and uncertainties in the securities market.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the trading prices for our and other biopharmaceutical companies&#8217; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common shares and any such sales may be on unfavorable terms. The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak further impacts our business, including our preclinical studies and clinical trials, results of operations and financial condition will depend on future developments which are highly uncertain and cannot be predicted with confidence. Such factors include but are not limited to the spread of the disease, the duration of the outbreak, travel restrictions, quarantines, shelter-in-place orders and social distancing in the United States, the Netherlands and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States, the Netherlands and other countries to contain and treat the disease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Clinical Testing of Our Antibody Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">All of our antibody candidates are in pre-clinical or early-stage clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our antibody candidates, particularly zenocutuzumab, MCLA-158, or MCLA-145, which we are developing with Incyte, are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our antibody candidates on a timely basis or at all.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain the requisite regulatory approvals to market and sell any of our antibody candidates, we or any collaborator for such candidates must demonstrate through extensive pre-clinical studies and clinical trials that such candidates are safe, pure and potent in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early-stage clinical trials of our antibody candidates may not be predictive of the results of later-stage clinical trials. Antibody candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not completed any clinical trials required for the approval of any of our antibody candidates. Although we are conducting ongoing clinical trials for zenocutuzumab, MCLA-158, and MCLA-145, concluding our work on the Phase I clinical trial of MCLA-117, and anticipating commencement of the Phase I clinical trial of MCLA-129 and pre-clinical studies for other antibody candidates, we may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following:&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or failure to recruit suitable patients to participate in a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or failure to establish the appropriate dose and schedule for antibody candidates in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the difficulty in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">lower than anticipated retention rates of patients in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to have patients complete a trial or return for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical sites deviating from trial protocol or dropping out of a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">investigator-sponsored studies of our product candidates, including expanded access protocols, may identify safety or efficacy concerns associated with our antibody candidates, or otherwise negatively affect patient enrollment in our ongoing and planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adding new clinical trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safety or tolerability concerns could cause us or our collaborators or regulatory authorities, as applicable, to suspend or terminate a trial if we or our collaborators or regulatory authorities, find that the participants are being exposed to unacceptable health risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to observe a meaningful clinical benefit&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or failure to obtain regulatory approval or authorizations to commence a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or failure to obtain institutional review board (IRB) or Ethics Committee approval at each site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our third-party research contractors failing to comply with regulatory requirements or applicable law, or to meet their contractual obligations to us in a timely manner, or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in regulatory requirements, policies and guidelines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing sufficient quantities of antibody candidate for use in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the quality or stability of an antibody candidate falling below acceptable standards&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the treatment landscape for our target indications that may make our antibody candidates no longer relevant&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third party actions claiming infringement by our antibody candidates in clinical trials outside of the United States and obtaining injunctions interfering with our progress&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires, epidemics or public health emergencies and U.S. or non-U.S. governmental actions or restrictions related thereto.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting, reporting on or completing our planned and ongoing clinical trials. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, the Competent Authorities of the EEA Member States (the 27 EU Member States plus Iceland, Liechtenstein, Norway and the UK) or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EEA Competent Authorities or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our antibody candidates, the commercial prospects of our antibody candidates will be harmed, and our ability to generate product revenues from any of these antibody candidates, if approved, will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our antibody candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our antibody candidates and impair our ability to commercialize our antibody candidates, if approved, and may harm our business and results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials must be conducted in accordance with the FDA, EU, EEA Member States, and other applicable regulatory authorities&#8217; legal requirements, other regulations or guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our antibody candidates produced under current good manufacturing practice (cGMP) requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice (GCP) requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the EEA and the United&#160;States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-EEA and non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EEA Competent Authorities, and different standards of diagnosis, screening and medical care.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, preliminary, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim, preliminary or &#8220;top-line&#8221; data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. Further, as a result of the COVID-19 or for other reasons, we may not be able to collect accurate or complete data at the time we collect such preliminary data, including as a result of the inability of sites to properly record data due to staffing limitations or the inability of patients to visit sites at scheduled times, the inability of CROs to access site data or for other reasons. In addition, we may report interim or preliminary analyses of only certain endpoints rather than all endpoints. As a result, top-line data should be viewed with caution until the final data are available. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the information we choose to publicly disclose regarding a particular study or clinical trial is based on more extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to disclose. Any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities, or otherwise regarding a particular antibody candidate or our business. Others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of particular programs, the approvability or commercialization of the particular antibody candidates, and our business in general. As a result, interim, preliminary or top-line data and analyses should be viewed with caution. Adverse differences between preliminary, top-line or interim data and final data or changes in what is material information regarding the results from a particular study or clinical trial could significantly harm our clinical development and business prospects and cause volatility in the price of our common shares. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our antibody candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of our antibody candidates or following approval, if any, we may need to abandon our development of such antibody candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects that may be caused by our antibody candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other comparable foreign authorities. In February 2015, we commenced a Phase 1/2 clinical trial in Europe of our most advanced antibody candidate,&#160;zenocutuzumab,&#160;for the treatment of various solid tumors, which was amended to treat patients having solid tumors harboring a NRG1 gene fusion. Additionally, in January 2018 we commenced a Phase&#160;2 clinical trial in Europe and the United States exploring zenocutuzumab, in combination with other agents, in patients with metastatic breast cancer. To date, patients treated with zenocutuzumab have experienced adverse reactions that may be related to the treatment, including infusion-related reactions, diarrhea, vomiting, fatigue, skin rash, sore mouth and shortness of breath. In May 2016, we commenced a Phase 1 clinical trial in Europe of our bispecific antibody MCLA-117. To date, patients treated with MCLA-117 have experienced adverse reactions that may be related to the treatment, most commonly infusion-related reactions including fever, cytokine release syndrome and chills. In May 2018 we commenced a Phase 1 clinical trial in Europe of our bispecific antibody MCLA-158 in patients with solid tumors. To date, patients treated with MCLA-158 have experienced adverse reactions that may be related to the treatment, most commonly infusion-related reactions and skin rash associated with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mAb</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> EGFR inhibitors. In May 2019, we commenced a Phase 1 clinical trial in the United States of our bispecific antibody MCLA-145 developed in collaboration with Incyte. To date, patients treated with MCLA-145 have experienced adverse events irrespective of causality including </span><span style="color:#000000;">blood alkaline phosphatase increase, anemia, and hypoalbuminemia, lymphocyte count decrease, and white blood cell count decrease.</span><span style="color:#000000;"> </span><span style="color:#000000;">Febrile neutropenia and elevated liver enzymes have been reported as serious adverse events</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA, the EMA, EEA Competent Authorities, or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our antibody candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Additionally, if any of our antibody candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may withdraw approvals of such products and require us to take our approved product off the market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy plan to ensure that the benefits of the product outweigh its risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to change the dose or the way the product is administered, conduct additional clinical trials or change the labeling of the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be subject to limitations on how we may promote the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of the product may decrease significantly&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be subject to litigation or product liability claims&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reputation may suffer.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected antibody candidate, if approved, or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our antibody candidates, if approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend on enrollment of patients in our clinical trials for our antibody candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. For our Phase 1/2 clinical trial of zenocutuzumab in solid tumors, we are enrolling up to 90 patients with tumors harboring NRG1 gene fusions. Solid tumors with NRG1 gene fusions occur infrequently, which could result in slow enrollment of clinical trial participants. In the Phase 1 clinical trial of MCLA-117, we announced in May 2020 we will not continue enrollment into the planned dose expansion cohorts in the trial, but plan to complete enrollment in the dose escalation phase. In the Phase 1 clinical trial of MCLA-158, we plan to enroll approximately 120 adult patients with solid tumors. In the Phase 1 clinical trial of MCLA-145, we plan to enroll approximately 118 adult patients with solid tumors or B-cell lymphoma. These trials and other trials we conduct may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trials will also compete with other clinical trials for antibody candidates that are in the same therapeutic areas as our antibody candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment depends on many factors, including the size and nature of the patient population, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating, and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our antibody candidates will increase our costs, slow down our antibody candidate development and approval process, delay or potentially jeopardize our ability to commence product sales and generate revenue and harm our reputation and ability to obtain financing. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our antibody candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become exposed to costly and damaging liability claims, either when testing our antibody candidates in the clinic or at the commercial stage&#59; and our product liability insurance may not cover all damages from such claims.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale&#59; however, the current and future use of antibody candidates by us and our collaborators in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our antibody candidates or any prospects for commercialization of our antibody candidates, if approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our antibody candidates were to cause adverse side effects during clinical trials or after approval of the antibody candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain adequate product liability insurance for our antibody candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our antibody candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our antibody candidates, our business will be substantially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a antibody candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any antibody candidate and it is possible that none of our existing antibody candidates or any antibody candidates we may seek to develop in the future will ever obtain regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our antibody candidates could fail to receive regulatory approval for many reasons, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that an antibody candidate is safe and effective for its proposed indication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to demonstrate that an antibody candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the data collected from clinical trials of our antibody candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United&#160;States, the EU or elsewhere&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve (or to clear or to certify) the companion diagnostics we contemplate developing with collaborators&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our antibody candidates, which would significantly harm our business, results of operations and prospects. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our antibody candidates. Even if we believe the data collected from clinical trials of our antibody candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our antibody candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve an antibody candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that antibody candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fast Track designation by the FDA for zenocutuzumab or potential future Fast Track designation of our other antibody candidates may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted a Fast Track designation for zenocutuzumab in the United States for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions that have progressed on standard-of-care therapy, and we may seek additional Fast Track designations for zenocutuzumab or for our other antibody candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing therapeutic candidates that meet certain criteria. Specifically, new biologics are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. With a Fast Track antibody candidate, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining a Fast Track designation does not change the standards for product approval, but may expedite the development or approval process. Even though the FDA has granted such designation for zenocutuzumab for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions that have progressed on standard-of-care therapy, it may not actually result in faster clinical development or regulatory review or approval. Furthermore, such a designation does not increase the likelihood that zenocutuzumab or any other antibody candidate that may be granted Fast Track designation will receive marketing approval in the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our antibody candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our antibody candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we may receive for our antibody candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a Risk Evaluation and Mitigation Strategy in order to approve our antibody candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our antibody candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs, and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or the rejection of product approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the products, manufacturers or manufacturing process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">warning or untitled letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">civil and criminal penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspension or withdrawal of regulatory approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizures, detentions or import bans&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">voluntary or mandatory product recalls and publicity requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">total or partial suspension of production&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">imposition of restrictions on operations, including costly new manufacturing requirements.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in our efforts to use and expand our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform to build a pipeline of antibody candidates or to use our Triclonics<span style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> technology platform to build a pipeline of trispecific antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to use and expand our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform to build a pipeline of antibody candidates and progress these antibody candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of antibody candidates directed at various cancers, we may not be able to develop antibody candidates that are safe and effective. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another important element of our strategy is to develop, use and exploit our Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform to build a pipeline of trispecific antibody candidates and collaborate with third parties in potentially researching and developing these trispecific antibody candidates through pre-clinical and clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in proof of concept pre-clinical candidates, we may not be able to develop or monetize these trispecific antibody candidates or demonstrate in the clinic that they are safe and effective. Even if we are successful in continuing to build our bispecific and trispecific pipelines, the potential antibody candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize our bispecific antibody candidates or if we do not successfully develop, collaborate, license or begin to commercialize our trispecific antibody candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain marketing approval of any of our antibody candidates in a major pharmaceutical market such as the United States or the EU, we may never obtain approval or commercialize our products in other major markets, which would limit our ability to realize their full market potential.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or territories regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have any antibody candidates approved for sale in any jurisdiction, whether in the Netherlands, the United States or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products, if any, will be harmed.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited resources and access to capital to fund our operations, we must decide which antibody candidates to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular compounds, antibody candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain antibody development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our antibody candidates or misread trends in the biopharmaceutical industry, in particular for our lead antibody candidates, our business, financial condition and results of operations could be materially adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the importation, storage, controlled use, handling, release and disposal of, and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, animal byproducts, genetically modified organisms, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaborators may engage in misconduct or other improper activities, including noncompliance with applicable law, regulatory standards and requirements, which could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaborators may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)&#160;the regulations of the FDA, the EMA and other regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities&#59; (ii)&#160;manufacturing standards&#59; (iii)&#160;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad&#59; or (iv)&#160;laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our pre-clinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, individual imprisonment, other sanctions, contractual </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain laws and regulations require us to test our antibody candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval of Our Antibody Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our antibody candidates and may affect the prices we may set. The successful commercialization of our antibody candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the EU, and other foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the ACA) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishment of a Center for Medicare Innovation at the Centers for Medicare&#160;&#38; Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act of 2017 (TCJA), includes a provision repealing, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court's decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal, or replace the ACA will impact the ACA or our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our future customers and accordingly, our financial operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting and, beginning in 2018, CMS began paying for clinical laboratory services based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care plans pay for laboratory services. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the 21st Century Cures Act changed the reimbursement methodology for infusion drugs and biologics furnished through durable medical equipment in an attempt to remedy over- and underpayment of certain products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our antibody candidates or additional pricing pressures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for any future products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU,&#160;including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU&#160;member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our antibody candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict how the policies of changing political administrations could impact, impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications.&#160;For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority.&#160;If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, policies of the individual government agencies, including the FDA or similar regulatory authorities, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our antibody candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are required by the FDA</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> or similar authorities</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> to obtain approval </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(or clearance, or certification) </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of a companion diagnostic test in connection with approval of any of our antibody candidates, and we do not obtain or face delays in obtaining approval </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(or clearance, or certification) </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If safe and effective use of any of our antibody candidates depends on an diagnostic that is not otherwise commercially available, then the FDA may require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our antibody candidates, if at all. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to develop or obtain one that would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostics is time consuming and costly.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities, and, to date, the FDA has generally required premarket approval of companion diagnostics labeled for use with cancer therapies. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or a comparable regulatory authority requires approval (or clearance, or certification) of a companion diagnostic for any of our antibody candidates, whether before or after such candidate obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such antibody candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval (or clearance, or certification) of a companion diagnostic could delay or prevent approval or continued marketing of such antibody candidate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidate, if approved, on a timely or profitable basis, if at all.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval, clearance or certification of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU. On May 25, 2017, the new In Vitro Medical Devices Regulation (2017/746 or &#8220;IVDR&#8221;) entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA Member States, regulations are directly applicable, i.e., without the need for adoption of EEA Member States laws implementing them, in all EEA Member States and are intended to eliminate current differences in the regulation of medical devices among EEA Member States. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. The IVDR will, however, only become applicable in May 2022.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulation of companion diagnostics will be subject to further requirements as of the entry into force of the <span style="font-style:italic;">in-vitro</span> diagnostic devices Regulation (No 2017/746) which introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authorities or the EMA. These modifications may make it more difficult and costly for us to obtain regulatory clearances or approvals for our companion diagnostics or to manufacture, market or distribute our products after clearance or approval is obtained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the global pandemic of COVID-19, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to healthcare laws, regulation and enforcement&#59; our failure to comply with these laws could harm our results of operations and financial conditions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not currently have any products on the market, if we obtain FDA approval for any of our antibody candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our proposed sales, marketing and education programs and constrain our financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid&#59; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or&#160;qui tam&#160;actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services&#59; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal Food, Drug and Cosmetic Act (FDCA) which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, and that require the tracking and reporting of gifts and other remuneration and items of value provided to healthcare professionals and entities&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us or our collaborators, from research institutions, and directly from individuals.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most health care providers, including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH. Any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered health care provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. Even when HIPAA does not apply, according to the Federal Trade Commission (FTC), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule. As such, we, <span style="color:#000000;">our collaborators, research institutions, health care providers and other entities that provide personally identifiable information to us</span> may be subject to state <span style="color:#000000;">information security laws, and state </span>laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and global data protection landscape is rapidly evolving, and we may be affected by or subject to new or amended laws and regulations in the future. <span style="color:#000000;">For example, California recently enacted legislation, the California Consumer Privacy Act (CCPA) which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context.</span> Further, <span style="color:#000000;">the CPRA was also recently voted into law by California residents. </span>The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our and our collaborators&#8217; clinical trial programs and research collaborations outside the U.S. may implicate international data protection laws, including, in Europe, the GDPR and local laws further implementing or supplementing the GDPR. The GDPR implements more stringent operational requirements for processors and controllers of personal data including requirements for such companies to be able to ensure and be able to demonstrate compliance with the GDPR. If our or our collaborators&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#8364;20&#160;million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. In addition to statutory enforcement, a non-compliance can lead to compensation claims by affected individuals, negative publicity and a potential loss of business.<span style="color:#000000;"> Further, following the withdrawal of the United Kingdom from the EU on January 31, 2020, we have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, with </span><span style="font-style:italic;color:#000000;">each</span><span style="color:#000000;"> regime having the ability to fine up to the greater of &#8364;20 million/ &#163;17 million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, including how data transfers between EU member states and the United Kingdom will be treated. These changes may lead to additional compliance costs and could increase our overall risk.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to EU/national laws on personal data export, as we may transfer personal data from the EU/EEA to other jurisdictions which are not considered by the European Commission to offer &#8220;adequate&#8221; protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. In addition, in July 2020, the CJEU invalidated the Privacy Shield, under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. We employ model clauses which remain valid according to the recent CJEU decision, but the changes and uncertainty in this area of law could require us to make operational changes and could increase costs and may lead to governmental enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner among jurisdictions in which we operate. <span style="color:#000000;">We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws both inside and outside the United States. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations regardless of merit and even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claims that <span style="color:#000000;">we or any collaborators fail to comply with applicable federal, state, or local, legal or regulatory requirements, could subject us to a range of regulatory actions that could affect our or any collaborators&#8217; ability to seek to commercialize our antibody candidates, if approved. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization of Our Antibody Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that compete with our antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any antibody candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our antibody candidates or our technology obsolete, less competitive or uneconomical. Our competitors may, among other things:&#160;</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain quicker regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish superior proprietary positions covering our products and technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">implement more effective approaches to sales and marketing&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">form more advantageous strategic alliances.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, existing and future collaborators may decide to market and sell products that compete with the antibody candidates that we have agreed to license to them. While we have agreements governing their committed activities, we have limited influence over their actual performance, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, retaining manufacturers to produce clinical trial materials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our products, or lose such designation for zenocutuzumab in the United States, our competitors may sell products to treat the same conditions and our revenue will be reduced.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment&#59; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. During this period, the EMA cannot accept another application for a MA, or grant a MA or accept an application to extend an existing MA for the same indication, in respect of a similar medicinal product. The application for orphan drug designation must be submitted before the MAA. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained orphan drug designation from the FDA for zenocutuzumab for the treatment of patients with pancreatic cancer and potentially may seek that or a similar designation from the EMA for zenocutuzumab, and we may seek such designation from the FDA and EMA for other clinical assets, where supported by data in the appropriate indications that meet the criteria for orphan status. Even though we obtained orphan designation in the United States for zenocutuzumab and may obtain such designation for other antibody </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates in the United States and/or the EU, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same drug with the same active moiety for the same condition if the FDA or the EMA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation, when appropriate, we may not receive such designation.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our antibody candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our antibody candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our antibody candidates, assuming approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize and attract additional collaborators to invest in the development of our antibody candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our antibody candidate and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our antibody candidate, pricing of existing drugs may limit the amount we will be able to charge for our antibody candidate. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our antibody candidates and may not be able to obtain a satisfactory financial return on products that we may develop.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of any future products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our antibody candidates, if approved. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our antibody candidates, if approved. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not cover or provide adequate payment for our antibody candidates, if approved. We expect to experience pricing pressures in connection with the sale of any of our antibody candidates that are approved due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA, the EMA or any other regulatory authority approves the marketing of any antibody candidates that we develop on our own or with a collaborator, physicians, healthcare providers, patients or the medical community may not accept or use them. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our antibody candidates that are approved will depend on a variety of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of market introduction&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number and clinical profile of competing products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to provide acceptable evidence of safety and efficacy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of any side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">relative convenience and ease of administration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-effectiveness&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient diagnostics and screening infrastructure in each market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">marketing and distribution support&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and other insurers, both public and private&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other potential advantages over alternative treatment methods.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure of our antibody candidates, if approved, to gain market acceptance will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no marketing, sales and distribution capabilities because all of our antibody candidates are still in clinical or pre-clinical development. If any of our antibody candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our antibody candidates, or to outsource this function to a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our antibody candidates. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any approved products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have never commercialized an antibody candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our products on our own or together with suitable collaborators.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never commercialized an antibody candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for our antibody candidates, if approved, which we may license to others, we will rely on the assistance and guidance of those collaborators. For antibody candidates for which we retain commercialization rights, we will have to develop </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our own sales, marketing and supply organization or outsource these activities to a third party. We may rely on outside consultants to provide advice on commercialization strategies, which may fail to deliver or provide effective guidance to maximize any commercial opportunity, if any, that may arise from our antibody candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may affect our ability to commercialize our antibody candidates on our own include obtaining effective advice from consultants on commercialization strategy, recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our antibody candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our antibody candidates, if approved. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our antibody candidates, we may not generate revenues from them or be able to reach or sustain profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our antibody candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our antibody candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2006.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if our antibody candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our antibody candidates and our business could be substantially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct our pre-clinical studies and clinical trials and to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA, and comparable foreign regulatory authorities for all of our antibody candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with the antibody candidate produced under cGMP </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our antibody candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our antibody candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any antibody candidates that we develop. Moreover, as a result of the COVID-19 pandemic, certain of our third-party CROs have been affected and in some instances have experienced cessation or mitigation of activity and may experience closures and labor shortages, which may negatively affect our pre-clinical and clinical development activities. In addition, the use of third-party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our antibody candidates. As a result, our results of operations and the commercial prospects for our antibody candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The collaboration and license agreement, or the Collaboration Agreement, with Incyte Corporation (Incyte) is important to our business. If suitable monospecific or bispecific antibody candidates are not identified for further development and commercialization activities under the Collaboration Agreement, or if we or Incyte fail to adequately perform under the Collaboration Agreement, or if we or Incyte terminate the Collaboration Agreement, the development and commercialization of our antibody candidates would be delayed or terminated and our business would be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Collaboration Agreement may be terminated:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in its entirety or on a program-by-program basis by Incyte for convenience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in its entirety or on a program-by-program basis by either party due to a material breach of the Collaboration Agreement, or any one or more programs under the Collaboration Agreement, as applicable&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">on a program-by-program basis (but not in its entirety), by either party if the other party challenges the terminating party&#8217;s patents for such program, and such challenge is not withdrawn within 30 days.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Collaboration Agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to us, subject to payment to Incyte of a reverse royalty of up to 4% on sales of future products, depending on the stage of development as of the date of termination, if we elect to pursue development and commercialization of monospecific or bispecific antibody candidates arising from the terminated programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the Collaboration Agreement could cause significant delays in our antibody candidate development and commercialization efforts, which could prevent us from commercializing our antibody candidates without first expanding our internal capabilities or entering into another agreement with a third party. Any suitable alternative collaboration or license agreement would take considerable time to negotiate and could also be on less favorable terms to us. In addition, under the Collaboration Agreement, Incyte agreed to conduct certain clinical development activities. If the Collaboration Agreement were to be terminated, and whether or not we identify another suitable collaborator, we may need to seek additional financing to support the research and development of any terminated antibody candidates so that we may continue development activities, or we may be forced to discontinue development of terminated antibody candidates, each of which could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Collaboration Agreement, with the exception of MCLA-145 where we retain full U.S. rights, we are dependent upon Incyte to successfully develop and commercialize any antibody candidates that are identified for further development under the Collaboration </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement. With the exception of those programs where we retain certain co-development rights, we have limited ability to influence or control Incyte&#8217;s development and commercialization activities or the resources it allocates to development of product candidates identified under the Collaboration Agreement. Our interests and Incyte&#8217;s interests may differ or conflict from time to time, or we may disagree with Incyte&#8217;s level of effort or resource allocation. Incyte may internally prioritize programs under development within the collaboration differently than we would, or it may not allocate sufficient resources to effectively or optimally develop or commercialize antibody candidates arising from such programs. If these events were to occur, our ability to receive revenue from the commercialization of products arising from such programs would be reduced, and our business would be adversely affected.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The collaboration and license agreement, or the Lilly Collaboration Agreement, with Eli Lilly is important to our business. If suitable monospecific or bispecific antibody candidates are not identified for further development and commercialization activities under the Lilly Collaboration Agreement, or if we or Eli Lilly fail to adequately perform under the Lilly Collaboration Agreement, or if we or Eli Lilly terminate the Lilly Collaboration Agreement, the development and commercialization of our antibody candidates would be delayed or terminated and our business would be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lilly Collaboration Agreement may be terminated:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in its entirety or on a program-by-program basis by Eli Lilly for convenience&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in its entirety or on a program-by-program basis by either party due to a material breach of the Lilly Collaboration Agreement, or any one or more programs under the Lilly Collaboration Agreement, as applicable.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Lilly Collaboration Agreement is terminated with respect to one or more programs, depending on the stage of development, certain rights in the terminated programs revert to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the Lilly Collaboration Agreement could cause significant delays in our antibody candidate development and commercialization efforts, which could prevent us from commercializing our antibody candidates without first expanding our internal capabilities or entering into another agreement with a third party. Any suitable alternative collaboration or license agreement would take considerable time to negotiate and could also be on less favorable terms to us. In addition, under the Lilly Collaboration Agreement, Eli Lilly agreed to conduct certain pre-clinical and clinical development activities. If the Lilly Collaboration Agreement were to be terminated, and whether or not we identify another suitable collaborator, we may need to seek additional financing to support the research and development of any terminated antibody candidates so that we may continue development activities, or we may be forced to discontinue development of terminated antibody candidates, each of which could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Lilly Collaboration Agreement, we are dependent upon Eli Lilly to successfully develop and commercialize any antibody candidates that are identified for further development under the Lilly Collaboration Agreement. We have limited ability to influence or control Eli Lilly&#8217;s development and commercialization activities or the resources it allocates to development of product candidates identified under the Lilly Collaboration Agreement. Our interests and Eli Lilly&#8217;s interests may differ or conflict from time to time, or we may disagree with Eli Lilly&#8217;s level of effort or resource allocation. Eli Lilly may internally prioritize programs under development within the collaboration differently than we would, or it may not allocate sufficient resources to effectively or optimally develop or commercialize antibody candidates arising from such programs. If these events were to occur, our ability to receive revenue from the commercialization of products arising from such programs would be reduced, and our business would be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The collaboration and license agreements with Simcere, and Betta Pharma, and the research and license agreement with Ono are important to our business. If our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> antibodies licensed in these collaboration and license agreements fail to advance or experience unacceptable safety or efficacy results if clinically developed, this could adversely impact the reputation of our platform and our ability to engage in future collaborations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our collaboration agreements with Simcere or Betta Pharma or our research and license agreements with Ono are terminated with respect to one or more programs, or the pre-clinical assets associated with these agreements fail to advance into the clinic, or experience negative results with respect to safety, efficacy, manufacturability, or other features of research and development, this could adversely affect the reputation of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform and our ability to engage in future collaborations or licensing agreements. While we have certain contractual provisions in place in our collaboration agreements with Simcere and Betta Pharma that permit us to supervise development efforts associated with our pre-clinical assets with respect to Simcere, or MCLA-129, which we anticipate entering the clinic in 2021 with Betta Pharma, which have product rights in China, we cannot guarantee that these assets will be developed in China in accordance with our standards as applied to our wholly owned programs. Ono is currently pursuing at least one antibody program generated by us through use of our proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform in an area outside oncology. To the extent this asset does not successfully advance through clinical development, this may impair our ability to leverage our platform in areas outside oncology or to engage in future license agreements to further expand the use of our platform and generate future revenue. Should any of these collaborations or license agreements fail or be terminated, any suitable alternative collaboration or license agreement would take considerable time to negotiate, if at all, and could also be on less favorable terms to us. If these agreements were to be terminated, and whether or not we identify a suitable alternative collaborator, we may need to seek additional financing to support the research and development of any terminated antibody candidates so that we may continue </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development activities, or we may be forced to discontinue development of terminated antibody candidates, each of which could have a material adverse effect on our business.</span><span style="font-size:8pt;">&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to enter into new strategic relationships our business, financial condition, commercialization prospects and results of operations may be materially adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development programs and the potential commercialization of our antibody candidates will require substantial additional cash to fund expenses. Therefore, for some of our antibody candidates and with respect to our recently developed Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, we may decide to enter into new collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of those bispecific and trispecific antibody candidates. For instance, we have license and collaboration agreements with Ono, Incyte, Eli Lilly, Simcere and Betta, under which we have licensed the development and commercialization of certain of our monospecific or bispecific antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Collaborations are complex and&#160;time-consuming&#160;to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of a particular bispecific or trispecific antibody candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our antibody candidates to market, further research and develop new trispecific antibody candidates, enhance our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms and generate product revenue. If we do&#160;enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not be able to control the amount and timing of resources that the collaborator devotes to the product development program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the collaborator may experience financial difficulties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to relinquish important rights such as marketing, distribution and intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a collaborator may experience technical, clinical, intellectual property, manufacturing or other setbacks in the research or development of a product program arising from our collaboration adversely affecting the financial return of our collaboration or the reputation of our technology platform&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our willingness to complete our obligations under any arrangement.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently rely on third-party suppliers and other third parties for production of our antibody candidates and our dependence on these third parties may impair the advancement of our research and development programs and the development of our antibody candidates. Moreover, we intend to rely on third parties to produce commercial supplies of any approved antibody candidate and our commercialization of any of our antibody candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA or comparable foreign regulatory authorities<span style="color:#000000;"> following inspection of their facilities and procedures to manufacture our antibody candidates and products</span>, fail to provide us with sufficient quantities of antibody product or fail to do so at acceptable quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on and expect to continue to rely on third-party contract manufacturing organizations (CMOs) for the supply of cGMP-grade clinical trial materials and commercial quantities of our antibody candidates and products, if approved. Reliance on third-party providers may expose us to more risk than if we were to manufacture antibody candidates ourselves. The facilities used by our CMOs to manufacture our antibody candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. We have limited control over the manufacturing process of, and beyond contractual terms, we are completely dependent on our CMOs for compliance with cGMP for the manufacture of our antibody candidates. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, or are unable to do so in a timely manner, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities or may result in delay of our ability to obtain marketing authorization, if any, of our antibody candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our antibody candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which would significantly impact our ability to develop, obtain regulatory approval for or market our antibody candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our antibody candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our collaborators, our CMOs and other third parties for the manufacture, filling, storage and distribution of our antibody candidates means that we are subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely affect our business, financial condition and results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Growth in the costs and expenses of components or raw materials may also adversely influence our business, financial condition and results of operations. Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on our CMOs to purchase from third-party suppliers the materials necessary to produce our antibody candidates for our clinical trials, and will rely on our existing and future collaborators to purchase from third-party suppliers the materials necessary to develop and produce our antibody candidates for future clinical trials and, upon approval, our products for commercialization. There are a limited number of suppliers for raw materials that we use to manufacture our antibody candidates and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our antibody candidates for our clinical trials, and if approved, ultimately for commercial sale. Apart from contractual measures, we do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers or manufacturers paid by our collaborators. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of an antibody candidate to complete the clinical trial or have secured resupply capacity, any significant delay in the supply of an antibody candidate, or the raw material components thereof, for a planned or an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our antibody candidates. If our manufacturers, collaborators or we are unable to purchase these raw materials after regulatory approval has been obtained for our antibody candidates, the commercial launch of our antibody candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our antibody candidates. Moreover, as a result of the COVID-19 pandemic, third-party manufacturers have been affected, which could disrupt or delay their activities or ability to source materials and as a result we could face difficulty sourcing key components necessary to produce supply of our product candidates, which may negatively affect our pre-clinical and clinical development activities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on our manufacturers and other subcontractors to comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If our manufacturers or other subcontractors fail to acquire the proper licenses or otherwise infringe third party proprietary rights in the course of completing their contractual obligations to us, we may have to find alternative manufacturers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or market our antibody candidates, if approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property and Information Technology</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on patents and other intellectual property rights to protect our technology, including antibody candidates and our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform and Triclonics<span style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> technology platform, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform, Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform, our common light chain transgenic murine technology, our CH3 domain dimerization technology, our heavy chain variable regions and binding domains that bind particular antigens, our monospecific antibodies, bispecific antibody, trispecific antibody and antibody clinical candidates, products, their format and methods and host cells used to produce, screen, manufacture and purify those antibody and antibody clinical candidates, the methods for treating patients using those candidates, among other aspects of our technology or on licensing-in such rights. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our platform technologies, and antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, or have issued and even if such patents cover our Biclonics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;technology platform, Triclonics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technology platform, our common light chain transgenic murine technology, our CH3 domain dimerization technology our heavy chain variable regions and binding domains that bind particular antigens, our monospecific antibodies, antibody, trispecific antibody and antibody clinical candidates, products, their format and methods and host cells used to produce, screen, manufacture and purify those antibody and antibody clinical candidates, the methods for treating patients using those candidates, and other technologies, third parties may initiate opposition, interference, re-examination, post-grant review, inter </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partes</span><span style="font-style:italic;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to our technology, including our antibody candidates. Furthermore, if third parties have filed such patent applications on or before March&#160;15, 2013, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&#160;15, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued patents covering one or more of our products or the Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology or Triclonics<span style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> technology platforms could be found invalid or unenforceable if challenged in court.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect our competitive position, we may from time to time need to resort to litigation to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. As enforcement of intellectual property rights is difficult, unpredictable and expensive, we may fail in enforcing our rights&#8212;in which case our competitors may be permitted to use our technology without being enjoined, required to pay us any license fees, or compensate us for lost profits or reasonable royalty. In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize technology covered by our patents we seek to enforce, such as those covering our antibody candidates or methods, our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms, our common light chain transgenic murine technology, or our CH3 domain dimerization technology, among other technologies, and then compete directly with us, without payment to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we were to initiate legal proceedings against a third party to enforce a patent covering our technology, one of our products or methods, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States or in certain jurisdictions in Europe, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of utility, novelty, obviousness, non-enablement or lack of written description or as constituting unpatentable subject matter. Grounds for an unenforceability assertion could be an allegation that someone substantively involved in prosecution of the patent withheld but-for material information from the U.S. Patent and Trademark Office (USPTO) or engaged in affirmatively egregious misconduct, during prosecution, with a specific intent to deceive the USPTO. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our technologies, products, methods or certain aspects of our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights of third parties could adversely affect our ability to commercialize our antibody candidates, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our antibody candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our technology platforms, methods or candidates or elements thereof, our manufacture or uses relevant to our development, or other attributes of our antibody candidates or our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;technology platform or Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. In such cases, we may not be in a position to develop or commercialize products or bispecific or trispecific antibody candidates unless we successfully </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue litigation, opposition, inter </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partes</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or related post-grant proceedings to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. In addition, we are aware of issued patents and/or pending patent applications held by third parties that could be alleged as covering some of our antibody candidates, irrespective of the merits. We believe that if such patents or patent applications (if issued as currently pending) were asserted against us, we would have counterclaims and defenses against such claims, including non-infringement, the affirmative defense of safe harbor designed to protect activity undertaken to obtain federal regulatory approval of a drug, including under 35 U.S.C. &#167; 271(e) and similar foreign exceptions to infringement, and defenses concerning patent invalidity and/or unenforceability. However, if such counterclaims and defenses were not successful and such patents were successfully asserted against us such that they are found to be valid and enforceable, and infringed by our antibody candidates, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize our antibody candidates. We could also be required to pay substantial damages. Similarly, the targets of certain of our antibody candidates have also been the subject of research by many companies, which have filed patent applications or have patents related to such targets and their uses. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, if at all, and any such litigation would be costly and time-consuming.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we failed to identify relevant patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform technologies could have been filed by others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to claim broad coverage in the areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our methods, antibody candidates or the use of our bispecific and trispecific antibody candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third party intellectual property right holders, including our competitors, may actively bring infringement claims against us. The granting of orphan drug status in respect of any of our antibody candidates does not guarantee our freedom to operate and is separate from our risk of possible infringement of third parties&#8217; intellectual property rights. We may not be able to successfully settle or otherwise resolve such potential infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing any approved products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail in any such dispute, in addition to being forced to pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing any of our antibody candidates that are held to be infringing or be forced to redesign antibody candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if the breadth or strength of protection provided by our or our present or future licensors&#8217;, collaborators&#8217; or partners&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future antibody candidates. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to compete may be adversely affected if we are unsuccessful in defending against any claims by competitors or others that we are infringing upon their intellectual property rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights.&#160;In addition, many companies in intellectual property-dependent industries, including those producing therapeutics to treat and potentially cure cancer, have employed intellectual property litigation as a means to gain an advantage over their competitors. As a result, we may be required to defend against claims of intellectual property infringement that may be asserted by our competitors against us and, if the outcome of any such litigation is adverse to us, it may affect our ability to compete effectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our involvement in litigation, and in any interferences, opposition, pre and post-grant administrative proceedings or other intellectual property proceedings inside and outside of the United States may divert management from focusing on business operations, could cause us to spend significant amounts of money and may have no guarantee of success. Any potential intellectual property litigation successfully adjudicated against us could also force us to do one or more of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">stop selling, incorporating, manufacturing or using our products in the United States and/or other jurisdictions that are covered by the subject intellectual property&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant technology, which license may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">redesign those technologies, products or processes that use any allegedly infringing or misappropriated technology, which may result in significant cost or delay to us, or which redesign could be technically infeasible&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully infringed certain intellectual property rights.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware that significant number of patents and patent applications may exist relating to aspects of therapeutic antibody technologies filed by, and issued to, third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that we will ultimately prevail if any of this third-party intellectual property is asserted against us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings and the legal costs associated with them, could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining necessary rights to our antibody candidates through acquisitions and in-licenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have rights and own our intellectual property, including issued patents and pending patent applications, relating to and covering our antibody candidates and Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platforms. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our antibody candidates may require specific formulations to work effectively and efficiently or companion diagnostics for safely and effective administration of our therapeutic candidates and the rights to these formulations and companion diagnostics may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we may identify as necessary for our antibody candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of an antibody candidate or program, we may have to abandon development of that antibody candidate or program and our business and financial condition could suffer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registered or unregistered trademarks, trade names or service marks may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks, trade names, and service marks, which we need to build name recognition by potential collaborators, partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names and service marks then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks, trade names or service marks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks, trade names or service marks throughout the world.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering each of our antibody candidates, our business may be materially harmed.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents typically have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our antibody candidates are obtained, once the patent life has expired for a candidate, we may be open to competition from competitive medications, including biosimilar or generic medications. Given the amount of time required for the development, testing and regulatory review of new antibody candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, causing our revenue from applicable products to be reduced, possibly materially, and potentially harming our ability to recover our investment in such product or obtain a reasonable return on that investment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and conditions of FDA marketing approval of our antibody candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We enjoy only limited geographical protection with respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of intellectual property rights&#160;in those jurisdictions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally file our first patent application (i.e., priority filing) in the Netherlands. International applications under the Patent Cooperation Treaty (PCT) are usually filed within 12 months after the priority filing, where we pursue patent applications in the U.S., across the E.U., and other PCT participating jurisdictions, as based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our antibody candidates may be marketed or manufactured or our platform technologies may be utilized. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others.&#160;It is also quite common that depending on the country, the scope of patent protection may vary for the same antibody candidate and/or technology.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may use our and our existing or future licensors&#8217;, collaborators&#8217; or partners&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our existing or future licensors, collaborators or partners have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our antibody candidates or our platform technologies, and our and our existing or future licensors&#8217;, collaborators&#8217; or partners&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may be able to make compounds that are the same as or similar to our antibody candidates but that are not covered by the claims of the patents that we own or have exclusively licensed&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the patents of third parties may have an adverse effect on our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">it is possible that our pending patent applications will not lead to issued patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third parties performing manufacturing or testing for us using our antibody candidates or technologies could use the intellectual property of others without obtaining a proper license&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not develop additional technologies that are patentable.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our antibody candidates and technology platforms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2011, the America Invents Act (AIA) was enacted in the United States, resulting in significant changes to the U.S. patent system. An important change introduced by the AIA was a transition to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention, which went into effect on March&#160;16, 2013. Therefore, a third party that now files a patent application in the USPTO before we do could be awarded a patent covering an invention of ours even if we created the invention before it was created by the third party. While we are cognizant of the time from invention to filing of a patent application, circumstances could prevent us from promptly filing patent applications for our inventions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA were changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower burden of proof in USPTO proceedings compared to the burden of proof in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its continued implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, and the patent applications of our existing and future collaborators or licensors and the enforcement or defense of our issued patents.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, there is complexity and uncertainty related to European patent laws.&#160;For example, the European Patent Convention was amended in April 2010&#160;to limit the time permitted for filing divisional applications. In addition, the EPO patent system is relatively stringent in the type of amendments that are allowed during prosecution. These limitations and requirements could adversely affect our ability to obtain new patents in the future that may be important for our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Confidentiality agreements with employees, contractors, agents, consultants, collaborators and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider proprietary trade secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and/or confidential know-how are difficult to maintain as confidential.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors, collaborators and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors, collaborators and advisers may unintentionally or willfully disclose our confidential information </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or we may be unaware of such disclosure to enforce our confidentiality agreements. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances and to guarantee our freedom to operate, we may also decide to publish some know-how to prevent others from obtaining patent rights covering such know-how.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we take measures including by policy, procedure and contract to try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our existing or future licensors or collaborators fail to maintain the patents and patent applications covering our antibody candidates, our competitors might be able to enter the market, which would have an adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of social media could give rise to liability, breaches of data security, or reputational harm.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our employees use social media to communicate internally and externally. While we have policies and procedures in place governing employee use of social media, there is risk that the use of social media by us or our employees to communicate about our antibody candidates, technologies or business may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us, our clinical trials, or our antibody candidates, our technologies, and company generally in social media could seriously damage our reputation, brand image, and goodwill. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our computer systems and data and those of our current or future CROs or other contractors and consultants are vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly increasing in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">frequency and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#8220;hacktivists,&#8221; nation states, and others</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s a company with an increasingly global presence, our systems are subject to frequent attacks, which are becoming more commonplace in the industry, including attempted hacking, phishing attempts, such as cyber-related threats involving spoofed or manipulated electronic communications, which increasingly represent considerable risk. Due to the nature of some of the attacks</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> described herein</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology, including in the hiring of IT personnel, and improvements to IT infrastructure and controls, there can be no assurance that our efforts will prevent service interruptions or security breaches.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any cybersecurity incident could adversely affect our business, by leading to, for example, the loss of trade secrets or other intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical trial patients, customers, and others. Although to our knowledge we have not experienced any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations. We could be subject to <span style="color:#000000;">breach notification requirements, </span>regulatory actions taken by governmental authorities, litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties. Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our business, prospects, operating results, share price and shareholder value, and financial condition.&#160;We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or personal data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media, and other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also seriously harm our business. Any security compromise affecting us, our collaborators or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future growth and ability to compete depends on retaining our key personnel, recruiting additional qualified personnel and managing transitions among these personnel, such as the 2019-2020 transition of our former President and Chief Executive Officer, and resignation of our former Chief Medical Officer, hiring of our new Chief Medical Officer and resignation of our former Chief Scientific Officer occurring in 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends upon the contributions of our senior leaders, including our board of directors, our senior management, and other key scientific and technical personnel, many of whom have been instrumental for us and have substantial experience with our therapies and related technologies. The loss of key senior management, managers and senior scientists could delay our research and development and clinical trial activities<span style="color:#000000;"> or impair our ability operate the company effectively</span>. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business. Our success also depends on our ability to manage transitions among our senior management and other key personnel. In December 2019, Ton Logtenberg, Ph.D., stepped down as an executive director, a position he held since co-founding our company in 2003, and as President, Chief Executive Officer and Principal Financial Officer, and Sven &#8220;Bill&#8221; Lundberg, M.D. was appointed as an executive director and as President, Chief Executive Officer and Principal Financial Officer as of January 1, 2020. In April 2020, L. Andres Sirulnik, M.D., Ph.D. resigned as Executive Vice President, Chief Medical Officer effective April 24, 2020, and Andrew Joe, M.D., was appointed as Senior Vice President and Chief Medical Officer, effective July 27, 2020. Further, in April 2020, Mark </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throsby, Ph.D., resigned as the Executive Vice President and Chief Scientific Officer of the Company with an effective date of July 31, 2020. These changes in our senior management </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> disruptive to our business, and if we are unable to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manage orderly transitions in these cases or for other key personnel in the future, or if we are unable to recruit </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suitable replacement for the Chief Scientific Officer position, or retain our existing senior </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management, managers and senior scientists</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our business may be adversely affected.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug and clinical development, regulatory affairs and sales and marketing. To manage our growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Shares</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of the shares.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. We have registered and intend to continue to register all common shares that we may issue under our equity compensation plans. Once registered, these common shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates who hold such shares. In addition, in connection with entering into the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which we issued and sold to Incyte 3,200,000 of our common shares. Incyte&#8217;s ability to sell these common shares is subject to certain limitations, including limitations on the volume of shares that may be sold during a given time period. On August 21, 2019, we filed a Registration Statement on Form F-3, as amended by Post-Effective Amendment No. 1 to Form F-3 on Form S-3, to register the shares of common stock sold to Incyte. As a result, these shares can be freely sold in the public market. In connection with entering into a settlement agreement with Regeneron Pharmaceuticals, we entered into a Share Subscription Agreement with Regeneron, pursuant to which we issued and sold to Regeneron 600,000 of our common shares. Regeneron&#8217;s ability to sell these common shares is subject to certain limitations, including limitations on the volume of shares that may be sold during a given time period. In addition, in connection with entering into the Lilly Collaboration Agreement, we entered into a Lilly Share Subscription Agreement with Eli Lilly, pursuant to which we issued and sold to Eli Lilly 706,834 of our common shares. Eli Lilly&#8217;s ability to sell these common shares is subject to certain limitations, including that Eli Lilly has agreed not to transfer, sell, or otherwise dispose of the shares for a certain period of time following the closing date, subject to certain customary exceptions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then board of directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of our articles of association may make it more difficult for a third party to acquire control of us or effect a change in our board of directors. These provisions include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the authorization of a class of preferred shares that may be issued to a friendly party&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possibility to appoint our board members for staggered terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a provision that our board members may only be removed by the general meeting of shareholders by a two-thirds majority of votes cast representing more than 50% of our outstanding share capital (unless the removal was proposed by the board of directors)&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a requirement that certain matters, including an amendment of our articles of association, may only be brought to our shareholders for a vote upon a proposal by our board of directors.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at 12 February 2021, a bill is pending in Dutch Senate which, if enacted in its current form, would introduce a statutory cooling-off period of up to 250 days during which the general meeting of shareholders would not be able to dismiss, suspend or appoint members of the board of directors (or amend the provisions in the articles of association dealing with those matters) unless those matters would be proposed by the board of directors. This cooling-off period could be invoked by the board of directors in case:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">shareholders, using either their shareholder proposal right or their right to request a general meeting of shareholders, propose an agenda item for the general meeting of shareholders to dismiss, suspend or appoint a member of the board of directors (or to amend any provision in the articles of association dealing with those matters)&#59; or</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">a public offer for the </span><span style="color:#000000;">c</span><span style="color:#000000;">ompany is made or announced without the </span><span style="color:#000000;">c</span><span style="color:#000000;">ompany's support, provided, in each case, that the board of directors believes that such proposal or offer materially conflicts with the interests of the </span><span style="color:#000000;">c</span><span style="color:#000000;">ompany and its business.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cooling-off period, if invoked, ends at occurrence of the earliest of the following events:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the expiration of 250 days from:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in case of shareholders using their shareholder proposal right, the day after the deadline for making such proposal expired&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in case of shareholders using their right to request a general meeting of shareholders, the day when they obtain court authorization to do so&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in case of a hostile offer being made, the first following day&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the day after the hostile offer having been declared unconditional&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the board of directors voluntarily terminating the cooling-off period.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, shareholders representing at least 3% of our issued share capital may request the Dutch Enterprise Chamber of the Amsterdam Court of Appeals for early termination of the cooling-off period. The Dutch Enterprise Chamber of the Amsterdam Court of Appeals must rule in favor of the request if the shareholders can demonstrate that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the board of directors, in light of the circumstances at hand when the cooling-off period was invoked, could not reasonably have come to the conclusion that the relevant shareholder proposal or hostile offer constituted a material conflict with the interests of the company and its business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the board of directors cannot reasonably believe that a continuation of the cooling-off period would contribute to careful policy-making&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if other defensive measures have been activated during the cooling-off period and not terminated or suspended at the relevant shareholders' request within a reasonable period following the request (i.e., no 'stacking' of defensive measures).</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the cooling-off period, if invoked, the board of directors must gather all relevant information necessary for a careful decision-making process. In this context, the board of directors must at least consult with shareholders representing at least 3% of our issued share capital at the time the cooling-off period was invoked and the works council. Formal statements expressed by these stakeholders during such consultations must be published on our website to the extent these stakeholders have approved that publication. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately one week following the last day of the cooling-off period, the board of directors must publish a report in respect of its policy and conduct of affairs during the cooling-off period on our website. This report must remain available for inspection by shareholders and others with meeting rights under Dutch law at our office and must be tabled for discussion at the next general meeting of shareholders.<span style="font-weight:bold;font-style:italic;"> </span> If this legislation passes, this may make it more difficult for a third party or group of third parties to acquire control of us or effect a change in our board of directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our anti-takeover provision may prevent a beneficial change of control.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted an anti-takeover measure pursuant to which our board of directors may, without shareholder approval, issue (or grant the right to acquire) preferred shares. Pursuant to a call option agreement entered into with an independent special purpose foundation, we may issue an amount of preferred shares up to 100% of our issued capital held by third parties immediately prior to the issuance of such preferred shares.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preferred shares will be issued to the foundation for their nominal value, of which only 25% will be due upon issuance. The voting rights of our shares are based on nominal value and as we expect our shares to continue to trade substantially in excess of nominal value, preferred shares issued at nominal value can obtain significant voting power for a substantially reduced price and thus be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a fixed rate. Subject to the foundation exercising its call option under the call option agreement, the board may issue these preferred shares to protect us from influences that do not serve our best interests and threaten to undermine our continuity, independence and identity. These influences may include a third-party acquiring a significant percentage of our common shares, the announcement of a public offer for our common shares, other concentration of control over our common shares or any other form of pressure on us to alter our strategic policies. The foundation&#8217;s articles of association provide that it will act to serve the best interests of us, our associated business and all parties connected to us, by opposing any influences that conflict with these interests and threaten to undermine our continuity, independence and identity. This foundation is structured to operate independently of us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Holders of our common shares outside the Netherlands may not be able to exercise preemptive rights.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of an increase in our share capital, holders of our common shares are generally entitled under Dutch law to full preemptive rights, unless these rights are excluded either by a resolution of the general meeting of shareholders, or by a resolution of the board (if the board has been designated by the general meeting of shareholders for this purpose). Certain holders of our common shares outside the Netherlands, in particular U.S. holders of our common shares, may not be able to exercise preemptive rights unless a registration statement under the Securities Act is declared effective with respect to our common shares issuable upon exercise of such rights or an exemption from the registration requirements is available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a Dutch public company with limited liability (<span style="font-style:italic;">naamloze vennootschap</span>). Our corporate affairs are governed by our articles of association and by the laws governing companies incorporated in the Netherlands. The rights of shareholders and the responsibilities of members of our board may be different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board is required by Dutch law to consider the interests of our company, its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, the interests of our shareholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are not obligated to and do not comply with all the best practice provisions of the Dutch Corporate Governance Code. This may affect the rights of our shareholders.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the Dutch Corporate Governance Code (DCGC). The DCGC contains both principles and best practice provisions for board of directors, shareholders and general meetings of shareholders, financial reporting, auditors, disclosure, compliance and enforcement standards. The DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, including Nasdaq. The principles and best practice provisions apply to our board (in relation to role and composition, conflicts of interest and independence requirements, board committees and remuneration), shareholders and the general meeting of shareholders (for example, regarding anti-takeover protection and our obligations to provide information to our shareholders) and financial reporting (such as external auditor and internal audit requirements). We do not comply with all the best practice provisions of the DCGC. As a result, the rights of our shareholders may be affected and our shareholders may not have the same level of protection as a shareholder in another Dutch public company with limited liability (<span style="font-style:italic;">naamloze vennootschap</span>) listed in the Netherlands that fully complies with the DCGC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims of U.S. civil liabilities may not be enforceable against us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated under the laws of the Netherlands. Most of our assets are located outside the United States. The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. With respect to choice of court agreements in civil or commercial matters, we note that the Hague Convention on Choice of Court Agreements entered into force for the Netherlands, but has not entered into force for the United States. Consequently, a final judgment for payment given by a court in the United&#160;States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit to the Dutch court the final judgment rendered by the U.S. court. If and to the extent that the Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the court of the Netherlands will, in principle, give binding effect to the judgment of the U.S. court, unless such judgment contravenes principles of public policy of the Netherlands or is irreconcilable with a judgement of a Dutch court or foreign court that is acknowledged in the Netherlands. Dutch courts may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Code of Civil Procedure (<span style="font-style:italic;">Wetboek van Burgerlijke Rechtsvordering</span>). As a result of the above, it may not be possible for investors to effect service of process within the United States upon us or members of our board or certain experts named herein who are residents of the Netherlands or countries other than the United States or to enforce any judgments against the same obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As of January 1, 2020, we were no longer a foreign private issuer, and we are required to comply with the provisions of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules of Nasdaq applicable to U.S. domestic issuers, which will continue to require us to incur significant expenses and expend time and resources.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020, we were no longer a foreign private issuer, and we are required to comply with all of the provisions applicable to a U.S. domestic issuer under the Exchange Act, including filing an annual report on Form 10-K, quarterly periodic reports and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current reports for certain events, complying with the sections of the Exchange Act regulating the solicitation of proxies, requiring insiders to file public reports of their share ownership and trading activities and insiders being liable for profit from trades made in a short period of time. We are also no longer exempt from the requirements of Regulation FD promulgated under the Exchange Act related to selective disclosures. We are also no longer permitted to follow our home country&#8217;s rules in lieu of the corporate governance obligations imposed by Nasdaq, and are required to comply with the governance practices required by U.S. domestic issuers listed on Nasdaq. We are also required to comply with all other rules of Nasdaq applicable to U.S. domestic issuers, including that our articles of association specify a quorum of no less than one-third of our outstanding voting common shares for meetings of our common shareholders, the solicitation of proxies and the approval by our shareholders in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control and certain private placements. In addition, we are required to report our financial results under U.S. Generally Accepted Accounting Principles, including our historical financial results, which have previously been prepared in accordance with International Financial Reporting Standards. We expect to continue to incur significant legal, accounting, insurance and other expenses and to expend greater time and resources to comply with these requirements. In addition, we may need to develop our reporting and compliance infrastructure and may face challenges in complying with the new requirements applicable to us.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common shares less attractive to investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act and a smaller reporting company under the rules promulgated under the Exchange Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved, and reduced executive compensation disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. We could be an emerging growth company for up to five years following the initial public offering of our common shares, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our common shares held by non-affiliates exceeds $700&#160;million as of the end of our second fiscal quarter, in which case we would no longer be an emerging growth company as of the fiscal year-end. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common shares held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data or supplemental financial information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be classified as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. investors in our common shares.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the value of our assets, including goodwill, and composition of our income, assets and operations for the taxable year 2020, we do not believe we were a PFIC for U.S. federal income tax purposes for that taxable year. A non-U.S. company generally will be considered a PFIC for any taxable year if (i) at least 75% of its gross income is passive income (including interest income), or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income. The value of our assets generally is determined by reference to the market price of our common shares, which may fluctuate considerably. In addition, the composition of our income and assets is affected by how, and how quickly, we spend the cash we raise. It is possible the Internal Revenue Service could determine that we were a PFIC for the taxable year 2020. If we were to be treated as a PFIC for any taxable year during which a U.S. Holder holds a common share, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder. Once treated as a PFIC, for any taxable year in which a U.S. Holder owns equity in such foreign corporation, a foreign corporation will generally continue to be treated as a PFIC for all subsequent taxable years with respect to such U.S. Holder. If we were to be a PFIC, &#8220;excess distributions&#8221; (as such term is defined in the United States Internal Revenue Code of 1986, as amended (U.S. Tax Code)) to a U.S. Holder, and any gain recognized by a U.S. Holder on a disposition of our <span style="color:#000000;">common </span>shares would be taxed in potentially unfavorable ways. Among other consequences, our dividends would be taxed at the regular rates applicable to ordinary income, rather than the 20% maximum rate applicable to certain dividends received by an individual from a qualified foreign corporation, and, to the extent that they constituted excess distributions, certain interest charges may apply, and gains on the sale of our shares would be treated in the same way as excess </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">distributions</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, the U.S. Holder would be subject to detailed reporting obligations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The tests for determining PFIC status are applied annually and it is difficult to make accurate predictions of future income and assets, which are relevant to the determination of any future PFIC status. As such, we cannot provide any assurances regarding our PFIC status for any past, current or future taxable years. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we cannot provide any assurances that we will furnish to any U.S. Holder information that may be necessary to comply with the aforementioned reporting and tax payment obligations.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our common shares</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including the potential availability and advisability of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an election to treat us as a qualified electing fund </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or a mark-to-market election</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our common shares and is:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a citizen or individual resident of the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an estate, the income of which is subject to U.S. federal income taxation regardless of its source&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a trust that (a) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the U.S. Tax Code or (b) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a U.S. Holder is treated as owning at least 10% of our common shares, such holder may be subject to adverse U.S. federal income tax consequences.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our common shares, such U.S. Holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group (if any) as such term is defined in the Tax Code. A United States shareholder of a controlled foreign corporation may be required to report annually and include in its U.S. taxable income, as ordinary income, its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may extend the statute of limitations with respect to such United States shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether we or any of our future non-U.S. subsidiaries is treated as a controlled foreign corporation or whether such investor is treated as a United States shareholder with respect to any such controlled foreign corporations. Further, we cannot provide any assurances that we will furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax payment obligations. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our common shares. The risk of being subject to increased taxation may deter our current shareholders from increasing their investment in us and others from investing in us, which could impact the demand for, and value of, our common shares.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The price of our common shares may be volatile and may fluctuate due to factors beyond our control.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share price of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">positive or negative results of testing and clinical trials by us, strategic partners or competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in entering into strategic relationships with respect to development and/or commercialization of our antibody candidates or entry into strategic relationships on terms that are not deemed to be favorable to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">technological innovations or commercial product introductions by us or competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in government regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments concerning proprietary rights, including patents and litigation matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">public concern relating to the commercial value or safety of any of our antibody candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">financing or other corporate transactions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">publication of research reports or comments by securities or industry analysts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general market conditions in the pharmaceutical industry or in the economy as a whole&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other events and factors, many of which are beyond our control.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other market and industry factors may cause the market price and demand for our common shares to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their common shares and may otherwise negatively affect the liquidity of our common shares. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not expect to pay cash dividends for the foreseeable future, any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares, which is uncertain.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not paid any cash dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings will be reinvested in our business and that cash dividends will not be paid until we have an established revenue stream to support continuing cash dividends. Payment of any future dividends to shareholders will in addition effectively be at the discretion of the general meeting, upon proposal of the board of directors, after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future cash dividends may be made only if our shareholders&#8217; equity exceeds the sum of our paid-in and called-up share capital plus the reserves required to be maintained by Dutch law or by our articles of association. Accordingly, investors cannot rely on cash dividend income from our common shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. In addition, the low trading volume of our common shares may adversely affect the trading price of our common shares, and our shareholders may not be able to sell their common shares for a price higher than the price they paid for our common shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts publish inaccurate or unfavorable research about our business, the price of our common shares and our trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common shares depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the price of our common shares would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and trading volume to decline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will continue to incur increased costs as a result of operating as a public company with limited liability (naamloze vennootschap), and our management team will be required to devote substantial time to new compliance initiatives and corporate governance practices.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we no longer qualify as an emerging growth company or a smaller reporting company, we will continue to incur significant legal, accounting and other expenses related to our operation as a public company. The Sarbanes-Oxley Act of 2002 (SOX), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market, or Nasdaq, and other applicable securities rules and regulations impose various requirements on reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our board of directors and other personnel will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of SOX (Section&#160;404) we are required to furnish a report by our management on our internal control over financial reporting with our Annual Report on Form 10-K. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To maintain compliance with Section&#160;404, we engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources and have engaged outside consultants and adopted a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to maintain effective internal control over financial reporting as required by Section&#160;404. Material weaknesses in our internal control over financial reporting could also reduce our ability to obtain financing or could increase the cost of any financing we obtain. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES_MERUS_20F">Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease approximately 12,320 square meters of office and laboratory space in Utrecht, the Netherlands. This facility serves as our corporate headquarters and central laboratory facility. The leases for this space expire on October&#160;31, 2021, which we plan to extend through at least 2022. We also entered into a lease for 7,583 square feet of additional office space in Cambridge, Massachusetts, which commenced on April&#160;1, 2019 and has a term of seven years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS_MERUS_20F">Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings, which could be deemed to be material.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Particular legal proceedings are described in Note 10 of the Consolidated Financial Statements appended to this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Market Information and Holders</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded on The Nasdaq Global Market under the symbol &#8220;MRUS.&#8221; Trading of our common stock commenced on May&#160;24, 2016, following the completion of our initial public offering. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, the number of holders of record of our common shares was 5. This number does not include beneficial owners whose shares are held in street name. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not repurchase any of our equity securities during the quarter ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">Item 6. Selected Financial Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.  </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our Consolidated Financial Statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these Consolidated Financial Statements and the notes thereto included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those factors set forth in Part I, Item&#160;1A. &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage oncology company developing innovative antibody therapeutics. Our pipeline of full-length human multispecific antibody candidates are generated from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains, or Fabs, against virtually any target. Each antibody binding domain consists of a target-specific heavy chain paired with a common light chain. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies that bind to a wide range of targets and display novel and innovative biology. These platforms, referred to as Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>, allow us to generate large numbers of diverse panels of bispecific and trispecific antibodies, respectively, which can then be functionally screened in large-scale cell-based assays to identify those unique molecules that possess novel biology, which we believe are best suited for a given therapeutic application. Further, by binding to multiple targets, Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> may be designed to provide a variety of mechanisms of action, including simultaneously blocking receptors that drive tumor cell growth and survival and mobilizing the patient&#8217;s immune response by engaging T cells, and/or activating various killer cells to eradicate tumors.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology platforms employ an assortment of patented technologies and techniques to generate human antibodies. We utilize our patented MeMo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> mouse to produce a host of antibodies with diverse heavy chains and a common light chain that are capable of binding to virtually any antigen target. We use our patented heavy chain and CH3 domain dimerization technology to generate substantially pure bispecific and trispecific antibodies. We also employ our patented Spleen to Screen<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology to efficiently screen panels of diverse heavy chains, designed to allow us to rapidly identify Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> therapeutic candidates with differentiated modes of action for pre-clinical and clinical testing. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform we have produced, and are currently developing, the following candidates: MCLA-128 (zenocutuzumab) for the potential treatment of solid tumors that harbor Neuregulin 1 (NRG1) gene fusions&#59; MCLA-158 for the potential treatment of solid tumors&#59; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors. <span style="Background-color:#FFFFFF;color:#000000;">In 2021, we are planning to commence a clinical trial in the United States for MCLA-129, for the potential treatment of solid tumors, which is also the subject to collaboration and license agreement, which permits Betta Pharmaceuticals Co. Ltd. (Betta) to exclusively develop MCLA-129 in China, while Merus retains full ex-China rights</span>. Furthermore, we have a pipeline of proprietary antibody candidates in pre-clinical development and intend to further leverage our Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform to identify multiple additional antibody candidates and advance them to clinical development. Further, Merus is developing its next generation Triclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> technology, and has pre-clinical trispecific antibody candidates capable of simultaneously binding three targets at once.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Funding Our Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage company and have not generated any revenue from product sales. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our antibody candidates from discovery through pre-clinical development and into clinical trials and seek regulatory approval and pursue commercialization of any approved antibody candidate. In addition, if we obtain regulatory approval for any of our antibody candidates, if appropriate, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that we will require additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations, business development and licensing opportunities with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical companies&#8217; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms. See &#8220;Impact of COVID-19 Pandemic&#8221; below and &#8220;Risk Factors&#8212;The COVID-19 pandemic caused by the novel coronavirus has and may continue to adversely impact our business, including our pre-clinical studies and clinical trials, financial condition and results of operations.&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. Our inability to raise capital as and when needed would have a negative impact </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, we expect that our existing cash, cash equivalents and marketable securities of $207.8 million as of December&#160;31, 2020, combined with the aggregate immediate proceeds from the closing of the collaboration and license agreement and share purchase agreement with Eli Lilly and Company (Eli Lilly) in January 2021 of $60.0 million and the aggregate net proceeds from a follow-on offering of $129.7 million in January 2021, will fund our operations at least into the second half of 2024.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Programs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Zenocutuzumab, or &#8220;Zeno&#8221; (MCLA-128: HER3 x HER2 Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NRG1 gene fusion (NRG1+) Cancers: Phase 1/2 eNRGy trial clinical data and program update planned for Q2 2021</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to enroll patients in the Phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. We plan to present efficacy and safety data from the eNRGy trial and Early Access Program (EAP) at the 2021 American Society of Clinical Oncology Annual Meeting, with results on more than 30 patients with NRG1+ pancreatic, non-small cell lung and other cancers across the eNRGy trial and EAP&#160;&#160;with the opportunity for four or more months of follow up. At that time, we plan to also discuss details of the program and overall strategy.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zeno is currently in the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. We believe that Zeno continues to demonstrate encouraging single agent activity in NRG1+ cancers and has been observed to be well tolerated, consistent with previously reported safety data in the overall patient population treated with Zeno monotherapy. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, Zeno was granted Orphan Drug Designation by the U.S. FDA for pancreatic cancer and in January 2021, Fast Track Designation for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions that have progressed on standard-of-care therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MCLA-158 (Lgr5 x EGFR Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>): Solid Tumors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1 trial continues: dose expansion in patients with gastro-esophageal and head-and-neck cancers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing MCLA-158 for the potential treatment of solid tumors. Our phase 1 clinical trial of MCLA-158 is ongoing in the dose expansion phase. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 15, 2021, we presented in a poster session interim clinical data from the phase 1 dose escalation study of MCLA-158 at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium. As of a data cut-off of September 2020, MCLA-158 was administered to 33 patients over 11 dose levels (5-1500 mg, flat dose), a heavily pretreated population having received a median of four lines of prior therapy. As of the cut-off date, MCLA-158 was observed to be well tolerated, and no dose limiting toxicities occurred. The recommended phase 2 dose was established at 1500 mg administered intravenously once every two weeks. Enrollment of patients with gastro-esophageal and head-and-neck cancers continues at this dose in the expansion phase of the open-label, multicenter trial, and preliminary evidence of antitumor activity has been observed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MCLA-145 (CD137 x PD-L1 Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>): Solid Tumors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1 trial advancing with clinical update planned for 2H 2021</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCLA-145 is currently being evaluated in a phase 1 open-label, multicenter dose escalation study, including a safety dose expansion phase, in patients with solid tumors. MCLA-145 is the first drug candidate co-developed under our global collaboration and license agreement with Incyte Corporation (Incyte), which permits the development and commercialization of up to 11 bispecific and monospecific antibodies from our Biclonics&#174; platform. Merus retains full rights to develop and commercialize MCLA-145, if approved, in the United States, and Incyte is responsible for its development and commercialization outside the United States. We plan to present a clinical update at a major medical conference in the second half of 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MCLA-129 (EGFR x c-MET Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>): Solid Tumors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">First patient planned to be dosed in 2021</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to evaluate MCLA-129 in a phase 1 open-label, multicenter dose escalation study, including a safety dose expansion phase, for the treatment of various solid tumors, with a plan to dose a first patient in the United States in 2021. MCLA-129 is subject to collaboration and license agreement, which permits Betta Pharmaceuticals Co. Ltd. (Betta) to exclusively develop MCLA-129 in China, while Merus retains full ex-China rights.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, Betta announced that the Chinese National Medical Products Administration had accepted its Investigational New Drug application of MCLA-129 injection</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-style:italic;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19 Pandemic </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current <span style="color:#000000;">COVID</span>-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities, clinical trial sites and business operations, as well as the U.S. and Dutch economies and international financial markets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are currently continuing our ongoing clinical trials, the COVID-19 pandemic and related precautions have directly or indirectly impacted enrollment, new, planned clinical trial site openings, patient visits, and on-site monitoring of our clinical trials <span style="color:#000000;">and source verification of clinical data required for presentation of clinical data</span> for zenocutuzumab, MCLA-158 and MCLA-145, our conclusion of the MCLA-117 trial, and anticipated commencement of the clinical trial for MCLA-129. We have observed a moderate to high impact on clinical trial enrollment and operations as a consequence of the COVID-19 pandemic during the fourth quarter ended December 31, 2020, particularly at sites in countries not yet open to recruitment, and to a lesser extent in countries where COVID-19 related restrictions have been eased, with adjustments made to allow remote visits for some patient follow-up, and reduced onsite monitoring by the sponsor or contract research organization (CRO). <span style="color:#000000;">As a result of the COVID-19 pandemic, we may experience further disruptions that could severely impact our business, preclinical studies and clinical trials. </span>The extent of the impact to our overall clinical development timeline is uncertain at this time and we continue to monitor and assess the COVID-19 pandemic on a regular basis.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the COVID-19 pandemic, certain of our CROs and third-party suppliers, as well as collaborators in the U.S. and China that are developing or collaborating with us to develop certain of our pre-clinical and clinical-stage antibody candidates have been affected. As a result of such impact, we may face difficulties with and delays in performance of certain chemistry manufacturing and controls and testing associated with our clinical candidates<span style="color:#000000;">, including as it relates to sourcing materials required for such manufacture that may be diverted for other purposes associated with COVID-19, or difficulties or delays associated with testing of our pre-clinical antibody candidates associated with our collaborations with Incyte, Eli Lilly and Simcere, which may delay or prevent their potential clinical development</span>. While we currently do not anticipate any interruptions in our clinical trial supply of drug candidates, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our third-party suppliers and contract manufacturing partners' ability to manufacture our clinical trial supply or source materials necessary for their manufacture.<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the spread of COVID-19, on March 18, 2020, we temporarily suspended our laboratory research activities at our facilities in Utrecht, the Netherlands to help secure the safety of our employees and to adhere to government recommendations of social distancing and limited public exposure in connection with the COVID-19 pandemic. We have since re-opened our offices and laboratory in Utrecht, maintaining social distancing and imposing other requirements consistent with government guidance. Further, <span style="color:#000000;">we have recommended our employees in the U.S. and Netherlands work from home when possible and for those employees working at our offices and laboratory in Utrecht and offices in Cambridge Ma., they are required to maintain social distancing and follow requirements consistent with the guidance provided by the CDC, Federal, state and local regulations for the U.S. and RIVM for the Netherlands. While we use reasonable business practices to mitigate the risk of exposure to COVID-19 while on company-operated premises, we cannot guarantee that traveling to and from and visiting the office will not expose employees to infectious agents or eliminate inherent risks to our workforce and our business operations resulting from COVID-19. Given the uncertainty caused by the COVID-19 pandemic we cannot be certain that we will not suspend our laboratory research activities at our facilities or suspend use of our offices in the future.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, there is significant uncertainty caused by the COVID-19 pandemic and impact of related responses. The future impact of COVID-19 on our business and clinical trials will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the Netherlands, the United States and other countries, business closures or business disruptions, the ultimate impact of COVID-19 on financial markets and the global economy, and the effectiveness of actions taken in the Netherlands, the United States and other countries to contain and treat the disease. See &#8220;Risk Factors&#8212;The COVID-19 pandemic caused by the novel coronavirus has and may continue to adversely impact our business, including our pre-clinical studies and clinical trials, financial condition and results of operations.&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaborations and Other Revenue Generating Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Item&#160;1, &#8220;Business<span style="font-size:12pt;">&#8212;</span>Our Collaborations&#8221; and Note 12, &#8220;Collaborations,&#8221; of the notes to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for a description of the key terms of our arrangements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations for the Years Ended December&#160;31, </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a comparison of collaboration revenue for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,580</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,831</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,437</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,237</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-95.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,163</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,083</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192.9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,348</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,405</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-4.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(215</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-100.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,133</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,190</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-3.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue from each collaboration partner consists of revenue recognized from the amortization of deferred revenue related to upfront payments for licenses or options to obtain licenses in the future, research and development services reimbursement revenue earned and milestone payments earned under collaboration and license agreements with our collaboration partners.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue for the year ended December&#160;31, 2020 decreased $1.4 million as compared to the year ended December&#160;31, 2019, primarily as a result of a decrease of $4.1 million in Ono milestone revenue due to the achievement of milestones in 2019 that did not recur in 2020, partially offset by an increase in Betta milestone revenue due to a $2.0 million earned in the fourth quarter. The change in exchange rates did not materially impact collaboration revenue.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we have total deferred revenue of $99.9 million, which primarily relates to the upfront payment received under our Incyte collaboration agreement and is expected to be recognized over the next five years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a comparison of operating expenses for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,040</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,680</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,360</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,781</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,110</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,821</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,790</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,031</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs consist principally of the costs associated with our research and development activities, conducting pre-clinical studies and clinical trials, and activities related to our regulatory filings. Our research and development expenses consist of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>salaries for research and development staff and related expenses, including share-based compensation expenses&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>expenses incurred under agreements with contract research organizations (CROs) contract manufacturing organizations, and consultants that conduct and support clinical trials and pre-clinical studies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs to develop product candidates, including raw materials and supplies, product testing, and facility related expenses&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note that we do not allocate employee-related costs, depreciation, rental and other indirect costs to specific research and development programs because these costs are deployed across multiple programs under research and development and, as such, are separately classified as unallocated research and development expenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense for the year ended December&#160;31, 2020 increased $14.4 million as compared to the year ended December&#160;31, 2019, primarily as a result of an increase in manufacturing related costs, and higher pre-clinical research and development-related costs related to our programs, particularly increases in costs for zenocutuzumab, and a $2.0 million milestone earned by Betta incurred in the fourth quarter, offset by decreases in costs for MCLA-145.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our development programs progress, as we continue to support the clinical trials of our antibody candidates as treatments for various cancers and as we move these candidates into additional clinical trials. There are </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">numerous factors associated with the successful commercialization of any of our antibody candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control may impact our clinical development programs and plans.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, intellectual property, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses and professional fees for auditing, tax and legal services, including intellectual property and general legal services. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense for the year ended December&#160;31, 2020 increased <span style="font-size:12pt;">$1.7 million</span> as compared to the year ended December&#160;31, 2019, primarily as a result increases in stock-based compensation, insurance, facilities, intellectual property related costs and other items, partially offset by a decrease in consulting and personnel costs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect general and administrative expenses to increase as we grow as a company, driven by the need to support a growing workforce, engaging in financing transactions, establishing and maintaining our intellectual property rights, fulfilling our compliance requirements as a public company and related legal costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a comparison of other income, net, for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,889</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-84.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (losses) gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,432</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,615</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,047</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-684.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income and gains</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-100.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,132</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,832</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-346.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net consists of<span style="color:#000000;"> interest earned on our cash and cash equivalents held on account, accretion of investment earnings and net foreign exchange gains or losses on our foreign denominated cash, cash equivalents and marketable securities.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Tax Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a comparison of income tax expense for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">625</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120.8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159.3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to income taxes in the Netherlands and the U.S. Our current and deferred tax provision represents taxable income attributed to our U.S. operations as a consequence of allocating income to that jurisdiction. No current or deferred provision for income taxes has been made for income taxes in the Netherlands due to losses for tax purposes. Further, given a history of losses in the Netherlands, no deferred tax assets in excess of deferred tax liabilities are recognized as it is not more likely than not that they will be recovered.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss for the year ended December&#160;31, 2020 was $85.5 million, compared to $55.2 million for the year ended December&#160;31, 2019. The increase in net loss was primarily due to the decrease in collaboration revenue and increases in research and development and general and administrative expenses discussed above.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash requirements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We require external sources of financing to fund our operations. Since inception through December 31, 2020, we have raised an aggregate of $566.9 million, of which $125.4 million was non-equity funding through our collaboration agreements, $330.8 million was from the sale of common shares and $110.7 million was from private funding sources prior to our initial public offering. As of December&#160;31, 2020, we had $207.8 million in cash, cash equivalents and marketable securities that are available to fund our current and future operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our existing cash, cash equivalents and marketable securities, we may receive research and development co-funding and are eligible to earn a significant amount of milestone payments under our collaboration agreements. Our ability to earn these payments and the timing of earning these payments is dependent upon the outcome of our research and development activities and is uncertain at this time. Our collaboration and license agreements may require payment of milestones to third parties contingent on future events.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity or debt financings, collaboration arrangements and government grants. Except for any obligations of our collaborators to make license, milestone or royalty payments under our agreements with them, and government grants, we do not have any committed external sources of liquidity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our shareholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common shareholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to raise any additional funds that may be needed through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product candidate development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary uses of capital are: clinical trial costs, third-party research and development services, personnel, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. Because our product candidates are in various stages of clinical and pre-clinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. In addition, our expenditures as reported in our financial statements may be expected to be variable due to that uncertainty. We enter into contracts in the normal course of business with CROs for clinical and pre-clinical research studies, external manufacturers for product candidates for use in our clinical trials, and other research supplies and other services as part of our operations. These contracts generally provide for termination on notice, and therefore are cancelable contracts and are not contractual obligations. Our material contractual obligations, if any, are described elsewhere in this Annual Report on Form 10-K, including Notes 9 and 10 of the attached Consolidated Financial Statements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash, cash equivalents and marketable securities as of December&#160;31, 2020, combined with the aggregate immediate proceeds from the closing of the collaboration and license agreement and share purchase agreement with Eli Lilly in January 2021 of $60.0 million and the aggregate net proceeds from the January 2021 follow-on offering of $129.7 million will be sufficient to fund our planned operating expenses and capital expenditure requirements into at least the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, particularly as the process of testing product candidates in clinical trials is costly and the timing of progress in these trials is uncertain. As a result, we could use our capital resources sooner than we expect.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sources and uses of cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of cash flows for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,901</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,048</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,853</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,486</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,172</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,658</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-106</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,520</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,232</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,712</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-47</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in operating cash </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the year ended December&#160;31, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increased </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.9 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as compared to the year ended December 31, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">primarily</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> o</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perating cash receipts related to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> collaboration</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> arrangements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (upfront payments, milestones, and research and development reimbursements)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decreas</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.9 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, operating cash out flows related to operating expenses</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and taxes</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increas</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12.7 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">flows related to other income increas</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.2 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2020 decreased $25.7 million as compared to the year ended December&#160;31, 2019, primarily as a result of the decrease in net cash inflows from the maturity of debt&#160;securities used to fund current operations of $27.0 million offset by the decrease in purchases of property, equipment and intangibles of $1.3 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2020 decreased $34.7 million as compared to the year ended December&#160;31, 2019, primarily as a result of the decrease in receipt of proceeds from our equity issuances of $36.1 million offset by increases in proceeds received from option exercises of $1.4 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Management</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our objective in managing our cash resources (cash, cash equivalents, and marketable securities) is to safeguard Merus&#8217; ability to continue as a going concern and to minimize the cost of capital to provide returns for shareholders and benefits for other stakeholders. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once we receive a source of financing, our cash resources are invested to preserve capital as a primary goal, and to derive some return as a secondary consideration. Cash and cash equivalents include deposits and investments held with financial institutions with an original maturity date of less than three months. Marketable securities include commercial paper, securities issued by several public corporations and the U.S. Treasury with a maturity date of greater than three months at the date of settlement. Cash and cash equivalents are held at banks and financial institutions with credit ratings varying between A and AAA, while investments are in highly rated vehicles with identical credit ratings.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our invested cash resources are deployed to achieve our operating objectives in furthering our programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our accounting policies are more fully described in Note 2 to our Consolidated Financial Statements included elsewhere in the Annual Report on Form 10-K. As disclosed in Note 2, the preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ significantly from those estimates. We believe that the following discussion addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require management&#8217;s most difficult, subjective and complex judgments on material matters. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant judgement is required in applying our accounting policies concerning revenue recognition. Our collaboration arrangements may be subject to the scope of many accounting standards in addition to the standards applicable to revenue from contracts with customers, including whether all or part of the arrangement may be a collaboration arrangement as defined in the accounting standards or whether financial instruments exchanged in the same arrangement may be subject to other guidance. Such matters may impact the initial recognition, subsequent accounting and disclosures concerning the arrangement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration arrangements typically include a license to our intellectual property and significant judgement is applied in determining whether the particular license is distinct from other performance obligations in the arrangement. We consider whether the counterparty may be able to utilize the license in the absence of the provision of other performance obligations by us. Each collaboration features unique terms to a license and the provision of other performance obligations also varies. Such considerations impact the timing of recognition of consideration allocated to performance obligations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key estimate in the application of our revenue recognition policy concerns the method of recognition of revenue over time as performance obligations are completed. Methods may include an input-based, output-based or other rational allocation method. Such estimates are often derived from expectations on the outcome of research and development activities which are subject to uncertainty. Changes in these estimates impact the timing of revenue recognition. These estimates have not materially changed in the periods presented in our Consolidated Financial Statements. For example, with respect to the license and related activities performance obligation of the Incyte collaboration arrangement recognized as revenue over time as access to the platform for the generation of potential product candidates is provided to the customer, an increase of one year in the estimate as of January 1, 2020 would have decreased revenue recognized for the year ended December 31, 2020 by approximately $2.5 million, excluding the effects of foreign exchange translation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expense for stock-based compensation for options granted to employees is typically determined based on the grant-date fair value of those options. The grant date fair value is derived from the use of valuation models which are commonly used. These valuation models use inputs which require estimates that are reflective of future expectations including the forward expected risk-free interest rate, volatility of our shares, and the expected exercise behavior of employees. We employed the Black Scholes option pricing model to value its stock options for the year-ended December 31, 2020, and a Hull-White option pricing model in prior years. While historical averages may be indicative of future expectations, such assumptions may or may not be accurate. Significant judgement must be employed to derive reasonable estimates in determining the grant-date fair value.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimates involved in the valuation of stock-based compensation have not materially changed in the periods presented in our Consolidated Financial Statements, as disclosed in Note 13 under the subheading of &#8220;<span style="font-style:italic;">Stock Option Valuation</span>&#8221;. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The actual weighted-average grant-date fair value of options granted for the year ended December 31, 2020 was $11.75. While valuation inputs in the valuation models employed may be interdependent, as an example, an increase of one year in the expected exercise behavior of employees would have increased the weighted-average grant-date fair value of options granted for the year ended December 31, 2020 to $12.34. Similarly, an increase of 1% in the estimated volatility of our shares would increase the weighted-average grant-date fair value of options granted for the year ended December 31, 2020 to $11.84. We granted 1,258,341 options for the year ended December 31, 2020, and we recognize compensation expense based on the grant-date fair value on a straight-line basis over the requisite service period of the awards, generally from the date of grant through each vesting date. Options granted generally vest over four years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our evaluation of our ability to continue as a going concern requires us to evaluate our future sources and uses of cash sufficient to fund our currently expected operations in conducting research and development activities one year from the date our financial statements are issued. We evaluate the probability associated with each source and use of cash resources in making our going concern determination. The research and development of pharmaceutical products is inherently subject to uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of pending and recently adopted accounting pronouncements, see Note 2 to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable as a Smaller Reporting Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item&#160;9A. Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations on Effectiveness of Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive and financial officer, has evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15(e) and 15d-15(e) under the Exchange Act). Based on such evaluation, our principal executive and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control - Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Attestation Report of the Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for "emerging growth companies."</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None<span style="font-size:12pt;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Biographical Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anand Mehra, M.D., age 45, <span style="font-weight:normal;">has served as a non-executive director of our board since August 2015 and as Chairman of our board of directors effective since June 2020. Dr. Mehra held various positions at Sofinnova Investments (f.k.a. Sofinnova Ventures) from 2007 to January 2020, most recently holding the position of a managing general partner, where he focused on working with entrepreneurs to build drug development companies. He led the firm&#8217;s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc. (&#8220;Aclaris&#8221;), and Spark Therapeutics. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan&#8217;s private equity and venture capital group and as a consultant at McKinsey &#38; Company. He currently serves as a member of the board of directors of the publicly held Aclaris. Within the past five years, he also served on the boards of directors of the publicly held pharmaceutical companies Marinus Pharmaceuticals, Inc., Spark Therapeutics, Inc. and Aerie Pharmaceuticals. Dr. Mehra received a B.A. degree in political philosophy from the University of Virginia and an M.D. degree from Columbia University&#8217;s College of Physicians and Surgeons. We believe that Dr. Mehra&#8217;s extensive experience in the life science industry, his service on the board of directors of other public life science companies and his extensive leadership experience qualify him to serve on our board of directors. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mark Iwicki, age 54, <span style="font-weight:normal;">has served as a non-executive director of our board of directors since June 2015. From June 2015 until July 2018, Mr. Iwicki served as the Chairman of our board of directors. Mr. Iwicki currently serves as the Chairman and Chief Executive Officer of Kala Pharmaceuticals, Inc., a pharmaceutical company, where he has been employed since April 2015. From February 2014 to November 2014 Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics. From December 2012 to January 2014, Mr. Iwicki served as President and Chief Executive Officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr. Iwicki served in several roles, including Chief Commercial Officer, President and Chief Operating Officer and Director and Chief Executive Officer at Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Iwicki held executive positions, including Vice President and Business Unit Head, at Novartis Pharmaceuticals Corporation, a pharmaceutical company. Mr. Iwicki currently serves on the board of directors of Akero Therapeutics, Inc., Pulmatrix, Inc., Kala Pharmaceuticals, Inc. Within the past five years, he also served on the board of directors of the publicly held pharmaceutical company Aimmune Therapeutics Inc. Mr. Iwicki received a B.A. in business administration from Ball State University and an M.B.A. from Loyola University.</span><span style="Background-color:#FAF9F8;font-size:6.5pt;font-family:Arial;font-weight:normal;"> </span><span style="font-weight:normal;">We believe that Mr. Iwicki is qualified to serve on our board of directors due to his leadership, commercial and business experience in the biotechnology industry and breadth and knowledge about our business as well as his tenure as CEO and independent director in several publicly traded biotechnology companies.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Len Kanavy,<span style="font-weight:normal;"> </span>age 59,<span style="font-weight:normal;"> has served as a non-executive director of our board of directors since July 2018. Mr. Kanavy most recently served as Senior Vice President, Commercial Business Operations at Genentech, a biotechnology company, from September 2006 to September 2016, where he was responsible for strategic decisions for the U.S. commercial business, including product launches, valuation of business development opportunities, clinical development plan options and pricing. From 2014 to 2016, he was a board member of the Genentech Access to Care Foundation. Prior to joining Genentech, Mr. Kanavy was Vice President, Commercial Operations at Novartis Pharmaceuticals, where he led teams in business analytics, strategy, and product launches. Mr. Kanavy holds a B.S. in Business Administration and an M.B.A. with a specialization in Finance from the University of Scranton. We believe that Mr. Kanavy is qualified to serve on our board of directors due to his leadership, business development and commercial experience in the biotechnology industry.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Bill Lundberg, M.D., age 57, <span style="font-weight:normal;">has served on our board of directors since June 2019 and as an executive director since December 2019. Since December 2019, Dr. Lundberg has served as our President, Chief Executive Officer and Principal Financial Officer. From January 2015 to February 2018, Dr. Lundberg was Chief Scientific Officer of CRISPR Therapeutics AG (&#8220;CRISPR&#8221;), a biotechnology company, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR&#8217;s first CRISPR-based product from inception to regulatory filing for clinical trials. From February 2011 to January 2015, Dr. Lundberg was Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc. (&#8220;Alexion&#8221;), where he oversaw research and development from discovery through early-stage development, and prior to that, he was Director and Chief Medical Officer of Taligen Therapeutics, Inc. (&#8220;Taligen&#8221;), a biotechnology company, which was acquired by Alexion in 2011. Prior to Taligen, he held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus/Antisoma, Wyeth (now Pfizer), and Genzyme. Dr. Lundberg currently serves on the board of directors of Vor Biopharma. Dr. Lundberg received an M.D. from Stanford University and M.B.A. from the University of Massachusetts. He completed post-doctoral training at the Whitehead Institute/MIT, and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute. We believe that Dr. Lundberg is qualified to serve on our board of directors due to his experience in the field of medicine, clinical drug development, scientific experience, leadership and business experience.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gregory D. Perry</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, age 60, </span><span style="font-weight:normal;">has served as a non-executive director of our board of directors since May 2016 and Vice Chairman of our board of directors since August 2018. Mr. Perry has served as the Chief Financial Officer at Finch Therapeutics Group, a microbiome therapeutics company, since May 2018. Mr. Perry served as the Chief Financial and Administrative Officer of Novelion Therapeutics Inc., a biopharmaceutical company (&#8220;Novelion&#8221;), from November 2016 to December 2017. Prior to Novelion, Mr. Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc., a biopharmaceutical company from July 2015 until its merger with Novelion in November 2016. </span><span style="font-weight:normal;">Prior to that, he served as Chief Financial </span><span style="font-weight:normal;">and Business Officer of Eleven Biotherapeutics, Inc., now Sensen Bio, a fusion-protein therapeutics company, from January 2014 to June 2015. Prior to that, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics Holdings Corp. , a biomaterials and biotechnology company, from September 2013 to December 2013, and prior to that he served as Senior Vice President and Chief Financial Officer of ImmunoGen, Inc., a biotechnology company, from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role he held until 2013. Before that, he was he was the Chief Financial Officer of Elixir Pharmaceuticals and, prior to that Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Since February 2018, Mr. Perry has served on the board of directors of Kala Pharmaceuticals, including as chair of its audit committee. From December 2011 to February 2016, Mr. Perry served on the board of directors of Ocata Therapeutics, including as chair of its audit committee and a member of its compensation committee, until it was acquired by Astellas Pharma Inc. Mr. Perry received a B.A. in Economics and Political Science from Amherst College. We believe that Mr. Perry is qualified to sit on our board of directors based on his financial experience, leadership and business experience and breadth and knowledge about our business. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Paolo Pucci, age 59, <span style="font-weight:normal;">has served as a non-executive director of our board of directors since June 2020.&#160;&#160;Mr. Pucci served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology company engaged in the research and development of targeted therapeutics, from June 2008 until its acquisition by Merck in January 2020. Prior to joining ArQule, Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities including President of the Oncology &#38; Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci earned an MS in economics and accounting from Universit&#224; degli Study di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. Within the past five years, Mr. Pucci previously served on the boards of directors of Algeta ASA, until its acquisition by Bayer AG, and Dyax Inc., until its acquisition by Shire Plc (which was subsequently acquired by Takeda Pharmaceutical Company Ltd.), New Link Genetics Inc and ArQule Inc., until its acquisition by Merck Inc. He currently serves on the boards of directors of publicly held life sciences companies West Pharmaceuticals Services, Inc., Replimmune Group Inc., and Trillium Therapeutics Inc. We believe that Mr. Pucci is qualified to serve on our board of directors due to his leadership, international business and biotechnology experience in large multinational pharmaceutical corporations as well as his tenure as CEO and independent director in several publicly traded biotechnology companies.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Victor Sandor, M.D.C.M.,<span style="font-weight:normal;"> </span>age 54,<span style="font-weight:normal;"> has served as a non-executive director of our board of directors since June 2019. From September 2014 to December 2019, Dr. Sandor was the Chief Medical Officer at Array BioPharma (&#8220;Array&#8221;), a pharmaceutical company, where he oversaw clinical development through regulatory approval of Braftovi and Mektovi for the treatment of BRAFV600E/K mutant melanoma and Braftovi for the treatment of BRAFV600E mutant colorectal cancer. Prior to joining Array, from February 2010 to September 2014, he was Senior Vice President for Global Clinical Development at Incyte Corporation (&#8220;Incyte&#8221;), a pharmaceutical company, where he oversaw clinical development through regulatory approval of Jakafi for the treatment of myelofibrosis and polycythemia vera. Prior to joining Incyte, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec and, prior to that held positions of increasing responsibility in oncology product development at AstraZeneca, where he played a lead role in the registration of Arimidex(r) (anastrozole) for adjuvant use and the development of early stage programs through proof-of-concept. Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.</span><span style="Background-color:#FAF9F8;font-size:6.5pt;font-family:Arial;font-weight:normal;"> </span><span style="font-weight:normal;">He currently serves on the boards of directors of publicly held life sciences companies ADC Therapeutics and Prelude Therapeutics. We believe that Dr. Sandor is qualified to serve on our board of directors due to his experience in the field of medicine, clinical drug development and scientific experience.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information About Our Executive Officers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Joe, M.D., age 55, <span style="font-weight:normal;">has served as our Chief Medical Officer since July 2020.&#160;&#160;His responsibilities include overseeing clinical and regulatory strategy and activities at Merus. He brings over 20 years of experience in clinical drug development and translational research within industry and academic medicine. Dr. Joe most recently led the immuno-oncology program at Sanofi, which included co-development of LIBTAYO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (cemiplimab-rwlc) with Regeneron in skin, lung and other cancers. Previously at Merck Sharp &#38; Dohme Corp., he led the KEYTRUDA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pembrolizumab) New Indications Development Team in obtaining the first tumor/histology-agnostic drug approval in Microsatellite Instability-High (MSI-H) cancer, and the first immuno-oncology drug approval in a gynecological malignancy (cervical cancer). Dr. Joe also played key roles at Novartis in the global approval of Zykadia<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (ceritinib) in ALK-positive lung cancer and at Roche in the global approval of ZELBORAF<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (vemurafenib) in BRAF-mutant metastatic melanoma. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;">Dr. Joe is an Assistant Professor of Medicine at Columbia University Irving Medical Center. He received</span><span style="font-weight:normal;"> </span><span style="font-weight:normal;">B.S. degrees in chemistry and </span><span style="font-weight:normal;">b</span><span style="font-weight:normal;">iology from the Massachusetts Institute of Technology and an M.D. from the Mount Sinai School of</span><span style="font-weight:normal;"> </span><span style="font-weight:normal;">Medicine.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alexander ("Lex") Berthold Hendrik Bakker, Ph.D., age 54,<span style="font-weight:normal;"> has served as our Chief Development Officer since October 2010. His responsibilities include strategic scientific leadership, management of pre-clinical and clinical development and manufacturing, business development support, external collaboration and partnership management. Prior to joining Merus, Mr. Bakker directed pre-clinical and clinical development at Crucell N.V., a biotechnology company. Mr. Bakker holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cornelis Adriaan ("John") de Kruif, Ph.D., age 57,<span style="font-weight:normal;"> has served as our Chief Technology Officer since January 2013 and previously served as our Chief Scientific Officer from April 2007 to January 2013. His responsibilities include management of antibody discovery, antibody platform technology development, antibody engineering, external collaborations, partnerships management and operational activities. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company, specializing in vaccines and biopharmaceutical technology. Mr. de Kruif holds a Ph.D., in Antibody Engineering from Utrecht University.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Hui Liu, Ph.D., age 48,<span style="font-weight:normal;"> has served as our Chief Business Officer since December 2015 and Head of Merus U.S. since October 2018. His responsibilities include business development, alliance management, product strategy, finance and Merus operations in the U.S. Prior to joining Merus, Dr. Liu served as Vice President and Global Head, Business Development &#38; Licensing, Oncology, from 2013 to 2015, and as Vice President and Global Head, Business Development &#38; Licensing, Vaccines &#38; Diagnostics, from 2009 to 2012, at Novartis AG. Prior to Novartis, Dr. Liu held positions of increasing responsibilities in business development at Pfizer, Inc. from 2004 to 2009 and in the R&#38;D organization at Pfizer and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004, Dr. Liu was an investment banker at Goldman Sachs and Citigroup. Dr. Liu holds a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Peter B. Silverman, J.D., age 43, <span style="font-weight:normal;">has served the Company since 2014, first as outside counsel, Head of Utrecht since April 2020, General Counsel since February 2018 and our Chief Intellectual Property Officer and Head of US Legal since February 2017. His responsibilities include all aspects of the Company&#8217;s legal and intellectual property matters, and he provides significant contributions to the Company&#8217;s management and operations of the headquarters in Utrecht. Prior to joining Merus, Mr. Silverman was a Partner at Kirkland &#38; Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters and technologies. Mr. Silverman was an associate at Kaye Scholer LLP (now Arnold &#38; Porter Kaye Scholer LLP), and prior to that Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law, graduating magna cum laude and Order of the Coif. He is admitted to practice law in New York. Mr. Silverman also holds a B.A. in biology from the University of Rochester.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Code of Ethics</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of our Code of Business Conduct and Ethics on our website at www.merus.nl in the &#8220;Investors &#38; Media&#8221; section under &#8220;Corporate Governance.&#8221; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq&#8217;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above. The information contained on our website is not incorporated by reference into this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining information required by this Item 10 will be included in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 will be included in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 will be included in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 will be included in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 14. Principal Accoun</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ting Fees and Services. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 will be included in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, and Financial Statement Schedules. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.33%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following Report and Consolidated Financial Statements of the Company are included in this Annual Report on Form 10-K:<br /> </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
</td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;">Index to Consolidated Financial Statements</span></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:91.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:7.1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:85.5pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_OF_IND_REG_PUBLIC_ACCT"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:7.1%; border-top:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:85.5pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:85.5pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:85.5pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:85.5pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:85.5pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements and Schedules.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.33%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because the required information is either presented in the consolidated financial statements or the notes thereto or is not applicable or required. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits.</p></td></tr></table></div>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:13.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:13.61%;text-indent:-0.28%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:40.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="10" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference to</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filings Indicated</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:40.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Description</p></td>
<td valign="bottom" style="width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:8.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Articles of Association and By-Laws</p></td>
<td colspan="4" valign="middle" style="width:8.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;3.1</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0066CC;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312519308317/d844194dex3.htm"><span style="text-decoration:underline;">Articles of Association of Merus N.V., as amended on December 5, 2019 </span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-K</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/6/19</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:42.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Instruments Defining the Rights of Security Holders</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.1</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mrus-ex41_15.htm"><span style="text-decoration:underline;">Description of Securities</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.2</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516606452/d326237dex41.htm"><span style="text-decoration:underline;">Registration Rights Agreement, dated May&#160;24, 2016, by and among the Registrant and the shareholders party thereto</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-K</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/27/16</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.3</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518047493/d539820dex992.htm"><span style="text-decoration:underline;">Registration Rights Agreement, dated February 13, 2018, by and among the registrant and the Investors identified on Exhibit A attached thereto</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-K</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.2</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/15/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.4</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518047493/d539820dex991.htm"><span style="text-decoration:underline;">Securities Purchase Agreement, dated February 13, 2018, by an among the registrant and the Investors identified on Exhibit A attached thereto</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-K</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/15/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="top" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:8.52%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="top" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Material Contracts &#8211; Management Contracts and Compensation Plans</p></td>
<td colspan="4" valign="middle" style="width:8.52%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.1</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex41.htm"><span style="text-decoration:underline;">Merus N.V. 2010 Employee Option Plan, as amended</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.2</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex42.htm"><span style="text-decoration:underline;">Merus N.V. 2016 Incentive Award Plan and forms of award agreements thereunder, as amended</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.3</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000156459020037712/mrus-ex101_38.htm"><span style="text-decoration:underline;">Merus N.V. Non-Executive Director Compensation Program</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/20</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.4</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex104.htm"><span style="text-decoration:underline;">Form of Board of Directors Indemnification Agreement</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1/A</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/16</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.5</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000156459020037712/mrus-ex104_70.htm"><span style="text-decoration:underline;">Employment Agreement, dated July 2, 2020, by and among Merus US, Inc., the Registrant and Andrew Joe</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/20</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.6</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex47.htm"><span style="text-decoration:underline;">Employment Agreement, dated December&#160;16, 2015, by and among Merus US, Inc., the Registrant and Hui Liu, as amended on March&#160;2, 2016</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.7</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000156459020051276/mrus-ex103_39.htm"><span style="text-decoration:underline;">Employment Agreement, dated August 20, 2020 between Peter Silverman and Merus N.V.</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/20</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.8</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000156459020011100/mrus-ex10113_131.htm"><span style="text-decoration:underline;">Employment Agreement, dated January 1, 2019, by and among Merus US, Inc., the Registrant and Sven A. Lundberg</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1.13</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/16/20</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.9</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex410.htm"><span style="text-decoration:underline;">English language translation of Employment Agreement, dated as of August&#160;5, 2010, by and between the Registrant and Alexander Bakker</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.10</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000156459020024280/mrus-ex102_51.htm"><span style="text-decoration:underline;">Settlement Agreement, dated April 16, 2020, by and between the Registrant and Mark Throsby</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/11/20</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.11</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000156459020037712/mrus-ex103_69.htm"><span style="text-decoration:underline;">Consultancy Agreement, dated April 13, 2020, by and between the Registrant and Victor Sandor</span></a></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/20</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:40.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="10" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference to</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filings Indicated</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:40.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Description</p></td>
<td valign="bottom" style="width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.12</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex49.htm"><span style="text-decoration:underline;">English language translation of Employment Agreement, dated as of July 19, 2008, by and between the Registrant and Mark Throsby, as amended on March 10, 2010</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1.13</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex411.htm"><span style="text-decoration:underline;">English language translation of Employment Agreement, dated as of April&#160;2, 2007, by and between the Registrant and John de Kruif, as amended on March&#160;10, 2010</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Material Contracts &#8211; Banking and Financing</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.2.1</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex108.htm"><span style="text-decoration:underline;">English language translation of Loan Agreement between the Registrant and Co&#246;peratieve Rabobank Utrechtse Heuvelrug U.A., dated December&#160;29, 2005</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/19/15</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.2.2</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516434605/d29248dex109.htm"><span style="text-decoration:underline;">English language translation of letter amendment, dated October&#160;21, 2015, to Loan Agreement between the Registrant and Co&#246;peratieve Rabobank Utrechtse Heuvelrug U.A.</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1/A</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/21/16</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.2.3</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1091.htm"><span style="text-decoration:underline;">English language translation of letter amendment, dated March&#160;15, 2016, to Loan Agreement between the Registrant and Co&#246;peratieve Rabobank Utrechtse Heuvelrug U.A.</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1/A</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9.1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/16</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.2.4</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1092.htm"><span style="text-decoration:underline;">English language translation of letter amendment, dated March&#160;15, 2016, to Loan Agreement between the Registrant and Co&#246;peratieve Rabobank Utrechtse Heuvelrug U.A.</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1/A</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9.2</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/16</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Material Contracts &#8211; Leases</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.3.1</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1012.htm"><span style="text-decoration:underline;">English language translation of Lease Agreement between the Registrant and Stichting Incubator Utrecht, dated April&#160;22, 2016</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1/A</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/16</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.3.2</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex4151.htm"><span style="text-decoration:underline;">English language translation of Amendment to Lease Agreement, dated as of November&#160;1, 2016 by and between the Registrant and Stichting Incubator Utrecht</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15.1</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.3.3</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518245788/d592967dex993.htm"><span style="text-decoration:underline;">English language translation of the Lease, dated May&#160;1, 2018, by and between the Registrant and Stichting Incubator Utrecht</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-K</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.3</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/10/18</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Material Contracts &#8211; Collaboration and License Agreements</p></td>
<td colspan="4" valign="middle" style="width:7.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.4.1&#8224;</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312517148152/d355766dex412.htm"><span style="text-decoration:underline;">Collaboration and License Agreement, dated December&#160;20, 2016, by and between the Registrant and Incyte Corporation</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/28/17</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.4.2&#8224;</p></td>
<td valign="bottom" style="width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:40.74%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312517148152/d355766dex413.htm"><span style="text-decoration:underline;">Share Subscription Agreement, dated December&#160;20, 2016, by and between the Registrant and Incyte Corporation</span></a></p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:1.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/28/17</p></td>
<td valign="top" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.18%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:9.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:40.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="12" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference to</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filings Indicated</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:40.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="background-color:#FFFFFF;width:9.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.4.3&#8224;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex109.htm"><span style="text-decoration:underline;">Contract Research and License Agreement and Addendum between the Registrant and ONO Pharmaceutical Co., Ltd., dated April&#160;8, 2014</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/19/15</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.4.4&#8224;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex419.htm"><span style="text-decoration:underline;">Contract Research and License Agreement by and between the Registrant and Ono Pharmaceuticals Co., Ltd., dated March&#160;14, 2018</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-F</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37773</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.19</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/18</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.4.5&#8224;&#8224;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mrus-ex1045_90.htm"><span style="text-decoration:underline;">Collaboration and License Agreement, dated January 18, 2021, by and between the Registrant and Eli Lilly and Company</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="background-color:#FFFFFF;width:9.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="background-color:#FFFFFF;width:9.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Exhibits</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;21.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1651311/000119312516535709/d29248dex211.htm"><span style="text-decoration:underline;">List of Subsidiaries</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1/A</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-207490</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/8/16</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;23.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mrus-ex231_439.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting firm</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;31.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mrus-ex311_8.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;32.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mrus-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="background-color:#FFFFFF;width:9.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;width:42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Calculation Linkbase Document</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Label Linkbase Document</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Presentation Linkbase Document</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:9.96%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:40.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.92%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith.</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnished herewith.</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the exhibit have been omitted. Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None<span style="font-size:6pt;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sven A. Lundberg</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sven (Bill) Ante Lundberg</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and <br />Principal Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sven A. Lundberg</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer, <br />Principal Financial Officer and Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sven (Bill) Ante Lundberg</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Harry Shuman</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Accounting Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Harry Shuman</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Anand Mehra</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anand Mehra</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Mark T. Iwicki</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mark T. Iwicki</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Len Kenavy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Len Kenavy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Greg D. Perry</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Greg D. Perry</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Paolo Pucci</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paolo Pucci</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Victor Sandor</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Victor Sandor</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:94.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_OF_IND_REG_PUBLIC_ACCT"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:94.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" style="width:94.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:94.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:94.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:94.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors<br />Merus N.V.:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Merus N.V. and subsidiary (together, &#8216;the Company&#8217;) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG Accountants N.V.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2009.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rotterdam, The Netherlands<br />March 16, 2021</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands except per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,082</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">197,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001651311_20201231" decimals="-3" scale="3">46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001651311_20191231" decimals="-3" scale="3">941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable (related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,623</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AssetsCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AssetsCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">247,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,009</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="C_0001651311_20201231" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="C_0001651311_20191231" decimals="-3" scale="3">288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Assets" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">231,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:Assets" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:TaxesPayableCurrent" contextRef="C_0001651311_20201231" decimals="-3" scale="3">206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of lease obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001651311_20201231" decimals="-3" scale="3">625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001651311_20191231" decimals="-3" scale="3">941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred revenue (related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001651311_20201231" decimals="-3" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001651311_20191231" decimals="-3" scale="3">780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion (related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:Liabilities" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">128,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:Liabilities" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">132,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 10)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000080">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000081">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common shares, &#8364;<ix:nonFraction unitRef="U_iso4217EUR_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001651311_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217EUR_xbrlishares" id="F_000095" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001651311_20191231" decimals="INF">0.09</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001651311_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001651311_20191231" decimals="INF" format="ixt:numdotdecimal">45,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001651311_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001651311_20201231" decimals="INF" format="ixt:numdotdecimal">31,602,953</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001651311_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001651311_20191231" decimals="INF" format="ixt:numdotdecimal">28,882,217</ix:nonFraction></ix:nonFraction> shares issued and outstanding as at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommonStockValue" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:CommonStockValue" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">490,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">441,395</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,071</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001651311_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">400,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001651311_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">131,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">231,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands except per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue (related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20190101_20191231" decimals="-3" sign="-" scale="3">215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:Revenues" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:Revenues" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,040</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">75,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (losses) gains</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income and gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="mrus:MiscellaneousIncomeAndGains" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="mrus:MiscellaneousIncomeAndGains" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">54,957</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency translation adjustment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">78,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss per share allocable to common stockholders:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000136" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001651311_20200101_20201231" decimals="2" sign="-">2.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000137" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001651311_20190101_20191231" decimals="2" sign="-">2.28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,256,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000139" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,218,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:ProfitLoss" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:ProfitLoss" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange losses (gains)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="mrus:ForeignExchangeGain" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,957</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="mrus:ForeignExchangeGain" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:ShareBasedCompensation" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:ShareBasedCompensation" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of discount on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax benefit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" scale="3">89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets and lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">19,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">79,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">63,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">87,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,223</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from stock options exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange impact on cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net&#160;&#160;increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">197,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">164,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">197,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUPPLEMENTAL DISCLOSURES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease obligations acquired from operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash purchases of property, equipment and intangibles</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash financing costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="mrus:FinanceCostIncurredButNotYetPaid" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="mrus:FinanceCostIncurredButNotYetPaid" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" scale="3">320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax refunds received</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:ProceedsFromIncomeTaxRefunds" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:ProceedsFromIncomeTaxRefunds" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,082</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">197,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="mrus:RestrictedCashAndOtherAssets" contextRef="C_0001651311_20201231" decimals="-3" scale="3">201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="mrus:RestrictedCashAndOtherAssets" contextRef="C_0001651311_20191231" decimals="-3" scale="3">201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">197,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands except share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000208" name="us-gaap:SharesOutstanding" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">23,358,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">360,045</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">259,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000214" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">5,462,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options and vesting of restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000220" name="mrus:StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">60,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency translation adjustment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:SharesOutstanding" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">28,882,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">441,395</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">131,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000247" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,451,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options and vesting of restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000253" name="mrus:StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">269,455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency translation adjustment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000274" name="us-gaap:SharesOutstanding" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">31,602,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">490,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">400,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,071</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:StockholdersEquity" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </p><ix:nonNumeric id="F_000281" name="us-gaap:NatureOfOperations" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus N.V. is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the &#8220;Company&#8221;).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has generated an accumulated loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001651311_20201231" decimals="-5" sign="-" scale="6">400.1</ix:nonFraction> million as of December&#160;31, 2020. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its bispecific antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved bispecific antibody candidate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations with third parties and business development opportunities. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#8217;s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, the Company expects that its existing cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001651311_20201231" decimals="-5" scale="6">207.8</ix:nonFraction> million as of December 31, 2020, combined with the aggregate immediate proceeds from the closing of the collaboration and share purchase agreements with Eli Lilly &#38; Co (Eli Lilly) in January 2021 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_mrusCollaborationAndSharePurchaseAgreementsMember_20210101_20210131" decimals="-5" scale="6">60.0</ix:nonFraction> million and the aggregate net proceeds from the January 2021 follow-on offering of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusFollowOnPublicOfferingMember_20210101_20210131" decimals="-5" scale="6">129.7</ix:nonFraction> million in January 2021, will fund the Company&#8217;s operations at least into the second half of 2024.</p></ix:nonNumeric><ix:nonNumeric id="F_000282" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000282_dcnt_5ebab44f-5822-4849-8bd4-cee0a3aab8fd">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000297" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Preparation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the U.S. ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). </p></ix:nonNumeric><ix:nonNumeric id="F_000298" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries are entities controlled by the Company, consisting of Merus N.V.&#8217;s wholly owned subsidiary Merus US, Inc. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. All significant intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric id="F_000299" name="mrus:FunctionalAndPresentationCurrencyPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Functional and Presentation Currency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items recorded in each of the Company&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates (the <span style="color:#000000;">"</span>functional currency<span style="color:#000000;">"</span>). Merus US, Inc.&#8217;s functional currency is the U.S. dollar. The functional currency of Merus N.V. is the euro. After measuring foreign currency denominated transactions into an entity&#8217;s functional currency, to the extent that a subsidiary&#8217;s functional currency differs from its parent, a subsidiary&#8217;s financial position and results of operations are translated into its parent&#8217;s functional currency. The Company&#8217;s consolidated financial position and results of operations are translated into the U.S. dollar as the Company&#8217;s reporting currency.</p></ix:nonNumeric><ix:nonNumeric id="F_000300" name="us-gaap:UseOfEstimates" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000300_dcnt_54dd6a6c-221e-40b4-ac94-74051d61be03">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amounts of collaboration revenue and expenses during the reporting period. Actual results and outcomes may differ materially from management&#8217;s estimates, judgments and assumptions. </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_5ebab44f-5822-4849-8bd4-cee0a3aab8fd" continuedAt="F_000282_dcnt_86b9163d-80ee-43d9-a019-cc03e29b06b9"><ix:continuation id="F_000300_dcnt_54dd6a6c-221e-40b4-ac94-74051d61be03">
</ix:continuation><ix:nonNumeric id="F_000301" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, marketable securities and accounts receivable. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments as defined by the Company. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit the Company&#8217;s credit exposure to any single issuer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts <span style="color:#000000;">receivable</span> represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. </p></ix:nonNumeric><ix:nonNumeric id="F_000302" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subsequent Events </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers events or transactions that occur after the balance sheet date but before the consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company evaluated all events and transactions through the date these financial statements were filed with the Securities and Exchange Commission. </p></ix:nonNumeric><ix:nonNumeric id="F_000303" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level 1 &#8211; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level 2 &#8211; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined through the use of models or other valuation methodologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level 3 &#8211; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined by the reporting entity&#8217;s own assumptions utilizing the best information available and includes situations where there is little market activity for the asset or liability. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The asset&#8217;s or liability&#8217;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers its cash, cash equivalents, accounts receivable, marketable securities due with maturities 12 months or less, and accounts payable financial instruments to reflect their fair value given their short maturity and risk profile of the counterparty.</p></ix:nonNumeric><ix:nonNumeric id="F_000304" name="mrus:GoingConcernPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to <span style="color:#000000;">continue</span> as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs, and <span style="color:#000000;">comparing</span> <span style="color:#000000;">those</span> needs to the current cash, cash equivalent and marketable security balances. After considering the Company&#8217;s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable securities as of December&#160;31, 2020, the Company did not identify conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year from the date these financial statements were issued.</p></ix:nonNumeric><ix:nonNumeric id="F_000305" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000305_dcnt_f46c4fd5-e47f-4fbc-99ca-5dc324fd65f2">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid debt securities with original final maturities of <ix:nonNumeric id="F_000350" name="us-gaap:AdditionalCashAndCashEquivalentRelatedText" contextRef="C_0001651311_20200101_20201231">three months or less</ix:nonNumeric> from the date of purchase to be cash equivalents. Instruments subject to restrictions are not included in cash and cash equivalents.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_86b9163d-80ee-43d9-a019-cc03e29b06b9" continuedAt="F_000282_dcnt_277f9065-f275-477a-9034-de65680011e7"><ix:continuation id="F_000305_dcnt_f46c4fd5-e47f-4fbc-99ca-5dc324fd65f2">
</ix:continuation><ix:nonNumeric id="F_000306" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities that are debt securities with a remaining maturity when purchased of greater than three months as held-to-maturity as the Company has the positive intent and ability to hold such debt securities through maturity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities that are classified as held-to-maturity are initially recognized and measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Interest income from these debt securities is included in interest income. Marketable securities are classified as current if their expected maturity is within one year or less of the balance sheet date and non-current if their maturity is beyond one year of the balance sheet date.</p></ix:nonNumeric><ix:nonNumeric id="F_000307" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are amounts due from collaboration partners as a result of research and development services provided or milestones achieved but not yet paid.</p></ix:nonNumeric><ix:nonNumeric id="F_000308" name="us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Allowance for Credit Losses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its cash equivalents, accounts receivable and held-to-maturity marketable securities financial assets for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current environment, the Company concluded there is generally no expected credit losses for these financial assets. With respect to held-to-maturity marketable securities which are comprised of debt securities, the Company evaluates expected credit losses on a pooled basis based on issuer-type which have similar credit risk characteristics. The allowance for credit losses is immaterial for all periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000309" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p><ix:nonNumeric id="F_000320" name="mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Asset Category</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Useful Lives</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000351" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000352" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeFurnitureAndEquipmentMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000353" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of useful life or term of lease</ix:nonNumeric></p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes expenditures for new property and equipment and improvements to existing facilities and charges the cost of maintenance to expense. The Company eliminates the cost of property retired or otherwise disposed of, along with the corresponding accumulated depreciation or amortization, from the related accounts, and the resulting gain or loss is reflected in the results of operations. </p></ix:nonNumeric><ix:nonNumeric id="F_000310" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets are identifiable non-monetary assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or self-creation) and from which future economic benefits (inflows of cash or other assets) are expected. The useful lives of intangible assets are assessed to be definite-lived and amortized over the useful economic life. The Company&#8217;s intangible assets are comprised of purchased licenses to intellectual property and software licenses. </p></ix:nonNumeric><ix:nonNumeric id="F_000311" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000311_dcnt_654515ce-d6a5-4a70-896d-d95b5c1dadab">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets to be held and used, including property and equipment, operating lease right-of-use assets and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. <ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001651311_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> such impairments were recorded in 2020 or 2019. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_277f9065-f275-477a-9034-de65680011e7" continuedAt="F_000282_dcnt_69d598a5-7cf9-487d-8014-82ac8ed6465e"><ix:continuation id="F_000311_dcnt_654515ce-d6a5-4a70-896d-d95b5c1dadab">
</ix:continuation><ix:nonNumeric id="F_000312" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company does not have any finance leases.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease, and excludes non-lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets also include the effect of any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has real estate operating lease agreements with lease and non-lease components, which are generally accounted for separately as operating lease costs and variable lease costs. Non-lease components in real estate leases refer to services provided by the lessor related to the premises. Fixed and variable lease payments are both allocated to lease and non-lease components. The allocation is determined on a relative fair value basis of the services provided relative to the operating lease of premises. With respect to equipment leases, the Company has elected not to allocate payments amongst lease and non-lease components as a practical expedient as afforded under ASC 842, <span style="font-style:italic;">Leases</span>.</p></ix:nonNumeric><ix:nonNumeric id="F_000313" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records deferred taxes to recognize the future effects of temporary differences between the tax basis and financial statement carrying amount of assets and liabilities. The Company measures the deferred taxes using enacted tax rates expected to apply when the temporary differences are realized and records a valuation allowance to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available, reversing taxable temporary differences and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the technical merits, facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to an underpayment of income taxes, if applicable, as a component of income tax expense. </p></ix:nonNumeric><ix:nonNumeric id="F_000314" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000314_dcnt_7607f901-a6ed-4ea8-a105-59bf1e935bed">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for an arrangement, the Company performs the following five step analysis: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">identify the contract(s) with a customer&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">identify the performance obligations in the contract&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iii.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">determine the transaction price&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iv.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">allocate the transaction price to the performance obligations in the contract&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">v.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">recognize revenue when (or as) the entity satisfies a performance obligation. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i)&#160;licenses, or options to obtain licenses, to product candidates or future product candidates directed to specific targets (referred to as &#8220;exclusive licenses&#8221;) and (ii)&#160;research and development activities to be </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_69d598a5-7cf9-487d-8014-82ac8ed6465e" continuedAt="F_000282_dcnt_b9d4a25f-37be-45f9-8624-66039c663980"><ix:continuation id="F_000314_dcnt_7607f901-a6ed-4ea8-a105-59bf1e935bed" continuedAt="F_000314_dcnt_7cbf47cf-173b-4208-a2bd-c9143c625e8b">
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performed on behalf of the collaboration partner related to the licensed targets.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also derives revenue from government grants.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must use judgment to determine: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the transaction price under step (iii) above&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as unbilled receivables.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Licenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the rights and obligations set out in the contract, the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i)&#160;at the inception of the arrangement as an upfront fee or payment, (ii)&#160;upon the exercise of an option to acquire a license or (iii)&#160;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based milestones or royalty revenue resulting from any of its arrangements.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_b9d4a25f-37be-45f9-8624-66039c663980" continuedAt="F_000282_dcnt_deb58646-4e5c-4f1a-9d30-0bbb43c90c60"><ix:continuation id="F_000314_dcnt_7cbf47cf-173b-4208-a2bd-c9143c625e8b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period as described under&#160;<span style="font-style:italic;">Exclusive Licenses&#160;</span>above. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it&#160;is probable that a significant revenue reversal would not occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government Grants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the R&#38;D cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. Government grant revenue may be subject to review by a government authority in periods subsequent to their recognition and may result in the reversal of grant revenue previously recognized. Reversals of grant revenue are presented as contra revenue in the consolidated statement of operations.</p></ix:continuation><ix:nonNumeric id="F_000315" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000315_dcnt_a0e80032-27b2-48f0-bcc4-00449ba769ca">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are expensed as incurred. Research and development expenses are comprised of costs incurred in providing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract research and development services, and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When third-party service providers&#8217; billing terms do not coincide with the Company&#8217;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs, contractual services costs and costs for supply of its product candidates incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period, past history in conducting similar activities and the expected duration of the third-party service contract, among other considerations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of research and development expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The WBSO (<span style="font-style:italic;">afdrachtvermindering speur- en ontwikkelingswerk</span>) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_deb58646-4e5c-4f1a-9d30-0bbb43c90c60"><ix:continuation id="F_000315_dcnt_a0e80032-27b2-48f0-bcc4-00449ba769ca">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this act, a contribution is paid towards the labor costs of employees directly involved in research and development. </span><span style="color:#000000;">For the year ended December 31, </span><span style="color:#000000;">2020</span><span style="color:#000000;"> and </span><span style="color:#000000;">2019</span><span style="color:#000000;">, the Company recognized</span><span style="color:#000000;"> </span><span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="mrus:IncreaseDecreaseInResearchAndDevelopmentExpense" contextRef="C_0001651311_20200101_20201231" decimals="-5" scale="6">6.0</ix:nonFraction> million</span><span style="color:#000000;"> and </span><span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="mrus:IncreaseDecreaseInResearchAndDevelopmentExpense" contextRef="C_0001651311_20190101_20191231" decimals="-5" scale="6">4.5</ix:nonFraction> million</span><span style="color:#000000;"> as a reduction of research and development expenses, respectively.</span></p></ix:continuation><ix:nonNumeric id="F_000316" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee share-based compensation based on the grant date fair value of the share-based compensation award. The Company grants stock options at exercise prices equal to the fair value of the Company&#8217;s common stock on the date of grant, based on observable market prices. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For share-based payments subject time-based vesting, the Company recognizes employee stock-based compensation expense on a straight-line basis over the requisite service period of the awards, generally from the date of grant through each vesting date. The Company recognizes forfeitures at the time they occur. The actual expense recognized over the vesting period will only represent those options that vest&#59; the effect of forfeitures in the recognition of periodic compensation expense are not estimated prior to their occurrence. </p></ix:nonNumeric><ix:nonNumeric id="F_000317" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Earnings (Loss) per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company computes basic earnings (loss) per share by dividing income (loss) allocable to common stockholders by the weighted average number of shares of common stock outstanding. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The Company computes diluted earnings (loss) per share after giving consideration to the dilutive effect of stock options and restricted stock units (&#8220;RSU&#8221;) that are outstanding during the period, except where such non-participating securities would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric id="F_000318" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in <ix:nonFraction unitRef="U_mrusSegment" id="F_000358" name="us-gaap:NumberOfReportableSegments" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.</p></ix:nonNumeric><ix:nonNumeric id="F_000319" name="mrus:PendingAccountingPronouncementsPolicyTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pending Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span>. The new <span style="color:#000000;">guidance</span> aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for the Company at the beginning of 2021, including interim periods within that reporting period, although early adoption is permitted. The Company does not expect the impact of adoption to be significant.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU 2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808)</span>, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative <span style="color:#000000;">arrangement</span> participant if the participant is not a customer. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. As of December 31, 2020, none of the Company&#8217;s arrangements fall within the scope of ASC 808. However, as the Company may engage in future collaborative arrangements in the future, this ASU may apply to those new arrangements.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000283" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000283_dcnt_d5c6dc73-9b37-40bc-ba8d-a58f4d909879">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Investments in Debt Securities</p><ix:nonNumeric id="F_000321" name="mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities are classified in the consolidated balance sheet as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,053</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,009</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000283_dcnt_d5c6dc73-9b37-40bc-ba8d-a58f4d909879">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000322" name="us-gaap:DebtSecuritiesHeldToMaturityPastDueTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes debt securities by maturity at December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Maturity</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After one year through five years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000323" name="us-gaap:DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes debt securities by credit-quality indicator:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Quality Indicator as of December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AAA</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AA- to AA+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A- to A+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The credit quality indicator was derived from publicly available ratings published by Moody&#8217;s or a comparable credit rating agency, last updated as of December 31, 2020. </p><ix:nonNumeric id="F_000324" name="us-gaap:HeldToMaturitySecuritiesTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,053</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,053</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,709</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0001651311_20191231" decimals="-3" scale="3">41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0001651311_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allowance for credit losses applicable to debt securities was immaterial in all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of money market funds is determined based on publicly available market price for these funds (Level 1). The fair value of other debt securities is determined based on the publicly available inputs which includes a market price for the same or similar instruments adjusted for estimates in interest yield (Level 2).</p></ix:continuation><ix:nonNumeric id="F_000284" name="mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000284_dcnt_a563d667-af7d-4e4b-955e-ed5e8adf5367">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Prepaid Expenses and Other Assets </p><ix:nonNumeric id="F_000325" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical and manufacturing costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="mrus:PrepaidClinicalAndManufacturingCostsCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="mrus:PrepaidClinicalAndManufacturingCostsCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid general and administrative costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="mrus:PrepaidGeneralAndAdministrativeCosts" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="mrus:PrepaidGeneralAndAdministrativeCosts" contextRef="C_0001651311_20191231" decimals="-3" scale="3">789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001651311_20201231" decimals="-3" scale="3">80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001651311_20191231" decimals="-3" scale="3">259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000284_dcnt_a563d667-af7d-4e4b-955e-ed5e8adf5367">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other assets totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" contextRef="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" contextRef="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million as of December 31, 2020 and 2019, respectively. The nature of the restriction relates to amounts held as collateral for a credit card borrowing arrangement.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000285" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Property and Equipment, net </p><ix:nonNumeric id="F_000326" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment and furniture</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" scale="3">117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001651311_srtStatementGeographicalAxis_countryNL_20200101_20201231" decimals="-5" scale="6">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001651311_srtStatementGeographicalAxis_countryNL_20190101_20191231" decimals="-5" scale="6">0.9</ix:nonFraction> million for the years ended December&#160;31, 2020, and 2019, respectively. Property and equipment are predominantly located in the Netherlands.</p></ix:nonNumeric><ix:nonNumeric id="F_000286" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Intangible assets, net </p><ix:nonNumeric id="F_000327" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,898</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software licenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20201231" decimals="-3" scale="3">288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20191231" decimals="-3" scale="3">264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,343</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001651311_20191231" decimals="-3" scale="3">956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001651311_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001651311_20190101_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million for the years ended December&#160;31, 2020, and 2019, respectively. Intangible assets are predominantly located in the Netherlands.</p><ix:nonNumeric id="F_000328" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense over the next five years are expected to be as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expected</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0001651311_20201231" decimals="-3" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0001651311_20201231" decimals="-3" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0001651311_20201231" decimals="-3" scale="3">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0001651311_20201231" decimals="-3" scale="3">196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0001651311_20201231" decimals="-3" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total remaining value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000287" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000287_dcnt_9e8f66cf-21f7-4b9c-b598-bf1627308993">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Accrued Expenses </p><ix:nonNumeric id="F_000329" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="mrus:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="mrus:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued personnel costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="mrus:AccruedGeneralAndAdministrativeExpenses" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="mrus:AccruedGeneralAndAdministrativeExpenses" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000287_dcnt_9e8f66cf-21f7-4b9c-b598-bf1627308993">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000288" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000288_dcnt_059c872f-b898-432f-9c56-fad5e6c1f656">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Income Taxes </p><ix:nonNumeric id="F_000330" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss from operations before income tax expense are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">81,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">53,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">54,957</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000331" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of income tax expense (benefit) from continuing operations are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" scale="3">86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" scale="3">63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" scale="3">26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax benefit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" scale="3">89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000332" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parent company is subject to income tax in the Netherlands where a greater proportion of economic activity is attributed. A reconciliation of the Netherlands statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands statutory income tax rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000507" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001651311_20200101_20201231" decimals="INF" scale="-2">25.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000508" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001651311_20190101_20191231" decimals="INF" scale="-2">25.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in tax rates</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000509" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="C_0001651311_20200101_20201231" decimals="3" scale="-2">10.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000510" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="C_0001651311_20190101_20191231" decimals="3" scale="-2">1.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000511" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="C_0001651311_20200101_20201231" decimals="3" sign="-" scale="-2">2.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000512" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="C_0001651311_20190101_20191231" decimals="3" sign="-" scale="-2">3.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000513" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001651311_20200101_20201231" decimals="3" sign="-" scale="-2">33.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000514" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001651311_20190101_20191231" decimals="3" sign="-" scale="-2">23.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000515" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001651311_20200101_20201231" decimals="3" sign="-" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000516" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001651311_20190101_20191231" decimals="3" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000517" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001651311_20200101_20201231" decimals="3" sign="-" scale="-2">0.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000518" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001651311_20190101_20191231" decimals="3" sign="-" scale="-2">0.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000288_dcnt_059c872f-b898-432f-9c56-fad5e6c1f656">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018 and 2020, Dutch tax authorities enacted new tax rates applicable to future periods which impact the measurement of deferred income taxes. The effect of the change in the valuation allowance each year reflects the increase or decrease in the valuation allowance against deferred tax assets attributable to the Netherlands.</p><ix:nonNumeric id="F_000333" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the Company&#8217;s deferred tax assets (liabilities) consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,966</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excess interest carryforward</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="mrus:DeferredTaxAssetsLeaseObligation" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="mrus:DeferredTaxAssetsLeaseObligation" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_0001651311_20201231" decimals="-3" scale="3">494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_0001651311_20191231" decimals="-3" scale="3">319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">95,170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax asset valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,645</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="mrus:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="mrus:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001651311_20201231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001651311_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001651311_20201231" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001651311_20191231" decimals="-3" scale="3">288</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After consideration of all positive and negative evidence, the Company believes that it is more-likely-than-not that our Netherlands deferred tax assets that are not supported by reversing temporary differences will not be realized. As a result, the Company established a valuation allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001651311_20201231" decimals="-5" scale="6">93.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001651311_20191231" decimals="-5" scale="6">57.9</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. The increase in the valuation allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001651311_20200101_20201231" decimals="-5" scale="6">35.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001651311_20190101_20191231" decimals="-5" scale="6">13.2</ix:nonFraction> million <span style="font-size:12pt;">&#160;</span>for the years ended December&#160;31, 2020 and 2019, respectively, is primarily attributable to the increase in net operating loss carryforward deferred tax assets for which a full valuation allowance applies and change in tax rates. As of December&#160;31, 2020, the portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits would be credited directly to contributed capital totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" contextRef="C_0001651311_20201231" decimals="-2" scale="3">2.1</ix:nonFraction> million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company did not have any net operating losses for U.S. federal or state income tax purposes. <ix:nonNumeric id="F_000334" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000334_cnt_1">The Company had net operating loss carryforwards for Dutch income tax purposes, the amount and expiry are as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000334_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiry Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Netherlands Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss&#160;Carryforward</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000548" name="mrus:ExpirationDateCarryForwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20200101_20201231">2024</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000549" name="mrus:ExpirationDateCarryForwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20200101_20201231">2025</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">110,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000550" name="mrus:ExpirationDateCarryForwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20200101_20201231">2026</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">95,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000551" name="mrus:ExpirationDateCarryForwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20200101_20201231">2027</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">266,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001651311_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> unrecognized tax benefits. As of December&#160;31, 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001651311_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> accrued interest or penalties related to underpayments of income taxes and <ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> amounts have been recognized in the consolidated statements of operations. The Company will recognize interest and penalties related to an underpayment of income taxes in income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions as well as in the Netherlands. The statute of limitations for assessment by the Internal Revenue Service (IRS), and Massachusetts tax authorities is closed for tax years prior to 2017. The statute of limitations for assessment by the Netherlands tax authorities is closed for tax years prior to 2015. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p></ix:continuation><ix:nonNumeric id="F_000289" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000289_dcnt_5532aa58-0220-4674-b815-3090c0e2cd17">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Operating Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000561" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001651311_20180101_20181231">Merus N.V. leases its corporate headquarters under an agreement term of <ix:nonNumeric id="F_000560" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001651311_20181231" format="ixt-sec:durwordsen">five years</ix:nonNumeric>, which expires in the fourth quarter of 2021. On May 1, 2018, Merus N.V. leased additional space to expand its corporate headquarters under a separate agreement. Under the terms of the new agreement, the term began on May 1, 2018 and also expires in the <ix:nonNumeric id="F_000562" name="mrus:OperatingLeaseExpirationTerm" contextRef="C_0001651311_20180101_20181231">fourth quarter of 2021.</ix:nonNumeric>&#160;</ix:nonNumeric> Given the Company&#8217;s current plans, the renewal term has not been included in the estimate of the lease term. Fixed lease payments increase annually and include an </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000289_dcnt_5532aa58-0220-4674-b815-3090c0e2cd17" continuedAt="F_000289_dcnt_8b6a84dc-5ec0-4734-87ca-c0f1d931689c">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase based on an inflationary measure.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable payments include amounts due to t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he lessor </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional services </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and cost reimbursements</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, <ix:nonNumeric id="F_000564" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331">Merus US, Inc. entered into a lease agreement for office space in Cambridge, Massachusetts. The lease commenced in the second quarter of 2019 and has a term of <ix:nonNumeric id="F_000563" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190331" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>, and <ix:nonNumeric id="F_000567" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331">may be extended for another <ix:nonNumeric id="F_000565" name="mrus:LesseeOperatingLeaseExtendedTermOfContract" contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331" format="ixt-sec:durwordsen">five years</ix:nonNumeric>.</ix:nonNumeric> Given the Company&#8217;s current plans, the renewal term has not been included in the estimate of the lease term.</ix:nonNumeric> Fixed lease payments increase annually and include an increase on an inflationary measure. Variable payments include amounts due to the lessor for additional services and cost reimbursements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operating leases relate to its real estate leases that are not classified as finance leases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a lease with Kadans Science Partner XII B.V. (&#8220;Kadans&#8221;), pursuant to which the Company agreed to lease approximately <ix:nonFraction unitRef="U_utrsqm" id="F_000568" name="mrus:AreaOfPropertySubjectToOrAvailableForOperatingLease" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731" decimals="INF" format="ixt:numdotdecimal">5,070</ix:nonFraction> square meters of office and laboratory space in a new multi-tenant office building that is to be constructed in Utrecht, the Netherlands. The initial term of the lease is <ix:nonNumeric id="F_000569" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190731" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date that the premises are completed in accordance with certain specifications provided in a development agreement (described below), which is expected to occur in mid-2022. The lease will renew for <ix:nonFraction unitRef="U_mrusRenewalTerm" id="F_000571" name="mrus:LesseeOperatingLeaseNumberOfRenewalTerm" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> <ix:nonNumeric id="F_000570" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190731" format="ixt-sec:duryear">5</ix:nonNumeric>-year terms following the initial term, unless earlier terminated by the Company or Kadans, except that the earliest Kadans may terminate the lease is <ix:nonNumeric id="F_000572" name="mrus:LesseeOperatingLeaseTerminationTerm" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731" format="ixt-sec:duryear">20</ix:nonNumeric> years from the completion date. The lease provides for an estimated initial rent of approximately &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000573" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731" decimals="-5" scale="6">1.3</ix:nonFraction> million per annum. <ix:nonNumeric id="F_000575" name="mrus:OperatingLeaseRentAdjustmentDescription" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731">The rent amount is subject to adjustment based on the consumer price index (the &#8220;CPI&#8221;) beginning on January 1, 2019 through the completion date and then annually thereafter, subject to certain limitations if the CPI is greater than <ix:nonFraction unitRef="U_xbrlipure" id="F_000574" name="mrus:ConsumerPriceIndex" contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtRangeAxis_srtMinimumMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731" decimals="INF" scale="-2">3.0</ix:nonFraction>%.</ix:nonNumeric> The final initial rent amount is contingent upon, among other things, the parameters of the final constructed premises, the final floor area, and the CPI adjustment described above, and will be determined upon the completion date and recorded in a first rider, signed by the Company and Kadans, to the lease. The Company is also responsible for certain fit-out costs and service fees related to the premises. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company also entered into a development agreement with Kadans and another party, Genmab B.V., which provides for the design, development and construction of the new multi-tenant office building of which the premises is a part.</p><ix:nonNumeric id="F_000335" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost recorded in the Company&#8217;s consolidated statement of operations and statement of cash flows were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:OperatingLeaseCost" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:OperatingLeaseCost" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:VariableLeaseCost" contextRef="C_0001651311_20200101_20201231" decimals="-3" scale="3">375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:VariableLeaseCost" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">297</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost included in operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:LeaseCost" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:LeaseCost" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid to lessors included in operating cash outflows</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:OperatingLeasePayments" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:OperatingLeasePayments" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s non-lease cost and other costs paid to the lessor are primarily related to services provided by the lessor in operating the premises that includes fees, operating costs, taxes and insurance related to the leased premises. </p><ix:nonNumeric id="F_000336" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000336_dcnt_79a6281a-c964-46db-9924-6eb10c152e94">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of the Company&#8217;s operating lease obligations as of December 31, 2020 were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001651311_20201231" decimals="-3" scale="3">614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001651311_20201231" decimals="-3" scale="3">630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001651311_20201231" decimals="-3" scale="3">645</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001651311_20201231" decimals="-3" scale="3">662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001651311_20201231" decimals="-3" scale="3">222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001651311_20201231" decimals="-3" scale="3">397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000289_dcnt_8b6a84dc-5ec0-4734-87ca-c0f1d931689c"><ix:continuation id="F_000336_dcnt_79a6281a-c964-46db-9924-6eb10c152e94">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000337" name="mrus:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease terms and discount rates related to the Company&#8217;s leases were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining operating lease term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000593">4.2</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000594">4.8</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000595" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001651311_20201231" decimals="3" scale="-2">4.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000596" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001651311_20191231" decimals="3" scale="-2">5.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000290" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Indemnities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited&#59; however, the Company has directors&#8217; and officers&#8217; insurance coverage that is intended to limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, clinical sites and customers. Under these provisions, the Company may indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities, such as gross negligence, willful misconduct or at times, other activities. These indemnification provisions may survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions may be unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 5, 2018, an unnamed third party and Regeneron Pharmaceuticals Inc., or Regeneron filed notices of opposition against the Company&#8217;s EP 2604625 patent, entitled &#8220;Generation of Binding Molecules,&#8221; in the European Opposition Division of the European Patent Office (the &#8220;EPO&#8221;). The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. Regeneron withdrew its opposition pursuant to a global December 20, 2018 settlement with the Company. On August 20, 2018, the Company timely responded to these submissions with respect to the unnamed third party. An opposition hearing was held in June 2019, wherein the EPO revoked the EP 2604625 patent in its entirety under Art. 123(2) EPC. The Company timely appealed that decision in December 2019 before the Technical Board of Appeals for the EPO seeking reinstatement of the patent and proposing auxiliary requests for certain amended claims, with further proceedings to be scheduled in the future. As this opposition proceeding continues, the Company cannot be certain that it will ultimately prevail.<span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be involved in various other claims and legal proceedings relating to claims arising out of the Company&#8217;s operations. </p></ix:nonNumeric><ix:nonNumeric id="F_000291" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000291_dcnt_35e9aaf1-ac98-4fec-9006-114868ffde49">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stockholders&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of common stock entitles the holder to <ix:nonNumeric id="F_000597" name="us-gaap:CommonStockVotingRights" contextRef="C_0001651311_20200101_20201231">one vote</ix:nonNumeric> on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to dividends when and if declared by the board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Issuances<span style="font-size:12pt;font-style:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 7, 2019, the Company completed an underwritten public offering in which the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000598" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107" decimals="INF" format="ixt:numdotdecimal">5,462,500</ix:nonFraction> common shares, including <ix:nonFraction unitRef="U_xbrlishares" id="F_000601" name="mrus:NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107" decimals="INF" format="ixt:numdotdecimal">715,500</ix:nonFraction> common shares pursuant to the underwriters&#8217; option to purchase additional shares, at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000599" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107" decimals="INF">14.50</ix:nonFraction> for aggregate net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107" decimals="-5" scale="6">74.0</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 23, 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000602" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123_20201123" decimals="INF" format="ixt:numdotdecimal">766,666</ix:nonFraction> common shares, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000603" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123" decimals="INF">15.00</ix:nonFraction> for aggregate proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123_20201123" decimals="-5" scale="6">11.5</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 24, 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000605" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124_20201124" decimals="INF" format="ixt:numdotdecimal">384,615</ix:nonFraction> common shares, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000606" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124" decimals="INF">15.60</ix:nonFraction> for aggregate proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124_20201124" decimals="-5" scale="6">6.0</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 3, 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000608" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203_20201203" decimals="INF" format="ixt:numdotdecimal">1,300,000</ix:nonFraction> common shares, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000609" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203" decimals="INF">16.90</ix:nonFraction> for aggregate proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203_20201203" decimals="-5" scale="6">22.0</ix:nonFraction> million.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000291_dcnt_35e9aaf1-ac98-4fec-9006-114868ffde49">

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2021, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000611" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001651311_us-gaapPlanNameAxis_mrusTwoThousandSixteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101" decimals="INF" format="ixt:numdotdecimal">2,336,997</ix:nonFraction> shares of common stock were reserved for additional grants of stock awards under the Company&#8217;s 2016 Incentive Award Plan. Stock-based compensation expense related to the equity compensation plan is more fully described in Note 13, <span style="font-style:italic;">Employee Benefit Plans</span>.</p></ix:continuation><ix:nonNumeric id="F_000292" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000292_dcnt_321bbe3d-2e2b-4ab5-85bb-753b45ca8482">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Collaborations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Incyte</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, pending regulatory clearance, Incyte agreed to pay the Company a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="mrus:NonRefundableUpfrontPaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231" decimals="-5" scale="6">120.0</ix:nonFraction> million, non-refundable upfront payment, and purchased <ix:nonFraction unitRef="U_xbrlishares" id="F_000613" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231" decimals="-5" scale="6">3.2</ix:nonFraction> million common shares at a stated price per share of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000614" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231" decimals="INF">25.00</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="mrus:RevenueFromCollaborativeArrangement" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231" decimals="-5" scale="6">80.0</ix:nonFraction> million. In exchange, the Company granted Incyte with a license to certain of its intellectual property and committed to collaborate with Incyte to research, discover and develop monospecific or bispecific antibodies utilizing the Company&#8217;s proprietary bispecific technology platform. The collaboration is managed by a joint steering committee in which both parties are represented and is tasked with overseeing the activities which significantly contributes to the collaboration. The collaboration may encompass up to 11 product candidates that result from the Company&#8217;s application of its proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. During the course of the initial research term, Merus proposes product candidates to Incyte, which evaluates whether to designate proposed product candidates from the Company to make a selection for further research. Proposed product candidates begin at a pre-clinical stage of development. Incyte has certain rights to replace product candidates, including the right to substitute a product candidate after initial selection. The Company would be entitled to future consideration in the form of cost reimbursements for research services, development milestones, commercialization milestones and royalties related to the programs under the arrangement.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At inception of the collaboration, two potential bispecific product candidates were under preliminary evaluation. After further research, a lead candidate was ultimately selected for the first product candidate, designated MCLA-145, and the other potential product candidate was not pursued. For the designated product candidate (MCLA-145), the Company retains the exclusive right to develop and commercialize products and product candidates in the United States, while Incyte has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States. For MCLA-145, the parties will conduct and share equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in each party&#8217;s respective territories. For all other programs under the arrangement to be selected by Incyte, Incyte will be responsible for all research, development and commercialization costs. The Company may elect to co-fund the development of certain of the other programs in the future, in which case costs and benefits would be shared. The Company has not elected to co-fund any programs to date.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At inception of the arrangement, the Company identified a performance obligation comprised of a combined delivery of a license and related activities, including the activities of the joint steering committee, to which to allocate consideration. The arrangement also allowed for optional future research services to advance selected product candidates through discovery and research. The transaction price was comprised of fixed consideration of an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="mrus:NonRefundableUpfrontPaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231" decimals="-5" scale="6">120.0</ix:nonFraction> million and proceeds from the sale of shares of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="mrus:RevenueFromCollaborativeArrangement" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231" decimals="-5" scale="6">80.0</ix:nonFraction> million. All other consideration under the arrangement was determined to be variable consideration and fully constrained at inception. $<ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="mrus:RevenueFromCollaborativeArrangement" contextRef="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndRelatedActivitiesMember_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231" decimals="-5" scale="6">152.6</ix:nonFraction> million of the transaction price was allocated to the license and related activities performance obligation after accounting for the purchase of common shares by Incyte</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 23, 2017, the Company completed the sale of shares and exchange of the license. The Company initially deferred the transaction price allocated to the license and related activities performance obligation as deferred revenue, to be recognized as revenue over time as the primary benefit of the license to Incyte is access to the platform for the generation of potential product candidates. Development milestones, commercialization milestones and royalties are variable consideration, fully constrained, to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy. Cost reimbursements for research services are recognized as they are performed over time as these are considered a separate performance obligation.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At December 31, 2020, the Company is currently engaged in research and development activities for MCLA-145 and developing candidates for the other programs. No development or commercialization milestones have been achieved to date.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ONO </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 14, 2018, the Company granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market bispecific antibody candidates based on the Company&#8217;s Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform against two undisclosed targets directed to a particular undisclosed target combination. ONO is responsible for identifying lead candidates and conducting further non-clinical and clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development. Additionally, ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has also agreed to fund the Company&#8217;s research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000292_dcnt_321bbe3d-2e2b-4ab5-85bb-753b45ca8482" continuedAt="F_000292_dcnt_6fdd7e8f-3588-43dc-b845-5003d96c6b07">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreed upon research plan. The Company retains all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_mrusAntibody" id="F_000619" name="mrus:NumberOfBispecificAntibodies" contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONO agreed to pay the Company an upfront, non-refundable payment of &#8364;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217EUR" id="F_000620" name="mrus:NonRefundableUpfrontPaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314" decimals="-5" scale="6">0.7</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company was entitled to &#8364;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217EUR" id="F_000621" name="mrus:PaymentToCompensateResearchServices" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314" decimals="-5" scale="6">0.3</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million intended to compensate the Company for research services already completed upon entering into the agreement, and &#8364;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217EUR" id="F_000622" name="mrus:OverTimePaymentForFullTimeEquivalentFunding" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314" decimals="-5" scale="6">0.2</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million to be paid to the Company over time for full time equivalent funding. The Company is entitled to research and development milestones in addition to royalties on future sales</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified performance obligations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: (1) provision of a license for the target combination</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) research and development services. The Company concluded that Ono would be able to develop and benefit from the license, independent of the research and development services.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research and development services are capable of being performed by third parties with an appropriate sub-license, and are recognized over time as these services are delivered. </span><span style="Background-color:#FFFFFF;color:#000000;">Milestone payments are fully constrained as variable consideration to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 3, 2016, the Company was engaged to perform manufacturing services for Ono in support of their clinical trials that was the subject of a prior arrangement with Ono initiated in 2014. The Company was entitled to compensation to oversee and support a manufacturing process with the use of an outside third-party and to deliver quantities of manufactured product. The Company identified one performance obligation to provide manufacturing supervision services involving the transfer of know-how and the development of a <span style="Background-color:#FFFFFF;color:#000000;">manufacturing</span> process with the third-party and three performance obligations related to the services provided in connection with the delivery of product each having separate and distinct requirements. The Company acts as an agent for Ono with respect to the third-party manufacturing costs incurred for the underlying product and presents the recovery of such costs net in research and development expense in the consolidated statement of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company received &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000623" name="mrus:DevelopmentMilestonesReceived" contextRef="C_0001651311_20190101_20191231" decimals="-5" scale="6">3.7</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="mrus:DevelopmentMilestonesReceived" contextRef="C_0001651311_20190101_20191231" decimals="-5" scale="6">4.1</ix:nonFraction> million) for the year ended December 31, 2019 for development milestones received from Ono based on their progress. The amounts are recognized as revenue in the consolidated statement of operations for the year ended December 31, 2019. <ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="mrus:DevelopmentMilestonesReceived" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction> comparable development milestones were received in the year ended December 31, 2020. Research and development services were completed in 2018.</span><span style="color:#000000;">&#160;&#160;&#160;</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Simcere</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the Company granted Simcere an exclusive license to develop and commercialize up to <ix:nonFraction unitRef="U_mrusAntibody" id="F_000626" name="mrus:NumberOfBispecificAntibodies" contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> bispecific antibodies to be produced by Merus utilizing the Company&#8217;s Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform in China. The Company will retain all rights outside of China. The Company has agreed to lead research and discovery activities, while Simcere has agreed to be responsible for the Investigational New Drug (&#8220;IND&#8221;) enabling studies, clinical development, regulatory filings and commercialization of these potential product candidates in China. The Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="mrus:NonRefundableUpfrontPaymentsReceived" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180131" decimals="-4" scale="6">2.75</ix:nonFraction> million, relating to three separate research programs. The Company may be entitled to future development milestone payments.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At inception of the arrangement, the Company identified <ix:nonFraction unitRef="U_mrusPerformanceObligation" id="F_000628" name="mrus:NumberOfPerformanceObligation" contextRef="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndPerformanceMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentArrangementMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> performance obligations comprised of the combined delivery of a license and performance of research and development activities with respect to each program. The Company performs research and development activities to achieve candidate nomination. The Company concluded that these activities were not distinct from the underlying license for each program as Simcere would not be able to benefit from the license apart from research and development activities at this phase of development</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The transaction price under the arrangement comprised fixed consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="mrus:RevenueFromCollaborativeArrangement" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="-4" scale="6">2.75</ix:nonFraction> million. </span><span style="color:#000000;">The transaction price was allocated to each separate performance obligation on a relative standalone fair value basis. </span><span style="Background-color:#FFFFFF;">The Company deferred the portion of the upfront payment allocated to the three performance obligations as deferred revenue, to be recognized over time</span><span style="color:#000000;">. </span><span style="Background-color:#FFFFFF;">Compensation for research and development services prior to candidate nomination are allocated to each program performance obligation and also recognized over time. Development milestone payments allocated to each of the program performance obligations are constrained as variable consideration to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has achieved <ix:nonFraction unitRef="U_mrusMilestone" id="F_000630" name="mrus:NumberOfMilestonesAchieved" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200930" decimals="INF" format="ixt-sec:numwordsen" scale="6">two</ix:nonFraction> milestones under this agreement and has received an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="mrus:MilestonePaymentsReceived" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200701_20200930" decimals="-5" scale="6">1.3</ix:nonFraction> million in milestone payments, including a milestone payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="mrus:MilestonePaymentsReceived" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrusSecondBispecificAntibodyResearchProgramMember_20200701_20200930" decimals="-5" scale="6">0.5</ix:nonFraction> million for the quarter ended September 30, 2020, concerning the generation of functional data associated with the second bispecific antibody research program. <span style="Background-color:#FFFFFF;color:#000000;">At December 31, 2020, <ix:nonNumeric id="F_000633" name="mrus:DescriptionOfResearchAndDevelopmentPrograms" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200101_20201231">research and development for one of the three programs is on-going.</ix:nonNumeric></span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Betta</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 10, 2018, the Company granted Betta an exclusive license to develop and commercialize in China MCLA-129, a proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> produced by its Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. The Company retains all rights outside of China. Betta has agreed to retain a contract manufacturing organization with experience in filing IND applications with U.S. regulatory authorities and CTAs with European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of the world. As a key strategic component of the collaboration, Betta will be responsible for IND enabling studies and manufacturing of clinical trial </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000292_dcnt_6fdd7e8f-3588-43dc-b845-5003d96c6b07" continuedAt="F_000292_dcnt_2a8398c1-8fd1-4a28-ba02-c0f7462d72d8">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materials in China, which the Company intends to use to assist regulatory filing and early stage clinical development in the rest of the world. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to a non-refundable upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="mrus:NonRefundableUpfrontPaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210" decimals="-5" scale="6">1.0</ix:nonFraction> million, Betta and the Company will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. The Company is also eligible to receive an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="mrus:ContingentMilestonePaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210" decimals="-5" scale="6">12.0</ix:nonFraction> million in milestone payments contingent upon Betta achieving certain specified development and commercial goals as well as tiered royalty payments of net sales of any products resulting from the collaboration in China. In turn, Betta is also entitled to milestone payments based on the Company&#8217;s progress. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified a single combined performance obligation, being the delivery of the MCLA-129 license including activities necessary to complete the technology transfer. The Company had no other commitments. The transaction price is comprised of fixed consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="mrus:NonRefundableUpfrontPaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210" decimals="-5" scale="6">1.0</ix:nonFraction> million and fully allocated to the single performance obligation which would be fulfilled at a point in time. The technology transfer to deliver the license was completed in 2018 and Company recognized the revenue related to this performance obligation of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="mrus:RevenueRelatedPerformanceObligationAmountAsRevenue" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20180101_20181231" decimals="-5" scale="6">1.0</ix:nonFraction> million as revenue for the year ended December 31, 2018. <span style="Background-color:#FFFFFF;color:#000000;">Development milestone payments allocated to the performance obligation are constrained as variable consideration to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the quarter ended December 31, 2020, both the Company and Betta achieved a development milestone both valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="mrus:DevelopmentMilestonesReceived" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million. The amounts are recognized as milestone revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="mrus:MilestoneRevenue" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million and research and development cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million in the Company&#8217;s statement of operations for the year ended December 31, 2020.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contract Assets, Liabilities, Revenues and Expenses</p><ix:nonNumeric id="F_000338" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its collaboration arrangements. The dollar amounts in the tables below are in thousands.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billings</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" scale="3">644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" scale="3">644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash receipts</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:ProceedsFromCustomers" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:ProceedsFromCustomers" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" scale="3">772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:ProceedsFromCustomers" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" scale="3">607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:ProceedsFromCustomers" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" sign="-" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" sign="-" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" scale="3">41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" sign="-" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231" decimals="-3" scale="3">46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231" decimals="-3" scale="3">46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled receivables</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231" decimals="-3" scale="3">155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231" decimals="-3" scale="3">155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued receivables</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231" decimals="-3" scale="3">581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231" decimals="-3" scale="3">581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billings</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" sign="-" scale="3">644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="mrus:Billings" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" sign="-" scale="3">644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" sign="-" scale="3">94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="mrus:AdjustmentsToContractAssetsReceivables" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" sign="-" scale="3">94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,623</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">108,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231" decimals="-3" scale="3">336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,721</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized in the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" sign="-" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" sign="-" scale="3">743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" sign="-" scale="3">943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" scale="3">69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="mrus:ForeignCurrencyExchangeTranslation" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" scale="3">84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231" decimals="-3" scale="3">151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231" decimals="-3" scale="3">711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231" decimals="-3" scale="3">862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231" decimals="-3" scale="3">151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231" decimals="-3" scale="3">474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231" decimals="-3" scale="3">625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231" decimals="-3" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231" decimals="-3" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000339" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000339_dcnt_2ea6f0fe-bb5b-484c-8b7e-977e999e501b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000292_dcnt_2a8398c1-8fd1-4a28-ba02-c0f7462d72d8"><ix:continuation id="F_000339_dcnt_2ea6f0fe-bb5b-484c-8b7e-977e999e501b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The balance of unbilled receivables predominantly represents reimbursement revenue under the Company&#8217;s collaboration arrangements earned in the period to be billed and collected in the next period, generally quarterly. Incyte is a related party as a shareholder, as more fully described in Note 15.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses from collaborations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in deferred revenue at the beginning of the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231" decimals="-3" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231" decimals="-3" scale="3">738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231" decimals="-3" scale="3">938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="mrus:UpfrontPayments" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" scale="3">99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="mrus:ReimbursementRevenues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" scale="3">252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" scale="3">284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" scale="3">680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses from collaborations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" scale="3">680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="us-gaap:OperatingExpenses" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in deferred revenue at the beginning of the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231" decimals="-3" scale="3">196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231" decimals="-3" scale="3">945</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000293" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true" continuedAt="F_000293_dcnt_822c77e0-6097-45fa-8d14-1e983c70d804">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Employee Benefit Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2010 Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2010, the Company established the Merus B.V. 2010 Employee Option Plan (the &#8220;2010 Plan&#8221;) that entitled key management personnel, staff and consultants providing similar services to purchase shares in the Company. Under the 2010 Plan, holders of vested options were entitled to purchase depositary receipts for common shares at the exercise price determined at the date of grant. Upon exercise of the option, common shares were issued to a foundation established to facilitate administration of share-based compensation awards and pool the voting interests of the underlying shares, and depositary receipts were issued by the foundation to the individual holders. In connection with the IPO, the 2010 Plan was amended to cancel the depositary receipts and allow individual holders to directly hold the common shares obtained upon exercise of their options. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted under the 2010 Plan generally vest in installments over a <span style="-sec-ix-hidden:F_000777">four-year</span> period from the grant date: <ix:nonFraction unitRef="U_xbrlipure" id="F_000778" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="2" scale="-2">25</ix:nonFraction>% percent on the first anniversary of the vesting commencement date, and the remaining <ix:nonFraction unitRef="U_xbrlipure" id="F_000779" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" decimals="2" scale="-2">75</ix:nonFraction>% of the options vest in <span><ix:nonNumeric id="F_000780" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" format="ixt-sec:durmonth"><ix:nonNumeric id="F_000781" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231" format="ixt-sec:durmonth">36</ix:nonNumeric></ix:nonNumeric> month</span>ly installments for each full month of continuous service provided thereafter. Options expire after <ix:nonNumeric id="F_000782" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_20200101_20201231" format="ixt-sec:duryear">8</ix:nonNumeric> years from the date of grant. The last grant of options pursuant to the 2010 Plan occurred in 2016, with no further grants expected.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000293_dcnt_822c77e0-6097-45fa-8d14-1e983c70d804" continuedAt="F_000293_dcnt_6c334b37-1c58-4a3a-bb4a-983b4b543cea">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2016 Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company established the 2016 Incentive Award Plan (the &#8220;2016 Plan&#8221;). All incentive award grants since 2016 are being made under the 2016 Plan. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted to employees under the 2016 Plan generally vest in installments over a <span style="-sec-ix-hidden:F_000783"><span style="-sec-ix-hidden:F_000784">four-year</span></span> period from the grant date: <ix:nonFraction unitRef="U_xbrlipure" id="F_000785" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000786" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231" decimals="2" scale="-2">25</ix:nonFraction></ix:nonFraction>% percent vest on the first anniversary of the vesting commencement date, and the remaining <ix:nonFraction unitRef="U_xbrlipure" id="F_000787" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000788" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231" decimals="2" scale="-2">75</ix:nonFraction></ix:nonFraction>% of the options vest in <span><ix:nonNumeric id="F_000789" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" format="ixt-sec:durmonth"><ix:nonNumeric id="F_000790" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231" format="ixt-sec:durmonth">36</ix:nonNumeric></ix:nonNumeric> month</span>ly installments for each full month of continuous service provided thereafter. Certain options may vest dependent on the attainment of performance criteria. Options expire after <span><ix:nonNumeric id="F_000791" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231" format="ixt-sec:duryear"><ix:nonNumeric id="F_000792" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231" format="ixt-sec:duryear">10</ix:nonNumeric></ix:nonNumeric> years</span> from the date of grant. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted to non-executive directors consist of initial option grants as well as subsequent annual awards. The initial award of options granted vest in installments over a <span style="-sec-ix-hidden:F_000793"><span style="-sec-ix-hidden:F_000794">three-year</span></span> period: <ix:nonFraction unitRef="U_xbrlipure" id="F_000795" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000796" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231" decimals="2" scale="-2">33</ix:nonFraction></ix:nonFraction>% of the options vest on the first anniversary of the vesting commencement date, and <ix:nonFraction unitRef="U_xbrlipure" id="F_000797" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000798" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231" decimals="2" scale="-2">67</ix:nonFraction></ix:nonFraction>% of the options vest in <span><ix:nonNumeric id="F_000799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" format="ixt-sec:durmonth"><ix:nonNumeric id="F_000800" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231" format="ixt-sec:durmonth">24</ix:nonNumeric></ix:nonNumeric> month</span>ly installments thereafter. Each subsequent award vests over a <span style="-sec-ix-hidden:F_000801"><span style="-sec-ix-hidden:F_000802">one-year</span></span> period in <span><ix:nonNumeric id="F_000803" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231" format="ixt-sec:durmonth"><ix:nonNumeric id="F_000804" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231" format="ixt-sec:durmonth">12</ix:nonNumeric></ix:nonNumeric> month</span>ly installments. The Company measures the fair value of an option through the application of an option pricing model, as more fully described below.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs granted to employees under the 2016 Plan vest in installments over a <span style="-sec-ix-hidden:F_000806"><span style="-sec-ix-hidden:F_000807">four-year</span></span> period from the grant date. Certain RSUs may vest dependent on the attainment of performance criteria. <ix:nonNumeric id="F_000805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">Each RSU represents the right to receive one common share.</ix:nonNumeric> The fair value of an RSU is determined by reference to the price of the underlying common share.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of common shares authorized for issuance for future grants under the 2016 Plan as of January 1, 2021 totaled <ix:nonFraction unitRef="U_xbrlishares" id="F_000808" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101" decimals="INF" format="ixt:numdotdecimal">2,336,997</ix:nonFraction>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share-Based Compensation Expense</p><ix:nonNumeric id="F_000340" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-5" scale="6">8.0</ix:nonFraction> million in unrecognized stock-based compensation that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of <ix:nonNumeric id="F_000816" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" format="ixt-sec:duryear">1.3</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Valuation</p><ix:nonNumeric id="F_000341" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing model to measure the fair value of stock option awards. In prior years, a Hull-White option-pricing model was used. Key weighted average assumptions used in this pricing model on the date of grant for options granted to employees are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" scale="-2">1.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" scale="-2">2.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual life of options (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">10.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000820">10.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term of options (years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000821">6.3</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility of underlying stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000822" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" scale="-2">86.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000823" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" scale="-2">87.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000824" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000825" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based upon the U.S. Treasury yield curve in effect at the time of grant, with a term that approximates the expected life of the option. The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates. A simplified method using a weighted-average mid-point between an award&#8217;s vesting date and expiry is used to estimate the expected life of options in all periods presented as a sufficient history of participant exercise behavior is not readily observable. The Company has applied an expected dividend yield of <ix:nonFraction unitRef="U_xbrlipure" id="F_000826" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction>% as the Company has not historically declared a dividend and does not anticipate declaring a dividend during the expected life of the options. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000293_dcnt_6c334b37-1c58-4a3a-bb4a-983b4b543cea" continuedAt="F_000293_dcnt_df6d580f-57f2-439c-9342-1cf05fd57fd3">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Activity</span></p><ix:nonNumeric id="F_000342" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity for the year ended December&#160;31, 2020: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000827" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001651311_20191231" decimals="INF" format="ixt:numdotdecimal">3,314,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000833" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001651311_20191231" decimals="2">14.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000828" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,258,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000834" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001651311_20200101_20201231" decimals="2">16.16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000829" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">202,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000835" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001651311_20200101_20201231" decimals="2">7.16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000830" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001651311_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">622,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000836" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001651311_20200101_20201231" decimals="2">16.62</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000831" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001651311_20201231" decimals="INF" format="ixt:numdotdecimal">3,748,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000837" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001651311_20201231" decimals="2">15.59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000839">5.9</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001651311_20201231" decimals="INF" format="ixt:numdotdecimal">2,140,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001651311_20201231" decimals="2">15.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000840">4.1</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001651311_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of options granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000843" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001651311_20200101_20201231" decimals="2">11.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000844" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001651311_20190101_20191231" decimals="2">7.54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RSU Activity</p><ix:nonNumeric id="F_000343" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant-date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000845" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="INF" format="ixt:numdotdecimal">82,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000850" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="2">19.68</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">46,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000851" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">16.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000847" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">67,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000852" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">19.94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000848" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000853" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">21.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000849" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" format="ixt:numdotdecimal">59,775</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000854" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2">16.48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000344" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intrinsic Value of Stock Options Exercised and Vested RSUs</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fair value of RSUs vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-3" scale="3">961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000856" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="-3" scale="3">726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate intrinsic value of options exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001651311_20190101_20191231" decimals="-3" scale="3">112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Employment Benefit Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has established a post-employment benefit plan for employees of the Netherlands that entitles executive officers and other staff members to retire at the age of 67 and receive annual payments based upon the average salary earned during the service period. The Company has insured the benefit liabilities through purchased non-participating annuities from an insurance company and has no other obligation other than to pay the annual insurance premiums to the insurance company. After purchasing the insurance, the Company has no further obligation (legal or constructive) to pay further amounts if the insurance fund has insufficient assets to pay all employee benefits relating to current and prior service. Contributions to purchase non-participating annuities are expensed as incurred as service costs. Company contributions to the post-employment benefit plan totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20200101_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231" decimals="-5" scale="6">1.3</ix:nonFraction> million in the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">401(k) Savings Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined contribution 401(k) savings plan (the &#8220;401(k) Plan&#8221;). <ix:nonNumeric id="F_000861" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231">The 401(k) Plan covers substantially all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax basis. The Company matches contributions to the 401(k) Plan, matching <ix:nonFraction unitRef="U_xbrlipure" id="F_000862" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231" decimals="INF" scale="-2">50</ix:nonFraction>% of an employee&#8217;s contribution up to a maximum of <ix:nonFraction unitRef="U_xbrlipure" id="F_000863" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231" decimals="INF" scale="-2">3</ix:nonFraction>% of the participant&#8217;s compensation.</ix:nonNumeric> Company contributions to the 401(k) Plan totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000865" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million in the years ended December&#160;31, 2020 and 2019, respectively.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000293_dcnt_df6d580f-57f2-439c-9342-1cf05fd57fd3">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Executive Settlement</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, in connection with the departure of the Chief Executive Officer of the Company, the Company awarded benefits, including the following: cash compensation of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:PostemploymentBenefitsLiabilityCurrent" contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20191231" decimals="-5" scale="6">0.9</ix:nonFraction> million, a grant of <ix:nonFraction unitRef="U_xbrlishares" id="F_000867" name="mrus:GrantOfRestrictedStockUnit" contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">30,000</ix:nonFraction> RSUs, extended vesting of his equity incentive awards through June 30, 2021 and extended exercisability of his equity incentive awards through December 31, 2021. The cash compensation is to be paid by the Company by January 31, 2020. There were no substantive service conditions associated with the benefits awarded other than the passage of time. The Company incrementally recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:PostemploymentBenefitsPeriodExpense" contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231" decimals="-5" scale="6">1.8</ix:nonFraction>&#160;million in general and administrative expense associated with these benefits in the consolidated statement of operations for the year ended December 31, 2019.</p></ix:continuation><ix:nonNumeric id="F_000294" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The two-class method was not applied for the years ended December&#160;31, 2020 and 2019 due to the net loss recognized in each of those periods. </p><ix:nonNumeric id="F_000345" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share allocable to common stockholders are computed as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands&#160;except&#160;per&#160;share&#160;data)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000869" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000870" name="us-gaap:NetIncomeLoss" contextRef="C_0001651311_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000871" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001651311_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,256,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000872" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001651311_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,218,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share allocable to common stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000873" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001651311_20200101_20201231" decimals="2" sign="-">2.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000874" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001651311_20190101_20191231" decimals="2" sign="-">2.28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000295" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Related Party Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into the Incyte collaboration and license agreement and the Incyte share subscription agreement in which the terms and transactional amounts incurred between Incyte and the Company are more fully described in Note 12. Incyte is a shareholder with holdings representing approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000875" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231" decimals="3" scale="-2">10.1</ix:nonFraction>% of the outstanding shares of the Company as of December 31, 2020, and <ix:nonFraction unitRef="U_xbrlipure" id="F_000876" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231" decimals="3" scale="-2">11.1</ix:nonFraction>% as of December 31, 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000296" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001651311_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16. Subsequent Events</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 18, 2021, the Company entered into a Collaboration and License Agreement (the &#8220;Collaboration Agreement&#8221;) and Share Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with Eli Lilly and Company, an Indiana corporation (&#8220;Eli Lilly&#8221;). Eli Lilly has agreed to pay an upfront, non-refundable payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000877" name="mrus:NonRefundableUpfrontPaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118" decimals="-6" scale="6">40</ix:nonFraction> million for the rights granted under the Collaboration Agreement within 30 days following the Effective Date. Eli Lilly will fund the research and development activities to be conducted by the Company for each program under an agreed research plan and budget. With respect to each product arising from each program, the Company is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="mrus:FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118" decimals="-6" scale="6">290</ix:nonFraction> million in future contingent development and regulatory milestones and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000879" name="mrus:CommercialSalesMilestones" contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118" decimals="-6" scale="6">250</ix:nonFraction> million in commercial sales milestones, for a total of up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000880" name="mrus:MilestonePaymentsReceivable" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118" decimals="-8" scale="9">1.6</ix:nonFraction> billion for a single product generated from all three programs. The Company is further eligible to receive, on a product-by-product and country-by-country basis, tiered royalties based on the level of worldwide aggregate annual net sales at percentages ranging from the mid-single digits to low double digits until the royalty term expires. In connection with entering into the Collaboration Agreement, pursuant to the Subscription Agreement, on January 18, 2021, Eli Lilly agreed to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000881" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118" decimals="INF" format="ixt:numdotdecimal">706,834</ix:nonFraction> common shares of the Company at a price per share of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000882" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118" decimals="3">28.295</ix:nonFraction> for aggregate gross proceeds to the Company of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118" decimals="-6" scale="6">20</ix:nonFraction> million. Eli Lilly agreed not to transfer, sell, or otherwise dispose of the Shares for a period of time following the Closing Date, subject to certain customary exceptions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 21, 2021, the Company entered into an underwriting agreement with Jefferies LLC and SVB Leerink LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), in connection with the issuance and sale by the Company in a public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000884" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121" decimals="INF" format="ixt:numdotdecimal">4,848,485</ix:nonFraction> common shares of the Company, nominal value &#8364;<ix:nonFraction unitRef="U_iso4217EUR_xbrlishares" id="F_000885" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121" decimals="2">0.09</ix:nonFraction> per share, at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000886" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121" decimals="2">24.75</ix:nonFraction> per share, less underwriting discounts and commissions. The Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000887" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121" decimals="INF" format="ixt:numdotdecimal">727,272</ix:nonFraction> common shares at the public offering price, less underwriting discounts and commissions. On January 21, 2021, the Underwriters exercised this option in full. The closing of the offering occurred on January 25, 2021, resulting in aggregate net proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121" decimals="-5" scale="6">129.7</ix:nonFraction> million.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>mrus-ex41_15.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mrus-ex41_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"><a name="page86"></a>&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page116"></a>Exhibit 4.1</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</p>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">REGISTERED PURSUANT TO SECTION 12 OF THE</p>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.78%;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, Merus N.V. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. Set forth below is a summary of certain information concerning our share capital as well as a summary of certain material provisions of our articles of association (our &#8220;Articles of Association&#8221;) and relevant provisions of Dutch law. Because the following is only a summary, it does not contain all of the information that may be important to you. The summary below does not purport to be complete and is qualified in its entirety by reference to applicable Dutch law and our Articles of Association, which has been publicly filed with the Securities and Exchange Commission.</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.14%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated on June 16, 2003 as a private company with limited liability (<font style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</font>) under Dutch law. In connection with the initial public offering of our common shares, we converted into a Dutch public company with limited liability (<font style="font-style:italic;">naamloze</font> <font style="font-style:italic;">vennootschap</font>).</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:4.09%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are registered with the Dutch Trade Register (<font style="font-style:italic;">handelsregister</font>) under number 30189136. Our corporate seat is in Utrecht, the Netherlands, and our registered office is Yalelaan 62, 3584 CM Utrecht, the Netherlands.</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share Capital</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Common Shares</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized share capital is &#8364;8,100,000, comprised of 45,000,000 common shares and 45,000,000 preferred shares, nominal value &#8364;0.09 per share.</p>
<p style="line-height:17pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Preferred Shares</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.36%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 24, 2016, we entered into a call option agreement (the &#8220;call option agreement&#8221;) with an independent foundation (<font style="font-style:italic;">stichting</font>) under Dutch law called Stichting Continu&#239;teit Merus (the &#8220;Protective Foundation&#8221;) which agreement was most recently amended on August 27, 2018, pursuant to which the Protective Foundation would be allowed to acquire a number of preferred shares, which number is equal to the lesser of the following numbers: (i) the total number of shares (of whichever class) of our issued capital held by third parties immediately prior to the issuance of such preferred shares less the number of preferred shares already held by the Protective Foundation at that time (if any) and less one; or (ii) the maximum number of preferred shares that may be issued under our authorized capital as included in the Articles of Association, without approval by our general meeting of shareholders or our board of directors. There are no preferred shares outstanding and we have no present plans to issue any preferred shares other than pursuant to an exercise by the Protective Foundation of its rights under the call option agreement.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Articles of Association</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.85%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set forth below is a summary of relevant information concerning our share capital and material provisions of our Articles of Association and applicable Dutch law. This summary does not constitute legal advice regarding those matters and should not be regarded as such.</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Amendment of Articles of Association</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwrjt5hibe5u000001.jpg" title="" alt="" style="width:749px;height:4px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:92.87%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page117"></a>Exhibit 4.1</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.02%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The general meeting of shareholders can only resolve to amend the Articles of Association at the proposal of the board of directors. A resolution by the general meeting of shareholders to amend the Articles of Association requires a simple majority of the votes cast.</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Company&#8217;s Shareholders&#8217; Register</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.25%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must keep our shareholders&#8217; register accurate and up-to-date. The board of directors keeps our shareholders&#8217; register and records names and addresses of all holders of registered shares, showing the date on which the registered shares were acquired, the date of the acknowledgement of the transfer by or notification of the transfer to us as well as the amount paid on each share. The register also includes the names and addresses of those with a right to use and enjoyment in common shares belonging to another person (<font style="font-style:italic;">vruchtgebruik</font>) or a pledge in respect of registered shares, as well as any other particulars which must be recorded in our shareholders&#8217; register pursuant to Dutch law.</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Corporate Objectives</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.36%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate objectives are: (1) to develop products and services in the area of biotechnology, (2) to finance group companies or other parties, (3) to borrow, to lend to raise funds, including the issue of bonds, promissory notes or other financial instruments or evidence of indebtedness as well as to enter into agreements in connection with the aforementioned, (4) to supply advice and to render services to group companies and other parties, (5) to render guarantees, to bind us, to provide security, to warrant performance in any other way and to assume liability, whether jointly and severally or otherwise, in respect of obligations of group companies or other parties, (6) to incorporate, to participate in any way whatsoever in, to manage, to supervise and to hold any other interest in other entities, companies, partnerships and businesses, (7) to obtain, alienate, encumber, manage and exploit registered property and items of property in general, (8) to trade in currencies, securities and items of property in general, (9) to develop and trade in patent, trademarks, licenses, know-how and other intellectual property rights, and (10) to perform any and all activity of an industrial, financial or commercial nature and to do anything which in the broadest sense is connected with or may be conducive to the above-mentioned objects.</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Limitation on Liability and Indemnification Matters</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dutch law, directors may be held liable by us or by third parties for damages in the event of improper or negligent performance of their duties, including as a result of infringement of our Articles of Association or of certain provisions of the Dutch Civil Code. In certain circumstances, they may also incur additional specific civil and criminal liabilities. Directors and certain other officers are insured under an insurance policy taken out by us against damages resulting from their conduct when acting in the capacities as such directors or officers. We have also entered into agreements with our directors and our senior management to indemnify them against expenses and liabilities to the fullest extent permitted by law. These agreements provide, subject to certain exceptions, for indemnification for related expenses including, among other expenses, attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred by any of these individuals in any action or proceeding. In addition, our Articles of Association provide for indemnification of our current and former directors (and such other of our current or former officer or employee as designated by our board of directors), including reimbursement for reasonable legal fees and damages or fines based on acts or failures to act in their duties. No indemnification shall be given to an indemnified officer (1) if a competent court or arbitral tribunal has established, without possibility for appeal, that the acts or omissions of such indemnified officer that led to the financial losses, damages, expenses, suit, claim, action or legal proceedings resulted from either an improper performance of his or her duties as an officer of the company or an unlawful or illegal act, (2) to the extent that his or her financial losses, damages and expenses are covered by insurance and the insurer has settled, or has provided reimbursement for, these financial losses, damages and expenses (or has irrevocably undertaken to do so) and (3) in relation to proceedings brought by such indemnified officer against us, except for proceedings brought to enforce indemnification to which he or she is entitled pursuant to our Articles of Association or an agreement between such indemnified officer and us which has been approved by our board of directors. Furthermore, indemnification under our Articles of Association will generally not be available in instances of willful (<font style="font-style:italic;">opzettelijk</font>), intentionally reckless (<font style="font-style:italic;">bewust roekeloos</font>) or seriously culpable (<font style="font-style:italic;">ernstig verwijtbaar</font>) conduct unless Dutch law provides otherwise.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwrjt5hibe5u000002.jpg" title="" alt="" style="width:749px;height:4px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page118"></a>Exhibit 4.1</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Shareholders&#8217; Meetings and Consents</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">General Meeting</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.18%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General meetings of shareholders are held in Utrecht, Amsterdam, Rotterdam, The Hague or in the municipality of Haarlemmermeer (Schiphol Airport), all of which are in the Netherlands. The annual general meeting of shareholders must be held within six months of the end of each financial year. Additional extraordinary general meetings of shareholders may also be held, whenever considered appropriate by the board of directors. An additional extraordinary general meeting of shareholders must also be held within three months after our board of directors has considered it to be likely that our shareholders&#8217; equity has decreased to an amount equal to or lower than half of our paid up and called up capital, in order to discuss the measures to be taken if so required. If our board of directors has failed to ensure the annual general meeting of shareholders or the mandatory extraordinary general meeting of shareholders is held, each shareholder or others with meeting rights under Dutch law may be authorized by the competent Dutch court in preliminary relief proceedings to do so.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.18%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Dutch law, one or more shareholders or others with meeting rights under Dutch law, who jointly represent at least one-tenth of the issued capital may request us to convene a general meeting, setting out in detail the matters to be discussed. If our board of directors has not taken the steps necessary to ensure that such meeting can be held within six weeks after the request, the requesting party/parties may, on their application, be authorized by the competent Dutch court in preliminary relief proceedings to convene a general meeting of shareholders.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.53%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General meetings of shareholders can be convened by a notice to be published in a Dutch daily newspaper with national circulation, which shall include an agenda stating the items to be voted and/or discussed and any other particulars required under Dutch law. The agenda shall include such items as have been included therein by the board of directors. The agenda shall also include such items requested by one or more shareholders or others with meeting rights under Dutch law, representing at least 3% of the issued share capital. Requests must be made in writing and received by us at least 60 days before the day of the meeting. No resolutions shall be adopted on items other than those which have been included in the agenda, unless by a unanimous vote of all shareholders and others with voting rights.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Dutch Corporate Governance Code (the &#8220;DCGC&#8221;), shareholders are expected to exercise the right of requesting the convening of a general meeting of shareholders or of putting an item on the agenda only after consulting the board of directors in that respect. If one or more shareholders intend to request that an item be put on the agenda that may result in a change in our strategy (e.g., the removal of directors), the board of directors should be given the opportunity to invoke a reasonable response time of up to 180 days after the board of directors is informed of the intentions of the shareholder(s). The board of directors should use this period for further deliberation, constructive consultation (in any event with the shareholder(s) who have made the request) and the exploration of alternatives. At the end of the response period, the board of directors should report its actions to the general meeting of shareholders. The response time may be invoked only once for any given general meeting of shareholders and may not be invoked for an agenda item in respect of which the response period has been invoked previously or for a general meeting of shareholders if a shareholder holds at least 75% of our issued share capital as a consequence of a successful public offer (irrespective of whether the offer was friendly or hostile).</p>
<p style="line-height:4pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.53%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The general meeting is presided over by the chairman of the board of directors. If no chairman has been elected or if he or she is not present at the meeting, the general meeting shall be presided over by the chief executive officer. If no chief executive officer has been elected or if he or she is not present at the meeting, the general meeting shall be presided over by another director present at the meeting. If no director is present at the meeting, the general meeting shall be presided over by any other person appointed by the general meeting. In each case, the person who should chair the general meeting pursuant to the rules described above may appoint another person to chair the general meeting instead. Directors may always attend a general meeting of shareholders. In these meetings, they have an advisory vote. The chairman of the meeting may decide at his or her discretion to admit other persons to the meeting.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.42%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shareholders and others with meeting rights under Dutch law are authorized to attend the general meeting of shareholders, to address the meeting and, in so far as they have such right, to vote. For this purpose, those who have voting rights and/or meeting rights under Dutch law on the record date for a general meeting of shareholders (i.e., the 28th day prior to the meeting) and are recorded as such in a register designated by the board of directors shall be</p>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwrjt5hibe5u000003.jpg" title="" alt="" style="width:749px;height:4px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:92.87%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page119"></a>Exhibit 4.1</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.53%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considered to have those rights, irrespective of whoever is entitled to the shares at the time of the general meeting of shareholders. The board of directors is free to determine, when convening a general meeting of shareholders, whether to apply a record date.</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Quorum and Voting Requirements</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each common share and each preferred share carries the right to cast one vote at the general meeting of shareholders. This right can be exercised in person or by proxy. No vote may be cast at a general meeting of shareholders in respect of a share belonging to us or any of our subsidiaries or in respect of a share for which we or any of our subsidiaries holds the depository receipts. Persons with a right to the use and enjoyment of our shares held by another person and pledgees of shares belonging to us or our subsidiaries are not precluded from exercising their voting rights if the right to use and enjoyment or pledge was created before the relevant share belonged to us or one of our subsidiaries. We and our subsidiaries may not vote shares in respect of which we or any of our subsidiaries hold(s) a right of use and enjoyment or a pledge. Shares which cannot be voted pursuant to these rules will not be taken into account for the purpose of determining the number of votes cast, or the amount of the share capital that is represented, at a general meeting of shareholders.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.18%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to any provision of mandatory Dutch law and any higher quorum requirement stipulated in our Articles of Association, if and for as long as the Company is subject to the rules and requirements of a securities exchange and such securities exchange requires the Company to have a quorum for the general meeting of shareholders, then the general meeting of shareholders can only pass resolutions if at least one third of our issued and outstanding shares are present or represented at such general meeting.</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Board of Directors</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Election of Directors</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.53%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our Articles of Association, the directors are appointed by the general meeting of shareholders upon nomination by our board of directors. However, the general meeting of shareholders may at all times overrule the</p>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.67%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">binding nomination by a resolution adopted by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital. If the general meeting of shareholders overrules the binding nomination, the board of directors shall make a new nomination. If the nomination comprises one candidate for a vacancy, a resolution concerning the nomination shall result in the appointment of the candidate, unless the nomination is overruled.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.71%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At a general meeting of shareholders, a resolution to appoint a director can only be passed in respect of candidates whose names are stated for that purpose in the agenda of that general meeting of shareholders or in the explanatory notes thereto. Upon the appointment of a person as a director, the general meeting of shareholders shall determine whether that person is appointed as executive director or as non-executive director.</p>
<p style="line-height:4pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Duties and Liabilities of Directors</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.89%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dutch law, the board of directors as a collective is responsible for our management, strategy, policy and operations. The executive directors manage our day-to-day business and operations and implement our strategy. The non-executive directors focus on the supervision on the policy and functioning of the performance of the duties of all directors and our general state of affairs. Each director has a statutory duty to act in the corporate interest of the company and its business. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the company also applies in the event of a proposed sale or break-up of the company, provided that the circumstances generally dictate how such duty is to be applied and how the respective interests of various groups of stakeholders should be weighed. Any resolution of the board of directors regarding a material change in our identity or character requires approval of the general meeting of shareholders.</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Dividends and Other Distributions</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Amount Available for Distribution</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwrjt5hibe5u000004.jpg" title="" alt="" style="width:749px;height:4px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:92.87%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page120"></a>Exhibit 4.1</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.18%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a Dutch public company with limited liability (<font style="font-style:italic;">naamloze vennootschap</font>), we may only make distributions to the extent that our shareholders&#8217; equity exceeds the sum of the paid-in and called-up share capital plus the reserves as required to be maintained by Dutch law. Under our Articles of Association, a dividend is first paid out of the profit, if available for distribution, with respect to any preferred shares. After that, the board of directors shall determine which part of the remaining profit shall be added to our reserves. After reservation by the board of directors of any profit, the remaining profit will be at the disposal of the general meeting of shareholders for distribution on our common shares. However, a distribution to the holders of common shares can only be resolved upon by the general meeting upon a proposal of the board of directors.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.18%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may only make a distribution of dividends after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The board of directors is permitted, subject to certain requirements, to declare interim dividends (or other interim distributions) without the approval of the general meeting of shareholders. The general meeting of shareholders, subject to certain requirements and a proposal to that effect made by the board of directors, may decide to make distributions from our distributable reserves. The board of directors, however, may resolve to charge amounts to be paid up on shares against our reserves, irrespective of whether those shares are issued to existing shareholders.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.36%;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends and other distributions shall be payable on such date and, if it concerns a distribution in cash, in such currency as determined by the board of directors. If it concerns a distribution in the form of assets, the board of directors shall determine the value attributed to such distribution for purposes of recording the distribution in our accounts with due observance of applicable law (including the applicable accounting principles). Claims to dividends and other distributions not paid within five years from the date that such dividends or distributions became payable, will lapse and any such amounts will be considered to have been forfeited to us (<font style="font-style:italic;">verjaring</font>). For the purpose of calculating the amount or allocation of any distribution, shares held by us in our own capital shall not be taken into account. No distribution shall be made to us in respect of shares held by us in our own capital.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate paying any cash dividends for the foreseeable future.</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Squeeze out Procedures</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.78%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dutch law, a shareholder who, alone or together with one or more group companies, for his/their own account contribute(s) at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of their shares to the claimant. The proceedings are held before the Enterprise Chamber of the Amsterdam court of Appeal (the &#8220;Enterprise Chamber&#8221;). The Enterprise Chamber may grant the claim for squeeze out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.96%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chamber on the value to be paid for the shares of the minority shareholders. Once the order to transfer becomes final before the Enterprise Chamber, the shareholder acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the shares to be acquired whose addresses are known to such shareholder. Unless the addresses of all of them are known to the acquiring shareholder, such shareholder is required to publish the same in a Dutch daily newspaper with a national circulation.</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Protective measures</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.89%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. Our governance arrangements include several provisions that may have the effect of making a takeover of our company more difficult or less attractive. In this respect, our general meeting of shareholders has granted the right to the Protective Foundation to acquire preferred shares pursuant to the call option agreement. The call option is continuous in nature and can be exercised repeatedly on multiple occasions. If the Protective Foundation exercises the call option pursuant to the call option agreement, a number of preferred shares, which number is equal to the lesser of the following numbers: (i) the total number of shares (of whichever class) of our issued capital held by third parties immediately prior to the issuance of such preferred shares less the number of preferred shares already held by the Protective Foundation at that time (if any) and less one; or (ii) the maximum number of preferred shares that may be issued under our authorized capital as included in the Articles of Association, will be issued to the Protective Foundation. These preferred shares will be issued to the Protective</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwrjt5hibe5u000005.jpg" title="" alt="" style="width:749px;height:4px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:92.87%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page121"></a>Exhibit 4.1</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.89%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foundation under the obligation to pay up to 25% of their nominal value upon issuance. In order for the Protective Foundation to finance the issue price in relation to the preferred shares, the Protective Foundation intends to enter into a finance arrangement with a bank. As an alternative to securing financing with a bank, subject to applicable restrictions under Dutch law, the call option agreement provides that the Protective Foundation may request us (1) to provide, or cause our subsidiaries to provide, sufficient funding to the Protective Foundation to enable it to satisfy the payment obligation (or part thereof) in cash and/or (2) to charge an amount equal to the payment obligation (or part thereof) against our profits and/or reserves in satisfaction of such payment obligation. The Protective Foundation&#8217;s articles of association provide that it will promote and protect the best interests of us, our associated business and our stakeholders and opposing influences that conflict with these interests and threaten our strategy, continuity, independence and/or identity. These influences may include a third party acquiring a significant percentage of our common shares, the announcement of an unsolicited public offer for our common shares, other concentration of control over our common shares or any other form of undue pressure on us to alter our strategic policies. The Protective Foundation is structured to operate independently of us.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.18%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated above, if the Protective Foundation would exercise its call option, the preferred shares to be issued pursuant thereto shall be issued against the obligation to pay up to 25% of their nominal value. The voting rights of our shares are based on nominal value and, as we expect our common shares to trade substantially in excess of nominal value, preferred shares issued at 25% of their nominal value can carry significant voting power for a substantially reduced price compared to the price of our common shares and thus can be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a pre-determined rate.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.53%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Protective Foundation would be expected to require us to cancel its preferred shares once the perceived threat to the company and its stakeholders has been removed or sufficiently mitigated or neutralized. However, subject to the same limitations described above, the Protective Foundation would continue to have the right to exercise the call option in the future in response to a new threat to the interests of us, our business and our stakeholders from time to time.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.14%;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our Articles of Association contain certain provisions which might have the effect of delaying or preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of us. These provisions include:</p>
<p style="line-height:3pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:8.5pt;font-family:Arial;color:#000000;">requirements that certain shareholder matters, including the amendment of our Articles of Association may only be voted on by the general meeting of shareholders at the proposal of our board of directors;</font></p></td>
<td valign="top" style="width:1.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="line-height:3pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:8.5pt;font-family:Arial;color:#000000;">a provision that our directors may only be removed by the general meeting of shareholders by a two-thirds majority of votes cast, provided such majority represents more than half of our issued share capital if such removal is not proposed by our board of directors; and</font></p></td>
<td valign="top" style="width:2.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:8.5pt;font-family:Arial;color:#000000;">our directors being appointed on the basis of a binding nomination by our board of directors, which can only be overruled by the general meeting of shareholders by a resolution adopted by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital (in which case the board of directors shall make a new nomination).</font></p></td>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, we have implemented staggered terms of our directors, as a result of which our directors are not all subject to election in any one year.</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Dutch cooling-off period in face of shareholder activism or hostile take-over</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at 12 February 2021, a bill is pending in Dutch Senate which, if enacted in its current form, would introduce a statutory cooling-off period of up to 250 days during which the general meeting of shareholders would not be able to dismiss, suspend or appoint members<font style="font-size:9pt;"> </font>of the board of<font style="font-size:9pt;"> </font></p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directors</font><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (or amend the</font><font style="font-family:Calibri;"> </font><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provisions in the Articles of Association dealing with those matters) unless those matters would be proposed by </font><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the board of directors</font><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This cooling-off period could be invoked by the </font><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board of directors</font><font style="font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in case:</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:6.41%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shareholders, using either their shareholder proposal right or their right to request a general meeting of shareholders, propose an agenda item for the general meeting of shareholders to dismiss, suspend or appoint a member of the board of directors (or to amend any provision in the Articles of Association dealing with those matters); or</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:6.41%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a public offer for the Company is made or announced without the Company's support, provided, in each case, that the board of directors believes that such proposal or offer materially conflicts with the interests of the Company and its business.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cooling-off period, if invoked, ends at occurrence of the earliest of the following events:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the expiration of 250 days from:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:12.81%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in case of shareholders using their shareholder proposal right, the day after the deadline for making such proposal expired;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:12.81%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in case of Shareholders using their right to request a general meeting of shareholders, the day when they obtain court authorization to do so; or</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in case of a hostile offer being made, the first following day;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the day after the hostile offer having been declared unconditional; or </p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:6.41%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the board of directors voluntarily terminating the cooling-off period.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, shareholders representing at least 3% of the Company's issued share capital may request the Dutch Enterprise Chamber of the Amsterdam Court of Appeals for early termination of the cooling-off period. The Enterprise Chamber must rule in favour of the request if the shareholders can demonstrate that:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:6.41%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  the board of directors, in light of the circumstances at hand when the cooling-off period was invoked, could not reasonably have come to the conclusion that the relevant shareholder proposal or hostile offer constituted a material conflict with the interests of the Company and its business;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:6.41%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the board of directors cannot reasonably believe that a continuation of the cooling-off period would contribute to careful policy-making;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:6.41%;text-indent:-6.41%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if other defensive measures have been activated during the cooling-off period and not terminated or suspended at the relevant shareholders' request within a reasonable period following the request (i.e., no 'stacking' of defensive measures).</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the cooling-off period, if invoked, the board of directors must gather all relevant information necessary for a careful decision-making process. In this context, the board of directors must at least consult with shareholders representing at least 3% of the Company's issued share capital at the time the cooling-off period was invoked and the Company&#8217;s works council. Formal statements expressed by these stakeholders during such consultations must be published on the Company's website to the extent these stakeholders have approved that publication. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately one week following the last day of the cooling-off period, the board of directors must publish a report in respect of its policy and conduct of affairs during the cooling-off period on the Company's website. This report must remain available for inspection by shareholders and others with meeting rights under Dutch law at the Company's office and must be tabled for discussion at the next general meeting of shareholders.<font style="font-weight:bold;font-style:italic;color:#000000;"> </font></p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Listing</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common shares are listed on The Nasdaq Global Market under the symbol &#8220;MRUS.&#8221;</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. transfer agent and registrar for our common shares is American Stock Transfer &amp; Trust Company, LLC.</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="line-height:16pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page122"></a><a name="page122"></a>6</p>
<p style="margin-top:12pt;margin-bottom:9pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4.5
<SEQUENCE>3
<FILENAME>mrus-ex1045_90.htm
<DESCRIPTION>EX-10.4.5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mrus-ex1045_90.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.4.5</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;"><a name="_cp_text_1_1050"></a><a name="_cp_blt_1_1155"></a><a name="_cp_blt_2_1154"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">COLLABORATION AND LICENSE AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1"></a>between</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_4"></a>ELI LILLY AND COMPANY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERUS N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_6"></a>&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="zzmpTOCHeader_Primary"></a>Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="mpTableOfContents"></a><a name="_cp_text_1_115"></a>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825865">DEFINITIONS1</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825866">GOVERNANCE AND JOINT STEERING COMMITTEE18</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825867">Alliance Managers18</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825868">Project Managers19</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825869">Joint Steering Committee19</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825870">Working Groups19</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825871">Function and Powers of the JSC19</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825872">Meetings20</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825873">Decisions21</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825874">Authority21</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825875">TARGET SELECTION AND REPLACEMENT22</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825876">Lilly Targets22</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825877">Additional Targets22</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825878">Replacement Targets22</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825879">Reserved Targets22</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825880">Gatekeeper Process23</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825881">RESEARCH PROGRAM23</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825882">Research Program Overview and Responsibilities23</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825883">Diligence Efforts23</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825884">Research Term24</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825885">Research Plans24</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825886">Records; Reports25</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825887">Research Program Funding25</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825888">Certain Standards Applicable to Work26</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825889">Subcontracting27</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825890">Lilly Materials27</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825891">Merus Materials27</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825892">DEVELOPMENT, REGULATORY AND COMMERCIAL MATTERS28</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825893">Responsibilities; Parallel Target Pair Programs28</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:1.12%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_textHF_105_1286"></a>Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(continued)</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooperation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</font></a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825895">Reports29</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825896">Regulatory Responsibilities29</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825897">Adverse Event Reporting29</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825898">LICENSE RIGHTS30</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825899">License Grant to Lilly30</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825900">Existing Third Party Agreements30</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825901">License Grant to Merus30</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825902">Third-Party Sublicenses30</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825903">No Implied Rights31</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825904">Retained Rights31</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825905">Safe Harbor Research31</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.8</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825906">Inclusion of Third Party IP31</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825907">EXCLUSIVITY32</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825908">Merus Exclusivity Obligations32</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825909">Certain Sequence Exclusivity33</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825910">Transactions Involving Competing Programs33</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 8</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825911">FEES, ROYALTIES, &amp; PAYMENTS34</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825912">Upfront Payment34</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825913">Equity Investment34</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825914">Milestone Payments34</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825915">Royalties on Products36</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825916">Method of Payment; Currency Conversion37</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825917">Records and Audits38</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825918">Late Payments38</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825919">Taxes38</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 9</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825920">INTELLECTUAL PROPERTY39</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825921">Ownership of Intellectual Property39</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825922">Patent Prosecution and Maintenance41</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:1.12%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.12%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_textHF_105_1286"></a>Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(continued)</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Infringement and Misappropriation by Third Parties</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</font></a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825924">Defense and Settlement of Third Party Claims45</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825925">Patent Extensions; Patent Linkage46</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825926">CREATE Act46</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825927">Trademarks46</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 10</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825928">REPRESENTATIONS, WARRANTIES AND COVENANTS46</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825929">Mutual Representations and Warranties46</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825930">Merus Representations and Warranties47</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825931">Mutual Covenants48</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825932">Compliance49</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825933">Disclaimer51</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 11</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825934">INDEMNIFICATION51</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825935">Indemnity51</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825936">Insurance52</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 12</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825937">CONFIDENTIALITY52</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825938">Confidential Proprietary Information52</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825939">Publicity54</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825940">Publication55</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 13</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825941">TERM &amp; TERMINATION55</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825942">Term.55</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825943">Termination for Material Breach55</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825944">Termination by Lilly57</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825945">Effects of Termination57</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825946">Reversion of Product Rights58</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825947">Survival58</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825948">Bankruptcy Code58</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 14</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825949">GOVERNING LAW; DISPUTE RESOLUTION59</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825950">Governing Law59</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825951">Disputes59</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:1.12%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.12%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_textHF_105_1286"></a>Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(continued)</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;margin-left:1.19%;margin-right:1.04%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation; Equitable Relief</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</font></a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.54%;">
<tr>
<td valign="top" style="width:14.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">Article 15</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825953">MISCELLANEOUS60</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825954">Entire Agreement; Amendment60</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825955">Limitation of Liability60</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825956">Independent Contractors60</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825957">Notice60</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825958">Severability61</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825959">Non-Use of Names61</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825960">Assignment62</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825961">Merus Change of Control62</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825962">Waivers65</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.10</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825963">Force Majeure65</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.11</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825964">Interpretation65</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.12</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825965">Counterparts; Electronic Signatures66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.13</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825966">Expenses66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.14</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825967">Further Assurances66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.15</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825968">No Third Party Beneficiary Rights66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.16</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825969">Construction66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.17</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825970">Cumulative Remedies66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc61825971">Extension to Affiliates66</a></p></td>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:1.12%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.12%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_9kR3WTr2AA588Sskht80jm43r013J"></a><a name="_9kR3WTr2AA588Sskht80jm43r013J"></a>COLLABORATION AND LICENSE AGREEMENT</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4CC7AAUumjvA2lo65t235L"></a><a name="_9kR3WTr19A459K5tsgpqs8"></a><a name="_9kR3WTr2444EFH5tsgpqs8"></a><a name="_9kR3WTr24447GT8ggeu141KBy3"></a><a name="_9kR3WTr24447HU8ggeu141KBy3"></a><a name="_9kR3WTr19A468XEn7F"></a><a name="_9kR3WTr24448DaEn7F"></a>This<font style="font-weight:bold;font-variant: small-caps;"><a name="_9kMHG5YVt4CC7AAUumjvA2lo65t235L"></a> Collaboration and License Agreement</font><a name="_9kR3WTr19A459K5tsgpqs8"></a><a name="_9kR3WTr2444EFH5tsgpqs8"></a> (&#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is entered into as of January 18, 2021<a name="_9kR3WTr24447GT8ggeu141KBy3"></a><a name="_9kR3WTr24447HU8ggeu141KBy3"></a> (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;) by and between <font style="font-weight:bold;font-variant: small-caps;">Merus N.V.,</font> a corporation organized and existing under the laws of the Netherlands and having an address at Yalelaan 62, 3584 CM Utrecht, The Netherlands (&#8220;<font style="font-weight:bold;font-style:italic;">Merus</font>&#8221;), and <font style="font-weight:bold;font-variant: small-caps;">Eli Lilly and Company</font>, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.&nbsp;&nbsp;(&#8220;<font style="font-weight:bold;font-style:italic;">Lilly</font>&#8221;).&nbsp;&nbsp;<a name="_9kR3WTr19A468XEn7F"></a><a name="_9kR3WTr24448DaEn7F"></a>Lilly and Merus are each hereafter referred to individually as a &#8220;<font style="font-weight:bold;font-style:italic;">Party</font>&#8221; and together as the &#8220;<font style="font-weight:bold;font-style:italic;">Parties</font><font style="font-style:italic;">.</font>&#8221;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Merus is a biotechnology company engaged in the research and development of bispecific antibody therapeutics in immuno-oncology;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Lilly is a pharmaceutical company engaged in the research, development, manufacturing, marketing and distribution of pharmaceutical products, including therapeutic products;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Merus and Lilly desire to collaborate to research, discover and develop certain Compounds or Products using the Merus Know-How and Merus Patents (each as defined below);</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Lilly desires to obtain from Merus, and Merus desires to grant to Lilly, certain exclusive license rights to research, discover, develop, manufacture, and commercialize such Compounds or Products, subject to the terms and conditions of this Agreement; and </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;">, </font><font style="font-weight:normal;font-variant: normal;">in connection with the above and the Parties entering into this Agreement, Lilly is making an equity investment in Merus through an acquisition of common shares of Merus stock pursuant to that certain Share Subscription Agreement, dated as of the Effective Date, between the Parties (&#8220;</font><font style="font-style:italic;font-variant: normal;">Purchase Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;).</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Now, Therefore<font style="font-weight:normal;font-variant: normal;">, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref403999813"></a><a name="_Ref506472410"></a><a name="_Toc61825865"></a><a name="_Ref61288101"></a><font style="Background-color:#auto;text-decoration:none;">Article 1</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref61288101"></a>DEFINITIONS</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms used in this Agreement and the Exhibits hereto shall have the following meanings (or as defined elsewhere in this Agreement):</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2995899AK6imtukw1"></a><a name="_Ref403664285"></a><a name="_Ref440447035"></a><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">1st Extension Term</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">2nd Extension Term</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Acquirer</font><font style="color:#000000;">&#8221; has the meaning set forth in the definition of &#8220;Change of Control.&#8221; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Acquisition Transaction</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.6</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">ADC</font><font style="color:#000000;">&#8221; means a monospecific antibody that is conjugated to a payload with a linker.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Additional Target</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 3.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref536021574"></a><a name="_9kMHG5YVt4666GIMHz5A61ztm"></a><a name="_9kR3WTr2334DJolx384z"></a><a name="_cp_text_1_118"></a><font style="Background-color:#auto;text-decoration:none;">1.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Affiliate</font><font style="color:#000000;">&#8221; means, with respect to either Party, any entity that, at the relevant time (whether as of the Effective <a name="_9kMHG5YVt4666GIMHz5A61ztm"></a>Date or thereafter), directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party, for so long as such control exists.&nbsp;&nbsp;As used in this </font><font style="text-decoration:underline;color:#000000;">Section 1.7</font><font style="color:#000000;"><a name="_9kR3WTr2334DJolx384z"></a>, &#8220;control&#8221;<a name="_cp_text_1_118"></a> means: (a) to possess, directly or indirectly, the power to direct or cause the direction of the management or policies of an entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b) direct or indirect ownership of [*] or more of the voting share capital or other equity interest in such entity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Agreement</font><font style="color:#000000;">&#8221; has the meaning set forth in the Preamble.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK39"></a><font style="Background-color:#auto;text-decoration:none;">1.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Alliance Manager</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 2.1</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_120"></a><a name="_cp_text_1_122"></a><a name="_cp_text_1_124"></a><font style="Background-color:#auto;text-decoration:none;">1.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Applicable Laws</font><font style="color:#000000;">&#8221;<a name="_cp_text_1_120"></a> means the applicable provisions of any and all federal, national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, guidelines or requirements, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, or permits of or from any court, arbitrator, Regulatory Authority, Governmental Authority, taxing authority<a name="_cp_text_1_122"></a>, national securities exchange or exchange <a name="_cp_text_1_124"></a>listing organization having jurisdiction over or related to the relevant subject item that may be in effect from time to time during the Term.&nbsp;&nbsp;For the avoidance of doubt, Applicable Laws include all applicable data protection and privacy laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Background Know-How</font><font style="color:#000000;">&#8221; means Lilly Background Know-How or Merus Background Know-How.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Biclonics&#174; Antibody</font><font style="color:#000000;">&#8221; means any bivalent mono- or bispecific bivalent antibody (a) the rights to which are Controlled by Merus or its Affiliates as of the Effective Date or during the Research Term; or (b) that is discovered or generated under the Agreement; that in each case of (a) and (b), contains at least one (1) Target Binder either: [*]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_137"></a><a name="_cp_blt_2_136"></a><a name="_cp_blt_1_139"></a><a name="_cp_blt_2_138"></a><a name="_cp_blt_1_141"></a><a name="_cp_blt_2_140"></a><a name="_9kR3WTr5B889C"></a><a name="_9kMHG5YVt7DAABE"></a><font style="Background-color:#auto;text-decoration:none;">1.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Biosimilar Product</font><font style="color:#000000;">&#8221; means, with respect to a Product, and on a Product-by- Product and country-by-country basis, any product (including a &#8220;generic product,&#8221; &#8220;biogeneric,&#8221; &#8220;follow-on biologic,&#8221; &#8220;follow-on biological product,&#8221; &#8220;follow-on protein product,&#8221; &#8220;similar biological medicinal product,&#8221; or &#8220;biosimilar product&#8221;) approved by way of: (a) a Regulatory Approval process governing approval of interchangeable or biosimilar biologics as described in 42 U.S.C. &#167; 262, or is the subject of a notice with respect to such Product under 42 U.S.C. &#167; 262(l)(2); or (b) an abbreviated regulatory mechanism or equivalent process for Regulatory Approval to those set forth in subclause (a) by the relevant Regulatory Authority in a country, where such approval referred to or relied on (1)&#160;the Marketing Authorization for such Product held by Lilly or its Affiliate or Sublicensee in such jurisdiction or (2)&#160;the data contained or incorporated by reference in the Marketing Authorization for such Product held by Lilly or its Affiliate or Sublicensee in such jurisdiction, and that in each case: (i) is sold in the same country (or is commercially available in the same country) as such Product by any Third Party that is not a Sublicensee of Lilly or its Affiliates and that did not purchase such product in a chain of distribution that included any of Lilly or any of its Affiliates or its Sublicensees; and (ii) either (A) contains an active ingredient that is &#8220;highly similar&#8221; to such Product (as the phrase </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">&#8220;</font><font style="color:#000000;">highly similar</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> is used in 42 U.S.C. &#167; 262(</font><font style="color:#000000;">i</font><font style="color:#000000;"><a name="_9kR3WTr5B889C"></a>)(2), and subject to the factors set forth in FDA</font><font style="color:#000000;"><a name="_9kMHG5YVt7DAABE"></a>&#8217;</font><font style="color:#000000;">s Guidance for Industry, </font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">Quality Considerations in Demonstrating </font><font style="color:#000000;">Biosimilarity</font><font style="color:#000000;"> of a Therapeutic Protein Product to a Reference Product,</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> (April 2015), at Section V, and any successor FDA guidance thereto)</font><font style="color:#000000;">, or (</font><font style="color:#000000;">B</font><font style="color:#000000;">) meets the equivalency determination by the applicable Regulatory Authority in </font><font style="color:#000000;">any </font><font style="color:#000000;">country</font><font style="color:#000000;"> or jurisdiction outside the United States</font><font style="color:#000000;"> (including a determination that the product is </font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">comparable,</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">interchangeable,</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">bioequivalent,</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">biosimilar</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> or other term of similar meaning, with respect to the Product), in each case, as is necessary to permit substitution of such product for the Product under Applicable Law in such country</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Bona Fide Financing Transaction</font><font style="color:#000000;">&#8221; means a transaction or series of transactions resulting in a Change of Control of Merus where: (a) such Change of Control is a result of a </font><font style="font-style:italic;color:#000000;">bona fide</font><font style="color:#000000;"> transaction [*]; and (b) the Acquirer in the resulting Change of Control is not [*].&nbsp;&nbsp;For the purpose of this definition, [*]</font><font style="font-style:italic;color:#000000;">, mutatis mutandis</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_186"></a><font style="Background-color:#auto;text-decoration:none;">1.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Business Day</font><font style="color:#000000;">&#8221;<a name="_cp_text_1_186"></a> means any day, other than any Saturday, Sunday, or any day that banks are authorized or required to be closed in: (a) Indianapolis, Indiana, (b) Boston, Massachusetts, or (c) the Netherlands.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.16</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Calendar Quarter</font><font style="color:#000000;">&#8221; means each respective period of three (3) consecutive months ending on March&#160;31, June&#160;30, September&#160;30, and December&#160;31 of any Calendar Year.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.17</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Calendar Year</font><font style="color:#000000;">&#8221; means each respective period of twelve (12) consecutive months commencing on January 1 and ending on December 31.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.18</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Change of Control</font><font style="color:#000000;">&#8221; means:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59195552"></a><a name="_DV_M20"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">with respect to either Party: (i) the acquisition by a Third Party, in one transaction or a series of related transactions, of direct or indirect beneficial ownership of more than [*] of the outstanding voting equity securities of such Party; (ii) a merger or consolidation involving such Party, as a result of which a Third Party acquires direct or indirect beneficial ownership of more than [*]<a name="_DV_M20"></a> of the voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (iii) a sale of all or substantially all of the assets of such Party in one transaction or a series of related transactions to a Third Party.&nbsp;&nbsp;The acquiring or combining Third Party in any of (i), (ii)&#160;or (iii), and any of such Third Party&#8217;s Affiliates (whether in existence as of or any time following the applicable transaction, but other than the acquired Party and its Affiliates as in existence prior to the applicable transaction or Affiliates it controls after the applicable transaction) are referred to collectively herein as the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Acquirer</font><font style="color:#000000;">&#8221;; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">with respect to the acquisition of Merus by a Lilly Competitor, whether in one transaction or a series of related transactions, in addition to the items in </font><font style="text-decoration:underline;color:#000000;">Section 1.18(a)</font><font style="color:#000000;">, the acquisition of: (i) majority control of the board of directors or equivalent governing body of Merus; (ii) direct or indirect beneficial ownership of more than [*] of the outstanding voting equity securities of Merus; (iii) the ability to cause the direction of the management or allocation of corporate resources of Merus; or (iv) all or substantially all of the assets of Merus related to the transactions contemplated by this Agreement; in which case such Lilly Competitor and its Affiliates (other than Merus and its Affiliates in existence prior to the applicable transaction) shall also be considered an Acquirer. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.19</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Cell Line Generation</font><font style="color:#000000;">&#8221; means, with respect to a given </font><font style="color:#000000;">Lilly Target or Lilly Target Pair that is the subject of a Research Program, that a cell line for the GMP manufacturing of a Collaboration Compound</font><font style="color:#000000;">, Monospecific Compound</font><font style="color:#000000;"> or Modified Compound or Product directed to such Lilly Target or Lilly Target </font><font style="color:#000000;">P</font><font style="color:#000000;">air </font><font style="color:#000000;">has been generated.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.20</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Change of Control Notice</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMHG5YVt4AA7CDBBCEPUiR2rz8s3"></a><a name="_9kMHG5YVt4BB7CECBCEPUiR2rz8s3"></a><font style="Background-color:#auto;text-decoration:none;">1.21</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Claim</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7CDBBCEPUiR2rz8s3"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7CECBCEPUiR2rz8s3"></a>Section&#160;11.1.1</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.22</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Clinical Trial</font><font style="color:#000000;">&#8221; means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-Marketing Authorization human clinical trial, as applicable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.23</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Code</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 13.7</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.24</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Collaboration Compound</font><font style="font-style:italic;color:#000000;">&#8221; </font><font style="color:#000000;">means, with respect to each Research Program any Research Compound that satisfies the Success Criteria [*]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.25</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Combination Product</font><font style="color:#000000;">&#8221; has the meaning set forth in the definition of &#8220;Net Sales&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24448HRFwvoutlkobTzw4KHC3VhE7N"></a><font style="Background-color:#auto;text-decoration:none;">1.26</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commercial Milestone Event</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.3</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.27</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commercial Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.3</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.28</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commercialization</font><font style="color:#000000;">&#8221; means any and all activities directed to the offering for sale and sale of a Product (or other compound, product or therapy, as the context requires) including: (a) activities directed to storing, marketing, promoting, detailing, distributing, importing, exporting, selling and offering to sell that Product or other compound, product or therapy; (b) conducting Clinical Trials after Marketing Authorization of a Product, or other product or therapy; (c) interacting with Regulatory Authorities regarding the foregoing; and (d) seeking Regulatory Approvals (as applicable) for and registration of that Product, or other product or therapy (</font><font style="font-style:italic;color:#000000;">i.e.</font><font style="color:#000000;">, other than Marketing Authorization, which is addressed within &#8220;Development&#8221;) in the Field in the Territory.&nbsp;&nbsp;When used as a verb, &#8220;</font><font style="font-weight:bold;color:#000000;">to Commercialize</font><font style="color:#000000;">&#8221; and &#8220;</font><font style="font-weight:bold;color:#000000;">Commercializing</font><font style="color:#000000;">&#8221; means to engage in Commercialization and &#8220;</font><font style="font-weight:bold;color:#000000;">Commercialized</font><font style="color:#000000;">&#8221; has a corresponding meaning.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59109892"></a><font style="Background-color:#auto;text-decoration:none;">1.29</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commercially Reasonable Efforts</font><font style="color:#000000;">&#8221; of a Party means, with respect to the performance of Research, Development, Manufacturing, and Commercialization activities with respect to a Compound or Product, the carrying out of such activities with that level of efforts and resources commonly applied by such Party to carry out such a task or obligation, consistent with the general practice followed by such Party relating to other pharmaceutical compounds, products or therapies owned by it, or to which it has exclusive rights, which are of similar market potential at a similar stage in their development or product life, taking into account issues of safety and efficacy, product profile, the competitiveness of Third Party products in development and in the marketplace, supply chain management considerations, [*] the compound, product or therapy (including with respect to patent or regulatory exclusivity), the regulatory structure involved, the profitability of the applicable compound, product or therapy [*], and other relevant technical, legal, scientific or medical factors.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.30</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Compassionate Use Product</font><font style="color:#000000;">&#8221; means any unit of Product that is transferred, sold or otherwise disposed of under a treatment IND, as named patient sales, under any expanded access program, as test marketing, as emergency use sales, or as compassionate use sales.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr255479KFwvoutlkobTzw4KHC3VhE7N"></a><a name="_Ref405220381"></a><font style="Background-color:#auto;text-decoration:none;">1.31</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Competing Program</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.3.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.32</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Compound</font><font style="color:#000000;">&#8221; means a: (a) Research Compound, (b) Collaboration Compound, (c) Monospecific Compound, or (d) Modified Compound, as the context dictates.&nbsp;&nbsp;For clarity, [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr244489JFxplkhs84mqZW02FEy6FBH"></a><a name="_9kMHG5YVt4AA7BJICDEQL3vrqnyEAswfc68LK4C"></a><a name="_9kMHG5YVt4BB7BKJCDEQL3vrqnyEAswfc68LK4C"></a><font style="Background-color:#auto;text-decoration:none;">1.33</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Confidential Proprietary Information</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7BJICDEQL3vrqnyEAswfc68LK4C"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7BKJCDEQL3vrqnyEAswfc68LK4C"></a>Section&#160;12.1.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2AA59GQFxplkhs84mqUM83xAIPPAURFE"></a><font style="Background-color:#auto;text-decoration:none;">1.34</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Confidentiality Agreement</font><font style="color:#000000;">&#8221; means that certain Mutual Confidentiality Agreement between the Parties having an effective date of May 28, 2020, including the First Amendment with an effective date of May 28, 2020, and the Second Amendment with an effective date of May 28, 2020.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2444EGKFx384zxrk"></a><a name="_9kR3WTr2444DNSF5wt"></a><font style="Background-color:#auto;text-decoration:none;">1.35</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Control</font><font style="color:#000000;">&#8221;<a name="_9kR3WTr2444EGKFx384zxrk"></a> or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Controlled</font><font style="color:#000000;">&#8221; means, with respect to any Know-How, Patents, or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license, or otherwise) to grant to the other Party a license, covenant not to sue, sublicense, access, or right to use (as applicable) under such Know-How, Patents, or other intellectual property rights, on the terms and conditions set forth herein; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that in respect of any rights that the granting Party controls pursuant to a Third Party agreement, such rights shall not be considered to be Controlled by the granting Party hereunder: [*].<a name="_9kR3WTr2444DNSF5wt"></a> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.36</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Cover</font><font style="color:#000000;">&#8221; means, with respect to a particular subject matter at issue and a relevant Patent, that one or more claims of such Patent would be infringed, absent ownership of or a license under such Patent, by the Exploitation of such subject matter (considering claims of patent applications to be issued as then pending).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.37</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Development</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Develop</font><font style="color:#000000;">&#8221; means any and all activities directed to the non-clinical and clinical drug development activities that are necessary or useful to obtain Marketing Authorization for a Compound or Product (or other compound, product or therapy, as the context requires) including design and conduct of Clinical Trials and the preparation and filing of Regulatory Filings and all regulatory affairs related to the foregoing.&nbsp;&nbsp;When used as a verb, &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Developing</font><font style="color:#000000;">&#8221; means to engage in Development and &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Developed</font><font style="color:#000000;">&#8221; has a corresponding meaning.&nbsp;&nbsp;For clarity, &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Development</font><font style="color:#000000;">&#8221; shall not include any Commercialization activities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24449AK6vwny32suAkU0x5LID4WiF8O"></a><a name="_9kMIH5YVt4AA7BGLLGTEstyvq"></a><font style="Background-color:#auto;text-decoration:none;">1.38</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Development/Regulatory Milestone Event</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section <a name="_9kMIH5YVt4AA7BGLLGTEstyvq"></a>8.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.39</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Development/Regulatory Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMIH5YVt4AA7BJICDEQL3vrqnyEAswfc68LK4C"></a><a name="_9kMIH5YVt4BB7BKJCDEQL3vrqnyEAswfc68LK4C"></a><font style="Background-color:#auto;text-decoration:none;">1.40</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Disclosing Party</font><font style="color:#000000;">&#8221;<a name="_9kMIH5YVt4AA7BJICDEQL3vrqnyEAswfc68LK4C"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMIH5YVt4BB7BKJCDEQL3vrqnyEAswfc68LK4C"></a>Section&#160;12.1.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_215"></a><a name="_cp_text_4_216"></a><a name="_cp_text_1_219"></a><font style="Background-color:#auto;text-decoration:none;">1.41</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;"><a name="_cp_text_4_216"></a>Dispute</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_219"></a>Section 14.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_221"></a><a name="_cp_blt_2_220"></a><a name="_cp_blt_1_223"></a><a name="_cp_blt_2_222"></a><font style="Background-color:#auto;text-decoration:none;">1.42</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Divestiture</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.3.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.43</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Dollar</font><font style="color:#000000;">&#8221; means a U.S.&nbsp;&nbsp;dollar, and &#8220;$&#8221; is to be interpreted accordingly.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_225"></a><a name="_cp_blt_2_224"></a><font style="Background-color:#auto;text-decoration:none;">1.44</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Effective Date</font><font style="color:#000000;">&#8221; has the meaning set forth in the introductory paragraph of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_228"></a><font style="Background-color:#auto;text-decoration:none;">1.45</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Eli Lilly and Company Animal Care and Use Requirement for Animal Researchers and Suppliers</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.7</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_4_230"></a><a name="_cp_field_47_231"></a><a name="_cp_text_1_233"></a><font style="Background-color:#auto;text-decoration:none;">1.46</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Eli</font><font style="font-weight:bold;color:#000000;"> </font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly and Company Good Research Practices</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_field_47_231"></a>Section <a name="_cp_text_1_233"></a>4.7</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_246"></a><a name="_cp_blt_2_245"></a><font style="Background-color:#auto;text-decoration:none;">1.47</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">E.U.</font><font style="color:#000000;">&#8221; means the European Union, as comprised as of the date of inquiry, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that solely for the purposes of this Agreement, E.U shall be deemed to include the United Kingdom.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.48</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">EU5 Market</font><font style="color:#000000;">&#8221; means individually each of the United Kingdom, Germany, France, Spain and Italy. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_240"></a><a name="_cp_text_1_244"></a><font style="Background-color:#auto;text-decoration:none;">1.49</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Executive Officers</font><font style="color:#000000;">&#8221;<a name="_cp_text_1_240"></a> means (a) with respect to Merus, [*], and<a name="_cp_text_1_244"></a>&#160;with respect to Lilly, [*]; or any other person that such person in the foregoing (a) or (b) designates from time to time having no less decision-making authority than the officer listed here for the respective Party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_248"></a><a name="_cp_blt_2_247"></a><font style="Background-color:#auto;text-decoration:none;">1.50</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Existing Patents</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 10.2.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.51</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Existing Third Party Agreements</font><font style="font-style:italic;color:#000000;">&#8221; </font><font style="color:#000000;">means the agreements entered into between Merus and a Third Party prior to the Effective Date, whereby the Third Party is licensed by Merus (including any option to take a license) to develop and commercialize a monospecific antibody directed against a target selected from within a target pair combination researched or developed by Merus, where such target is also a Lilly Target hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.52</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Exploit</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Exploitation</font><font style="color:#000000;">&#8221; means, as applicable, to do any or all of Researching, Developing, Manufacturing, having Manufactured, using, having used, Commercializing or otherwise exploiting.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.53</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Extension Fee</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.54</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Extension Terms</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.55</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">FDA</font><font style="color:#000000;">&#8221; means the United States Food and Drug Administration or any successor agency thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_250"></a><a name="_cp_blt_2_249"></a><a name="_9kR3WTr24447CQCimm"></a><font style="Background-color:#auto;text-decoration:none;">1.56</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Field</font><font style="color:#000000;">&#8221; means all uses including, without limitation, any and all uses for the diagnosis, prevention, amelioration, and treatment of any disease or medical condition in humans and animals.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref61004482"></a><font style="Background-color:#auto;text-decoration:none;">1.57</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Final Research Deliverables</font><font style="color:#000000;">&#8221; means, on a Research Program-by-Research Program basis, those deliverables required to be provided by Merus to Lilly during the course of or at the completion of all activities under each Research Plan, in order for such Research Program to be considered fully performed prior to the expiry of the Research Term, such deliverables being those as set forth on </font><font style="text-decoration:underline;color:#000000;">Schedule 1.57</font><font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.58</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Firewall Period</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> means, in the case of a Change of Control of Merus in which the Acquirer of Merus has a Competing Program, the period commencing on the effective date of the Change of Control and ending on the earlier of </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.59</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Firewalls</font><font style="color:#000000;">&#8221; means effective walls and screens established between Merus, on the one hand, and on the other hand an Acquirer of Merus that has a Competing Program, to ensure that no [*] are accessible [*].&nbsp;&nbsp;For purposes of this definition, &#8220;Firewalls&#8221; shall include [*].&nbsp;&nbsp;For clarity, where senior management personnel review and evaluate plans and information regarding the activities under this Agreement solely in connection with making portfolio decisions among product opportunities, including such other product or product candidates, such senior management personnel shall not be deemed to be working on the Competing Program under this Agreement so long as they do not pass information from one program to another.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_260"></a><a name="_cp_blt_2_259"></a><font style="Background-color:#auto;text-decoration:none;">1.60</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">First Commercial Sale</font><font style="color:#000000;">&#8221; means, with respect to a Product and a country, the first sale of such Product by Lilly (or its Affiliates or their Sublicensees) to a Third Party for end use or consumption of such Product in such country after Regulatory Approval required to market and sell the Product has been granted with respect to such Product in such country.&nbsp;&nbsp;[*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_262"></a><a name="_cp_blt_2_261"></a><a name="_cp_blt_1_264"></a><a name="_cp_blt_2_263"></a><font style="Background-color:#auto;text-decoration:none;">1.61</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Force Majeure Event</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.10</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK31"></a><a name="OLE_LINK32"></a><font style="Background-color:#auto;text-decoration:none;">1.62</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">FTE</font><font style="color:#000000;">&#8221; means the equivalent of a full-time Merus employee&#8217;s work performing activities under a Research Plan, which is at least [*] work hours per Calendar Year.&nbsp;&nbsp;<a name="OLE_LINK31"></a><a name="OLE_LINK32"></a>If any such individual works partially on work under a Research Plan for a Research Program and partially on other work in a Calendar Quarter, then the &#8220;FTE&#8221; to be attributed to such individual&#8217;s work hereunder shall be calculated based upon the percentage of such individual&#8217;s total work time in such Calendar Quarter that such individual spent working under a Research Plan for such Research Program based on [*] working hours per Calendar Year, applied consistently throughout the Calendar Year.&nbsp;&nbsp;[*].&nbsp;&nbsp;For clarity, no individual person can ever constitute more than a single FTE.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_28_267"></a><a name="_Ref524164189"></a><font style="Background-color:#auto;text-decoration:none;">1.63</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">FTE Rate</font><font style="color:#000000;">&#8221; means the rate of FTE costs actually incurred by Merus and agreed upon in advance by the Parties pursuant to the Research Budget, which shall not exceed [<a name="_cp_text_28_267"></a>*] per FTE per Calendar Year.&nbsp;&nbsp;The FTE Rate includes costs of salaries, benefits, other human resources-related costs associated with the employment of employees, supplies [<a name="_Ref524164189"></a>*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_280"></a><a name="_cp_blt_2_279"></a><a name="_Ref536045943"></a><font style="Background-color:#auto;text-decoration:none;">1.64</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Gatekeeper</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 3.5.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="DocXTextRef19"></a><a name="DocXTextRef17"></a><a name="DocXTextRef20"></a><a name="_Ref370301792"></a><font style="Background-color:#auto;text-decoration:none;">1.65</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Good Laboratory Practices</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">GLPs</font><font style="color:#000000;">&#8221; means the applicable then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations as defined in 21 C.F.R.&nbsp;&nbsp;Part 58, the Council Directive 87/18/EEC, as amended, the principles for Good Laboratory Practice and/or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (&#8220;OECD&#8221;), and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Product is Developed, to the extent such standards are not less stringent than United States Good Laboratory Practice<a name="DocXTextRef19"></a><a name="DocXTextRef17"></a><a name="DocXTextRef20"></a><a name="_Ref370301792"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_282"></a><a name="_cp_blt_2_281"></a><font style="Background-color:#auto;text-decoration:none;">1.66</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Good Manufacturing Practices</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">GMPs</font><font style="color:#000000;">&#8221; means all applicable current Good Manufacturing Practices including, as applicable: (a) the principles detailed in the US Current Good Manufacturing Practices, 21 C.F.R.&nbsp;&nbsp;Parts 4, 210, 211, 601, 610 and 820; (b) European Directive </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">2003/94/EC and </font><font style="color:#000000;">Eudralex</font><font style="color:#000000;"> 4; (c) the principles detailed in the WHO TRS 986 Annex 2, TRS 961 Annex 6, TRS 957 Annex 2, and TRS 999 Annex 2</font><font style="color:#000000;">; (d) ICH Q7 guidelines; and (e</font><font style="color:#000000;">) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_285"></a><a name="_cp_blt_2_284"></a><a name="_Ref533774289"></a><font style="Background-color:#auto;text-decoration:none;">1.67</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Good Research Practices</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">GRP</font><font style="color:#000000;">&#8221; means all applicable current Good Research Practices including, as applicable: (a) the research quality standards defining how Lilly&#8217;s research laboratories conduct good science for non-regulated work as set forth in </font><font style="text-decoration:underline;color:#000000;">Exhibit 4.7 Part A</font><font style="color:#000000;"> of this Agreement; (b) the Research Quality Association (RQA) 2014 Quality in Research Guidelines for Working in Non-Regulated Research; (c) the WHO Quality Practices in Basic Biomedical Research Guidelines, and (d) the equivalent Applicable Laws if any, in any relevant country, each as may be amended and applicable from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_288"></a><a name="_cp_blt_2_287"></a><font style="Background-color:#auto;text-decoration:none;">1.68</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Government Official</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 10.4.5</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_286"></a><a name="_cp_blt_1_290"></a><a name="_cp_blt_2_289"></a><a name="_cp_blt_1_292"></a><a name="_cp_blt_2_291"></a><a name="_cp_blt_1_294"></a><a name="_cp_blt_2_293"></a><a name="_Ref30181701"></a><font style="Background-color:#auto;text-decoration:none;">1.69</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Governmental Authority</font><font style="color:#000000;">&#8221; means any national, international, federal, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, and any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body)<a name="_cp_text_1_286"></a><a name="_cp_blt_1_290"></a><a name="_cp_blt_2_289"></a><a name="_cp_blt_1_292"></a><a name="_cp_blt_2_291"></a><a name="_cp_blt_1_294"></a><a name="_cp_blt_2_293"></a><a name="_Ref30181701"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.70</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">HCDR3</font><font style="color:#000000;">&#8221; means the third heavy chain complementarity-determinant region determined by the amino acid sequence of the variable (V) domain [*]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.71</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Homology Exclusivity Period</font><font style="color:#000000;">&#8221; means, on a Research Program-by-Research Program basis, the period commencing on the earlier of: (a) the date that Merus provides Lilly with the Final Research Deliverables for such Research Program, or (b) the date the Research Term for such Research Program expires, and in each case of (a) or (b), ending [*] following such date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.72</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">IND</font><font style="color:#000000;">&#8221; means an investigational new drug application filed with the FDA or any similar application filed with a Regulatory Authority in a country outside the U.S. required to commence Clinical Trials of a pharmaceutical product in such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_296"></a><a name="_cp_blt_2_295"></a><a name="_9kMHG5YVt4AA7CHFBCGfb7tkm3I3"></a><a name="_9kMHG5YVt4BB7CIGBCGfb7tkm3I3"></a><a name="_9kMHG5YVt4BB7CJHBCGfb7tkm3I3"></a><font style="Background-color:#auto;text-decoration:none;">1.73</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Indemnitee</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7CHFBCGfb7tkm3I3"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7CIGBCGfb7tkm3I3"></a><a name="_9kMHG5YVt4BB7CJHBCGfb7tkm3I3"></a>Section&#160;11.1.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_298"></a><a name="_cp_blt_2_297"></a><a name="_9kMHG5YVt4AA7CKIBCGfb7tkm3I3"></a><a name="_9kMIH5YVt4BB7CJHBCGfb7tkm3I3"></a><font style="Background-color:#auto;text-decoration:none;">1.74</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Indemnitor</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7CKIBCGfb7tkm3I3"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMIH5YVt4BB7CJHBCGfb7tkm3I3"></a>Section&#160;11.1.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.75</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Indication</font><font style="color:#000000;">&#8221; means any intended use of a Product (a) for any therapeutic treatment, prevention, mitigation, cure, or diagnosis of a recognized disease or condition, (b) of a manifestation of a recognized disease or condition, or (c) for the relief of symptoms associated with a recognized disease or condition, in each case (a), (b) and (c), as provided for in the U.S.&nbsp;&nbsp;Code of Federal Regulations (CFR) labeling requirements in 21 CFR Part 201 (or an equivalent requirement in any country outside the United States) and for which a separate application for Marketing Authorization, or a supplement to an existing application for Marketing Authorization (in each case, such application or supplement to be based on the results of a novel pivotal clinical study), is required for the purpose of obtaining Marketing Authorization in a country.  [*].</font><font style="font-size:11pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_300"></a><a name="_cp_blt_2_299"></a><a name="_9kR3WTr24448BRKotxutlstvB"></a><a name="_9kMHG5YVt4AA7CLQLFaV83nk"></a><font style="Background-color:#auto;text-decoration:none;">1.76</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Infringement</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7CLQLFaV83nk"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.3.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.77</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Initial Research Plan</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_302"></a><a name="_cp_blt_2_301"></a><a name="_cp_blt_1_304"></a><a name="_cp_blt_2_303"></a><a name="_cp_blt_1_306"></a><a name="_cp_blt_2_305"></a><font style="Background-color:#auto;text-decoration:none;">1.78</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Initial Research Term</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.79</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Initial Target</font><font style="color:#000000;">&#8221; means [*].</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24448CSKryzht2y4"></a><font style="Background-color:#auto;text-decoration:none;">1.80</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Initiation</font><font style="color:#000000;">&#8221; means, with respect to a Clinical Trial, the first dosing in the first human subject in such Clinical Trial<a name="_9kR3WTr24448CSKryzht2y4"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref405220327"></a><font style="Background-color:#auto;text-decoration:none;">1.81</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Internal Compliance Codes</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 10.4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.82</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Internal Merus Program</font><font style="color:#000000;">&#8221; means a </font><font style="font-style:italic;color:#000000;">bona fide</font><font style="color:#000000;"> internal program of research and development activities directed to a Target that [*] is (a) being conducted by Merus or its Affiliates, or (b) the subject of [*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24448EUK4wp51x38"></a><a name="_9kR3WTr24448GWK4wp51x38"></a><a name="_cp_text_2_308"></a><font style="Background-color:#auto;text-decoration:none;">1.83</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Inventions</font><font style="color:#000000;">&#8221; means all discoveries, developments, processes, methods, formulations, compositions of matter, articles of manufacture, materials, and inventions, whether or not patentable, that are created, conceived of, or discovered by or on behalf of a Party (whether solely or jointly by the Parties) in the course of performing activities under this Agreement, together with all intellectual property rights therein<a name="_9kR3WTr24448EUK4wp51x38"></a><a name="_9kR3WTr24448GWK4wp51x38"></a><a name="_cp_text_2_308"></a>. </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.84</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[</font><font style="font-weight:bold;font-style:italic;color:#000000;">*</font><font style="font-weight:bold;color:#000000;">]</font><font style="font-weight:bold;font-style:italic;color:#000000;"> Know-How</font><font style="color:#000000;">&#8221; has the meaning set forth in [*].</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.85</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[</font><font style="font-weight:bold;font-style:italic;color:#000000;">*</font><font style="font-weight:bold;color:#000000;">]</font><font style="font-weight:bold;font-style:italic;color:#000000;"> Patents</font><font style="color:#000000;">&#8221; has the meaning set forth in [*].</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.86</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Joint Patent</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(c)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.87</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Joint Research Program Know-How</font><font style="color:#000000;">&#8221; means any: (a) Research Program Know-How created, conceived of, or discovered jointly by the Parties (whether by employees of the Parties or their Affiliates or Third Parties acting on their behalf); (b) or improvements made by either Party under this Agreement to [*]; or (c) any [*]. </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.88</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Joint Research Program Patent</font><font style="color:#000000;">&#8221; means any Patent that Covers any Joint Research Program Know-How [*].</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_316"></a><a name="_cp_blt_2_320"></a><a name="_cp_blt_2_325"></a><a name="_9kR3WTr25546CVkrs"></a><a name="_9kMHG5YVt4AA7EKHEESN65px628YaL25EAG"></a><a name="_9kMHG5YVt4BB7ELIEESN65px628YaL25EAG"></a><font style="Background-color:#auto;text-decoration:none;">1.89</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">JSC</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7EKHEESN65px628YaL25EAG"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7ELIEESN65px628YaL25EAG"></a>Section&#160;2.3</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.90</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Know-How</font><font style="color:#000000;">&#8221; means any non-public proprietary scientific or technical information, inventions, discoveries, results and data of any type whatsoever, in any tangible or intangible form, including non-public inventions, discoveries, databases, safety information, practices, methods, instructions, techniques, processes, drawings, documentation, specifications, formulations, formulae, knowledge, know-how, trade secrets, materials, skill, experience, test data and other non-public information and technology applicable to formulations, compositions or products or to their Exploitation or to methods of assaying or testing them, including pharmacological, pharmaceutical, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, Personal Information, physical and analytical, safety, quality control data, manufacturing, and stability data, materials, studies and procedures, and manufacturing process and development information, results and data.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.91</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> has the meaning set forth in the Preamble</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.92</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Background Know-How</font><font style="color:#000000;">&#8221; means: any and all Know-How that Lilly or any of its Affiliates: (a) Controls as of the Effective Date; or (b) discovers, creates or acquires outside the scope of the Research Program, in each case of (a) and (b) that is necessary or reasonably useful for the Exploitation of a Compound or Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.93</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Background Patent</font><font style="color:#000000;">&#8221; means any Patent: (a) that solely Covers any Lilly Background Know-How; and (b) that Lilly or any of its Affiliates (i) Controls as of the Effective Date or (ii) acquires outside the scope of the Research Program.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.94</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Competitor</font><font style="color:#000000;">&#8221; means a company that: [*] has a [*] program [*] expected or intended to have application for [*]; and [*] either (i) has a market capitalization of [*], or (ii) during the Calendar Year [*], had reported [*] sales of [*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.95</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly De-Novo Sequence</font><font style="color:#000000;">&#8221; means a [*] sequence that binds a Lilly Target and is: (a) discovered, created or generated by or on behalf of Lilly or its Affiliates (but not by Merus, its Affiliates or any of their respective subcontractors, in each case, pursuant to this Agreement) in connection with the exercise of its rights or the performance of its activities under this Agreement, (b) included in a Modified Compound or Product derived from such Modified Compound, and (c) not (i) [*], or (ii) [*].&nbsp;&nbsp;For clarity, any Lilly De-Novo Sequence would be included within the Lilly Sole IP.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMIH5YVt4AA7CDBBCEPUiR2rz8s3"></a><a name="_9kMIH5YVt4BB7CECBCEPUiR2rz8s3"></a><font style="Background-color:#auto;text-decoration:none;">1.96</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Indemnitee</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;11.1.1</font><font style="color:#000000;"><a name="_9kMIH5YVt4AA7CDBBCEPUiR2rz8s3"></a><a name="_9kMIH5YVt4BB7CECBCEPUiR2rz8s3"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.97</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Know-How</font><font style="color:#000000;">&#8221; means all Know-How Controlled by Lilly or any of its Affiliates as of the Effective Date or during the Term, in each case, that is mutually and specifically agreed by the JSC in writing to be necessary or reasonably useful for Merus to conduct activities under any Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.98</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Patent</font><font style="color:#000000;">&#8221; means any Patent Controlled by Lilly or any of its Affiliates as of the Effective Date or during the Term, that Covers any Lilly Know-How.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.99</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Prosecuted Patents</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.2.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.100</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Research Program Know-How</font><font style="color:#000000;">&#8221; means any Research Program Know-How created, conceived of, or discovered solely by or on behalf of Lilly or any of its Affiliates (other than by Merus or its Affiliates).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.101</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Research Program Patent</font><font style="color:#000000;">&#8221; means any Patent that Covers any Lilly Research Program Know-How and that does not Cover any Merus Platform IP or Lilly Target Binder IP.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.102</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Sole Arising IP</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.1.2(a)</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.103</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Sole IP</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.2.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.104</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Target Binder</font><font style="color:#000000;">&#8221; means a Target Binder [*] for potential use in a Collaboration Compound [*] in accordance with the process set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.2</font><font style="color:#000000;">.&nbsp;&nbsp;[*].&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.105</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Target Binder IP</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> means any Know-How that</font><font style="color:#000000;">:</font><font style="color:#000000;"> </font><font style="color:#000000;">(a) is generated in the performance of activities under this Agreement by or on behalf of either Party either alone or jointly (including jointly with the other Party)</font><font style="color:#000000;">;</font><font style="color:#000000;"> </font><font style="color:#000000;">and </font><font style="color:#000000;">(</font><font style="color:#000000;">b</font><font style="color:#000000;">) is </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> to any Lilly Target Binder </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.106</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Target Binder Patents</font><font style="color:#000000;">&#8221; means any Patent that: (a) Lilly or any of its Affiliates Control as of the Effective Date or during the Term; and (b) Covers any Invention within the Lilly Target Binder IP.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.107</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Target Pair</font><font style="color:#000000;">&#8221; means any Lilly Target together with CD3, but not any additional Target.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.108</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Targets</font><font style="color:#000000;">&#8221; means, individually or collectively, the Initial Target, the Additional Targets, and any Replacement Targets, but in each case excluding any and all Replaced Targets.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24447DXO27uv"></a><a name="_9kMJI5YVt4AA7CDBBCEPUiR2rz8s3"></a><a name="_9kMJI5YVt4BB7CECBCEPUiR2rz8s3"></a><font style="Background-color:#auto;text-decoration:none;">1.109</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Losses</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;11.1.1</font><font style="color:#000000;"><a name="_9kR3WTr24447DXO27uv"></a><a name="_9kMJI5YVt4AA7CDBBCEPUiR2rz8s3"></a><a name="_9kMJI5YVt4BB7CECBCEPUiR2rz8s3"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.110</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Manufacture</font><font style="color:#000000;">&#8221; and &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Manufacturing</font><font style="color:#000000;">&#8221; means any and all activities related to the production, manufacture, formulation, finishing, packaging, labeling, shipping and holding of any Compound or Product, or other compound, product or therapy, or any component, intermediary or precursor thereof (including, for clarity, expression vectors, cell lines, culture media and feeds), and including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture, quality assurance and quality control (including testing).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.111</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Marketing Authorization</font><font style="color:#000000;">&#8221; means, collectively, all Regulatory Approvals (including any Pricing and Reimbursement Approval) from the relevant Regulatory Authority necessary to initiate marketing and selling a Product in a country or jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.112</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Materials Transfer Record</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.9</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.113</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus</font><font style="color:#000000;">&#8221; has the meaning set forth in the Preamble. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.114</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Background Know-How</font><font style="color:#000000;">&#8221; means any and all Know-How that Merus or any of its Affiliates Controls, and: (a) that exists as of the Effective Date; or (b) that is discovered, created or acquired outside the scope of the Research Program after the Effective Date, in each case ((a) and (b)), [*] for the Exploitation of a Compound or Product.&nbsp;&nbsp;For clarity, any Manufacturing-related Know-How disclosed to Lilly pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 5.1</font><font style="color:#000000;"> shall be deemed Merus Background Know-How for all purposes hereunder.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56698158"></a><font style="Background-color:#auto;text-decoration:none;">1.115</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Background Patent</font><font style="color:#000000;">&#8221; means any Patent: (a) that Covers any Merus Background Know-How; and (b) that Merus or any of its Affiliates Controls (i) as of the Effective Date or (ii) that is acquired outside the scope of the Research Program.&nbsp;&nbsp;For clarity, each of the Patents set forth on </font><font style="text-decoration:underline;color:#000000;">Exhibit 10.2.4</font><font style="color:#000000;"> as of the Effective Date are Merus Background Patents.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.116</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus External Costs</font><font style="color:#000000;">&#8221; means costs, expenses, and charges [*] in the performance of Research under the applicable Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMHG5YVt4AA7CFDBCFQUgHv4si"></a><a name="_9kMHG5YVt4BB7CGEBCFQUgHv4si"></a><font style="Background-color:#auto;text-decoration:none;">1.117</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Indemnitee</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7CFDBCFQUgHv4si"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7CGEBCFQUgHv4si"></a>Section&#160;11.1.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.118</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Internal Costs</font><font style="color:#000000;">&#8221; means [*] in the performance of the Research under the applicable Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.119</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Know-How</font><font style="color:#000000;">&#8221; means, individually or collectively, the Merus Background Know-How, the Merus Platform IP, the Merus Research Program Know-How and Merus&#8217;s share in the Joint Research Program Know-How, in each case, [*] for, the Exploitation of Compounds or Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.120</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Materials</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.10</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.121</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Patent</font><font style="color:#000000;">&#8221; means any Patent that is a Merus Background Patent, Merus Platform Patent or Merus Research Program Patent and Merus&#8217;s share in each Joint Patent (subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.1.4</font><font style="color:#000000;">), but specifically excluding any Patent that is assigned to Lilly pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(d)</font><font style="color:#000000;">, from and after the date of such assignment.</font><font style="font-size:8pt;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk56783872"></a><font style="Background-color:#auto;text-decoration:none;">1.122</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Platform IP</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font><font style="color:#000000;">means all Inventions and Know-How that: (a) (i) Merus or any of its Affiliates Controls as of the Effective Date or during the Term, or (ii) is generated in the performance of activities under this Agreement by or on behalf of either Party either alone or jointly (including jointly with the other Party) including any of their Affiliates, employees, independent contractors or consultants in the course of conducting activities under this Agreement; and (b) relates to the Merus Platform Technology or any component of the Merus Platform Technology [*].</font><font style="font-style:italic;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.123</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Platform Patent</font><font style="color:#000000;">&#8221; means any Patent that (a) Merus or any of its Affiliates Control as of the Effective Date or during the Term and (b) Covers any subject matter within the Merus Platform IP.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk64414387"></a><font style="Background-color:#auto;text-decoration:none;">1.124</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Platform Technology</font><font style="color:#000000;">&#8221; means Merus&#8217;s proprietary: (a) Biclonics&#174; [*] technology [*]; (b) [*] binding domains or variants thereof; (c) technology for [*] into bi-specific constructs; (d) [*]; and (e) [*], that in each case of (a) through (e), [*] are not [*] publicly available (</font><font style="font-style:italic;color:#000000;">i.e</font><font style="color:#000000;">., [*]).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.125</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Prosecuted Patents</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.2.2(b)</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.126</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Research Program Know-How</font><font style="color:#000000;">&#8221; means any Research Program Know-How created, conceived of, or discovered solely by or on behalf of Merus or any of its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.127</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Research Program Patent</font><font style="color:#000000;">&#8221; means any Patent that Covers any Invention within the Merus Research Program Know-How, and that does not Cover any Merus Platform IP or Lilly Target Binder IP.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.128</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Sole Arising IP</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.1.2(b).</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.129</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Sole IP</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.2.3</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.130</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Milestone Events</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24449FYJpmuA72tWN3GxzFL"></a><a name="_9kR3WTr24449HaJpmuA72tWN3GxzFL"></a><font style="Background-color:#auto;text-decoration:none;">1.131</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Milestone Payments</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.3</font><font style="color:#000000;"><a name="_9kR3WTr24449FYJpmuA72tWN3GxzFL"></a><a name="_9kR3WTr24449HaJpmuA72tWN3GxzFL"></a>.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.132</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Modified Compound</font><font style="color:#000000;">&#8221; means any analog, derivative, or modified version of a Collaboration Compound that is generated by or on behalf of Lilly or any of its Affiliates (other than by Merus or its Affiliates during the Research Term), in each case that is directed against the applicable Lilly Target Pair, but excluding such Lilly Target Pair together with a third Target (and, for clarity, Lilly is not licensed under the terms of this Agreement to generate any such multi-specific compound), and excluding any analog, derivative, or modified version of a Collaboration Compound where the modification is [*].&nbsp;&nbsp;For clarity, where a Modified Compound generated by or on behalf of Lilly or any of its Affiliates is [*], such compound shall be considered a Modified Compound for all purposes hereunder.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.133</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Monospecific Compound</font><font style="color:#000000;">&#8221; means any compound directed against a Lilly Target alone (as a monospecific or as an ADC), wherein the compound incorporates, is derived from, or is a modification to [*] of a Collaboration Compound or a Modified Compound. </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.134</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Net Sales</font><font style="color:#000000;">&#8221; means, with respect to a particular Product, the gross amount invoiced by Lilly, its Affiliates, or any Sublicensee thereof to unrelated Third Parties (excluding any Sublicensee) for such Product in the Territory, less: </font></p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;margin-left:7.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such amounts shall be determined from the books and records of Lilly or the applicable <font style="color:#000000;">Sublicensee</font>, maintained in accordance with U.S. GAAP or, in the case of Sublicensees, U.S. GAAP or IFRS, as consistently applied across Lilly&#8217;s product portfolio. [*]. [*], Net Sales of the Product shall be deemed to be the cash value of such other payment.&nbsp;&nbsp;</p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the Product is sold as part of a Combination Product (where &#8220;<font style="font-weight:bold;font-style:italic;">Combination Product</font>&#8221; means any pharmaceutical product which comprises the Product and other active compound(s) and/or ingredient(s)), the Net Sales of the Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the Combination Product (as defined in the standard Net Sales definition) by the fraction, A / (A+B) where A is [*] in the same period of time and in the same country of sale as the Combination Product, and B is [*] in the same period of time and in the same country of sale as the Combination Product.&nbsp;&nbsp;For clarity, a Product that is an ADC would not be considered a Combination Product [*].</p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the weighted average sale price of the Product can be determined but the weighted average sale price of the other compound(s) or ingredient(s) cannot be determined, Net Sales for purposes of determining royalty payments shall be calculated by multiplying the Net Sales of the Combination Product by the fraction A / C where A is [*] in the same period of time and in the same country of sale as the Combination Product and C is [*] of the Combination Product.</p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the weighted average sale price of the other compound(s) or ingredient(s) can be determined but the weighted average sale price of the Product cannot be determined, Net Sales for purposes of determining royalty payments shall be calculated by multiplying the Net Sales of the Combination Product by the following formula: one (1) minus (B / C) where B is [*] in the same quantity as contained in the Combination Product in the same period of time and in the same country of sale as the Combination Product and C is [*] of the Combination Product.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_367"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_367"></a>In the event that the weighted average sale price of both the Product and the other compound(s) or ingredient(s) in the Combination Product cannot be determined, the Net Sales of the Product shall be deemed to be equal to </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Net Sales of the Combination Product.</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average sale price for a Product, other compound(s) or ingredient(s), or Combination Product shall be calculated on a Combination Product-by-Combination Product and country-by-country basis once each Calendar Year and such price shall be used during all applicable royalty-reporting periods for such Combination Product in such country for the entire following Calendar Year.&nbsp;&nbsp;When determining the weighted average sale price of a Product, other compound(s) or ingredient(s), or Combination Product, the weighted average sale price shall be calculated by dividing the sales dollars (translated into Dollars) by the units of active ingredient sold during the twelve (12) months (or the number of months sold in a partial Calendar Year) of the preceding Calendar Year for the respective Product, other compound(s) or ingredient(s), or Combination Product.&nbsp;&nbsp;In the initial Calendar Year, a forecasted weighted average sale price will be used for the Product, other compound(s) or ingredient(s), or Combination Product.&nbsp;&nbsp;Any over or under payment due to a difference between forecasted and actual weighted average sale prices will be [*] the following Calendar Year.</p>
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;text-indent:7.46%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]<font style="font-weight:bold;font-style:italic;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.135</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Parallel Program</font><font style="color:#000000;">&#8221; means a Lilly program outside of the scope of this Agreement that: (a) is directed to [*]; (b) includes at [*]; and (c) [*], has not been terminated or [*].&nbsp;&nbsp;For clarity: [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMHG5YVt3BC68AZGp9H"></a><font style="Background-color:#auto;text-decoration:none;">1.136</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Party</font><font style="color:#000000;">&#8221; and &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Parties</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt3BC68AZGp9H"></a> has the meaning set forth in the Preamble.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.137</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Party Specific Regulations</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 10.4.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.138</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Patent Working Group</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.139</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Patents</font><font style="color:#000000;">&#8221; means: (a) pending patent applications including provisional or non-provisional applications, issued patents, utility models and designs; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing; and (c) extensions, renewals or restorations of any of the foregoing by existing or future extension, renewal or restoration mechanisms, including supplementary protection certificates or the equivalent thereof, including in any country of the world.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.140</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Patent Challenge</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 13.2.4(c)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.141</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.8.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr24449GcIr640"></a><font style="Background-color:#auto;text-decoration:none;">1.142</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Person</font><font style="color:#000000;">&#8221;<a name="_9kR3WTr24449GcIr640"></a> means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.143</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Personal Information</font><font style="color:#000000;">&#8221; means, in addition to any definition for any similar term (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, &#8220;personal data&#8221; or &#8220;personally identifiable information&#8221; or &#8220;PII&#8221;) provided by Applicable Laws, or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">by either Party in any of its own privacy policies, notices or contracts, all information that identifies, could be used to identify</font><font style="color:#000000;">,</font><font style="color:#000000;"> or is otherwise associated with an individual person, whether or not such information is associated with an identified individual person.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2775BCABMiynHHJJs"></a><font style="Background-color:#auto;text-decoration:none;">1.144</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Phase I Clinical Trial</font><font style="color:#000000;">&#8221;<a name="_9kR3WTr2775BCABMiynHHJJs"></a> means a clinical trial of a Product generally consistent with 21 C.F.R.&nbsp;&nbsp;&#167;&#160;312.21(a) (or the non-United States equivalent thereof).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2775BDBBMiynHHJJt"></a><font style="Background-color:#auto;text-decoration:none;">1.145</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Phase II Clinical Trial</font><font style="color:#000000;">&#8221;<a name="_9kR3WTr2775BDBBMiynHHJJt"></a> means a clinical trial of a Product generally consistent with 21 C.F.R.&nbsp;&nbsp;&#167; 312.21(b) (or the non-United States equivalent thereof).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2775BECBMiynHHJJu"></a><font style="Background-color:#auto;text-decoration:none;">1.146</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Phase III Clinical Trial</font><font style="color:#000000;">&#8221;<a name="_9kR3WTr2775BECBMiynHHJJu"></a> means a clinical trial of a Product generally consistent with 21 C.F.R.&nbsp;&nbsp;&#167; 312.21(c) (or the non-United States equivalent thereof).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_370"></a><a name="_cp_blt_1_373"></a><a name="_cp_blt_2_372"></a><a name="_9kMJI5YVt4666GHJ7vuirsuA"></a><font style="Background-color:#auto;text-decoration:none;">1.147</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Pricing and Reimbursement Approval</font><font style="color:#000000;">&#8221;<a name="_9kMJI5YVt4666GHJ7vuirsuA"></a> means, with respect to a Product, the approval, agreement, determination or decision of any Regulatory Authority establishing the price or level of reimbursement for such Product, as required in a given country or jurisdiction prior to sale of such Product in such country or jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_375"></a><a name="_cp_blt_2_374"></a><a name="_cp_blt_1_379"></a><a name="_cp_blt_2_378"></a><a name="_Hlk59055762"></a><a name="_cp_blt_1_394"></a><a name="_cp_blt_2_393"></a><font style="Background-color:#auto;text-decoration:none;">1.148</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Product</font><font style="color:#000000;">&#8221; means any pharmaceutical product, in any preparations and presentations, in any dosage strengths, compositions, formulations, and routes of administration, in each case, that incorporates, contains or comprises a Compound other than a Research Compound.&nbsp;&nbsp;For clarity: (a) Products shall not include any compound or product that is directed to a Lilly Target Pair together with any other Target, and Lilly is not licensed by Merus to generate any such multi-specific product under the terms of this Agreement; and (b) where the same Compound is Developed or Commercialized as a monotherapy or as part of a combination therapy in multiple preparations, presentations, dosage strengths, compositions, formulations, or routes of administration, each of the foregoing shall constitute the same &#8220;Product&#8221;<a name="_cp_blt_1_394"></a><a name="_cp_blt_2_393"></a> for all purposes hereunder.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.149</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Product Patent</font><font style="color:#000000;">&#8221; means any Patent within the Merus Patents (excluding any Merus Platform Patents) or Lilly Patents (excluding any Lilly Target Binder Patent), in each case, that Covers the composition of matter, or method of using or making, a specific Collaboration Compound, Modified Compound, Monospecific Compound or Product, including [*] (and for clarity, excluding any such Patent that only Covers [*]. [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;"> that where the [*] of any specific Collaboration Compound, or any Modified Compound or Monospecific Compound for which [*]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.150</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Project Manager</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 2.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_400"></a><a name="_cp_blt_2_399"></a><a name="_9kMHG5YVt3BC6DFZGrwr7"></a><a name="_cp_text_1_398"></a><a name="_9kMHG5YVt4BB7FHJLWOsx1yxpwxzFHGpbE75LOO"></a><font style="Background-color:#auto;text-decoration:none;">1.151</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prosecute and Maintain</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prosecution and Maintenance</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt3BC6DFZGrwr7"></a> with respect to a particular Patent, means all activities associated with the preparation, filing, prosecution and maintenance of such Patent, together with the conduct of interferences, derivation proceedings, inter partes<a name="_cp_text_1_398"></a> review and post-grant review, the defense of oppositions and other similar proceedings with respect to that Patent, including any activities associated with claims, including as a claim, counterclaim or declaratory judgment action, of unpatentability, invalidity or unenforceability of such Patent that are brought by a Third Party in connection with an Infringement under </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7FHJLWOsx1yxpwxzFHGpbE75LOO"></a>Section&#160;9.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_404"></a><a name="_cp_blt_2_403"></a><font style="Background-color:#auto;text-decoration:none;">1.152</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prosecuting Party</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.2.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.153</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Purchase Agreement</font><font style="color:#000000;">&#8221; has the meaning set forth in the Recitals.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_406"></a><a name="_cp_blt_2_405"></a><a name="_9kR3WTr24447EeKcdk23wvYNwGO"></a><a name="_9kMJI5YVt4AA7BJICDEQL3vrqnyEAswfc68LK4C"></a><a name="_9kMJI5YVt4BB7BKJCDEQL3vrqnyEAswfc68LK4C"></a><font style="Background-color:#auto;text-decoration:none;">1.154</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Receiving Party</font><font style="color:#000000;">&#8221;<a name="_9kMJI5YVt4AA7BJICDEQL3vrqnyEAswfc68LK4C"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMJI5YVt4BB7BKJCDEQL3vrqnyEAswfc68LK4C"></a>Section&#160;12.1.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_408"></a><a name="_cp_blt_2_407"></a><a name="_Hlk60951354"></a><font style="Background-color:#auto;text-decoration:none;">1.155</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Reduced Payment Product</font><font style="font-style:italic;color:#000000;">&#8221; </font><font style="color:#000000;">means any Product that: (a) is a Monospecific Compound comprising any Target Binder of a Collaboration Compound or a Modified Compound that [*]; or (b) a Collaboration Compound or Modified Compound that [<a name="_Hlk60951354"></a>*]. For clarity, [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.156</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Regulatory Approvals</font><font style="color:#000000;">&#8221; means, collectively, any and all approvals (including supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations, permits, notifications, and authorizations (including marketing and labeling authorizations) or waivers of any Regulatory Authority that are necessary for the Exploitation of a pharmaceutical product (including any Product) in any country or jurisdiction, including Pricing and Reimbursement Approval, as applicable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_410"></a><a name="_cp_blt_2_409"></a><font style="Background-color:#auto;text-decoration:none;">1.157</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Regulatory Authority</font><font style="color:#000000;">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the Exploitation of pharmaceutical products (including any Product) in a given jurisdiction.&nbsp;&nbsp;For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product (including any Product) to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority includes any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_413"></a><a name="_cp_blt_2_412"></a><a name="_9kR3WTr24449EcKgx3kt87IhMz032"></a><a name="_cp_text_1_411"></a><font style="Background-color:#auto;text-decoration:none;">1.158</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Regulatory Filings</font><font style="color:#000000;">&#8221;<a name="_cp_text_1_411"></a> means, collectively, any and all applications, filings, submissions, approvals (including supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations, permits, notifications, and authorizations (including marketing and labeling authorizations) or waivers with respect to the Exploitation of a Product made to or received from any Regulatory Authority in a given country, including INDs.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.159</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Relevant Third Party IP</font><font style="font-style:italic;color:#000000;">&#8221; </font><font style="color:#000000;">has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;6.8</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_417"></a><a name="_cp_blt_2_416"></a><a name="_cp_blt_1_419"></a><a name="_cp_blt_2_418"></a><font style="Background-color:#auto;text-decoration:none;">1.160</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Replaced Target</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;3.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.161</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Replacement Period</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;3.3</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_421"></a><a name="_cp_blt_2_420"></a><font style="Background-color:#auto;text-decoration:none;">1.162</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Replacement Target</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;3.3</font><font style="color:#000000;"><a name="_cp_blt_1_421"></a><a name="_cp_blt_2_420"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.163</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research</font><font style="color:#000000;">&#8221; means any and all activities directed to the discovery, identification, generation, screening, testing, validation, functional testing, assessment and optimization of a Compound or Product (or other compound, product or therapy, as the context requires) in advance of Development, including the selection, discovery, generation, optimization or identification of Target Binders.&nbsp;&nbsp;When used as a verb, &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Researching</font><font style="color:#000000;">&#8221; means to engage in Research, and &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Researched</font><font style="color:#000000;">&#8221; has a corresponding meaning.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_423"></a><a name="_cp_blt_2_422"></a><font style="Background-color:#auto;text-decoration:none;">1.164</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Budget</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.165</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Compound</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="color:#000000;"> means, with respect to each Research Program, each compound that is created, conceived of, discovered or delivered by or on behalf of Merus or its Affiliates under the applicable Research Plan that: [*]&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.166</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[</font><font style="font-weight:bold;font-style:italic;color:#000000;">*</font><font style="font-weight:bold;color:#000000;">]</font><font style="font-weight:bold;font-style:italic;color:#000000;"> Know-How</font><font style="color:#000000;">&#8221; means any Know-How </font><font style="color:#000000;">comprising any panel of </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> antibody constructs </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> to identify or select the Collaboration Compounds associated with such Research Program </font><font style="color:#000000;">[</font><font style="font-style:italic;color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, but specifically excluding</font><font style="color:#000000;">: </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, and (b) any </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, </font><font style="color:#000000;">including in each case, </font><font style="color:#000000;">the sequences thereof</font><font style="color:#000000;"> (including, for clarity, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.167</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[</font><font style="font-weight:bold;font-style:italic;color:#000000;">*</font><font style="font-weight:bold;color:#000000;">]</font><font style="font-weight:bold;font-style:italic;color:#000000;"> Patents</font><font style="color:#000000;">&#8221; means any Patent containing claims that Cover any [*]. </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.168</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Continuance Scenario</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.2(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_425"></a><a name="_cp_blt_2_424"></a><a name="_Ref520371581"></a><font style="Background-color:#auto;text-decoration:none;">1.169</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Expenditures</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.6.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.170</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Plan</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.171</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Program</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.1</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.172</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Program Know-How</font><font style="color:#000000;">&#8221; means all Know-How created, conceived of, or discovered by or on behalf of either Party, either alone or jointly (including jointly with the other Party), during the Research Term in the performance of the Research Program that is not Merus Platform IP or Lilly Target Binder IP.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.173</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Program Patent</font><font style="color:#000000;">&#8221; means any Patent that Covers Research Program Know-How and that does not Cover any Merus Platform IP or Lilly Target Binder IP, but excluding any [*].</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.174</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Term</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.3</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.175</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Transfer</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.2(a)(i)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.176</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Transfer Scenario</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_429"></a><a name="_cp_blt_2_428"></a><a name="_cp_blt_1_431"></a><a name="_cp_blt_2_430"></a><a name="_cp_blt_1_433"></a><a name="_cp_blt_2_432"></a><font style="Background-color:#auto;text-decoration:none;">1.177</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Reserved Target</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 3.4.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.178</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Review Period</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 4.6.3(d)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.179</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Residuals</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 12.1.5</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_435"></a><a name="_cp_blt_2_434"></a><font style="Background-color:#auto;text-decoration:none;">1.180</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Royalty</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.4.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMHG5YVt4AA7FJKMHeZD0o8MxY3C"></a><a name="_9kMHG5YVt4BB7FKLMHeZD0o8MxY3C"></a><font style="Background-color:#auto;text-decoration:none;">1.181</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Royalty Term</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7FJKMHeZD0o8MxY3C"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7FKLMHeZD0o8MxY3C"></a>Section&#160;8.4.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.182</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Royalty-Bearing Claim</font><font style="color:#000000;">&#8221; means with respect to a [*] Product, any Valid Claim in any: (a) Product Patent that Covers [*] the composition of matter of such Product, or [*] a method of use of such Product [*], or (b) Merus Patent [*] that Covers the [*] composition of matter of such Product, [*], or [*] a method of use of such Product [*], in each case of (a) and (b), [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_437"></a><a name="_cp_blt_2_436"></a><a name="_cp_blt_1_439"></a><a name="_cp_blt_2_438"></a><a name="_cp_blt_1_443"></a><a name="_cp_blt_2_442"></a><font style="Background-color:#auto;text-decoration:none;">1.183</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Sublicensee</font><font style="color:#000000;">&#8221; means a Third Party that is granted a license or sublicense to Exploit Products in the Field in the Territory, beyond the mere right to purchase Products from Lilly and its Affiliates and resell such Products, and excludes Lilly&#8217;s Affiliates or Third Party subcontractors that act solely for Lilly or its Affiliates in the supply chain or that perform discrete services (as opposed to being granted broad rights or responsibilities) on behalf of Lilly or its Affiliates.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.184</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Success Criteria</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> means, on a Research Program-by-Research Program basis, those specific requirements set forth in the applicable Research Plan qualifying a Research Compound to be designated as </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> Collaboration Compounds, subject to the number of lead and back-up Collaboration Compounds</font><font style="color:#000000;"> for each such Research Program</font><font style="color:#000000;"> </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.185</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Target</font><font style="color:#000000;">&#8221; means a tumor-associated antigen.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.186</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Target Binder</font><font style="color:#000000;">&#8221; means one or more: [*] that is sufficient to confer specific antigen binding to CD3 or a Lilly Target.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_445"></a><a name="_cp_blt_2_444"></a><a name="_9kMHG5YVt4AA7FLGDEgRw5"></a><font style="Background-color:#auto;text-decoration:none;">1.187</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Term</font><font style="color:#000000;">&#8221;<a name="_9kMHG5YVt4AA7FLGDEgRw5"></a> has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.188</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Terminated Compound</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 13.4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.189</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Terminated Product</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 13.4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.190</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Terminated Target</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 13.4.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_447"></a><a name="_cp_blt_2_446"></a><a name="_cp_blt_1_451"></a><a name="_cp_blt_2_450"></a><a name="_9kR3WTr24449IiMr5x076H"></a><font style="Background-color:#auto;text-decoration:none;">1.191</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Territory</font><font style="color:#000000;">&#8221;<a name="_cp_blt_1_451"></a><a name="_cp_blt_2_450"></a><a name="_9kR3WTr24449IiMr5x076H"></a> means worldwide.</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_455"></a><a name="_cp_blt_2_454"></a><a name="_cp_text_1_453"></a><font style="Background-color:#auto;text-decoration:none;">1.192</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Third Party</font><font style="color:#000000;">&#8221;<a name="_cp_text_1_453"></a> means any Person other than&#160;Lilly or Merus (or their respective Affiliates).</font></p>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_457"></a><a name="_cp_blt_2_456"></a><a name="_9kMHG5YVt4666BKkOt7z298J"></a><font style="Background-color:#auto;text-decoration:none;">1.193</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">U.S.</font><font style="color:#000000;">&#8221; means the United States of America<a name="_9kMHG5YVt4666BKkOt7z298J"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53660207"></a><a name="_Ref534375952"></a><a name="_cp_text_1_21"></a><a name="_cp_text_1_25"></a><font style="Background-color:#auto;text-decoration:none;">1.194</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Unavailable Target</font><font style="color:#000000;">&#8221;<a name="_Ref534375952"></a> means, with respect to a Target, that, at the relevant time, such Target is the subject of: (a) (i) at least [*], or (ii) an [*], in each case ((i) and (ii)) for use of such Target [*], or that grants (or is intended to grant) rights for such Target that [*], or (b) an [*]<a name="_cp_text_1_21"></a><a name="_cp_text_1_25"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_463"></a><a name="_cp_blt_2_462"></a><font style="Background-color:#auto;text-decoration:none;">1.195</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Valid Claim</font><font style="color:#000000;">&#8221; means a claim contained in: (a) an issued and unexpired Patent that has not been revoked or held unenforceable, unpatentable or invalid by a judgment of a court or other governmental agency of competent jurisdiction, such judgment being final and unappealable (or judgment from which no appeal was taken within the allowable time period) or (b) a Patent application that has been pending [*] or less from the filing date and that has not been abandoned (without the possibility of refiling) or finally rejected by a judgment of a court or other governmental agency of competent jurisdiction, such judgment being final and unappealable (or judgment from which no appeal was taken within the allowable time period). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMIH5YVt4666CEZGrwr7"></a><a name="El2u91O"></a><a name="El2v91O"></a><a name="El2w91O"></a><a name="_cp_blt_1_465"></a><a name="_cp_blt_2_464"></a><font style="Background-color:#auto;text-decoration:none;">1.196</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Withholding Tax Action</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 8.8.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.197</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Working Group</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section 2.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506472105"></a><a name="_9kR3WTr2995DMQqA2mqtbTx75vm1I58HDJI6893"></a><a name="_9kR3WTr299676HqA2mqtbTx75vm1I58HDJI6893"></a><a name="_9kR3WTr2996BJQqA2mqtbTx75vm1I58HDJI6893"></a><a name="_Toc61825866"></a><a name="_Ref56952379"></a><font style="Background-color:#auto;text-decoration:none;">Article 2</font><font style="font-weight:normal;text-transform:none;margin-left:198pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref56952379"></a>GOVERNANCE AND JOINT STEERING COMMITTEE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825867"></a><a name="_Ref535526255"></a><a name="_9kR3WTr2885CIFCCQL43nv406WYJ03C8E"></a><a name="_9kR3WTr2995CJGCCQL43nv406WYJ03C8E"></a><a name="_Ref506473215"></a><a name="_Ref266882840"></a><a name="_Ref272511750"></a><a name="_Ref272328969"></a><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Alliance Managers</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Within [*] following the Effective Date, each Party shall appoint one (1) individual to act as the Alliance Manager for such Party (each, an &#8220;<font style="font-weight:bold;font-style:italic;">Alliance Manager</font>&#8221;).&nbsp;&nbsp;Without limiting the responsibilities and authorities of Project Managers or the JSC (as expressly set </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forth herein), the Alliance Managers shall each be the primary point of contact for the Parties regarding the collaboration and related activities contemplated by this Agreement and shall help facilitate all such activities hereunder</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Alliance Manager shall be permitted to attend meetings of the JSC and any sub-committee as a nonvoting observer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either Party, upon prior </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notice to the other Party, may change its Alliance Manager</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, the same employee may, but need not, be both the Alliance Manager and a Project Manager.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825868"></a><a name="_Ref42033048"></a><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Project Managers</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Lilly and Merus shall each assign one (1) employee to serve as the primary point of contact between the Parties with respect to each Lilly Target being Researched under the Research Programs (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Project Manager</font>&#8221;).&nbsp;&nbsp;Each Project Manager shall have appropriate technical expertise in connection with the subject matter of the applicable Research Program.&nbsp;&nbsp;The Project Managers shall regularly communicate with each other to address Research Program-related issues, needs and updates and facilitate communications and organization of Working Groups associated with the Research Plan.&nbsp;&nbsp;Either Party, upon reasonable prior notice to the other Party, may change its Project Manager.&nbsp;&nbsp;For clarity, the same employee may, but need not, be the Project Manager for multiple Lilly Targets.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825869"></a><a name="_Ref54103864"></a><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Joint Steering Committee</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_473"></a>.&nbsp;&nbsp;Within [*] after the Effective Date, the Parties shall establish a cross-functional, joint steering committee (the &#8220;<font style="font-weight:bold;font-style:italic;">JSC</font>&#8221;<a name="_cp_text_1_473"></a>) composed of up to [*] senior representatives from each Party (<font style="text-decoration:underline;">provided</font> that each Party has an equal number of representatives) that will oversee and manage the collaboration between the Parties with respect to each Research Program.&nbsp;&nbsp;The JSC may, from time to time, establish subcommittees and Working Groups as it deems necessary to further the purposes of this Agreement.&nbsp;&nbsp;Each Party shall appoint its respective representatives to the JSC from time to time, and may change its representatives, in its sole discretion, effective upon written notice to the other Party designating such change.&nbsp;&nbsp;The representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to, and ongoing familiarity, with the Research and applicable Research Programs.&nbsp;&nbsp;[*]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825870"></a><a name="_Ref535526289"></a><font style="Background-color:#auto;text-decoration:none;">2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Working Groups</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_471"></a>.&nbsp;&nbsp;The Parties may establish working groups consisting of members from both Merus and Lilly (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Working Group</font>&#8221;) to oversee aspects of the activities of each Research Program.&nbsp;&nbsp;From time to time, the Parties may establish additional Working Groups as needed to oversee particular activities and/or projects.&nbsp;&nbsp;Each Working Group shall undertake the activities delegated to it by the JSC (excluding the Patent Working Group, which shall be separately constituted hereunder and shall not report to, or accept delegation from, the JSC).&nbsp;&nbsp;During the process of establishing each Working Group, and subject to the foregoing, such Working Group and the JSC shall agree regarding which matters such Working Group will resolve on its own and which matters such Working Group will advise the JSC and/or the Project Managers regarding (and with respect to which such advice-specific matters the JSC will resolve)<a name="_cp_text_1_471"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825871"></a><a name="_Ref356925262"></a><a name="_Ref267485794"></a><font style="Background-color:#auto;text-decoration:none;">2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Function and Powers of the JSC</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The JSC will:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref520368187"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) approve the Initial Research Plan attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit 4.4.1</font><font style="color:#000000;"> within [*] of the Effective Date, (ii) prepare, discuss, and approve each subsequent Research Plan for each Research Program, and (iii) prepare, review, discuss, and approve any amendments that may be necessary or desired to the Research Plans;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59121041"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">oversee the implementation of the Research Plans, including the activities, timing and deliverables thereunder, and coordination of such activities and timing across Research Programs and mutually agree [*], as described in </font><font style="text-decoration:underline;color:#000000;">Section 4.1</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">discuss the progress of the Research and the Research Programs generally, and the discovery, identification, selection and validation of the Compounds and Products; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_479"></a><a name="_cp_blt_2_478"></a><a name="_Ref508177210"></a><a name="_Ref507510259"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">provide a forum for the Parties to share and discuss information relating to the research and validation of the Lilly Targets, Compounds and Products, including the results of the activities being carried out under the Research Plans;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_481"></a><a name="_cp_blt_2_480"></a><a name="_Ref58359226"></a><a name="_cp_change_197"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">address issues arising in the performance of the Research Plans<a name="_cp_change_197"></a>, including specifically [*]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_483"></a><a name="_cp_blt_2_482"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">direct and oversee any operating Working Groups on all significant issues, and resolve disputed matters that may arise at the Working Groups; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_485"></a><a name="_cp_blt_2_484"></a><a name="_Ref59186940"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">facilitate the exchange of Know-How or materials (pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 4.9</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">Section 4.10</font><font style="color:#000000;">, as applicable) as required hereunder, including by establishing a recordation process for, [*] the Final Research Deliverables;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">agree and specifically identify any information or materials Lilly provided to Merus for the conduct of activities under any Research Plan and that are non-public and proprietary to Lilly as Lilly Know-How, not otherwise documented or addressed under </font><font style="text-decoration:underline;color:#000000;">Section 2.5(e)(iii)</font><font style="color:#000000;">; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_487"></a><a name="_cp_blt_2_486"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">perform any and all tasks and responsibilities that are expressly attributed to the JSC under this Agreement or as otherwise agreed by the Parties in writing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825872"></a><a name="_Ref388011138"></a><a name="_Ref41749982"></a><a name="_Ref53758688"></a><font style="Background-color:#auto;text-decoration:none;">2.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Meetings</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref357778478"></a><a name="_9kMHG5YVt4666BIeKt862"></a><a name="_Ref224826007"></a><a name="_Ref224819992"></a><a name="_Ref224819938"></a><a name="_Ref224819786"></a><a name="_Ref224819344"></a><a name="_Ref224819011"></a><a name="_Ref224818984"></a><a name="_Ref224818943"></a><a name="_Ref224818789"></a><a name="_Ref245188937"></a><a name="_Ref245188727"></a><a name="_Ref388011201"></a><a name="_Ref520301055"></a><a name="_Ref506473700"></a><a name="_Ref537847"></a><a name="_Ref357778478"></a>.&nbsp;&nbsp;The JSC will meet at least [*] during the Research Term.&nbsp;&nbsp;<a name="_9kMHG5YVt4666BIeKt862"></a>The JSC may conduct such meetings by telephone, videoconference, or in person.&nbsp;&nbsp;Each Alliance Manager may call special meetings of the JSC with at least [*] prior written notice, or a shorter time period in exigent circumstances, to resolve particular matters requested by such Party that are within the purview of the JSC, the resolution of which cannot be reasonably postponed until the next regularly scheduled JSC meeting.&nbsp;&nbsp;Meetings of the JSC are effective only if at least [*] of each Party participates in such meeting, not including the Alliance Manager.&nbsp;&nbsp;Each Alliance Manager shall be permitted to attend meetings of the JSC, and any Working Group, as a non-voting observer.&nbsp;&nbsp;Each Alliance Manager may invite a reasonable number of other participants, in addition to its representatives, to attend JSC meetings in a non&#8209;voting capacity; <font style="text-decoration:underline;">provided</font><font style="font-style:italic;"> </font>that if either Alliance Manager intends to have any Third Party (including any consultant) attend such a meeting, such Alliance Manager shall provide prior written notice to the other Alliance Manager.&nbsp;&nbsp;Such Alliance Manager shall ensure that each such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.&nbsp;&nbsp;Each Party is responsible for its own expenses incurred in connection with participating in and attending all such meetings.&nbsp;&nbsp;The [*] Alliance Manager or his/her designee shall keep minutes of each JSC meeting that records in writing all decisions made, action items assigned or completed and other appropriate matters.&nbsp;&nbsp;The [*] Alliance Manager shall send meeting minutes to all members of the JSC promptly after a meeting for review.&nbsp;&nbsp;Each JSC member shall have [*] from receipt in which to comment on and to approve the minutes (such approval not to be unreasonably withheld, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditioned or delayed)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a JSC member, within such time period, does not notify the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alliance Manager</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties acknowledge and agree that, notwithstanding the requirements of this </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">2.6</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the JSC to meet </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Parties shall communicate and meet (as appropriate, including via the Project Managers) on a more informal basis as needed to discuss </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the progress of the Research Program</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref224826007"></a><a name="_Ref224819992"></a><a name="_Ref224819938"></a><a name="_Ref224819786"></a><a name="_Ref224819344"></a><a name="_Ref224819011"></a><a name="_Ref224818984"></a><a name="_Ref224818943"></a><a name="_Ref224818789"></a><a name="_Ref245188937"></a><a name="_Ref245188727"></a><a name="_Ref388011201"></a><a name="_Ref520301055"></a><a name="_Ref506473700"></a><a name="_Ref537847"></a>s.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825873"></a><a name="_Ref59132192"></a><font style="Background-color:#auto;text-decoration:none;">2.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Decisions</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref357008407"></a><a name="_cp_text_1_488"></a>.&nbsp;&nbsp;In conducting themselves on the JSC or any Working Group, and in exercising their rights under this <font style="text-decoration:underline;">Article 2</font>, all representatives of both Parties shall consider diligently, reasonably and in good faith all input received from the other Party.&nbsp;&nbsp;The JSC will use reasonable efforts to make decisions on all matters by consensus, with the representatives of each Party having, collectively, one (1) vote on behalf of that Party.&nbsp;&nbsp;If the JSC cannot reach consensus or a dispute arises that cannot be resolved within the JSC, either Party may refer such dispute to the Executive Officers for resolution<a name="_Ref357008407"></a>.&nbsp;&nbsp;If consensus cannot be reached with respect to a decision within [*]<a name="_cp_text_1_488"></a> after attempted resolution by the Executive Officers, then:</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56969320"></a><font style="Background-color:#auto;text-decoration:none;">2.7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Merus shall have final decision-making authority with respect to: [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that Merus, in exercising its final decision-making authority with respect to subclause (b), shall not resolve any such a matter in a manner that: (i)&#160;excuses, reduces, or materially delays Merus&#8217;s obligations under this Agreement; (ii) amends, modifies, or waives compliance with the terms of this Agreement or any Research Plan; or (iii) materially increases Lilly&#8217;s obligations (including payment obligations) as a result, and in the case of the foregoing subclauses (i) through (iii), the status quo shall persist unless and until the Parties mutually agree; and</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56434067"></a><a name="_cp_text_1_499"></a><a name="_cp_text_1_503"></a><a name="_cp_text_2_494"></a><font style="Background-color:#auto;text-decoration:none;">2.7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Lilly shall have the final decision-making authority with respect to: [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that Lilly, in exercising its final decision-making authority, shall not<a name="_cp_text_1_499"></a> resolve any such a matter in a manner that: (i)&#160;excuses, reduces, or materially <a name="_cp_text_1_503"></a>delays its obligations under this Agreement; or (ii) amends, modifies, or waives compliances with the terms of this Agreement; and </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> further that Lilly shall not have the right to exercise its final decision-making authority to: [*] in a manner that would require Merus to incur costs [*] that Lilly does not agree to reimburse, or [*] require Merus to violate or take any action in conflict with <a name="_cp_text_2_494"></a>any agreement Merus may have with any Third Party, or [*].&nbsp;&nbsp;In the case of the foregoing subclauses [*], the status quo shall persist unless and until the Parties mutually agree.</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.7.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Limitations on Final Decision Right</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the final decision making rights of a Party set forth in </font><font style="text-decoration:underline;color:#000000;">Sections 2.7.1</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">2.7.2</font><font style="color:#000000;">, neither Party shall exercise its right to finally resolve a dispute in connection with matters under this </font><font style="text-decoration:underline;color:#000000;">Article 2</font><font style="color:#000000;">: [*]</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825874"></a><a name="_Ref508270018"></a><font style="Background-color:#auto;text-decoration:none;">2.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Authority</font></p>
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_511"></a><a name="_9kMHG5YVt4BB8DLSsC4osvdVz97xo3K7AJFLK8A"></a><a name="_9kMHG5YVt4BB7FOSsC4osvdVz97xo3K7AJFLK8A"></a><a name="_9kMHG5YVt4BB898JsC4osvdVz97xo3K7AJFLK8A"></a>.&nbsp;&nbsp;<a name="_cp_text_1_511"></a>The Alliance Managers, Project Managers, JSC, and each Working Group have <a name="_9kMHG5YVt4BB8DLSsC4osvdVz97xo3K7AJFLK8A"></a><a name="_9kMHG5YVt4BB7FOSsC4osvdVz97xo3K7AJFLK8A"></a><a name="_9kMHG5YVt4BB898JsC4osvdVz97xo3K7AJFLK8A"></a>only the powers assigned expressly to them in this <font style="text-decoration:underline;">Article 2</font> and elsewhere in this Agreement (or in the case of Working Groups, as expressly assigned to them by the JSC).&nbsp;&nbsp;Each Party retains the rights, powers, and discretion granted to it under this Agreement and neither Party may delegate or vest such rights, powers, or discretion in the Alliance Manager, a Project Manager, the JSC, or any Working Group, unless expressly provided for in this Agreement or the Parties expressly so agree in writing.&nbsp;&nbsp;The JSC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JSC shall be in contravention of any terms and conditions of this Agreement.&nbsp;&nbsp;It is understood and agreed that issues to be formally decided by the JSC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JSC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2.8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Discontinuation of JSC</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">The JSC will automatically disband upon the expiration of the Research Term</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Once disbanded, all </font><font style="color:#000000;">approval rights of the JSC, or final </font><font style="color:#000000;">decision making</font><font style="color:#000000;"> authority granted to a Party pursuant to this Agreement, shall become approval rights of the corresponding Party (</font><font style="font-style:italic;color:#000000;">i.e.</font><font style="color:#000000;">, mutual agreement by the Parties or final decision making authority by a Party)</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825875"></a><a name="_Ref41815924"></a><a name="_Ref54286760"></a><font style="Background-color:#auto;text-decoration:none;">Article 3</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref41815924"></a><a name="_Ref54286760"></a>TARGET SELECTION AND REPLACEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825876"></a><a name="_Ref41874655"></a><a name="_Ref529796923"></a><a name="_Ref531997394"></a><a name="_Ref1563778"></a><a name="_Ref528659503"></a><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Lilly Targets</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;During the Research Term, Lilly will have the right to select up to three (3) Targets to be included as Lilly Targets for Research.&nbsp;&nbsp;As of the Effective Date, the Parties have identified the Initial Target to be the subject of Research under this Agreement.&nbsp;&nbsp;During the Research Term, Lilly may (a) select up to [*] as Lilly Targets for Research and (b) until the expiration of the [*] replace any Lilly Targets (pursuant to <font style="text-decoration:underline;">Section 3.3</font>) for Research, <font style="text-decoration:underline;">provided</font> that there may be no more than [*] under this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41841379"></a><a name="_Toc61825877"></a><a name="_Ref41769563"></a><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Additional Targets</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref41771621"></a><a name="_Ref45231442"></a><a name="_Ref41771621"></a><a name="_Ref45231442"></a>.&nbsp;&nbsp;During the Research Term, Lilly shall have the right to name up to [*] to be included as Lilly Targets for Research under this Agreement (&#8220;<font style="font-weight:bold;font-style:italic;">Additional Targets</font>&#8221;).&nbsp;&nbsp;Lilly may exercise such right [*] during the Research Term by providing written notice to Merus, through the JSC, of the identity of the Additional Target, <font style="text-decoration:underline;">provided</font> that Lilly may not name any Unavailable Target as an Additional Target.&nbsp;&nbsp;[*]&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref42035898"></a><a name="_Toc61825878"></a><a name="_Ref56967511"></a><font style="Background-color:#auto;text-decoration:none;">3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Replacement Targets</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Until the expiration of [*] (the &#8220;<font style="font-weight:bold;font-style:italic;">Replacement Period</font>&#8221;), Lilly shall have the right to replace [*] with a replacement Target (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Replacement Target</font>&#8221;); <font style="text-decoration:underline;">provided</font> that Unavailable Targets shall not be eligible to be selected by Lilly as Replacement Targets.&nbsp;&nbsp;Lilly may exercise such right [*] by providing written notice to Merus, through the JSC, of the identity of the Replacement Target as well as the Lilly Target to be replaced (such target, the &#8220;<font style="font-weight:bold;font-style:italic;">Replaced Target</font>&#8221;).&nbsp;&nbsp;[*]&nbsp;&nbsp;For clarity, (a) Lilly may at its discretion and subject to the process set forth in this <font style="text-decoration:underline;">Section 3.3</font>, [*], subject to the [*] limit in the aggregate across all Research Programs, (b) all rights in Replaced Targets shall revert to Merus, and the licenses to Lilly with respect to Collaboration Compounds arising from such Research Program shall not include any rights with respect to such Replaced Targets, and (c) a Replacement Target that replaces an Initial Target or Additional Target may itself be eligible to be replaced by a Replacement Target at any time during the Replacement Period, <font style="text-decoration:underline;">provided</font> that [*].&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825879"></a><a name="_Ref54283574"></a><font style="Background-color:#auto;text-decoration:none;">3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reserved Targets</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Promptly following the Effective Date, by and through the Gatekeeper process described in Section 3.5 below, the Parties shall identify up to [*] as Targets to be reserved under this Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Reserved Targets</font>&#8221;).&nbsp;&nbsp;Lilly may maintain a maximum of [*].&nbsp;&nbsp;During [*], unless otherwise agreed by Lilly in writing, Merus may not, directly or indirectly, either alone or with or through one (1) or more Third Parties (a) engage in [*] subject to any rights granted under any Existing Third Party Agreement that have been notified to Lilly in accordance with <font style="text-decoration:underline;">Section 6.2</font>, [*]; or (b) collaborate or enter into any arrangement with, or work for the benefit of, any Third Party in connection with [*] any Reserved Target in combination with CD3 (alone or with another Target, <font style="font-style:italic;">i.e.</font>, a multispecific) or subject to any rights granted under any Existing Third Party Agreement [*].&nbsp;&nbsp;Upon the earlier of the expiration of [*], any Reserved Target that has not been selected by Lilly </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a Lilly Target pursuant to the terms of this </font><font style="text-decoration:underline;">Article 3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will cease to be a Reserved Target and shall cease to be subject to the terms of this Agreement.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825880"></a><a name="_Ref56808106"></a><font style="Background-color:#auto;text-decoration:none;">3.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Gatekeeper Process</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref524164247"></a><a name="_Ref526083769"></a><a name="_Ref524164247"></a><a name="_Ref526083769"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54287938"></a><a name="_Ref524164248"></a><a name="_Ref526034501"></a><a name="_Ref526035014"></a><a name="_Ref528165955"></a><font style="Background-color:#auto;text-decoration:none;">3.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties have agreed on an independent third party to act as an information gatekeeper (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Gatekeeper</font><font style="color:#000000;">&#8221;) through which (a) the Parties have worked, prior to the Effective Date, to identify the Initial Target, and (b) during the Research Term: [*]<a name="_Ref524164248"></a><a name="_Ref526034501"></a><a name="_Ref526035014"></a><a name="_Ref528165955"></a> The costs of the Gatekeeper shall be shared equally by the Parties.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54288389"></a><a name="DocXTextRef65"></a><a name="DocXTextRef66"></a><font style="Background-color:#auto;text-decoration:none;">3.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As of the Effective Date, Merus has provided to the Gatekeeper the list of Unavailable Targets, and from time to time thereafter in response to Lilly notifying the Gatekeeper that it wishes to inquire whether a Target is Unavailable so long as Lilly has not yet designated [*]<a name="DocXTextRef65"></a> Lilly Targets during the Research Term, (a) Merus will provide the Gatekeeper [*] with a then-current list of all Unavailable Targets (such list of Unavailable Targets, as updated from time to time as set forth in this </font><font style="text-decoration:underline;color:#000000;">Section 3.5.2</font><font style="color:#000000;">, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Unavailable Target List</font><font style="color:#000000;">&#8221;<a name="DocXTextRef66"></a>) and (b)&#160;[*].&nbsp;&nbsp;Upon receipt of an inquiry, the Gatekeeper will notify Merus of its receipt of an inquiry from Lilly without disclosing the subject Target, after which Merus will [*] provide the Gatekeeper with any updates to the Unavailable Target List.&nbsp;&nbsp;The Gatekeeper will inform Lilly in writing whether the subject Target is an Unavailable Target within [*] of receipt of Merus&#8217;s updated Unavailable Target List and, if the Target is a not an Unavailable Target, the Gatekeeper will inform Lilly of the availability of such Target.&nbsp;&nbsp;If the Gatekeeper notifies Lilly in response to an inquiry that a Target is an Unavailable Target, Lilly will not have exhausted any of its rights to identify Targets as a result of the inquiry.&nbsp;&nbsp;If, during the Research Term, [*].</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> [*], unless, as of such date, [*]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Research Term, [*].</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825881"></a><font style="Background-color:#auto;text-decoration:none;">Article 4</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"><br /><br /></font><font style="text-transform:none;color:#000000;">RESEARCH PROGRAM</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825882"></a><a name="_Ref54104009"></a><a name="_Ref58970261"></a><font style="Background-color:#auto;text-decoration:none;">4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research Program Overview and Responsibilities</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr5DA4ENp"></a><a name="_9kR3WTr2444DKcV1rvqm"></a><a name="_9kR3WTr2444DLdV1rvqm"></a><a name="_9kR3WTr2664BFMFvtjap6tw517nV07v97DpaGE4"></a>.&nbsp;&nbsp;<a name="_9kR3WTr5DA4ENp"></a>Merus and Lilly will collaborate in a<a name="_9kR3WTr2444DKcV1rvqm"></a><a name="_9kR3WTr2444DLdV1rvqm"></a><a name="_9kR3WTr2664BFMFvtjap6tw517nV07v97DpaGE4"></a> program, on a Lilly Target-by-Lilly Target basis, to Research Compounds and Products directed against such Lilly Target Pair (each such program, a &#8220;<font style="font-weight:bold;font-style:italic;">Research</font> <font style="font-weight:bold;font-style:italic;">Program</font>&#8221;).&nbsp;&nbsp;During the Research Term, each Party will be responsible for conducting all Research specifically allocated to such Party in the applicable Research Plan.&nbsp;&nbsp;Under each Research Plan, the Parties will endeavor to [*] based on the scientific facts and circumstances, prior to commencing the applicable Research Plan.  For clarity: (a) the target [*]; and (b) Merus shall not, without Merus&#8217;s prior written consent, be obligated to [*] for each Research Program.&nbsp;&nbsp;Merus&#8217;s performance of its respective Research obligations shall be funded as set forth in <font style="text-decoration:underline;">Section 4.6</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825883"></a><a name="_Ref54089100"></a><a name="_Ref56953356"></a><font style="Background-color:#auto;text-decoration:none;">4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Diligence Efforts</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk60955364"></a>.&nbsp;&nbsp;Each Party shall use Commercially Reasonable Efforts to execute and to perform, or cause to be performed, in a good scientific manner and in compliance with Applicable Law, the Research activities assigned to it in each Research Plan with respect to each Lilly Target and Lilly Target Pair.&nbsp;&nbsp;With respect to each Research Program, Merus&#8217;s obligations under a Research Plan shall cease upon the earlier of (a) the expiration of the Research Term and (b) Merus&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fulfillment of its obligations under the applicable Research Program and delivery to Lilly of the Final Research Deliverables</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lilly may provide Lilly Target Binders to be engineered into a </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Compound</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by Merus pursuant to any such Research Program for the generation of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the applicable Research Program</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk60955364"></a> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that: (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) such Collaboration Compounds incorporating a Lilly Target Binder (where such Lilly Target Binder is incorporated prior to the delivery to Lilly of the Final Research Deliverables) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; and (ii) Lilly otherwise retains all rights in and to such Lilly Target Binders as are contributed to any given Research Program, including, for the avoidance of doubt, all rights to Exploit monospecific, bispecific or multispecific compounds, any components thereof, and all products incorporating the foregoing (outside the scope of this Agreement), that in each case utilize such Lilly Target Binder (and that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are not developed or generated utilizing the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus Platform Technology </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in each case, Merus has disclosed to Lilly hereunder</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), and such compounds and products shall not be subject to the payment of any consideration to Merus hereunder by reason of such Lilly Target Binder being so used</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825884"></a><a name="_Ref29131709"></a><a name="_Ref41816217"></a><a name="_Ref42258954"></a><font style="Background-color:#auto;text-decoration:none;">4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research Term</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref29131781"></a>.&nbsp;&nbsp;The period of time in which the Research Programs shall be conducted will commence on the Effective Date and continue until the earlier of (a) the date upon which a total of three Research Programs have delivered at least [*] and (b) the [*] of the Effective Date (the &#8220;<font style="font-weight:bold;font-style:italic;">Initial Research Term</font>&#8221;).&nbsp;&nbsp;At least [*] in advance of the expiration of such Initial Research Term, Lilly may [*], by written notice to Merus, elect to further extend the term of such Research Program by an additional six (6) months (such extension, the &#8220;<font style="font-weight:bold;font-style:italic;">1st Extension Term</font>&#8221;) and, at least [*] in advance of the expiration of such 1st Extension Term, may further elect to extend the term of such Research Program by another additional six (6) months (such further extended term, the &#8220;<font style="font-weight:bold;font-style:italic;">2nd Extension Term</font>&#8221;, and with the 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> Extension Term, the &#8220;<font style="font-weight:bold;font-style:italic;">Extension Terms</font>&#8221;), <font style="text-decoration:underline;">provided</font> that (a) the 2nd Extension Term shall be solely for [*], (b) [*], and (c) as consideration for [*], Lilly shall pay to Merus [*] &#8220;<font style="font-weight:bold;font-style:italic;">Extension Fee</font>&#8221;).&nbsp;&nbsp;[*] Extension Fee shall be payable by Lilly no later than the date of expiration of [*].&nbsp;&nbsp;The Initial Research Term, together with any Extension Term, and any further extensions as may be mutually agreed by the Parties (in each case, solely to extent such extensions occur), shall be deemed the &#8220;<font style="font-weight:bold;font-style:italic;">Research Term</font><font style="font-style:italic;"><a name="_Ref29131781"></a>.</font>&#8221;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825885"></a><a name="_Ref56946156"></a><a name="_Ref528697521"></a><a name="_Ref528737845"></a><a name="_Ref528697142"></a><font style="Background-color:#auto;text-decoration:none;">4.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research Plans</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41819214"></a><a name="_Ref56968607"></a><a name="_9kMHG5YVt3DE6FHSMt01jnhRw3r5K"></a><a name="_9kR3WTr1AB45EXKryzhldRz0jx0rfewzI"></a><a name="_9kMLK5YVt7FC78A"></a><a name="_9kR3WTr1AB4EJTKryzhldRz0jx0rfewzI"></a><a name="_9kR3WTr26647EN2ciz0w2poiSx4s6L"></a><a name="_9kMHG5YVt3DE6FIcMrzldituwCtV07v9"></a><a name="_cp_text_1_496"></a><font style="Background-color:#auto;text-decoration:none;">4.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Content</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties shall conduct the Research Program for each Lilly Target Pair pursuant to a comprehensive written research plan (each, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Plan</font><font style="color:#000000;">&#8221;) that sets forth, for each such Research Program: (a) the objective of the applicable Research Plan and the Research activities to be conducted by each of the Parties, and the allocation of activities and responsibilities between the Parties; (b) [*]; (c) the [*] of such activities; (d) the applicable Success Criteria; and (e) [*].&nbsp;&nbsp;<a name="_9kMHG5YVt3DE6FHSMt01jnhRw3r5K"></a>The Research Plan for the Initial Target<a name="_9kR3WTr1AB45EXKryzhldRz0jx0rfewzI"></a><a name="_9kMLK5YVt7FC78A"></a> is attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit 4.4.1</font><font style="color:#000000;"><a name="_9kR3WTr1AB4EJTKryzhldRz0jx0rfewzI"></a> (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Initial Research Plan</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;<a name="_9kR3WTr26647EN2ciz0w2poiSx4s6L"></a>The Research Plan(s) for Additional Targets<a name="_9kMHG5YVt3DE6FIcMrzldituwCtV07v9"></a> and any Replacement Targets<a name="_cp_text_1_496"></a> shall be drafted by Merus promptly following the selection of the applicable Lilly Target, and Merus shall thereafter: (i) provide a draft of such Research Plan to the JSC [*], and (ii) </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that [*], in each case following the date on which Lilly names an Additional Target or Replacement Target as a Lilly Target for inclusion in the Lilly Target Pair in accordance with </font><font style="text-decoration:underline;color:#000000;">Article 3</font><font style="color:#000000;">.&nbsp;&nbsp;Each Research Plan shall substantially follow, in form and substance, the form of the Initial Research Plan, except to the extent the Parties agree to any deviations from such form with respect to any particular Additional Target or Replacement Target.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref166099"></a><a name="_Ref41819257"></a><font style="Background-color:#auto;text-decoration:none;">4.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Approval and Amendments</font><font style="color:#000000;">.&nbsp;&nbsp;The JSC shall regularly review the Research Plans (including the coordination of the activities across Research Programs and to account for the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">number of active Research Plans at any given time) and the progress of activities being conducted under the Research Plans, in no event less frequently than </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Either Party may propose amendments to the Research Plan for a particular Research Program from time to time as appropriate, to take into account completion, commencement, or cessation of activities contemplated in the then-current Research Plan for such Research Program or any newly available information related to such Research Program</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Such amendments shall be effective upon JSC approval and subject to the decision making in accordance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;</font><font style="text-decoration:underline;color:#000000;">2.7</font><font style="color:#000000;">. </font><font style="color:#000000;"> </font><font style="color:#000000;">The Parties understand and agree that </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825886"></a><a name="_Ref61288143"></a><font style="Background-color:#auto;text-decoration:none;">4.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Records; Reports</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref2333391"></a><a name="_Ref61288154"></a><font style="Background-color:#auto;text-decoration:none;">4.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Records</font><font style="color:#000000;">.&nbsp;&nbsp;Merus shall maintain, or cause to be maintained, during the Research Term and for a reasonable period of time thereafter that is consistent with industry standards, complete and accurate records (paper and electronic) of its Research data and results for each Research Program in sufficient detail and in a good scientific manner appropriate for scientific, patent, and regulatory purposes, which records will reasonably reflect all work performed by or on behalf of Merus under the Research Plan for each Research Program.&nbsp;&nbsp;Lilly may request a copy of any such records of Merus, except that Merus may redact any portion of such records that Merus reasonably determines to constitute Confidential Proprietary Information that is not licensed to Lilly hereunder, or to which Lilly does not otherwise have a right hereunder.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref528737865"></a><font style="Background-color:#auto;text-decoration:none;">4.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reports and Data Package</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party shall regularly report to the other Party through the JSC (or its designated Working Group) its results in conducting Research under the Research Plan for each Research Program.&nbsp;&nbsp;For each Research Program, Merus shall provide the JSC with: (a) the Final Research Deliverables set forth in the Research Plan for such Research Program, [*] after the completion of Merus&#8217;s Research for such Research Program; and (b) at each regularly-scheduled JSC meeting, for any then ongoing Research Program during the Research Term, a reasonably detailed summary of [*] for such Research Program under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56987291"></a><a name="_Ref59048535"></a><a name="_Ref59173826"></a><a name="_Ref60994148"></a><font style="Background-color:#auto;text-decoration:none;">4.5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Modified Compound Notice</font><font style="color:#000000;">.&nbsp;&nbsp;On a Research Program-by-Research Program basis, where Lilly has generated a Modified Compound or Monospecific Compound that it intends to Develop as a Product, [*], a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Modified Compound Notice</font><font style="color:#000000;">&#8221;), </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that [*] and shall in any event treat it as Lilly&#8217;s Confidential Proprietary Information [*]; </font><font style="text-decoration:underline;color:#000000;">further</font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> [*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref507080530"></a><a name="_Ref507081143"></a><a name="_9kR3WTr29967AIIbXtfnuxyohrjX56p36xbjO84"></a><a name="_Ref534383836"></a><a name="_Toc61825887"></a><a name="_Ref520917149"></a><font style="Background-color:#auto;text-decoration:none;">4.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:none;font-weight:bold;color:#000000;">Research Program Funding</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41819984"></a><a name="_Ref45219070"></a><a name="_Ref54104161"></a><font style="Background-color:#auto;text-decoration:none;">4.6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:none;font-weight:bold;color:#000000;">Merus Research Costs</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;Lilly will fund (in accordance with </font><font style="color:#000000;">Section 4.6.3</font><font style="text-decoration:none;color:#000000;">) all Merus Internal Costs and Merus External Costs (collectively, &#8220;</font><font style="font-style:italic;text-decoration:none;font-weight:bold;color:#000000;">Research Expenditures</font><font style="text-decoration:none;color:#000000;">&#8221;) in accordance with the Research Budget set forth in the applicable Research Plan.&nbsp;&nbsp;[</font><font style="color:#000000;">*] On at least an annual basis for each Research Program, no later than July 31 in each Calendar Year, the Parties shall discuss through the JSC the Research Expenditures incurred during the prior [*], and the Research Expenditures expected to be incurred during the following [*].&nbsp;&nbsp;Following such discussion, the JSC shall amend (if applicable) and approve the Research Budget for the applicable Research Program for the following Calendar Year.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref531942530"></a><a name="_cp_text_1_668"></a><a name="_cp_text_1_669"></a><font style="Background-color:#auto;text-decoration:none;">4.6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance with Research Budget</font><font style="color:#000000;">.&nbsp;&nbsp;Merus shall promptly notify Lilly once its Research Expenditures [*].&nbsp;&nbsp;Following such notice by Merus, the Parties shall discuss in good faith whether to amend the Research Budget; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that Merus shall use Commercially Reasonable Efforts to manage the Research Expenditures to avoid exceeding the Research Budget absent any change in the Research Plan or any scientific or regulatory reasons beyond the reasonable control of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Merus (taking into account </font><font style="color:#000000;"><a name="_cp_text_1_669"></a>matters of objectively reasonable calculation and efficiency of application of Research Expenditures</font><font style="color:#000000;">)</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53744013"></a><font style="Background-color:#auto;text-decoration:none;">4.6.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Calculations of Research Expenditures; Reimbursement by Lilly</font><font style="color:#000000;">.&nbsp;&nbsp;The Research Expenditures shall be calculated and reimbursed in accordance with this </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.6.3</font><font style="color:#000000;"> as follows: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_670"></a><a name="_cp_text_1_671"></a><a name="_cp_text_1_673"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_670"></a>Lilly shall only be obligated to reimburse Merus to the extent that the nature and scope of the work performed by Merus: (i) [<a name="_cp_text_1_671"></a>*]; <a name="_cp_text_1_673"></a>or (ii) has otherwise been approved in advance in writing by Lilly via the JSC; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_675"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Merus shall invoice Lilly for reimbursement of Merus Internal Costs for each Research Plan on a [*].&nbsp;&nbsp;Lilly shall then have [*] after its receipt of such invoice to review such invoice and raise any amounts disputed in good faith to Merus.&nbsp;&nbsp;For any amounts payable under an applicable invoice during such period that are not subject to a reasonable dispute by Lilly, Lilly shall pay the undisputed amounts under any such invoice [*].&nbsp;&nbsp;Merus shall submit with [*] for such applicable invoiced period, including [<a name="_cp_text_1_675"></a>*]; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_677"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Merus shall invoice Lilly for reimbursement of Merus External Costs for each Research Plan [*].&nbsp;&nbsp;Irrespective of whether such payments are made in advance or in arrears, Lilly shall then have [*] after its receipt of such invoice to review such invoice and raise any amounts disputed in good faith to Merus.&nbsp;&nbsp;For any amounts payable under an applicable invoice not disputed by Lilly in good faith, during such [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that if Lilly reimburses Merus for advance payments made by Merus [<a name="_cp_text_1_677"></a>*]; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56954438"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For the duration of Lilly&#8217;s funding commitment with respect to such Research Program, and for a period of [*] thereafter (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Review Period</font><font style="color:#000000;">&#8221;), Merus shall maintain complete and accurate books and records regarding the Research Expenditures invoiced to Lilly.&nbsp;&nbsp;[*] </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;"> (subject only to replacing references to &#8220;Lilly&#8221; with references to &#8220;Merus,&#8221; and vice versa, and other analogous changes, including changes related to the subject matter of the audit); and&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Without prejudice to Lilly&#8217;s right to recoup any improperly paid amounts identified after an invoiced amount has been paid (including where such amounts are identified as a result of an audit pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 8.6</font><font style="color:#000000;">), any payment dispute shall be resolved in accordance with the procedures set forth in </font><font style="text-decoration:underline;color:#000000;">Section 14.2</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that the existence of any such dispute shall not relieve Lilly of its obligations to make payment on any non-disputed invoiced amounts or entitle Lilly to any reduction or offset with respect to any amounts otherwise payable under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825888"></a><a name="_Ref534384475"></a><a name="_Ref536046319"></a><font style="Background-color:#auto;text-decoration:none;">4.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:none;font-weight:bold;color:#000000;">Certain Standards Applicable to Work</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_681"></a>.&nbsp;&nbsp;<font style="Background-color:#FFFFFF;"><a name="_cp_text_1_681"></a>All Research conducted by either Party for non-regulated work under this Agreement will be conducted in accordance with the Research Plans, Eli Lilly and Company Good Research Practices, Eli Lilly and Company Animal Care and Use Requirement for Animal Researchers and Suppliers and all Applicable Laws, including those regarding data privacy and data security laws and regulations.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">Eli Lilly and Company Good Research Practices</font><font style="Background-color:#FFFFFF;">&#8221; means the compiled set of shared research quality standards defining how Lilly&#8217;s research laboratories conduct good science for non-regulated work as set forth in </font><font style="text-decoration:underline;Background-color:#FFFFFF;">Exhibit 4.7 Part A</font><font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">Eli Lilly and Company Animal Care and Use Requirement for Animal Researchers and Suppliers</font><font style="Background-color:#FFFFFF;">&#8221; means the guidelines relating </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">to animal care and use for research done on behalf of Lilly as set forth in </font><font style="text-decoration:underline;Background-color:#FFFFFF;">Exhibit </font><font style="text-decoration:underline;Background-color:#FFFFFF;">4.7</font><font style="text-decoration:underline;Background-color:#FFFFFF;"> Part B</font><font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;If Lilly reasonably requests, </font><font style="Background-color:#FFFFFF;">[</font><font style="Background-color:#FFFFFF;">*</font><font style="Background-color:#FFFFFF;">]</font><font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;If Merus </font><font style="Background-color:#FFFFFF;">[</font><font style="Background-color:#FFFFFF;">*</font><font style="Background-color:#FFFFFF;">]</font><font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;Merus maintains all rights to redact information and shield from such audit any </font><font style="Background-color:#FFFFFF;">c</font><font style="Background-color:#FFFFFF;">onfidential </font><font style="Background-color:#FFFFFF;">i</font><font style="Background-color:#FFFFFF;">nformation </font><font style="Background-color:#FFFFFF;">of a Third Party, to the extent Merus deems such measures</font><font style="Background-color:#FFFFFF;"> necessary to protect </font><font style="Background-color:#FFFFFF;">Merus</font><font style="Background-color:#FFFFFF;">&#8217;</font><font style="Background-color:#FFFFFF;">s</font><font style="Background-color:#FFFFFF;"> </font><font style="Background-color:#FFFFFF;">obligations</font><font style="Background-color:#FFFFFF;"> to any </font><font style="Background-color:#FFFFFF;">such </font><font style="Background-color:#FFFFFF;">Third Party.</font><font style="Background-color:#FFFFFF;">&nbsp;&nbsp;</font><font style="Background-color:#FFFFFF;">Additionally, Lilly may </font><font style="Background-color:#FFFFFF;">[</font><font style="Background-color:#FFFFFF;">*</font><font style="Background-color:#FFFFFF;">]</font><font style="Background-color:#FFFFFF;">, in each case </font><font style="text-decoration:underline;Background-color:#FFFFFF;">provided</font><font style="Background-color:#FFFFFF;"> </font><font style="Background-color:#FFFFFF;">that </font><font style="Background-color:#FFFFFF;">Lilly has requested </font><font style="Background-color:#FFFFFF;">[</font><font style="Background-color:#FFFFFF;">*</font><font style="Background-color:#FFFFFF;">]</font><font style="Background-color:#FFFFFF;"> does not unreasonably interfere with </font><font style="Background-color:#FFFFFF;">Merus</font><font style="Background-color:#FFFFFF;">&#8217;</font><font style="Background-color:#FFFFFF;">s</font><font style="Background-color:#FFFFFF;"> operations.&nbsp;&nbsp;Lilly may also request that Merus exercise its rights, upon reasonable notice, to conduct a compliance audit under </font><font style="Background-color:#FFFFFF;">Merus</font><font style="Background-color:#FFFFFF;">&#8217;</font><font style="Background-color:#FFFFFF;">s</font><font style="Background-color:#FFFFFF;"> agreements with Third Party subcontractors engaged in performing activities under this Agreement</font><font style="Background-color:#FFFFFF;">, if any, </font><font style="text-decoration:underline;Background-color:#FFFFFF;">provided</font><font style="Background-color:#FFFFFF;"> that such request may be made</font><font style="Background-color:#FFFFFF;"> no more than </font><font style="Background-color:#FFFFFF;">[</font><font style="Background-color:#FFFFFF;">*</font><font style="Background-color:#FFFFFF;">]</font><font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;All such audits shall be done at Lilly</font><font style="Background-color:#FFFFFF;">&#8217;</font><font style="Background-color:#FFFFFF;">s cost and expense</font><font style="Background-color:#FFFFFF;"> and the parties shall cooperate</font><font style="Background-color:#FFFFFF;"> in good faith with respect to</font><font style="Background-color:#FFFFFF;"> the exercise of any such audit right</font><font style="Background-color:#FFFFFF;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825889"></a><a name="_Ref41837515"></a><font style="Background-color:#auto;text-decoration:none;">4.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Subcontracting</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Each Party may engage its Affiliates or Third Party subcontractors (including contract research organizations and contract manufacturing organizations) to perform such portions of its research obligations under the Research Program that it customarily engages for its other similar research activities.&nbsp;&nbsp;The activities of any such Third Party subcontractors will be considered activities of such subcontracting Party under this Agreement.&nbsp;&nbsp;The subcontracting Party shall ensure compliance by such Third Party subcontractors with the terms of this Agreement, including any applicable Research Plans.&nbsp;&nbsp;The subcontracting Party shall ensure, prior to engaging any Third Party subcontractor, that such Third Party subcontractor is subject to written agreements containing terms and conditions that: (a)&#160;protect the rights of the Parties under this Agreement, including by imposing obligations of confidentiality on each such Third Party subcontractor that are no less than the obligations of confidentiality on each Party under this Agreement; (b) do not under any circumstance impose any payment obligations or liability on the non-subcontracting Party; and (c)&#160;are otherwise consistent with the relevant terms of this Agreement, including with respect to each Party&#8217;s obligations [*].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825890"></a><a name="_Ref43458704"></a><font style="Background-color:#auto;text-decoration:none;">4.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Lilly Materials</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In connection with the execution of the Research Plan, Lilly may need to transfer certain Lilly materials to Merus that are not otherwise delivered under a supply or other separate agreement between the Parties or their Affiliates.&nbsp;&nbsp;In each such case, the Parties will mutually agree on the terms of such material transfer.&nbsp;&nbsp;Any such materials provided to Merus shall be accompanied by a materials transfer record substantially in the form of <font style="text-decoration:underline;">Exhibit 4.9</font> (each a &#8220;<font style="font-weight:bold;font-style:italic;">Materials Transfer Record</font>&#8221;) or as otherwise agreed through the JSC pursuant to <font style="text-decoration:underline;">Section 2.5(e)</font> or <font style="text-decoration:underline;">2.5(g)</font>.&nbsp;&nbsp;In the event of such transfer, unless otherwise mutually agreed by the Parties in writing, Lilly shall be responsible for obtaining all necessary approvals and/or filings as required under Applicable Laws for the exportation of any such materials to Merus and Merus shall be responsible for obtaining all necessary approvals and/or filings as required under Applicable Laws for their importation and use by Merus.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825891"></a><a name="_Ref43458844"></a><font style="Background-color:#auto;text-decoration:none;">4.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Materials</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In order to execute the Research Plan, Merus may need to transfer certain materials to Lilly that are not otherwise delivered under a supply or other separate agreement between the Parties or their Affiliates (&#8220;<font style="font-weight:bold;font-style:italic;">Merus</font><font style="font-style:italic;"> </font><font style="font-weight:bold;font-style:italic;">Materials</font>&#8221;).&nbsp;&nbsp;On a Research-Program-by-Research Program basis, Lilly may use any Merus Materials that [*]; <font style="text-decoration:underline;">provided</font>, however, that all other Merus Materials may only be used by Lilly for activities under the Research Plan, or such other activities [*].&nbsp;&nbsp;Unless otherwise mutually agreed by the Parties in writing, Merus shall be responsible for obtaining all necessary approvals and/or filings as required under Applicable Laws for the exportation of Merus Materials to Lilly and Lilly shall be responsible for obtaining all necessary approvals and/or filings as required under Applicable Laws for their importation and use by Lilly.&nbsp;&nbsp;All Merus Materials </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will at all times remain the property of Merus and will be held confidential in respect to Third Parties and will not be transferred to a Third Party without prior written permission of Merus, unless the Third Party agrees to terms and use limitations at least as restrictive as those set forth in this Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and such transfer is documented by a materials transfer record similar to the Material Transfer Records used under this Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Upon the termination of this Agreement, Lilly will, at </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sole discretion and Lilly</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s cost, either (a) dispose of any residual Merus Materials not consumed by Lilly in the performance of this Agreement in accordance with Applicable Laws, or (b) upon request, return such Merus Materials to Merus.&nbsp;&nbsp;Any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus Ma</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terials provided to Lilly by Merus</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or by Lilly to any Third Party (to the extent permitted herein)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be accompanied by a Materials Transfer Record.&nbsp;&nbsp;Without limiting the foregoing, following the completion of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a given </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Program with respect to a Lilly Target Pair, at Lilly</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s request, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus may </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfer or cause to be transferred to Lilly any Manufacturing-related Merus Know-How reasonably necessary or useful for the Exploitation by Lilly of a Compound or Product and licensed to Lilly under </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">6.1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506472124"></a><a name="_9kR3WTr29967DOqA2mqtel2s9Fw5KJUQ3BVHGV"></a><a name="_Toc61825892"></a><a name="_Ref532002592"></a><a name="_Ref41816659"></a><font style="Background-color:#auto;text-decoration:none;">Article 5</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref532002592"></a><a name="_Ref41816659"></a>DEVELOPMENT, REGULATORY AND COMMERCIAL MATTERS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825893"></a><a name="_Ref42039023"></a><a name="_Ref54795381"></a><a name="_Ref405217718"></a><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Responsibilities; Parallel Target Pair Programs</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58999972"></a><a name="_9kMON5YVt48867ER3lplmfw1LQ79CII28"></a><a name="_9kMML5YVt48867BbX3qxxx"></a><font style="Background-color:#auto;text-decoration:none;">5.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">General Development Responsibilities</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kMON5YVt48867ER3lplmfw1LQ79CII28"></a>Except with respect to Research activities to be conducted by Merus pursuant to a Research Plan, Lilly shall be solely responsible for the Exploitation of Compounds<a name="_9kMML5YVt48867BbX3qxxx"></a> and Products with respect to Lilly Target Pairs (or in the event Lilly pursues a Monospecific Compound, directed to each applicable Lilly Target as a monospecific or ADC), including all Manufacturing and Commercialization activities, in all cases, in accordance with the terms of this Agreement.&nbsp;&nbsp;With respect to each Lilly Target Pair for which Merus has delivered to Lilly a lead Collaboration Compound and the JSC-specified number of back-up Collaboration Compounds arising under the applicable Research Plan for such Research Program: (a) until [*], Lilly shall use Commercially Reasonable Efforts, at its own expense, to Develop and obtain Marketing Authorization [*] Product directed to each such Lilly Target Pair [*] in each of the United States, Japan, and at least two (2) of the EU5 Markets, and (b) following [*] arising from activities under this Agreement, Lilly shall use Commercially Reasonable Efforts to Commercialize such Product in each [*].&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, including the foregoing sentence, all decisions concerning the Exploitation of Compounds and Products, including the clinical and regulatory strategy of Compounds and Products, the marketing and sales of Products, and the design, price, and promotion of Products, shall be at the sole discretion of Lilly.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59135242"></a><font style="Background-color:#auto;text-decoration:none;">5.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">[*] Programs </font><font style="color:#000000;">[</font><font style="font-weight:bold;color:#000000;">*</font><font style="color:#000000;">].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825894"></a><a name="_9kR3WTr2995EJIIeMr25BD"></a><a name="_Ref_ContractCompanion_9kb9Ur1AB"></a><a name="_Ref535533813"></a><a name="_Ref41859888"></a><a name="_Ref41781564"></a><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cooperation</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMON5YVt48867BbX3qxxx"></a><a name="_9kMIH5YVt4666DLSHyxqwvnmq2GxYo3IE1q26aW"></a><a name="_9kMPO5YVt48867ER3lplmfw1LQ79CII28"></a>.&nbsp;&nbsp;<a name="_9kMON5YVt48867BbX3qxxx"></a>If Lilly reasonably requests assistance or input from Merus with respect to activities related to seeking, obtaining or maintaining Regulatory Approval or Marketing Authorization or with respect to Commercialization in the United States, Japan or E.U. being undertaken by Lilly in respect of a Compound or Product, Merus shall (at Lilly&#8217;<a name="_9kMIH5YVt4666DLSHyxqwvnmq2GxYo3IE1q26aW"></a>s expense), use its Commercially Reasonable Efforts to cooperate in good faith with Lilly in response to such request (<font style="font-style:italic;">e.g.</font><a name="_9kMPO5YVt48867ER3lplmfw1LQ79CII28"></a>, by responding to regulatory inquiries relating to the Research of a Compound by Merus, intellectual property matters with respect to Merus Know-How, Merus Patents, etc.), <font style="text-decoration:underline;">provided</font> that Merus shall not be required to generate any additional data or other Know-How in connection with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such requests</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unless </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> relevant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> data</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or Know-How</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonably capable of</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being produced or generated by Lilly or a Third Party contractor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lilly agrees in writing to reimburse Merus for its reasonably incurred </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">internal costs and out-of-pocket </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses in connection with the generation of such additional data or other Know-How</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825895"></a><a name="_Ref54103031"></a><a name="_Ref60778238"></a><font style="Background-color:#auto;text-decoration:none;">5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reports</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Lilly shall keep Merus reasonably informed as to the progress and results of its and its Affiliates&#8217; and Sublicensees&#8217; Development activities under this Agreement, and shall provide Merus with a high-level written report summarizing its Development activities and the results thereof with respect to each Product and Lilly Target on at least [*] basis, including, by way of example, the Initiation and completion of Clinical Trials, submission of applications for, and receipt of, any Marketing Authorizations, and shall include in such report in respect of each such Product, the anticipated dates of commercial launch in each of the U.S., Japan, and the EU5 Markets as well as any required report [*].&nbsp;&nbsp;Each such report shall also include a list of any safety issues or adverse events associated with the administration of the Products during such Development or any subsequent Commercialization of such Product.&nbsp;&nbsp;With respect to any material safety issue or material adverse event arising in connection with: (a) in respect of Lilly, the Exploitation of any Compound or Product, or (b) in respect of Merus, [*], solely where such material safety issue or material adverse event under this subclause is attributable to [*], the applicable Party shall notify the other Party directly (as well as the JSC) within [*] following such adverse event, and the Parties shall cooperate in good faith to address any issues arising from such adverse event.&nbsp;&nbsp;Upon the notified Party&#8217;s request, the notifying Party shall make appropriate personnel reasonably available to answer any reasonable questions the notified Party has in relation to any such report.&nbsp;&nbsp;The notifying Party&#8217;s obligations under this <font style="text-decoration:underline;">Section 5.3</font> shall cease with respect to a Product upon the First Commercial Sale of a Product in the U.S., <font style="text-decoration:underline;">provided</font> that each Party shall continue to provide the other Party with information regarding safety issues or adverse events that relate to (i) with respect to Lilly [*] in a Product, and (ii) with respect to Merus [*] as in a Lilly Product, as long as Lilly is Exploiting such Product(s) hereunder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825896"></a><a name="_Ref56880060"></a><font style="Background-color:#auto;text-decoration:none;">5.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Regulatory Responsibilities</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;As between the Parties, Lilly shall be responsible for the preparation, submission, and maintenance of all Regulatory Filings and obtaining Regulatory Approvals (including the preparation and submission of the IND filing and for seeking IND approval) with respect to Compounds and Products and shall have sole control over all interactions with the applicable Regulatory Authority.&nbsp;&nbsp;Merus shall reasonably cooperate with Lilly, at Lilly&#8217;s reasonable request and expense, with respect to any regulatory matters related to Compounds or Products related to seeking, obtaining or maintaining Regulatory Approval or Marketing Authorization or with respect to Commercialization in the United States, Japan or E.U., <font style="text-decoration:underline;">provided</font> that such cooperation relates to the work Merus conducted pursuant to the applicable Research Plan, and <font style="text-decoration:underline;">provided</font> further that nothing in this <font style="text-decoration:underline;">Section 5.4</font> shall require Merus to generate any additional data or other Know-How.&nbsp;&nbsp;Lilly will own all right, title and interest in and to any and all Regulatory Filings and Regulatory Approvals for Compounds and Products and, as between the Parties, all such Regulatory Filings and Regulatory Approvals will be held in the name of Lilly, and Merus shall execute all documents and take all actions as are necessary [*] to vest such title in Lilly.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825897"></a><font style="Background-color:#auto;text-decoration:none;">5.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Adverse Event Reporting</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Lilly shall establish, hold, and maintain the global safety database for Collaboration Compounds, Monospecific Compounds, Modified Compounds and Products with respect to information on adverse events concerning the Collaboration Compounds, Monospecific Compounds, Modified Compounds and Products, as and to the extent required by Applicable Law.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825898"></a><a name="_Ref508278635"></a><a name="_Ref532560029"></a><a name="_Ref58269476"></a><font style="text-decoration:none;Background-color:#auto;">Article 6</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /></font><font style="text-transform:none;color:#000000;"><br /><a name="_Ref508278635"></a><a name="_Ref532560029"></a><a name="_Ref58269476"></a></font><font style="text-transform:none;color:#000000;">LICENSE</font><font style="text-transform:none;color:#000000;"> RIGHTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506475644"></a><a name="_9kR3WTr2996AFHDVKifr6yNVwtD"></a><a name="_Toc61825899"></a><a name="_Ref520283138"></a><a name="_Hlk59059597"></a><a name="_Ref54796162"></a><a name="_Ref58284049"></a><a name="_Ref59062328"></a><a name="_Ref339022668"></a><a name="_Ref439761946"></a><a name="_Ref437250129"></a><a name="_Ref440985133"></a><a name="_Ref520537395"></a><a name="_Ref534960058"></a><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;"><a name="_Ref520537395"></a><a name="_Ref534960058"></a>License Grant to Lilly</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, and on a Research Program-by-Research Program basis, Merus (on behalf of itself and each of its Affiliates) hereby grants to Lilly and each of its Affiliates an exclusive (even as to Merus and its Affiliates, but subject to <font style="text-decoration:underline;">Section 6.2</font>), worldwide, royalty-bearing license, with the right to grant sublicenses (through multiple tiers, as provided in <font style="text-decoration:underline;">Section 6.4</font>), under all Merus Know-How, Merus Patents and Merus Sole Arising IP in connection with any and all Compounds or Products directed against: (a) any Lilly Target (solely where such Compound or Product is a Monospecific Compound); or (b) any Lilly Target Pair (but excluding any multi-specific compounds or products directed against the Lilly Target Pair together with one or more additional Targets); [<font style="text-decoration:underline;">*</font>] subject to the terms and conditions of this Agreement, including <font style="text-decoration:underline;">Sections 8.3</font> and <font style="text-decoration:underline;">8.4</font>.&nbsp;&nbsp;[*].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825900"></a><a name="_Ref59709194"></a><a name="_Ref59717197"></a><font style="Background-color:#auto;text-decoration:none;">6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Existing Third Party Agreements</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties acknowledge and agree that the exclusive license granted to Lilly in </font><font style="text-decoration:underline;color:#000000;">Section 6.1</font><font style="color:#000000;"> in respect of Monospecific Compounds developed by Lilly may be subject to one or more Existing Third Party Agreement(s), in which case, Lilly&#8217;s rights may be non-exclusive in respect of any compounds or products generated by such Third Party pursuant to such agreement that are directed to such Lilly Target. [*]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[*]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[*]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825901"></a><a name="_Ref520538283"></a><a name="_Ref520916748"></a><a name="_Ref532248170"></a><font style="Background-color:#auto;text-decoration:none;">6.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">License Grant to Merus</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, Lilly (on behalf of itself and each of its Affiliates) hereby grants to Merus and each of its Affiliates a worldwide, fully paid, royalty-free, non-sub-licensable (except to Third Party subcontractors acting on its behalf, as permitted by <font style="text-decoration:underline;">Section 4.8</font>), non-exclusive license under any Lilly Know-How, Lilly Patents and Lilly Sole Arising IP (but solely such Lilly Know-How, Lilly Patents and Lilly Sole Arising IP as Lilly discloses to Merus, by and through and as approved in writing by the JSC on a Research Plan-by-Research Plan basis, for use under and in accordance with a Research Plan), solely as directed by the JSC in its written approval for such use.&nbsp;&nbsp;The foregoing license shall expire at the end of the applicable the Research Term.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref420591159"></a><a name="_9kR3WTr299689DEddtltliu912"></a><a name="_Toc61825902"></a><a name="_Ref528595585"></a><a name="_Ref534378804"></a><a name="_Ref506474247"></a><a name="_Ref59709179"></a><font style="Background-color:#auto;text-decoration:none;">6.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Third-Party Sublicenses</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_520"></a><a name="_cp_text_1_522"></a><a name="_cp_text_1_523"></a><a name="_9kR3WTr299688CFZSaa0mxlXtt7JsZ85v96xll7"></a><a name="_Ref507063720"></a>.&nbsp;&nbsp;Lilly and its Affiliates may grant one or more sublicenses under the rights and licenses granted to it solely under license scope of <font style="text-decoration:underline;">Section&#160;6.1</font>, in full or in part, to Third Parties (with the right to sublicense through multiple tiers); <font style="text-decoration:underline;">provided</font><a name="_cp_text_1_520"></a> that: <a name="_cp_text_1_522"></a>(a)&#160;any such permitted sublicense is consistent with and subject to the terms and conditions of this Agreement; and (b)&#160;Lilly shall remain responsible for performance of such Party&#8217;<a name="_cp_text_1_523"></a>s obligations under this Agreement and shall be responsible for all actions of each such Sublicensee as if such Sublicensee were the Party hereunder<a name="_9kR3WTr299688CFZSaa0mxlXtt7JsZ85v96xll7"></a><a name="_Ref507063720"></a>.&nbsp;&nbsp;As soon as reasonably practicable (but in any case within [*]) after the execution of any such sublicense agreement that grants rights to a Third Party to conduct clinical Development and Commercialization of Products in the United States, Japan or an EU5 Market (but excluding, for clarity, sublicenses granted solely for the purposes of a party carrying out promotional, marketing or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">distribution activities on behalf of Lilly)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Lilly shall provide </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with written notice </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereof</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including the identity of the sublicensee and the scope of the license granted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825903"></a><a name="_Ref508268096"></a><a name="_Ref520281734"></a><a name="_Ref534374710"></a><font style="Background-color:#auto;text-decoration:none;">6.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Implied Rights</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_580"></a><a name="_cp_text_1_585"></a>.&nbsp;&nbsp;<a name="_cp_text_1_580"></a>Except as expressly set forth in this Agreement, neither Party shall be granted, by implication or otherwise, any license or right to or under any other intellectual property interest, including any trademarks, Know-How, or Patents, of the other Party<a name="_cp_text_1_585"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825904"></a><a name="_Ref61004436"></a><font style="Background-color:#auto;text-decoration:none;">6.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Retained Rights</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M162"></a>.&nbsp;&nbsp;Notwithstanding the exclusive license granted to Lilly pursuant to <font style="text-decoration:underline;">Section 6.1</font><a name="_DV_M162"></a> during the Term, Merus shall retain all rights under the Merus Know-How and Merus Patents (a) to perform, and to subcontract pursuant to <font style="text-decoration:underline;">Section 4.8</font>, its obligations under this Agreement, and (b) for any purpose outside the scope of the license granted under <font style="text-decoration:underline;">Section 6.1,</font> subject in each case of (a) and (b) to Merus&#8217;s obligations under <font style="text-decoration:underline;">Article 7</font>.&nbsp;&nbsp;For clarity, nothing herein shall limit Merus&#8217;s ability to use its panel of CD3 antibodies included within the Merus Platform Technology or Merus Platform IP or that is otherwise Covered by a Merus Patent for Exploitation of internal programs or with a Third Party for any bispecific or multispecific compound or product that is not directed to (i) a Lilly Target Pair, or (ii) a Reserved Target in combination with CD3 during the period such Target constitutes a Reserved Target.&nbsp;&nbsp;On a Lilly Target-by-Lilly Target basis, subject to Merus&#8217;s exclusivity obligations pursuant to <font style="text-decoration:underline;">Section 7.1</font> (if applicable), Merus retains all rights to use and commercialize any [*] against such Lilly Target that Merus discovers, identifies or generates without use of or reference to [*] generated with respect to such Lilly Target, provided that subject to the terms of the Existing Third Party Agreements, such retained use is not with respect to development or commercialization of (A) a Monospecific Compound, or (B) a bispecific compound against the Lilly Target Pair, or multispecific compounds including a Lilly Target Pair (excluding any Replaced Target or a Terminated Target), but in each case of (A) and (B), excluding any Terminated Product or Terminated Compound.&nbsp;&nbsp;For clarity, subject to Merus&#8217;s exclusivity obligations under <font style="text-decoration:underline;">Section 7.1</font> (if applicable), Merus&#8217;s rights set out in this <font style="text-decoration:underline;">Section 6.6</font> shall apply if Merus discovers, identified or generates a [*] sequence directed against a Lilly Target that is identical to (1) any sequence [*], or (2) any [*] sequence directed against a Lilly Target used in a Research Program, <font style="text-decoration:underline;">provided</font> such [*] sequence is discovered, identified or generated without use of or reference to the [*] generated with respect to such Lilly Target.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825905"></a><font style="Background-color:#auto;text-decoration:none;">6.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Safe Harbor Research</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Subject to Merus&#8217;s exclusive grant of rights in <font style="text-decoration:underline;">Section 6.1</font> and its obligations under <font style="text-decoration:underline;">Article 7</font>, but otherwise notwithstanding anything to the contrary in this Agreement, by entering into this Agreement, neither Party is forfeiting any rights that such Party may have to perform research activities in compliance with 35 U.S.C. &#167; 271(e)(1) or any experimental or research use exemption that may apply under Applicable Law or in any country.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825906"></a><a name="_Ref59017186"></a><a name="_Ref59014001"></a><font style="Background-color:#auto;text-decoration:none;">6.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Inclusion of Third Party IP</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref47701411"></a><a name="_cp_text_1_452"></a>. <a name="_Ref47701411"></a> <a name="_cp_text_1_452"></a>If Merus, in its sole discretion, enters into an agreement with a Third Party after the Effective Date pursuant to which Merus in-licenses any Know-How, Patents, or other intellectual property rights, that would constitute Merus Know-How or Merus Patents if Controlled by Merus, (any such Know-How, Patents or other intellectual property rights, collectively, &#8220;<font style="font-weight:bold;font-style:italic;">Relevant Third Party IP</font>&#8221;) then Merus shall, [*] following the execution of such agreement, provide Lilly with a written summary of [*]; and (b) a proposed allocation of [*] that would arise as a result of Lilly&#8217;s or any of its Affiliate&#8217;s or Sublicensee&#8217;s use or practice of such Relevant Third Party IP in connection with the Exploitation of Products under this Agreement.&nbsp;&nbsp;Within [*] following Lilly&#8217;s receipt of the written summary described above, the Parties (through the JSC) shall meet and determine in good faith (i) an allocation of [*] payment made in respect of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtaining rights to the Relevant Third Party IP (based on the relative value of any sublicense that would be granted under such Relevant Third Party IP to Lilly (as compared to the value of the rights retained by Merus or granted to its other sublicensees)), and (ii) those payments (or portions thereof) that may become due under the applicable Third Party agreement by reason of exercise by Lilly or any of its Affiliate&#8217;s or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicensee&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise of any sublicense of rights to such Relevant Third Party IP.&nbsp;&nbsp;Within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> following the final determination of (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and (ii) above, which determination would not be subject to either Party&#8217;s final decision making authority at the JSC and would instead be subject to resolution in accordance with </font><font style="text-decoration:underline;">Section</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">14.2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Lilly shall elect, in its sole discretion on written notice to Merus, to either (A) agree in writing to reimburse Merus for those allocable amounts paid or payable by Merus (as such amounts become due) under such Third Party agreement in accordance with final determination of such allocation described in (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and (ii) above, in which case the relevant Know-How, Patents, or other intellectual property rights that were licensed by Merus shall be &#8220;Controlled&#8221; by Merus and included within the Merus Know-How or Merus Patents and licensed to Lilly under this Agreement, or (B) notify Merus that it does not desire a sublicense under such Relevant Third Party IP, in which case the Relevant Third Party IP would not be &#8220;Controlled&#8221; by Merus for the purposes of this Agreement, and Lilly would have no responsibility for any payments under the Third Party Agreement under which Merus acquired rights to the Relevant Third Party IP.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref388011526"></a><a name="_Ref506474332"></a><a name="_9kR3WTr2995EIEJVSxm5D2676N"></a><a name="_Toc61825907"></a><a name="_Ref41853094"></a><font style="Background-color:#auto;text-decoration:none;">Article 7</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref41853094"></a>EXCLUSIVITY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825908"></a><a name="_Ref41853329"></a><a name="_Ref59188737"></a><a name="_Ref54103079"></a><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus Exclusivity Obligations</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;On a Lilly Target-by-Lilly Target basis, during the Term of this Agreement, and other than in connection with its obligations under this Agreement, neither Merus, nor any of its Affiliates (subject, in the case of Affiliates that control Merus in the future, to <font style="text-decoration:underline;">Section 15.8</font>), shall, directly or indirectly, either alone or with or through one (1) or more Third Parties:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref61262486"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">engage in (i) any Exploitation activities with respect to any of the Collaboration Compounds, or any Modified Compounds or Monospecific Compounds of which Merus has received notice under </font><font style="text-decoration:underline;color:#000000;">Section 4.5.3</font><font style="color:#000000;"> (subject to </font><font style="text-decoration:underline;color:#000000;">Section 6.2</font><font style="color:#000000;"> in respect of existing Third Party rights, and subject to </font><font style="text-decoration:underline;color:#000000;">Section 7.1(a)(ii)(B)</font><font style="color:#000000;"> [*], (ii) any Exploitation activities with respect to any compound or product that includes the same [*] that binds the Lilly Target in (A) any Collaboration Compound, or (B) Modified Compound or Monospecific Compound for which Merus has received a Modified Compound Notice under </font><font style="text-decoration:underline;color:#000000;">Section 4.5.3</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that at the time Merus receives such Modified Compound Notice, such sequence was not [*], and </font><font style="text-decoration:underline;color:#000000;">further provided</font><font style="color:#000000;"> that the total number of [*] sequences binding the Lilly Target on which Merus is restricted shall in no event exceed [*] per Research Program at any given point in time (and in the event Lilly issues a Modified Compound Notice at a time which there are already a number of sequences in the aggregate that reach such cap, [*]), (iii) Research (other than with respect to the practice of any rights expressly reserved by Merus pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 6.6)</font><font style="color:#000000;">, Development or Commercialization of any monospecific antibody (including an ADC) directed against a Lilly Target (excluding any Replaced Target or a Terminated Target), but excluding any Terminated Product or Terminated Compound, subject to any Existing Third Party Agreements for which Merus has provided Lilly written notice pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 6.2</font><font style="color:#000000;">, or (iv) Exploitation of any [*] absent a license from Lilly in respect of Lilly&#8217;s joint interest in such rights, as further described in </font><font style="text-decoration:underline;color:#000000;">Section 9.1.4</font><font style="color:#000000;">; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">engage in any Exploitation activities</font><font style="color:#000000;"> with respect to any </font><font style="color:#000000;">compound or product directed against any Lilly Target Pair (a </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Restricted Product</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">), </font><font style="color:#000000;">including for clarity</font><font style="color:#000000;">, </font><font style="color:#000000;">any Restricted Product that also binds one or more other Target(s) in addition to the Lilly Target Pair (</font><font style="font-style:italic;color:#000000;">i.e.</font><font style="color:#000000;">,</font><font style="color:#000000;"> a multispecific product);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">collaborate or enter into any arrangement with, or work for the benefit of, any Third Party involving any of activities in subclauses (a) or (b), or enter into any agreement to do any of such activities in subclauses (a) or (b); or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">grant any Third Party any license, sublicense, covenant not to assert or other rights (including to or under any Merus Know-How or Merus Patents) to or otherwise enable such Third Party to (or assign, convey, transfer or sell any rights to a Third Party to) conduct any activities falling within subclauses (a), (b) or (c), </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that subject to </font><font style="text-decoration:underline;color:#000000;">Section 15.8</font><font style="color:#000000;">, the foregoing shall not prevent, or place any restrictions on Merus&#8217;s ability to enter into any Change of Control transaction.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_59"></a>Subject to the obligations of this <font style="text-decoration:underline;">Article 7</font><a name="_cp_text_1_59"></a>, Merus will otherwise be free to Exploit itself, or to grant rights to any Third Party with respect to (1) any Target (that, where not in combination with another Target, is not a Lilly Target) and (2) any Target combination that is not a combination of a Lilly Target and CD3 (with or without any other Target(s)).&nbsp;&nbsp;For clarity, Merus does not exclusively license rights to any CD3 antibody under this Agreement to Lilly for any Lilly Target Pair, and any and all CD3 antibodies Controlled by Merus or its Affiliates are and will remain available to Merus or its Affiliates for use in any Internal Merus Program or with any Third Party. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825909"></a><a name="_Ref59062412"></a><a name="_Ref59063381"></a><a name="_Ref61215687"></a><a name="_Ref60994171"></a><a name="_Ref41860411"></a><a name="_Ref532232413"></a><a name="_Ref534970942"></a><a name="_Ref4673728"></a><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Certain Sequence Exclusivity</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.  On a Research Program-by-Research Program basis, during the Homology Exclusivity Period for such Research Program, [*] binds the Lilly Target in the designated lead Collaboration Compound included in the Final Research Deliverables for such Research Program.&nbsp;&nbsp;If Lilly elects, [*] that binds the Lilly Target in such lead Collaboration Compound, and Lilly notifies Merus (at its sole discretion) of the sequence of such [*] by delivering a Modified Compound Notice with respect thereto: [*].&nbsp;&nbsp;For clarity, if Lilly generates such a Modified Compound and elects not to notify Merus of the sequence thereof, the rights granted to Lilly with respect to such sequence shall remain non-exclusive in accordance with <font style="text-decoration:underline;">Section 6.1(b)(ii)</font>. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825910"></a><font style="Background-color:#auto;text-decoration:none;">7.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Transactions Involving Competing Programs</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41856253"></a><a name="_cp_text_1_556"></a><a name="_cp_text_1_557"></a><a name="_cp_text_1_558"></a><a name="_9kR3WTrAG856BFJKnap173yB32J4sTVCE7CHCBo"></a><a name="_cp_text_1_560"></a><a name="_cp_text_1_290"></a><a name="_cp_text_1_562"></a><font style="Background-color:#auto;text-decoration:none;">7.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Acquisition of Existing Competing Program</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the exclusivity obligations set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.1</font><font style="color:#000000;">, if, after the Effective Date, any Third Party becomes an Affiliate of Merus that Merus controls (as such term is defined in the definition of &#8220;Affiliate&#8221;<a name="_cp_text_1_556"></a>) as a result of a merger, acquisition, consolidation, asset sale, or other similar transaction (whether in a single transaction or series of related transactions), and, as of the closing date of such transaction, such Third Party is engaged in: <a name="_cp_text_1_557"></a>(a) the Exploitation of a compound or product; <a name="_cp_text_1_558"></a>or (b) the licensing, conveyance, sublicensing or other grant of rights in Patents and Know-How with respect to such a compound or product, in each case of (a) and (b) that would cause Merus to breach its exclusivity obligations set forth in </font><font style="text-decoration:underline;color:#000000;">Section 7.1</font><font style="color:#000000;"> (such activities in (a) and (b), a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Competing Program</font><font style="color:#000000;">&#8221;), then Merus shall provide Lilly with written notice of such transaction promptly[*], and Merus shall (or shall cause such Affiliate to), within [*]<a name="_9kR3WTrAG856BFJKnap173yB32J4sTVCE7CHCBo"></a> after the closing of such transaction, either: (i) <a name="_cp_text_1_560"></a>complete a Divestiture of such Competing Program; or (ii) wind down and terminate the Competing Program.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Divestiture</font><font style="color:#000000;">,&#8221; means, [<a name="_cp_text_1_290"></a>*].&nbsp;&nbsp;&#8220;Divestiture&#8221; does not mean that following the sale or transfer of rights to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="_cp_text_1_562"></a>the Competing Program by such Party to a Third Party that such Party waives any right to receive</font><font style="color:#000000;"> a continuing share of profit, royalty payment, or other economic interest in the success of </font><font style="color:#000000;">such Competing Program so long as such Party does not undertake or support any diligence or performance obligation with respect to such Competing Program</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref535529294"></a><font style="Background-color:#auto;text-decoration:none;">7.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Existing Competing Program of a Merus Acquirer</font><font style="color:#000000;">.&nbsp;&nbsp;If after the Effective Date any Third Party becomes an Acquirer of Merus as a result of a Change of Control of Merus, and, as of the closing date of such transaction, such Acquirer is engaged in a Competing Program, then the provisions of </font><font style="text-decoration:underline;color:#000000;">Section 15.8</font><font style="color:#000000;"> shall apply.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506472080"></a><a name="_Toc61825911"></a><a name="_Ref45222898"></a><font style="Background-color:#auto;text-decoration:none;">Article 8</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref45222898"></a>FEES, ROYALTIES, &amp; PAYMENTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref440443610"></a><a name="_Toc61825912"></a><a name="_Ref520302225"></a><a name="_Ref520302274"></a><a name="_Ref339287253"></a><a name="_Ref404007530"></a><font style="Background-color:#auto;text-decoration:none;">8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Upfront Payment</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref437250090"></a>.&nbsp;&nbsp;As partial consideration for the rights granted by Merus to Lilly pursuant to the terms of this Agreement, Lilly shall pay to Merus a one-time, non-refundable, non-creditable license fee payment equal to Forty Million Dollars ($40,000,000) within thirty (30) days following the Effective Date<a name="_Ref437250090"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825913"></a><font style="Background-color:#auto;text-decoration:none;">8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Equity Investment</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Lilly will make an equity investment to acquire common shares of Merus pursuant to the terms of the Purchase Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref508382701"></a><a name="_Toc61825914"></a><a name="_Ref56952451"></a><a name="_Ref41868188"></a><a name="_Ref42032868"></a><font style="Background-color:#auto;text-decoration:none;">8.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Milestone Payments</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">On a Product-by-Product basis, Lilly shall pay to Merus certain non-refundable, non-creditable milestone payments, as follows (subject to </font><font style="text-decoration:underline;color:#000000;">Section 8.3.3</font><font style="color:#000000;">): (a) within [*] following any Product achieving a development or regulatory milestone event set forth in </font><font style="text-decoration:underline;color:#000000;">Table 8.3</font><font style="color:#000000;"> below, by or on behalf of Lilly or its Affiliates (including by and through a Sublicensee acting within the scope of the license granted in </font><font style="text-decoration:underline;color:#000000;">Section 6.1</font><font style="color:#000000;">)  (each, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Development/Regulatory Milestone Event</font><font style="color:#000000;">&#8221;), Lilly shall pay to Merus the corresponding Milestone Payment indicated in </font><font style="text-decoration:underline;color:#000000;">Table 8.3</font><font style="color:#000000;"> (each such Milestone Payment, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Development/Regulatory Milestone Payment</font><font style="color:#000000;">&#8221;); and (b) within [*] following the end of the Calendar Quarter in which any Product achieves a commercial milestone event set forth in </font><font style="text-decoration:underline;color:#000000;">Table 8.3</font><font style="color:#000000;">, by or on behalf of Lilly or its Affiliates (including by and through a Sublicensee acting within the scope of the license granted in </font><font style="text-decoration:underline;color:#000000;">Section 6.1</font><font style="color:#000000;">) (each, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commercial Milestone Event</font><font style="color:#000000;">&#8221;), Lilly shall pay to Merus the corresponding Milestone Payment indicated in </font><font style="text-decoration:underline;color:#000000;">Table 8.3</font><font style="color:#000000;"> (each such Milestone Payment, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commercial Milestone Payment</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Development/Regulatory Milestone Events and Commercial Milestone Events may be referred to individually or collectively as &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Milestone Events</font><font style="font-style:italic;color:#000000;">,</font><font style="color:#000000;">&#8221; and Development/Regulatory Milestone Payments and Commercial Milestone Payments may be referred to individually or collectively as &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Milestone Payments</font><font style="color:#000000;">&#8221;.&nbsp;&nbsp;For clarity, each Milestone Payment shall be payable only once per Product (recognizing that the Milestone Events for the &#8220;first Indication for a Product&#8221; and &#8220;second Indication for a Product&#8221; will be separately payable once for each Product), no Milestone Payment shall be payable for subsequent or repeated achievements of the same Milestone Event with respect to the same Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Development/Regulatory Milestone Events for the Initiation of a Clinical Trial are intended to be sequential, and achievement of a Development/Regulatory Milestone Event </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">for Initiation of a Clinical Trial shall result in deemed achievement of all earlier Development</font><font style="color:#000000;">/Regulatory</font><font style="color:#000000;"> Milestone Events</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">The Development/Regulatory Milestone Events for the First Commercial Sale of a Product for a first or second Indication are intended to be sequential to the Development/Regulatory Milestone Events applicable to the Initiation of a Clinical Trial for such Indication, and achievement of a Development/Regulatory Milestone Event for the First Commercial Sale of a Product for a particular Indication shall result in deemed achievement of the following Development</font><font style="color:#000000;">/Regulatory</font><font style="color:#000000;"> Milestone Events (in each case, solely to the extent not already achieved once for such Product): Initiation of the first Phase I Clinical Trial; Initiation of the first Phase II Clinical Trial; and, as applicable, either</font><font style="color:#000000;">:</font><font style="color:#000000;"> (</font><font style="color:#000000;">a</font><font style="color:#000000;">) the Initiation of the first Phase III Clinical Trial for the first Indication for a Product or (</font><font style="color:#000000;">b</font><font style="color:#000000;">) the Initiation of the first Phase III Clinical Trial for the second Indication for a Product</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Similarly, achievement of each Commercial Milestone Event measured by annual Net Sales shall result in achievement of all Commercial Milestone Events measured by a lower amount of </font><font style="color:#000000;">a</font><font style="color:#000000;">nnual Net Sales</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53742807"></a><a name="_Ref58267147"></a><font style="Background-color:#auto;text-decoration:none;">8.3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding the foregoing, Lilly will only be required to pay Merus [*] of each Milestone Payment for any Reduced Payment Product that achieves the applicable Milestone Event.&nbsp;&nbsp;For clarity, a Product that incorporates, contains or comprises a Modified Compound is not a Reduced Payment Product, unless such Product otherwise meets the definition of a Reduced Payment Product.</font><font style="font-size:13pt;color:#000000;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table 8.3 &#8211; Milestone Payments</font> [</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:481.9pt;;">
<tr>
<td style="width:356.9pt;"></td>
<td style="width:125pt;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Development/Regulatory<font style="font-style:italic;font-weight:normal;"> </font>Milestone Event</p></td>
<td valign="middle"  BGCOLOR="#D9D9D9" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payment</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Development/Regulatory Milestone Payments Per Product:</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">USD $290 Million</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercial Milestone Event</p></td>
<td valign="middle"  BGCOLOR="#D9D9D9" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payment</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:481.9pt;;">
<tr>
<td style="width:356.9pt;"></td>
<td style="width:125pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</font></p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:-1pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Commercial Milestone Payments Per Product:</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:111.5pt;;text-indent:-112.5pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">USD $250 Million</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825915"></a><a name="_Ref339269852"></a><a name="_Ref506475724"></a><a name="_Ref507154089"></a><a name="_9kR3WTr29968BIKfWAxl53p0"></a><font style="Background-color:#auto;text-decoration:none;">8.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalties on Products</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref438556016"></a><a name="_9kR3WTr2885DHIKFcXBym6KvW1A"></a><a name="_9kR3WTr2995DIJKFcXBym6KvW1A"></a><a name="_Ref437250390"></a><a name="_Ref438642318"></a><a name="_Ref506473625"></a><a name="_Ref507510956"></a><a name="_Ref339023283"></a><a name="_cp_field_47_732"></a><a name="_9kMHG5YVt4886CGXKifr6ykWfBy5555Bwbzw8NF"></a><a name="_cp_text_1_733"></a><a name="_cp_text_1_734"></a><font style="Background-color:#auto;text-decoration:none;">8.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Term</font><font style="color:#000000;">.&nbsp;&nbsp;Lilly shall pay Merus royalties as set forth in this </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_field_47_732"></a>Section&#160;8.4</font><font style="color:#000000;"> <a name="_9kMHG5YVt4886CGXKifr6ykWfBy5555Bwbzw8NF"></a>on a Product-by-Product<a name="_cp_text_1_733"></a> and country-by-country basis in the Territory during the period of time beginning on the date of the First Commercial Sale of such Product in such country and continuing until the later of: (a) the expiration or abandonment of the last-to-expire Royalty-Bearing <a name="_cp_text_1_734"></a>Claim in such country; (b) the expiration of any period of data, regulatory, or market exclusivity, or supplemental protection certificates (other than Patent rights) covering the Product in such country (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Regulatory Exclusivity</font><font style="color:#000000;">&#8221;); or (c) [*] years after the First Commercial Sale of such Product in such country (the&#160;&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Royalty Term</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Upon the expiration of the Royalty Term for a Product in a particular country, then subject to </font><font style="text-decoration:underline;color:#000000;">Section 8.4.4</font><font style="color:#000000;">, the licenses granted by Merus to Lilly under </font><font style="text-decoration:underline;color:#000000;">Section&#160;6.1</font><font style="color:#000000;"> with respect to such Product and such country shall survive and become perpetual, fully-paid, and royalty-free, and shall remain exclusive (even as to Merus and its Affiliates).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2995FKJKGdXBym6KtQz44"></a><a name="_Ref437250356"></a><a name="_Ref507062436"></a><a name="_Ref54104583"></a><a name="_Ref339287557"></a><a name="_Ref339023360"></a><a name="_9kR3WTr2664ABWV1ovvvv1qeAx444"></a><a name="_9kR3WTr2664ACZU8vj3HsTy7"></a><a name="_9kMH4L6ZWu59978CcY4ryyy"></a><a name="_9kR3WTr2444BIeU8vj3H"></a><font style="Background-color:#auto;text-decoration:none;">8.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Rates</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kR3WTr2664ABWV1ovvvv1qeAx444"></a>On a Product-by-Product<a name="_9kR3WTr2664ACZU8vj3HsTy7"></a> and country-by-country basis, during the Royalty Term<a name="_9kMH4L6ZWu59978CcY4ryyy"></a>, Lilly shall pay to Merus a tiered royalty equal to the percentages of annual Net Sales of such Product, as set forth in </font><font style="text-decoration:underline;color:#000000;">Table 8.4.2</font><font style="color:#000000;"> <a name="_9kR3WTr2444BIeU8vj3H"></a>below (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Royalty</font><font style="color:#000000;">&#8221;), calculated by multiplying the applicable royalty rate percentage by the corresponding portion of aggregate Net Sales for such Product in such Calendar Year.&nbsp;&nbsp;Notwithstanding the foregoing, Lilly will only be required to pay Merus: [*] of the applicable royalty percentage set forth below for Net Sales of any Reduced Payment Product.&nbsp;&nbsp;For clarity, a Product that incorporates, contains or comprises a Modified Compound is not a Reduced Payment Product, unless such Product otherwise meets the definition of a Reduced Payment Product.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-0.03%;width:481.9pt;;">
<tr>
<td style="width:417pt;"></td>
<td style="width:64.9pt;"></td>
</tr>
<tr style="height:26.5pt;">
<td valign="middle"  BGCOLOR="#BFBFBF" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Net<font style="font-weight:normal;"> </font>Sales<font style="font-weight:normal;"> </font>Per Product</p></td>
<td valign="middle"  BGCOLOR="#BFBFBF" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty<font style="font-weight:normal;"> </font>Rate</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2995FJIKHiNktmHKpn0"></a><a name="_Ref464552150"></a><a name="_Ref506969068"></a><a name="_Ref536196858"></a><a name="_Ref339023368"></a><a name="_Ref438500848"></a>[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref47394342"></a><a name="_Ref459101533"></a><a name="_9kMHG5YVt4BB7HMLMIfZD0o8MvS166"></a><font style="Background-color:#auto;text-decoration:none;">8.4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Valid Claim</font><font style="color:#000000;"><a name="_Ref459101533"></a>.&nbsp;&nbsp;From the first full Calendar Quarter during the Royalty Term for a Product for which there is no Royalty-Bearing Claim that Covers such Product in such country, the Royalty rates provided in </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB7HMLMIfZD0o8MvS166"></a>Section&#160;8.4.2</font><font style="color:#000000;"> for the Product will be reduced in such country by (a) [*], after which, the foregoing reduction shall increase to [*] (in addition to any reductions in </font><font style="text-decoration:underline;color:#000000;">Section 8.4.4</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.4.5</font><font style="color:#000000;">, but subject to </font><font style="text-decoration:underline;color:#000000;">Section 8.4.6</font><font style="color:#000000;">).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref1560204"></a><a name="_Ref42040612"></a><a name="_Ref56669689"></a><a name="_Ref57043668"></a><a name="_Ref535538911"></a><a name="_Ref520381847"></a><a name="_cp_text_1_741"></a><a name="_cp_text_1_736"></a><font style="Background-color:#auto;text-decoration:none;">8.4.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Biosimilar Products</font><font style="color:#000000;"><a name="_cp_text_1_741"></a>.&nbsp;&nbsp;<a name="_cp_text_1_736"></a>On a country-by-country and Product-by-Product basis, following the first commercial sale of one (1) or more Biosimilar Products with respect to a Product in any country in the Territory during the Royalty Term, the Royalty rates provided in </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.4.2</font><font style="color:#000000;"> for such Product will: be (a) permanently reduced in such country by [*] percent in such country during the Royalty Term once such Biosimilar Product(s) has or have a combined market share of [*] or more in such country; or (b) by [*] percent in such country during the Royalty Term once such Biosimilar Product(s) has or have a combined market share of [*] or more in such country, in which case, [*].&nbsp;&nbsp;The determination of market share for the purpose of this </font><font style="text-decoration:underline;color:#000000;">Section 8.4.4</font><font style="color:#000000;">, shall be measured in local currency, over the Calendar Quarter, as reported by IQVIA or other customary market intelligence service used by Lilly and reasonably acceptable to Merus.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2995FNMKIhSozvUMvFNuR7K13JP"></a><a name="_Ref383956224"></a><a name="_Ref381316939"></a><a name="_Ref464552254"></a><a name="_Ref506969073"></a><a name="_Ref_ContractCompanion_9kb9Ur1BH"></a><a name="_Ref520303612"></a><a name="_Ref56669714"></a><a name="_Ref59060987"></a><a name="_Hlk58918283"></a><a name="El2_73O"></a><a name="_cp_text_1_748"></a><a name="_Ref494986816"></a><a name="_Ref496719558"></a><font style="Background-color:#auto;text-decoration:none;">8.4.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Third</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Party</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Payments</font><font style="color:#000000;">.&nbsp;&nbsp;On a Product-by-Product and country-by-country basis, Lilly may deduct from any Royalty payments to Merus under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.4</font><font style="text-decoration:underline;Background-color:#E6E6E6;">:</font><font style="color:#000000;"> (a) for each Product that is not a Reduced Payment Product, an amount equal to [*] of [*] made by Lilly to a Third Party in connection with sales of such Products in such country under this Agreement in consideration for a right or license under such Third Party&#8217;<a name="_cp_text_1_748"></a>s interest in any Patents that would, absent such a right or license, be infringed [<a name="_Ref494986816"></a><a name="_Ref496719558"></a>*] in the applicable country in the Territory (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Necessary Third Party IP</font><font style="color:#000000;">&#8221;), and (b) for each Reduced Payment Product, an amount equal to [*] of [*] made by Lilly to a Third Party in connection with sales of such Reduced Payment Product in a given country in the Territory under this Agreement in consideration for a right or license under such Third Party&#8217;s interest in any Patents that would, absent such a right or license, be infringed [*] (i) [*], or (ii) any [*], in each case, in such Reduced Payment Product in the Field in the applicable country in the Territory.&nbsp;&nbsp;For clarity, such deduction shall not apply where any payments made by Lilly to a Third Party in connection with sales of such Reduced Payment Products in such country under this Agreement in consideration for a right or license under such Third Party&#8217;s interest in any Patents that would, absent such a right or license, be infringed in whole or in part by [*] of said Reduced Payment Product.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56815223"></a><a name="_Ref151314221"></a><a name="_Ref42040664"></a><font style="Background-color:#auto;text-decoration:none;">8.4.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Floor</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the foregoing </font><font style="text-decoration:underline;color:#000000;">Sections 8.4.3</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">8.4.4(a)</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">8.4.5</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">15.8.2(a)(iv)</font><font style="color:#000000;"> with respect to any Product in any Calendar Quarter, except in the case of a reduction under </font><font style="text-decoration:underline;color:#000000;">Section 8.4.4(b)</font><font style="color:#000000;">, the Royalty that would otherwise have been due under </font><font style="text-decoration:underline;color:#000000;">Section 8.4.2</font><font style="color:#000000;"> with respect to Net Sales of such Product in the applicable country(ies) during such Calendar Quarter shall not be reduced by more than [*] as a result of all such reductions.&nbsp;&nbsp;For clarity, the foregoing [*] floor shall not apply to the reduction in royalties taken pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 8.4.4(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.4.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Payment; Reports</font><font style="color:#000000;">.&nbsp;&nbsp;Royalty payments due by Lilly to Merus under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.4</font><font style="color:#000000;"> will be calculated and reported for each Calendar Quarter.&nbsp;&nbsp;All Royalty payments due under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.4</font><font style="color:#000000;"> shall be paid within [*] after the end of each Calendar Quarter and shall be accompanied by a report setting forth Net Sales and Royalties for each Product sold by Lilly and its Affiliates and Sublicensees in the Territory and providing notice of any Commercial Milestone Event that have been achieved in such Calendar Quarter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_752"></a><a name="_Toc61825916"></a><a name="_9kR3WTr2995FGFLbHvzvstwYO4Hy0GgcOMA76It"></a><a name="_Ref507137546"></a><a name="_Ref520918953"></a><a name="_Ref2333423"></a><font style="Background-color:#auto;text-decoration:none;">8.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Method of Payment; Currency Conversion</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Unless otherwise agreed by the Parties, all payments due under this Agreement shall be paid in Dollars by wire transfer or electronic funds transfer of immediately available funds to an account designated by the payee; <font style="text-decoration:underline;">provided</font> however, that Lilly shall only be required to disburse funds to the payee&#8217;s jurisdiction of incorporation or to a jurisdiction in which the payee has a significant business presence.&nbsp;&nbsp;When conversion of payments from any currency other than Dollars is required, Lilly&#8217;s then-current standard exchange rate </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">methodology will be employed for the translation of foreign currency sales into Dollars; </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that this methodology is used by Lilly in the translation of its foreign currency operating results, is consistent with U.S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAAP</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825917"></a><a name="_Ref339287015"></a><a name="_Ref437250935"></a><a name="_Ref532029930"></a><a name="_Ref58365589"></a><font style="Background-color:#auto;text-decoration:none;">8.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Records and Audits</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_760"></a>.&nbsp;&nbsp;Lilly shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate records which may be necessary to ascertain properly and to verify the Royalties and Milestone Payments due hereunder.&nbsp;&nbsp;Such records shall be kept for such period of time required by Applicable Laws, but no less than [*] following the end of the Calendar Quarter to which they pertain.&nbsp;&nbsp;Merus shall have the right, but not more than [*] during the Term, to [*] have an independent, certified public accountant [*] inspect Lilly&#8217;s records for the purpose of determining the accuracy of Royalties and Milestone Payments [*].&nbsp;&nbsp;No period will be audited more than once and each audit must be reasonable in scope.&nbsp;&nbsp;[*].&nbsp;&nbsp;The independent, certified public accountant selected shall keep confidential any information obtained during such inspection and shall report to Merus and Lilly only the amounts of Net Sales and Royalties and/or Milestone Payments due and payable.&nbsp;&nbsp;Such audits may be exercised during normal business hours upon reasonable prior written notice to Lilly.&nbsp;&nbsp;Merus shall bear the full cost of such audit unless such audit discloses an underpayment by Lilly of more than [<a name="_cp_text_1_760"></a>*], of the amount of Royalties or other payments due under this Agreement for the audited period, in which case, Lilly shall bear the cost of such audit and shall remit to Merus the amount of any underpayment within [*] of the date the auditor&#8217;s written report is received.&nbsp;&nbsp;Any overpayment by Lilly revealed by an audit shall be [*] within [*] of the receipt of the request).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825918"></a><a name="_Ref339023610"></a><a name="_Ref385254620"></a><a name="_Ref506474825"></a><a name="_Ref520387420"></a><font style="Background-color:#auto;text-decoration:none;">8.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Late Payments</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If any payment properly due under this Agreement and not subject to a good faith dispute is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at the rate of prime (as reported in <font style="font-style:italic;">The Wall Street Journal </font>(Eastern U.S. edition)) plus [*] or the maximum rate allowable by Applicable Law, whichever is less.&nbsp;&nbsp;The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2996BDHOlKv0w"></a><a name="_Toc61825919"></a><a name="_Ref59195365"></a><a name="_Ref506475734"></a><a name="_Hlk59182791"></a><a name="_Hlk59182752"></a><a name="_Hlk59182829"></a><font style="Background-color:#auto;text-decoration:none;">8.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Taxes</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref507167044"></a><a name="_9kR3WTr29969AJqA2mqthf2E6z71t9SA2IPPOFI"></a><a name="_9kR3WTr2996CCIqA2mqthf2E6z71t9SA2IPPOFI"></a><font style="Background-color:#auto;text-decoration:none;">8.8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cooperation</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">and</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Coordination</font><font style="color:#000000;"><a name="_Ref507167044"></a><a name="_9kR3WTr29969AJqA2mqthf2E6z71t9SA2IPPOFI"></a><a name="_9kR3WTr2996CCIqA2mqthf2E6z71t9SA2IPPOFI"></a>.&nbsp;&nbsp;The Parties acknowledge and agree that it is their mutual objective and intent to minimize, to the extent feasible and in compliance with Applicable Laws, taxes payable with respect to their collaborative efforts under this Agreement and that they shall use reasonable efforts to cooperate and coordinate with each other to achieve such objective. Where any payment due to Merus hereunder is subject to any withholding or similar tax, the Parties shall use their commercially reasonable efforts to take all such actions as shall enable them to take advantage of any applicable double taxation agreement or treaty. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59172000"></a><a name="_Ref61004987"></a><a name="_Ref507082070"></a><font style="Background-color:#auto;text-decoration:none;">8.8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Payment</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">of</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Tax</font><font style="color:#000000;">. The upfront, milestones, royalties and other amounts payable by Lilly to Merus to this Agreement (each, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Payment</font><font style="color:#000000;"><a name="_Ref507082070"></a>&#8221;) shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law. Except as provided in this </font><font style="text-decoration:underline;color:#000000;">Section 8.8.2</font><font style="color:#000000;">.  Merus shall be solely responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by Lilly) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Lilly shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if Merus is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to Lilly or the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">appropriate Governmental Authority (with the assistance of Lilly to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Lilly of its obligation to withhold such tax and Lilly shall apply the reduced rate of withholding or dispense with withholding as the case may be; provided that Lilly has received evidence, in a form satisfactory to Lilly, of </font><font style="color:#000000;">Merus&#8217;s</font><font style="color:#000000;"> delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> prior to the time Payments are due. If in accordance with the foregoing, Lilly withholds any amounts of tax, it shall pay to Merus the balance when due, make timely payment to the proper tax authority of the withheld amount and send to Merus proof of such payment within </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> following such payments.</font><font style="color:#FF0000;font-family:TimesNewRomanPSMT;"> </font><font style="color:#000000;">Notwithstanding the foregoing, the Parties acknowledge and agree that if Lilly (or its Affiliates or successors) is required to make a payment to Merus subject to a deduction or withholding of tax, and if such deduction or withholding of tax arises or is increased solely as a result any action taken by Lilly or its Affiliates or successor or assignee, including without limitation the assignment or transfer of all or a portion of this Agreement by the payor pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 15.7</font><font style="color:#000000;"> or otherwise, or there is a change, whether by corporate continuance, merger or other means, in the tax residency of Lilly, or payments arise or are deemed to arise through a branch of the payor (each a </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Withholding Tax Action</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">), then notwithstanding anything to the contrary herein, the payment by Lilly (in respect of which such deduction and withholding of tax is required to be made) shall be increased by the amount necessary to ensure that Merus receives an amount equal to the same amount that it would have received had no Withholding Tax Action occurred.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59171948"></a><a name="_Toc61825920"></a><a name="_Ref520464141"></a><a name="_Ref47391488"></a><font style="Background-color:#auto;text-decoration:none;">Article 9</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref520464141"></a><a name="_Ref47391488"></a>INTELLECTUAL PROPERTY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825921"></a><a name="_Ref388012015"></a><a name="_Ref441002807"></a><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><a name="_Ref339024016"></a><a name="_Ref437251055"></a><font style="Background-color:#auto;text-decoration:none;">9.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Ownership of Intellectual Property</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53751612"></a><a name="_cp_text_1_762"></a><a name="_Ref405220436"></a><a name="_Ref389146758"></a><a name="_Ref373080696"></a><font style="Background-color:#auto;text-decoration:none;">9.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Background IP</font><font style="color:#000000;">.&nbsp;&nbsp;As between the Parties, and subject to the licenses granted under this Agreement and the requirements of this </font><font style="text-decoration:underline;color:#000000;">Section 9.1</font><font style="color:#000000;">: (a) Lilly shall solely own (or retain ownership of) all rights, title and interests in and to the Lilly Background Know-How and Lilly Background Patents; and (b) Merus shall solely own (or retain ownership of) all rights, title and interests in and to the Merus Background Know-How and Merus Background Patents.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56861663"></a><font style="Background-color:#auto;text-decoration:none;">9.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Ownership of Arising IP.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56875032"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Lilly Ownership</font><font style="color:#000000;">.  Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(d)</font><font style="color:#000000;">, as between the Parties, and subject to the licenses and obligations of exclusivity granted hereunder, Lilly shall solely own (or retain ownership of) all rights, title and interests in and to: (i) all [*] and [*]; (ii) any [*] and [*]; and (iii) except as expressly set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(b)(i)</font><font style="color:#000000;">, all Inventions and Know-How made following the completion of activities under the applicable Research Plan (or the expiration of the Research Term, if earlier) solely by or on behalf of Lilly or its Affiliates ((other than by Merus or its Affiliates)) in connection with the exercise of its rights or the performance of its activities under this Agreement (collectively (i) through (iii) the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Sole Arising IP</font><font style="font-style:italic;color:#000000;">&#8221;). </font><font style="color:#000000;"> Notwithstanding the foregoing, [*].  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56875034"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus Ownership</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(d)</font><font style="color:#000000;">, as between the Parties, and subject to the licenses and obligations of exclusivity granted hereunder, Merus shall solely own (or retain ownership of) all rights, title and interests in and to all: (i) Merus Platform IP and Merus </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Platform Patents</font><font style="color:#000000;">;</font><font style="color:#000000;"> (</font><font style="color:#000000;">ii</font><font style="color:#000000;">) all </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> </font><font style="color:#000000;">and </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">;</font><font style="color:#000000;"> </font><font style="color:#000000;">and </font><font style="color:#000000;">(iii) </font><font style="color:#000000;">except as expressly set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(a)</font><font style="text-decoration:underline;color:#000000;">(</font><font style="text-decoration:underline;color:#000000;">i</font><font style="text-decoration:underline;color:#000000;">)</font><font style="color:#000000;">, all Inventions and Know-How made </font><font style="color:#000000;">following the completion of activities under the applicable Research Plan (or the expiration of the Research Term, if earlier) </font><font style="color:#000000;">solely by or on behalf of Merus or its Affiliates in connection with the exercise of its rights or the performance of its activities under this Agreement</font><font style="color:#000000;"> (collectively (</font><font style="color:#000000;">i</font><font style="color:#000000;">) through (iii) the </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Sole Arising IP</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-style:italic;color:#000000;">)</font><font style="font-style:italic;color:#000000;">. </font><font style="color:#000000;">Notwithstanding the foregoing, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56862383"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Joint Ownership.</font><font style="color:#000000;">  Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(d)</font><font style="color:#000000;">, as between the Parties, each Party shall own an equal, undivided interest in and to: (i) any Joint Research Program Know-How and Joint Research Program Patents; and (ii) except as expressly set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2(a)(i)</font><font style="color:#000000;">, or </font><font style="text-decoration:underline;color:#000000;">9.1.2(b)(i)</font><font style="color:#000000;">, any other Inventions and Know-How that are made following the completion of activities under the applicable Research Plan (or the expiration of the Research Term, if earlier) jointly by or behalf of the Parties or their Affiliates in connection with the performance of the Parties&#8217; activities under this Agreement ((i) and (ii), collectively, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Joint Know-How</font><font style="color:#000000;">&#8221; and any Patents Covering such Joint Know-How (including all Joint Research Program Patents), the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Joint Patents</font><font style="color:#000000;">&#8221;), [*].&nbsp;&nbsp;Each Party shall promptly disclose to the other Party in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the conception, discovery, development, making, or reduction to practice of any Joint Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59115802"></a><a name="_Ref59185099"></a><a name="_Ref59186552"></a><a name="_Ref59912928"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Assigned [*] Patents</font><font style="color:#000000;">.  Notwithstanding </font><font style="text-decoration:underline;color:#000000;">Sections 9.1.2(a)</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">9.1.2(b)</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">9.1.2(c)</font><font style="color:#000000;">, as between the Parties, Lilly shall own [*], (B) a specific [*] disclosed by [*], or (C) on a Research Program-by-Research Program basis, [*] provided that [*] of such Compound that binds [*]; and (ii) does not include claims that [*].&nbsp;&nbsp;For the avoidance of doubt, all Patents and Patent applications [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_770"></a><font style="Background-color:#auto;text-decoration:none;">9.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Inventorship</font><font style="font-style:italic;color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Inventorship as between the Parties will be determined in accordance with U.S patent laws.&nbsp;&nbsp;<a name="_cp_text_1_770"></a>All such determinations shall be documented to ensure that the Patent claims in any divisional or continuation patent applications reflect appropriate inventorship.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59735740"></a><font style="Background-color:#auto;text-decoration:none;">9.1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Rights of Joint Owners</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the express licenses and obligations of exclusivity granted hereunder, and the obligations of the Parties with respect to any Joint Know-How and Joint Patents, each Party shall have full rights to exploit, license and transfer any Joint Know-How and Joint Patents, in each case, without any obligation or requirement of an accounting to the other Party, so long as such use, sale, license, or transfer is subject to and consistent with the terms of this Agreement, including exclusivity obligations; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, that neither Party may Exploit, license or transfer [*], without the express consent of the other Party, where such consent may be conditioned on [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, that each Party may, [*], and the other Party is deemed to have consented to such enforcement action by operation of this section.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_773"></a><a name="_cp_blt_1_778"></a><a name="_cp_blt_2_777"></a><font style="Background-color:#auto;text-decoration:none;">9.1.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Independent Development</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the licenses and obligations of exclusivity granted hereunder, nothing in this Agreement shall be construed as limiting either Lilly&#8217;s or Merus&#8217;s right to research, develop, improve and in-license technology, including technology related to the Lilly Background Know-How (in the case of Lilly) or Merus Background Know-How (in the case of Merus), outside the scope of this Agreement in its ordinary course of business.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_815"></a><a name="_Ref42029054"></a><a name="_cp_text_1_816"></a><a name="_cp_text_1_818"></a><a name="_cp_text_1_822"></a><font style="Background-color:#auto;text-decoration:none;">9.1.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Contribution of [*] Know-How</font><font style="color:#000000;">.&nbsp;&nbsp;[*] shall inform [*]<a name="_cp_text_1_816"></a> in writing, prior to contributing to any Research to be conducted under any Research Plan, <a name="_cp_text_1_818"></a>any portion of the [*] Know-How or [*] Patents<a name="_cp_text_1_822"></a> that are in-licensed from a Third Party, together with any material conditions or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">restrictions associated with such contribution, including any conflict with </font><font style="color:#000000;">the ownership and use rights with respect to Patents and Know-How contemplated by this Agreement</font><font style="color:#000000;">. </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> shall not so contribute any such </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> Know-How or </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> Patents without </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> prior written consent therefor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_830"></a><a name="_cp_blt_2_829"></a><a name="_Ref56955794"></a><a name="_9kMKJ5YVt4666BIeKt862"></a><font style="Background-color:#auto;text-decoration:none;">9.1.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Assignment Obligations</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kMKJ5YVt4666BIeKt862"></a>Each Party shall cause all employees, independent contractors, consultants, and others who perform activities for such Party under this Agreement to be under an obligation to assign (or, if such Party is unable to cause such person or entity to agree to such assignment obligation despite such Party using reasonable efforts to negotiate such assignment obligation, provide a license, preferably exclusive, under) to such Party their rights in and to any Inventions and all intellectual property rights therein, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public institutions that have standard policies against such an assignment (in which case a Party shall obtain a suitable license, preferably exclusive, or right to obtain such a license, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that this exception shall not apply to Research Program Know-How).&nbsp;&nbsp;Each Party shall use reasonable efforts to promptly disclose to the other Party all Inventions that are [*] to the Parties&#8217; activities under this Agreement or to any obligation to assign hereunder, including any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing such Inventions, and all information relating to such Inventions [*] for the preparation, filing and maintenance of any Patent with respect to such Invention in accordance with the terms of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56875179"></a><font style="Background-color:#auto;text-decoration:none;">9.1.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Assignment of Arising IP</font><font style="color:#000000;">.&nbsp;&nbsp;The assignments by each Party necessary to accomplish the ownership provisions set forth in </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2</font><font style="color:#000000;"> are hereby made, and each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and cooperation, to implement the provisions of </font><font style="text-decoration:underline;color:#000000;">Section 9.1.2</font><font style="color:#000000;">.&nbsp;&nbsp;Without limiting the foregoing, [*]&nbsp;&nbsp;Each inventing Party shall take (and cause its employees, agents, contractors and sublicensees (if applicable) to take) such further actions reasonably requested by the other Party to evidence any such assignment set forth in this </font><font style="text-decoration:underline;color:#000000;">Section 9.1.8</font><font style="color:#000000;">, and to reasonably support the other Party&#8217;s efforts to Patent or obtain other intellectual property rights in connection with any assigned Inventions or Know-How in accordance with the terms of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825922"></a><a name="_Ref506474867"></a><a name="_9kR3WTr299699GIaGrwr7kd9B2n4MB7D015fX0E"></a><font style="Background-color:#auto;text-decoration:none;">9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Patent Prosecution and Maintenance</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref56978162"></a><a name="_Ref520464966"></a><a name="_Ref507326365"></a><a name="_9kR3WTr29968FNICeLqxlzlNy3yEK"></a><a name="_Ref507532604"></a><a name="_Ref506474921"></a><a name="_Ref53771948"></a><a name="_Ref56978162"></a><a name="_Ref520464966"></a><a name="_Ref507326365"></a><a name="_9kR3WTr29968FNICeLqxlzlNy3yEK"></a><a name="_Ref507532604"></a><a name="_Ref506474921"></a><a name="_Ref53771948"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57030093"></a><a name="_Ref469914521"></a><a name="_cp_blt_2_831"></a><a name="_cp_blt_1_861"></a><a name="_cp_blt_2_860"></a><a name="_Ref532249373"></a><a name="_Ref42037377"></a><a name="_Ref534971337"></a><font style="Background-color:#auto;text-decoration:none;">9.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Patent Representatives; Patent Working Group</font><font style="color:#000000;">.&nbsp;&nbsp;Promptly following the Effective Date, the Parties shall establish a working group to oversee the strategy for Prosecution and Maintenance of any Patents hereunder (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Patent Working Group</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Each Party shall designate to the other Party in writing a patent Prosecution and Maintenance representative to liaise with the other Party&#8217;s Prosecution and Maintenance representative with respect to the Prosecution and Maintenance of Patents under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.2</font><font style="color:#000000;"> as soon as practicable following the Effective Date (but in no event more than [*] following the Effective Date).&nbsp;&nbsp;Each Party may update its patent Prosecution and Maintenance representative at any time upon written notice to the other Party. The [*] patent Prosecution and Maintenance representatives, and any additional members designated by the Parties (in such numbers as the Parties mutually agree)<a name="_Ref469914521"></a>, will serve as members of the Patent Working Group.&nbsp;&nbsp;The Patent Working Group shall serve as a forum for the exchange of information between the Parties pursuant to which each Party responsible for handling the Prosecution and Maintenance of Patents in accordance with this </font><font style="text-decoration:underline;color:#000000;">Section 9.2</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prosecuting Party</font><font style="color:#000000;">&#8221;) may keep the other Party reasonably informed of the status of the any applicable Patent and to make decisions regarding the filing, Prosecution and Maintenance, as set forth in this </font><font style="text-decoration:underline;color:#000000;">Section 9.2</font><font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref520474515"></a><a name="_Ref520552314"></a><a name="_cp_text_1_836"></a><font style="Background-color:#auto;text-decoration:none;">9.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Rights to Prosecute and Maintain Patents</font><font style="color:#000000;"><a name="_Ref520474515"></a><a name="_Ref520552314"></a>.&nbsp;&nbsp;<a name="_cp_text_1_836"></a>As between the Parties, subject to the provisions of this </font><font style="text-decoration:underline;color:#000000;">Section 9.2</font><font style="color:#000000;">: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56986551"></a><a name="_cp_text_1_837"></a><a name="_cp_text_4_853"></a><a name="_Ref56978567"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Lilly as the Prosecuting Party</font><font style="color:#000000;">:&nbsp;&nbsp;Lilly has (i) the sole right (at Lilly&#8217;<a name="_cp_text_1_837"></a>s sole cost and expense), but not the obligation, <a name="_cp_text_4_853"></a>to Prosecute and Maintain each Lilly Background Patent and Lilly Target Binder Patent, (ii) the first right, but not the obligation, to Prosecute and Maintain all (A) Product Patents [*], (B) [<a name="_Ref56978567"></a>*] and (C) [*], in each case, at Lilly&#8217;s sole cost and expense, (</font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, in each case of (i) and (ii), that Lilly shall [*] in a manner reasonably likely to [*], and Merus shall have the secondary right (at its sole cost and expense) to Prosecute and Maintain any Patent described in (ii), as provided in </font><font style="text-decoration:underline;color:#000000;">Section 9.2.5,</font><font style="color:#000000;"> and (iii) the sole right (at Lilly&#8217;s sole cost and expense), but not the obligation, to Prosecute and Maintain each Patent owned or Controlled by Lilly that is not covered by </font><font style="text-decoration:underline;color:#000000;">Section 9.2.2(a)(i)-(ii)</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">9.2.2(b)</font><font style="color:#000000;">, but that Covers any Invention or subject matter within the Lilly Sole Arising IP (collectively, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Prosecuted Patents</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56986549"></a><a name="_Ref56978550"></a><a name="_Ref56985464"></a><a name="_Ref56886335"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus as the Prosecuting Party</font><font style="color:#000000;"><a name="_Ref56978550"></a><a name="_Ref56985464"></a><a name="_Ref56886335"></a>.&nbsp;&nbsp;Merus has (i) the sole right (at Merus&#8217;s sole cost and expense), but not the obligation, to Prosecute and Maintain each Merus Background Patent and Merus Platform Patent, and (ii) the first right to, but not the obligation, to Prosecute and Maintain each [*], each [*] (</font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, in each case of (i) and (ii), that Merus shall [*] in a manner reasonably likely to [*], and Lilly shall have the secondary right (at its sole cost and expense) to Prosecute and Maintain any such Patent described in (ii) in each case, as provided in </font><font style="text-decoration:underline;color:#000000;">Section 9.2.5</font><font style="color:#000000;">, and (iii) the sole right (at Merus&#8217;s sole cost and expense), but not the obligation, to Prosecute and Maintain each Patent owned or Controlled by Merus that is not covered by </font><font style="text-decoration:underline;color:#000000;">Section 9.2.2(a)</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">9.2.2(b)(i)-(ii)</font><font style="color:#000000;">, but that Covers any Invention or subject matter within the Merus Sole Arising IP (collectively, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Prosecuted Patents</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_883"></a><a name="_cp_blt_2_882"></a><a name="_cp_blt_1_888"></a><a name="_cp_blt_2_887"></a><a name="_cp_blt_1_891"></a><a name="_cp_text_1_889"></a><a name="_Ref53771901"></a><a name="_Ref56886309"></a><font style="Background-color:#auto;text-decoration:none;">9.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cooperation</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">of</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">the</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Parties; Coordination of Filings; Step-In Rights</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">General Information Rights</font><font style="color:#000000;">.&nbsp;&nbsp;With respect to each of the Merus Prosecuted Patents and the Lilly Prosecuted Patents, the Prosecuting Party shall (i) keep the other Party (through the Patent Working Group) reasonably informed of the status of any applicable Patent or application, including by promptly providing the Patent Working Group with all material correspondence received from any Patent authority in connection therewith (including with respect to any office actions); (ii) promptly [*], </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that, subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.2.3(b)</font><font style="color:#000000;"> and without limiting </font><font style="text-decoration:underline;color:#000000;">Section 9.2.4</font><font style="color:#000000;"> with respect to [*], the Parties shall discuss such Prosecution and Maintenance only with respect to claims that specifically relate to any Collaboration Compound, Monospecific Compound, Modified Compound or Product,</font><font style="font-size:11pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font><font style="color:#000000;">(B) [*] shall discuss such Prosecution and Maintenance only with respect to claims that [*] (C) all decisions relating to any [*]; and (D) all decisions relating to any [*]:</font><font style="font-size:11pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font><font style="color:#000000;">(x) Lilly shall have final-decision making authority in respect thereto solely with respect to [*]; and (z) Merus shall otherwise have final-decision making authority in respect to all [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that Merus shall not exercise such final-decision making authority in a manner reasonably likely to [*].  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59065622"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party shall cooperate fully with the other Party in the Prosecution and Maintenance of Patents under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.2</font><font style="color:#000000;"> at its own cost (except as expressly set forth otherwise in this </font><font style="text-decoration:underline;color:#000000;">Article 9</font><font style="color:#000000;">), including by executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, to enable the other Party to apply for and to Prosecute and Maintain such Patents in any country as permitted by this </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.2</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Each Party and the Patent Working Group shall consider in good faith the interests of the other Party and shall strive to maximize the benefit of any Inventions (and associated Patents) contemplated under this Agreement for both Parties</font><font style="color:#000000;">; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that where </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> asserts the subject-matter of an Invention to be novel and inventive or otherwise patentable subject matter, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> </font><font style="color:#000000;">will not (either itself or through an Affiliate or Third Party or in support of an assertion by such Affiliate or Third Party) make any assertion to the contrary or act in a manner reasonably likely to have a detrimental effect on such Invention or any associated Patents</font><font style="color:#000000;">,</font><font style="color:#000000;"> </font><font style="color:#000000;">except </font><font style="color:#000000;">to the extent</font><font style="color:#000000;"> reasonably required </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> to</font><font style="color:#000000;"> comply with </font><font style="color:#000000;">37 C.F.R. </font><font style="color:#000000;">&#167;</font><font style="color:#000000;"> 1.56</font><font style="color:#000000;">, in which case, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> shall provide </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> with reasonable advance notice of its proposed assertion or activity and shall discuss with </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> in good faith prior to making such assertion or undertaking such activity</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59065630"></a><a name="_Ref59174293"></a><a name="_Ref61428262"></a><a name="_Ref56985588"></a><a name="_cp_text_1_892"></a><a name="_Ref58967084"></a><a name="_Ref59134865"></a><a name="_Hlk61428230"></a><font style="Background-color:#auto;text-decoration:none;">9.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Separation of Patent Claims; Identification of Assigned <a name="_Ref58967084"></a><a name="_Ref59134865"></a>Product Patents</font><font style="color:#000000;">.&nbsp;&nbsp;If a Party determines that an application for a Patent filed, or sought to be filed, by the other Party claims, (a) on the one hand, any Merus Background Know-How, Merus Platform IP, [*] (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Sole IP</font><font style="font-style:italic;color:#000000;">&#8221;)</font><font style="color:#000000;">, and (b) on the other hand, any Lilly Background Know-How, Lilly Target Binder IP, [*] (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Sole IP</font><font style="color:#000000;">&#8221;), then the Parties agree that, to the extent practicable, such application shall be divided into two (2) or more Patent applications, so that each application shall contain claims that cover only one of Merus Sole IP (as applicable), on the one hand, or the Lilly Sole IP, on the other hand, so as to more effectively enable the distinct ownership rights and Prosecution and Maintenance of such Patent applications by the Parties.&nbsp;&nbsp;Similarly, an attempt shall be made to divide Patent applications into those that claim [*].  Without limiting the foregoing, on a Research Program-by-Research Program basis, upon delivery of the Final Research Deliverables in respect of each Collaboration Compound and in respect of any Modified Compound, that includes a [*], Merus shall, working through the Patent Working Group, seek to identify any Patents [*] that disclose or include claims that specifically recites [*]: (i) such [*] or (ii) the [*] and, in each case of (i) or (ii), if any such Patents exist, [<a name="_Hlk61428230"></a>*], provided that Merus will, in any case, consider any such request in good faith.&nbsp;&nbsp;All such efforts pursuant to this </font><font style="text-decoration:underline;color:#000000;">Section 9.2.4</font><font style="color:#000000;"> shall be coordinated through the Patent Working Group.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53756334"></a><a name="_Ref59197284"></a><font style="Background-color:#auto;text-decoration:none;">9.2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Step-in Rights</font><font style="color:#000000;">.&nbsp;&nbsp;The applicable Prosecuting Party for any Patent for which it has the first (but not sole) right to Prosecute and Maintain shall notify the Patent Working Group in writing of its intention to suspend or cease any Prosecution and Maintenance of any such Patent at least [*] prior to any filing or payment due date, or any other due date that requires action, in connection with the ongoing Prosecution and Maintenance of such Patent.&nbsp;&nbsp;In such event, the Prosecuting Party shall permit the other Party, at the other Party&#8217;s discretion and at its sole expense, to continue Prosecution and Maintenance of such Patent, and will take all actions and execute all documents reasonably necessary for the other Party to assume such Prosecution and Maintenance as the Prosecuting Party for such Patent.&nbsp;&nbsp;Without limiting the foregoing, if a Party is the Prosecuting Party of any Joint Patent that it intends to abandon, then the other Party shall have the option to elect by providing written notice to the Patent Working Group to [*] continue Prosecution and Maintenance of such Joint Patent [*], as contemplated above [*].&nbsp;&nbsp;Upon receipt of such request, the Prosecuting Party [*].&nbsp;&nbsp;Following any [*], subject in all cases to the rights and licenses granted by the Parties hereunder.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref339286908"></a><a name="_9kR3WTr2995DFHJUMqvzwvnuvxDFEnZC53JMMLP"></a><a name="_Toc61825923"></a><a name="_Ref57031315"></a><font style="Background-color:#auto;text-decoration:none;">9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Infringement and Misappropriation by Third Parties</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2885AJOJDYT61li"></a><a name="_9kR3WTr2995BBFJDYT61li"></a><a name="_Ref403995289"></a><a name="_Ref384282644"></a><a name="_Ref507405943"></a><a name="_Ref468734220"></a><a name="_Ref_docxtools_319"></a><a name="_cp_text_1_897"></a><font style="Background-color:#auto;text-decoration:none;">9.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Notice</font><font style="color:#000000;"><a name="_Ref468734220"></a><a name="_Ref_docxtools_319"></a>.&nbsp;&nbsp;<a name="_cp_text_1_897"></a>Each Party shall notify the other within [*] of becoming aware of any alleged or threatened infringement by a Third Party of any of the Merus Patents, Lilly Patents, or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Joint Patents, which infringing activity involves the Exploitation </font><font style="color:#000000;">by a Third Party of any </font><font style="color:#000000;">compound or product </font><font style="color:#000000;">that is directed to </font><font style="color:#000000;">the same</font><font style="color:#000000;"> Lilly Target or Lilly Target Pair to which a Product </font><font style="color:#000000;">under this Agreement</font><font style="color:#000000;"> is also directed</font><font style="color:#000000;">, in each case</font><font style="color:#000000;">,</font><font style="color:#000000;"> in the Field in the Territory, and any related declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Merus Patents, Lilly Patents, or Joint Patents</font><font style="color:#000000;"> with respect to any such Third Party compound or product</font><font style="color:#000000;"> (collectively </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Infringement</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_919"></a><a name="_cp_blt_2_918"></a><a name="_Ref405220456"></a><a name="_Ref57031334"></a><a name="_Ref529871200"></a><a name="_Ref520552648"></a><a name="_Ref532249411"></a><a name="_Ref520712259"></a><a name="_9kMHG5YVt4666ADTMqvzwvnuvxD"></a><font style="Background-color:#auto;text-decoration:none;">9.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Lilly Sole Enforcement Rights</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.8</font><font style="color:#000000;"><a name="_9kMHG5YVt4666ADTMqvzwvnuvxD"></a>, as between the Parties, Lilly has the sole right to initiate any proceedings or take other appropriate actions against: (a) misappropriation or violation of any Lilly Background Know-How, or any Know-How within the Lilly Sole IP [*]; or (b) Infringement of any Lilly Background Patent, or any Lilly Target Binder Patent, or any Patent within the Lilly Sole IP [*] or to defend against any challenge to any of the foregoing.&nbsp;&nbsp;Lilly shall keep Merus reasonably informed of the status of such enforcement efforts and shall consider in good faith Merus&#8217;s comments thereon, to the extent such actions are relevant to Merus&#8217;s rights under such Patents and Know-How pursuant to this Agreement, including under </font><font style="text-decoration:underline;color:#000000;">Section 8.4</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref830555"></a><font style="Background-color:#auto;text-decoration:none;">9.3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus Sole Enforcement Rights</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.6</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">9.3.8</font><font style="color:#000000;">, as between the Parties, Merus has the sole right to initiate any proceedings or take other appropriate actions against: (a) misappropriation or violation of any Merus Sole IP (other than those Patents and claims for which Lilly has the first right pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.4</font><font style="color:#000000;">) and [*], or (b) Infringement of any Merus Background Patent, Merus Platform Patent or any Patent within the Merus Sole IP (other than those Patents and claims for which Lilly has the first right pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.4</font><font style="color:#000000;">) or to defend against any challenge to any of the foregoing.&nbsp;&nbsp;Merus shall keep Lilly reasonably informed of the status of such enforcement efforts and shall consider in good faith Lilly&#8217;s comments thereon, to the extent such actions are relevant to Lilly&#8217;s rights under such Patents and Know-How pursuant to this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57030591"></a><a name="_Ref57031275"></a><a name="_Ref59064303"></a><a name="_Ref60777994"></a><font style="Background-color:#auto;text-decoration:none;">9.3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Product IP, Joint Product IP, Research Program IP</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.8</font><font style="color:#000000;">, as between the Parties, Lilly has the first right, but not the obligation, to bring and control any legal action in connection with: (a) any misappropriation or violation of any (i) Joint Know-How excluding [*], or (ii) any other Research Program Know-How that [*], (b) an Infringement of any (i) Joint Patent (other than [*]), (ii) Product Patent, (iii) any claim of any [*] Patent that Covers and recites [*], (c) any defense against any challenge to (i) any Joint Know-How or Joint Patent (other than [*]), (ii) any Product Patent, (iii) any claim of any [*] Patent that Covers and recites [*].&nbsp;&nbsp;Lilly shall keep Merus reasonably informed of the status of such enforcement efforts and shall consider in good faith Merus&#8217;s comments thereon.&nbsp;&nbsp;Lilly shall provide Merus with drafts of all material papers to be filed with the court and shall in good faith consider all reasonable comments thereto by Merus before filing such papers.&nbsp;&nbsp;Merus may, at its own expense, be represented in any such action by counsel of its own choice.&nbsp;&nbsp;If Lilly does not bring such legal action within [*] after the notice provided pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.1</font><font style="color:#000000;">, Merus may bring and control any legal action in connection with the events set forth in subclauses (a) through (c) above, in each case, at Merus&#8217;s sole cost and expense as it reasonably determines appropriate.&nbsp;&nbsp;In connection with any obligation described in this </font><font style="text-decoration:underline;color:#000000;">Section 9.3</font><font style="color:#000000;"> to keep the other Party reasonably informed of any enforcement efforts, the Parties will discuss in good faith the commencement of any action prior to the initiation thereof (through the Patent Working Group or otherwise) and discuss in good faith the strategy for any enforcement any such Know-How </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">or Patents contemplated in this </font><font style="text-decoration:underline;color:#000000;">Section </font><font style="text-decoration:underline;color:#000000;">9.3</font><font style="color:#000000;">.&nbsp;&nbsp;Without limiting the foregoing, where Lilly is the enforcing party under this </font><font style="text-decoration:underline;color:#000000;">Section </font><font style="text-decoration:underline;color:#000000;">9.3.4</font><font style="color:#000000;"> or under </font><font style="text-decoration:underline;color:#000000;">Section </font><font style="text-decoration:underline;color:#000000;">9.3.2</font><font style="color:#000000;">, Lilly will not </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.3.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">[*] Know How; Patents. </font><font style="color:#000000;">Subject to </font><font style="text-decoration:underline;color:#000000;">Section 9.3.8</font><font style="color:#000000;">, as between the Parties, either Merus or Lilly may initiate proceedings or take other appropriate actions against: (a) misappropriation or violation of any [*]; or (b) Infringement of any [*], or to defend against any challenge to any of the foregoing.  For a period of not less than [*], the Parties will discuss in good faith the commencement of any action prior to the initiation thereof (through the Patent Working Group or otherwise) and discuss in good faith the strategy for any enforcement of any such Know-How or Patents contemplated in this </font><font style="text-decoration:underline;color:#000000;">Section 9.3</font><font style="color:#000000;">. Without limiting the foregoing, the Party that initiates any such action shall keep the other Party reasonably informed of the status of such enforcement efforts and shall consider in good faith such other Party&#8217;s comments thereon, to the extent such actions are relevant to such other Party&#8217;s rights under such Patents and Know-How pursuant to this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref61281685"></a><a name="_cp_blt_1_929"></a><a name="_cp_blt_2_928"></a><a name="_cp_blt_1_936"></a><a name="_cp_blt_2_935"></a><a name="_cp_blt_1_938"></a><a name="_cp_blt_2_937"></a><a name="_Ref405220457"></a><a name="_Ref42043893"></a><font style="Background-color:#auto;text-decoration:none;">9.3.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Request to Enable Enforcement Against Other Third Party<a name="_cp_blt_1_929"></a><a name="_cp_blt_2_928"></a><a name="_cp_blt_1_936"></a><a name="_cp_blt_2_935"></a><a name="_cp_blt_1_938"></a><a name="_cp_blt_2_937"></a><a name="_Ref405220457"></a><a name="_Ref42043893"></a> Infringers. </font><font style="color:#000000;">Where Lilly identifies [*], Lilly may by written notice request that Merus [*]. The Parties shall discuss any such requests made by Lilly in good faith, including by and through the Patent Working Group. Merus shall promptly respond to such request [*].</font><font style="text-decoration:underline;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.3.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Allocation of Recoveries</font><font style="color:#000000;">.&nbsp;&nbsp;Any recoveries resulting from enforcement action relating to a claim of misappropriation, violation or Infringement (including any defense) shall be first applied against payment of each Party&#8217;s costs and expenses in connection therewith (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses).&nbsp;&nbsp;[*] will retain [*]; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that [*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_940"></a><a name="_cp_blt_2_939"></a><a name="_Ref405220458"></a><a name="_Ref56864637"></a><a name="_9kMIH5YVt4BB7FHJLWOsx1yxpwxzFHGpbE75LOO"></a><a name="_9kMHG5YVt4666AFcGp9H"></a><a name="_9kMIH5YVt4666ADTMqvzwvnuvxD"></a><a name="_9kR3WTr29969BIKQ8hir6yhrvbX5LE0235LNAqn"></a><a name="_Ref506475075"></a><a name="_Ref532249540"></a><a name="_Ref2333726"></a><font style="Background-color:#auto;text-decoration:none;">9.3.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;At the request and expense of the Party bringing an action under this </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMIH5YVt4BB7FHJLWOsx1yxpwxzFHGpbE75LOO"></a>Section&#160;9.3</font><font style="color:#000000;">, the other Party shall provide reasonable assistance in connection therewith, <a name="_9kMHG5YVt4666AFcGp9H"></a>including by executing reasonably appropriate documents, cooperating in discovery and joining as a party<a name="_9kMIH5YVt4666ADTMqvzwvnuvxD"></a> to the action if required by Applicable Law to pursue such action.&nbsp;&nbsp;In connection with any such enforcement action, the Party bringing the action shall not enter into any settlement admitting the invalidity or non-infringement of, or otherwise impairing the other Party&#8217;s rights in, the applicable Patents, or imposing any material <a name="_9kR3WTr29969BIKQ8hir6yhrvbX5LE0235LNAqn"></a><a name="_Ref506475075"></a><a name="_Ref532249540"></a><a name="_Ref2333726"></a>cost or liability on, or admission by, the other Party, in each case without the prior written consent of the other Party.&nbsp;&nbsp;If there is more than one controlling Party with respect to a misappropriation, violation or Infringement, the Parties shall negotiate in good faith to determine control over the handling of the action.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825924"></a><a name="_Ref60945202"></a><font style="Background-color:#auto;text-decoration:none;">9.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Defense and Settlement of Third Party Claims</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref253920223"></a><a name="_9kMJI5YVt4666ADTMqvzwvnuvxD"></a><a name="_9kMKJ5YVt4666ADTMqvzwvnuvxD"></a><a name="_9kMH0H6ZWu5777DFaHsxs8"></a><a name="_9kMLK5YVt4666ADTMqvzwvnuvxD"></a><a name="_9kMHG5YVt4BB8BDKMSAjkt80jtxdZ7NG2457NPC"></a><a name="_Ref506475592"></a><a name="_Ref253920223"></a>.&nbsp;&nbsp;Each Party shall promptly notify the other in writing of any allegation by a Third Party that the activity of either of the Parties pursuant to this Agreement infringes or may infringe the intellectual property rights<a name="_9kMJI5YVt4666ADTMqvzwvnuvxD"></a> of such Third Party.&nbsp;&nbsp;Merus has the sole right to control any defense of any such claim involving alleged infringement of Third Party rights by Merus&#8217;s<a name="_9kMKJ5YVt4666ADTMqvzwvnuvxD"></a> activities at its own expense and by counsel of its own choice, and Lilly may, at its own expense, to be represented in any such action by counsel of its own choice.&nbsp;&nbsp;Lilly has the sole right to control any defense of any such claim involving alleged infringement of Third Party rights by Lilly&#8217;s activities at its own expense and by counsel of its own choice, and Merus may, at its own expense, to be represented in any such action by counsel of its own choice.&nbsp;&nbsp;Neither Party may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMH0H6ZWu5777DFaHsxs8"></a>settle any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMLK5YVt4666ADTMqvzwvnuvxD"></a> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> litigation under this </font><font style="text-decoration:underline;"><a name="_9kMHG5YVt4BB8BDKMSAjkt80jtxdZ7NG2457NPC"></a>Section&#160;</font><font style="text-decoration:underline;">9.4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This </font><font style="text-decoration:underline;">Section&#160;</font><font style="text-decoration:underline;">9.4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall also govern </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506475592"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825925"></a><font style="Background-color:#auto;text-decoration:none;">9.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Patent Extensions; Patent Linkage</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506475467"></a><a name="_Ref378106170"></a><a name="_Ref405220460"></a><a name="_9kMH1I6ZWu5777DFaHsxs8"></a><a name="_9kMH2J6ZWu5777DFaHsxs8"></a><a name="_Ref506475467"></a><a name="_Ref378106170"></a><a name="_Ref405220460"></a>.&nbsp;&nbsp;[*] Patent claiming or covering a Collaboration Compound, Monospecific Compound, Modified Compound or Product should be extended, and thereafter [*]<a name="_9kMH1I6ZWu5777DFaHsxs8"></a> in obtaining patent<a name="_9kMH2J6ZWu5777DFaHsxs8"></a> term restorations, supplemental protection certificates or their equivalents, and other forms of patent term extensions for a given Collaboration Compound, Monospecific Compound, Modified Compound or Product with respect to any applicable [*] in any country or region where applicable.&nbsp;&nbsp;The Parties shall also cooperate in addressing all issues relating to patent linkage in any country or region where applicable.&nbsp;&nbsp;[*] shall have final decision making authority with respect to all decisions regarding such patent term extensions or regarding issues of patent linkage.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825926"></a><font style="Background-color:#auto;text-decoration:none;">9.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">CREATE Act</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr23348Arsss49vxyhvypoo65t235L"></a><a name="_9kMML5YVt4666GHJ7vuirsuA"></a><a name="_9kR3WTr2775BFEGiDwWEGt"></a><a name="_9kR3WTr27769CNFy0ruru363aV34n14vu15miy2"></a><a name="_9kR3WTr2775BGFGiDwWEGs6v"></a>.&nbsp;&nbsp;It is the Parties&#8217;<a name="_9kR3WTr23348Arsss49vxyhvypoo65t235L"></a> intention that this Agreement is a &#8220;<a name="_9kMML5YVt4666GHJ7vuirsuA"></a>joint research agreement&#8221;<a name="_9kR3WTr2775BFEGiDwWEGt"></a> as that phrase is defined in 35 U.S.C. &#167; 102(c)<a name="_9kR3WTr27769CNFy0ruru363aV34n14vu15miy2"></a> as amended by the Cooperative Research and Technology Enhancement (CREATE) Act<a name="_9kR3WTr2775BGFGiDwWEGs6v"></a>, including the provisions of 35 U.S.C. &#167; 102(b)(2)(c).&nbsp;&nbsp;The Parties agree to cooperate and to take reasonable actions to maximize the protections available for the Compounds and Products under such safe harbor provisions.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825927"></a><font style="Background-color:#auto;text-decoration:none;">9.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Trademarks</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Lilly shall have the right to select, and will be free, in its sole discretion, to use and to register in any trademark office in the Territory, any trademark that specifically relates to a Product or service-mark associated with use of a Product.&nbsp;&nbsp;As between the Parties, Lilly shall own all right, title and interest in and to any such trademarks or service-marks adopted by Lilly, and is responsible for the registration, filing, maintenance and enforcement thereof.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506472251"></a><a name="_9kR3WTr29969DMqA2mqtip21F5784K89IEKPZIE"></a><a name="_9kR3WTr2996CDJqA2mqtip21F5784K89IEKPZIE"></a><a name="_Toc61825928"></a><a name="_Ref53824598"></a><font style="Background-color:#auto;text-decoration:none;">Article 10</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref53824598"></a>REPRESENTATIONS, WARRANTIES AND COVENANTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825929"></a><a name="_Ref722907"></a><a name="_Ref437609045"></a><font style="Background-color:#auto;text-decoration:none;">10.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Mutual Representations and Warranties</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506475950"></a><a name="_Ref506475950"></a>.&nbsp;&nbsp;Each of Lilly and Merus represent and warrant, as of the Effective Date, that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">it is duly organized and validly existing under in the Applicable Laws of the jurisdiction of its incorporation or formation, as applicable, has full corporate, limited liability company or other power and authority, as applicable, to enter into this Agreement and to carry out the provisions hereof, and has sufficient facilities, experienced personnel or other capabilities (including via Affiliates and/or Third Parties) to enable it to perform its obligations under this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate, limited liability company or other action, as applicable; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_951"></a><a name="_9kMNM5YVt4666GHJ7vuirsuA"></a><a name="_9kMIH5YVt4666AFcGp9H"></a><a name="_cp_text_1_952"></a><font style="Background-color:#auto;text-decoration:none;">10.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">this Agreement is legally binding upon it and enforceable in accordance with its terms (except as the enforceability thereof may be limited by bankruptcy, bank moratorium or similar laws affecting creditors&#8217; rights generally and laws restricting the availability of equitable remedies and may be subject to general principles of equity whether or not such enforceability is </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="_cp_text_1_951"></a>considered in a proceeding at law or in equity) and the execution, delivery and performance of this Agreement by it have been duly authorized by all necessary corporate action and do not and will not</font><font style="color:#000000;">: </font><font style="color:#000000;"><a name="_9kMNM5YVt4666GHJ7vuirsuA"></a>(a)&#160;conflict with, or constitute a default or result in a breach under, any </font><font style="color:#000000;">agreement</font><font style="color:#000000;">, instrument or </font><font style="color:#000000;"><a name="_9kMIH5YVt4666AFcGp9H"></a>understanding, oral or written, to which it is a </font><font style="color:#000000;">party</font><font style="color:#000000;"><a name="_cp_text_1_952"></a> or by which it may be bound, or violate any Applicable Law</font><font style="color:#000000;">; </font><font style="color:#000000;">or (b)&#160;require any consent or approval of its stockholders or similar.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_953"></a><a name="_Toc61825930"></a><a name="_Ref722909"></a><font style="Background-color:#auto;text-decoration:none;">10.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus Representations and Warranties</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Merus, on behalf of itself and its Affiliates, represents and warrants to Lilly that, as of the Effective Date:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref357090828"></a><font style="Background-color:#auto;text-decoration:none;">10.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Targets Encumbered</font><font style="color:#000000;">.&nbsp;&nbsp;The Initial Target is not an Unavailable Target.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_958"></a><a name="_Ref524707348"></a><font style="Background-color:#auto;text-decoration:none;">10.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Grants that Conflict with this Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_cp_text_1_958"></a>Merus and its Affiliates have not granted, and will not grant during the Term, any rights (or other encumbrances) to any Third Party to Merus Know-How that prevent or conflict with the rights granted to Lilly hereunder<a name="_Ref524707348"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_960"></a><font style="Background-color:#auto;text-decoration:none;">10.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Control over Know-How and Patents</font><font style="color:#000000;">.&nbsp;&nbsp;Merus has Control over all Know-How and Patent rights owned by it or its Affiliates that are [<a name="_cp_text_1_960"></a>*] Exploitation of Compounds with respect to the Lilly Target identified as of the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref42036780"></a><a name="_Ref524707360"></a><font style="Background-color:#auto;text-decoration:none;">10.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Existing Patents</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_field_47_962"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All Patent rights contained in the Merus Patents existing as of the Effective Date that are issued or subject to a pending application for issuance (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Existing Patents</font><font style="color:#000000;">&#8221;) are listed on </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_field_47_962"></a>Exhibit 10.2.4</font><font style="color:#000000;"> and all such Existing Patents are: (i) to the extent issued (unless otherwise indicated on </font><font style="text-decoration:underline;color:#000000;">Exhibit 10.2.4</font><font style="color:#000000;">), subsisting and to Merus&#8217;s knowledge, not invalid or unenforceable, in whole or in part, or confer a valid right to claim priority thereto; (ii) solely and exclusively owned or exclusively licensed to Merus, free of any encumbrance, lien or claim of ownership by any Third Party that would conflict with the rights granted to Lilly under this Agreement; (iii) to the extent subject to a pending application for issuance, being diligently prosecuted in the respective patent offices in which such applications have been filed in accordance with Applicable Law and, for pending applications, to Merus&#8217;s knowledge, Merus and its Affiliates have presented all information material to patentability to the relevant patent examiner at the relevant patent office of the U.S. Patent and Trademark Office in compliance with 37 CFR &#167; 1.56; and (iv)&#160;filed and maintained properly and correctly, and all applicable fees applicable thereto have been paid on or before the due date for payment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To Merus&#8217;s knowledge, neither Merus nor any of its Affiliates have taken any action that would render any invention claimed in the Existing Patents unpatentable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Existing Patents represent all Merus Patents that relate to the Merus Know-How or the exploitation thereof under this Agreement, as such activities are contemplated as of the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Third Party Agreements</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section 6.2</font><font style="color:#000000;">, there are no license or other agreements with Third Parties to which Merus or its Affiliate is a party regarding the exploitation of (a) any Merus Know-How or (b) other materials, in each case, contemplated to be provided by Merus to Lilly hereunder, under which license or other agreements Merus contemplates granting Lilly a sublicense or covenant not to sue, as to which the absence of rights under such license </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">or </font><font style="color:#000000;">agreement may impair Lilly&#8217;s ability to Exploit Compounds or Products hereunder</font><font style="color:#000000;">, or which license or other agreement otherwise conflicts with the rights granted to Lilly hereunder</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref357090830"></a><a name="_Ref524164347"></a><a name="_cp_text_1_971"></a><a name="_Ref524164348"></a><font style="Background-color:#auto;text-decoration:none;">10.2.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Litigation and Actions Relating to Intellectual Property</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_cp_text_1_971"></a>Merus: (a) has not received any written notice of any threatened claims or litigation seeking to invalidate or otherwise challenge the Merus Know-How or Merus Patents, or Merus&#8217;s or its Affiliates&#8217; rights therein; (b) is not aware of any pending or threatened action, suit, proceeding or claim by a Third Party asserting that Merus or any of its Affiliates is infringing or has misappropriated or otherwise is violating any Patent right, trade secret or other proprietary right of any Third Party as would reasonably be expected to impair the ability of Merus to fulfill any of its obligations under this Agreement; and (c) is not aware of any Patent right, trade secret or other proprietary right of any Third Party that Merus reasonably believes would be infringed, misappropriated or otherwise violated [*]<a name="_Ref524164348"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref524164349"></a><font style="Background-color:#auto;text-decoration:none;">10.2.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Other Material Claims and Actions</font><font style="color:#000000;">.&nbsp;&nbsp;There are no claims, actions, or proceedings pending or, to Merus&#8217;s knowledge, threatened by any Third Party; nor, to Merus&#8217;s knowledge, are there any formal inquiries initiated or written notices received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Merus or its properties, assets or business, which if adversely decided, would, individually or in the aggregate, have a material adverse effect on, or prevent Merus&#8217;s ability to conduct the Research or to grant the licenses or rights granted to Lilly under this Agreement.<a name="_Ref524164349"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.2.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Assignment by Employees, Agents and Consultants</font><font style="color:#000000;">.&nbsp;&nbsp;Merus has obtained from each of its current employees, consultants and contractors who are expected to perform research or development activities pursuant to this Agreement, written agreements containing industry standard obligations of confidentiality and non-use and an assignment to Merus of all inventions (and all of such Person&#8217;s rights thereto) generated in the course of their engagement or employment, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_978"></a><a name="_cp_text_1_980"></a><a name="_cp_text_1_982"></a><a name="_cp_text_1_984"></a><font style="Background-color:#auto;text-decoration:none;">10.2.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Government Funding</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_cp_text_1_978"></a>The inventions claimed or covered by the Merus Patents: (a<a name="_cp_text_1_980"></a>)&#160;were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States of America or any agency thereof; <a name="_cp_text_1_982"></a>(b)&#160;are not a &#8220;subject invention&#8221; as that term is described in 35 U.S.C.&nbsp;&nbsp;<a name="_cp_text_1_984"></a>Section 201(e) and (c) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C.&nbsp;&nbsp;&#167;&#167; 200-212, as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R.&nbsp;&nbsp;Part 401.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825931"></a><a name="_Ref722785"></a><font style="Background-color:#auto;text-decoration:none;">10.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Mutual Covenants</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMPO5YVt4666GHJ7vuirsuA"></a><a name="_9kMHzG6ZWu5777HIK8wvjstvB"></a><a name="_9kMLK5YVt4666BIeKt862"></a><font style="Background-color:#auto;text-decoration:none;">10.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Employees, Consultants and Contractors</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kMPO5YVt4666GHJ7vuirsuA"></a>Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants and contractors who perform Research or D<a name="_9kMHzG6ZWu5777HIK8wvjstvB"></a>evelopment activities pursuant to this Agreement, which agreements<a name="_9kMLK5YVt4666BIeKt862"></a> will obligate such persons to obligations of confidentiality and non-use and to assign inventions in a manner consistent with the provisions of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532565543"></a><a name="_cp_text_1_1003"></a><a name="_cp_text_1_1004"></a><a name="_Ref377138518"></a><a name="_Ref405220465"></a><font style="Background-color:#auto;text-decoration:none;">10.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Debarment</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party represents, warrants and covenants to the other Party that neither it nor its officers, employees, agents, consultants or any other person used by such Party in the performance of the respective Research and D<a name="_cp_text_1_1003"></a>evelopment activities under this Agreement is: (a) debarred or disqualified under the U.S.&nbsp;&nbsp;Federal Food, Drug and Cosmetic Act; (b) listed by any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or non-procurement programs (as that term is defined in 42 U.S.C</font><font style="color:#000000;"><a name="_cp_text_1_1004"></a>. </font><font style="color:#000000;">&#167;</font><font style="color:#000000;">1320a-7b(f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program; or (c) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Each Party will not during the Term knowingly, employ or use, directly or indirectly, including through Affiliates the services of any such person</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, directly or indirectly, including through Affiliates or, in the case of Lilly, Sublicensees, which directly or indirectly relate to activities contemplated by this Agreement, such Party shall promptly notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services</font><font style="color:#000000;"><a name="_Ref377138518"></a><a name="_Ref405220465"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Protection of Information</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party agrees that during the Term of this Agreement, and without limiting its obligations hereunder, each Party shall implement technical and organizational measures to protect all confidential information under the Agreement that are appropriate and that provide no less protection than [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532032348"></a><a name="_Ref534566712"></a><a name="_Toc61825932"></a><font style="Background-color:#auto;text-decoration:none;">10.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref405220466"></a><font style="Background-color:#auto;text-decoration:none;">10.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance with Agreement; Applicable Laws</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_Ref405220466"></a>Each Party covenants to the other that in the performance of its obligations under this Agreement, such Party shall comply with, and shall cause its Affiliates and its and its Affiliates&#8217; employees and contractors to comply, with all Applicable Laws and in all material respects with the terms of this Agreement.&nbsp;&nbsp;No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Laws.&nbsp;&nbsp;Without limiting the foregoing, each Party represents that it has not and will not use in any capacity the services of any person or entity who is: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">debarred or has been convicted of a crime for which a person or entity can be debarred under any governmental statute (including 21 USC Section 335a, as amended (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Section 335a</font><font style="color:#000000;">&#8221;)) or, to such Party&#8217;s knowledge, threatened to be debarred or indicted for a crime or otherwise engaged in conduct for which a person or entity can be debarred under any governmental statute, including Section 335a;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">disqualified under 21 CFR 312.70 or, to such Party&#8217;s knowledge, threatened to be disqualified thereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">suspended by the Office for Protection of Research Risks under 45 CFR Part 46 or, to such Party&#8217;s knowledge, threatened to be suspended thereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">excluded by the federal government from participation in federal healthcare programs as set forth by the Department of Health and Human Services Office of Inspector General at http://exclusions.oig.hhs.gov and the Excluded Parties List System at http://www.sam.gov, which includes the General Services Administration or, to such Party&#8217;s knowledge, threatened to be disqualified or indicted for a crime for which a person can be so excluded; or</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to such Party</font><font style="color:#000000;">&#8217;</font><font style="color:#000000;">s knowledge, the subject of any past or pending governmental or regulatory investigation, inquiry, warning or enforcement action, including a </font><font style="color:#000000;">government-mandated corporate integrity agreement, or has violated any applicable anti</font><font style="color:#000000;">&#8209;kickback or false claims laws or regulations related to their conduct of research</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54105058"></a><font style="Background-color:#auto;text-decoration:none;">10.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance with Party Specific Regulations</font><font style="color:#000000;">.&nbsp;&nbsp;In carrying out their respective obligations under this Agreement, the Parties agree that each Party will meet its obligations with respect to all judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party&#8217;s activities contemplated by this Agreement (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Party Specific Regulations</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Neither Party shall be obligated to pursue any course of conduct that would result in such Party being in material breach of any Party Specific Regulation applicable to it; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that in the event that a Party refuses to fulfill its obligations under this Agreement in any material respect on such basis, it shall provide written notice thereof to the other Party and such other Party shall have the right to terminate this Agreement in accordance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2</font><font style="color:#000000;">; however, under such circumstances, such termination shall be the sole remedy for such terminating Party and such terminating Party shall not be entitled to any other remedy under law or equity.&nbsp;&nbsp;All Party Specific Regulations are binding only in accordance with their terms and only upon the Party to which they relate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref534566679"></a><a name="_cp_text_1_1006"></a><font style="Background-color:#auto;text-decoration:none;">10.4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance with Internal Compliance Codes</font><font style="color:#000000;">.&nbsp;&nbsp;All Internal Compliance Codes shall apply only to the Party to which they relate.&nbsp;&nbsp;The Parties agree that each Party shall operate in a manner consistent with its Internal Compliance Codes applicable to its performance under this Agreement.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Internal Compliance Codes</font><font style="color:#000000;"><a name="_cp_text_1_1006"></a>,&#8221; as used in this </font><font style="text-decoration:underline;color:#000000;">Section 10.4.3</font><font style="color:#000000;">, means a Party&#8217;s internal policies and procedures intended to ensure that a Party complies with Applicable Laws, Party Specific Regulations, and such Party&#8217;s internal ethical, medical and similar standards.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.4.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance with Anti-Corruption Laws</font><font style="color:#000000;">.&nbsp;&nbsp;In connection with this Agreement, each Party shall comply with all Applicable Laws applicable to the performance of its obligations or exercise of its rights, including, where applicable, all local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws enacted to implement the Organisation of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International Business Transactions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref405220467"></a><a name="_cp_text_1_1008"></a><a name="_cp_text_1_1010"></a><a name="_cp_text_1_1012"></a><a name="_cp_text_1_1014"></a><a name="_cp_text_1_1015"></a><a name="DocXTextRef54"></a><a name="_cp_text_1_1017"></a><a name="DocXTextRef55"></a><a name="_9kMJI5YVt4666AFcGp9H"></a><a name="_9kMKJ5YVt4666AFcGp9H"></a><a name="_cp_text_1_1019"></a><font style="Background-color:#auto;text-decoration:none;">10.4.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Prohibited Conduct</font><font style="color:#000000;">.&nbsp;&nbsp;Without limiting the other obligations of the Parties set forth in this </font><font style="text-decoration:underline;color:#000000;">Section 10.4</font><font style="color:#000000;">, each Party covenants to the other that, as of the Effective Date and in the performance of its obligations under this Agreement through the expiration and termination of this Agreement, such Party and, to its knowledge, its Affiliates and its and its Affiliates&#8217;<a name="_cp_text_1_1008"></a> employees and contractors, in connection with the performance of their respective obligations under this Agreement, have not made, offered, given, promised to give, or authorized, and will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or transfer of anything of value, directly or indirectly through Third Parties, to any Government Official for the purpose of: (a<a name="_cp_text_1_1010"></a>) improperly influencing any act or decision of the Person or Government Official; (b<a name="_cp_text_1_1012"></a>) inducing the Person or Government Official to do or omit to do an act in violation of a lawful or otherwise required duty; (c) </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="_cp_text_1_1014"></a>securing any improper advantage; or (</font><font style="color:#000000;">d</font><font style="color:#000000;">) inducing the Person or Government Official to improperly influence the act or decision of any organization, including any government or government </font><font style="color:#000000;">instrumentality, to assist any Party in obtaining or retaining business</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">For the purpose of this </font><font style="text-decoration:underline;color:#000000;">Section </font><font style="text-decoration:underline;color:#000000;">10.4.5</font><font style="color:#000000;">, </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Government Official</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"><a name="_cp_text_1_1015"></a> means</font><font style="color:#000000;"><a name="DocXTextRef54"></a>: </font><font style="color:#000000;">(x)</font><font style="color:#000000;"><a name="_cp_text_1_1017"></a> any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital</font><font style="color:#000000;"><a name="DocXTextRef55"></a>; </font><font style="color:#000000;">(y)</font><font style="color:#000000;"><a name="_9kMJI5YVt4666AFcGp9H"></a> any candidate for political office, any political </font><font style="color:#000000;">party</font><font style="color:#000000;"><a name="_9kMKJ5YVt4666AFcGp9H"></a> or any official of a political </font><font style="color:#000000;">party</font><font style="color:#000000;"><a name="_cp_text_1_1019"></a>, in each case for the purpose of obtaining or retaining business for or with, or directing business to, any Person, including either Party</font><font style="color:#000000;">; </font><font style="color:#000000;">or (z) any Person acting in an official capacity on behalf of any of the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.4.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Compliance with Data Protection and Privacy Laws.&nbsp;&nbsp;</font><font style="color:#000000;">In connection with this Agreement, the Parties shall comply with all Applicable Laws with respect to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security (technical, physical and administrative), disposal, destruction, disclosure, or transfer (including cross-border) of Personal Information, including providing any notice, obtaining any consent or prior authorization, and conducting any assessment required under Applicable Laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825933"></a><font style="Background-color:#auto;text-decoration:none;">10.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Disclaimer</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4BB8EFLsC4osvkr43H79A6MABKGMRb"></a><a name="_9kMHG5YVt4BB8BFOsC4osvkr43H79A6MABKGMRb"></a>.&nbsp;&nbsp;<a name="_9kMHG5YVt4BB8EFLsC4osvkr43H79A6MABKGMRb"></a><a name="_9kMHG5YVt4BB8BFOsC4osvkr43H79A6MABKGMRb"></a>EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS Article 10, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS.&nbsp;&nbsp;NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENTS OR THAT ANY PATENTS WILL ISSUE BASED ON A PENDING APPLICATION.&nbsp;&nbsp;WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT ANY RESEARCH PROGRAM WILL BE SUCCESSFUL, IN WHOLE OR IN PART.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506472280"></a><a name="_9kR3WTrAG8567IqA2mqtaGY3zr1B8120tBKGM"></a><a name="_9kR3WTr29969ENqA2mqtaGY3zr1B8120tBKGM"></a><a name="_Toc61825934"></a><font style="Background-color:#auto;text-decoration:none;">Article 11</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br />INDEMNIFICATION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825935"></a><font style="Background-color:#auto;text-decoration:none;">11.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Indemnity</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref339287219"></a><a name="_9kR3WTr2885AB99ACNSgP0px6q1"></a><a name="_9kR3WTr2995ACA9ACNSgP0px6q1"></a><a name="_Ref438641975"></a><a name="_Hlk56824569"></a><a name="_9kMIH5YVt4BB7CIGBCGfb7tkm3I3"></a><a name="_9kMJI5YVt4BB7CJHBCGfb7tkm3I3"></a><a name="_9kR3WTrAG856EG9ACms0mm09BGCzt140x54w9NW"></a><a name="_cp_text_1_1020"></a><a name="_9kR3WTrAG856FH9ACnt0mhvzjiq328B1DgPDC09"></a><a name="_9kMHG5YVtCIA79EFBCFpu2oo2BDIE1v362z76yB"></a><a name="_cp_text_1_1025"></a><a name="_9kMHG5YVtCIA78EGBCFqv2ojx1lks54AD3FiRFE"></a><a name="_9kMHG5YVtCIA78FHBCFrw2oz023m03uwuDE5GLK"></a><a name="_9kMIH5YVt4BB7CGEBCFQUgHv4si"></a><font style="Background-color:#auto;text-decoration:none;">11.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">By Merus</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMIH5YVt4BB7CIGBCGfb7tkm3I3"></a><a name="_9kMJI5YVt4BB7CJHBCGfb7tkm3I3"></a>Section&#160;11.1.3</font><font style="color:#000000;">, Merus shall defend, indemnify and hold harmless Lilly and its Affiliates, and their respective directors, officers, employees, and agents (each, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Lilly Indemnitee</font><font style="color:#000000;">&#8221;) from and against any and all costs, fees, expenses, losses, liabilities, and damages, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Losses</font><font style="color:#000000;">&#8221;) to which any Lilly Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Claim</font><font style="color:#000000;">&#8221;<a name="_9kR3WTrAG856EG9ACms0mm09BGCzt140x54w9NW"></a>) to the e<a name="_cp_text_1_1020"></a>xtent such Losses arise out of: [<a name="_9kR3WTrAG856FH9ACnt0mhvzjiq328B1DgPDC09"></a>*];<a name="_9kMHG5YVtCIA79EFBCFpu2oo2BDIE1v362z76yB"></a> except, in each case, to the extent such Losses result from matters subject to subclauses<a name="_cp_text_1_1025"></a><a name="_9kMHG5YVtCIA78EGBCFqv2ojx1lks54AD3FiRFE"></a> (a), (b)<a name="_9kMHG5YVtCIA78FHBCFrw2oz023m03uwuDE5GLK"></a>, or (c) of </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMIH5YVt4BB7CGEBCFQUgHv4si"></a>Section&#160;11.1.2</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref339286983"></a><a name="_9kR3WTr2885ADB9ADOSeFt2qg"></a><a name="_9kR3WTr2995AEC9ADOSeFt2qg"></a><a name="_Ref506473126"></a><a name="_9kMJI5YVt4BB7CIGBCGfb7tkm3I3"></a><a name="_9kMKJ5YVt4BB7CJHBCGfb7tkm3I3"></a><a name="_9kR3WTrAG856DF9ADpu0mxy01ky1susBC3EJI8A"></a><a name="_9kMHG5YVtCIA78GIBCEou2oo2BDIE1v362z76yB"></a><a name="_cp_text_1_1027"></a><a name="_9kMHG5YVtCIA78HJBCEpv2ojx1lks54AD3FiRFE"></a><a name="_cp_text_1_1028"></a><a name="_9kMKJ5YVt4BB7CECBCEPUiR2rz8s3"></a><font style="text-decoration:none;Background-color:#auto;">11.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">By Lilly</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMJI5YVt4BB7CIGBCGfb7tkm3I3"></a><a name="_9kMKJ5YVt4BB7CJHBCGfb7tkm3I3"></a>Section&#160;</font><font style="text-decoration:underline;color:#000000;">11.1.3</font><font style="color:#000000;">, Lilly shall defend, indemnify and hold harmless Merus, its Affiliates, and their respective directors, officers, employees and agents (each, an </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Merus Indemnitee</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">) from and against any and all Losses to which any Merus Indemnitee may </font><font style="color:#000000;"><a name="_9kR3WTrAG856DF9ADpu0mxy01ky1susBC3EJI8A"></a>become subject as a result of any Claim to the extent such Losses arise out of: </font><font style="color:#000000;">[*</font><font style="color:#000000;">]</font><font style="color:#000000;">;</font><font style="color:#000000;"> except, in each case, to the extent such Losses result from</font><font style="color:#000000;"> matters subject to</font><font style="color:#000000;"><a name="_9kMHG5YVtCIA78GIBCEou2oo2BDIE1v362z76yB"></a> </font><font style="color:#000000;">sub</font><font style="color:#000000;">clause</font><font style="color:#000000;">s</font><font style="color:#000000;"><a name="_cp_text_1_1027"></a> (a)</font><font style="color:#000000;"><a name="_9kMHG5YVtCIA78HJBCEpv2ojx1lks54AD3FiRFE"></a>, </font><font style="color:#000000;">(b)</font><font style="color:#000000;"><a name="_cp_text_1_1028"></a> </font><font style="color:#000000;">or (c) </font><font style="color:#000000;">of </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMKJ5YVt4BB7CECBCEPUiR2rz8s3"></a>Section&#160;</font><font style="text-decoration:underline;color:#000000;">11.1.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2885AFD9AEdZ5rik1G1"></a><a name="_9kR3WTr2995AGE9AEdZ5rik1G1"></a><a name="_9kR3WTr2995AHF9AEdZ5rik1G1"></a><a name="_9kR3WTr2885AIG9AEdZ5rik1G1"></a><a name="_Ref438641888"></a><a name="_Ref506473140"></a><a name="_9kMHG5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a><a name="_9kMIH5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a><a name="_cp_text_1_1030"></a><a name="_cp_text_1_1032"></a><a name="_9kMJI5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a><font style="Background-color:#auto;text-decoration:none;">11.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Procedure</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kMHG5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a>A Party that intends to claim indemnification under this </font><font style="text-decoration:underline;color:#000000;">Article 11</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Indemnitee</font><font style="color:#000000;">&#8221;) shall promptly notify the Indemnitor (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Indemnitor</font><font style="color:#000000;">&#8221;) in writing of any Claim in respect of which the Indemnitee intends to claim such indemnification.&nbsp;&nbsp;<a name="_9kMIH5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a>The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Claim shall only relieve the Indemnitor of its indemnification obligations under this </font><font style="text-decoration:underline;color:#000000;">Article 11</font><font style="color:#000000;"> if and to the extent the Indemnitor is actually and materially prejudiced thereby.&nbsp;&nbsp;The Indemnitor has sole control of the defense or settlement thereof.&nbsp;&nbsp;The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification, at the Indemnitor&#8217;s expense.&nbsp;&nbsp;The Indemnitee may participate at its expense in the Indemnitor&#8217;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#8217;s own selection at its own expense.&nbsp;&nbsp;The Indemnitor shall not settle any Claim without [*].&nbsp;&nbsp;So long as the Indemnitor is actively defending the Claim in good faith, the Indemnitee shall not [*].&nbsp;&nbsp;<a name="_cp_text_1_1030"></a>If the Indemnitor does not assume and conduct the defense of the Claim as provided above: (a) the Indemnitee may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnitee may deem reasonably appropriate [<a name="_cp_text_1_1032"></a>*]; <a name="_9kMJI5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a>and (b) the Indemnitor shall remain responsible to indemnify the Indemnitee as provided in this </font><font style="text-decoration:underline;color:#000000;">Article 11</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825936"></a><font style="Background-color:#auto;text-decoration:none;">11.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Insurance</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMLK5YVt4666AFcGp9H"></a>.&nbsp;&nbsp;<a name="_9kMLK5YVt4666AFcGp9H"></a>During the Term, each Party shall maintain such types and amounts of liability insurance (including self-insurance) as is normal and customary in the industry generally for similarly situated parties and adequate to cover its obligations under this Agreement, and Merus will upon request provide Lilly with a certificate of insurance in that regard, along with any amendments and revisions thereto.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506472045"></a><a name="_9kR3WTr2995DLPqA2mqtaHTyA2yxu5LHz3CLc"></a><a name="_9kR3WTr2995FOQqA2mqtaHTyA2yxu5LHz3CLc"></a><a name="_9kR3WTr2996BHOqA2mqtaHTyA2yxu5LHz3CLc"></a><a name="_Toc61825937"></a><a name="_Ref42283738"></a><font style="Background-color:#auto;text-decoration:none;">Article 12</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref42283738"></a>CONFIDENTIALITY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825938"></a><a name="_Ref439761723"></a><a name="_9kR3WTr2996ABAABNI0sonkvB7ptcZ35IH19IEK"></a><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Confidential Proprietary Information</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr28859HGABCOJ1tpolwC8quda46JI2AJF"></a><a name="_9kR3WTr29959IHABCOJ1tpolwC8quda46JI2AJF"></a><a name="_Ref339287039"></a><a name="_Ref506472921"></a><a name="_Ref163537878"></a><a name="_cp_text_1_139"></a><a name="_cp_text_1_141"></a><font style="Background-color:#auto;text-decoration:none;">12.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Confidential Proprietary Information</font><font style="color:#000000;">.&nbsp;&nbsp;In connection with this Agreement, Lilly may disclose certain confidential information that is Lilly Know-How to Merus and Merus may disclose certain confidential information that is Merus Know-How to Lilly (such confidential information, &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Confidential Proprietary Information</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Without limiting the foregoing, the terms of this Agreement are the Confidential Proprietary Information of both Parties and shall be treated confidentially by each of the Parties, subject to the exceptions set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;12.1.5</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_cp_text_1_139"></a>Information exchanged by the Parties pursuant to the Confidentiality <a name="_cp_text_1_141"></a>Agreement shall be deemed Confidential Proprietary Information disclosed under this Agreement, and shall be subject to the terms of this Agreement from and after the Effective Date.&nbsp;&nbsp;All Confidential Proprietary Information containing </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Personal Information shall be handled in accordance with all data protection and privacy laws, rules and regulations applicable to such Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506475194"></a><a name="_9kR3WTr29969HHABDeOwCC2o0739E"></a><a name="_Ref339287911"></a><a name="_Ref506644397"></a><a name="_Ref506644123"></a><a name="_9kMIH5YVt4666ABLHzrnmjuA6osbY24HG08HDJ"></a><a name="_cp_text_2_5"></a><font style="Background-color:#auto;text-decoration:none;">12.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Restrictions</font><font style="color:#000000;"><a name="_Ref506644123"></a>.&nbsp;&nbsp;A Party (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Receiving Party</font><font style="color:#000000;">&#8221;) that has received or receives Confidential Proprietary Information from the other Party (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Disclosing Party</font><font style="color:#000000;">&#8221;) shall keep all the Disclosing Party&#8217;<a name="_9kMIH5YVt4666ABLHzrnmjuA6osbY24HG08HDJ"></a>s Confidential Proprietary Information in confidence with the same degree of care with which the Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree of care)<a name="_cp_text_2_5"></a>.&nbsp;&nbsp;A Receiving Party shall not use the Disclosing Party&#8217;s Confidential Proprietary Information except in connection with the performance of its obligations and exercise of its rights under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr29969FFABESUzhvB517C"></a><a name="_Ref439760856"></a><a name="_Ref1727326"></a><a name="_9kMHG5YVt4BB8BJJCDFgQyEE4q295BG"></a><a name="_9kR3WTrAG85778ABEoh063DEA4s34oqAA97vx8J"></a><a name="_9kR3WTrAG85789ABErk01xtlyzyyq1HGMF0GB8S"></a><font style="Background-color:#auto;text-decoration:none;">12.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Exceptions</font><font style="color:#000000;">.&nbsp;&nbsp;The obligations of confidentiality and restriction on use of Confidential Proprietary Information under </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB8BJJCDFgQyEE4q295BG"></a>Section 12.1.2</font><font style="color:#000000;"><a name="_9kR3WTrAG85778ABEoh063DEA4s34oqAA97vx8J"></a> do not apply to any information that the Receiving Party can prove by competent written evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available to the public; (b) is known by the Receiving Party at the time of receiving such information, other than by previous disclosure of the Disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; (c) <a name="_9kR3WTrAG85789ABErk01xtlyzyyq1HGMF0GB8S"></a>is hereafter furnished to the Receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or (d) is independently discovered or developed by the Receiving Party without the direct or indirect use, reference or reliance upon of Confidential Proprietary Information belonging to the Disclosing Party.&nbsp;&nbsp;Specific information shall not be deemed to be within any of the foregoing exclusions merely because it is embraced by more general information falling within those exclusions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2996ADCABFeMv4w4G2nNN94yBJQQBD"></a><a name="_Ref339287930"></a><a name="_Ref532026544"></a><font style="Background-color:#auto;text-decoration:none;">12.1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Permitted Disclosures</font><font style="color:#000000;">.&nbsp;&nbsp;The Receiving Party may disclose Confidential Proprietary Information belonging to the Disclosing Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56707986"></a><a name="_Ref381319915"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Prosecution and Maintenance of Patents as permitted by this Agreement, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that [*] (not to be unreasonably withheld, conditioned or delayed);</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Filings for Product that such Party has a license or right to develop hereunder in a given country or jurisdiction, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that [*]; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151391348"></a><a name="_9kR3WTr2996A98ABFrq668zk1J8324G6uxy773E"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">prosecuting or defending litigation as permitted by this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59196988"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">complying with applicable court orders or governmental regulations, including mutually recognized security laws;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57027554"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in response to a valid request by a U.S., state, foreign, provincial, or local tax authority, in which case either Party may disclose [*]; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_1034"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">disclosure to its and its Affiliates&#8217;<a name="_cp_text_1_1034"></a> employees, consultants, contractors and agents, and to Sublicensees (in the case of Lilly), in each case on a need-to-know basis in connection with the Exploitation of Products in the Field in the Territory, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">disclosure to potential and actual investors, acquirers, licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">or potential investment, acquisition, or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4BB8CBACDHts88A1m3LA546I8wz099"></a><a name="_cp_field_47_1036"></a><a name="_9kMIH5YVt4BB8CBACDHts88A1m3LA546I8wz099"></a><a name="_cp_field_47_1038"></a><a name="_9kMKJ5YVt4BB8DJQsC4osvcJV0C40zw7NJ15ENe"></a><a name="_9kMKJ5YVt4BB7FNRsC4osvcJV0C40zw7NJ15ENe"></a><a name="_9kMKJ5YVt4BB7HQSsC4osvcJV0C40zw7NJ15ENe"></a>Notwithstanding the foregoing, if a Party is required to make a disclosure of the other Party&#8217;s Confidential Proprietary Information pursuant to <font style="text-decoration:underline;"><a name="_9kMHG5YVt4BB8CBACDHts88A1m3LA546I8wz099"></a><a name="_cp_field_47_1036"></a>Section&#160;12.1.4(c)</font><font style="text-decoration:underline;Background-color:#E6E6E6;">,</font> or <font style="text-decoration:underline;">Section 12.1.4(d)</font>, or a copy of this Agreement pursuant to <font style="text-decoration:underline;">Section 12.1.4(a)</font>, it shall give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Proprietary Information at least as diligent as such Party would use to protect its own Confidential Proprietary Information, but in no event less than reasonable efforts.&nbsp;&nbsp;Subject to the foregoing, any information disclosed pursuant to this <font style="text-decoration:underline;"><a name="_9kMIH5YVt4BB8CBACDHts88A1m3LA546I8wz099"></a><a name="_cp_field_47_1038"></a>Section 12.1.4</font><a name="_9kMKJ5YVt4BB8DJQsC4osvcJV0C40zw7NJ15ENe"></a><a name="_9kMKJ5YVt4BB7FNRsC4osvcJV0C40zw7NJ15ENe"></a><a name="_9kMKJ5YVt4BB7HQSsC4osvcJV0C40zw7NJ15ENe"></a> remains Confidential Proprietary Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 12.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref536204802"></a><a name="_Ref56708631"></a><a name="_Ref532026547"></a><a name="_Ref534634105"></a><font style="Background-color:#auto;text-decoration:none;">12.1.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Public Domain Information [*]</font><font style="color:#000000;">.&nbsp;&nbsp;Nothing in this Agreement shall prevent a Party from using any Know-How that is in the public domain.&nbsp;&nbsp;A Party shall also not be restricted under, and shall not be in breach of, this Agreement from [*] on an &#8220;as is, where is&#8221; basis, with all faults and all representations and warranties disclaimed and at such Party&#8217;<a name="_Ref534634105"></a>s sole risk.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kMH0H6ZWu577BCEiPu3"></a><a name="_cp_text_1_1041"></a><a name="_cp_text_1_1043"></a><a name="_9kMKJ5YVt4669JOidtltliu91o3"></a><a name="_9kMLK5YVt4669JOidtltliu91o3"></a><font style="Background-color:#auto;text-decoration:none;">12.1.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Disclosure of Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kMH0H6ZWu577BCEiPu3"></a>Notwithstanding the foregoing, either Party or its Affiliates may disclose the relevant terms of this Agreement: (a) to the extent required or advisable to comply with the rules and regulations promulgated by the U.S.&nbsp;&nbsp;Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"><a name="_cp_text_1_1041"></a> that such Party shall submit a confidential treatment request in connection with such disclosure and shall submit with such confidential treatment request only such redacted form of this Agreement as may be mutually agreed in writing by the Parties; (b) upon request from a Governmental Authority (such as a <a name="_cp_text_1_1043"></a>tax authority), </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that the disclosing Party uses reasonable efforts to ensure the Governmental Authority maintains such terms as confidential; [*], </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"><a name="_9kMKJ5YVt4669JOidtltliu91o3"></a> that any sublicensee<a name="_9kMLK5YVt4669JOidtltliu91o3"></a>, collaborator or potential sublicensee or collaborator agree in writing to be bound by obligations of confidentiality and non-use no less protective of the Disclosing Party than those set forth in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref2334019"></a><a name="_9kMHG5YVt4BB8CDCCDPK2uqpmxD9rveb57KJ3BK"></a><font style="Background-color:#auto;text-decoration:none;">12.1.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Survival</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party&#8217;s obligations under this </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB8CDCCDPK2uqpmxD9rveb57KJ3BK"></a>Section 12.1</font><font style="color:#000000;"> apply during the Term and continue for [*] thereafter with respect to Confidential Proprietary Information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref439761746"></a><a name="_9kR3WTr2996ACBACbbumumn5M"></a><a name="_Toc61825939"></a><a name="_Ref506645408"></a><font style="Background-color:#auto;text-decoration:none;">12.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Publicity</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref437251303"></a><a name="_Ref506475266"></a><a name="_Ref440400529"></a><a name="_9kMHG5YVt4BB8CFECDHgOx6y6I4pPPB60DLSSDF"></a><a name="_9kMIH5YVt4BB8CEDCEddwowop7O"></a><a name="_Ref339287199"></a><a name="_Ref389212237"></a><a name="_Ref506473198"></a><a name="_9kMJI5YVt4BB8CEDCEddwowop7O"></a><a name="_Ref437251303"></a><a name="_Ref506475266"></a><a name="_Ref440400529"></a>.&nbsp;&nbsp;Following the Effective Date, the Parties shall issue a joint press release in a mutually agreed upon form.&nbsp;&nbsp;Thereafter, either Party may make subsequent public disclosure of the contents of such press release and, except as permitted under <font style="text-decoration:underline;"><a name="_9kMHG5YVt4BB8CFECDHgOx6y6I4pPPB60DLSSDF"></a>Section 12.1.4</font> and this <font style="text-decoration:underline;"><a name="_9kMIH5YVt4BB8CEDCEddwowop7O"></a>Section 12.2</font>, neither Party shall issue any subsequent press release or public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party, not to be unreasonably withheld, conditioned, or delayed; <font style="text-decoration:underline;">provided</font> that neither Party will be prevented from complying with: (a) any duty of disclosure it may have pursuant to Applicable Laws or pursuant to the rules of any recognized stock exchange or quotation system subject to the restrictions set forth in <font style="text-decoration:underline;">Sections 12.1.4</font> and <font style="text-decoration:underline;">12.1.5</font>; or (b) any valid request received from a U.S., state, foreign, provincial, or local tax authority<a name="_Ref339287199"></a><a name="_Ref389212237"></a><a name="_Ref506473198"></a>.&nbsp;&nbsp;If either Party desires to issue a press release or other public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, [*], the issuing Party will provide the other Party with a copy of the proposed press release or public statement.&nbsp;&nbsp;The issuing Party shall specify </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with each such proposed press release or public statement, taking into account the urgency of the matter being disclosed and time periods for disclosure mandated by Applicable Law, a reasonable period of time within which the Receiving Party may provide any comments on such proposed press </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">release or public statement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the reviewing Party provides any comments, the Parties shall consult with one another on such proposed press release or public statement and work in good faith to prepare a mutually acceptable press release or public statement, </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that nothing in this </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">12.2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall prohibit a Party from making a disclosure as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or for appropriate market disclosure</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Party may repeat any information relating to this Agreement that has already been publicly disclosed in accordance with this </font><font style="text-decoration:underline;"><a name="_9kMJI5YVt4BB8CEDCEddwowop7O"></a>Section</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">12.2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such information continues as of such time to be accurate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and is disclosed in substantially the same context as the previously approved disclosure</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_9kR3WTr2885CLHADcbumumfx628"></a><a name="_9kR3WTr2995DD8ADcbumumfx628"></a><a name="_Ref438640122"></a><a name="_Toc61825940"></a><a name="_Ref506473461"></a><a name="_Ref508197045"></a><a name="_Ref534631378"></a><a name="_Ref60999713"></a><font style="Background-color:#auto;text-decoration:none;">12.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Publication</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref310517131"></a><a name="_Ref439761837"></a><a name="_Ref310517131"></a><a name="_Ref439761837"></a>.&nbsp;&nbsp;Lilly shall be entitled to issue scientific publications and make presentations with respect to any of the Research Programs, Lilly Targets, Compounds, Products, and their testing in accordance with Lilly&#8217;s internal guidelines [*]. Merus shall not issue any scientific publications regarding any of the foregoing without Lilly&#8217;s prior written consent.&nbsp;&nbsp;Notwithstanding the foregoing, (a) Merus shall not be restricted, and shall have the first right, in Merus&#8217;s sole discretion, to publish or present any information relating to [*], <font style="text-decoration:underline;">provided</font> that any such publication does not [*]; (b) Lilly shall not publish or present any information relating to [*] without Merus&#8217;s prior written consent and (c) nothing in this <font style="text-decoration:underline;">Section 12.3</font> shall be construed to limit any right of either Party to make any publications in relation to its activities performed outside of the scope of this Agreement, provided that such publications are made in accordance with any obligations such Party may have hereunder regarding the non-use and non-disclosure of any Confidential Proprietary Information of the other Party.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_1049"></a><a name="_Ref506472213"></a><a name="_9kR3WTr2996AEMqA2mqtaIl54DG98H9B4BKGM"></a><a name="_Toc61825941"></a><a name="_Ref508034558"></a><font style="Background-color:#auto;text-decoration:none;">Article 13</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref508034558"></a>TERM &amp; TERMINATION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57027576"></a><a name="_Toc61825942"></a><a name="_Ref507138962"></a><a name="_9kR3WTr2996BELqA2mqtaJWt9HKPA9ACNHOXMIO"></a><a name="_9kR3WTr2996BIPqA2mqtaJWt9HKPA9ACNHOXMIO"></a><a name="_9kMHG5YVt4BB8CGOsC4osvcKn76FIBAJBD6DMIO"></a><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Term</font><font style="color:#000000;">.&nbsp;&nbsp;<a name="_9kMHG5YVt4BB8CGOsC4osvcKn76FIBAJBD6DMIO"></a>This Agreement commences on the Effective Date and, unless terminated earlier as provided in this </font><font style="text-decoration:underline;color:#000000;">Article 13</font><font style="color:#000000;">, shall continue on a Product-by-Product basis until the expiration of the last Royalty Term in the Territory for such Product (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Term</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825943"></a><a name="_Ref151391856"></a><a name="_Ref151407599"></a><a name="_Ref151410175"></a><a name="_Ref151412432"></a><a name="_Ref376902090"></a><a name="_Ref376943617"></a><a name="_Ref376943734"></a><a name="_Ref377141334"></a><a name="_Ref377141519"></a><a name="_Ref506215177"></a><a name="_Ref506543719"></a><a name="_Ref508034536"></a><a name="_Ref520551201"></a><a name="_Ref520551239"></a><a name="_Ref520551332"></a><a name="_Ref520651523"></a><a name="_Ref528932470"></a><a name="_Ref532044969"></a><a name="_Ref532044970"></a><a name="_Ref532229485"></a><a name="_Ref534962381"></a><a name="_Ref404007148"></a><a name="_Ref339288047"></a><font style="Background-color:#auto;text-decoration:none;">13.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination for Material Breach</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_1062"></a><a name="_9kR3WTr2996AGFBDDQF11nykOxHPJw9TA9IAC5C"></a><a name="_Ref506213197"></a><a name="_Ref507150862"></a><font style="Background-color:#auto;text-decoration:none;">13.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination</font><font style="color:#000000;">.&nbsp;&nbsp;Either Party may terminate this Agreement, in whole or on a Research Program-by-Research Program or Target-by-Target basis, upon written notice to the other Party if such other Party materially breaches its obligations under this Agreement and, after receiving written notice from the non-breaching Party identifying such material breach in reasonable detail, fails to cure such material breach within [*] from the date of such notice; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that if such non-payment related breach is not reasonably capable of cure within such [*], the breaching Party may submit, prior to the end of such [*], a reasonable plan to cure the breach within an additional [*], in which case the other Party may not terminate this Agreement for so long as the breaching Party is [*] to implement such cure plan within such additional [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_1063"></a><a name="_9kMHG5YVt4BB8CIHDFFSH33p0mQzJRLyBVCBKCE"></a><a name="_9kMIH5YVt4BB8CIHDFFSH33p0mQzJRLyBVCBKCE"></a><font style="Background-color:#auto;text-decoration:none;">13.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Dispute</font><font style="color:#000000;">.&nbsp;&nbsp;If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party in accordance with </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMHG5YVt4BB8CIHDFFSH33p0mQzJRLyBVCBKCE"></a>Section </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:underline;color:#000000;">13.2.1</font><font style="color:#000000;">, and such alleged breaching Party provides the other Party notice of such dispute within such </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> period, then the non-breaching Party may not terminate this Agreement under </font><font style="text-decoration:underline;color:#000000;"><a name="_9kMIH5YVt4BB8CIHDFFSH33p0mQzJRLyBVCBKCE"></a>Section</font><font style="text-decoration:underline;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">13.2.1</font><font style="color:#000000;"> unless and </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_1066"></a><a name="_Ref532229990"></a><a name="_Ref535878109"></a><a name="_cp_text_5_1003"></a><a name="_cp_text_2_1004"></a><font style="Background-color:#auto;text-decoration:none;">13.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Lilly Option to Continue Agreement</font><font style="color:#000000;"><a name="_cp_text_5_1003"></a>.&nbsp;&nbsp;<a name="_cp_text_2_1004"></a>Notwithstanding anything to the contrary under this Agreement, if Merus materially breaches this Agreement, as finally determined under </font><font style="text-decoration:underline;color:#000000;">Article 14</font><font style="color:#000000;">, during the Research Term such that Lilly would otherwise have the right to terminate this Agreement under </font><font style="text-decoration:underline;color:#000000;">Section 13.2</font><font style="color:#000000;">, Lilly shall have the option to cause the Research Transfer Scenario to occur by written notice to Merus.&nbsp;&nbsp;[*].&nbsp;&nbsp;For clarity, the Agreement shall continue in accordance with its terms, save as expressly set forth in this </font><font style="text-decoration:underline;color:#000000;">Section 13.2.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59195409"></a><font style="Background-color:#auto;text-decoration:none;">13.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination for Patent Challenge</font><font style="color:#000000;">.&nbsp;&nbsp;Except to the extent&#160;the following is&#160;unenforceable under the laws of a particular jurisdiction:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Merus may immediately terminate this Agreement with respect to any Product that is Covered by any licensed Merus Patent(s) the subject any Patent Challenge commenced by Lilly or its Affiliates or sublicensees, individually or in association with any other Person, in respect of any Merus Patent anywhere in the world.&nbsp;&nbsp;For clarity, the foregoing right of termination shall not apply with respect to any Patent Challenge where the Patent Challenge is [*].&nbsp;&nbsp;For clarity, if a Third Party that is not a sublicensee of Lilly commences a legal action challenging the validity, enforceability or scope of any Merus Patent anywhere in the world, and Lilly&#8217;s sole involvement in such action is to respond to a subpoena or take another action that is otherwise compelled by Applicable Law, then such involvement shall not be deemed to be a Patent Challenge.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Lilly may immediately terminate the license granted in </font><font style="text-decoration:underline;color:#000000;">Section 6.3</font><font style="color:#000000;"> in respect of any licensed Lilly Patent(s) the subject of the Patent Challenge, if Merus or its Affiliates or sublicensees, individually or in association with any other Person, commences a Patent Challenge in respect of any Lilly Patent anywhere in the world.&nbsp;&nbsp;For clarity, the foregoing right of termination shall not apply with respect to any Patent Challenge where the Patent Challenge is [*].&nbsp;&nbsp;For clarity, if a Third Party that is not a sublicensee of Merus commences a legal action challenging the validity, enforceability or scope of any Lilly Patent anywhere in the world, and Merus&#8217;s sole involvement in such action is to respond to a subpoena or take another action that is otherwise compelled by Applicable Law, then such involvement shall not be deemed to be a Patent Challenge.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59045554"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For the purposes of this </font><font style="text-decoration:underline;color:#000000;">Section 13.2.4</font><font style="color:#000000;">, a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Patent Challenge</font><font style="color:#000000;">&#8221; shall mean any declaratory judgment action, </font><font style="font-style:italic;color:#000000;">inter </font><font style="color:#000000;">partes review, post-grant review, opposition or similar proceeding or other legal action challenging the validity, enforceability or scope of any Merus Patent or Lilly Patent (as applicable) anywhere in the world.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref43323928"></a><a name="_Ref51964545"></a><font style="Background-color:#auto;text-decoration:none;">13.2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination of Program Exclusivity</font><font style="color:#000000;">.&nbsp;&nbsp;If Lilly or any Person within Lilly charged with making such decisions in accordance with its usual internal business practices, [*].&nbsp;&nbsp;In addition, if Lilly has ceased material Development and Commercialization activities under this Agreement with respect to any Research Program (including all Collaboration Compounds, Modified Compounds, or Products within such Research Program and directed to the applicable Lilly Target or Lilly Target Pair) for a continuous period of [*].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825944"></a><a name="_9kR3WTr29967CEBFhPu3vxqx628w8oP3C0q"></a><a name="_Ref532218770"></a><a name="_Ref384033217"></a><a name="_Ref507155105"></a><a name="_Ref506475387"></a><a name="_Ref404006966"></a><font style="text-decoration:none;Background-color:#auto;">13.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination by Lilly</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref508267681"></a><a name="_Ref536196614"></a><font style="Background-color:#auto;text-decoration:none;">13.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Partial Termination</font><font style="color:#000000;">.&nbsp;&nbsp;Lilly may, at any time in its sole discretion and without cause, terminate this Agreement in whole or on a Research Program-by-Research Program (which termination would apply with respect to the Lilly Target and Lilly Target Pair to which such Research Program relates) or country-by-country basis upon [*] prior written notice to Merus.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref536203782"></a><a name="_Ref532229914"></a><font style="Background-color:#auto;text-decoration:none;">13.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;Lilly may, in its sole discretion, terminate this Agreement in its entirety at any time and without cause upon [*] prior written notice to Merus<a name="_Ref532229914"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref506475759"></a><a name="_9kR3WTr2995EE8BIVBjjhxEAyeY3C46z6FBH"></a><a name="_Toc61825945"></a><a name="_Ref507155066"></a><a name="_Ref56818011"></a><a name="_Ref439762008"></a><a name="_Ref339289149"></a><a name="_Ref420591328"></a><font style="Background-color:#auto;text-decoration:none;">13.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Effects of Termination</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The following shall apply upon termination of this Agreement made in accordance with this <font style="text-decoration:underline;">Article 13</font>:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56818644"></a><a name="_9kMHG5YVt46669IVAiigw363MD05"></a><a name="_cp_text_1_1098"></a><font style="Background-color:#auto;text-decoration:none;">13.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination of Licenses</font><font style="color:#000000;">.&nbsp;&nbsp;All licenses granted under </font><font style="text-decoration:underline;color:#000000;">Article 6</font><font style="color:#000000;"><a name="_9kMHG5YVt46669IVAiigw363MD05"></a> shall terminate automatically as of the termination <a name="_cp_text_1_1098"></a>effective date; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that if Lilly (or its Affiliates or Sublicensees) has inventory of usable Product(s) as of the effective date of termination, then Lilly (and its Affiliates and Sublicensees) may continue to sell off such inventory of Products in the Field in the Territory (and fulfill customer orders therefor) until [*] and shall pay Merus any applicable royalties due based on such sales in accordance with </font><font style="text-decoration:underline;color:#000000;">Section 8.4</font><font style="color:#000000;">.&nbsp;&nbsp;Any permitted sublicense granted by Lilly or its Affiliate to a Third Party under the licenses granted to Lilly under this Agreement [*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref536201045"></a><a name="_9kMML5YVt46669IVAiigw363MD05"></a><font style="Background-color:#auto;text-decoration:none;">13.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Destruction of Confidential Proprietary Information</font><font style="color:#000000;">.&nbsp;&nbsp;Each Receiving Party shall destroy (at the Disclosing Party&#8217;<a name="_9kMML5YVt46669IVAiigw363MD05"></a>s written request) all such Confidential Proprietary Information of the Receiving Party in its possession as of the effective date of expiration or termination [*], </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="font-style:italic;color:#000000;"> </font><font style="color:#000000;">that each Receiving Party may retain and continue to use such Confidential Proprietary Information of the Disclosing Party to the extent necessary to exercise any surviving rights, licenses or obligations under this Agreement.&nbsp;&nbsp;Notwithstanding the foregoing, a Receiving Party shall not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing Party&#8217;s Confidential Proprietary Information under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54105342"></a><a name="_Ref59176534"></a><a name="_9kR3WTr2664AHgInuiwttuWV0913w38tjb6D1F"></a><a name="_9kMI6M6ZWu59979HkLqxlz"></a><a name="_9kMJI5YVt4886BEeOt2uwpw1mcUz6u8"></a><a name="_9kMKJ5YVt4886BEeOt2uwpw1mcUz6u8"></a><font style="Background-color:#auto;text-decoration:none;">13.4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Terminated Targets</font><font style="color:#000000;">.&nbsp;&nbsp;In the event this Agreement is terminated with respect to a particular Research Program, then the Lilly Target and Lilly Target Pair that is the subject of each such Research Program shall be &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Terminated Target(s)</font><font style="color:#000000;">&#8221;, and each Product and any Compound contained in such Product that was directed against such Terminated Target(s) shall be designated a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Terminated Product</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Terminated Compound</font><font style="color:#000000;">&#8221; (as the case may be)</font><font style="font-style:italic;color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">If this Agreement is terminated in its entirety, all Lilly Targets and Lilly Target Pairs shall be Terminated Targets and all Products shall be Terminated Products and all Compounds shall be Terminated Compounds.&nbsp;&nbsp;<a name="_9kR3WTr2664AHgInuiwttuWV0913w38tjb6D1F"></a>Upon designation of a Target as a Terminated Target<a name="_9kMI6M6ZWu59979HkLqxlz"></a>: (a) the Target<a name="_9kMJI5YVt4886BEeOt2uwpw1mcUz6u8"></a> shall cease to be a Lilly Target and the Parties shall conclude the Research Program with respect to such Terminated Target (if not already concluded) in an orderly manner (as determined by the JSC and at the cost of Lilly); (b) Lilly&#8217;<a name="_9kMKJ5YVt4886BEeOt2uwpw1mcUz6u8"></a>s obligations to pay Milestone Payments or Royalties on Products in respect of that Terminated Target shall cease (except to the extent payable prior to the date thereto); (c) Lilly shall cease all its activities under this Agreement in relation to all Terminated Compounds and Terminated Products, and (d) all licenses granted by Merus to Lilly under this Agreement shall terminate.&nbsp;&nbsp;In addition, if this </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Agreement </font><font style="color:#000000;">is</font><font style="color:#000000;"> terminated by Lilly under </font><font style="text-decoration:underline;color:#000000;">Section </font><font style="text-decoration:underline;color:#000000;">13.3</font><font style="color:#000000;"> or by Merus under </font><font style="text-decoration:underline;color:#000000;">Sections </font><font style="text-decoration:underline;color:#000000;">13.2.1</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">13.2.4</font><font style="color:#000000;">, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref465863125"></a><a name="_Toc61825946"></a><a name="_Ref61288386"></a><a name="_Ref56818026"></a><a name="_Ref2333821"></a><a name="_Ref53824543"></a><font style="Background-color:#auto;text-decoration:none;">13.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reversion of Product Rights</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref465863039"></a><a name="_Ref465863039"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59176556"></a><font style="Background-color:#auto;text-decoration:none;">13.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Early Termination [*]</font><font style="color:#000000;">.&nbsp;&nbsp;If this Agreement is terminated by Lilly under </font><font style="text-decoration:underline;color:#000000;">Section 13.3</font><font style="color:#000000;"> or by Merus under </font><font style="text-decoration:underline;color:#000000;">Sections 13.2.1</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">13.2.4</font><font style="color:#000000;">, with respect to one or more Lilly Targets (including termination of given Research Program that is directed to such Lilly Target) [*].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Other Termination [*]</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of any termination of this Agreement by Lilly under </font><font style="text-decoration:underline;color:#000000;">Section 13.3</font><font style="color:#000000;"> or by Merus under </font><font style="text-decoration:underline;color:#000000;">Sections 13.2.1</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">13.2.4</font><font style="color:#000000;"> (or any partial termination of this Agreement with respect to any Terminated Target (and all associated Terminated Products and Terminated Compounds)) that is not a termination described in </font><font style="text-decoration:underline;color:#000000;">Section 13.5.1</font><font style="color:#000000;">, then, in addition to those general effects set forth in </font><font style="text-decoration:underline;color:#000000;">Section 13.4</font><font style="color:#000000;">, as applicable and which will apply only with respect to the applicable Terminated Target (and all associated Terminated Products and Terminated Compounds), on the request of Merus, [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825947"></a><a name="_Ref59195465"></a><a name="_Ref61288389"></a><font style="Background-color:#auto;text-decoration:none;">13.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Survival</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.&nbsp;&nbsp;Except as set forth in this <font style="text-decoration:underline;">Section 13.6</font> or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement: <font style="text-decoration:underline;">Article 1</font> (to the extent such definitions are used in surviving provisions), <font style="text-decoration:underline;">Sections 2.7 </font>(solely with respect to decisions made prior to expiration or termination and subject to the limitations in <font style="text-decoration:underline;">Section 2.8</font>), <font style="text-decoration:underline;">4.3</font> (solely with respect to amounts accrued prior to termination or expiration), <font style="text-decoration:underline;">4.5.1</font> (as applicable to retention of record following the Research Term), <font style="text-decoration:underline;">4.6</font> (solely with respect to costs incurred prior to the expiration or termination of this Agreement), <font style="text-decoration:underline;">4.7</font> (with respect to Research conducted prior to such expiration or termination), <font style="text-decoration:underline;">4.8</font> (with respect to responsibility and compliance), <font style="text-decoration:underline;">4.10</font>, <font style="text-decoration:underline;">8.3</font> (solely in respect to Milestone Events reached prior to such expiration or termination), <font style="text-decoration:underline;">8.5</font> to <font style="text-decoration:underline;">8.8</font> (in each case solely to the extent required to make final reimbursements, reconciliations or other payments owed following termination or expiration), <font style="text-decoration:underline;">Sections 9.1</font> (other than <font style="text-decoration:underline;">9.1.2(d)</font> or <font style="text-decoration:underline;">9.1.6</font>), <font style="text-decoration:underline;">9.2</font> (solely in respect of Joint Patents, Joint Know-How, Research Compound Panel Know-How and Research Compound Panel Patents), <font style="text-decoration:underline;">9.3</font> (solely in respect of Joint Patents, Joint Know-How, Research Compound Panel Know-How and Research Compound Panel Patents), <font style="text-decoration:underline;">9.4</font>, <font style="text-decoration:underline;">Article 11</font>, <font style="text-decoration:underline;">Article 12</font> (for [*] period in <font style="text-decoration:underline;">Section 12.1.7 </font>except that Section<font style="text-decoration:underline;"> 12.1.5</font> shall survive in perpetuity), <font style="text-decoration:underline;">Sections 13.4</font> through <font style="text-decoration:underline;">13.7</font>, <font style="text-decoration:underline;">Article 14</font>, and <font style="text-decoration:underline;">Sections 15.1</font>, <font style="text-decoration:underline;">15.2</font> to <font style="text-decoration:underline;">15.7</font>, <font style="text-decoration:underline;">15.9</font>, <font style="text-decoration:underline;">15.10</font> to <font style="text-decoration:underline;">15.17</font> and <font style="text-decoration:underline;">15.18</font> (with respect to responsibility for Affiliates). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825948"></a><a name="_Ref532045259"></a><a name="_Ref54105385"></a><a name="_Ref61288391"></a><font style="Background-color:#auto;text-decoration:none;">13.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Bankruptcy Code</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M483"></a><a name="OLE_LINK217"></a><a name="OLE_LINK218"></a><a name="DocXTextRef164"></a><a name="_DV_M484"></a><a name="Code"></a><a name="DocXTextRef165"></a><a name="_cp_text_1_1104"></a><a name="DocXTextRef161"></a><a name="_cp_text_1_1105"></a><a name="DocXTextRef162"></a><a name="DocXTextRef163"></a>.&nbsp;&nbsp;<a name="_DV_M483"></a><a name="OLE_LINK217"></a><a name="OLE_LINK218"></a>If this Agreement is <a name="DocXTextRef164"></a>rejected by a Party as a debtor under Section 365<a name="_DV_M484"></a> of the United States Bankruptcy Code<a name="Code"></a> or similar provision in the bankruptcy laws of another jurisdiction (the &#8220;<font style="font-weight:bold;font-style:italic;">Code</font>&#8221;<a name="DocXTextRef165"></a>), then, notwithstanding anything else in this Agreement to the contrary, all licenses and rights to licenses granted under or pursuant to this Agreement by the Party in bankruptcy to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Code (or similar provision in the bankruptcy laws of the jurisdiction), licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the Code (or similar provision in the bankruptcy laws of another applicable jurisdiction).&nbsp;&nbsp;The Parties agree that a Party that is a licensee of rights under this Agreement shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against a Party under the Code, the other Party </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall be entitled to a complete duplicate of, or complete access to (as such other Party deems appropriate), any such intellectual property and all embodiments of such intellectual property, if not already in such other Party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1104"></a>s possession, shall be promptly delivered to such other Party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef161"></a>: </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1105"></a> upon any such commencement of a bankruptcy proceeding upon written request therefor by such other Party, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef162"></a>or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef163"></a> if not delivered under </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the foregoing subclause (a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, upon the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing provisions of this </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">13.7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are without prejudice to any rights a Party may have arising under the Code</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="border-bottom:double 2.5pt;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825949"></a><a name="_cp_text_1_1106"></a><a name="_Ref535523072"></a><a name="_Ref367258251"></a><font style="Background-color:#auto;text-decoration:none;">Article 14</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_cp_text_1_1106"></a><a name="_Ref535523072"></a>GOVERNING LAW; <a name="_Ref367258251"></a>DISPUTE RESOLUTION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M521"></a><a name="_cp_blt_1_1175"></a><a name="_cp_blt_2_1174"></a><a name="_DV_M522"></a><a name="_DV_M524"></a><a name="_DV_M526"></a><a name="_cp_blt_1_1109"></a><a name="_cp_text_1_1107"></a><a name="_9kR3WTr2996AHGDIVM8zw6yzyXM4ohMBD900CJF"></a><a name="_Toc61825950"></a><a name="_Ref441070233"></a><a name="_Ref507139116"></a><a name="_Ref507150895"></a><a name="_Ref520921900"></a><a name="_Ref57042866"></a><a name="_Ref556696"></a><a name="_Ref506472465"></a><a name="_cp_text_4_1108"></a><font style="Background-color:#auto;text-decoration:none;">14.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">G<a name="_cp_text_4_1108"></a>overning Law</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664CMbAsB4sLFx6qsH"></a><a name="_9kR3WTr2664DEbWryvgQIv406BbSAIA3JFBHIBg"></a><a name="_9kR3WTr2664DFaHhmqsLP4uz"></a><a name="_9kR3WTr2664DGeSioymCL3B3wC84A"></a><a name="_cp_text_4_1110"></a>.&nbsp;&nbsp;<a name="_9kR3WTr2664CMbAsB4sLFx6qsH"></a>This Agreement is governed by and will be construed in accordance with the laws of the State of New York, without reference to its conflict of laws principles.&nbsp;&nbsp;<a name="_9kR3WTr2664DEbWryvgQIv406BbSAIA3JFBHIBg"></a>The United Nations Convention of International Contracts<a name="_9kR3WTr2664DFaHhmqsLP4uz"></a> on the Sale of Goods<a name="_9kR3WTr2664DGeSioymCL3B3wC84A"></a> (the Vienna Convention) does not apply to this Agreement.<a name="_cp_text_4_1110"></a>&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1121"></a><a name="_cp_blt_2_1120"></a><a name="_Toc61825951"></a><a name="_Ref54105416"></a><a name="_Ref59017359"></a><a name="_Ref2332296"></a><a name="_Ref57043723"></a><font style="Background-color:#auto;text-decoration:none;">14.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Disputes</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref357090850"></a><a name="Dispute"></a><a name="_DV_M543"></a><a name="_Ref357090851"></a>.&nbsp;&nbsp;The Parties recognize that controversies or claims arising out of, relating to, or in connection with this Agreement may arise from time to time.&nbsp;&nbsp;It is the objective of the Parties to establish procedures to facilitate the resolution of disputes in an expedient manner by mutual cooperation and without resort to litigation.&nbsp;&nbsp;To accomplish this objective, the Parties shall follow the procedures set forth in this <font style="text-decoration:underline;">Section 14.1</font> to resolve any dispute<a name="_Ref357090850"></a>.&nbsp;&nbsp;I<a name="Dispute"></a>f any dispute, claim or controversy of any nature arising out of or relating to this Agreement, including any action or claim based on tort, contract or statute, or concerning the interpretation, effect, termination, validity, performance or breach of this Agreement (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Dispute</font>&#8221;), arises between the Parties, such Dispute shall, following any discussion and attempted resolution through the JSC, if applicable, first be referred to the Executive Officers of each Party for resolution.&nbsp;&nbsp;Either Party, may make such referral by written notice to the other Party, and within [*] after receipt of such written request, the Parties shall exchange the names of the respective Executive Officers to whom such Dispute is referred.&nbsp;&nbsp;The Executive Officers shall have an additional [*] following such exchange of names to attempt to resolve the Dispute (<font style="font-style:italic;">i.e.</font>, [*] from the date of notice of referral of the Dispute).&nbsp;&nbsp;If, following such period, the Executive Officers have not succeeded in negotiating a resolution of the Dispute, and a Party wishes to pursue the matter, the Parties, the Dispute shall be subject to final resolution in any federal court having jurisdiction thereof located in New York, New York as further described in <font style="text-decoration:underline;">Section 14.3</font>.<a name="_DV_M543"></a><a name="_Ref357090851"></a>&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1173"></a><a name="_cp_blt_2_1172"></a><a name="_cp_text_1_1156"></a><a name="_Toc61825952"></a><a name="_Ref357090852"></a><a name="_Ref2256424"></a><a name="_Ref730257"></a><font style="Background-color:#auto;text-decoration:none;">14.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Litigation; Equitable Relief</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1157"></a><a name="_cp_text_1_1159"></a><a name="_cp_text_1_1160"></a><a name="_cp_text_1_1161"></a><a name="_cp_text_1_1165"></a><a name="_cp_text_1_1171"></a><a name="_Ref357090853"></a><a name="_cp_text_1_1157"></a>.&nbsp;&nbsp;<a name="_cp_text_1_1159"></a>The Federal courts located in New York, New York shall have exclusive jurisdiction over, and shall be the exclusive venue for resolution of, any Dispute not resolved through the informal Dispute-resolution procedures described above.&nbsp;&nbsp;<a name="_cp_text_1_1160"></a>Either Party may<a name="_cp_text_1_1161"></a>, at any time and without waiving any remedy under this Agreement, seek from any court having jurisdiction any temporary injunctive or provisional relief necessary to protect the rights or property of that Party.&nbsp;&nbsp;<a name="_cp_text_1_1165"></a>Any final judgment resolving a Dispute may be enforced <a name="_cp_text_1_1171"></a>by either Party in any court having appropriate jurisdiction.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825953"></a><a name="_Ref53824680"></a><font style="Background-color:#auto;text-decoration:none;">Article 15</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Ref53824680"></a>MISCELLANEOUS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825954"></a><a name="_Ref2334100"></a><font style="Background-color:#auto;text-decoration:none;">15.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Entire Agreement; Amendment</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMH3K6ZWu5777HIK8wvjstvB"></a><a name="_9kMH4L6ZWu5777HIK8wvjstvB"></a><a name="_9kMH5M6ZWu5777HIK8wvjstvB"></a><a name="_9kMJI5YVt4CC7BISHzrnmjuA6osWOA5zCKRRCWT"></a><a name="_9kMKJ5YVt4CC7BISHzrnmjuA6osWOA5zCKRRCWT"></a>.&nbsp;&nbsp;<a name="_9kMH3K6ZWu5777HIK8wvjstvB"></a>This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement<a name="_9kMH4L6ZWu5777HIK8wvjstvB"></a> and all the covenants, promises, agreements<a name="_9kMH5M6ZWu5777HIK8wvjstvB"></a>, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, <a name="_9kMJI5YVt4CC7BISHzrnmjuA6osWOA5zCKRRCWT"></a>including the Confidentiality Agreement.&nbsp;&nbsp;<a name="_9kMKJ5YVt4CC7BISHzrnmjuA6osWOA5zCKRRCWT"></a>The foregoing may not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Confidentiality Agreement.&nbsp;&nbsp;No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825955"></a><a name="_9kR3WTr2996BGEDFXLtu2vw51781ZXtnw78HY"></a><a name="_Ref151408743"></a><a name="_Ref151411619"></a><a name="_Ref381320203"></a><a name="_Ref464554576"></a><font style="Background-color:#auto;text-decoration:none;">15.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Limitation</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">of</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Liability</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4BB8DIGFHZNvw4xy739A3bZvpy9AJa"></a><a name="_9kMKJ5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a>.&nbsp;&nbsp;NEITHER PARTY MAY RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; <font style="font-style:italic;text-decoration:underline;">PROVIDED</font>, <font style="font-style:italic;text-decoration:underline;">HOWEVER</font>, THAT THIS <font style="text-decoration:underline;">SECTION&#160;15.2</font> SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER <font style="text-decoration:underline;text-transform:uppercase;">Article 11</font><font style="text-transform:uppercase;">, [*] OR CONFIDENTIALITY OBLIGATIONS UNDER </font><font style="text-decoration:underline;text-transform:uppercase;">Article 12</font> OR A PARTY&#8217;<a name="_9kMHG5YVt4BB8DIGFHZNvw4xy739A3bZvpy9AJa"></a><a name="_9kMKJ5YVt4BB8BGPsC4osvcIa51t3DA342vDMIO"></a>S GROSS NEGLIGENCE OR WILFUL MISCONDUCT.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc61825956"></a><font style="Background-color:#auto;text-decoration:none;">15.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Independent Contractors</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref404085453"></a><a name="_Ref440727457"></a>.&nbsp;&nbsp;The relationship between Lilly and Merus created by this Agreement is solely that of independent contractors.&nbsp;&nbsp;This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties.&nbsp;&nbsp;Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party<a name="_Ref404085453"></a><a name="_Ref440727457"></a>.&nbsp;&nbsp;The Parties (and any successor, assignee, transferee, or Affiliate of a Party) shall not treat or report the relationship between the Parties arising under this Agreement as a partnership for United States tax purposes, without the prior written consent of the other Party unless required by Applicable Laws.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_1178"></a><a name="_cp_blt_1_1188"></a><a name="_cp_blt_2_1187"></a><a name="_9kR3WTr2995BJGDJdT61li"></a><a name="_Toc61825957"></a><a name="_Ref406331945"></a><font style="Background-color:#auto;text-decoration:none;">15.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Notice</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1180"></a><a name="_9kR3WTrAG857FGDJqbgpu52z0nl7Ery24J7FTRI"></a><a name="_cp_text_1_1182"></a><a name="_9kR3WTrAG857GHDJrlliurkw8CI1pu4I874y2wI"></a><a name="_cp_text_1_1184"></a><a name="_9kMHG5YVtCIA79HIFLsdirw7412pn9Gt046L9HV"></a><a name="_9kMHG5YVtCIA79IJFLtnnkwtmyAEK3rw6KA9604"></a><a name="_9kMHG5YVt4BB7DLIFLfV83nk"></a><a name="_cp_field_47_1186"></a>.&nbsp;&nbsp;Any notice required or permitted to be given by this Agreement must be in writing, in English.&nbsp;&nbsp;<a name="_cp_text_1_1180"></a>Any and all notices or other communications or deliveries required or permitted to be provided hereunder must be in writing and will be deemed given and effective if<a name="_9kR3WTrAG857FGDJqbgpu52z0nl7Ery24J7FTRI"></a>: <a name="_cp_text_1_1182"></a>(a) delivered by hand or by overnight courier with tracking capabilities;<a name="_9kR3WTrAG857GHDJrlliurkw8CI1pu4I874y2wI"></a> <a name="_cp_text_1_1184"></a>(b) mailed postage prepaid by first class, registered, or certified mail; or<a name="_9kMHG5YVtCIA79HIFLsdirw7412pn9Gt046L9HV"></a> (c) delivered by facsimile or electronic mail followed by delivery via either of the methods set forth in clauses (a)<a name="_9kMHG5YVtCIA79IJFLtnnkwtmyAEK3rw6KA9604"></a> and (b) of this <font style="text-decoration:underline;"><a name="_9kMHG5YVt4BB7DLIFLfV83nk"></a><a name="_cp_field_47_1186"></a>Section&#160;15.4</font>, in each case, addressed as set forth below unless changed by notice so given:<br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:29.85%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Merus:</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Merus N.V. <br />Yalelaan 62, <br />3584 CM Utrecht, <br />The Netherlands<br />Attn: General Counsel<br />Telephone: 31 85 016 2557<br />E-mail: p.silverman@merus.nl </p></td></tr></table></div>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:37.31%;text-indent:-29.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy (which shall not constitute notice) to:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:37.31%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP<br />3175 Hanover Street<br />Palo Alto, CA 94304</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:37.31%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USA<br />Attn: Kate Hillier<br />Email: khillier@cooley.com<br /></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.46%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:29.85%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Lilly:</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_1189"></a><a name="_cp_text_1_1190"></a><a name="_cp_text_1_1191"></a><a name="_cp_text_1_1192"></a><a name="_cp_text_1_1199"></a><a name="_cp_text_1_1200"></a><a name="_cp_text_1_1201"></a><a name="_cp_text_1_1202"></a><a name="_cp_text_1_1203"></a><a name="_cp_text_1_1189"></a>Eli Lilly and Company <br /><a name="_cp_text_1_1190"></a>Lilly Corporate Center<br /><a name="_cp_text_1_1191"></a>Indianapolis, Indiana 46285<br /><a name="_cp_text_1_1192"></a>Attn: Vice President, Corporate Business Development <br />Fax: (317) 651-3051<br /><font style="Background-color:#000000;color:#000000;"><br /></font><a name="_cp_text_1_1199"></a>with a copy (which shall not constitute notice) to:<br /><br /><a name="_cp_text_1_1200"></a>Eli Lilly and Company<br /><a name="_cp_text_1_1201"></a>Lilly Corporate Center<br /><a name="_cp_text_1_1202"></a>Indianapolis, IN 46285<br /><a name="_cp_text_1_1203"></a>Attn: General Counsel<br />Fax: (317) 433-3000</p></td></tr></table></div>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1204"></a>Merus shall also provide a copy of any notice (via e-mail if available) to Lilly&#8217;s Alliance Manager.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1212"></a><a name="_cp_blt_2_1211"></a><a name="_Toc61825958"></a><a name="_Ref2334138"></a><font style="Background-color:#auto;text-decoration:none;">15.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Severability</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.&nbsp;&nbsp;All remaining portions will remain in full force and effect and in such event, the Parties shall negotiate in good faith to promptly replace the invalid, unenforceable, or illegal provision with a valid, enforceable, and legal provision that most closely effectuates the original intent of the Parties.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1214"></a><a name="_cp_blt_2_1213"></a><a name="_Toc61825959"></a><a name="_Ref61289477"></a><font style="Background-color:#auto;text-decoration:none;">15.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Non-Use of Names</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref339287363"></a>.&nbsp;&nbsp;Merus shall not use the name, trademark, logo, or physical likeness of Lilly or its respective officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without Lilly&#8217;s prior written consent.&nbsp;&nbsp;Merus shall require its Affiliates to comply with the foregoing.&nbsp;&nbsp;Lilly shall not use the name, trademark, logo, or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">physical likeness of Merus or its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior written consent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref339287363"></a>Lilly shall require its Affiliates and Sublicensees to comply with the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1227"></a><a name="_cp_blt_2_1226"></a><a name="_9kR3WTr2995BKHDMTK90pv2uwC"></a><a name="_Toc61825960"></a><a name="_Ref506473636"></a><a name="_Ref506562680"></a><a name="_Ref59196709"></a><font style="Background-color:#auto;text-decoration:none;">15.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Assignment</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1215"></a><a name="_cp_text_1_1217"></a><a name="_cp_text_1_1219"></a><a name="_cp_text_1_1221"></a><a name="_cp_field_47_1223"></a><a name="_9kMHG5YVt4BB7DMJFOVMB2rx4wyE"></a><a name="_cp_field_47_1225"></a>.&nbsp;&nbsp;Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party&#8217;<a name="_cp_text_1_1215"></a>s consent to: <a name="_cp_text_1_1217"></a>(a) its Affiliate, <font style="text-decoration:underline;">provided</font> that<a name="_cp_text_1_1219"></a> such Party shall remain primarily liable for any acts or omissions of such Affiliate; <a name="_cp_text_1_1221"></a>or (b) to an Acquirer in connection with a Change of Control, subject to <font style="text-decoration:underline;"><a name="_cp_field_47_1223"></a>Section 15.8</font>.&nbsp;&nbsp;Any permitted assignee shall, in writing to the non-assigning Party, expressly assume performance of such assigning Party&#8217;s rights and obligations.&nbsp;&nbsp;Any permitted assignment is binding on the successors of the assigning Party.&nbsp;&nbsp;Any assignment or attempted assignment by either Party in violation of the terms of this <font style="text-decoration:underline;"><a name="_9kMHG5YVt4BB7DMJFOVMB2rx4wyE"></a><a name="_cp_field_47_1225"></a>Section&#160;15.7</font> is null, void and of no legal effect.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1229"></a><a name="_cp_blt_2_1228"></a><a name="_Toc61825961"></a><a name="_Ref532232477"></a><a name="_Ref53747232"></a><font style="Background-color:#auto;text-decoration:none;">15.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Merus Change of Control</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1231"></a><a name="_cp_blt_2_1230"></a><a name="_Ref532249315"></a><a name="_Ref54105465"></a><a name="_bookmark0"></a><a name="_bookmark1"></a><a name="_bookmark2"></a><a name="_Ref31737536"></a><font style="Background-color:#auto;text-decoration:none;">15.8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Notification of Change of Control</font><font style="color:#000000;">.&nbsp;&nbsp;Merus shall provide Lilly with written notice of any Change of Control of Merus promptly, but no later than the earlier of: (a) [*] following the (i) first public announcement of such Change of Control<a name="_bookmark0"></a><a name="_bookmark1"></a><a name="_bookmark2"></a> or, (ii) if earlier and not prohibited by the terms of any written agreement between Merus and such any Third Party, the execution of a definitive agreement relating to such Change of Control, or (b) unless prohibited under Applicable Law or by the terms of any written agreement between such Party and any Third Party, at least [*] prior to the earlier of: (i) the first public announcement of, or (ii) the execution of any agreement pertaining to, such transaction, which notice in each case of (a) or (b) shall summarize the nature of the transaction and the identity of the Acquirer (a &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Change of Control Notice</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;If Merus undergoes a Change of Control that is not [*], then </font><font style="text-decoration:underline;color:#000000;">Section <a name="_Ref31737536"></a>15.8.2</font><font style="color:#000000;"> shall apply.&nbsp;&nbsp;For avoidance of doubt, (a) a Change of Control of Merus [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32015193"></a><a name="_Ref56982755"></a><a name="_cp_text_4_1175"></a><font style="Background-color:#auto;text-decoration:none;">15.8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Effects of Change of Control</font><font style="color:#000000;">.&nbsp;&nbsp;If there is a Change of Control of Merus during the Research Term, then Merus shall continue to conduct the Research Program, in accordance with the terms of this Agreement, and the Research Continuance Scenario set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.2(b)</font><font style="color:#000000;"><a name="_cp_text_4_1175"></a> shall apply.&nbsp;&nbsp;Notwithstanding the foregoing, solely where (1) such Change of Control occurs following [*], (2) at such time, Merus has generated at [*] for such Research Program, and (3) the Acquirer is [*], Lilly may elect, by written notice to Merus, which notice shall be delivered, if at all, within [*] following the applicable notice of such Change of Control delivered to Lilly pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 15.8.1</font><font style="color:#000000;">, to either continue with the Research Continuance Scenario set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.2(b)</font><font style="color:#000000;">, or to step in to assume responsibility for the conduct of the remaining activities pursuant to each Research Plan (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Activities</font><font style="color:#000000;">&#8221;), in which case the Research Transfer Scenario set forth in </font><font style="text-decoration:underline;color:#000000;">Section 15.8.2(a)</font><font style="color:#000000;"> shall apply.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32183332"></a><a name="_Ref54105510"></a><a name="_cp_text_1_1176"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research Transfer Scenario</font><font style="color:#000000;">.&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Transfer Scenario</font><font style="color:#000000;">&#8221; means [<a name="_cp_text_1_1176"></a>*], the following shall apply: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56983712"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">within [*] following receipt of Lilly&#8217;s written notice, Merus shall disclose or deliver to Lilly, to the extent not previously provided, the Merus Know-How solely consisting of [*] which in each case, [*] for Lilly to complete each applicable Research Plan (as constituted at the time of such Change of Control) and for Lilly&#8217;s Exploitation of each Compound or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Product (including for regulatory purposes)</font><font style="color:#000000;">.&nbsp;&nbsp;In addition,</font><font style="color:#000000;"> upon Lilly</font><font style="color:#000000;">&#8217;</font><font style="color:#000000;">s reasonable request and expense, Merus will: (A) provide </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">; and (B) </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Transfer</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The</font><font style="color:#000000;"> </font><font style="color:#000000;">Research</font><font style="color:#000000;"> Transfer to be undertaken under the foregoing shall be overseen by a Working Group established for such purposes, which Working Group may put in place a technology transfer plan expressly identifying </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.&nbsp;&nbsp;For clarity </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, whether or not at the date of such transfer, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, and to enable Lilly with respect to the</font><font style="color:#000000;"> </font><font style="color:#000000;">licenses granted in </font><font style="text-decoration:underline;color:#000000;">Section </font><font style="text-decoration:underline;color:#000000;">6.1</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that in no event will Merus be required to transfer to Lilly (1) any Merus Platform Technology, or (2) more than </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> Research Compounds that have met the Success Criteria</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Promptly following the </font><font style="color:#000000;">conclusion or termination of any Research Program that has been the subject of a Research Transfer</font><font style="color:#000000;">,</font><font style="color:#000000;"> Lilly shall return to Merus all Research Compounds and other components of the Research Transfer</font><font style="color:#000000;"> (in each case, solely to the extent such materials would not have otherwise constituted part of the Final Research Deliverables that Merus would have delivered to Lilly pursuant to such Research Plan)</font><font style="color:#000000;"> and on </font><font style="color:#000000;">Merus&#8217;</font><font style="color:#000000;">s</font><font style="color:#000000;"> request, certify such complete return in writing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32531117"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the JSC shall be immediately disbanded, and all approval rights of the JSC, or final decision making authority granted to a Party pursuant to this Agreement, shall become approval rights of the corresponding Party (</font><font style="font-style:italic;color:#000000;">i.e.</font><font style="color:#000000;">, mutual agreement by the Parties or final decision making authority by a Party); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[*]; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59057454"></a><a name="_cp_text_2_1185"></a><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any documented internal and out-of-pocket expenses Lilly incurs in performance of such Research or take over from Merus, that were not otherwise to be borne by Lilly, shall [*];</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to Prosecution and Maintenance of Merus Research Program Patents that are [*], Lilly shall have sole control over Prosecution and Maintenance of such Patents, without the need to provide information to, consult with, or consider the comments of, Merus, the JSC or the Patent Working Group]; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Solely in the event of a Change of Control to a Lilly Competitor, Merus shall thereafter have no right to: (A) [*] to the extent prosecuted by Lilly in accordance with this Agreement; (B) [*]; (C) [*]; (D) to take over Prosecution and Maintenance of [*]; or (E) to have the final say over any [*]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.39%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59096128"></a><a name="_Ref54105644"></a><a name="_Ref56981707"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research Continuance Scenario</font><font style="color:#000000;">.&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Research Continuance Scenario</font><font style="color:#000000;">&#8221; means that Merus shall continue the Research Activities, if any, being conducted under any Research Plan, and the Research Program and this Agreement shall continue in the same manner as prior to the Change of Control, and in which case: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Lilly will maintain its rights under this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.85%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Merus shall continue to perform the Research Activities hereunder, with the same level of diligence applied to such activities after the consummation of such Change of Control when compared with those that were in place prior to the consummation of such Change of Control, where the &#8220;same level of diligence&#8221; shall require that Merus dedicates at least the same level of effort, including by dedicating the same number of FTEs and other resources to such Research Program as it was applying prior to such Change of Control or as were committed to be </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">applied pursuant to the then applicable Research Plan (including as described in any timelines, schedules, Gantt charts, plans or protocols set forth therein) </font><font style="color:#000000;">for the remainder of the Research Term</font><font style="color:#000000;">;</font><font style="color:#000000;"> and</font><font style="color:#000000;"> </font><font style="color:#000000;">the Research Term shall be automatically extended without any requirement for Lilly to pay additional consideration, until the later of </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that in each case, it is reasonably likely that the remaining Research Activities under the then current Research Plan can be completed within such timeframe.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.8.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Acquirer Engaged in Competing Program.&nbsp;&nbsp;</font><font style="color:#000000;">If Merus undergoes a Change of Control and, as of the closing date of such Change of Control transaction, such Acquirer is engaged in a Competing Program or is a Lilly Competitor, then regardless of any other elections Lilly may make hereunder, Merus shall implement (as of the closing of such transaction) and enforce Firewalls for the duration of the Firewall Period. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1208"></a><a name="_cp_blt_2_1207"></a><a name="_cp_blt_2_1209"></a><a name="_Ref59066038"></a><font style="Background-color:#auto;text-decoration:none;">15.8.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Covenant Not to Sue [*]</font><font style="color:#000000;">.&nbsp;&nbsp;Following any Change of Control of Merus to [*].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.8.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Firewall Audits</font><font style="color:#000000;">.&nbsp;&nbsp;Lilly shall have the right, through a designated Third Party auditor, to monitor and audit Merus&#8217;s (and, as applicable, its Affiliates&#8217;) compliance with its obligations under this Agreement to implement and enforce Firewalls under this </font><font style="text-decoration:underline;color:#000000;">Section 15.8</font><font style="color:#000000;">, and to require Merus (or its Affiliates) to promptly remediate any non-compliance identified by such audit.&nbsp;&nbsp;In connection with such audit, duly authorized representatives of Lilly&#8217;s designated auditor may make an on-site visit to Merus (or its Affiliate) for the purpose of conducting such audit.&nbsp;&nbsp;Lilly may conduct such audits from time to time as reasonably necessary to confirm Merus&#8217;s compliance with such Firewall requirements, no more than [*] per Calendar Year, or more frequently if [*].&nbsp;&nbsp;Such audits shall be conducted during Merus&#8217;s regular business hours, for a duration only as reasonably necessary to confirm Merus&#8217;s compliance with the applicable Firewall requirements, and shall not unreasonably interfere with or impede Merus&#8217;s business operations.&nbsp;&nbsp;Lilly shall provide Merus with written notice of such audit at least [*] prior to such requested audit (or such shorter period as may be designated by Lilly if Lilly reasonably believes at any time that Merus is not in compliance with such Firewall requirements).&nbsp;&nbsp;All such audits shall be conducted at Lilly&#8217;s cost and expense.&nbsp;&nbsp;The auditor shall only be permitted to disclose to Lilly the existence of any non-compliance with Merus&#8217;s obligations under this Agreement to implement and enforce Firewalls under this </font><font style="text-decoration:underline;color:#000000;">Section 15.8</font><font style="color:#000000;">, but may not disclose the substance of such findings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:14.93%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref59130168"></a><font style="Background-color:#auto;text-decoration:none;">15.8.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Acquiror IP</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, and without limiting any obligations with respect to the implementation of any Firewalls hereunder [*], in the event of a Change of Control of Merus where (a) the Acquirer merges with, consolidates with or acquires Merus or an Affiliate of Merus, or (b) Merus or an Affiliate of Merus transfers to an Acquirer all or substantially all of its assets to which this Agreement relates (each of (a) or (b), an &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Acquisition Transaction</font><font style="color:#000000;">&#8221;), then any technology or intellectual property right owned or controlled by any Acquirer (and not Controlled by Merus or its Affiliates) immediately prior to the effective date of such Acquisition Transaction shall not be deemed be &#8216;Controlled&#8217; by Merus or its Affiliates after the effective date of such Acquisition Transaction for purposes of this Agreement.&nbsp;&nbsp;[*] and [*] in the Field and in the Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1250"></a><a name="_cp_blt_2_1249"></a><a name="_Toc61825962"></a><a name="_Ref2334148"></a><font style="Background-color:#auto;text-decoration:none;">15.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Waivers</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or in any other instance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1252"></a><a name="_cp_blt_2_1251"></a><a name="_Toc61825963"></a><a name="_Ref56984547"></a><font style="Background-color:#auto;text-decoration:none;">15.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Force</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Majeure</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Neither Party shall be in breach of this Agreement or otherwise liable to the other for any failure or delay in performing any of its obligations under this Agreement or for other nonperformance hereunder (excluding, in each case, the obligation to make payments when due) during any period in which such delay or failure is caused by a Force Majeure Event.&nbsp;&nbsp;In such event, the affected Party shall notify the other Party of the Force Majeure Event, and use Commercially Reasonable Efforts to overcome such Force Majeure Event and resume performance of its obligations under this Agreement as soon as and to the extent practicable, <font style="text-decoration:underline;">provided</font> that in no event shall any Party be required to prevent or settle any labor disturbance or dispute.&nbsp;&nbsp;All delivery dates under this Agreement that have been affected by a Force Majeure Event shall be tolled for the duration of such Force Majeure Event.&nbsp;&nbsp;&#8220;<font style="font-weight:bold;font-style:italic;">Force Majeure Event</font>&#8221; means an event, act, occurrence, condition or state of facts, in each case outside the reasonable control of a Party, including: (a) acts of God (b) fires, floods, earthquakes or other natural disasters; (c) war (threats), riots, armed conflicts, terrorist attacks or bombings; (d) sanctions, embargo, import and export restrictions, quota or prohibitions and license restrictions; (e) any law or action taken by a government or public authority, including without limitation laws or action related to public safety or public health; (f) any &#8220;lockdown&#8221;, quarantine or other similar restrictions imposed by any Governmental Authority in connection with any applicable epidemic or pandemic; (g) labor or trade disputes, strikes, industrial action or lookouts; (h) fire, explosions or damages to the necessary facilities; or (i) non-performance by suppliers or subcontractors due to a Force Majeure Event in each case that interfere with the normal business operations of such Party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1254"></a><a name="_cp_blt_2_1253"></a><a name="_Toc61825964"></a><a name="_Ref2334150"></a><a name="_Ref61289577"></a><font style="Background-color:#auto;text-decoration:none;">15.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Interpretation</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page_0_3_54"></a><a name="_DV_M597"></a><a name="DocXTextRef202"></a><a name="DocXTextRef203"></a><a name="DocXTextRef204"></a><a name="DocXTextRef205"></a><a name="DocXTextRef206"></a><a name="DocXTextRef207"></a><a name="DocXTextRef208"></a><a name="DocXTextRef209"></a><a name="DocXTextRef210"></a><a name="DocXTextRef211"></a>.&nbsp;&nbsp;The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.&nbsp;&nbsp;Unless specified to the contrary, references to Articles, Sections, Appendices or Exhibits mean the particular Articles, Sections, Appendices&#160;or Exhibits to this Agreement and references to this Agreement include all Exhibits hereto.&nbsp;&nbsp;<a name="page_0_3_54"></a><a name="_DV_M597"></a>In the event of any conflict between the main body of this Agreement and any Exhibit hereto, the main body of this Agreement shall prevail.&nbsp;&nbsp;<a name="DocXTextRef202"></a>Unless context otherwise clearly requires, whenever used in this Agreement: (a)&#160;the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed as incorporating, also, &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;<a name="DocXTextRef203"></a>; (b)&#160;the word &#8220;day&#8221; or &#8220;year&#8221;<a name="DocXTextRef204"></a> means a calendar day or year unless otherwise specified; (c)&#160;the word &#8220;notice&#8221;<a name="DocXTextRef205"></a> means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (d)&#160;the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221;<a name="DocXTextRef206"></a> and derivative or similar words refer to this Agreement as a whole and not merely to the particular provision in which such words appear; (e)&#160;the words &#8220;shall&#8221; and &#8220;will&#8221;<a name="DocXTextRef207"></a> have interchangeable meanings for purposes of this Agreement; (f) provisions that require that a Party, the Parties or a committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221;<a name="DocXTextRef208"></a> or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (g)<a name="DocXTextRef209"></a> words of any gender include the other gender; (h)<a name="DocXTextRef210"></a> words using the singular or plural number also include the plural or singular number, respectively; (i)<a name="DocXTextRef211"></a> references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof; (j) the phrases &#8220;non-refundable&#8221; and &#8220;non-creditable&#8221; shall not prohibit, limit or restrict either Party&#8217;s right to obtain damages in connection with a breach of this Agreement; (k) the word &#8220;or&#8221; means </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unless the context dictates otherwise because the subjects of the conjunction are mutually exclusive; and (l) neither Party shall be deemed to be acting on behalf of the other Party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1256"></a><a name="_cp_blt_2_1255"></a><a name="_Toc61825965"></a><a name="_Ref381317787"></a><a name="_Ref2334152"></a><font style="Background-color:#auto;text-decoration:none;">15.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Counterparts;</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Electronic</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Signatures</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref404702392"></a>.&nbsp;&nbsp;This Agreement may be executed in any number of counterparts, each of which is deemed an original, but all of which together constitute one instrument.&nbsp;&nbsp;This Agreement may be executed and delivered electronically and upon such delivery such electronic signature will be deemed to have the same effect as if the original signature had been delivered to the other Party<a name="_Ref404702392"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1258"></a><a name="_cp_blt_2_1257"></a><a name="_Toc61825966"></a><font style="Background-color:#auto;text-decoration:none;">15.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Expenses</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and execution of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1259"></a><a name="_Ref357090861"></a><a name="_Toc61825967"></a><a name="_Ref524164374"></a><a name="_cp_text_1_1260"></a><a name="_DV_M590"></a><font style="Background-color:#auto;text-decoration:none;">15.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">F<a name="_DV_M590"></a>urther Assurances</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Lilly and Merus hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and deliver any and all documents and take any action as may be reasonably necessary to carry out the intent and purposes of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1261"></a><a name="_Ref357090863"></a><a name="_Toc61825968"></a><a name="_Ref524164376"></a><a name="_cp_text_1_1262"></a><a name="_DV_M594"></a><font style="Background-color:#auto;text-decoration:none;">15.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Third Party<a name="_DV_M594"></a> Beneficiary Rights</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This Agreement is not intended to and shall not be construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, except as otherwise expressly provided for in this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1263"></a><a name="_Ref357090868"></a><a name="_Toc61825969"></a><a name="_Ref524164381"></a><a name="_cp_text_1_1264"></a><a name="_DV_M607"></a><font style="Background-color:#auto;text-decoration:none;">15.16</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">C<a name="_DV_M607"></a>onstruction</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef199"></a><a name="DocXTextRef200"></a><a name="DocXTextRef201"></a>.&nbsp;&nbsp;<a name="DocXTextRef199"></a>The Parties hereto acknowledge and agree that: (a)<a name="DocXTextRef200"></a> each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)<a name="DocXTextRef201"></a> the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1265"></a><a name="_Ref357090869"></a><a name="_Toc61825970"></a><a name="_Ref524164382"></a><a name="_cp_text_1_1266"></a><a name="_DV_M609"></a><font style="Background-color:#auto;text-decoration:none;">15.17</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">C<a name="_DV_M609"></a>umulative Remedies</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_1269"></a><a name="_Ref357090846"></a><a name="_Toc61825971"></a><a name="_cp_text_1_1267"></a><a name="OLE_LINK4"></a><a name="OLE_LINK5"></a><a name="_DV_M535"></a><font style="Background-color:#auto;text-decoration:none;">15.18</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">E<a name="_DV_M535"></a>xtension to Affiliates</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_1268"></a><a name="_cp_text_1_1270"></a>.&nbsp;&nbsp;<a name="_cp_text_4_1268"></a>Except as expressly set forth otherwise in this Agreement, each <a name="_cp_text_1_1270"></a>Party shall have the right to extend the rights and immunities granted in this Agreement to one or more of its Affiliates.&nbsp;&nbsp;All applicable terms and provisions of this Agreement, except this right to extend, shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to the Party extending such rights and immunities.&nbsp;&nbsp;For clarity, Lilly extending the rights and immunities granted hereunder shall remain primarily liable for any acts or omissions of its Affiliates.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[signature page follows]</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.46%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">In Witness Whereof<font style="font-weight:normal;font-variant: normal;">, the Parties have caused this Agreement to be executed as of the Effective Date by their duly authorized representatives.</font></p>
<p style="margin-bottom:42pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Merus N.V.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"> /s/ Bill Lundberg</font><font style="text-decoration:underline;margin-left:198pt;"></font><font style="text-decoration:underline;"><br /></font>Name: Bill Lundberg<font style="margin-left:198pt;"></font><br />Title: CEO<font style="margin-left:198pt;"></font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:42pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Eli Lilly and Company</p>
<p style="margin-bottom:48pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ David A. Ricks</font><font style="text-decoration:underline;margin-left:198pt;"></font><font style="text-decoration:underline;"><br /></font>Name: David A. Ricks<font style="margin-left:198pt;"></font><font style="margin-left:246pt;"></font><font style="margin-left:279pt;"></font><br />Title: Chairman and Chief Executive Officer<font style="margin-left:198pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_textHF_1_1294"></a>[<font style="font-style:italic;">Signature Page to Collaboration and License Agreement</font>]</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule 1.57</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Final Research Deliverables</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[*]</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Schedule 1.57</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 4.4.1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exhibit 4.4.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 4.7 &#8211; Part A </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exhibit 4.7</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 4.7 &#8211; Part B</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exhibit 4.7</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 4.9</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form of Materials Transfer Record</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">The Material(s) described below is/are supplied by one Party to the other Party subject to the terms and conditions of the Collaboration and License Agreement between Merus and Lilly effective ____ (&#8220;</font><font style="text-decoration:underline;">Agreement</font><font style="text-decoration:none;">&#8221;).&nbsp;&nbsp;For clarity, defined terms used herein and not defined herein have the meanings ascribed to such terms in the Agreement.&nbsp;&nbsp;This Exhibit may be executed in one or more counterparts, including by facsimile or &#8220;PDF&#8221; exchange, each of which shall be deemed to be an original as against any party whose signature appears thereon, but all of which together shall constitute but one and the same instrument.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direction of Transfer:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Segoe UI Symbol;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;margin-left:36pt;"></font><font style="font-family:Times New Roman;">To Lilly, from Merus</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Segoe UI Symbol;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;margin-left:36pt;"></font><font style="font-family:Times New Roman;">To Merus, from Lilly</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description of Material(s):<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In signing below, the Merus scientist and Lilly scientist acknowledge that they understand and will abide by the terms and conditions under which the Material(s) is/are provided.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.46%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lilly Representative Signature<font style="margin-left:36pt;"></font>Merus Representative Signature</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.46%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lilly Representative Name<font style="margin-left:36pt;"></font>Merus Representative Name</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.46%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date<font style="margin-left:36pt;"></font>Date </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exhibit 4.9</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 10.2.4</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Existing Patents</p>
<p style="margin-bottom:8pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exhibit 10.2.4</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>mrus-ex231_11.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mrus-ex231_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1 </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm&nbsp;&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors <br />Merus N.V.:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statements (File Nos. 333-211497 and No. 333-230708) on Form S-8 and registration statement (File No. 333-233383) on Form S-3 of Merus N.V. of our report dated March 16, 2021, with respect to the consolidated balance sheets of Merus N.V. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes, which report appears in the December 31, 2020 Annual Report on Form 10-K of Merus N.V.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">/s/ <font style="font-style:normal;">KPMG Accountants N.V.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rotterdam, The Netherlands<font style="font-family:Calibri;"><br /></font>March 16, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>mrus-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mrus-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sven (Bill) Ante Lundberg, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Merus N.V.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sven A. Lundberg</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sven (Bill) Ante Lundberg</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principal Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Principal Financial Officer)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>mrus-ex321_10.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mrus-ex321_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Merus N.V. (the &#8220;Company&#8221;) for the period ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sven A. Lundberg</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sven (Bill) Ante Lundberg</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principal Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gtqsgrqcdg4e000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H!Q # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **ANK@6T!D(S@]*BLKY;S=A2-M.SM<7,KV+=%%%(84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 44R6:*!"\LBHHZECBL&Y\;^';20I
M-J408>F3_*FDWL)R2W9T-%8UCXKT34F"VVH1.QZ G'\ZV 01D'(-#36X)I["
MT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'5
MO^/!OJ*J:%TDJWJW_'@WU%5-"_Y:UHO@,7_$1LT445F;!1110 4444 %%%%
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M;:A \ZC:(U<9XK(\$^)KSQ58W4MW:>0J$*O!&>M>/Z0[:=\24#$@K<D?G_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ;B<Y90>@_R:J_!>QV:=>7A'WWV@_E7.:I\./$4VGK>3[KJ_E;+ N/E%>I>
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MI-16R"E3DU*<MV>._!R".3Q#<3/CS$C.W/X5U7Q:\10VNB?V7'(#/.1N4'H
M:X&+P?XNT'56&GQ2H^2JR1D8(J_JGPX\13:>MY.6NKZ5OF4L/E%:-1<^9LPC
M*:I."B=%\%['9IU[>D??<*#^=<9XTF.K_$9XE^9?/6(?3/\ ]>O7? VB7.A>
M$EM9X]MR=S,N>_.*X#1?!&N2>.!J%]:;(!*9"Q8'Z5,9+GE(N=.7LX02.R\?
MS?V7\/&@7@M&L(_+_P"M7+?!:U7S=0NV(R%"C]:[WQSH$OB'PW+9VY'FJ=Z
M]R*\<TOPKXSL;B2ULHYK<2?*Y#  BE"SIM7*J\T:RE:Z-GXN^(H=0OH=,MG#
MK <N0?XO\FND\/PMI7PAEE48>6)G_-:Y#5?AAK4,UKY,9N9'^::3<.#FO8(M
M$4^%%TAP!F#RS['&*)N*BDA4XSE.4I(\>^$D,<_B^667!9(RRY]<BN\^*?B*
M#3O#TE@D@-S<_+M!Z+WKSA_!GBO0=98Z?%(&W$)+&1R*T-1^'?B2[TTW]XS7
M-_(W^K+#Y15R47-2;,X.<:;@HZFO\%++G4+TCTC!_(UF?&.],^OV]F#_ *I,
MX^O_ .JO0_AUH%QH'AT0W<>R=VW,,YKCOB9X)U74M;_M.PB\Y'0*R@\C%3&2
M=6[-)PDL.HI'H/@RT6Q\)V$0_P">>3^9KQ'QP7U+Q_/"[X!D$8)[#-=Y\/=+
M\51:@CZM+*EE"F$C8CFJ?Q!^'NH7FK-JVE+YF_ET!P0?6B#49N["JI3I*RV)
M;?X2330Q^;K4YB*@[1R/YUU?AOX?Z/X<F$\(,]R/^6C]OPKSNUN/B,L"VD:3
M *-H)Q7H/@32M;L;6>;7+AI+B9@0I(.T<U,^:VK*I*#DK1.PHHHK [ HHHH
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M$_@JP\3B SO)&\(PK(<<4E.*MZW!TIM2=K:61QWQ'V:=X7T^PL$CB$[!':,
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M&7\1&W11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $+6MN\O
MFM!&T@_B*C-3444 %%%% !1110 4444 %%%% !1110!'';PPEC%$B%NI50,U
M)110 4444 %(R*ZE74,IZ@BEHH BAMX;<8AB2,'KM4"I:** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *RM<_U"?6M6LK7/\ 4)]:J&Y%3X6.T7_CT;_>K3K,T7_CT;_>K3HEN%/X
M4%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"$!A@U@:EIDR2^=;9.3T':N@HH6CN)JZL9VG7,IC,5R-LB#GWJCJ*WM])MB7
M]R#CKUI]WL_M*4-(5.SC!ZU?TOFPC(.:K;4C?033; 6<.&.7/6KU%%2:(***
M* "BBB@ HHHH **** "BBB@ HHHH **** *>J?\ 'B]4-"^_+]*OZI_QXO5#
M0O\ 62_2M%\#,9?Q$;=%%%9FP4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %96M_\>Z?6M6LK6_\ CW7ZU4-R*GPL=HG_ !Z-_O5IUF:)
M_P >C?[U:=$MPI_"@HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BCH,FJ":Q9/=?9Q*/,Z<]*B52,;*3M<:BWL7Z***L04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\>K?[U:=9FB?\>K?[U:=$MPI_"@HHHJ2PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0G )/:EI"-RD'N,4 <Q<^+[07+6OEOL8[/-["L.\MW27
M<#\V=R..XJ#Q%HTFEW;2 %K64\'TINEWRL@L;IOD/^ID/\)]*^>QBG7E[.II
M);'KTX1A%3IZKJ==X?UL7<8MK@XG0=3_ !5OUYK?;]-<W#-Y3Q<DYKIO"GBR
MS\1VS+$_[^+AU/4^]=V68BK5@X5%K'K_ %U.'%0A"2<7N=)1117IG,%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<$ZA_&&U@"#)T/TKO:\XU1IE\12M;Y\T-\N/I0!Z#]DM_^>*?]\T?9+?_
M )XI_P!\UQ'VSQ'_ '9?^^31]L\1_P!V7_ODT =O]DM_^>*?]\TR:TMQ"Y\E
M/NG^&N+^V>(_[LO_ 'R:0W?B)@05EP?]DT )X?C1_$CJR@K\W!'O6_XHMX8]
M'=DB53D<@>]<I;VNK6MR9XH)5D/?::L71UV\A,4T<K(>VTT ;GA&WAETMFDC
M5COZD5D^*8HX]7B5$"C X ]Z@L_[<L8C%;Q2JI.<;34-W;:O>S"6>"1G'0[3
M0!W<-G;&PC)A3/E#G'M7'^'8T?Q"RLH*\\$4"X\0K&$"S;0, ;35.WM-6M;C
MSXH)5D/?:: /1?LMO_SQC_[YH^RV_P#SQC_[YKB/M?B/TF_[Y-'VOQ'Z3?\
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M:+PG/O4*:H^26Z9H UZ*J17\;\'@U861'^Z0: 'T444 %%%% !1110 4444
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MZ8HBEFP !DG%9;>(=+1BIG7(_P!DU?O/^/*;_<->>:;:V%S-/]MN/*P?E]Z
M.R_X2/2O^>Z_]\FC_A)-*_Y[K_WR:Y[^RM!_Y_\ ]?\ Z]']E:#_ ,__ .O_
M ->@#H?^$DTK_GL/^^31_P ))I7_ #V'_?)KGO[*T'_G_P#U_P#KT?V5H/\
MS_\ Z_\ UZ .A_X232O^>P_[Y-'_  DFE?\ /8?]\FN>_LK0?^?_ /7_ .O1
M_96@_P#/_P#K_P#7H Z'_A)-*_Y[#_ODT?\ "2:5_P ]A_WR:Y[^RM!_Y_\
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MH Y+_A"4_P"?IJ#X*0#/VIJZVD;[I^E 'GVA0_9_$R19SM8C-=AKO_(&N/\
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M:17*JAW2SL>%'UK>G3^U(XZU?[$#NH('DFPN9)7Y9CVK015MU,4!W2'AY?\
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M/=-U6337EV0)+N/\0Z4 :/\ PDNJ?\^R_P#?LT?\)+JG_/LO_?LT?\)7<?\
M/C#_ -\__6H_X2NX_P"?&'_OG_ZU !_PDNJ_\^R_]^S1_P )+JO_ #[+_P!^
MS1_PE=Q_SXP_]\__ %J/^$KN/^?&'_OG_P"M0 ?\)+JO_/LO_?LT?\)+JO\
MS[+_ -^S1_PE=Q_SXP_]\_\ UJ/^$KN/^?&'_OG_ .M0 ?\ "2ZK_P ^R_\
M?LTG_"2ZK_S[+_W[-+_PE=Q_SXP_]\__ %J/^$KN/^?&'_OG_P"M0 G_  DN
MJ_\ /LO_ '[-(VOZC.OER0!4/4B,BG?\)7<?\^,/_?/_ -:D/BJ<@@V,//\
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M']W)T]C7<UY.K%6# X(Z5Z%H.I"_L5W']ZG#"@#6HHHH *1L[3CK2TA( YH
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M@ HHHH *\^^+/_( M_\ KK_A7H->??%D@:!;Y_YZ_P"%73^-&5?^&SF/A?\
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M<5TE !2,-PQ2TC$A>* *1LDC'RX ZU79E5MNX&I#/.ZD2J!SVJL]NK-D$@T
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M$&B  )Z@4 5_L[MN+$ 'UJ58HUY.6/Z5$\Y^; Z=S2!99#T."/PI@3F54X&
M/05"TY.-HZGO3UMP,;VZ=A3@$11@#ZF@" +-(.AX/?BK40:,DL^?3%1&X&.,
MGG%3021LW()QZ4@+MK<,\FQL],BKM00&,_< !J>@ HHHH **** "BBB@ HHH
MH *1BJ@LQ  ZDTM131":-D;H1@T 07$J;<IM;Z5FO<.I)9#@5>>U$2Y!&!4&
M5/<'VH C6=&XSCV-/*H_4 _2F/;QL<XP34?D2Q_<;(':@"3^S_,7Y#\OI6?J
M>@17EDT-P!S]W:.E6VN9TB*C*L>AJ(3SR1@,V6'!(IIM.Z$TI*S/*]6\,WFG
MNR/"98<\$#-87]DVJODVF&_W:]R^S-(6W@ 'UYK.UG2[8:7<O%"OG;."%KJC
MB.C1Y]3!6NXL\K2W(09 BC'KQ3M0MH)K'8,%,9Y[FL[4?/DLWV,WF(<CGTK!
M;6;J2+RF;'8UO)-LY*;BDRE-"$=@.@/!K=T*Z>:)X7.63[IK"=\BMKP];L%E
MG88!X%5U(>Q[7X#U=6TES=3A5@X)8]JY[QUJVFZO>PM;SDF/AB%SFN:B\W["
M420JKMS@^E9U[*UI&7CC,@'6L53BI\QNZTYTU"Q5O]+^TW/GVMUM;&""N,_C
M6+=V]S:R8N 3GHW4&M>TUJVN7$<BF-CTSTK2>*.5/*F7?$WZ?2M?-&%^C.1L
M\R7\(49.\5T.L6TCP2!?]8A#"KD.FP64FVWBRQZ'J36M>Z/>)91WKP$*1AJ'
M;J"N]EL</%KUVD/EY&1QFJ$TQD8LQRQZUTEQHUK=.7!,;'KBDM] M87#R.TF
M.QZ4)6!S3W&>'K5HK:29QC>>*[OP-$9-9=N=JKSBN< +;8HD]@ *]$\*:1)I
M]H)&!\V7D\=*BM)1A8UPL'.JF=0#''PH"\TQK@>YP>]-6V<\L0O.:E$42]LY
M]:X#VB$M(Y8 '\!BG"W8MEV X_&I'F501GIZ5$TQ)PH[=: )5AB7!QEAW-3Q
MQN_"CCVJFJ3.RMSTZFK41>,8+Y/M2 T;6%X0VYL@G@>E6*KVDQE5@>JFK% !
M1110 4444 %9VM?\>7_ A6C6=K7_ !Y?\"%5'<B?PLBT/_4R?6M:LG0_]3)]
M:UJ)[A3^%!1114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7GGQ;'_$BM3M#!9P2I[\BO0ZY[Q?X=/B32?LR2!)%;<I/2K@[239G5BY
M0:1YO\-RLWBB^GC@6&,VI&Q3]*YB>XMQ->6C:;#+.\YVW#?>7->L>"_!$OA^
M2XGNY5>65=@"= *Q9OA?<OX@:X2Y3[(TF_G[W7I6ZJ1YF<;HSY$K'HND*4T:
MR4]1 @/_ 'R*NTR&(0P1Q#HBA1^%/KE9WK8****!A1110 4444 %%%% !111
M0 4444 %4=9_Y ]W_P!<S5ZHKF 7-M)"W1U(-"W$]CYML]DMSIULEJBS)=JS
M2YY8;A77_$*>*U\5VLD]G'=(+8#RY.F<"M>P^&%S;ZZEQ)<H;:.3>N,Y.#FM
M7QKX%F\07<%U:3(DB+L8/W%=3J1YD<"HS4'IJ)\+5SH]W,L*0QRW#,D:=%''
M%=[6'X5T'_A'M&2T9]\F=S$=,UN5SS=Y-G92BXP284445)H%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YY\0]3+316"-\
MH&YJ]#KQGQ3<&X\0W1)SM; K?#QO.YQXV?+3MW,:G(=KJ3V.:;17<>0==?0_
M;+."\M 9 $"L!R5K%CAFDN% C?@C/%5['4[G3V/DN0#U4]*U=-U*ZU#4%B8J
M%().U16#A*/H=D:L9M7W%U/3;F_O0Z[54* "YQVJK<^'+RUM'N'*;%]&I9!*
MUU)EVVACU-9>MZI-+:&UBF?RE/)SUJ5*26A;A3E+5;D5%,AR84SUQ3ZZ5L<+
M5G8****!!1110 4444 %%%% !4D,\MO*LL3E'7H0:CHH&>E>%_&2W>VSOV"R
M]%<_Q5VO49KP)&9'#*2&!R"*]5\'^(!JEB+>9O\ 2(ACGN*XZU*WO1/3PF)<
MO<GN=11117,=X4444 %%%% !7!G_ )'+_MI_2N\K@S_R.7_;3^E '9W_ !83
M_P"X:\^TW3'U26;%PL>P_P 1ZUZ#?_\ (/G_ -PUY[I>EW6HRS"WDV;3SS0!
MH_\ "*2?\_L7Y_\ UZ/^$4D_Y_8OS_\ KT[_ (1;5/\ GX_\>-'_  BVJ?\
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MK31//%N^4_A4*W%R5=7?<2<C% $X2-,''([FD:<< '.?3I48BD<@G@8ZFGK
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M#RKQ'H<VDWSOLS YR".@KE+K1+>Z<R(WEN>N.E>ZW44=]$8I8@ZL.A%<S<^
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MY]Y/THLPYD6J*J_:I/\ GWD_2C[5)_S[R?I19AS(M455^U2?\^\GZ4?:I/\
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MMLH=NWK17^%#PGQLV_W\7'4#O3EN5X# J33EG1L<XSV-/*H_4 ^XKE/0'I-
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M/N&LNPSM"\TJJ3@[E8=N%56/11;N0-Q"\]^:D$,0ZC?]:C,Y)&!W[TW;+)G
M.,]ZX#VB=IE4'!''85$9R20HQQUI_P!G'.]LY["GYC3H ,#J: (525V5N?J:
MM0N\2_-)D^PJ'SUW 9ZU:MVA?ELFD!=M)_.5L]0:L5'$(PO[L#%24 %%%% !
M1110 5G:S_QY?\"%:-9VL_\ 'E_P*JCN3/X61:'_ *J3ZUK5D:'_ *J3ZUKT
M3W%3^%!1114EA1110 4444 %%%% %:U^]-_OFK-5K7[TW^^:R_$>LRZ:;.VM
MU'GWDOE(S=%X)S^E-[BCL;M%<O%JQL-0:WNM1>:4(S>6R8SCTXH@\8I+IGV]
M[.2.)W*1 D9<YQZTAG445S$WB\6AGCN[*2*:)/,V9!ROKUJ7_A+[+SWCVG:L
M7F!^Q/I]: .BHKCK?Q;?7?B"WLDT\K!-!YNYC\PZ>_O571?%MW':2RW]O(\(
MN?*\[C R<#^= '=T5FZMK$6E6\<A1I'E8)&B]6)K"U/Q7<1V5_"EH\-]!$'"
MDCH>,]: .OHK#\.3W#>'8;J[+M(\8<[B.XS4=CXHCN]9&FO 4D9=RG((/7W]
MJ .@HKFM4\0WMEXIL]+ALQ)#/&7+YYXQ[^]/D\5P1Z9=7K0OMMYQ"R^I) _K
M0!T5%<K<^,A%+<+%82RK;QK)(P(X! /K[T^W\90O+$+BUD@CFB:6-FQR "3T
M^E '3T5S*^+E!MI)K.2.VN7V1RDC!//O[5;T77VUJ6?R[21(8I#&9&(Y(_&@
M#;HK$DU]FU2:RM+1YS!CS6!&%SSZ^]4+CQK;PW,R+;N\<+[)'&.#WH ZJBO/
M+WQ%?B;5S%.P2)X_*&.@.W_&M[Q-J-S9:#;3P2%9&EC4GV)YH Z6BN*'BQ=/
M6]ED$]P8Y$39QU(7I^=:#>+X;870OK=[>2W0/M)'(/\ ^J@#I:*P-*\3Q:C?
M+:M \;NGF(3R"*WZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/PLQG\:-^BBBLS8*YGQBQ%I",\%JZ:N8\8_\>L'^]0!QM%%% !1110 4444
M%%%% !1110 4444 36O_ !]1\X^85VGV=UYC?\ZXJVXN8_\ >%=LMR!]]2*
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M QVJOIGA"+3BLDA$DHY (X%=4)9'5%' QC %<U6JFN6)VX;#.,N>98'EQ\
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M9&<9YH PQX8MA]K^=O\ 28EC;V  ']*1_"MG*UIO9B+:)H@/4,,&MXD#J:*
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M7D<[X-T9]/CD-U:&.X4X#G^(5UM%%8RDY.[.JG!0CRH****DL**** "BBB@
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ME8?PCA:5EW&I.]K&G1114EA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7!G_D<O\ MI_2N\K@S_R.7_;3^E ':7W_ !XS_P"X:YCP9_K[
MOZ_UKI[[_CQG_P!PUS'@S_7W?U_K0!U]%%% !1110 4444 %%%% !2'H:6D/
M0T <'IG_ "-__;0UU>N_\@:X_P!TURNF?\C<?^NAKJM=_P"0-<?[IH YSPM_
MR#;[Z?TJ/P9_R$)?]VG>&)$33KX,ZJ2.,GVIO@S_ )"$O^[0!VDMS#"Z+)(J
MLYPH)ZU+7%^+)&75K7#$8P?UKK8+B)H4_>H3C^\* )Z*0.IZ,#^-+0 4444
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MG))_K4^G>&SIUS+<FZ,SM#Y0&P+@#/\ C6_10!Q%CX*FGL'BO[G;F61E14Z
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M )4?\)CI_P#=?\J ,G^RO$7_ #V?_OLT?V5XB_Y[/_WV:UO^$QT_^Z_Y4?\
M"8Z?_=?\J *.B:#?VVK+<W(&!R3FM[7?^0-<?[IK/_X3'3_[K_E534_%%E=Z
M?+!&&W.N!F@#G].TFZO[:::!PJQ_>!.,UJ^#1C491Z+5CPG_ ,@F^^O]*S?#
MVHV^G7\KW#%5(P.* .DUSP^VJSI*LVPJ,8Q60WA/4D_U=U_X^16^GB/37Z3X
M^HJPFL6#]+E/SH Y0Z'KL7W)F/T<TGV?Q)!WD/XDUV2WMJ_2XB_[[%2":)ND
MB'Z,* .)^W^)(?O1N1[I2_\ "2:S%_K(?S6NWRA[J:-B'^%3^% '&+XPO5^_
M;*:F3QJ?X[3'T-=2UK _WHD/X5"^EV+_ 'K9/RH Q$\:6I^_"X^@JPGB[3FZ
MEU^HJX^@:8_6U2H'\+:8W2(K]* .6UR_@U#6();=MR_*/UKJ];_Y%V3_ *YB
MH!X2L$E61#("IR.:M>(!MT*=1V7% &9X+_X\YO\ >KJ*Y?P7_P ><W^]744
M%%%% !1110!7O?\ CSE_W36/HO\ Q]M]*V;W_CSE_P!TUC:-_P ?;?2M(_"S
M&?QHZ"BBBLS8**** "BBB@ HHHH **** "BBB@ HHHH **** "F-$K=0*?10
M!6-N1GRVQ4,-K<%6$\F>>,>E7Z* (4MHTZ#/UJ4 #H*6B@ HHHH **** "BB
MB@ HHHH **** $Q3&A1OX14E% %62WD$;"%L-CC-,BM96C47#Y8=<5=HH B2
M"-.BBI,8I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!CQI(N'4$'U%"1I&H5%  [ 4^B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH CDACE&'16'N*>%51@  4M% !1110 4444 %%%% !1110 4444
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M^_+_ -^V_P */^$_T3^_+_W[;_"CE?87-'N=317*_P#"?Z)_?E_[]M_A2_\
M"?Z)_?E_[]M_A1RL.:/<ZFHA<PM/Y(<&3&<>U<Q+X^T5HG >7)!Q^[;_  K$
MTOQ?IL-^LLK2[1$%)\L]?RIJ+!R5KW/1ZC\^/S_)W#S,9V^U<K+\0]'1E"^<
MP/4^6>/TK-7QYIIUA;DI,$*;3\AX_2I:?8N+B^IV&GW,D]Q=*YR(WPOY"M"N
M&T[QMI$%Q=,[2@2297]VWH/:KH^(.C^<4)FV@<-Y9Y_2A1E;5!*4;Z,V4_Y&
M&3_KW'_H51ZS(D,]G)(VU5D!)/:L(>-]%74VN-\N#%M_U;>OTK'\3^,;*_@:
M.V,I&WC]V>OY4G"23T*A4@YJ[.PM[N&ZUM)8FRABP#^)I!<N?%C0L?W:0Y'Z
M5YYH_B2VMHK#SC,&C'S_ "'U/M6[+XSTM-?-V@E9&CV$^6?;VHIJ3U:'7=-.
MR=ST".5)D#HV5/>L>>Z1;B]CX.Y <^E8]KX[T>&QVEI=P!X\MO\ "N1_X2JV
M:UOL"8M,6V_(>,FM.1V9ASKFB:=A?;3>0EBP>X '/ P0:WDN,:!=1C(*L3G\
M:\OT[65@22&6"8[G+;]IK?NO%=NVGM:P"0AX\,=AZUA"G*SN=U:K#F2BS=FU
M6:VTQ((6QNE7)]B172:X?^)1;,?]DG\J\PDU^#[$B"*4NA4_</.#6]JOCBRU
M+1%AACF25-H(*'T^E;RB_:-(XZ<XJBF^C_R,CQ1KUQ=ZA'''(#% 28^.AJW+
MXE:2/38P")Q\K#M]:XUI]TJY27&3DE#4[7H6\AD2.3Y"#G8?2LO9R:9U>WA&
M44GIJ;FO*9/$)'K$/ZTGB.XVP6T43 X@VN/3FLN756N-4-Q,LA^3&0AJM<W?
MGRRY24@@ $H:TG3;A\S"C64:J=]+(RY?^/QO]^NATV/S-(N!G&)\_P#CM8DH
M4G>(I=V_).P]*VH;V".V4*DNPG&=AY-8X?#OG;D=F-QL?8I4]7MZ6*#J4BE1
M"?WI 8DYIRZ4T<"LS#.<TRXG4O\ )%+C</X#6F;R)H5+1R[>F=AK6&&BV[HY
MJN/J1C'E>^Y-9+LME7TJQ44(D,2M':SE'/RGRSS^E3F&[ R;*XX_Z9G_  KM
MBXQBE<\BHI3FY6W.\\ J1IUP2.KC'ZUU]<;X#NU>QDA,<BMN_B0@5V5<<U:3
M.^FVXIL0]#5>Q_X]_P :L'H:KV/_ ![_ (TNA74LT444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_'G+_NFL;1O^/MOI6D?A9C/XT=!11169L%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""\_X])?]
MTUC:-_Q^-]*V;S_CTE_W36+HW_'X?I6D?A9C/XT=#11169L%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-OZ5P'B[_D.RUW\G_(;B_P"N;?TK@/%W_(=EK>A\1S8KX#!HHHKK. ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!!>?\ 'I)_NFL71_\ C\/TK:N_^/23_=-8NC_\?I^E:1^%
MF,_C1T-%%%9FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "-]TU7JPWW35>FB631MD8I]5U.#FK':AC04444AA1
M110 4444 %%%% !1110 4444 %4-7_X\6^M7ZHZM_P >+?6G'<F?PLJ:%TDK
M9K&T+_EI6S3G\1-+X0HHHJ30**** "BBB@ HHHH K6OWIO\ ?-6:K6OWIO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@""[_X]9/]TUBZ/_Q^GZ5MW?\ QZR?[IK$T?\ X_3]*TC\
M+,9_&CH:***S-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-W_ ,>L
MG^Z:Q-'_ ./X_2MN[_X]9/\ =-8FC_\ '\?I6D?A9C/XT=#11169L%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI'_'\?I6W=?\>LG^Z:P](_X_C]*TC\+,9_&CHJ***S-@HHHH **** "BBB@
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M.W12,\_7K5NB@"DND6"EB+5/FZTZYTRSO-GVBW238,+GM5NB@"J-.LU4J+=
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M'%7-#TR2[\:0WNAV=Q:Z='@LTF1D#K25)6NRGB'>T4>Q7FH6EA'ONKB.)?\
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M:Y31;SQEXB@&I6FHVZJ7_P!3Z#\J.2[?2P*IRI7=VSTC4]7L='MQ/?3B*,G
M)&>:L6MU#>VT=Q V^*095L=17B_Q'GUV74;73[QXS&X5HU4?Q8Y_6NFL=3UO
MP=X9EGUIXF14"6T:C'/^<4>S]SFN'MOWG+;0](H)P,GM7C\6M>.IK!]>4H+0
M9;RR/X?RK:\(>)]4U;0M5U'4)%,<:'RP%Q@X-$J;2;[#C7C)I6W+^@^,KO6?
M%EWIJP1BV@S\XSGCBNWKP+PE)K\][J,FB1KYDC,7F8<*,YKL_ /BO5+S5;O2
MM6</)""0V.F.M5.GIIT1G2KZ^]U9I7_C2ZB\;PZ%;0QO&3AV.<CC-6KWQ?<P
M>+8M&BT^1XV(#2[3@9KCO"P_M3XE:C?MRMOE@?IQ6OX<\17^K>.+^-S&;2WW
M 8C&>.G-'*DEZ78>T;;UZV1Z0.E5[VY%G937+8Q&A8YKR\>)O$/BC7[JRTN[
MAM(H"0H?JU;6MW&KZ;\/KT:Q*CW+ H&3N#FLW!I&L:J;TZ%[P1XKO/$QO&GA
MCCCA?:A7/-=A7@OAR?Q-;^'+B;246&U1M\DK#EOI7?>#?&$UWX3NM1U5@3:G
MEP,9'/\ A6E2G:[70RHUKI*74[RBO)4\0^)_$J75]974%E90YV[CRV/PK5\&
M>-KNZT?4)M6*L+/_ ):*,!NM0Z;2N:*O%M+N>BUQ.H>,[F'QQ!H-M!&\;8WN
M<Y&17+V^O^,O$TEQ?:5LBM(2=H(ZX_"JO@$W6M>/IKZ^ \Z%2']F! JX4[.\
MC.=>ZM'J]SVCM1116)U!1110 4444 %%%% $=Q_J'^E8^F_\?E;$_P#J'^E8
M^F_\?E7'9F4_B1N4445!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)7$<3N
M>@&: .:/C6U/BHZ$D#M*#@N#P*W-5U&+2=-FO9@2D2[B!7E?@53JOQ%U'4&Y
M6/)!^N175?%&]^S>$I(@<-,P3\.:TE&W*NK,85&U*3V1M>&?$<7B6P:[AA>-
M0Q7#=ZW*\QL[Z;PM\*X;JW(2XDP5)'KBL@>)O&>I>'VU"#9';P#+RE<%_IQ3
ME3U=MD3&M:*YMV>R,P5"QZ 9KBO#/C&[U[Q)>V/D1K;09 <9SP<5!X;\476I
M> [N^O2#-$CKO QGCBN \(/XAF:_?1(U5G8M),PZ=\=*<:=G)/H*=:ZBX]3W
MRN/E\8W0\7KHT6G2-%NPTVTX'&:Q_A_XMU'4+F\L-58/);C.['US_*D\)>)+
MW5?$NJR7+1?9+8,01& >#ZTE"SU[7*=7FBK:7=CTFBO)I/%'B?Q5K%Q#X?*Q
MVL)X8CK^-&@^+?$E[XMM])O'11%D3 *.>#25)L'B(IGK-%>6:EXIUO6O%<VC
M:5<Q6B1$KN?J2*Z.SU#5O#F@WEUXAGBE,1_=%/XNE3R-1NRU53E9'845Y#_;
MWBO6M.N-9AO(+.TCR41NI _"MSPUXZGF\*7>H:F 7MCM# 8#GC'\Z;IM*_8E
M5XMI=ST*N)A\9W5SXZ?0X8(S!&2&?G/2N5MM<\;ZW!-K%D42TC)*H1U'Y4?"
M])M2\3ZAJ=R/WH')]^E7&G:[ET1G*MS64>K/8****Q.H*?&V#BF44#+-%(IR
MM+4E!1110 4444 %%%% !5+5/^/!ZNU2U3_CP>G'<F?PLHZ']Z3Z5MUB:']^
M3Z5MU4]R:7PA1114&@4444 %%%% !1110!6M?O3?[YJS5:U^]-_OFK--[BCL
M%%%%(84444 9\G_(;B_ZYM_2J/B#P=HOB6+;J-FCN.D@&&%7'4#78FR>8SW^
ME:5 'FT'P6\.1W&^5IYH\_ZMWXKO-,TFPT>U6VL+:.")>R"KM% !5<V-J9_.
M,"&3^\15BB@"HVEV+.7-M&6)SG'>J=KX;T^VNKBX\H.\[[VW=C6O10!6DL+6
M9P\D",PX!Q4BVT*R^:L:B3&W=CG%2T4 5FL+1HV0VZ%6.XC'>@:?:+%Y8MTV
M9SC'>K-% %>\M([VSDM9.(W7:<5C6/A*TL[B*5I'E$*E45L8 -=#10! ;2W-
MOY!A3RO[N.*(;*V@5EBA10WWL#K4]% %7^S;+8B?9H]J-N48Z'UJ22TMY95E
M>)6D7HQ'(J:B@"#[%;"+RO)3R\YVXXS45]8+>B,%RNPY&*N44-7'&3B[HQ_[
M"38Z^<VUSN88')I?[# +D3OEP W YQT[5KT5/*C3VT_Z2,;^P(_^>K?=V]!T
M]*;%X=A@;=%(RG&. .E;=%'*@]M/^D8Q\/Q-$D9E8HARHP.*#H$95U,S$2?>
M&!S^E;-%'*@]M/\ I(Q4\/11HR+*0K=1@<U*NC;94D%P^Z,;5/' ]*U:*.5!
M[:?](0#  SFEHHJC(**** "BBB@ HHHH **** "BBB@!#T-5['_CW_&K!Z&J
M]C_Q[_C3Z"ZEFBBBD,**** "HI>HJ6HI>HH0F1T4451)B>+EN7\,7L=I&TDS
MQE55>O2L'X:Z#-I>B2M>P;)II-Q##D5W-%4I637<B4%*2D^A3U.T-YI=Q:IA
M3)&5%>/^'X_%/AZ:]TVST\EIF.)&' ]\U[91@9SBB,N6_F*I3Y[.]K'E?P^\
M.:G:>)[R_P!3B8. 0';N2:HZY8:YIGQ!?5;>Q:Y4M\AQD<\5[%1@'J*KVKYD
MR/8+EY;];GF?CW0M6UK3M.U**#=<0KF2(>_-&G>)M?D6"UA\/!) 0K2,F!]:
M],I  .@ H4]+-#='7F3U/./B-INJ:O\ V9;6]LSCAI=O0&KWC;3KS_A"(--L
M(&D?Y5(7L 17=45/-HEYW*]FKN5]U8\_;P]>Q?# Z=#&1<M'ED[GG-4OAT=:
MM[9M(N-/,-L Q,K#!R1_]:O3:, =!5>TO>_4GV*7+9['C%G::UX.\17L@THW
MD,[$@A<]3FN]\-:EJ^K&<WNG+96Y7"#&"374D ]0#2TG.ZLT.-+E=T]#Q6RL
M_$?A3Q/?-9Z>9_M#$*V,CDYJYX?\.ZY-X_74-6A8X^=G[ ^E>O8&<XHJE5?8
MCZNN^E[A7F5QHNH:C\4H[R6W<6D."'/3@UZ;141ERNYK."FK,\D^)/AG4=1\
M06T]A;NZNFUF7L<UO3^'IM$^'$UA9PF2ZECP^WJ21S7>T4^=\O*3[%<[GU//
MO#'A>Y3P#<V,R&*XN06P?7_(KF=!N_$_A&VN-+BTEI2[?*X&0#7L])@9S@4_
M:-MM]2?8)))/8\\\%>$;Z"\N=:U; O)P=J_W<BN7M+/Q)X=\67TMIIYE>=F"
MN1Q@G.<U[91@9SCFCVCO?Y Z"Y;)^9Y#X8\.:T/&\NH:G"S,JLV\]"V#@5<U
MO7=<OX+K3+KP_P":[,523;QC/!KU*DP,YP,T.I>UT-4;)V>YY=IG@74(_ =Y
M9R86ZG/F"//3'.*H>'M5UWP_8#36\/F:1&.U]E>PTF!G.!FCVK;=^HO8))<K
MM8SM!FO;C2HY=0@6&=N3&O85I445#=V;15E8****0PHHHH **** "BBB@ HH
MHH XSXFWOV7P?.@.#*0G\ZYCP3K7A?3?#L45^\9N6.YMR$XKTW4M)LM7@$%[
M")8P<@&LG_A!/#O_ $#TK2$DHM,PJ4Y.:DNA'J>J^'9-'BMKN1$L[M<)Q@5Y
MA$@T3QK:P>';YYX)'7<J\@ GD?E7K][X9TJ_LH[2>U4PQ#" =J9I7A71]&D\
MRSM$63^\>33A.,7<52E*=EH>9^,;V,_$>Q-\VR"':6)''05>^*5\E_HNEW-L
MQ>T:0G<!P>E=_JOA;2=:G6:]M5>1?XNE37&@:;<Z8NG2VR&V085,=*2FDH^0
M.E)N6NYYKXA\:V \%Q:9II+RO$JN0IPO'-%L?['^$#R='N3_ .A 5WL/@K08
M+5K=+%-C]<]?SJ]<:#IUSIT>GRVZFVCQM3L,4W.-FEU8HTIW3?1'F/@GQ3H^
M@^$[A)G*WAR2NTY8]J;X*@FCM=9\2SH45XV,>1UX->@3^!] N)TE>Q0,N, <
M"M9M+LVT\V/D*+8KM**,#%.51.[6["%&2LF]$>7?#W_1]#UW5G_BW 'ZU)\,
MY(;/3]4UJ].(RW+8^N:]'M]!TZUTZ2PAMU6WD^\@[T6^@:;:Z:^GQ6RBV?.Y
M/6DZB=_,(T6N7RNSR'QA;:' ZZMH.H%;J1\F-#WJ]XQU.\F\ Z5;W9;[3<8)
MSU(&/\:[ZV\">'[6Y$Z62E@<@,<@?A6EJ&@:;J;0F[ME?R?N#L*?/&R0>QE=
MO:Z..UD)H7PM6)0%9X@/J2:YO[%-:?!YFC4[II=SX'\/->LW^D66IVBVMU"'
MA7HM/33;-+ 6(@3[,%V[",C%3SZ/S97L7==DK'CWAS2_"D^B12W^IS1RX_>1
M!\#/TQ71>);/3K;X;S'0XMMN[<D#EASS71?\*_\ #OG^;]B&<YQGBMXZ=:&P
M^P^0GV;;M\O'&*<ZB>Q-.BXJSL>5Z!XQTW1? 7V:$EKYE8%%4YR1UJ]\(;4R
M0ZAJ+CYI).OUSFNOM?!.@V;2-'8IEP0=W-:NFZ79Z3;?9[*$11DYP/6G*I'5
MKJ$*,TXWV1<HHHK$Z0HHHH **** "BBB@".?_4/]*Q]-_P"/RMB?_4/]*QM-
M_P"/RKCLS*?Q(W:***@U"BBB@ HHIDKB.&1ST52: ,*_\9Z)IM\;.YNPLPZ@
M G%;D,T=Q"DT3!D<94CO7SKJ5L^L7FM:GR1!(V#^)KUSPWKL-I\/8+Z=P!#%
MCGN>U:RII0OU.>%9RJ.+V-C5_%>D:),L-[=!)",[0,FM#3]0M]3LDN[5]\+C
M*G%?/>MBXU6*36[LMNN9MD*G^[S_ (5Z3<:_)X(\$Z2L,"RS2 +M8X]*;I6B
MNXHUVYOL>BU%=7"6MK+._P!V-2Q_"N?U3Q++IG@\:Q)"OG&,,(\\9-8MYXGG
MU'X:W&IW$2PO,I154^H_^O63B[/R-O:1T\]3=\,^+;?Q,+IH8'B6!MI9CP:W
M8KF"<D0SQR%>H1P<?E7C^AWU[X=^'KWEK:><URYWMG&T<C-0_#?4=:M[LF"P
M:X@N9 ))F8_+Z_SK9TM7;H<\<0TH\W4])UCQEIVBZK!I\X=IINFT=*Z%3N4$
M=Z\Z?7+?4_B&NGMID$GDGF=NJ\9]*L>(?'\UKJW]DZ)9_:[I>&] :SY&TK;L
MU]JDY-O1'?$X!)[5S&F^,[;4_$D^CPV[[H<YDSQQ5'0_$VKWUKJ"ZOIQM'MX
MBP;UKFOAH\?VW6-;N6 C!)WGL.<TU"U^;HA2JWY>7JSUJBO,YOB'K.I74RZ!
MI1N((3\TAK8\&>.#XBFFL[NW$%W%U4'KZTO9RM<I5H-V.THKS.?XGW":S>6$
M%@)FC;;"%/+'WJ;PQ\0;_4O$7]DZG9+!(W3'44*G)JX.O!.QTVO^+M/\/7$$
M%T':28@*%%;L,HFACE7.UU##/O7GVN:Y;W'CNUTAM-AN"I&9'ZK^E7/$_CO^
MR+Y-*TJU%U>D8V#HOM0HMI6W8>T2E*[T1W%%</H'BS69[FXBUO3#:I%&9-_L
M,_X5F1^//$&L3SOHFDK-;0M@L3R?TH]F[V#VT;7/1+R\AL+62YG<+&@R37&R
M_$$^?^ZL<P@_Q2 ,1].M/\1R:AJ7@VWN9K5HIA(DDT([ ,"?TKB/LR27B:I-
M-$T!E!,0^\  0*J$%=W(JU&K<IZ_I.JV^L6"7=N3M;J#U!]*LW%Q':V[SS-M
MC098^E<]X)LY;;2))98S']HE:14/\(.*9\0;[[%X0O#G#2+L%1)6=D:PD^2[
M-;1]?L-=B>2PE,BH<$X(J#Q%XFLO#=O'->!CYC;551S7/_"JR^S>$UF(PTSD
M_AQ4/CK7H;;6-/TQ]/ANVE8']X?N_I5."]IRHSC5?LN=FSJ_C6RTK0;?56B=
MX[@ HG0\UNZ;>C4=.ANU0H)5W!3U%>4_%6ZCCDTRP50L:#<R+V'%2+\1=6TE
M+)9=*$5@P"(S=6%-4^:-UW)=;EG:71'KE%<AXI\:#0]!M=0MXEE:XP55CCBL
MS1O'>J:QJ<.W3?+T\J2\Q]A4J$GJ:NM!.QZ%17F5]\1]2NM3EMM!TW[5'"<,
M_K5GP_\ $2\UOQ!#IOV!8Q@^:2>5-"IR:N)UX)V/1*KWU[%I]E+=3G$<:Y-<
M'K_Q(ETCQ))ID5FLRHO!!Y+>E-G\8ZC_ ,(G>7VK:8B_/L2)^C X]O>ER2M<
M;K0ORG5^'/$UGXEMY9K1758VVG<.M;=<3I&OV&C>"EU6:TCM5DY$4?\ $>U8
M<_Q!\2)9_P!J+HZKIV>&8]1^54X>\TB(UDHIRZGJ5%<;/X_MH?"46L^42\IV
MK'_M?Y%4-+\5>++RXMII=%7[%.P^8'H#WZ4O9R*=:&GF>@T4#H,T5!J%%%%
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M16)TA1110 ^-L'%356J=#E:3*0ZBBBD,**** "BBB@ JGJG_ !X/5RJ>J?\
M'A)3CN3/X64-#^_)]*VZQ-#^_)]*VZJ?Q$TOA"BBBH- HHHH **** "BBB@"
MM:_>F_WS5FJUK]Z;_?-6:;W%'8****0PHHHH @:V!O%N,\JI&*GHHH ****
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MB]L^M9^@7DEY<R,=$-A&%X=PN6_(UT51-ZFM.*MJ'08HHHJ#4**** "BBB@
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MS^'INXS_ %KI_ S6G_"&6Y4IM"'S?KCG-:^DZ!8Z/9-:V\>5?[Y;DM]:QIO
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MV<7V)=)N,UW'QKOLE7^\F/TKRWPOJD/@[Q/JFGZL?(2XE,D<C< Y/_UZ]8
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M7W(XKPO?6VF^)M>BO)EA9I XWG&1@5'X:O8+_P :Z]<6S[XF0;6'?[U==?\
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MCXYU>\M"&MT@*,Z]"<&NLN/"VC77F&6RC+2-N9N<DU;L-)L=,MC!:6Z11MU
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M>$;;<2=I(&?2G-*\FN@J,I)13ZHZ&\O;:PMVGNI5BB7JS&LN'QAH4Z%TU"+
M.#DU@^//W^JZ+92'%O+-\X['@U7^(6CZ?;:5;3PP)'*DJJI7CBIC%.U^I<YR
M3?+T.VFU2R@N(();A%EG&8U)^]3KK4;2RDBCN9EC:9MJ ]S7%:^<>)_#A/\
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M"\OH-;U'1KRY>Y%OAHW<Y./\FER:?B/VNNW6QVE%%%0:!1110 4444 %%%%
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MXK"TD>%3H\27\UQ%<(@62)I'Z_3->GP6L%L"(8E0'KM'6HVTVR>7S6MHR_\
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MGBC8[V'0<5U]%"E:WD#IIW\S@;N'4/#/BRXU."RDN[.Z4;Q%C*GCUI]I!?\
MB;Q1;ZG<V4EI9VH.Q9,;F/X?A7=T4U.UO(3I7;UT9R&C6%U#XYU2ZDA98)$
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MT^1D^U5OP/2)'6.-G8X51DFJ^GZC;:G;?:+6021DXR/6N&TO5+_6M)U33GU
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M]6.SHK-T$77]BVS7DC27#)N=F]ZTJEJSL:1=U<****0PHHHH **** "BBB@
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M2.M<[;^ - M[CS5M20#D(SDJ/PS7444TVMB91C+=&=I>B6&CPRPV4(C25MS
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M%8$-N4C([XIP@Y-$U*JBG8]2!R 1T-+7/6'B+SO$$VCS0>4\:!HVW??%2?\
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M5+44O44(3(STK@_ P,6L:_;-Q()L_H*[RN532KK3O&[7UO$6M;M,3$?PD?\
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M6Q][ZUGQ^$-#BN1<+81[P=P^48!H4U=?('3=K+NS5LYVN;*&9EVLZABOI4]
M  P.E%9O<V6BU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[A^E8-I_R
M$5_WC6\WW3]*P;7_ )"*_P"\:N.S,JFZ-^BBBH-0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M H.O!%3=6^933YO^W2_X/TNR@\*6:I;Q_O859\KG)(KF/AP@CUS7[5#B,2'
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M]/RKJO#VHZ]J%S(^I:>MI;X^0$_,3^5.3U<D13CHHROH='7E]A&FI_%R[-T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX]:=4&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%12]14M12]10A,CHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 0_=-8%O_R$%_WJWST-8%O_ ,A ?[QJX[,RJ;HZ
M"BBBH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)[UYUJ-MKGP]CCNK;4/M6F!PIADZ@5UC^$99] 33YM5N3,C;Q< D-G\ZR_\
MA7MS>RQC5=:N+JWC.1$1@-]>:(-1>^@5%*2ORZG:6%T+VPAN0,"10V*LTR&)
M((4BC&$08 I]9NU]#>-[:A1112&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %12]14M12]10A,CHHHJB0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#6!;_ /(0'^]6^>E8%O\
M\A ?[U7'J95-T=!1114&H4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3E&XTVIHUP,TAH?1
M112*"BBB@ HHHH **** "H;O_CTE_P!TU-4-W_QZ2_[IIK<3V,/1_P#C]/TK
MHJYW2/\ C^_"NBJJFYG1^$****@U"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gtqsgrqcdg4e000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )^ U\# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBHC<1
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M_OH4 2T5%]HA_P">T?\ WT*/M$/_ #VC_P"^A0!+147VB'_GM'_WT*/M$/\
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MT*/M$/\ SVC_ .^A0!+147VB'_GM'_WT*/M$/_/:/_OH4 2T5%]HA_Y[1_\
M?0H^TP_\]H_^^A0!+12 A@"""/:@\4 +147VB'_GK'_WT*/M$/\ SVC_ .^A
M0!+147VB'_GM'_WT*/M$/_/:/_OH4 2T5%]HA_Y[1_\ ?0H^T0_\]H_^^A0!
M+147VB'_ )[1_P#?0H^T0_\ /:/_ +Z% $M%1?:(?^>T?_?0H^T0_P#/:/\
M[Z% $M%1?:(?^>T?_?0H^T0_\]H_^^A0!+147VB'_GM'_P!]"C[1#_SVC_[Z
M% $M%1?:(?\ GM'_ -]"C[1#_P ]H_\ OH4 2T5%]HA_Y[1_]]"C[1#_ ,]H
M_P#OH4 2T5%]HA_Y[1_]]"C[1#_SVC_[Z% $M%1?:(?^>T?_ 'T*/M$/_/:/
M_OH4 2T5%]HA_P">T?\ WT*/M$/_ #VC_P"^A0!+147VB'_GM'_WT*/M$/\
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M1_[_ )KN#(@(4L 3T!-"R(Q(5@<=<&@#A_\ A6=K_P!!;4?^_P":/^%9VO\
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MYKNJ* .%_P"%9VO_ $%M1_[_ )H_X5G:_P#06U'_ +_FNZHH X7_ (5G:_\
M06U'_O\ FC_A6=K_ -!;4?\ O^:[JB@#A?\ A6=K_P!!;4?^_P":/^%9VO\
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M6U'_ +_FNYS2T <+_P *SM?^@MJ/_?\ -'_"L[7_ *"VH_\ ?\UW5(6"C)(
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M^+"[H;F;1[F/3)I B7)Z<]\8]ZGU;QIJ$.L74=K-:+;P1K($D^_(" <#GWH
M]%I,BN _X3#5M26273;6-$MX5EF6;[QR,X'3TJ.Y\<7\UQ:K:QQ6\<L>_?.#
MM<YP0#P!TH ]$HJO92O/9Q2RA0[*"P4Y&?K5B@ HHHH *RO$?_(N:C_U[O\
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M\O\ _O\ FC_A5.D?\_E__P!_S0!V_P!KMO\ GXB_[[%'VNV_Y^(O^^Q7$?\
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M0!V_VNV_Y^(O^^Q1]KMO^?B+_OL5Q'_"J=(_Y_+_ /[_ )H_X53I'_/Y?_\
M?\T =O\ :[;_ )^(O^^Q1]KMO^?B+_OL5Q'_  JG2/\ G\O_ /O^:/\ A5.D
M?\_E_P#]_P T =O]KMO^?B+_ +[%'VNV_P"?B+_OL5Q'_"J=(_Y_+_\ [_FC
M_A5.D?\ /Y?_ /?\T =O]KMO^?B+_OL4?:[;_GXB_P"^Q7$?\*ITC_G\O_\
MO^:/^%4Z1_S^7_\ W_- ';_:[;_GXB_[[%'VNV_Y^(O^^Q7$?\*ITC_G\O\
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MJW_Y[Q?]]BC[5;_\_$7_ 'V*XO\ X5;I/_/W??\ ?\T?\*MTG_G[OO\ O^:
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M@!DW^I?Z&N'^&'_(,U'_ *^W_G7<3?ZE_H:X?X8?\@S4?^OM_P"= '=T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4AZ4M(>E '!>+_P#D>?#G^\W\C7?5P/B__D>?#G^\W\C7
M?4 <!XH_Y*+X=_X'_P"@FN_K@/%'_)1?#O\ P/\ ]!-=_0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5E>(_^1<U'_KW?_T$UJUE>(_^1<U'_KW?_P!!- &3\.O^1,L_JW_H
M1K4\4_\ (K:G_P!>[_R-9?PZ_P"1,L_JW_H1K4\4_P#(K:G_ ->[_P C0!E_
M#G_D2;'Z-_Z$:ZNN4^'/_(DV/T;_ -"-=70 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AKSY
MO^2R1_\ 7G_5J]!->?-_R62/_KS_ *M0!Z%1110 R;_4O]#7#_##_D&:C_U]
MO_.NXF_U+_0UP_PP_P"09J/_ %]O_.@#NZ*** "BBB@ HHHH **** "BBHI[
MF*VA:69U1%&22: )::TB(,NZJ/4G%<!K7Q(B1V@T:$W,HX+G[HKC[N_UK5V+
MWU^ZJ?\ EG$<#]*ZJ>%G+5Z'#5Q].&BU9ZU>^)]'L0?.OH@1V#9_E6'/\2M#
MB.(WEE_W4/\ A7G":;;*<E-[>K<U8$,:_=C4?05T+!P6[.*695'\*2.V/Q1T
MO=Q:W!'KM-2P_$W19&Q(LT?NR'_"N&PO]T4C1QL,%%/U%7]4I$+,*QZQ8^*=
M&U# @O8R3V8X/ZUKJZ.,JP8'N#7@\FG6[G*KL;^\G!J]IVNZYH#CR)VNK<'F
M.0Y./K6,\%_(SII9DGI41[917-^'/&.GZZ@C#>3=#[T+\&ND[5Q2BXNS/3A.
M,US184445)04444 %%%% !1110 4444 %(>E+2'I0!P7B_\ Y'GPY_O-_(UW
MU<#XO_Y'GPY_O-_(UWU ' >*/^2B^'?^!_\ H)KOZX#Q1_R47P[_ ,#_ /03
M7?T %%%% !1110 4444 %%%(3@9H HZKJ*:;:-,W+=%7U-<9-?WUTY>6X=<]
M%7H*N:_>B]U+RXVS'#Q_P*LVN6I-MV1ZF'HJ,;M:LGCOKZ$YCNW^AK0A\37L
M7^MA24#NO!K(HJ%.2V9M*E"6Z.@/BOY?ELWW>["L^?7=2N&RKK"OHO6J&:,T
MW4D^I,:%*.R-O3/$<B2"&^.58X60?UKJ4D210R,&4]"#7G1 (P1D5+!=7=JN
M+>Y=5_NGD5<*K6C,:N$C)WAH>A;A1D5P7]J:EU^U_P#CHJY:>)+RW<"Y598_
M[RC!%:*M$P>#J)::G945!:7<-[ )H6#*:GK4Y6FG9A1110(**** "BBB@ HH
MHH **** "LKQ'_R+FH_]>[_^@FM6LKQ'_P BYJ/_ %[O_P"@F@#)^'7_ ")E
MG]6_]"-:GBG_ )%;4_\ KW?^1K+^'7_(F6?U;_T(UJ>*?^16U/\ Z]W_ )&@
M#+^'/_(DV/T;_P!"-=77*?#G_D2;'Z-_Z$:ZN@ HHHH **** "BBB@ HHHH
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M[94Y5AZUT/AW5S?6Y@N"!<1<,/7WKT\)B'+W)[G#B:%O?B;M%%%=YQ!1110
M4444 %%%% !1110 AKSYO^2R1_\ 7G_5J]!->?-_R62/_KS_ *M0!Z%1110
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M.33Z0# Q2TQ%W1IQ;:Q"6.%<%37=+TXKS9AD<'# Y!]#74Z1XACE5+>Z_=S
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M_7G_ %:O037GS?\ )9(_^O/^K4 >A4444 ,F_P!2_P!#7#_##_D&:C_U]O\
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MW_)9(_\ KS_JU 'H5%%% #)O]2_T-</\,/\ D&:C_P!?;_SKN)O]2_T-</\
M##_D&:C_ -?;_P Z .[HHHH **** "BBB@ HHHH XCQQX5;4XAJ-BNV]A&<#
M^,>E>?VUT908Y%*3)PZ'J#7NQ48KB?%G@=-38W^FD0WR\^S_ %KMPV)Y?<GL
M>;C,'S^_#<X>BJS3S6EP;74(F@F4X^88!^E6001D'(KT-.AXS33LP_"DVK_=
M'Y4M%,04444@"BBB@ IKNL:%V.%'4U%<74=NN7//91U-:_A_PC>^(IEN;]6@
ML0<B,\%ZF<XP5Y&E.E*I+EBB/POX?F\3:FMS.I73H3D?[9KV"*-88UC0 *HP
M *BL[*"QMT@MXPD:#  JQ7E5JSJRNSZ##X=48V6X4445B= 4444 %%%% !11
M10 4AZ4M(>E '!>+_P#D>?#G^\W\C7?5P/B__D>?#G^\W\C7?4 <!XH_Y*+X
M=_X'_P"@FN_K@/%'_)1?#O\ P/\ ]!-=_0 4444 %%%% !44\(F@>,]&!%2T
M4 >?76G7.G2%)(F:,'Y74<8JLKJW0BO2"BL,$9^M9U]H=E>(<Q!'[.O45SRH
M]CT(8U;31Q51SS"! Q!.3CBKE]I]QIDFV;+QD_+(!_.H.&%8--:,[8M25UJA
MH.5!]12T44#(UES*R;3QWI+B!;A0K9P#VJ6B@!%&U0HZ#I3$F5Y&0=5ZU)32
M53+$#G]: '4$XZD5HV6@WE\HDD801'IQ\QK:MO"UA"0TN^9AW<YK2-.3,)XB
MG!VN4?"UHSW$MXRD+C:A-=4.E-CB2) D:A5'0"GUTPCRJQYE6HZDN8***#P*
MHS$:N%ERMS,'SNWG-;6HZM-).T-LVQ%.&<=2?:L.>T>1VE6=_-/4L>M<6.PT
ML13Y8O4VH5%3E=AVJ*168JT:EF0YX[5JZ5I45ZO[Z=MZ_>1>*Z.&PMK:$QQ1
M!5(P?>N'"Y9.%13F]NQT5L5&47%+<Y4'< 1T-+4U]:-83D'_ %+'Y6]*ARN,
MY&/K7TB::/$E%Q=F/AYNH5'4N*Z]>E<WHUL9[L3D?NX_ND]S72UC-W9TTE:(
M5E>(_P#D7-1_Z]W_ /036K65XC_Y%S4?^O=__034&AD_#K_D3+/ZM_Z$:U/%
M/_(K:G_U[O\ R-9?PZ_Y$RS^K?\ H1K4\4_\BMJ?_7N_\C0!E_#G_D2;'Z-_
MZ$:ZNN4^'/\ R)-C]&_]"-=70 4444 %%%% !1110 5@^(-%-[&+FWXN8AD8
M_BK>HJ*E-5(\LBX3<)<R.!M;OS@8Y!LF7AU/K5JM76_#ZWA^TVI\NZ'<=&KG
MENG@E^SWJ&*4<9/0UXM:C*D[/8]2G5C45UN7*#S0"",@Y!HK(T$P/04O2BB@
M HHHH ***BGN8[==TC >@[F@"1V"*68X [U!864FNW@)!%E&>3_>JI+;7^H1
M>:8FCM<^G)K1M=4GL[5;>$*JJ,#CFL)XRC0J)5D^X.$I1_=[G9Q(L4:QH,*H
MP!3ZXQ-<O4?)<,/0UO:;K$=[A&^63T]:]/"9QAL1+D3L_,\ZK@ZM-<SU-6BB
MBO6.4**** "BBB@ HHHH 0UY\W_)9(_^O/\ JU>@FO/F_P"2R1_]>?\ 5J /
M0J*** &3?ZE_H:X?X8?\@S4?^OM_YUW$W^I?Z&N'^&'_ "#-1_Z^W_G0!W=%
M%% !1110 4444 %%%% !37=47<S  =R:9//';P232, B+DDUX7XO\=WNKW<D
M%G,T5FIP IY:MJ-&55V1S8G$PH1N]SJOB;KFEBT6SCABGNG_ (QU3\:YGP]X
M9UN^T07UHX=<X$;]37$%V=PSL6.><U]%^"WAD\*V+0H%78 1[XKMJ7P]-*)Y
ME&V,K-STT/*)Y+W3Y/+U"QFA([XR*$U"VD'RRCZ&O<IK:&X7;+$KKZ,*Q+KP
M5H%V29-/B!/=1BHCC5]I&L\L?V&>7":,C.]?SI#/$O611^->@O\ #/P\Q^6&
M5?HX_P *<GPU\/(<FWD?_>8?X5?URF9?V=5\CS5]2MD. ^\^BC-7++2M<UE@
M+.R:*)O^6LG%>J67A31=/P;>PB!]2.:V$0(H50 !T K.>-_E1O3RWK-G%:!\
M/K/3Y%NK]C=W77YONC\*[5$5%"JH '0 4ZBN.<Y3=Y,]&G2A35HH****@T"B
MBB@ HHHH **** "BBB@ I#TI:0]* ."\7_\ (\^'/]YOY&N^K@?%_P#R//AS
M_>;^1KOJ . \4?\ )1?#O_ __037?UP'BC_DHOAW_@?_ *":[^@ HHHH ***
M* "BBB@ HHIKL%4L3@#DF@!DT,<\9CD0,I'((KS[Q:;+PU&)4GR7/RP&JWBO
MXG?8KB2STE5>1#AI6Y&:\RU/6+W7K]9[^;<Q( ] *ZJ>"]IK/8X:N:^PO&B]
M?P/5=!MKO7].2\A5$1B1AB<UK?\ ",7^/]=']*U_"MC%8>'K2&$@KY8;([D\
MUM5Q3HP4G8]6GC*S@G+<\\N[*ZT]L7,1"GHZ\BHMRD9!%>B2Q)*A1U#*>H-9
MQ\/:86S]D3\!64J+OH=,,:K>^CC(Q)<2".WC,CGT' KI=*\.K$ZW%YAY1T3L
M*W+:T@M5VPQ*B^@%3U<*26K,JN*E)6CHA H   X%+116IR!1110 57O9/)LI
M7]%JQ5/5!G3)Q_LT <K$,1@D\GDT^FH<HI]J=0 L5R;*X6Y'W5/S@=Q5V;6[
MBXXMQY:?WCU-9\B[HV7U%1VQ)MU]N* ))D:Y4B:5WSUYQ2Z79V\=XL4@9XW/
MR[F/!I:L:?&9M2B4#A/F- 6.I2-(T"HH51V IU%% !65XC_Y%S4?^O=__036
MK65XC_Y%S4?^O=__ $$T 9/PZ_Y$RS^K?^A&M3Q3_P BMJ?_ %[O_(UE_#K_
M )$RS^K?^A&M3Q3_ ,BMJ?\ U[O_ "- &7\.?^1)L?HW_H1KJZY3X<_\B38_
M1O\ T(UU= !1110 4444 %%%% !1110 52O],M=0C*3Q!O0]Q5VBDXIJS&FT
M[HXZX\-7MF2UA/OC_P">;UGR75S:MMN[5XR/X@,BO0:9)$DHPZ!A[UQ3P,'K
M%V.J&+DOB5SA8[^VDZ2 >QJ;S8ST=?SKHYO#VF3G+VJ GN!50^$-+/1''T:N
M=X&HMK&ZQ=/S,<S1@9+K^=02ZA;1_P#+3<?1:WU\(Z6#S&[?5JNV^A:=;$&.
MU3([D4+ U'NT#Q=/I<Y.(:C?D+:VK(I_C>MO3O"\<,HN+US/,.QZ#\*Z)5"C
M &!2UUTL'"&KU9S5,5.2LM$,,:>7L"C;C&,5Q6J6QMKZ08PI.17<52OM.BOH
M\.,,.AKES7 /%T;0^);#PM?V,[O9G$4^*1H95=3@@UHSZ!=Q,=@#K[4^ST*X
MDD4S#:@/.:^0CE^+5114&F>N\11Y;W.HMW,D$;G^(9J6F1H(T5 . ,4^OT*"
M:BD]SY]VOH%%%%4(**** "BBB@!#7GS?\EDC_P"O/^K5Z":\^;_DLD?_ %Y_
MU:@#T*BBB@!DW^I?Z&N'^&'_ "#-1_Z^W_G7<3?ZE_H:X?X8?\@S4?\ K[?^
M= '=T444 %%%% !1110 4444 <?\1KY[+PG<>62&E^3(KP&OI'Q9HO\ ;N@W
M%FO$A&4/O7@=SX<U:UN3;R64V\''"DYKT\%**@UU/#S*G-U%*VAF(A=PBC)8
MX KZ.\'6+V'ABSAD!#[ 2#VR*\[\$_#VY>[CO]4C,<2'<L9')/O7L*@*H &
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MK:G_ ->[_P C67\.O^1,L_JW_H1K4\4_\BMJ?_7N_P#(T 9?PY_Y$FQ^C?\
MH1KJZY3X<_\ (DV/T;_T(UU= !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 E&*6B@ HHHH **** "BBB@ HHHH 0UY\W_)9(_P#K
MS_JU>@FO/F_Y+)'_ ->?]6H ]"HHHH 9-_J7^AKA_AA_R#-1_P"OM_YUW$W^
MI?Z&N'^&'_(,U'_K[?\ G0!W=%%% !1110 4444 %%%% !3##$S;FC0GU*T^
MB@!, # %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4AZ4M(>E '!>+_^1Y\.?[S?R-=]7 ^+_P#D>?#G^\W\C7?4 <!XH_Y*+X=_
MX'_Z":[^N \4?\E%\._\#_\ 037?T %<?XH\:3^&YG+:1<3VR $S(1C^==A7
M)?$C_D2K[Z#^8H =H/BZ;5X)+BXTN:SMUC\P2R$8(_ U)X4\9VGBF2[2W1HV
MMW*D-_$/6N:\2:L^G_"^R@MPS7-W$D,:KU.>#C\ZYOP[?R^&_%6FF?39["VN
M8O)D:5<!FZY_2@#T?Q1XVLO#-]9VLZ,[7+8.W^ >IK3U77[32=,6_GWM$PR
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MG_D2;'Z-_P"A&NKH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG#,"D /.>K4 :/A^)A;R2GH[9%;-,CC6*,(@PH& *?0 4444 %%%% !1110
M5E>(_P#D7-1_Z]W_ /036K65XC_Y%S4?^O=__030!D_#K_D3+/ZM_P"A&M3Q
M3_R*VI_]>[_R-9?PZ_Y$RS^K?^A&M3Q3_P BMJ?_ %[O_(T 9?PY_P"1)L?H
MW_H1KJZY3X<_\B38_1O_ $(UU= !1110 4444 %%%(3@$^U '-ZU=&>]^S@_
MNX^3]:HTZ5M]W<.>ID--H AN(]R;U^^O(-/B<21JWK3S5>UX,B]@W% $Q7D,
MIVL.C>E=%I&H?:XS'(?WJ=?<>M<_5C36*:K"5_B!!^F* .KHI!2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 AKSYO^2R1_\ 7G_5J]!->?-_
MR62/_KS_ *M0!Z%1110 R;_4O]#7#_##_D&:C_U]O_.NXF_U+_0UP_PP_P"0
M9J/_ %]O_.@#NZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@#@O%__ "//AS_>;^1K
MOJX'Q?\ \CSX<_WF_D:[Z@#@/%'_ "47P[_P/_T$UW]<!XH_Y*+X=_X'_P"@
MFN_H **** "BBB@ HHHH **** "BBB@""XM(;I-DR!A67+X>&[,$Y0>C#-;=
M% &"?#\A7#3H<]?D_P#KU6E\,!%+&\\M!UP*Z>N>UJ\,LWV1#A5Y<C^5 $$.
MH16-LT-G'A5_Y:L?O50^UW]U()VN-HP0 !V--N.+9@..*?#_ *E,>@H N6NH
MW=N ID#H.Q%(]K;ZS=ED8VMQW&<AA5>D^8,KQG#J<@T :4?ADQG(G#-ZE:D/
MA^4GBZ4#_<_^O6EIUV+RU63^(<,/0U<H RK;0K:(AY?WKCNW2M0 *,#@4M%
M!1110 4444 %%%% !1110 5E>(_^1<U'_KW?_P!!-:M97B/_ )%S4?\ KW?_
M -!- &3\.O\ D3+/ZM_Z$:U/%/\ R*VI_P#7N_\ (UE_#K_D3+/ZM_Z$:U/%
M/_(K:G_U[O\ R- &7\.?^1)L?HW_ *$:ZNN4^'/_ ")-C]&_]"-=70 4444
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M\,/^09J/_7V_\Z[B;_4O]#7#_##_ )!FH_\ 7V_\Z .[HHHH **** "BBB@
MHHK.O]<L--'^D38/HH)/Z4 :-%9%CXETG4'V07:;_P"ZW!_6M8$'I0%Q:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/2EI#TH X
M+Q?_ ,CSX<_WF_D:[ZN!\7_\CSX<_P!YOY&N^H X#Q1_R47P[_P/_P!!-=_7
M >*/^2B^'?\ @?\ Z":[^@ HHHH **** "BBB@ HHHH **** "BBB@!DK^7$
M[^@S7&B0RLTS?>D;=777@+6DJCJ5-<? /W*>P - #I%W1LOJ*CM6W0@'[RG!
MJ:JLA\BX# 95^& [>] %JB@'(R** -'0I"EW+%V<;A]:Z(5S&C@G5 1_"O-=
M/0 4444 %%%% !1110 4444 %%%% !65XC_Y%S4?^O=__036K65XC_Y%S4?^
MO=__ $$T 9/PZ_Y$RS^K?^A&M3Q3_P BMJ?_ %[O_(UE_#K_ )$RS^K?^A&M
M3Q3_ ,BMJ?\ U[O_ "- &7\.?^1)L?HW_H1KJZY3X<_\B38_1O\ T(UU= !1
M110 4444 %%%% #7174JP!!Z@UAWNBPQ))/'*T:@9*]16]574(S+83(O4KQ0
M!Q4-H-YFD=V9N@)Z"K/DQYSMHB_U:^N.?:GT 5VMV5C)%(P8]0>0:6.<[]DJ
M[7[>AJ>F2Q+*F#VZ&@!]:N@-^\N$]\UAV\C'=&_WT_45MZ&5C6XF?A1QF@#?
MJ&:Z@@'[V54^IKG[W6Y)V,=NPCC'\1/)JAM#G+-O8]R<T =&VN6*_P#+0GZ#
M-*FM6+G'F[?][BN=P!V'Y48![#\J .PCECE7=&X9?4&GUQL-Q+9R"6%B%!^9
M<\&MN77H$5?+1I&(SA>U FTMS7HK$C\01EL2P.@]>M:T%S#<QAXG#"FTT":>
MQ+1112&%%%% !1110 4444 (:\^;_DLD?_7G_5J]!->?-_R62/\ Z\_ZM0!Z
M%1110 R;_4O]#7#_  P_Y!FH_P#7V_\ .NXF_P!2_P!#7#_##_D&:C_U]O\
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MXR+C'UKZKTQ633+97^\(P#^58XE*Z9TX)OE:+=%%%<QW!1110 4444 %%%%
M!116;K%Z;6V"H?WDG"T -O\ 5X[5S'$/,E].P^M9KZY>>6^Z)""I& >:H!<<
MYR3U)[TZ@"C!()%)Y#9.0:EJQ9Z;%=WTB;BCLNX,*NMX<NP?EGC(]Q7S]?+*
MO.W#5,]*GBH<MI:&)(/,E2+L3D_2KX&!@5$]E)::@ZRLK$+@8%2U[>78=T**
M3W>YY.-J^TJZ;(*DM>+^W(Z[Q4=6--C\W4XQCA/F-=LMCGIKWD=7VI#TI:0]
M*YSL."\7_P#(\^'/]YOY&N^K@?%__(\^'/\ >;^1KOJ . \4?\E%\._\#_\
M037?UP'BC_DHOAW_ ('_ .@FN_H **** "BBB@ HHHH **** "BBB@ HHHH
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M]6H ]"HHHH 9-_J7^AKA_AA_R#-1_P"OM_YUW$W^I?Z&N'^&'_(,U'_K[?\
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M(UWU ' >*/\ DHOAW_@?_H)KOZX#Q1_R47P[_P #_P#037?T %%%% !1110
M4444 %%%% !1110 4444 %9VJZ?]LARG$J<J:T:* .'F5C')$X*R#J#1;N'A
M4^@P:ZN\TVWO!EUP_9AUK)'AEDE+I=$ ]B* ,_MUJ:RLWU"8 9\E?OMZ^U:4
M6@(&S/*7']T<"MB*&.% D:A5'0"@ CC6- BC  P!3Z** "BBB@ HHHH ****
M "BBB@ HHHH *RO$?_(N:C_U[O\ ^@FM6LKQ'_R+FH_]>[_^@F@#)^'7_(F6
M?U;_ -"-:GBG_D5M3_Z]W_D:R_AU_P B99_5O_0C6IXI_P"16U/_ *]W_D:
M,OX<_P#(DV/T;_T(UU=<I\.?^1)L?HW_ *$:ZN@ HHHH **** "BBB@ JIJ-
MR+6RD?\ BQ@5;K"\0L=L$8Z%LF@#'0';ECECRQ]Z;.NZ!Q^-2=Z#R,4 ,A;=
M$A]13ZK6[!7>(]CP?6K- "'!&#WK?T*<R67ED\QG;6#6MX?^]/\ 6@#<QD50
MN]'MKH[L%']5XK0HH PQX>YP;EBOTINL>%[+5=%?3G7"D<-W!]:WJ*-A-)JS
M/G;7/AGK>F3,;> W,.>&3KBN;?0-6C;:^GS@C_9KZLP/2FF*,]47\JW6(DCE
ME@X-Z:'RY;>%M;NFQ%ITY_"NOT/X4:O=.K7TGV:/N,G->ZA%'10/PI<"E*O)
M[#CA(1WU,3P]X8L/#UJ(K5,O_%(>IK<HHK%NYTI)*R"BBB@84444 %%%% "&
MO/F_Y+)'_P!>?]6KT$UY\W_)9(_^O/\ JU 'H5%%% #)O]2_T-</\,/^09J/
M_7V_\Z[B;_4O]#7#_##_ )!FH_\ 7V_\Z .[HHHH **** "D;IBEH- ''3QF
M&\FB(QALCW!YIM;&N6;%5NHURR<,!Z5C*P89% %>?]Y-'%_">6^E6:K_ /+Z
M<_W>*L4 %-8;RJ#JQQ3JL:=";C44&,K'\S4 =2G$:CT IU)VK&U'5RC&"UP7
M'5NPH UVEC3[SJ/J:%EC?[CJWT-<<^Z8[IF,A/J::/,@!>W;8X'&* +?B?QO
M9: #$I$US_<';ZUYW>?$S6;ASY.V)>P KF=:EFFU>YDN"3(7.:H5PU*TF[+0
M^CPN7T5!2DKMG3CQ[KP;=]J/Y"M.R^)^K0,/M")*O?M7$1QO*X1%+,3@ "NP
MT?P2\R+-?,44\A!UITO:S?NABXX*A&]1?YGH7A_Q]INLLL,C?9YS_"_>I-3B
M^SW[29'ES?,&]ZY@>$-,5?D1E<='!Y%;^D64E_;2V%[,[F$9B8GMZUVJ,TO>
M/GZE2C*7[J_S"J\TI=O)BY)ZL.U33:3>6Y*R"5X^Q4YIJ1B(;5A<?\!H('(@
M1 J]!3J58YY#A+>4_P# 35VVT6YG(,[")/0=: *44#W<ZP1C.3\Q]!77QH(X
MU0#@#%16ME#9Q[85QZGUJQ0 4444 %(>E+2'I0!P7B__ )'GPY_O-_(UWU<#
MXO\ ^1Y\.?[S?R-=]0!P'BC_ )*+X=_X'_Z":[^N \4?\E%\._\  _\ T$UW
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !65XC_ .1<U'_KW?\ ]!-:M97B/_D7-1_Z]W_]
M!- &3\.O^1,L_JW_ *$:U/%/_(K:G_U[O_(UE_#K_D3+/ZM_Z$:U/%/_ "*V
MI_\ 7N_\C0!E_#G_ )$FQ^C?^A&NKKE/AS_R)-C]&_\ 0C75T %%%% !1110
M 4444 %9.MVIGMED3[T9SCUK6KE]4O'N[IXE8B*,X('<TXJ[L3*2BKLS5NX7
M.W?\W]WO6A::;<WARRF*+U/4U1^S1!PZH X_B'6M?3]7>%A%=-E#PKGM]:IP
M:(C54G8NW&CP/:"*,!'7E6[YKG9G^RR^5<$(V>,GK5+Q?\0$T]FM--8/..&D
M!X6O+KW6M0U"8RW-S([9SRW2N:=>,78]7#Y=5K1YMD>O>8&QL^=CT"\YKI=(
MLVM+0;Q^\<Y:O,/AIK<G]K&QG(<.,JQZBO7QTK2$U)71RUZ$J,W"0M%%%48A
M1110 4444 %%%% !1110 4444 %%%% !1110 AKSYO\ DLD?_7G_ %:O037G
MS?\ )9(_^O/^K4 >A4444 ,F_P!2_P!#7#_##_D&:C_U]O\ SKN)O]2_T-</
M\,/^09J/_7V_\Z .[HHHH **** "BBB@!&4,I4C(-<UJ6F/9R&6%2T)ZJ/X:
MZ:D(!&#0!PDK!)DF'*]&]JLC!&0<UN7NAVTY9U/E$]<=#63'I5C;S?OM3 4?
MP!L4 5F?Y@B#<Q...U=3IMBMG;!<@NW+-ZU6B&F16K^08W&.2#DFH[.ZO%+Q
M>3N5,8RW.#0!-K%\;>W$49_>R<#V%<^JA1C\SZU+>7#76H2,RE?+^7![5'0
M4AZ&EJ&>4)M7G+'L* ,_5O ::WIJ7EJ1'=$9/^U7G&H>']3TR5DN+608/W@,
MBOH'3[NT>%(89%)48V]ZAUXQBP*LBL7.T9%93H1FSNP^85:$;;H\Q\(^'UA@
M%]<(#(_W5/85V%-1%C0(H^4<"G5V0@H1Y4>1B*\Z]1U)]0JWI.?[4&W^YS52
MM70;<EI;EAP?E7W%$WH325Y&[@$4GEI_<7\J=16!UB!0.@ I:** "BBB@ HH
MHH *0]*6D/2@#@O%_P#R//AS_>;^1KOJX'Q?_P CSX<_WF_D:[Z@#@/%'_)1
M?#O_  /_ -!-=_7 >*/^2B^'?^!_^@FN_H **** "BBB@ HHHH **** "BBB
M@ HHHH **** *&JZS8Z+;"XOYUAB)QN:L1/B+X8=@HU2+)/'!_PKG/C=_P B
M='_UU_I7SM:?\?D/^\* /M.*19HED0Y5AD'UI]4=&_Y UG_UR6KU !1110 4
M444 %%%% !1110 4444 %%%% !65XC_Y%S4?^O=__036K65XC_Y%S4?^O=__
M $$T 9/PZ_Y$RS^K?^A&M3Q3_P BMJ?_ %[O_(UE_#K_ )$RS^K?^A&M3Q3_
M ,BMJ?\ U[O_ "- &7\.?^1)L?HW_H1KJZY3X<_\B38_1O\ T(UU= !1110
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M@6S_ .N2U>H **** "BBB@ HHHH **** "BBB@ HHHH *RO$?_(N:C_U[O\
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MO]#7#_##_D&:C_U]O_.NXF_U+_0UP_PP_P"09J/_ %]O_.@#NZ*** "BBB@
M[5R=_,;C4)&)RJ?*HKJI#B-C[5QBDDL3W- #J:Q*8D7[R'<,4.ZQJ68X J#]
M[<=28XST]30!V$.H6[VT<CRHNY>[ 5@ZNT"W'VF&:-D;[P##BJ,<"1J%&2!Z
MG-*\,<BE608/7B@!X8$9!R/6I+6W:^N5B490'YSVQ3=(TZV>Y:WEWXQN7YC7
M66]K%;1[(D"B@"1$"(J@< 8IU%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(>E+2'I0!P7B_P#Y'GPY_O-_(UWU<#XO_P"1Y\.?[S?R-=]0
M!P'BC_DHOAW_ ('_ .@FN_K@/%'_ "47P[_P/_T$UW] !1110 4444 %%%%
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M/4]A0!>T:(RW[2#[L:X_&ND'2JUA9I96RQCENK'U-6J "BBB@ HHHH ****
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M_P#037?UP'BC_DHOAW_@?_H)KOZ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LKQ'_R+FH_]
M>[_^@FM6LKQ'_P BYJ/_ %[O_P"@F@#)^'7_ ")EG]6_]"-:GBG_ )%;4_\
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M,Y">E=&.E>91PZC5G5>\G^!Z,ZEX1AV%HHHKK,@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 0UY\W_)9(_\ KS_JU>@FO/F_Y+)'_P!>?]6H ]"HHHH
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M!_D5IT <V?!M@=;N-5W2>?/"86&>,'/^-6_#WART\-V+6EF6*,Y<[CW-;-%
M!1110 4444 %%%% !65XC_Y%S4?^O=__ $$UJUE>(_\ D7-1_P"O=_\ T$T
M9/PZ_P"1,L_JW_H1K4\4_P#(K:G_ ->[_P C67\.O^1,L_JW_H1K4\4_\BMJ
M?_7N_P#(T 9?PY_Y$FQ^C?\ H1KJZY3X<_\ (DV/T;_T(UU= !1110 4444
M%%%% !1110 4444 )BC [#%+10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 AKSYO^2R1_P#7G_5J]!->?-_R62/_ *\_ZM0!Z%1110 R
M;_4O]#7#_##_ )!FH_\ 7V_\Z[B;_4O]#7#_  P_Y!FH_P#7V_\ .@#NZ***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *0]*6D/2@#@O%_\ R//AS_>;^1KOJX'Q?_R//AS_ 'F_
MD:[Z@#@/%'_)1?#O_ __ $$UW]<!XH_Y*+X=_P"!_P#H)KOZ "BBB@ HHHH
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M6U/_ *]W_D:R_AU_R)EG]6_]"-:GBG_D5M3_ .O=_P"1H R_AS_R)-C]&_\
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M\B38_1O_ $(UU=<I\.?^1)L?HW_H1KJZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $->?-_R
M62/_ *\_ZM7H)KSYO^2R1_\ 7G_5J /0J*** &3?ZE_H:X?X8?\ (,U'_K[?
M^==Q-_J7^AKA_AA_R#-1_P"OM_YT =W1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2TAZ4
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M@#@/%'_)1?#O_ __ $$UW]><^-KVVTWQSH%W=RK% F_<[=!\IKH?^$_\+_\
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M9'UW$?\ ?1K4\4Y/A?4@!DFW?^1H R_AS_R)-C]&_P#0C75UYQX&\8^']/\
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M] NW_P"^:/\ A$- _P"@7;_]\UMT4 8G_"(:!_T"[?\ [YH_X1#0/^@7;_\
M?-;=% &)_P (AH'_ $"[?_OFC_A$- _Z!=O_ -\UMT4 8G_"(:!_T"[?_OFC
M_A$- _Z!=O\ ]\UMT4 8G_"(:!_T"[?_ +YH_P"$0T#_ *!=O_WS6W10!B?\
M(AH'_0+M_P#OFC_A$- _Z!=O_P!\UMT4 8G_  B&@?\ 0+M_^^:/^$0T#_H%
MV_\ WS6W10!B?\(AH'_0+M_^^:/^$0T#_H%V_P#WS6W10!B?\(AH'_0+M_\
MOFC_ (1#0/\ H%V__?-;=% &)_PB&@?] NW_ .^:/^$0T#_H%V__ 'S6W10!
MB?\ "(:!_P! NW_[YH_X1#0/^@7;_P#?-;=% &)_PB&@?] NW_[YH_X1#0/^
M@7;_ /?-;=% &)_PB&@?] NW_P"^:/\ A$- _P"@7;_]\UMT4 8G_"(:!_T"
M[?\ [YH_X1#0/^@7;_\ ?-;=% &5:^&](L9UGMK"&*1>C*O-:O2BB@"E?Z18
M:F%%[:QS!>F\9Q5'_A$- _Z!=O\ ]\UMT4 8G_"(:!_T"[?_ +YH_P"$0T#_
M *!=O_WS6W10!B?\(AH'_0+M_P#OFC_A$- _Z!=O_P!\UMT4 8G_  B&@?\
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M^:/^$0T#_H%V_P#WS6W10!%;VT-K"L,$:I&HPJJ.!3I(UE1D=0RL,$'O3Z*
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= +YJU8Z#IFFRF6SLHH7(P608-:-% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gwrjt5hibe5u000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwrjt5hibe5u000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ."3(# 2(  A$! Q$!_\0
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
MGVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:
M7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RJ5=65D#&!P"<5=\E/2CR4]*
, '@Y /K12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gtqsgrqcdg4e000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -L!G\# 2(  A$! Q$!_\0
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MKC*FN UW5+B"[14;C=71Z)J(>#]ZW.* -^HI)XXCACBECF23[IK&UF&[DES
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5._^X*N53O_ +@KQ\__ .1=
M5]#2E\:+E%%%>P9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !VKQ78_\ PG5R=K8R.<?6O:JS/[%L_M37'D+O/4T
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MJ6VTFUMF)CA523GBKLL2RQ&-AE2.E 'DV@6[3.4*GENXIVL02:3JXGP=BYX
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MU0'WK"U:&S-Z4AMQGU H [+P22;&,FNUKE_"5J8].C)&*Z>@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *IW_P!P5<JG?_<%>/G_ /R+JOH:4OC1<HHHKV#,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q
M2=:6B@ HHHH I:A9)>0,A4$FN+N?!MP9,PS%%] 17H-)M'I0!Q>F>$C!,LD[
M>8P[FNO@@6",*J@ 5* !VI: #K1BBB@ JK>7L5G$SNRC SR:==W*VT)<D<#-
M>*^/?&TK;H(PR[3C(H [R#X@6LMXT&$&&VYS776MW'=1*Z,#D9X-?(":O<+>
M>:)'^]GK7L7@3QH\JK%(">W- 'LM)BH;:<3Q*P[C-3T %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW1]*6@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!!=0BX@>,]&&*X74_AW9WT_F.><^E>@T4 >?Z;\/+2QG613R/:NXM+<6T
M.Q>E6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]:6N<V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKKG;="2.XH YF?\ Y"L?UKJ(_N"N6G_Y"L?UKJ8_N"@!]%%% !1110 4444
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M15$A1110 4444P%49-:^EVAED!QWK-@3<ZCWKLM'M J9Q7/6D;4XFK9VXBC
MQVJS0!@45R'0%&*** "BBB@ HHHH IW\7F1].E5]#N##=LI/\5:3C*'Z5A_Z
MB[R.,M0U=6!:,].MW#PJ?:I:S-(F\V!>>U:0KB:LSJ6PM%%%(84444 %%%%
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MJG,C;HHHKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT"<PZ@037H4+;XE;UKS")C!>D^]>D:;)OLHS[5A66MS:D^A;HHHK U"BBB@
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M2[AZUW.@S;[6-?05Q>I+W]ZZ;PS)N 7T%9UE>)=/<Z>BBBN4Z HHHH ****
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MJDW"N4U7[?\ V\GDC]USF@#JP0>E+5>UW^5\_6GO.D?WC0!+13$D5QD4XG%
M"T4UI%49-,2XC<X!H EHHHH *9+_ *IJ?3)?]4U '+S_ /(5C^M=1']P5R\_
M_(5C^M=1']P4 /HHHH **** "BBB@ J.X_X]W^E24R49B8>U 'F6L_+J4?\
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MDI:XSI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJI=V:7$95AVJW24)V \S\0>&BI:2),YYZ5Q-Q;/ Y##%>^7%LDZ$,.U<5KOA
MA) SQISUZ5VT,0UHSEJT;ZH\PHK2OM,FM7(=<#-9[+@UZ,9J2.*4&F-HHHJB
M0HHHH **** "BBB@ HHHH ***7O0!H:5S=Q_6O8_#X(L?RKR/1(MU['GUKV#
M36C@M@IXXKS,6]3OPZT-.BHUE1NAJ2N(Z@HHHH **** "BBB@ HHHH ****
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MZ53;PO>+U'Z5LL1%F3HR1S]%;A\-W?I^E*OAJ[/;]*?MX"]E(P\4H0DUT/\
MPC%W&NYAQ]*DM-&+2X9>AJ)8F**C0;,NRTV6=Q@<9KM-+TA($!9>:N66FQP(
M/EYK150HP*X*M=S.RG241JQ*HP*=L%.HKG-2%X%?M5.6U,9W(*TJ0@$8- RM
M8ZD\#A)&XKI[6Y6>,$'K7)7-MU91S4VFWS0RB-FZ4 =?144$HE0$=ZEH ***
M* "BBB@ HHHH **** "J-]?);H><$5)>7*P1$YZ5R=W<O=3D Y!H 6YO)KJ0
MA3D40VF>6%2V]N% )'-6QP* (UA51P*=L%.HH C:)6[50NK$,IP*TZ0@$<T
M<+J&G$$_+6!/:LA/%>DWMHKJ2!64FFQ3':RY)KII5W#<PJ4E(X$J0:;7;WOA
M25\M$N!]*Q)_#UU"?F'Z5WPQ$6CCE1:,.BK[Z=*AY'Z5%]CD]/TK55(LCD95
MHJT+*0]JF32YGZ#]*/:1#D90%;FA_P"M_&HAH-SC./TJWI5N]O.0WK6-2:DM
M#2$&GJ=C'_JU^E.IL?\ JU^E.KF-PHHHH **** "BBB@ HHHH #TK%U1\N@]
MZV3]T_2L*Y/F7*CT:F@9UGAJ'$><=JZ<=*QM"BV0#Z5LUQ3=V=,5H%%%%24%
M%%% !1110 4444 %%%% !1110 4444 %%%% !3)%W+BGT4 >>>(83',S =Z=
M82;H5'M6EXDMLQEL5B:<_P"\*>E=D'>)RS5I&K1115""BBB@ HHHH **** "
MBBB@#-U$_)6OX5'[\GVK%U$_+^-;_A=,/GVJ*GPE4_B.JI:**Y#I"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)&LBX-/
MHH Y[5/#\%TI.S)K@]6\+SPL2B8 ]J]=QFJMQ9Q3J0RYS6U.M*)G.FI'@T]J
M\#885!C%>NZCX7AF5BD7-<=J'A6YC8E5P![5W4\2GN<D\.UL<E15VXT^6W;#
M#]*J%#74IIG.X-#:*7::2J)"BBB@ HHI0,T )4D:%FQ3HX6=@!70:5HLDCJS
M+Q]*QJ55%&D*;DPT>RF#K(HZ5URS7@7K4MK8QP( %Q5O8OI7DU)N3N>E"/*K
M%%;V\C.2U7[76RI E:F-$K#I5:6T!'RCFLRSJ+:]BN -IZU:KAXYYK-\[L**
MZ73M12X15S\U &G11U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %4[_ .X*N53O_N"O'S__ )%U7T-*7QHN444=Z]@S
M$KQ?35/_  LRZ.#CCM[FO:#7.0^'8X]:DO=@W-WH T;NW^T::5Q_":\<T>--
M'\47DMTA*,_''M7N80>7M]JYG5/#$5RYD1 &)R30!B76L::MJ<0_,R\54\)Q
M/=I?#!VL#C(K43PH[. W(!KI-.TJ+3+=RJ <<XH \N<-X>U==P(5Y,\"NTU#
MQ?:MH[H =Q05F:_/:7%XB-$-V[ )JC?:>L=A(Y*D;<XS0!@^'[S[9K\+_P"V
M:U_%2D^.[<@'H?Z51\)V)FU..9%(56]*])O=!CNM3CNR@+*.M ''^(=-<V[W
M2CI5KPOXFAL[!(9@2PKMI],CGM3"R YKFKCPIMD)C4 >U '->+M87Q!"]C"#
MS5G4;%K7P;;H1R,_TKH]/\*I',)9$!K:OM*CN;)8-HP.U '+^# 05X[5)\1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=_\
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M!0O8L+N%:6CW/1">E03)O3%4[*0PWAYH&=HIR,TM06S[XEJ>@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBZKZ&E+XT7****]@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "F3?ZIJ?3)?]6U '+S_ /(5C^M=1%]P5RMTZQZI&7..:Z"._M@G^L%
M%VBJO]H6W_/04?VA;?\ /04 6J*KI>P.<*^34X((R* %HHHH **** "BBB@
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M0M7-P+YDP<UN:VW[MJQK#E : - #%%%% @HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^?\ _(NJ^AI2^-%RBBBO8,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M*6B@!DJ[D(]JXR]C,%TS>K5VW:L#6K/<@91[T 5(7W(*EK.M9BKE3VK04Y%
M"T444 %%%% @HHHH *.U%% &1>IY;;O4U=M) R#Z4E]%O3BJEG)MD*GM0,UJ
M*13D4M @HHHH **** "BBB@ J*<X2I:JWK[8Z (M,4M>-]:["(8B7Z5R^CJ#
M.3Q74H1L'(H&/HHHH *KWJYM7^E6*AN"IA89% '&$;+C'O6DARM4;W"78Q5N
M Y2@"6BBB@ HHHH$%%%% !1110 5G7LGS;:O2,%0FLEV\V84 6;*/Y<UH5#;
MIM2IJ "BBB@ HHHH **** "BBFNVU2: *]W)A2/6I-(A+,&([U1D8SSJ!ZUT
MNF6OEQ<B@9I*,"G4E% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)%W(17,:M
M:E)&D KJJI7ML)HR,4 <U9S94*>M7:S;B%[6X)YP*MP3"1!0!/1110(****
M"BBB@ HHHH **** "BBB@ HHHH *",BBB@#.NXL,&':MC0[O<A5C[52G7<A^
ME5]/E,-PJYZM0,[/M134.4!]J=0 4444 %%%% !1110 4444 %%%% !1110
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M4D 4 9,,XD45-6;+#):R$\D58AN0PP>* +5%("".M+0(**** "BBB@ HHHH
M**** "BBB@ HHHH :X^4UFCY;V/_ 'JTG.%-9R?/>QX_O4#.SMSF)?I4M10+
MMC7Z5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R5=R
M$>U<?JUN8)U8#J:[.LC5[3S8]P'04 9=O*)$'L*FK+LY#%(RMZ]ZU!R* "BB
MB@04444 %%%% !2'I2U',VU"?:@9F7+>9.@S_$*[&Q54MTY'2N!>1C.2 3@U
ML6NL/&JJP/% '8T5BV^MHV <5IPW22C(84 3T4@.:6@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %)2T4 %(1D<TM% %"ZL5F4\"N>NM.>%B5S785%+ L@P0* .-CN7C.UE
M/'K5V.97'45=O-(#9*_I6-+:2V[9 8T :.:*SDNW4X92*MI<*PY(H FHI RG
MH:6@04444 %%%% !2TE% !12$@=Z@EN%4<'- Q+F4*I%&DVYFEWD=#51$DNI
M1\IQFNITZT$$?3J* +ZC"@>U+110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5'-&'0CU%244 <=JEH;>8,H/7/%.M9Q(O/:N@O[03QM
MQSBN4>-[*;&#@F@#5HJ&&82+UJ:@ HHHH$%%%% !5"^EP !W-6II0BYS5"")
MKRXQ@X!H&7]+TL2Y=AU]:GN-$!^[Q6W:0"*%0/2I\#TH XF;2Y8#E6;BHX;Z
M:VD 8-C/>NVD@608('Y5AZII:[&91T':@"[IVHK<)R1FM2N"TZ=[:[5#G&:[
MB"3S(P: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG?_ '!5
MRJ=_]P5X^?\ _(NJ^AI2^-%RBBBO8,PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ IDD2R#! I]% &->:2KY(K%FL9+<_*"<5V=0RV
MZ2#D4 <>ES(G#+BK*7*MU(K3NM(1\D"LJ72WB.5!H L!U/0TZLS_ $B(_=J1
M;J0?>&* +]%55NU[FI1<1G^*@1+3'0..:3SD_O4><GK0!1GL^<K58&6(]#6L
M9H\<FJ\KQ'N*!D"WSJ.12MJ1%5I>3\G-,BL99W&5.* )OM,D[84$YK1L=,:1
M@S@U:T[1U3!85O1Q+&N * ([:V6%  .E6:0D 9-59[Z.(?>YH M$@=:R=9D4
MP]>U5+C66R0IS61>ZA),N#0 FFNHN6R?XJV-3FC, PP/RURD;R+(2H[U=+S3
M+@@T 3Z3(JR\G'S5V,,\90?,*X6*&2,Y -74O)X^QH [,,#T-*1D5S$&L2*0
M&K7MM224#+<T .O;%9T/K7-7=@]NQ90:[%75^AS44]LLRX(H XI;YXCAABIA
MJ)(XJWJ.BY)916.;26%_NG% %M[R1N@J'9),>0:?%M'WN*NQ21#N* &06@7D
MU<"@"F>='ZTOG)ZT"'T5'YT?]ZFFXC'\5 $U%5&NQV-1-=2M]T4#+QD5>IJ"
M2Z"]#FJRI/,>5-6X=)9SE@: *;2RRG 4U9MM->9LL#6S;:4D>"16C'$J# %
M%.TTY(@#5]5"C %.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 @4*,"F2RI&,L<4RXN%A0DG%<Y?ZDTK%$.: +=]JVW*HU8SRS7#'(X-+'
MTK;G'6KJ1*@XH HFW"C+54=/,? ]:N7DQ^Z*=:0<[B.M #;>R &2*NK JBI0
M,#%% #/+6FF!34M% BE)9J>14&)8&^4=*U*:R!AS0,++574A9#BM^"Y251@Y
MKDY[7'S*.:?:7TENX#' % '7,@<<U2N-.CD'3]*DM+Q9D'/-6Z .<FT4$G"U
M5;2I$Z+76TUD!H Y V,P_AI/L<W]VNN,"&D^SI0!R8L9C_#3UTJ1NJUU7D(*
M>$ Z4 <W'HGJM78=(C7J*V:* *D=C&G2K*H%Z4ZB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5]C'I721N'4$5Q,BM;R[AW-=)IEV)$ )Y H U:*!R** "BBB@ HHHH ****
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M7#0RO97&23@FNNLKI9XEP><4 6Z*** "BBB@ HHHH **** "J=_]P5<JG?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\[2:!FE12 @CBEH ****!!1110 4444 %%%% $<HS&WTJKIC;)S_ +U7)/\
M5M]*HV1Q<?\  J!G8Q'*#Z5)4-N<QCZ5-0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5'4(!+"W':KU-==RD4 </%FVG96XRU:BG(!J+6K,I*KJ.AS4-G/O
M7!/2@"Y1110(**** "BBB@ HHHH **** "LF\7;?Q,.QK6K-OU_?*WI0,ZK3
M9?,@!]JNUD:"^^U-:] !1110 4444 %4[_[@JY5._P#N"O'S_P#Y%U7T-*7Q
MHN4445[!F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444@H 6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J7
M_P#Q[O\ 2K=5+_\ X]W^E &%H?\ K)/]X_SKIQT%<QH?^LD_WC_.NG'04 +1
M110 4444 %%%% !1110 U_N'Z5R.LC%POUKKR,BN8U^+$J&@!EN?D_"IJJVC
MY7%6J "BBB@04444 %%%% !1144LHC7F@".Z=0N#61\ZR9'3-755[J7 Y&:V
M4TD& DKSB@9FVMP&7!-7*S;BW>UE]!FK-O.''6@"S1110(**** "BBB@ HHH
MH 9(<1M]*HV/-Q_P*K5R^U#]*@TA"\Q/O0,ZVW_U8^E34R,80?2GT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%)0!4OK831-D<XKD94:SN-O0$UW)&1BL
M35]/\P%U7H* *44@D7(J2LJWE,+['/>M16##(H 6BBB@04444 %%%% !1110
M 50OZOUGZ@><4 ;/AHYLVK<K$\-KBT:MN@84444 %%%% !5._P#N"KE4[_[@
MKQ\__P"1=5]#2E\:+E%%%>P9A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %,:14ZFG]JX'QYXB.CRP(&(+D#B@#N?M">H_.C[0GJ/SKR>W\07<Z
M!E9^1GI5A-8O2P^9_P J /4U<.,BG5S_ (<N99[7=(3GWK>+J.I'YT .HIH=
M3T8?G3J "BBDR/44 +12;U]1^=&X>HH 6BF^8O\ >'YTN0>AH 6BD) ZD4GF
M+_>'YT .II< X-+N'J/SKF=5O98M66-6.WF@#I@0:6J=C(7A!8U:+J.K#\Z
M'44@93T8?G1GWH 6BDW*.X_.DWK_ 'A^= #JJ7__ ![O]*MYS52__P"/=_I0
M!A:'_K)/]X_SKIQT%<QH?^LD_P!X_P ZZ<=!0 M%%% !1110 4444 %%%% !
M61K-OYJ;@.@K7J*>,21,".HH XRT?8Y4^M:0.15._MFMI\CIFGP7 88H M44
M9S10(**** "BFLX4<U4FNP.!0,GFG$8JD ]U)A?6EB@ENG[XKH;#3A$ 67F@
M!NG:>(E#,M:P48Q2JH48%+0!G7]BLR$@<XKF9H9+63VKMR,BJ%Y8+,I(7F@#
MGH+D,,5;!S5&ZLI+:3(Z"FPW6,!J -"BHTE#"I*!!1110 445#-*$6@"K>R<
MJ!WK2T:WQEL5DPQM=3#V-=990"*,<=J!EP=!2T44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %)2T4 %,D0.A!'6GT4 <QJNFE6,B#&*S[:X*'8YYKLIH5E0
M@CK7-:EIK1N9$& * ) 01D4M9MO<E"$?.:T%8,,B@!U%%% @HHHH **** "L
MN_;-RB^M:3G:A-9(!N;^,CH#0,ZK18_+ML5IU!;1^7$ /2IZ "BBB@ HHHH
M*IW_ -P5<JG?_<%>/G__ "+JOH:4OC1<HHHKV#,**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %5+__ (]W^E6ZJ7__ ![O]* ,/0O]9)_O'^==,.@KF-#_ -9)
M_O'^==..@H 6BBB@ HHHH **** "BBB@!&^Z?I7)ZT<W"?6NK?[A^E<EJ_\
MQ\+]: )+<83\*FJ*#[E2T %%%% @HHHH **** "BBB@"K<VX<9':LN2:6)MG
M8\5O'I6?>6P/S =*!B6<88;C6@!@5EVDY4[3ZUJ*<B@!:***!!1110 4444
M%%%% #)1F-OI5+3SMN/^!5>?_5M]*HV0_P!(_P"!4#.PMSF,?2I:AM_]6/I4
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4A.!FEJA?W:P1L,X.* *
M^IZ@(E95;FN<4/=R[WI9'>\GW'D9J_#$(UP* %BB$:X%2444""BBB@ HHHH
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M* "BBB@!DIQ&WTJGIPW3_P# JL7+;4/TINC)F4GWH&=3",(/I4M(HPH^E+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444A.!0!'/*(XV/H*Y'4;MKF<*IR
M,X-:FLWWEC8#][BL>RA+$NP[YH LVL C3I5FBB@04444 %%%% !1110 4444
M %4-0Z5?K/OS\X'K0,V/#/\ QYM]:W:QO#J[;0ULT %%%% !1110 53O_N"K
ME4[_ .X*\?/_ /D75?0TI?&BY1117L&84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !52_\ ^/=_I5NJE_\ \>[_ $H PM#_ -9)_O'^==..
M@KF-#_UDG^\?YUTXZ"@!:*** "BBB@ HHHH **** "LC6HMZ9]!6O5:\B\R!
M_I0!R5DWS,/>M&LH?N9R#W:M-#E: '4444""BBB@ HHHH **** "BBB@!&&5
M(K)N4,4P(K7JG>QY!;TH&/M9-R59K+LGQP:U!0 4444""BBB@ HHI#TH J7K
MX*CUK0T:'&3BLF<F690.QKIM,BV1#CM0,T!T%+110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 57NI1'$Q]JG/ K UR[V *#UXH QKB5KRYSG(5JT8D"*,>E
M4K"+[S-W.:T* "BBB@04444 %%%% !1110 4444 %9=\V;R-?4UIL<*362P,
MVHQ?6@9UFDQ^7;XK0J*W39$![5+0 4444 %%%% !5._^X*N53O\ [@KQ\_\
M^1=5]#2E\:+E%%%>P9A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444C=* ,'7I=B*,]:R[!,%F]:L>(GR8Q[TVU7$8/M0!8HH
MHH ****!!1110 4444 %%%% !39&VH3[4ZJ%[/MP@[\4 0Q(;N\0CHK5VMO$
M(HE ':L'0++"L[#KSS71C@4#"BBB@ HHHH **** "J=_]P5<JG?_ '!7CY__
M ,BZKZ&E+XT7****]@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *J7_\ Q[O]*MU4O_\ CW?Z4 86A_ZR3_>/\ZZ<=!7,:'_K)/\ >/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *8_W3]*?3)/NGZ4 <AKAW2H/]JK,(Q"OTJMK7$J_
M[U6HO]4OTH ?1110(**** "BBB@ HHHH ***1F"C)H&,FD$:')[5G6T+WUR#
M@X5J2YE:>0(G/.*Z/1[ 6Z;B.6&: -*VA$,2@>E3444 %%%% !1110 4444
M%4[_ .X*N53O_N"O'S__ )%U7T-*7QHN4445[!F%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5')$LBD$5)10!SU_HY)W0KBLAXKBW/S']*
M[<C/6H7M(9/O)F@#C!=D=<T&Y9N :ZTZ9;'_ )9BA=,MA_RS% '*)#<S_=/Z
M5?M=%F8@RC(^E=$MI"GW4Q4P  XH IVVGPP*,)@U<  &!2T4 %%%% !1110
M4444 %%%% !1110 4444 %4[_P"X*N53O_N"O'S_ /Y%U7T-*7QHN4445[!F
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$X&: ,'Q/=/
M;6;,C$?+7@.M^+[Z&[=5N''S&O;O&-Y&+-QN7.WUKYJU]@UZY']XT >D>!?$
MMW>S*))F;YN]>YV3EX%)]!7S5\/9EBG7<0/F[U]%Z5=)+;KM8'@=#0!IT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M._\ N"KE4[_[@KQ\_P#^1=5]#2E\:+E%%%>P9A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4R52T; >E/HH \C\>6=XB,R-(0?2O#=0247#;
MU;.>]?7VI:;%?0,K(IR,<BO&_$_P_8WJF)"0S<XH&><^&DN#=1K$KX+=0*^A
MO"-I<1VJF5FZ#K6#X.\#)9*'D49'/(KTR"!((PJJ!@=J!$HZ4M%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53O\ [@JY
M5._^X*\?/_\ D75?0TI?&BY1117L&84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44F0*-P]: %HI,BEH **3(
MI: "BBB@ HHHH **,TF: %HHHH **** "HWAC<Y9%/U%244 -5%7[J@?04ZB
MB@ HHHH **** "BBB@ HHI,B@!:*3</6C</6@!:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *IW_W!5RJ=_P#<%>/G_P#R+JOH:4OC1<HHHKV#,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YO6?$46G;@T@&*Q5\:(_205A^-HEFNI%;I6CX>\'Z;=6<;R9R1Z4 :$7C:W
M5P)9@,FNGLM4AO(-\;[N,UP'BSP=IMC;))#G=G/2IO!T\BF2(_ZM01^&* .N
M765,Y3=T.*V8GWH#ZBN3A72OM)/F?/NYXK2O-=LM,1 \NT$<4 ;M%<?/XXTY
M.1<<58TWQ?8WSA8YLDF@#J:3-4Y]0B@MS*S84"N9N/'.GQ2[3<4 ;FH:JEHY
M5FQBH9-:06/GA^*X'6?$%MJ$S&*7=FMFQ^ROHB_:FQ'ZT =;IVI+=XPV<UJU
MS&ER:;;HK029'TIUWXML+4E7FP10!TF:6N(/CS3A)@W'4UTFG:O!?QAHWW<9
MH TZ*Q=4U^UTY<RR;:Q%\=Z>6(-QWH [6BN>L?%-E>D".;.:WHY!(N0: "61
M8HR[' %4X=3@E<*KY)JAXEU*.TTV4,V&Q7F^C>)XO[22-I: /90<C(I:QTUB
M!++SF?Y?6L2X\<V$4A4S]* .SHKG--\565^X2.;)KH4<.@8=Z %8X4GT%<KJ
MWB>*Q<J9 .<5U$N?*?\ W37CWB.U2ZU K)TWT =*OC1&Z2"I8O&"O(J^8.35
M?1O!.ESP*SYR1_=K7C\":2CA@#D'^[0!M:??"ZC!SFM"LV.TMM+@)4X51Z5B
MWWC2PM7VM/B@#K:*Y/3_ !E8WDBHD^2:ZB&59DW*<B@"2BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOM&&(XH \[UWPY=!EDL\*PY/%8TX\0"UD03?*%P>#_C6SKAU*RN"[R$Q[LX
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MW%Q4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN?M"1 2>M 'F%W"Q\<S-CCC^9KU"P&-.4>QI#I%DUR9S"/,/4U<5%1-JC H
M\FL(F'C"Z;'\5>D2_P#'E%]*E72+))VF6$"1NII;X!8E Z"O'S__ )%U7T-*
M7QHNT445[!F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)12T %%%% !111F@ HHHH **
M3\:6@"M/8V]R,2QAOK50>'M+5MPM4S6I10!#%;0P#$:!14U&:Q[_ %V*QNEA
M8#+4 ;%%5[2Z6ZCWK5B@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRE9!%N([ 4FG^.7NW.ZV9%]2*XN+3S?^()-S<''!KN;W1E@T>,PQC<!U YH
MI:A\0WM25CM&D(]%S46G?$>2YFV2V3Q@G&64BN>M;YK+4)!/:;ESC++70NFF
M:NL6)(8&4CIQ0!WEC>K>0JX[C-6ZRM'M([:$!)A(,=C6K0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 53O\ [@JY5._^X*\?/_\ D75?0TI?&BY1117L
M&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 53O_ +@JY5._^X*\?/\ _D75?0TI?&BY16?]
MIE_O4?:9?[U1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?
M]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9
M_P!IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%
M%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H
M45G_ &F7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R
M9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[
M)FA16?\ :9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?Y
MA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_
MF'LF:%%9_P!IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_
MA_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7
M^'^8>R9H45G_ &F7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/
MY7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0
M_E?X?YA[)FA16?\ :9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V
M[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H48'I6?]IE_O4?:9?[
MU']NT/Y7^'^8>R9H4F >HJA]IE_O4?:9?[U']NT/Y7^'^8>R9?VK_='Y4M9_
MVF7^]1]IE_O4?V[0_E?X?YA[)FA@>E)M7^Z/RJA]IE_O4?:9?[U']NT/Y7^'
M^8>R9H4F!Z50^TR_WJ/M,O\ >H_MVA_*_P /\P]DR_M7^Z/RIDZ[H)%'=2*I
M_:9?[U'VF7^]1_;M#^5_A_F'LF<=:^'94U*24QG!?-=U;1!(5!4<#TJK]ID]
M12_:9?6C^W:'\K_#_,/9,T*,#TK/^TR_WJ/M,O\ >H_MVA_*_P /\P]DR_@>
ME& >HJA]IE_O4?:9?[U']NT/Y7^'^8>R9?VCT'Y4M9_VF7^]1]IE_O4?V[0_
ME?X?YA[)FA@>E%9_VF7^]1]IE_O4?V[0_E?X?YA[)E_ /4#\J-H'0#\JH?:9
M?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?\
M:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?
M]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9
M_P!IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%
M%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H
M45G_ &F7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R
M9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[
M)FA16?\ :9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?Y
MA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_
MF'LF:%%9_P!IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_
MA_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7
M^'^8>R9H45G_ &F7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/
MY7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0
M_E?X?YA[)FA16?\ :9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V
M[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_
M;M#^5_A_F'LF:%%9_P!IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]
M1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[
MU']NT/Y7^'^8>R9H45G_ &F7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9
M?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]I
ME_O4?V[0_E?X?YA[)FA16?\ :9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1
M]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U
M'VF7^]1_;M#^5_A_F'LF:%%9_P!IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?
M[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE
M_O4?:9?[U']NT/Y7^'^8>R9H45G_ &F7^]1]IE_O4?V[0_E?X?YA[)FA16?]
MIE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_
MVF7^]1]IE_O4?V[0_E?X?YA[)FA16?\ :9?[U'VF7^]1_;M#^5_A_F'LF:%%
M9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H4
M5G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_P!IE_O4?:9?[U']NT/Y7^'^8>R9
MH45G_:9?[U'VF7^]1_;M#^5_A_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)
MFA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_ &F7^]1]IE_O4?V[0_E?X?YA
M[)FA16?]IE_O4?:9?[U']NT/Y7^'^8>R9H45G_:9?[U'VF7^]1_;M#^5_A_F
M'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?\ :9?[U'VF7^]1_;M#^5_A
M_F'LF:%%9_VF7^]1]IE_O4?V[0_E?X?YA[)FA16?]IE_O4?:9?[U']NT/Y7^
K'^8>R9H53O\ [@J/[3+_ 'JAGE>1?F->9F^;TJ^"G3C%W:\BZ=-J29__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gtqsgrqcdg4e000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (: [T# 2(  A$! Q$!_\0
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MN_'U]H.G7MG:06T"2AYTSNR!0!Z#17+:AXTTOPPMM9Z_?C[=)$7S%$Q#X/;
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M&A1145TQ6TF93@A"0?PJSG)<CUHKQOX?7MIJZQOJGB'66U,W3A81<3>60"<
MX^7&!71P>/KS5];U#1[719FBM9#%/=!@%08&#USFE<#T ,&&5((]0:6O)?!_
MB\Z)X&TFW6WEOM2O[F2.WA##YL<DDD] !5_5?B!J4GA_7H(-/:SUK3(]TJ,X
M(52,AU(//!HN!Z465?O$#/J:6O)Y]>NKWP3H=YK]G(TDMW$(VBG*ER0?F./Y
M5KZA\1;NVO=9M[31)+E-*(::02 #9M!)Y/6BX'H!90VTL ?3- 8,,J01[&O-
MKO7=.U7Q3HMU%#<>;=Z=++$_FD*HXX*]#6!X.\=7F@^%X);K2YYM.-\T,EV7
M'!9R 0,YP,T7 ]IHIL<BRQ)(ARK@,#[&G4P"BBB@ HHHH **** "BBB@ HHK
M%U?Q;H.A7"V^IZE%;2LNX*^<D>O H VJ*\ UGXDW?A?Q=#=6/B%=9T68_- 2
M2T8].:]LT'7K#Q'I,.HZ=,)(9!GCJI[@^]*X&G117F/Q"\;ZYX<\4V-IIHB-
MH+?[3<JR DJ&.[![<"@#TZBO//'/CF[TW2+ Z"T;7=W&9]S*&"Q@#)Q]2*A?
MQSJ]U9>&M/T](3J^K6ZS22N/DC7;DMC^E%P/2:*\_P#%&K^*/"?A2XOKB^M+
MF82HL<BQ8X.<@C&*[2>^6UTB2^F("QPF1C]!F@"Y17F?@7QOK6K>(I+'7%C2
M*[A-Q8;$ ^0,PY]3Q7I,I=87:-=T@4E5)ZGL* 'T5P/A?Q+X@O?'.IZ-K MD
MCMXED2.$9VY]3CFH?'&O>)_"<46JK>64EF]TL(M/+^8JV>^,YXHN!Z)17G]]
MXFUS5/$_]B:-+;V+Q62W4DDZ;MQ89V@?C6UX%\1S>)_#OVRY55N(IG@EV="R
MXY'YT7 Z:BL>R\0VU[XCO]%2*59[)%=W;&U@P!X_.JOCG6;K0/!]_J5DRK<0
MIE"ZY /TH Z*BN,\.ZCJS:>NJZIKMG=VPMO/D@@B4,G&>W-8_B3XD6E[X4U"
MX\.W4HN+<*WF^6P SG@$CK1<#TNBN6N_&^F:1%;07;RS7;PB5XX(F<JO=C@<
M"LCQ/\3+;2K+2+O3(C>0WTRJ75#@+NP1T^]UXH ] HKBO^$C27Q99'^T9X(9
M;%YS8O$1D#'S'T//ZU/:_$CP]=W%K$D\H6YD\J.5HF";\XV[L8S0!UU%>8^(
M/$UY8Z;XJGM-8DDFLVCV)Y>!!DGH>]='X<\<:7K$MKIPFE%[) KKYL;*)>.2
MI(Y[T =71113 **** "BBB@ HHHH **** "BBB@ HHHH **** &NZQH7=@JC
MJ2:XZ&]M?^%D7+_:(]AL@-VX8ZBK_C[(\#ZKC_GC_6OF/>^<[C]<UUX;#^T3
M=SEQ%?V;2L?7R.DB!T8,IZ$'@TZN9^'I)\!:02<_N3_Z$:Z:N62Y9-'3%\R3
M"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JPGW!]*KU83[@^E)@5Z***8
M!1110 4444 %%%% !1110 5X_P#M!_\ (K:7_P!?R_\ H+5[!7C_ .T'_P B
MMI?_ %_+_P"@M2>P'IV@@-X:TQ2,@V<6?^^!6%J'PT\,WMG/$FGK#)(#B1&.
M5/KUK>T#_D7-+_Z](O\ T 5HTG%/<N%24'>+L>"Z+\'-0;Q,\&IDKIL#9\U?
M^6P[ ?UKUO3?!>@:1=1W5EIZ1SH,*^XD_P ZWZ*F-*,=C>MC*M;XF%1SH9;>
M2,=64@5)16ARGG'@_P />)_"\"V)L=.FMS<,[3%_G"L<\5K>&O"][I-SXADN
M&C(U"X,D6T]!M Y_*NQHI6 \JM/AUK%AI.ASVTUN-5TFXDD5'Y216&",YK2@
M\"ZC?)XDO=5GACU#68?)VQ#*1*%P._->AT46 \VE\'Z]>^$M(TJX%JDNGW4;
M@HW#(H//7KS5Q/!NHK-XN<M%C5XRL'/0[ O/XUWM%%@/-M/\":I:WV@3.\6V
MPT^2VEPW5F(QC\JRX/AYXF;0K?P_<7%F-.-X+B5P#O50^[:.>]>NT46 9#$L
M$$<2_=10H_"GT44P"BBB@ HHHH **** "BBB@ KE?$OP]\/^++V.[U6V:2:-
M-@*N1QU_K7544 ?.7B'X5S:EXH@T[0/#]U8Z>C8EO9PVUO<9KW+PKX8L?"6A
MPZ98J=JC+N>KMW-;=%*P!7 Z_P"'KG5OB1;2O:NVG2:7-;RS;?E!8,,9]>:[
MZB@#Q#0/!WB'^S]>?5+69I;>T-EIZ%#ETR3D>O:M6/P]K>D)X3UZWTZ6XFL+
M);>ZM ,2 %<' ]1Z5ZU118#S3QQ+J_BOP5=06OA^_BD26-ECD0AWQG.%QGCC
M\ZD\1ZEK.O\ A&32+#0=3MI[AHX6DFA*A%W#<WY UZ/118#R34?!OB#0[_0-
M5M;RXU-K!UB,*1 %8SC/0=.M=[9Z$^FWT^I'5-1NMR,?LTA4J.^  H.?QK>H
MHL!Y;H4VJ#XH:AJLOA_4X;.]C2)))(" I'!)]!5/5/[6UGQ[]KUGP_JTNDV#
M8M((8"R2-_?;BO7J*+ <!XLL[.\NX+IO#&I7-VT V2VQ=,9Z(Y7ICWJ]X%\*
M/HG@QM,O5*/<R/+*B.<KNQQGKVKL:* /-='^&T%GXWU*]E2Y%CMC-LWVI\EA
MC.><D9SUKH/B+IUUJ7@/4K*RMWGG>/"1H,LU=510!YIH5K&GANZT^V\,:A8W
MKZ>T;RRQ.%=MO09[DU5N/#5^OP3@TN'3'&I;?GA6/YR=['GOTQ7JM%%@/+/L
M&K^'O%-YJ7]C76H07UBL*^0FXQL!T(QP*SI_!^M6/@K2F%E)/<P:G]MDM8AE
ME4OG:!ZXKV2BBP'FFHZ;J>I^.K/58]-N8[=M)EC8NA&QSMPI]^*QSX8U<?#S
M0[(:9.+N'4A+)&(_F5?-SN/X5['118#QS4_#6M2V7C-8]-G=KQHC;C8?WN,Y
MQZUHZ;I>KZMXQ\.W$VCS:=!H]J8Y9)%PLC;2N%]1S7J5%%@"BBBF 4444 %%
M%% !1110 4444 %%%% !1110 4444 97B6WM;KPY?PWC,MNT1WE3@XKQ'P1X
M'M/$&I/'?F>.%X3-$$(!VYP,Y'I7IWQ*O771(=*@YGU"81  \[>_]*31;&/3
M?')LHA\D.FH@_#%=5*<H4W9[G/4@IS5^AU&CZ7!HNDVVFVQ<PVZ[5+GGKG^M
M7J**Y6[NYT)6T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K"?<'TJO5A
M/N#Z4F!7HHHI@%%%% !1110 4444 %%%% !7C_[0?_(K:7_U_+_Z"U>P5X_^
MT'_R*VE_]?R_^@M2>P'I^@?\BYI?_7I%_P"@"M&L[0/^1<TO_KTB_P#0!6C3
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;ZOYC307.WR%B4LTI;H !WKG_";6\3>*%NF03B[8R[^NWRUQ^'6N<T@;=/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!_\ (K:7_P!?R_\ H+4GL!Z?H'_(N:7_ ->D7_H K1K.T#_D7-+_ .O2+_T
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M4DC^[_I$A _ G%=!14<\K6N7RJ]PHHHJ1A1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ *T:SM _P"1<TO_ *](O_0!6C3 **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR+FE_P#7I%_Z *T:8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\(:%'!;P+8*([>8SQ+O;Y7]>OO5;4? /AK5IYI[W35EDFD$DC>8XRP &>#Z
M4FG:PUN>6'4/$NE:#IEO<ZO=22ZK<;I&CF!>% #A,D@ G/KVJR=;\3+%8Z/>
M:E/:VMSJ'E+?&53((^NTE6.#VZUZ5'X \-1V4EF--#02,&*O*[8(S@@DY'4]
M*D/@KPZ-&.F?V6AM V\)N;.[UW9SG\:=KL1R/PWC,/C/Q1$;\WVQH@+ACDM]
M[O7I]><VFK:1X0>:2U\+:A:"9EC=]CD.1G'7\:ZS1]>FU6=XWTF\M%5<[YT*
M@^PXJW3DE=DJ<6[(K>*/%^E^&4CCU!I UPK!-BYZ?_KKQ[PAK-G>^*-(@ORW
MV>U9A N,[G;H:U?C1J5I=ZC86]O<))+ '$JJ<[<XZUPOA/\ Y&S2_P#KX6O1
MH48JBY/=G#6JR=51Z'U311VHKS#T HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBD+!02Q  ZDU']HA_P">J?G2'8EKC=7N?&5C%=741TTVT0+*"6W8'_ :[!9$
M?[C!L>AK-\1_\BYJ'_7!J4E=%TW:231SVBWOC+4K:RO7.G"UG"NP!.X*>3VZ
MXKL'N8(2%EGB1B.C.!65X1_Y%+2O^O9/_013]5\,:3K<ZS7]LTDBC:")77C\
M"*2O8J;BYV>B\B_]NL_^?J#_ +^"ID=)%#(RLIZ%3D5YKH'A#1;OQ'KMM/;R
M-%;2JL2_:)/E!4'^]7HEE90:?:1VMLFR&,85<DX_$TTV]Q581@[)EBBBBJ,@
MJG/JVG6TQBGOK>*1>J/( 1^%7*R+_P ,Z+J$\EU=Z=!-.X^9V7DX%)WZ%0Y;
M^\3C7=()P-3M/^_R_P"-7U974,K!E(R"#P:\]\!^%]$O/#:3W&FP22^<XW,O
M/!KT&.-(HECC4*B !0.PI1;:NRZL81E:(ZBBBJ,@HHHH *L)]P?2J]6$^X/I
M28%>N'^)YM[;0+74IV4M8W*31PL,^<0?N_C7<5Q/Q-3R]"M=16![B2QNDF6!
M8R_F8/0@?2A[#1G0?%G1GA5I-#U=&(Y LP1_.NL\->(K3Q'927-I:W5NB/L*
MW$6PDX],UR$/Q=L/*7?H&KHV.5%JW'Z5UWAGQ+!XFLI+F"TNK98WV%;B,H3Q
MUY% C<HHHI@%%%% !1110 5X_P#M!_\ (K:7_P!?R_\ H+5[!7C_ .T'_P B
MMI?_ %_+_P"@M2>P'I^@?\BYI?\ UZ1?^@"M&L[0/^1<TO\ Z](O_0!6C3 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHDN(9)GA25&EC^^@89
M7ZBI: .*U[XI^&O#>JRZ;J4EPES'R0(P1^'-5M,^,/A/5K^WLK6:Y,\[A$4Q
M#J?QKSK]H;0A'?:?K4:C]Z/)D/N!Q^@KG_@7HO\ :/C@7CH6BLH]^>P8]/Y5
M-QGU'1115""BBFNZ11L\C!449+$X % 'E7CKX@Z3(S:2L-SY]M=*SL4&TXZX
MY]ZLR^/+[Q<T>F>%+::)Y.)KF=0!&OM@GFO)_%<JWGBC4KFW/F0O.=KKR#7I
MWP2C=++4]Z%<R+U'M7HU*4*=)2ZG!"K.=7EZ'7:/X)TS1])D2:%+JZ<%Y9Y%
MR6;%4OAUIEB_A2UN&M8C,';#E>>M;.LW?B"*=HM.TR&YMV3&]I0I!^F:P?"T
M/BK1-.M]-DTFW,2N2TOG#(!//&:Y;R<7=G3:*DM#O**!TYHK V"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM&&LY+-OWDK@C8PZ?C7KB7/Q"T*-4EL[358$ &]#A\?G2I5)6]Y%XS#4^?\
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)7YLJ&ST]ZN,$U>X.=G:QZ&S!5+,0 .237G/B#6KSQAJ$GA[0'VV:G%[>8X
M[@5'J6L:EXIO!X9T2X9H8AMOM1 P#Z@$?TKM]"T&Q\/Z9'964050/G;NY[DU
M:2IJ[W);=31;'"^(9/#5AX:L]/L+BV9H;F/=@?,<9R37=Z9J>D7;M%IUQ;NX
M&66(4-X=T1V+-I%B6)R2;=>?TJQ::5I]@[-9V-M;LPP3%$%)_*IE-.-AQBT[
MENBBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)(D,322,%11EF/8
M5X9XS^)L5UXIL'T^)9K339O,#'_EHV"O'MR:]KU2:TM],N9;XI]E6,F3?TQW
MKYM;PE-K&JVMS9P?9--U&[,5OO/(&"?KT%85G+11/3RZ%)R<ZG0]&\.V5S\2
M[G^VM:N%.FQ2$0V$9XX_O5W^MV\5KX5O8((UCB2W8*JC@#%)X9\-V7A?28[&
MS0<<R/W=NY-86NZ]K%S:7NGP^&+UMZM&LOF)@^_6J2Y8Z[F$YNK4M#X5L;GA
M'_D4M*_Z]D_]!%;5<+X=US6;'3].TR?PQ>KY:)"\N]-HZ#/7.*W]9M_$4TT9
MT>]M+>,+\XG0L2?R-5%Z&-2F^=W9E^%_^1M\3?\ 7=/_ $$5U]<#8^&?&-A?
MWMY#J^F^;>,&DS$>H&/2NTTY+V.QC74)8Y;H#YWC&%/THB.ORN5T[DL]K;W*
M%)X4D4C!#+FO!_B1\-VTBY&I:2NZTGDVM%W1CZ>U>]3.T<$CHAD95)"#JWM7
MG7BC5-=US35LXO"][&5F63<TB8(!^M35C%K4VP52I"I>+TZEOX=> 8O"]C]J
MNP)-0F4;SV0>@KNW^XWTKG-)\1:G>WD5M<>';RUC(YFD="!^1S3M4D\5B^E7
M3;>P:TXV&5R&Z<Y_&G&RCH9U>>I4O4>I5^'*@>%%( &9WS@>]=;7 :#IOC30
MM.6RB@TZ1 Y;+.<\UW<!E-O&9U592HWA>@/?%5':Q%=>^W>]R2BBBJ,0HHHH
M *L)]P?2J]6$^X/I28%63_5/_NFO#O _C27PX-<M8]"O;X/J4K^9!T' &.GM
M7N3C<C#U&*Y'P#X:O?#5IJD5ZT9-U?O<)L.?E(&/Y4=1]#'_ .%J7'_0HZK_
M )_"NK\,^(7\16,ER^FW%@4?9LGZGC.:W**!!1113 **0D $DX Y)K+B\3:)
M/<+;Q:I:O,S;0BR DGTH U:*I7>L:;83)#=WUO#(_P!U9) ":FN;VUL[<W%S
M<110C^-W 'YT 3UX_P#M!_\ (KZ7_P!?R_\ H+5ZS:7MK?P">TN(YXCT:-@1
M7DW[0?\ R*VE_P#7\O\ Z"U)[ >GZ!_R+FE_]>D7_H K1K.T#_D7-+_Z](O_
M $ 5HTP"BBB@ HHHH **X_XEZI=Z1X-N+JRN9+>4.@\R/J 6 ./PKF/#FMH;
ME;A?$VKWTD4)E:VGMY$1L#)&6&*5P/5Z*\BO_B!KNK:%8ZE;6$FG6DMW'&LW
MF F3GD8!SBMK4/B3<6]S>M8Z+->:=IQ"WETK*-IP"< G)QFBX['H=%>5P>.]
M:OO$VKQ16N_2H;02HZ.%9 <X;KG)Q5J+X@WL%GH5O9Z5-J%UJ-JTRAI1NR,]
M23[4"/2J*\U7Q^VJ#195@N+:6XGEAEB$F K*!UP>1S67X?\ B-K%G8-/J6G3
MW5@M^T$E\7'R9<@8&<D#BBX['KU%-CD66))%.5<!A]#3J8@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O&D@PZ*P]&&:PG
M\/Q)XK37"\211VQA,>P=<@YS6_45S;PW=M);W"!XI!AU/0B@"#^T=/7<_P!I
M@!QR0PS67I*PW\DNH.4=Y&(4#HBC^M<EXE\)Z!:ZQH<-I96\:SSNDFW'/R,1
MG\<5U/ABQL+/3V^QP)$Y8B7:.216DXI1374P<I.5F9>O^$=*CTN_O46<3B-I
M 1.W!ZTN@^$-(FTNQO)4G>9D5R6F)!/TKE?'?C?4K+6+W1X/*-L4"G*@GD<U
M2\.>/O$4KP:796D5RP39&G Z=R:V5&I[.]SG=:G[2QK?$;5M3\,VD,&G74D,
M<DN]&7^$8.1_*O,+;Q%K$EQ-'_:$R_;7'GE3RW '\J](U'PAXD\6S&'4K^%9
MD&\ISMB]N!U_PK T3X8WU[K-[;K?0*=/G5')S\WRAN./>NBA.G"FU)ZD3564
M[K8]I\/:+9:'I,-K91[5V@LQ^\Q]2:U:9$GEQ(G7:H%/KSF[NYZ*5E8****0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKDO'/B=]%L([&P7S=4OCY
M4$:]1G^+\*F3LKETX.<E%&'XEO)O&GB-/"^GDBQMV#W\ZGC_ ':T?$]I!8ZI
MX2M;>,)#%>[54=AY;U;\/:7:>!_##3WK,9Y#YMU(J%V9S[ $USOB7Q=I>H:O
MH,]L+MX[6[\R4_9)!M78P_N^I%9/17>YVQO*2C37NJ_Y'I]%8^C^)M-UV22.
MR>8O&,L)('3C_@0%;%;)W.!IIV84444Q!1110 4444 %%%% !1110 4444 %
M%%% !5A/N#Z57JPGW!]*3 KT444P"BBB@ HHHH IZJ)SI-TMJF^=HB$7.,DB
MO+](M[KPA'I;ZWX9LE@+QPF[C?=(LC$ ,WU8_K7J=_:F]L9K99GA:12!(AY4
M^HKBT\(^(]1EM+77=8AN--M)%D C0AYBIRN[\0#2ZC*ND:)I_B6\\27VJ0"Y
ME%RT,9<G]V@12,>G)-8VB Z^WA?2M29Y[6))&*N3B39\JY]:ZB_\*:[;ZI>R
MZ!J<-O:Z@=T\<J$E&Q@E?P _*GW/@B>UTK2ET6]$-_I@Q'+(N1+D8(;Z]:2$
M-T"TAT7Q_JFF6*&*SDM8[CR@3M5R6!QZ<**\K^,OCJTUUET&*UFCEL;[YI&/
M#8!''YU[-X9\/7VGW=WJ>KW:7.I76%8QKA44=%'Z_G7GWQ^M+:'P[ITT<$:R
MO?+N<+R?E:F]@/5= _Y%S2_^O2+_ - %:-9V@?\ (N:7_P!>D7_H K1I@%%%
M% !1110!SOC;0+CQ)X<ET^UE2.9G1U9QD<,#_2L6UT/QB8Q:W=QI?V4Q^6QB
M@(;&,==U:<7CW1G\0ZAI$DWE26*YD=P<''7'TJX/&7ATV\DXU6#RDQELG'/I
MZ_A2T YUO =V?!6DZ(+F/S;.X25WQPP%5+_X>:P)M3M=+U:*#2]4;=<(\>70
MD -M.>^*[5O$NC+IR7_]H0FV<[5<'.3Z8'.:R];\?:)H^DV^H_:!/#/*(D,?
MKG!SZ8I:#3,/_A7^H6.KW3Z;>0K8W5D+:2.1,L, X(.?>K.D>!;O3]1\/7#W
M,;+IEH\$@ ^\6W<C\ZWF\9^'8R%DU6!&.WY22,9Z=JMVGB'2+^>>"UU""62
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M1&"Y'\#=&^A[UC&;2L:^ZV7+83+;1BY96F"_.RC )]JEHHJ#4**** "BBB@
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M_P#:#_Y%;2_^OY?_ $%J]@KQ_P#:#_Y%;2_^OY?_ $%J3V ]/T#_ )%S2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_5YU*2J7O;T/3Z*JZ=<3W=C%-<VK6LS#+0LV2OXU:K4YVK.P4444""BBB@
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M 4444 %6$^X/I5>K"?<'TI,"O1113 **** "BBB@ HHHH **** "O'_V@_\
MD5M+_P"OY?\ T%J]@KR#]H/_ )%?2_\ K^7_ -!:D]@/3M _Y%S2_P#KTB_]
M %:-9V@?\BYI?_7I%_Z *T:8!114-U=P65L]Q<RK%"@RSL>!0!-16'_PF/A[
M_H+6W_?=:]O<0W=ND\$BR1.,JRG@BFXM;H2DGL2T45Q>O?$O1_#^K2Z==13M
M+'C)0<<TX0E-VBA2E&*O([2BN.\/_$?1_$5^UI;K+$RH7+2\# K ^*/BT6NG
M6T>CZHJW(D/F")@3C%7&C-SY6B75BH\USJ?#?A*W\/ZWK6H1*,ZA*''^R!GC
M]:Z>OF*U\;>(?M<)DU>?R_,7=DCIGFO?5\8:*=.DGAOX)GBA,AC5\$X&<5=7
M#3IVZD4\1&IY'045Y2?C?8@D?V--Q_TV'_Q-=WX6\11^*-&34HK=H%9BNQFR
M>#BLY49P5Y(N-6$G:+-NBBBLS0**** "BBB@ HHHH ***P_$_BBR\*V,=W>I
M(R2/L 0<YIQBY.R$VDKLW*;)(D4;22,%11DD]A7GB?&30'D1!!<@LP&2OK5[
MQ#\0/#T>DW,"7GG321$!(AN()'>M/85$TFB/;0MHS<_X3#P]_P!!>T_[^BM*
MRO[74;<3V<\<\1.-Z-D5\D$\D^IKUGX?OXO?PRL.BQV26ID8B:;).?3&:Z:V
M$4(WN<]+%.<K6.ZUCXBZ#H>I26%Y+(L\?W@(R1_*I] \=Z+XDOFL]/ED:4+N
M(9"./QKP7QI%J:^*+H:J8WO.-[1*=OX5?^'6D7FK:^\%KJ$M@XB),B+DD>E4
M\+35+FN2L3-U.6Q]'M(B#+NJCW.*YKQ?XC@TWPY?2VFHVZ7D:?(!(I;.?2LZ
M/X9V+_\ '[JFI7/L9L '\J;JGPRT:31KB&PM_P#363$<TTA8Y]37+%4U)79T
MR=1K1'DW_"R_%>/^0F?^^%KT_P ">'8]5M8/$VL3-?7UPF5\WE8P>P%<3_PI
MG7_^?BU_.O8/">DSZ'X:L].N&5I84"L5Z5TXF=+E_='/AX5.:]08W@WP\[%F
MTFU))R?W8JYIVA:7I,C26-C# [#!9$ )%:-%<3G)JUSLY5V"BBBI&,E0R1.@
M8H64@,.H]ZX^V^'_ -DGEF@UR_225][N#\S?CUKLZ*+@<Q?>#_MFK)J2:K=P
M7"0B+<A[#_&LGP!HEQ!I^I&YN[EEDN9(_*D&!T'S?C_2N]I  O0 ?2BX6,>V
M\.6UMX8_L)9'-OY7E;CUQ6E96J6-E#:QDE(D" GK@5/10!QWQ(.NCPM-_8F.
MG[_;]_9WQ7SSX?U'4-*URVN+&X\BX$@4LYPO)_B]OK7TUK7AZ;5[@2+JUY:H
M%V^7"5VG\Q7)M\'=*;SMU_=GSCF3E>3^5<]6G*4DT>K@\52I4G"?4]"LW>2S
MA>5D9V0%BA^4GVJ>O,=)U6_^'^JIHFMNT^D2MBTO3_!_LM7ID;I+&LB,&1AD
M$="*VC*Z//JTW!WZ/8=1115&04444 %%%% !1110 4444 %%%% !1110 444
M4 %%<5XONM?TA;C4HM;L;2P1?ECEMRS9],[QFN5\+^+?$7B:WE=/$.FVTD1^
M:.6U.<9X.=]9NHD['3#"RG#G3T/3=9L;^_MECL-1:R<-DNJ!B1Z<UQ$=OXC;
MQ;+HC>)W&R 2AO+7)Z<8Q5S7?B5INF:4\5E<IJ&J!=H6$<;O6O"&\0ZR?$/]
MJ&XE&H&3.??TQZ>U9U*D58[,)A*DXMNR]4?4.C6%_86[QW^HM?,6RK,@4@>G
M%>?_ !5\7Z?8BSTZ,B:ZBN4G=4_A"G.#4FG:=\0O$.GQ3WFL0Z;%(H^1(<L1
M[Y/!KA?'7PWU+0Y(;U;QK];F0(S,N&WD\=^]$Y2Y?=0L-1I>VM4DK^1ZI;_$
M_P ,-I$-[+>!)'7)@"DN#Z8%4C\1=1U$[-"\-7MQN^[),NQ#^)IGP]^&]OH-
ME]KU2-)[^8 [67(C'I]:]#2-(UVHBJ!V48JX\[6NASU)4*<VH+F]3RK7O"_C
MCQEIQ34;FUM(ERZ6J'[QQT)'7\:\\\*_#[4];\126,\;6\=HX^TNW\/H!]:]
M]UVT\17,\9T;4;6UB"X<30%R3^#"N;M/"OC&QO[R]AUVP\V[(,N;1L<9QCY_
M>HE23=SIHXR4:;BFE<Z^:PN;?1%LM)FCMYHT5(Y)%R!CU%<I?>%O%^H7=G<S
MZY9&2T??$1!C!_*NRTR.^BT^)-1FBFNAG?)$A53SZ9/\ZMULXIH\^-64'H8N
MBVOB"WFD.L:C;W497Y!%%M(/Y"LV]^'^F7\TTD]WJ)$IRR"\D"_EG%=911RI
MJS$JLXN\=#DK+X?:782P/!=:B!"043[9)M&.@QG&*ZVBBFDEL*<Y3^)W"BBB
MF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %6$^X/I5>K"?<'TI,"O1113 **** "BBB@ HHHH **** "OGOXK>*6
M\1SMH;6PA6PO"PE#9+8!'3\:^A.U?,?CS3;VP\2ZA=W5M)#;S73".1UPK9/:
MNG"PA.3YSFQ,YQBN0]4\!_$2UU*R-I?B"RCLH(XUD>3[^!CO]*POB7XXFCU"
MSCT#6'"!&\[R'.,\8_K4'PN\&)=SW<VN:4[0F-6@,H(!SW'KQ71^+OA9#K$E
MI_9!@L(X0P=0A.XG'O[5K:C3K>1/[V=+S/.-%\?:_'K-J]SJ5[<0"0%XE8L6
M&>F*[;QAXUN=4\+WEL- OX8)4P)Y4  'J>:CT/X0WVE:U:7TFHPND$BN5$?7
M!^M>IZAIMKJEA)8W<0DMY!ADSC/Y45JM)33BKBI4JO(TV?)/&*]O\+?\)S/X
M9L/L!L;>T6/$?F<LXR>>E=%_PK#PE_T"U_[^-_C746-E;Z=916=JFR")=J+G
M.!17Q49I**"CAY0;NSC?[(\>W/SR:[9VYZ;$CR/Y5X_XWL-5@\47,>H2F[N!
MC=,B'!X^E?350R6=M*Y>2VA=CU+(":RI8GDE>QI4H*:M<^=?A[X;@UWQ$;34
M(IA (BW&5R<CO7I>O_";3+W3XK?1TALI%?<TC DL/3-=_':V\+;HK>)&]50
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MZO::?<7$7BB]FDBB9UB5FRY R!^-9'A#X5>(_$.E27>H:OJ6F3+,4$,V\$@
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M6],TJ]ABN-65&@M&\T"5OD!]2.A_&N"8B5O$/B72+3['8)ITD,)C38)VQ]\
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M<G:'3K^.XD4;BH5A@?B*I>-]'U'7-%CL].6%G\^-W$Q^4JK \^O2N<BU#5-
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M)6,N"<_D*CTOQ;H.MW9M-/U&*XG"[BBJP./7D5>U1;);&6XOH(98H5+GS4#
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M$BCMO+VG_OHUTE% !4-U:P7ML]O<Q++"XPR,.#4U%,#D+OX>:+-K6G7\%I!
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M_B/1&US3UAANY+2XBD$L,R<[6'J.XK*TCP8\5Q=7FMZ@VI7EQ%Y&_9L5$YX
MR?4UUM%*P' P_#[4 D.G7&ORRZ)"X9;4Q88@'(!;/3..U=ZBA$5%&%48 I:*
M "L/1O#JZ9)JQDF\Y-0G,I7;C:",8]ZW**+ <$GP_O0Z6+ZY(VAI+YBV?E_-
M_N[L]/PI=5\%:Y=>)I-7LM=A@&P)#%):[_* ';YA7>446 SM$M=1L]/$6J7R
M7ESN)\U(]@QZ8R:T:**8!5A/N#Z57JPGW!]*3 KT444P"BBB@ HHHH ****
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05%%P*M6$^X/I3J*38'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gwrjt5hibe5u000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwrjt5hibe5u000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ."3(# 2(  A$! Q$!_\0
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
MGVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:
M7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RJ5=65D#&!P"<5=\E/2CR4]*
, '@Y /K12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gtqsgrqcdg4e000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /+!5,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI"P49)P* %HK/FU>VA.-VX^U)%K-M*V"=M<_UJCS<O,K
MFGLIVO8T:*:KJZY4Y%.KHO<S"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[6M0;S#!&<
M=:WW.(V/M7%7;%[J1CW->7FE:4*:C'J=>$@I2N^A#G/6BBBOG#TC6TC4'BF$
M3G*-^E=/U&:X:$XF4CUKMHB3$I/I7T.4UI3@X/H>=BX)2374?1117K'&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#,UM]MB1ZFN5KH_$#_N57UKG*^9S25Z]NQZF$5J84445Y
MQTFGH:[K[/I755SOAY,RR-Z"NBKZ;*XVP]^YY>+=Z@4445Z)S!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 44R2:.(9=@/J:JG5;0'&^LY580TD[%*$GLB[1445Q%,,HX/XU+5J2DKH3
M36X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)X@
MC)C5QT%<[7;W5NMS T;=ZY*[L)K60@J2O8U\]FF'DJGM$M&>CA*BY>5E6BEP
M?2K=GI\MU( %(7N37F0IRF^6*.N4E%79L>'XBL#.1][BMFHK>!;>%8U[5+7U
MN&I>RI*'8\>K/GFY!1116YF%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<]KEZ6?R%/ ZUT!^Z?I7&7Y)O9<_P!ZO,S6K*%+E74ZL)!2
MG=]"M1117S9Z84^.-I9 BCDFF5O:)8?\MY!]*WPU!UZB@C.K45.-V:FGV@M;
M95Q\QZU;HHKZV$%"*C'9'CRDY.["BBBK$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 -=%D4JXR#VK$N]*@^U1HGR[CSBMVJ#_ #:HH]%S
M7+BJ4)I*2ZFM*<HMV8EMI%O;L&QN8>M:%%%;4Z4*:M!6(E*4G=A1116A(444
M4 %%%% !1110 44C,%4DG %8MYK@C8I",D=ZQK8BG15YLN%.4W:)MT5RXUVZ
M#9.W\JU+'6([DA'&UJYZ684*DN5.QI/#5(JYJ4445W& 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1137=8T+,< 4-V =7,:U9M%.95'RMR:T)=>A1RJJ6QWJ.
M748M0C6!5PSG'/:O+Q=2AB(."EKT.NC&I3ES6T.=HKH)?#X(!C?''>FQ>'R&
M_>2 CVKRO[.Q%[6.OZS3M>YFZ?9M=7"C'RCJ:ZZ.-8HPBC %,M[6*V3;&N/>
MIJ]S!818>&N[."O6]H_(****[3 **** "BBB@ HHHH ***1F"C)- "T54>\
M/RBFK>\\BLO;PO:Y?)(NT4R.19!D&GUHFGJB HHHI@%%%% !1110 4444 (S
MJ@RQ 'O6=!*DNI.P8' P.:RM8O9&N#$K$**S8IY(I Z,0:\7$9E%55%+1,[J
M>&;A>^YW-%5K&?[1:)(>O2K->Q"2G%274XFFG9A1115""BBB@ HHHH ****
M,C7+IHH1&IP6KF:W/$*GS(SVQ6'7R^93E+$-/H>KADE35@I58HP93@BDHK@.
M@[#3+C[19JQ^\.#5VL+P_+\KQ^G-;M?78.I[2C&3/'K1Y9M!111729!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IL@W(1[4ZBAJZ R&&&(I*M7%NP;<HR#5;:WI7F3@XNQU)IH?"
M2)5QZUJ#I5.VMR#O:KE=F'BXQU,:C3>@4445N9A1110 4444 %%%% !1110
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MDI",@BDU=#0V,YC!I]10'AE]#4M*+N@>X44450@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH J7]XEI"2W)/ %8-MK,EN2-@*D^M6
M/$"OO1OX:PZ^>QV+JQKVB[6/1P]&#IW?4[:UNDNH1(GXU/6-X?5A Q/W3TK9
MKVL-4E4I1G+=G%5BHS:04445N9A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4UV"*6-.J"Z!,7%3-VBV
MAI796^TD2%E'!JU!.)1CO6;5BT!\W/:N.E5ES6-IP5C0HHHKN, HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN+>.YCV2#(K-&@P
MA\DG'I6O16-3#TJCO-7+C4G%63&11)#&$08 I]%%:I)*R(;N%%%%, HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME=WMU!V%C[UB>%R?^%HR_5JN_#76;BTU*YT.7#(AP&'KFJ/AC_DJ,OU:M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUU/\S5PG)19G4I0=1-H[>W@CMH$AB4+&@PH':I:**R.@**** "BBB@ HHHH
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M;UW>F>:;BT[,F,E)70ZBFLZ(,NP7ZG%#2(J[F=0#W)I%#J*A:[MT8*TT8)Z
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M#,DBJ/<XI%#Z*@6\MFZ3QG_@8J<'(R* "BD9E498@#U)J%+RV=]JSQEO0,*
M)Z*8TL:D!G4$] 3UIQ( R3Q0 M%-61'&5=6 ZD&HC>VROL,\8;TW"@">BDW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'\Z.1V'[6-['7T5PVM>/)=*\0-IBVGFD@[=H))-5#XYU?3[Z :KIRPVTS8#
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MX7E/C'^V?,_=[2-OUQ5GQ=H$GB#3DMXWVE6SFL^9>YY&G(_?\_\ (YWQ@<^
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MQH =6)J_AJUUB^MKFX9CY!RJ@\9SFMNF&6-3@R*#Z$TTVG=":35F.10B!5&
M!@4M("",@YI:0Q&^Z:X3P!_Q_:I_UU/\S7=M]TUPG@#_ (_M4_ZZG^9JX_"S
M*?QQ.\HHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"R/D5UM%4I-:(ATXMW:&QQK%&J( %48 %.HHJ2PHHHH **** "BBB@ HHHH
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M7\4;@2^(UC!R$4?RK#T.-!&TCK=#GAHBP'Z5GZH_F:BQWR,,#F3.?UIJ/O\
M,2Y_NE$KGH!7T5X5A\GPY:+ZH#^8%?/,*[[B)/5@*^D=&3R]'M%](E_D*BOL
MC7"+5LO4445S'>%%%% !1110 4444 8<*Q?\)-,1!*'\H?O"/E/-;E8T)/\
MPD4H^T CRQ^[V\CGUK9H **** "BD9U099@/J:Q)]2N+XR0Z?D21GYBR\&@"
M_>ZG#9Q%S\^&"D+VS5%EOM3\Z-B8K:2/Y'7[P-6K/288)9)FR\DI!8,<C./2
MM   8 P!0!1M]*MX3'(ZB29!@2-UJ\ %& ,4M% !1110 4444 %%%% !1110
M 5 UG [LYC7>PP6QR14]% " !0 .@H;.TXI:* .)O-WVI]W7-05N:O8A[@&'
MESU K)-I.&VF-L_2OD<10G"HU:Y[%.I&441JI=@H&2:ZW2[7[-:@'[QY-9^D
MZ6RN)IAC'05O5Z^681P7M9[G'BJRE[J"BBBO7.,**** "BBB@ HHHH X+QI_
MR-.B_C_,5WHZ5P7C3_D:=%_'^8KO1TJY?"C*'Q2"BBBH-1DDJ0QEY&"J.I-9
M*^*]$:X\D:C!OSC&ZN6^)NK/;06EDKLB3/ARO7&*QKI_#+:&8H8YQ<A,J^UL
M[L5I&%X\S,:E5J7*CU62Z@AMC<22JL(&2Y/&*H7'B71[6-7EOX55NA+=:X:R
MO+JX^&-\+C>&C0JI;(..*7P7X1L]0T'[7?,\SR9 RQP*?LTKWZ$JLY<JBMST
M&#5+&YM#=17,;P 9+@\"I;2]MKZ+S;69)4SC<IKS;PE;>3KNL:('8VX+!03G
M'2I_ MV^EZQJ6D7#$;&+ID]B2:'!:V[7!5GI==;'?3ZC9Q7 M9+E$F<?*A/)
MK!T*QC@UV]E75/M#-UBW9V<USNC[]?\ 'E[>DDP6I*+SQV-/\&LQ\::R"3C;
MZ_[1H4;?<$JEWY7L=S-K>FP-(LMY$K1_?!/2G66JV.H0--:W*2QKU93P*\M3
M1?[<^(EY!-*X@4Y90Q&>!6SXTBC\-Z EEIFZ+[4Y0G/3BER*R[L?M97D[:(Z
MR7Q9H<,_DOJ4 <'!!:M6"YAN81+#(KQD9##I7(:;X&THZ&OG(SS/'N+ECG)%
M9'@6>:PUS4]%:1GAA8[-QS@#%')'5+= JDU9R6C.[?7=,C$A:]B'E_?YZ4EA
MKNF:FQ6SO(I6'4*<UYCX>T*/7/%VI"YE?R8VSL#$9Y-6M9TR+PWXUTU]/+1I
M,<,N[@\@4U"-TF]Q.K.SE;1'I=QJ-G:2)'<7"1N_"ACUJE_PD^C&Z^S?VA#Y
MN<;=W-</\1HGNM9TN%9&3S'P2#CM3O%?A"QT_P +"YMS(MS'M/F;SDTE%<JE
M(J527,XQ6QW5[X@TK3V5;J]BB9N@9JNVUU!=PB6WD62,]&4\5Y[X:\)6FI>&
MUO+]Y)YI8\[BYXIOP_NY;2TU:W+LR6Q8IDYQUIR@E=7U1,:LGRMK1G=7^N:;
MIAQ>7<43'LQQ3[#5K'4T+6=S',!UVG->2Z-J>F:CJU[>ZR9I6\PA% ) %6K&
MZ@MO&UN^C+.+:7AU(..E-4N@GB.O3\3U*;5+&WG\B:YC27&=I/.*J0^)M&N+
MK[-%J$+2YQM#<UY[XKLVU+Q]:6IE>-'0[MI(R,BK/C;PO9:-H\-[9;XYXFSN
MW'FI4(V3?4J52=Y**V.I\8>)8=!TII$GC6Y)&U&/)%/\,^*;+6-/MPUY"UVZ
M M&#SFN9\66D&H^!(;^="TZA0&S6KX'T&QAT*SO8XB+AHP=V:KE2@[]&3SSE
M4C;9HZ&]\0Z5ITGEW5[%&_\ =9N:MVE[;7\(FM9EEC/\2GBO*+8VECXFO%\1
M0RD2-^[<Y( R:]*T*WTZ&SSIK[H7Y'S9Q4N"4;EQJ.4FC5HHHK,V"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B9%--X:VP1EW
M\Y" ![UE:7XW;3-#CM+RPG6ZC3:H"<&O1I(HY5VR(K#.<$9J%]/M)6#/;1,1
MT)45<9)1Y692IMRYXLX3P/I5VL&I:I=QLCW(8JI'..:C\%Z=+-#KMO+&R"64
M@$CKP*]&5%5=JJ OH!21PQQ9\N-5R<G QFASNWZ6%&E9+79W/+O#>LR^#9KK
M3M1M9O)\QFC=%SG)I]Q)<^-?%%I+!;21V5L<EG7&>0:]*GLK:Y.9H(W/JR@T
MZ&WAMUVPQ(@_V1BJ]HK\S6I/L7;EOH><^+K&[T?Q+9:W;0-+%'@.%&<  UKQ
M>/$O98(+*QG:1R VY.!ZUV,D22KMD164]B,U%#86D#;HK>-&]0H%)35DI+8I
MTVI-Q=KGGVO6#7OQ#LA+ 7A9 'XXZU%;PWO@GQ+Y<2/)IERW0#A2?_UUZ48(
MC()#&I<=&QS1)!%-CS8U?'3<,T1J620G1NV[ZCHW$D:N.A&:=2  # & *6LS
M<\X\?6\TWB;1FCC9E5QD@=/F%>B(/W(^E(\$4C!GC5F7H2.E253E[JB0HVFY
M=SSGPI;S1^.=3=XV"D\$C@\50UF[;2/B*+Z6VF>$+U1<]Z]16")'+K&H8]2!
MR:;):6\S;I((W/JR@U2G9I]E8B5*\6K[NYS%KX]LKJY2%;2Z!8X!,?%9/CV"
M6?6='>.-F E4G Z<UW:V-HK96VB!'<(*D>"*0@O&K%>A(Z4E))II;#<)2BXR
M>YS_ (IT@:MX8>$+F54!3U!K*\):Q<P^$9O/AD,]J",$<GK7<8!&,<5&MM B
MLJQ( W4!>M)2T:[C</>4ET/&;'6EOM>?4];M+J38W[J,)D"O2-#\5VNKW MH
M;:>+ XWI@5M?V?9_\^L/_? I\=K;PMNB@C0^JJ!5.<6K6(A3E%WN8-WXEFM_
M$L.EBT9D?K)@X'-<[XOMYI?&>E2)$S*&Y('3BO0C;PM*)#$A<=&QS0T$3N'>
M-68="1TI1DHM/L5.FYQ<6]Q3_J?^ UYWX%MYHO%.LN\;*K,<$CK\QKT>HT@B
MC9F2-59NI ZTHRY;^94X<UO(\LUBZ?2/B-]NEMIGA"D91<^E=5:^/;*ZN8X%
MM+I2YP"8^*Z>2TMYFW201N?5E!IJV-HC!EMH@1T(057,K)-;$>SDI-Q>YP7C
M^"6XU727CB9EW@G Z<BNB\6Z.-7\-31!<R*A9..];[P12$%XU;;TR.E/(!&"
M.*GF]U(OD]YR?4X?PCK%Y'X5D$MO(T]J2NTCD@'%._X6+9B!A+97*S@8V^7W
MKLTMX8P0D2*&ZX'6H&TRQ=][6L);UV"J<E)MM$QA*,4D]CS_ ,#:9=W/B*\U
MJ:!H(I?N*PQGFO2Z:B)&NU%"J.P%.I3ES#IPY%ZB-]TUPG@#_C^U3_KJ?YFN
M[;[IKA/ '_']JG_74_S-$?A8I_'$[RBBBH-0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC..M<GXG
M\;V.@Q-&C"6YQPH/2FDV[(F4E%79NZIJ]GI%LTUU*J #@$\FO'/%?C^[UB1[
M:S9HK;IQU:N>UG7K_7;II;F4[2>$'05GA0OUKJA24=6>?5Q#GI'8:%R=S')-
M>A?"]YDU29@2+=5)8]LXKE+7P_J%W9/>K"1!'R2>,BM2X\6VUEH2Z?H\)BD<
M8ED)R:J7O*R,Z?N/F8_XBZ\-7UKR(6W0PG'![]*Y- 6 4=2<5$@=G+L26)R2
M:ZOP=H+ZWJT8VGRXR&8]N.:>D(BUJ3]3U3P-I:V7AN$2(-T@#'(KROQ_;B#Q
M7,H7:" ?TKWJ&)885B0851@"O*/BGI96^AO@,*PPQK"E+WSLKPM2270\YCD$
M5S$Y_A;-?1%EJ,-OX;@O';]VL*D_D*^<YL <#->D^&]7;7/!MSI!?%S&I*\]
M1_D5I5C=)F&&GRMH;J'Q4O4O&%K;QF%3W)R:[;PIXPM?$5OC(2X7[R5X-*C1
MS/%(,,IP:ET[4;G2+U+JV<JRG./6B5*+6@0Q,U*\CZ;HKG/"GBFW\06"D,%G
M4892:Z.N5IIV9Z,9*2N@HHHI#"BBB@#&A5O^$CE/V9 /+'[WG)YZ5LUAPF'_
M (2:8"20R>4,J2=O6MR@ J&YNH;2$R3.$7IDFDN[J.SMGGE/RH,FLF&&;59W
MEE='L7 *)MYS0 ACNM8EDCE_=6Z.&CD3^(5LPP) @51R!@GUIZ(L:!%&% P!
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBD9@BEF. * %J*XF6"(N?P%
M9\NNV\<FT MCN#1#,NIW 8?ZM.<>M<DL53E[E-WD;*E):R6A8LH6),\OWVZ>
MU7-H]*4# P**Z(04(V,Y2;=PHHHJR0HHHH **** "BBB@ HHHH X+QI_R-.B
M_C_,5WHZ5P7C3_D:=%_'^8KO1TJY?"C*'Q2"BBBH-3A?B)HUQ>06M];1&5[=
M]S(!U&*KVGBW1!9HLVF2B<#!7R^_YUZ"0&&& (/8U5_LNQW[_LD.[UV"KC*R
MY692IMRYD<WK,RZAX%O7M[5H@\9VIMP>U3^!8GB\+0I(I5OFX(KI?*C,?E[%
MV?W<<4J1I&NU%"KZ 4<VC7<?L_>4GT//O#5O,GC[5I&C8(S-AB.#TK.\?6MY
MI&NQ:K81,QE78VT>V/ZUZ@L$2.76-0QZD#DT2P13@"6-7 Z;AFCGU3[$^R]U
MKN[G*^ ]*>P\/":92)[CYWSUS63X0MYH_&.L.\;*K+P2.OS&O0U554*H 4=
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M=A\GO-]SGO",;Q^$;5'4JPB'!KF_ ]E*;C6HY(V42,0"1UZUZ*B(B!$4*HZ
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M-17%@=7C:U6/<&&,^E>3A,SKK$*<M4^AT8K!4YT>5:-=3RJ**2:010H7<G
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M]^@S,C#!-<H\;([1R*5=3@@U:TC5KG0[Y;B!CMS\R]B*[#6-)MO$VF?VSI(
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M[-EE620D$*?4^U>L4F!Z5,96T*G!R::=K'!_\)Y?_P#0'F_[Y;_"C_A/+_\
MZ \W_?+?X5WF!Z48'I3YH]A<D_YC@_\ A/+_ /Z \W_?+?X4?\)Y?_\ 0'F_
M[Y;_  KO,#THP/2CFCV#DG_,<'_PGE__ - >;_OEO\*/^$\O_P#H#S?]\M_A
M7>8'I1@>E'-'L')/^8X/_A/+_P#Z \W_ 'RW^%'_  GE_P#] >;_ +Y;_"N\
MP/2C ]*.:/8.2?\ ,<'_ ,)Y?_\ 0'F_[Y;_  H_X3R__P"@/-_WRW^%=Y@>
ME&!Z4<T>P<D_YC@_^$\O_P#H#S?]\M_A1_PGE_\ ] >;_OEO\*[S ]*,#THY
MH]@Y)_S'!_\ ">7_ /T!YO\ OEO\*/\ A/+_ /Z \W_?+?X5WF!Z48'I1S1[
M!R3_ )C@_P#A/+__ * \W_?+?X4?\)Y?_P#0'F_[Y;_"N\P/2FR21Q+EV"CU
M-'-'L')/^8X7_A/+_P#Z \W_ 'RW^%'_  GE_P#] >;_ +Y;_"NR_M&R_P"?
MB/\ .C^T;'_GXC_.G=?RBM+^8XW_ (3R_P#^@/-_WRW^%'_">7__ $!YO^^6
M_P *[+^T;'_GXC_.C^T;'_GXC_.BZ_E"TOYSC?\ A/+_ /Z \W_?+?X4?\)Y
M?_\ 0'F_[Y;_  KLO[1L?^?B/\Z/[1L?^?B/\Z+K^4+2_G.-_P"$\O\ _H#S
M?]\M_A72>']9FUBW>2:U: J<88$9_.KW]HV/_/Q'^=']I67_ #\Q_G2>JT0X
MW3UD6Z*J?VG9?\_,?YTHU&S8X%PA/UJ;,TYEW+586MZY]B)@A&92/RK<5E=<
MJ<@]ZXK6;9EU-V<'! P:\[,JU2E1O3W.G#0C.=I&8QENI3)*Q8GUJ3Y8Q[TH
M)+".-<L>PJR\=MID7GW[ R?PQ=Z^=PV%JXF=H:ON>C6KTZ,;RT&P6;3*9IV$
M4"]2>,U1O]<4(UIIR[4Z&3')JE?ZG=:J^TDI .B#I38X$A7+5]A@<LI857>L
MCYO%YA.N[1T1A:QHS7<!GR3(O/)ZUS$-M-/,((8V>0G& *])@M[C4I?(MD)!
MX)["NO\ #_@^RT@_:&C5KEN2V.E=\ZBBCEI47-Z;'*^$OAR%V7FJ#+=5CKTR
M&".WC$<2!5'0 5)17)*;D]3TH4XP5D%%%%26%%%% "$!A@C(/:O+_'W@?>&U
M/3H_F'+H*]1I'570JPR",$549.+NB*E-35F?+I!.4888<$&M'0=<N=!OUEC)
M,1.'0]"*[?Q[X':W=]2TZ/Y#S(BCI7#Z7I<FISA"-J@_,376I1E&YYCISA.R
MW.OU;P]:^(((]7TH@!\>:@[5H:7IMO96PC11O[FFZ6K^'RJP\Q'AU[&MFY@C
MEB%[9\Q-RRC^&OGLXC6G3O!^ZMT>Y@(TX2O)>\R&UNI=/N1+&3CN*[C3[^*_
MMQ)&>>X]*X4$2KCO4EE>2Z;<AT)VD_,/6O(P&.>'ERR^%_@>AB*"J*ZW/0:*
MK65Y%>P++&0?4>E6:^JC)25T>4TT[,Y+4;L)XA-J)Y2TZ!-JQG"^^:Z+3[3[
M):JA;>W4L1R:D^QV_P!I^T>4OG$8W8YJ>F(***CEFC@3?*X1?4T 2452_M;3
M_P#G[B_.C^UM/_Y^XOSIV8KHNT52_M;3_P#G[B_.C^UM/_Y^XOSHLPNB[15+
M^UM/_P"?N+\Z/[6T_P#Y^XOSHLPNB[15+^UM/_Y^XOSH_M;3_P#G[B_.BS"Z
M+M%4O[6T_P#Y^XOSH_M;3_\ G[B_.BS"Z+M%4O[6T_\ Y^XOSH_M;3_^?N+\
MZ+,+HNT52_M;3_\ G[B_.C^UM/\ ^?N+\Z+,+HNT52_M;3_^?N+\Z/[6T_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1W'_'O)_NG^525%<?\ 'M)_NG^5 GL>'ZE_R$9_]^JM6M1_Y",_^]56O56Q
M\_+=A11102%%%% !1110 4444 %%%% !70^#?^0]%7/5T/@W_D/15-3X6:T?
MXB/7"JNN& (/8U"MC:H^]8(PWKM%6!THKS+GNV04444#"BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 444WS$W[-Z[O3/- #J*H:QJL.CZ>]W/]
MQ3BG:7J":II\5W&"%D&0#3L[7%=7L7:***0PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J*X_X]I/]T_RJ6HYQF"0#NIH!['AVH_\A&?_
M 'JJU<U5#'JEPC=0]4Z]1;'STMV%%%%,D**** "BBB@ HHHH **** "NA\&_
M\AZ*N>KH_!:%]>CP.E34^%FM'^(CUP=****\P]X**** "BBB@ HHHH ****
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M18T]35/^WM*_Y_HOSKE_BBS#PXH5F7+X.#CTIND^!M$N=,MYI!(7903^^/\
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MKFJ5^961WT,'R2YI,=1117,=P4444 %%%% !1110 4444 %%%% !2'D$4M%
M'SA\1]/^P^*[@!<*_(-<A7K?QDTP^;;7RCC!#&O)*]"D[Q1XU>/+4:"BBBM#
M$**** "BBB@ HHHH **** %!(.1P17H/@?XAW&C3)9WS&2U)QDG[M>>T5,HJ
M2LRX3E!W1]:V%_;ZC:K<6TBNC#.0:LU\W^$/'%YX=ND1W,EJ3AE)Z5[]HVN6
M>N627-I(&##)&>17#4IN#/5HUXU%YFE5:^O[?3K5[BYD"1J,DDTS4M3MM*LW
MN;J0(BC/)KP+QMXZN?$-V\,#E+13A0#UHITW-CK5E37F3^.O'MQKMPUI:N4M
M%..#]ZN#HHKNC%15D>1.;F[L***E2*3*N8V* \\4R3KO"'@2?Q"/M-PY@M!_
M&>_YUI^+OAJ-%T[[=8W#3PJ/FSC^E5M4\7A_#>GZ5I#-%($ EVG!)KT#0K9C
MX'6T\076PS$G+GG'45A*4D[G;"G3DN5+7N>*Z'K=UH6HI=6SD%3R,]17T5X4
M\4VOB/3DDC<"<#YTSS7G?BKX;Z?!HC:CI$I8(-QRV<BO/= U^\\/ZBEQ;N0
M?F7L11*,:JNMQ0G+#RM+8^IZ*P_#/B6T\1Z<D\#CS /G3/(-;E<C33LSTHM2
M5T%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %)@>@I:* "BBB@
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MSL/:NR:RMGN%N&A4RJ,!\<BEN+6"[39/$LB^C"H4K<OD:.G\7G_D9$0/_"(
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MF-'6HCU@=****\T]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKB/'?@B'Q!9M<6Z!;M!D$#[U=O13C)Q=T3."FK,^2;VRFL+I[>="CH<$$57K
MW_Q]X%AUNU:\M$"W:#/ ^]7@UU:S6=P\$Z%'4X((KOIU%-'D5J+IRL0T445H
M8A77^!_&,_AW4%21RUJYPRD]*Y"BIDDU9E1DXNZ/K6POX-1LX[FW</&XR"*L
MUX%\/?'$FBW:V5W(3:N<#)^[7O%O<1W4"S1,&1AD$5PU(.#/7HU54C<Y_P 9
M>)K7P_I+F;#22*0B'O7S=>W)O+V6X*A3(Q; &,5WOQ=N)G\1)"Q/EJIVC\J\
MZKJHP2C<\_%5'*=NP445U.C>!=3UG2Y;Z)"$094'^*M&TMS",7)V1+X"TG2M
M7U1H-3DVY'R#.,FKOB'X=7]AK*PV2&2WF;Y&'85QQ%SIE[@[HYHV^E>U^ O'
M46LVRV%^RK=(,(Y[UG-RB^9&]%0FN26C+FE7%AX)T6"QU2Z\R67JK'.,US/C
M7P=C&OZ$WR_?8(:Y[XC:-JMGK+W5R[S0.<H_851TKQ[J6F:--IP/F(XPI8_=
M%1&#^*+-)U(ZTYJR6QOQ_%6[A\/_ &-HLWBC:)3CBO.[N[FO;AYYW+NQR234
M4DC2R,[?>8Y--K:,%'8Y9U)3W8445TGA3PE>>)+Y51"L /S.1Q5-I*[)C%R=
MD0^&?"]YXBOUBA0B+/S/C@"OH;PYX;L_#U@D%O&-^/F?')-2Z%H-GH-@EM:Q
M@8'S-CDUJUPU*KF_(]:A05-7>X4445D= 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 45FZ_J+:5HMS>HH9HDW &J&E>(7N_#7]J2198 G
M:O/2G;1OL2Y)24>YT-%96@:S_;>GBZ\EXLG[K#%:M#33LQQDI*Z"BBBD,**P
MM:\1#2+RVM_LTDOG'&54D#G%;B-N0-C&13MI<7,KV%HHHI#"BBB@ HJI!J=I
M<W4EO%,K2Q_>4'I6?K^OC1!!_H[R^:P7Y5)QDXIV=["<DE<VZ*C@E\Z!),$;
MAG!J2D-.ZN%%%% !1110 45RGB/Q/-H^L6-G'$K+<-@DGIR!75 Y&:?*[7)4
MDVXBT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:K^F^';#3.88AN]36M6%6MS*R.W#X7V;YI;A1117.=@4444 %%%% !1110
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MB@ HHHH **** "BBB@!" P((R#7D_P 1/A^)5?4],B^8<R(HZUZS3719$*,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R/CC2!=V'VI%S)'UK
MR[O7O<\*SP/$XR&&*\8U_36TS5)8MIV;OE/M79AYW7*>9C:5GSHRZ***Z3SP
MKU/P'=M<:2T3'/EFO+0"3@#)->L>"M.:RT@,XPTG)%88BW(=F"3]IH=-1117
M">N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -DC26-HY%#*PP0:\4^(?P_:RD?4M-CS">711TKVVHYH8[B%HI5#(P
MP015PFX.Z,JM)5(V9\BD8.#17I/Q"\!/ID[ZA8(3;L<LH_AKS8C!P:[XR4E=
M'D5*;A*S"BBBJ(-'1-6GT?4X;J!RI5AG!ZBOIS0]375](M[U?^6J!C7REWKZ
M+^&)D/A"#S,]!M^F*YL1%6N=N"D^9Q.SHHHKD/2"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".6>*$ RNJ ]
M,FG@@C(.0:YOQA:6=U:VXO+UK55?(*L1D_A6FVH6.DV$#7%P%C.%5F[YZ4[:
M7)YO>L:5%8,_C#1+>=8I+Q0Q]C4]YXFTFQA66:[4*PR,<T<K#GCW->BJ6FZM
M9:M!YMG,LB^U0S>(=+M[B2"6Z59(QEE/:BSO8?,K7-.BL2R\5Z/?S-%!=J7'
M8\4V3QAHL=W]F:\429QT.*.5[6%SQM>YNT5!+>00VIN9) (0,EO:DLKZWU"W
M6>UD$D;=&%*P[HL452AU:RN+V2TBG#3Q_>7TJ";Q#I<$TL,ETJR1??4]J=F'
M,C4HK%L/%6D:C<_9[>Z5I.RD8S6K<7,-I"99Y B#J30TUN"DGL2T5SZ>,]#D
MG\D78W$X!(.*WD=9$#HP93R"*&FMQ*2>S&7%Q%:P/-,P6-!EB>U-M+R"]@$U
MO('0]"#61XS)'A/42/\ GB:S? EQ'!X1CEF<*BLQ))]Z:C>+?8F4VIJ/<Z]F
M5%+,0 .I-1BYA:%I5D4HO5@:RI]0T_6M(N?)NCY.TAI%R,5FZ3;6MKX6NEL[
MMKF/Y_G9B>?QI-63;*YKM)=3H+;4[2[MWGAF5XT^\0>E.LM0MM0C9[:59%4X
M)![UP/@DD^$=4))Z-_(U=^&))TFZ).?W[]?K6CII7\K&4:K?+YW.[HK&U#Q1
MI.FR^5<70#^@&:M:=K%CJL>^SG60#KZUG9VN:\RO:Y?HK,N?$&F6EP\$]TJ2
M(,LIIVEZY8:PKFRF\P(<'BBSM<?,KVN:-%(2%&2< 5AW7B_1;.X\F6\7>#@@
M G%"3>P-I:LW:*JV^H6MW:_:89E:'^]65+XST.&?RFO!N!P< XHY7>PG**5[
MF\S!5+,< =:J6FIVE\DC6\RN(R0V#TQ2274-WIDDT$@=&3((KA?AT2;#5LDG
M]Y)_Z$::C=._0F4[.*74[RTU*TOGD2WF5VC.& /0U;KSKX=L?[3U?)/^O[_0
M5U5[XLT>PG,$UT!(.H )Q3E"S20H5.9-ON;=%5[.]M[^W6>VD#QMT-6*AJQH
MFGJ@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S*BEF( '4FLTZ_
M8"7RS+T[]JB\2221Z9\F0&<!B/2LZ&QL_L*@HA4KRV* -R?5;.WC5WF&&Z8/
M6DMM6L[H'RY0".H;@UQ>B1Q7-].LK^8L9PBMS4OB)(K58GA/E.S8;;QQ0!U3
M:_IZR^69><XR.E3SZI:6\2R/,NUNF#UK!M[*T-@O[M#E<EB.^*QM'CCGU2XC
ME<ND38C5CQB@#M;;5[.[R(Y0".S<&HGUZP27RS+D^HZ5ROB*.*UCBD@/E2%L
M';QFM.TLK0V*Y1&RN2Q% &]-JEG!"LK3+M;I@]:9:ZO9W9(CEP1V;BN,TJ.*
M?5IXI'WQQM\BGI5CQ#%%:VZRP?NY,@?+QQ0!T\FO6$4IC,N2.I'2IY=3M(8!
M,TR[3TP>M<_8V5JVGH2BON7)8]36/IJ1S:O+!(^Z*,Y12>* .UMM9LKIML<N
M&]&XJ.77K"*4QM+D@X)'(%<SX@BAMK198L12;@ 5XXJYI]G;-IZ,R*Y=<LQ'
M.: .@EU6SB@$S3+M/3!IMKJ]G=MMCEPWHW%<;IL,,NLSQ.VZ.,_(A/%3>(HX
MK6V66 ^5+G'R\4 =1)KUA'+Y9ER<X)'2IY=4M(8!,TR[#TP>M<_8V=JU@I**
MVY<LQ'.:Q].2*;6YX'<M#&WR*3Q0!VMMK%E=MMCEPWHW%1RZ[80R^6TN2.I'
M(%<UX@BBMK030XCE!X*\5;TZSM6T]&*JY899CU- '0R:I9QVXF:9=AZ8-1VV
MLV5T^U)<-Z-Q7%V212ZW);N^Z%#E5)XS5SQ!##;67G0XCE#  KP<4 =--KMC
M!*8VER1UQR!4SZG:);B<S+L/0YKG=+M;:33XW95=G7+,W7-95M'$^O/;%R8%
MY5">,T =G;:U973[$EPWHW%-FUVQ@E\MI<L.NWG%<YKL,%O9>=&!'(I^4KP:
MFTFUMI-/61E5V?EB>3F@#HVU.T6V\\S+Y?KFHK;6K*ZDV)+ACT#<9KC(HXF\
M0/:ER8!R$SQFM'6[>""P::,".1!\I7@T =%/KEC;R^6\N6[[><5+_:=G]F\_
MSEV?6N:T:UMY-/61PLCM]YFY-9OEP_V]]FW_ +C.=F>,T =E;ZW8W,FQ)<-V
MW<9K&\31Z3?HT4KCSU'#*,XJOK5M;PZ>TJ!8W7[K+P:31+>";3TFD DD<98M
MR::;3NB914E9GG5W;_9KAH]P8#H13(8FGF6)?O,<"M3Q+%'#K#K$ %P#@5E0
ML4E5E.&!R#7HQDW&YX<X)5''S.STK0=/TZ=)=1EWR#G8N"!7>1:A9"T$J2H(
ME&.O2N7T&"&>Q$TH$DK?>+<U1GCB77TM@Y$#<L@/&:\^<W)W9[5.E&FK1.Q@
MURQGD$:RX)Z;N,TZYUJRM7V/+EO1>:P-5M;:+3W=55&094KP<U7T""">Q\Z7
M$LA)!+<G%2:'5IJEF]N9Q,NP=>:AAUVPFE\M9<$]-W -<;>)"FN1VZ/MA?EU
M!XS6OJ5I:II[L%5"J_*PZT ;USK-E:OLDERWHO-/CU2SD@,RS+L'7)Z5R?A^
M&&XLO.FQ+*3R6YQ52_CA36X+='*12'YT!XH ["+7K"67RQ+@]B>!4EUK%G:,
M%DDRQ[+S6%?VEHE@QV*NU<JP'.:H>'(HKJU,TY\V4GG?SB@#KXM4M)H#*LR[
M1UR>E01Z]82R^6)<$G )Z5Q^IQQ0ZS!!&Y2.0_O%4\5L7MG:+8.=BKM7(8"@
M#<N=8L[0@22@D]EYI\.IVD\+2),NU>N3TKD/#T4-S \LQ\V0,5&[GBJ^KK%!
MJL$43E$D/[Q5/% '8)KUA)+Y8EP2>">E2W6KV=I@22@D] O)K#N;*T6P;Y%4
M*O##K69X=CCNHY))SYL@8@;^<#/% '96^I6MU&7CE&!UR>E5SK]@)?+\WOC/
M:N1UH+:7B+;,4\P8D"^E;$5E:?8%_=H05R6Q0!N7&JV=M&KO,N&Z8.<T6VK6
M=V#Y<HR.H/!KB]$CBN+ZX65_,6-L1ACGBG^(HXK58W@;RG8X.WC(H ZMM?T]
M9?+,O.<9'2II]4L[>)9'F7:W3!ZUA065I]@'R(05R6(K'TB.*XU.>.1]Z1-B
M-6/ % ':6NK6=WGRY1D=FX-1/KU@DOEF7)!P2.E<KXBCBM(HY(#Y4A8#Y>,B
MM.ULK3[ OR*P*\L1R: -Z;5+2"%97F7:W3!ZTRVU>SNR1'* 1V;@UQ>DQQ3Z
MM/%(Y>./[BL>.M6/$44-K;++"?*E+!?EXX/6@#J)->L(Y?+,N2#@D=*GEU2S
MA@$K3+M/3!ZU@6-G:MIZ$HK;ERS$<UCZ;'%-K,\+OOBC^XI/% ':6VL6=VVV
M.4!O1N*CDUZPBE\LRY(ZD<@5S'B&.&UM1-#^ZESP5XJ[I]G:MIZL45RPRS$<
MYH W+VZTZ>P;[0Z/#(,8SG->!^-?#D%A>O=:>2ULYSMQ@BO2;%(I==GMW<M#
M&?D0GBD\;V=HOA^=PBJX'&!6E.;BS&O24XZG@U%*WWC]:OZ):1WVL6UM+G9(
M^#BN]NRN>.E=V&Z3ITNIZC#;1+DLPS]*^C-'N=/T#2[?3C)EHE"MMYYKF+GP
M[INB:4LUHFR88P_?FMS2;6WET])'57=QEBW)S7%5J<^QZN'H>S5WN=(VIVBV
M_GF9=A[YJ*VUJRN9-B2X;L&XS7%P1Q/K[6I<F!>0A/&:T-<@@@L3+&!'(I^4
MKP:Q.DZ.?7+&WE\MI<L.NWG%2G4[06WG^<OE^N:YO2+6WDL%D=5D=^69N366
ML<1\0-:[SY YV9XS0!V=OK=C<R;$EPQZ;N,T7&MV-O)Y;RY;OMYQ7.ZW;V\&
MGO+&HCD094KP<TNBVUO+IZR.!([?>9N30!TW]IV?V?S_ #EV?6HH-<L;B3RU
MEPW;=QFN-:.'^WOLP?\ <9R4SQFM+6+:WBT]I$58W4?*R\&@#H;G6K*VD\MY
M<MWV\XJ4:G:-;F<3+L'4YKEM#MX)[!9I0))''S%N35":.(:_':AR(&Y*9XH
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M&['D4E[K7H*W-%_XC.\;:1:Z)J.F7>GQB%_,VG;WZ5)\1-5=6TVS<OY,NUI
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M&W@#FKC\+3W,YVYTUM8D\!O=+INHP21RK;JQ\KS!CCBD^'/_ !X:M_UTD_\
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M>8 : %UZ\FTC59+:S<I$<<5L/:0+X36^ _T@KOWYYS7/^(D-UKUP5Y"5M37
M_P"$&3![8_2@"AX=NI=9U5;>]D,D:CA:3Q'=S:/JKPV3E(SU6HO"\9M?$,"M
MQO&?TIOB5#=^(+L+SY>30!AZBQ>97)W,R@DT:4BR:G;JPR"XR/QJ&=MV#Z<5
M8T?_ )"UM_UT'\Z]&'\,\.I_&?J=%XBNY='U)H[%_+5ER16M;6<$OA=KY^;@
M\[^^:P?$R&YUB;'/EKD_G6Q;W 7P$W/1L?K7G'N&5H%[/JNJQ6UY(7B!^[ZU
M9\33/HNIF.P8QJRC(K.\/1FVURR<\"0@BK?BU3=:](B\D(#^E &Q96D$_A>2
M^E&ZX*[M^>]86BWT^IZM!9W<A:$G&WUK7L)]O@J89Z<?H:P-"0V^OV<AX#'/
MZ4 :GBF9]$U!%L&\M77Y@*T-.M(+OPQ/?3_-/@G?GH:RO%JF[UQHAR50G]*O
M:5/L\%7:D],_TH R-*O[C4=5CL[F0M#G[M:/BN0Z)J""P/E!DRP'UK&TE#!J
MUO,>CMQ6IXR!N=9V#DJA_G0!I:+:0W_AV6]N/GG.?F/;%<]IFI7-]J4-G<2E
MH"^,?C6YH,_E>$+I<_<)_G7-Z9&8=2M9^@=P1^= &]XK/]AW:?8#Y>Y1D"K>
M@VL.HZ'<7ER-\X4G<>Q -9_C'-WJL<0Y)0&K?AV;RO#=\N?NC'Z&@##T[4;F
M]U6WL9I2;=GVD>U:_BS_ (DDT#6!\LN.<=ZY[34,.IVEP> 9!BMWQIFYO[>$
M<G8#^E &GX4@BU33;BZN_P!Y*3M)/TKEY-4NDU)K)9B+?S2N/;-='X.D\K2K
MV/\ N\_I7(31EKHW(Z&8\_C0!UGB:"+2-.M[BS_=S8'([TSPFJZV;B2_/FLB
M\9[<TGB^7SK33XA_RT48_.F>"B;:XOHCU$>/UH Q[C4KF#4391RD0&3;CVS6
M_P"(K>+2M(M;JS^28D?-ZURLZ&2]>X[++U_&NF\3R>?I&GQ_WP* &^%,:X]P
M]^?,9%XSVK&O=2N;75)K&&4BW#[0/:M7P23;W-Y&>"4_QKG[Q#->SW(Z"3!-
M '6:]:PZ;HMK=VHV3D9+#OP*J^%/^)Y<R&_/FE!@ U-XFF\S0-/3/WAC]!57
MP;FTU&:(\'83^E &;J6IW-CJ<]G!*5@#D8KH-=M(=.T"&\MODGX.X=\URNI1
MF;4;F?L)#G\ZZ7Q%/YGAJS3/W\#]: (?";G7+^07Y\S8N5!K,U/4+C3]3DM+
M:4K"6QC\:O\ @T&TU=XSP=G]:QM30SZI<3=D?G\Z .JU6T@L?#4%[ -LYQ\^
M>M<W;7$FL6.H?;7+^5$"H]\UO:W-O\'V29^]C^M<Y8H;9+R(\%X136Y,OA9Y
M-,,3./\ :-6M*D:+4X'0X96R#5:?_CXD_P!XU/IO_(0A_P!ZO1E\)XD/B1[/
MX5F?6[\1W[>8J+POX56UZ_GTK5I[:SD*1;C\OI4O@Y3:ZTB'@E"?TJCKR&YU
MV^D[*Q->:>Z=+?6=O!X72]C&)\!M^><FLOPS<2:UJHBOW\Q%4D+5Z_N-W@>(
M9^\=O\JR_"B&UUN+=P74T &NWDVDZK);V<A2,]JVI;."/PJ+X?\ 'P<'?WS7
M.>($-SK5TXZ1\G\ZW;J?_B@H\'DL!^IH S_#-U+K.JK#?.711D+3?$%W+H^J
MR6]DY2,XR*9X40VNO6H;CS,&H_$J&[\03[>B 4 ;PM(/^$3%]C_2"N_?WS61
MX?NYM7U:.VO)"\0Z+6C]H \##GV_2L?PS&;7Q!;[N-XS^E %GQ+=2Z-JK16+
MF-&ZBM:.S@?PJU\PS<8W;^^>*PO%"&[\072KSY8)_2M>"X \ R\]"1_*@#+T
M*\FU;5X[:\D+Q#/R_2I_$UQ)HNJ-'8MY:LN2*H>'D-MK-NYX\SI5CQ8INM;F
M"\[%R?SH VK.S@G\,/?2<SG)WUA:#?W&J:I#:W<A>+/2M>RGV>!)>>C8_6L#
M0(S;:Q8R'@2$$?G0!I^*)FT34ME@WEJRC(K1TZT@N?#,U[,-T^W=O]\&LGQ<
MIN]?:->2$!K1TN?9X-N1G[O'Z&@#'TB^N-2U6"SNI2T);&WUJ[XGF?1=05+!
MC&&'(%9.BH;?7+*0]&8']*T?%JF[UYHEY*IN_3- &KIUI!=^&9KV<;I\9WYZ
M&L+2[^XU#58[.YE+0;L8K8TB<+X)O.?NY_E7.Z2AAU2WG/ =N* -OQ8YT.^C
M_L\^7O3+ ?6K6DVL-]X=FOKC+3\_-Z8JAXS!NM8$8Y*H:M:)-Y?@R\7/W"?Y
MT 9&E:A<W^J16=Q*6AW=/QKU6*-88EC0851@"O(-*C,&JV<QX$CY'YU["#E0
M?6@!:*** "BBB@!K(K_>4-]10R(PPR@@>HIU% "8&,8&/2A45!A5 'L*6B@!
MH1 VX* Q[XHV(&W!1N]<<TZB@!K(KXW*#CID4I4,,$ CT-+10 @55&%  ] *
MC-O"7WF)-WKM%2T4 -"(IR$4'U H"(&W!0&/?%.HH :R*_WE!QZBE(!&" 1Z
M4M% $/V2WW;O)CSZ[14H  P  /:EHH 0@,,$ @]C0%51@* /0"EHH 8(HUSA
M%&>N!UI0BJNU5 'H!3J* &A$4850 >P%*J*@PJ@?04M% $<D$,O^LB1OJM*D
M4<8PB*OT&*?10 W8F[=M&[UQS3J** "HFMH';<T2%O4J*EHH 0* ,  #T J)
MK6W9MS0QD^NT5-10 @15&%4 >@%(J(@PJ@9ZX%.HH :J(N=JJ,]<"F&U@9MQ
MA0MZ[14M% "  #   ]J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>0$C:O/_ 'U4FC2M?:U?RY)&S^M %:'1V/AVYF)7>TP(Y]":MW5G)=?V.A(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 0W7_ !Z3?[A_E7AU\<WTQ/\ >KW&[_X])O\
M</\ *O#KW_C]F_WJZ\-U/.Q_V2O11174>:%%%% !5[1N-6M_]\?SJC5[1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ H[44=J /FWXC_\CK?_ /70_P!*Y.NL^(__ ".M_P#]=#_2N3KT8?"C
MQ*OQL****LS"O6?@U_Q\W/TKR:O6?@U_Q\W/TK*M\#-\-_%1[+1117 >P%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $-W_QZ3?[A_E7AU[_Q^S?[
MU>XW?_'I-_N'^5>'7O\ Q^S?[U=>&ZGG8_[)7HHHKJ/-"BBB@ J]H_\ R%;?
M_?'\ZHU>T?\ Y"MO_OC^=*6Q4/B1[C1117EGT(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=J*.U 'S;\1_^1UO_
M /KH?Z5R==9\1_\ D=;_ /ZZ'^E<G7HP^%'B5?C844459F%>L_!K_CYN?I7D
MU>L_!K_CYN?I65;X&;X;^*CV6BBBN ]@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;..=@KN(HD@C6.-0J@8 %/HK*<Y2>IU4Z4::M$****@T"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".:&.XB
M:*50R,,$$5Y5XJ^%'VB9[K2FVECDQUZS151FXO0SJ4HU%:1\SS^ O$$$A4V3
M$#N#4]C\.]?O)0IM2BG^(FOI#:#U H  Z 5M]8D<_P!2A?<X#PA\-K71&6ZO
M,37(Z9Z"O0  !@445C*3D[LZ80C!6B%%%%26%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .16M?\ KG7%>$^?B'JH]S_.FW[TH] 4;0A/J[":WJ.H^*/%1T6QN&@MH_\
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MTX6::6F@JB<91E)W5SV"O-?BIUTS_KM_2O2J\U^*G73/^NW]*SI_''U-JO\
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MS(YW[3D\B_14<,\5Q$)(9%=#T93Q49OK47/V<SIYW]S/-38NZW+%(S!%+,<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\32./B1IJAV"Y'&?8U=^&FKV4/AYH)ITCDB;#!CCUK!U;5K;5/B58&V;>J,
M6'3H:T:?M_Z[&',OJUOZW+WQ5></I:02,KN0!@]R16MH'@." 6^I7L\TEV")
M"?,.,_2LSXG?\?VB_P#71/\ T(5Z1;KNL8U]5J.9QI:=V;<BE6][LCR>XO8O
M$OB^:WO[QH;*WX"!B,_E]*7Q18Z1I%M'J&B7CK<1,"5\PG-4M-TO3H_&]Y:Z
MR@42-E"QP.]=O+X5\(Q)NE\@+[O_ /7JKJ*C8S47-RO89JNNW)^'JWT1(E:,
M D?A65H/A#3-1\+_ &V[FD>XE0L7,IX/-;'C3RK#P2\5E&&@*@#;T XYKA=*
MMX#IT<,?B1H87'SQL5&*4=5+ETU'-\KBI:Z&M\-=+@.L7Q9I'-LYV,7..N*L
MV,C_ /"V9TWMMV'C/'W:ZKPAIVDZ;8-%IUREPS<NX(R?RKC7N(]+^+#RW3".
M.12 S<#I5*7-4^3)<.6DGYHZ[XA,R^$+PJ2#L/(-5/"C,WP\RQ).Q^2?:JOQ
M'U_3QX;GM4G62652 $.:L>$O^2=_\ ?^596_<R]3=M.O&W8S?A/_ ,@_4/\
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MPUU>RA\/-!-.D<D1^8,<>M5%MQE?R(DE&I"VVI1\2R./BCI:AV"G;QGV-/\
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M+#_PHA11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,V.BM<&WWGSV+-N.:VJ*5V-Q3MY'&7GPZT^XN7EBN+F'><LJ28!K9T+PQ8:
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M38+51Q&N*N444F[N[*BE%604444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gtqsgrqcdg4e000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .3 \,# 2(  A$! Q$!_\0
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MYK;UCQ3?^'?"L5Q>X:]D''&*R<';F[FZK1NX]CNZ*\8LM9\<:I -0M@&B)R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI !N4=>*UYDIP;['/[.3IS2[GH1A@_L'9M7R_)_I7B7@S,?Q!80?=RW2KO\
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MH_M.V_OC\Z +E%4_[3MO[X_.C^T[;^^/SH N453_ +3MO[X_.C^T[;^^/SH
MN453_M.V_OC\Z!J5MG&\?G0!<HI 01D=Z6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH SKI0VH0 C(S5WR(O[B_E5.X_P"0E!]?Z5H4 1^1%_<7\J/(
MB_N+^5244 1^1%_<7\J/(B_N+^5244 1^1%_<7\J/(B_N+^5244 1^1%_<7\
MJ/(B_N+^5244 1^1%_<7\J/(B_N+^5244 1^1%_<7\J/(B_N+^5244 1^1%_
M<7\J/(B_N+^5244 1^1%_<7\J/(B_N+^5244 1^1%_<7\J58T4Y50/H*?10
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M[7YK*X4!%!(P!7I->%_"[_D<+C_=->Z5I6BDU;L98:<I)W[A1116)TA1110
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M "BBB@ HHHH *IZE_P >A^HJY5/4O^/0_44 68?]4OTI],A_U2_2GT %%%%
M!1110 4444 %%%% !1110 4444 %%%% &?<?\A*#Z_TK0K/N/^0E!]?Z5H4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4]2_P"/0_45<JGJ7_'H?J* +,/^
MJ7Z4^F0_ZI?I3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/N/^0E!
M]?Z5H5GW'_(2@^O]*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>I?\>A
M^HJY5/4O^/0_44 68?\ 5+]*?3(?]4OTI] !1110 4444 %%%% !1110 444
M4 %%%% !1110!GW'_(2@^O\ 2M"L^X_Y"4'U_I6A0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5RJ>I?\ 'H?J* +,/^J7Z4^F0_ZI?I3Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#/N/\ D)0?7^E:%9]Q_P A*#Z_TK0H **** "BBB@ HHHH Y?Q
M)X#T?Q1<)/J$6YT& <5\X:YX7T^T^)\&D1)BV:0*1^=?6]?,?B;_ )+9:_\
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MQ2OT.SL_CIY=Y''J>FRP1N>&*@5Z/J7BZTM/"CZ[!^^A$>\!:X7XWZ-IL?A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF$C [G%>B!%'10/H*6FTG%Q[B6DD^QY=\&?#>I^'=(GBU*W,+LQP"?>O4:0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5/4O^/0_45<JGJ7_'H?J* +,/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>I?\>A^HJY5/4O\
MCT/U% %F'_5+]*?3(?\ 5+]*?0 4444 %%%% !1110 4444 %%%% !1110 4
M444 9]Q_R$H/K_2M"L^X_P"0E!]?Z5H4 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M>I?\>A^HJY5/4O\ CT/U% %F'_5+]*?3(?\ 5+]*?0 4444 %%%% !1110 4
M444 %%%% !1110 4444 9]Q_R$H/K_2M"L^X_P"0E!]?Z5H4 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@U=LM+LM.!%I;I$#UVU<HH 9+$DT31R*&1A@@]ZCM;.WLH?*MXEC3).!4]%
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M]ZS=_9S]5^12^.'S(OA+I]F?!%A.;:,R^6/FV\]ZXOQ%I-OJ_P 8K>WN1F,
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MH **** "BBB@ HHHH *IZE_QZ'ZBKE4]2_X]#]10!9A_U2_2GTR'_5+]*?0
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M%]:WOQ=T-K:>.4"UER4;./F%>N5XQJ6A6FB?%K18[0$*]M(3G_>%>ST %(2
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZE_P >A^HJY5/4O^/0_44
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M5<JGJ7_'H?J* +,/^J7Z4^F0_P"J7Z4^@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH S[C_D)0?7^E:%9]Q_R$H/K_2M"@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \K\5?\E?T+_K
MUE_]"%>J5Y7XJ_Y*_H7_ %ZR_P#H0KU2@ HHHH **** "BBB@ HHHH ****
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M^M:7A+QW:^)9Y;1X'MKR+[\4A&>N.U"UV!Z;G7T444 >5^*O^2OZ%_UZR_\
MH0KU2O*_%7_)7]"_Z]9?_0A7JE !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !117!>-=8\6Z?>HFA:<UQ$>I"
M _UH [VBO M3^)GCC2;RWM+S3#'-/_JU,8R><>M=#I7B3XA3ZC;I=:,Z6[.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D(!Z@&EHH \7^*H \=^'< =?_9Q7LL:KL'RC\J\;^*W_(^>'?K_ .SBO8)K
MB.TLVGE8*B+DDT <[X[\5P>%?#\UT[#SBI$:^IKR_P"$_A6XU[69_%6K(6W.
M3$']C_@:RM:NKOXH_$!=/@+'3K9\,1TP#C-?0.DZ;!I.F0V<"!4C4#CZ4 7
M   !@"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MIZE_QZ'ZBKE4]2_X]#]10!9A_P!4OTI],A_U2_2GT %%%% !1110 4444 %%
M%% !1110 4444 %%%% &?<?\A*#Z_P!*T*S[C_D)0?7^E:% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4R6))HVCD4,C#!![T^B@#FG^'_ (4E<N^B
M6K,>22#_ (UIZ9H&EZ,C)I]E%;JW4(.M:5% '.WO@7PYJ%T;FXTN!Y2?F8@\
M_K6S9:?:Z=;"WM($BB'15Z59HHV5@\SG]1\$^'M4N?M%UID$DIZL0<FM73]+
MLM*MA;V5ND,0_A4<5;HH6F@;F%JG@[0=8G\Z]TZ&67^\PYJ_IFCZ?H\'DV%K
M' GH@J]10M-@>H4444 >5^*O^2OZ%_UZR_\ H0KU2O*_%7_)7]"_Z]9?_0A7
MJE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !117FGQ6^(7_"(Z>MO:D&[F!Q_LT 8'Q5D0^//#V'7@\\]/G%
M3_%WQH\-I%H&ER;KJY^5MAZ \8KY[U3Q/JVKZ@M[=7<C2J<H2WW?I76?#;58
M+_QW;S:Y(T\C'",YS\V>* />OA9X,3PUH*3S)F\N!O=B.>>U>@TU-OEKL^[C
MC%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M>I?\>A^HJY5/4O\ CT/U% %F'_5+]*?3(?\ 5+]*?0 4444 %%%% !1110 4
M444 %%%% !1110 4444 9]Q_R$H/K_2M"L^X_P"0E!]?Z5H4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
M?BK_ )*_H7_7K+_Z$*]4KROQ5_R5_0O^O67_ -"%>J4 %%%% !1110 4444
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M(T&  *F1%C1410%48 %.H 3:#V'Y4M%% !1110 4444 %%%% !1110 4444
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M 53U+_CT/U%7*IZE_P >A^HH LP_ZI?I3Z9#_JE^E/H **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<!X[^*&F^#QY&/.NB.$4]*[B]E,-E/(.JH2/RKXI\;ZE/J7BS4)9F)(E(&3
M0!TWA_XHOH_BV\UEK<L+D\KQQSFM[38M<^,.O&6XF,6G1G)4<#'X5XS7L/P#
MU2>#Q++9@DQ2@ CTH ^A?#OAG3_#>GI:V4*KM'+8Y/XULT44 %%%% !1110
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M 53U+_CT/U%7*IZE_P >A^HH LP_ZI?I3Z9#_JE^E/H **** "BBB@ HHHH
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M/P%X;_X1CPQ;6+#]X%&_ZUIZ=X<TK2N;2SB0^NT9K5H **** "BBB@ HHHH
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M^&M$T[1[:>PM$4N@);'/2OC[0-*N-8UBWM+>-F9G'0=*^V]"LS8:+:VS=4C
M/Y4 :( '2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\2N=$?1/BQH\;WD]R7MY#NE;)'S"O;:\K\5?\E?T+_KUE_\ 0A7JE !1110
M4444 %%%% !1110 4444 %%%% !17'^-OB#IG@VVS<-YD[#Y8E.#7E<7[1,G
MVW]Y8-]GST&W.* /H2BN4\._$#1-?T<Z@ETD2J/G5FY6N+\5_&NTM)6LM"C-
MY<G@,A!&?QH ]2U#5;+2H&FO+B.%%&<L<5Y+XG^-2F9K#P[;M<SGY0P&17-V
M/@[QG\0KD76LW$EI:,<[#D C\#7K7ACX;Z'X:A7RK=99AU>0;CG\: /*=-\
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MHB1J%10JCL!BG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUI]E-NA@QC9CBL6/P#X;CNOM"Z7 ),YS@_XUTM% #(H8X(Q'$@1%X %/HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ7_ !Z'ZBKE4]2_X]#]10!9
MA_U2_2GTR'_5+]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 9]Q_R
M$H/K_2M"L^X_Y"4'U_I6A0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4%Y.;:TDF5"Y1<A1U-3TA (P1D4,#RO4O%WC6-9KR#1I%M(B>&C!)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4]2_P"/0_45<JGJ7_'H?J*
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M+Z6+.\N%$M[!&@/)9P*],L]1\+6MJD/VNT;:.I<45JD+6>HL-1J7YEH4U\?
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MGZ1WUV'_ +^"N+DI_P QZWM*W\IZ3_:5G_S\Q?\ ?8JEJFNVMI822QSHS@<
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ME:%9]Q_R$H/K_2M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH4%Q,93(V<\UK_\ "J]!_P"FWYUTWA[3Y-,T:&UE(+IG) K4H X7_A5>@_\
M3;\Z/^%5Z#_TV_.NZHH X7_A5>@_]-OSH_X57H/_ $V_.NZHH X7_A5>@_\
M3;\ZG@^&VC6P/EF49]Z[.BFFUJA2BI*S.1'@#3>0SR8]C51OA9H3,6/G9/O7
M<T4Y2E+<F%.,/A1PO_"J]!_Z;?G1_P *KT'_ *;?G7=45)9PO_"J]!_Z;?G4
MA^&^FP6Y2U>16_VC7;44XR<7=$SA&:M(\BTGPZ+_ ,07&G,^/(&XGUYQ73R_
M#+1K@AI3*6QV--\.6D\7C?5)GC98VC #'O\ -7<54JDI;F=.A"F[Q1PO_"J]
M!_Z;?G1_PJO0?^FWYUW5%0;'"_\ "J]!_P"FWYT?\*KT'_IM^==U10!PO_"J
M]!_Z;?G4D7PRT6 EHC*&]S7;44TVG=":35F>=S?#V3SOW4PV9[U>'PWTV:W"
M73R,W^R:[:BKE5G)69C##TX/F2.%_P"%5Z#_ --OSH_X57H/_3;\Z[JBLS<X
M7_A5>@_]-OSI1\*]"!!'G<>]=S10!YMXC\&VVE:7+=VSMMB4DAC1X<\&P:KI
M<%[<.=DR!@%/K7:>(M/DU31+FTB(#R(0"1[4[P]I\FEZ#9V4I!>*,*2!Z5K[
M:=K7,/JU+FYK',GX6:$S$GSLGWI/^%5Z#_TV_.NZHK(W.%_X57H/_3;\Z/\
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M% %F'_5+]*?3(?\ 5+]*?0 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH *IZE_P >A^HJY5/4O^/0_44 68?]4OTI],A_U2_2GT %%%%
M!1110 4444 %%%% !1110 4444 %%%% &?<?\A*#Z_TK0K/N/^0E!]?Z5H4
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MC^SK;_GF/RJW10!4_LZV_P">8_*C^SK;_GF/RJW10!4_LZV_YYC\J/[.MO\
MGF/RJW10!4_LZV_YYC\J4:=; Y\L<>U6J* $  &!2T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gwrjt5hibe5u000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwrjt5hibe5u000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ."3(# 2(  A$! Q$!_\0
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
MGVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:
M7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RJ5=65D#&!P"<5=\E/2CR4]*
, '@Y /K12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gtqsgrqcdg4e000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -R!CP# 2(  A$! Q$!_\0
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M-:/EI_<7\J/+3^XOY4 9W]M1?\\9/R-']M1?\\9/R-:/EI_<7\J/+3^XOY4
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MCY:?W%_*D\M/[B_E0!G_ -M1?\\9/R-']M1?\\9/R-:'EI_<7\J7RT_N+^5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR2!L9H ].HKR"P\<ZK;W:K=^;,A_NJ:]5T^[%Y:1S;2-RYP: )IIT@C+R,
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M>-#KA%O-O,V>IKO: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX=;V4/\ >!&:]AF_X]Y/]P_RKRGPC;V&C7+-)>ALGJ:]"?Q'I+1,OVQ.5(H
M\?U)@OC6(DXY/\Q7M&F7$7]FP?.OW?6O&_$^C6NH:E]H@U$H><%:S8]+O$V@
M:].%';=0!ZKXTUF&SL/E*LY. #S7FYEU_4-.ED6V@^S[NH S_*M!=+M[C2UC
MNM6:1QS\QK-@TW$;VW]IND9/K0 GA!766]$G#9YQ^%3:=;1S^,I=Z@C(ZCW-
M7M!TRRTUI]]_O\P]35RPLM.@UY[PWHPV*!EKXBP"'30(D"KL'W1CM4GA 6)\
M/W&]4+;.<@5N:_>Z#J>FF":^C7Y0,_A7E=SIEK!)+]EUYQ&3]U3Q0(EA\D>)
M[SR<=.WXU1O%U!O$:?9D5FV\!J9X<%O;:_(9+OS%.!N/>NP\1:1IUQ(MU::B
M$D"CA:!F9J&B^([U83<6\"J!P5KTKP593V6G1I-V7UKS33[*2:ZC^T:Q*J(>
MYKU+2M6TJQM$B-^CD#J:!"^,_P#D!R5X_P"$O"]GK.J3BX9Q^\/W37K&OZMI
M6H:<T*WB9-<KX4M]-TF]DE:]7YGSS0!D^,/ ^G:3"DD#R$Y[FK/AT8\,$?6N
MC\5SZ9JT"JMZO'I69I<&FVFCFV-ZN3F@#BO#WANQUO6Y%NI&4&0CY3BO1[;X
M9:%;3+(ES*2IR,O_ /7KSBX\/*EZ\UMJSQY8GY34D.G7JS*3K]P0#S\U '?^
M-;2*TT+R(F)4'J37GOAGP.NM-(YEF7Y_X6(KKI([6XTA8)]2+OGJQK2\(MIF
MCJP>]7EL\T >=:OX<D\-ZK 59V!?^-B:]8TS7X+/PPEQ+M!P>WM6%XL@TS5[
MB.1+U?E;/%95]:VT^C+:+?[<'M0!5O=2U/QE?&WMROV<DJ2#BO0O#'AFVT6T
MRV"[+\V3FO'8/#;6LA:#5Y(\G/RFNMT1GLXI!/J\DN1QN- &;\4S9&X;RV(D
MWC.WZU9^%ALO.3<Q,N[C=4AT;3M0U62XN[\,K#[K41Z58:=K$5Q:7X5%'(7I
M0!#\1(4GU*WC/W6;''XUL:%\.=*O-"6XD>7>5)X/M576[6QU.:UD-Z,Q]:[/
M1M5TNRT9;8WJ9"D4 >1OH\&E>+(XH2Q49Z_6MGQI$LT%E&W 9<']:OWVGZ?<
M>(%O!>C I?$]C8:G:PI'? ,BXR* &^&_ASHM_IL<TUQ*&8<X?_Z]=IHG@S2]
M#D\RUF=F _B;/]:\BAT:Z@0)%KDZJ.@!K<T*":UNU:XUN5U]&- &=\0+(7GB
M&WBR0"Q'!J\/AH#HZW237&=N<;SC^=:&K:?87NI6MQ]N!\OK7;0:II2Z,+4W
MB9"D4 >9>"9FT;7!!* 0,\MR:]+N?%&D7C+8RS,KR<<<5Q46GZ?#K_VK[8I7
M%,\2:387#QW-KJ.V1!T6@#/\6>'K32[Y+ZUD=V=\_,V:]+\#7TEYHB-( #G'
M%>56VF?;[B-;S4G"(V?F->KZ)?Z-I-@MNE[&<=Z '^,?^01-_NUY-X9\+6.M
M:M<?:9'7GLV*]2U_5-*U"QDB6]3+#'%>23>'S%>R2VVKR1AC_": -?Q=X+TK
M1(1-;S.SAAU;/]:M:1?RS>&;B-@-HX%8L'AW[9*OVS7967.<,:[E+31K31'M
M([Y&9@.: ./T0N!?[.NVK?@E8'\0R?:0"=O\0^M:^@66EV<ESYMZI$@QS6#K
MFB6T6H/=6&J%2W&$H [Z_'AY;^,2MMEQQM KA/%_E_VG8>2<IO\ E_6I?#^E
M6[7T=Q>ZJQVGHQK0UVPTV\O+5DOEVQ-GB@##\4;_ .SK??G9YH_F*[S1([(^
M%&.V,],D@9Z5GZE8Z-J&BK;M?(KJ<YKAFTR:!FMHM7E\ECG@\4 .T_CQ1((/
MN^;SBK5Q"DGCR;< ?F'4>YKH?#&CZ1IL<DLVH+)*_.6ZYJ%[#3CXFDOOMHVL
M0?UH L_$F"*/1 4C53L7D+CM64,_\(=)_P!<:Z+Q>=-UG3?)2]4':!Q]*SQ:
MZ<- >S^VKDQ[: ,#P^9!X<.W_GF?Y5I_#9+1F<S!2V]OO >M:'AZRTJSTLVT
MMZO*$<_2N5OM$CL+YGL=4<*23\IH ]%F'ATZ@%#D3;N H'6N(\4^'VN-2:;3
M?GEW9PQJ]X9TJRAF^TWFJEGSG#4WQ)IUM)=M=6FK,,G.U30!@C5M>T6=$U"W
M@$8QR #_ $KVCPW?I?Z;'(O]T9KQN'28M2N5^V:@P4?WJ]6T;4=&TNR2%;V,
MX4"@#.\?VCRZ:SJ.%!-<[\+M4A4"V9@&!/6NYU#5M&OK5X7NX\,,5Y+K/A^W
MM+UKC3=59,]DH ]:U[Q1::/"6>09QD5PWB+7GUK2O-B)*;2:YBPT7^T+I#J&
MK2;!P0YKT;[/H"Z+]B%W$"$V[L4 97PX6R;2_G"%^<[@*YKQ,(U\86_V; Z_
M=XJM<Z,-.NF%CJS^6>RFMGPUHFGQ7BWE]J?F.ISAZ ,WQ%G[1IF[KO\ \:M>
M,_\ D P?]=!_2M/Q#8Z9?W]M)'>J%C?.!2^(+33M0TV*!;T?*X/'X4 <UJGG
M?\(=-LZ;1_*DT"U\13Z45MK>!HRG);KC\J[&.PT>?P[)827R L!S7'?V=)83
M/#;:K)Y;' P>@H LZ3H6J6=W<W$R!6,39"GV-'P[$3^)!]I +B5OO<]ZZ;PO
M:6-G$TEWJQE9T*E7/M7-ZWH5K;:G]KT[4RIY.$H ] U8>'AJ$(G8++N^7:!U
MKC/B,D'DVQB V^>.2/<5%H&D6\E^EU?ZLQ\MMP#FMGQM9:7K-I&D-^JE'W#;
M0 MZ$'@=\ =!T^E<_P"$]_\ 8>L[.N/\*NV=O;_V*]G+J!.3WK5\)6VE:9;W
ML4UXI$WK^% &/\-%MVUNX^T!2^SG<,^M+\2A;+/B$*).,;15/6M#MK;4I+S3
MM59-YQM3BFZ5H5O>WR3ZCJC$#L] $>O^8=$M/,_YY<5VV@VD'_" Q/Y:%C$>
M=H]*SO$MGI5]:P00WB@1KMXK9TRZTRU\+)IYO5W*A% ''_#L;?%N!P,G^=>U
MUY/X5M=.TG7?M;7HQSUKT1?$.ENV%NT)- &I13(Y$EC#H<J>AI] !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '/1?\C3/_N_XUJ7/^M_"LN+_ )&F?_=_QK4N?];^%>-GO^Z_
M-?J:TOB%U#_5I_O5;7[B_2J6I,%B0GINI5U&W"CYNU>R9%VBJ?\ :5O_ 'J/
M[2M_[U %RBJ?]I6_]ZC^TK?^]0!<HJG_ &E;_P!ZC^TK?^]0!<HJG_:5O_>H
M_M*W_O4 7**I_P!I6_\ >H_M*W_O4 7**I_VE;_WJ/[2M_[U %RBJ?\ :5O_
M 'J/[2M_[U %RBJ?]I6_]ZC^TK?^]0!<HJG_ &E;_P!ZC^TK?^]0!<HJG_:5
MO_>H_M*W_O4 7**I_P!I6_\ >H_M*W_O4 7**I_VE;_WJ/[2M_[U %RBJ?\
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M;_WJ ,[_ (1'1_\ GT6E_P"$2T?_ )]%K0_M*W_O4?VE;_WJ ,[_ (1+1_\
MGT6C_A$='_Y]%K1_M*W_ +U']I6_]Z@#._X1'1_^?1:/^$1T?_GT6M'^TK?^
M]1_:5O\ WJ ,[_A$='_Y]%H_X1'1_P#GT6M'^TK?^]1_:5O_ 'J ,[_A$='_
M .?1:7_A$M'_ .?1:T/[2M_[U']I6_\ >H S_P#A$M'_ .?5:/\ A$M'_P"?
M5:T/[2M_[U']I6_]Z@#._P"$1T?_ )]%H_X1'1_^?1:T?[2M_P"]1_:5O_>H
M SO^$2T?_GT6C_A$='_Y]%K1_M*W_O4?VE;_ -Z@#._X1+1_^?1:/^$1T?\
MY]%K1_M*W_O4?VE;_P!Z@#/_ .$2T?\ Y]5I/^$1T?\ Y]%K1_M*W_O4?VE;
M_P!Z@#/_ .$2T?\ Y]%H_P"$2T?_ )]%K0_M*W_O4?VE;_WJ ,[_ (1'1_\
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M_P!Z@#/_ .$2T?\ Y]%H_P"$2T?_ )]%K0_M*W_O4?VE;_WJ ,[_ (1'1_\
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M?_GT6M'^TK?^]1_:5O\ WJ ,[_A$M'_Y]%I?^$2T?_GT6M#^TK?^]1_:5O\
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MM_[U']I6_P#>H S_ /A$M'_Y]%H_X1+1_P#GT6M#^TK?^]1_:5O_ 'J ,_\
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MY15/^TK?^]1_:5O_ 'J +E%4_P"TK?\ O4?VE;_WJ +E%4_[2M_[U']I6_\
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M#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B?V /^>[4?V /^>[5MT4
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M#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B?V /^>[4?V /^>[5MT4
M8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B?V /^>[4?V /^>[5
MMT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B?V /^>[4?V /
M^>[5MT4 8G]@C_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B?V /^>[4
M?V /^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B?V /
M^>[4?V"/^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W10!B
M?V /^>[4?V /^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y[M6W
M10!B?V /^>[4?V /^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_8 _Y
M[M6W10!B?V /^>[4?V /^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y[M1_
M8 _Y[M6W10!B?V /^>[4?V /^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_8 _Y
M[M1_8 _Y[M6W10!B?V /^>[4?V /^>[5MT4 8G]@#_GNU']@#_GNU;=% &)_
M8 _Y[M1_8 _Y[M6W10!R&G:?]E\4S?O"WR]_QKHKG_6_@*RXO^1IG_W?\:U+
MG_6_A7C9[_NOS7ZFE+XA=0_U:?[U6U^XOTJIJ'^K3_>JVOW%^E>R9BT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '/1?\C3/_N_XUJ7/^M_"LN+_
M )&F?_=_QK4N?];^%>-GO^Z_-?J:TOB%U#_5I_O5;7[B_2JFH?ZM/]ZK:_<7
MZ5[)D+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]%_R-,_^[_C
M6I<_ZW\*RXO^1IG_ -W_ !K4N?\ 6_A7C9[_ +K\U^IK2^(74/\ 5I_O5;7[
MB_2JFH?ZM/\ >JVOW%^E>R9"T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK8WB7MNLL9R",U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH YZ+_D:9_P#=_P :U+G_ %OX5EQ?\C3/_N_X
MUJ7/^M_"O&SW_=?FOU-:7Q"ZA_JT_P!ZK:_<7Z54U#_5I_O5;7[B_2O9,A:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PU.W2Z\1HD@#
M#S>AKT^O-KK_ )&=/^NM '7+X=T\)DP1X'M38M#TJ;)CCB;!P<4GB/4_[-TP
M,&PTAV#\:Y;PQJ5S::JME<R;C*2XQZ9_^O0!UW_"-Z?_ ,^\?Y4?\(WI_P#S
M[Q_E3K;7K>>Y>#!5E.,GO3&\1VJW\UJ0=T2Y)SP: %_X1O3_ /GWC_*C_A&]
M/_Y]X_RK+/CBT#D^7)M!P:O7GBJTM(8G96/F#( H F_X1O3_ /GWC_*C_A&]
M/_Y]X_RJF_BZ!+=9C#+ANG!HL?%UK=7@MMK!R,\T 7/^$;T__GWC_*C_ (1N
MP_Y]X_RJK=>*[:"78L;OCKM&:2T\7V=RTB['4H,G=Q0!;_X1O3_^?>/\J/\
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M^\?Y4T^'],49,,0'TK/'C&&190()00I()!K&MO%AN"5E5RN[TH ZE?#^FO\
M=AC-./AS3P,F"/'TJC!XBM8)(HBC9DZ5>O=>MX(&)!;(Z"@!BZ#I;?=BB-/'
MAS3R/]1'^5<U=^)$BTHSVRLK;\5H:9XMB<Q13(^]QP<4 :O_  C>G_\ /O'^
M5<UXVT6TM-'62*)%;S!R*ZF37+>-E7!)8XXK%\=R"3P^K#C,@H TO"__ ""T
M'^R*W*P_"_\ R#$_W16[0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM'H/RHVCT'Y4 ><_8?&'_01'Y?\ UZ/L/C#_ *"(_+_Z]>C;1Z#\J-H]!^5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !33(@."P'XT.<(3[5P^KZO/!JOE*>-P_G5
MP@YNR$W8[KM7F_C-B-7L,?\ /3_&O0[=MUM&Q[J#7G?C3_D,6'_73_&M,/\
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M2Y_UOX5XV>_[K\U^IK2^(74/]6G^]5M?N+]*J:A_JT_WJMK]Q?I7LF0M%%%
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M4C<.A]ZZ,/))ZD3IS:T1Z=:_\></^X/Y5YYXT_Y"]A_UT_QKNH+V".QB9I%
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MGAQ;^*%"6_=C'!KHZ*Y?9QM8T>-K.2DWJCE+'PHEK+O!?\32ZEX62^N!(2_
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M^J^>]3%U;7WE"1OSK3TBRN;P'+L<>]%1<C2?4*5"52#G'9'N!UC3A_R]Q?\
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M]]5XY;Z5/+8M-N;(4GK7*13737#)YC<,1UI13E3<ULANC)5O8]3Z/_M?3_\
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M/T"KAIPIJ;V9M^"-2LXK0"2YC7Y>YK2\3:E92:<VRYC/T->9ZOX>DT9E2,D
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M_OUT7@\#[1-_US-<[K__ "%G_P!^NB\'_P#'Q-_US-+'?' >7?[M5,+Q&/\
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MCM6GXJTVYG4-'%D;16;X8_X^U_"O6VLH9; %D!X%98>IR5),O,HW4/D>0Z%
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MLJ3]UAF/\:!YAI@_XJ ?[Y_G7ILP']F=/X:\RTS_ )& ?[Y_G7ITW_(,_P"
MTJ&S*S/^) \Q8#_A)#]1_.O4R!]A3C^ ?RKRQO\ D9#_ +P_G7JA_P"/%/\
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M7ZUTXW^.B,)_R+Y'3^*0/[+EX_@KB/!@'FW/_7$_R-=QXI_Y!<O^Y7#^#/\
M6W/_ %Q/\C7++^-$TP_^X5#B=3Q_:[_[Q_G77>$P,FN2U/\ Y"[_ .\?YUUW
MA/O79COXL#++O]TJ'+>*/^1GN/K72^#0#JL?^[7.>*/^1GG^M=)X,_Y"L?\
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M/[+/-<;J)']HM_O&NGT59#HYQG-<C>*POFSUW486FE1DKCQE=O&1ERG:^&F
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MK'ALM3$P)WXS_>-*-)/J$JK3V.]HJ*W!%O&&ZA>:EK$V"BBB@ HHHH ****
M.>B_Y&F?_=_QK4N?];^%9<7_ "-,_P#N_P"-:ES_ *W\*\;/?]U^:_4UI?$+
MJ'^K3_>JVOW%^E5-0_U:?[U6U^XOTKV3(6BBB@ HHHH **** "BBB@ HHHH
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MP]4&6;([_P"%>?7/_(4?_>/\Z]#^'O\ K9O\^E+'?QX^@8)?[!/U.Q\3(O\
M9N<>M<+H('VEO]X_SKO/$O\ R#?SKA-"_P"/D_[Q_G7)-_O$:81+ZI,X_7_^
M0L_^_71>#P/M$W_7,_RKG=?_ .0L_P#OUT7@_P#X^)O^N9KLQWQP,\N2^K53
M"\1C_B9FM?PLH+\CO61XC_Y"9K8\*_?_ !HQV\!98OW%0RO%@ U5\?WJO^$P
M#JB CM5'Q;_R%7_WJO>$O^0HG^[3QWPTPROX*I#XM4"[7 I/"\2F\7@=13O%
MW_'VM+X6_P"/M/J*6-?N0#*TFJAZRVFV\MGN:-2=M>;K"D?B5% &-YKU1/\
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MU%"HHX=ICKQOCRSX=13:'([&N!N/^0Q/_P!=#7H/AX8M6'H#7G]Q_P AF?\
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MU:3*GB;_ ) #_P"Z/Y5QVC_ZY?K78^)O^0 _^Z/Y5QVC_P"N7ZUVU?\ <S/
M_P"_L[C4+66XT)!&N>:XZULYK>X/FKCFO7_#]K'<:2@=0>.]<OXHLXK>X^10
M..U83J_[/R%X6/\ MS8LW_(MS_\ 7*O/M&M99Y@(US7H$W_(MW'_ %RK)^'=
MLD]V0Z@_+WKII0YL(T<M2O[''<_8[WP?;R06&)!@YJAXR^X/I78P0)!& @ '
MM7'>,ON#Z5Q37+"QOAJOM<5S]S&T_P#Y LG_ %S/\J\^L+>2>_=8UR=Y_G7H
M6G_\@63_ *YG^58'@B!)M;VN 1N/7ZUVX:/-A9(QQ=7V6.Y^QV_@RUE@C;S%
MQFKGBT?Z*>*Z*VM8X$&Q0/I7/>+?^/6N*4>6%C6G6]MBE,YKPZI>%@HYYKB+
MS3;J+5)I'3"[R<UZ'X*0/-@CN:TO%>FV\5A+(L:AL9S6E"KR4&NYIB8WQ\69
M/@7_ %K?2NI\2?\ 'BU<MX'_ -<WTKJ?$?\ QXM6-/\ AE8O_?4<-H*EKN0#
MKOKE];TR[&N3RF/Y2V<UV/A50VJ$'^_74^(=,MQ9RR>6N[:3FML+5]G3EYDX
M^-\7$XSP8,7J@^E>@:U_R#F_W:X/PD,:E7>:U_R#F_W:PI? S3'_ .]1."T+
M_D-M_OUZ/J?_ !XM_NFO.-"_Y#C?[]>CZG_QXM_NFBC\+)S'^/ \PTS_ )&
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M"U_X^&KOQ_R)8_WJX"U_X^&KOQ_R)8_WJ<_]\"7_ "+4>?Q?\?#?[U=_:?\
M("?_ *YUP$7_ !\-_O5W]I_R G_ZYT5O]["/_(M. C_X_&KO]$_Y%:Z_WO\
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MU7_D8F^H_G7I2?\ (.'T%11ZE9C]@\VN_P#D/+_UTKTNR_Y!?_ 3_*O-+O\
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M#Z5V]<1XR^X/I6-7X3;+_P".BGX=L_MNGM%ZH15SP_X3_LR_\[:.I-2>"/\
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M4[3Z4X_[ZPQ/_(N@<+8_ZP?[U=]>?\BY)_N"N!L?]8/]ZN^O/^1<D_W!2?\
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M_,Z;_D _]LZX*#_C\_&N]F_Y /\ VSK@H/\ C\_&NZ'^Z,PA_P C ]>\%?\
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ME5^$[LO_ (Z)/ _^J_X#79UQG@?_ %7_  &NSHH_ A9A_O$@HHHK4X@HHHH
M**** "BBB@ K)UW_ (\9/I6M63KO_'C)]*F6QK0_B(X#0O\ D.-_OUZ/J?\
MQXM_NFO.-"_Y#C?[]>CZG_QXM_NFL:/PL]/,?X\#S#3/^1@'^^?YUZ=-_P @
MS_@->8Z9_P C /\ ?/\ .O3IO^09_P !I4-F5F?\2!YBW_(R'_>'\Z]4/_'B
MG^X/Y5Y6W_(R'_>'\Z]4/_'BG^X/Y4Z/469[4_0\J?\ Y&4_]=:]0B_Y!W_
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MSP__ "+F<%<_\A1_]X_SKT/X>_ZV;_/I7G=S_P A1_\ >/\ .O1/A[_K9O\
M/I1COXT?0>"_W"?J=GXE_P"09^=<'H/_ !\M_O'^==YXE_Y!GYUP>@_\?+?[
MQ_G7)/\ B(TP?^Z3.0U__D+-_OUT7@[_ (^)O^N9KG=?_P"0LW^_71>#O^/B
M;_KF:[,;\4#++O\ =JIA>(_^0F:VO"2[I@/4UB^(_P#D)FMSP=_Q]+]:,=O
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MWC]T_2EI#]T_2NB4G)W9XZ5CR_Q'_P AA/\ >KM_#W_'C']*XCQ'_P AA/\
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M/,-,_P"1@'^^?YUZ=-_R#/\ @->8Z9_R, _WS_.O3IO^09_P&L:&S/1S/^)
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MC_%8Z_\ N,3IZ***Z3Q3#U_2SJ,2J.U1^'](.F@ ^E=!14\BOS&_UB?L_9]
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M5YY<_P#(4?\ WC_.O0_A[_K9O\^E=.._C1]",%_N$_4[/Q+_ ,@S\ZX/0?\
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M_P"/=?I5KQC_ ,>K54\$_P#'NOTJWXQ_X]6J%_".R?\ OQG^#/OO]:U_&?\
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M,P_@P-&D/W3]*6D/W3]*Z3QCR_Q'_P AA/\ >KM_#W_'C']*XCQ'_P AA/\
M>KM_#W_'C']*YJ?QL]O&_P"[0-JBBBND\0*#THH/2@#@_&OW#]*O>"?^/7_@
M-4?&OW#]*O>"?^/7_@-<R_BGM5/]P1UU%%%=)XIR/C'_ (]3]*H>!.@^E7_&
M/_'J?I5#P)T'TKF?\5'M0_W!G>T445TGBA1110!A>)O^/%O]VN/\+_\ '^?I
M7=ZO:&[MB@[BL+1]!>SN=YK"<6YIGJX:M".&E%O4ZIHEEB"L,C%5X=-AAD+J
MH!)STJX.% ]J6MK(\Q3DM$PHHHIDA1110 4444 07?\ Q[O]*\KN_P#D9?\
M/K7J\Z;XF7U%<9/X<=]6^T=OI6-:+=K'IY=6A3YN9]#KK'_CSB_W15FHK9/+
M@1?08J6M5L>=+63"BBBF2(1D8JI+IT,K[F49^E7**&KE1DX[$<42Q+M4<5)1
M102W<**** "BBB@ KB/&7W!]*[>N(\9?<'TK*K\)W9?_ !T2>!_]5_P&NSKC
M/ _^J'^[79T4?@0LP_WB04445J<04444 %%%% !1110 4444 %4M5_X\G^AJ
M[5+5?^/)_H:4MBZ?QH\OTS_D8!_O'^=>G3?\@S_@->8Z9_R, _WC_.O3IO\
MD&?\!KGH;,]?,_XD#S%O^1D/^\/YUZH?^/%/]P?RKRQO^1D/^\/YUZJB[K.,
M?[ _E3H]19GM3]#RA_\ D93_ -=:]0B_Y!WX&N4;PW(=7-QVWYZ5UQ3R[(KZ
M TZ46KW,\?6A44%%['EVJ_\ (>6O4=.YTV#_ '*\NU7_ )#ZUZEIO_(-M_\
M<I4?B9IF?\*F,DTR"67S&4$_2K21JB;0.*?16]CR'.35FRE-IL,SAF4$CVJU
M%&L481>@I]%%D#G)JS84444R2I<:?%<'+J#CU%30P+;Q;$  J6@]*5D4YR:L
M>=>-_P#CZ3Z5O>#_ /CR7_=K!\;_ /'TGTK>\'_\>2_[M<\?XK/8K_[C$Z>B
MBBND\4**** "BBB@ HHHH P/%7_(+E_W*Y'X>?\ (3D_W/\ &NZUFS-Y9O&.
MZXK#\+Z"^EWC2-T*XK"46ZB9ZM"M".#G!O5G7T445N>4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!ST7_(TS_[O^-:ES_K?PK+B_Y&F?\ W?\
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M_P @/\!12_WMBQG^Y4SB+#_6'ZUW.M?\BG:?2N&L/]8?K7<ZU_R*=I]*<?\
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MH/\ Q\M_O'^==YXE_P"09^=<'H/_ !\M_O'^=<D_XB-,)_NDSD-?_P"0L_\
MOUT7@[FYF_ZYFN=U_P#Y"S_[]=-X(&=08>JUV8[XH&67?[M5,7Q%:RG42VTX
M^E:W@\%;M0?6N\UO1+9K!IBHW8]*X_0$$>JE1_?K'%55.445ET;4*AZ1=?\
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M-F>OF?\ $@>9-_R,A_WA_.O68/\ CWC_ -P?RKR9O^1C/U'\Z]9@_P"/>/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M5[V(S6[(.X-6**!IV=SA+/PW+#JGGG.-Q/2NNN5V:>R^BU<Q5:__ ./23Z5"
M@HK0Z:F(G6FG+H>6-_R,A^H_G7K,'_'O'_N#^5>3-_R,A^H_G7K,'_'O'_N#
M^594.IW9KM3]"2H;G_4/]#4U0W/^H?Z&MWL>1'<\IU7_ )#PKU+3?^0=!_N5
MY;JO_(>%>I:;_P @Z#_<K"C\3/8S+^%3+5%%%=!XP4444 %%%% !0>E%!Z4
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MU[P5_P >P^E>0Q?\?+_[U>O>"O\ CV'TJ,5_O+'3_P"1<B7QQ_R#_P#@55/
M'_'M)_OU;\<?\@__ (%53P!_Q[2?[]<K_BFD?^1>_4T/&W_'FGTKFM"_Y!K?
M[A_E72^-O^/-/I7-Z%_R#6_W#_*J7\="A_R+V>?7/_(4?_>/\Z]#^'O^MF_S
MZ5YY<_\ (4?_ 'C_ #KT/X>_ZV;_ #Z5U8[^/'T(P7^X3]3L_$O_ "#/SKA-
M!_X^F_WC_.N[\2_\@S\ZX;PZF^\*CNQ_G7)/^(C3!_[I,XW7_P#D+M_OUT_@
M;_D)'Z5/J7@RXNKTS+NP6STK:\-^&IM.NS(V>GI77C'S2A8Y\#5C"A4C)ZLZ
MG6O^02WTKS[1/^0PW^_7H6M<:4PKSW1/^0PW^_7'5^)'1@/X$ST:[_Y!LG^Z
M:\RTK_D9A]3_ #KTV[_Y!LG^Z:\RTK_D9A]3_.BM\40R[^'4]#TVY_Y!3?[M
M>;1?\AUO]X5Z3<_\@IO]VO-HO^0ZW^\*=;=!EOPS/2X_^/'_ (#_ $KR]O\
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MXH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M U:YB=<';&%X^@J\)5C#$2E)Z'-F698:K1IQC+5%70_^/RW^M=!XV_Y!\?\
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MVO-H?^0ZW^\*])N?^04W^[7FT7_(=;_>%.MN@R[X9GI<?_'C_P !_I7E[?\
M(T)_OFO4(_\ CQ_X#_2O+V_Y&A/]\TJW0,MWJ>AZA%_R#3_NUYIJ/_(<_'^M
M>EQ?\@T_[M>::C_R'/Q_K3K;(66?',]*TK_CRC_W15ZJ.E?\>4?^Z*O5O'8\
MJK\;"BBBF9A7F?C?_D)?\"'\Z],KS/QO_P A+_@0_G6-?X#T\J_W@ZWPQ_QX
MK]!6_6!X8_X\5^@K?K2'PHX\3_%844451@%%%% !1110 5R?B]&:W; )^@KK
M*K7-G%=+B3^53./,K&V'JJE44V<;X.C97?*D<]Q7=U4MM.AM2?+'7VJW2A'E
M5B\565:ISH****LY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *JW_\ QZ2?2K55;_\ X])/I2>Q
M4/B1Y8W_ ",A_P!X?SKUF#_CWC_W!_*O)F_Y&0_[P_G7K,'_ ![Q_P"X/Y5A
M0ZGK9I\-/T)*AN?]0_T-35#<_P"H?Z&MWL>1'<\IU7_D/"O4M-_Y!T'^Y7EN
MJ_\ (>%>I:;_ ,@Z#_<K"C\3/8S+^%3+5%%%=!XP4444 %%%% !0>E%!Z4 >
M=>-_^/I/I6]X/_X\E_W:P?&__'TGTK>\'_\ 'DO^[7-'^*SVJ_\ N,3IZ***
MZ3Q0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH YZ+_D:9_P#=_P :U+G_ %OX5EQ?\C3/_N_XUJ7/^M_"O&SW
M_=?FOU-:7Q"ZA_JT_P!ZK:_<7Z54U#_5I_O5;7[B_2O9,A:*** "BBB@ K-U
M?28=5M6AE Y[FM*N1\8>()-%B,B[L CI0!37X?Q^;DS@IGIBNNT[3X]/M4AC
M PHQQ6'8^,;.6SB=\[BN3S6_9WD=Y"LL?0T 6:*** "BD)QUH#J>C _C0 M%
M(65>K 4;@1G(Q0!SOC3_ ) C?4UX$X)NY/\ >->W^.]2AATAHRP+9]:\6A9'
ME=C_ 'C6E.M[.YR8C$*G;EU9LZ5<M;21LHRP/%=5)J6I:@C!4D5<5SVA6ZW%
M_"I'!:O8H=*M;>Q?;'@[#_*N&"<FV;8JGC,0XRKZ+H>.VMK)/JBQ$G<2:C\0
MVK6+1@G.:V[( >)P!_?/\ZI^./\ 60_7_&NC 4XSF^8Z,PRJC0Y;:W,C3(A<
M31@]V K2\962:9<PI'CYH@W'T%4-#_U\/^\/YUN?$2*1[VW*HQ_<KT'L*O!T
MXRQ$HM:&V9X'#PH4W&.Z.=T]3/)&HZM6AK-A):0AY&)4GO5?15*WMN""#GO6
M_P"-?^0='_O5%"DIUG$RS+*Z$*,)1T;1RMK)L8%?6MO7]5%W801@<HF*P].0
M28!]:Z#7-(2RLH)<#YUS4T^:G7?+K8Y,7A<5AL/&7-S19@Z7_K8O]X5V/B/_
M ) 9^@KCK20+-&1T#"NGUR^CFT4JIYX[UIAY.6);9URS&E7PD:>TD<E8?ZP_
M6NYUK_D4[3Z5Q&GH[2$JI//85W&M@KX4M001QWK2/^^'HXE_\)T#A+'_ %@_
MWJ[Z\_Y%R3_<K@]/1F<84GYNPKOKM'_X1UQL;.STI2_WQA5_Y%T3SZU_X^&K
MV3P/_P @E/K7CMO&Z7!W(1SW%>Q>!_\ D$I]:C$_[RRO^9<O4J^._N#_ ':?
MX,_U'X4SQW]P?[M/\&?ZC\*YO^7I;_W!$GC?_D'_ (U4\ ?\>TG^_5OQQ_R#
MOQJIX _X]I/]^A_Q0C_R+WZFAXV_X\T^E9?@G[J_2M3QM_QYI]*R_!/1?I0_
MXH4_]P9U&O6+7VG/$N<D=JQ?"^A2Z;/,SY^8]Z[#L*6MG!.7,>=#%3C2=);,
MQ?$G_(-/XUQ?A;_D(_\  S_.NU\2_P#(-/XUQ7A?_D)?\#/\ZQJ?Q$>C@_\
M=)GID?\ JU^E.IL?^K7Z4ZND\5E+4X&N+-HUZFN3TWP[-;Z@93NP6S7<T5$H
M*3NSII8F=*#A'J4;T;=/D'^R:\PTK_D9A]3_ #KU+4.;.7C^$UYAI43CQ*"4
M;&3V]ZQK?$CT,M?[JIZ'I=S_ ,@IO]VO-H?^0ZW^\*]*N0?[+8?[->;Q1O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ H/2B@]* /.O&__ !])]*WO!_\ QY+_ +M8/C?_ (^D^E;W@_\
MX\E_W:YH_P 5GM5_]QB=/11172>*%%%% !1110 4444 %%%% !1110 4444
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M[&5;3]#U6R_X]D^E3XJ"R_X]D^E6*W6QY,OB84444R0HHHH *3%+10 4444
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M*,]57%3;12U$8*+NCHK8F=6*C+H%%%%6<X4444 %%%% !1110 4444 %%%%
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MO.I[R/:S/>GZ'DUI_P C0/\ ?;^=>J)_R#O^ UY7:?\ (T#_ 'V_G7JL2[K
M =UJ*&S*S7>'H>5ZM_R,I_WQ_.O5K+_CTC_W!_*N#O\ P]<3:UYX0[=P/ZUW
M]LI2V13V4#]*=&+4G<SS"I&=.FHO9'E&J?\ (RC_ *ZUZ=I0S8(/:O,=4_Y&
M4?\ 76O3])_X\4I4?B9IF?\ "I^A7N=$M[F;S&7FM&"$01A%Z 8J6BNA)(\B
M524E9L****9 4444 8/BJU%QI3<<YKF/!ER8;B2%C_'BN\OH1/:NGL:\QTR0
MVWB/RNF9#6,]))GG8I<E>,SU8'(S2TR$YB!I];'HA1110!Q_CC_D'G_>JIX
M_P"/:3_?JWXX_P"/ _[U5/ '_'M)_OUS/^,>U'_D7OU-#QK_ ,>:_2LOP1]U
M?I70>)["2^ME5 20.U4/#&DRV('F*1Q5-/VES.G5BL$XWU.M'04M(.E+6YY)
MC>)?^0:?QKBO"_\ R$O^!G^==KXE_P"0:?QKBO"__(2_X&?YUS5/XB/:P?\
MNDSTR/\ U:_2G4V/_5K]*=72>*PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP8]^XEYGHFCC%C']*T:IZ<FRT0>U7*T6QVP^%!1113*./\<?\>!_WJJ> /\
MCVD_WZN>-E9K X&>:J^ 59;:3(Q\]<S_ (I[4?\ D7OU.YHHHKI/%"BBB@#&
M\2_\@T_C7%>%_P#D)?\  S_.NU\2_P#(-/XUQ7A?_D)?\#/\ZYJG\1'M8/\
MW29Z9'_JU^E.IL?^K7Z4ZND\5A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 'V_G7K-G_Q[)]*\FM/^1H'^^W\Z]9L_^/9/I10ZAFWV/0GHHHKH/&"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JM_\ \>DGTJU56_\
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M_P#R$O\ @9_G7-4_B(]K!_[I,],C_P!6OTIU-C_U:_2G5TGBL**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-=)H'AA8 LLXRW^T*V=,T&WL(QA!N'<5K@8&!51AK=ET<)9\]35B(BQH%4
M5'=@FTE"]2IQ4U(0""#WK0[CP3Q#XJO_  [K+1G>P!SR:Z_P;X[?666-UP<X
MZUG>/?!TNKZXSPI\I7TK$\-V7_"*:DB7,3?,V=V, 4#/=T;<@-.JEIU]%>6R
M/&P(([&KM @HHHH **** "BBB@ HHHH 1E####--6&-3E4 I]% [L****!!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&SW_ '7YK]36E\0NH?ZM/]ZK:_<7Z54U#_5I_O5;7[B_2O9,A:*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW,5O-,LC 'S6_F: .OG\8JNOQ6&[EWVUQ^N.P\;,-QQYH[^]4Y)TG\?VI0Y
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M"X9!D_6M#PAXI6YC%K<-B5!@YH [JBD5@PR#2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<CXTL9;
MRS58QD[JZZFM&CCYE!^HJ91YE8VH5G1J*:Z'B_\ PCUU_</Y4G_"/77]P_E7
MLWV>'_GDGY4?9X?^>2?E6'U9'K?VU/L>-#P]=9^X?RKM/"&GRVDB[UQ^%=C]
MGA_YY)^5.6-$^ZH'T%5"@HNYAB,TE6@X-#ZY3QKIAO=*D*KEE4D5U=,DC65"
MK $'UK<\H\#\&:3=3W[I<1ML^;J*@L='NU\3M;[&\IY3VKWJ'3;6!MT<2*?9
M:!IEJLWFB%-P.<[: /./&&FR1:79P1H3L;L*KW5E,W@@($.X/G&*]3GLX;@
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MVG%>A>+[>^:Q865LLI_NGI7 7$>K7-E):#2X@[C&0O/\J $^'D3W%CJB?Q-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% ",H8889%5Q8VP?<(EW>M6:* $ "C '%+110 4444 %%%% !1
M110 4444 <]%_P C3/\ [O\ C6I<_P"M_"LN+_D:9_\ =_QK4N?];^%>-GO^
MZ_-?J:TOB%U#_5I_O5;7[B_2JFH?ZM/]ZK:_<7Z5[)D+1110 4444 %%%% !
M1110 4444 %%%% !1110 C*K## $>XH5%7[J@?04M% !1110 4444 %%%% !
M112$@=30 M%-WKZBER* %HI,BEH **.E(#GI0 M%%% !1110 44F0:6@ HHH
MH **** .3\7>%H]7M7EA7$X&%VC%<]X1U:[L;R33[L8"'8N3UKTWK5)=)LQ.
M9O(3>3G.* +:MN7-.I.%'I2T %%(2!WI: "BBB@ HHHH **** "BBB@ HHHH
M ***3(H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .>B_Y&F?_=_QK4N?];^%9<7_ "-,_P#N_P"-:ES_ *W\
M*\;/?]U^:_4UI?$+J'^K3_>JVOW%^E5-0_U:?[U6U^XOTKV3(6BBB@ HHHH
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MW1!!)Y&XT >I*P89!S06"C).*Y_PUJ,MY:CS,9!Q3_$U_+96;&+J5H UOML
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ML6621%/(P:Q'M)=4MK]HE.&8XQWK=T/PE9SP[I8.<]Z["RT:SLHC'%$%!ZT
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M_$5E' LK3* W2JT'BS3Y9=@G3- '0T5FG6[,2I&9EW/T%-N==LK9T2295+G
MS0!J4TN <$U1N-6MK>#S7E4+ZUQ6I>,8AKL$4<H*$<X- 'H)G0'!89IX((R*
M\RO]<874<@N"$+9ZUT=AXML#&J-<+NH ZNBHK>=+B,/&00>]2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]%_R-,_^[_C6I<_Z
MW\*RXO\ D:9_]W_&M2Y_UOX5XV>_[K\U^IK2^(74/]6G^]5M?N+]*J:A_JT_
MWJMK]Q?I7LF0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YYXU)%[!_P!=A_.O0ZXKQ5IDUW=Q-&N0) ?UH Y36[47WCVR
M@DY0P#(/T%;&O^'[*P^RS00A' SFGW6CW#^-[.Z"_NUA )_*MWQ'8RW,4(09
MPM '"ZM&U[!:*YR#(,UM:]X=T^T\,"XB@"S9'S4D^BW+);#;]UP371:_8R7'
MAOR$&6XH Y6ZD;^S[<9Z)67J=O\ :8+)&(VEQG-='<:/<-:1*%Y"XK-U71K[
M[+:M"O,;9- &IJ?AG38="66*%5EX.ZL![J1HQ&2<(,"M*XO[^^L%L47]YD=J
ML7'AV9;>,A?F*\T 87B*PMFM-)<QC<\@W'UK5URU@L])C$"!1N%3:]HUS+IV
MG[%R86R:=>VMSJ.F1KMY#"@#+N)'OM4L+:0_N60!E/>MS6?#>GVNGI<6\2I(
M@SFJ^I:#=0R6U[ O^J09J*YO]0U1(K6->G#Y% &!>3S:AI,0=C_K #GZUT6I
M>&].B\)27"P 3! 0WX477AN:&RCC1>0X-='J5E)+X5DMP/G* ?I0!#X-9AIL
M:$\!:;X^O9;/1XC$2"\@4X]"15KPS9R6MHJN,'%3>*-).KZ:L2C)1MPH Q=(
M\+:;=Z?YD\*L[X)/UKF[ #S=8M&&8HOE0>@XK2@U34=,@:U9?G!PO':I](T"
MX%OJ%U*OS7(R/TH J^#-*LUF$@B 8CK7>:G*;736=.,"N=\,Z=-:$;QCBNIN
M[<75J8CT- 'GFCZ;;ZOJ-PUZHD&_@&M*XT"'2;BYN+1D1-AP@/(K.\N]T*_F
M?;\CME<"K=DFHZO<SR./W+H=M '(V%Y%<W3F]M'N"&(R![U9MY3!?@6EI)"C
M-SQ6I!9W/A^Y/F1@J23TS6A8&_U"9F\I!&#_ ': ,RT8MJ%^6Z^6?ZUH^ OX
MO]\_SIT6D7"ZA>.5X="!5OP?IL]D6\Q<?.30!T'B.9H-!N9$.&5>*XWPYHMG
MJ]NUQ=QAY&7.37<ZM;?;-,F@_OC%<!!<W6@O)",; ,+B@"L-.BT_Q6R0@!?+
M/2H?#^E1:EJ\QF4,HD/!J/3[FYO?$Y>7NAKI/"VESVU]-(ZX#29% &5/:QS:
MV]B5Q#&V #5_Q)H%CIVDK<VL2QR[A\PJQK^CW%O??;;9>6;+5G7ES?ZY"MFJ
M\ @]* ,^0R?;;2XYVHHR:SM0EEU+4D9&^6%\UW%]X?=?#[A%_?!1BLC0_#=Q
M':W+S)\[)Q0!3%\=3N18$Y YQ4=]HEG#XALT,0^9<G]*N^'/#EU#K37$R\$8
MK0\1:?<+K=M<1K\J+S0!B:GIT4EW!$J@)NP15_7= L+'0X)X( LID&6_*I_[
M/N+BYADV\!LUL^(;"6YT.&)!E@X/\J +OA9RVF?,<XQ6[6/X=MGMK#8XP:V*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#GHO\ D:9_]W_&M2Y_UOX5EQ?\C3/_ +O^
M-:ES_K?PKQL]_P!U^:_4UI?$+J'^K3_>JVOW%^E5-0_U:?[U6U^XOTKV3(6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YZ+_D:9_P#=_P :U+G_
M %OX5EQ?\C3/_N_XUJ7/^M_"O&SW_=?FOU-:7Q"ZA_JT_P!ZK:_<7Z54U#_5
MI_O5;7[B_2O9,A:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GHO
M^1IG_P!W_&M2Y_UOX5EQ?\C3/_N_XUJ7/^M_"O&SW_=?FOU-:7Q"ZA_JT_WJ
MMK]Q?I534/\ 5I_O5;7[B_2O9,A:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#GHO^1IG_W?\:U+G_6_A69;X/BJ<?[/^-:=S_KOPKQL]_W7YK]3
M6E\0^^C>6)0G4&JGDZICB5<5>^UP_P!ZC[9#_>KK_M/!_P#/V/WHCDEV*'DZ
MK_SV6CR=5_Y[+5[[7#_>H^UP_P!ZC^T\'_S]C]Z#DEV*/DZK_P ]EH\G5?\
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M_P!ZC^T\'_S]C]Z#DEV*/DZK_P ]EH\G5?\ GLM7OM</]ZC[7#_>H_M/!_\
M/V/WH.278H^3JO\ SV6CR=5_Y[+5[[7#_>H^UP_WJ/[3P?\ S]C]Z#DEV*/D
MZK_SV6CR=5_Y[+5[[7#_ 'J/M</]ZC^T\'_S]C]Z#DEV*/DZK_SV6E\G5?\
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M=^UP_P!ZC[7#_>H_M/!_\_8_>@Y)=BCY.J_\]EH\G5?^>RU>^UP_WJ/M</\
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MDEV*/DZK_P ]EH\G5?\ GLM7OM</]ZC[7#_>H_M/!_\ /V/WH.278H^3JO\
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M4PW+"HF[KKZFE.,E+5%.BBBOS([0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gtqsgrqcdg4e000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *F!A<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%5Y[ZUM6"SSQQD] S8IL.H
MV=Q)Y<5S$[GLK9-%F*Z+5%0)>6\D[0),C2KU0'D43WMM:D">=(R>FYL9H'<G
MHJ.&XAN%W0R*Z^JG-07&IV-HX2XNHHV/0,V*+"NBW14)N[=8//,R"+^_GBHD
MU.QD)"743$#/#"BS"Z+=%4O[7T[_ )_8?^^Q5J.5)8Q)&X9#T8'BBS"Z'T54
M&J6)N/LXNXO._N;AFK= [A112$@#).!0 M%4WU6QC?8]U$&]"U68Y8YEW1NK
M+Z@U$:D).R=RG&2U:'T4459(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% %)[N;SVCCCW;:/M%U_SPHM
M_P#C_F^E7: *7VBZ_P">%'VBZ_YX5=HH I?:+K_GA1]HNO\ GA5VB@"E]HNO
M^>%'VBZ_YX5=HH I?:+K_GA1]HNO^>%7:* *7VBZ_P">%'VBZ_YX5=HH I?:
M+K_GA1]HNO\ GA5VB@"E]HNO^>%'VBZ_YX5=HH I?:+K_GA1]HNO^>%7:* *
M7VBZ_P">%'VBZ_YX5=HH I?:+K_GA1]HNO\ GA5VB@"E]HNO^>%'VBZ_YX5=
MHH I?:+K_GA1]HNO^>%7:* *7VBZ_P">%'VBZ_YX5=HH I?:+K_GA5M"S("P
MPQZBG44 %%%% !1110 4444 >(_&7_D8]._ZYG^8KUG1O^17LO\ KT7_ -!K
MS;XKZ)J>I:[82V=E-/&J$%HU) Y%>F:5#)%X=M(70K(MLJE3U!VULW^Y2\SE
M@G]8D_)'A_@[2[75OB3-!=QB2-9I7VGH2"2*]=\6V=M:>#M4%O!'%F!L[% S
MQ7G_ (%T+5+/XC7%U<6,\4&^4^8R$#G.*]+\6V\MUX6U"""-I)7A8*JC))Q3
MK/X4NPL-&RDVNIYO\(G,>EZRZ]54$?K61\,;>+5/'%Q/>*)'5&D ?GG(KJ/A
M/HU]8VNI)?VDL E( \Q<9ZUS.I>'?$/@OQ3)J.DVSS0%B495)&T]C6K:]HUW
M1SQC)4HNVS/;&TRR:ZCN3:Q>=']UPN"*\0O_ /DLP_Z^X_Y"NK\-ZSXRU_Q#
M:RW=JUKI\>3(-A4-P?7WK%O=!U5_BR+Q;"<VWVE&\T(=N !SFHI1Y*BN^AK7
MDJE.\5U11^)<C7GCZ"UF8^2H10.V"37K\^E6)\./:&WB\D0XQM'I7#_$WP7>
MZI<1:OI<9DFC7:Z+U..A%8+^+O&EQI/]D#2I!,5\LR",[L5-N>FE'H5S>SK2
ME);D'PED>'Q==V\9/E&)LCZ$53M[*WU#XM26]S&)(C<L2I[XR:[WX:>"[G08
M)K_45VW<ZX"=U'O7.:;H.JQ_%9KQ[&=;?SW;S2AVXP>]:\R]I\C!TY*BKK=F
MK\8-.LX/#MI+#;QQNDFT%% XXJQH3%O@Q+DYQ XJY\5].O-2\.0QV5M).ZRY
M*QKDXXIFB:9>Q?":2QDMI%NC"X$17YL_2L4_W3]3I<?W^G8YOX/N8[+6W7JJ
M@C\FK+^'5O%JOC^XFO%$C+OD ?GG/_UZZ;X2Z+?V$6IK?VDL"R[0/,7&>M<[
MJ_AOQ#X.\52:II-N\L)<LC(I(P>QK9R7M'KNCG49>QB[;,]J?3+&2XCN&M8O
M.C^XX7!%>+:SHGB#P9XKFUJQMC<0,Y<,%W#!Z@XZ5T?A[6O&?B#7[9[FU:UL
M(\E_D*AN/>H[SQEXMTF\N;6\T3[3%O(B?RS@CM]:RC&4)&]24*D;V:\S9\%^
M/[+Q+>?99K1+;4 O8?>%=E/IMG<W,=S-;1O-']QV'*UY-\/_  OJTWBM]>OK
M0VD.2P0KC)/H*]CJ:J2:Y2Z#E*+YRM-I]I/<QW$MNCS1_<<CE:C32=/1IF6T
MB!G&)"%^]]:NT5E<WLB*VMH+.!8;>)8XUZ*HP!576D:31+Q%^\8FQ5^D90Z%
M6&01@T/4:T/"/A!,D/BR:*0@,\)49]<BO>*\1\3>!];T#Q"VKZ!&\D1<NHC&
M2GMCTI9?&WCN\MS9QZ:RRL-I=86S_.NF:]I:43AI3]A>$D9/B%AJ/Q6*V_S?
MZ5&N1[8K4^,:XU?3E/:  UM?#[P!>VFI?VWK2XGR62-NN3W-8_QH_P"0Y8X_
MYY?U---*4(+H2XR]G.;TO_F>B6N@Z6G@H6RVD0C:WR3M&<XZYKS3X12/%XKN
MX$)\LPMG\Q39-9\;V.B+HS6CR12(!',L9)*^QKK/A=X0N]%@GU'4(S'/,NU$
M8<@>]%N52;>X7YW!16QQ-O96^H?%J2WN4#Q&Y8E3WQDUW7Q8TNR3P@)8[>*.
M2%U"%5 .,]*\VU&+4)?B+=#2R1>+.S1X]1S6EKMYXS\6>3I5UITB^6V"%C(!
M/J:.5N,+,E347436Y:L+ZXB^#5VJLP'V@H#[$"NF^#NGVO\ PC]Q=F-&F>7:
M6(R0*U[3P.$^'K:#(P$[J69O1\5Y[H]QXN\ SSVB::\T+G^X2I/J#0Y*7,EU
M*494^24EHA_Q5M8;'QC:36R+&[A68*,<Y%:?Q8=I/#.AN_WF4$_]\U1L/#OB
M+QOXGCU35[=K>W1@3N4@8'85T?Q9T:]OM*TZ+3[26<1-@B-<X&,4OAY(O<;3
ME[2:6C-CX>Z!IL/A*SG^R1/+,N]W=03G-<3\8X8HM8T[RXT3*G.U0,\BO3O!
MMM-:>$M/@N(VCE2/#(PP1R:XWXM>&]0U1+2^L8&F,.0ZH,GM4N7[Z_F:.'^S
M62ULCM]#MX8_#UJZ0QJQMQEE4 GBO(/!'_)5KC_KM-_,UU_P^UKQ'?2I8:C8
MF*SA@VB0QD$G@#^M<=KV@Z_X5\9RZKIUM)*K2M)&ZH2/F['\ZN.E1WZIF<WS
M4HM+9HZ7XU_\@NP_ZZ&I;W_DBB_]<?\ &N1\0V'C/Q19+J5_9R>6AVQP(AS]
M<5W-WI=\_P (UL5M9#="''E;?F[]JEKEIVOU&FYU7)+2QD_!S2K*?3KN\FMH
MY)@X4,XS@5SNO6\5C\78TMT$:^>K848 S7<_"73+W3=$NDO;:2!FER!(N":Y
MSQ)H6J3_ !4CNXK&=[?S$/F!#MQ]:OF_?^1FX/ZLM-;B?&G_ )".F?\ 7,_S
MKKM<BC?X6;FC5F6S&"1DCBN?^+>C:CJ5]ISV5G-.JIAC&N<'-=I<:3/?^ ?[
M-VE9VM-@4]FQ63?[E>IT13]O+T.+^#%O#+I]\9(8W(D&"R@XJ#XPZ,89[/6H
M%Q@['(]>W]:PO#,_BWPE>365KI<C>:X!WQDCZBO7?%&E'7/"5Q;2J/.:/>/9
MA5U7RS4T9T(\U%TFM3ROQCXL_M?P7HUG&^9I0/- /.0,?SKU'P-I T;PI9P;
M<.Z>8_U//]:\'\(:1+JOBRSLG!*QR;G'H!_]>OII%"(J*,!1@45K1C9==0PU
MYRYI=%86BBBN8[@HHHH *;(66-BHRP' IU% %+[1=?\ /"C[1=?\\*NT4 4O
MM%U_SPH^T77_ #PJ[10!2^T77_/"C[1=?\\*NT4 4OM%U_SPH^T77_/"KM%
M%+[1=?\ /"C[1=?\\*NT4 4OM%U_SPH^T77_ #PJ[10!2^T77_/"C[1=?\\*
MNT4 4OM%U_SPH^T77_/"KM% %+[1=?\ /"C[1=?\\*NT4 4OM%U_SPH^T77_
M #PJ[10!2^T77_/"C[1=?\\*NT4 4OM%U_SPH^T77_/"KM% %+[1=?\ /"C[
M1=?\\*NT4 4OM%U_SPH^T77_ #PJ[10!0>[N44LT. *N0OYD*N1C(S45]_QZ
M/]*=:_\ 'K'_ +HH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .2\<^'M.U#1KR_N(2UQ!;L8V!QC
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M_P"/^;Z5=JE;_P#'_-]*NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8![444
M4 &!Z4444 & .@I" >H!I:* $  Z "C SG%+10 4FU<YVC\J6B@ HP/2BB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[[_ (]'
M^E.M?^/6/_=%-OO^/1_I3K7_ (]8_P#=% $U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^E7:I6__ !_S?2KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO]=@C3;6O]:G'^&KBVMO$VMVTS+'/)<[HU(Y8<]*7QR"EUHUQ,I:SBNLS\9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVCB8G. 216UX*\*Z3=>$(I;NUBGFNE+R2.N6R?>FX)7;V_S$JLI62WU_ K^
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M--<6^]Y)!N/3L3TIN"C>_02JRERJ/5'=VUS!>0+/;RK)$XRK*>#4C,%4LQ
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M]=)"&Z!NI_"N!U2PM]$^*6C-I\2P+<HRR)&, XQVI-=N;"W^)\;ZT5>T%O\
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M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2M_\ C_F^E7:I6_\
MQ_S?2KM !1110 4444 %%%% !1110 4444 <9XPT._U37M#N;2'?%;2EI3N
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M5:WS.=\/W'B&^N9I]6M8[2W*XCA4Y.?4US.DV'B/POX@OTM=-2ZM+R?S!)O
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M**7.[W#V:M;SO^IQMEHE_%\1[O57BQ:20A5?(Y./2DT'0[^S\<ZSJ,\6VVN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-O\ (X_P9J%S#8W%ROAY[^6>9B\YVG/MR:WO!ECJ<'BK4+I].>QL;A=PB)&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ%J.;@6:MA0,M[U)H2WWB^WMV*PPM+C^+.!56W\=6QD"7-N\8/\ $#D5@SP
MC(K,GMNO% 'K5M<PW<"S02!T8<$5+7E&C:Y<Z'<\$O;L?G3_  KTS3]0M]2M
MEGMW#*>H[B@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%9&N:];:-;DL0TQ^Y&*:3;LB9245=D^
MK:C8V%HQO678XQL/5J\CM472_$[ZIHKO;P.V3"W(/K5J]OKK5KLSW+$D]!V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY1+$Q1U.017=^&O%27RK:7A"7 X5NS4 =71110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0L,@BHM2\*:EKOAM;34[]&U".3S(Y47 4CIQ2NG%7Z#M)2E9;G.>,K[Q#?\
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ME56R%!K:UP Z'?9 /[E_Y4FC6E[9Z<L5_=_:KC.6DQBI[^W-WI]Q;JP4RQE
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MK*L?"/BBPLCI$.KPIIV2 PC^<*>W7^E-N+;?H3%3C%+U*?@?3O[8\":I83*
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M4\"6JK!&!);Y?Y?O''>LOX4_+H=Y&/NI<L%'IR:ZO1],?3?#]OISN'>*+86
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]]_QZ/]*=:_\
M'K'_ +HIM]_QZ/\ 2G6O_'K'_NB@":BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH I:CIL&HP&.5?F_A8=17"W^GW&F3^7*/E/W6'0UZ/5>\LX;Z
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M(BB4LQ'I0!9HJIIFI0:MI\5[;$F&494D5;IM6T8DTU=!1112&%%%% !1110
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M?@?58=&^&\U[<KOBA=_E]?F.!1**LTN@0G*\6WNBY-\0YX8S<GP_?BS7K,5
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M72:??+>V^[&V5#MD0]5-<U2IS;;'?0H*#O+<MT445@=84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2M_^/^;Z5=JE
M;_\ '_-]*NT %%%% !1110 4444 %%%% !1110!YE\0[%=2\7:#:,[()"PW*
M>1TJZW@'5+Z:&'5M=>YL(6#+%LP6QTR:[&[T:QOK^VO;B$//;',3>E7ZT4VH
MI(Q=%2DV^ISOB7PPNNZ5;6$4PMT@D1E^7/"XX_2MV*$1VJ0-\P5 I]^*EHJ+
MNUC112=T<')X%U'3[Z>?P_K#6<,[;GA9-P!]JU?#?A%=&NIK^\NFO=1FX:9A
MC ] *Z>BJYY6L3[*%[G%ZQX)NI=<;5]%U(V-Q*,2C;D-4-M\/I4UJSU:YU1[
MB[B;=(SK][V'I7=44*I);"=&#=V<MXI\(MKES;7]E=FSO[?[DH&<BL:X^'5Y
MJ7DW&I:R\]Y'(&#%?E '8"O0J*(SE'8<J4).[.?\3^%H/$=E$C2M#<P'=#,O
M53638>$-;-W;R:KK\EQ! P98T7;NQTS7;44E-K8)4XR=V<GK_@Y]0U--5TR]
M:QU!1@N!D./<4:7X?U^/4(KG4]=:>.,Y\F./:&^O6NLHH4VE8'3BW<Y+Q)X-
M?5-3BU;3;UK+4(QM\P#(8>]9DWP[N[^:WO-1UA[B\BE#[BOR@#L!7H%%-3DM
M@E2A)MOJ(HPH'H,5R_B;PG)K%_;:E87AM+^W&%DVY!'IBNIHJ4VG=%2BI*S.
M#?P'?WM_9ZAJ6LM/<V\H?&S"X'8#-:^N:%J]W>I=Z5K#6C!=K1LNY372T4^=
MDJE%7.6\.^$Y=,U*?5=1O3>7\J[2^W 4>PKIW7?&R],@BG44I-RW*C%1V.>\
M+>&CX<CO$-P)OM$YEX7&,]J3PUX9.@76H3&X$OVN7>!MQMKHJ*?.Q*G%6\@K
MGM.\-&Q\4WVL_: PNEV^7M^[T[_A70T4DVMBG%/<XO6?!E[/XA;6-(U,V4\J
MA)04W CI76VD4L%I%%-*99%7#.1]XU/11S.UA*"3;74R?$>B1^(-$GT]WV>8
M/E?&=I]:SO#7A%-!\/SZ;)/Y[3Y\R3;C.:Z>BA2:30."<E+JCC?!_@5/"U[=
M7+77VAI?E3Y<;%STJWXD\(C6+N'4+*[:RU"$8691G(]"*Z>BFYR;N2J<5'EM
MH<?8>'?$?VV&74?$!DAB8$Q1Q[=WU.35[5_#!U/Q'IFJBX""R))3;G=G'?\
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M,J]4(K?HH<VQ*G%7\SA[+P?KAN;?^T_$$D]M P98T7;NQTR:U6\,$^,X]?\
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MEVY8$]=HX'\J[ZHK:VBM+:.W@0)%&-JJ.PJ6G.7-*XJ4.2"B%%%%0:!1110
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MB@ HHHH I6__ !_S?2KM4K?_ (_YOI5V@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]]_QZ/]*=:_
M\>L?^Z*;??\ 'H_TIUK_ ,>L?^Z* )J*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Q7)UJ]\M?^/&!OG/_ #T;T^E;+*'1E;H1@TR&&.WB
M$<2A4'0"FG835QX 4  8 Z"EHHI#"BBB@ JM>6%IJ$)BNX$E0]F%6:* W.6_
MX5YX:\[S/L SG.-QQ_.M^RTVSTZ(16END*C^Z*M44W)O<E0BMD%07L8ELIHS
M_$A%3TR;_4R?[II%,^7)XO)NY8_[K$5(G2EO_P#D)W/_ %T;^=(G2O0Z'B=1
MDE=)X*\81>%+BY>:VDG28 80],5S<G>MKPGXAM_#]Y--<:<;U74 *.WZ&E)7
M5BX.TT[V.^_X7-I__0*N?^^O_K5YOXEUM?$&O3Z@D;1I(?E1CR!7<?\ "S=,
M_P"A6;\Q_P#$UP.MZC'JNLW%Y%;?9DD;(B_NU%.-GM8UK5'*-N:_R*T?2EDI
M(^E+)6ISF[X#MQ<>,[!3_"^[\J^AJ\ ^'/\ R.MI]#7O]<M?XCT,'\#"LW4M
M!TS5UQ>VD<I]2,'\ZTJ*P3L=32>C.8MO 'ARVF\U-/4L#GYF)'\ZZ2&&*WC$
M<,:H@Z*HP*?13;;W%&,8[(****104444 ,FA2>)HI%#(PP0:RK&9M.N1IMPQ
M*'_CWD/<>A]ZV*BGMHKD*)4#;3N7V--,375$M%%%(84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %*W_ ./^;Z5=JE;_ /'_
M #?2KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 5[[_CT?Z4ZU_X]8_\ =%-OO^/1_I3K7_CUC_W1
M0!-1110 4444 %%%% !1110 4444 %0W5S#9VSW%PX2)!EF/:IJYOQS!-/X8
MF$*,^UU9E7J5!YH6XF[)LM:?XHTS4I6CA>12%+ R)@$>HJO_ ,)KHOV@1>=(
M%+;!*4^3/3K5.XU?3]6T&2STTE[IK4[5$9!3CIG%84^J:=-X CTF.-C?%!$(
M/+.X/GKT]>:UY5?8Q]H[;H[/4?$VF:7.L-Q,?,=-Z*JY+#VJG_PG.A_9Q,L\
MC<X9%3YE^HK*M;-T\::4L\>YHM/ )(S@\TNB6B+JGB=C !N?@[>O!I<L4OZ[
MV#GDW_7:YT-SXETJUL;>\EN0(+@XC8#.>,U33QOHKK)^^D#I_P LRAW'Z"N.
MM8&?PYX81XBP%T,J5Z?*:Z4VL9^)0D,((%EPVWH<BFX13^_\!*I-_A^)N6>O
MZ=?::]_%.!!'G>6X*X]:IVOC#2+N[CMUDD1I#B-G3"L?8UQD]G<RZ/XDC@B<
MXO Y0#[R@*3BK^M:A9:SI.E6&F R7?FQD*J$&+&,D\<4*";!U9)>E_F=/?>+
M-*T^ZEM9I7,\8!9$7)P?_P!5:.FZE:ZM9I=V<F^)NA]*YC2;8?\ ";ZS))%E
MA!& Q7_>S4_@9#'::BA4JHO)-H(QQN-)Q5BE.7-J=711169L%%%% !1110 4
MR;_4R?[II],F_P!3)_NF@#YAO_\ D*7/_70_SI$Z4M__ ,A2Y_ZZ'^=(G2O0
M/%ZC)*[[X211RZQ>"1%8",=1]:X"2O0OA!_R&;W_ *YC^M14^!FE#^(CUW['
M;?\ /"/_ +YKY]\=(J>,]05%"J)#@"OHFOGCQ[_R.NH_]=#6-#XCKQ?P(PH^
MU*])'2O72<!TGPY_Y'6T^AKW^O /AS_R.MI]#7O]<M?XCT,)\ 4445B=0444
M4 %%%% !5'5-7L]'MQ->2;58X4 9+'T J]7'^+F%KKNB7UPK&SAE/F$+D(3C
M!-.*NTB9OEBV;$'B;3)[&:\\UHXH?O\ F+@BHK#Q;I6H7:VT<DB2N,H)$V[O
MI6#XKOK75M)6;3U:>&WN$><K&1N7GVYINM7UIKVK:+%I699(IO,9U0CRUP>I
M(]ZT4$S)U&NO_!-RY\::-:S2Q/,Y>)RD@5,[<>M*/&>BM<Q0K<$^:0%D"_+D
M]!FL/1K93:^*6:'YGED&2O)'-4KFU"?#*P"0X<3H<!>?]90HQ_+\0<YZV\_P
M.PU'Q/I>EW7V:XE;SR@<(JY)!]/RJH?'.A^0LJSNP)^8*F2GU]*SK> /\0XI
M'CSMT],,1T.6J'1;-%A\3GR "TS8^7J.:5HI78^>3=EW_2YU-SKVG6FG1W\M
MP/(D ,9');/I4.F^)M-U.62*&1UE1=QCD7:<>M<) KVVD>%KVYB=K.!OWORD
M[?E."16Q<W$.L^,K:YTW,D5O;/YTJJ0#E3@<]>HIN"5_F2JLG9^GXFNWCG0P
M5_?N5+;2P3A3G')KHD=9$5T.589!'>O/+.T4?#'4!Y&)&,S'Y>2=S8KM-"S_
M &%9;LY\H9S2E%):%PG)O4T:***S-0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH I6_\ Q_S?2KM4K?\ X_YOI5V@ HHHH **** "BBB@ HHHH **** "
MBBJ=OJMA=74EK!=Q23Q_?13R* ND7**KWUY%I]E-=S9\N)2S8]!5!/$5E)X=
M.MJ6^R!"_3G S_A3MU%=)V->BJFFZA#JNG0WMOGRI5W+D5;H:MHP335T%%%%
M(84444 %%%% !163KOB*P\/6RS7KD;SM1%&68^U/T37+?7;1KBWCEC"MM*RH
M5-.SM<GF5^7J:=%%%(H**** "BLR^\0Z1ILGEWFH01/_ '2V3^E6[.^M=0A$
MUI<1S1G^)#FG9VN+F5[%BBBBD,**** "BBB@ HHHH **KWM]:Z=:M<WDRPPK
MU=N@IO\ :-I_9W]H"=3:[-_F=L4>8KJ]BU17,Z5XXTO5[MH8%G" $B5HR$('
MO6WI^J66J1-+8W"S(K;25SP:;BUN)3B]F6Z**IZAJECI42R7UPD",VU2V>32
M*O8N44T2(4#AAM/(-))(D432R,%11N8GL* 'T54T_4[+58#/8W"SQAMI9<]:
MMT-6$FGJ@HHHH&%%%% !1110 452OM7L--DA2\N4A:9ML8;/S&KFY< E@,].
M:+"NMA:*JZC?PZ9I\U[<$^5"I9L>@INEZE!JVG0WUL28I1E<BG9VN%U>Q<HH
MHI#"BBB@ HHI"P! ) )Z#- "T44A( R2 />@!:*3(QG/%9FE:]9ZQ/=PVQ8M
M:OLDR._^13LV)M+<U****0PHHHH **** "BBB@ HHHH ***J:EJ$&E:?->W)
M(AB7<V!VH MT55TZ_AU33X;VW),4J[ER.U620!DG IM-.S$FFKH6BD!!&0<B
MEI#"BBB@ HHHH **** "BBB@ HJE-J]A;ZA%82W*)=2C*1G.35V@5T%%%% P
MHHHH **** "BBB@ HHHH **** "BBJNHW\.F:?->7!(BB4LV* +5%5-,U"'5
M=.AO;?/E2KN7-6Z;33LQ)IJZ"BBBD,**** "BBB@ HHHH KWW_'H_P!*=:_\
M>L?^Z*;??\>C_2G6O_'K'_NB@":BBB@ HHHH **** "BBB@ HHHH *0@$8(!
M![&HKJ0PVLLB_>5217/:7KU_?:%I]X(H6DGDVR9;;@>U-*Y+DEN=#%:V\!)A
M@CC)ZE4 S2"RM5F\T6T0D_O!!G\Z2XO[2U8+<7$43'H'8#-8VK:^;34=+CMI
M(G@N9"KOG(  -"3;"3C%79O^6GF>9L7>!C=CFD$4:EB$4%OO8'7ZU"FH6DD+
MRI<1M'']Y@PP*IZ+K]CKEOYMK(.&(V$\\468[HT1;PA5411@*<J-HX^E.\M/
M,\S8N_&-V.:;/<0VT?F3R+&@_B8X%87B'7FT^PM;FR>.199TC+9R,$X-"3;L
M)M)79O+%&N[;&HW?>P.M1QV=M"Y>*WB1SU94 -);WMM=$K#/'(Z_>"MG%(=1
MLUN/(-S$)C_!N&:-1W1.(T#EPBAFZD#DT)&D>=B*N3DX&,U1DO+I=9CMECC-
MLT99G+?,#]*G?4;-&56NH@6. "PY-%F%T6:*.HS12&%%%% !1110 4R;_4R?
M[II],F_U,G^Z: /F&_\ ^0I<_P#70_SI$Z4M_P#\A2Y_ZZ'^=(G2O0/$ZD<E
M>A?"#_D,WO\ US']:\]DKT+X0?\ (9O?^N8_K45/@9K0_BH]DKYW\>_\CKJ/
M_70U]$5\[^/?^1UU'_KH:QH?$=>,^!&%'3GZ4V.G/72>>=)\.?\ D=;3Z&O?
MZ\ ^'/\ R.MI]#7O]<M?XCT<)\#"BBBL3J"BBB@ HHHH *9)%',A25%=3U##
M(K)\4:I-H^BR7< 4R*Z@;NG) J6&^NY-1@A,4?D20"1GW?-NQZ4TM+DN23L7
MTMH(HS''#&J'JJJ *2&TM[<DPP11D]2B 5%)J=C%*8I+N%9!U4N,UD)X@V^*
M;BPFDB2TC@$@<G')QWH2;!RBC?$4:A@L:C=][ Z_6@PQ&,1F)"@Z+M&*HZCK
M=EINEMJ$DJM"!P5/WOI5BPO[?4;5+BWD5U90>#G&:+,=U>Q-Y48?>$7?C&['
M.*!%&N["*-WWL#K4<][;6I43SQQENF]L9K$N=?>W\60:>SQK:/;M*SD]P1W_
M !H2;$Y);F\8(3%Y1B3R_P"YM&/RI(;:"W4K##'&IZA% S1#<P3P^;%*CQ_W
ME.14<-_:7,ICAN8I'7JJL"11J/0F\F(1F,1IL/5=HQ^5. "@!0 !T K.L[ZX
MDN;Q;I(HX86PC!\DC Z^E6EO[1Y_(6XC,N,[ PS19A=%BBBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** *5O\ \?\ -]*NU2M_^/\ F^E7: "BBB@
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M*P.H**** "BBB@ HHHH KWW_ !Z/]*=:_P#'K'_NBFWW_'H_TIUK_P >L?\
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M10 4444 %%%% !1110 4444 4K?_ (_YOI5VJ5O_ ,?\WTJ[0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI-6LB6BBBLS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_.O!O&URT'C"_C"(P60\L,FOH*OG#XAS-'XWU$ #_6&L:&LCKQ:2@BDE\_\
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M%% %*W_X_P";Z5=JE;_\?\WTJ[0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^KR:H\:06?*D#''/^%;WANV\26\-S_;]U'/D?N]@''Y5X5Y-^]MJSVQ8VJ3
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M%2>'-)@U 0^<DLBKC/0'O1R/02JQU\CHZ0D*"20 .I-<!=>/=5A@&I)H,O\
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M5]+GM]%9^AWCZAH=G=O]Z6(,:T*S:L[,WBU))H****0PHHHH **** "BBB@
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MJC"J /0"EK.33=T;032LW<****104444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %*W_X_YOI5VJ5O_P ?\WTJ[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 454U2^&F:7<WK(7$$9<J.^!5?0-837M&@U%(C
M&LHSM)Z4[.UQ75[&G52^TNQU)0MY:Q3@=/,0'%6Z*0S.LM!TK3I-]I86\+_W
MDC -:-127,$4J123(LC_ '59@"?I5'Q!K"Z#HMQJ+Q&185SM!ZT]6+1+0TZ*
MIZ7?KJ>EV]ZJ%%F0.%/:KE#33LP335T%%%(2 "2< =32&+14<-Q#<IO@E21<
MXRC9&:DH **PM/\ $L=_XEOM&6!E:U7<7)X:MVFTT)23V"BLBY\1V5IKUOH\
MF_[3.NY<*<?G6O1;J":;L%%%%(845D^(]<C\/:/)J$D32JA VJ>>3BKUC="^
ML8+I5*B5 P![9IV=KBYE>Q8HJ.::*WC,DTBQH.K,<"GJZN@9&#*1D$'@TABT
M444 %%%% !1110 4444 %%%% !1110 4444 %%1?:8#<&#S4\X#)3<-V/I6;
MKGB*RT#[-]KW_P"D2"--JD\FFDV[";25V:]%(C!T5AT89%+2&%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"E;_\?\WTJ[5*W_X_YOI5V@ HHHH **** "BBB@ HHHH
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M$?E4'H3^%9-UXK\2Z#/;RZYI]N+.9PA:$G*9_&K7BG6KGPSI^EZ7IFSSK@K
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MZ//J<TU3;%[>*OOH>CT5RGB[Q)=:-;:=+9K&1<RA6WC/!K5\0ZE-I?AVZOX
MIEBCW*&'%19VN:<ZO8UJ*Y"7Q/>I\/AKH6/[5Y0<C!VYS]:QX_$/C35]*74]
M.LK:&W5-V)0=TF.N.:KD>M^A'MHZ6ZGH]%<YX;\41ZQX:;4[A1$T.Y9AV!'6
ML&VUWQ7XC66^T:.T@L58B/S@2TF/Q%'([M/H/VL;)KJ>@T5S/A'Q+-KD=S;7
ML(AO[1]DR+TSZBMW4;Q=/TZXNW!*PQER!WP*F2<79E1DI*Z+-%>?:9J_C+6K
M5=4LA8BT=CL@8'<5SZYZ_A6A-XFU&P\:V>EWT<2VEW&-C '(?TSFJ]F[V(]K
M&U^AV-%<MXO\27.C/86E@J/>7<H4!QD;>]4=6\1:U<>(QH.CBWCGCB$DLLP)
M';H,CUI*#8Y5(Q=F=L2 "3P!4%I?6M\C/:SI*J-M8H<X/I7.;_%O]A723)9_
M;E/[MQG:R]^,]>M<;\.F\3[9_L@M#9_:SY^_.[/&<<U487OJ3*K9I6W/7:*X
MK5?$VJW>OOH?A^*$SPKF>:7E4]J9IOB76-.\10Z+XAC@+7 )@GA! )';J:2@
MVBG5BG8[BBN"UKQ?J]IXNDT2PM$N&>(&+@\,<<D^G6J,WC+Q+X=U2.SURRAG
M:Y7]Q]GR,MV'?O0J;:]1.M%-I]#TNBO.+SQ/XKT&XM;W6+:V_L^=PI6,'='G
MU.:]$CD$L2R+T89%)Q:5RHU%)V'T445)84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7OO^/1_I3K7_CUC
M_P!T4V^_X]'^E.M?^/6/_=% $U%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-ZUYLDMYW^\T#E=WUQ6AH?AG3M $ALT??)]]W8LQ_$TY5+ZW)A2<;)HU)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O??\>C
M_2G6O_'K'_NBFWW_ !Z/]*=:_P#'K'_NB@":BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E;_ /'_
M #?2KM4K?_C_ )OI5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)&DJ;)$5U/4,,
MBG44 (JA5"J  .@ I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MKWW_ !Z/]*=:_P#'K'_NBFWW_'H_TIUK_P >L?\ NB@":BBB@ HHHH ****
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M3JX#P.LT.M7D$KLQ51G)KOZB<>5V-J53VD>:U@HHHJ#0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E;_\ '_-]*NU2M_\
MC_F^E7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME-D7)1B59<\<5:^(G_(3M/\ =/\ 2J6B?\CY_P!M35WXB?\ (3M/]W_"M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%_ST7\Z//B_YZ+^= $E%1^?%_P ]%_.CSXO^>B_G0!)14?GQ?\]%_.CSXO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7>SAD<LRY)IO\ 9]O_
M '*M44 5?[/M_P"Y1_9]O_<JU10!5_L^W_N4?V?;_P!RK5% %7^S[?\ N4?V
M?;_W*M44 5?[/M_[E']GV_\ <JU10!5_L^W_ +E']GV_]RK5% %7^S[?^Y1_
M9]O_ '*M44 5?[/M_P"Y1_9]O_<JU10!5_L^W_N4?V?;_P!RK5% %7^S[?\
MN4?V?;_W*M44 5?[/M_[E']GV_\ <JU10!5_L^W_ +E']GV_]RK5% %7^S[?
M^Y1_9]O_ '*M44 5?[/M_P"Y1_9]O_<JU10!5_L^W_N4?V?;_P!RK5% %7^S
M[?\ N4?V?;_W*M44 5?[/M_[E']GV_\ <JU10!5_L^W_ +E']GV_]RK5% %7
M^S[?^Y1_9]O_ '*M44 5?[/M_P"Y1_9]O_<JU10!5_L^W_N4?V?;_P!RK5%
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MU10!5_L^W_N4?V?;_P!RK5% %7^S[?\ N4?V?;_W*M44 5?[/M_[E']GV_\
M<JU10!5_L^W_ +E']GV_]RK5% %7^S[?^Y5E%"(%4<#I2T4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gtqsgrqcdg4e000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /)!70# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]XT :=%9GE7O]XT>5>_WC0!IT5F>5>_WC1Y5[_>- &G169Y5[_>-'E7O]XT
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MM?QUXNM]#NH(I=/CN"XSENU:WA3P[I4>DV5XEE$)_+#;\<YQ7GOQB_Y"UO\
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M'E.-Z?M>MSZ*1PZ!E.0>AK@_%GQ)MM"NC9VT?GW ZCTK;\%ZH-7\,6TV[+A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >'?&/\ Y#5K_NG^E=;\/-!TV[\,PS3VL;R'N5!J
M?QOX"E\47L-Q'/Y>P$$<5T?A?1#H&C1V3/O*]36ZFE1Y>IR.E)XCF:T-.WLK
M:T7;!!'&/]E0*YWX@_\ (IW7T_I74UD^(]).M:/-9*^TN.#6!U6TT/(?@_\
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MPBDFLG:ZO&>Z8<$D'%:N<79I[&"I32<7&[?4N?!__D!3_4_SKS[Q=_R/\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=+(UK*L7WRA
M"_7%344 >,P?#?6+OQ/]MOB/*,N]B1U%>Q01""WCB7HBA?RJ2BKE-R23Z&4*
M48-R74****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JU[_P >S59J
MM>_\>S4 )I__ !["K55=/_X]A5J@ HHHH *JW_\ QZM5JJM__P >K4 +8?\
M'JM6:K6'_'JM6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7O\ Q[-5FJU[_P >S4 )
MI_\ Q["K55=/_P"/85:H **** "JM_\ \>K5:JK?_P#'JU "V'_'JM6:K6'_
M !ZK5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "JU[_Q[-5FJU[_ ,>S4 )I_P#Q["K5
M5=/_ ./85:H **** "JM_P#\>K5:JK?_ /'JU "V'_'JM6:K6'_'JM6: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *K7O_'LU6:K7O_'LU ":?_Q["K55=/\ ^/85:H *
M*** "JM__P >K5:JK?\ _'JU "V'_'JM6:K6'_'JM6: "BBB@ HHHH *Y[QG
MXE'A70)=2,7F;"!MSZUT->=_&?\ Y$*X_P!]?YU%1M1NBH*[U*W@3XEWOB^_
M$;:6\,!&1+G(_E74'QUH0UX:,;H_;#_!M-<[\%@/^$$MSCL/Y5Y=+_R79?\
M>K5I>T4#-/\ =RGV/=];\::+X?O(;74+DQRS?<&TG/:MV"=+F!)HCE' 93[5
M\^?&[_D<M&_#_P!"KW70/^0!8_\ 7%?Y5,-87\RI:22\C2JEJFK6>CV;75[,
ML42]2:NUSGB_PE;^+K&.SNI72)6R=O>D[]!JW4P?^%R>$OM0A^VGDXW;#75O
MKD,^A2:EIY%RH0L@4]:\-^*_P[\/>&/#:7-BHCN 0!Q@M76? -KMO"4HG+&(
M.-F[TQ3C:2E;H3*\6O,ATSXRW-QXHAT>[TIH&D?;EC_]:O84;<BMZC-?._C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*K7O_'LU6:K7O_'LU ":?_Q["K55=/\ ^/85:H **** "JM__P >K5:JK?\
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M5WJ5R/>I:*&K@<9X2^'=AX5U&ZOHY'FN)VR6<YQ79T447Z!UN%%%% !1110
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MZ]%M/B]H][/Y$<%P&(."8F_PIIWA&W8'I-G-_&?7H'U+3-$DN%BA>0/,Q/
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:]_P"/9JLU6O?^/9J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC.X]'/4?K1=Z1>Z+XVAU'3;9Y+6Y^6=4'"DGK4Q\^I4O+H=Y12 Y4'&,BEH
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M]17["A&X*!E@/I7KU%)*P-W*6E:;!I&FPV5NN(XEP*NT453=W<25M#%\6?\
M(L7_ /UR;^1K"^%/_(AV'_7,5N^+/^18O_\ KDW\C6%\*?\ D0[#_KF*0SMZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_(UA?"G_ )$.P_ZYBMWQ9_R+%_\ ]<F_D:POA3_R(=A_US% ';T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5:]_P"/9JLU6O?^/9J $T__ (]A5JJNG_\ 'L*M4 %%%% !56__
M ./5JM55O_\ CU:@!;#_ (]5JS5:P_X]5JS0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &+XL_Y%B__P"N3?R-87PI_P"1
M#L/^N8K=\6?\BQ?_ /7)OY&L+X4_\B'8?]<Q0!V]%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+XL_Y%B_\
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M'MX.EA?:>[*[\S)@U.\MYA+%<.K@YSFO7/"OCRUN-,5=1F"3)P23UKQD DX
M)-=YX;^'<VKZ>+F>7R=WW0<UG1E-/W3LQU.@X7JZ'IUKXGTJ]N%@@N5:1C@
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M:K55;_\ X]6H 6P_X]5JS5:P_P"/5:LT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!B^+/^18O_P#KDW\C6%\*?^1#L/\
MKF*W?%G_ "+%_P#]<F_D:POA3_R(=A_US% ';T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445B:]XHTW0("]U.H?'"9Y--)O1";25V;+ND:%G8*HZDG%>#_%;6TU#6([>
MWG#Q1@@[3QFGZSXVUSQ9>&RTI)$A8XPG4_6KEO\ ".]N-+>>XFQ=MR%-=$(J
MF[R9Q5:DJRY::T/+*]&^$-U.GB(P*3Y3K\WITK&E^''B.*9HQ8R,!_$%XK4^
M'>JQ>&O$4EKJ$?EO(=N6_A-;3:E%V.6E%PJ)RT/?:*:CK(@=3E2,@TZN ]@*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J>H:9::G"8KJ)74^M7**-QIM.Z.8MO >AVUQYR6H+ YY-=)'&D2
M!$4*HX %/HI**6Q4ZLY_$[A1113($(# @C(->>>)OA+I>N7QOK:9[*Z)R7C[
M_K7HE%*W4=SRBT^#*-,C:EK%Q<QH<B,\ _K79:WX,LM7\,?V$K&"W"[5(&<5
MTM%-ZJS$M'<\EA^"201"*/Q!=+&/X0N/ZUT7AOX8:+X?N1=8:YN1_P M).37
M<44[L5B"[MOM-G);JYCWK@,.U>7:A\%EU(.MSK]R\;-NVE./YUZQ14V5[E7Z
M'G'A[X5GP_?6\\>MW$D<)!$13 /ZUI^+?A[;>)KA+M;N6UN4& Z?_KKM**;U
MW$M#R4?!N6\D4:GK=Q<0*?\ 5D<']:]*T;1[30].CLK*,)$@XQ6A13OI85M;
MG%>(OA[;^(_$5KJEU=OMMSE8=O'4'^E=G'&L4:QH,*HP!3J*2T5AO5W.=\8>
M%(?%NE?89IC$NX-N ST.:T](TQ-)T>WTY'++"FP,1UJ_11LFNX>9R&A^!+?1
M?$MYK*7#/)<]4*].2?ZU:\8>$(/%UG%;S3M$(W5P0,]#FNEHI6T2[ G9M]SB
M?$'P\@U[2[#3Y;QTAM,<!?O<8KKK&TCL+**UB'R1J%'X58HIW"QD>(]!M_$>
MC3:=<'"R*1NQG%<_;?#R&#P;+X=:]=X7)(<KR.:[>BE9:KN.^WD>52_!BVMX
M8_[,U*:UE489E'WOUK<\(?#6Q\,7;WTDS75Z_65QR*[FBJ3:):6P4444AA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KW
M_CV:K-5KW_CV:@!-/_X]A5JJNG_\>PJU0 4444 %5;__ (]6JU56_P#^/5J
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M3Z+=1S^'XHXFC(9ANX&*ZCX3DGP#IY(P?+%24=O1110 4444 %%%% !1110
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MMX9_M"S57<M@9/M3>BN**N^4[.BO%+#Q3\1KZQCO8;")XG&X?,W(_*M;P_\
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M.J*.I)Q7GOBOXG6>FAK;3OW]QTR.@_&JC%R=D1.I&"O([75-:L='MVFNYU0
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M5HPY?,J&M2_D=9X#_P"1-T__ *Y+_(5Q?QLT2"30(]5B0)<V\@(=1@]S7:>
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M_(L7_P#UR;^1K"^%/_(AV'_7,4 =O1110 4444 %%%% !1110 4444 %%%%
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M1#AA]>:IJR*WMXK6%8H8U1%&  *EHHK$Z0HHHH **** "BBB@ HHHH ****
M.(^('@Z/7M/:Y@0"[B&00.37'_#SQ?+I-]_8FJ,57=M4L?NFO9R 1@]*\F^)
M7@MAG6=.0B1>7"_SK:G)-<DCEK0<7[2!ZPK!U#*<@C(-+7G'PX\:#4K<:;>O
MBYCX!;O7H]9RBXNS-Z<U./,@HHHJ2PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:M:O>Z3=6L9 :6)D!/N*
MY#X:^#[WPE:7D=Y(C&:5G7:#T)KO**%H[@]58*XWXD>%;KQ;X<-A:2(DN[(+
M=.E=E12:N--IW1XM8^#_ (D6-C'90ZM;I"@VC&[(%:_A_P"%<HU5-5\1WK7U
MTARH)R ?QKU*BJOK<FVEA$540(HPH& *6BBD,\M^(O@'6?$6N6FI:3<Q126^
M"-X/7\*H1>&_B<A0'6+?:N!C#=*]AHI15E9 ]7<Y#5K'Q3)X:M8=/NH5U%0/
M-=P<'K7FFH?#7QWJ6O0:Q/J%H;J'&P[6[5[U13ZW#I8Y'P?8^)[6.9-?N89L
MC">6#QQ[UD>&O!%_I/C[4]:FD0V]R3L !SUS7HM%.^MQ6TL<5\2/"EYXKT>*
MULW17216.X'L0:Z+1["2PT"VL9"#)'%L)%:=%)*R:[C>K3['FWA/P-J6A>)=
M8U&66,I=@^7@'CDG^M.\$^!+W2/$NH:SJDB233L=F > 17H]%"TM;HK ];^;
MN%>8-X U&R^(_P#;^GRQI;2#$B8.>E>GT4+22D#U31Y!XF^%VJ:UXRFUFWO!
M!P3$5R"&SQ5*^\'?$#7(UTO4+^,6(.&90V6%>V44DK*W0&];F-X8\/V_AK1(
M-.MQ\L:X)]36S115-MN[$E9604444AA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5KW_CV:K-5KW_CV:@!-/\ ^/85:JKI
M_P#Q["K5 !1110 55O\ _CU:K55;_P#X]6H 6P_X]5JS5:P_X]5JS0 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 +8?\>JU9JM8?\ 'JM6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME<+'=0LQZ!9 35BO O!/P\\7:3XHM+N_N6:WC<%AGM7OM249?B/_ )%S4/\
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M3MS2MTV)5^6-^IK^ _'WB7Q-K1M[BT188GVR_,,BO7*\L^$^A:A!/?ZS?0-
M;MRRQL,$ UZG5/9"6[/$?C!?S:IXFTGP[$Y6*9QY@!Z_-BO5= T"PT?2+>UA
MMHAM09)49)Q7C_Q)!T[XJZ->R\1.PY/3[U>Z6LBS6L4B'*LH(-33_AW\V.?\
M2WD9=_HUK$7U"ULX_MT:-Y9  SQ7SQ?ZIXG_ .%IP7!M%_M!<;(]PP>:^H*\
M1U#_ )+W8_1?YFB"_>17K^02?N,] T#5M>?0KJZUFV6&:-&90"#G ->=6?Q>
MUS6%DLM,L#+>AL9'0#\J]CUO_D!WG_7%OY&O)_@3:0>7JEQY:^;Y^-W?&!1'
MWI/R0/2*]2QXOOM7OOA;<2:S (;G<05![9%=E\-/^1'T_P#W/ZUG?&#_ )$6
MY_SW%:/PT_Y$?3_]S^M$'?G^0I*SA\SKJ\J^,>JN]K9:';G,MW*H8#TR*]48
MA5)/05\XZYXI%W\4VO6LY[RVL^ L*[L''_UJG1R466KJ+DBUJ6C_ /"O/%VA
M7<(*P2*$E/U->^),MQIPF4Y5XMP/U%>!?$;QHOBG0Q$FB7T,L+;UD>+ &*]+
M^&?B :[X'B9FS+"AC8>F!BK5W!WZ?J1HI*W4\GTGQ+/H'Q$UA;.U:XNII"$4
M ^@%=1=?$7Q=X;NH+C7=."V,K<E3G _ 5!\/((9/BIK+R(K.KG:3VX%=G\88
M89/ %\TH&Y4)7/KQ4WY:<9%M<U22.STO48=5TZ&\@.8Y5!%7*X;X2O(_@&R,
MF<_-C/UKN:N:M)I&<7=:A1114E!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 56O?^/9JLU6O?^/9J $T_P#X]A5JJNG_ /'L*M4
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M*/X,\UYY\.]+@\4^(]6UG4E\_9,R1J_(&#4/Q#TR'PMXLTG5=,7R/,D"NJ\
M\@4EIR\W4;ZVZ'KVK:S8:):-<W]PD,0[L:YBR^*GA:]O%MDU"-68X4DGG]*X
MOQ9.WBCXBZ7H\C$VH4.Z \'#5TGQ \&Z6/!\TEK;)%-;*"CH,'C%*]H\S&K-
M\J/1(Y%EC5T8,K#((IU<3\+=4EU/P7:M,Q9XQM)/U-=%<>(=*M9FBGO8D=>H
M+@5<ERNQ,7=7(?%G_(L7_P#UR;^1K"^%/_(AV'_7,5/XH\2Z/-X<O8X[Z%F:
M)@ ''H?>H/A0<^ [ C_GF*D9V]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 =!FO$OB=K4FL:W#H]JQ95;! [FO4_%&L1Z+H5Q<NP#;2J_4B
MO*/ASI$FO^)9=7NE+(C[P3ZYK:DK7FSEQ#<FJ:ZGJ7A#1$T/08( N'*[F/UK
M?I    .@I:R;N[G3%**L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /"OC D2:[#Y<85BF6('7FO-J]^^)'@
MZ77[5;JT&;B(=/45XLWAS55N?(-E+OSC[AQ7=1DN4\G$TY*HW8[7X1ZM<1ZZ
MUAO8PNA;'88KW2O-/AIX*GT8'4+U=LSC"KZ UZ77-6:<M#NPT91IVD%%%%9'
M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@=HQ6[XL_P"18O\ _KDW\C6%\*?^1#L/^N8J2CMZ*** "BBB@ HHHH ****
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M6[BTN5"626,J%/&*L^%/^1]\3?\ 7 ?^A&NK\-7^M7]^QO-%-C;A3@LJY)_
MUF>&O#>H6GC/6[NY@9+>YC"QN>A^8TO+R8=&_-$/PE=G@U?<Q.)^Y^M5_![N
M?B1KJEB0"V!G_:JC867BOP?JVH6VGZ:]U;73[DD51A?S/O6CX!\/:]8>)M1U
M#5X=IN03N P,DT+5I^7Z"EHFO,YWPGX7@\2^)=9_M&5Y+>.0XB)XZFH?#_A2
M.Y\>ZEH+W,G]EPL66#MQBNX\":!J&E:OJ\UW T:3OE">_)I-!\/ZC:?$?4]3
MF@9;64-L<]#G%$-'%>7Z#DV^9^?ZG/Z#9)X7^*LNDV#LMG+$C&// )R:TO$L
M7@\:W,VIK+>W3=8XUW%/R-7+CP]J+_%+^U5@;[(847S.V0#_ (U@MH^N^'O%
MM_=QZ.VI173923:#MXQW-):J-^S&]&VO(9\,+Z,>*-6L;+SDL5!:..08*\^E
M9_@SPC:>(O$VL/?LSP)(<1=CR:Z+P+X>UNS\5:AJ6I6?D)<)E0%P!SG%9&EZ
M9XQ\+:WJ-]::<UQ;SN3Y849/)]33TNK]A;IV[EG0+?\ X1/XGRZ19NWV&=2P
MCSPO(%>MW,RV]K),QPJ*3FO-_"/A_6=0\5S^)-<MS;LP(BB8<@'FNM\9QZA/
MX;N8--B:2XD&T!?K1*Z@NX*SF^QY;HFKZ-K&O:]J&J7D*&3=%$'8="N#6U\)
M-;A,VI:*DRR)#(S1D'^'.!6[X7^'6D6>A6\>H:=#)=$9D+H"<YK)D\&W>@_$
M&UU'1;/;8R@).(P  .335HRY?*PG[R<OF86G^'H_$OQ-UF"\F<VL>W,6>&XJ
M]I-@GA3XH_V=I[,EI/'N,>>!S6_X7T'4;'QYJ^H7%NR6\^W8QZ'BDO\ P]J,
MWQ*@U-(&^RK%M,G8'-*&G)Z?H.>O,9_B*'P<NKSG4%EO;MARL:[BGY&LOX97
MR#6=;L;0S+8J28XY1@J-OI3X]%U[PYXGU&=-';48[K[DNT';R3W/O5_P-X<U
MRS\0:M?:E:>2+G)7"X'W0*4%I\F.6_S12\'7SZ;9^*+M/O1R2$?]]"G^"O!M
MAXJTB76-9!N;BX9L%C]WDBM?PIX4O8HM=M[^!HX[N1]A/<%LUCZ./%_@N*?2
MX-)DO+8L3#(@&!G/J:>G7L@>VG=C?",]UH/B;6M!AF9[>)&>$$_=Y Q7/:./
M#NIZ1JL^NSA]2\V55WMSPQVXYKK]$\/7VG6>L^(M=/DW-Q&Q*@8*+Q7&>&=!
MUB\LI[Z#3[.>'SI&5I(0S'YCWI>3[!YKN=[\'M'6Q\.&Y,+(\IR&;.2*])KB
M/A_XH;68KBPFM!;SV;>6RJ !TSQBNWJY:D1ZA1114E!1110 4444 %%%% !1
M110 4444 %%%% !5:]_X]FJS5:]_X]FH 33_ /CV%6JJZ?\ \>PJU0 4444
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MJJ, # K>I[J4$<M!<\G48M%%%8'6%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A8*,DX%9O\
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M9JM>_P#'LU ":?\ \>PJU573_P#CV%6J "BBB@ JK?\ _'JU6JJW_P#QZM0
MMA_QZK5FJUA_QZK5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,7Q9_R+%_\ ]<F_D:POA3_R(=A_US%;OBS_ )%B_P#^
MN3?R-87PI_Y$.P_ZYB@#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\B
M^+&OM++%HULV68C>!^E>GZQJ,6E:7/>2L L:YKQ'PM8S>+_&LE[< M"CDDG]
M*VI+[3Z'-B)-I06[/3?AYX?&B>'HF=<33 ,WJ*Z^D50B!5& .@I:RD[NYO"*
MC%)!1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH R_$2AM#N@0YRAX0D'I[5\Z_9?$'_  DS
M*4G\GRURN\[]F>.>M?3Q (P:H?V/8_VC]O\ (3[1M"[\<X%)*TKC;O&Q%X>
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M0<&I*0#  I:0PHHHH **** "BBB@ HHHH *K7O\ Q[-5FJU[_P >S4 )I_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN>6M\)IKS3VLK_6)IH%7;&F]L#ZUT.I>!8=0\-6NCF;:L#JP;GG!!_I78T4
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MOBS_ )%B_P#^N3?R-87PI_Y$.P_ZYB@#MZ*** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JU[_Q[
M-5FJU[_Q[-0 FG_\>PJU573_ /CV%6J "BBB@ JK?_\ 'JU6JJW_ /QZM0 M
MA_QZK5FJUA_QZK5F@ HHHH **** "BBB@ HHHH **** "BBN5\97GB&&WBAT
M" /-(V"[*"%]\4FQI'545X=K.L_$'P68=1U.YM[FT9@)%2';MR?<UZ<GBNV/
M@Y=?<8C,/F8S3TY7+L+K;N='17C-EJ/C[QA'-J>F7-O:608B))(=Q;'N#6[X
M!\<7U_?7>BZZ%6_M<Y(&T, ,DXII=.HF^IZ317D>H^*_$OBGQ)<:3X9>*"&V
M.))I(]PSG'8BF:=XM\2^%O$\&D>)I(IX;CB.:./:,_F:4=;>8Y:7\CU^BO/_
M !]XUNM(FMM*T= ^HW1PA(R%SQTKEM1O?B'X4MH]7OKNWN;7(,L:0D%1^)]Z
M2?4;1[3165X=UF+7]$M]0BZ2KDCTK5JFFG9DIW5S%\6?\BQ?_P#7)OY&L+X4
M_P#(AV'_ %S%;OBS_D6+_P#ZY-_(UA?"G_D0[#_KF*0SMZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KW_CV
M:K-5KW_CV:@!-/\ ^/85:JKI_P#Q["K5 !1110 55O\ _CU:K55;_P#X]6H
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M"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7O_'LU6:K
M7O\ Q[-0 FG_ /'L*M55T_\ X]A5J@ HHHH *JW_ /QZM5JJM_\ \>K4 +8?
M\>JU9JM8?\>JU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#%\6?\BQ?_ /7)OY&L+X4_\B'8?]<Q6[XL_P"18O\ _KDW
M\C6%\*?^1#L/^N8H [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***H:SJ46E:7/=RL $7-"U$W979
MYM\6/$9"QZ/:M\\A&_!]ZZ'X;>'!HVA)/(F)YQN.1R!7G7AFPG\9^-'O;@%H
M4?<2>G'2O>HT6*-40851@"MZCY8J".6BO:3=1_(=1116!UA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5:]_X]FJS5:]_X]FH 33_ /CV
M%6JJZ?\ \>PJU0 4444 %5;_ /X]6JU56_\ ^/5J %L/^/5:LU6L/^/5:LT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5:]_X]FJS5:]_X]FH 33_ /CV%6JJZ?\ \>PJ
MU0 4444 %5;_ /X]6JU56_\ ^/5J %L/^/5:LU6L/^/5:LT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^+/^18O_ /KD
MW\C6%\*?^1#L/^N8K=\6?\BQ?_\ 7)OY&L+X4_\ (AV'_7,4 =O1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445C>)]8CT31)[IV (7"CU--*[L)M)79YG\4]?>_U&+1+1LX;#@'OG_Z]=[X
M$T!-#\/PJ5Q-(-S'ZUYEX TB;Q+XGEU6[!:-'W9/<]J]T "J% P!TK:H^5*"
M.:@G.3JL6BBBL#J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JM>_P#'LU6:K7O_ ![-0 FG_P#'L*M55T__ (]A5J@ HHHH *JW
M_P#QZM5JJM__ ,>K4 +8?\>JU9JM8?\ 'JM6: "BBB@ HHHH **** "BBB@
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M5 !1110 55O_ /CU:K55;_\ X]6H 6P_X]5JS5:P_P"/5:LT %%%% !1110
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M1K\B97CI7G>LK_PCWQ:TRXG^2&5-F\].6KO?B'K-I;>#+IO.0F5,( >M3/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:7:!H9D;/;<,U:K%JQT)I[!1110,**** "BBB@ HHHH **** "BBB@ HHHH
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M)K5TN68_(3ZYZUZY6M5_970PP\6[U);L****Q.D**** "BBB@ HHHH ****
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MPHHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *K7O_ ![-5FJU[_Q[-0 FG_\ 'L*M55T__CV%6J "BBB@ JK?_P#'JU6J
MJW__ !ZM0 MA_P >JU9JM8?\>JU9H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#%\6?\BQ?_\ 7)OY&L+X4_\ (AV'_7,5
MN^+/^18O_P#KDW\C6%\*?^1#L/\ KF* .WHHHH **** "BBB@ HHHH ****
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M:12BK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JM>_\>S59JM>_P#'LU ":?\ \>PJU573_P#CV%6J "BBB@ JK?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !1110 4444 %%%% !11D9HH **** "BBB@ HHHH **** "BBB@
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M_OLT<]3^4/JV'_Y^H]T^TP_\]%_.N/\ B-<W"^&I)-/U VTZY*E6(SQ7G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *K7O_'LU6:K7O\ Q[-0 FG_ /'L*M55T_\
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M$T+0J5<,0Y/0&O9[1)([6-)<>8%^;'2IJ*J$5!61%>O.O+FFPHHHJC$****
M"BBB@ HHHH *Y+Q[H6IZ]I"VNFM$K[LL7)'&*ZVBE)*2LRH2<'S+<\53X6:R
M(UWRP[N^":TO#/@+7]%\2QWCR6YME&" QS7K%%1&E&,N9(Z:N.K58<DGH%%%
M%:'(%%%% !1110 4444 %%%% '*>/-&U;7=%^P:7,D7F'$C,<<5%I/@6RL/!
MC:&\:,9$(D;'5N>?UKL**5E9KN.^J?8X#X>^$M7\)37=K<3I)8,Q,(!Y'/\
MA7?T453=R;6"BBBD,**** "BBB@ HHHH *\U^)_@S7/&*V]K8W$<=HIS(K,>
M>:]*HI-)[C3L>;R_"VUD^'HT !!<!,B3_;QC-0_"_P #ZYX,>X@O;B*2T<_*
MJL>*].HJKN[?<FRLEV"BBBD,**** "BBB@ HHHH *1L[3CKCBEHH \;UGX7:
MSXA\>KJNI7$36*2Y6/.3M]*N_$;X4MXE%I/I;1PW$"A<GC(  %>KT4K:)=AW
MU;.=\%Z9J>C^'+>QU259)HEV[E.<UT5%%4W=W)2LK!1112&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP_\ ] RW_P"^!1_PAGA__H&6_P#WP* ,W_A9GAO_ )^9/^^?_KT?\+,\-_\
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MD?S6&60'TH W?^%F>&_^?F3_ +Y_^O1_PLSPW_S\R?\ ?/\ ]>M+_A#/#_\
MT#+?_O@4?\(9X?\ ^@9;_P#? H S?^%F>&_^?F3_ +Y_^O1_PLSPW_S\R?\
M?/\ ]>M+_A#/#_\ T#+?_O@4?\(9X?\ ^@9;_P#? H S?^%F>&_^?F3_ +Y_
M^O1_PLSPW_S\R?\ ?/\ ]>M+_A#/#_\ T#+?_O@4?\(9X?\ ^@9;_P#? H S
M?^%F>&_^?F3_ +Y_^O1_PLSPW_S\R?\ ?/\ ]>M+_A#/#_\ T#+?_O@4?\(9
MX?\ ^@9;_P#? H S?^%F>&_^?F3_ +Y_^O1_PLSPW_S\R?\ ?/\ ]>M+_A#/
M#_\ T#+?_O@4?\(9X?\ ^@9;_P#? H S?^%F>&_^?F3_ +Y_^O3'^*/AB-E#
M73@L<#Y?_KUJ_P#"&>'_ /H&6_\ WP*\[^(/AO2;3Q#X<C@LH426\VN HY&T
MT =E_P +,\-_\_,G_?/_ ->C_A9GAO\ Y^9/^^?_ *]7XO!F@&%"=,M^5'\
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MH_X69X;_ .?F3_OG_P"O6E_PAGA__H&6_P#WP*/^$,\/_P#0,M_^^!0!F_\
M"S/#?_/S)_WS_P#7H_X69X;_ .?F3_OG_P"O6E_PAGA__H&6_P#WP*/^$,\/
M_P#0,M_^^!0!F_\ "S/#?_/S)_WS_P#7H_X69X;_ .?F3_OG_P"O6E_PAGA_
M_H&6_P#WP*/^$,\/_P#0,M_^^!0!F_\ "S/#?_/S)_WS_P#7IA^*/A@2B/[4
M^XC.-H_QK5_X0SP__P! RW_[X%>;7OAS2E^,5C9BRB%NUK*Q3:,$@K0!V_\
MPLSPW_S\R?\ ?/\ ]>C_ (69X;_Y^9/^^?\ Z]:7_"&>'_\ H&6__? H_P"$
M,\/_ /0,M_\ O@4 9O\ PLSPW_S\R?\ ?/\ ]>C_ (69X;_Y^9/^^?\ Z]:7
M_"&>'_\ H&6__? H_P"$,\/_ /0,M_\ O@4 9O\ PLSPW_S\R?\ ?/\ ]>C_
M (69X;_Y^9/^^?\ Z]:7_"&>'_\ H&6__? H_P"$,\/_ /0,M_\ O@4 9O\
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M_P"/9JLU6O?^/9J $T__ (]A5JJNG_\ 'L*M4 %%%% !56__ ./5JM55O_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#UJ+G49Q%$3@'%%P-.BJ>F:I::Q9)>64GF0OT;%<EXT^((\'ZG9P36;207!
M,N[ 7FAZ.P+57.YHJ"RNH[ZRAN8CE)4##\14]#T!.X4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 56O?^/9JLU6O?\ CV:@!-/_ ./85:JKI_\ Q["K5 !1110
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\
MGFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $
M7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E
M1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK
M^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]G
MA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9
MX?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4
MM% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^
M>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_
M )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10
M!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFO
MY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">
M:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?
M9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'
MV>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY
M5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'
M_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA
M_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T
M4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YY
MK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\
MGFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $
M7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E
M1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK
M^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]G
MA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9
MX?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4
MM% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^
M>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_
M )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFOY4?9X?\ GFOY5+10
M!%]GA_YYK^5'V>'_ )YK^52T4 1?9X?^>:_E1]GA_P">:_E4M% $7V>'_GFO
MY4?9X?\ GFOY5+10!%]GA_YYK^5'V>'_ )YK^52T4 (JJ@PHP*6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gtqsgrqcdg4e000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,)!;$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN2^(/C5? N@)JC69N
M@THCV!MO7O0!UM%<G\/O&B^.O#[:JMH;4+*8]A;=T[UUE !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DG[0W_(@0_\
M7VG\C7K=>2?M#?\ (@0_]?:?R- "_L]?\D]E_P"OM_Z5ZU7DO[/7_)/9?^OM
M_P"E>M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>2?M#?\B!#_ -?:?R->MUY)^T-_R($/_7VG\C0 O[/7_)/9?^OM
M_P"E>M5Y+^SU_P D]E_Z^W_I7K5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->TFY16BU.S;=T'GKG^=7([B"7_5S1O_ +K T 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D
MG[0W_(@0_P#7VG\C7K=>2?M#?\B!#_U]I_(T +^SU_R3V7_K[?\ I7K5>2_L
M]?\ )/9?^OM_Z5ZU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT$JHETN]W'J05Q0![317ED'QX\+S2;626,8SN9ABM*W^,?A*<$M?QQ8[.XH
M]!HKDX?B9X-F5?\ BH+)6/\ "7YJ_%XS\.3MMBUBU<GL&H W:*H0ZWIEP"8K
MV)\=<&L_Q1XKL?#.@OJEPX9.B8/WB>E &_17RY?_ ![\0S7SR6Z0)"&^12O;
MWKU7X9?%2+QB&LKY5AOU&1C@/[#WH ].HHHH **** "BBB@ HHHH **1AE2,
MXS6)=:<\2O(]_*@))&7K*K4E!72N85JLJ:NHW^=C<HKE=(MY+^UWG4)=^XC
M?WKI;>(P0+&7+E>Y/)J,/7=9<W+9$87$RKQ4N6R?F2T445T'4%%%% !1110
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MGOXGSTP:TA-$W25#]&%?/^K_  CTRRG6&+Q1/;NQ^4(&;^M8[^#]<T=@-/\
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MG_A;G@7_ *&"V_(_X4^'XK^";B>.&+7K=I)&"*H!Y). .E?&=:&A?\C#IO\
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M>W,2@J5;C&?0UP.B_!^;Q"\SZ7XC@N&A.V1EC;*GI0!['_9_PR_OZ9_WR/\
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M\*3\7_\ /@_Z?XT 8?@[Q3;>''F:X@DE\Q<#81ZUUO\ PM33?^?&Y_,5G?\
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MOPM10=-O_MXS?^%J:;_SXW/YBC_A:FF_\^-S^8K2^PVG_/K!_P!^Q1]AM/\
MGU@_[]BN6V"_Y]O_ ,"./ER[_GT__ C-_P"%J:;_ ,^-S^8H_P"%J:;_ ,^-
MS^8K2^PVG_/K!_W[%'V&T_Y]8/\ OV*+8+_GV_\ P(.7+O\ GT__  (S?^%J
M:;_SXW/YBC_A:FF_\^-S^8K2^PVG_/K!_P!^Q1]AM/\ GU@_[]BBV"_Y]O\
M\"#ER[_GT_\ P(S?^%J:;_SXW/YBC_A:FF_\^-S^8K2^PVG_ #ZP?]^Q1]AM
M/^?6#_OV*+8+_GV__ @Y<N_Y]/\ \",W_A:FF_\ /C<_F*/^%J:;_P ^-S^8
MK2^PVG_/K!_W[%'V&T_Y]8/^_8HM@O\ GV__  (.7+O^?3_\",W_ (6IIO\
MSXW/YBC_ (6IIO\ SXW/YBM+[#:?\^L'_?L4?8;3_GU@_P"_8HM@O^?;_P#
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M: .A\77O@+PM?76EMHT$UY=AL;47]VW0 >E,M=!\'^!/!L>NZO8)<&Z.]8Y
M"<D?=&:\W^,=RL7Q&:=2'"2%N#UP17J;6VC?%3X<6&FIJ$<%Q H(W-]Q\=_6
M@!NGZ9X+^*'AJZ;3-*CL9E4C"JH9??BJGP6@%MX?UVW'2+S4'X$BM+P[I6D_
M"'PU=O>ZK#<7#*>4) ;G.,5E?!J]@FT77Y/-0>897 )QP230!\ZWG_']<?\
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M2-Y\? =3_$*ZJWATT21E-4B9LC"B1>?UKS*>'C&IS*FOOV/)I8'DJ\RHJZ_
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M?XG:3?(T=SH(52#\P3_ZU)>?$#PQ*S-9:*;@]BT3#/Y5B7GBF\U!&ALO"*Q
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M44 %%%% !1110 4444 %>2?M#?\ (@0_]?:?R->MUY)^T-_R($/_ %]I_(T
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MW'OMYDE7U4YJ:O%;CP%XP\/2&;2=2>XC7[L*EC3[?XF>)- 81^(M*=47C(0
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M/$>DR6-VN0W*L.H/:M:BDTFK,J$I0DI1W1\]7/P^U;PSXFLS9SI)(908G*9
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MZ/\ A5B_]!(_]^Z/[-Q/\OXH/[(QG\OXH\VHKTG_ (58O_02/_?NC_A5B_\
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MJ)0"I/7 &>]?0-^0MA,2Q4!3R.U?-O@KXG0^#O$>JQ:K-<7=M+*1'MYV_,:
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M1K15U*YYW:7=_P"/M8EEN=96R@#?+&6(S^57M8T'Q#X#$6KV6HM<VH.2N6(
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MWX*O/$EN\\$\<,:G;EP3DTM_X+N[#7+?2WN8F><@!P#@<9KTC3&C\.Z;H]D
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M\Q_A6D)Q47&1M3G%1<9=2Y%\/]?-WY)MXPR ,W[P<"NS\?LEIX4AM)''FE0
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M#S/N'RH,GK7E'_",:Y_T"[G_ +XKK_\ A>^D_P#0'O/^^UH_X7OI/_0'O/\
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MYB_]"%=<OW%^E<C\0O\ D!P_]?,7_H0KKE^XOTJ%\;,X_&_D+1115F@4444
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M.'_KYB_]"%=<OW%^E0OC9G'XW\A:***LT"BBB@ HHHH **** "BBB@ HHHH
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M;8G$RKSYY;D7V:#_ )Y)_P!\T?9H/^>2?]\U+15F%V1?9H/^>2?]\T?9H/\
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M24Y1V953#TJKO.*9MZ5XLU;1]1DOK6X/G2'+[LD,?<5U ^,_BL#&ZS_[\_\
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MSC_^%7>$/^@2G_?1H_X5=X0_Z!*?]]&NPHH]G#L'UO$?SO[V<?\ \*N\(?\
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M%7>$/^@2G_?1KL**/9P[!];Q'\[^]G'_ /"KO"'_ $"4_P"^C1_PJ[PA_P!
ME/\ OHUV%%'LX=@^MXC^=_>SC_\ A5WA#_H$I_WT:/\ A5WA#_H$I_WT:["B
MCV<.P?6\1_._O9Q__"KO"'_0)3_OHUK:'X3T;PY)+)I5FMNTH"N02<@5M44U
M"*U2)EB:TURRDVO4****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I7K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\?B*R^R71"7\ VNIZG'']*SA)Q?)([L51A5A]9H[=5V?^1W-%%%;'F!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !?_ -!B3_OD4?6H=@_L'$?S+\?\CZ@HKY?_ .%G^+_^@Q)_WR*/^%G^+_\
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M$>&/BQ:Z#HL5B]I*[)W&*V?^%XV7_/C-^0J8UX6U9I5RK$<[Y(:'KU%>0_\
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M>/(L7<H<&G%.3LB*M2-*#G+9'*45[=/\-/ L-^VGOK4B7HX\EI1N_E7#^/?
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M&5QDKGE35XW!JDE5I.]-[/MY,497T>YK4445YY84444 %%%% !1110 4444
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MX_[XH_X4???\_P"/^^*/85.P?VIA/YSR:BO6?^%'WW_/^/\ OBC_ (4???\
M/^/^^*/85.P?VIA/YSR:BO6?^%'WW_/^/^^*/^%'WW_/^/\ OBCV%3L']J83
M^<\FHKUG_A1]]_S_ (_[XH_X4???\_X_[XH]A4[!_:F$_G/)J*]9_P"%'WW_
M #_C_OBC_A1]]_S_ (_[XH]A4[!_:F$_G/)J*]9_X4???\_X_P"^*/\ A1]]
M_P _X_[XH]A4[!_:F$_G/)J*V/$V@R>&]9?3I)/,95#;L8ZUCUFTT[,[834X
MJ4=F%%%%(H^E;"#2;CX:VD>M2F*R-N-[!L8&/6L_P=I7P_M=963P_J#37G&%
M,I;^E4M5N8&^#\<8FC+_ &4#;N&>GI7"?"6:.'Q?&975 <<L<#O7:YI2BK'R
M\,/*5"K/F:LWIT9U'CW1QKOQ&L[ M@2<GZ 5VLVF6>@);V5GX2;48V #3*J'
M;[G-<9XOURUTSXFV=\TJM''PQ4YZBN\O;J[UJ.*XT7Q';6<6WD.@;/YFJC;F
MEW,ZSJ*G23^&WG:_R.(\?^$M.L[[2]3@MA"9;A$>+C')].E=/X@G\,>%=(@U
M&]TR"20H%2-44;SCZ5RGC-=6MKC3%U'7[>_B^TH=L<87'/7BCXPW$,WAO2Q%
M-&Y$@R%8'^&I;4>9I&L(2JNC"<KIWVN:?AO2M \17-QXJ-DL=ML"K!@84KUR
M,8K+U7Q5X+U^QN[!M/BLI4.V-P%!8^V!2_";7=.?P_-H5U,L4A+,"QQG<:@U
M+X?^'M!@O-2O=2CN,G=$B-RI_"E=N"<;>9?+"&(E"JY75N6US>\%>$;'1_"4
M>IMI1U&\G&XPG!/?IFKFL^'++Q)X8NI9_#[:3<1*6C4A0<X_V:7P=XE@U?P?
M!:6>HQVE]$NUF< XZ^M0ZY!XDM=#O9W\76DRI$S&-85RWMUK1*/)HM#EE*JZ
M[<I6E?K?_AC,^'.B:7)X"OQJ=M$_ESNCR%1N &.A[5I^'-9\*>)+J?1K?2(H
MS$-H=E4ENW!Q[5!\+/+N_AW?&\;$<EQ(9&_*K'AKPKHWA2_NM7_M2&59.57(
MRO.?6E!.T;;%5Y1]I54V^:^EK[F-X2_LWPI\2-0T%;(RO,0T4IP?+XR>O-7?
MBCXKTS3@VF3Z2)[F:,[)\+\O;OS7'VWB6RNOB^=7,@%NQ*;C],5U7Q)\-6&L
M+_;?]J0@11,!$""6)Y'\JA-N#43HE3C'%4Y5KZI7WW*^KZ;8I\'M.N%M(!,T
M"DR",;CP>];FB:?H%OX!@O\ 4K.#RXHP[OL&3P.^*R-8N8&^#6FQB:,N(%!7
M<,]#VJ:\NK=O@U/&)X]_V;&W<,]!VJM$[^1E)2E!1N]9LT-$N_"WCO2KVWM=
M+B@>!3D!5W8Z Y [U\_W]NUK?SPNI4HY&#Z9KU+X(3Q0W.M>;*B9@7&Y@,\F
MO/?%#J_B*\9""I?@BL:CYH*74]/!0]CB:E*-^70Z?P;\-KGQ):)J,>IV\"HZ
MDHZDD]Z]5\6^!9_$/AFRTN*_@@:W(S(ZD@X]*^=K&_N+6XB*7$J1JX)"N0*]
M'\;>-=/U3PAI]IIU_+]KC*^8%)4_G3IS@H--&>+H8F6(A*,M+Z:;'%>+/#,O
MA36/[.ENH[EO+#[XP0.:ZCX._P#(UC\*\]EFEG??+(\C>KL2:[_X12I#XI5I
M7"*>A8X%9TVO:*QV8R,EA)*3N['H.L?#5M1\<R:_/J<4=N6#^4N0XQ[_ (56
M\<WEEXLURR\.6DRR%6#S,I^Z%/(^N#7GWQ.O;I?'5_Y-U,(21MV2':>.V.*R
MO"&L-HOB>VOKH.48[2S9Z$CFM95(\SBEUU."E@ZKIQK2E=J/NJWD>[2Z79Z"
M+>QL_"3ZA%@ S (=OUSS7&?$/PGI]EJ6CZE;VODFYFV2Q<8 "YZ=*[V_GOM7
M6*XT?Q#!90NN0LD8)/YUP'CI-8LKW1UU/6X;Z,W&0J1A=OR]:UJ)<NQY^"E/
MVJ?-KK=:W?Z'6^(;GPOX5TRSOK[3;=Y'0".-44;S@9[5@^!7TCQ'KFOWT6G0
M+;L1Y<;QJ=GR]N*S_C5(DFDZ"J.K, <@')^Z*/@FC)#JZLI4\<$?[)J7*]7E
MZ&T:2C@'6N^9^?F4_#'@ZUUOX@ZG).@^QVTQ B48YP"/PKT9;6UEU Z<W@XI
M; [?M>V/:1Z^M</X2\1VVC_$+6+*[/EK/.2K8[X  KN;NUU^ZO&>R\56T$3'
MY8C"I(_6JII6T,\9*HZB4W965M_T.,TZ#3/!7Q7DTX6)G2_C00L2#Y3DDD\_
MTK=^)/BK3-&MTM;S2?M4DXPCX7Y>/>N"U:YN['XKZ>^J7ZWK0E2TL:8XP>,"
MNY\<^';#Q+%;:E_:,:I;C<8QR6XJ4WRR432I""K4IU7>ZU>NY0\)W.GIX8M9
M+'PG)J,A!+#"%ASZD5?\9>'=.U/P6U]+I']G7*KYGE *&0C/!Q6MI%Q'J7A:
M"/0=3@LY5'+F,'@'GBF^([D2>"+N&2_BN[F.,B1TP,G!YQ5\JY=>QS.I+VZE
M'1\W=W_R/F:H(K6**5I$SN;KS5@*Q&0"<=>*2N!-H^NE",FFUL%=]\'/^2A6
M_P#UPD_E7 UWWP<_Y*%;_P#7"3^572^-'-CO]VJ>C/I&BBBO4/@PHHHH ***
M* "BBB@ HHHH \#^-GC#5)-;A\)Z1(ZNZJT@CZR!AT_2E\1:;J^A_ <6FK';
M=J=Q*OG@L".:S?&\J^'_ (_:;J=ZI%H@C8OC@\&O9-9LM#\<>'_LKWL;VTH!
M)C8'% 'RZ_@W7K'P=9^+XY&:T9E9=LF6!SQQ^%?37PQU^3Q#X)L;B=M]PD86
M5O5JY3QUJ&@>#?AK_8,%RDVT;(XP06YSSC\:O_ ZQEM/ D<D@PMQMD3W&* /
M3:*** "BBB@ HHHH **** "O)/VAO^1 A_Z^T_D:];KR3]H;_D0(?^OM/Y&@
M!?V>O^2>R_\ 7V_]*]:KR7]GK_DGLO\ U]O_ $KUJ@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *.K:5:ZSI\ME=QJ\<BD<CH?6O"Y8=7^
M$7B8/&7ET69^<<@#\*^@JS=<T.RU_39+&]B5XW'!(SM/J*[\%C/8MPJ*\);K
M]291OJMPT36[/7M-BO;.571QG /(K2KY]@FU?X1>)C%*'ET69^W( _QKW72M
M5M=8T^*\M)5DCD4'*G./:C&X/V+4X.\'LPC*^Y=HHHK@*"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]@]K3_F7WF4SLYRS%CZDTX3R@8$K@>S&M/\ X177_P#H$7G_ 'Z-'_"*Z_\
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MLK6]?ZT\C:D\1V%RS:M-;C^U!P3S\['^,GU%+_PDMH(_[15&&I=#\QQN_O\
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M_P B!#_U]I_(T +^SU_R3V7_ *^W_I7K5>2_L]?\D]E_Z^W_ *5ZU0 4444
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M?R- "_L]?\D]E_Z^W_I7K5>2_L]?\D]E_P"OM_Z5ZU0 4444 %%%% !1110
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MOUARQ6'?,GNNJ^1K&5O=9ZA134=)$#HP92,@@Y!IU>*:!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT8PAE0-M'M7D/QV\.:-I7@>&?3],MK:4W2J7BC"G'/% &K^SU_R3V7_K[?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M36J_')OYE**6PU8T081%7Z#%.HHK 8445%<>;]GD\@ R[3L!.!GM0@,GQ?\
M\B?JW_7L_P#*F^#O^15T_P#ZX+_*N9U6S\=ZEIMU9-:V02="A/VGL?PI-+LO
M'FF:=!9I:V16) H)N?3\*]+V"]AR<\;WOOY$7U/1**AM?/\ LT?VE5$VT;@I
MR,U-7G-69855U#3[;5+.2UNHEDBD&""*M44)M.Z XOP9X.'A/4[Z.#FUE&Y#
MZ$GI7:445I6K2K3YY[B2L%%%%9#"BBB@ HHHH **** "BBB@ KB?BK_R(]S]
M?Z&NVKC?B=;S7/@RXC@B>60GA44D]#75@G;$0]4*6Q\D45I?\([K7_0)OO\
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M[H+,S:*TO^$=UK_H$WW_ 'X;_"C_ (1W6O\ H$WW_?AO\*/:P[H+,[GX%?\
M)1T_Z]9?Z5]/5\W?!32-2LOB"DMU87,,?V:0;Y(F49X[FOI&OB>())XNZ[+]
M3II?"%%%%>&:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y)^T-
M_P B!#_U]I_(UZW7DG[0W_(@0_\ 7VG\C0 O[/7_ "3V7_K[?^E>M5Y+^SU_
MR3V7_K[?^E>M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 -=%D0HX!4C!![USTO@
M+PO-<>>^BVC.>3E.I]:Z.BKA5G#X&T*R9#;6L%E;I;VT2Q1(,*BC@"IJ**EM
MMW8PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?R- "_L]?\D]E_Z^W_I7K5>2_L]?\D]E_P"OM_Z5ZU0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y)^T-_R($/_ %]I
M_(UZW7DG[0W_ "($/_7VG\C0 O[/7_)/9?\ K[?^E>M5Y+^SU_R3V7_K[?\
MI7K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5+5-'T[6K86VI6<5U"&W!)5R,^M7:* *6F:1I^BVIMM-LXK6 MN*1+
M@9]:NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#:/*\B+Y\Y[4 5_^&@O!?_3_ /\ ?C_Z]'_#07@O_I__ ._'_P!>I?AM\/\
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M_P"\^RQ?+NSW]ZO?$3X?2'X?>'1HOAX_VE\OVKR(OG^Y_%^- '7?\-!>"_\
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M^A?L/^_0KA/BW\/K ^"6_P"$<\/Q?;_M"8^S1?/MYS^% %K_ (:"\%_]/_\
MWX_^O1_PT%X+_P"G_P#[\?\ UZUO"'P_T >$-*_M+P_:_;?LZ^=YL7S;N^?>
MMO\ X0#PE_T+]A_WZ% ''?\ #07@O_I__P"_'_UZ/^&@O!?_ $__ /?C_P"O
M78_\(!X2_P"A?L/^_0KB_BI\/]-/@6Y'A_P_#_:'FIL^SQ?/C/- #_\ AH+P
M7_T__P#?C_Z]'_#07@O_ *?_ /OQ_P#7J_X#^'^ACP-HXU?P_;?VAY \_P Z
M+Y]V3U]ZZ+_A /"7_0OV'_?H4 <=_P -!>"_^G__ +\?_7H_X:"\%_\ 3_\
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M8?\ ?H5Y9\:OA\AT_2_^$7\/#S/-?SOLD7.,<9H Z+_AH+P7_P!/_P#WX_\
MKT?\-!>"_P#I_P#^_'_UZ?\ #3X?Z2/ MB-=\/P?VA\WF?:(OGZ\9KEOB?\
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M;H?-SC&X5JA@PR""#T(H 6BLJY\1Z3:7'D37L2R>FX5IQR)*@>-U93R"#D4
M.HJ"[O+>PMS/<RK'&.K,<4EG?6^H0">VD$D9Z,* +%%%% !1110 4444 %%%
M% !1110 4444 %%%% !14-S=P6<)EN)5C0=2QQ52PUW3-3D9+2[CD9>H##-
M&C7*?$3PG/XU\(S:-;7,=M(\J.))%) VG/:NKI&944LQ 4<DF@#@_A;X!NO
M&D7ME=WL-TUQ,) T2D  #&.:[VLE/$ND/=_95OH3+G&-PK5!!&000>XH 6BJ
M>H:K9:7&KWDZ1*QP-QZU9BE2:)9(VW*PR#0 ^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **AN;J"TA,MQ*L:#J6.*IV.O:9J4C1VEW%(XZ@,*
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MH+N$2V\J2(>A4YJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH90RE6&0>"*\9_:*18_!>FJ@ 47?0?[M '=?#8D^![$DDG;W^@KK:Y+X:_\
M(C6/^[_05UM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ3X(?3=/ ,YN(WY'89S5SX<:'=^'_"D%C>#$R  UUU% !1110 4444 %%%%
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M\=^ -8UOXB:=JUJ@-M!,KL2#T# U[3110 4444 %%%% !1110 4444 %%%%
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M"VGNXHYC_ S@&@#0HK+F\1:/;SB&74;59#V,R\?K6C'+'-&)(I%D0]&4Y!H
M?16?>Z[I>G,%NKZWB8_PM*H/Y9J:SU&SU!-]I=0S#OY;AL?E0!:HJ&YN[>SB
M,ES/%"@_BD<*/UJE9^(-)OY/+MM0MG?^Z)5R?UH TZ*BN+F*U@::=U2-1DLQ
MP!5&/Q#I,MJURNH6_DC@L95Q_.@#3HJA9:SINH\6E[!*P_A212?R!KR_XN?$
M:[\-WFGV.D7*K),W[]E8909':@#U^BN<\.>([&]\.P7+WL;LB#S6WC@^]71X
MGT8VQN!J-MY8;;N\U>OYT :U%5AJ%FUJ+K[5"(",^89!M_.J$?BK0Y9A$NIV
MNXG',RX_G0!L451U/4[;3M*FOI)HUB1"0Y88)QQS7C_@+XFW>M^.+J+4[Y8[
M,;A%&6&.@Q0![:64'!('XTM>9>-3K4OB[39--UJ*ULR@+PM*H+\^AYKT:V8I
M91-*XR$&YB>* )Z*RI/$NBQ3^2VIVF_./]<O^-:44T4Z!X9$D0]&1@10 ^BL
MXZ]IBWSV9O81<(<,A<9'ZTS_ (2/1_M/D?VE:^9TQYR_XT :E%(K*ZAE8,IY
M!!X-+T% "$@=2!2UXKXI\7:MK'Q2M/#6BWLENENV9]@SO (/\J]<O=6L-,*)
M=W,<);[H=@,_G0!>HK,G\0Z1;*AFU"V3>,@&5<_SJW%=V]U;--;3QRI@X:-@
MP_2@";>G]Y?SIU?'UY\2_%D.NW"#5IO*CN6&,#@!J^H/#VO+JG@R'6"X.8&D
M)^@/^% '0%U!P6'YT%@!DD8^M?(OB+XH^)Y=?OIK'5)DLS*?+ 48 ]*]PUN\
MUB?X.VFJVEVZ7L=F)W=1RQQ0!Z717$?"[Q:_BSPE%<W)_P!+C8QR#O\ +@9K
MMZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KYMO_\ DXZ\_P!_^@KZ2KYMO_\ DXZ\_P!_^@H TOC3KE]J7BO3?#%M.T=O
M.P20 ]6W8JQJOP:7PYX0NM0TS5+F.]2 F4# ##T^E9GQGL[C0O'^D^(#"\EH
MC"5W X!#=/K76>)/BWHVI^![B.Q;S;ZY@*B%2"4)]10!RWP3GFM='\02@DS)
M$>G<[JA^!FCV&J>*M:O;R)'N+>4M%NZ@DG.*TOV?X_M46LI*O,B'</\ @5<=
M?G7/A)XZGN88F-K*Y<,P^1P><?AF@#W+X@?$+2?!C6UEJ<$DJWD;$!4R,#@U
MP_P_\2^!KGQ6PTG2C'>SDD2-%C:/0<URGBGXG^&O&'V:75=-NC/;H54IMQS4
M?PET2ZU#Q\VIV5E+'IH!*.PX XXH ^HJ\ _:)N7EFTBT;/E+-N'XCFO?Z\G^
M./A&[U_0+>^L(S)/9.9&11RPP ,4 =UX/T>QT;PU96]A$B1F)6.WN2 35;6O
M GA_7M6AO]0LHI9X^FY<[N>M>)^$OCI+H6E+IVJVCRM#\JE!SQZYK/O_ (G>
M)/&?C.P31//A1&VK#&<94D9+?2@#V'XI>(_^$,\$$:>/)9_W,6S^#/<5YYX-
M^#4/BO0FUC7-1N#=78W*5 . ><_6NO\ B[X:U'6?AY"%_>7ELPDEVC@@9S69
M\._BKHECX4CLM4F6VN+4;-CG!.* .9\%:EJW@'XG1^$Y;EI["=@-K'[H.2"/
M?BJ'QC$\GQ*A6U9TDD9%#)U&<5:\.>?X^^,R:[90LMG;, [$=AD9J?XC#'Q@
MLQZ,@_E0!;\8?!RVL/"LFLMJ-Q-J*@-(S@?-QGK6K\*O%MW%\*=5O)V+MIY*
M0Y/8+FN^^(?_ "(5W_US_P#937E?PATR35_A+XCLX1F624A!ZG90!F^!_!9^
M*M[>Z[KE[-L+E4"X..>G/:NF\#> O$W@_P <,MG/G1<YD#MC<O/:L3X2>,++
MP5)?:#KKBU:-V;>YP"<]*ZG1?B]=^(/'QTG3K03::^%615R0><DGTH Y/XJZ
M^^O^/5\,SWQMM.A(\T[L*>AYS6'XIT/0/"%K;:SX6UXS7D+JI0,N3D\]/I5K
MXH:''I?Q,_M+58)&TNZ*\KUZ &I=97X:6,< L5GOII2 $A9202<8H ]*U#7'
M\0?!62_F.9WLR9>?XL5Y9\*/ +^,]/D^W7\\6FQ.2(4P0S=\YKU34[&WL?@W
M<"VMY;>.2U+>5+]Y>.AK*_9Y_P"10G_Z[O\ TH \_M]*E^'?QG@TFPNI'A.U
MFW<;@P)P<5;^.7AJTL/$.E7T;,9-2_UN1TZ"K7CW_DX6W_ZYP_\ H-:'[009
M;CPS,5/EQC+-Z<B@#6_X0VP\,?"J\GM'9FND\Q]P YVD5PWPG^'4/C;1[I[Z
M\GCM(Y<"- "-V.O->BWWB73-;^$\T-C<)*\$6V0*<[3@]:A_9S_Y$N__ .OO
M^E $GQ \)I9>$[/18-6CL=/1OWF^0(9>.1CO7CGBO3?!NG:;&NCWUW-?Q\EM
MB["?J*[3X^RW/_"5V4=ZLAT@*I&SJ6P<X]ZI>-M7\%IX(BLM!LX9;N2-=\T8
M&Z,X'WC0!WGA"Q/C;X+BSU:>20;"^\\G*Y(KS#X8>";#7/&\]I<RR>7:DLN
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MPWL8%)")V!\P\U]!5\[?!!&D^(WB1T&54DD^WF&OHF@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gtqsgrqcdg4e000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -9!F$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS5SY9TY22LT8P<J=6,&[ID7P;_Y %U_UU-1_&#_4:/\ ]?0I/@W<1C3+VU+
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M?&;$J#B%L>W(KWVNK$NR45ZG%@XWO)^@4445RG>%%%% !1110 4444 %%%%
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MY3;J^V6&4DE1[9Z5UEG\:H4@V:AI<OVA1SY; #/T-<5<?;/B#XS$]M:-&LK
M$@<(H[DUV4E-2Y9['F5G2:YZ;M([GXR2K/X?TR5?NO(2/R%<GX5\$:[KFBI>
M6&HF"!F(">81T-=7\8(#!X:TN(9(C<@G\!6!X-^)EIX8T!-.FT^>9U=FWHX
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MX<?\COKW_79__0C6U_WLFNQS\K]E!/\ F/5%BC0Y1%4GC(%/HHKD/1"BBB@
MHHHH **** "BBB@ HJO<W2VVW<"=WI4']JQ?W&H OT50_M6+^XU']JQ?W&H
MOT50_M6+^XU']JQ?W&H OT50_M6+^XU']JQ?W&H OT50_M6+^XU6H)UN(]Z@
M@9QS0!+1110 4444 %%%% !67J?-S#]/ZUJ5EZE_Q\P_3^M %X6T./\ 5K^5
M+]FA_P">:_E4@Z4M $7V:'_GFOY4?9H?^>:_E4M% $7V:'_GFOY4?9H?^>:_
ME4M% $7V:'_GFOY4?9H?^>:_E4M% $7V:'_GFOY4?9H?^>:_E4M% $7V:'_G
MFOY4?9H?^>:_E4M% $7V:'_GFOY4?9H?^>:_E4M% $7V:'_GFOY4Y(8T;<J
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M HHHH **** "LO4O^/F'Z?UK4K+U+_CYA^G]: -,=*6D'2EH **** "BBB@
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MEZE_Q\P_3^M &F.E+2#I2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^TDE=71<\;ZUX-U'PU=064EHUTJYB,,>TY^N*Z7X<3R3^!K3S&+%4*@FN?\
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MI?\ 'S#]/ZT :8Z4M(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** &[%W;MHW>N.:=110 T(@;<%4,>^*=CG-%% !@>E%%% !@#H*, ]1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 5[W_ (\Y/I46F?\ 'K_P
M*I;W_CSD^E1:9_QZ_P# J +M%%% !1110 4444 %9>I?\?,/T_K6I67J7_'S
M#]/ZT :8Z4M(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5EWW_']%6I67??\?T5 &I1110 4444 %%%% !1110!7
MO?\ CSD^E1:9_P >G_ C4M[_ ,><GTJ+3/\ CT_X$: +M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>]_P"/.3Z5
M%IG_ !Z_\"J6]_X\Y/I46F?\>O\ P*@"[1110 4444 %%%% !67J7_'S#]/Z
MUJ5EZE_Q\P_3^M &F.E+2#I2T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %9=]_Q_15J5EWW_']%0!J4444 %%%% !11
M10 4444 5[W_ (\Y/I46F?\ 'I_P(U+>_P#'G)]*BTS_ (]/^!&@"[1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7
MO?\ CSD^E1:9_P >O_ JEO?^/.3Z5%IG_'K_ ,"H NT444 %%%% !1110 5E
MZE_Q\P_3^M:E9>I?\?,/T_K0!ICI2T@Z4M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !67??\?T5:E9=]_Q_14 :E%%%
M !1110 4444 %%%% %>]_P"/.3Z5%IG_ !Z?\"-2WO\ QYR?2HM,_P"/3_@1
MH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWO\ QYR?2HM,
M_P"/7_@52WO_ !YR?2HM,_X]?^!4 7:*** "BBB@ HHHH *R]2_X^8?I_6M2
MLO4O^/F'Z?UH TQTI:0=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K+OO^/Z*M2LN^_X_HJ -2BBB@ HHHH ****
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MS.K:\+?UHSTBBBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *][_P ><GTJ+3/^/7_@52WO_'G)]*BTS_CU_P"!4 7:***
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M'17)>(?B+H7AO6;?2KV5OM4^W:JC.,G S57Q)\5/#/AF86]U=&6YVAC#&/F
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MP_\ PN;P5_T$G_[]FC_A<W@K_H)/_P!^S7F__#-UW_T&H?R/^%'_  S==_\
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M %>]_P"/.3Z5%IG_ !Z_\"J6]_X\Y/I46F?\>O\ P*@"[1110 4444 %%%%
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M0F=US\W4]HB9FB5F&&(YI]%%2P6B"BBB@84444 %%%% !1110 4444 %%%%
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M*>H(IU% #$BCBC\M$54'\('%.  & .*6B@! H4< "EHHH ;L7=NVC/K3J**
M$ "C &*"H888 CWI:* $  & ,"F300SKMFC5P.S#-244 -"(%"A1@=!CI2D!
MA@C-+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A(4$DX Y)I:ANT:
M6SGC3[S1LH^I% UN5_[9TW_G^@_[[%']LZ;_ ,_T'_?8KQO_ (5YXG_YY-_W
M\'^-'_"O/$__ #R;_OX/\:Y_:S_E/4^I8;_GZCV3^V=-_P"?Z#_OL4?VSIO_
M #_0?]]BO&_^%>>)_P#GDW_?P?XT?\*\\3_\\F_[^#_&CVL_Y0^I8;_GZCVF
M"_M+I]D%S'(P&<*V:LUYSX"\+:QHFKR3Z@A6-HRHRV>>*]&K6$G)7:L<&(IP
MISY8.Z"BBBK,3SOXO>)KO0_#D5IISE+R_E$*LIY4'.2*;H'PA\-6VCQC4K-;
MV]E7=-/+R2QZXSTK%^.44D":'JFTM#;W(#^V<UZMIUW#?:?!<V\BR12("K*<
M@TH)<DGUO;Y65OU'-^]%=+7^=S T;0M)^'NCWSQ7$D>G@^:1*^1&/05S;?%J
M:2%M0M/#.HSZ.O)O AQM[G&/3WJ7XSW$A\ 72VLJM^\59=K9P/>L[0],\<W/
MA.UM[.YT3[!);A478_W2*$Y2YGVLOP!I1LN]V:OB_P <>=\/VU30K6ZNX[J,
MCS8 <P^I..G3%9?PF\8ZMJ&BZ=I]WI&HR(4YU&16*-P.^*FLO"E_X1^%FN65
M_<Q3R2*T@\H':N3G'/UK8^#Y!^&FE8_N?T%5&RG.W9?K^1$KN,;]W^AJ:#XQ
MM]=\0ZKI$4#))IY 9B>&Z?XTE[XRM[+QI:>&V@8S7$>\29X%<9\.B%^*/B]"
M<-N4X_!*9KLB/\?-(574E;<Y /3I4PU]G?[2U^YE2T53RV^]'86WCJU;QI/X
M:N[=[:X4;H7<\3#V_7\JDM/&MMJ7C&X\/V=NTWV9,SSC[J'^[]>M<%\<DAWZ
M4^FF0>( Y\CR/O;<'.?;K6M\$S8OX9N'!8ZLT[?;3)]_=GO[=:*?O1;?2_S_
M *Z^85/=>G6WR_KH:7@"_P!!GNM=;2-.^RO#.1.?[Y !STJA_P +AM+B2YM-
M.TB[OM1AF>/[-"I8X4XR<=*S?A+_ ,?7B[_KZ?\ ]!%3?!BVA^T>)9_*7S?M
M[C?CG&YJ(WE9?W4_R_S"?NM_XFOS+MI\9])N;)T-E=+JROY?]G!,R%OIU_2M
M/PK\2(-?UJ31;[3;C2]35=ZP3@@E?7G'J*Y;PC96S?'/Q.Q@0E$5DR/NGVJ;
MQ&JQ?'K0'0!6>!@Q'?E:J#3<+_:_#1_Y"FG%2_N_\#_,ZGQ%X[ETK4VTW3=#
MOM3NT7<XAC.U1]1FD\)_$.W\1:I-I%W83Z=JD*[VMIA@[?7GZBLS4?'&K7GC
M&Z\/^%]+M9KFU7_2;BYR%7\B#7+:1_; ^.\1UG[(+LVG/V7.W'R]<TJ>K2?6
MXZFB;[6_3_,36?$5KX:^.=Q>722R;K,)''$NYG8[@ !]2*ZS2?BK%/KT.DZS
MH]WI$US_ ,>YN%(#_F!6&L5K)^T0_P!I6-B+/*;_ %^?I4GQO2(1:$\0 O1>
M*(]OWMO.:5+X*:?73[Y,)*\IVZ:_@CUVBHX-WV>/=][:,U)38D[JX4444#"L
MN^_X_HJU*R[[_C^BH U**** "BBB@ HHHH **** *][_ ,><GTJ+3/\ CT_X
M$:EO?^/.3Z5%IG_'I_P(T 7:*** "BBB@ HHHH **** "BBB@ J#[';>=YWD
M1^9_>V\U/10 4@4 D@ 9I:* "BBB@!DL,<Z;)45U/9AFFPV\-NNV&)8QZ*,5
M+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445$;F 2;#/&'_NEQF@"6BBB@ HHHH *
M*** "BBC.!DT %%,CFBF!,4J2 '!*L#BGT %%%% !1110 454MM4LKNZFMK>
MX22:$XD13RM6Z "BBB@"O>_\><GTJ+3/^/7_ (%4M[_QYR?2HM,_X]?^!4 7
M:*** "BBB@ HHHH *R]2_P"/F'Z?UK4K+U+_ (^8?I_6@#3'2EI!TI: "BBB
M@ HHHH **** "BBB@ HHHH **** /+_BWXCU30;SP^FG7+0K<W:I*!_$.:]0
MKQGXY_\ '_X6_P"OY/ZU[-0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M74KG3-1GNK:.5VF>4YVD=>]/O?BWX/L;6&XEU+(FSM1 "W!(R1GU%<=\.?\
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MM[F&[@6>WE26)QE71@0:EH **** /&?CG_Q_^%O^OY/ZU[-7C/QTXOO"Y/\
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MO/\ OC_ZU']O^)_^?J\_[X_^M1]7EW#Z]'LSV"BN$\&:GK%YJ<B:A-</&$)
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M +M%%% !1110 4444 %%%% !1110 4444 1W'_'M+_N'^5>>?!W_ ) 6J_\
M82G_ /1C5Z'<?\>TO^X?Y5YY\'?^0%JO_82G_P#1C4 >CT444 %%%% !1110
M 4444 %%<Y>>,].L=1DLYPZE#@N.15VT\2Z3>8\J\3G^_P#+_.JY)6O8S56#
M=KFM13(YHI1F.1''^RP-/J30**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:/\ A&M%_P"@;!_WS1]8K>0?4\%_>^]'A/G6?]Q/^^11YUG_ '$_[Y%>[?\
M"-:+_P! V#_OFC_A&M%_Z!L'_?-'UBMY!]3P7][[T>$^=9_W$_[Y%'G6?]Q/
M^^17NW_"-:+_ - V#_OFC_A&M%_Z!L'_ 'S1]8K>0?4\%_>^]'A/G6?]Q/\
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MW#_*O//@[_R M5_["4__ *,:O0[C_CVE_P!P_P J\\^#O_("U7_L)3_^C&H
M]'HHHH **** "BBB@ HHHH Y#5/ =MJ%U+<K=21R2,6(QD9/XUSUW\/M2BRU
MO)%*H]\&O4**UC6FCFGA:4M;'CKZ=XBTLYV7<:CNK'%>E^&FNI-"MY;MRTKC
M)SU%:Q /4 TH  P!BB=7G5FAT<.J4KIA5:ZO[6Q"&ZG2+><+N/4U9KE/%_A^
M_P!;\DVKKMCYV$XYJ()-V9K4E*,;Q5V=1'-%,H:.164]"#3Z\<DT_7]$DRJ7
M$9'\4?S#]*O6?CK5K1@EQMF Z[Q\U;/#O[+N<JQB6DU8]5HK \/>)XM?+HEN
M\3(,MDY%;]82BXNS.N$XS5XA1112*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y75/'%KI>H2V<
MEK([1G!8,.:J,7+1$3J1@KR9U5%<3_PLBR_Y\IO^^Q_A1_PLBR_Y\IO^^Q_A
M5^QGV,_K5'^8[:BN)_X619?\^4W_ 'V/\*/^%D67_/E-_P!]C_"CV,^P?6J/
M\QVU%<7'\1;.214%E*"Q ^\/\*[)&WQJX[C-1*$H[EPJPJ?"[CJ***DT(+J]
MM;) ]U.D2L< N<9J5)$E171@RL,@CO7C?QZMGO8] M$=E\ZZ*9!QU%;/P=U:
M8Z5?>'[Z1C=Z7.T?SGEER<?H*</>BW_6G_#A/W;'I4LL<,;22N$11DL3P*CM
M;RWO8O-MIDE3.-R'(KS/XOZC/>QV'A:P<BXOGWS;3RL:\D_H:J_ X_8?#6LH
M[LR6]VZ@L>REA_2IB[J3>R_X%_S"?NN*[_\ !_R/5KJ]MK*(RW4Z1(.K.<5%
M9:MI^H@FSNXIP.NQLUXUX=TJ3XL^)=0U?69Y3H]K*8K:V5L D>OYBNVM_A7H
MFF:U::II#36,L#Y9(W^5QZ$4TGHY=0ENTNAVBWMLUVUJLR&=1DQYY J>O(M)
M9O\ AH/45W''V3IG_?KUVA:PC+O_ )M ])./;_),KW=_:V**UU<1PJQP"YQD
MU.K*ZAE(*D9!'>O#OB7!=>.?&<N@6<CB+2[1YV*'_EI@X'YK7=?"G7FUKP9
MDS9NK,F"8=P02!^@HA[T6_ZMM?[PG[LDOZOO;[CN***P_%-AK&IZ8+71KY+*
M61L23%<D+WQ[TGY#2N::7]I)=M:I<1M.HR8P>13[FZ@LX3+<2K%&.K,<"O$O
M NC?\(_\:[W3Q=37&VTW/)*V2S'J:ZGXU@-X/A1FVHURBMSCC(S1)VA&2ZV_
M.P15Y./;_*YVP\1Z,3@:E;DG_;K3#J4W@C;C.:\QTKX;> KN"W,9MY9B@)5+
MA2<_0&M;XH27VG?#N\&E>8K(JH3'RP3(!_3-.;Y$*'OM'2GQ'HPN_LIU*W$^
M<;-_.:TP0P!!!!Z$5X4WA_P WPI.IAH#??9@QG$O[[S<<C'USVKT/X6-J+>
MM/.I&0R;?D\P?-M[9JN762[$WT3[G9T445)17O?^/.3Z5%IG_'K_ ,"J6]_X
M\Y/I46F?\>O_  *@"[1110 4444 %%%% !67J7_'S#]/ZUJ5EZE_Q\P_3^M
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MW[_Z)_6N@\:_\BS<_0?S%<_\-?OW_P!$_K71'^"SBG_O43T&BBBN<[0HHHH
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MYF7.TC/^-)-QBFMTW]SL-I2=GM;\3C?!X/BWQAK_ (LD^:UAC:WLR>PP<_\
MH5)\)8FG\,^)XD^\U[,!_P!]/7?>%?"L7ACPG#HL4BNRQE7E QN8]ZI> _!L
MO@^TU"&:[2Y-W<O."J%=H))QU]Z;BO>@MN6WXK_@LF[=I=;W_ Y'X#W4<>B:
MEI;D+=P7;LZ'K@X_PKUPLJXRP&>F37FOB#X77+Z_)KOA76&T>_FYFPN5?\!B
MI-(\">)Y-7MK[Q)XIDO8[=MZ6\*E%S[Y)S5<W/:^G<&N5NQD:3_R<+J/_7I_
M\77J>J7L>G:7<WDK!4AC+$FO.M?^&FO7GC6?Q'H?B2/39)8PA4PECW[@CUIE
MQ\/_ !O?Z7>6&H^,HKJ&YCV%3;L,<@_WO:L]?9**W2_5E:>T<GL_\D<?X#\5
M7]K=ZMKK>'+^^DU.4MYL: KM[ 9/O5WX8:S+I7Q%U33+FSFL(=2)F@AG&#OX
MS_6O8?#NB0^'] L]*BPRVT83=CKCO7.>+O <VO>)-(URPO8[2ZL'Y+(6WKSQ
MP1ZUHK1FDMMOD0[R@[[O7YD6KS_$5=5N!I=MIC608^49'.XCMGY:[+3#>MIT
M)U%8UNRO[P1G*Y]JMUC>)=/UC4M-\G1=333[G=DRO&7X], BHO96W+M=WV/.
MM(_Y.%U+_KS_ ,:])U_P[IGB;3S8:K"9;<G.T.5.?J*\QA^%/C.#Q#)KL?C*
MW%_(FQI/LK<C_OJNSUKPYXEU#1+"&R\1FTU*V.9;A4.V;KU&?ZT[+V<8OI_F
MV+7G;77_ ".(^('PWT7PSX6NM;T*:ZL+RT7S%9;ER&P.F":UK[QY<6/PGTS4
M[BW2>^OT$*)(/E+$XR:BN/AQXK\1M';^*/$ZSZ:K O;P1E/,_$DUUOB3P-IV
MO^%H]$&8$@ ^SNO6-AT-)WY&N[7W=?O&K<Z?9/\ X!Y@?@S>#0QK<.I@:J3]
MJ%L8QY&[KC;T[^E>B_#3Q7)XK\,":>%8KBV<P2A!A21Z5SP\$_$+[!_99\7V
MXLPNSS! V_;Z9W5VOA'PK:>$=$33K4ESG=)(W5V/4U::][MT_KT(=]+[]3?H
MHHJ2BO>_\><GTJ+3/^/7_@52WO\ QYR?2HM,_P"/7_@5 %VBBB@ HHHH ***
M* "LO4O^/F'Z?UK4K+U+_CYA^G]: -,=*6D'2EH **** "BBB@ HHHH ****
M "BBB@ HHHH \@^,_P#R&?"G_7\/Y&O7Z\@^,_\ R&?"G_7\/Y&O7Z "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>O'__ ",^H?4UZ+\&O^2=
M6/U;^9KSOQXN_P 57ZYQEL5T7P]\9Z9X9\)6VF7WF>?&3G8I(ZFN6E*,92NS
MVL91J5*5/D5]/\CV*BN'_P"%IZ#_ --_^^#1_P +3T'_ *;_ /?!K;VL.YYW
MU/$?R,[BBN'_ .%IZ#_TW_[X-'_"T]!_Z;_]\&CVL.X?4\1_(SN**X?_ (6G
MH/\ TW_[X-'_  M/0?\ IO\ ]\&CVL.X?4\1_(SN**X?_A:>@_\ 3?\ [X-'
M_"T]!_Z;_P#?!H]K#N'U/$?R,[BBN'_X6GH/_3?_ +X-'_"T]!_Z;_\ ?!H]
MK#N'U/$?R,U_&O\ R+-S]!_,5S_PU^_?_1/ZU5U[Q]I&M:5+96WF^;)TW*0*
MM?#7[]_]$_K773DI46T>97I3IXN*FK:?YGH-%%%8'4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !67??\?T5:E9=]_Q_14 :
ME%%% !1110 4444 %%%% %>]_P"/.3Z5%IG_ !Z?\"-2WO\ QYR?2HM,_P"/
M3_@1H NT444 %,F,@A<Q &3!V@],T^BD]4"/GKXDZ5XELI]*U?6=8=I)K]8X
M[:W8K&B=1Z9/%>[7=\NG:)+>R<K!"7/X"O,_CK_R#O#_ /V$D_D:[GQ7&\O@
M/4XT&6:S<#'^[2D[496Z-_DBU%.K"_5?J>;>"_"2?$.*^\0^)+FYF$\S+;1)
M,R*BC@$8(]*F\%W]SX,\?ZKX3N+N6XL5B-S 96+%%],GZUT7P8E1_A[:QJ1N
MB9E<>AW&N0UV)[[XWZBMOR4TIE)'K@553]W*T=N5_E>Y$/WD6Y=_UL2^#_#H
M^)EYJFO>(;BYDMQ.T5O;I,R*H&.>"*M>$GNO!?Q5N/"7VJ:?3;F+SH!*Q8H>
M. 3]:U?@=*C^#9XP?FCNG5A[UFZK_I/[0^G+%RT-KN?'8?+5V4*D8K9K]+_F
M3=RISD]U_G;\CV"BBBH*([C_ (]I?]P_RKSSX._\@+5?^PE/_P"C&K6\7Z#X
MHU2Y\[1?$BZ;;+#AXC"6+'G)R&%8GP3CDB\+WT<TGFRI?3*\F/O,';)_&@#T
MRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (!&",U
M#':P12M+'"B.W4JH&:FHH"P50UK45TK2IKLX)1?E![GM5^H+NSM[ZW,%S$LD
M9ZJPIJU]297L[;G)Z5\0+2Y81WT?D.?XA]VNN@N(;F,20R*ZGH5-<5K'P^BD
M!DTR38W7RWZ'Z>E<JDNM^&+G \R'!Y!SL;_&NCV<)ZP9Q>WJTM*JNNY[)17*
M>&O&"ZQ*MI-"RW&/O*,J?\*ZNL)1<79G9"I&:YHA1114EA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!1[2E_*+V.(_G.)_X6-J/_/I;_F:/^%C:C_SZ6_YFNV_X1G1O^?"'_O@4?\
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MYKA\-6HMW:=]R_IGQ*US3G"7JBY4=1(-I'Y8KUG0=7_MO2(K_P AX ^?E?\
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MYGX/3+'\1O$\V<JJROGVW@U4CNO$/Q=\<:A9VVK2V&EVI.U8SC YQ^)Q5?X
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MSG@'-;?P;1!\4M0,-L]O"T$K11N,%4)!'Z5-%=.G*_R_,NKU?5/^OD:?P?\
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M8D2!6((3&>PQ7K_PD\17?B/P/;7%ZYDN(CY;N>K5BZH#_P ,^#_L&K_Z!1\
MO^1!;_KL?Y5JOBJ1Z*WYF3^&G+O?\CU6BBBLS0**** "BBB@"O>_\><GTJ+3
M/^/7_@52WO\ QYR?2HM,_P"/7_@5 %VBBB@ HHHH **** "LO4O^/F'Z?UK4
MK+U+_CYA^G]: -,=*6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH \@^,
M_P#R&?"G_7\/Y&O7Z\@^,_\ R&?"G_7\/Y&O7Z "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8O%O_
M "5SQ%_P#_T!:]F^%G_(H#_KN_\ 2O&?%O\ R5SQ%_P#_P! 6O9OA9_R* _Z
M[O\ TKG7\9GJS_Y%Z]3MZ***Z#R@HHHH **** "BBB@"E>Z/I^HNKWEJDS*,
M MGBJG_"*Z'_ - Z+\S_ (UL452E);,ATX-W:,?_ (170_\ H'1?F?\ &C_A
M%=#_ .@=%^9_QK8HHYY=P]E#LCSGQWI&GZ;:VK6=JD+.S!BN>>E;G@'_ ) '
M_ ZH_$G_ (\K+_?;^E7O /\ R /^!UO)MT5<XX)+%-+L=51117,=X4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5EWW_']%6I67??\?T5 &I1110 4444 %%%% !1110!7O?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !1110 4444 %9=]_Q_15J5EWW_']%0!J4444
M%%%% !1110 4444 5[W_ (\Y/I46F?\ 'I_P(U+>_P#'G)]*BTS_ (]/^!&@
M"[1110 4444 %%%% !1110 4444 %%%% $=Q_P >TO\ N'^5>>?!W_D!:K_V
M$I__ $8U>AW'_'M+_N'^5>>?!W_D!:K_ -A*?_T8U 'H]%%% !1110 4444
M%%%% !1110 4444 %%%% &'XHT1=9TQE51]HC&8V_I7!>%-9DT/5S;W&X0R-
ML=3_  GUKUFO./'F@^1-_:ENN$<XD ['UKHHR37)+J<6)IN+56&Z/1E8,H93
MD$9!I:Y'P/KWV^R^Q3OF>$?+GNM==6,XN+LSJIS52*D@HHHJ2PHHHH ****
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M_P AGPI_U_#^1KU^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /F+Q;_R5SQ%_P#_T!:]F^%G_ "*
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M#/)_,U-H?A/0_#>_^R=.AM6?[S(O)K9HH6FP/7<**** *][_ ,><GTJ+3/\
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MNC?S-=17+^ ?^19C_P"NC?S-=14U/C9=#^%'T"BBBH-0HHHH **** "BBB@
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M[2_[A_E7GGP=_P"0%JO_ &$I_P#T8U 'H]%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** *][_QYR?2HM,_X]?\ @52WO_'G)]*BTS_CU_X%0!=HHHH
M**** "BBB@ K+U+_ (^8?I_6M2LO4O\ CYA^G]: -,=*6D'2EH **** "BBB
M@ HHHH **** "BBB@ HHHH \@^,__(9\*?\ 7\/Y&O7Z\@^,_P#R&?"G_7\/
MY&O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^8O%O\ R5SQ%_P#_P! 6O9OA9_R* _Z[O\ TKQG
MQ;_R5SQ%_P  _P#0%KV;X6?\B@/^N[_TKG7\9GJS_P"1>O4[>BBBN@\H****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110 4444 %%%% !67J7_ !\P_3^M:E9>I?\ 'S#]/ZT :8Z4M(.E+0 4444
M%%%% !1110 4444 %%%% !1110!Y!\9_^0SX4_Z_A_(UZ_7D'QG_ .0SX4_Z
M_A_(UZ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'S%XM_P"2N>(O^ ?^@+7LWPL_Y% ?]=W_ *5X
MSXM_Y*YXB_X!_P"@+7LWPL_Y% ?]=W_I7.OXS/5G_P B]>IV]%%%=!Y04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/H&UF-Q9PS$8,B!B/J*\B\9Z]X@TOQ2OG3LD,;!X53@.OOZ]Z]9TW_D%VO\
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M_P"10'_7=_Z5SK^,SU9_\B]>IV]%%%=!Y04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9=]_Q_15J5EWW_']%0!J4444 %%%
M% !1110 4444 5[W_CSD^E1:9_QZ?\"-2WO_ !YR?2HM,_X]/^!&@"[1110
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M^E02>(O!K6=_"P8H55G'7C@_G63X)\8V^N6\>EZKL-U&!L+='Q_6O00 HPH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YB\6_\
M)7/$7_ /_0%KV;X6?\B@/^N[_P!*\9\6_P#)7/$7_ /_ $!:]F^%G_(H#_KN
M_P#2N=?QF>K/_D7KU.WHHHKH/*"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K+OO^/Z*M2LN^_X_HJ -2BBB@ HHHH ****
M"BBB@"O>_P#'G)]*BTS_ (]/^!&I;W_CSD^E1:9_QZ?\"- %VBBB@ HHHH *
M*** "BBB@ HHHH **** ([C_ (]I?]P_RKSSX._\@+5?^PE/_P"C&KT.X_X]
MI?\ </\ *O//@[_R M5_["4__HQJ /1Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH YGQAX?&K6)GA4?:81D?[0]*Y+
MP?X@;2+[[%=$K;R'!S_ :]3KSSQMX8\MFU.S3Y#S*H'0^M=%*::Y)'%B*<HR
M]K#='H2L'4,IRI&012UP7@KQ1N"Z9>O\PXB<G]*[VLIP<'9G32JJI'F04445
M!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*KJ5=0RD8((X-
M+10!XU\0?"2Z=J O+&/;!-R5'16K<T86-U\.+JRNKCYXE9F\QLX..,>V17=:
MOI<.KZ?):S#[P^4^A]:\LD\%:M=7TVFJ3&%&3)_"P[4U1IN$I+<T^NU_:4Z<
MW[E]^IB>"==&@^(D9W_T>4^7(?;UKWM'61 Z,&5AD$=Z^;]8T._T.[:"\A9"
M#\KX^5OH:[+P1X_.G*FFZHY:V&%CD[I['VKBHU.5\LCV\?A?;)5J6OZGL%%1
MP3Q7,*S0R*\;#(93D&I*[#P-@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"O>_\><GTJ+3/^/7_@52WO\ QYR?2HM,
M_P"/7_@5 %VBBB@ HHHH **** "LO4O^/F'Z?UK4K+U+_CYA^G]: -,=*6D'
M2EH **** "BBB@ HHHH **** "BBB@ HHHH \@^,_P#R&?"G_7\/Y&O7Z\@^
M,_\ R&?"G_7\/Y&O7Z "BBB@ HHHH AN[J*RM);F=ML42%W;T &37#1_&+PA
M(W_'ZP3./,*';_*NE\7?\BEJO_7K)_Z":X#X4:=I%Q\*HY-3M[=HB\N]I0,8
MW&DK^\^UOQO_ )#=K+S/3=,U:PUFR2\TZZCN+=^CH>*N5XG\([H:9)XHGLTE
MDT6&4M;I&I.2.N,5TG_"WK3_ * &L?\ @,_^%4[:6ZI/[R5?6_1M?<>D5QFM
M?%#PWHE\UG)<M/.G$BP*6V?6JR_$!-7\.:S<6^GWMG):VKNK7$3("=IQC(]J
MS/@UHMHW@XZI- CW>H2R/-(PR3\QXI)-M^7Z[#;22\V=SH'B32O$UC]KTNZ2
M:,'# =5/H16M7C?A2%/#WQRUC2+0".TNX?.\M>@/S=*]>NY?)LYI1_!&S?D*
M&UR*:ZJX)/F<>QS?B+XA:!X:N1:W=R7NL9,$2EF JWX:\9:+XKCD.F70>2/_
M %D3##)]17 ?"&R@UJ^UKQ-=QK+=W%TR*[#)4 ]!^=5=9@B\,?'32)+!!#'J
M<3>>JC ; /\ \2*([Q4NJ^[2X2^U;[/Z.S/1?$GC?0_"VU-0N@)WY2! 2[?A
M4?AOQ]H/BB9[>QN<7*#)@D!5L5PG@:VA\1_%/Q+J]\BS264ODV^X9V#+=/R%
M1_$NUA\/?$'PSKEE&L,TTWE2E!C?G/6B&\5+[7X7V">G-;[/X]ST?Q)XRT7P
MM&IU*Z"RO]R%02[?053\.?$/P_XFNC:6=R4N@,^3*I5B*X?PS!%XH^,FM:A?
M()AIV(85;D*>>?TIOQ<LX=%\2>&M>LHUANFNQ"[H,%E/K^=$->7F^U^'8);R
M4?L_CU/7+[4+33;5[F]N(X(4&6=S@"LKPWXOTCQ6MPVDW'G+ VUF XJOX@\'
MZ=XLDM)]4,LMO I;[-N_=N3CEAW_ /KUPWP3@BMKWQ'#"@2-+HJJ@< 8%$=9
M-/L_T%)^ZI+NOQO_ )'K]%%% PHHHH **** "BBB@#YB\6_\E<\1?\ _] 6M
M?2/C!;^"++^R9=/DG8,9-ZGU_&NB^)WA?3=-U'^W+=91>WT@68LV5P%[#MT%
M5_"GPL\->+]'_M/54N6N?,:/,<NT8'3C%<Z_C,]6?_(O7J5?^&D+/_H#R_F/
M\:/^&D+/_H#R_F/\:Z?_ (4'X(_YY7W_ '_'^%'_  H/P1_SROO^_P"/\*Z#
MRCG[3]H[2GN%6ZTJX2(]63!(_6O9=.OH=4TVVO[?/DW$2RIGT(R*^.O'7AVP
MT#XA7.C6(D%I',B*';+8.,\_C7UYX<MX[3PUIEO%GRX[:-5R>P44 :=%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9=]_Q_15J5EWW
M_']%0!J4444 %%%% !1110 4444 5[W_ (\Y/I46F?\ 'I_P(U+>_P#'G)]*
MBTS_ (]/^!&@"[1110 4444 %%%% !1110 4444 %%%% $=Q_P >TO\ N'^5
M>>?!W_D!:K_V$I__ $8U>AW'_'M+_N'^5>>?!W_D!:K_ -A*?_T8U 'H]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!+:RAQW&>1]:RJ4I0.BC7C56FY=HHHK,W"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &M&C$%D4D="1TIU%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>]_X\Y/I46F?\>O_
M  *I;W_CSD^E1:9_QZ_\"H NT444 %%%% !1110 5EZE_P ?,/T_K6I67J7_
M !\P_3^M &F.E+2#I2T %%%% !1110 4444 %%%% !1110 4444 >0?&?_D,
M^%/^OX?R->OUY!\9_P#D,^%/^OX?R->OT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MB?Q2_P"1G7_KE_6O6?#G_(M:9_U[1_\ H(KRKXG6\TOB962)F'E=0/>LB#Q+
MXFMK>."*>=8XU"J #P!7(IJ%1MGO2PSQ&&IJ+M8]_HKP3_A*_%7_ #\W'Y&C
M_A*_%7_/S<?D:OZQ'L<O]E5/YD>]T5X)_P )7XJ_Y^;C\C1_PE?BK_GYN/R-
M'UB/8/[*J?S(][HKP3_A*_%7_/S<?D:/^$K\5?\ /S<?D:/K$>P?V54_F1[W
M17@G_"5^*O\ GYN/R-'_  E?BK_GYN/R-'UB/8/[*J?S(\_^++!?BQ>L3@"4
M$G\37T[I7B#1UT>Q!U.T!%O&"#,O]T5\]:KI#ZUJ$E]?VKS7$GWG*\FJ7_")
MVW_/@W_?-'UB/8/[*J?S(^GO^$AT;_H*6?\ W^7_ !H_X2'1O^@I9_\ ?Y?\
M:^8?^$3MO^?!O^^:/^$3MO\ GP;_ +YH^L1[#_LJI_,CZ>_X2'1O^@I9_P#?
MY?\ &C_A(=&_Z"EG_P!_E_QKYA_X1.V_Y\&_[YH_X1.V_P"?!O\ OFCZQ'L'
M]E5/YD?3W_"0Z-_T%+/_ +_+_C1_PD.C?]!2S_[_ "_XU\P_\(G;?\^#?]\T
M?\(G;?\ /@W_ 'S1]8CV#^RJG\R/I[_A(=&_Z"EG_P!_E_QH_P"$AT;_ *"E
MG_W^7_&OF'_A$[;_ )\&_P"^:/\ A$[;_GP;_OFCZQ'L']E5/YD?4]KJ%G?;
MOLEU#/MZ^6X;'Y59KR#X.Z5_9E[?"* Q1NHW C&3VKU^MH2YE<\^O1=&;@PH
MHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MN^_X_HJU*R[[_C^BH U**** "BBB@ HHHH **** *][_ ,><GTJ+3/\ CT_X
M$:EO?^/.3Z5%IG_'I_P(T 7:*** "BBB@ HHHH **** /(/%X&K_ !L\/Z9<
M#?:Q0F7RST+?-S6[\9--M[GX<WTIB4/; 21L!@J0#TKGO'TJ^'?BWX>U^Z^2
MQ=#"\AZ!CN_Q%:/Q:\4Z9<>"I-,L+R*ZO-0(CBBB8,S @\X_*H=W126]W]]_
M\K%K2K=]E]UCL/ EX]_X'TBYD)+O ,D_4UT58OA'3FTGPGIMBXPT,(!'ZUM5
MO5:=25NYC2^!&%XG\5:+X7LDDUF^2T6XW)$65CN('3@&N1^"TT=SX;U">%MT
M4M_,Z-Z@R,0:[S5-$TO6XXX]4T^VO$C)*+/&'"D]QFGZ;I.GZ/;?9].LX;6'
M.?+A0*,_05F67**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH YW7?"-EK"F1 (+CLZCK]:\^N+'6
M/#%[N7S$P>)$Y4U['4<T$5Q$8YHU=#U5AD5M"LXZ/5'-5PT9OFCHSA]'^(*/
MMAU*/:>GFKT_&NTM;ZVO(P]O.DBGI@URFL> ;6YW2V#>3(>=A^Z?\*Y"?2M=
M\/2F15EC4'_61$[?SJ^2G/X78Q]K6HZ35UW/8J*\PT_X@ZA;X6ZC2=1_P$UT
MEIX^TF< 3>9$Q]5X_.LY49KH;PQ5*76QU=%9UOKVE7('E7T))[;QFKZ.LB[D
M8,/45FTUN;J2>S'4444AA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!7O?^/.3Z5%IG_'K_P*I;W_ (\Y/I46F?\ 'K_P*@"[1110 4444 %%%% !
M67J7_'S#]/ZUJ5EZE_Q\P_3^M &F.E+2#I2T %%%% !1110 4444 %8^J>*M
M#T:01ZAJ4$,A_A+<_E5O5[S^S](NKL_\LHRU>4_"_P *:=XJTN[\3:_;)?7E
M[,P'GC<%7C& >G4TE=MI=!NR2;ZGK-AJ-GJ=N+BRN8YXC_%&V:M5XUX.A_X1
M#XO:GX<M&9=-N(A+'$3PK<=/S->RU6CBI+J3JI.+Z!1152_U2QTN(2W]U%;Q
MDX#2-@&D,\H^-D@BU7PJY&0+Y?ZU[%7@_P 9O$.CZCJ'AL6>HV\YBO%=_+?.
MU>>37KG_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E
M_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#
M=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E
M_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#
M=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E
M_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#
M=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E
M_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#
M=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E
M_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#
M=E_W]%'_  F7AO\ Z#=E_P!_10!N45A_\)EX;_Z#=E_W]%'_  F7AO\ Z#=E
M_P!_10!LM#$YR\2,?4J#3?LUO_SPB_[X%9'_  F7AO\ Z#=E_P!_11_PF7AO
M_H-V7_?T4#NS7^S6_P#SPB_[X%'V:W_YX1?]\"LC_A,O#?\ T&[+_OZ*/^$R
M\-_]!NR_[^B@+LU_LUO_ ,\(O^^!1]FM_P#GA%_WP*R/^$R\-_\ 0;LO^_HH
M_P"$R\-_]!NR_P"_HH"[-?[-;_\ /"+_ +X%'V:W_P">$7_? K(_X3+PW_T&
M[+_OZ*/^$R\-_P#0;LO^_HH"[-?[-;_\\(O^^!1]FM_^>$7_ 'P*R/\ A,O#
M?_0;LO\ OZ*/^$R\-_\ 0;LO^_HH"[-?[-;_ //"+_O@4?9K?_GA%_WP*R/^
M$R\-_P#0;LO^_HH_X3+PW_T&[+_OZ* NS7^S6_\ SPB_[X%'V:W_ .>$7_?
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M10!N45F67B+1M2G\BRU*VGEQG9&X)K3H **** "BBB@ HHHH **** "BBB@
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MS_H+:M_W\7_XFO7Z* /(/^&>/#G_ $%M6_[^+_\ $T?\,\>'/^@MJW_?Q?\
MXFO7Z* /(/\ AGCPY_T%M6_[^+_\31_PSQX<_P"@MJW_ '\7_P")KU^B@#R#
M_AGCPY_T%M6_[^+_ /$T?\,\>'/^@MJW_?Q?_B:]?HH \@_X9X\.?]!;5O\
MOXO_ ,31_P ,\>'/^@MJW_?Q?_B:]?HH \@_X9X\.?\ 06U;_OXO_P 31_PS
MQX<_Z"VK?]_%_P#B:]?HH ^>_"7A6W\+_')M*L[NZD@MXPX,K EL@<'CWKZ$
MK!7P?HZ>*I/$@AD_M*10K/YAVXX_AZ=JWJ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *R[[_C^BK4K+OO^/Z*@#4HHHH **** "BBB@ HHHH
MKWO_ !YR?2HM,_X]/^!&I;W_ (\Y/I46F?\ 'I_P(T 7:*** "BBB@ HHHH
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MBB@ HHHH **** *][_QYR?2HM,_X]?\ @52WO_'G)]*BTS_CU_X%0!=HHHH
M**** "BBB@ K+U+_ (^8?I_6M2LO4O\ CYA^G]: -,=*6D'2EH **** "BBB
M@ HHHH **** "BBB@ HHHH **Y#7?B7X9\/WIL[N]WW"_?CB&XK]:V- \3:3
MXFLS=:5=I.@.& ZJ?0T+570/1V9KT444 %%%% !1110 4444 %%%% !1110
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M2HM,_P"/3_@1J6]_X\Y/I46F?\>G_ C0!=HHHH **** "BBB@ HHHH ****
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M2;U_*G@GF9P#[;B?2B.O+?[6WZ?>$M+VZ;GM]%(IW*&]1FEH **** "BBB@
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MR[8M^[W8)R1ZUV%4M6D1-*O SJI,#\$_[)J9[7*CO8\W^!2+'X8U!$ "K>.
M!V&XU3UV)/$_QOL=+O!YME8P^88CT+?-@_RJY\#I$'AW4074$WKX&?\ :-4K
MR1-%^/UO-<D)#>VY"NW3/S<5:UJ4_3\>70S>D*EN[^[FU_ M?&K1;6W\,6^L
MVD*0WME.FR5!@A>>/T%>CZ%=F^T*RNFZR1!C7 ?&W4(3X-33XW5[FZN$6.-3
MDGK7?>'[5K+P_8VS?>CA4&E#X9>OZ:_H5/XH^C_/3]32HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :Z+)&R,,JP((]JY]O"OAS3=+NU&FVT<#AGE)7J3
MR2370D@ DG ')->1^+_$ESXWUEO!_AV=4M0<7]Z&P%'=1_GM4RN_=6[*6FKV
M13^"8>ULO$-W &&FK(Y@!Z9 R<5:^$6GP:U?Z]XAOXUGNGNVCC=QG:@)&!^0
MKT#2-!L-%\+G1M-*;%@9,@@EB1C)K@O@I=Q6L6O:5.ZQW$%\YV,<$C<>:T37
M.TND;+[T9N_)?O*[_&Q5U"VC\,?':QEL4$,&H08EC7@,W//ZU[-7CVMR)KGQ
MVTNVM2)%LH-\K+R%//'Z5[#4P_A1OY_=?0J?\5^B^^P4444 %%%% !1110 4
M444 %%%% !1110 4444 (ZJZ,C#*L,$5Q&I7?@3PMI]Y;3?8(L*?-@5@78_3
MKFNW9E1"S$!0,DFN3U3P;X0\2>;=W=K;S-,,M,KX)]\BIDFT[%1:ZG&_!BRN
M;#0]=U,Q/#8W$[RVJ,,?*,X.*/A+8P:]J.M^)[Z-9KF>Y9$+C.P ]!^=4?AA
M/<P^(?$WAVUNI+K28(V\AG8MM/ V@GZUH?!6YCL(]9T.=U2ZM;IBR,<'D_\
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MX0'\35VBDU=#1R&D:IXVGU**/5/#T%M:$_/*MVC%1] :N^//^1$UK_KTD_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M U**** "BBB@ HHHH **** *][_QYR?2HM,_X]/^!&I;W_CSD^E1:9_QZ?\
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M!4 7:*** "BBB@ HHHH *R]2_P"/F'Z?UK4K+U+_ (^8?I_6@#3'2EI!TI:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZNH&>:QOE&/.@X+>F:FG>"B^U_Q*J6FY>:C^!P7[04]K/?:';P.C7PE!PIY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"O>_P#'G)]*BTS_ (]?^!5+>_\ 'G)]*BTS_CU_X%0!=HHHH **** "
MBBB@ K+U+_CYA^G]:U*R]2_X^8?I_6@#3'2EI!TI: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LN^_X_HJU*R[[_C^B
MH U**** "BBB@ HHHH **** *][_ ,><GTJ+3/\ CT_X$:EO?^/.3Z5%IG_'
MI_P(T 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *][_ ,><GTJ+3/\ CU_X%4M[_P ><GTJ+3/^/7_@5 %VBBB@
M HHHH **** "LO4O^/F'Z?UK4K+U+_CYA^G]: -,=*6D'2EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R[[_C^BK4K
M+OO^/Z*@#4HHHH **** "BBB@ HHHH KWO\ QYR?2HM,_P"/3_@1J6]_X\Y/
MI46F?\>G_ C0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG]J2?\\1^=']J2?\\1^=:>!Z"C ]!0!F?VI)_P \1^=']J2?\\1^=:>!Z"C
M]!0!F?VI)_SQ'YT?VI)_SQ'YUIX'H*,#T% &9_:DG_/$?G1_:DG_ #Q'YUIX
M'H*,#T% &9_:DG_/$?G1_:DG_/$?G6G@>@HP/04 9G]J2?\ /$?G1_:DG_/$
M?G6G@>@HP/04 9G]J2?\\1^=']J2?\\1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)
M_P \1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)_SQ'YUIX'H*,#T% &9_:DG_ #Q'
MYT?VI)_SQ'YUIX'H*,#T% &9_:DG_/$?G1_:DG_/$?G6G@>@HP/04 9G]J2?
M\\1^=']J2?\ /$?G6G@>@HP/04 9G]J2?\\1^=']J2?\\1^=:>!Z"C ]!0!F
M?VI)_P \1^=']J2?\\1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)_SQ'YUIX'H*,#
MT% &9_:DG_/$?G1_:DG_ #Q'YUIX'H*,#T% &9_:DG_/$?G1_:DG_/$?G6G@
M>@HP/04 9G]J2?\ /$?G1_:DG_/$?G6G@>@HP/04 9G]J2?\\1^=']J2?\\1
M^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)_P \1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI
M)_SQ'YUIX'H*,#T% &9_:DG_ #Q'YT?VI)_SQ'YUIX'H*,#T% &9_:DG_/$?
MG1_:DG_/$?G6G@>@HP/04 9G]J2?\\1^=']J2?\ /$?G6G@>@HP/04 9G]J2
M?\\1^=']J2?\\1^=:>!Z"C ]!0!F?VI)_P \1^=']J2?\\1^=:>!Z"C ]!0!
MF?VI)_SQ'YT?VI)_SQ'YUIX'H*,#T% &9_:DG_/$?G1_:DG_ #Q'YUIX'H*,
M#T% &9_:DG_/$?G1_:DG_/$?G6G@>@HP/04 9G]J2?\ /$?G1_:DG_/$?G6G
M@>@HP/04 9G]J2?\\1^=']J2?\\1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)_P \
M1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)_SQ'YUIX'H*,#T% &9_:DG_ #Q'YT?V
MI)_SQ'YUIX'H*,#T% &9_:DG_/$?G1_:DG_/$?G6G@>@HP/04 9G]J2?\\1^
M=']J2?\ /$?G6G@>@HP/04 9G]J2?\\1^=']J2?\\1^=:>!Z"C ]!0!F?VI)
M_P \1^=']J2?\\1^=:>!Z"C ]!0!F?VI)_SQ'YT?VI)_SQ'YUIX'H*,#T% &
M9_:DG_/$?G1_:DG_ #Q'YUIX'H*,#T% &9_:DG_/$?G1_:DG_/$?G6G@>@HP
M/04 9G]J2?\ /$?G1_:DG_/$?G6G@>@HP/04 9G]J2?\\1^=']J2?\\1^=:>
M!Z"C ]!0!F?VI)_SQ'YT?VI)_P \1^=:>!Z"C ]!0!DS:A)-$T9B W#KFK>F
M@BUY_O5;P/04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gtqsgrqcdg4e000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0:",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HK-UO6K70=.DO;O=Y<8R0HR:Y ?&'PX3C;<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !147VF#S/+\^/?_=WC-2T %%%127$$3!9)HT)Z!F S0!+1
M2 AAD$$'N*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **BN;B.U@::4X11DFL?1?%FFZ]
M<20V1D+1D@[EP.*=G:XG))V9NT444AA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4H7MU'S2A4:O>R(M4^(^N:EJ4EOH,,@VDJ  #G'>J;>-_&NCRK)J\4JQ=PR
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M8@_Y*-)_UU/\ZT?B @D\7VJL,@OS^5:\L>9:'/SRY'KU.V^'OBN7Q!I[K>2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O O'@/_">6?'_+1/\
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M?M).3)MYS1"?+<*M)SM;H>6_$GP]]@-MK%FFUAM!"^PIFN:J=8^&T<F"7CB
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MA^T@Y$FWG-79H8YXS'*@=#U!JI5+M>1%.BXIKN>.?#:[.GZ;K-V#CRHMV?\
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MVT^"*3IN5>:N=2$EL13HU(/<T^U%%%8'4%%%% !1110 4444 %%%% !1110
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MT2-]Z:9;JWJ%K4CC2) B*%4= *4JBY>6*'"C)3YY.XZBBBLCH"BBB@ HHHH
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M+LUS_H$V_P#W\-'_  NS7/\ H$V__?PT>RGV#ZQ3[GO5%>"_\+LUS_H$V_\
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M  NS7/\ H$V__?PT>RGV#ZQ3[GO5%>"_\+LUS_H$V_\ W\-'_"[-<_Z!-O\
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M *!-O_W\-'_"[-<_Z!-O_P!_#1[*?8/K%/N>]45X+_PNS7/^@3;_ /?PT?\
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M *!-O_W\-'_"[-<_Z!-O_P!_#1[*?8/K%/N>]45X+_PNS7/^@3;_ /?PT?\
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M@O\ PNS7/^@3;_\ ?PT?\+LUS_H$V_\ W\-'LI]@^L4^Y[U17@O_  NS7/\
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MNS7/^@3;_P#?PT?\+LUS_H$V_P#W\-'LI]@^L4^Y[U17@O\ PNS7/^@3;_\
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M+LUS_H$V_P#W\-'LI]@^L4^Y[U17@O\ PNS7/^@3;_\ ?PT?\+LUS_H$V_\
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MK%/N>]45X+_PNS7/^@3;_P#?PT?\+LUS_H$V_P#W\-'LI]@^L4^Y[U17@O\
MPNS7/^@3;_\ ?PT?\+LUS_H$V_\ W\-'LI]@^L4^Y[U17@O_  NS7/\ H$V_
M_?PTO_"[-<_Z!5O_ -_#1[*?87UBGW/>:*Y3P-XENO$VDB[N($BR2/E.>E=7
M4--.S-8R4E=!1112*"FR?ZMOI3J;)_JV^E 'S-X\_P"1QU#_ 'ZYRNC\=_\
M(XZA_OUSE>E#X4>'4^-A1115$!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110![W\(O^157_?:O0Z\\^$7_ "*J_P"^
MU>AUY]7XV>U0_AH****S-0ILG^K;Z4ZFR?ZMOI0!\S>._P#D<=0_WZYRNC\=
M_P#(XZA_OUSE>E#X4>'4^-A1115$!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110![W\(O^157_ 'VKT.O//A%_R*J_
M[[5Z'7GU?C9[5#^&@HHHK,U"FR?ZMOI3J;)_JV^E 'S-X[_Y''4/]^N<KH_'
M?_(XZA_OUSE>E#X4>'4^-A1115$!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110![W\(O\ D55_WVKT.O//A%_R*J_[
M[5Z'7GU?C9[5#^&@HHHK,U"FR?ZMOI3J;)_JV^E 'S-X[_Y''4/]^N<KH_'?
M_(XZA_OUSE>E#X4>'4^-A1115$!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110![W\(O^157_?:O0Z\\^$7_(JK_OM7
MH=>?5^-GM4/X:"BBBLS4*;)_JV^E.ILG^K;Z4 ?,WCO_ )''4/\ ?KG*Z/QW
M_P CCJ'^_7.5Z4/A1X=3XV%%%%40%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC'_H$W'Y4?\ "O?&/_0)N/RH]O /JE3L8=%;G_"O?&/_ $";C\J/^%>^,?\
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M;/\ P@7B[_H%7'Y4?\(%XN_Z!5Q^5'MX!]4J=C&HK9_X0+Q=_P! JX_*C_A
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M&/\ T";C\J/^%>^,?^@3<?E1[> ?5*G8PZ*W/^%>^,?^@3<?E1_PKWQC_P!
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M_P"%>^,?^@3<?E1[> ?5*G8PZ*W/^%>^,?\ H$W'Y4?\*]\8_P#0)N/RH]O
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M O%W_0*N/RH_X0+Q=_T"KC\J/;P#ZI4[&-16S_P@7B[_ *!5Q^5'_"!>+O\
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M^,%&3I5Q^5-_X0+Q=_T"KC\J/;P#ZI4[&-16S_P@7B[_ *!5Q^5'_"!>+O\
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M_*CV\ ^J5.QAT5N?\*]\8_\ 0)N/RH_X5[XQ_P"@3<?E1[> ?5*G8PZ*W/\
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M^E4ZN)]P?2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *1ONGZ4M(WW3]* *MA_JC_O&K=5+#_5'_>-6Z "B
MBB@ I#TI:0]* *EK_P ?4]7*IVO_ !]3U<H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HI_NCZU+44_P!T?6@"O1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 H^\/K5RJ8^\/K5
MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &O]QOI52K;_ '&^E5* "BBB@#*O=2EMKDQJJD =ZK_VU/\ W%J+
M5O\ C_;Z"J-?,XG&5XUI14M+GJ4J--P3:-/^VI_[BT?VU/\ W%K,HK'Z]B/Y
MV:>PI]C3_MJ?^XM']M3_ -Q:S**/KV(_G8>PI]C3_MJ?^XM']M3_ -Q:S**/
MKV(_G8>PI]C3_MJ?^XM']M3_ -Q:S**/KV(_G8>PI]C3_MJ?^XM']M3_ -Q:
MS**/KV(_G8>PI]C3_MJ?^XM']M3_ -Q:S**/KV(_G8>PI]C3_MJ?^XM']M3_
M -Q:S**/KV(_G8>PI]C3_MJ?^XM']M3_ -Q:S**/KV(_G8>PI]C3_MJ?^XM'
M]M3_ -Q:S**/KV(_G8>PI]C3_MJ?^XM']M3_ -Q:S**/KV(_G8>PI]C3_MJ?
M^XM']M3_ -Q:S**/KV(_G8>PI]C3_MJ?^XM']M3_ -Q:S**/KV(_G8>PI]C3
M_MJ?^XM UN<'.Q:S**/KV(_G8>PI]C8_X2&Y_P">:4?\)#<_\\TK'HH^O8C^
M=A["GV-C_A(;G_GFE'_"0W/_ #S2L>BCZ]B/YV'L*?8V/^$AN?\ GFE'_"0W
M/_/-*QZ*/KV(_G8>PI]C8_X2&Y_YYI1_PD-S_P \TK'HH^O8C^=A["GV-C_A
M(;G_ )YI1_PD-S_SS2L>BCZ]B/YV'L*?8V/^$AN?^>:4?\)#<_\ /-*QZ*/K
MV(_G8>PI]C8_X2&Y_P">:4?\)#<_\\TK'HH^O8C^=A["GV-C_A(;G_GFE'_"
M0W/_ #S2L>BCZ]B/YV'L*?8V/^$AN?\ GFE'_"0W/_/-*QZ*/KV(_G8>PI]C
M8_X2&Y_YYI1_PD-S_P \TK'HH^O8C^=A["GV-C_A(;G_ )YI1_PD-S_SS2L>
MBCZ]B/YV'L*?8V/^$AN?^>:4?\)#<_\ /-*QZ*/KV(_G8>PI]C8_X2&Y_P">
M:4?\)#<_\\TK'HH^O8C^=A["GV-9M?N'&"B4S^VI_P"XM9E%'U[$?SL/84^Q
MI_VU/_<6C^VI_P"XM9E%'U[$?SL/84^QI_VU/_<6C^VI_P"XM9E%'U[$?SL/
M84^QI_VU/_<6C^VI_P"XM9E%'U[$?SL/84^QI_VU/_<6C^VI_P"XM9E%'U[$
M?SL/84^QI_VU/_<6C^VI_P"XM9E%'U[$?SL/84^QI_VU/_<6C^VI_P"XM9E%
M'U[$?SL/84^QI_VU/_<6C^VI_P"XM9E%'U[$?SL/84^QI_VU/_<6C^VI_P"X
MM9E%'U[$?SL/84^QI_VU/_<6C^VI_P"XM9E%'U[$?SL/84^QI_VU/_<6C^VI
M_P"XM9E%'U[$?SL/84^QI_VU/_<6C^VI_P"XM9E%'U[$?SL/84^QI_VU/_<6
MK-AJ,MU<>6ZJ!C/%8=:&C_\ '[_P$UOA<97G6C&4M&S.K1IJ#:1T%7$^X/I5
M.KB?<'TKZ4\L6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "D;[I^E+2-]T_2@"K8?ZH_[QJW52P_U1_P!XU;H
M**** "D/2EI#TH J6O\ Q]3U<JG:_P#'U/5R@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *BG^Z/K4M13_='UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 */O#ZU<JF/O#ZU
M<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!K_ '&^E5*MO]QOI52@ HHHH YW5O\ C_;Z"J-7M6_X_P!OH*HU
M\AB_X\_5GLT?X:"BBBN<T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K0T?_ (_?^ FL^M#1_P#C
M]_X":Z<'_O$/4SK?PV=!5Q/N#Z53JXGW!]*^N/&%HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&^Z?I2TC?=/
MTH JV'^J/^\:MU4L/]4?]XU;H **** "D/2EI#TH J6O_'U/5RJ=K_Q]3U<H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HI_NCZU+44_W1]: *]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "C[P^M7*IC[P^M7* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH :_W&^E5*MO]QOI52@ HHHH YW5O
M^/\ ;Z"J-7M6_P"/]OH*HU\AB_X\_5GLT?X:"BBBN<T"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K0T?_C]_P" FL^M#1_^/W_@)KIP?^\0]3.M_#9T%7$^X/I5.KB?<'TKZX\8
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "D;[I^E+2-]T_2@"K8?ZH_[QJW52P_U1_P!XU;H **** "D/2EI#
MTH J6O\ Q]3U<JG:_P#'U/5R@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG^Z/K4M
M13_='UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 */O#ZU<JF/O#ZU<H ***XWQ]KN
MIZ+!9_V8RK),Y4Y7.>*<5=V)G)15V=E17,>#?$;:[8/]I8"YC;:R],U6.OWX
M\;2Z;O7[,NW V\\T^1WL+VD;)]SL**\\NM9\1WOB=M,TZ\@A7YB#)'GI3SKG
MB'0-6MX-:GBN(9W"(T4>T T_9LGVR['H%%8&N>*+?1[=#Y32S2KF-%/-8EG#
MXXOH/M"ZC:0*Y)5'A.0.W>DHNUV-U$G9:G=45S>@7^K^=-:ZK$9)$;"RHNU3
M6;XD\2ZK%%*FG6LELT WM-*N58>@HY'>P.HE&YVU%8?A74KG5-#M[JZ8-*Z
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M*R7EPD2MP&8X!-16FL:=?/LM;R*5O13FE9EW6Q>HHHI#"BBB@ HHHH ****
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M=9_8=E_<;_OJC^P[+^XW_?5']DU^Z#ZY3.3HKK/[#LO[C?\ ?5']AV7]QO\
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M$^X/I5.KB?<'TKWCSQ:*YOQGK%UHVCM/9LJRX."1D5RQNO'4.BPZNVI6DL+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 -?[C?2JE6W^XWTJI0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2K]X?6DI5^\/K0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH BG^Y^-5ZL3_ '/QJO0 4444 %%%% !1110
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M\(W-UJA^U20(PB,@^X IP!2?"BYFNH=3T\7+1I$GR$?P<UN> +&ZM?!=]#/
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M#_SH/85.QIT5F?VU!_<:C^VH/[C4?7L/_.@]A4[&G2K]X?6LO^VH/[C4HUN
M$'8U'U[#_P Z#V%3L;]%8_\ PD-O_P \WH_X2&W_ .>;T?7L/_.@]A4[&Q16
M/_PD-O\ \\WH_P"$AM_^>;T?7L/_ #H/85.QL45C_P#"0V__ #S>C_A(;?\
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M_='UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 */O#ZU<JF/O#ZU<H ***@N;VVLP#
M<SQQ ]"[8S0!/14<4T4Z;XI%=3W4YIGVRW\\P><GFCJF>: N3T52FU;3[=]D
MUY"C>C.!3H-4L;I]D%W#(WHK9IV8KHMT4A( ))P!UJ@=<TH$@ZA;@C@_.*5@
M;2W-"BH;>Z@NDWV\R2*.ZG-%Q=V]H@>XF2)2< N<4#N345'#/%<1B2&170]"
MIR*DH **** "BH6N[=9U@:9!*W1">34U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^
MXWTJI5M_N-]*J4 %%%% '.ZM_P ?[?051J]JW_'^WT%4:^0Q?\>?JSV:/\-!
M1117.:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXN;*.:Y@\B5ADIG.*M4U!MC4'L *=6!UH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_<;Z54JV_W&^E5* "BBB@#G
M=6_X_P!OH*HU>U;_ (_V^@JC7R&+_CS]6>S1_AH****YS0**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "M#1_^/W_ (":SZT-'_X_?^ FNG!_[Q#U,ZW\-G05<3[@^E4ZN)]P?2OK
MCQA:*** "BHYKB&W3?-(L:^K'%.1TE171@RL,@@\&@!U%%% !1110 4444 %
M%(SJB%G8*H&23VJ.&YAN5W02I(OJIS0!+1137D2-"[L%4=230 ZBHXIXIUW1
M2*Z],J<U)0 4444 %%%% !144MU! 0)9D0GH&.,U+U&: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BHYKB&W7=-*D8]6.*>K*ZAE(*G
MD$=Z %HHHH **** "BBB@ I&^Z?I2TC?=/TH JV'^J/^\:MU4L/]4?\ >-6Z
M "BBB@ I#TI:0]* *EK_ ,?4]7*IVO\ Q]3U<H **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ_XPT*RL_!\=Q#&$GB* 2 88\]S4J$=+]2W4G=VZ&YXBNC%<V976S8K)( $
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)*^I,J<FE9:+H>?V@NO"7C;[%I\VZ"5R=BC[HS6_\96SI>F _>9CC\JZO1O
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M)6;-5L%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5%/\ ='UJ6HI_NCZT 5Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %'WA]
M:N53'WA]:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 U_N-]*J5;?[C?2JE !1110!SNK?\ '^WT%4:O:M_Q
M_M]!5&OD,7_'GZL]FC_#04445SF@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:&C_\ '[_P$UGU
MH:/_ ,?O_ 373@_]XAZF=;^&SH*N)]P?2J=7$^X/I7UQXP,JL,,H/U%   P!
M@4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %(WW3]*6D;[I^E %6P_U1_WC5NJEA_JC_O&K= !1110 4AZ4M(>E
M %2U_P"/J>KE4[7_ (^IZN4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44_P!T?6I:
MBG^Z/K0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 4?>'UJY5,?>'UJY0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^
MXWTJI5M_N-]*J4 %%%% '.ZM_P ?[?051J]JW_'^WT%4:^0Q?\>?JSV:/\-!
M1117.:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5H:/_P ?O_ 36?6AH_\ Q^_\!-=.#_WB'J9U
MOX;.@JXGW!]*IU<3[@^E?7'C"T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4C?=/TI:1ONGZ4 5;#_ %1_WC5N
MJEA_JC_O&K= !1110 4AZ4M(>E %2U_X^IZN53M?^/J>KE !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5%/]T?6I:BG^Z/K0!7HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 4?>'
MUJY5,?>'UJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% #7^XWTJI5M_N-]*J4 %%%% '.ZM_Q_M]!5&KVK?\
M'^WT%4:^0Q?\>?JSV:/\-!1117.:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5H:/\ \?O_  $U
MGUH:/_Q^_P# 373@_P#>(>IG6_ALZ"KB?<'TJG5Q/N#Z5]<>,+1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-
M]T_2EI&^Z?I0!5L/]4?]XU;JI8?ZH_[QJW0 4444 %(>E+2'I0!4M?\ CZGJ
MY5.U_P"/J>KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5%/\ ='UJ6HI_NCZT 5Z*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** %'WA]:N53'WA]:N4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_N-]*J5;?[C?
M2JE !1110!EWNF27-R9%=0".]5O[$F_YZ+6[17#/+J$Y.4EJ_,WCB:D59&%_
M8DW_ #T6C^Q)O^>BUNT5/]EX;M^)7UJJ87]B3?\ /1:/[$F_YZ+6[11_9>&[
M?B'UJJ87]B3?\]%H_L2;_GHM;M%']EX;M^(?6JIA?V)-_P ]%H_L2;_GHM;M
M%']EX;M^(?6JIA?V)-_ST6C^Q)O^>BUNT4?V7ANWXA]:JF%_8DW_ #T6C^Q)
MO^>BUNT4?V7ANWXA]:JF%_8DW_/1:/[$F_YZ+6[11_9>&[?B'UJJ87]B3?\
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M\]%K=HH_LO#=OQ#ZU5,+^Q)O^>BT?V)-_P ]%K=HH_LO#=OQ#ZU5,+^Q)O\
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M?7\Z//B_OK^=1?8HO[HH^Q1?W10!+Y\7]]?SH\^+^^OYU%]BB_NBC[%%_=%
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M%'V=/04 2>8G]X4>8G]X5']G3T%'V=/04 2>8G]X4>8G]X5']G3T%'V=/04
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M_CZGJY5.U_X^IZN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBWO(+K=Y+[MO6G&O3D[1DFQ.G)*[1/1116I!%/\ <_&J]6)_N?C5>@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M_PYTF_"L"M
M_P .=)OPKNR[_>8F&)_A,WJ***^I/)(I_N?C5>K$_P!S\:KT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7$^X/I
M5.KB?<'TH 6BC..M)N7^\/SH 6BJ>H:I9Z7$);R81H>A-3V]Q'=6Z3PMNC<9
M4^HHL*ZO8EHHHH&%%%% !1110 444F0.I% "T44A('4XH 6BDW+_ 'A^= (/
M0YH 6BBCK0 4450U#6+'2WA2\G$33':@/<T;B;2W+]%-C=98U=#E6&0:=0,*
M*3<O]X?G2T %%%% !1110 4444 %%'6B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D;[I^E+2-]T_2@"K8?ZH_[QJW52P_U1_P!XU;H ****
M "D/2EI#TH J6O\ Q]3U<JG:_P#'U/5R@ HHHH **** "BBB@ KPOQ_>:A+X
MH6W@NYHAM;A'(%>Z5X;XL7?X^A0]&R/U%;4?B.;%?"CK/A=KDUQ9/IEU*7EA
MRVYSDG)K/^(FLW%UJT.E6,TB$QL7*,0<CZ5C7=R/!7C;SAQ;R1IN/0>M6?#\
M#:[K.J:]]Z.-F$9] 15\J4N<QYVX^SZDWPNU.=)=0DO+B65(8R3O8G&#2+J6
MH^//%4EJL[0Z?"Q13"Q5B.O:L[P0I:T\0*HR3"^/^^C6C\(MD=Y>QR<2^8,
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M[FIW(K>HS45EJC7#/1BT445B=(4444 %%%% !44_W1]:EJ*?[H^M %>BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% !2-]T_2EI&^Z?I0!5L/]4?\ >-6ZJ6'^J/\
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MJI0 4444 <[JW_'^WT%4:O:M_P ?[?051KY#%_QY^K/9H_PT%%%%<YH%%%%
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M444?V5A_/[P^MU#E_P"P+S_8_P"^J/[ O/\ 8_[ZKJ**/[*P_G]X?6ZAR_\
M8%Y_L?\ ?5']@7G^Q_WU7444?V5A_/[P^MU#E_[ O/\ 8_[ZH_L"\_V/^^JZ
MBBC^RL/Y_>'UNH<O_8%Y_L?]]5J:18360D\W'S=,&M2BM*.7T:,U.-[HB>(G
M./*PHHHKN,"*?[GXU7JQ/]S\:KT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %7$^X/I5.KB?<'TH 6BBB@ HHHH
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M_.D_YY-1YTG_ #R:@"Q15?SI/^>34>=)_P \FH L457\Z3_GDU'G2?\ /)J
M+%%5_.D_YY-1YTG_ #R:@"Q15?SI/^>34>=)_P \FH L457\Z3_GDU'G2?\
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M #P>@"[15+[3/_SP>C[3/_SP>@"[15+[3/\ \\'H^TS_ //!Z +M%4OM,_\
MSP>C[3/_ ,\'H NT52^TS_\ /!Z/M,__ #P>@"[15+[3/_SP>C[3/_SP>@"[
M15+[3/\ \\'H^TS_ //!Z +M%4OM,_\ SP>C[3/_ ,\'H NT52^TS_\ /!Z/
MM,__ #P>@"[15+[3/_SP>C[3/_SP>@"[15+[3/\ \\'H^TS_ //!Z +M%4OM
M,_\ SP>C[3/_ ,\'H NT52^TS_\ /!Z/M,__ #P>@"[15+[3/_SP>C[3/_SP
M>@"[15+[3/\ \\'H^TS_ //!Z +M%4OM,_\ SP>C[3/_ ,\'H NT52^TS_\
M/!Z/M,__ #P>@"[15+[3/_SP>C[3/_SP>@"[15+[3/\ \\'H^TS_ //!Z +M
M%4OM,_\ SP>C[3/_ ,\'H NT52^TS_\ /!Z/M,__ #P>@"[15+[3/_SP>C[3
M/_SP>@"[15+[3/\ \\'H^TS_ //!Z +M%4OM,_\ SP>C[3/_ ,\'H NT52^T
MS_\ /!Z/M,__ #P>@"[15+[3/_SP>C[3/_SP>@"[15+[3/\ \\'H^TS_ //!
MZ +M%4OM,_\ SP>C[3/_ ,\'H MO]QOI52D:YG*G]P]0>=)_SR:@"Q15?SI/
M^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/
M^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/
M^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/
M^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/
M^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q2K]X?6JWG2?\\FI1-+D?NFH U*
M*I?:9_\ G@]'VF?_ )X/0!=HJE]IG_YX/1]IG_YX/0!=HJE]IG_YX/1]IG_Y
MX/0!=HJE]IG_ .>#T?:9_P#G@] %VBJ7VF?_ )X/1]IG_P">#T 7:*I?:9_^
M>#T?:9_^>#T 7:*I?:9_^>#T?:9_^>#T 7:*I?:9_P#G@]'VF?\ YX/0!=HJ
ME]IG_P">#T?:9_\ G@] %VBJ7VF?_G@]'VF?_G@] %VBJ7VF?_G@]'VF?_G@
M] %VBJ7VF?\ YX/1]IG_ .>#T 7:*I?:9_\ G@]'VF?_ )X/0!8G^Y^-5Z9)
M<3%>86%1>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15
M?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15
M?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15
M?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15?SI/^>34>=)_SR:@"Q15
M?SI/^>34>=)_SR:@"Q5Q/N#Z5E^=)_SR:IUN9]H_</0!>HJE]IG_ .>#T?:9
M_P#G@] %VBJ7VF?_ )X/1]IG_P">#T 7:*I?:9_^>#T?:9_^>#T 7:*I?:9_
M^>#T?:9_^>#T 7:*I?:9_P#G@]'VF?\ YX/0!=HJE]IG_P">#T?:9_\ G@]
M%VBJ7VF?_G@]'VF?_G@] %VBJ7VF?_G@]'VF?_G@] %VBJ7VF?\ YX/1]IG_
M .>#T 7:*I?:9_\ G@]'VF?_ )X/0!=HJE]IG_YX/1]IG_YX/0!=HJE]IG_Y
MX/1]IG_YX/0!=HJE]IG_ .>#T?:9_P#G@] %VBJ7VF?_ )X/1]IG_P">#T 7
M:*I?:9_^>#T?:9_^>#T 7:*I?:9_^>#T?:9_^>#T 7:*I?:9_P#G@]'VF?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ?ZU<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M='M:?\R^\.278LT56^WVG_/=/SH^WVG_ #W3\Z/:T_YE]X<DNQ9HJM]OM/\
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M444 %%%% !1110 4444 %%%% !1110 4444 %7$^X/I5.KB?<'TH XSXD_\
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MO#ZU<H **** "BBB@ HHIDLJ0Q-)*P5%&2QZ"@!]%06UW;WB%[>995'=34]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:TZYF!OL_C6>,#Y#"N![UST(1G":>Z5S:K-PE%]&['34445SFX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6_X<Z3?A6!6
M_P"'.DWX5W9=_O,3#$_PF;U%%%?4GDD4_P!S\:KU8G^Y^-5Z "BBB@ HHHH
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M@5O^'.DWX5W9=_O,3#$_PF;U%%%?4GDD4_W/QJO5B?[GXU7H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *N)]P?2
MJ=7$^X/I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(WW3]*6D;[I^E %6P_P!4?]XU;JI8?ZH_[QJW0 44
M44 %(>E+2'I0!4M?^/J?ZU<JG:_\?4_UJY0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %13_='UJ6HI_NCZT 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %'WA]:N53'WA]:N4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 U_N-]*J5;?[C?2JE !1110!SNK _;FX["J6#Z&NM,:,<E%)]Q2>5
M'_SS7\J\:ME3J5'/FW\CMABU&*C8XVYM([J+9*FX=LCI62=-O;,_Z-,[)V3'
M KTCRH_^>:_E1Y4?_/-?RK6C@*M)<JG==FB)UX3=^74\[$NJXP;8_7-2)8W5
MP<W$CA>Z$<5Z!Y4?_/-?RH\J/_GFOY53P,OL-+Y?\$2K+K=_,XY(O)0)''Q3
M7,YX$9'O79^5'_SS7\J/*C_YYK^5<_\ 9+O=RO\ +_@FOUM;)'$I9EGWRDN>
MP(Z5:P?0UUGE1_\ /-?RH\J/_GFOY42RJ<MY_@"Q<5M$Y/!]#1@^AKK/*C_Y
MYK^5'E1_\\U_*H_L=_S_ (#^NKL<G@^AHP?0UUGE1_\ /-?RH\J/_GFOY4?V
M._Y_P#ZZNQR>#Z&C!]#76>5'_P \U_*CRH_^>:_E1_8[_G_ /KJ[')X/H:,'
MT-=9Y4?_ #S7\J/*C_YYK^5']CO^?\ ^NKL<G@^AHP?0UUGE1_\ /-?RH\J/
M_GFOY4?V._Y_P#ZZNQR>#Z&C!]#76>5'_P \U_*CRH_^>:_E1_8[_G_ /KJ[
M')X/H:,'T-=9Y4?_ #S7\J/*C_YYK^5']CO^?\ ^NKL<G@^AHP?0UUGE1_\
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M'BT7?A1=8> )(V=L0.<XK(G\:Z_:0I=7.@+'9,P EWGH>]7?AND<W@>SWHK
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M1110 4444 %%%% !1110 4444 %13_='UJ6HI_NCZT 5Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** %'WA]:N53'WA]:N4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 U_N-]*J5;?[C?2JE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^Q'_GH_YT 7**I_8C_ST?\ .C[$?^>C_G0!<HJG]B/_ #T?\Z/L1_YZ/^=
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M\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H
MN453^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_
M )Z/^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V
M(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_S
MH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH N453^Q
M'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH_P"=
M'V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_
M #H N453^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H N453
M^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/
M^='V(_\ /1_SH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\
M/1_SH N453^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH N4
M53^Q'_GH_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH N453^Q'_GH
M_P"='V(_\]'_ #H N453^Q'_ )Z/^='V(_\ /1_SH M/]P_2JE#69"D^8_YU
M7^S?[;?G0!8HJO\ 9O\ ;;\Z/LW^VWYT 6**K_9O]MOSH^S?[;?G0!8HJO\
M9O\ ;;\Z/LW^VWYT 6**K_9O]MOSH^S?[;?G0!8HJO\ 9O\ ;;\Z/LW^VWYT
M 6**K_9O]MOSH^S?[;?G0!8HJO\ 9O\ ;;\Z/LW^VWYT 6**K_9O]MOSH^S?
M[;?G0!8HJO\ 9O\ ;;\Z/LW^VWYT 6**K_9O]MOSH^S?[;?G0!8HJO\ 9O\
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M1110 4444 %%%% !44_W1]:EJ*?[H^M %>BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!1
M]X?6KE4Q]X?6KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 -?[C?2JE6W^XWTJI0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2K]X?
M6DI5^\/K0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH BG^Y^-5ZL3_<_&J] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5Q/N#Z53JXGW!]* %H
MIDDT4*[I9$1?5FP*K_VIIY.!?6W_ ']7_&@5T6Z*@^V6NY5^TQ;FX4;QDU/0
M,**** "BHTN(9)#&DJ,XZJ&!(J2@ HHHH **** "BHUN(7D,:RHSCJH89_*D
M>Y@CD$;S1JYZ*6 )H"Y+11U&110 4444 %%1_:(1+Y1FC\P\[-PS^524 %%%
M% !16/J7B2QTK4(;*XW^;*,KM7(K74AE##H1FG9B33=D+1112&%%%% !1110
M 4444 %%9-QXAL[;6[;2I-_VBXSLP..*UJ=FA)I[!14:W$+R-&LJ&1>"H89'
MX5)2&%%%% !16,?$MBNM#2CO^T%MOW>*V:;30DT]@HHHI#"BBB@ HHHH ***
M* "D;[I^E+2-]T_2@"K8?ZH_[QJW52P_U1_WC5N@ HHHH *0]*6D/2@"I:_\
M?4_UJY5.U_X^I_K5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG^Z/K4M13_ '1]
M: *]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "C[P^M7*IC[P^M7* "BBB@ HHHH ***9
M)+'$,R2*@]6.* 'T4BLK*&4@J>A!I: "BD9E1=S,% [DXI(Y(Y5W1NKKZJ<B
M@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2JE6W^XWTJI0
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MWC5N@ HHHH *0]*6D/2@"I:_\?4_UJY5.U_X^I_K5R@ HHHH **** "BBB@
MKR#QMXRU_3]?%IIMSY:;22-N>E>OUX9XN3S/'D2?W@P_45K12;U.;$MJ*L=]
M\//%%QKNF&*^??>1Y+M[=JH^/_%E[IEU#8Z5/MGD0L2!G&*YC3+G_A#O&\D,
MS;8)HT^G/-+9HVO^+-0U)OGM[<NB9Z8(J^1<W-T,_:2<.3J;OPX\5ZIK$]T-
M5N@\<29R1C'-,O?&.K:_XF;2=!8VR1,4:<C<K>]<YX')6T\0%."(7QC_ 'C6
MC\(HUDO+V60YE$G?KTIRBDW(F$Y248WW.KBA\6:/=6SW5[_:<4SA&2),>6/4
MYK!N_%VLQ_$ Z8MSBU\PC9CM7JE>'WW_ "58_P#74_TJ*=I-W1K63@E9]3VZ
M,EHD)ZE037"?$+Q-?Z0;>VTN;9<2J> ,UVZR+%:+(QPJH"?RKR-;F'7_ (DL
M9YD%M;R%5WL ,&IIK6[Z%UI-126[-SX<^+-1UFXDLM4EWW" MR,<5Z-7BFHR
MIX:^(44EK+&89@JDQL#U^E>D:EXUTO2W59DNGW=#%"6'Z4ZD;N\>I-&I:+4G
ML;=]=I8V<MS)]V-2V/7%>,Z[\2];ENXI; /:VLA^0L 0P]J]1TKQ#IOB1&CA
MAG*X.1-$5!_.O,?BK:P6E[I\-O$L4:DX51@"G22YK-"Q$GR<T7H>NVES*^B0
MW14RRF .5'5CBN-O3XOO;2;4[>\.GQ@;EM9$RP]LUV6C?\@6R_ZXK_*L+QSX
MDMM&T6:+?NNI5(C1>>?>HCO9(TG;ENV8/@/QM>W\MW8:HQFN(0[^9T&%'2H(
M?$FO>+-=GM=$N_LD$)^9BNX8J+X>^&+H1WFIW"[)+A'51_O UF>&;YO GB;4
MK>_MYV23 W1QE^_M6S4;OE.=2GRQYGH;&@^,-6LO$C:1K,QG.3MDQ@5Z>#E0
M?45X)=:M%J_CRWN+5)%7.,,A4]17O4?^J3_=%9U8VL;8>3=U>]AU%%%9'0%%
M%% !1110 5%/]T?6I:BG^Z/K0!7HHHH **** *U_=BQLY+@J6"#.!7&VWC^_
MO0[V?AN[GC5RN]&&,C\:Z?Q#_P @2X^E<#X-\8:=HVF3VUS'=,_GN<QPEAU]
M:UA&\;VN85)M32O9'=:%J]YJB2-=Z7-8[.@E(^;\JR]1\;)#?&STRS?4IE'S
M+"1QZ]:76/$<=UX1N[^P$J%4R/,0J:K^![2WLM$FU!T#3,6=G RV.N*5E:[0
M.3;44_F+!XWNA>PQ:CH=Q8PR'!FE8;5K0\2>*H] L8KE;=KD2LJJ$.,YZ5F7
M'CWPY<D1W5O<D'@>9;D"L[XC3P_V-8SQ@B$31L !VR*I1O)71+J-0;4KFC%X
MTUB4*5\+7NT]]R_XU=U[Q>=#MH)'T^2264+^[!&03VJGI_C_ $@011>5>[L8
M_P"/=L5D?$.[CS8W6&\O?&^,<XR.U"C>5FA.HU!M2N:;>/+VW*/>^'KJV@/6
M5V& /7K77V-[#J%JEQ P96&>*X#7/%EGK^FC2+&&3[1<KY:FXC*#/U-=?X9T
MV72]'B@F(+[1G!R*F44E>UBZ<FY6O=&S17-^,K*_N=,$]A/)'+!EMJG&[V-<
MBWBV\U>V@T6V+K>@KYC#((QUYI1@VKHJ=51=F>I454TVU:SL8X6E>5@,EGZU
MRWC+5[H7]MHEHQ22Y7?O4X( //\ .DHW=D5*?+&[.THKBHO"NI:?<6MS::G<
MW.6!E29^ /:NM%[;K\LES"KCJID'%#78(R;W5C+\3>(E\.64=PUNT^]MH53B
MD\,>)H?$MK)-%$8VC(#(3D@UC?$)DETZQ*LKJ9CR#D=*P] W^&M>M4D)6"_!
MDXZ>E6HIP\S*522J6Z'I-_>QZ?92W,I^6-2V/6N8T#QY#KM^;9+-XQGY7+##
M5'XVOS/]CTVU.Z2:0"0?[)K!\/62Z=XO%J !Y9*\41@N6["=27.DMC>O?'4\
M.L2:;9Z-/>2HNX^6PZ5/9>*M6N;I8I?#5Y"AZNQ&!^M<O!K=KH?Q!O+BZ69D
M: */*0L?TKM])\6:?K,_DVT=RK9Q^\A*BG*-EHA0FY/61B7OCO4K .\_AJ[6
M-21O+#!_6EL_'6IWT4<T'AF\>&3E7#+@C\ZT_&__ " 7_&I?!/\ R*&G?]<Z
M7N\M[#]_GY>8W87:2%'9"C,H)4]O:GT45D= 4444 */O#ZU<JF/O#ZU<H *X
MGQ;XEO+74K32-.8Q7-R_EB3J%.*[:N5\8>$E\001SV\K07UN2\3)QEO<U4+7
MU,ZJDX^Z4K>U\7:9<Q376H"_A/#11I@C/>NNNK^VL+;S[R988P,EF[5P=MXI
MUOPW>VMEXCMXEM"H031DLQ/09J+Q"SZUXNM;%IF%J'!*@\,".AJW%MZF:FHK
M3?S.N@\8^'KF410ZK;N[=%!/-8_Q$<_V-"R,1DG!!]J9XL\,:9;^&V-I;1P3
M1LI$J+AN*P-0O)+WP#9S2L6;S'7)]L4XQ5TT*<Y6<9'2M//#X2T^2/5H[#Y%
M!DD!.>:Z2WN%M]+%Q=72.B+N>;H,>M>>>+/^2>Z=_P!L_P"=/\2W<[:=HFG1
MN4CN91&^#U!44N6X>TY;^B-S7/%>AW^DS6]GJ<,LS#A4)R:=\-V+>% 22?W[
M\D^]5=?\)Z9;>$FCA@2*9%'[Y%^;\ZL?#-=OA%%SG$SC/XT.W)H./-[5<W8U
MO$^M0Z-I4DK7*0RXRFZL'P9XVL]0TX)J.IQ&]:9E5#P2,\5M^+K2WN="F,T*
M.5'!8=*Y[X;Z1ITOA_[2]G$TRW#X<KR,&DE'DNQR<_:I([*+5K">\DM(KI&N
M(SM:,=0:6ZU6QLIDAN;E(Y'("JW4DUP.@?\ )1=4_P"N_P#04[QU_P C)IO_
M %V2CD7-8/:OEYO,[N\U:PT^:*&[NHXI)?N*QY:J4/B[0)[CR(M4@:4G;M!.
M<UQOQ(MA>>)M"@+L@8-\R]>M.\=:#8VGAVRDM(5MY_,7,T8PQZ4U".E^HI59
M)NW0[*\\5:'I]RUM=ZE!%,APR,3D5JK-&\ F5P8RNX-VQZUY\OAFQF\$M<7*
M^?<R1Y,[C+9^M9D.K72^!6"3/N^TF ,3R%Z4<B>P_:M?$CNY_&/AZVF:*;5;
M=)%ZJ2>*T[;4+2\MC<V\Z20@9+KTKEO#GA/2Y- A:ZMX[B9U^:5UR36%X7:2
MQU74]-$C-#Y<K*">!P:7+%WMT!5)*W-U.WF\5:%;J&FU*! >A)-/G\2Z-;6Z
MSS:A"D38PQ/!K@? VA6FI:A>2WB^<J8*QN,@5/XVTQM/UJUU)K02:3&@C:)%
MW?-G^Z*?)'FL+VL^3FL=SIWB'2=6=DL+Z*=EZA#TK3KF/"^H>'KXN=*M5MY5
M WAH]C?E73UG)69M!W5PHHHI%!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 U_N-]*J5;?[C?2JE !1110!SNK?\ '^WT%9[N
ML:%V. .IK0U;_C_;Z"O,/'/BAH ;"V;#'AR.H-?.0P53&8V5*'<]*>(C0H*<
MC-\9^*VNYC8V;?(#R0>OM7&?8+HKN\EL>M.T\^;JD)?G+C.:].:WQ- JQ6_E
ME3D%@#7VDJE/*H1HTH]#Y]1EC9.I-GED=I/+G9$S8]*>=/NP0# V37IRV:I;
MR&WMX0^3]_@5R5_K%U9WJI+;VY*G'RMD5IA\SJ8B3C3BM/,BKA(TDG)G/?V=
M=9YA;%:=LUU9!#;VS;AU..M=+KNK?9=,AD2UB!<#/'M4>A:N;C1KV5[6(M"!
MMXK*IBZM:A[2=-.-[6O\BXT(0J<BEKZ%*?6!J;K#J-FPPH&XX&/>L35M)-B1
M/ WF6[\JZ],5V5A"M]IC2W$"+)(Y08':L\Z=):SSZ3/\T+G;$Q[5PT<72PM7
MDI>ZH[QO=-=6O0WJ49587GK?9_YEGP5XM,+K97C_ "G[K$_D*].5@ZAE.0:^
M=Y5:TNV5204;@UZ;X'\3F[1;&Y;+C 4]S7/GV4)Q^MT%IU7ZF^6XYI^PJ?([
MRD)"C). *6LW7IVM]$NI4.&5,BOD:<.>:BNI[<Y<L7+L7(+N"Y5S#*KA#AL=
MC52?7M+MIC%->Q)(.JDUE1R-IGASST4;Y\9^II^AZ):O8+-=1+/*_5G&377[
M"E%2G-NU[*VYS>VJ2:C%*]KLVO[0M/LXN//3RB0 _:IXY$E0.C!E/0BN7U[3
MTTW0I1&[,K3*P!_A]A52WUO5[6TAF-M%]BS@L3\V/I36"52'/2?7KH)XIPGR
MU%TZ'73WEO:D">54)Z9J<$$ CH:YW5=35;6VG$$<GF;2-XZ9--U7Q!<6,\=O
M!"K22 ! >F<5G'"3FDHK5W_ MXF,6^;96_$Z2BN9L]<U*/5(;/5((HS*I93&
M<\5/J=]K4-X5LXK0P8&#+*%-)X2:GRMK77?0:Q,''F2?W:F^2 "3T%16]S#=
M1^9!('3)&1ZBLK1-6DU6&ZCG5!+"=C[#D9Q5/0F^S:S<V )VJN_'U-'U9I34
MMXA[=-Q:V9TU:>B_\?+_ .[696GHO_'R_P#NT\#_ +Q#U+Q'\-F[2K]X?6DI
M5^\/K7UAXY<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH BG^Y^-5ZL3_<_&J] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5Q/N#Z53JXGW!]* ,3
MQ/H+Z_I_V9)EB//)&:T=+LSI^EVUH7#F% I8=ZMTC,JC+$ >I-.[M8GE5^8Y
MC5O"DFI:_::DMRJ+!('*$<F@^%)/^$Q@US[2NR)&7R\<G-=,DB2+N1U9?53D
M4ZGS,7LX[F#KFFZ[>.#I>JI:*#R&0FLO1O!U[;:TNJ:KJ"7EP@(1E4C /6NR
MHH4FE8'3BW=G%W?@W4$\22ZMI&I1VGFH$="I.0*ZZU26.UC2>022@89P.IJ:
MBDY-[CC!1V/)O$6G/J/Q1E2*7RIDMT9'/8UT=OX,U*ZU2"\UW4X[[R,A%52N
M!6S)X7M9/$C:V99/.9 FSM@5M-+&CA&D16;H"V":T<]%8RC25VY=SCK_ ,&7
MR:PVH:'J,=BS($(92W%,TGP/>6>OQZO>:@D\^=TA"D;C7;T5//*UB_91O<XW
M4?!]^WB/^U](U%+-F0(P92<CO3[OPA=WVK:;?SWR-):DE_E/SUU]%+G8>RB<
MEK/A">YOEO\ 2KQ+.\"A3(03D5)I6C^)[:_CEO\ 78KFW4_-&(R,BNIHHYW:
MP_9QO<YC3_"LEEXI?6#<JRLA7RP.>:DU7PR^H^(M-U07"HMI)O*$<M70":)I
M-@D0O_=##-/HYG>X>SC:QR/B/PC=ZKK$6IV%\EK<1IL#,I/%=%I<%W;:?'%?
M7 N+A?O2 8S5RBDY-JPU!)W1Y9X]LA?^-K&$G:?)RI]#D8-; \%ZQ?W5I)K&
MKQW5O VY8PA':M[4O"]MJ6M0ZG)+(LL2[0HZ&MP#"@>@JW/1)&2I)R;D<MK'
MA#^T=3M+F&=8H[=-@0CKS534?!=^=7?4=(U&.SFD4*Y92V0*[6BI4VBW2BSA
MM*\"WEGXEBUFZU%)Y%C97 4C<3WK2T;PK)I?B6]U9KA76YC"! .1@UT]%#FV
M"I16QS>K^&'U+Q+9:JMPJ+;1-&4(Y.:CT;PI)I?B>[U9KE76>(1A .1C-=11
M1S.UA^SC>YSNK^&GU/Q)8:H)U1;5&0H1RV35+5O!]S-J/]H:1>I973*%=V4G
M(%=?10I- Z<6<QI.C^);:]634=;CNK<?>C6,C-5-0\&WHUE]2T34$L99%VMN
M4G-=E11SN]Q>SC:QP]CX$N(/$=GK5Q?)+<19,QP?WA]O2NXHHI.3>Y48*.QQ
M.H^#-2?7I=4TK4X[225]S;D)S5O7O"4VJ""ZM;M;?5(PH:X(.& ]JZNBGSLG
MV4=3B[?P?JEU?P7&NZI'?+"<HJH5Q79(BQQJBC"J, 4ZBDY-E1@H['$ZUX%E
MU/69-2AO$BFSNC)!^4TEEX)U"75H[K7-22^BB7"1JI&".AKMZ*KGE:Q/LH7N
M<MKOA.6]O([[2[I;.\4Y,C#.:;IVC>*8+M7O-?BGA'5!&1FNKHI<SM8?LXWN
M(.@S2T45)84444 %%%% !2-]T_2EI&^Z?I0!5L/]4?\ >-6ZJ6'^J/\ O&K=
M !1110 4AZ4M(>E %2U_X^I_K5RJ=K_Q]3_6KE !1110 4444 %%%% !7D'B
M+0-5N/&\%S#8RO "<N!QU%>OT54)\K,ZE-35F>5?$OPI>W\%K=V%N\TYP'5!
MR,"M3P;X>NM+\)W,<T#+<3C<5(YS@UZ#15>T?+RD^PCS\YY5\//#U_;W>IQZ
MA9R0Q3*R@N.O)JO)H.M^"O$XN]-MI+ZSG)=HX5Y7M@YKUVBCVKO<7L$HI)['
M%6WB#7M9N[>&+2;G3E1PTKS $.OIQ7&Z]I&L6GCM]4@TNXN81(2/+ YKV>BA
M5+/1#E1YEJSSZZ\6ZS=:7-:IX7OXW:+8K$KP<?6L?P7\/H[R">Y\06LJSN05
M&[:17K-%'M+*RT#V-VG)W/*?&GP[@M;.*YT*VE>X5P2-VXXKL_""W$GAVUCU
M&R,=PB8;S%&<UT=%)S;5F.-*,9<R*MTXLK5Y8+7S&4$A(P 37C/C,:[XHN[>
M:+P[>0B(DD-@Y_6O<**(3Y7<*M+VBM<XW1-?U.32_LSZ%=V\D,&%9\<D"O/4
M@UV[U]]1UCP_>W2[LJBX&/UKW2BFJEMD3*BY)7>QQ^D>)[Z9Q;'PU>6L:)PS
ME<<=JAO/%E]%=.@\)7<V/XP%YKMJ*7,K[%\DK6N>9^%O"EY?Z])KFJQ>2H)$
M=NRX8 ]*]+ P,#M2T4I2<F.$%!604445)84444 %%%% !44_W1]:EJ*?[H^M
M %>BBB@ HHHH R_$/_($N/I7%^!M;T2QTB>*^N[:.7[0YVR#G&:]&DC29"DB
MAE/4&LL^&-$9BQTRW))R3MJXR5K,RG"3DI(JW3Z9XIT:ZL=.NX9 PPQ3H*YG
MPIKZZ"\VCZVAM0K,4FEX5E[5W=EI=CIV[[':QP;_ +VP8S3;S2-/U!]]W:13
M,.,N,T*2VZ"<)-J2W.!\9ZKI.J100:;<03S'("QCFE\<*5T#2588(DA!!^HK
MMHO#NCP2K)%IT".O1@O(JW<6%I=HJW%NDBJ05##H15*:5K$NE)IWZD6GP0_8
M8CY4?3^Z*XGXA ?;+(8&/-CX_P"!"O0U544*HP!T%07%A:7;*UQ DA4Y!8=*
MF,K.YI.'-'E.5\;Z(MUH*WMNJK<6:;X]HP2:U?"6JKJFAPM_RTB4))]:VWC2
M2,QNH9",$&HK:SMK-66VA2)6.2%'4TN:\; H6GS(R/%6N+HNF,5P;B4%85_O
M-7G_ /9U_P"'+RV\18W+<8,JA?NEC7JUS86MZ8S<P)*8SE"PZ&G36EO<0""6
M%7B'\)'%5&:BK$SI.;O?T$L[J*\M8YX7#JPZBN%\:":P\4Z?K!C8VT,9C=^P
M)(KO8((K:(10QJB#HJCBFW-K!>0F&YB66,\E6'%3&5G<J<'*-C!/C'37:UBL
MI5NY)2%98SRG'4TD_@C1+ZY>[F@F\V0[F_>$<UJV^A:5:2^9;V,,;_WE7FM"
MCFM\(*#?QZG!^-K&#3M'T^WMP1&LYP"<]JB\3:?++X0M+^W_ -?;QC;@<]:[
MNYL[>[55N(5D"G(##H:4VT+0>08U,6,;<<52G:Q+I7;\SSCP4)O$.M/J]XIV
M)$(U![,O%3VG_)0IO]]OY5WMK8VMDFRV@2)2<X48I!86BW!N!;H)CR7QS0YZ
ML2HM)*YYQ87^GZ?\1+R34)HHHS  #)TSS7;VGB+0+FX6&UOK9I6Z*G4_I5BX
MT#2;N4RW%A!(Y_B9>:2#P_I%K,LL&GP1R+T95Y%$I18X0G':QE^-^= 8CWJ;
MP3_R*&G?]<ZVY[:&YC\N:-73^ZPI8((K:%888UCC4855Z"IYO=L7R>_S$E%%
M%26%%%% "C[P^M7*IC[P^M7* "N3\0ZEKFCW\4]K:RW]K(V##".5'N37644T
M[,F2NMSS#4AK'CB_M[-])N--@1A(TDX!'RG..*O>)O#U]9WEKJFEJTLD)!>-
M1DM@5Z#15^T?0S]BG>[U/-]0UC7?$FGKI@T.[LG=@6GDP5P.O2K.N^';FV\*
M6UA:Q-,Z,6(0>HKOZ*7/V'[*][L\[\2Z3?W/@>QM8;61YT\O<@'(P:F\1^'K
MN\T'3Y[:-A=V9\S9CDG XKOJ*%-H'13N>8W.K^)-;TE-+71KJTE*?-/( 5)'
MXUTOP_L;K3_#"P7D31S"5R0PZ\]:ZFBASNK)!&G:7,W<I:M9F^TV:W!P67BN
M%\&7NK:)$=)N-$NF4W#M]HX"X)KT>BDI65BI0O)23/.=7M=4\.^+!JEG8RW\
M-PQ=TA'*_G6;JD6O>(=>L=2.F7%M;K*H,#@;EQ_%GTKUBBJ52W0AT;]=#A?&
M6F7MYXHT2>WMGDBBW>8RCA:M^-K"ZO="M(K:!Y9%D4E5[5U]%+G>GD4Z:=_,
MYN.TN!X,6V,3>=Y>-G>N:T;PQ>77A"ZM+B)H)A<-*@<=?2O2:*%-H'23>IYK
MIGB#Q#HFG+I\N@7EU)$,"9, ']:T?#7AZ\@AO=1O ?M$ZOM0CD @\5W-%#GV
M0E2MN[V.)\":=>6,UX;JW>(-C;N'6KFM>)KZQNO(C\.W5['UWIMQ^M=512YK
MN[0U!J/*F>>^&]+O;_Q3=:U-9R6$<F"(9!Z?2O0J**)2NQP@HJP4445)8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2
MJE6W^XWTJI0 4444 <[JW_'\WT%>)>.M&N+;4GN]I:.0EL^E>VZM_P ?[?05
MBZEIT&IVC03*"".#BO#PF8/ XZ52VC=F=M?"_6,.H]3P.QD,5["X4MM8' KN
MI=2M9#%/+IT_F(."'KG-=T.XT'4L["8PV5-1)XBG4_-$C#T)K[3$4UC%&K2U
M5N]CY^E-T&X3T^1U:ZX;R$Q7.GS%>@P0.*YW5[>%V4VEC*A'WBS9J,>*9PP(
M@C&.V:5_%,SY_P!&BYZ\UC0P=:A/FIPLNUS2I7IU(VE+\"35KBZO[.*);60*
M@ S]!2:3+<V6FW4!M)&\_&"*A'B24)L\E,9S3!XBG67<(UQZ9XK?V%7V?LN1
M6O?<S]I#GY^;4TKO6K\-%]D@>.- -P(SR*ENM9N[^6RD,3+M^\Q'6LH>(I%!
M7[/&0>N:!KQV!?)0;>F*YIY>G:7LE=7L_4U6)W7/HRIK6W[;E>XR:Z?P!H\\
MNHI>E2L<9!!/>LK0-"N-?U$.RD1@Y)KV.PL(=.M5@@4!5&.E<6<YE'"X=82#
MO)JS\CHP&$=:K[:6B1:K#\6!O["N"H) 3G%;E5[ZV%W9RP-T<8KXJA-0JQD^
MC/?K0<Z;BNJ,>2W-[X7@6/EE0-CZ5#HOB&RALA!>2K;RIU5SS6EHEM<VMM)%
M<JH ;"8.?EJ:71].FD+R6<3,>I*UU2JTES4YZJ]TT<ZIU'RU(:.UG<Q-;U!=
M0T1W1"J+.H4G^(>M.U( >%6X'W#70?8[;R1#Y*>6.BXXIS6T+Q>4T:F/IM(X
MJ5B8145%:)W&\/*5VWJU8X_4?^0)IW^ZG\ZL7P!UVSR.Z_RKIFL[=T5&A0JO
MW01TI6M8&D61HE++T..E6L9%=._XDO"OOV_ YS7N/$-F1U\LX_.LRX^QS:U<
M#692L:QJ44MMR:[>2VAED61XU9UX#$=*AGTRRNGWSVT<C>K"G2QD8146GHK7
M6^_0*F%E)MIK5WU.;\$>2IU0V_\ J?.&SG/&*L:>?.\:7DR_<,"K^/-;T5E;
MVL+I:PI'N'11C)K/T/3);0237( G=B, YXSQ1/$0FZE3NDO/^M!0H2@J<.SO
M_7WFS6GHO_'R_P#NUF5IZ+_Q\O\ [M8X'_>(>ITXC^&S=I5^\/K24J_>'UKZ
MP\<N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 13_ '/QJO5B?[GXU7H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *N)]P?2J=7$^X/I0 R::.WA:
M:9PD:#+,>@%<OK?B?1KO3)[>UU*&2;!PJL<]*K_$.ZFCL;6TB8JMRY1R#VQ5
M74O"VFCP;&T4"0W C!,R+\QK2,5HV83G)MQCT-'P!.$\'1RRR?*)')9CVS6D
M?%_A]9?*.K6XDSC;D]:\]ANYK?P'IEI%(RBYN)(F8>E==_PA^DS>&T#6L8G6
M+<9@OS$BG**O=DPG+E2CT1U4MS#!;-<RR*L*KN+GH!ZUF6WBK0KR<0V^IP22
M-T53R:X&RGU/5/!31+(TAMY)/,R?O(#@"M7PK?\ AAQ;VZ6"PZBD?S%XMO(]
MS1R)(I56VK'9W^LZ=I:*]]=QP*W +GK3;#7=+U0D6-[%.1P=AZ5Y?J&LZ;<^
M.+C^VA-):1QKY<*1EUR,]J=%JFG)XPLYO#\%Q'"48RQF$HI/:G[/0GV^IZ=?
MZ[I>EMMOKV*!CV<UQ'B'5;74/&V@/8W2RQE&R4/'6H='M$\2>,;F;4D$L:Q#
M$;<@$5'K>B6VD?$#1S;?*DP8B,# 7GH*(Q2=NHISE*-^ESTSG[-PVT[>">U8
M&CW%W)JUVDNLV]U&C_ZE%(,?L:WG_P"/0_[E><^#_P#D;M?_ .NO]*B*NF:S
ME:44=K)XIT.*-I'U.!45BA)/0CM5NPU6QU1"]C<QSJ.I0UYAX!T.TU*^U&2\
M7SH_/E B<94'<>:U/#T TOQS?V=LQ6W,H C'0"JE!*Z1$:LG9M:,[G5]1@TS
M3I;B:=8<*=K-Z]JX[PAXWAU">:+4=2AWG B7IFNOUJT@N]*N$N(ED41L0&'?
M%<'\/-'TZ::[DDLXF=,;21TI12Y7<<W+VB2&Z5J,%M\0Y9KBY"0>2QW,>*[R
MQ\0:3J<ACLKZ&=QU"&O.+32(=3^(KP2L5C6)CM X..U7=0T^#1/'^D+8((8[
MF;#H@P#Q5RBF_D9PG**\KG>W^M:;I>/MUY%!GIO-&GZUINK%A87D5QL&6V'I
M7EKZUIC>,II-;6:XAC#((1$77V-3:?J=D?&MI_84,\-O/*!*IA*+BI]GH5[?
M4]8F8K#(PZA217(>$]=O]3\0:G:W4H:*! 4&.G-==/\ \>TO^X?Y5Y_X$_Y&
MS61_L+_.IBO=9I-M3B=+XPU*YTK0C<VC[)?,5<X[&KN@W<M[I,4\[;I&ZFL?
MX@_\BP?^NR?SK1\+_P#(!@HM[@)OVEO(R?&/B&[L98=+TYO*O;@;DF(R% //
M%1V,?BK3;NV:_O5OX9V (BCQY?N:M>+O"QUQ$N;>1H[R$80CCWZUBZ=XIUG1
M;^'3=?M8XT=@D4B,6+'WJEK'0B3:G[QZ'134<2('7H>E.K(Z#BKM/%FIW]W]
MAO%T^"!]J^;'GS!CJ*C\)^);^2^NM+U:3S;FW0R-*!@$9]*ZS5-1M],L9)[A
M]J@8 '4UP.@:=<R1ZKKLR;#-$T:CV!XK56<=3GDG&2LR<ZOXB\2:O=0:-=+9
MP6S[&9TW!N]6?#OB'5+?69]'UN3S+B--ZR 8#9Z 4?#?F&^)^\7&?RJEKO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYGOQQ%&*Y8[&'16Y_8D7_/5ORH_L2+_GJWY5']F8GM^)7UJEW,.BMS^Q(O\
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M 6Z*J?;D]#^5'VY/0_E0!;HJI]N3T/Y4?;D]#^5 %NBJGVY/0_E1]N3T/Y4
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M 6Z*J?;D]#^5'VY/0_E0!;HJI]N3T/Y4?;D]#^5 %NBJGVY/0_E1]N3T/Y4
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M 6Z*J?;D]#^5'VY/0_E0!;HJI]N3T/Y4?;D]#^5 %NBJGVY/0_E1]N3T/Y4
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MW#@=?2K>Q?[H_*JH^\/K5R@!-B_W1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:*
M$V+_ '1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B_
MW1^5&Q?[H_*EHH 38O\ ='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH 38O]T?E
M1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B_P!T?E1L7^Z/RI:* $V+_='Y4;%_
MNC\J6B@!-B_W1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_ '1^5&Q?[H_*
MEHH 38O]T?E1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH 3
M8O\ ='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_=
M'Y4;%_NC\J6B@!-B_P!T?E1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B_W1^5&
MQ?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_ '1^5&Q?[H_*EHH 38O]T?E1L7^Z
M/RI:* $V+_='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH 38O\ ='Y4;%_NC\J6
MB@!-B_W1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B
M_P!T?E1L7^Z/RI:* &.J[#\HZ>E5-H]!^57'^XWTJI0 FT>@_*C:/0?E2T4
M)M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+10 FT>@_*C:/0?E2T4 )M'H/RHVCT'
MY4M% ";1Z#\J-H]!^5+10 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\
MJ-H]!^5+10 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+10
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M6B@!-B_W1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_ '1^5&Q?[H_*EHH
M38O]T?E1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH 38O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :_W&^E5*MO]QOI52@ HHHH
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M2CW.V^V6_P#SV3\Z/MEO_P ]D_.N)HH_MB?\J#ZE'N=M]LM_^>R?G1]LM_\
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M9-9M6=CH335R"ZU*RLCBYNHH3_MMBGVUY;7B;[:=)5]4.:\/\67LGBG4;F\
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M %%%% !1110 4444 -?[C?2JE6W^XWTJI0 4444 0W?_ !Z2_P"[7DWQ!_Y
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MWYH@DW9A5E*,;Q/2891/!'*HPKJ&&?>LC7O$*Z$(RUE<W.__ )XKG%:.G?\
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M7]VS$%@//.S\L]*C\":K/--?:;,D6RT<(C1+C(]Z0>#M=2%X(O$LJ0-GY O
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M"--Z73NCD5U'Q7JNB7-U9"PBT\[AM9 #BCX?60U/2=4M;I@=[C)0\=.U7XO
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M!47^Z*U*^'Q'\67J>_2^!!1116)84444 %%%% !1110 4444 %%%% !1110
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MZH_[QJW52P_U1_WC5N@ HHHH *0]*6D/2@"I:_\ 'U/]:N53M?\ CZG^M7*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J*?[H^M2U%/]T?6@"O1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 H^\/K5RJ8^\/K5R@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH 4?>'UJY5,?>'UJY0 4444 %%%%
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ME% %/R9_[WZT>3/_ 'OUJY10!3\F?^]^M'DS_P![]:N44 4_)G_O?K1Y,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8HT!1KIU/SCDQ-'LQZUM44T[":3W,?2M"73+^YN1,7\\ 8(Z5<U
M/3XM3LVMY>AY!]#ZU<HHN[W!125CE]-\-:G87,;-KD\D"-DQ$#!'I3+SPC</
M>23V&J268D)+JBCYB:ZNBGSLGV<;6.?M?"\=OHEQ9/.9)YU*O<$<FGGPZO\
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MM4(O"%\]W%+?:U-=QI_RS=1@UUU%',P]G$:BA$5!T48%.HHJ2PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gtqsgrqcdg4e000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0!!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]7L-'MC<:A=1V\0ZO(V!0!=HK-TG7]*UR,R:9>PW*#J8VS6E0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[UXSH6I_$GQ0)M4TV9C;Q-O*L^W('8>M $GQP_Y'2WY/WQ_.O?/!'_(IV/\
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MLN%!$B>E 'S]XI_Y*_U/^L7O[U[SXP\+W?BOP3;V-G*$F" C+8!X%>#>*?\
MDK__ &T7^=>Y^.M2N]+^'T=Q93&*41C##\* ,7X4?#75_!ES//J4L>7& D<F
MX5ZS7BGP1\2:OKJW7]H7;3;?N[CTZ4OBWP[\3+OQ!<2Z/<(+-F_=@S!<#\Z
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MJ /:J**HZOJ,>E:7<7DK +$A;D^@H O45\CZW\1?%5[>W>HVE[)'9&0[!DC
MKWGX2ZO>ZSX0M[F^F,LI498T =_17BWQS\2:MH3V TV[:'>/FP>O)KE=+TCX
MKZQI\=[:7:M#(,J3. ?YT ?2=%>(^%_#GQ/MM>MY=5N4-FK#S!YX;(_.O;J
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M_(UT]<Q\0?\ D1]4_P"N+?R- '@'P)_Y':3_ '3_ "-=-^T%I$YN[75@P\E
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MM[669C@(A;\A7R3JFMV&N?%)K[49]EGY^2Q&<"OH3XH^(E\/^#[J4-^\D4H
M#SS7B'PD^']CXTGNY]463RD&1COR* /4/$?Q"\$:GX3N-+&IJP>'8%\L_P"%
M>/?"G74T;QY''&^()Y-F?8FO:/\ A1'A#_GG/^8_PKPSQSH"^ _&J)9!A%&P
M="?PH ]O^.#!O!>Y3P2#7,_L\_\ 'I<_[QK5\=S/XB^$UO=V_P"\*QJ7QSC
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M6!T_ UL?&'XBZ1?>'_[(TJX6[>X&2T?\/:K/P)\+W6E:/=:E<QE/M/W0PYP
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MUZA^T#_R+4/^\O\ ,5YA\/+F.[^)<<\4?EH\A*KZ#->G_M ?\BU#_O+_ #%
M%OX#:=:P>'I+E(L3/]YC7/\ [1EO$%TZ8*!(7.2._!JE\&O'T&@K_9NLG[/;
M2C,4S?=%9'QF\76GBS7+>QTQC/' ^!(O1NHXH ]2^!<CMX'C4G(!XKT?4M-M
MM6L);*[3?!*NUU]17(_"K0)-!\&VT,RE9'4,0:[F@#'T#PQI?AFU:WTR$Q1L
M<D$YK8HHH *XSXA-XF72,^&E#7/I_DUV=% 'RKXQE^)9T&8>((MMB1\_(_QK
M.\!R>/%LW'AB/=#_ !<__7KW3XTACX!O%4$Y4\#Z5SG[/Z2)HDVY6 SW'UH
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MEX-\ :=X*25;&>:7S.IDQ_2NMHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVTQOIE"/CH#7T5<VL%Y T%Q$LD3##*W0USEG\._"UC>?:H-(MUD!R" >/UH
MH_"S09=!\%64%PFVX*9?CZUV](H"J%48 Z"EH ^?/'?_ "7O3_K#_P"RU]!U
M\^>._P#DO>G_ %A_]EKZ#H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7/C7]LM3F)D?!_"@#Z/'2EI!TI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Y\\=_\E[T_ZP_^RU]!U\^>._\ DO>G_6'_ -EKZ#H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!#TYKP#6].L]:^.,-E+"K1J?G7'N*]_/"D^U>#:!F]_: U.;JL,F ?
MP6@#W.TM(+*W2&")8T48 45/110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7SY\//^2X:Q_UUE_FU?0=?/GP\_Y+AK'_ %UE_FU 'T'1110
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M-$^J?S->_P ?^K7Z"O /C1_R431/JG\S7O\ '_JU^@H =1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O7\NRF?\
MNJ37B?PN3[=\1->ONN+CK^"U['KC^7H=X_\ =B)KR/X"J9GUR\8<R7/!_ 4
M>V4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\^?#S_DN&
ML?\ 767^;5]!U\^?#S_DN&L?]=9?YM0!]!T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9'B??_PCMYLSNV<8K7IDL2S1-&XR
MK#!!JZ<N6:EV*A+EDF?*S9W'=G/?-:?AWS?[=M?)W;MXZ5TGCKPLFG>(8X[0
MY^U-D+Z$UV7@GP#_ &1(+V^ ,^.%[5]GB,QHQPWM/YEHCZFMC:2H<_=:(] A
MSY$>>NT?RI]%%?$GR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\_?&C_ )*)HGU3^9KW^/\ U:_05X!\:/\ DHFB
M?5/YFO?X_P#5K]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444C<*3[4 >7^*Q]N^(EA$IRL:@D?G7J"\(H]J
M\PT_&H?$ZYSR(1C]:]0[5Z./]V-.GVC^9VXS10AV04445YQQ!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S]\:/\
MDHFB?5/YFO?X_P#5K]!7@'QH_P"2B:)]4_F:]_C_ -6OT% #J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4%W=V]E;M-<S+%&!RS'BISP,U\W_''QK>/JYT>
MTF9($7YPIZF@"]H6HV>K?':ZG2Y22!6Q&X/#<]J^@1TXKX-T[4KK3+Z.[MI6
M253G<#7V+\.?$+>(O"-G<RMNN F)#[T ==1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$8X4GVKR^U!U+XG3MU\I /YUZ=,P6"1CV4FO,O B-/XRU:Z/(WE1^!->C@?=
MI59]E^9W832G4EY'J%%%%><<(4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?/WQH_Y*)HGU3^9KW^/_5K]!7@
M'QH_Y*)HGU3^9KW^/_5K]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^!$]Y/DR"(J2?H?\* $^!.BV=[X=N;^YMTDEE=@SLN2<DUSO@K=H'QGO[=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRSXMZQJ
MC-I_A[293%-?R%"X;!&!GK^%>IUY=\5M%U-KO2M=TN(RR64V74#)P>.GXT >
M=>1X\%^/!7VX[^OG>9SCI]ZNE\"WOB'P;XR7PWKEPUS#.,QR%]V#P.M>M6%E
M!/;PZG-:H+YH\LVT9S7FND:5KGB/XF2:IJ-OY%K9M^ZXQNZ4 >P@Y&:*0#
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MO\VH ^@Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'045B>*];AT#P]=7
MTS;51#@T >-_$6[?QG\1[+PU V887 <CIU'^->[:?:)8:?;VL:@+%&J\>PQ7
MC7P7T6;4;Z^\3WZ[VGD)A<CM_D5[=0 4444 <=\2O$TOA;PG/>PKF1@57VKX
M\OM1N=0U":]GD9IY6W,V>:^H_COC_A FS_?/\J^4: /:_@=XWO(=870KB1I(
M9>4R?N_YS7TI7Q[\'<?\+%L<^A_F*^PJ "BBB@ HHHH **** "BBB@ HHHH
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M-$^J?S->_P ?^K7Z"O /C1_R431/JG\S7O\ '_JU^@H =1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A7
MQWUF\E>UT.TA+O,WRA>I//2O=:\.^-&LV.D:WI5VJ%KZUE$H!'! S0!YK;^"
M?'OV=#''>(I&0OI7;?#/PQXNT[QA%<:H+D6P1@=_0G%;EC\?-"^QQBYMY%E
M 8*F171>%_BWHGB?64TVTBD69@2"R8Z4 >C#I2T44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'SYX[_P"2]Z?]8?\ V6OH.OGSQW_R7O3_ *P_^RU]
M!T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7"^,_AG8^,;M+BYG:-E&.!
M7=5YW\3OB)_PAEE&EO'YEU*< >E &!_PS_H__/X__?/_ ->MOPK\(=-\+ZTF
MI6]RSR*" "OK^->3?\+P\3DY$/!Z?NJZOX>?%+7?$?BJ+3[V+;$ZDY\O'2@#
MW:B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y\\=_\E[T_ZP_^
MRU]!U\^>._\ DO>G_6'_ -EKZ#H **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %?/GP\_P"2X:Q_UUE_FU?0=?/GP\_Y+AK'_767^;4
M?0=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !X%>68
M^W?%9Y!RL0 'Y"O4)CMA<^@KS3P4!?\ B_4[DG.Q\9KT<#[L*M3LK?>=V$]V
M%2?E^9Z=1117G'"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\_?&C_ )*)HGU3^9KW^/\ U:_05X!\
M:/\ DHFB?5/YFO?X_P#5K]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-9WPU@V>%XYB,-([']37HTO<P4Y=VD=U/W<+)]VD=E1117G'"%%%% !1110
M4444 %%%<_X@\7:?H"$2R!IL9"9JZ=*=27+!79<*<JDN6*NSH**YKP_XUT[7
MF\I'"3GHA-=+3JTITI<LU9A4IRIRY9JS"BBBLR HHHH **** "BBB@ HHHH
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M^R<U7))+FMH5RRM>Q/1114DA1110!#=2^3:R2?W5S7S=XDNY;S7KN21V/S\
MGI7TK(@DC9&&01BOGKQIH[Z=XDF1<,)3O4+SBO?R&4%4DGO8]G)Y1522>YC:
M3<R6FJ6\T3LK*XZ'%?2FEW!NM-@F;JR#/Y5X)X6\,7VJ:O#^Y98U;<S,N!@5
M]!6L"VUM'"HP%4"JSZI3E*,5NAYQ.#E%+<EHHHKYX\4**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#Y^^-'_ "431/JG\S7O\?\ JU^@KP#XT?\
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M=.O-+NDN;<M$-Z'C(Q7TK0 4444 %%%% !1110 4444 %%%% !1110 4444
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MQD@'I7 :1X6L/^%12Q_9D#R6K/N(YSM)KGO@+>O:VFI63$D1LQ_+- ':>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:9IUOI.GPV5J@2*)=J@5;H ^8-3\+V/A+XRZ=IVGY\D-&W/O@U]/U\^>._\
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M4S7OA[>SP'+(G>N-C0R2*@(!)QS7H>DS:[\-H;?5[>XM9(;D;O*$H)/U'X4
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MKYR^*VD6&D>/]%CL;9(5+(2%&,\U]&Q_ZM?H* '4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>)?%>E^
M%;'[5J<WEH3@ #))K;KP3XU6%]K/B;2M+$GEVUQ($#M]U22: .H/QT\)[L^9
M(??RC6MX<^*V@>)=673K*20S,"0"A'2N%M_V?+9K:,MJ4;,5R2%-=)X/^#UO
MX5UY-32\61E4@* >] 'J=%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\^>._^2]Z?]8?_9:^@Z^?/'?_ "7O3_K#_P"RU]!T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?5/YFO?X_P#5K]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEKZ#KY\\=_\ )>]/^L/_ ++7T'0 4444 %%%% !1110 4444 %%%% !1110
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M.<\U]$_L[6:'3=2N)$5F:48)'^R*^=>]?6/P1L[:W\%0RPG]Y*-TGUH ].
M& ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\^?#S_DN
M&L?]=9?YM7T'7SY\//\ DN&L?]=9?YM0!]!T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ?S->_Q_ZM?H*\ ^-'_)1-$^J?S->_Q_ZM?H* '4444 %%%% !1110 4444
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M* /G[XT?\E$T3ZI_,U[_ !_ZM?H*\ ^-'_)1-$^J?S->_P ?^K7Z"@!U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '/\ C6_M]/\ "=_+<%<>60 >YKYWT?X:ZEXHTF[UJ%UAC5B5C*_>
M%=_\4M5EU_Q'I_A:T8E6DW2E?QZUZGH^G6^A^'H;7:HCAC^<XZU[U#$3R_#1
M</BF[_+_ ()DTIR]#Y8T#3Y+GQ#;:*8AE9PTF1U -?5^F:;::?:1);6T41"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHI&944LQPHY)H \W^*,S2_8[&(Y:4\@?C7F7B%F.H88
M\JH'Z"NA\=>(!/XG,EI(&6!OE85CV_AO6M;MWOXK:21.I;%?9X"FL/0@ZCLK
M?F?48."HTHN;M_P3G^]=]H/C/7;#3%AAM7FB3@-CH*Q=+\%ZOJ-XL/V:1%W8
M9B.E>[:/HUOI6F0VBQH2B@,V.IK+-,;AX146E-D9ABJ,8J+2D>=I\3]51</I
MN2.IVFL7Q-\0+W6-/-HUL8 W4@8S7MAMH",&&/G_ &17EGQ6MH+=;?RH54D<
MD#ZUPX&OA:M>,52L_4X\)5P]2LHJG9^IY5WS6YI_B?4++39-/CG987]^E8==
MS\.M"T[6[FXCOX!(%^[[5]!BYTX4G.HKI'M8B4(4W*:ND=-X+N_#6D6XD^TJ
M]W)R[MUYKMSXETS[,\XN4VJ,]:YNX^&&E./W(,?/:N?UOX:BQTZ>ZCO7"QC.
MW/!KYJ<<'B:G,ZCN^Z/!DL-7G=S=WW,7Q)\0M3O-3D%C<O#;H<*$/7WK;\">
M/;J6^^PZG,9 Y^1W/(]J\L/6M#0R1K5J0<?O!7O5<OH.@Z:CLCV*F"HNBX6/
MIP$$ CH>:6HX/^/>+_<'\JDKX9[GR3"BBB@ KR/XC;+_ ,7:=99!5EPWYUZT
M[!8V8G  KQ:(MK7Q*.XY6&3*_3BO5RF-JDJO\J9Z.7*TY5/Y4SU+0O#VG:-;
M)]EMD20J-S <FMFFH,1J/0"G5YLYRG+FD[LX)SE-WD[A1114$A1110 4444
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MI?PJRGH<<BMFB@#S71_@MX;TG4%NU1G9&RH;I_.O2(XTBC6-%"JHP !TIU%
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M1110!\_?&C_DHFB?5/YFO?X_]6OT%> ?&C_DHFB?5/YFO?X_]6OT% #J***
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M"BBBLQA1110 4444 %%%% !1110 4444 %%%% !1110 5YW\5_ <OC'1!]B
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M'+G5M9BE\MEAB;)8BOHJU6$*3FW96/;JU(QIN;>EC4O]/UKPU$8)T:YTV09
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MYX&LY[#PG9P7((D"Y.?H*Z.OS*M%1J2BMKG8M@HHHK,84444 %%%% !1110
M4444 %%%% !1110 4444 8OB7PQ8>*=-:QU!28SZ=J\7\1? :ZM9&NM O H4
M9"'[WZ"O>KR^M;"$S7<Z0QCJSG KSKQ-\:/#VBAX;>0W4V.#'@K_ #H \AL?
M$WCSP QCN[>?[,K_ #-+T(]J]?\  7Q<L?%]RM@T#PW>W)W8P<5XUK_CKQ%\
M0@UG;Z6&A+8!C!)'UKL_A/\ "W6M&U^+6=0"1Q!" F3NY% 'OU%%% !1110
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MB&1V&!TXS4?C>8Z[\9K?3)5+Q0SX"G\:=X6_Y.#E_P"NC_R:F:B0/VA\D_\
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M2.>E %VBN7\+>*9/$%Q=Q/9RP>0V 77 :C6?%,NF>(++35LY95N'"^8JY"T
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M!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZUO44 <Q<>#HKCQ@OB$WDH<($\D#Y>!CUJ[XF\/)XETS[%)</ ,YW)UK:HH
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M4W%Q,X)4"O5_%7@31O%L0^WP9E7[KJ<&L/P_\(M T34$O?+::6,Y3>V0/SH
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M5T*,H*D8(IU% $<4$4"[8D5%] ,4GV:'SQ-Y:^8/XL<U+37D2)"[L%4=230
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MRGOIV2PAN)1'*P!0,<?E7=/H*27%AX8TM!)>2L#<38R /3]*X[P_<K879O
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MDJDW.6[.&I-SDY2W84445F0%%%% !1110 4444 %%%% !1110 4444 %%%%
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MYX]HGP5,KK-XCOI+MNN%8C'YYKF_'7P>N;&<W&AQF6$_\L^X_&OHAF"*68X
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MWKL/]K6[6UK&=[$CKCMS7T]I]C#IMC%:0*%CC4  4 8\/@?PS;D&+1[92.F
M?\:T(-"TNWSY-C"F>N%K1HH C6"%% 6) !T^6G;$'1%_*G44 <[XN\(6'BW2
MGL[I "?NN!R#7D%I^SUC5!Y]X_V96ST'(].E?0-% &=HFC6N@Z7%8VB!(XQ@
M8%:-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SY\//\ DN&L?]=9
M?YM7T'7SY\//^2X:Q_UUE_FU 'T'1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1169KFM6^AZ=)=W# 8'R@]S50A*<E&.[*C%R?*MRAXL\
M2P^']-=]P-PPPB]\UX5K9OKB;[;?;MTY)7=Z5WFA:9>>-=>.JW^[['$WR(>G
M^>*S?BD8%U.V@@4*(DQ@?05]/ET88>JJ"UD]WV\CWL%&%"HJ2UD]WV\CS\$@
M@CJ*[+P_;>(/$\7V2.]D6TB^]GH!7&UKV/B"^TZRDMK24QK*,.1WKV,13E.'
MN6OY]#U*\)2C[EK^9UM_I_A[PJNV5QJ%X!G8YXKC=0U.XU2;RU7;&3\D2]!6
MII_A>]U*UDU&ZD*6R+N:1C6]\._#27VLM>R1YMH#\A(X)KC]I2P\)5)RYI+?
MU['+STZ,93E+F:. DMYH6VR1LI]"*[?X>>%/[5U'[1>VP>S4'(8<$]J]#UQ/
M"@O%&HK")@..<5T.EBR%DGV ((<<;:\[%9Q.5"T8--]?\CBQ&9RE1M&+3?4I
MIX3T*-=JZ;"!]#3)?!^@S(5;38?K@UN45X/UBK>_,_O/&]M4WYG]YYWJ?PKL
M+@F2TE:%AT50,5A?\([XNT EK*X=X%[ =?TKV&D(!&",UV4\TKI<L[27F=4,
MPJI6E[R\SR:#XAZE9(T&IZ:K#&&8CFO.-5NH[S4IKB) B.Q(4=J^C-<TFWU'
M2KB'R$+LAVG;SG%?..H6<EC?2V\JD,C$<U[F4U:%5RE"/*SU\MJ4JCDX1LS2
M\*7=O9Z];R7,2R)N P?6OI!2"@(Z$5\T>'M/N-1UBWB@0L0X)QZ9KZ6C7;&J
M^@KAS]1]I!K>QQYRESQ[CJ\W\?\ C>73';3[%]DV.7'45Z-(RHA9B !U)KYV
M\:W$=SXBG>*3S%!QFN;)\-"M7O-72,,LH1JU?>5TBUH_CO6+*^22>[DFBS\R
M,>*]LLM>L;K3XKIIXUWJ&(STKYH )( [UZ5HGPVN]1TR&YDOY8A( 0@/:O6S
M/!X6RG-\GRW/2Q^%P]E*3Y?D>E3>)]*@&6ND_.N*\=^.(&TTVFG3_O)!RRGI
M4D7PJB# RWLKCT)K-\3?#=+/3&N++=)(G)6O.PM/ 1K1]]OY:'#AX8.-5>]<
M\O+NQ)+$D]>:]8^$NIN\4]D_W4.5KRDPR!RA0[@<8KUWX5Z'<6D$M[.A59?N
MYKV<W</JK4OD>IF3C]7=STRBBBOBCY4**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y^^-'_ "431/JG
M\S7O\?\ JU^@KP#XT?\ )1-$^J?S->_Q_P"K7Z"@!U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &=K>L6VA:5-?W3!8XQGZFO"M0^
M.M^VI;K:W00*W R>179_&Z2Y3PR!%GRRWSX_"OFFOJ\DRVA5HNK55VS"I-IV
M1])6_P ;M);1//E0"]QQ"#WKE)-4\:_$>Z:.S62SL2<-MZ$5S?PET"TUSQ&!
M>0^;'%\V#7T_;6EO9Q+';PI&JC "C%88V6&RZJXT87EW?3T'&\UJ>8:=\+]+
M\+Z'>:E>K]MNXH6E!E[,!FOGC5;LWNI3SE0NYCP.W-?:&KQPS:/>1W#[(6B8
M.WH,<U\::Y#;V^LW4=K)YD*R':WKS7;D.)G7E4E4=WH355K6*UE>36-W'<P.
M5D1@017T]\/?B+9>(-)CBO)TCO(U&\,>M?-N@P6$^IHFHR^7;]2:DU98X]0F
MDTKS$M5/#*2*]',,%2QG[N6C74B$G'4^OKWQ#I=A;-/-=QA%&>M>::_\:859
MK?0;7[7(>-WH?PKR*T\.:GJ&B#4'O9/)(X!<U4\/>(;KPUJ!>&-9"IZ,H->7
MA\DH1N[\[739&CJ/T/1HO#WCGQU*)=0N9K:QDZIZ"NVT/X9^&O#,1GOREU*B
M[MTW:O-+WXS:^;?9;H(&QU _^M7-CQ%J'B6<C6-;DB4GD@@5I+!XVI&S:IP[
M1_X N:*\ROX]U%+_ ,4W?D;1;HY$87H!6!I]P;6_@F!QL<&EU&&*"_EC@G,\
M:L0LA_B%5:]ZE3C&DH+:QDWK<^PM+\7:<WA>WU*YN(T7RP2,UY+XX^,UQ>"2
MQT3]U'T\X'FO/T\,Z_)X9_M5O-73U7*DL<$5SX,DA^120OH*\7"9/AH5'-OF
ML_DC2525K$YM+N_D=U62>=CO?'/7FF6^F7EU=K;1P.92<;<5WVE^*=)\+>%2
M-/C235I\AW89*@__ *ZY;3_&&I6&K_V@KJ9"<M\HY_2O4A5K2YN6.BVOU_X!
M%D=A>_!Z\LO#<>J&?]]LWO$_05SS>*(1HJZ4FDVR3+\OV@9W?SKKK2?Q/\5K
ME8Q*\.G(<.4X%>DV_P (?#L>B_8Y+??.5YF).<^O6O'GCXX>T<8^:5]ET]31
M1O\ "<!X?^$=KJ_A=[MKS?>RKN51_#[5Y/J^D3Z/JDMC./WD;8KT[Q!H'B3X
M9O)=Z7?2M9/UR<@5Y7?:C<:A=O=7#EI7.237?E\JM24JG.I0>WD1.RTL>W?!
M?P5+"6UJZ \MAB.O:Y[NWM5+3RJ@'J:^7?!WQ%U[1[,Z59 S;S^Z7T)KJHO"
M/CKQE,&UF[FMH6Y';C\J\3,,!.IB)5,3448]/3T-8225DCM_%WQ1T.QLKJR@
MG\RZ*D*%/>OF6^N)+J^FGDSO=LG-?3.@?![0]-VR7R&\G'\;FL+QM\&(-0N?
MMFCGR2?O1CH36N6XW 86;IP;UZL4XREJ>%:*&;6K,*,MYHQ7V=I0<:5:B3[W
ME+_(5Y/X&^#JZ3J*:AJ;^8T?W8R.]>QJH10JC  P!7'GN.I8F<8TG>W4JE%I
M:E74]/@U33IK2X0/'(I&#7SZ-7OOA5XCU&QV&2WG3]RIZ#)/2OH:\NHK*TDN
M)F"I&I))KYO\4/J/Q&\0WUQIL.ZWL5!&!UP34Y,N;GA4_A];]^@5/+<[#X8^
M%YM:U.;Q5JZEWD;,*O\ P^XKV5ERA53CC QVKS7X2>*5U+26TBY 2\M/E*=.
M*],KCS.51XEJ>EMO3H5"UM#X]^(%O+;^,K\2AAE\@GO7/6L3S744<8)9G &/
MK7LWQ:LK?7?&VFZ99HOGR B1U[<BND\(_!BRT6_CO;V<W6 &56 X-?4QS6E1
MPD)5-)-:(P]FW+0[7P+:3V/A*SAN,^8%R<_05TE-1%C0(HPH& *=7Q%6?M)N
M;ZG2E9!1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP7XUK)I/B
M72=;ECWV\4H)4]#UKWJL/Q3X6L/%FDO87Z JP^5NZGU% ')Z;\7?#3:)'.]P
MD<BI_JL\]*\Y^'UVWB?XQS:G:QE+;8_S 8'2K=Q^ST_V[]Q<?Z-GNW/\Z]6\
M#^ ]/\%V)BMANE?EG/)H ZVBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUB^=NK-R:T]0U&VTRV:>ZE5$49Y->?V/Q7M6L&:ZC(N . HZFL>"SUOQ_?\
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M_'_JU^@KP#XT?\E$T3ZI_,U[_'_JU^@H =1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\^?#S_DN&L?]=9?YM7T'7SY\//^2X:Q_P!=9?YM0!]!T444 %%%% !2
M$@#). *6N0^(.MS:-H>8#AY25SZ5K0I2K5%3CNS2E3=6:@NIM3>(M,@N1 ]U
M'O/^T*THY$EC#QN&4\@@Y%?+DEW<2RF1Y6+$YSFM^R\<ZQ8Z;]CCG^4<*3U
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M^,[#Q;8":V.V8??C)Y6NFKRJE.=*3A-6:+3OL%(0#U -+14#$  Z #Z4M%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5*[L=.N6!NX('8=#)BKM>%?&4^*O[8A_L0WGE;>?)QCK0!Z\^B:"Z,A
MM+3!&#P*\A\)/9:'\8I],L%B:UF1V; Y5L=C7E^?B-CKJ?Z5Z/\ !WP-J\?B
M Z_K"R*VUAB3J2: /?J*** "BBB@ HHHH **** "BBB@ HHHH **1F"J2QP!
MU)JI#JMA<3>3%=1O(/X0>: +E%%% 'SYX[_Y+WI_UA_]EKZ#KY\\=_\ )>]/
M^L/_ ++7T'0 4444 %%%% 'GOQAO6M?!5P@S^\&#7R%7V-\5]--_X)NRHRT:
MY KXZ(*D@C!% " D=*.IK8\,^'[GQ)K,-A;(26/S$#H*^@M)_9^T2)%>^N9G
MD'.%QC^5 'S=:O/;SK-%$69>F5)%=M:?$?Q+;V@@@L;=5 P&$!S_ #KZ5T[X
M=>&=.A$8TV&7'\3KS6DOA+0$&%TJV _W: /C?7];US60KZFTI0'Y00<"L&OL
MKQ?\/-*US09K6UM(89\91@.]?,M]\-/$EGJILA82R -M\Q1Q0 _X;>#5\9^(
MC922;(HU#N?49Q7T]X=^&_AWPVF+:T5W/5I #S7._"3X<MX2L6O+W!O9AC@=
M!Z5ZA0 U(TC0(BA5'0"H;FRM;U0MS DH'0.,U8HH @MK.VLU*VT*1*>RC%3T
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%[:]_SYC_/X5U/@#XK:MXE\41Z==6VR-E)S]/PH ]OHH'2B@ HHHH ****
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M7_?0H LT56^WVG_/S%_WT*/M]I_S\Q?]]"@"S3#'&3DHI/KBH?M]I_S\Q?\
M?0H^WVG_ #\Q?]]"@"S15;[?:?\ /S%_WT*/M]I_S\Q?]]"@"S15;[?:?\_,
M7_?0H^WVG_/S%_WT* +-%5OM]I_S\Q?]]"C[?:?\_,7_ 'T* +-%5OM]I_S\
MQ?\ ?0H^WVG_ #\Q?]]"@"S15;[?:?\ /S%_WT*/M]I_S\Q?]]"@"S15;[?:
M?\_,7_?0H^WVG_/S%_WT* +-%5OM]I_S\Q?]]"C[?:?\_,7_ 'T* +-%5OM]
MI_S\Q?\ ?0H^WVG_ #\Q?]]"@"S15;[?:?\ /S%_WT*/M]I_S\Q?]]"@"S15
M;[?:?\_,7_?0H^WVG_/S%_WT* +-%5OM]I_S\Q?]]"C[?:?\_,7_ 'T* +-%
M5OM]I_S\Q?\ ?0H^WVG_ #\Q?]]"@"S15;[?:?\ /S%_WT*/M]I_S\Q?]]"@
M"S15;[?:?\_,7_?0H^WVG_/S%_WT* +-%5OM]I_S\Q?]]"C[?:?\_,7_ 'T*
M +-%5OM]I_S\Q?\ ?0H^WVG_ #\Q?]]"@"S15;[?:?\ /S%_WT*/M]I_S\Q?
M]]"@"S15;[?:?\_,7_?0H^WVG_/S%_WT* +-%5OM]I_S\Q?]]"C[?:?\_,7_
M 'T* +-%5OM]I_S\Q?\ ?0H^WVG_ #\Q?]]"@"S15;[?:?\ /S%_WT*/M]I_
MS\Q?]]"@"S15;[?:?\_,7_?0H^WVG_/S%_WT* +-%0+>VKL%6>,L>@#5/0 4
M444 %%%% !1110 4444 %%%% !7SG\1+C_A(OBS:Z-*6:&&;:5[=Z^C*^<=1
MQ_PT.,_\_)_K0!L_&GPK96WABTO+.!8&MU!)0=>M>D?#G4FU/P=9RLQ)5 O-
M<S\;O^1'D_W*U?A!_P B+;?3_&@#OJ^?/AY_R7#6/^NLO\VK6U+X[WEAJEU:
M+X>+K#*T88LW."1GI7F'AOQ_/HWCR]U]--\Y[AW8PY/RYS_C0!]>45X1_P -
M!7W_ $+?_C[?X4']H*] R?#?_C[?X4 >[T5X)'^T3<3$B/P^KXZ[9&/]*D_X
M:"OO^A;_ /'V_P * /=Z0@,"",@]17A#?M"7B*6;PX HZDNW^%-C_:'NIEW1
M^'E=?578_P!* /79_"&BW%T;A[*,N3D]>36Q;V\-K L,$82-1@*.U>&_\-!7
MW_0M_P#C[?X4V3]H:ZB7=)X="KZEV_PK256<U:3N7*I.2M)W/>:*\&3]H6[D
M4,GAT,IZ$.W^%._X:"OO^A;_ /'V_P *S(/=Z*\$D_:(N8<>9X>5,]-TC#^E
M/'[0=ZP!'AS(/0[V_P * />**\(_X:"OO^A;_P#'V_PIK_M#7<8!?PZ%!.!E
MV_PH ]YHKPC_ (:"O?\ H6__ !]O\*/^&@K[_H6__'V_PH ]WHKP9OVAKM&5
M6\.@%N@+MS^E._X:"OO^A;_\?;_"@#W>BO"/^&@K[_H6_P#Q]O\ "F_\-#7?
MF>7_ ,(Z-^,[=[9_E0![S17A'_#05]_T+?\ X^W^%'_#05]_T+?_ (^W^% '
MN]%>#+^T-=,[(OAT%EZ@.W'Z4[_AH*^_Z%O_ ,?;_"@#W>BO"/\ AH*^_P"A
M;_\ 'V_PJ-/VBKB1RB>'U9AU D;/\J />Z*\(_X:"OO^A;_\?;_"@_M!WH!)
M\-X Z_.W^% 'N]%>"1_M$W,V?+\/J^.NV1C_ $J3_AH*^_Z%O_Q]O\* /=Z*
M\&?]H6[C0L_AP*HZDNW^%)'^T/=2KNC\.AE]0[?X4 >]45X1_P -!7W_ $+?
M_C[?X4R3]H>ZA7=)X>5%]2[#^E 'O5%>#)^T+>2*&3PX&4]"';_"G?\ #05]
M_P!"W_X^W^% 'N]%>"2_M$W$./-\/JF>FZ1A_2I!^T'>D9'AO@_[;?X4 >[T
M5X1_PT%??]"W_P"/M_A4;_M%7$;A'\/JK'H#(V?Y4 >]T5X1_P -!7W_ $+?
M_C[?X4?\-!7W_0M_^/M_A0![O17@G_#15QYOE?\ "/KYG]WS&S_*I/\ AH*^
M_P"A;_\ 'V_PH ]WHKPC_AH*]_Z%O_Q]O\*C3]HJXD<HGA]68=0)&R/TH ][
MHKPC_AH*^_Z%O_Q]O\*0_M!WH!)\-X ZG>W^% 'O%%>"1_M$W,V?*\/J^.NV
M1CC]*D_X:"OO^A;_ /'V_P * /=Z*\&?]H6[C4L_AP*HZDNW^%)'^T/=2KNC
M\.AE]0[?X4 >]45X1_PT%??]"W_X^W^%(W[0EXJEF\.  =27;_"@#WBBO!U_
M:$O'4,OAP%3T(=O\*7_AH*^_Z%O_ ,?;_"@#W>BO!I/VA;N-"[^'0JCN7;_"
MO5/ WBH^,?#D>JM;BW+,5V Y]* .EHHHH **** "BBB@ HHHH **** "BBB@
M#-U[6K;P_H]QJ5VV(H5+&O"6^+7B[4#/JMCIB'3X6/()P0/_ -5=?\>-0>V\
M)_9E^[.-IY^M7/A_H=O'\,!;/"H$D9)R,]<T =!X"\:P>,M&6Z51',O#IZ&N
MMKY^^"-P\'C35M.4_N5DDP/H37T#0!\_?&C_ )*)HGU3^9KW^/\ U:_05X!\
M:/\ DHFB?5/YFO?X_P#5K]!0 ZBBB@ HHHH I:M8C4M*N+,G'FH5S7R7XH\%
M:IH&KS6QMY)(]QVN!U%?8-5[BQM;H?OX(W]V4$UZF6YG/!-V5TR)P4CYJ^&7
MP]NM:UA;F_M2MC$?F#CK7T-;>&-&M%58;")=HXXK2@MX;9-D,:(OHHQ4M1CL
MRJXNIS;+L$8**(DM8(UVI"@'^Z*>$0=$4?A3J*\^[+(+NT@O;62VN(U>)QAE
M(KRV^^!.C7>I/=)>SPQLV[RE48^E>LT5T8?&5\/?V4K7$XI[F3X?\/6'AS3U
MM+&((O\ $W=C6M116$YRG)RD[MC"BBBI **** "BBB@ HHHH **** "BBB@
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M&UCMX5VQH,** .>_X5_X=_Z!\?Y"K>G^$-&TNZ%S:6B1R@8# "MVB@ HHHH
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MV_V:'R1(/W?EC;T7MTKWS^Q-*_Z!EG_WX7_"N=7X=:4GC:3Q2&F^VNP8C?\
M+V[?A78T 9TVB:7Y,FW3+/.TX_<+_A7CGPX\(7=I\1]=N-1TM/L<CDQ>9$"O
MWCTR*]THH H?V)I7_0,L_P#OPO\ A6?KN@Z?)H=XD&F6GFM&0N(%SG\JWZ*
M/&O@MX3FTZ#61K.EQ R7(,7G1 \8/3(KU;^Q-*_Z!EG_ -^%_P *OT4 </\
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M\D"(+GTXKNQXP^+NT8LX\8X_T8?X5-\:#_Q<31/K'_,U[_'_ *M?H* /GO\
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MI%C<HV+8<$'![5<_X3#XO?\ /FG_ (##_"O6/ GAN\\.6U_'=NK&>Y>5=HZ
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M.M:(@^%?B;4O%7A07^J.CW&_&40*.GH*[FO+O@1_R(7_ &T_I7J-9#"BBB@
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MP,91G/W: />J*** "BBB@ HHHH **** "BBLKQ+JIT7P[?:BB;W@B+JH[D4
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MO#%H+C4[E(48X&3UK*\/?$CPYXDO/LEC>HT^,A,\F@#KZ*** "BBB@ HHHH
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MQ0MK2T^)FB1Z6BHX=0XBXYRM>L?$35YM&^&DMSDK(8TC/_ ABO&Y-/U'X?\
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M[PH [+P!J#:AX/T]W.66%5)/? %=/7$_"S_D2K/_ '!_*NVH **** "BBB@
MHHHH **** /GWXS7=O?^-M)LKF4)##]\GH!D5Z?H&L^#=3CM[*RFL)YXXU4J
MH4G(%<?XS^$E_P"*_&HU%YU6P;&X;OF'3M7%^/\ X>'X>_9-5T2XE"AAYGS$
M=Q[T >R?$N^&E^![P1?NRR[5V\8K@_@EX=L[_P $WEW>6ZR3SR.N]UR<8%3^
M*=9;7O@[;WKG+[=K'U( K<^"H ^'L?'<_P A0!P7PSE?1OBYJ^D1,1;"0@(.
MF>*^B:^<?"/_ "7O6/\ KL?Z5]&CH* %HHHH **** "BBB@ HHHH **** $/
M0U\YZY\-]5UK4-5UK59)$MH=S(CGJ!Z5]&U@^,@!X2U' _Y8M_*@#QGX *(]
M9OD7[JE@/UK7^/\ ([Z?:VV?D:0#'XBLGX!_\AW4/]YOZUJ_'Y62RM)R#L61
M2?S% ':Z#:)#\)H+<@%5L<?^.UYU^SP[!]30?=+'^E>CZ'=1S_"B&X'"-99&
M?]VO-_V>%8RZDP!QO//Y4 >_T444 %%%% !1110 4444 %5+C3+*[F6:>VC>
M1>CE1D5;K"\6>)+3PQHDM]<R*IP1&"?O&@#@_C=XGM-,\.+IB.INISCR^X'K
M6?X$L+C2_@[J$K@K]HC+J3Z5Q_AWPYJOQ2\6OK6H*ZV"OE=W0CT'YU[CXET^
M.R\!W=G;(%CBMRJ@>E 'FG[/,(:#6YS]X7('Z&L?Q,HMOCA;RQ<,X&3^5;7[
M/$JK:ZY$?O&Y!_0UB^*'$WQOMXX_F90,@?A0!]#P$FWC)ZE14E16_%M&#_=%
M2T %%%% !1110 4444 %-DC25"DBAE/4$9!IU,EECA0O(ZHH[DXH XCQ_P"(
M[#P-X9N)8K55,XV*$7'S'I7"_ S1Y;F]O/$,[?/(S8'US7K6IZ5I7BFQD@G\
MNXB(QD$'!KP[X?7,_A_XM7.AV\S&RRX"$\=Z &>, U_\9+6WE.420$ _C7H'
MQGA3_A7=PQ'S(G!_$5P'BP_8_C1;32@[6< ?K7H'QGE7_A7=RI/+)P/Q% $W
MP3D:3X?6I<DD5Z/7G'P21D^'UJ&4CZBO1Z "BBB@ HHHH **** "BBJ]_=+9
M6,UPW2-"WZ4 >3?&GQ')LM?#=DY%S=, =I['_P#57F>@Z!_PC?Q)LK!O]:A&
M_P"M6]-\7Z5=?$Z\UG76+01R'R5(SCK5+4_&VF7/Q3.MIN^R+)G.* /5?CE/
M(G@U(U/RNHR/P-:_POLUMOA=;P]04<G\2:Y?XL:E#K_PXM=5L\M;R+D''UKJ
MOAC=QW/POMYER%$;CGVS0!YO\%F,?Q#UU5^Z9Y!_X\U?1-?.OP8!?XB:ZRC(
M\^3G_@35]%4 %%%% !1110 4444 %%%% 'E/QZOEB\#&U#8:293CUZUYSX>^
M(OB/POX8M-FFR#3HF^:4J<')KZ)U:VTFZC5-32!ESP)<?UJCK.CZ5/X5O(%M
MH3;B%F4!1C(!Q0!0\+^,[7QAX5N+VWPLJQ/O3N.*\D^$*&\^(^KSRG+(<C/U
MI_P3=TO_ !);(3Y0B8!?3[U,^#L@M_B)K$<@(9C@ CWH O?&Y%A\1Z3<(,2>
M:.?SKVOP^Q?0;-F.28Q7BGQP<2>(-)A3F3S1\H_&O:O#P*Z!9 C!$0XH TZ*
M** "BBB@ HHHH **** "BBB@ HHHH X'XC_$6V\&6#1K\]XZX11VSWKYZ\':
MA<ZK\18+Z[9FEFFWDGW.:^BO$OPYLO%/B2'4;]B8H0"$!ZD8_P *\4^RPV?Q
MD6W@0)&DV% 'O0!]'>);_P#LW0+RYSAEC.T^]>!_"SPM:>/[O4]4UMFGE5R!
MGGGBO9?B,2/!UYC^X:XCX (J^'KA@H!+\GUZ4 <MX(DF\'?%VX\/12%;1Y=I
M4GITKZ-KYROO^3BYO^NZ_P EKZ+3[B_2@!U%%% !1110 4444 %%%% '%?$W
M3-8U;PP;71F83,V&V]2*XCP]\&=.B\)S/K4):^==Q9LY4U[97GWQ3\<6WA?0
M)8%D4WDZE43/(]Z //\ X,WLVE>+M2T))2UN&)4$],?_ *ZI^-)V\9_%J#0)
MY"+6'D@'@]*U?@7X>N9'O?$-VK R-\A;N#61HH#_ +0TFX9^1CS]* &_$KPA
M;^ M0T?4]#WP[Y LA7VQ_C7OGAN_&I>'[.ZW;F>,%C[UYA\?O^0-I_\ UV_J
M*[KX=_\ (F6/^X/Y4 =51110 4444 %%%% !1110 R7=Y3;/O8XKPV#X27FM
M>/;B]U_?+8.689)]\5[K6-XHGOK?0KA].0O<[3M '>@#Y[TFU7PG\:?L6ER$
M6X<C8#]>#7H7QP\1/I_AE-.CD*27GR9!P?\ /%<!\.Y[>+XF/-XF22/4W<^7
MO4A<\]:W?VA<&YT7'0RC^M $,/PKTUOA=)?JF_5/)WK*#WKJ/@;K4MUH4FG7
M$I>6W8CD\C&:ZS:J?#L!0 /LW:O-_@1_R%=4_P!]J /=Z*** "BBB@ HHHH
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M6G\%-(\42:G:7L4^-'5LRIYG4?3->Z^*] _X270I]-\[RO-&-WI6=X%\&_\
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M9XKZ*KF_!_@S3_!VF?9;- 7;F1_[QKI* "BBB@ HHHH **** "BBB@ HHHH
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MQ>\/ZIJOAXW.DRN+B Y*(2"1WKRFT^)GBF/PRWAYM*NGG.8A*8FR<\>E?3I
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M?1X&% ]!7F?PV^&<GAB:74]2F6XOICNSCE:]-H **** "BBB@ HHHH ****
M,SQ!K$&A:+<7\[ +$F0">IKY[T#P_J'Q7\83:SJ+%=,ADPNXXR/0"O5?BQX<
MUCQ/H,-CI74.2_/48KS33? GQ(T>U%M87/E1#^$'_P"O0!] :=I]IIMA'8VB
MHD4:X"KBOGQ?^)/^T 99ODC=2 S< YQ7:>!=$\>67B5)M=NS)9",@KGOQCO6
MC\2OALWB=HM1TZ00WT'0C^+_ #B@#F/C]J*/;Z-:1,K&6;)P<XZ8KU#P/:M:
M>$K&-NIC!_2O*]!^$^O:IK-O=^*+OS(K8_+&><XZ=Z]R@A2W@2&,81!A1[4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB1XOUO6ULVB8[AP"F.?RH ^C:*X#X=7GBJZDOAXBA$85_P!UCTKOZ "BBB@
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M'QIJDTUC:A;BZ<G8=G KM?AA_P DGO\ _KFW\A7-_ "*,ZM=R%%+AN&QR.E
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M LGAZ27Q!.[ZA("<[CQ6I\(M<_L_Q]<Z-93,^FR/^[W'/'%6OAIX&\'^(O#
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M==-1MID89W8_"J'Q_MX4U.S98E#':"0.W%=SJ.GVEM\&(!% B[K-7.!W('-
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MZG=-JQ(ZOT_ 5D:ZJ_\ "]X1@8\U>/RH [BZ\>^(-*^'4.JW]NL5Z9"NUE[
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M_DG5U_OC^1KG?@MI-EJG@TQ7ULDR[CPP^M '&6/V_P")?Q035%MG6RBV]1P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM<T>WU[29M/N
M@3#*/FQ65X2\%:;X0MWAT]2%8Y.37344 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!%<01W-N\,JAD<8(-8'ASP9IWAFZNIK!2@N7WNN>,UTE% !1110 4444
M%<-XC^%NA>)]46^OT=F'! 8X_G7<T4 4-(TBST2PCLK*(1PH, "K]%% !111
M0!R>H> -*U/Q3;Z_<AFN8&W(,G KJP H '04M% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gwrjt5hibe5u000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwrjt5hibe5u000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ."3(# 2(  A$! Q$!_\0
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
MGVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:
M7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH
M S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2
M\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$
M_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_
MY]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E
M/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_
M*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/
M[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[
M<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2
MCR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?
M:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?
MRH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#
M-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R
M4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_
M )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_G
MVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]
M* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\J
MTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_M
MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ
M/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/
M)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I
M?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*
MC^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W
M^W$_Y]I?RH_MQ/\ GVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3
MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
MGVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:
M7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RJ5=65D#&!P"<5=\E/2CR4]*
, '@Y /K12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gtqsgrqcdg4e000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (< [\# 2(  A$! Q$!_\0
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M$MK:D-?S&>?<Y.7(QQ[5S=QX(\-7%Q.[VMR(9F+/;K<L(]Q[[<T>UA:WD@6
MK7O8SO#UI9ZQXJ\.66KA9;6'0UEMX)3\CR%L$X/4XJ_I-N- \;>)D\*6<5Y*
M(XV^R^<$16/49YQ]*I^*8K9/[+LSH$USIUI#Y<5Q;2E;B$CT.>A%.^'<#Z1J
M^J:E'IDEG:W(5(HYI"SMCJS$^M5[2+=UYF?U2K?EMKH7?%[ZMK/@:^D\2Z!;
MV4L,L9@VSB7/S#/.!BFW'A;1M1^*-E97%E&;2+2A(L"C";B<9Q75:Q<VVNZ;
M)87MN3 Y!(5R#D'/6HU:R77EUD6S?;!;BV!+G&T'/3^M0JD>:_\ 6S1J\%7Y
M;6_JZ//;:SU"]\;>((;?0;#58[63R(DO+G9Y,8Z!5(/'O63?C5;;PNFDF:T>
M"35U3[+%>;HT!Y\MG[#->@ZYH&C:]J+:A+;SV]VXVO+;3M&7'^UCK4RZ)H"^
M''T$:6ILG.XY<[B_][=US[T*I&W]=P^I5[[?U8YV'2]3LO&FA7+Z7I.A'<8R
MEO>@FX3'3;@9QZU[)7FNB^'-%T34DU".&YN;F,;8GNIVD\L=\9Z5UG_"0G_G
M@/;FJ]M"UKD_4:]]C>HK!_X2$]H![<T?\)"?^> ]N:/;0']1K]C>HK!_X2$_
M\\!^='_"0G_G@/SH]M /J-?L;U%<-\/_ !;?^)[S6TO!&$M+KRX0JXPOOZUW
M-:)W.1IIV84444Q!1110 4444 %%%% !1110 5G:[I$>NZ-<:;-(T<<X +J.
M1@@_TK1HI-7 P-=\*6FNZ5;6<DTL,MJ0T%Q']Y&'>J6D>!X['56U/4-2N-3N
M_*,2-.  BD8( ]ZZRB@#@E^&%L)5@.KWATE)_/73SC8#G.,^F>U:.M^!XM3U
M)-1L-1N-,NQ%Y+/  =Z>A%=911;2P[F1X=\/VOAO2Q96S/)EB\DK_>D8]2:\
MF^)'_):O#'T3^9KW"O#_ (D?\EJ\,?1/YFAB1[@.E<9XKE\<IJ2#PW;64EGL
M^9IGPVZNS'2B@#XF\72:Q)XFO3KF\7WF'S W0?3VKT[X6W'Q"_X1V1=#AAEL
M1)\IN6QC_=SVKVS6/!7AS7[I;G4])@N)U_C8$$_7'6M>RL;73K1+6S@2"",8
M6-!@"E88S2S>MI=L=15%O#&/.5#E0W?%97C;1AKWA#4;''SM$6C/HPY%=!2$
M @@C(/6J$>(3:P_C'PAX3\,;R;B[N!'>J#RJ1'+9_(5+J7Q U&75M;AL]2>P
M32I3;VEK%:&03E.NXCIGI7;>'_AKIGA[Q9=Z_!<S223[]D+@;8MQY*U)/X$:
M+6+S4-&UZ^TG[<_F74,*(ZR-W8;@=I/M2 XF]O-3\0^,_"-W XT^]N;%F=GC
MR8_7@]Z2^\8:TO@778[J:*>]TO5(K83M$")%9QR5/&>M>B/X0@?Q#IFL/>W#
MS6$)B4/@^9GN3ZUE77PSLKK3M8LVOYU74[R.[=@HRA4@@#VXH HKJ^O>)?&-
M]HNFZDNFV^F01,[B(.TKN,XQV%8YU6;P]X]\5ZE/MGGM=+C=L# 9A787_@-)
M=;.KZ7J]YI=Y+$L5PT"HPF4<#(8'!]Q4D7@.P_M74+VYN9[H7]JMK-')CD#O
MD=Z .!T3Q_K,FH:'/_:$NH?VC.L=W9BS9$MU?H5?OCO7M-<CHW@N[T:2WA3Q
M-J4NFVQ_<V3+&  .BEPNX@>F:ZZA %%%%, HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N%^*W_ "*</_7[!_Z&*[JN
M%^*W_(IP_P#7[!_Z&*3 [E?NCZ4M(OW1]*6F 4444 %%%% !1110 4444 %%
M%% !1110 5Y?JGAN]@^)]QKS[/LDUN$7!^;/TKU"O'M0O[M_C1>6C7$AMTM
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M.<YS7?5PE6%!2:T7ZV/(P^88>IBY0B]79?=>YT?^>:/\\_YZT?YYI/\ //\
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MI4TC^?H1B,1+F]C1UG^"\W_D,L--N_$5VNIZL"EL#F"W/IV)KKE544*H"JO
M'I2@ # & /TH;.TXX/;/:HJUG4?9+9=C3#X>-%=V]WU9B>*?^0;%U_X^(_\
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M2?U_6C]?Z^] "_\ Z_\ Z])1_P#K_P#KTO\ G_Z] "?_ *__ *]'_P"NC_\
M7_\ 7I?_ -?_ ->@"M?S/;6$\T?WT0L*\LE\7:E+?0W;&/S(00OR\<UZAJ:&
M32[E%ZF,XY]NM>/6FE7E].L4$6YG)VG/!QUKV<KA2<92J6/F<^J8B-2G&DWK
MV[W5CNO#%B=:;^VM1D\Z7<0B'HF/:NRZ>V/TK$\*:?<Z9HB6]TH20,3CK@5N
M?IC]*\_%SYJKL]%MZ'L9?2]GAXN2]YZOO?S#],?I2=/;'Z4OZ8_2D(XP?_U5
MS':1?:8 ?]:@Q[]*<DT;G".I(]#G%8VKZ=:Q6RND(5C*H)!]36I;V-M;-OAB
M",1@GTK*,IN7*TCGA4JNHX-+3S+/^?I24OZ8_2C].WT]JU.DS?A1JM]J%SX@
MBNIWDC@NRL:L?NCT%>EUPWPZ\/V^C'5KB'4([EKJY+LB8S$?[IYZUW-=\/A/
MEZM_:._<****HS"BBB@ HHHH .@R:X/5?B*[7TFG>&M*FU6[C)5W Q$A^O>M
MKQ5XEDT)+6WM+![_ %"\8I!;H<9QU)/85Q^G>,-?NIKBQT+PC';3VF3>+*P0
M!O0'O4WNQEA+SXJRQ^;]BTJ+//E,3FG6WQ"UK1I$B\7:!+:H3C[5;?.@]SZ5
MUWA;7O\ A(M$2^:W:VF#M%-"W5'7J*UY88IXVCFC61&&"K#(-,6XRUNH;VUC
MN;=Q)#*H9&'<5Q7Q!\:7_A^ VNE6,TMR55Y+@K^[A4MC)]37;P016T*PP1K'
M&@PJJ, 5S7Q$ _X074SCG8O/_ A2EL.)L/J<-GH0U&]D"(L(D=C]*X_P;XVO
MM:_X2"]U"(Q6MF0\$17!"8)S^.*D\4Z+KFMZ7HL6F+!):Q;9+B&5]OF8 P/I
M7/>'X_$%WK7BVSFL;:-9(=DGEOG:VPA0OK2DWS/Y@OA7R+?_  DOB]-!C\8/
M-;?V7(X?[#Y?S"$M@'=USBM2\U_7?$'B&32O#MQ#9QV\"S2SRQAR2PR% KG#
MXFTYOA#;Z(DRMJIC6Q^QY_>"0'!XK1T2^MO"GCB^CUF9;1;FSB:*24X5MJX(
MSZU5E=KIT#6U^IU'A#Q)-JNFW2:J8HKVQN#;SL#M5F'0C/K7FOQ#FBF^-'AD
MQ2I( $R58'N:UM/\*CQ[HNLR?:IK.UNM3\Z"6,8+JHQGZ&N#U#P:O@SXK^'K
M-+Z6[$CJ^^7J.3Q2ULKAHGH?3(Z44#I7,^(/&EEX>O%M9[>YD=DW9C0D5<8N
M3M$B4XP5Y'345\S7?B?6)+V=X]2NE1G)5=YX&:[#P-X].EV]RNJ->7;.P*D
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MSX.\>7&@>';V>[TZ]N[.+4)%GO-V5C!;CJ<D#VHN![5145O/'=6T5Q$VZ.5
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M(.#K4 )Z=:5T!U=%9.C^)M'U]I%TR^CN&CY8+VK3FF2W@DFD8*D:EF)[ 47
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MMJ:Q;:U0?T_2C]/Z4G^>.WTH_P \?TIE&;K?_'G'QTE3\.:TAT'].U9NM_\
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M/PETJ9[._P#$]ZI^UZM,74MU$>>*])KS?X)ZK>:EX"A6[!Q;N8HV(ZK7I%"
MSM4U&RM;6>.>[AB<Q-A7< ]*XWX6ZII\?A%8GO;=9#<RX4R '[U-^(]E&DT-
M])I\%PC+L9G!RM<+I,=M#-%#:Z-;RR!]R@*2<YKAJXZG2J\DKW,Y58Q=F>\7
M=[;6,#3W,RQQ@9RQKDIM:U7Q)*UMHD;6]KT>[<=1[4^S\-7VL3K>^(9BP'*6
MJ'Y5^M=;#!%;Q+%"BHBC 515VJU]_=C^+_R'K+R1D:)X8LM''F >?=-]^>3E
MC6W1173"G&FN6*LBDDE9&#H__(P:O_O+_*MZL'1_^0_J_P#O+_*MZL\/\'S?
MYBCL%<_XP_Y \?\ U\Q?^A"MV4.T3"-@KD<$CH:YN_T'6=1@$,^IQ% X<8C[
M@Y%+$<S@XQ5[A.]K(Z<=**R;*TU>*Y5KJ^BEB Y54P36M6L).2U5AIA1115C
M"BBB@ HHHH **** "BBB@ HHHH *\WU:VT%?B)-/#.YU@VX$L9^Z%]:](KQ:
M]!_X7G?'''V,<]JSJ_"SIPCM6B=A_GG^M)_GG^M+_GG^M)_GFN(^C%_SS_6D
M_P \_P!:7_/-'^>?ZT '^>:/\\_YZT?YYH_SS0(RO$.I?V9I$LH_UK#9&/4G
M^M5O#NFG3]#)D_U\RF20GU-9U]G7O%D5FO-K9?-)[M6W>Z0UW+N6]GA7&-B'
MBNUI4Z:IMV;U?Z(\R+E6K2K15U'W5^K_ $(?"O\ R (?]]__ $(_K6U_G_/O
M6#:>&_L818M0N1&C;MF>/I6[V_S_ )S6%=Q<W*+O<ZL(IQI*$U:R2#_/^?>L
MR[_Y#ME_N-T_SUK3_P _Y]ZS+K_D.V7^X_2N6K\*]5^96(^%>J_,U/\ /%)_
MGC^E+1_GC^E:'0)_GC^E!&01Z^G]*/\ /']*R]3U86Q%O;CS+E^ J]JF<U!7
M9G5JQIQYI&4\6GV=Y-!?1F0LX9"#DX-:&BVR>=/=QJ4B<[8U'H.]9MYI,L=J
MMU/*3<R2 'T /85T\$2P0)$@^51@8KDHTVYZJUOOU/-PE&3JWE&R6J[Z[7)?
M\\4G^>/\]*7_ #Q2?YX_STKM/5%^'=OH4)U9M)F:2=[DFZ!Z*WH/:NYKRCX.
M#_3O$W'_ "^G^5>KUWQV/F*KO-^H44451F%%%% !1110 5S7CO7+G0/"UQ=V
M04W3$1Q%N@8G -=+6/XGT.W\1:!<Z=<OY:2+D2 XV$=#4RO;0<=SS'1-#URQ
M\?6^GZEXBN[F;4M*EDD.XA8F/ VC/:NG^'5_JL%[K'AK5[O[9+I<@6.Y/5T/
M3/O7G[Z?XUT[Q';7=OX@TBY>UMS:Q7$DR@A">X]17I7P\\/PZ-:7EQ)JD6I:
ME=R>9=3HX;GTIQWN*3Z?UYG:T444P"BB@$'H<T %%)D9QGFE) ZG% !7A_Q(
M_P"2U>&/HG\S7N%>'_$C_DM7ACZ)_,TF![@.E8>L>&TU>Z6=K^[@(7;MB? K
M<'2BIG3C-6DA-)Z,\RUOPQ-HUQ&UK<WTT=Q\N48YW]L^U;-IX!1+9-VJ7J2,
M,N$? S79D ]0#2URQP%)2;MI^1"I1N0VEN+2TBMP[R"-0NYSDGZUS_CW0;GQ
M)X2NK"S91<DAXP_1BIS@UTU%=B22L:'&:6FJ>(](72=;T6\TF&*)%::*\"L[
MKC[I0YQQWQ6=XH\(7*1^&[;28[J[AL]2$\SSW'F,J]R68Y(KT2BBP'D4/@'5
MU^*;RF,_\(VLYOD^9=OFD=,9S574/!OB";P!XMT]--=KJ\U59[>+>F9(PZ'(
MYQT!ZU[/118#C_![M%(+?_A#'T4B(![C; !(1V.PDG\:SO#&DZOHFL>++^33
MG<7$OF6JAU_?<=N>/QKT&B@#QGPGX.\2>'/&-GXBFL!*VK^=_:,*%!]C+,"N
M.>??&:27P-KTG@?5$BLWAU>+5'O+(;ERPSV.<#/O7L]%%@/'U\#ZS;^'/"\?
MV1I;Y-42]OSN7*DG+$\\X]JM-I'B7PYJ?BNWL=$;4[;7)&E@N$G11$77!#AB
M#@9[9KU:BBP'D5MX+UWPG=>&]4LK,:H]C;-!<V\;JK?,<Y4M@<5)XL\):MX[
MU[0YK_2I;.S\F=+C$RLT.1\I.#R<]AD5ZS118#D_A\FN6?AQ=,UZT\FXL6,$
M<JLI6:,?=88/''K6/XIT[7HOB)IFO:9I)OK:UM7651*J$D]ER>OZ5Z)10!XI
M+X/\477AS4X38-!/XBU1'NHUE4FUMP<DDYP2?09K4USP!J^E:EH6L:3J&H:K
M<6$RH8;AXP%B/!Q@+7J]%%@/'6TKQ;I\GBV.W\.M<Q:S(5A<3HI3*XW,">GZ
M^U>C>$M$?0/".G:1.X>2W@"2$=">I_G6Y118#S:_^%NF7'C>SOXM+M_[+6%A
M<(9&RTA/!QFNRUG3=WA2]TZPAZVKQ0Q@_P"R0!S6O10!Y=\/K.\T73=+TV\\
M"R6]Y$ACEU'%OQU.20V[VJ_X.\/:GIOAKQ!;7=F8I[JXF>)2RDN#G!X/\Z]"
MHHL!XW9>$?$6E:=X/U:+33<7>CO,)[#S5#,DG&5.<9 ]ZU;/PMK6KW7BS6KV
MR%A/JUNL%O:/(&90JX!8CC)KT^BBP'D-QH?B&_\ AA9Z(VASPWEE<1 JTL9$
MBALEAANGUK>TO0-4@\?>(]0EM&6UNM.BAADW+AW .1US7H%%%@/&M'\'Z_;:
M3X0AETYUDL;V22X7>O[M23@]>?PH;1O%UA;>+K"W\/FXBUJ9TAF$Z+Y888W,
M">F#VYXKV6BBP&1X6TA]!\+:;I4CAY+6W6-F'0D#FM>BBF 4444 4]1O);*W
M$D-G+=,3C9'C/ZUBGQ7<"[6U.AWGGLN\)E<X]>M=-7/R_P#(\V__ %YO_P"A
M"N:MSIIQE:[2Z$ROT9HZ;?SWR.TUC-:%3@"7'/Y5?HHK>*:5F[E(Q=9TG3_[
M+O9OL4'F>6S;M@SGUINB:3IYTFSE-E 9/+!W%!G-4/$GC+P_8VU]87.I11W2
MQE3&<Y!(IGAKQGX>O+2QL;?4X9+ED"B,9R36'LX^VVZ?J39<QUU%%%=)04A^
MZ?I2TA^Z?I0!POPM_P"0/JO_ &$[C_T*N[KA/A;_ ,@?5?\ L)W'_H5:OC7Q
M?:^$=&:XD_>7<GRV\ ^\[=JE; 9GQ"\;-X?M8]+TI/M.O7Q\NW@7DIG^(UYE
M>?":QL-3\-0ZK--->:G.WVPJV!G&<"N]\!>#+II;CQ5XA8R:W?J=F?\ EW0]
M /0UP?C'4-9L_%>EP7-Y*TMM<-Y;$]..HKGKUU2:NMR93Y3WC2=)LM$TV&PT
M^!8;>(855JKJWB73='7;--OF/W88_F8_A7&Z&OBW5[0QFZ>&WD.3-)]['M75
MZ3X3T[2V\XH;BZ/6:7DU$*]6M%.G&WFR5*4EHCG[V'7_ !=;.)(%L-/ W*KC
M+O4_P^T-+2SFOI5!F=RBDCH!7:3?ZA_]TUC^%/\ D"#_ *ZO_.I6&C&O&4G=
MV8N1*2;-NBBBN\U"BBB@#!T?_D/ZO_O+_*MZL'1_^0_J_P#O+_*MZL,/\'S?
MYDQV"BBBMR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\WU;7;&;XAS
M:0FG(EW%;AVN\#+#T->D5Y!J&FWD?QDO+]K=Q:O:@+*1\I-9U?A9TX-M5HV.
ME_SS_6C_ #S_ %H_S]*7_/-<1]&'^>?ZU%<.\4#O'&9'4<)G&?:I?\_2C]/K
M0A/5'.2^(K^">.&31Y!)*<(#(.:GN-;GM-(NKN[LS;-&,(&8'<3THU?_ )#F
ME?[YK-UPG7/$5KHZ']Q"?-G_ ,#7?"%.?+[ME:[WZ'DU:M:FII3;=[):;M>G
M0N^$=.>TTPW,^3<W3>8Y/;/05T'^?\^](JA5"J, # 'I[4%E!Y8#ZFN.K4=2
M;F^IZ-"E&C25-=!W^?\ /O1_G_/O3=Z9^\/S_P \TZH-;A_G_/O67=?\AVR_
MW'Z?YZUJ5EW7_(=LO]QNE9U?A7JOS,,1\*]5^9J?YXH_SQ_2D) &2>*P[[4I
MKR<V.F\L>'E'1:<ZB@M2JU:-)7>_1=R34M5?S?L5@OFW+<,R]$J?3-*2R7S)
M#YMP_+.?Z5)IVF0Z?%A?FD;[[GJQJ]_GBLX4VWSSW_(RIT92E[6MOT71?\'S
M,S6_^/./I_KD_GVK2'W1_3^E9NM_\><?_75/YUI#[H_I5Q_B2^7ZEP_C2]%^
MHO\ GBC_ #Q_GI125H= [X=ZY8ZM_:T%KIZ6KVUR4D=0/WI]37<5YC\)M.O+
M*Z\0RW,#QI+>$QLPP&'M7IU=\/A/EZK;J._<****HS"BBB@ HHHH *XWXH"\
M/@:\^QO(AX\QH_O!,\_I795Q?Q3-T/ =[]FD:,' E93SLSS^E1/X2H?$<UHW
MP^^'=YI-M<)<K/O0,SM<\DD<YKMO"GAS0/#\=PNAE2LI!DQ)NYKAM$^&OPYO
M=)MIX+DR!XP687I7G'.1GBNX\)^%]!\-1W":&Q992#)F<R?UXK3JS-:I'25Y
MY\3KKQ-'ITJZ6L=OIL2*]Q<E_G;Y@-JBO0ZYOQ[!-<^"M1A@B>65E7:B#)/S
M"HEL6C'\6WU\VFZ!I5I<O ^IR+').I^8* "<>]9Q:[\"^)_L4-Y<7=A<V4LR
MK</N*2(,\'WK1\765]'IF@:M:6LEQ)IDBR20(/F92,' ]16;_I?COQ1]KAL;
MJST^VLI80]U'L9Y'7' ]!1+K;?4([*YF?8-4C\$0^-QJ]VVJ-MNFBW_NMA/W
M-OIBM0"Z\=>*[BSGOKBTL;.VC<1V[[2SL,Y)]JR?[3U5_ \/@E=$OEU5<6C2
MF+]R$!^_NZ8Q6J'NO OBRXNY]/NKRQO+6-1):Q[RKJ,8(]Z?NW?;I_7]:AK;
MSZ_U_6A/H/C.'PWHNH1>([UBFGWIM4G<99P1E<_A7GOB7Q3I7BKXO>'+K2;C
MSH8RB,V,<Y->D>%_"T.N:1J-SXDTM634;PW,=M..8P!A<^^*\^\7^']*\/\
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MP*]"K@/AKX;O-#?6;FYDB9+RY,D6P]O>N_KOA\*/EZM_:._<****HS"BBB@
MHHHH *Y_QK'92^%[I-0M)[NV(&^&#.YORKH*SM;UFTT'2Y=0OBPMX_O;5W'\
MJF5K:C6YX8+3P5!&2/"NN(@Y."P%=]\*;KP]=VVH/X?LKNWC5PLIN&)R?;-#
M?&3P?M/S7#<=/LYY_2H/A7-)J6I^(=8M[*6STJ\N UM&Z[<GN0*J.[$]CTVB
MBB@ I  .@Q2T4 )@9S@9H(!ZC-+10 5X?\2/^2U>&/HG\S7N%>'_ !(_Y+5X
M8^B?S-)@>X#I10.E%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K E_Y
M'FW_ .O-_P#T(5OU@2_\CS;_ /7F_P#Z$*PK[1]43(WZ***W*,+QK_R)6L?]
M>K_RJ/P+_P B1I/_ %[K_*G^-?\ D2M8_P"O5_Y5'X&('@?222 !;+D_A4_:
M Z*H+N\MK"W:XNIDAB099W. *X?Q+\4M.TRZ_LO1H7U?5F.U8+;Y@I]R*Q[/
MP'XC\8W"ZAXVOVBMB=R:9;M@ >C&G<";5/B7?ZW=-I?@BP:]FSM:\=<1I[U7
M3X.#6[::Z\5ZI<7FI3+\K(WRPGV%>F:7I&GZ+:+:Z=:16\*C 5%Q67XF\2MX
M=2%VLVFBER-X;&#6=2I&G'GGL)M)79YE\)/AQI45U<ZU<,\\]G=R00JWW1M.
M-WUKNM:O)O$>J#0]/<BV0_Z5*O8>E<#X,\5W3Z3?:986Q%S=W\K+)N^Z&:O7
M= T6+1=/6)?FF?YI9#U9JYG/ZQ+V<-EO_D0WSNR+MC90Z?9QVMN@6.,8 %<9
MXV_Y'+PA_P!?;?\ H-=M=)-):RI;R+',RD([#(4]CBO+=?\ #?BV;7=$DN->
MM'FCG8PL(" IQW]:ZI.,(^1>B1ZO16-H-GK=HDHUG48+QF/R&*(IMK9JQC)O
M]3)_NFL?PK_R!!_UU?\ G6Q-_J)/]TUC^%?^0(/^NK_SK&7\:/H_T)?Q&W11
M16Y05G:C?W5HZK;Z?)<@CDH<8K1HJ9)M63L#.0LKK5K74KVY;1IBMP00 PXQ
M746<\MQ:K)- T#GK&W45/16=*DZ?VKDJ-@HHHK8H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "O'+^ZN&^-E[ TSF%;0$(3P/PKV.O-]6TS1X_B'-J$5
M\&U1[<+);Y'R+ZXK.K\)TX17K1+_ .F/TI/TQ^E'Z8_2C],?I7$?1A^F/TK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P (ZB?#:#Q='<7!UTJMZUSYK<DG)7'3;CC%:EG9Q^.?&5W'K+226EI:1>7
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MKU7YFG2_KG]:2C_/-:'0'ZY_6@YP<<D],]Z/\\T?YYH Q;V'5KR,1F* *'#
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M@>X#I10.E%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU KAA5G4DXQZ_A_P3R*=>I6FX4[*^K?;I]Y-I>E?9B;BY/F73\ECV]A6F_\
MJV^AIW^?\^U-?_5M]#_GZ5UP@H1LCTZ=*-*'+$S]"_Y!4?\ O-_/^5:/^?\
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M3V\@RKH<@UXQ\2/^2U>&/HG\S0P1[@.E% Z44P"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*I9B !R
M2: %HJE_:^G?\_UO_P!_!3XM2LIY!'%=PNYZ*K@DU'/'N*Z+5%%%6,*\U\>^
M+_$GAZZE@@TVVEL9(SLE9CD\<UZ43@9->;^.[]?$-I<:9ID'VEH$9Y)AT3 Z
M9KFQ51PAIN]O,B;LM#C_  QK?B'QG)I&G-8PC38FWR8;JH/)->Y2RP65JTDC
M)%#$N22<!0*\^^$VG0:-X$AU2[=(_-1F9V. J GO6'>ZAJ?Q:UAM-TII+;PO
M;OBXNAP;@CL/:EAZ;@FY+5_ET""MN.U/4]4^*NL/H^C/):^'H'Q=773SO8>U
M0#X<^&;3XLZ=IB:>K6HTYIS&QR&=3@$UZSH^CV6A:;#86$*Q01+@ #K[FN1N
M?^2X6'_8(D_]"%=#+.[CC2&-8XU"HHPJ@< 4ZBBJ HZS_P @6]_ZXM_*FZ'_
M ,@2S_ZY"G:S_P @6]_ZXM_*FZ'_ ,@2S_ZY"L/^7WR_4G[1H4445N4%':BL
MJ^.N?:#]A6S,../-)S43ERJ]KB;L5O"G_'A=_P#7W+_Z$:WJY33M/\2:;#)'
M']@822-(=Q/4G-=1#YODIYVWS,?-MZ9K+#-\BBTU84-K#Z***Z"@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH K7>H6ECM^TSK%N^[N[U5_X2'23TOHOS
MJ[/:V]SCSX4DV]-RYQ7.Z!I]F]YJP>VB(6Z(7*C@8%<]25132C;4EMW.F1UD
M170Y5AD$=Z=2*H50J@ #H!2UN4%5[VRAU"V:WG#&-NNUL&K%5-1:^6S8Z<D3
MW'\(E.%HY5+1B>QRS^'; >*8[(>=Y!M?,*^8?O;L5U=C8PZ?;""W#",'(W-F
MN#DO?% \;Q0&WL?M1LR0-YV[=W\\UW.FM?M: ZBD27&>1$<BLZ>%5*\K+7\C
M*G*+;LBY6-XM_P"13U3_ *]VK9KR;XB>-]1L-2O="BA@-M)$%+$'=R*ZJ%.5
M2:40KU(TX-R.^TJ\@T_PE9W-S((XH[=2S$^U<C:VUW\0]86]O%>+0;5_W4)X
M\X^I]JY;P_J=]XXU&PT&^D6*PMTRR1<;POK7MMM;0VEM';P1A(HUVJH'05M4
M7L&_YG^!C3?MTOY5^)5OK^RT*P66<^5;KA%"KG'X"O*-0US2Y?B!/J2SOY1@
M"@[#G->IZ[J"Z9IK7+6WV@!@-F!W[UY1J&IH?'D[/:(DZP!FM^.%QUSTKSJN
M)ITTXR3;Z^GW'5#F5:+3M9]KG56EU%>VZSP$F-NAQBI6947<Q  [YK!'B))(
M42SMF>=OX%'"TJZ9?ZBV_4)C''VBC-><Z\9/]TK_ -=SZ%8OF25)<S\M$3W6
MO1(_DVJ-<3>B=!5<:?J.IMOOIC%#VB2M>UL;>S3;#&%]2.IJQ_GC^E+V4I_Q
M'\EL/ZO.IK6E\EM_P3G+K2(+>_M(X1MCD.''][%=& %  & !@8_STK-O_P#D
M)6/^\>E:?^>/\]*=*$8RE9#P].$)SY5;7] _S_GVIK_ZMOH?\_2E_P _Y]J1
M_P#5M]#_ )^E;'4]C/T+_D%1_P"\W\_Y5I?Y_P ^U9NA?\@J/_>;^?\ *M+_
M #_GVK.E_#CZ&.&_@P]$)_G_ #[4O^?\^U)_G_/M2_Y_S[5H;B?YYI?\\TG^
M>:7_ #S_ %H 3_//]:7_ #S1_GG^M)_GG^M "_YY_K1_GG^M)_GG^M'^>?ZT
M '^>:7_//^>M)_GFE_SS_GK0(/AUHEGI7]K3VU\MR]S<EY$!YC/H:[FO*/@X
M3]O\3<G_ (_3U^E>KUWQV/F*OQOU"BBBJ,PHHHH **** "LKQ)J.F:5H5U=:
MN%:R5,2*5SN'IBM6N-^*,%O-X%O6N)A$(L2*6Z$@\#\:F;M$J.K/&9(?!UY.
M]Q:>&_$Z6LC9$4#$1GZ#TKV/X<:CI=SI4MII.@W6DP6Q V7"8+D]\]ZY?1OB
M_9C2;9;CP]?)(L84^7!E3@=17<>$O%MMXIBN'M[&XM1"0#YT>W=GTJDK72(>
MMF=+1110,\X^*TUR)?#MO;VRW?G7G_'N[85R!QGV%9US=WECKUQ'K6D6=OJC
MZ=,;2]LF(7:%)*D>HKMO%WAI_$-G;FVN/L]]:2^=;RXR WO[5E:=X2U:]US^
MU?$UY#.\<#00Q0+A0&&&)]ZBSU7];%:;G/MI-E_PHJWE$,:S"V2Y$N!N\W.=
MV?7-6_"$4>I>.M4N+U!/)'9PHAD&=H*C.,^M*/ /B Z?'X>?5X3X?CFW!=G[
MTQ@Y"9]*U-3\):K:ZY_:WAJ]AMI9(!!-',N58 8!^M7?WG+H^G]?<*VENQRM
MOXENO!.F^('T[36OXX]6V1VZ9P@89.,=JX2[\6WGB[XJ^'[N]TI].>-U01MG
MD9//(KWOPGX:_P"$?TN2*YE%S=W,IGN)2.&<^E>7_$957XT^& J@#"=![FIL
MTD@O=W/<1THH'2BJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)D8QZ=*WZ*R^KT[WM^+)Y4%%%%;E!1110 4444 %%%% !1110 4444 %%%%
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M"[E0 FJ?BH :(0!@"1,#\:VH_P#5K]!4T**IU9=79?J*,;-CJ***[#0****
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MSW =**!THJA!1110 4444 %%%% !1110 4444 %%%% !1110 444A( R3@4
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MG3A+>VC<V_\ /-+_ )YI/\\_UH_SS_6N(^B%_P \T?YYH_SS_6C_ #S_ %H
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MD,EG'+#)A7D8Y'TKM?&GBZW\0SPW%FMW:W"C;(K."N/:N6LIWBNHPUS*D+2
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M&F:A">5(/7\JZ:,</*-Z+2\F<];#5L')TZD6_-;,Z;Q3;ZI<640TN\6U</\
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M1L"97!;.2<D5ZQ7S)X6AU&X\0VL>E2I%>$_NW;H*]4/AWX@3IB77[=/]P?\
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M11A5& *PO"?_ !X7?_7W+_Z$:WZO#RE*DG-W?F*E3C".B&R2)$A>1PBCJ2<
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M"?Y_S[TO^?\ /O2?Y_S[TO\ G_/O0,3_ #_GWI?\_P"?>C_/^?>C_/\ GWH
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M+_/-(9$ )+J .IS7-W'BMQ<M);6OG:?$VR:<'G/^S]*&["2;V.FP.P'X4O\
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M=%\)ZUJ5M]M2[-N).A8D%Q5&\T_5;3Q/;Z,VH,TLV,2!S@5[3,+"S55GN8X
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MZ:ER-3%DLGS+&Q;)'KCM7L=YH.EZE?6]]=6<4UQ!S'(PY%3W6IV%BZ)=7EO
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MPSK%TMK9:K \[_=0G!/YTEJ#TW.DHHHI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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0BG;11M% #:*=M%&T4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gtqsgrqcdg4e000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtqsgrqcdg4e000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -R!N\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%<3\6/\ DG]W_P!=8O\ T,4X*\DF*HW&#:.3_P"%VR_] J/_ +[-'_"[9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JKJ(+:;<JH))C; 'TJU10#/F/PQ87B^*K'=:
M3C$ZYS&>.:^G*B6UMU?>L$0?^\$&:EK2I4YV84*/LDU<*XCXJVD]YX*E2WB>
M5Q*AVHI)QGTKMZ0@,,$ CT-1%V=S6<>:+CW/F'1;KQ%X?N'GT^UNHY'7:3Y+
M=*T;S7O&VL(UO*=1:-^&C6)P#^E?17D0_P#/*/\ [Y%*L4:'*HJGV&*W==-W
ML<BPC2MS:'A_A#X5W]Y=17>L((;12#Y9.6?V]J[?XG7,NG>#?L-E#(PG(AQ&
MI.%Q[?2N\IDD4<R[98T<>C*#4.JW)-FT:$8P<8]3QGX/Z#-_:]QJ5S Z+$F(
MRZ$9)R#U]J]HVCT'Y4V.*.)=L<:HOHHQ3ZF<^=W+I4U3CRGFGQ?T)[[1[:^M
MXB\MN^'VKD[>?ZFL/X.75W:ZK=6$T$RPRIN4LA !&2:]E=%D4JZAE/4$9!ID
M=M!"<Q01H3W5 *I5/<Y69NA^]]HF<!\1/A_)XB<:CIQ47J+AD/'F#ZUY+9R^
M)?"UU)]FCO+5LX?$; -_C7T]44MO!.,2PQR?[Z@TX5FE9ZBJ892ES1=F?.\W
MB[QGK,?V9);ME?@B%&Y^M>O?#K1[[1_#2QWXVS2,7*DY(ZUU$5G:VYS#;0Q_
M[D8'\JGI3J*2LE8=*@X2YI.["O /BY8&U\7FX"XCGC4K[D#G^=>_UYW\6]".
MH^'EU")<RVAR?]T]?Y4496F&*AS4W8W?A_?K?^#+"3=ET0JX].37COQ!:_UK
MQO=!+:=EC<01_NS@@'C^==9\%M5RE]I;MT_>J#Z<"O6#:VYD\PP1%\YW%!G\
MZKF]G-D*/MZ25S+\+:2FC^&[*T"@$1AF&.C$9/ZUK21))&R,HPP(/%/HK%N[
MN=222L?,_BK1+O1_%EW'!;R[%E+Q%4) &>*]_P##M[)J/A>UN)(V20P[2K @
MY Q6I):V\S;I8(G;U9 34BJJ*%50JCH ,"M)U.9)&%*A[.3:>Y\PM87G_"6+
M_HD__'VI_P!6?[PKZ<C&(E!]*9]EM_,\S[/%OZ[M@S^=34JE3GL.C1]G?7<Y
MCXA123>!]32)&=C%PJC)/(KROX36ES%XQ1Y+>5%$;99D('0U[TRAE*L 0>H(
MJ..V@A.8H8T)[J@%$:EHN(3H\U13OL2T445F;G#_ !)UK6=&T^S;1DD+R.P<
MHA8@#&.E>.ZYJ/B7Q"8CJ-M=2>4,+^X;BOIAD5QAE#?49IOD0_\ /*/_ +Y%
M:PJJ*V.:K0=1_%H?-NB:QXI\/6[P:=;W4<;MN8>0W6O<_!U_J&K>%HKC4D*W
M394AE*G\C6_Y$/\ SRC_ .^13PH484 #T HG44N@Z5%TW\5T?+M[IVJVFO7,
ML=C<ATN'92(6/<^U=!_PF_CDIM"W8XQQ ]?0!AB8Y,:$^I44GD0_\\D_[Y%6
MZZ>Z,UA6MI'SQH_@CQ#XKU+[1=QRQH[9EFG!!_(\FO>[&PCT70TL[5?EMXB$
M'OU_G6ATHK.=1S-J5"-/;<^?[[QGXUG:XA,5R(WRI40/T/%<K:6^L6-_%>P6
M5TL\3[U;R6X/Y5]3>1">L2?]\BCR(?\ GE'_ -\BM%72V1A+".3NY'D_@3Q5
MXIU'Q'%:ZE'-]F<'<7B8 <>IKURF+%&ARL:J?4"GUC.2D[I6.FG!P5F[A7&_
M$^&6?P/=I%&\C97Y57)^\*[*D95=2KJ&4]01D4HNSN5./-%Q/'_@Q;3PW.H-
M+!)&I"X+(1GK7K&HV46I:?/9SJ&CF0JP-31PQ0@B*)$!Z[5 I]5.?-+F)I4^
M2'*?+WB#POJ&AZO/:-;3.BM\DBH2&'UKUOX/6L]MX=N3/#)%OE!7>I&>OK7H
M4D$,W^MBC?']Y0:<B+&H5%"J.@ P*N=9RC8QIX94Y\R9XE\8[2XE\1V;QP2N
MOV?&Y4)'WC7>?"Z*2'P3 LL;HWF,<,N#VKKY((9L>;#')CIN4&G(BQJ%10JC
MH ,"I=2\%$N-'EJ.=]SS7XO>'GO],@U.WB9YK<[&55R=IYS^E8OP>O[RTU"Y
MTV>"=8)1O7*$ -W/Y"O96574JZAE/4$9%1QVT$)S%#&A/=4 IJI[G*Q.A^\]
MHF<CX^\$KXJL5>V*I?0_<8]&'H:\76S\3>$=19H8KJWE7@O&I*G\1Q7TW3)(
M8IEVRQHX]&4&B%5Q5GJ@JX=3?,G9GSO/\0O%MW:M:M,^'!4E4.X@U'X)\.ZO
M>>*;"Y%G,L44ZR222(5&,\]>M?0@TO3E.186H/J(5_PJRB)&NU%55'91@5?M
MDE:*,UA6VG*5[&5XFN[O3_#-[<V*EKF*/,8"Y).1VKPC4_$OB_5[%[.\ANGA
M?&Y?(?M7T:0",$9'O3/(A_YY1_\ ?(K.$U'H:U:+J;.Q\P:/)KVA7WVRPM+J
M.;:5SY+=#7L'PUU_7M8DO$UE) J*"A>,KSQZUW_D0_\ /*/_ +Y%.5$3[B*O
MT&*J=526Q%+#NF[\QYS\9+X0^&H;/=@SRA@/7:1_C69\%=/(@O[]EQ\PC4^H
MQ_\ 6KG_ (L:LVJ>*4T^#+K;#: /[YZC]*]8\#Z+_87A:TMF'[QEWN?<\_UJ
MG[M*W<B/OXARZ(Q?BQ]N/AA!9"4@R?O1&"3CCTKGO@VNHQS7J3),EK@<.I S
MSTS7KCHDBE7564]0PR*2.&*$8BC1 >RJ!6:J6ARV-G1O4]I<?7!_%";6;;3+
M*YT9KA9(Y29/(!)QQCIVKO*0@$8(R#VJ8NSN:SCS1:/ %^)WC"!/)8*6]7A;
M=_.LE=.\3>-M7#S13RRGC?*I55'L37T8VF6#MN:QMBWJ8ES_ "J>.&*$8BC1
M!Z*H%:^V2^%'*\+*6DI71B^$O#L7AG08;%3ND^]*WJQZU\_>)+76+WQ%?33V
MEW(QF8!O*8_*"0.WI7T]3##$QR8T)]2HJ857%MFE6@IQ44[6/G/2_$?BS1K)
M;2QMKB*%>P@?FKR^.?'.X?)<GGH8'KWWR(?^>4?_ 'R*/(A_YY)_WR*KVT7]
MDA8:2T4QED[RV%O)*,2-$K-]2!FIZ**P.L*\R^,6AM>:3;ZG"A9[8[9"!T3G
M^IKTVO._BYKG]G^'5T^-OWEX=K#T7KG\Q6E*_.K&.(M[-W/&/#VFOJ^O6=FJ
M[@\B[A_LYY_2OJ:WA6VMHH$^[&@0?0#%>*_!K1S/K-QJ<B?+ FU"1U)R#7M]
M7B)7E8QP<+0YNYY-\3O ES?77]LZ7#O8C]^@ZD^OOVKE-%\?^)_#MHED;<O!
M&,*L\+97VKZ$JM)I]E,<RV=NY]6B4_TI1JZ<LE<N>'][F@['BA\?>--;NHHK
M2W>)"P&886'YFO3?&>AW'B#P?-9H1]JVAUSZCD_RKHH;6WM_]3!%%_N(!_*I
M:F4U=.*M8N%)I-2=[GS7X?UC6_!.J2%+.0%OEDCDC//TK1U^^\5^-+&:\N+1
MTL;,;Q&(RN>V<'J>>U>^2V5I.VZ:UAD;U>,$_K4@AB$?EB)!&?X=HQ^56ZRO
M>VIBL*[<O-H>4_!>WGA743+#)&"%P74C/)K*^,=K<2^(+5XX)77RCRJ$CM7M
M<<,4(Q%$B ]E4"DD@AFQYL4<F.FY0:E5??YC1X>]+V=SEOAM%)%X)L4E1D8*
M>&&#U-=;2*JHH5%"J.@ P*6LY.[N;0CRQ2"BBBD4>+_$OP%>'4I=8TR#S()!
MNE1!\P;N<=\U@:=X_P#%NC62V"(651M7SH6+#Z5]#D C!&:K/I]E(VY[.W9O
M4Q*3_*ME5TM)7.66&][F@['SSI_A[Q#XXUQI[F.4;B#)-*I4!?;->[II<6E>
M&&L+9/ECAVX4?>..3^-:R1I&NV-%1?11BG5,ZCD72H*G?JV?-WA*RNU\>V3-
M:S!1<,23&<#@U[+\0?#+^)O#QAMP/M4+;XB?U'XXKIUM;='WK!$K_P!X( :E
MIRJMR4ET%3PZC!Q>MSYCTO4/$7A&_D^RQ3P2$E61HVVL?ZUJ7=CXL\96\^IW
MZS>3;+D*R$?]\J>>]?0,MG:SMNEMH9&'0O&":E$:*FP(H7^Z!Q5NOUMJ9K":
M6<M#QWX,6T\-_J!E@D0%5P60CUKV2HXX(8<^5$B9Z[5 J2LIRYI7.BE3]G'E
M/(OC/;3S/8-%!)( 3DJA..*WOA'#+#X1VRQ/&3*W#J1WKO)(8IAB6-' [,H-
M*D:1+MC147T48%-U+PY2%1M5=2YY1\:+>>9-/,4,D@!.2BDXZUL?""&6#PDZ
MRQ/&3<.0'4CL*[Z2&*88EC1P.S*#2I&D2[8T5%'91@4.I[G*"HVJ^TN>4?&>
MVGG73FBADD"A@2BDXYK4^#]O+%X6NDFB>/=.<!U(R-HKT*2&*9=LL:./1E!I
M4C2)=L:*B^BC H]I[G*"HVJ^TN?//C;PWJ>A>*I[V*"1X9)C-%(B$A><@'%:
MH^(7BW6+*/3;*S*S./+,J1-G\^U>X211S)LEC1U]&7(J.&SM;<YAMH8S_L(!
M_*K]LFM49_5FI-QE9,^;M,T;4K#QE;V]S;2^;'<+O(0D=?6O<_'T<DO@V_2-
M&=BAPJC)Z&N@^S0&7S##'YG][8,_G4C*&4JP!!Z@BIE5YFGV+IT.2+C?<\*^
M$=I<Q>*I&DMY47R>K(0.HKMOB7X+E\16D=[81JU[",,"<;U]/PYKNX[>"$DQ
M0QH3U*J!4M$JK<N9!##I4^1GSGH7BGQ-X.5[..V<0!SF.:%B >^*UKCXE^+]
M4 ALK4H3QF*!MWYBO;Y;*UG.9K:&3_?C!_G1#96EN<PVL,9]4C _E5.K%ZN)
M"P\TK*>A2\.->OX=L6U$L;LPJ9=W7=CG-:E%%8O5G4E96"BBBD,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *CG@BN8'AF0/&XVLIZ$5)10!DZ9X8T71[E[C3]/BMYG&&9"<D
M?B:UJ**;;>XDDM$%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8LGA+09=3_ +1DTR%KPMN\TDYSZ]<5L@ # X I:*;;>XDDM@HHHI#"BBB@
M HHHH **** "BBB@ HHHH *RM6\-Z/KKQOJ=A'<M&,(7)X'X&M6BFFUL)I-6
M92TS2+#1K;[/I]JEO#G.U,_UJ[112!)+1!1110,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *0FBB@!,FDR:=24 )N:C<U+BC% #=
MS4F]J=BC% #=[^U)O?VI^*3;0 SS']ORH\R3V_*G[:3;0 SS)/;\J3S9/4?E
M4FVC;0!'YLOJ/RI/.E]1^52;:390!'YTOJ/RH\Z;U'Y5)LHV4 1>?-ZC\J3S
MY_4?E4NRCRZ (?M$_J/RI/M$_J/RJ;RZ/+]J (?M-QZC\J3[3<>H_*IO+%'E
MT 0?:KCU7\J3[5<^J_E4_E^U'E#TH @^U7/JOY4GVNY]5_*I_*]J/*'I0!7^
MUW7JO_?-)]LNO5?^^:L^4*3RO:@"O]LNO5?^^:3[9=^J_P#?-6/)%'DCTH K
M_;+OU7_OFD^VW?\ >7_OFK'DCTH\D>E %?[;=_WE_P"^:3[;>?WE_P"^:L^2
M*/)% %7[=>?WE_[YH^W7G]Y?^^:L^0/2CR!Z4 5OMUY_>7_OFD^W7G]Y?^^:
MM>0/2D\@4 5OM][_ 'E_[YH^WWO]Y/\ OFK/D"CR!0!6^WWO]Y/^^:/M][_>
M3_OFK/D"CR!0!6^WWO\ >3_OFC[?>_WD_P"^:L^0*/(% %;[?>_WD_[YH^WW
MO]Y/^^:L^0*/(% %;[?>_P!Y/^^:/M][_>3_ +YJSY H\@4 5OM][_>3_OFC
M[?>_WD_[YJSY H\@4 5OM][_ 'D_[YH^WWO]Y/\ OFK/D"CR!0!6^WWO]Y/^
M^:/M][_>3_OFK/D"CR!0!6^WWO\ >3_OFC[?>_WD_P"^:L^0*/(% %;[?>_W
MD_[YH^WWO]Y/^^:L^0*/(% %;[?>_P!Y/^^:/M][_>3_ +YJSY H\@4 5OM]
M[_>3_OFC[?>_WD_[YJSY H\@4 5OM][_ 'D_[YH^WWO]Y/\ OFK/D"CR!0!6
M^WWO]Y/^^:/M][_>3_OFK/D"CR!0!6^WWO\ >3_OFC[?>_WD_P"^:L^0*/(%
M %;[?>_WD_[YH^WWO]Y/^^:L^0*/(% %;[?>_P!Y/^^:/M][_>3_ +YJSY H
M\@4 5OM][_>3_OFC[?>_WD_[YJSY H\@4 5OM][_ 'D_[YH^WWO]Y/\ OFK/
MD"N3U?X@>&M$U233KRY<7,8RZJN<"@#H_M][_>3_ +YH^WWO]Y/^^:R9_%N@
M0>'QKAO5>P)QO7U]*I:7\0O"VK7B6D-]Y<TGW!*I&[Z4 =']OO?[R?\ ?-'V
M^]_O)_WS5GR!1Y H K?;[W^\G_?-'V^]_O)_WS5GR!1Y H K?;[W^\G_ 'S1
M]OO?[R?]\U9\@4>0* *WV^]_O)_WS1]OO?[R?]\U9\@4>0* *WV^]_O)_P!\
MT?;[W^\G_?-6?(%'D"@"M]OO?[R?]\T?;[W^\G_?-6?(%'D"@"M]OO?[R?\
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M\+Q\0^HH ^K:*^4O^%X^(?44?\+Q\0^HH ^K:*^4O^%X^(?44?\ "\?$/J*
M/JVBOE+_ (7CXA]11_PO'Q#ZB@#ZMHKY2_X7CXA]11_PO'Q#ZB@#ZMHKY2_X
M7CXA]11_PO'Q#ZB@#ZMHKY2_X7CXA]11_P +Q\0^HH ^K:*^4O\ A>/B'U%'
M_"\?$/J* /JVBOE+_A>/B'U%'_"\?$/J* /JVBOE+_A>/B'U%'_"\?$/J* /
MJVBOE+_A>/B'U%'_  O'Q#ZB@#ZMHKY2_P"%X^(?44?\+Q\0^HH ^K:*^4O^
M%X^(?44?\+Q\0^HH ^K:*^4O^%X^(?44?\+Q\0^HH ^K:*^4O^%X^(?44?\
M"\?$/J* /JVBOE+_ (7CXA]11_PO'Q#ZB@#ZMHKY2_X7CXA]11_PO'Q#ZB@#
MZMHKY2_X7CXA]11_PO'Q#ZB@#ZMHKY2_X7CXA]11_P +Q\0^HH ^K:*^4O\
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M/:GXHQ0 S9[4;/:GXHQ0 S9[4;/:GXHQ0 S9[4;/:GXHQ0 S9[4;/:GXHQ0
MS9[4;/:GXHQ0 S9[4;/:GXHQ0 S9[4;/:GXHQ0 S9[4;/:GXHQ0 S9[4;/:G
MXHQ0 S9[4;/:GXHQ0 S;S7@U]?W-C\7-<6UT9M3DEMPHC!  R#US7OM<W8>#
MK6P\7W?B))W:>Y0(T9' Q0!Y!JWA>^\,_":X345"37=\)O*!R(P3TK?^*=AI
MT?PUL+P1QIJ$;Q&W9>&SN'2O1O%OA>V\7:*VFW4KQ(6W!TZ@US%A\(].BO8+
MC4M3OM26W(,44\C;%(Z<9(H Z_P\99?#>F23@^:UK&7SUSM%:6SVIRHJ(%4
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M(YKE]3\-JQ=2@93WH \/HKLM:\(O%E[=?PKD987AD*.I!'K0!'1110 4444
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MH]6TJVOHU*+.F\*>HH <VF6;7DEVT"F>1-C/CDCTJ/\ L:P_LTZ?]G3[*?\
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M8$C\10 [^S+/[7#=>0OG0Q^7&^.57TI;?3K2UNY[J&%4FG.9&'5JM49!Z&@
MHHHH **** "BBB@#B-&_Y*7J_P#UQ'_LM=O7$:)S\2-9/I$/_9:[>@ HHHH
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M&@:=@<&K>[-/'J30!G'3V9O:H6T\+)N/0=JV2W%(0K87% &(U@LLF[9TJS'
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MV6O>"/&&M7 T.35M*U0Y)BY*\#@]/2IO &D:AHE_X@\42Z%-;)<X^RV2CY@
M2<=?>@!/MWBE_C/8Z7?:GF!09VMX.%" C .#SP:]BEEC@B:25U2-1DLQP!7B
MWAJ[URY^*\VNWOAN]BCNXU@1G Q$N "3S[5[)>V4&HV4EI=(6AE&'4$C/Y4
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M'1VT:R,+WMQ=LS;F>9RQR?3/:LG_ (0'2QHUOIRO(JQ3>>TG5G;U/YUU?:@
MHHHH **** "BBB@#B-"_Y*/K7_7,?^RUV]</X?\ ^2B:W_N#^2UW% !1110
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M136I1P3VZ50O(B[J2@)'?% %"X@#,2!P:YW4[ 89@M=;)A< BJ5S"74@KUH
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M - '"Q:)=73YCB*J3QD5L:=X/N#.K7"G8.V*])BTV**=<* .PQ5XB..14*@
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M[WM6[10!S.HV,UGJ<%S!;&:!(O+V#'%:'AZRFLM.VS#:[L6V^E:U% !1110
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MNWP/D)XKU;5B\DH1,_A7&>([;]T<IAA[4 <7101@XHH *LV-P;:Y5QZU6HH
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M JMM//2G.0,$=Z<D89>::RE.#0!/;R^6I..:A8F63)[TT.>@I\;C> PH T[
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MH: C;7-PK>A0?XTG_"TO#W]Z?_O@?XUP_B^.-?&%ZH10 %X ]A6-L3^X/RH
M]1_X6EX>_O3_ /? _P :/^%I>'O[T_\ WP/\:\NV)_<'Y4JQ*S!5C!8G &*
M/4/^%I>'O[T__? _QH_X6EX>_O3_ /? _P :Y0>$K.UAC;5=1BM99!D1X)(^
MO%8^H:9%9WWV>WD2Z4@%6C'6@#T/_A:7A[^]/_WP/\:/^%I>'O[T_P#WP/\
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M /? _P :L_$"W@3PC=%844_+R%'J*\:55VCY1T]* /7/^%I^'?[T_P#WP/\
M&C_A:?AW^]/_ -\#_&O)-J_W1^5&U?[H_*@#UO\ X6GX=_O3_P#? _QH_P"%
MI^'?[T__ 'P/\:\DVK_='Y4;5_NC\J /6_\ A:?AW^]/_P!\#_&C_A:?AW^]
M/_WP/\:\DVK_ '1^5&U?[H_*@#UO_A:?AW^]/_WP/\:/^%I^'?[T_P#WP/\
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MF7 P,^]9GV"T_P"?=/RI?L%I_P ^Z?E0!+#_ *B/_=%-N+>.ZA:*5<J?TJ4
M 8'044 1^&_$MWX/OUM+MFDTN1N&/.RO9+6ZAO;:.XMW#Q.,JP[UXU<6\=S"
MT4J@J:=X;\27?@^_%K=,TNF2M@$_P4 >TT5#:W4-[;)<6\BR1.,JP-34 %%%
M% !1110 4444 >8?'S_DEUQ_U]0_^A5\GU]8?'S_ ))=<?\ 7U#_ .A5\GT
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M P,4C2;C2=>,5(L.[D\"@"M@-][K4MO!YUPJ ]3S4S+$J8[T[3W2.[7=WXH
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M+9&: .^L(/L]K'&!T45:#8[4H0@ >E.",><4 -ZG(%.W*G;FD;Y1P*8PW 4
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MFMV5L89C%+#O=$^]G!K45+Z3PM8KHA(=9SY_EG!ZGKC\*NW!?_A.M-\P@O\
M9CDCUP: //KFRE3SYXH7%JDA4,W;D\&A=+O6,86W8F4;D_VA77FUFU+PUJ]I
M:)YDXO&.P=>K5)JL\NC2>'6? :,;7 /KD?UH XB*RN9C*(X6;RAF3_9JQ'HF
MI36_GQVCM'C.?_K5VFOPQZ%I>H3PN-VHR?)C^Z3S_.K.D6$ME=:>6FN[@/'D
MN&/E*/3TH \\@TZ\N5+0V[N VTX'0U/'HM\VI0V,D#1RR'C/IZUUJ7$MEH&N
MRVS^6ZW/RD=ONTV_NI?LGAR[DE/G%@&DSR1QUH R!X?_ +*\1P6FHQ^9;2G:
M'[$XK)UBQ_LW5[FT_AC?"_2NF\31W[>++5Y#(;9W7RB2<9QV_6LOQJ5/BBXV
M]@ ?KS0!S]%%% "'[I^E>K?#7_D5(_\ KHW\S7E)^Z?I7JWPU_Y%2/\ ZZ-_
M,T 3_$+_ )%"Z_X#_,5XLOW1]*]I^(7_ "*%U_P'^8KQ9?NCZ4 +5O38K>>^
M2.YN#;QG/[T=C52B@#MIK_3]%\,WFG1ZB;^:Z^[P<)U]?K6&/$E_<);VMS(O
MV=&&0!V%8N .@HH ZCQCKK7VL/\ 8+QS:M$%*C@9YS5F*XTK7_#MK8WEY]DN
MK4X#$$@BN.HP#U% '7:S=VFI?V3H&FN9HX& ,F/O>M5_&MRG]J0Z="?W-E&$
M ]^A_E7.V\\MK,LT#E)%^ZP[4DLLD\K2RL7D<Y9CU)H [C6?[%UZTL9&U58)
M+> (4*GDU8T_Q'ID?AZ.2XD!U"UC:*+CDY&,_K7G>!Z4N!Z4 ;CZ3$?##:Q<
M3,MS+,0B$_>YY-.\(7UOI^LF:ZDV1F,C/O6-+=3S11Q22LT<?W%)X%14 =5=
M:I9R>"IK)9?](:Z+A,=1Q_A3K;5;-/!]I9M+B=+L.RXZ#)YKDZ,4 =NVLV!\
M=I?>>/LXBVE\'KMJ.UU'3=2TK4-'NKG[.)+@RQRD$@\UQF!C%&!0!UVJ:Q86
MT.E:;9RF>*SDWR2XZGV_.M"?5M+LO%<.M0W?FI<#;(@!S'QUK@:,#TH [;7-
M28V%SY6N1S12GY850@D>AI-2ET;Q%96=U-?_ &:6WA\MXL')^E<3@>E&!Z4
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MEDY;TK4\86-S)?BX2$F)8QEO2L*UU:^LHO*MYBB9SBGS:YJ-Q$T4MP61NHH
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MM\'G;TH YGPFHEU^>0C/S5Z<<;1Q7G_@NU9;R>1U(^:O0<X7I0!$47.<8H8
MKBGMRO3FF%3]* !4'<\4TN2<=A3ER.O-."\YH CY!Z4X?,O I=Q'&*=$>>E
M$7)&#Q1O9%QG(J9UXYJ,1[QA5- $._/O3P>>O2C9Y>>*:#QR* -:&Z@N(A'<
MKDCHPIQAL$^8N3[50MF"D[AD4R9PSG'% %NZU -$(H%V1C]:SPX+=>:."1FF
MLNTY6@"S#<>6>F?6AR;I\(AJ"*-IIU5.IZUV&GZ6MO$I91N- '-Q:?<&0!@0
M*L36DD9'7%=4T"A@3BDFCA8;0 : ..YY#5#Y:@\&NAOM+3RRR<&N;D7RW;)Z
M4 -D) /-9$UR$G&6Y!JU/<M+\D0Y]:HG1WDEWLQ)- '7W"_;O#X8?PK7'PQK
M(Q7."#7H&FV@@\.N'Y^6O/;I6%TS0@@;N: .ETW3UN&7/(6KFHO#!#Y:$;AZ
M4_3/W6FAMV&*U@7/F&Y)9LY- &C&KO;-*1]U<U%X:\6076H-8R-^\5L 5<C9
MAIL@"\;#D_A7DFDWZ:;XW,K'Y?,.?SH ^DXTWQ@GIBI/E5!QBJ6F7L=W8K*C
M9!7BK!?]UTS0 UY.P-0.R[2<TQB1DBL^YE<?+T)H 9<ODG'2J#N%R14KL0/F
M-9UY<K&>#UH KS2O<3A #MS6U:V:Q1@XZU0L$\V7S,<5L_.< 4 )P!@"F9^;
MFK&W:.2,U$RY/2@!.,\5R7C73C<Z9(WH,UUO [5EZ['YNG2C'530!\YRILE9
M?0TRKFJ1>3J$J_[54Z "NN\+R;8"#ZUR-=7X=!%L2/6@"AXFQ]M! ZUAUN>(
M\FZ7-8= 'TE^SU_R!KK_ 'O\:ZSXQ_\ (BW%<G^SU_R!KK_>_P :ZSXQ_P#(
MBW% 'R#6SX>3=>@^E8U='X8CS(6Q0!NZ]-Y>E%1W%)\/X5)>0GO5;Q0X6R5?
M6I? ,I#.M 'I@''6@N1QVI%/R@T&@!N\$\TOWNU-;:*7S.,'B@!IPII,L"33
MV53SFD"'MR* &E21NIN3G-2G.<<U"< D'K0 \@GG--+^HJY96+W W$_+3+R%
M8GPM %="3P15NTN9+=N#\IZBJ)+ XIZ;ASF@#6::RD7?)%@^U0R:@D<92UC"
M9[]ZI22!QC'2F?*>AP: '+/DDOUI58;PQZ5"R\X--W#[OI0!H2-$XX&*J[MI
MI8+>21L\[:M-9'>* *^Y2!N'-*QC'05/)9@\YYJNR%1AEZ=Z (V#$\=*:5VC
M.:1F?/'2JEY<^5&<<MZ4 4M3N@59<_A6EHMY'8:0SH!O(KE95NKBXW%#MS6Q
M*CQ:>J@$'O0!2DOKB[NR\A(R:DO(7N$6-,EC3+>5#)M(YK4L(REQYS#*CM0!
M;TC2%TZR\V3[Q'>I-6OQ:Z7)(.PS5'6]:(3"GY?05"TPO-)<RC@+0!Y;<O<Z
MYJC8!9B>*[?P3H=UIURTLZX!JOX)LH9=1N9=HX;BO0&(CP#Q0!(XC8 $=:AN
MXHR@7'%/,L:-EC4<TJS#"'K0!0D)BB=4&1619V5YYC2.W&>!6\L31Y#<U!*9
M K$+@"@!)$1H@#@-63=[D7:AZU-'<F1V1@<CO4 7<S'=F@"73X"1R36U;(5Y
M]*I:<A. .M:[QE5&V@ ;/EL3TQ7-7FHB"X4)R ><5MW<SF/RDZD<UG6FA^9/
MN?GG)S0!/++=:I;A%!2/%8]SX995+ ?C7<0PQPQA0HX%+/'OB(Q0!X%KMDUE
M?LI'6LNNP\>Q"+4ABN/H [;PX^;'!YK$\2?\?V<5K>&3_HIJAXH5?/4B@#G:
M^J/V??\ DGLG_7VW_H*U\KU]4?L^_P#)/9/^OMO_ $%: /5Z*** "BBB@ HH
MHH **** "BBB@ KSBXUFUT/XCWMQ>;UC>!0"%)YP*]'JO+8VL[[Y8$=CW(H
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MU"WN+R22X2#E$(/!JG?ZF+^_FNY&.Z5MQ^4\5[C_ &'I?_/C!_WS1_8>E_\
M/C!_WS0!X-Y\?]X_]\FCSX_[Q_[Y->\_V'I?_/C!_P!\T?V'I?\ SXP?]\T
M>"F>/!^8]/[IKN_!7B_2]'\/K:W3.)0[$C:?4UW_ /8>E_\ /C!_WS4BZ3IZ
M+A;2(#TVT <#XP\9:5JOAVXM;9Y#*^,#8?45YJ)%VCKT_NFOHAM*L&&&M(B#
M_LU'_8>E_P#/C!_WS0!\^>8OO_WR:/,7W_[Y-?0?]AZ7_P ^,'_?-']AZ7_S
MXP?]\T ?/GF+[_\ ?)H\Q??_ +Y-?0?]AZ7_ ,^,'_?-']AZ7_SXP?\ ?- '
MSYYB^_\ WR:/,7W_ .^37T'_ &'I?_/C!_WS1_8>E_\ /C!_WS0!\^>8OO\
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M".,D\UT6]@,K0 ^5N.:9$NX9YS0V95R1R*C^TM%@<<4 2RCC!YS7&>(%-M.
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MG@7:#@5%-*9&W$$T^"'><M5HVZXXQB@"A\I7CK368@=*DFBP3@XJ ;MW)R*
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MRQNS*CJS*<, <XI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUD/H0>E<K964I^*27,EL3&M@H$A7@''K5GX?VLUM>^(O-A:)7O04R, C;U%
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MK@YZTSC.* 'L0>V*C*G&%I.AZTGF/T44 3)&$&2<4K.>FXYJ,[F')I5SG%
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M)>Q$X09:G1+<3L!@JM #;B1Y9O*A!('4U?L[3REW8^:I8K9(1TY]:OQ;3@4
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MCN[V")VZ*[@&K+74"V_VAIHQ#C/F%AMQ]:Y/QII7AV#3+[5-4M(I9Y(C&A<
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MV@S61B0"RG: 31])L ?-^M=M5>RL;73K9;:S@2&%?NH@P!5B@ HHHH ****
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MN[L+^[U?5&A-_= +LA&$B09P!P/6NKHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT%[KER(X(V"9[5Z+X=\./I$ D*$2$=: /6](M--32UT^WC12B#Y@!G-9<]F
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M .HIOF)_?'YT>8G]\?G0 ZBF^8G]\?G1YB?WQ^= #J*;YB?WQ^='F)_?'YT
M.HIOF)_?'YT>8G]\?G0 ZBF^8G]\?G1YB?WQ^= #J*;YB?WQ^='F)_?'YT .
MHIOF)_?'YT>8G]\?G0 ZBF^8G]\?G1YB?WQ^= #J*;YB?WQ^='F)_?'YT .H
MIH=3T8'\:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >8?'S_DEUQ_U]0_^A5\GU]8
M?'S_ ))=<?\ 7U#_ .A5\GT %%%% !1110!K:3J[V;A'),9/Y5W%GJ231+AM
MX/Z5YC5[3]4FL7RIRO<&@#U:&0+@J:T8KH@CGBN&T_6HYU4A\-W6MZ&\60#G
M% '3?;%; +5,'63'S#CWKG""RX#$5/8^$]<U>1GTZ\Z?P$T ;18J>*8SLW%5
M9_#GB_3H_P!Y:^;CN/\ ]5<[JNL:YI:D3:=(A]<4 =6[M@ '%0RLN<EAGZUY
MC<^-]08%0NPU1'B'5;E\*['/I0!ZPMRA.W>/SKI?#SV<=PKR*&.>IKRS2!<&
M-6F9MQZYKIH;J6&/ ..* /5=<\=6FEV!2SPTH'\/:O.F\>:O>.TAN"B]AFN=
M-V[RR;LG/K3H;/<O/ - &]#XKUR67)NVV_6HKO5=0N7)EN&/XU3CA$8PM2;,
MB@#J?"'BF6WN%L[V4E"?E.:]-O\ 3[;5+-&)X(X->$JHCF21>JG)KUFQ\36L
MGAM65P'1<$4 6XK?2/#J>;<W"1L?4C-6H]9T+7A]E$L<I/&"17B7BRYNM7O2
M[SML'0 UD6&HOI-W%<)(P*'GF@#Z#C\*Z+8R&Y,*C'.3BI)_$^AVP%N]U&H/
M&T$5Y]KGCP7'AQ CX=EQD&O)9Y9[B;S6D<LQX^8T ?0UYHEA=XO;)T9#R2#4
MKW@TW379AE57BO,?"/B*ZL(#;3.QC/J:W=:\81"P^R*H9G&* ./U+6[C6=6D
MRQ$2G@4A4!<*=I]JA@A2)GDZ%CFI"#G(- %=+S5[&?S(+N0+Z9K>M/B%JEK^
MZE<R9'.:QR2>#4+VRL=V/QH T-?_ +,\2VI:6().1UKR35M'N--G;RR3'G@B
MO0'$D,F>JTDT$5PGSJ#GUH \K,TO0NU-,CGJQKO+WPO;3Y:/Y36#<^%KJ+F/
MYA0!S]%:$FC7D76(UT/AGX>:KXCD'EILC'5C0!QP!)P!6KIOAS5=5<+:6<KY
M[[3BO<_#WPCT?3Y%-X_VB8=1VKT:&#1O#]MG9#$JCH ,T ?.5K\)M;:$S72B
M&,#)S5VP\+6FFM^\ =QWKT7Q;XW6^!M[7"0CT[UY[=ZU'&"7;'UH OR20P+V
M&*Y36?$0C+10MENF1VK+U7Q%)<,R0'"^M<^S%F+,<DT /FF>>0N[$DU'110
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MISVQTH \<TWPY-.P><;4]#75V^G16L6Q  !5J:=<'& .V*QK_5EMT^=^G04
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MPKL:* .._P"%>V?_ $$+S_OL?X4?\*]L_P#H(7G_ 'V/\*[&B@#CO^%>V?\
MT$+S_OL?X4?\*]L_^@A>?]]C_"NP)"J2Q  ZDT*RNH92"#T(H X__A7MG_T$
M+S_OL?X4?\*]L_\ H(7G_?8_PKL:* .._P"%>V?_ $$+S_OL?X4?\*]L_P#H
M(7G_ 'V/\*[&B@#CO^%>V?\ T$+S_OL?X4?\*]L_^@A>?]]C_"NQHH X[_A7
MMG_T$+S_ +['^%'_  KVS_Z"%Y_WV/\ "NQHH X[_A7MG_T$+S_OL?X4?\*]
ML_\ H(7G_?8_PKL:* .._P"%>V?_ $$+S_OL?X4?\*]L_P#H(7G_ 'V/\*[&
MB@#CO^%>V?\ T$+S_OL?X4?\*]L_^@A>?]]C_"NQHH X[_A7MG_T$+S_ +['
M^%'_  KVS_Z"%Y_WV/\ "NQHH X[_A7MG_T$+S_OL?X4?\*]L_\ H(7G_?8_
MPKL:* .._P"%>V?_ $$+S_OL?X4?\*]L_P#H(7G_ 'V/\*[&B@#CO^%>V?\
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M@ HHHH ^DOV>O^0-=?[W^-=9\8_^1%N*Y/\ 9Z_Y UU_O?XUUGQC_P"1%N*
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M"'_41_[HI],A_P!1'_NBGT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8?'S_DEUQ_U]0_\
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MZ*Y_6M9@DTB^-AJT%M-;'$DS@E8SSUX/I4TOB72=-CCBO]2A281!VX/(]>E
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M#(XO@W+-+\VYOH3DBMNPT^TOOB-$;JV2;RM%4IO7.TY KT0Z;8D3 V<&)_\
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M*@II 5_[%TO_ )\X?^^:/[%TO_GSA_[YJQ13L!7_ +%TO_GSA_[YH_L72_\
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M\X?^^:L446 =;6MK: BWB2,'LHI\\,-Q'Y<R*ZGL:BHHL(K_ -B:5_SY0_\
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MH?\ OFC^Q-*_Y\H?^^:L446 K_V)I7_/E#_WS1_8FE?\^4/_ 'S5BBBP%?\
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M]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\
MSXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-
MIO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@
M4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&
M#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3
M?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9
M_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_
M  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_
M[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_PGNA_
M\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_A1_P
MGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?]\-_
MA1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_^>[?
M]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X3W0_
M^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@#&_X
M3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?]\"@
M#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\ SXP?
M]\"@#&_X3W0_^>[?]\-_A1_PGNA_\]V_[X;_  K9_L;3?^?&#_O@4?V-IO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!DOW*@J>7[E052$%%%%, HHHH **** "BBB@ HHHH *0_=;Z&EH
M/0CU% 'C&F>'6UWQ[JH%W)!M;^ XS2>(/#TO@O6[#5%O&NM\@79(<XKH;SX?
MZNNNW.I:9JGV?SSD@5/9_#Z\N-0ANM=U%KSR3N1#TS2 IZWJUK<>(X1::?\
M;=1$8)C;D+6-I!O%^*,7VNW2U9XN8X^!VKJM9\$WK:__ &OH]UY$S#:P]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 R0$I@5%L;TJQ13N!7V-Z4;&]*L447
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!D3:_%")/]&N"4S_!P?UK'T?QHU_<31S6;@+]WRQG\ZZX
MHIZJ.?:H8;.VMV9HH40L<L0.M5==B&I7W,R\UO\ XEEQ-!%(DB#@R+CFGVMD
M;&(WCW<CG9N<,>#6C<6T5U;O!*@*.,$5G+H9\IH7O9WBQ@*2.!^5%T%G<S]#
MU*235'26X$BW0,D:_P!WOBKWB/STLA-#.T>P@D =:L'1;0/;O&OEM ?E*]QZ
M4[5--_M.$1-/)&G<+WHNKW"SY;&/J\LPNW,SS)"L.Z(Q]"_/6K]GJOFZ?"I<
M?;'B!53W.*EFTJ2>..-[R7RU&&''S?I5Z.WCBB6-% "+M4XZ475@2=SE;.\F
MAU*S#23>=-(5F1QQCGI^0KKZSH=*"W@N9YGF=?N;L86M&DW<<4UN%%%%(H**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "LLHDVMR+* RK&-H/3G-:E5;FPCN9!)N9) ,;EZD4T)D&CD^1*N25
M60A?S-:-100);Q".,8 J6A@M$%%%%(84444 %%%% !1110!YA\?/^277'_7U
M#_Z%7R?7UA\?/^277'_7U#_Z%7R?0 4444 %%%% PHHHH ***4"@!*<!FI8H
M&D. *T8;2.-<ORU)LTC"Y3ALWDY(P*NI;Q1#IDU*%=CA1Q5RWL6)!?I47-XQ
M2*\5O+,<*N!5Z+2L\L:O(\4"[5&33E6>8_(I I%6(EL88P,XJ58X5Z 59739
M2/G:@Z:R]#0#(NGW5J01NPR%JU B1\,!FK!P#E1Q3),PQ..U-.5X-:H8-_#3
M+BV61<@<T!<RRJE>0*A:UC?JHJ4@QRE&J4#N:+C29GMI<3'@4PZ5&%ZUJY%5
M[J=53:.2:ELUC3;912RCSM S5Q+*-0.!559'!R%-.\R9N>:AR.F-+0M/;0XY
M J(V4#<@57>23')-$-RR, W0TTS.I"Q-]@B+=*=]BB'\(JQN#KD4@([FK.9C
M/L\0'W12I"G]T5;AMC(<GI5Z&Q#<*,TQ&2+>/NHJ-[6%_P"$5KS6H#;,8-9E
MTK6WO0,IOI:-TJK)I3@?*:NB^_V34R70;JI% C$:PF3J,U#);KCYTQ70M<Q[
ML,*&A@G3M2'9')2V*D90\^E49('0\BNDN;!T<E.E4V4?==::9$J:9A8I*TYK
M-&Y0_A5%XF0X(JTS"4&B*BEQ24R HHHH **** "BBB@#["^#_P#R3^RKJO$/
M_( O?^N1KE?@_P#\D_LJZKQ#_P @"]_ZY&@1\0:O_P A:Z_ZZ&J57=7_ .0M
M=?\ 70U2H ****!A1110 4444 %%%. H 3%*%S4T-N\K  &MBUTM0 7&34MF
ML*;9EP6;R]L"M:TTU00",FM.+3CCI@5=2%85^49-0V=,*:1!%IZ1J"W%6AY:
MC"C-$43S/\QP*TH[2)!V-(O;8S]S9X6GKN9AQ6H(XP.@J*0(@)&*+"YF0BV!
MP34OD1=*KQW8#[3TJWA7Y% 69$UJI^[5.:,Q'.*TP,<9J&Z"E#0%F9@&>:<(
MU;D@4@5@?:G9*T KB^0A["H9S'&N.*E=F"_**B6Q>8[G-2W8Z*<;D2W*(G'6
MD6[9^V*O1Z4HZU)_9J#H*SYCJ5)F:9V4Y-6(G65,]ZFFT[<M4_L\ELW&=M7%
MF-6#1/@>E* !VH4AD]Z6+YI M6<;3N2Q0%^0*G6R;K5C 1!MK5M3;B#Y\9Q0
M%S >W(Z55DF$1PU:EVR1R-M/!K.:U-TV: NR(7$;#FG#RG'059BTN->M2_8H
MEHL"EW,\P0-P<55N=+5QN4 BM=K!"<J<4T6LJ< Y%+4OW&<C<Z4F< ;365-8
M21DX&17=30!CATJJ^GJPRM4I6,Y4%+8X5D*G!&*975W.E@@Y3\:P[G3WB)*C
M(JU*YRSI.)0HIQ4@TVJ,@HHHH$%%%% !7U1^S[_R3V3_ *^V_P#05KY7KZH_
M9]_Y)[)_U]M_Z"M 'J]%%% !1110 4444 %%%% !1110 4444 %%%% !3)8H
MYXRDBAE/4$4^B@#GYM,NM,D,^FL6CZM"?Z5>T_6(+W]VW[N<<%&K2K,U#1H;
MS]XG[J<='7BJO?<FS6QIT5S\&J76FR"WU)"4Z+,.AK=CE29 \;!E/0BDU8::
M8^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT&#5*1E.DGJCD:*FEA:)RK#!%1$8J[G*XM"4444R0KZH_9]_Y)[)_P!?;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVOJC]GW_ ))[)_U]M_Z"M?*]?5'[/O\ R3V3_K[;_P!!6K.<]7HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFA>)QE74J1]:X[PQ(VC:[>:%,<(S&6#/H><?J*K>)F_=E?N=I1114F@4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5Y)Y4F"+;NZGJPZ"K%% '-7DSM(99X) PDPG3 %6K=HF@OC( '+'ANO05L2
MPQS*%D4$ Y%0RZ?:S2^8\2EO6JN3RL;IH8:=!NSG8.M6Z0  8 P!2U)2"BBB
M@ HHHH **** /,?CY_R2ZX_Z^H?_ $*OE2)=S@>]?5?Q[_Y)=<?]?4/_ *%7
MRW91[YP/2DS2FKLVK6([D0=JZ:RN)K; C8BL/3T_?9:MZ%06SC%82/4HW1;D
MD>1=SDDFH54'G%2OT I=GRUSMGKTHW0U<=*& / %- ^>K.P;>M(UY="BY*G%
M.&-N:D>,;LU$X]*9EJB-OK4D9[&H2IZYIR$[O:J1G+<N!01Q2$#IFDW@#@U$
MSFD4K)$C-M&.M1L2PI@))ZU*"!3(;;8U5)J3D4J]<TK9ZXJ&]3HC'W2.53M!
MJ';Q4LI..*B!R.N*=S/EL- QUI.&JQ&N?<5*(D]*9+L4=N#TJ0;B.:LE >W%
M-"Y/'&*9FG9D!4XZ5"P);;5YCA#ZU#;0$N7?\*$.6HQ+7'45*MLBG/>K+4P-
MS3>HHJSU&[,#VJG-\V0#FK[_ #*0*H-$Z,3CBDBY$EJ3MVGM4KJ2*S_M05\5
M82X#+UIHRD1R<$BLZX!+8S6J8]P.>]9\\)1^F:M&$BU9+\HK;M8QCI6+;';@
M=*W[$C9BAA!%F.'!R:M J!BHG^5<DTL97;G-0="V'FFG..:BEN55L#FH)9SM
MR#33,Y1)BX%,>4B,GO5-9F9N33Y)0%H;"-,JO*Q;)JO=S.1CFI#(">!3]@?&
M12N6Z=RI;6Q9MS5HK'@4(BBIU Q4MFU.GH59E!4C%8$I\B\##L:Z5HPV>:P]
M3B1)1CFKBS"O"SN=EI>MQ/9!93\P%<?XAE6>X:0<\TJR&.( <9K-OW..35QC
M9W.:K6<H<IRFH?\ 'PU4ZN7_ /KS5.NA'C3W/L+X/_\ )/[*NJ\0_P#( O?^
MN1KE?@__ ,D_LJZKQ#_R +W_ *Y&F0?$.K_\A>Y_ZZ&JB=:MZO\ \A>Z_P"N
MAJO$N7 I,N"NSJM"5HH@V.M=?#J4C0B($US>F+LMU&.<5LVPYR17/(]F@K6-
M2$$G/6KBCVJM;@]JN;MHKBF]3UN@C<=*:#0TE-5CGD5 #F)[5&Q[U(6%0-DG
M@TXCBB"7DYQ4.<=ZFD1B:B*<ULBI+L*)..:;O8M[48QVIRX YIBNV!H)P.M#
MXSP:9R?>@EBX9NE.C3GFG*.,"IXXP*38XQZLDB48I[Q\9IJ#FGLPQ63W![E1
MV(.*:'8'VI9&YJ(OVK5*XW*Q.)!FI?,&,U0W9/%.\P]*7(+F1H+*,9IQDR.*
MH(_OS4AFVKG-3R!9;CY)-O4U1N09A@4OF%Y,MTIY/.16BC8GVBV*2VS1CFFD
M[:N,3WJ*0*5) YJD1+4BW;E^6G1H/XJ9$,Y[5+TH)O8>%)X45NZ?#MA!QS65
M:N-V=M;T+GRAQ0*SW%<\8J%F&,9IS$DGFHB%'6M(HY*DM1I.*86YIS8Q49)[
M"M$CEE(>":;S2?-CTI>3P*9&XN,&ID5C2(N",U8+>6N<5G.5CLP]*Y7E(3O6
M=,V34]TY8^E4'8UC>YZ'(HH;)*47U-1A&?EJ=Y98Y:IAZ4#*4]OGH*Q[B(I)
MDUTQ"XZ5BZ@H\PDC@5<6<U:&A<T+4UMV,3?=-6M<NDEAPG3%<G9W>Z[95' J
M]<3LT; GM6ECCOH<9J!W7+GWKZ:_9^_Y)])_U]M_Z"M?,5X<SO\ 6OIW]G[_
M ))[)_U]M_Z"M;QV/)J_$>KT4451D%%%% !1110 4444 %%17#3+ Q@4-)V#
M=*Q-,U&\DTF]EN&5IX6(&T<4[";LSH**Y?1]2FDM?M<^H^:RPF1H",8.#[4B
M:AJ<$-OJ4\JM;S2!3"!]U3T/Y4^4GG1U-%(IW*".XS2U)84444 %%%% !7(>
M-+1[8VVNVX_?6C?/CNO^177U#=VT=Y:26\HRDBE333LR9*ZL-L+I+ZQAN8SE
M9%!!JQ7'>#KF2RN[S0[D_-;MF+/=?\FNQHDK,(NZN%%%%(H**** "BBB@ HH
MHH **** "BBB@ JK?V$.H6YAE''8CM5JB@#$LO#5K:S>8[&7'0,.*N2:-82_
M>MU'T&*OT4[L7*C&?PU9'[AD3Z.:C/AUD_U-_.OU)/\ 6MVBCF8N5&#_ &=J
M\/\ JKT-_O"D,GB"'JD,@]O_ -5;]%%PY3!&JZK%_KM-)'JI/^%.'B-4_P!?
M:S1_\!K<IIC0]44_A1=!9]S*3Q)IS=92O^\,5:CU:PE^[=1_G4KV-K)]^!#^
M%5I-#T^3_EW5?H31H'O%U)XI/N2*WT-25BMX:M?^6<LL?T-1?V!=(?W.HRCZ
M_P#ZJ+(+OL;]%8/V+6X?N7JR?44?:==A^];)*/4'_P"O18.;R-ZBL#^W+V/_
M %VFN/\ =_\ UU(OB6#I);S(?<4<K#F1MT5F1Z]I[]9MI]P:M)J-I)]RX0_C
M19CNBS13!+&W213^-.R#T-(8M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 457%]:F;RA.F_TS5B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,CUH 6BL:*Z
MEFO)%>Z\O:^ F.M/>>[G>>2&0)' <8_O8YIV)YC6HJ&UG^T6L<N,;E!(J:D4
M%%%% !1110 4444 >8_'O_DE]Q_U]0_^A5\P:<A,NX=J^G_CW_R2ZX_Z^H?_
M $*OF;3!\K5,C>CN=#IT!=OK75Q:1-]F$@4XK/\ !]F+JZ16Y%>D7,"1(8E
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ML>DM3F9S^];ZU#3Y#EB:974CP9;GV%\'_P#DG]E75>(?^0!>_P#7(UROP?\
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M9]_Y)[)_U]M_Z"M;H\J>YZO1113("BBB@ HHHH **** "BBB@ HHHH ****
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M76+AFM],==MO:L,%A_>/Z5UE0U;0UC*ZN%%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5VLK=IO-,8+^M$EE;RR>8\8+>M6**+A9   , 8%%%% !1110 4444 %%
M%% 'F/Q[_P"277'_ %]0_P#H5?*L3;7!%?57Q\_Y)=<?]?4/_H5?*2&DS2F]
M3HX7_P!7)70PMYD0QWKEK1\VG7D5T&GS9A6LGL=U)^\=7I&E/<V[-GI5*]MS
M;3,C>M;_ (:ND\HH>M/U^P6:/SE'(ZURO<]R'PG)DX'!IBL<'-.9 &P::01T
MIBN(5+&C&*>K>M+G/:D-*Y$-V?:G\@4I<*<8I?,!/2AE10^+'>K"BHXL'I4V
M/6I--B1!DUHP6VX9*U2ME^?.*VH&RM<U:36QE7FUL4+B,+T%0*HQS6G<[<5F
MO@&BG)M"IR<D/"C&,U#(!BG;Q33ACQ5I&L45'!W<59L("]Y&/]H4UXB!FM'0
M8?-OT&>AK2<K0)GI=GK^EAH]+B4?W15V,;N2<5G6MPL<21YZ"DO]4AMHMQ8+
MCWKAP^+=).,5J?-3I2J5'8U9  ,Y'UHCVR<AAQ7GE[XR <HC\4EEXQ\M^6R*
MT=>OO8V_L^HD>BL"#US5"Z#,&&>*K:9XBM;U,;@&^M/O[M,9!P#4U\6ZL%!K
M4QA0G":N>,^.;8_VFS"L*S?,>T]179>,(@]P)1R#7-P:7-(V^->*[Z3]P]Z<
M6[,NZ=S*,UWVGD?9UP<\5P44<ENX#<&NHTV[V1KEJX<4FI*1SX^E*4$T:UW;
MI,F7%<W?6T<62HQ6[->JZ8!K"OY0RD5RKWIWBK'%A85%(Q9P,9SFJ+D] *NR
M,.14 &#S7ITM$>[&-XV(%''(JQ&.*7:,9Q2J1T%7S7*C%(<<]J;@DT[/-. Q
MS0:   .E(W/2C)%!/%(0QAQTIH4>M#$YH![&J(OJ2H%Q1(1MXI@Z<58M[&6Z
M. ,#UHMJ.3]TQI6.XDU5+@\GFM75+ V1^8YS6+(^U2175%:'AUY/F,S4)=S[
M17-ZA)NFQG@5KW4H.^0GZ5STK%G)]:TB<-66A&:2BBM#E/L+X/\ _)/[*NJ\
M0_\ ( O?^N1KE?@__P D_LJZKQ#_ ,@"]_ZY&@1\0:O_ ,A:Z_ZZ&JBU;U?_
M )"UU_UT-4Q0-&]HEQL?83UKJXV) (K@;*7RIU;WKMK2;?$I]16,D>A1GH;]
MI)@#)YK35MRUFZ5:-='@]*TFC:V?:XKDJ1ZGMT)J4;  :FV_+0I4]*>P.WBN
M:3U-)/4J./2F!<\DXJ0[J%B9^>@JKZ%75AZ\=Z>'STIC1E1Q48R#4VN3:Y,Y
M&*@)[YJ3JM1%>V:$"T'1LV[K6YI]MYI!(K"C3YL9KJ-)P !FN?$:(X\8W&%T
M:D5DNS&*JW=JJ(2*UT/R<53OB!"U:XG"TZ=)3CN>)3J2YSG/-5&/<U7N)PX-
M1W,OEN>*S)[DGO65.E?4]VE1OJ)<R#.!5+)W9I)9B>G)JS9VCSR*6!"]Z]"$
M;(ZW))<J-:Q'EVFX]343L3+[59E"HHC3H*C6$CG%-E1T1:B<[0!4X=CQZ573
M,:YQ2K(Y;I@&H<+C=F.FPYJN"$?(JR8F(J-K7Y<XII6&_AT*>K*)K,MC)%<G
MNRQ [5W<,!92CKE37,ZKH\EO,SH/D-;(XIK6Y2A<CO6C'("/6L$EX3W-:-I.
M& K*:.FG*ZL:.S<-QXH#JO>GJH9>M,:%:R3+BQ&N&(Q46=YZT,HZ4L:**U3T
M!QU'I%GK3\!1BF#)X6I%7/6DV6E9#3TR*;[FE?Y>!4>>:!B-]ZDP2:>W3@4T
M9%49-:A\W0T=J=R13<8- ]1XX%12S"-"Q. *>Q(KG]<U A/)CY8^E.*,JL[(
MAEU..ZNC%C(%2J%!^48%9^EV)4&:0?,:TCA%)KH2/)G*[,W5[ORH2 >37(2,
M68D]ZU=9N?,GV@\"L<GFM8HX*TN@VOJC]GW_ ))[)_U]M_Z"M?*]?5'[/O\
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MX:TF^N?M$]HC2=R!U^M:D44<$2Q1($11@*!P*MU$UL9QI-.[9R'V?QDW_+Q
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MJ\F(#J/RKT.CJ,&FIL3IIH\"L[.ZN+R.&WBD\XM@?*>#7I$=CXP@C7;?12
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MC"KVG7HM/ES\II6&IFFME;VX_>R9;N*D6TL[E<*AJ+S+1V\QWSFHI]9A@4I
MH'O2Y33VNA!JFC6,,6_ W>E88\N+[J@5)=Z@T[Y=\UFSW '.0*M(YYSN6I+E
M1]:S+[4Q"A^;+50N]45 0ARWK6)-<-*Q+'-4HG/.JD27-V\[EF;-5&;-(6S2
M5HD<DZCD%)115&04444 %?5'[/O_ "3V3_K[;_T%:^5Z^J/V??\ DGLG_7VW
M_H*T"/5Z*** "BBB@ HHHH **** "HYX4N(6BD!*,,$ XJ2B@"A9Z/9V4K2Q
M1DR$8+.Q8X_&F1Z%8177VA8CN#;@-QV@^N.E:5%.[%RH****0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *K7UC;ZC:M;W,8>-NH-6:* ,'2_".EZ5<_:(8LR?PECG%;U%%-MO<226P
M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%-,B!MI=0WH30 ZBN>DNI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEC^ZQJS_ &M*1@X-=?\ \*;\4?\ /N*7_A3?BC_GA1REJJSD4U5@WS*,5/\
MVI">2G-=/_PISQ3_ ,^XI?\ A3GBC_G@*7*4JQS*:A;N?F&*D:\MT&Y3GVKH
MO^%.^*/^>%+_ ,*=\4?\\*.4?M3DWU=L_(H I!K$P["NL_X4[XH_YX"C_A3O
MBC_G@*.4?MCE5UF0-DJ*LC7$(^9*Z+_A3OBC_G@*/^%.^*/^>%+D#VQSC:U$
M1PE-_M>%OO)72_\ "G?%'_/ 4?\ "G?%'_/ 4<H>V.9.I6_]RD&I0$_<Q73_
M /"G?%'_ #PH_P"%.^*/^>%/E8O:HYS[;;,.N*/M=KZUT?\ PIWQ3_SPH_X4
M[XI_YX4<H>U.8DU&!3@#-1MJD6/E3FNJ_P"%.>*/^> I/^%.>*?^?<4<HO:G
M&OJ<K=.*KO=R2?>8UW7_  IOQ1_S[BD_X4WXH_Y]Z?*2ZK. ,A/4TW=7H/\
MPIOQ1_S[BC_A37BC_GW%%B7-L\]S29KT/_A37BC_ )]Q1_PIKQ1_S[BG8FYY
MW17HG_"FO%'_ #[BC_A37BC_ )]Q185SSNBO1/\ A37BC_GW%'_"FO%'_/N*
M N>=T5Z)_P *:\4?\^XIR?!CQ,S8:$ 4!<\YIZ1/(<*I->LV7P1U8,&N!D>E
M:_\ PK+4K2/$%BK,.A- 'DEGX=O;K!V%5]36O%X?L;$;[R<''49KL;KP!XSE
M&V* 1K[5DR_"7Q?.29$+9]Z ,677-.L1MM(06'1L5C7GB&\NB?G*J>PKK?\
MA37BC_GW%21?!CQ,T@#PA5[F@#WOX0L7\ V;,<DUUFMH'T6[4G ,9K&\!:1)
MX?\ "MM83_ZQ!S6SK"/<:-=1Q#+M&0!0!\>:WX:F;4KB2W8."Y-<W/8W%N2)
M(R,>U>@7'A#QA#JD[Q6<K(7) JY%X8\13C9=Z.QSWQ0!Y717J4_PLU.X!>.R
MD0GMBL:Y^%?B2(_)9.P^E '#45UW_"M/$_\ T#I/RH_X5KXG_P"@=)^5 '(T
M5UW_  K7Q/\ ] Z3\J/^%:^)_P#H'2?E0,Y&BNN_X5KXG_Z!TGY4?\*U\3_]
M Z3\J .1HS77?\*U\3_] Z3\J/\ A6OB?_H'2?E0!R5%=;_PK7Q/_P! Z3\J
M/^%:^)_^@=)^5 7.3S1DUUG_  K7Q/\ ] Z3\J/^%:^)_P#H'2?E0%SE0Y'>
MI$N9$^ZY%=-_PK7Q1_T#I/RI?^%:^*/^@=)^5*Q7.S"359T&-V:E&M3@=JV/
M^%;>*/\ H'2?E1_PK;Q1_P! Z3\J7*4JK,U=<D P13AKS#^&M#_A6WBC_H'2
M?E1_PK;Q1_T#I/RHY2O:LH?V\V>5J5?$ QRE6O\ A6WBC_H'2?E2_P#"MO%'
M_0.D_*ERC59HA7Q& .$J3_A*GVXP<?6G?\*W\4?] Z3\J/\ A6_BC_H'2?E1
MR%?6&59/$3,>%J/^WCG)6KW_  K?Q1_T#I/RH_X5MXH_Z!TGY4<HG7;*1UX?
MW:8VNM_",5H?\*V\4?\ 0.D_*C_A6WBC_H'2?E1RB]LS);6IB>U-.LS^M;'_
M  K;Q1_T#I/RI/\ A6WBC_H'2?E3Y1>V9A2:I.X^]4!O9FZN?SKI/^%;>*/^
M@=)^5'_"M?%'_0.D_*CE)=5LY8RL>I-,+&NK_P"%:^*/^@=)^5'_  K7Q/\
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M 8ATEW8=\5[5\)[2^LO";Q7]N8)?M#$(1VP* .[HHHH **** "BBB@ HHHH
M**** $9@JEB< #)-8B>)8'E7]Q(+=I/*$YZ;LX]*UKM6>SG11EFC8 >^*X[[
M5#/X=BTV,@WAGV&+^(')YJHJY$FT=L#D9'0TM,B!6%%/4* :<3A2?2I+%HJC
M"UW.GF"55!) &T5)Y=W_ ,]E_P"^13L*Y:HJKY=W_P ]E_[Y%'EW?_/9?^^1
M2"Y:HJKY=W_SV7_OD4>7=_\ /9?^^10%RU157R[O_GLO_?(H\N[_ .>R_P#?
M(H"Y:HJKY=W_ ,]E_P"^11Y=W_SV7_OD4!<M450D:\CEC3S5._\ V14OEW?_
M #V7_OD4[!<M455\N[_Y[+_WR*/+N_\ GLO_ 'R*07+5%5?+N_\ GLO_ 'R*
M/+N_^>R_]\B@+EJBJOEW?_/9?^^11Y=W_P ]E_[Y% 7+5%5?+N_^>R_]\BCR
M[O\ Y[+_ -\B@+EJBJC+=JC-YR\#/W13(#=S1!_-49[;13L%R]157R[O_GLO
M_?(H\N[_ .>R_P#?(I!<M455\N[_ .>R_P#?(H\N[_Y[+_WR* N6J*J^7=_\
M]E_[Y%'EW?\ SV7_ +Y% 7+5%5?+N_\ GLO_ 'R*/+N_^>R_]\B@+EJBJOEW
M?_/9?^^143M=K.D?FK\V>=HIV"Y?HJKY=W_SV7_OD4>7=_\ /9?^^12"Y:HJ
MKY=W_P ]E_[Y%'EW?_/9?^^10%RU157R[O\ Y[+_ -\BCR[O_GLO_?(H"Y:H
MJKY=W_SV7_OD4>7=_P#/9?\ OD4!<M455\N[_P">R_\ ?(IKK=HA;SEX']T4
M!<N451A^URPI)YRC<,XVBI/+N_\ GLO_ 'R*87+5%5?+N_\ GLO_ 'R*/+N_
M^>R_]\BD%RU157R[O_GLO_?(H\N[_P">R_\ ?(H"Y:HJKY=W_P ]E_[Y%'EW
M?_/9?^^10%RU157R[O\ Y[+_ -\BCR[O_GLO_?(H"Y:HJ@S7:W"Q>:O(SG:*
ME\N[_P">R_\ ?(IV"Y:HJKY=W_SV7_OD4>7=_P#/9?\ OD4@N6J*J^7=_P#/
M9?\ OD4>7=_\]E_[Y% 7+5%5?+N_^>R_]\BCR[O_ )[+_P!\B@+EJBJOEW?_
M #V7_OD4>7=_\]E_[Y% 7+5%4IOM<4+/YRG:,XVBB,7;QJWG*,C^Z*=@N7:*
MJ^7=_P#/9?\ OD4>7=_\]E_[Y%(+EJBJOEW?_/9?^^11Y=W_ ,]E_P"^10%R
MU157R[O_ )[+_P!\BCR[O_GLO_?(H"Y:HJKY=W_SV7_OD4>7=_\ /9?^^10%
MRU157R[O_GLO_?(J+==_:1#YJ\KG.T4[!<OT55\N[_Y[+_WR*/+N_P#GLO\
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M;>Q":E*))^Y%<+JG_)7K/_KG0!UOAJRUJT5QJUSYQ/2NAH-%, HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15+4-0^P1J
MPL[NYW'&+>/>1]:;?:F;&V2;[#>W&[^""+>P^HS3L*Z+]%5K&\^W6PF^S7%O
MG^"X38WY59I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\46_F
MZ2TRC]Y PD4CVK 5?[;MK[4 #F)5$7L1C/\ 6NXDC66-HW&588(/>H+;3[:S
M@:"",+&W452E9$2A=G-:).VLZO)? Y6* (O^]SFJVC6P,MY#-J$MK*LS$IOV
M@@D\\UUUG86UA&4MHPBDY.*BN](LKU]\T"E_[PX-/F%R.QDIID$5AJ+6ETUQ
M-*OS'>&YXJAHMM#-I$6[5982J[7B,@7;[8-=5:6-M91E+>,(IZ^]5YM"TZ>4
MRO;KN/7;QFES!R&/?6=O8^$KE+:4RQG)W$YYS533&.AWD,MQE[>[4 2GJI]*
MZHZ?:FS-IY0\DC&T4LMA;3VHMI(@T2] >U',')K=&7JEG:7-X)XKY;:]1>'W
M@9%/\.ZC<7T$R7!#M"^SS%'#^]6I]$L+DJ9802JA0<\XJW;VT-K$(H(U1!V
MHNK#2=[DM%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gwrjt5hibe5u000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwrjt5hibe5u000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ."3(# 2(  A$! Q$!_\0
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
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MTH\E/2@#-_MQ/^?:7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RH_MQ/\
MGVE_*M+R4]*/)3TH S?[<3_GVE_*C^W$_P"?:7\JTO)3TH\E/2@#-_MQ/^?:
M7\J/[<3_ )]I?RK2\E/2CR4]* ,W^W$_Y]I?RJ5=65D#&!P"<5=\E/2CR4]*
, '@Y /K12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>mrus-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T01:02:00.9486889+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 86139572bfd14d72a654e4791bd938db -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:mrus="http://www.merus.nl/20201231" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merus.nl/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.merus.nl/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrus-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrus-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrus-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrus-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompany" id="Role_DisclosureTheCompany">
        <link:definition>100060 - Disclosure - The Company</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities" id="Role_DisclosureInvestmentsInDebtSecurities">
        <link:definition>100080 - Disclosure - Investments in Debt Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets" id="Role_DisclosurePrepaidExpensesAndOtherAssets">
        <link:definition>100090 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100100 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet" id="Role_DisclosureIntangibleAssetsNet">
        <link:definition>100110 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100120 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100130 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases" id="Role_DisclosureOperatingLeases">
        <link:definition>100140 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations" id="Role_DisclosureCollaborations">
        <link:definition>100170 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>100180 - Disclosure -  Employee Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare" id="Role_DisclosureLossPerShare">
        <link:definition>100190 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100200 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100210 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables" id="Role_DisclosureInvestmentsInDebtSecuritiesTables">
        <link:definition>100240 - Disclosure - Investments in Debt Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherAssetsTables">
        <link:definition>100250 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100260 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables" id="Role_DisclosureIntangibleAssetsNetTables">
        <link:definition>100270 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100290 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables" id="Role_DisclosureOperatingLeasesTables">
        <link:definition>100300 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables" id="Role_DisclosureCollaborationsTables">
        <link:definition>100310 - Disclosure - Collaborations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables" id="Role_DisclosureEmployeeBenefitPlansTables">
        <link:definition>100320 - Disclosure -  Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareTables" id="Role_DisclosureLossPerShareTables">
        <link:definition>100330 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" id="Role_DisclosureTheCompanyAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - The Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails" id="Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails">
        <link:definition>100370 - Disclosure - Investments in Debt Securities - Summary of Classification of Debt Securities in Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails" id="Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails">
        <link:definition>100380 - Disclosure - Investments in Debt Securities - Summary of Debt Securities by Maturity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails" id="Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails">
        <link:definition>100390 - Disclosure - Investments in Debt Securities - Summary of Debt Securities by Credit Quality Indicator (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" id="Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails">
        <link:definition>100400 - Disclosure - Investments in Debt Securities - Summary of Fair Value of Debt Securities by Major Security Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100410 - Disclosure - Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails" id="Role_DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Prepaid Expenses and Other Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100430 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" id="Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails">
        <link:definition>100450 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" id="Role_DisclosureIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails" id="Role_DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails">
        <link:definition>100470 - Disclosure - Intangible Assets, Net - Schedule of Expected Amortization Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>100480 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails" id="Role_DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Summary of Components of Loss from Operations Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Summary of Components of Expense for (Benefit) from Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" id="Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Summary of Components of Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails" id="Role_DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="Role_DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails" id="Role_DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails">
        <link:definition>100560 - Disclosure - Operating Leases - Summary of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails" id="Role_DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails">
        <link:definition>100570 - Disclosure - Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2" id="Role_DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2">
        <link:definition>100580 - Disclosure - Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" id="Role_DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails">
        <link:definition>100590 - Disclosure - Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Stockholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails" id="Role_DisclosureCollaborationsAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Collaborations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails" id="Role_DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails">
        <link:definition>100620 - Disclosure - Collaborations - Summary of Company&apos;s Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" id="Role_DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails">
        <link:definition>100630 - Disclosure - Collaborations - Summary of Company&apos;s Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" id="Role_DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
        <link:definition>100650 - Disclosure - Employee Benefit Plans - Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails" id="Role_DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails">
        <link:definition>100660 - Disclosure - Employee Benefit Plans - Summary of Key Weighted Average Assumptions used in Pricing Model on date of Grant for Options Granted to Employees (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" id="Role_DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails">
        <link:definition>100670 - Disclosure - Employee Benefit Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails" id="Role_DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails">
        <link:definition>100680 - Disclosure - Employee Benefit Plans - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails" id="Role_DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails">
        <link:definition>100690 - Disclosure - Employee Benefit Plans - Intrinsic Value of Stock Options Exercised and Vested RSUs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails" id="Role_DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails">
        <link:definition>100700 - Disclosure - Loss per Share - Summary of Basic and Diluted Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100720 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mrus_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_ReimbursementRevenues" name="ReimbursementRevenues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_MiscellaneousIncomeAndGains" name="MiscellaneousIncomeAndGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_CollaborationRevenueMember" name="CollaborationRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_CollaborationRevenueRelatedPartyMember" name="CollaborationRevenueRelatedPartyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_GrantRevenueMember" name="GrantRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_ForeignExchangeGain" name="ForeignExchangeGain" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_FinanceCostIncurredButNotYetPaid" name="FinanceCostIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_RestrictedCashAndOtherAssets" name="RestrictedCashAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" name="PrepaidExpensesAndOtherAssetsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" name="FunctionalAndPresentationCurrencyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_PendingAccountingPronouncementsPolicyTextBlock" name="PendingAccountingPronouncementsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" name="DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_CollaborationAndSharePurchaseAgreementsMember" name="CollaborationAndSharePurchaseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_MarketableSecuritiesCurrentMember" name="MarketableSecuritiesCurrentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_MarketableSecuritiesNonCurrentMember" name="MarketableSecuritiesNonCurrentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_CorporatePaperNotesAndBondsMember" name="CorporatePaperNotesAndBondsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_StandardPoorsAAMinusToAAPlusRatingMember" name="StandardPoorsAAMinusToAAPlusRatingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_StandardPoorsAMinusToAPlusRatingMember" name="StandardPoorsAMinusToAPlusRatingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_PrepaidClinicalAndManufacturingCostsCurrent" name="PrepaidClinicalAndManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_PrepaidGeneralAndAdministrativeCosts" name="PrepaidGeneralAndAdministrativeCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_OfficeEquipmentAndFurnitureMember" name="OfficeEquipmentAndFurnitureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_AccruedGeneralAndAdministrativeExpenses" name="AccruedGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_DeferredTaxAssetsLeaseObligation" name="DeferredTaxAssetsLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_ExpirationDateCarryForwards" name="ExpirationDateCarryForwards" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_TaxYear2024Member" name="TaxYear2024Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_TaxYear2025Member" name="TaxYear2025Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_TaxYear2026Member" name="TaxYear2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_TaxYear2027Member" name="TaxYear2027Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_OperatingLeaseExpirationTerm" name="OperatingLeaseExpirationTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_MerusUSIncMember" name="MerusUSIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_KadansSciencePartnerXIIBVMember" name="KadansSciencePartnerXIIBVMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_LesseeOperatingLeaseExtendedTermOfContract" name="LesseeOperatingLeaseExtendedTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" name="AreaOfPropertySubjectToOrAvailableForOperatingLease" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" name="LesseeOperatingLeaseNumberOfRenewalTerm" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_LesseeOperatingLeaseTerminationTerm" name="LesseeOperatingLeaseTerminationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_ConsumerPriceIndex" name="ConsumerPriceIndex" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_OperatingLeaseRentAdjustmentDescription" name="OperatingLeaseRentAdjustmentDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_TwoThousandSixteenIncentiveAwardPlanMember" name="TwoThousandSixteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" name="NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_NonRefundableUpfrontPaymentsReceivable" name="NonRefundableUpfrontPaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_RevenueFromCollaborativeArrangement" name="RevenueFromCollaborativeArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_IncyteCollaborationAndLicenseAgreementMember" name="IncyteCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_LicenseAndRelatedActivitiesMember" name="LicenseAndRelatedActivitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_SecondONOResearchAndLicenseAgreementMember" name="SecondONOResearchAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_SimcereCollaborationAndLicenseAgreementMember" name="SimcereCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_LicenseAndPerformanceMember" name="LicenseAndPerformanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_SecondBispecificAntibodyResearchProgramMember" name="SecondBispecificAntibodyResearchProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_BettaCollaborationAndLicenseAgreementMember" name="BettaCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_NumberOfBispecificAntibodies" name="NumberOfBispecificAntibodies" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_PaymentToCompensateResearchServices" name="PaymentToCompensateResearchServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_OverTimePaymentForFullTimeEquivalentFunding" name="OverTimePaymentForFullTimeEquivalentFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_DevelopmentMilestonesReceived" name="DevelopmentMilestonesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_NonRefundableUpfrontPaymentsReceived" name="NonRefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_NumberOfPerformanceObligation" name="NumberOfPerformanceObligation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="mrus_MilestonePaymentsReceived" name="MilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_DescriptionOfResearchAndDevelopmentPrograms" name="DescriptionOfResearchAndDevelopmentPrograms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_ContingentMilestonePaymentsReceivable" name="ContingentMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" name="RevenueRelatedPerformanceObligationAmountAsRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_MilestoneRevenue" name="MilestoneRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_Billings" name="Billings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_AdjustmentsToContractAssetsReceivables" name="AdjustmentsToContractAssetsReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_ForeignCurrencyExchangeTranslation" name="ForeignCurrencyExchangeTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="mrus_UnbilledReceivablesMember" name="UnbilledReceivablesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_DeferredRevenueMember" name="DeferredRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_IncyteMember" name="IncyteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_OnoMember" name="OnoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_OtherMember" name="OtherMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_CollaborationAgreementMember" name="CollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_TwoThousandTenPlanMember" name="TwoThousandTenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_TwoThousandSixteenPlanMember" name="TwoThousandSixteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_NonExecutiveDirectorsMember" name="NonExecutiveDirectorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_SubsequentAwardMember" name="SubsequentAwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_FourZeroOnePlanMember" name="FourZeroOnePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_GrantOfRestrictedStockUnit" name="GrantOfRestrictedStockUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="mrus_MerusNVMember" name="MerusNVMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" name="FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_CommercialSalesMilestones" name="CommercialSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_MilestonePaymentsReceivable" name="MilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" name="CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mrus_UnderwritersMember" name="UnderwritersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>28
<FILENAME>mrus-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T01:02:00.9486889+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 86139572bfd14d72a654e4791bd938db -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="mrus-20201231.xsd#TemplateLink" roleURI="http://www.merus.nl/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MiscellaneousIncomeAndGains" xlink:type="locator" xlink:label="mrus_MiscellaneousIncomeAndGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="mrus_MiscellaneousIncomeAndGains" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ForeignExchangeGain" xlink:type="locator" xlink:label="mrus_ForeignExchangeGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mrus_ForeignExchangeGain" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10230.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidGeneralAndAdministrativeCosts" xlink:type="locator" xlink:label="mrus_PrepaidGeneralAndAdministrativeCosts" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidClinicalAndManufacturingCostsCurrent" xlink:type="locator" xlink:label="mrus_PrepaidClinicalAndManufacturingCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="mrus_PrepaidClinicalAndManufacturingCostsCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="mrus_PrepaidGeneralAndAdministrativeCosts" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AccruedGeneralAndAdministrativeExpenses" xlink:type="locator" xlink:label="mrus_AccruedGeneralAndAdministrativeExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="mrus_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mrus_AccruedResearchAndDevelopmentExpensesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mrus_AccruedGeneralAndAdministrativeExpenses" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredTaxAssetsLeaseObligation" xlink:type="locator" xlink:label="mrus_DeferredTaxAssetsLeaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mrus_DeferredTaxAssetsLeaseObligation" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ReimbursementRevenues" xlink:type="locator" xlink:label="mrus_ReimbursementRevenues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UpfrontPayments" xlink:type="locator" xlink:label="mrus_UpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="mrus_UpfrontPayments" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="mrus_ReimbursementRevenues" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>29
<FILENAME>mrus-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T01:02:00.9486889+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 86139572bfd14d72a654e4791bd938db -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="mrus-20201231.xsd#TemplateLink" roleURI="http://www.merus.nl/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MiscellaneousIncomeAndGains" xlink:type="locator" xlink:label="mrus_MiscellaneousIncomeAndGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GrantRevenueMember" xlink:type="locator" xlink:label="mrus_GrantRevenueMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationRevenueRelatedPartyMember" xlink:type="locator" xlink:label="mrus_CollaborationRevenueRelatedPartyMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationRevenueMember" xlink:type="locator" xlink:label="mrus_CollaborationRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10170.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_CollaborationRevenueMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_CollaborationRevenueRelatedPartyMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_GrantRevenueMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="mrus_MiscellaneousIncomeAndGains" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:type="locator" xlink:label="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:type="locator" xlink:label="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="mrus_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAndSharePurchaseAgreementsMember" xlink:type="locator" xlink:label="mrus_CollaborationAndSharePurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrus_CollaborationAndSharePurchaseAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrus_FollowOnPublicOfferingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeFurnitureAndEquipmentMember" xlink:type="locator" xlink:label="mrus_OfficeFurnitureAndEquipmentMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="mrus_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_LaboratoryEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_OfficeFurnitureAndEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MarketableSecuritiesNonCurrentMember" xlink:type="locator" xlink:label="mrus_MarketableSecuritiesNonCurrentMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MarketableSecuritiesCurrentMember" xlink:type="locator" xlink:label="mrus_MarketableSecuritiesCurrentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mrus_MarketableSecuritiesCurrentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mrus_MarketableSecuritiesNonCurrentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StandardPoorsAMinusToAPlusRatingMember" xlink:type="locator" xlink:label="mrus_StandardPoorsAMinusToAPlusRatingMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StandardPoorsAAMinusToAAPlusRatingMember" xlink:type="locator" xlink:label="mrus_StandardPoorsAAMinusToAAPlusRatingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StandardPoorsAAARatingMember" xlink:type="locator" xlink:label="srt_StandardPoorsAAARatingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExternalCreditRatingStandardPoorsMember" xlink:type="locator" xlink:label="srt_ExternalCreditRatingStandardPoorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExternalCreditRatingStandardPoorsMember" xlink:type="locator" xlink:label="srt_ExternalCreditRatingStandardPoorsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CreditRatingStandardPoorsAxis" xlink:type="locator" xlink:label="srt_CreditRatingStandardPoorsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CorporatePaperNotesAndBondsMember" xlink:type="locator" xlink:label="mrus_CorporatePaperNotesAndBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="mrus_CorporatePaperNotesAndBondsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:to="srt_CreditRatingStandardPoorsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CreditRatingStandardPoorsAxis" xlink:to="srt_ExternalCreditRatingStandardPoorsMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CreditRatingStandardPoorsAxis" xlink:to="srt_ExternalCreditRatingStandardPoorsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="srt_StandardPoorsAAARatingMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="mrus_StandardPoorsAAMinusToAAPlusRatingMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="mrus_StandardPoorsAMinusToAPlusRatingMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CorporatePaperNotesAndBondsMember" xlink:type="locator" xlink:label="mrus_CorporatePaperNotesAndBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="mrus_CorporatePaperNotesAndBondsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeEquipmentAndFurnitureMember" xlink:type="locator" xlink:label="mrus_OfficeEquipmentAndFurnitureMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="mrus_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_OfficeEquipmentAndFurnitureMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_NL" xlink:type="locator" xlink:label="country_NL" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_NL" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ExpirationDateCarryForwards" xlink:type="locator" xlink:label="mrus_ExpirationDateCarryForwards" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2027Member" xlink:type="locator" xlink:label="mrus_TaxYear2027Member" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2026Member" xlink:type="locator" xlink:label="mrus_TaxYear2026Member" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2025Member" xlink:type="locator" xlink:label="mrus_TaxYear2025Member" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2024Member" xlink:type="locator" xlink:label="mrus_TaxYear2024Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2024Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2025Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2026Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2027Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="mrus_ExpirationDateCarryForwards" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OperatingLeaseRentAdjustmentDescription" xlink:type="locator" xlink:label="mrus_OperatingLeaseRentAdjustmentDescription" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ConsumerPriceIndex" xlink:type="locator" xlink:label="mrus_ConsumerPriceIndex" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseTerminationTerm" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseTerminationTerm" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" xlink:type="locator" xlink:label="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseExtendedTermOfContract" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseExtendedTermOfContract" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OperatingLeaseExpirationTerm" xlink:type="locator" xlink:label="mrus_OperatingLeaseExpirationTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeAndLaboratoryMember" xlink:type="locator" xlink:label="mrus_OfficeAndLaboratoryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_KadansSciencePartnerXIIBVMember" xlink:type="locator" xlink:label="mrus_KadansSciencePartnerXIIBVMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:type="locator" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MerusUSIncMember" xlink:type="locator" xlink:label="mrus_MerusUSIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mrus_MerusUSIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrus_KadansSciencePartnerXIIBVMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_OfficeAndLaboratoryMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_OperatingLeaseExpirationTerm" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_LesseeOperatingLeaseExtendedTermOfContract" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_LesseeOperatingLeaseTerminationTerm" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_ConsumerPriceIndex" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_OperatingLeaseRentAdjustmentDescription" order="11100.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandSixteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandSixteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="mrus_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrus_UnderwrittenPublicOfferingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrus_TwoThousandSixteenIncentiveAwardPlanMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11030.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestoneRevenue" xlink:type="locator" xlink:label="mrus_MilestoneRevenue" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" xlink:type="locator" xlink:label="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="mrus_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DescriptionOfResearchAndDevelopmentPrograms" xlink:type="locator" xlink:label="mrus_DescriptionOfResearchAndDevelopmentPrograms" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestonePaymentsReceived" xlink:type="locator" xlink:label="mrus_MilestonePaymentsReceived" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfMilestonesAchieved" xlink:type="locator" xlink:label="mrus_NumberOfMilestonesAchieved" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfPerformanceObligation" xlink:type="locator" xlink:label="mrus_NumberOfPerformanceObligation" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceived" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceived" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DevelopmentMilestonesReceived" xlink:type="locator" xlink:label="mrus_DevelopmentMilestonesReceived" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OverTimePaymentForFullTimeEquivalentFunding" xlink:type="locator" xlink:label="mrus_OverTimePaymentForFullTimeEquivalentFunding" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PaymentToCompensateResearchServices" xlink:type="locator" xlink:label="mrus_PaymentToCompensateResearchServices" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfBispecificAntibodies" xlink:type="locator" xlink:label="mrus_NumberOfBispecificAntibodies" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RevenueFromCollaborativeArrangement" xlink:type="locator" xlink:label="mrus_RevenueFromCollaborativeArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_BettaCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_BettaCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SecondBispecificAntibodyResearchProgramMember" xlink:type="locator" xlink:label="mrus_SecondBispecificAntibodyResearchProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LicenseAndPerformanceMember" xlink:type="locator" xlink:label="mrus_LicenseAndPerformanceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SecondONOResearchAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_SecondONOResearchAndLicenseAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LicenseAndRelatedActivitiesMember" xlink:type="locator" xlink:label="mrus_LicenseAndRelatedActivitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_IncyteCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_IncyteCollaborationAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_LicenseAndRelatedActivitiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_SecondONOResearchAndLicenseAgreementMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_LicenseAndPerformanceMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="mrus_SecondBispecificAntibodyResearchProgramMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_BettaCollaborationAndLicenseAgreementMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_RevenueFromCollaborativeArrangement" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NumberOfBispecificAntibodies" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_PaymentToCompensateResearchServices" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_OverTimePaymentForFullTimeEquivalentFunding" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_DevelopmentMilestonesReceived" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceived" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NumberOfPerformanceObligation" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NumberOfMilestonesAchieved" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_MilestonePaymentsReceived" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_DescriptionOfResearchAndDevelopmentPrograms" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_ContingentMilestonePaymentsReceivable" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_MilestoneRevenue" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12050.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ForeignCurrencyExchangeTranslation" xlink:type="locator" xlink:label="mrus_ForeignCurrencyExchangeTranslation" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AdjustmentsToContractAssetsReceivables" xlink:type="locator" xlink:label="mrus_AdjustmentsToContractAssetsReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCustomers" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_Billings" xlink:type="locator" xlink:label="mrus_Billings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OtherMember" xlink:type="locator" xlink:label="mrus_OtherMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OnoMember" xlink:type="locator" xlink:label="mrus_OnoMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredRevenueMember" xlink:type="locator" xlink:label="mrus_DeferredRevenueMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnbilledReceivablesMember" xlink:type="locator" xlink:label="mrus_UnbilledReceivablesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="mrus_UnbilledReceivablesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="mrus_DeferredRevenueMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_IncyteMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OnoMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OtherMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_CollaborationAgreementMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_Billings" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCustomers" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_AdjustmentsToContractAssetsReceivables" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_ForeignCurrencyExchangeTranslation" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ReimbursementRevenues" xlink:type="locator" xlink:label="mrus_ReimbursementRevenues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UpfrontPayments" xlink:type="locator" xlink:label="mrus_UpfrontPayments" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OtherMember" xlink:type="locator" xlink:label="mrus_OtherMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OnoMember" xlink:type="locator" xlink:label="mrus_OnoMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_IncyteMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OnoMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OtherMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_CollaborationAgreementMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_UpfrontPayments" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_ReimbursementRevenues" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GrantOfRestrictedStockUnit" xlink:type="locator" xlink:label="mrus_GrantOfRestrictedStockUnit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" xlink:type="locator" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FourZeroOnePlanMember" xlink:type="locator" xlink:label="mrus_FourZeroOnePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentRetirementBenefitsMember" xlink:type="locator" xlink:label="us-gaap_PostemploymentRetirementBenefitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SubsequentAwardMember" xlink:type="locator" xlink:label="mrus_SubsequentAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonExecutiveDirectorsMember" xlink:type="locator" xlink:label="mrus_NonExecutiveDirectorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandSixteenPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandSixteenPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandTenPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandTenPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrus_TwoThousandTenPlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrus_TwoThousandSixteenPlanMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mrus_NonExecutiveDirectorsMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="mrus_SubsequentAwardMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_2" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PostemploymentRetirementBenefitsMember" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_2" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="mrus_FourZeroOnePlanMember" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="12970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" order="13010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="13130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="13200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="13250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="13320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="13400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="13440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PostemploymentBenefitsLiabilityCurrent" order="13510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrus_GrantOfRestrictedStockUnit" order="13530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" order="13550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" xlink:type="locator" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MerusNVMember" xlink:type="locator" xlink:label="mrus_MerusNVMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_IncyteMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="mrus_MerusNVMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="mrus_MilestonePaymentsReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CommercialSalesMilestones" xlink:type="locator" xlink:label="mrus_CommercialSalesMilestones" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" xlink:type="locator" xlink:label="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnderwritersMember" xlink:type="locator" xlink:label="mrus_UnderwritersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrus_UnderwritersMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_CommercialSalesMilestones" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_MilestonePaymentsReceivable" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11130.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>30
<FILENAME>mrus-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T01:02:00.9496874+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 86139572bfd14d72a654e4791bd938db -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UpfrontPayments" xlink:type="locator" xlink:label="mrus_UpfrontPayments" />
    <link:label xml:lang="en-US" xlink:label="mrus_UpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPayments" xlink:to="mrus_UpfrontPayments_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ReimbursementRevenues" xlink:type="locator" xlink:label="mrus_ReimbursementRevenues" />
    <link:label xml:lang="en-US" xlink:label="mrus_ReimbursementRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ReimbursementRevenues" xlink:to="mrus_ReimbursementRevenues_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable (related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Including Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue (related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion (related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MiscellaneousIncomeAndGains" xlink:type="locator" xlink:label="mrus_MiscellaneousIncomeAndGains" />
    <link:label xml:lang="en-US" xlink:label="mrus_MiscellaneousIncomeAndGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Miscellaneous income and gains.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MiscellaneousIncomeAndGains" xlink:to="mrus_MiscellaneousIncomeAndGains_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationRevenueMember" xlink:type="locator" xlink:label="mrus_CollaborationRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CollaborationRevenueMember" xlink:to="mrus_CollaborationRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationRevenueRelatedPartyMember" xlink:type="locator" xlink:label="mrus_CollaborationRevenueRelatedPartyMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationRevenueRelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue (related party).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CollaborationRevenueRelatedPartyMember" xlink:to="mrus_CollaborationRevenueRelatedPartyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationRevenueRelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue (Related Party) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationRevenueRelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue Related Party [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GrantRevenueMember" xlink:type="locator" xlink:label="mrus_GrantRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_GrantRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GrantRevenueMember" xlink:to="mrus_GrantRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_GrantRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_GrantRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue from contracts with customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange (losses) gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MiscellaneousIncomeAndGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Miscellaneous income and gains</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MiscellaneousIncomeAndGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Income And Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per share allocable to common stockholders:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ForeignExchangeGain" xlink:type="locator" xlink:label="mrus_ForeignExchangeGain" />
    <link:label xml:lang="en-US" xlink:label="mrus_ForeignExchangeGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign exchange gain.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ForeignExchangeGain" xlink:to="mrus_ForeignExchangeGain_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FinanceCostIncurredButNotYetPaid" xlink:type="locator" xlink:label="mrus_FinanceCostIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="mrus_FinanceCostIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance cost incurred but not yet paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FinanceCostIncurredButNotYetPaid" xlink:to="mrus_FinanceCostIncurredButNotYetPaid_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RestrictedCashAndOtherAssets" xlink:type="locator" xlink:label="mrus_RestrictedCashAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="mrus_RestrictedCashAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RestrictedCashAndOtherAssets" xlink:to="mrus_RestrictedCashAndOtherAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ForeignExchangeGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign exchange losses (gains)</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ForeignExchangeGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Exchange Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of discount on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt And Equity Securities Unrealized Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets and lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets And Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange impact on cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease obligations acquired from operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Lease Obligations Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash purchases of property, equipment and intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FinanceCostIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash financing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FinanceCostIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Cost Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax refunds received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Income Tax Refunds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_RestrictedCashAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash included in other assets</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_RestrictedCashAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Other Assets</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:type="locator" xlink:label="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" />
    <link:label xml:lang="en-US" xlink:label="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised and stock options exercised and restricted stock units vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:to="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:type="locator" xlink:label="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" />
    <link:label xml:lang="en-US" xlink:label="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised and restricted stock units vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:to="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and vesting of restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and vesting of restricted stock units, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised And Stock Options Exercised And Restricted Stock Units Vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of prepaid expenses and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:to="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Preparation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" xlink:type="locator" xlink:label="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for functional and presentation currency.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" xlink:to="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Functional and Presentation Currency</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Functional And Presentation Currency Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="mrus_GoingConcernPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_GoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GoingConcernPolicyTextBlock" xlink:to="mrus_GoingConcernPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_GoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_GoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Accounts Receivable Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Credit Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable Allowance For Credit Losses Policy Or Methodology Change Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings (Loss) per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PendingAccountingPronouncementsPolicyTextBlock" xlink:type="locator" xlink:label="mrus_PendingAccountingPronouncementsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_PendingAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pending accounting pronouncements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PendingAccountingPronouncementsPolicyTextBlock" xlink:to="mrus_PendingAccountingPronouncementsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_PendingAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pending Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PendingAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pending Accounting Pronouncements Policy [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of property plant and equipment estimated useful lives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives Table [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" xlink:type="locator" xlink:label="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of balance sheet classifications of debt securities measured at amortized cost (held-to-maturity).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" xlink:to="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Classification of Debt Securities in Consolidated Balance Sheet</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Balance Sheet Classification Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Debt Securities by Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Past Due Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Debt Securities by Credit Quality Indicator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Credit Quality Indicator Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Debt Securities by Major Security Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Gross Excluding Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expected Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Loss from Operations Before Income Tax Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Expense for (Benefit) from Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Deferred Tax Assets (Liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Operating Loss Carryforwards [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Lease Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:type="locator" xlink:label="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of weighted average remaining lease terms and discount rates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company&apos;s Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Condensed Financial Statements Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company&apos;s Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Key Weighted Average Assumptions Used in Pricing Model on Date of Grant for Options Granted to Employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic Value of Stock Options Exercised and Vested RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:label xml:lang="en-US" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAndSharePurchaseAgreementsMember" xlink:type="locator" xlink:label="mrus_CollaborationAndSharePurchaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and share purchase agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CollaborationAndSharePurchaseAgreementsMember" xlink:to="mrus_CollaborationAndSharePurchaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and Share Purchase Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Share Purchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="mrus_FollowOnPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FollowOnPublicOfferingMember" xlink:to="mrus_FollowOnPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:type="locator" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:to="us-gaap_AdditionalCashAndCashEquivalentRelatedText_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Cash And Cash Equivalent Related Text</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="mrus_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LaboratoryEquipmentMember" xlink:to="mrus_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeFurnitureAndEquipmentMember" xlink:type="locator" xlink:label="mrus_OfficeFurnitureAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office furniture and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OfficeFurnitureAndEquipmentMember" xlink:to="mrus_OfficeFurnitureAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Furniture And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Held To Maturity Nonaccrual [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Nonaccrual [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MarketableSecuritiesCurrentMember" xlink:type="locator" xlink:label="mrus_MarketableSecuritiesCurrentMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_MarketableSecuritiesCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MarketableSecuritiesCurrentMember" xlink:to="mrus_MarketableSecuritiesCurrentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_MarketableSecuritiesCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current marketable securities [member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MarketableSecuritiesCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MarketableSecuritiesNonCurrentMember" xlink:type="locator" xlink:label="mrus_MarketableSecuritiesNonCurrentMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_MarketableSecuritiesNonCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MarketableSecuritiesNonCurrentMember" xlink:to="mrus_MarketableSecuritiesNonCurrentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_MarketableSecuritiesNonCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current marketable securities [member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MarketableSecuritiesNonCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Non Current [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Held To Maturity Nonaccrual [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Nonaccrual [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within one year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After one year through five years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditQualityInformationAbstract" xlink:type="locator" xlink:label="us-gaap_CreditQualityInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditQualityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Quality Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditQualityInformationAbstract" xlink:to="us-gaap_CreditQualityInformationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Held To Maturity Credit Quality Indicator [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Credit Quality Indicator [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CorporatePaperNotesAndBondsMember" xlink:type="locator" xlink:label="mrus_CorporatePaperNotesAndBondsMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_CorporatePaperNotesAndBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate paper notes and bonds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CorporatePaperNotesAndBondsMember" xlink:to="mrus_CorporatePaperNotesAndBondsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_CorporatePaperNotesAndBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate paper and notes [member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CorporatePaperNotesAndBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Paper Notes And Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency securities [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Corporations And Agencies Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. treasuries [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CreditRatingStandardPoorsAxis" xlink:type="locator" xlink:label="srt_CreditRatingStandardPoorsAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CreditRatingStandardPoorsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Rating, Standard &amp; Poor&apos;s</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CreditRatingStandardPoorsAxis" xlink:to="srt_CreditRatingStandardPoorsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CreditRatingStandardPoorsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Rating Standard Poors [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExternalCreditRatingStandardPoorsMember" xlink:type="locator" xlink:label="srt_ExternalCreditRatingStandardPoorsMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ExternalCreditRatingStandardPoorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External Credit Rating, Standard &amp; Poor&apos;s</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="srt_ExternalCreditRatingStandardPoorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ExternalCreditRatingStandardPoorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">External Credit Rating Standard Poors [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StandardPoorsAAARatingMember" xlink:type="locator" xlink:label="srt_StandardPoorsAAARatingMember" />
    <link:label xml:lang="en-US" xlink:label="srt_StandardPoorsAAARatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AAA [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StandardPoorsAAARatingMember" xlink:to="srt_StandardPoorsAAARatingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StandardPoorsAAARatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Standard Poors A A A Rating [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StandardPoorsAAMinusToAAPlusRatingMember" xlink:type="locator" xlink:label="mrus_StandardPoorsAAMinusToAAPlusRatingMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_StandardPoorsAAMinusToAAPlusRatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Standard poors AA minus to AA plus rating.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_StandardPoorsAAMinusToAAPlusRatingMember" xlink:to="mrus_StandardPoorsAAMinusToAAPlusRatingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_StandardPoorsAAMinusToAAPlusRatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AA- to AA+ [member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_StandardPoorsAAMinusToAAPlusRatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Standard Poors A A Minus To A A Plus Rating [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StandardPoorsAMinusToAPlusRatingMember" xlink:type="locator" xlink:label="mrus_StandardPoorsAMinusToAPlusRatingMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_StandardPoorsAMinusToAPlusRatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Standard poors A minus to A plus rating.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_StandardPoorsAMinusToAPlusRatingMember" xlink:to="mrus_StandardPoorsAMinusToAPlusRatingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_StandardPoorsAMinusToAPlusRatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A- to A+ [member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_StandardPoorsAMinusToAPlusRatingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Standard Poors A Minus To A Plus Rating [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Fair Value</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidClinicalAndManufacturingCostsCurrent" xlink:type="locator" xlink:label="mrus_PrepaidClinicalAndManufacturingCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidClinicalAndManufacturingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical and manufacturing costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PrepaidClinicalAndManufacturingCostsCurrent" xlink:to="mrus_PrepaidClinicalAndManufacturingCostsCurrent_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidGeneralAndAdministrativeCosts" xlink:type="locator" xlink:label="mrus_PrepaidGeneralAndAdministrativeCosts" />
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidGeneralAndAdministrativeCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid general and administrative costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PrepaidGeneralAndAdministrativeCosts" xlink:to="mrus_PrepaidGeneralAndAdministrativeCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidClinicalAndManufacturingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical and manufacturing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidClinicalAndManufacturingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical And Manufacturing Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidGeneralAndAdministrativeCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid general and administrative costs</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PrepaidGeneralAndAdministrativeCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid General And Administrative Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Investments Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash held on account as collateral</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Investments Noncurrent</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeEquipmentAndFurnitureMember" xlink:type="locator" xlink:label="mrus_OfficeEquipmentAndFurnitureMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeEquipmentAndFurnitureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office equipment and furniture.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OfficeEquipmentAndFurnitureMember" xlink:to="mrus_OfficeEquipmentAndFurnitureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeEquipmentAndFurnitureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment and Furniture</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeEquipmentAndFurnitureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment And Furniture [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_NL" xlink:type="locator" xlink:label="country_NL" />
    <link:label xml:lang="en-US" xlink:label="country_NL_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Netherlands</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_NL_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">NETHERLANDS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses of Intellectual Property [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software Licenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Future Amortization Expense Current And Five Succeeding Fiscal Years [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="mrus_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="mrus_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="mrus_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AccruedGeneralAndAdministrativeExpenses" xlink:type="locator" xlink:label="mrus_AccruedGeneralAndAdministrativeExpenses" />
    <link:label xml:lang="en-US" xlink:label="mrus_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedGeneralAndAdministrativeExpenses" xlink:to="mrus_AccruedGeneralAndAdministrativeExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued general and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Netherlands</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. state</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. state</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Netherlands statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in tax rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredTaxAssetsLeaseObligation" xlink:type="locator" xlink:label="mrus_DeferredTaxAssetsLeaseObligation" />
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredTaxAssetsLeaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeferredTaxAssetsLeaseObligation" xlink:to="mrus_DeferredTaxAssetsLeaseObligation_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets And Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess interest carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Interest Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredTaxAssetsLeaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredTaxAssetsLeaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax asset valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance, attributable to increase in net operating loss carryforward deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:type="locator" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:to="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ExpirationDateCarryForwards" xlink:type="locator" xlink:label="mrus_ExpirationDateCarryForwards" />
    <link:label xml:lang="en-US" xlink:label="mrus_ExpirationDateCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration date carry forwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ExpirationDateCarryForwards" xlink:to="mrus_ExpirationDateCarryForwards_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2024Member" xlink:type="locator" xlink:label="mrus_TaxYear2024Member" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2024.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TaxYear2024Member" xlink:to="mrus_TaxYear2024Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Year 2024</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year2024 [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2025Member" xlink:type="locator" xlink:label="mrus_TaxYear2025Member" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2025.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TaxYear2025Member" xlink:to="mrus_TaxYear2025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Year 2025</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year2025 [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2026Member" xlink:type="locator" xlink:label="mrus_TaxYear2026Member" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2026.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TaxYear2026Member" xlink:to="mrus_TaxYear2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Year 2026</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year2026 [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2027Member" xlink:type="locator" xlink:label="mrus_TaxYear2027Member" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2027.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TaxYear2027Member" xlink:to="mrus_TaxYear2027Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Year 2027</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TaxYear2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year2027 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ExpirationDateCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiry Year</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ExpirationDateCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Date Carry Forwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Netherlands Tax Loss Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, tax related penalties and interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OperatingLeaseExpirationTerm" xlink:type="locator" xlink:label="mrus_OperatingLeaseExpirationTerm" />
    <link:label xml:lang="en-US" xlink:label="mrus_OperatingLeaseExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OperatingLeaseExpirationTerm" xlink:to="mrus_OperatingLeaseExpirationTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MerusUSIncMember" xlink:type="locator" xlink:label="mrus_MerusUSIncMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_MerusUSIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merus US Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MerusUSIncMember" xlink:to="mrus_MerusUSIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_MerusUSIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merus US Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MerusUSIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merus U S Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:type="locator" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScenarioPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScenarioPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_KadansSciencePartnerXIIBVMember" xlink:type="locator" xlink:label="mrus_KadansSciencePartnerXIIBVMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_KadansSciencePartnerXIIBVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Kadans Science Partner XII B.V.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_KadansSciencePartnerXIIBVMember" xlink:to="mrus_KadansSciencePartnerXIIBVMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_KadansSciencePartnerXIIBVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Kadans Science Partner XII BV</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_KadansSciencePartnerXIIBVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Kadans Science Partner X I I B V [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeAndLaboratoryMember" xlink:type="locator" xlink:label="mrus_OfficeAndLaboratoryMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeAndLaboratoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OfficeAndLaboratoryMember" xlink:to="mrus_OfficeAndLaboratoryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeAndLaboratoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Building</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OfficeAndLaboratoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OperatingLeaseExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OperatingLeaseExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Term</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseExtendedTermOfContract" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseExtendedTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended term of contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LesseeOperatingLeaseExtendedTermOfContract" xlink:to="mrus_LesseeOperatingLeaseExtendedTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, extended term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, options to extend description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" xlink:type="locator" xlink:label="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" />
    <link:label xml:lang="en-US" xlink:label="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The area of property under operating lease arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" xlink:to="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseNumberOfRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease number of renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:to="mrus_LesseeOperatingLeaseNumberOfRenewalTerm_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseTerminationTerm" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseTerminationTerm" />
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseTerminationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease termination term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LesseeOperatingLeaseTerminationTerm" xlink:to="mrus_LesseeOperatingLeaseTerminationTerm_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ConsumerPriceIndex" xlink:type="locator" xlink:label="mrus_ConsumerPriceIndex" />
    <link:label xml:lang="en-US" xlink:label="mrus_ConsumerPriceIndex_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">consumer price index.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ConsumerPriceIndex" xlink:to="mrus_ConsumerPriceIndex_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OperatingLeaseRentAdjustmentDescription" xlink:type="locator" xlink:label="mrus_OperatingLeaseRentAdjustmentDescription" />
    <link:label xml:lang="en-US" xlink:label="mrus_OperatingLeaseRentAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease rent adjustment description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OperatingLeaseRentAdjustmentDescription" xlink:to="mrus_OperatingLeaseRentAdjustmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property available for operating lease</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property Subject To Or Available For Operating Lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseNumberOfRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, number of renewal term</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseNumberOfRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Number Of Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseTerminationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, termination term</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LesseeOperatingLeaseTerminationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Termination Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, estimated rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ConsumerPriceIndex_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consumer price Index</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ConsumerPriceIndex_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consumer Price Index</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OperatingLeaseRentAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent adjustment description</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OperatingLeaseRentAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Rent Adjustment Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost included in operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid to lessors included in operating cash outflows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining operating lease term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="mrus_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UnderwrittenPublicOfferingMember" xlink:to="mrus_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandSixteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandSixteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandSixteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TwoThousandSixteenIncentiveAwardPlanMember" xlink:to="mrus_TwoThousandSixteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandSixteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandSixteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common shares pursuant to underwriters&apos; option to purchase additional shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" xlink:to="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Issue price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares pursuant to underwriters&apos; option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Shares Pursuant To Underwriters Option To Purchase Additional Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for additional grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonRefundableUpfrontPaymentsReceivable" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RevenueFromCollaborativeArrangement" xlink:type="locator" xlink:label="mrus_RevenueFromCollaborativeArrangement" />
    <link:label xml:lang="en-US" xlink:label="mrus_RevenueFromCollaborativeArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of revenue from collaborative arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueFromCollaborativeArrangement" xlink:to="mrus_RevenueFromCollaborativeArrangement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_IncyteCollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_IncyteCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incyte collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteCollaborationAndLicenseAgreementMember" xlink:to="mrus_IncyteCollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_IncyteCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incyte Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_IncyteCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incyte Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LicenseAndRelatedActivitiesMember" xlink:type="locator" xlink:label="mrus_LicenseAndRelatedActivitiesMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_LicenseAndRelatedActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and related activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LicenseAndRelatedActivitiesMember" xlink:to="mrus_LicenseAndRelatedActivitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_LicenseAndRelatedActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Related Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LicenseAndRelatedActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Related Activities [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SecondONOResearchAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_SecondONOResearchAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_SecondONOResearchAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second ONO research and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SecondONOResearchAndLicenseAgreementMember" xlink:to="mrus_SecondONOResearchAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_SecondONOResearchAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second ONO Research and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_SecondONOResearchAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second O N O Research And License Agreement [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Simcere collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simcere Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Simcere Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LicenseAndPerformanceMember" xlink:type="locator" xlink:label="mrus_LicenseAndPerformanceMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_LicenseAndPerformanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and performance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LicenseAndPerformanceMember" xlink:to="mrus_LicenseAndPerformanceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_LicenseAndPerformanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Performance</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_LicenseAndPerformanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Performance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SecondBispecificAntibodyResearchProgramMember" xlink:type="locator" xlink:label="mrus_SecondBispecificAntibodyResearchProgramMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_SecondBispecificAntibodyResearchProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second bispecific antibody research program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SecondBispecificAntibodyResearchProgramMember" xlink:to="mrus_SecondBispecificAntibodyResearchProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_SecondBispecificAntibodyResearchProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Bispecific Antibody Research Program</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_SecondBispecificAntibodyResearchProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Bispecific Antibody Research Program [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_BettaCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_BettaCollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_BettaCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Betta collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_BettaCollaborationAndLicenseAgreementMember" xlink:to="mrus_BettaCollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_BettaCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Betta Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_BettaCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Betta Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payments Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_RevenueFromCollaborativeArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Collaborations, transaction price as revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_RevenueFromCollaborativeArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Collaborative Arrangement</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfBispecificAntibodies" xlink:type="locator" xlink:label="mrus_NumberOfBispecificAntibodies" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfBispecificAntibodies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of bispecific antibodies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfBispecificAntibodies" xlink:to="mrus_NumberOfBispecificAntibodies_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfBispecificAntibodies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of bispecific antibodies under collaboration and license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfBispecificAntibodies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Bispecific Antibodies</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PaymentToCompensateResearchServices" xlink:type="locator" xlink:label="mrus_PaymentToCompensateResearchServices" />
    <link:label xml:lang="en-US" xlink:label="mrus_PaymentToCompensateResearchServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to compensate research services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PaymentToCompensateResearchServices" xlink:to="mrus_PaymentToCompensateResearchServices_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OverTimePaymentForFullTimeEquivalentFunding" xlink:type="locator" xlink:label="mrus_OverTimePaymentForFullTimeEquivalentFunding" />
    <link:label xml:lang="en-US" xlink:label="mrus_OverTimePaymentForFullTimeEquivalentFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Over time payment for full time equivalent funding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OverTimePaymentForFullTimeEquivalentFunding" xlink:to="mrus_OverTimePaymentForFullTimeEquivalentFunding_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_PaymentToCompensateResearchServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to compensate research services</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_PaymentToCompensateResearchServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Compensate Research Services</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OverTimePaymentForFullTimeEquivalentFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over time payment for full time equivalent funding</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OverTimePaymentForFullTimeEquivalentFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Time Payment For Full Time Equivalent Funding</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DevelopmentMilestonesReceived" xlink:type="locator" xlink:label="mrus_DevelopmentMilestonesReceived" />
    <link:label xml:lang="en-US" xlink:label="mrus_DevelopmentMilestonesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DevelopmentMilestonesReceived" xlink:to="mrus_DevelopmentMilestonesReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_DevelopmentMilestonesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones received</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DevelopmentMilestonesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones Received</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceived" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="mrus_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonRefundableUpfrontPaymentsReceived" xlink:to="mrus_NonRefundableUpfrontPaymentsReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payments Received</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfPerformanceObligation" xlink:type="locator" xlink:label="mrus_NumberOfPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfPerformanceObligation" xlink:to="mrus_NumberOfPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Performance Obligation</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfMilestonesAchieved" xlink:type="locator" xlink:label="mrus_NumberOfMilestonesAchieved" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfMilestonesAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestones achieved.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfMilestonesAchieved" xlink:to="mrus_NumberOfMilestonesAchieved_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestonePaymentsReceived" xlink:type="locator" xlink:label="mrus_MilestonePaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="mrus_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestonePaymentsReceived" xlink:to="mrus_MilestonePaymentsReceived_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DescriptionOfResearchAndDevelopmentPrograms" xlink:type="locator" xlink:label="mrus_DescriptionOfResearchAndDevelopmentPrograms" />
    <link:label xml:lang="en-US" xlink:label="mrus_DescriptionOfResearchAndDevelopmentPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of research and development programs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfResearchAndDevelopmentPrograms" xlink:to="mrus_DescriptionOfResearchAndDevelopmentPrograms_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfMilestonesAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NumberOfMilestonesAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DescriptionOfResearchAndDevelopmentPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of transaction price under fixed consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DescriptionOfResearchAndDevelopmentPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Research And Development Programs</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="mrus_ContingentMilestonePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="mrus_ContingentMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent milestone payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ContingentMilestonePaymentsReceivable" xlink:to="mrus_ContingentMilestonePaymentsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_ContingentMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ContingentMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Milestone Payments Receivable</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" xlink:type="locator" xlink:label="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" />
    <link:label xml:lang="en-US" xlink:label="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue related performance obligation amount as revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" xlink:to="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue related performance obligation as revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Related Performance Obligation Amount As Revenue</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestoneRevenue" xlink:type="locator" xlink:label="mrus_MilestoneRevenue" />
    <link:label xml:lang="en-US" xlink:label="mrus_MilestoneRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestoneRevenue" xlink:to="mrus_MilestoneRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_MilestoneRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MilestoneRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Revenue</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_Billings" xlink:type="locator" xlink:label="mrus_Billings" />
    <link:label xml:lang="en-US" xlink:label="mrus_Billings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Billings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_Billings" xlink:to="mrus_Billings_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AdjustmentsToContractAssetsReceivables" xlink:type="locator" xlink:label="mrus_AdjustmentsToContractAssetsReceivables" />
    <link:label xml:lang="en-US" xlink:label="mrus_AdjustmentsToContractAssetsReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to contract assets receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdjustmentsToContractAssetsReceivables" xlink:to="mrus_AdjustmentsToContractAssetsReceivables_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ForeignCurrencyExchangeTranslation" xlink:type="locator" xlink:label="mrus_ForeignCurrencyExchangeTranslation" />
    <link:label xml:lang="en-US" xlink:label="mrus_ForeignCurrencyExchangeTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency exchange translation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ForeignCurrencyExchangeTranslation" xlink:to="mrus_ForeignCurrencyExchangeTranslation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnbilledReceivablesMember" xlink:type="locator" xlink:label="mrus_UnbilledReceivablesMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_UnbilledReceivablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unbilled receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UnbilledReceivablesMember" xlink:to="mrus_UnbilledReceivablesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_UnbilledReceivablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled Receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_UnbilledReceivablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Receivables [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredRevenueMember" xlink:type="locator" xlink:label="mrus_DeferredRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeferredRevenueMember" xlink:to="mrus_DeferredRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_DeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_IncyteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incyte.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteMember" xlink:to="mrus_IncyteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_IncyteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incyte</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_IncyteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incyte [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OnoMember" xlink:type="locator" xlink:label="mrus_OnoMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_OnoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ono.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OnoMember" xlink:to="mrus_OnoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_OnoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ono</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OnoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ono [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OtherMember" xlink:type="locator" xlink:label="mrus_OtherMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherMember" xlink:to="mrus_OtherMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CollaborationAgreementMember" xlink:to="mrus_CollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_Billings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Billings</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_Billings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Billings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCustomers" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash receipts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Customers</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_AdjustmentsToContractAssetsReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_AdjustmentsToContractAssetsReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Contract Assets Receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ForeignCurrencyExchangeTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ForeignCurrencyExchangeTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Exchange Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized in the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current balance at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_UpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_UpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ReimbursementRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ReimbursementRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandTenPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandTenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandTenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2010 Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TwoThousandTenPlanMember" xlink:to="mrus_TwoThousandTenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandTenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2010 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandTenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Ten Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandSixteenPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandSixteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TwoThousandSixteenPlanMember" xlink:to="mrus_TwoThousandSixteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_TwoThousandSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonExecutiveDirectorsMember" xlink:type="locator" xlink:label="mrus_NonExecutiveDirectorsMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_NonExecutiveDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-executive directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonExecutiveDirectorsMember" xlink:to="mrus_NonExecutiveDirectorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_NonExecutiveDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Executive Directors</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_NonExecutiveDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Executive Directors [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SubsequentAwardMember" xlink:type="locator" xlink:label="mrus_SubsequentAwardMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_SubsequentAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SubsequentAwardMember" xlink:to="mrus_SubsequentAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_SubsequentAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Award</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_SubsequentAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Award [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentRetirementBenefitsMember" xlink:type="locator" xlink:label="us-gaap_PostemploymentRetirementBenefitsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentRetirementBenefitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Postemployment Retirement Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentRetirementBenefitsMember" xlink:to="us-gaap_PostemploymentRetirementBenefitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentRetirementBenefitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Retirement Benefits [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FourZeroOnePlanMember" xlink:type="locator" xlink:label="mrus_FourZeroOnePlanMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_FourZeroOnePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Four zero one plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FourZeroOnePlanMember" xlink:to="mrus_FourZeroOnePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_FourZeroOnePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401 (K) Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FourZeroOnePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Four Zero One Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of options granted share-based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting rights, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting rights, required service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" xlink:type="locator" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" />
    <link:label xml:lang="en-US" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" xlink:to="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of RSUs granted to employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of RSUs granted share-based payments</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares authorized for issuance for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" xlink:type="locator" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" />
    <link:label xml:lang="en-US" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual life of share-based compensation awards, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" xlink:to="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual life of options (years)</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Contractual Life Of Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term of options (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility of underlying stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited or expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Forfeited or expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of RSUs, Non-vested, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of RSUs, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of RSUs, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of RSUs, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of RSUs, Non-vested, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant-date Fair Value, Non-vested, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant-date Fair Value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant-date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant-date Fair Value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant-date Fair Value, Non-vested, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of RSUs vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions to post-employment benefit plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefit Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan , description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Defined Contribution Pension And Other Postretirement Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employer matching contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percent of employees compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GrantOfRestrictedStockUnit" xlink:type="locator" xlink:label="mrus_GrantOfRestrictedStockUnit" />
    <link:label xml:lang="en-US" xlink:label="mrus_GrantOfRestrictedStockUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant of restricted stock unit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GrantOfRestrictedStockUnit" xlink:to="mrus_GrantOfRestrictedStockUnit_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitsLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive settlement, cash compensation to be paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsLiabilityCurrent" xlink:to="us-gaap_PostemploymentBenefitsLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitsLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_GrantOfRestrictedStockUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant of RSUs</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_GrantOfRestrictedStockUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Of Restricted Stock Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive settlement expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits Period Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MerusNVMember" xlink:type="locator" xlink:label="mrus_MerusNVMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_MerusNVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merus NV.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MerusNVMember" xlink:to="mrus_MerusNVMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_MerusNVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merus N V [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MerusNVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merus N V [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Noncontrolling Owners</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" xlink:type="locator" xlink:label="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" />
    <link:label xml:lang="en-US" xlink:label="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future contingent development and regulatory milestones receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" xlink:to="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CommercialSalesMilestones" xlink:type="locator" xlink:label="mrus_CommercialSalesMilestones" />
    <link:label xml:lang="en-US" xlink:label="mrus_CommercialSalesMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial sales milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CommercialSalesMilestones" xlink:to="mrus_CommercialSalesMilestones_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="mrus_MilestonePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="mrus_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestonePaymentsReceivable" xlink:to="mrus_MilestonePaymentsReceivable_lbl" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and License Agreement and Share Subscription Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" xlink:to="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement and Share Subscription Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement And Share Subscription Agreement [Member]</link:label>
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnderwritersMember" xlink:type="locator" xlink:label="mrus_UnderwritersMember" />
    <link:label xml:lang="en-US" xlink:label="mrus_UnderwritersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UnderwritersMember" xlink:to="mrus_UnderwritersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mrus_UnderwritersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_UnderwritersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future contingent development and regulatory milestones receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Contingent Development And Regulatory Milestones Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CommercialSalesMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sales milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_CommercialSalesMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sales Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="mrus_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>31
<FILENAME>mrus-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T01:02:00.9496874+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 86139572bfd14d72a654e4791bd938db -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merus.nl/20201231/role/TemplateLink" xlink:href="mrus-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mrus-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MiscellaneousIncomeAndGains" xlink:type="locator" xlink:label="mrus_MiscellaneousIncomeAndGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GrantRevenueMember" xlink:type="locator" xlink:label="mrus_GrantRevenueMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationRevenueRelatedPartyMember" xlink:type="locator" xlink:label="mrus_CollaborationRevenueRelatedPartyMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationRevenueMember" xlink:type="locator" xlink:label="mrus_CollaborationRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_CollaborationRevenueMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_CollaborationRevenueRelatedPartyMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_GrantRevenueMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="mrus_MiscellaneousIncomeAndGains" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RestrictedCashAndOtherAssets" xlink:type="locator" xlink:label="mrus_RestrictedCashAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FinanceCostIncurredButNotYetPaid" xlink:type="locator" xlink:label="mrus_FinanceCostIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ForeignExchangeGain" xlink:type="locator" xlink:label="mrus_ForeignExchangeGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mrus_ForeignExchangeGain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mrus_FinanceCostIncurredButNotYetPaid" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="mrus_RestrictedCashAndOtherAssets" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="mrus-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:type="locator" xlink:label="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" xlink:type="locator" xlink:label="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompany" xlink:href="mrus-20201231.xsd#Role_DisclosureTheCompany" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompany">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="mrus-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets" xlink:href="mrus-20201231.xsd#Role_DisclosurePrepaidExpensesAndOtherAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="mrus-20201231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="mrus-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="mrus-20201231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare" xlink:href="mrus-20201231.xsd#Role_DisclosureLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="mrus-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="mrus-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mrus-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PendingAccountingPronouncementsPolicyTextBlock" xlink:type="locator" xlink:label="mrus_PendingAccountingPronouncementsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="mrus_GoingConcernPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" xlink:type="locator" xlink:label="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrus_FunctionalAndPresentationCurrencyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrus_GoingConcernPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrus_PendingAccountingPronouncementsPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="mrus-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" xlink:type="locator" xlink:label="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAbstract" xlink:to="mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsTables" xlink:href="mrus-20201231.xsd#Role_DisclosurePrepaidExpensesAndOtherAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="mrus-20201231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:type="locator" xlink:label="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareTables" xlink:href="mrus-20201231.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="mrus_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAndSharePurchaseAgreementsMember" xlink:type="locator" xlink:label="mrus_CollaborationAndSharePurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrus_CollaborationAndSharePurchaseAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrus_FollowOnPublicOfferingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:type="locator" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdditionalCashAndCashEquivalentRelatedText" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrus_IncreaseDecreaseInResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeFurnitureAndEquipmentMember" xlink:type="locator" xlink:label="mrus_OfficeFurnitureAndEquipmentMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="mrus_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_LaboratoryEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_OfficeFurnitureAndEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MarketableSecuritiesNonCurrentMember" xlink:type="locator" xlink:label="mrus_MarketableSecuritiesNonCurrentMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MarketableSecuritiesCurrentMember" xlink:type="locator" xlink:label="mrus_MarketableSecuritiesCurrentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mrus_MarketableSecuritiesCurrentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mrus_MarketableSecuritiesNonCurrentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_HeldToMaturitySecurities" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StandardPoorsAMinusToAPlusRatingMember" xlink:type="locator" xlink:label="mrus_StandardPoorsAMinusToAPlusRatingMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_StandardPoorsAAMinusToAAPlusRatingMember" xlink:type="locator" xlink:label="mrus_StandardPoorsAAMinusToAAPlusRatingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StandardPoorsAAARatingMember" xlink:type="locator" xlink:label="srt_StandardPoorsAAARatingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExternalCreditRatingStandardPoorsMember" xlink:type="locator" xlink:label="srt_ExternalCreditRatingStandardPoorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CreditRatingStandardPoorsAxis" xlink:type="locator" xlink:label="srt_CreditRatingStandardPoorsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CorporatePaperNotesAndBondsMember" xlink:type="locator" xlink:label="mrus_CorporatePaperNotesAndBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditQualityInformationAbstract" xlink:type="locator" xlink:label="us-gaap_CreditQualityInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditQualityInformationAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="mrus_CorporatePaperNotesAndBondsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:to="srt_CreditRatingStandardPoorsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CreditRatingStandardPoorsAxis" xlink:to="srt_ExternalCreditRatingStandardPoorsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="srt_StandardPoorsAAARatingMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="mrus_StandardPoorsAAMinusToAAPlusRatingMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ExternalCreditRatingStandardPoorsMember" xlink:to="mrus_StandardPoorsAMinusToAPlusRatingMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CorporatePaperNotesAndBondsMember" xlink:type="locator" xlink:label="mrus_CorporatePaperNotesAndBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="mrus_CorporatePaperNotesAndBondsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidGeneralAndAdministrativeCosts" xlink:type="locator" xlink:label="mrus_PrepaidGeneralAndAdministrativeCosts" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PrepaidClinicalAndManufacturingCostsCurrent" xlink:type="locator" xlink:label="mrus_PrepaidClinicalAndManufacturingCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="mrus_PrepaidClinicalAndManufacturingCostsCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="mrus_PrepaidGeneralAndAdministrativeCosts" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeEquipmentAndFurnitureMember" xlink:type="locator" xlink:label="mrus_OfficeEquipmentAndFurnitureMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="mrus_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_OfficeEquipmentAndFurnitureMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_NL" xlink:type="locator" xlink:label="country_NL" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_NL" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AccruedGeneralAndAdministrativeExpenses" xlink:type="locator" xlink:label="mrus_AccruedGeneralAndAdministrativeExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="mrus_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mrus_AccruedResearchAndDevelopmentExpensesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mrus_AccruedGeneralAndAdministrativeExpenses" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredTaxAssetsLeaseObligation" xlink:type="locator" xlink:label="mrus_DeferredTaxAssetsLeaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mrus_DeferredTaxAssetsLeaseObligation" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:type="locator" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ExpirationDateCarryForwards" xlink:type="locator" xlink:label="mrus_ExpirationDateCarryForwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2027Member" xlink:type="locator" xlink:label="mrus_TaxYear2027Member" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2026Member" xlink:type="locator" xlink:label="mrus_TaxYear2026Member" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2025Member" xlink:type="locator" xlink:label="mrus_TaxYear2025Member" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TaxYear2024Member" xlink:type="locator" xlink:label="mrus_TaxYear2024Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2024Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2025Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2026Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="mrus_TaxYear2027Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="mrus_ExpirationDateCarryForwards" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails">
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OperatingLeaseRentAdjustmentDescription" xlink:type="locator" xlink:label="mrus_OperatingLeaseRentAdjustmentDescription" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ConsumerPriceIndex" xlink:type="locator" xlink:label="mrus_ConsumerPriceIndex" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseTerminationTerm" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseTerminationTerm" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" xlink:type="locator" xlink:label="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LesseeOperatingLeaseExtendedTermOfContract" xlink:type="locator" xlink:label="mrus_LesseeOperatingLeaseExtendedTermOfContract" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OperatingLeaseExpirationTerm" xlink:type="locator" xlink:label="mrus_OperatingLeaseExpirationTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OfficeAndLaboratoryMember" xlink:type="locator" xlink:label="mrus_OfficeAndLaboratoryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_KadansSciencePartnerXIIBVMember" xlink:type="locator" xlink:label="mrus_KadansSciencePartnerXIIBVMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:type="locator" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MerusUSIncMember" xlink:type="locator" xlink:label="mrus_MerusUSIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mrus_MerusUSIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrus_KadansSciencePartnerXIIBVMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrus_OfficeAndLaboratoryMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_OperatingLeaseExpirationTerm" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_LesseeOperatingLeaseExtendedTermOfContract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_LesseeOperatingLeaseNumberOfRenewalTerm" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_LesseeOperatingLeaseTerminationTerm" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_ConsumerPriceIndex" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mrus_OperatingLeaseRentAdjustmentDescription" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandSixteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandSixteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="mrus_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrus_UnderwrittenPublicOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrus_TwoThousandSixteenIncentiveAwardPlanMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestoneRevenue" xlink:type="locator" xlink:label="mrus_MilestoneRevenue" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" xlink:type="locator" xlink:label="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="mrus_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DescriptionOfResearchAndDevelopmentPrograms" xlink:type="locator" xlink:label="mrus_DescriptionOfResearchAndDevelopmentPrograms" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestonePaymentsReceived" xlink:type="locator" xlink:label="mrus_MilestonePaymentsReceived" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfMilestonesAchieved" xlink:type="locator" xlink:label="mrus_NumberOfMilestonesAchieved" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfPerformanceObligation" xlink:type="locator" xlink:label="mrus_NumberOfPerformanceObligation" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceived" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceived" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DevelopmentMilestonesReceived" xlink:type="locator" xlink:label="mrus_DevelopmentMilestonesReceived" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OverTimePaymentForFullTimeEquivalentFunding" xlink:type="locator" xlink:label="mrus_OverTimePaymentForFullTimeEquivalentFunding" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_PaymentToCompensateResearchServices" xlink:type="locator" xlink:label="mrus_PaymentToCompensateResearchServices" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NumberOfBispecificAntibodies" xlink:type="locator" xlink:label="mrus_NumberOfBispecificAntibodies" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_RevenueFromCollaborativeArrangement" xlink:type="locator" xlink:label="mrus_RevenueFromCollaborativeArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_BettaCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_BettaCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SecondBispecificAntibodyResearchProgramMember" xlink:type="locator" xlink:label="mrus_SecondBispecificAntibodyResearchProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LicenseAndPerformanceMember" xlink:type="locator" xlink:label="mrus_LicenseAndPerformanceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SecondONOResearchAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_SecondONOResearchAndLicenseAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_LicenseAndRelatedActivitiesMember" xlink:type="locator" xlink:label="mrus_LicenseAndRelatedActivitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="mrus_IncyteCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_IncyteCollaborationAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_LicenseAndRelatedActivitiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_SecondONOResearchAndLicenseAgreementMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_LicenseAndPerformanceMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="mrus_SecondBispecificAntibodyResearchProgramMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_BettaCollaborationAndLicenseAgreementMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_RevenueFromCollaborativeArrangement" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NumberOfBispecificAntibodies" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_PaymentToCompensateResearchServices" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_OverTimePaymentForFullTimeEquivalentFunding" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_DevelopmentMilestonesReceived" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceived" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NumberOfPerformanceObligation" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NumberOfMilestonesAchieved" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_MilestonePaymentsReceived" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_DescriptionOfResearchAndDevelopmentPrograms" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_ContingentMilestonePaymentsReceivable" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_RevenueRelatedPerformanceObligationAmountAsRevenue" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_MilestoneRevenue" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet_li0l2" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ForeignCurrencyExchangeTranslation" xlink:type="locator" xlink:label="mrus_ForeignCurrencyExchangeTranslation" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_AdjustmentsToContractAssetsReceivables" xlink:type="locator" xlink:label="mrus_AdjustmentsToContractAssetsReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCustomers" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_Billings" xlink:type="locator" xlink:label="mrus_Billings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OtherMember" xlink:type="locator" xlink:label="mrus_OtherMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OnoMember" xlink:type="locator" xlink:label="mrus_OnoMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_DeferredRevenueMember" xlink:type="locator" xlink:label="mrus_DeferredRevenueMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnbilledReceivablesMember" xlink:type="locator" xlink:label="mrus_UnbilledReceivablesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="mrus_UnbilledReceivablesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="mrus_DeferredRevenueMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_IncyteMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OnoMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OtherMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_CollaborationAgreementMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_Billings" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCustomers" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_AdjustmentsToContractAssetsReceivables" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_ForeignCurrencyExchangeTranslation" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet_li0l2" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ReimbursementRevenues" xlink:type="locator" xlink:label="mrus_ReimbursementRevenues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UpfrontPayments" xlink:type="locator" xlink:label="mrus_UpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAgreementMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OtherMember" xlink:type="locator" xlink:label="mrus_OtherMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_OnoMember" xlink:type="locator" xlink:label="mrus_OnoMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_IncyteMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OnoMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_OtherMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_CollaborationAgreementMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_UpfrontPayments" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_ReimbursementRevenues" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_GrantOfRestrictedStockUnit" xlink:type="locator" xlink:label="mrus_GrantOfRestrictedStockUnit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" xlink:type="locator" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FourZeroOnePlanMember" xlink:type="locator" xlink:label="mrus_FourZeroOnePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentRetirementBenefitsMember" xlink:type="locator" xlink:label="us-gaap_PostemploymentRetirementBenefitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_SubsequentAwardMember" xlink:type="locator" xlink:label="mrus_SubsequentAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonExecutiveDirectorsMember" xlink:type="locator" xlink:label="mrus_NonExecutiveDirectorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandSixteenPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandSixteenPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_TwoThousandTenPlanMember" xlink:type="locator" xlink:label="mrus_TwoThousandTenPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrus_TwoThousandTenPlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrus_TwoThousandSixteenPlanMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mrus_NonExecutiveDirectorsMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="mrus_SubsequentAwardMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PostemploymentRetirementBenefitsMember" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="mrus_FourZeroOnePlanMember" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="13120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="13190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="13240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="13310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="13390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="13430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PostemploymentBenefitsLiabilityCurrent" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrus_GrantOfRestrictedStockUnit" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" order="13540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" xlink:type="locator" xlink:label="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MerusNVMember" xlink:type="locator" xlink:label="mrus_MerusNVMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_IncyteMember" xlink:type="locator" xlink:label="mrus_IncyteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrus_IncyteMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="mrus_MerusNVMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="mrus-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="mrus_MilestonePaymentsReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CommercialSalesMilestones" xlink:type="locator" xlink:label="mrus_CommercialSalesMilestones" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" xlink:type="locator" xlink:label="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:type="locator" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_UnderwritersMember" xlink:type="locator" xlink:label="mrus_UnderwritersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="mrus-20201231.xsd#mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" xlink:type="locator" xlink:label="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrus_UnderwritersMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_CommercialSalesMilestones" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mrus_MilestonePaymentsReceivable" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>mrus-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrus="http://www.merus.nl/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrus-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001651311_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001651311_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001651311_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_mrusCollaborationAndSharePurchaseAgreementsMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrus:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusFollowOnPublicOfferingMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeFurnitureAndEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrus:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAARatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAAMinusToAAPlusRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">mrus:StandardPoorsAMinusToAPlusRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mrus:CorporatePaperNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtStatementGeographicalAxis_countryNL_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtStatementGeographicalAxis_countryNL_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mrus:TaxYear2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrus:MerusUSIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrus:MerusUSIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrus:KadansSciencePartnerXIIBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrus:KadansSciencePartnerXIIBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtRangeAxis_srtMinimumMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrus:KadansSciencePartnerXIIBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrus:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-07</startDate>
            <endDate>2019-11-07</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-07</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123_20201123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-23</startDate>
            <endDate>2020-11-23</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-23</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124_20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-24</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203_20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapPlanNameAxis_mrusTwoThousandSixteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:IncyteCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:IncyteCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndRelatedActivitiesMember_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:LicenseAndRelatedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:IncyteCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SecondONOResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-14</startDate>
            <endDate>2018-03-14</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SecondONOResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-14</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SecondONOResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-14</startDate>
            <endDate>2018-03-14</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndPerformanceMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentArrangementMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:LicenseAndPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200701_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrusSecondBispecificAntibodyResearchProgramMember_20200701_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrus:SecondBispecificAntibodyResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:BettaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-10</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:BettaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:BettaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandTenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">mrus:SubsequentAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrus:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">mrus:SubsequentAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrus:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">mrus:FourZeroOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">mrus:FourZeroOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">mrus:FourZeroOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PostemploymentRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mrus:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mrus:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrus:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-18</instant>
        </period>
    </context>
    <context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-18</startDate>
            <endDate>2021-01-18</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrus:CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-18</startDate>
            <endDate>2021-01-18</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrus:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217EUR_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_mrusSegment">
        <measure>mrus:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_utrsqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="U_mrusRenewalTerm">
        <measure>mrus:RenewalTerm</measure>
    </unit>
    <unit id="U_iso4217EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_mrusAntibody">
        <measure>mrus:Antibody</measure>
    </unit>
    <unit id="U_mrusPerformanceObligation">
        <measure>mrus:PerformanceObligation</measure>
    </unit>
    <unit id="U_mrusMilestone">
        <measure>mrus:Milestone</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001651311_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0001651311_20200101_20201231" id="F_000003_2">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001651311_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="C_0001651311_20200101_20201231" id="F_000005">Merus N.V.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0001651311_20200101_20201231" id="F_000007">0001651311</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001651311_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001651311_20200101_20201231" id="F_000023">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331"
      id="F_000566">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <dei:DocumentFiscalYearFocus contextRef="C_0001651311_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_20200101_20201231"
      id="F_000777">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000783">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000793">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000801">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000806">P4Y</mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231"
      id="F_000784">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231"
      id="F_000794">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231"
      id="F_000802">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231"
      id="F_000807">P4Y</mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001651311_20201231"
      id="F_000080"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001651311_20191231"
      id="F_000081"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001651311_20201231" id="F_000593">P4Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001651311_20191231" id="F_000594">P4Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">0</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000819">P10Y</mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions>
    <mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000820">P10Y</mrus:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000821">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001651311_20200101_20201231" id="F_000839">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001651311_20200101_20201231" id="F_000840">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="C_0001651311_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001651311_20200101_20201231" id="F_000030">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001651311_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0001651311_20200101_20201231" id="F_000031">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001651311_20200101_20201231" id="F_000021">001-37773</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001651311_20200101_20201231" id="F_000022">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="C_0001651311_20200101_20201231" id="F_000024">Yalelaan 62</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="C_0001651311_20200101_20201231" id="F_000026">3584 CM</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="C_0001651311_20200101_20201231" id="F_000025">Utrecht</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="C_0001651311_20200101_20201231" id="F_000027">NL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="C_0001651311_20200101_20201231" id="F_000028">+31 30</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001651311_20200101_20201231" id="F_000029">253 8800</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001651311_20200101_20201231" id="F_000032">Common shares,  nominal value &#x20ac;0.09 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001651311_20200101_20201231" id="F_000006">MRUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001651311_20200101_20201231" id="F_000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001651311_20200101_20201231" id="F_000009">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001651311_20200101_20201231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001651311_20200101_20201231" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001651311_20200101_20201231" id="F_000018">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001651311_20200101_20201231" id="F_000012">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001651311_20200101_20201231" id="F_000014">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001651311_20200101_20201231" id="F_000015">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001651311_20200101_20201231" id="F_000016">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001651311_20200101_20201231" id="F_000017">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001651311_20200101_20201231" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001651311_20200630"
      decimals="-5"
      id="F_000020"
      unitRef="U_iso4217USD">464900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001651311_20210228"
      decimals="INF"
      id="F_000019"
      unitRef="U_xbrlishares">38126976</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000280">
&lt;p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the registrant&#x2019;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2021 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">163082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">197612000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">44673000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">42153000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">46000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">941000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">1623000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">1711000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">8569000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">4951000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">217993000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">247368000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">2009000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">4115000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">3715000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">3907000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">5215000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">2843000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">2876000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">410000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">288000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">1949000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">1905000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">231217000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">263376000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">3126000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">3029000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">21803000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">13536000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">206000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">1432000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">1380000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">625000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">941000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">19554000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">17901000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">46746000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">36787000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">2521000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">3872000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">237000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">780000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">79450000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">90637000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">128954000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">132076000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217EUR_xbrlishares">0.09</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001651311_20191231"
      decimals="INF"
      id="F_000095"
      unitRef="U_iso4217EUR_xbrlishares">0.09</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">45000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001651311_20191231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">45000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">31602953</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">31602953</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001651311_20191231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">28882217</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001651311_20191231"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">28882217</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">3211000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">2918000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">490093000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">441395000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">9071000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">1586000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">-400112000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">-314599000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">102263000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">131300000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">231217000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">263376000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">3363000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">5517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">26580000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusCollaborationRevenueRelatedPartyMember_20190101_20191231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">25831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusGrantRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">29943000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">31133000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">70040000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">55680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">35781000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">34110000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">105821000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">89790000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-75878000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-58657000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">1889000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">-9432000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">1615000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <mrus:MiscellaneousIncomeAndGains
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">0</mrus:MiscellaneousIncomeAndGains>
    <mrus:MiscellaneousIncomeAndGains
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">196000</mrus:MiscellaneousIncomeAndGains>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-9132000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-85010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-54957000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">194000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-85513000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-55151000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">7485000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">-1308000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">-78028000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-56459000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001651311_20200101_20201231"
      decimals="2"
      id="F_000136"
      unitRef="U_iso4217USD_xbrlishares">-2.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001651311_20190101_20191231"
      decimals="2"
      id="F_000137"
      unitRef="U_iso4217USD_xbrlishares">-2.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000138"
      unitRef="U_xbrlishares">29256203000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000139"
      unitRef="U_xbrlishares">24218083000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">-85513000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-55151000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">1165000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">902000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">279000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">236000</us-gaap:AmortizationOfIntangibleAssets>
    <mrus:ForeignExchangeGain
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">-8957000</mrus:ForeignExchangeGain>
    <mrus:ForeignExchangeGain
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">1068000</mrus:ForeignExchangeGain>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">9372000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">7834000</us-gaap:ShareBasedCompensation>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-40000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">531000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-122000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-89000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-1149000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">-633000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">112000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">2895000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">1029000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">-110000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">22000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">7023000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">3317000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">-19246000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">-18012000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">-79901000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">-63048000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">66845000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">60413000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">66646000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">87183000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">375000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">1287000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">2223000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-1486000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">24172000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">38072000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">74184000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">1448000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">48000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">39520000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">74232000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">7337000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">-2273000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-34530000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">33083000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">197813000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20181231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">164730000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">163283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">197813000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">3875000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">36000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">187000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <mrus:FinanceCostIncurredButNotYetPaid
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">71000</mrus:FinanceCostIncurredButNotYetPaid>
    <mrus:FinanceCostIncurredButNotYetPaid
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">164000</mrus:FinanceCostIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-322000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-320000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">24000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">163082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">197612000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <mrus:RestrictedCashAndOtherAssets
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">201000</mrus:RestrictedCashAndOtherAssets>
    <mrus:RestrictedCashAndOtherAssets
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">201000</mrus:RestrictedCashAndOtherAssets>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">163283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">197813000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000208"
      unitRef="U_xbrlishares">23358977</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">2366000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">360045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">-259448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">2894000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_20181231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">105857000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000214"
      unitRef="U_xbrlishares">5462500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">546000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">73474000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">74020000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrus:StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000220"
      unitRef="U_xbrlishares">60740</mrus:StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">6000</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">42000</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">0</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">0</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">48000</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">7834000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">7834000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">-1308000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">-1308000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">-55151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-55151000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000241"
      unitRef="U_xbrlishares">28882217</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">2918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">441395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">-314599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">1586000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">131300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000247"
      unitRef="U_xbrlishares">2451281</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">265000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">37906000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">38171000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrus:StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000253"
      unitRef="U_xbrlishares">269455</mrus:StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">28000</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">1420000</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">0</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">0</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">1448000</mrus:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">9372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">9372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">7485000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">7485000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">-85513000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">-85513000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000274"
      unitRef="U_xbrlishares">31602953</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">3211000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">490093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">-400112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">9071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">102263000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations contextRef="C_0001651311_20200101_20201231" id="F_000281">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. The Company &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Merus N.V. is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the &#x201c;Company&#x201d;).&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company has generated an accumulated loss of $400.1 million as of December&#160;31, 2020. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its bispecific antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved bispecific antibody candidate.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations with third parties and business development opportunities. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#x2019;s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on our current operating plan, the Company expects that its existing cash, cash equivalents and marketable securities of $207.8 million as of December 31, 2020, combined with the aggregate immediate proceeds from the closing of the collaboration and share purchase agreements with Eli Lilly &amp;amp; Co (Eli Lilly) in January 2021 of $60.0 million and the aggregate net proceeds from the January 2021 follow-on offering of $129.7 million in January 2021, will fund the Company&#x2019;s operations at least into the second half of 2024.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001651311_20201231"
      decimals="-5"
      id="F_000346"
      unitRef="U_iso4217USD">-400100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001651311_20201231"
      decimals="-5"
      id="F_000347"
      unitRef="U_iso4217USD">207800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_mrusCollaborationAndSharePurchaseAgreementsMember_20210101_20210131"
      decimals="-5"
      id="F_000348"
      unitRef="U_iso4217USD">60000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusFollowOnPublicOfferingMember_20210101_20210131"
      decimals="-5"
      id="F_000349"
      unitRef="U_iso4217USD">129700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000282">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Preparation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the U.S. ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsidiaries are entities controlled by the Company, consisting of Merus N.V.&#x2019;s wholly owned subsidiary Merus US, Inc. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Functional and Presentation Currency&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items recorded in each of the Company&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (the &lt;span style="color:#000000;"&gt;"&lt;/span&gt;functional currency&lt;span style="color:#000000;"&gt;"&lt;/span&gt;). Merus US, Inc.&#x2019;s functional currency is the U.S. dollar. The functional currency of Merus N.V. is the euro. After measuring foreign currency denominated transactions into an entity&#x2019;s functional currency, to the extent that a subsidiary&#x2019;s functional currency differs from its parent, a subsidiary&#x2019;s financial position and results of operations are translated into its parent&#x2019;s functional currency. The Company&#x2019;s consolidated financial position and results of operations are translated into the U.S. dollar as the Company&#x2019;s reporting currency.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amounts of collaboration revenue and expenses during the reporting period. Actual results and outcomes may differ materially from management&#x2019;s estimates, judgments and assumptions. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, marketable securities and accounts receivable. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments as defined by the Company. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit the Company&#x2019;s credit exposure to any single issuer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts &lt;span style="color:#000000;"&gt;receivable&lt;/span&gt; represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Subsequent Events &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers events or transactions that occur after the balance sheet date but before the consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company evaluated all events and transactions through the date these financial statements were filed with the Securities and Exchange Commission. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.73%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 1 &#x2013; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.73%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 2 &#x2013; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined through the use of models or other valuation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.73%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 3 &#x2013; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined by the reporting entity&#x2019;s own assumptions utilizing the best information available and includes situations where there is little market activity for the asset or liability. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The asset&#x2019;s or liability&#x2019;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers its cash, cash equivalents, accounts receivable, marketable securities due with maturities 12 months or less, and accounts payable financial instruments to reflect their fair value given their short maturity and risk profile of the counterparty.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Going Concern &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to &lt;span style="color:#000000;"&gt;continue&lt;/span&gt; as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#x2019;s cash needs, and &lt;span style="color:#000000;"&gt;comparing&lt;/span&gt; &lt;span style="color:#000000;"&gt;those&lt;/span&gt; needs to the current cash, cash equivalent and marketable security balances. After considering the Company&#x2019;s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable securities as of December&#160;31, 2020, the Company did not identify conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year from the date these financial statements were issued.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid debt securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Instruments subject to restrictions are not included in cash and cash equivalents.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies marketable securities that are debt securities with a remaining maturity when purchased of greater than three months as held-to-maturity as the Company has the positive intent and ability to hold such debt securities through maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities that are classified as held-to-maturity are initially recognized and measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Interest income from these debt securities is included in interest income. Marketable securities are classified as current if their expected maturity is within one year or less of the balance sheet date and non-current if their maturity is beyond one year of the balance sheet date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounts Receivable &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable are amounts due from collaboration partners as a result of research and development services provided or milestones achieved but not yet paid.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Allowance for Credit Losses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its cash equivalents, accounts receivable and held-to-maturity marketable securities financial assets for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current environment, the Company concluded there is generally no expected credit losses for these financial assets. With respect to held-to-maturity marketable securities which are comprised of debt securities, the Company evaluates expected credit losses on a pooled basis based on issuer-type which have similar credit risk characteristics. The allowance for credit losses is immaterial for all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes expenditures for new property and equipment and improvements to existing facilities and charges the cost of maintenance to expense. The Company eliminates the cost of property retired or otherwise disposed of, along with the corresponding accumulated depreciation or amortization, from the related accounts, and the resulting gain or loss is reflected in the results of operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets are identifiable non-monetary assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or self-creation) and from which future economic benefits (inflows of cash or other assets) are expected. The useful lives of intangible assets are assessed to be definite-lived and amortized over the useful economic life. The Company&#x2019;s intangible assets are comprised of purchased licenses to intellectual property and software licenses. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews long-lived assets to be held and used, including property and equipment, operating lease right-of-use assets and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No such impairments were recorded in 2020 or 2019. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company does not have any finance leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease, and excludes non-lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets also include the effect of any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has real estate operating lease agreements with lease and non-lease components, which are generally accounted for separately as operating lease costs and variable lease costs. Non-lease components in real estate leases refer to services provided by the lessor related to the premises. Fixed and variable lease payments are both allocated to lease and non-lease components. The allocation is determined on a relative fair value basis of the services provided relative to the operating lease of premises. With respect to equipment leases, the Company has elected not to allocate payments amongst lease and non-lease components as a practical expedient as afforded under ASC 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Deferred Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records deferred taxes to recognize the future effects of temporary differences between the tax basis and financial statement carrying amount of assets and liabilities. The Company measures the deferred taxes using enacted tax rates expected to apply when the temporary differences are realized and records a valuation allowance to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available, reversing taxable temporary differences and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized Tax Benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the technical merits, facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to an underpayment of income taxes, if applicable, as a component of income tax expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for an arrangement, the Company performs the following five step analysis: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;i.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;identify the contract(s) with a customer; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;ii.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;iii.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;determine the transaction price; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;iv.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;allocate the transaction price to the performance obligations in the contract; and &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;v.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i)&#160;licenses, or options to obtain licenses, to product candidates or future product candidates directed to specific targets (referred to as &#x201c;exclusive licenses&#x201d;) and (ii)&#160;research and development activities to be &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;performed on behalf of the collaboration partner related to the licensed targets.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also derives revenue from government grants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the accounting for these arrangements, the Company must use judgment to determine: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;the transaction price under step (iii) above; and &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as unbilled receivables.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive Licenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the rights and obligations set out in the contract, the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i)&#160;at the inception of the arrangement as an upfront fee or payment, (ii)&#160;upon the exercise of an option to acquire a license or (iii)&#160;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based milestones or royalty revenue resulting from any of its arrangements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Services&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promises under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period as described under&#160;&lt;span style="font-style:italic;"&gt;Exclusive Licenses&#160;&lt;/span&gt;above. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it&#160;is probable that a significant revenue reversal would not occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Government Grants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the R&amp;amp;D cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. Government grant revenue may be subject to review by a government authority in periods subsequent to their recognition and may result in the reversal of grant revenue previously recognized. Reversals of grant revenue are presented as contra revenue in the consolidated statement of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses are expensed as incurred. Research and development expenses are comprised of costs incurred in providing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract research and development services, and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When third-party service providers&#x2019; billing terms do not coincide with the Company&#x2019;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs, contractual services costs and costs for supply of its product candidates incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period, past history in conducting similar activities and the expected duration of the third-party service contract, among other considerations. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of research and development expenses. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The WBSO (&lt;span style="font-style:italic;"&gt;afdrachtvermindering speur- en ontwikkelingswerk&lt;/span&gt;) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;this act, a contribution is paid towards the labor costs of employees directly involved in research and development. &lt;/span&gt;&lt;span style="color:#000000;"&gt;For the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;"&gt;2020&lt;/span&gt;&lt;span style="color:#000000;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;"&gt;, the Company recognized&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;$6.0 million&lt;/span&gt;&lt;span style="color:#000000;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;"&gt;$4.5 million&lt;/span&gt;&lt;span style="color:#000000;"&gt; as a reduction of research and development expenses, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Share-Based Payments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures employee share-based compensation based on the grant date fair value of the share-based compensation award. The Company grants stock options at exercise prices equal to the fair value of the Company&#x2019;s common stock on the date of grant, based on observable market prices. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For share-based payments subject time-based vesting, the Company recognizes employee stock-based compensation expense on a straight-line basis over the requisite service period of the awards, generally from the date of grant through each vesting date. The Company recognizes forfeitures at the time they occur. The actual expense recognized over the vesting period will only represent those options that vest; the effect of forfeitures in the recognition of periodic compensation expense are not estimated prior to their occurrence. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Earnings (Loss) per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company computes basic earnings (loss) per share by dividing income (loss) allocable to common stockholders by the weighted average number of shares of common stock outstanding. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The Company computes diluted earnings (loss) per share after giving consideration to the dilutive effect of stock options and restricted stock units (&#x201c;RSU&#x201d;) that are outstanding during the period, except where such non-participating securities would be anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Pending Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;span style="font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;. The new &lt;span style="color:#000000;"&gt;guidance&lt;/span&gt; aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for the Company at the beginning of 2021, including interim periods within that reporting period, although early adoption is permitted. The Company does not expect the impact of adoption to be significant.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808)&lt;/span&gt;, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative &lt;span style="color:#000000;"&gt;arrangement&lt;/span&gt; participant if the participant is not a customer. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. As of December 31, 2020, none of the Company&#x2019;s arrangements fall within the scope of ASC 808. However, as the Company may engage in future collaborative arrangements in the future, this ASU may apply to those new arrangements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000297">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Preparation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the U.S. ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000298">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsidiaries are entities controlled by the Company, consisting of Merus N.V.&#x2019;s wholly owned subsidiary Merus US, Inc. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <mrus:FunctionalAndPresentationCurrencyPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000299">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Functional and Presentation Currency&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items recorded in each of the Company&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (the &lt;span style="color:#000000;"&gt;"&lt;/span&gt;functional currency&lt;span style="color:#000000;"&gt;"&lt;/span&gt;). Merus US, Inc.&#x2019;s functional currency is the U.S. dollar. The functional currency of Merus N.V. is the euro. After measuring foreign currency denominated transactions into an entity&#x2019;s functional currency, to the extent that a subsidiary&#x2019;s functional currency differs from its parent, a subsidiary&#x2019;s financial position and results of operations are translated into its parent&#x2019;s functional currency. The Company&#x2019;s consolidated financial position and results of operations are translated into the U.S. dollar as the Company&#x2019;s reporting currency.&lt;/p&gt;</mrus:FunctionalAndPresentationCurrencyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001651311_20200101_20201231" id="F_000300">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amounts of collaboration revenue and expenses during the reporting period. Actual results and outcomes may differ materially from management&#x2019;s estimates, judgments and assumptions. &lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001651311_20200101_20201231" id="F_000301">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, marketable securities and accounts receivable. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments as defined by the Company. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit the Company&#x2019;s credit exposure to any single issuer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts &lt;span style="color:#000000;"&gt;receivable&lt;/span&gt; represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000302">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Subsequent Events &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers events or transactions that occur after the balance sheet date but before the consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company evaluated all events and transactions through the date these financial statements were filed with the Securities and Exchange Commission. &lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000303">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.73%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 1 &#x2013; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.73%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 2 &#x2013; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined through the use of models or other valuation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.73%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 3 &#x2013; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined by the reporting entity&#x2019;s own assumptions utilizing the best information available and includes situations where there is little market activity for the asset or liability. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The asset&#x2019;s or liability&#x2019;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers its cash, cash equivalents, accounts receivable, marketable securities due with maturities 12 months or less, and accounts payable financial instruments to reflect their fair value given their short maturity and risk profile of the counterparty.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <mrus:GoingConcernPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000304">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Going Concern &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to &lt;span style="color:#000000;"&gt;continue&lt;/span&gt; as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#x2019;s cash needs, and &lt;span style="color:#000000;"&gt;comparing&lt;/span&gt; &lt;span style="color:#000000;"&gt;those&lt;/span&gt; needs to the current cash, cash equivalent and marketable security balances. After considering the Company&#x2019;s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable securities as of December&#160;31, 2020, the Company did not identify conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year from the date these financial statements were issued.&lt;/p&gt;</mrus:GoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000305">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid debt securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Instruments subject to restrictions are not included in cash and cash equivalents.&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:AdditionalCashAndCashEquivalentRelatedText contextRef="C_0001651311_20200101_20201231" id="F_000350">three months or less</us-gaap:AdditionalCashAndCashEquivalentRelatedText>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001651311_20200101_20201231" id="F_000306">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies marketable securities that are debt securities with a remaining maturity when purchased of greater than three months as held-to-maturity as the Company has the positive intent and ability to hold such debt securities through maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities that are classified as held-to-maturity are initially recognized and measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Interest income from these debt securities is included in interest income. Marketable securities are classified as current if their expected maturity is within one year or less of the balance sheet date and non-current if their maturity is beyond one year of the balance sheet date.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="C_0001651311_20200101_20201231" id="F_000307">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounts Receivable &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable are amounts due from collaboration partners as a result of research and development services provided or milestones achieved but not yet paid.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000308">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Allowance for Credit Losses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its cash equivalents, accounts receivable and held-to-maturity marketable securities financial assets for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current environment, the Company concluded there is generally no expected credit losses for these financial assets. With respect to held-to-maturity marketable securities which are comprised of debt securities, the Company evaluates expected credit losses on a pooled basis based on issuer-type which have similar credit risk characteristics. The allowance for credit losses is immaterial for all periods presented.&lt;/p&gt;</us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000309">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes expenditures for new property and equipment and improvements to existing facilities and charges the cost of maintenance to expense. The Company eliminates the cost of property retired or otherwise disposed of, along with the corresponding accumulated depreciation or amortization, from the related accounts, and the resulting gain or loss is reflected in the results of operations. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000320">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20200101_20201231"
      id="F_000351">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeFurnitureAndEquipmentMember_20200101_20201231"
      id="F_000352">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000353">Shorter of useful life or term of lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="C_0001651311_20200101_20201231" id="F_000310">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets are identifiable non-monetary assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or self-creation) and from which future economic benefits (inflows of cash or other assets) are expected. The useful lives of intangible assets are assessed to be definite-lived and amortized over the useful economic life. The Company&#x2019;s intangible assets are comprised of purchased licenses to intellectual property and software licenses. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000311">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews long-lived assets to be held and used, including property and equipment, operating lease right-of-use assets and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No such impairments were recorded in 2020 or 2019. &lt;/p&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000354"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001651311_20190101_20191231"
      decimals="INF"
      id="F_000355"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000312">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company does not have any finance leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease, and excludes non-lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets also include the effect of any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has real estate operating lease agreements with lease and non-lease components, which are generally accounted for separately as operating lease costs and variable lease costs. Non-lease components in real estate leases refer to services provided by the lessor related to the premises. Fixed and variable lease payments are both allocated to lease and non-lease components. The allocation is determined on a relative fair value basis of the services provided relative to the operating lease of premises. With respect to equipment leases, the Company has elected not to allocate payments amongst lease and non-lease components as a practical expedient as afforded under ASC 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000313">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Deferred Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records deferred taxes to recognize the future effects of temporary differences between the tax basis and financial statement carrying amount of assets and liabilities. The Company measures the deferred taxes using enacted tax rates expected to apply when the temporary differences are realized and records a valuation allowance to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available, reversing taxable temporary differences and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized Tax Benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the technical merits, facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to an underpayment of income taxes, if applicable, as a component of income tax expense. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000314">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for an arrangement, the Company performs the following five step analysis: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;i.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;identify the contract(s) with a customer; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;ii.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;iii.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;determine the transaction price; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;iv.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;allocate the transaction price to the performance obligations in the contract; and &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;v.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i)&#160;licenses, or options to obtain licenses, to product candidates or future product candidates directed to specific targets (referred to as &#x201c;exclusive licenses&#x201d;) and (ii)&#160;research and development activities to be &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;performed on behalf of the collaboration partner related to the licensed targets.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also derives revenue from government grants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the accounting for these arrangements, the Company must use judgment to determine: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;the transaction price under step (iii) above; and &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as unbilled receivables.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive Licenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the rights and obligations set out in the contract, the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i)&#160;at the inception of the arrangement as an upfront fee or payment, (ii)&#160;upon the exercise of an option to acquire a license or (iii)&#160;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based milestones or royalty revenue resulting from any of its arrangements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Services&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promises under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period as described under&#160;&lt;span style="font-style:italic;"&gt;Exclusive Licenses&#160;&lt;/span&gt;above. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it&#160;is probable that a significant revenue reversal would not occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Government Grants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the R&amp;amp;D cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. Government grant revenue may be subject to review by a government authority in periods subsequent to their recognition and may result in the reversal of grant revenue previously recognized. Reversals of grant revenue are presented as contra revenue in the consolidated statement of operations.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001651311_20200101_20201231" id="F_000315">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses are expensed as incurred. Research and development expenses are comprised of costs incurred in providing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract research and development services, and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When third-party service providers&#x2019; billing terms do not coincide with the Company&#x2019;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs, contractual services costs and costs for supply of its product candidates incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period, past history in conducting similar activities and the expected duration of the third-party service contract, among other considerations. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of research and development expenses. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The WBSO (&lt;span style="font-style:italic;"&gt;afdrachtvermindering speur- en ontwikkelingswerk&lt;/span&gt;) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;this act, a contribution is paid towards the labor costs of employees directly involved in research and development. &lt;/span&gt;&lt;span style="color:#000000;"&gt;For the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;"&gt;2020&lt;/span&gt;&lt;span style="color:#000000;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;"&gt;, the Company recognized&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;$6.0 million&lt;/span&gt;&lt;span style="color:#000000;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;"&gt;$4.5 million&lt;/span&gt;&lt;span style="color:#000000;"&gt; as a reduction of research and development expenses, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <mrus:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="-5"
      id="F_000356"
      unitRef="U_iso4217USD">6000000.0</mrus:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <mrus:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_0001651311_20190101_20191231"
      decimals="-5"
      id="F_000357"
      unitRef="U_iso4217USD">4500000</mrus:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001651311_20200101_20201231" id="F_000316">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Share-Based Payments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures employee share-based compensation based on the grant date fair value of the share-based compensation award. The Company grants stock options at exercise prices equal to the fair value of the Company&#x2019;s common stock on the date of grant, based on observable market prices. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For share-based payments subject time-based vesting, the Company recognizes employee stock-based compensation expense on a straight-line basis over the requisite service period of the awards, generally from the date of grant through each vesting date. The Company recognizes forfeitures at the time they occur. The actual expense recognized over the vesting period will only represent those options that vest; the effect of forfeitures in the recognition of periodic compensation expense are not estimated prior to their occurrence. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000317">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Earnings (Loss) per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company computes basic earnings (loss) per share by dividing income (loss) allocable to common stockholders by the weighted average number of shares of common stock outstanding. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The Company computes diluted earnings (loss) per share after giving consideration to the dilutive effect of stock options and restricted stock units (&#x201c;RSU&#x201d;) that are outstanding during the period, except where such non-participating securities would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000318">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000358"
      unitRef="U_mrusSegment">1</us-gaap:NumberOfReportableSegments>
    <mrus:PendingAccountingPronouncementsPolicyTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000319">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Pending Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;span style="font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;. The new &lt;span style="color:#000000;"&gt;guidance&lt;/span&gt; aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for the Company at the beginning of 2021, including interim periods within that reporting period, although early adoption is permitted. The Company does not expect the impact of adoption to be significant.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808)&lt;/span&gt;, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative &lt;span style="color:#000000;"&gt;arrangement&lt;/span&gt; participant if the participant is not a customer. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. As of December 31, 2020, none of the Company&#x2019;s arrangements fall within the scope of ASC 808. However, as the Company may engage in future collaborative arrangements in the future, this ASU may apply to those new arrangements.&lt;/p&gt;</mrus:PendingAccountingPronouncementsPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000283">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Investments in Debt Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities are classified in the consolidated balance sheet as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,009&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes debt securities by maturity at December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After one year through five years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes debt securities by credit-quality indicator:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit Quality Indicator as of December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;AAA&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;AA- to AA+&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;A- to A+&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate paper and notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The credit quality indicator was derived from publicly available ratings published by Moody&#x2019;s or a comparable credit rating agency, last updated as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate paper and notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate paper and notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,709&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allowance for credit losses applicable to debt securities was immaterial in all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of money market funds is determined based on publicly available market price for these funds (Level 1). The fair value of other debt securities is determined based on the publicly available inputs which includes a market price for the same or similar instruments adjusted for estimates in interest yield (Level 2).&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000321">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities are classified in the consolidated balance sheet as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,009&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">17654000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20191231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">34053000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20201231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">44673000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesCurrentMember_20191231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">42153000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20201231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapFinancialInstrumentAxis_mrusMarketableSecuritiesNonCurrentMember_20191231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">2009000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">62327000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">78215000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:DebtSecuritiesHeldToMaturityPastDueTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000322">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes debt securities by maturity at December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After one year through five years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesHeldToMaturityPastDueTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">62327000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">62327000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000323">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes debt securities by credit-quality indicator:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit Quality Indicator as of December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;AAA&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;AA- to AA+&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;A- to A+&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate paper and notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">10156000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">10156000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">15043000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">15043000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">9150000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">9150000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">7498000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">20480000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">27978000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_20201231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">17654000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAAMinusToAAPlusRatingMember_20201231"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">24193000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_srtCreditRatingStandardPoorsAxis_mrusStandardPoorsAMinusToAPlusRatingMember_20201231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">20480000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">62327000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000324">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,156&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate paper and notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate paper and notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,709&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">10156000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">10156000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">15043000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">1000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">15044000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">9150000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20201231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">9150000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">27978000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20201231"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">27978000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">62327000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">3000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">62328000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">34053000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">34053000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">1496000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">1498000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">3987000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">7000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20191231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">3994000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">38679000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">32000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_us-gaapInvestmentTypeAxis_mrusCorporatePaperNotesAndBondsMember_20191231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">38709000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">78215000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">41000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">78254000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000284">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Prepaid Expenses and Other Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical and manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid general and administrative costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash included in other assets totaled $0.2 million and $0.2 million as of December 31, 2020 and 2019, respectively. The nature of the restriction relates to amounts held as collateral for a credit card borrowing arrangement.&lt;/p&gt;</mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000325">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical and manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid general and administrative costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <mrus:PrepaidClinicalAndManufacturingCostsCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">4971000</mrus:PrepaidClinicalAndManufacturingCostsCurrent>
    <mrus:PrepaidClinicalAndManufacturingCostsCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">2779000</mrus:PrepaidClinicalAndManufacturingCostsCurrent>
    <mrus:PrepaidGeneralAndAdministrativeCosts
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">2460000</mrus:PrepaidGeneralAndAdministrativeCosts>
    <mrus:PrepaidGeneralAndAdministrativeCosts
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">789000</mrus:PrepaidGeneralAndAdministrativeCosts>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">80000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">259000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">1058000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">1124000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">8569000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">4951000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20201231"
      decimals="-5"
      id="F_000440"
      unitRef="U_iso4217USD">200000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231"
      decimals="-5"
      id="F_000441"
      unitRef="U_iso4217USD">200000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000285">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Property and Equipment, net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,695&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,493&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,088&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense was $1.2 million and $0.9 million for the years ended December&#160;31, 2020, and 2019, respectively. Property and equipment are predominantly located in the Netherlands.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000326">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,695&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,493&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,088&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">5695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20191231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">4538000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20201231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">1300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeEquipmentAndFurnitureMember_20191231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">1186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">79000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">496000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">7608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">5803000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">3493000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">2088000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">4115000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">3715000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001651311_srtStatementGeographicalAxis_countryNL_20200101_20201231"
      decimals="-5"
      id="F_000456"
      unitRef="U_iso4217USD">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001651311_srtStatementGeographicalAxis_countryNL_20190101_20191231"
      decimals="-5"
      id="F_000457"
      unitRef="U_iso4217USD">900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000286">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Intangible assets, net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net consists of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licenses of intellectual property&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software licenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,843&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense was $0.3 million and $0.2 million for the years ended December&#160;31, 2020, and 2019, respectively. Intangible assets are predominantly located in the Netherlands.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense over the next five years are expected to be as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total remaining value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,843&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000327">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net consists of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licenses of intellectual property&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software licenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,843&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">3898000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">3568000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20201231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">288000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001651311_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20191231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">264000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">4186000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">3832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">1343000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">956000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">2843000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">2876000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001651311_20200101_20201231"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001651311_20190101_20191231"
      decimals="-5"
      id="F_000469"
      unitRef="U_iso4217USD">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000328">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense over the next five years are expected to be as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total remaining value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,843&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">230000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">196000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">166000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">1651000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">2843000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000287">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued personnel costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000329">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued personnel costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mrus:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">15372000</mrus:AccruedResearchAndDevelopmentExpensesCurrent>
    <mrus:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">6618000</mrus:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">4854000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">4495000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrus:AccruedGeneralAndAdministrativeExpenses
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">1566000</mrus:AccruedGeneralAndAdministrativeExpenses>
    <mrus:AccruedGeneralAndAdministrativeExpenses
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">2402000</mrus:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">11000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">21000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">21803000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">13536000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000288">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of loss from operations before income tax expense are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,957&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of income tax expense (benefit) from continuing operations are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. state&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. state&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The parent company is subject to income tax in the Netherlands where a greater proportion of economic activity is attributed. A reconciliation of the Netherlands statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Netherlands statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in tax rates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018 and 2020, Dutch tax authorities enacted new tax rates applicable to future periods which impact the measurement of deferred income taxes. The effect of the change in the valuation allowance each year reflects the increase or decrease in the valuation allowance against deferred tax assets attributable to the Netherlands.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the Company&#x2019;s deferred tax assets (liabilities) consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Excess interest carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;494&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(93,645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(57,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,619&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After consideration of all positive and negative evidence, the Company believes that it is more-likely-than-not that our Netherlands deferred tax assets that are not supported by reversing temporary differences will not be realized. As a result, the Company established a valuation allowance of $93.6 million and $57.9 million as of December&#160;31, 2020 and 2019, respectively. The increase in the valuation allowance of $35.8 million and $13.2 million &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;for the years ended December&#160;31, 2020 and 2019, respectively, is primarily attributable to the increase in net operating loss carryforward deferred tax assets for which a full valuation allowance applies and change in tax rates. As of December&#160;31, 2020, the portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits would be credited directly to contributed capital totaled $2.1 million.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company did not have any net operating losses for U.S. federal or state income tax purposes. The Company had net operating loss carryforwards for Dutch income tax purposes, the amount and expiry are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expiry Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Netherlands Tax&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&#160;Carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;266,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company had no unrecognized tax benefits. As of December&#160;31, 2020, the Company had no accrued interest or penalties related to underpayments of income taxes and no amounts have been recognized in the consolidated statements of operations. The Company will recognize interest and penalties related to an underpayment of income taxes in income tax expense.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions as well as in the Netherlands. The statute of limitations for assessment by the Internal Revenue Service (IRS), and Massachusetts tax authorities is closed for tax years prior to 2017. The statute of limitations for assessment by the Netherlands tax authorities is closed for tax years prior to 2015. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000330">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of loss from operations before income tax expense are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,957&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">-3832000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">-1363000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">-81178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">-53594000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">-85010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">-54957000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of income tax expense (benefit) from continuing operations are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. state&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. state&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">391000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">243000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">234000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">40000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">625000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">283000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">-86000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">-63000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">-36000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">-26000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">-122000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">-89000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">194000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000332">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The parent company is subject to income tax in the Netherlands where a greater proportion of economic activity is attributed. A reconciliation of the Netherlands statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Netherlands statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in tax rates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000507"
      unitRef="U_xbrlipure">0.250</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001651311_20190101_20191231"
      decimals="INF"
      id="F_000508"
      unitRef="U_xbrlipure">0.250</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0001651311_20200101_20201231"
      decimals="3"
      id="F_000509"
      unitRef="U_xbrlipure">0.106</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0001651311_20190101_20191231"
      decimals="3"
      id="F_000510"
      unitRef="U_xbrlipure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="3"
      id="F_000511"
      unitRef="U_xbrlipure">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0001651311_20190101_20191231"
      decimals="3"
      id="F_000512"
      unitRef="U_xbrlipure">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001651311_20200101_20201231"
      decimals="3"
      id="F_000513"
      unitRef="U_xbrlipure">-0.335</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001651311_20190101_20191231"
      decimals="3"
      id="F_000514"
      unitRef="U_xbrlipure">-0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001651311_20200101_20201231"
      decimals="3"
      id="F_000515"
      unitRef="U_xbrlipure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001651311_20190101_20191231"
      decimals="3"
      id="F_000516"
      unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001651311_20200101_20201231"
      decimals="3"
      id="F_000517"
      unitRef="U_xbrlipure">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001651311_20190101_20191231"
      decimals="3"
      id="F_000518"
      unitRef="U_xbrlipure">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000333">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the Company&#x2019;s deferred tax assets (liabilities) consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Excess interest carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;494&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(93,645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(57,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,619&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">66572000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">33917000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">24966000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">23926000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">2080000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetInterestCarryforward>
    <mrus:DeferredTaxAssetsLeaseObligation
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">1058000</mrus:DeferredTaxAssetsLeaseObligation>
    <mrus:DeferredTaxAssetsLeaseObligation
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">1333000</mrus:DeferredTaxAssetsLeaseObligation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">494000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">319000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">95170000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">59495000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">93645000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">57876000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">1525000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">1619000</us-gaap:DeferredTaxAssetsNet>
    <mrus:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">1048000</mrus:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mrus:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">1331000</mrus:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">67000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">1115000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">1331000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">410000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001651311_20191231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">288000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001651311_20201231"
      decimals="-5"
      id="F_000543"
      unitRef="U_iso4217USD">93600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001651311_20191231"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">57900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001651311_20200101_20201231"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">35800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001651311_20190101_20191231"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">13200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital
      contextRef="C_0001651311_20201231"
      decimals="-2"
      id="F_000547"
      unitRef="U_iso4217USD">2100</us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000334">The Company had net operating loss carryforwards for Dutch income tax purposes, the amount and expiry are as follows (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expiry Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Netherlands Tax&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&#160;Carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;266,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <mrus:ExpirationDateCarryForwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20200101_20201231"
      id="F_000548">2024</mrus:ExpirationDateCarryForwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2024Member_20201231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">23129000</us-gaap:OperatingLossCarryforwards>
    <mrus:ExpirationDateCarryForwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20200101_20201231"
      id="F_000549">2025</mrus:ExpirationDateCarryForwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2025Member_20201231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">110165000</us-gaap:OperatingLossCarryforwards>
    <mrus:ExpirationDateCarryForwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20200101_20201231"
      id="F_000550">2026</mrus:ExpirationDateCarryForwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2026Member_20201231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">95568000</us-gaap:OperatingLossCarryforwards>
    <mrus:ExpirationDateCarryForwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20200101_20201231"
      id="F_000551">2027</mrus:ExpirationDateCarryForwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001651311_us-gaapTaxPeriodAxis_mrusTaxYear2027Member_20201231"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">37426000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">266288000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000557"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000558"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000559"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000289">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Operating Leases &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Merus N.V. leases its corporate headquarters under an agreement term of five years, which expires in the fourth quarter of 2021. On May 1, 2018, Merus N.V. leased additional space to expand its corporate headquarters under a separate agreement. Under the terms of the new agreement, the term began on May 1, 2018 and also expires in the fourth quarter of 2021.&#160; Given the Company&#x2019;s current plans, the renewal term has not been included in the estimate of the lease term. Fixed lease payments increase annually and include an &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;increase based on an inflationary measure.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable payments include amounts due to t&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;he lessor &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;additional services &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and cost reimbursements&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2019, Merus US, Inc. entered into a lease agreement for office space in Cambridge, Massachusetts. The lease commenced in the second quarter of 2019 and has a term of seven years, and may be extended for another five years. Given the Company&#x2019;s current plans, the renewal term has not been included in the estimate of the lease term. Fixed lease payments increase annually and include an increase on an inflationary measure. Variable payments include amounts due to the lessor for additional services and cost reimbursements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s operating leases relate to its real estate leases that are not classified as finance leases.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company entered into a lease with Kadans Science Partner XII B.V. (&#x201c;Kadans&#x201d;), pursuant to which the Company agreed to lease approximately 5,070 square meters of office and laboratory space in a new multi-tenant office building that is to be constructed in Utrecht, the Netherlands. The initial term of the lease is ten years from the date that the premises are completed in accordance with certain specifications provided in a development agreement (described below), which is expected to occur in mid-2022. The lease will renew for two 5-year terms following the initial term, unless earlier terminated by the Company or Kadans, except that the earliest Kadans may terminate the lease is 20 years from the completion date. The lease provides for an estimated initial rent of approximately &#x20ac;1.3 million per annum. The rent amount is subject to adjustment based on the consumer price index (the &#x201c;CPI&#x201d;) beginning on January 1, 2019 through the completion date and then annually thereafter, subject to certain limitations if the CPI is greater than 3.0%. The final initial rent amount is contingent upon, among other things, the parameters of the final constructed premises, the final floor area, and the CPI adjustment described above, and will be determined upon the completion date and recorded in a first rider, signed by the Company and Kadans, to the lease. The Company is also responsible for certain fit-out costs and service fees related to the premises. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company also entered into a development agreement with Kadans and another party, Genmab B.V., which provides for the design, development and construction of the new multi-tenant office building of which the premises is a part.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost recorded in the Company&#x2019;s consolidated statement of operations and statement of cash flows were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;375&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost included in operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,986&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid to lessors included in operating cash outflows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s non-lease cost and other costs paid to the lessor are primarily related to services provided by the lessor in operating the premises that includes fees, operating costs, taxes and insurance related to the leased premises. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of the Company&#x2019;s operating lease obligations as of December 31, 2020 were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(397&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average remaining lease terms and discount rates related to the Company&#x2019;s leases were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining operating lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000593"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000594"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="C_0001651311_20180101_20181231" id="F_000561">Merus N.V. leases its corporate headquarters under an agreement term of five years, which expires in the fourth quarter of 2021. On May 1, 2018, Merus N.V. leased additional space to expand its corporate headquarters under a separate agreement. Under the terms of the new agreement, the term began on May 1, 2018 and also expires in the fourth quarter of 2021.&#160;</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_0001651311_20181231" id="F_000560">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrus:OperatingLeaseExpirationTerm contextRef="C_0001651311_20180101_20181231" id="F_000562">fourth quarter of 2021.</mrus:OperatingLeaseExpirationTerm>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331"
      id="F_000564">Merus US, Inc. entered into a lease agreement for office space in Cambridge, Massachusetts. The lease commenced in the second quarter of 2019 and has a term of seven years, and may be extended for another five years. Given the Company&#x2019;s current plans, the renewal term has not been included in the estimate of the lease term.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190331"
      id="F_000563">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331"
      id="F_000567">may be extended for another five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <mrus:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_0001651311_deiLegalEntityAxis_mrusMerusUSIncMember_20190301_20190331"
      id="F_000565">P5Y</mrus:LesseeOperatingLeaseExtendedTermOfContract>
    <mrus:AreaOfPropertySubjectToOrAvailableForOperatingLease
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731"
      decimals="INF"
      id="F_000568"
      unitRef="U_utrsqm">5070</mrus:AreaOfPropertySubjectToOrAvailableForOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190731"
      id="F_000569">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrus:LesseeOperatingLeaseNumberOfRenewalTerm
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731"
      decimals="INF"
      id="F_000571"
      unitRef="U_mrusRenewalTerm">2</mrus:LesseeOperatingLeaseNumberOfRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190731"
      id="F_000570">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrus:LesseeOperatingLeaseTerminationTerm
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731"
      id="F_000572">P20Y</mrus:LesseeOperatingLeaseTerminationTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731"
      decimals="-5"
      id="F_000573"
      unitRef="U_iso4217EUR">1300000</us-gaap:OperatingLeaseExpense>
    <mrus:OperatingLeaseRentAdjustmentDescription
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731"
      id="F_000575">The rent amount is subject to adjustment based on the consumer price index (the &#x201c;CPI&#x201d;) beginning on January 1, 2019 through the completion date and then annually thereafter, subject to certain limitations if the CPI is greater than 3.0%.</mrus:OperatingLeaseRentAdjustmentDescription>
    <mrus:ConsumerPriceIndex
      contextRef="C_0001651311_srtCounterpartyNameAxis_mrusKadansSciencePartnerXIIBVMember_srtRangeAxis_srtMinimumMember_srtStatementScenarioAxis_us-gaapScenarioPlanMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusOfficeAndLaboratoryMember_20190701_20190731"
      decimals="INF"
      id="F_000574"
      unitRef="U_xbrlipure">0.030</mrus:ConsumerPriceIndex>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000335">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost recorded in the Company&#x2019;s consolidated statement of operations and statement of cash flows were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;375&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost included in operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,986&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid to lessors included in operating cash outflows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">1611000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">1386000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">375000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">297000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">1986000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">1683000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">2478000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">2273000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000336">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of the Company&#x2019;s operating lease obligations as of December 31, 2020 were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(397&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">1577000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">614000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">645000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">222000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">4350000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000591"
      unitRef="U_iso4217USD">397000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000592"
      unitRef="U_iso4217USD">3953000</us-gaap:OperatingLeaseLiability>
    <mrus:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000337">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average remaining lease terms and discount rates related to the Company&#x2019;s leases were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining operating lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000593"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000594"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</mrus:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001651311_20201231"
      decimals="3"
      id="F_000595"
      unitRef="U_xbrlipure">0.049</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001651311_20191231"
      decimals="3"
      id="F_000596"
      unitRef="U_xbrlipure">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000290">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Indemnities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; and officers&#x2019; insurance coverage that is intended to limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, clinical sites and customers. Under these provisions, the Company may indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#x2019;s activities, such as gross negligence, willful misconduct or at times, other activities. These indemnification provisions may survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions may be unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Litigation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 5, 2018, an unnamed third party and Regeneron Pharmaceuticals Inc., or Regeneron filed notices of opposition against the Company&#x2019;s EP 2604625 patent, entitled &#x201c;Generation of Binding Molecules,&#x201d; in the European Opposition Division of the European Patent Office (the &#x201c;EPO&#x201d;). The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. Regeneron withdrew its opposition pursuant to a global December 20, 2018 settlement with the Company. On August 20, 2018, the Company timely responded to these submissions with respect to the unnamed third party. An opposition hearing was held in June 2019, wherein the EPO revoked the EP 2604625 patent in its entirety under Art. 123(2) EPC. The Company timely appealed that decision in December 2019 before the Technical Board of Appeals for the EPO seeking reinstatement of the patent and proposing auxiliary requests for certain amended claims, with further proceedings to be scheduled in the future. As this opposition proceeding continues, the Company cannot be certain that it will ultimately prevail.&lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be involved in various other claims and legal proceedings relating to claims arising out of the Company&#x2019;s operations. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000291">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Stockholders&#x2019; Equity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to dividends when and if declared by the board of directors. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share Issuances&lt;span style="font-size:12pt;font-style:normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 7, 2019, the Company completed an underwritten public offering in which the Company sold 5,462,500 common shares, including 715,500 common shares pursuant to the underwriters&#x2019; option to purchase additional shares, at a price to the public of $14.50 for aggregate net proceeds of $74.0 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 23, 2020, the Company sold 766,666 common shares, at a price of $15.00 for aggregate proceeds of $11.5 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 24, 2020, the Company sold 384,615 common shares, at a price of $15.60 for aggregate proceeds of $6.0 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 3, 2020, the Company sold 1,300,000 common shares, at a price of $16.90 for aggregate proceeds of $22.0 million.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Equity Compensation Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2021, a total of 2,336,997 shares of common stock were reserved for additional grants of stock awards under the Company&#x2019;s 2016 Incentive Award Plan. Stock-based compensation expense related to the equity compensation plan is more fully described in Note 13, &lt;span style="font-style:italic;"&gt;Employee Benefit Plans&lt;/span&gt;.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="C_0001651311_20200101_20201231" id="F_000597">one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107"
      decimals="INF"
      id="F_000598"
      unitRef="U_xbrlishares">5462500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mrus:NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlishares">715500</mrus:NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107"
      decimals="INF"
      id="F_000599"
      unitRef="U_iso4217USD_xbrlishares">14.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20191107_20191107"
      decimals="-5"
      id="F_000600"
      unitRef="U_iso4217USD">74000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123_20201123"
      decimals="INF"
      id="F_000602"
      unitRef="U_xbrlishares">766666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123"
      decimals="INF"
      id="F_000603"
      unitRef="U_iso4217USD_xbrlishares">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201123_20201123"
      decimals="-5"
      id="F_000604"
      unitRef="U_iso4217USD">11500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124_20201124"
      decimals="INF"
      id="F_000605"
      unitRef="U_xbrlishares">384615</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124"
      decimals="INF"
      id="F_000606"
      unitRef="U_iso4217USD_xbrlishares">15.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201124_20201124"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">6000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203_20201203"
      decimals="INF"
      id="F_000608"
      unitRef="U_xbrlishares">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203"
      decimals="INF"
      id="F_000609"
      unitRef="U_iso4217USD_xbrlishares">16.90</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001651311_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwrittenPublicOfferingMember_20201203_20201203"
      decimals="-5"
      id="F_000610"
      unitRef="U_iso4217USD">22000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001651311_us-gaapPlanNameAxis_mrusTwoThousandSixteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101"
      decimals="INF"
      id="F_000611"
      unitRef="U_xbrlishares">2336997</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000292">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Collaborations &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, pending regulatory clearance, Incyte agreed to pay the Company a $120.0 million, non-refundable upfront payment, and purchased 3.2 million common shares at a stated price per share of $25.00, for an aggregate purchase price of $80.0 million. In exchange, the Company granted Incyte with a license to certain of its intellectual property and committed to collaborate with Incyte to research, discover and develop monospecific or bispecific antibodies utilizing the Company&#x2019;s proprietary bispecific technology platform. The collaboration is managed by a joint steering committee in which both parties are represented and is tasked with overseeing the activities which significantly contributes to the collaboration. The collaboration may encompass up to 11 product candidates that result from the Company&#x2019;s application of its proprietary Biclonics&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; technology platform. During the course of the initial research term, Merus proposes product candidates to Incyte, which evaluates whether to designate proposed product candidates from the Company to make a selection for further research. Proposed product candidates begin at a pre-clinical stage of development. Incyte has certain rights to replace product candidates, including the right to substitute a product candidate after initial selection. The Company would be entitled to future consideration in the form of cost reimbursements for research services, development milestones, commercialization milestones and royalties related to the programs under the arrangement.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;At inception of the collaboration, two potential bispecific product candidates were under preliminary evaluation. After further research, a lead candidate was ultimately selected for the first product candidate, designated MCLA-145, and the other potential product candidate was not pursued. For the designated product candidate (MCLA-145), the Company retains the exclusive right to develop and commercialize products and product candidates in the United States, while Incyte has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States. For MCLA-145, the parties will conduct and share equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in each party&#x2019;s respective territories. For all other programs under the arrangement to be selected by Incyte, Incyte will be responsible for all research, development and commercialization costs. The Company may elect to co-fund the development of certain of the other programs in the future, in which case costs and benefits would be shared. The Company has not elected to co-fund any programs to date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;At inception of the arrangement, the Company identified a performance obligation comprised of a combined delivery of a license and related activities, including the activities of the joint steering committee, to which to allocate consideration. The arrangement also allowed for optional future research services to advance selected product candidates through discovery and research. The transaction price was comprised of fixed consideration of an upfront payment of $120.0 million and proceeds from the sale of shares of $80.0 million. All other consideration under the arrangement was determined to be variable consideration and fully constrained at inception. $152.6 million of the transaction price was allocated to the license and related activities performance obligation after accounting for the purchase of common shares by Incyte&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On January 23, 2017, the Company completed the sale of shares and exchange of the license. The Company initially deferred the transaction price allocated to the license and related activities performance obligation as deferred revenue, to be recognized as revenue over time as the primary benefit of the license to Incyte is access to the platform for the generation of potential product candidates. Development milestones, commercialization milestones and royalties are variable consideration, fully constrained, to be recognized in future periods in accordance with the Company&#x2019;s revenue recognition policy. Cost reimbursements for research services are recognized as they are performed over time as these are considered a separate performance obligation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;At December 31, 2020, the Company is currently engaged in research and development activities for MCLA-145 and developing candidates for the other programs. No development or commercialization milestones have been achieved to date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ONO &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 14, 2018, the Company granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market bispecific antibody candidates based on the Company&#x2019;s Biclonics&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; technology platform against two undisclosed targets directed to a particular undisclosed target combination. ONO is responsible for identifying lead candidates and conducting further non-clinical and clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development. Additionally, ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has also agreed to fund the Company&#x2019;s research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;agreed upon research plan. The Company retains all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;five&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ONO agreed to pay the Company an upfront, non-refundable payment of &#x20ac;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company was entitled to &#x20ac;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million intended to compensate the Company for research services already completed upon entering into the agreement, and &#x20ac;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million to be paid to the Company over time for full time equivalent funding. The Company is entitled to research and development milestones in addition to royalties on future sales&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified performance obligations&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;: (1) provision of a license for the target combination&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) research and development services. The Company concluded that Ono would be able to develop and benefit from the license, independent of the research and development services.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The research and development services are capable of being performed by third parties with an appropriate sub-license, and are recognized over time as these services are delivered. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Milestone payments are fully constrained as variable consideration to be recognized in future periods in accordance with the Company&#x2019;s revenue recognition policy.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 3, 2016, the Company was engaged to perform manufacturing services for Ono in support of their clinical trials that was the subject of a prior arrangement with Ono initiated in 2014. The Company was entitled to compensation to oversee and support a manufacturing process with the use of an outside third-party and to deliver quantities of manufactured product. The Company identified one performance obligation to provide manufacturing supervision services involving the transfer of know-how and the development of a &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;manufacturing&lt;/span&gt; process with the third-party and three performance obligations related to the services provided in connection with the delivery of product each having separate and distinct requirements. The Company acts as an agent for Ono with respect to the third-party manufacturing costs incurred for the underlying product and presents the recovery of such costs net in research and development expense in the consolidated statement of operations.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company received &#x20ac;3.7 million (approximately $4.1 million) for the year ended December 31, 2019 for development milestones received from Ono based on their progress. The amounts are recognized as revenue in the consolidated statement of operations for the year ended December 31, 2019. No comparable development milestones were received in the year ended December 31, 2020. Research and development services were completed in 2018.&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#160;&#160;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Simcere&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2018, the Company granted Simcere an exclusive license to develop and commercialize up to three bispecific antibodies to be produced by Merus utilizing the Company&#x2019;s Biclonics&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; technology platform in China. The Company will retain all rights outside of China. The Company has agreed to lead research and discovery activities, while Simcere has agreed to be responsible for the Investigational New Drug (&#x201c;IND&#x201d;) enabling studies, clinical development, regulatory filings and commercialization of these potential product candidates in China. The Company received an upfront, non-refundable payment of $2.75 million, relating to three separate research programs. The Company may be entitled to future development milestone payments.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;At inception of the arrangement, the Company identified three performance obligations comprised of the combined delivery of a license and performance of research and development activities with respect to each program. The Company performs research and development activities to achieve candidate nomination. The Company concluded that these activities were not distinct from the underlying license for each program as Simcere would not be able to benefit from the license apart from research and development activities at this phase of development&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The transaction price under the arrangement comprised fixed consideration of $2.75 million. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The transaction price was allocated to each separate performance obligation on a relative standalone fair value basis. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company deferred the portion of the upfront payment allocated to the three performance obligations as deferred revenue, to be recognized over time&lt;/span&gt;&lt;span style="color:#000000;"&gt;. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Compensation for research and development services prior to candidate nomination are allocated to each program performance obligation and also recognized over time. Development milestone payments allocated to each of the program performance obligations are constrained as variable consideration to be recognized in future periods in accordance with the Company&#x2019;s revenue recognition policy&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, the Company has achieved two milestones under this agreement and has received an aggregate of $1.3 million in milestone payments, including a milestone payment of $0.5 million for the quarter ended September 30, 2020, concerning the generation of functional data associated with the second bispecific antibody research program. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;At December 31, 2020, research and development for one of the three programs is on-going.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Betta&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 10, 2018, the Company granted Betta an exclusive license to develop and commercialize in China MCLA-129, a proprietary Biclonics&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; produced by its Biclonics&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; technology platform. The Company retains all rights outside of China. Betta has agreed to retain a contract manufacturing organization with experience in filing IND applications with U.S. regulatory authorities and CTAs with European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of the world. As a key strategic component of the collaboration, Betta will be responsible for IND enabling studies and manufacturing of clinical trial &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;materials in China, which the Company intends to use to assist regulatory filing and early stage clinical development in the rest of the world. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to a non-refundable upfront payment of $1.0 million, Betta and the Company will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. The Company is also eligible to receive an aggregate of $12.0 million in milestone payments contingent upon Betta achieving certain specified development and commercial goals as well as tiered royalty payments of net sales of any products resulting from the collaboration in China. In turn, Betta is also entitled to milestone payments based on the Company&#x2019;s progress. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified a single combined performance obligation, being the delivery of the MCLA-129 license including activities necessary to complete the technology transfer. The Company had no other commitments. The transaction price is comprised of fixed consideration of $1.0 million and fully allocated to the single performance obligation which would be fulfilled at a point in time. The technology transfer to deliver the license was completed in 2018 and Company recognized the revenue related to this performance obligation of $1.0 million as revenue for the year ended December 31, 2018. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Development milestone payments allocated to the performance obligation are constrained as variable consideration to be recognized in future periods in accordance with the Company&#x2019;s revenue recognition policy&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In the quarter ended December 31, 2020, both the Company and Betta achieved a development milestone both valued at $2.0 million. The amounts are recognized as milestone revenue of $2.0 million and research and development cost of $2.0 million in the Company&#x2019;s statement of operations for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contract Assets, Liabilities, Revenues and Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its collaboration arrangements. The dollar amounts in the tables below are in thousands.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ono&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Billings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash receipts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,711&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Billings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000678"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,623&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized in the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;84&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;711&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(474&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The balance of unbilled receivables predominantly represents reimbursement revenue under the Company&#x2019;s collaboration arrangements earned in the period to be billed and collected in the next period, generally quarterly. Incyte is a related party as a shareholder, as more fully described in Note 15.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ono&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;695&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestones&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total collaboration revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,163&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating expenses from collaborations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized that was included in deferred revenue at the beginning of the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ono&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestones&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total collaboration revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating expenses from collaborations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized that was included in deferred revenue at the beginning of the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;945&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrus:NonRefundableUpfrontPaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231"
      decimals="-5"
      id="F_000612"
      unitRef="U_iso4217USD">120000000.0</mrus:NonRefundableUpfrontPaymentsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231"
      decimals="-5"
      id="F_000613"
      unitRef="U_xbrlishares">3200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231"
      decimals="INF"
      id="F_000614"
      unitRef="U_iso4217USD_xbrlishares">25.00</us-gaap:SharesIssuedPricePerShare>
    <mrus:RevenueFromCollaborativeArrangement
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231"
      decimals="-5"
      id="F_000615"
      unitRef="U_iso4217USD">80000000.0</mrus:RevenueFromCollaborativeArrangement>
    <mrus:NonRefundableUpfrontPaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161231"
      decimals="-5"
      id="F_000617"
      unitRef="U_iso4217USD">120000000.0</mrus:NonRefundableUpfrontPaymentsReceivable>
    <mrus:RevenueFromCollaborativeArrangement
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231"
      decimals="-5"
      id="F_000616"
      unitRef="U_iso4217USD">80000000.0</mrus:RevenueFromCollaborativeArrangement>
    <mrus:RevenueFromCollaborativeArrangement
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndRelatedActivitiesMember_us-gaapRelatedPartyTransactionAxis_mrusIncyteCollaborationAndLicenseAgreementMember_20161201_20161231"
      decimals="-5"
      id="F_000618"
      unitRef="U_iso4217USD">152600000</mrus:RevenueFromCollaborativeArrangement>
    <mrus:NumberOfBispecificAntibodies
      contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314"
      decimals="INF"
      id="F_000619"
      unitRef="U_mrusAntibody">5</mrus:NumberOfBispecificAntibodies>
    <mrus:NonRefundableUpfrontPaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314"
      decimals="-5"
      id="F_000620"
      unitRef="U_iso4217EUR">700000</mrus:NonRefundableUpfrontPaymentsReceivable>
    <mrus:PaymentToCompensateResearchServices
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314"
      decimals="-5"
      id="F_000621"
      unitRef="U_iso4217EUR">300000</mrus:PaymentToCompensateResearchServices>
    <mrus:OverTimePaymentForFullTimeEquivalentFunding
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSecondONOResearchAndLicenseAgreementMember_20180314_20180314"
      decimals="-5"
      id="F_000622"
      unitRef="U_iso4217EUR">200000</mrus:OverTimePaymentForFullTimeEquivalentFunding>
    <mrus:DevelopmentMilestonesReceived
      contextRef="C_0001651311_20190101_20191231"
      decimals="-5"
      id="F_000623"
      unitRef="U_iso4217EUR">3700000</mrus:DevelopmentMilestonesReceived>
    <mrus:DevelopmentMilestonesReceived
      contextRef="C_0001651311_20190101_20191231"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">4100000</mrus:DevelopmentMilestonesReceived>
    <mrus:DevelopmentMilestonesReceived
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000625"
      unitRef="U_iso4217USD">0</mrus:DevelopmentMilestonesReceived>
    <mrus:NumberOfBispecificAntibodies
      contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131"
      decimals="INF"
      id="F_000626"
      unitRef="U_mrusAntibody">3</mrus:NumberOfBispecificAntibodies>
    <mrus:NonRefundableUpfrontPaymentsReceived
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180131"
      decimals="-4"
      id="F_000627"
      unitRef="U_iso4217USD">2750000</mrus:NonRefundableUpfrontPaymentsReceived>
    <mrus:NumberOfPerformanceObligation
      contextRef="C_0001651311_srtProductOrServiceAxis_mrusLicenseAndPerformanceMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentArrangementMember_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131"
      decimals="INF"
      id="F_000628"
      unitRef="U_mrusPerformanceObligation">3</mrus:NumberOfPerformanceObligation>
    <mrus:RevenueFromCollaborativeArrangement
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20180101_20180131"
      decimals="-4"
      id="F_000629"
      unitRef="U_iso4217USD">2750000</mrus:RevenueFromCollaborativeArrangement>
    <mrus:NumberOfMilestonesAchieved
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200930"
      decimals="INF"
      id="F_000630"
      unitRef="U_mrusMilestone">2000000</mrus:NumberOfMilestonesAchieved>
    <mrus:MilestonePaymentsReceived
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200701_20200930"
      decimals="-5"
      id="F_000631"
      unitRef="U_iso4217USD">1300000</mrus:MilestonePaymentsReceived>
    <mrus:MilestonePaymentsReceived
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrusSecondBispecificAntibodyResearchProgramMember_20200701_20200930"
      decimals="-5"
      id="F_000632"
      unitRef="U_iso4217USD">500000</mrus:MilestonePaymentsReceived>
    <mrus:DescriptionOfResearchAndDevelopmentPrograms
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusSimcereCollaborationAndLicenseAgreementMember_20200101_20201231"
      id="F_000633">research and development for one of the three programs is on-going.</mrus:DescriptionOfResearchAndDevelopmentPrograms>
    <mrus:NonRefundableUpfrontPaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210"
      decimals="-5"
      id="F_000634"
      unitRef="U_iso4217USD">1000000.0</mrus:NonRefundableUpfrontPaymentsReceivable>
    <mrus:ContingentMilestonePaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210"
      decimals="-5"
      id="F_000635"
      unitRef="U_iso4217USD">12000000.0</mrus:ContingentMilestonePaymentsReceivable>
    <mrus:NonRefundableUpfrontPaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20181210"
      decimals="-5"
      id="F_000636"
      unitRef="U_iso4217USD">1000000.0</mrus:NonRefundableUpfrontPaymentsReceivable>
    <mrus:RevenueRelatedPerformanceObligationAmountAsRevenue
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20180101_20181231"
      decimals="-5"
      id="F_000637"
      unitRef="U_iso4217USD">1000000.0</mrus:RevenueRelatedPerformanceObligationAmountAsRevenue>
    <mrus:DevelopmentMilestonesReceived
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231"
      decimals="-5"
      id="F_000638"
      unitRef="U_iso4217USD">2000000.0</mrus:DevelopmentMilestonesReceived>
    <mrus:MilestoneRevenue
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231"
      decimals="-5"
      id="F_000639"
      unitRef="U_iso4217USD">2000000.0</mrus:MilestoneRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusBettaCollaborationAndLicenseAgreementMember_20201001_20201231"
      decimals="-5"
      id="F_000640"
      unitRef="U_iso4217USD">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000338">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its collaboration arrangements. The dollar amounts in the tables below are in thousands.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ono&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Billings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash receipts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,711&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Billings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000678"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,623&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized in the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;84&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;711&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(474&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231"
      decimals="-3"
      id="F_000641"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231"
      decimals="-3"
      id="F_000642"
      unitRef="U_iso4217USD">786000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231"
      decimals="-3"
      id="F_000643"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231"
      decimals="-3"
      id="F_000644"
      unitRef="U_iso4217USD">786000</us-gaap:ContractWithCustomerAssetNet>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000645"
      unitRef="U_iso4217USD">6546000</mrus:Billings>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000646"
      unitRef="U_iso4217USD">0</mrus:Billings>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000647"
      unitRef="U_iso4217USD">644000</mrus:Billings>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000648"
      unitRef="U_iso4217USD">644000</mrus:Billings>
    <us-gaap:ProceedsFromCustomers
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000649"
      unitRef="U_iso4217USD">6587000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000650"
      unitRef="U_iso4217USD">772000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000651"
      unitRef="U_iso4217USD">607000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000652"
      unitRef="U_iso4217USD">1379000</us-gaap:ProceedsFromCustomers>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000653"
      unitRef="U_iso4217USD">0</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000654"
      unitRef="U_iso4217USD">0</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000655"
      unitRef="U_iso4217USD">-11000</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000656"
      unitRef="U_iso4217USD">-11000</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000657"
      unitRef="U_iso4217USD">41000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000658"
      unitRef="U_iso4217USD">-14000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">20000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">6000</mrus:ForeignCurrencyExchangeTranslation>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">46000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">46000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">1711000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">155000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">155000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">6354000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">581000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">581000</us-gaap:AccruedLiabilitiesCurrent>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">-6546000</mrus:Billings>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">0</mrus:Billings>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">-644000</mrus:Billings>
    <mrus:Billings
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">-644000</mrus:Billings>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">0</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">-94000</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:AdjustmentsToContractAssetsReceivables
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">-94000</mrus:AdjustmentsToContractAssetsReceivables>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">104000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">0</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">2000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000684"
      unitRef="U_iso4217USD">2000</mrus:ForeignCurrencyExchangeTranslation>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">1623000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusUnbilledReceivablesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231"
      decimals="-3"
      id="F_000689"
      unitRef="U_iso4217USD">108538000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20191231"
      decimals="-3"
      id="F_000690"
      unitRef="U_iso4217USD">336000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20191231"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">1385000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20191231"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">1721000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">-18194000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">-200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">-743000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">-943000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">8660000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">15000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">69000</mrus:ForeignCurrencyExchangeTranslation>
    <mrus:ForeignCurrencyExchangeTranslation
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">84000</mrus:ForeignCurrencyExchangeTranslation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">99004000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">151000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">711000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">862000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">19554000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">151000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">474000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">625000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="-3"
      id="F_000709"
      unitRef="U_iso4217USD">79450000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20201231"
      decimals="-3"
      id="F_000710"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20201231"
      decimals="-3"
      id="F_000711"
      unitRef="U_iso4217USD">237000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_mrusDeferredRevenueMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000712"
      unitRef="U_iso4217USD">237000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000339">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The balance of unbilled receivables predominantly represents reimbursement revenue under the Company&#x2019;s collaboration arrangements earned in the period to be billed and collected in the next period, generally quarterly. Incyte is a related party as a shareholder, as more fully described in Note 15.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ono&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;695&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestones&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total collaboration revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,163&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating expenses from collaborations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized that was included in deferred revenue at the beginning of the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third Party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incyte&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ono&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestones&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total collaboration revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating expenses from collaborations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized that was included in deferred revenue at the beginning of the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;945&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000713"
      unitRef="U_iso4217USD">-18193000</mrus:UpfrontPayments>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000714"
      unitRef="U_iso4217USD">-200000</mrus:UpfrontPayments>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000715"
      unitRef="U_iso4217USD">-695000</mrus:UpfrontPayments>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000716"
      unitRef="U_iso4217USD">-895000</mrus:UpfrontPayments>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000717"
      unitRef="U_iso4217USD">8387000</mrus:ReimbursementRevenues>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000718"
      unitRef="U_iso4217USD">0</mrus:ReimbursementRevenues>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000719"
      unitRef="U_iso4217USD">-12000</mrus:ReimbursementRevenues>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000720"
      unitRef="U_iso4217USD">-12000</mrus:ReimbursementRevenues>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000721"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000722"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000723"
      unitRef="U_iso4217USD">2480000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000724"
      unitRef="U_iso4217USD">2480000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000725"
      unitRef="U_iso4217USD">26580000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000726"
      unitRef="U_iso4217USD">200000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000727"
      unitRef="U_iso4217USD">3163000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000728"
      unitRef="U_iso4217USD">3363000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000729"
      unitRef="U_iso4217USD">2036000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000730"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000731"
      unitRef="U_iso4217USD">1944000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000732"
      unitRef="U_iso4217USD">1944000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000733"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000734"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000735"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000736"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000737"
      unitRef="U_iso4217USD">2036000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000738"
      unitRef="U_iso4217USD">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">1944000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">1944000</us-gaap:OperatingExpenses>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231"
      decimals="-3"
      id="F_000741"
      unitRef="U_iso4217USD">18193000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20200101_20201231"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">738000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">938000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">-17839000</mrus:UpfrontPayments>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">-196000</mrus:UpfrontPayments>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000747"
      unitRef="U_iso4217USD">-643000</mrus:UpfrontPayments>
    <mrus:UpfrontPayments
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000748"
      unitRef="U_iso4217USD">-839000</mrus:UpfrontPayments>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">7992000</mrus:ReimbursementRevenues>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">99000</mrus:ReimbursementRevenues>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">153000</mrus:ReimbursementRevenues>
    <mrus:ReimbursementRevenues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">252000</mrus:ReimbursementRevenues>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">4142000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">284000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">4426000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000757"
      unitRef="U_iso4217USD">25831000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000758"
      unitRef="U_iso4217USD">4437000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">1080000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">5517000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000761"
      unitRef="U_iso4217USD">680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000762"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000763"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000764"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000765"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000766"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000767"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000768"
      unitRef="U_iso4217USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000769"
      unitRef="U_iso4217USD">680000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000770"
      unitRef="U_iso4217USD">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000771"
      unitRef="U_iso4217USD">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000772"
      unitRef="U_iso4217USD">0</us-gaap:OperatingExpenses>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20190101_20191231"
      decimals="-3"
      id="F_000773"
      unitRef="U_iso4217USD">17839000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOnoMember_20190101_20191231"
      decimals="-3"
      id="F_000774"
      unitRef="U_iso4217USD">196000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusOtherMember_20190101_20191231"
      decimals="-3"
      id="F_000775"
      unitRef="U_iso4217USD">945000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000776"
      unitRef="U_iso4217USD">1141000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000293">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Employee Benefit Plans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Share-Based Payments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2010 Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2010, the Company established the Merus B.V. 2010 Employee Option Plan (the &#x201c;2010 Plan&#x201d;) that entitled key management personnel, staff and consultants providing similar services to purchase shares in the Company. Under the 2010 Plan, holders of vested options were entitled to purchase depositary receipts for common shares at the exercise price determined at the date of grant. Upon exercise of the option, common shares were issued to a foundation established to facilitate administration of share-based compensation awards and pool the voting interests of the underlying shares, and depositary receipts were issued by the foundation to the individual holders. In connection with the IPO, the 2010 Plan was amended to cancel the depositary receipts and allow individual holders to directly hold the common shares obtained upon exercise of their options. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted under the 2010 Plan generally vest in installments over a &lt;span style="-sec-ix-hidden:F_000777"&gt;four-year&lt;/span&gt; period from the grant date: 25% percent on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in &lt;span&gt;36 month&lt;/span&gt;ly installments for each full month of continuous service provided thereafter. Options expire after 8 years from the date of grant. The last grant of options pursuant to the 2010 Plan occurred in 2016, with no further grants expected.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2016 Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2016, the Company established the 2016 Incentive Award Plan (the &#x201c;2016 Plan&#x201d;). All incentive award grants since 2016 are being made under the 2016 Plan. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted to employees under the 2016 Plan generally vest in installments over a &lt;span style="-sec-ix-hidden:F_000783"&gt;&lt;span style="-sec-ix-hidden:F_000784"&gt;four-year&lt;/span&gt;&lt;/span&gt; period from the grant date: 25% percent vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in &lt;span&gt;36 month&lt;/span&gt;ly installments for each full month of continuous service provided thereafter. Certain options may vest dependent on the attainment of performance criteria. Options expire after &lt;span&gt;10 years&lt;/span&gt; from the date of grant. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted to non-executive directors consist of initial option grants as well as subsequent annual awards. The initial award of options granted vest in installments over a &lt;span style="-sec-ix-hidden:F_000793"&gt;&lt;span style="-sec-ix-hidden:F_000794"&gt;three-year&lt;/span&gt;&lt;/span&gt; period: 33% of the options vest on the first anniversary of the vesting commencement date, and 67% of the options vest in &lt;span&gt;24 month&lt;/span&gt;ly installments thereafter. Each subsequent award vests over a &lt;span style="-sec-ix-hidden:F_000801"&gt;&lt;span style="-sec-ix-hidden:F_000802"&gt;one-year&lt;/span&gt;&lt;/span&gt; period in &lt;span&gt;12 month&lt;/span&gt;ly installments. The Company measures the fair value of an option through the application of an option pricing model, as more fully described below.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The RSUs granted to employees under the 2016 Plan vest in installments over a &lt;span style="-sec-ix-hidden:F_000806"&gt;&lt;span style="-sec-ix-hidden:F_000807"&gt;four-year&lt;/span&gt;&lt;/span&gt; period from the grant date. Certain RSUs may vest dependent on the attainment of performance criteria. Each RSU represents the right to receive one common share. The fair value of an RSU is determined by reference to the price of the underlying common share.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of common shares authorized for issuance for future grants under the 2016 Plan as of January 1, 2021 totaled 2,336,997. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, there was $8.0 million in unrecognized stock-based compensation that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of 1.3 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Option Valuation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option-pricing model to measure the fair value of stock option awards. In prior years, a Hull-White option-pricing model was used. Key weighted average assumptions used in this pricing model on the date of grant for options granted to employees are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual life of options (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000819"&gt;10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000820"&gt;10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term of options (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000821"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N/A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility of underlying stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The risk-free interest rate is based upon the U.S. Treasury yield curve in effect at the time of grant, with a term that approximates the expected life of the option. The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#x2019;s product candidates. A simplified method using a weighted-average mid-point between an award&#x2019;s vesting date and expiry is used to estimate the expected life of options in all periods presented as a sufficient history of participant exercise behavior is not readily observable. The Company has applied an expected dividend yield of 0.0% as the Company has not historically declared a dividend and does not anticipate declaring a dividend during the expected life of the options. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of stock option activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,314,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,258,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(202,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(622,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.62&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,748,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000839"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,140,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000840"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;RSU Activity&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of RSU activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant-date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.68&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,474&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(67,248&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,093&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,775&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value of Stock Options Exercised and Vested RSUs&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total fair value of RSUs vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate intrinsic value of options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Post-Employment Benefit Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has established a post-employment benefit plan for employees of the Netherlands that entitles executive officers and other staff members to retire at the age of 67 and receive annual payments based upon the average salary earned during the service period. The Company has insured the benefit liabilities through purchased non-participating annuities from an insurance company and has no other obligation other than to pay the annual insurance premiums to the insurance company. After purchasing the insurance, the Company has no further obligation (legal or constructive) to pay further amounts if the insurance fund has insufficient assets to pay all employee benefits relating to current and prior service. Contributions to purchase non-participating annuities are expensed as incurred as service costs. Company contributions to the post-employment benefit plan totaled $2.0 million and $1.3 million in the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;401(k) Savings Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a defined contribution 401(k) savings plan (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers substantially all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax basis. The Company matches contributions to the 401(k) Plan, matching 50% of an employee&#x2019;s contribution up to a maximum of 3% of the participant&#x2019;s compensation. Company contributions to the 401(k) Plan totaled $0.1 million and $0.1 million in the years ended December&#160;31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Executive Settlement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, in connection with the departure of the Chief Executive Officer of the Company, the Company awarded benefits, including the following: cash compensation of $0.9 million, a grant of 30,000 RSUs, extended vesting of his equity incentive awards through June 30, 2021 and extended exercisability of his equity incentive awards through December 31, 2021. The cash compensation is to be paid by the Company by January 31, 2020. There were no substantive service conditions associated with the benefits awarded other than the passage of time. The Company incrementally recognized $1.8&#160;million in general and administrative expense associated with these benefits in the consolidated statement of operations for the year ended December 31, 2019.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="2"
      id="F_000778"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      decimals="2"
      id="F_000779"
      unitRef="U_xbrlipure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      id="F_000780">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231"
      id="F_000781">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandTenPlanMember_20200101_20201231"
      id="F_000782">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="2"
      id="F_000785"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231"
      decimals="2"
      id="F_000786"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      decimals="2"
      id="F_000787"
      unitRef="U_xbrlipure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231"
      decimals="2"
      id="F_000788"
      unitRef="U_xbrlipure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      id="F_000789">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231"
      id="F_000790">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000791">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231"
      id="F_000792">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="2"
      id="F_000795"
      unitRef="U_xbrlipure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190101_20191231"
      decimals="2"
      id="F_000796"
      unitRef="U_xbrlipure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      decimals="2"
      id="F_000797"
      unitRef="U_xbrlipure">0.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231"
      decimals="2"
      id="F_000798"
      unitRef="U_xbrlipure">0.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      id="F_000799">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231"
      id="F_000800">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000803">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001651311_srtTitleOfIndividualAxis_mrusNonExecutiveDirectorsMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_mrusSubsequentAwardMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20190101_20191231"
      id="F_000804">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_20200101_20201231"
      id="F_000805">Each RSU represents the right to receive one common share.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_us-gaapPlanNameAxis_mrusTwoThousandSixteenPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101"
      decimals="INF"
      id="F_000808"
      unitRef="U_xbrlishares">2336997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000340">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000809"
      unitRef="U_iso4217USD">2969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000810"
      unitRef="U_iso4217USD">3186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000811"
      unitRef="U_iso4217USD">6403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001651311_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000812"
      unitRef="U_iso4217USD">4648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000813"
      unitRef="U_iso4217USD">9372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000814"
      unitRef="U_iso4217USD">7834000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="-5"
      id="F_000815"
      unitRef="U_iso4217USD">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000816">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000341">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option-pricing model to measure the fair value of stock option awards. In prior years, a Hull-White option-pricing model was used. Key weighted average assumptions used in this pricing model on the date of grant for options granted to employees are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual life of options (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000819"&gt;10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000820"&gt;10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term of options (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000821"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N/A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility of underlying stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000817"
      unitRef="U_xbrlipure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000818"
      unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000822"
      unitRef="U_xbrlipure">0.861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000823"
      unitRef="U_xbrlipure">0.870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000824"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000825"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="3"
      id="F_000826"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000342">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of stock option activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,314,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,258,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(202,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(622,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.62&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,748,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000839"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,140,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000840"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001651311_20191231"
      decimals="INF"
      id="F_000827"
      unitRef="U_xbrlishares">3314871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001651311_20191231"
      decimals="2"
      id="F_000833"
      unitRef="U_iso4217USD_xbrlishares">14.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000828"
      unitRef="U_xbrlishares">1258341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001651311_20200101_20201231"
      decimals="2"
      id="F_000834"
      unitRef="U_iso4217USD_xbrlishares">16.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000829"
      unitRef="U_xbrlishares">202207</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001651311_20200101_20201231"
      decimals="2"
      id="F_000835"
      unitRef="U_iso4217USD_xbrlishares">7.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001651311_20200101_20201231"
      decimals="INF"
      id="F_000830"
      unitRef="U_xbrlishares">622094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001651311_20200101_20201231"
      decimals="2"
      id="F_000836"
      unitRef="U_iso4217USD_xbrlishares">16.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000831"
      unitRef="U_xbrlishares">3748911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001651311_20201231"
      decimals="2"
      id="F_000837"
      unitRef="U_iso4217USD_xbrlishares">15.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000841"
      unitRef="U_iso4217USD">11454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001651311_20201231"
      decimals="INF"
      id="F_000832"
      unitRef="U_xbrlishares">2140953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001651311_20201231"
      decimals="2"
      id="F_000838"
      unitRef="U_iso4217USD_xbrlishares">15.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001651311_20201231"
      decimals="-3"
      id="F_000842"
      unitRef="U_iso4217USD">7122000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_20200101_20201231"
      decimals="2"
      id="F_000843"
      unitRef="U_iso4217USD_xbrlishares">11.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_20190101_20191231"
      decimals="2"
      id="F_000844"
      unitRef="U_iso4217USD_xbrlishares">7.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000343">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of RSU activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant-date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.68&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,474&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(67,248&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,093&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,775&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231"
      decimals="INF"
      id="F_000845"
      unitRef="U_xbrlishares">82642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231"
      decimals="2"
      id="F_000850"
      unitRef="U_iso4217USD_xbrlishares">19.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000846"
      unitRef="U_xbrlishares">46474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_000851"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000847"
      unitRef="U_xbrlishares">67248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_000852"
      unitRef="U_iso4217USD_xbrlishares">19.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000848"
      unitRef="U_xbrlishares">2093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_000853"
      unitRef="U_iso4217USD_xbrlishares">21.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="INF"
      id="F_000849"
      unitRef="U_xbrlishares">59775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="2"
      id="F_000854"
      unitRef="U_iso4217USD_xbrlishares">16.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000344">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value of Stock Options Exercised and Vested RSUs&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total fair value of RSUs vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate intrinsic value of options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-3"
      id="F_000855"
      unitRef="U_iso4217USD">961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="-3"
      id="F_000856"
      unitRef="U_iso4217USD">726000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000857"
      unitRef="U_iso4217USD">1750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000858"
      unitRef="U_iso4217USD">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20200101_20201231"
      decimals="-5"
      id="F_000859"
      unitRef="U_iso4217USD">2000000.0</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231"
      decimals="-5"
      id="F_000860"
      unitRef="U_iso4217USD">1300000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
      contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231"
      id="F_000861">The 401(k) Plan covers substantially all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax basis. The Company matches contributions to the 401(k) Plan, matching 50% of an employee&#x2019;s contribution up to a maximum of 3% of the participant&#x2019;s compensation.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000862"
      unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000863"
      unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000864"
      unitRef="U_iso4217USD">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000865"
      unitRef="U_iso4217USD">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:PostemploymentBenefitsLiabilityCurrent
      contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20191231"
      decimals="-5"
      id="F_000866"
      unitRef="U_iso4217USD">900000</us-gaap:PostemploymentBenefitsLiabilityCurrent>
    <mrus:GrantOfRestrictedStockUnit
      contextRef="C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231"
      decimals="0"
      id="F_000867"
      unitRef="U_xbrlishares">30000</mrus:GrantOfRestrictedStockUnit>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="C_0001651311_us-gaapRetirementPlanTypeAxis_us-gaapPostemploymentRetirementBenefitsMember_20190101_20191231"
      decimals="-5"
      id="F_000868"
      unitRef="U_iso4217USD">1800000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000294">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Loss per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The two-class method was not applied for the years ended December&#160;31, 2020 and 2019 due to the net loss recognized in each of those periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share allocable to common stockholders are computed as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&#160;thousands&#160;except&#160;per&#160;share&#160;data)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,256,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,218,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share allocable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000345">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share allocable to common stockholders are computed as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&#160;thousands&#160;except&#160;per&#160;share&#160;data)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,256,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,218,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share allocable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000869"
      unitRef="U_iso4217USD">-85513000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000870"
      unitRef="U_iso4217USD">-55151000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001651311_20200101_20201231"
      decimals="-3"
      id="F_000871"
      unitRef="U_xbrlishares">29256203000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001651311_20190101_20191231"
      decimals="-3"
      id="F_000872"
      unitRef="U_xbrlishares">24218083000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001651311_20200101_20201231"
      decimals="2"
      id="F_000873"
      unitRef="U_iso4217USD_xbrlishares">-2.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001651311_20190101_20191231"
      decimals="2"
      id="F_000874"
      unitRef="U_iso4217USD_xbrlishares">-2.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000295">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. Related Party Transactions &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into the Incyte collaboration and license agreement and the Incyte share subscription agreement in which the terms and transactional amounts incurred between Incyte and the Company are more fully described in Note 12. Incyte is a shareholder with holdings representing approximately 10.1% of the outstanding shares of the Company as of December 31, 2020, and 11.1% as of December 31, 2019.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231"
      decimals="3"
      id="F_000875"
      unitRef="U_xbrlipure">0.101</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20191231"
      decimals="3"
      id="F_000876"
      unitRef="U_xbrlipure">0.111</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001651311_20200101_20201231" id="F_000296">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. Subsequent Events&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 18, 2021, the Company entered into a Collaboration and License Agreement (the &#x201c;Collaboration Agreement&#x201d;) and Share Subscription Agreement (the &#x201c;Subscription Agreement&#x201d;) with Eli Lilly and Company, an Indiana corporation (&#x201c;Eli Lilly&#x201d;). Eli Lilly has agreed to pay an upfront, non-refundable payment of $40 million for the rights granted under the Collaboration Agreement within 30 days following the Effective Date. Eli Lilly will fund the research and development activities to be conducted by the Company for each program under an agreed research plan and budget. With respect to each product arising from each program, the Company is eligible to receive up to $290 million in future contingent development and regulatory milestones and up to $250 million in commercial sales milestones, for a total of up to approximately $1.6 billion for a single product generated from all three programs. The Company is further eligible to receive, on a product-by-product and country-by-country basis, tiered royalties based on the level of worldwide aggregate annual net sales at percentages ranging from the mid-single digits to low double digits until the royalty term expires. In connection with entering into the Collaboration Agreement, pursuant to the Subscription Agreement, on January 18, 2021, Eli Lilly agreed to purchase 706,834 common shares of the Company at a price per share of $28.295 for aggregate gross proceeds to the Company of approximately $20 million. Eli Lilly agreed not to transfer, sell, or otherwise dispose of the Shares for a period of time following the Closing Date, subject to certain customary exceptions.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 21, 2021, the Company entered into an underwriting agreement with Jefferies LLC and SVB Leerink LLC, as representatives of the several underwriters named therein (collectively, the &#x201c;Underwriters&#x201d;), in connection with the issuance and sale by the Company in a public offering of 4,848,485 common shares of the Company, nominal value &#x20ac;0.09 per share, at a public offering price of $24.75 per share, less underwriting discounts and commissions. The Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 727,272 common shares at the public offering price, less underwriting discounts and commissions. On January 21, 2021, the Underwriters exercised this option in full. The closing of the offering occurred on January 25, 2021, resulting in aggregate net proceeds to the Company of $129.7 million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <mrus:NonRefundableUpfrontPaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118"
      decimals="-6"
      id="F_000877"
      unitRef="U_iso4217USD">40000000</mrus:NonRefundableUpfrontPaymentsReceivable>
    <mrus:FutureContingentDevelopmentAndRegulatoryMilestonesReceivable
      contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118"
      decimals="-6"
      id="F_000878"
      unitRef="U_iso4217USD">290000000</mrus:FutureContingentDevelopmentAndRegulatoryMilestonesReceivable>
    <mrus:CommercialSalesMilestones
      contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118"
      decimals="-6"
      id="F_000879"
      unitRef="U_iso4217USD">250000000</mrus:CommercialSalesMilestones>
    <mrus:MilestonePaymentsReceivable
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118"
      decimals="-8"
      id="F_000880"
      unitRef="U_iso4217USD">1600000000</mrus:MilestonePaymentsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118"
      decimals="INF"
      id="F_000881"
      unitRef="U_xbrlishares">706834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118"
      decimals="3"
      id="F_000882"
      unitRef="U_iso4217USD_xbrlishares">28.295</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001651311_us-gaapRelatedPartyTransactionAxis_mrusCollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210118_20210118"
      decimals="-6"
      id="F_000883"
      unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121"
      decimals="INF"
      id="F_000884"
      unitRef="U_xbrlishares">4848485</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121"
      decimals="2"
      id="F_000885"
      unitRef="U_iso4217EUR_xbrlishares">0.09</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121"
      decimals="2"
      id="F_000886"
      unitRef="U_iso4217USD_xbrlishares">24.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001651311_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121"
      decimals="INF"
      id="F_000887"
      unitRef="U_xbrlishares">727272</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121"
      decimals="-5"
      id="F_000888"
      unitRef="U_iso4217USD">129700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818523576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merus N.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRUS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001651311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,126,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Yalelaan 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Utrecht<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3584 CM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">NL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+31 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">253 8800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares,
nominal value &#8364;0.09 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2021 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818595768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 163,082<span></span>
</td>
<td class="nump">$ 197,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">44,673<span></span>
</td>
<td class="nump">42,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable (related party)</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,569<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">217,993<span></span>
</td>
<td class="nump">247,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,115<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,907<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">231,217<span></span>
</td>
<td class="nump">263,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,126<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">21,803<span></span>
</td>
<td class="nump">13,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligation</a></td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Current portion of deferred revenue (related party)</a></td>
<td class="nump">19,554<span></span>
</td>
<td class="nump">17,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">46,746<span></span>
</td>
<td class="nump">36,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligation</a></td>
<td class="nump">2,521<span></span>
</td>
<td class="nump">3,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Deferred revenue, net of current portion (related party)</a></td>
<td class="nump">79,450<span></span>
</td>
<td class="nump">90,637<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">128,954<span></span>
</td>
<td class="nump">132,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">490,093<span></span>
</td>
<td class="nump">441,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">9,071<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(400,112)<span></span>
</td>
<td class="num">(314,599)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">102,263<span></span>
</td>
<td class="nump">131,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 231,217<span></span>
</td>
<td class="nump">$ 263,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627812287976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8364; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="nump">&#8364; 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">31,602,953<span></span>
</td>
<td class="nump">28,882,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">31,602,953<span></span>
</td>
<td class="nump">28,882,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627811391816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 29,943<span></span>
</td>
<td class="nump">$ 31,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">70,040<span></span>
</td>
<td class="nump">55,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">35,781<span></span>
</td>
<td class="nump">34,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">105,821<span></span>
</td>
<td class="nump">89,790<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(75,878)<span></span>
</td>
<td class="num">(58,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (losses) gains</a></td>
<td class="num">(9,432)<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MiscellaneousIncomeAndGains', window );">Miscellaneous income and gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(9,132)<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(85,010)<span></span>
</td>
<td class="num">(54,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(85,513)<span></span>
</td>
<td class="num">(55,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">7,485<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (78,028)<span></span>
</td>
<td class="num">$ (56,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share allocable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">29,256,203<span></span>
</td>
<td class="nump">24,218,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrus_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 5,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrus_CollaborationRevenueRelatedPartyMember', window );">Collaboration Revenue (Related Party) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">26,580<span></span>
</td>
<td class="nump">25,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrus_GrantRevenueMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (215)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MiscellaneousIncomeAndGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous income and gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MiscellaneousIncomeAndGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_GrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_GrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627812178296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (85,513)<span></span>
</td>
<td class="num">$ (55,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeGain', window );">Foreign exchange losses (gains)</a></td>
<td class="nump">8,957<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,372<span></span>
</td>
<td class="nump">7,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">Amortization of discount on investments</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,895)<span></span>
</td>
<td class="num">(1,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,023<span></span>
</td>
<td class="nump">3,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(19,246)<span></span>
</td>
<td class="num">(18,012)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(79,901)<span></span>
</td>
<td class="num">(63,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(66,845)<span></span>
</td>
<td class="num">(60,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">66,646<span></span>
</td>
<td class="nump">87,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,287)<span></span>
</td>
<td class="num">(2,223)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="nump">24,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">38,072<span></span>
</td>
<td class="nump">74,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">39,520<span></span>
</td>
<td class="nump">74,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Foreign exchange impact on cash, cash equivalents and restricted cash</a></td>
<td class="nump">7,337<span></span>
</td>
<td class="num">(2,273)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(34,530)<span></span>
</td>
<td class="nump">33,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">197,813<span></span>
</td>
<td class="nump">164,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">163,283<span></span>
</td>
<td class="nump">197,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Non-cash lease obligations acquired from operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash purchases of property, equipment and intangibles</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FinanceCostIncurredButNotYetPaid', window );">Non-cash financing costs</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refunds received</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND RESTRICTED CASH</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">163,082<span></span>
</td>
<td class="nump">197,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RestrictedCashAndOtherAssets', window );">Restricted cash included in other assets</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">$ 163,283<span></span>
</td>
<td class="nump">$ 197,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FinanceCostIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance cost incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FinanceCostIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange gain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RestrictedCashAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RestrictedCashAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627811521688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 105,857<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="nump">$ 360,045<span></span>
</td>
<td class="num">$ (259,448)<span></span>
</td>
<td class="nump">$ 2,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,358,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">74,020<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="nump">73,474<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,462,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested', window );">Exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested', window );">Exercise of stock options and vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,834<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,834<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(1,308)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,151)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(55,151)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">131,300<span></span>
</td>
<td class="nump">$ 2,918<span></span>
</td>
<td class="nump">441,395<span></span>
</td>
<td class="num">(314,599)<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,882,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">38,171<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">37,906<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested', window );">Exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested', window );">Exercise of stock options and vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,372<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">7,485<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(85,513)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(85,513)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 102,263<span></span>
</td>
<td class="nump">$ 3,211<span></span>
</td>
<td class="nump">$ 490,093<span></span>
</td>
<td class="num">$ (400,112)<span></span>
</td>
<td class="nump">$ 9,071<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,602,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised and stock options exercised and restricted stock units vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options exercised and restricted stock units vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741913720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus N.V. is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the &#8220;Company&#8221;).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has generated an accumulated loss of $400.1 million as of December&#160;31, 2020. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its bispecific antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved bispecific antibody candidate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations with third parties and business development opportunities. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#8217;s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, the Company expects that its existing cash, cash equivalents and marketable securities of $207.8 million as of December 31, 2020, combined with the aggregate immediate proceeds from the closing of the collaboration and share purchase agreements with Eli Lilly &amp; Co (Eli Lilly) in January 2021 of $60.0 million and the aggregate net proceeds from the January 2021 follow-on offering of $129.7 million in January 2021, will fund the Company&#8217;s operations at least into the second half of 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741667896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Preparation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the U.S. ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries are entities controlled by the Company, consisting of Merus N.V.&#8217;s wholly owned subsidiary Merus US, Inc. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. All significant intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Functional and Presentation Currency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items recorded in each of the Company&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates (the <span style="color:#000000;">"</span>functional currency<span style="color:#000000;">"</span>). Merus US, Inc.&#8217;s functional currency is the U.S. dollar. The functional currency of Merus N.V. is the euro. After measuring foreign currency denominated transactions into an entity&#8217;s functional currency, to the extent that a subsidiary&#8217;s functional currency differs from its parent, a subsidiary&#8217;s financial position and results of operations are translated into its parent&#8217;s functional currency. The Company&#8217;s consolidated financial position and results of operations are translated into the U.S. dollar as the Company&#8217;s reporting currency.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amounts of collaboration revenue and expenses during the reporting period. Actual results and outcomes may differ materially from management&#8217;s estimates, judgments and assumptions. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, marketable securities and accounts receivable. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments as defined by the Company. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit the Company&#8217;s credit exposure to any single issuer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts <span style="color:#000000;">receivable</span> represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subsequent Events </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers events or transactions that occur after the balance sheet date but before the consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company evaluated all events and transactions through the date these financial statements were filed with the Securities and Exchange Commission. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.73%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 1 &#8211; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.73%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 2 &#8211; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined through the use of models or other valuation methodologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.73%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 3 &#8211; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined by the reporting entity&#8217;s own assumptions utilizing the best information available and includes situations where there is little market activity for the asset or liability. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The asset&#8217;s or liability&#8217;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers its cash, cash equivalents, accounts receivable, marketable securities due with maturities 12 months or less, and accounts payable financial instruments to reflect their fair value given their short maturity and risk profile of the counterparty.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to <span style="color:#000000;">continue</span> as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs, and <span style="color:#000000;">comparing</span> <span style="color:#000000;">those</span> needs to the current cash, cash equivalent and marketable security balances. After considering the Company&#8217;s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable securities as of December&#160;31, 2020, the Company did not identify conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year from the date these financial statements were issued.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid debt securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Instruments subject to restrictions are not included in cash and cash equivalents.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities that are debt securities with a remaining maturity when purchased of greater than three months as held-to-maturity as the Company has the positive intent and ability to hold such debt securities through maturity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities that are classified as held-to-maturity are initially recognized and measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Interest income from these debt securities is included in interest income. Marketable securities are classified as current if their expected maturity is within one year or less of the balance sheet date and non-current if their maturity is beyond one year of the balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are amounts due from collaboration partners as a result of research and development services provided or milestones achieved but not yet paid.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Allowance for Credit Losses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its cash equivalents, accounts receivable and held-to-maturity marketable securities financial assets for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current environment, the Company concluded there is generally no expected credit losses for these financial assets. With respect to held-to-maturity marketable securities which are comprised of debt securities, the Company evaluates expected credit losses on a pooled basis based on issuer-type which have similar credit risk characteristics. The allowance for credit losses is immaterial for all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Asset Category</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Useful Lives</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or term of lease</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes expenditures for new property and equipment and improvements to existing facilities and charges the cost of maintenance to expense. The Company eliminates the cost of property retired or otherwise disposed of, along with the corresponding accumulated depreciation or amortization, from the related accounts, and the resulting gain or loss is reflected in the results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets are identifiable non-monetary assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or self-creation) and from which future economic benefits (inflows of cash or other assets) are expected. The useful lives of intangible assets are assessed to be definite-lived and amortized over the useful economic life. The Company&#8217;s intangible assets are comprised of purchased licenses to intellectual property and software licenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets to be held and used, including property and equipment, operating lease right-of-use assets and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No such impairments were recorded in 2020 or 2019. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company does not have any finance leases.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease, and excludes non-lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets also include the effect of any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has real estate operating lease agreements with lease and non-lease components, which are generally accounted for separately as operating lease costs and variable lease costs. Non-lease components in real estate leases refer to services provided by the lessor related to the premises. Fixed and variable lease payments are both allocated to lease and non-lease components. The allocation is determined on a relative fair value basis of the services provided relative to the operating lease of premises. With respect to equipment leases, the Company has elected not to allocate payments amongst lease and non-lease components as a practical expedient as afforded under ASC 842, <span style="font-style:italic;">Leases</span>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records deferred taxes to recognize the future effects of temporary differences between the tax basis and financial statement carrying amount of assets and liabilities. The Company measures the deferred taxes using enacted tax rates expected to apply when the temporary differences are realized and records a valuation allowance to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available, reversing taxable temporary differences and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the technical merits, facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to an underpayment of income taxes, if applicable, as a component of income tax expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for an arrangement, the Company performs the following five step analysis: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">identify the contract(s) with a customer; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">identify the performance obligations in the contract; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iii.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">determine the transaction price; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iv.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">allocate the transaction price to the performance obligations in the contract; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">v.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">recognize revenue when (or as) the entity satisfies a performance obligation. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i)&#160;licenses, or options to obtain licenses, to product candidates or future product candidates directed to specific targets (referred to as &#8220;exclusive licenses&#8221;) and (ii)&#160;research and development activities to be </p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performed on behalf of the collaboration partner related to the licensed targets.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also derives revenue from government grants.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must use judgment to determine: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">the transaction price under step (iii) above; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as unbilled receivables.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Licenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the rights and obligations set out in the contract, the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i)&#160;at the inception of the arrangement as an upfront fee or payment, (ii)&#160;upon the exercise of an option to acquire a license or (iii)&#160;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based milestones or royalty revenue resulting from any of its arrangements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period as described under&#160;<span style="font-style:italic;">Exclusive Licenses&#160;</span>above. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it&#160;is probable that a significant revenue reversal would not occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government Grants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the R&amp;D cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. Government grant revenue may be subject to review by a government authority in periods subsequent to their recognition and may result in the reversal of grant revenue previously recognized. Reversals of grant revenue are presented as contra revenue in the consolidated statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are expensed as incurred. Research and development expenses are comprised of costs incurred in providing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract research and development services, and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When third-party service providers&#8217; billing terms do not coincide with the Company&#8217;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs, contractual services costs and costs for supply of its product candidates incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period, past history in conducting similar activities and the expected duration of the third-party service contract, among other considerations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of research and development expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The WBSO (<span style="font-style:italic;">afdrachtvermindering speur- en ontwikkelingswerk</span>) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under </p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this act, a contribution is paid towards the labor costs of employees directly involved in research and development. </span><span style="color:#000000;">For the year ended December 31, </span><span style="color:#000000;">2020</span><span style="color:#000000;"> and </span><span style="color:#000000;">2019</span><span style="color:#000000;">, the Company recognized</span><span style="color:#000000;"> </span><span style="color:#000000;">$6.0 million</span><span style="color:#000000;"> and </span><span style="color:#000000;">$4.5 million</span><span style="color:#000000;"> as a reduction of research and development expenses, respectively.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee share-based compensation based on the grant date fair value of the share-based compensation award. The Company grants stock options at exercise prices equal to the fair value of the Company&#8217;s common stock on the date of grant, based on observable market prices. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For share-based payments subject time-based vesting, the Company recognizes employee stock-based compensation expense on a straight-line basis over the requisite service period of the awards, generally from the date of grant through each vesting date. The Company recognizes forfeitures at the time they occur. The actual expense recognized over the vesting period will only represent those options that vest; the effect of forfeitures in the recognition of periodic compensation expense are not estimated prior to their occurrence. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Earnings (Loss) per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company computes basic earnings (loss) per share by dividing income (loss) allocable to common stockholders by the weighted average number of shares of common stock outstanding. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The Company computes diluted earnings (loss) per share after giving consideration to the dilutive effect of stock options and restricted stock units (&#8220;RSU&#8221;) that are outstanding during the period, except where such non-participating securities would be anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pending Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span>. The new <span style="color:#000000;">guidance</span> aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for the Company at the beginning of 2021, including interim periods within that reporting period, although early adoption is permitted. The Company does not expect the impact of adoption to be significant.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU 2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808)</span>, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative <span style="color:#000000;">arrangement</span> participant if the participant is not a customer. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. As of December 31, 2020, none of the Company&#8217;s arrangements fall within the scope of ASC 808. However, as the Company may engage in future collaborative arrangements in the future, this ASU may apply to those new arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627819571432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Investments in Debt Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities are classified in the consolidated balance sheet as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,053</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,673</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,215</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes debt securities by maturity at December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Maturity</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After one year through five years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes debt securities by credit-quality indicator:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Quality Indicator as of December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AAA</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AA- to AA+</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A- to A+</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,498</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The credit quality indicator was derived from publicly available ratings published by Moody&#8217;s or a comparable credit rating agency, last updated as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,053</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,053</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,994</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,679</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,709</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allowance for credit losses applicable to debt securities was immaterial in all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of money market funds is determined based on publicly available market price for these funds (Level 1). The fair value of other debt securities is determined based on the publicly available inputs which includes a market price for the same or similar instruments adjusted for estimates in interest yield (Level 2).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818523160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Prepaid Expenses and Other Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical and manufacturing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,971</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid general and administrative costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,058</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,569</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other assets totaled $0.2 million and $0.2 million as of December 31, 2020 and 2019, respectively. The nature of the restriction relates to amounts held as collateral for a credit card borrowing arrangement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627742725464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Property and Equipment, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,695</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment and furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,608</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,493</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,088</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $1.2 million and $0.9 million for the years ended December&#160;31, 2020, and 2019, respectively. Property and equipment are predominantly located in the Netherlands.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627742286936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Intangible assets, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software licenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,832</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,343</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(956</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense was $0.3 million and $0.2 million for the years ended December&#160;31, 2020, and 2019, respectively. Intangible assets are predominantly located in the Netherlands.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense over the next five years are expected to be as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expected</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,651</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total remaining value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740286712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued personnel costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,495</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,566</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,402</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,536</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740323064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss from operations before income tax expense are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,832</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,363</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,178</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,010</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,957</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of income tax expense (benefit) from continuing operations are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax benefit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parent company is subject to income tax in the Netherlands where a greater proportion of economic activity is attributed. A reconciliation of the Netherlands statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands statutory income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in tax rates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018 and 2020, Dutch tax authorities enacted new tax rates applicable to future periods which impact the measurement of deferred income taxes. The effect of the change in the valuation allowance each year reflects the increase or decrease in the valuation allowance against deferred tax assets attributable to the Netherlands.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the Company&#8217;s deferred tax assets (liabilities) consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excess interest carryforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,058</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,170</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,495</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax asset valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,645</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,525</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,619</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,331</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,331</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After consideration of all positive and negative evidence, the Company believes that it is more-likely-than-not that our Netherlands deferred tax assets that are not supported by reversing temporary differences will not be realized. As a result, the Company established a valuation allowance of $93.6 million and $57.9 million as of December&#160;31, 2020 and 2019, respectively. The increase in the valuation allowance of $35.8 million and $13.2 million <span style="font-size:12pt;">&#160;</span>for the years ended December&#160;31, 2020 and 2019, respectively, is primarily attributable to the increase in net operating loss carryforward deferred tax assets for which a full valuation allowance applies and change in tax rates. As of December&#160;31, 2020, the portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits would be credited directly to contributed capital totaled $2.1 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company did not have any net operating losses for U.S. federal or state income tax purposes. The Company had net operating loss carryforwards for Dutch income tax purposes, the amount and expiry are as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiry Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Netherlands Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss&#160;Carryforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,129</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,426</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had no unrecognized tax benefits. As of December&#160;31, 2020, the Company had no accrued interest or penalties related to underpayments of income taxes and no amounts have been recognized in the consolidated statements of operations. The Company will recognize interest and penalties related to an underpayment of income taxes in income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions as well as in the Netherlands. The statute of limitations for assessment by the Internal Revenue Service (IRS), and Massachusetts tax authorities is closed for tax years prior to 2017. The statute of limitations for assessment by the Netherlands tax authorities is closed for tax years prior to 2015. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741691256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Operating Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus N.V. leases its corporate headquarters under an agreement term of five years, which expires in the fourth quarter of 2021. On May 1, 2018, Merus N.V. leased additional space to expand its corporate headquarters under a separate agreement. Under the terms of the new agreement, the term began on May 1, 2018 and also expires in the fourth quarter of 2021.&#160; Given the Company&#8217;s current plans, the renewal term has not been included in the estimate of the lease term. Fixed lease payments increase annually and include an </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase based on an inflationary measure.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable payments include amounts due to t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he lessor </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional services </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and cost reimbursements</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, Merus US, Inc. entered into a lease agreement for office space in Cambridge, Massachusetts. The lease commenced in the second quarter of 2019 and has a term of seven years, and may be extended for another five years. Given the Company&#8217;s current plans, the renewal term has not been included in the estimate of the lease term. Fixed lease payments increase annually and include an increase on an inflationary measure. Variable payments include amounts due to the lessor for additional services and cost reimbursements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operating leases relate to its real estate leases that are not classified as finance leases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a lease with Kadans Science Partner XII B.V. (&#8220;Kadans&#8221;), pursuant to which the Company agreed to lease approximately 5,070 square meters of office and laboratory space in a new multi-tenant office building that is to be constructed in Utrecht, the Netherlands. The initial term of the lease is ten years from the date that the premises are completed in accordance with certain specifications provided in a development agreement (described below), which is expected to occur in mid-2022. The lease will renew for two 5-year terms following the initial term, unless earlier terminated by the Company or Kadans, except that the earliest Kadans may terminate the lease is 20 years from the completion date. The lease provides for an estimated initial rent of approximately &#8364;1.3 million per annum. The rent amount is subject to adjustment based on the consumer price index (the &#8220;CPI&#8221;) beginning on January 1, 2019 through the completion date and then annually thereafter, subject to certain limitations if the CPI is greater than 3.0%. The final initial rent amount is contingent upon, among other things, the parameters of the final constructed premises, the final floor area, and the CPI adjustment described above, and will be determined upon the completion date and recorded in a first rider, signed by the Company and Kadans, to the lease. The Company is also responsible for certain fit-out costs and service fees related to the premises. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company also entered into a development agreement with Kadans and another party, Genmab B.V., which provides for the design, development and construction of the new multi-tenant office building of which the premises is a part.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost recorded in the Company&#8217;s consolidated statement of operations and statement of cash flows were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,386</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost included in operating expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,986</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid to lessors included in operating cash outflows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s non-lease cost and other costs paid to the lessor are primarily related to services provided by the lessor in operating the premises that includes fees, operating costs, taxes and insurance related to the leased premises. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of the Company&#8217;s operating lease obligations as of December 31, 2020 were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,350</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease terms and discount rates related to the Company&#8217;s leases were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining operating lease term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000593">4.2</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000594">4.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817697224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Indemnities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that is intended to limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, clinical sites and customers. Under these provisions, the Company may indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities, such as gross negligence, willful misconduct or at times, other activities. These indemnification provisions may survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions may be unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 5, 2018, an unnamed third party and Regeneron Pharmaceuticals Inc., or Regeneron filed notices of opposition against the Company&#8217;s EP 2604625 patent, entitled &#8220;Generation of Binding Molecules,&#8221; in the European Opposition Division of the European Patent Office (the &#8220;EPO&#8221;). The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. Regeneron withdrew its opposition pursuant to a global December 20, 2018 settlement with the Company. On August 20, 2018, the Company timely responded to these submissions with respect to the unnamed third party. An opposition hearing was held in June 2019, wherein the EPO revoked the EP 2604625 patent in its entirety under Art. 123(2) EPC. The Company timely appealed that decision in December 2019 before the Technical Board of Appeals for the EPO seeking reinstatement of the patent and proposing auxiliary requests for certain amended claims, with further proceedings to be scheduled in the future. As this opposition proceeding continues, the Company cannot be certain that it will ultimately prevail.<span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be involved in various other claims and legal proceedings relating to claims arising out of the Company&#8217;s operations. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627893946360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stockholders&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to dividends when and if declared by the board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Issuances<span style="font-size:12pt;font-style:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 7, 2019, the Company completed an underwritten public offering in which the Company sold 5,462,500 common shares, including 715,500 common shares pursuant to the underwriters&#8217; option to purchase additional shares, at a price to the public of $14.50 for aggregate net proceeds of $74.0 million.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 23, 2020, the Company sold 766,666 common shares, at a price of $15.00 for aggregate proceeds of $11.5 million.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 24, 2020, the Company sold 384,615 common shares, at a price of $15.60 for aggregate proceeds of $6.0 million.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 3, 2020, the Company sold 1,300,000 common shares, at a price of $16.90 for aggregate proceeds of $22.0 million.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2021, a total of 2,336,997 shares of common stock were reserved for additional grants of stock awards under the Company&#8217;s 2016 Incentive Award Plan. Stock-based compensation expense related to the equity compensation plan is more fully described in Note 13, <span style="font-style:italic;">Employee Benefit Plans</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627813685416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Collaborations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Incyte</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, pending regulatory clearance, Incyte agreed to pay the Company a $120.0 million, non-refundable upfront payment, and purchased 3.2 million common shares at a stated price per share of $25.00, for an aggregate purchase price of $80.0 million. In exchange, the Company granted Incyte with a license to certain of its intellectual property and committed to collaborate with Incyte to research, discover and develop monospecific or bispecific antibodies utilizing the Company&#8217;s proprietary bispecific technology platform. The collaboration is managed by a joint steering committee in which both parties are represented and is tasked with overseeing the activities which significantly contributes to the collaboration. The collaboration may encompass up to 11 product candidates that result from the Company&#8217;s application of its proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. During the course of the initial research term, Merus proposes product candidates to Incyte, which evaluates whether to designate proposed product candidates from the Company to make a selection for further research. Proposed product candidates begin at a pre-clinical stage of development. Incyte has certain rights to replace product candidates, including the right to substitute a product candidate after initial selection. The Company would be entitled to future consideration in the form of cost reimbursements for research services, development milestones, commercialization milestones and royalties related to the programs under the arrangement.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At inception of the collaboration, two potential bispecific product candidates were under preliminary evaluation. After further research, a lead candidate was ultimately selected for the first product candidate, designated MCLA-145, and the other potential product candidate was not pursued. For the designated product candidate (MCLA-145), the Company retains the exclusive right to develop and commercialize products and product candidates in the United States, while Incyte has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States. For MCLA-145, the parties will conduct and share equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in each party&#8217;s respective territories. For all other programs under the arrangement to be selected by Incyte, Incyte will be responsible for all research, development and commercialization costs. The Company may elect to co-fund the development of certain of the other programs in the future, in which case costs and benefits would be shared. The Company has not elected to co-fund any programs to date.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At inception of the arrangement, the Company identified a performance obligation comprised of a combined delivery of a license and related activities, including the activities of the joint steering committee, to which to allocate consideration. The arrangement also allowed for optional future research services to advance selected product candidates through discovery and research. The transaction price was comprised of fixed consideration of an upfront payment of $120.0 million and proceeds from the sale of shares of $80.0 million. All other consideration under the arrangement was determined to be variable consideration and fully constrained at inception. $152.6 million of the transaction price was allocated to the license and related activities performance obligation after accounting for the purchase of common shares by Incyte</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 23, 2017, the Company completed the sale of shares and exchange of the license. The Company initially deferred the transaction price allocated to the license and related activities performance obligation as deferred revenue, to be recognized as revenue over time as the primary benefit of the license to Incyte is access to the platform for the generation of potential product candidates. Development milestones, commercialization milestones and royalties are variable consideration, fully constrained, to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy. Cost reimbursements for research services are recognized as they are performed over time as these are considered a separate performance obligation.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At December 31, 2020, the Company is currently engaged in research and development activities for MCLA-145 and developing candidates for the other programs. No development or commercialization milestones have been achieved to date.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ONO </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 14, 2018, the Company granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market bispecific antibody candidates based on the Company&#8217;s Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform against two undisclosed targets directed to a particular undisclosed target combination. ONO is responsible for identifying lead candidates and conducting further non-clinical and clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development. Additionally, ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has also agreed to fund the Company&#8217;s research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreed upon research plan. The Company retains all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONO agreed to pay the Company an upfront, non-refundable payment of &#8364;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company was entitled to &#8364;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million intended to compensate the Company for research services already completed upon entering into the agreement, and &#8364;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million to be paid to the Company over time for full time equivalent funding. The Company is entitled to research and development milestones in addition to royalties on future sales</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified performance obligations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: (1) provision of a license for the target combination</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) research and development services. The Company concluded that Ono would be able to develop and benefit from the license, independent of the research and development services.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research and development services are capable of being performed by third parties with an appropriate sub-license, and are recognized over time as these services are delivered. </span><span style="Background-color:#FFFFFF;color:#000000;">Milestone payments are fully constrained as variable consideration to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 3, 2016, the Company was engaged to perform manufacturing services for Ono in support of their clinical trials that was the subject of a prior arrangement with Ono initiated in 2014. The Company was entitled to compensation to oversee and support a manufacturing process with the use of an outside third-party and to deliver quantities of manufactured product. The Company identified one performance obligation to provide manufacturing supervision services involving the transfer of know-how and the development of a <span style="Background-color:#FFFFFF;color:#000000;">manufacturing</span> process with the third-party and three performance obligations related to the services provided in connection with the delivery of product each having separate and distinct requirements. The Company acts as an agent for Ono with respect to the third-party manufacturing costs incurred for the underlying product and presents the recovery of such costs net in research and development expense in the consolidated statement of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company received &#8364;3.7 million (approximately $4.1 million) for the year ended December 31, 2019 for development milestones received from Ono based on their progress. The amounts are recognized as revenue in the consolidated statement of operations for the year ended December 31, 2019. No comparable development milestones were received in the year ended December 31, 2020. Research and development services were completed in 2018.</span><span style="color:#000000;">&#160;&#160;&#160;</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Simcere</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the Company granted Simcere an exclusive license to develop and commercialize up to three bispecific antibodies to be produced by Merus utilizing the Company&#8217;s Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform in China. The Company will retain all rights outside of China. The Company has agreed to lead research and discovery activities, while Simcere has agreed to be responsible for the Investigational New Drug (&#8220;IND&#8221;) enabling studies, clinical development, regulatory filings and commercialization of these potential product candidates in China. The Company received an upfront, non-refundable payment of $2.75 million, relating to three separate research programs. The Company may be entitled to future development milestone payments.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At inception of the arrangement, the Company identified three performance obligations comprised of the combined delivery of a license and performance of research and development activities with respect to each program. The Company performs research and development activities to achieve candidate nomination. The Company concluded that these activities were not distinct from the underlying license for each program as Simcere would not be able to benefit from the license apart from research and development activities at this phase of development</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The transaction price under the arrangement comprised fixed consideration of $2.75 million. </span><span style="color:#000000;">The transaction price was allocated to each separate performance obligation on a relative standalone fair value basis. </span><span style="Background-color:#FFFFFF;">The Company deferred the portion of the upfront payment allocated to the three performance obligations as deferred revenue, to be recognized over time</span><span style="color:#000000;">. </span><span style="Background-color:#FFFFFF;">Compensation for research and development services prior to candidate nomination are allocated to each program performance obligation and also recognized over time. Development milestone payments allocated to each of the program performance obligations are constrained as variable consideration to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has achieved two milestones under this agreement and has received an aggregate of $1.3 million in milestone payments, including a milestone payment of $0.5 million for the quarter ended September 30, 2020, concerning the generation of functional data associated with the second bispecific antibody research program. <span style="Background-color:#FFFFFF;color:#000000;">At December 31, 2020, research and development for one of the three programs is on-going.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Betta</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 10, 2018, the Company granted Betta an exclusive license to develop and commercialize in China MCLA-129, a proprietary Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> produced by its Biclonics<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology platform. The Company retains all rights outside of China. Betta has agreed to retain a contract manufacturing organization with experience in filing IND applications with U.S. regulatory authorities and CTAs with European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of the world. As a key strategic component of the collaboration, Betta will be responsible for IND enabling studies and manufacturing of clinical trial </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materials in China, which the Company intends to use to assist regulatory filing and early stage clinical development in the rest of the world. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to a non-refundable upfront payment of $1.0 million, Betta and the Company will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. The Company is also eligible to receive an aggregate of $12.0 million in milestone payments contingent upon Betta achieving certain specified development and commercial goals as well as tiered royalty payments of net sales of any products resulting from the collaboration in China. In turn, Betta is also entitled to milestone payments based on the Company&#8217;s progress. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified a single combined performance obligation, being the delivery of the MCLA-129 license including activities necessary to complete the technology transfer. The Company had no other commitments. The transaction price is comprised of fixed consideration of $1.0 million and fully allocated to the single performance obligation which would be fulfilled at a point in time. The technology transfer to deliver the license was completed in 2018 and Company recognized the revenue related to this performance obligation of $1.0 million as revenue for the year ended December 31, 2018. <span style="Background-color:#FFFFFF;color:#000000;">Development milestone payments allocated to the performance obligation are constrained as variable consideration to be recognized in future periods in accordance with the Company&#8217;s revenue recognition policy</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the quarter ended December 31, 2020, both the Company and Betta achieved a development milestone both valued at $2.0 million. The amounts are recognized as milestone revenue of $2.0 million and research and development cost of $2.0 million in the Company&#8217;s statement of operations for the year ended December 31, 2020.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contract Assets, Liabilities, Revenues and Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its collaboration arrangements. The dollar amounts in the tables below are in thousands.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billings</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash receipts</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6,587</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(772</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(607</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,711</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billings</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6,546</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,623</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">108,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized in the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8,660</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">99,004</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">711</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,554</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(474</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">79,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The balance of unbilled receivables predominantly represents reimbursement revenue under the Company&#8217;s collaboration arrangements earned in the period to be billed and collected in the next period, generally quarterly. Incyte is a related party as a shareholder, as more fully described in Note 15.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">695</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8,387</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,163</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses from collaborations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in deferred revenue at the beginning of the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17,839</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7,992</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,426</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25,831</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5,517</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses from collaborations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in deferred revenue at the beginning of the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17,839</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">945</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740002056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Employee Benefit Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2010 Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2010, the Company established the Merus B.V. 2010 Employee Option Plan (the &#8220;2010 Plan&#8221;) that entitled key management personnel, staff and consultants providing similar services to purchase shares in the Company. Under the 2010 Plan, holders of vested options were entitled to purchase depositary receipts for common shares at the exercise price determined at the date of grant. Upon exercise of the option, common shares were issued to a foundation established to facilitate administration of share-based compensation awards and pool the voting interests of the underlying shares, and depositary receipts were issued by the foundation to the individual holders. In connection with the IPO, the 2010 Plan was amended to cancel the depositary receipts and allow individual holders to directly hold the common shares obtained upon exercise of their options. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted under the 2010 Plan generally vest in installments over a <span style="-sec-ix-hidden:F_000777">four-year</span> period from the grant date: 25% percent on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in <span>36 month</span>ly installments for each full month of continuous service provided thereafter. Options expire after 8 years from the date of grant. The last grant of options pursuant to the 2010 Plan occurred in 2016, with no further grants expected.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2016 Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company established the 2016 Incentive Award Plan (the &#8220;2016 Plan&#8221;). All incentive award grants since 2016 are being made under the 2016 Plan. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted to employees under the 2016 Plan generally vest in installments over a <span style="-sec-ix-hidden:F_000783"><span style="-sec-ix-hidden:F_000784">four-year</span></span> period from the grant date: 25% percent vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in <span>36 month</span>ly installments for each full month of continuous service provided thereafter. Certain options may vest dependent on the attainment of performance criteria. Options expire after <span>10 years</span> from the date of grant. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted to non-executive directors consist of initial option grants as well as subsequent annual awards. The initial award of options granted vest in installments over a <span style="-sec-ix-hidden:F_000793"><span style="-sec-ix-hidden:F_000794">three-year</span></span> period: 33% of the options vest on the first anniversary of the vesting commencement date, and 67% of the options vest in <span>24 month</span>ly installments thereafter. Each subsequent award vests over a <span style="-sec-ix-hidden:F_000801"><span style="-sec-ix-hidden:F_000802">one-year</span></span> period in <span>12 month</span>ly installments. The Company measures the fair value of an option through the application of an option pricing model, as more fully described below.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs granted to employees under the 2016 Plan vest in installments over a <span style="-sec-ix-hidden:F_000806"><span style="-sec-ix-hidden:F_000807">four-year</span></span> period from the grant date. Certain RSUs may vest dependent on the attainment of performance criteria. Each RSU represents the right to receive one common share. The fair value of an RSU is determined by reference to the price of the underlying common share.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of common shares authorized for issuance for future grants under the 2016 Plan as of January 1, 2021 totaled 2,336,997. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,186</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,403</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,648</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $8.0 million in unrecognized stock-based compensation that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of 1.3 years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Valuation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing model to measure the fair value of stock option awards. In prior years, a Hull-White option-pricing model was used. Key weighted average assumptions used in this pricing model on the date of grant for options granted to employees are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual life of options (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">10.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000820">10.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term of options (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000821">6.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility of underlying stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based upon the U.S. Treasury yield curve in effect at the time of grant, with a term that approximates the expected life of the option. The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates. A simplified method using a weighted-average mid-point between an award&#8217;s vesting date and expiry is used to estimate the expected life of options in all periods presented as a sufficient history of participant exercise behavior is not readily observable. The Company has applied an expected dividend yield of 0.0% as the Company has not historically declared a dividend and does not anticipate declaring a dividend during the expected life of the options. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Activity</span></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity for the year ended December&#160;31, 2020: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,314,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.16</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202,207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(622,094</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.62</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,748,911</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.59</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000839">5.9</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140,953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000840">4.1</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RSU Activity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant-date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,642</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.68</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,474</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,248</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.94</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,775</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intrinsic Value of Stock Options Exercised and Vested RSUs</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fair value of RSUs vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate intrinsic value of options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Employment Benefit Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has established a post-employment benefit plan for employees of the Netherlands that entitles executive officers and other staff members to retire at the age of 67 and receive annual payments based upon the average salary earned during the service period. The Company has insured the benefit liabilities through purchased non-participating annuities from an insurance company and has no other obligation other than to pay the annual insurance premiums to the insurance company. After purchasing the insurance, the Company has no further obligation (legal or constructive) to pay further amounts if the insurance fund has insufficient assets to pay all employee benefits relating to current and prior service. Contributions to purchase non-participating annuities are expensed as incurred as service costs. Company contributions to the post-employment benefit plan totaled $2.0 million and $1.3 million in the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">401(k) Savings Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined contribution 401(k) savings plan (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers substantially all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax basis. The Company matches contributions to the 401(k) Plan, matching 50% of an employee&#8217;s contribution up to a maximum of 3% of the participant&#8217;s compensation. Company contributions to the 401(k) Plan totaled $0.1 million and $0.1 million in the years ended December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Executive Settlement</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, in connection with the departure of the Chief Executive Officer of the Company, the Company awarded benefits, including the following: cash compensation of $0.9 million, a grant of 30,000 RSUs, extended vesting of his equity incentive awards through June 30, 2021 and extended exercisability of his equity incentive awards through December 31, 2021. The cash compensation is to be paid by the Company by January 31, 2020. There were no substantive service conditions associated with the benefits awarded other than the passage of time. The Company incrementally recognized $1.8&#160;million in general and administrative expense associated with these benefits in the consolidated statement of operations for the year ended December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741777848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The two-class method was not applied for the years ended December&#160;31, 2020 and 2019 due to the net loss recognized in each of those periods. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share allocable to common stockholders are computed as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands&#160;except&#160;per&#160;share&#160;data)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,256,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,218,083</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share allocable to common stockholders</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741720696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Related Party Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into the Incyte collaboration and license agreement and the Incyte share subscription agreement in which the terms and transactional amounts incurred between Incyte and the Company are more fully described in Note 12. Incyte is a shareholder with holdings representing approximately 10.1% of the outstanding shares of the Company as of December 31, 2020, and 11.1% as of December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741851592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16. Subsequent Events</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 18, 2021, the Company entered into a Collaboration and License Agreement (the &#8220;Collaboration Agreement&#8221;) and Share Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with Eli Lilly and Company, an Indiana corporation (&#8220;Eli Lilly&#8221;). Eli Lilly has agreed to pay an upfront, non-refundable payment of $40 million for the rights granted under the Collaboration Agreement within 30 days following the Effective Date. Eli Lilly will fund the research and development activities to be conducted by the Company for each program under an agreed research plan and budget. With respect to each product arising from each program, the Company is eligible to receive up to $290 million in future contingent development and regulatory milestones and up to $250 million in commercial sales milestones, for a total of up to approximately $1.6 billion for a single product generated from all three programs. The Company is further eligible to receive, on a product-by-product and country-by-country basis, tiered royalties based on the level of worldwide aggregate annual net sales at percentages ranging from the mid-single digits to low double digits until the royalty term expires. In connection with entering into the Collaboration Agreement, pursuant to the Subscription Agreement, on January 18, 2021, Eli Lilly agreed to purchase 706,834 common shares of the Company at a price per share of $28.295 for aggregate gross proceeds to the Company of approximately $20 million. Eli Lilly agreed not to transfer, sell, or otherwise dispose of the Shares for a period of time following the Closing Date, subject to certain customary exceptions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 21, 2021, the Company entered into an underwriting agreement with Jefferies LLC and SVB Leerink LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), in connection with the issuance and sale by the Company in a public offering of 4,848,485 common shares of the Company, nominal value &#8364;0.09 per share, at a public offering price of $24.75 per share, less underwriting discounts and commissions. The Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 727,272 common shares at the public offering price, less underwriting discounts and commissions. On January 21, 2021, the Underwriters exercised this option in full. The closing of the offering occurred on January 25, 2021, resulting in aggregate net proceeds to the Company of $129.7 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627811544824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Preparation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the U.S. ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries are entities controlled by the Company, consisting of Merus N.V.&#8217;s wholly owned subsidiary Merus US, Inc. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. All significant intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FunctionalAndPresentationCurrencyPolicyTextBlock', window );">Functional and Presentation Currency</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Functional and Presentation Currency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items recorded in each of the Company&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates (the <span style="color:#000000;">"</span>functional currency<span style="color:#000000;">"</span>). Merus US, Inc.&#8217;s functional currency is the U.S. dollar. The functional currency of Merus N.V. is the euro. After measuring foreign currency denominated transactions into an entity&#8217;s functional currency, to the extent that a subsidiary&#8217;s functional currency differs from its parent, a subsidiary&#8217;s financial position and results of operations are translated into its parent&#8217;s functional currency. The Company&#8217;s consolidated financial position and results of operations are translated into the U.S. dollar as the Company&#8217;s reporting currency.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amounts of collaboration revenue and expenses during the reporting period. Actual results and outcomes may differ materially from management&#8217;s estimates, judgments and assumptions. </p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, marketable securities and accounts receivable. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments as defined by the Company. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit the Company&#8217;s credit exposure to any single issuer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts <span style="color:#000000;">receivable</span> represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subsequent Events </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers events or transactions that occur after the balance sheet date but before the consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company evaluated all events and transactions through the date these financial statements were filed with the Securities and Exchange Commission. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.73%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 1 &#8211; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.73%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 2 &#8211; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined through the use of models or other valuation methodologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.73%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 3 &#8211; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined by the reporting entity&#8217;s own assumptions utilizing the best information available and includes situations where there is little market activity for the asset or liability. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The asset&#8217;s or liability&#8217;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers its cash, cash equivalents, accounts receivable, marketable securities due with maturities 12 months or less, and accounts payable financial instruments to reflect their fair value given their short maturity and risk profile of the counterparty.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to <span style="color:#000000;">continue</span> as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs, and <span style="color:#000000;">comparing</span> <span style="color:#000000;">those</span> needs to the current cash, cash equivalent and marketable security balances. After considering the Company&#8217;s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable securities as of December&#160;31, 2020, the Company did not identify conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year from the date these financial statements were issued.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid debt securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Instruments subject to restrictions are not included in cash and cash equivalents.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities that are debt securities with a remaining maturity when purchased of greater than three months as held-to-maturity as the Company has the positive intent and ability to hold such debt securities through maturity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities that are classified as held-to-maturity are initially recognized and measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Interest income from these debt securities is included in interest income. Marketable securities are classified as current if their expected maturity is within one year or less of the balance sheet date and non-current if their maturity is beyond one year of the balance sheet date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are amounts due from collaboration partners as a result of research and development services provided or milestones achieved but not yet paid.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Allowance for Credit Losses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its cash equivalents, accounts receivable and held-to-maturity marketable securities financial assets for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current environment, the Company concluded there is generally no expected credit losses for these financial assets. With respect to held-to-maturity marketable securities which are comprised of debt securities, the Company evaluates expected credit losses on a pooled basis based on issuer-type which have similar credit risk characteristics. The allowance for credit losses is immaterial for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Asset Category</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Useful Lives</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or term of lease</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes expenditures for new property and equipment and improvements to existing facilities and charges the cost of maintenance to expense. The Company eliminates the cost of property retired or otherwise disposed of, along with the corresponding accumulated depreciation or amortization, from the related accounts, and the resulting gain or loss is reflected in the results of operations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets are identifiable non-monetary assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or self-creation) and from which future economic benefits (inflows of cash or other assets) are expected. The useful lives of intangible assets are assessed to be definite-lived and amortized over the useful economic life. The Company&#8217;s intangible assets are comprised of purchased licenses to intellectual property and software licenses. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets to be held and used, including property and equipment, operating lease right-of-use assets and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No such impairments were recorded in 2020 or 2019. </p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company does not have any finance leases.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease, and excludes non-lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets also include the effect of any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has real estate operating lease agreements with lease and non-lease components, which are generally accounted for separately as operating lease costs and variable lease costs. Non-lease components in real estate leases refer to services provided by the lessor related to the premises. Fixed and variable lease payments are both allocated to lease and non-lease components. The allocation is determined on a relative fair value basis of the services provided relative to the operating lease of premises. With respect to equipment leases, the Company has elected not to allocate payments amongst lease and non-lease components as a practical expedient as afforded under ASC 842, <span style="font-style:italic;">Leases</span>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records deferred taxes to recognize the future effects of temporary differences between the tax basis and financial statement carrying amount of assets and liabilities. The Company measures the deferred taxes using enacted tax rates expected to apply when the temporary differences are realized and records a valuation allowance to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available, reversing taxable temporary differences and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the technical merits, facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to an underpayment of income taxes, if applicable, as a component of income tax expense. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for an arrangement, the Company performs the following five step analysis: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">identify the contract(s) with a customer; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">identify the performance obligations in the contract; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iii.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">determine the transaction price; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iv.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">allocate the transaction price to the performance obligations in the contract; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">v.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">recognize revenue when (or as) the entity satisfies a performance obligation. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i)&#160;licenses, or options to obtain licenses, to product candidates or future product candidates directed to specific targets (referred to as &#8220;exclusive licenses&#8221;) and (ii)&#160;research and development activities to be </p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performed on behalf of the collaboration partner related to the licensed targets.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also derives revenue from government grants.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must use judgment to determine: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">the transaction price under step (iii) above; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as unbilled receivables.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Licenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the rights and obligations set out in the contract, the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i)&#160;at the inception of the arrangement as an upfront fee or payment, (ii)&#160;upon the exercise of an option to acquire a license or (iii)&#160;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based milestones or royalty revenue resulting from any of its arrangements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period as described under&#160;<span style="font-style:italic;">Exclusive Licenses&#160;</span>above. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it&#160;is probable that a significant revenue reversal would not occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government Grants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the R&amp;D cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. Government grant revenue may be subject to review by a government authority in periods subsequent to their recognition and may result in the reversal of grant revenue previously recognized. Reversals of grant revenue are presented as contra revenue in the consolidated statement of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are expensed as incurred. Research and development expenses are comprised of costs incurred in providing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract research and development services, and other outside costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When third-party service providers&#8217; billing terms do not coincide with the Company&#8217;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs, contractual services costs and costs for supply of its product candidates incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period, past history in conducting similar activities and the expected duration of the third-party service contract, among other considerations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of research and development expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The WBSO (<span style="font-style:italic;">afdrachtvermindering speur- en ontwikkelingswerk</span>) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under </p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this act, a contribution is paid towards the labor costs of employees directly involved in research and development. </span><span style="color:#000000;">For the year ended December 31, </span><span style="color:#000000;">2020</span><span style="color:#000000;"> and </span><span style="color:#000000;">2019</span><span style="color:#000000;">, the Company recognized</span><span style="color:#000000;"> </span><span style="color:#000000;">$6.0 million</span><span style="color:#000000;"> and </span><span style="color:#000000;">$4.5 million</span><span style="color:#000000;"> as a reduction of research and development expenses, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee share-based compensation based on the grant date fair value of the share-based compensation award. The Company grants stock options at exercise prices equal to the fair value of the Company&#8217;s common stock on the date of grant, based on observable market prices. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For share-based payments subject time-based vesting, the Company recognizes employee stock-based compensation expense on a straight-line basis over the requisite service period of the awards, generally from the date of grant through each vesting date. The Company recognizes forfeitures at the time they occur. The actual expense recognized over the vesting period will only represent those options that vest; the effect of forfeitures in the recognition of periodic compensation expense are not estimated prior to their occurrence. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Earnings (Loss) per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company computes basic earnings (loss) per share by dividing income (loss) allocable to common stockholders by the weighted average number of shares of common stock outstanding. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The Company computes diluted earnings (loss) per share after giving consideration to the dilutive effect of stock options and restricted stock units (&#8220;RSU&#8221;) that are outstanding during the period, except where such non-participating securities would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PendingAccountingPronouncementsPolicyTextBlock', window );">Pending Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pending Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span>. The new <span style="color:#000000;">guidance</span> aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for the Company at the beginning of 2021, including interim periods within that reporting period, although early adoption is permitted. The Company does not expect the impact of adoption to be significant.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU 2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808)</span>, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative <span style="color:#000000;">arrangement</span> participant if the participant is not a customer. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. As of December 31, 2020, none of the Company&#8217;s arrangements fall within the scope of ASC 808. However, as the Company may engage in future collaborative arrangements in the future, this ASU may apply to those new arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FunctionalAndPresentationCurrencyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for functional and presentation currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FunctionalAndPresentationCurrencyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PendingAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pending accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PendingAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing any changes to a creditor's accounting policies or methodology from the prior period and management's rationale for the change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741913720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Summary of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records property and equipment at cost. The Company calculates depreciation and amortization using the straight-line method over the following estimated useful lives: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Asset Category</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Useful Lives</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or term of lease</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627819586936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock', window );">Summary of Classification of Debt Securities in Consolidated Balance Sheet</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities are classified in the consolidated balance sheet as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,053</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,673</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,215</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock', window );">Summary of Debt Securities by Maturity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes debt securities by maturity at December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Maturity</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After one year through five years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock', window );">Summary of Debt Securities by Credit Quality Indicator</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes debt securities by credit-quality indicator:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Quality Indicator as of December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AAA</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AA- to AA+</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A- to A+</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,498</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Summary of Fair Value of Debt Securities by Major Security Type</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,156</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,327</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fair value of debt securities by major security type held at December&#160;31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,053</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,053</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasuries</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,994</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate paper and notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,679</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,709</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance sheet classifications of debt securities measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of credit quality indicator for investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of aging analysis for investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919253-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741833704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical and manufacturing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,971</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid general and administrative costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,058</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,569</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740288920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,695</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment and furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,608</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,493</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,088</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627742285816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Intangible Assets Gross Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software licenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,832</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,343</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(956</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Amortization Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense over the next five years are expected to be as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expected</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,651</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total remaining value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741492760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued personnel costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,495</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,566</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,402</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,536</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817815464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Components of Loss from Operations Before Income Tax Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss from operations before income tax expense are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,832</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,363</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,178</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,010</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,957</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Components of Expense for (Benefit) from Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of income tax expense (benefit) from continuing operations are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax benefit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parent company is subject to income tax in the Netherlands where a greater proportion of economic activity is attributed. A reconciliation of the Netherlands statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands statutory income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in tax rates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Components of Deferred Tax Assets (Liabilities)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the Company&#8217;s deferred tax assets (liabilities) consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excess interest carryforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,058</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,170</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,495</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax asset valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,645</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,525</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,619</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,331</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,331</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes</a></td>
<td class="text">The Company had net operating loss carryforwards for Dutch income tax purposes, the amount and expiry are as follows (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiry Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Netherlands Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss&#160;Carryforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,129</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,426</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627739156360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Cost</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost recorded in the Company&#8217;s consolidated statement of operations and statement of cash flows were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,386</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost included in operating expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,986</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid to lessors included in operating cash outflows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Obligations</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of the Company&#8217;s operating lease obligations as of December 31, 2020 were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,350</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease terms and discount rates related to the Company&#8217;s leases were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining operating lease term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000593">4.2</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000594">4.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted average remaining lease terms and discount rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740314344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its collaboration arrangements. The dollar amounts in the tables below are in thousands.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billings</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash receipts</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6,587</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(772</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(607</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,711</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billings</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6,546</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,623</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">108,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized in the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8,660</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">99,004</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">711</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,554</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(474</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">79,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The balance of unbilled receivables predominantly represents reimbursement revenue under the Company&#8217;s collaboration arrangements earned in the period to be billed and collected in the next period, generally quarterly. Incyte is a related party as a shareholder, as more fully described in Note 15.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">695</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8,387</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,163</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses from collaborations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in deferred revenue at the beginning of the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incyte</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ono</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17,839</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7,992</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,426</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25,831</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5,517</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses from collaborations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in deferred revenue at the beginning of the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17,839</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">945</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814268776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,186</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,403</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,648</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Key Weighted Average Assumptions Used in Pricing Model on Date of Grant for Options Granted to Employees</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing model to measure the fair value of stock option awards. In prior years, a Hull-White option-pricing model was used. Key weighted average assumptions used in this pricing model on the date of grant for options granted to employees are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual life of options (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">10.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000820">10.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term of options (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000821">6.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility of underlying stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity for the year ended December&#160;31, 2020: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,314,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.16</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202,207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(622,094</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.62</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,748,911</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.59</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000839">5.9</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140,953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000840">4.1</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant-date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,642</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.68</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,474</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,248</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.94</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,775</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Intrinsic Value of Stock Options Exercised and Vested RSUs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intrinsic Value of Stock Options Exercised and Vested RSUs</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fair value of RSUs vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate intrinsic value of options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817887144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share allocable to common stockholders are computed as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands&#160;except&#160;per&#160;share&#160;data)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,256,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,218,083</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share allocable to common stockholders</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817646200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400,112)<span></span>
</td>
<td class="num">$ (314,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,171<span></span>
</td>
<td class="nump">$ 74,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrus_FollowOnPublicOfferingMember', window );">Follow-on Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">$ 129,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrus_CollaborationAndSharePurchaseAgreementsMember', window );">Collaboration and Share Purchase Agreements | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrus_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrus_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrus_CollaborationAndSharePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrus_CollaborationAndSharePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741779496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashAndCashEquivalentRelatedText', window );">Cash and cash equivalents, maturities</a></td>
<td class="text">three months or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charges of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Reduction in research and development expenses</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashAndCashEquivalentRelatedText">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashAndCashEquivalentRelatedText</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627892602712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeFurnitureAndEquipmentMember', window );">Office Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful life</a></td>
<td class="text">Shorter of useful life or term of lease<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818339000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities - Summary of Classification of Debt Securities in Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems', window );"><strong>Debt Securities Held To Maturity Nonaccrual [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">$ 62,327<span></span>
</td>
<td class="nump">$ 78,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems', window );"><strong>Debt Securities Held To Maturity Nonaccrual [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">17,654<span></span>
</td>
<td class="nump">34,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrus_MarketableSecuritiesCurrentMember', window );">Current marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems', window );"><strong>Debt Securities Held To Maturity Nonaccrual [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">44,673<span></span>
</td>
<td class="nump">42,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrus_MarketableSecuritiesNonCurrentMember', window );">Non-current marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems', window );"><strong>Debt Securities Held To Maturity Nonaccrual [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mrus_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mrus_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mrus_MarketableSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mrus_MarketableSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814322152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities - Summary of Debt Securities by Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Within one year</a></td>
<td class="nump">$ 62,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">After one year through five years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Total</a></td>
<td class="nump">$ 62,327<span></span>
</td>
<td class="nump">$ 78,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814277928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities - Summary of Debt Securities by Credit Quality Indicator (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">$ 62,327<span></span>
</td>
<td class="nump">$ 78,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CreditRatingStandardPoorsAxis=srt_StandardPoorsAAARatingMember', window );">AAA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">17,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CreditRatingStandardPoorsAxis=mrus_StandardPoorsAAMinusToAAPlusRatingMember', window );">AA- to AA+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">24,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CreditRatingStandardPoorsAxis=mrus_StandardPoorsAMinusToAPlusRatingMember', window );">A- to A+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">20,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">10,156<span></span>
</td>
<td class="nump">34,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [member] | AAA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">10,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [member] | AA- to AA+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [member] | A- to A+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember', window );">Corporate paper and notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">27,978<span></span>
</td>
<td class="nump">38,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember', window );">Corporate paper and notes [member] | AAA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">7,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember', window );">Corporate paper and notes [member] | AA- to AA+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember', window );">Corporate paper and notes [member] | A- to A+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">20,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">9,150<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities [member] | AAA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities [member] | AA- to AA+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">9,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities [member] | A- to A+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">15,043<span></span>
</td>
<td class="nump">$ 1,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries [member] | AAA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries [member] | AA- to AA+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">15,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries [member] | A- to A+ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems', window );"><strong>Debt Securities Held To Maturity Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CreditRatingStandardPoorsAxis=srt_StandardPoorsAAARatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CreditRatingStandardPoorsAxis=srt_StandardPoorsAAARatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CreditRatingStandardPoorsAxis=mrus_StandardPoorsAAMinusToAAPlusRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CreditRatingStandardPoorsAxis=mrus_StandardPoorsAAMinusToAAPlusRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CreditRatingStandardPoorsAxis=mrus_StandardPoorsAMinusToAPlusRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CreditRatingStandardPoorsAxis=mrus_StandardPoorsAMinusToAPlusRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627743919048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities - Summary of Fair Value of Debt Securities by Major Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Total</a></td>
<td class="nump">$ 62,327<span></span>
</td>
<td class="nump">$ 78,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair Value</a></td>
<td class="nump">62,328<span></span>
</td>
<td class="nump">78,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Total</a></td>
<td class="nump">10,156<span></span>
</td>
<td class="nump">34,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair Value</a></td>
<td class="nump">10,156<span></span>
</td>
<td class="nump">34,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember', window );">Corporate paper and notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Total</a></td>
<td class="nump">27,978<span></span>
</td>
<td class="nump">38,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair Value</a></td>
<td class="nump">27,978<span></span>
</td>
<td class="nump">38,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Total</a></td>
<td class="nump">9,150<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair Value</a></td>
<td class="nump">9,150<span></span>
</td>
<td class="nump">3,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Total</a></td>
<td class="nump">15,043<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair Value</a></td>
<td class="nump">$ 15,044<span></span>
</td>
<td class="nump">$ 1,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=mrus_CorporatePaperNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740205240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PrepaidClinicalAndManufacturingCostsCurrent', window );">Prepaid clinical and manufacturing costs</a></td>
<td class="nump">$ 4,971<span></span>
</td>
<td class="nump">$ 2,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PrepaidGeneralAndAdministrativeCosts', window );">Prepaid general and administrative costs</a></td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 8,569<span></span>
</td>
<td class="nump">$ 4,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PrepaidClinicalAndManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical and manufacturing costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PrepaidClinicalAndManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PrepaidGeneralAndAdministrativeCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PrepaidGeneralAndAdministrativeCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817887144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash held on account as collateral</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818222328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 7,608<span></span>
</td>
<td class="nump">$ 5,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,493)<span></span>
</td>
<td class="num">(2,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,115<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">5,695<span></span>
</td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818483576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817953944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Summary of Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 4,186<span></span>
</td>
<td class="nump">$ 3,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(1,343)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses of Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">3,898<span></span>
</td>
<td class="nump">3,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741688984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Net Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740239064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Expected Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite Lived Intangible Assets Future Amortization Expense Current And Five Succeeding Fiscal Years [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 2,843<span></span>
</td>
<td class="nump">$ 2,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740138424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 15,372<span></span>
</td>
<td class="nump">$ 6,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel costs</a></td>
<td class="nump">4,854<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 21,803<span></span>
</td>
<td class="nump">$ 13,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627811570376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Loss from Operations Before Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (3,832)<span></span>
</td>
<td class="num">$ (1,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Netherlands</a></td>
<td class="num">(81,178)<span></span>
</td>
<td class="num">(53,594)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (85,010)<span></span>
</td>
<td class="num">$ (54,957)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814921032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Expense for (Benefit) from Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. state</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. state</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818094184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Netherlands statutory income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Changes in tax rates</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(33.50%)<span></span>
</td>
<td class="num">(23.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818642360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 66,572<span></span>
</td>
<td class="nump">$ 33,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">24,966<span></span>
</td>
<td class="nump">23,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Excess interest carryforward</a></td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeferredTaxAssetsLeaseObligation', window );">Lease obligation</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">95,170<span></span>
</td>
<td class="nump">59,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax asset valuation allowance</a></td>
<td class="num">(93,645)<span></span>
</td>
<td class="num">(57,876)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeferredTaxAssetsLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeferredTaxAssetsLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814227400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax asset valuation allowance</a></td>
<td class="nump">$ 93,645,000<span></span>
</td>
<td class="nump">$ 57,876,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance, attributable to increase in net operating loss carryforward deferred tax assets</a></td>
<td class="nump">35,800,000<span></span>
</td>
<td class="nump">$ 13,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital', window );">Deferred tax asset valuation allowance</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, tax related penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance for tax benefit to be credited to shareholders' equity if tax benefit subsequently becomes realizable. Includes, but is not limited to, adjustment to opening balance of retained earnings for change in accounting principle or correction of error, gain (loss) in comprehensive income (loss) but excluded from net income (loss), deductible expenditure for income tax purposes reported as reduction of shareholders' equity, and deductible temporary difference existing at date of quasi-reorganization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818168824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Netherlands Tax Loss Carryforward</a></td>
<td class="nump">$ 266,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2024Member', window );">Tax Year 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExpirationDateCarryForwards', window );">Expiry Year</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Netherlands Tax Loss Carryforward</a></td>
<td class="nump">$ 23,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2025Member', window );">Tax Year 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExpirationDateCarryForwards', window );">Expiry Year</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Netherlands Tax Loss Carryforward</a></td>
<td class="nump">$ 110,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2026Member', window );">Tax Year 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExpirationDateCarryForwards', window );">Expiry Year</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Netherlands Tax Loss Carryforward</a></td>
<td class="nump">$ 95,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2027Member', window );">Tax Year 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExpirationDateCarryForwards', window );">Expiry Year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Netherlands Tax Loss Carryforward</a></td>
<td class="nump">$ 37,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ExpirationDateCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ExpirationDateCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mrus_TaxYear2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mrus_TaxYear2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mrus_TaxYear2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mrus_TaxYear2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mrus_TaxYear2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627815002360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>m&#178; </div>
<div>RenewalTerm</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Merus N.V. leases its corporate headquarters under an agreement term of five years, which expires in the fourth quarter of 2021. On May 1, 2018, Merus N.V. leased additional space to expand its corporate headquarters under a separate agreement. Under the terms of the new agreement, the term began on May 1, 2018 and also expires in the fourth quarter of 2021.&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingLeaseExpirationTerm', window );">Operating lease, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">fourth quarter of 2021.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario Plan [Member] | Kadans Science Partner XII BV | Office Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease', window );">Area of property available for operating lease | m&#178;</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LesseeOperatingLeaseNumberOfRenewalTerm', window );">Operating lease, number of renewal term | RenewalTerm</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LesseeOperatingLeaseTerminationTerm', window );">Operating lease, termination term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, estimated rent expense | &#8364;</a></td>
<td class="nump">&#8364; 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingLeaseRentAdjustmentDescription', window );">Operating lease, rent adjustment description</a></td>
<td class="text">The rent amount is subject to adjustment based on the consumer price index (the &#8220;CPI&#8221;) beginning on January 1, 2019 through the completion date and then annually thereafter, subject to certain limitations if the CPI is greater than 3.0%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario Plan [Member] | Kadans Science Partner XII BV | Minimum | Office Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ConsumerPriceIndex', window );">Consumer price Index</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mrus_MerusUSIncMember', window );">Merus US Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Merus US, Inc. entered into a lease agreement for office space in Cambridge, Massachusetts. The lease commenced in the second quarter of 2019 and has a term of seven years, and may be extended for another five years. Given the Company&#8217;s current plans, the renewal term has not been included in the estimate of the lease term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LesseeOperatingLeaseExtendedTermOfContract', window );">Operating lease, extended term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, options to extend description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">may be extended for another five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The area of property under operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ConsumerPriceIndex">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>consumer price index.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ConsumerPriceIndex</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LesseeOperatingLeaseExtendedTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LesseeOperatingLeaseExtendedTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LesseeOperatingLeaseNumberOfRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease number of renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LesseeOperatingLeaseNumberOfRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LesseeOperatingLeaseTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease termination term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LesseeOperatingLeaseTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingLeaseExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingLeaseExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingLeaseRentAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease rent adjustment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingLeaseRentAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrus_KadansSciencePartnerXIIBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrus_KadansSciencePartnerXIIBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrus_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mrus_MerusUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mrus_MerusUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818048488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Summary of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,611<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost included in operating expenses</a></td>
<td class="nump">1,986<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid to lessors included in operating cash outflows</a></td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="nump">$ 2,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627819635912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">$ 3,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741727400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining operating lease term (in years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate for operating leases</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814697736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>Nov. 24, 2020</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
<th class="th"><div>Nov. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,072<span></span>
</td>
<td class="nump">$ 74,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrus_TwoThousandSixteenIncentiveAwardPlanMember', window );">2016 Incentive Award Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for additional grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,336,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrus_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="nump">766,666<span></span>
</td>
<td class="nump">5,462,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issue price per share</a></td>
<td class="nump">$ 16.90<span></span>
</td>
<td class="nump">$ 15.60<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="nump">$ 14.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares', window );">Number of common shares pursuant to underwriters' option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares pursuant to underwriters' option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrus_TwoThousandSixteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrus_TwoThousandSixteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrus_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrus_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627815422008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Details)<br> $ / shares in Units, &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 14, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Antibody</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>Antibody </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 10, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DevelopmentMilestonesReceived', window );">Development milestones received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">&#8364; 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,040,000<span></span>
</td>
<td class="nump">$ 55,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_IncyteCollaborationAndLicenseAgreementMember', window );">Incyte Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueFromCollaborativeArrangement', window );">Collaborations, transaction price as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_IncyteCollaborationAndLicenseAgreementMember', window );">Incyte Collaboration and License Agreement | License and Related Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueFromCollaborativeArrangement', window );">Collaborations, transaction price as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_SecondONOResearchAndLicenseAgreementMember', window );">Second ONO Research and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payment receivable | &#8364;</a></td>
<td class="nump">&#8364; 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PaymentToCompensateResearchServices', window );">Payment to compensate research services | &#8364;</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OverTimePaymentForFullTimeEquivalentFunding', window );">Over time payment for full time equivalent funding | &#8364;</a></td>
<td class="nump">&#8364; 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_SecondONOResearchAndLicenseAgreementMember', window );">Second ONO Research and License Agreement | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfBispecificAntibodies', window );">Number of bispecific antibodies under collaboration and license agreement | Antibody</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueFromCollaborativeArrangement', window );">Collaborations, transaction price as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceived', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfMilestonesAchieved', window );">Number of milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfResearchAndDevelopmentPrograms', window );">Description of transaction price under fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">research and development for one of the three programs is on-going.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere Collaboration and License Agreement | Second Bispecific Antibody Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere Collaboration and License Agreement | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfBispecificAntibodies', window );">Number of bispecific antibodies under collaboration and license agreement | Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere Collaboration and License Agreement | License and Performance | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfPerformanceObligation', window );">Number of performance obligation | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_BettaCollaborationAndLicenseAgreementMember', window );">Betta Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DevelopmentMilestonesReceived', window );">Development milestones received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRelatedPerformanceObligationAmountAsRevenue', window );">Revenue related performance obligation as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenue', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfResearchAndDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of research and development programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfResearchAndDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DevelopmentMilestonesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DevelopmentMilestonesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NonRefundableUpfrontPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NonRefundableUpfrontPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NonRefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NonRefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfBispecificAntibodies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of bispecific antibodies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfBispecificAntibodies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OverTimePaymentForFullTimeEquivalentFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Over time payment for full time equivalent funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OverTimePaymentForFullTimeEquivalentFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PaymentToCompensateResearchServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment to compensate research services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PaymentToCompensateResearchServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueFromCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueFromCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRelatedPerformanceObligationAmountAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue related performance obligation amount as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRelatedPerformanceObligationAmountAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrus_IncyteCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrus_IncyteCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_LicenseAndRelatedActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_LicenseAndRelatedActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrus_SecondONOResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrus_SecondONOResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrus_SimcereCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrus_SimcereCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrus_SecondBispecificAntibodyResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrus_SecondBispecificAntibodyResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_LicenseAndPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_LicenseAndPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrus_BettaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrus_BettaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627815284968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 21,803<span></span>
</td>
<td class="nump">$ 13,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember', window );">Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">18,193<span></span>
</td>
<td class="nump">17,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OnoMember', window );">Ono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_CollaborationAgreementMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="nump">6,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Cash receipts</a></td>
<td class="num">(6,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Ono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Cash receipts</a></td>
<td class="num">(772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="nump">644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Cash receipts</a></td>
<td class="num">(607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="nump">644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Cash receipts</a></td>
<td class="num">(1,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_UnbilledReceivablesMember', window );">Unbilled Receivables | Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">1,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="num">(6,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_UnbilledReceivablesMember', window );">Unbilled Receivables | Ono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_UnbilledReceivablesMember', window );">Unbilled Receivables | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="num">(644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_UnbilledReceivablesMember', window );">Unbilled Receivables | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at January 1, 2020</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Billings', window );">Billings</a></td>
<td class="num">(644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsToContractAssetsReceivables', window );">Adjustments</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_DeferredRevenueMember', window );">Deferred Revenue | Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">8,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at January 1, 2020</a></td>
<td class="nump">108,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="num">(18,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">99,004<span></span>
</td>
<td class="nump">108,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(19,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current balance at December 31, 2020</a></td>
<td class="nump">79,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_DeferredRevenueMember', window );">Deferred Revenue | Ono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at January 1, 2020</a></td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_DeferredRevenueMember', window );">Deferred Revenue | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at January 1, 2020</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current balance at December 31, 2020</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_DeferredRevenueMember', window );">Deferred Revenue | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignCurrencyExchangeTranslation', window );">Foreign exchange</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at January 1, 2020</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="num">(943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">$ 1,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current balance at December 31, 2020</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdjustmentsToContractAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to contract assets receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdjustmentsToContractAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_Billings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Billings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_Billings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ForeignCurrencyExchangeTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency exchange translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ForeignCurrencyExchangeTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OnoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OnoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_UnbilledReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_UnbilledReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=mrus_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627742096184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 70,040<span></span>
</td>
<td class="nump">$ 55,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">35,781<span></span>
</td>
<td class="nump">34,110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">105,821<span></span>
</td>
<td class="nump">89,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember', window );">Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">18,193<span></span>
</td>
<td class="nump">17,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementRevenues', window );">Reimbursement revenue</a></td>
<td class="nump">8,387<span></span>
</td>
<td class="nump">7,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Milestones</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total collaboration revenue</a></td>
<td class="nump">26,580<span></span>
</td>
<td class="nump">25,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,036<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,036<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">18,193<span></span>
</td>
<td class="nump">17,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OnoMember', window );">Ono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementRevenues', window );">Reimbursement revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Milestones</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total collaboration revenue</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">4,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementRevenues', window );">Reimbursement revenue</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Milestones</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total collaboration revenue</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_CollaborationAgreementMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">895<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementRevenues', window );">Reimbursement revenue</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Milestones</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">4,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total collaboration revenue</a></td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">5,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period</a></td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ReimbursementRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ReimbursementRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OnoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OnoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627742576024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=mrus_FourZeroOnePlanMember', window );">401 (K) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution plan , description</a></td>
<td class="text">The 401(k) Plan covers substantially all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax basis. The Company matches contributions to the 401(k) Plan, matching 50% of an employee&#8217;s contribution up to a maximum of 3% of the participant&#8217;s compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=mrus_FourZeroOnePlanMember', window );">401 (K) Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PostemploymentRetirementBenefitsMember', window );">Postemployment Retirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Contributions to post-employment benefit plan</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrent', window );">Executive settlement, cash compensation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Executive settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining vesting period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options granted share-based payments</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2010 Plan | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2010 Plan | Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting rights, required service period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options granted share-based payments</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares authorized for issuance for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,336,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | Non-Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options granted share-based payments</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | Non-Executive Directors | Subsequent Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options granted share-based payments</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting rights, required service period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | First Anniversary | Non-Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting rights, required service period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payments | 2016 Plan | Thereafter | Non-Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting rights, required service period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Postemployment Retirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_GrantOfRestrictedStockUnit', window );">Grant of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of RSUs granted to employees</a></td>
<td class="text">Each RSU represents the right to receive one common share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod', window );">Vesting period of RSUs granted share-based payments</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_GrantOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant of restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_GrantOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=mrus_FourZeroOnePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=mrus_FourZeroOnePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PostemploymentRetirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PostemploymentRetirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrus_TwoThousandTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrus_TwoThousandTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrus_TwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrus_TwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mrus_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mrus_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=mrus_SubsequentAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=mrus_SubsequentAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627814333336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 9,372<span></span>
</td>
<td class="nump">$ 7,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,969<span></span>
</td>
<td class="nump">3,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 6,403<span></span>
</td>
<td class="nump">$ 4,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627740149480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of Key Weighted Average Assumptions used in Pricing Model on date of Grant for Options Granted to Employees (Details) - Stock Option Activity<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions', window );">Contractual life of options (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of underlying stock</a></td>
<td class="nump">86.10%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual life of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627818571880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance</a></td>
<td class="nump">3,314,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,258,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(202,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited or expired</a></td>
<td class="num">(622,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance</a></td>
<td class="nump">3,748,911<span></span>
</td>
<td class="nump">3,314,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">2,140,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Beginning balance</a></td>
<td class="nump">$ 14.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">16.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="nump">7.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Forfeited or expired</a></td>
<td class="nump">16.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Ending balance</a></td>
<td class="nump">15.59<span></span>
</td>
<td class="nump">$ 14.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercisable</a></td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 11,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 7,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="nump">$ 7.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741517352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of RSU Activity (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Non-vested, Beginning balance | shares</a></td>
<td class="nump">82,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted | shares</a></td>
<td class="nump">46,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested | shares</a></td>
<td class="num">(67,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited | shares</a></td>
<td class="num">(2,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Non-vested, Ending balance | shares</a></td>
<td class="nump">59,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-date Fair Value, Non-vested, Beginning balance | $ / shares</a></td>
<td class="nump">$ 19.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-date Fair Value, Granted | $ / shares</a></td>
<td class="nump">16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-date Fair Value, Vested | $ / shares</a></td>
<td class="nump">19.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">21.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-date Fair Value, Non-vested, Ending balance | $ / shares</a></td>
<td class="nump">$ 16.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627829404296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Intrinsic Value of Stock Options Exercised and Vested RSUs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of RSUs vested</a></td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627741774520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Summary of Basic and Diluted Loss per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,513)<span></span>
</td>
<td class="num">$ (55,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding</a></td>
<td class="nump">29,256,203<span></span>
</td>
<td class="nump">24,218,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627817786360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember', window );">Incyte | Merus N V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrus_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mrus_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mrus_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139627815165016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,072<span></span>
</td>
<td class="nump">$ 74,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares | shares</a></td>
<td class="nump">4,848,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from public offering</a></td>
<td class="nump">$ 129,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum [Member] | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock | shares</a></td>
<td class="nump">727,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember', window );">Collaboration and License Agreement and Share Subscription Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember', window );">Collaboration and License Agreement and Share Subscription Agreement | Subsequent Event | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable', window );">Future contingent development and regulatory milestones receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CommercialSalesMilestones', window );">Commercial sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent development and regulatory milestones receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NonRefundableUpfrontPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NonRefundableUpfrontPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrus_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrus_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MON]>!*O:&_ ')@0KVL<M)5*\,I#?KYF,P_L7=:E^^!%E_C]02P,$%     @
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M%0UZ_ELO72!')4S%;7!4-&'*Y\1'XM-:FM)G [+;FZGX8(H!W:JQ6J_W[,K
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MD>\'Y/@ WE?6ALV" XS_99S] U!+ P04    " #"@G!2&>UF-F C  "6<@
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M$WP21*&9$@*P:.SO:G56#"PX!TG)O-L2=@[))\_'0,O#AO:#8#&(2]E]D&N
M!?5]HY+!6XA2BJLFJ9U0X4_Z>20R^3Y\F&AF*N)HIB5NG%-_MC[!9H)&XS(;
MVCBRG0?>G&"YTD@0K6@^=C+[4=0N?IE2.S-H= )SSD'4>A!4DX"J9Y<@HY3L
M0RZ!WB]R) O6GX:9AG^<N6D$8MO,9&Y VUKYV&]!?'1:S@X0U :7C]XQ1C@#
M!LIHO6$C?W8H1Q0&=&UQU7, .PY,%AFX5Q=.@D0:QZ*$^@W\9 A :Q7WSABA
MM*"NF$@ 9(:A0U&[807RMG+#-!9+S"7'<[#@3Q//F:CP&*);RL&4S>%W3JTY
MQ(AD^S@^QD]7$!)I5(A8"K9<]!SCM*J/0<LD2$0!:8VI92,IZ2!1'29=KO%[
M_(+^\38)+:9%#Y&0A!*,I,$Z &<2J2*) C^XL8BMUO2_B8 1G>!21V(VSKFL
MB_T "@:JA3Q=F2-)7Q;O$L$+@1T*('QL!9RIL4]S0)4N^7C(7Z*>)+ LXT0#
MMH11_+12!?<QR9<2R,-0 S<@B#_EWG2Y-:Y]TYF2@779YNP"][PU37W>N_.H
M/CZ3>77A$!98DB4*E'K6XRBG6]=@OI#BEIQ2]5LZP;)X<_2$+#*PHYZFC-)O
M5J)O3#Z!Y?O=<$@9TDHP5K03RS0Z013/K^O+N*VDXH<\-87T[- 0X.B5 P,<
MDU6&4C7*"90/"H/%Y:(@R:<@)6YG@BCZXTVT/A,EF[^9"5":"SCB%.?/X+VU
M6$3695-'J;!>G8]K37$P '!45T37)T(NY&OKVO.C\=-A5^;@,%L3AIT;+HD>
M/\;H<2JBQ!5J;@G="K$PSS"A%6_)A'A2 TP;X=08F* OY30#>DVW)]>+T(8
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M\B_?GG)#B_X!S*9?'ERY'KA,_\3 WW3X 'R_=J[7/W""\%.4/_X?4$L#!!0
M   ( ,*"<%*B?D)9-P4  .H-   8    >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULO5?=;]LX#'_W7T'DAD.+>8F_VB1=6R!-M[L"ZZ&WKMO#X1X46XZUR98G
MR<UR?_U1LN)\-,UVP' /346)I$C^2(H^7PCY1164:OA6\DI=] JMZ[/!0*4%
M+8GJBYI6>)(+61*-I)P/5"TIR:Q0R0=1$)P.2L*JWN6YW;N3E^>BT9Q5]$Z"
M:LJ2R.45Y6)QT0M[JXWW;%YHLS&X/*_)G-Y3_5#?2:0&G9:,E;123%0@:7[1
MFX1G5XGAMPP?&5VHC3483V9"?#'$37;1"XQ!E--4&PT$_SW2*>7<*$(SOCJ=
MO>Y*([BY7FE_:WU'7V9$T:G@GUBFBXO>J <9S4G#]7NQ^)TZ?TZ,OE1P97]A
MT?+&>&/:*"U*)XQTR:KV/_GFXK A, J>$8B<0&3M;B^R5EX332[/I5B --RH
MS2RLJU8:C6.5 >5>2SQE**<O;ZI'JC1&62M@%5S3F89[FC:2:4;5^4#C'89S
MD#I]5ZV^Z!E]802WHM*%@C=51K-M!0,TKK,P6EEX%1W4>$W3/L2A#U$0!0?T
MQ9W'L=47/ZMORT7X:S)36F)V_'U >=(I3ZSRY*>%\["^N ^'5;:T6M-$4D@Y
M48KEC&9&0A>X(RHE.,N(QKT9X:1**;153Q3D@F-QJC,/8TW+&94FWIZ)-_Z$
M8^^J%>C^'UFMHE&DRM2Q-R6J /JU88^$&S.]%UXX]$]/$ES$B1^<Q-ZTD1*/
M,'/E%ZK)C-,-F[TD\4^'L9=$?HB\?XCJ57J0_]=?1E$8O?8B/PC&W@>A"<>K
M3B,_CH:X&([\*#SQ/J#?K6>LFH-38GL/^P<#E>T$;K;$V[2AED T;(;"IAYL
M>WWFW3IN;U(*J5%G!E.AM/>)Z0)9145A28E<6S;)->I;[:,N*9IY 3FV);NS
M=FS'I?_N22IIQO2KKPWAQA]692PE6L@S;VI/X$]W<K,Z,7D@\J=N>Y/)!/]>
M@18PF;STW.JEL_'H9BL5L/;ITJ$&>8-[)AD"Q/44%ROW-E?N\*%_WP>-SXI"
M+S8@#D_\((EW2<L]%X]45J8P )^/*EWN2Y$Q:@]VJ*F0M9!8"E"3&EU%TZ$2
M&J6&?C(>K=,K\),1EL#0'P]''29=:D>)'XYCLVCYMN!J 8 G ,""&, D8IY!
M+D4)=3/C+.68=(^$<8LMVH9 J_8(JS0SD-X*D2VM:</7"!6:C55=UD1:$7=?
M*^GBX0/V 0U-W9;],P#WX3OI9?I'3I@$+.^&&AU[2^<SFN3VEJ"7-86"\NS'
M2NF:JE2RVKS3N]7T4&%2<$O_AC.&VMQX)Y1"U-X:XSX:XWY>_KE$"[<S+_F!
MS-O.N!_-/)=DD7<4><>[*==U-I-MEL'MC;[7&GXV=N'X?\;.O1_[L7.'3[##
M*C[%4';0V:K^/G*Q/QX-O6$GA_0X.8!9/,)G:^S%#C0DAQO/D7N%7GA)N$;-
M;&+S,*@1 YI]AW&T7M4OMU$!4M?8$RR8V&QW(3,MA"'$^)HPPLT3C[H ;6,B
MPZ8AJ4+_:-:'=7#;&M]*A/))N(&9UH1:<<ZT8X+"7YR<]W0H)U9+YNS'1%/4
MJ3EZ1Q\IA_"XO^=:@9SRB4O/W&S2=\_MK*H;G(86!4L+)%+>9"9H>ZT"14IJ
MVJ5B)8I+Y,=QKVGG*9)]QA';=&)DP"F+F:#:,8MA!#&0&I;,5()S*3KN[QL2
M!QOS=TGEW'YE*&S/3:7;4;S;[3YD)NW\OF9OOX)NB9RCA<!ICJ)!?WC2 ]E^
M6;2$%K6=YF="X[>!71;X,4:E8<#S7&!N.L)<T'W>7?X+4$L#!!0    ( ,*"
M<%*-&"9;" ,  *(&   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*U5
MR6[;,!"]ZRL((8<6,*S%=FP'M@$[2=$<@AI)VAZ*'FAI9!&A2)<<Q<G?=TC)
MJALT;@^]B-N\]V8A1[.]-H^V!$#V7$EEYV&)N+N((IN54'';USM0=%)H4W&D
MI=E&=F> YQY4R2B-X_.HXD*%BYG?6YO%3-<HA8*U8;:N*FY>5B#U?AXFX6'C
M3FQ+=!O18K;C6[@'_+Q;&UI%'4LN*E!6:,4,%/-PF5RLAL[>&WP1L+='<^8B
MV6C]Z!8W^3R,G4,@(4/'P&EX@DN0TA&1&S]:SK"3=,#C^8']@X^=8MEP"Y=:
M?A4YEO-P$K(<"EY+O-/[C]#&,W)\F9;6?]F^L1VE(<MJB[IJP>1!)50S\N<V
M#T> 2?P&(&T!J?>[$?)>7G'DBYG1>V:<-;&YB0_5H\DYH5Q1[M'0J2 <+M8&
M=ESD[/J9RFS!,JYR]@E+,&QI+:"=14@RSCC*6LI50YF^09FD[%8K+"V[5CGD
MOQ-$Y%_G9'IP<I6>9+R"K,\&28^E<1J?X!MT00\\W^#?@F;+5S&SR]H84,B^
M+3<6#=V<[R=4AYWJT*L._V>J3U,.^^ROK)T%'%MH;Y&U<?+&,M/TV"P"'1>,
M#%BA);U:H;87 =4 J@UAJ Z!JP-]DFGP[D:1I:XMD=KWP4$K(T]%QJ77JKBJ
M"TIB;8B)1"S:X"P8]J;CA,:T-QY/.^ 6%)@6QW.Z\,(5P+W<%ICVAN=Q,)Y,
M@QN%8, B]88,Q!/?2 @FY-9H&OCX@Z07CR;T3=)A\*"12U*;]$;GTT9]E 1W
M!#<B<Q%GW)9,J$S6=&=ITF:HS0PZ..V?Q?V4GJ&4OJ.HUQO6)>XX4_[&>D.7
MK1ZY:G?@&Y%\Z;,'2K'BE!<X)-RT#C4M3W($I\UXI6M%;I0@<Z="K]Z=N411
M7V:<909R@12$R=E&&^.+QK@Q7&V!>BCV_W2!HZ.^48'9^N[HV$FL:2'=;M>
METW?^67>=.];;K9"62:A(&C<'X]"9IJ.V"Q0[WP7VFBDGN:G)?U$P#@#.B^T
MQL/""72_I<5/4$L#!!0    ( ,*"<%(X&L-:&0,  ,H&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;*U566_;.!!^YZ\@M,$B 03K\B%G;0,Y6K1
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MW:Z0.:= 4(MU;8D_T6=2.6A(*)*H#0$)=2H%)X(M"6NH<P?B?O<'KLV;"A[
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M>]!5\QGD:7OS,>DSUQN<\S".UQ -@WDZ:H;R86'5SGT462IK5>DNMX(C.MJ
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MWQX.105#:TE)UL2<VCV/*9[17*1\55ESSYZ&?LOAY&2"-J0FLPK%*1'^CY%
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MU+.8*]\C4W\6Z>1:D[>&@0=6?GS%"[ D#XZ@JE/-:;YEA0Y<Z+:PV^G2WB$
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M:-I_-XK!M".K73A=AS&QU(Z&3C!+FO)H? #MK[1VNX5/T/TW9K\!4$L#!!0
M   ( ,*"<%(-!A_\IP(  !<&   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;*U5R6[;,!#]%4) ;X$V.UT"VT"<M&@.*8PD;0]%#Y0TDHAP4<E1%?]]
MAY2EN$!BH$ O$I=YRU"<T6HP]M&U ,B>E-1N';6(W462N+(%Q5UL.M"T4QNK
M.-+4-HGK+/ J@)1,\C1]FR@N=+19A;6=W:Q,CU)HV%GF>J6XW6]!FF$=9=&T
M<">:%OU"LEEUO(%[P*_=SM(LF5DJH4 [832S4*^CR^QBN_3Q(>";@,$=C9G/
MI##FT4]NJG64>D,@H43/P.GU&ZY 2D]$-GX=.*-9T@./QQ/[IY [Y5)P!U=&
M?A<5MNOH?<0JJ'DO\<X,G^&0S[GG*XUTX<F&,79!P67OT*@#F!PHH<<W?SJ<
MPQ'@??H*(#\ \N![% HNKSGRS<J:@5D?36Q^$%(-:#(GM/\H]VAI5Q .-W<@
M.4+%=MSBGCU8KAT/Y^56"1*_CTK* ]=VY,I?X<IR=FLTMHY]U!54?Q,D9&QV
MET_NMOE)QFLH8[;(SEB>YND)OL6<[2+P+?XY6_;CLG!H:?;SA,YRUED&G>5_
M.=737-EYS$[X?FB!71G5<;UG+7<,-(*E4*'1,*3-&UWN$1A=%,D+8_E8#+IB
M4I147,!X8P&HSC"L'D%<RRT]^\*55G0C;HX5F@VM*-L ($GE1OBS-RX95Z;7
MZ"BX[*UW50 . 'I2F 2G!+R>,O2H>RGW5%U>N0C9L"^& %D>3UA!@J/%UL@*
M+!4.MLR/A6X<-0QJ4HZ<THSQKK/F25 1 ]%F:9R]8:8.TM2H')(/'Q;8W+0S
MFPHK=!5!%20S7<>SX#[+/->+(=F'^*6KE!P5JP+;A);DZ/O028UU.Z_.7>]R
M+/;G\+%EWG+;"+H#$FJ"IO&[\XC9L0V-$S1=*/W"(#62,&RI<X/U ;1?&SK4
MP\0+S/^"S1]02P,$%     @ PH)P4@P=#;'M!0  2PX  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&ULI5?O;]LV$/U7""\8.L#Q#\5)G#8)D*0IUB+%
MBF9M/PS[0$MGFRM%JB05Q__]WI&2(J=IMF%?$DOB/=Z]>_<HG6ZL^^K71$'<
ME]KXL\$ZA.KE>.SS-972CVQ%!D^6UI4RX-*MQKYR)(L85.IQ-ID<C4NIS.#\
M--[[X,Y/;1VT,O3!"5^7I73;2])V<S:8#MH;']5J'?C&^/RTDBNZI?"I^N!P
M->Y0"E62\<H:X6AY-KB8OKR<\?JXX+.BC>_]%ES)PMJO?/&V.!M,."'2E =&
MD/AW1U>D-0,AC6\-YJ#;D@/[OUOT-[%VU+*0GJZL_J**L#X;S >BH*6L=?AH
M-[]24\\AX^56^_A7;-+:[&0@\MH'6S;!R*!4)OV7]PT/O8#YY <!61.0Q;S3
M1C'+US+(\U-G-\+Q:J#QCUAJC$9RRG!3;H/#4X6X<'Y;+SQ]J\D$<7V'O_YT
M' #+#\=Y W&9(+(?0$PS\=Z:L/;BVA14[ *,D4^75-8F=9D]B_B:\I$XF Y%
M-LDFS^ ==$4>1+R#?UND^.-BX8.#)/Y\!G[6P<\B_.S_</@\Q/1H)+[/\C<C
MWDE38UC$=![9 "=A3>+*EI4T6X%5Y*@0R@0K)&YK+1?6R21X4X@;E6. 2%RL
M'%')T"\X_N>?YEDV>;6[OEL3GTY?_1(1;M?24<PM=ZK:7;@#]O22#FNCPEI<
M:X64M-Y&Z*:*(2[$6U,H::3(K:O:A%XTR%U4"S;J :VE%Y)W*P0XJ"1#B[I:
M.DAR*(PU^QCSVA1RH8D?Q[SM4NS-)I@GK7DC>%NDU?$(>[%R$KP6 E'D&KZ?
M)"H6I8PXF(A";CUP-$Q.F54,NEXN*7J.P&12/^<-_@I.*NU*GJ3+UY&3@NY@
ME%5$CXZE@B+/I2T(Y)BBSCFUQ79'!UP 24!4SB+[LDD=3#34='M46B9E+.IB
M16$DOG!?\+A"KKQ-"\,;">F4YW+ 9KFSP:X,E1>DU4HQQ8!PE!.775=\M9>=
M/# -LI9UJ%VL)0":Z]RIV7"RJUK+8"%[Q!$\T( "?M(B'NX@YK8LR>5*:N$E
MUO>BAI$:B:B IVA[0I 5ZKA7,'5"._:FHR.QZ&E!"JZ:]=+P@#0)S0>1D0F)
M]H4UB&WI\"/Q^RX?R]J!(?<4+T/!P]EB[R^V^QW=*#&WM0ENR[>;GWSJ*%0"
M(?"L.[N5.HJ"3Z."P;@7FDGD"G$*Z@*'"*'W:/X*:0,8+J*%P2&?&))!5* ,
MC./D]0*"7W5]9K12%?L-!P4*"%&!T+8H;+UXN(G\E$XBCEE!E>2@E/M*05(C
M3#7WV30G<+2 :%F\5_2L9X9K**K:^1JC*)J%3SM,I/-[F^Q9S8,[U!@!D":.
M)T?#^<$L*@?1GCW.,WE]58,C[A(<E+E*BZ)S9/-1=G*8E-)1O'+6>VYJCLV\
MZ&I+6 A[I+FLD_#H^UR-346C+WY);BCP&J-1J!.65;51GEO@*^NIS?HVU9#D
MBWR5+>(CO$$]\J4K;>-0LRL!N5[\U8Q^3BY(GJ?XVL%TTGU.D6[TLG<89=-_
M/HQ,\J"-4SSFJ;#.,\4[@CDZ%O'-S54Z9SY?BAMB:7SE>S@4($NJV+@@4K;1
MKD$>4G>0<[<!.2^,+"GZJ2.4\ +O13JYK]ZF-)O#Y%,OJ#U/ALE%=H7*,<JS
M '.*&?+D/#9>%2<9(Z%R9+=,RD::L^%\-A_.YH?/2HS/)[S3H90[J>N8XL'1
M[-5D-#EYD-RP$>*C39(PHQQGH^/#_GH,N-]E'UJ)9N(;BRE+5);:VO<MJ;WM
M3C_.LT\6M]2FV:-[MEL?CU067'O^]4>L,5KP4Q2*HU#E<78\S(ZS1YR@/-[K
MR0+_8S$_U.A.(4WZL498=5-4/)JT3HSDS8PT_7IH;9[7SB77[78Z;'="-?@8
M2.;6LP:VW6>,86^:G8R..S=XZH5TW'O!QU&WBI\Q/IT5Z5V_N]M]*5VD#X2'
MY>DSZ[UTL'H/7I<(G4 Z@_3>TUX$6\7/A84-<('X<XVO/7*\ ,^7UH;V@C?H
MOA_/_P902P,$%     @ PH)P4LP[_]D))0  (G\  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&ULM5U;<]PVEG[WKV!I9W>MJE9;4F+'8R>IDF4GZRIG
MXK7LR</6/K!)=#?&;**'("5W?OV>&VYLD-(XV8>96&P2/#@XE^]< 'Y_9[K/
M=JM47WS9-:W]X63;]_L73Y[8:JMVI5V:O6KAE[7I=F4/?W:;)W;?J;*FAW;-
MD\OS\V=/=J5N3W[\GJZ][W[\W@Q]HUOUOBOLL-N5W>&5:LS=#R<7)^["![W9
M]GCAR8_?[\N-NE']I_W[#OYZXD>I]4ZU5INVZ-3ZAY.KBQ>O+I_A W3'W[6Z
ML]&_"YS*RIC/^,?;^H>3<Z1(-:KJ<8@2_G.KKE73X$A QS]ET!/_3GPP_K<;
M_2>:/$QF55IU;9K?=-UO?SAY?E+4:ET.3?_!W/V7D@D]Q?$JTUCZ_^*.[WWZ
M[4E1#;8W.WD8*-CIEO];?A%&1 \\/Y]XX%(>N"2Z^45$Y>NR+W_\OC-W18=W
MPVCX#YHJ/0W$Z197Y:;OX%<-S_4_WO!J%&9=W.A-J]>Z*MN^N*HJ,[2];C?%
M>]/H2BM;/';_.OW^20^OQ@&>5/*:5_R:RXG77%P6OYBVW]KB35NK.AW@"=#L
M";]TA+^ZG!WQM:J6Q3<7B^+R_/)\9KQO/".^H?&^F1@O-^/_N5K9O@/!^=^9
M%WSK7_ MO>#;B1>\*JVVR.?WG=J778E"F6/D["BHI"_LOJS4#R>@A59UM^HD
M.W3Q<:N*:[/;E^VAV--U51>ZMT5E6@LSK,L>+JQU6[:5+IO"]G !] WNT"W<
MM-LW&GY2()#]MMBH5G5ETQQ CRJUQT?+P+%]IV&0?:/HV1[>_&EYLRP>G]!_
M?KZZ>G]RNBRN@!+0.=4I')9OM*IH30_/]:8H]_#*JEPUJM@,0!_=98N=0HF$
MW^E9NG'HMZ;30#!H=.'?492V6 -)M2,B6M.;OFSKLJLM\*0F*2<F/3ZYNKD^
M.2W@Q_S=G_;()[KO$]P'/,:!?_)<RS[TRL!_X)F?KFY>X<1GI.>IEYZGL]+S
M/G 8:+CV2S@A1%\]6'$SK*RN==FA H#,%" 1NL<_0&[ZSC0-+/WJ0&P0\5J0
M2&E+7( !?U'=8(N_+?^^_(]_>WYY\=U+6]QM#<J.N6OA:>M><9!;/]TLBK<M
MZ',LL_(Z(*)E&@XPBFI!A%$HU)>]L3!6;Q:%Z8HM+'V'!MC2E5L@G^2H4_W0
MM2 6G=F1\.OVUC2W).<LV#@/&1Z%  ?"2^5*-W@-I6V]!A<"5^&%?L!^VYEA
MLZ4Q]^8.Y-+<HG#ZT7@R6?4"%MDQEV%!FJ%67G3O5U*:$MY* @HK=[?5U=:Q
M#15XAWIF"Q3/9NY.!5[-@GHV,'[D W3;JZZ2U5B534FC(9/ )K:V)+=J@6.@
M@RL%*Z,:#1Z**"8+$HG5<D8%GGD5>#8KM3\-+;T2V(!$O$?SU_8LM==#AU;E
MD-.%/SYJ\1:8#@*F*M/)&JD2."C60"36"[O7&%Q8L%YV0-,[6%0/6ELWK#P/
MUI-\, S?FIVN8(!;W9F6A%2[Y8H$%3 9&'ETR7CQI#B9X>YWGKO?S?+A$P@W
MT/,&M'B'8^<X.3M"WC6-AR6MV$=NBGE@'R+QNB6?T]7!+07;WZE_#AI>"^"H
M!3A)O /EW96?@6WN[8OB'T.]X=%PM4L+:'3/<MQORS[H.FKZWG3DYW9HX4EM
MX7XECX)S)!.A12=J;:O&X%+3G:A<L-Y(1?ZA!7HK$0#6R_7#%'_!*CA!(>#!
MIEP986ZG;E4[*'H"+": ::"N'CHGB3P">7#5:5.#$:CZ 5X'LP!8RT0#E@<K
M0)P]P#37Z(21FV!BT::3'0I,#UKP *;/NL;G7G*?STHN^*\*!@_R= WJ!E[B
M@[:?<U+\]:-%?E^W@ P'GA1)SAY0#"PYL02L^S^<&#EW!K)8Q4/S:O'8'8XM
M'J"H2KM=T/\7*-*W9<.K#B;BL^K)JUD%)B2(G@ Q,E *'H!;4E=:]B [>_*-
M&$. E?Y=\?K#B_&QAJ0-2<R^G-Z2?S\@ 0R[4(1((;?@A($#W4A\D5VZ'R)-
M T<,$D(Z7:PZ4]:B1>!%T<V6H#O(H766XZ Z$'GI]@B*I/-&9PXO 9HU1$@U
MH4J%"RYS1O2(DY95*%$3W&1[-T-T@QBSX)VV7*O-@.!.$"_0E7A&C(-[^!]H
M.K"O]CC 4>1^MP0<UH!5LV9-D K03G9LCP$)P"QV!#QS>%\#(36M1[@5Y,3N
M504N' $;S^N?H-#H-:S'ITBI1A:BN^>9H>ONL]Y,1B' !=:-$!',!+T9OAJ4
M675+AX-C&9Q1[;]ZU?[KK#(B& 4Y1!Z\N<7IY?1Y=HB\5SH:=XP\ 9R!'!:*
M?P2 F4 >$F!3@1* P^@%]HD<%)Q,(9.^&GI 1FO3J0=B.D*"R%%:DWUG;H&.
MHJQA 1BB*+R ;TGD5W4D<][B$L&FP%M[O4:I P/0"=WB*.-1@^]*I56!_@]$
M+<B:8\81 '10V'LR]N?9"0)0QE\PAO#H^R:U9F^^5%O2?J!B!\Q ]#CG)B[.
M0ZKC?![JE;HK_@Y34A!W$"K;3<G4UXU4T/5;NJZ#B2HYAOD"6@1FHU(+]+N,
M,YTC9@_."W1GA@;LFA)50NBX-QP56+#'A$-:1A6XT/ORX, .+0NZY](CC0.9
M%W!D %P[,,S1RL$K^CO$[6S982"  FC38";+T51*N>D,,V"U [7\7K+F.%N0
ML1W;9+K)M,?X*O,JF>]@*26 #$*FQ#/T<P$S@]*FU!E(2U>L XE;^+OLJNT!
M*1FLTQ^-60+G['2['QA%,OGXFF@(2AZ@2;4O'J'QNWSV\M$[D/FFN"C(&%Z\
M+/Y[,*@-;A:XF #"A[:L_S%8^.64C3DI)M^$@W:BB17&& P&HUFAW!-O4D F
M4#\7CU;P5E@2?B)>"M2^Y8CXRWGBD3H+MK\INPG:CF:T (]"(T5#A D^9#S'
M&H;<':6 Y"44S1N86.?6R]]D5FB]T;,L"J7IEAH,6=5C8@%O=W\EPAN)96RH
M!HY+=@8 @0WO9(.'RK%3$/#7IC$;('K,U&\\4^.DZ= &$AWUR)R9-8?G<.XK
M= Y=9PBX,ZB198(E+<?*&&O:(2LVWGF;NU0) 8$U^G=G=5:,P#BW3SGRVQ)6
M#LDGB,"(U,*"]H. UKNM8F]&G@HFU/>-DPQ>0I12G#5);4:%/[KK@<CH=W\Q
MTLQ8Q-%K2(ID2OW9^GB;"1J-TVQHX<AV'GAQO.6*DQYH1=.QH[<?):@$)E!6
M=0*V9\#Y%):O!X%_$?J\N 09I<0Y<@GT?I%"?K#^-$P>)W/2M)%81"<F<P/:
MULIENP7Q<:_E1!C%)(! T%F'V'3 G!!:[\-<1N<BJCY<S#K2GPW*(L5<73:1
M^:\\7USUG)<9A[6+)!)SJ(:$F;2>Q1EM#*PIHR+BMR >ADVE!I.!>3N T1CG
M%;495B#S*S/D@7-DLCD; $S_F+E/!:.#F2=-*<^R.?S.F76#@)[L+Z=]\.H*
M FJ74T!X"6(GM@:C_*H/$686T:.0MDK5(DR4XY.<@+%SN/WB,BSLY7P8C>_
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M&_?5HV63)0$.W@L$N>(X-@)Y.QD GH03P=NC!C-9#9&U+-YDKX>T@]B[+JK
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M"-%DXY.CD3J%Y0[EMS!6L@=!GH@;$:6=N=^JT?IX1M?8[4T;2!SDGMO%F.@
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M6D]].,2D0J6U8HF>&YQG/96B'2&&"FT=R;^MH?:A8L304*DP )^#%M!(I<W
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MN11403'UYM'XO&?MG<%/#AN]MZ96R5+*>[NYRJ=>: E!!9FQ" RG1[B JK)
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MX*910"(_"4,<HW1 K@$KIY153GF]5O(1K+TF430DPQ&Y0+I&-6V=<D'18J5
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MB*"L YZ74IIA8Q.,7^SB'U!+ P04    " #"@G!2LX6WG,(%  !9#P  &0
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M: '^7TAIMA,":&_3%_\!4$L#!!0    ( ,*"<%*-YX]_X0,  (@)   9
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M35743H'.UTK9_<(YZ.;T[!]02P,$%     @ PH)P4N >($5> P  ; H  !D
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MY%4<.;SQ'KQ[LA:2:&&T\1D/P(X][-C!CO; >BF7S!5E1]"_]\8:[C16ZM]
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M%A>=#BV-;MZ.QB"U].,W5V2'V6\K^]RB=@'67RI%KX:;Z.X!S_X 4$L#!!0
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M=?@BBP'Q+-]216G^%QV*MMX +?>I47$1;"N(P^3X*WX60E0",&L(($4 :1M
MBP":#_1863ZL6V'$=*+5 >FLM<V6;>3:Y-%V-&&23>/<:'LVM'%F>I<\R]38
M>3$I"A-T*Q<&S>5RKT,3RA1]1//C_"*UKIU<O* ;+5>A07_N112:%W27K,*E
M,$JC][?2B#!*/]@4C_-;]/[=!_0NZ^'[5NU3D:S2R=#8^K,JALNBUL_'6DE#
MK;=R>84H_AT1CWAGPF]:A^/@-'QH52NE(Z5T),]'&_.=RO%%1BOT7:%[8;)#
M#G%^?+6IT)V1<?J/HQ!:%D+S0EA#(9]%))*E/"?H,=#/ [,[^GDZ(I3XD^%S
M5;=Z*W],,"];G53%RJJ8LZK9;(9^Q#)>2.T:)"_3\7[5'I6%C+JJ?0SD%1VQ
M/^+LO(Y^V9__AHX?D5%H-ONMC9SC,NNX7SF#LI"@JYQ!34["<$#/RXD]()[G
M%O2H9RLY<86CN%]!,7 )DZZ2%I$GFGIL[#5H"@3";@3=JT2^V.>2?K(KC_7>
MXKV5NL 2S'I6%SB$>6=U>1T 'N:C5[@]TXPRCS==V  F[":38Q+0?Z@ECS%P
M"?L]SPG #(\[S\GXC3DY[1*PA=W<>DOL2Z!-@%W$ZU=S L CN*OF1615\P;"
MD,IBRPVU-_2^@.D$J$9HSVH# (E[->52F[56&R!'W)"[47JGM# 2[<1.:F07
M["A11K;".@%BD5'/ @/-B'N9Y1+8KS\T_< ?O\+ZF69T//*#AKD N!$WW-Z>
MB_9T)\ W$O3L;@!ZU+U@<_D;KZ:YSX+Q><DIL(VZV=92\DL83X%TM&]?63&6
MW9TE;4L="I"C;LBUD_T"U%, 'NW97E* (NUL,&G=83J6[Q3@1]WP>[R:7Z&-
M>I8ZR5X%(;&1R?(%I:!'&[&!:+1G\TD!<[2S_:1U_QE@[KU^=U)O18.QW_#N
M!)C'W,QK/R/MX<^ ?ZQG,\N AJRSF65U,]MP)S @'G,3[T+=+WD"L,J;LY[=
M+@,NLLYNE]5M[,G]<=HCX(^Y\7?9#%SP,&" 0]:SLV6 2M;9V;*ZLVT2'W#(
MW#C,Q3=:BM0.M!WV.3"-]VQ>.0".=S:OO&Y>[57-Z"ON%\VJ+\TQ"QI>*W#
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MT 3M'/!\H93=;=P%W1@N?@%02P,$%     @ PH)P4@4L(J?, @  X0@  !D
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M.-M<Z7\0$"9 ?U]PKEX[YI9K_FJ&?P!02P,$%     @ PH)P4H&4]FM5 @
M1@4  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC51-;]LP#/TKA-%#
M"W2U8Z?)5B0&\M%M.70HVG4[##LH-F,+E:5,HNMLOWZ2['A9T12]V!+%]_A(
M2IPT2C^:$I%@5PEIID%)M+T*0Y.56#%SH;8H[<E&Z8J1W>HB-%N-+/>@2H1Q
M%(W"BG$9I!-ON]7I1-4DN,1;#::N*J9_SU&H9AH,@KWACA<E.4.83K:LP'ND
MA^VMMKNP9\EYA=)P)4'C9AK,!E>+H?/W#M\X-N9@#2Z3M5*/;K/*IT'D!*'
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M$95=0-_74IH7PS;=YHZ=_ 502P,$%     @ PH)P4A6E]E:8 @  (0<  !D
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MA G0XVO.U6O'')/=K3CY!U!+ P04    " #"@G!2/UGI:JD"  "5!@  &0
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M;+UK+VLL8<'I+Y*I8NJ=>RB#'%=4K?CN"S1^!H8OY53:7[1KYH8>2BNI>-F
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MK\3WG BL*%N"&RXEN,1"O.B;L,(BED OP+1040(:$# K1,ZEQCJ>$H5I*D_
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MY44Y;98;Q7,[X3URI>=%NTSTA$Z$.:"_+SA7FXU)4,_\DW]02P,$%     @
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MG^U/[=*'!FXTQ%+EDEPC+*A9?R^8HKQH**B4%3#19*?.UXS:8QGW 2P7/%X
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MY=X/8V*=_K0X:S3=U9K2(YJFF'6@U_T :9(F!^"3L^'=Z]?PF-UI+4I;B]+
MUSO"UQCS^W;AR/*U^W."L]=R]@)G_PCGSM=+T?AJ6U]-^T=4<)C88;B0&K8H
M[&$[3Y_5KY&00FDT%0ZZ*>1BZPXY>Q[3=<MT=8#IE2']UI#^_QF2[ZX3FX'
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M8J"W/R@&52;D%Q/RK1.ZH8(2'BP1 ;?.S.R:9N+7< X<QZ\#/:\/[/7ZP\K
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M1\? 54KQA3;[7;\KM(:W=DN]U0O I#@P]5N4?D?*=4@W731KRMJOR3Z74U%
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M"H"CP.'H<OJ!;(#H[3B?5R90 ._$*3.!PK*3S!W[9 *@*%Z?"1265V3G"X
MV@F<=D.^;TD%)HY.8P!<C /.Q_MCRPZRHU\ 7>P=X7EY?XR1KZLHL(2!KH40
M Q[C@1T2#_^/33QRZ8@X8@!DC /208#C<P(QP"X^KPQA##B,3YDAC"TQH',I
M #'CU^<(8\M;LI,)<:_\9F C&&=";$D1.ID [(MQ]GDQP62@BPD P-@[W/-C
M A;P=4PPFS@7@@1HRH'M$P\F2!.:3B9(P*;$L7FO'E59MDS85C1X) 0DL$Z>
M5TI0 @OEVS>-I1G]22$<@9@$)DKO;6,/\DC;F[+DO<*1_6$  "4.P->4L$A;
MQE 2%R$DD% .D/!(3Y666IHD[&40MMYJ:88J#S J<8S^J*KJ?3#=:-?12W5=
ME,TRM0[4 E22<-<[O.P5)N),U;YS\=+_Y%CM6?*+2<1=*QMX*W'>6F R4$ )
MA$S.*[68 $&3M^]#)[9(TJ[M!.":>&]#>W D,4-*YJI63@"CR>F+%1,3JQ?]
M M+]H0!6D]-6XR06L')R !!+([?6 +T)CEYO>B0VWG+'0S\!VB8X;=_"CL1$
MJLMT0-,$IZF-&P-IB01 F9Q7-C+I586_?0\[,>--X=B@(V&_[-M[%]NG*#*T
M5',SZ:H=#GOUW"$.S]?5GUNJ>N*(N4;3JPD/3UO8\R)O[T%*#AEB:X5IKU<I
M'N+T]>;(BZ ]E46Q(P@A8:_Z.\2I^Q:4O,C>>^=CCGH4$O;*QD.<KQ:>O*),
M/>Q5@X?GE?HD8:_R.WS[QOB+C+U7'>?JZ!6%A]Z;XUZ8,>-2$E-7\7O8*P$/
M<=*^#C/6_*@+,_TS-P.';H[&C.4PC13T$#-=J]A/>WN';G!(^V.&V*K*J8MT
M_=,Z!"?SFS#3R8Y1S(Q[1U=7JIRW)WJKH"VBVI["W%W='1N^:<_*'ER_;8X3
MMT=B0<SV+/)/:3G/M),OU:,6&;YKDHKE]G3O]DM=K-L#LI.BKHM5^W&ATIDJ
MFP;Z]\>BJ%^^-!WL#EE?_P502P,$%     @ PH)P4K7+@OL"!@  72   !D
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M)_)V2$M1C<8S-1EM:OD;%K ?A'!@U* B$%J,3CJC$Z?1!R:D3:;-E<GF1#,
M/3]$0Y^Z+(R"R.(SZ'P&3I]7Q>Q-4,<%%':%0N=EN4&(9]HGQ)F<K&^LF-D4
MX$%^+.-90Z"__Y"5P96@>?F/PU?4^8J<'7Q<S;GD 5C%;[4;TP1$^@2$,,*#
M\3>H@A!'YO&'GN*OM^7.2_.G-2^;H>#RUBO6QJNYK=.[ ' 8#%P:5$$4(8O+
MC92 3I?7:49E%A7F*[AMO/FC0QPX)7U32)E".]QDLUXVN080:1;0Q \UIP:9
M'V)H<:NX#0\);JC(#0^'[K94KV\>G@Q'0%=9R0T5NN$AV0UU+&L3Y9+T32IL
MP\-Q&^I$-@VFKK(/IL(V='/[KKG,Y>4^8XLB_:]YN!)+"E;ULY71;[ 3YTPR
M!^A40,#0:?FF8*[K70$=1A\J:9!".7*C?)>L03J?Y1O78 H,(AA-S!. %,.1
MF^$[)PW:CG.#)+)<(4CQ'+EY[@X9I'-9<Z5+""26\$.*W @?,F?::ENF6!<1
M@@.+514&B!PP9)""-W+#>Y^00=O1[93T+2IT(S>Z]\L7I&-9,^F2]$TJ;B,W
MM_?)%Z2#6+/HDO0M*DXC-Z=_)%K:DELN>5UDIYJ* ^1^P+^1SKCKO5KA&WL?
M*EBP(C=VDWN78,$ZD2>1/Y@"DXA@\Q1@Q6WLYO;.P8)U/G^%:.A1%T'?YG%C
MU<3-<'>V8 .RB?9F8%*%Q.),(1N[G]_W3!>L/YQC.!D^Q!E4T+,]=F(5 ]@_
M8+Q@Q6[L9O<^\8(-ZR41(<,!V!G>6,$;N^&]7\+@[?AV2OHF%;ZQ&]_[) PV
M$5D?2EUE<ZFHC=W4_I&0P?H*3(##H5E=%!'?;)>H:"#N)_O!^O>"4ZI?GOW:
M"NX$?JC8(8KKQ,WU76*'Z+0.M=@QB6POE$0AG;B1OG/L$)W;>NP81,BWO#J0
MC65U-]S=L4,,RS%Z[!A4A"#+@Q-1+"?N1_H]<X<8ULFQECL&E>]#RVL-4?E
M)H?<]%!$)]N64?;8]C"LB^BP-*@LL"0*Z<2-]/URA[APW9K<F>A$$9VXB;Y/
M[A##6KIA*'65;?M(@=S?MMJ^?^ZT)3>WLB(M=PPB",EPT7B\L5&;4[ZH]Z]+
M>1.N"]'L2'9GNSWRLWIG>'#^'!Y?-#O=JDRS\7X=\T4JTR"C<UG2.PKD^/%F
M+[LY$&Q5;P<_,2%87G]<TCBAO!+([^>,B?>#Z@>Z_U$P_1]02P,$%     @
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M[H:NB\?G#U3.R!__!I7DDV:I^B_B4+AQ*$3CFT#=96 DAB*0?+HJG,DA6'(
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M:K>!UG.E[&[@7M!^]DQ_ 5!+ P04    " #"@G!2QV,@_5($  #@#P  &0
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MS#P#[#?S526 ]#Z*[[4[O;!X',N -K!618*T5XGWYN?+9T!A^#FRW_6'1V=
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MS86&G*V0,NC<8MM4Z8WEQ,B-LY>E-&A6;ICA[X0IFX#K*RG-86(_4/^@QO\
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M-ZL>S$74J]KY9W,\=UHE;-\J@S]02P,$%     @ PH)P4I>*NQS     $P(
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MFR^F#P R0B"CLT%.QNDW !DCD/'9(-/E? (@$P0RH85<;@2;Z'++U1L &B%
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #"@G!2F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M ,*"<%)P=6LUR08  .H:   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #"@G!2'2NF@?D%  !0&0  &
M            @($,#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ PH)P4@G28%YW @  A 8  !@              ("!.Q4  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,*"<%*008%R7 4  /43
M   8              " @>@7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " #"@G!2U@5J?*('  "5'P  &               @(%Z'0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ PH)P4F8:"$I9
M!0  NA<  !@              ("!4B4  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( ,*"<%+X1D3RK04  '$,   8              "
M@>$J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #"@G!2
M&>UF-F C  "6<@  &               @('$,   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ PH)P4J)^0EDW!0  Z@T  !@
M     ("!6E0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M ,*"<%*-&"9;" ,  *(&   9              " @<=9  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ PH)P4C@:PUH9 P  R@8  !D
M             ("!!ET  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " #"@G!2TJ4 "T\#   >!P  &0              @(%68   >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,*"<%(U;Q=?A0(
M &X%   9              " @=QC  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ PH)P4J5,=9:B!P  ,1,  !D              ("!
MF&8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #"@G!2
M_DL*K% (   P%0  &0              @(%Q;@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,*"<%)@S&6HS 8  .T/   9
M      " @?AV  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ PH)P4O%V_L#O P  /PD  !D              ("!^WT  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #"@G!2W#CHOZ@1   $.0
M&0              @($A@@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( ,*"<%)#F(4F=0P  +X@   9              " @0"4  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ PH)P4@WC<M#K
M @  0P8  !D              ("!K*   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " #"@G!2#08?_*<"   7!@  &0
M@('.HP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,*"
M<%(,'0VQ[04  $L.   9              " @:RF  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ PH)P4LP[_]D))0  (G\  !D
M         ("!T*P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " #"@G!2H8/@\KH"  #?!0  &0              @($0T@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,*"<%(31\$SDP0  (@-
M   9              " @0'5  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ PH)P4LR'#-FC @  K@4  !D              ("!R]D
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #"@G!2I!J6
M=<X"  #S!0  &0              @(&EW   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( ,*"<%*QU[GL)P,    '   9
M  " @:K?  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MPH)P4F;VC^B0 @  ;@4  !D              ("!".,  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " #"@G!2LX6WG,(%  !9#P  &0
M            @('/Y0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( ,*"<%*-YX]_X0,  (@)   9              " @<CK  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ PH)P4J:+];LK!@
MQ1   !D              ("!X.\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " #"@G!2#SHP0LX%   $#P  &0              @(%"
M]@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,*"<%)U
M6^C(H@(  +,%   9              " @4?\  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ PH)P4N >($5> P  ; H  !D
M     ("!(/\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,*"<%(!9N2A[@0  #T@   9              "
M@50. 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ PH)P
M4N7V;,5,!   HQ,  !D              ("!>1,! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " #"@G!2Y-^&HJ4"  !)!P  &0
M        @('\%P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( ,*"<%(;706Q$0(  ) $   9              " @=@: 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ PH)P4L$#JP8W P  Y L
M !D              ("!(!T! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " #"@G!23:)QFF0"  "2!0  &0              @(&.( $
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,*"<%(%+"*G
MS (  .$(   9              " @2DC 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ PH)P4H&4]FM5 @  1@4  !D
M ("!+"8! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #"
M@G!25F\# ZH"  !O!P  &0              @(&X* $ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,*"<%(5I?96F (  "$'   9
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M970U,RYX;6Q02P$"% ,4    " #"@G!2^E*:QQ(#  ")"   &0
M    @(%S.P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M ,*"<%+43MI4"P,  /\+   9              " @;P^ 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ PH)P4M!/F0 '!@  VA4  !D
M             ("!_D$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " #"@G!22,U.7KP"  !#!P  &0              @($\2 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( ,*"<%*,G;C JP(
M )('   9              " @2]+ 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ PH)P4AWLVV=* @  V 4  !D              ("!
M$4X! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #"@G!2
MU.K2K/T#  #F#0  &0              @(&24 $ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( ,*"<%)\_'T\M08  - A   9
M      " @<94 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ PH)P4OD&S@[^"   <#T  !D              ("!LEL! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #"@G!2M<N"^P(&  !=(
M&0              @('G9 $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( ,*"<%*48>,P#0@  #TO   9              " @2!K 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ PH)P4LB4&OH"
M P  J@@  !D              ("!9',! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " #"@G!2#JK5JBH#   ""0  &0
M@(&==@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( ,*"
M<%+'8R#]4@0  . /   9              " @?YY 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ PH)P4B GSVPY P  <PH  !D
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M=#<R+GAM;%!+ 0(4 Q0    ( ,*"<%)(VY_%=@(  &(.   -
M  "  >^. 0!X;"]S='EL97,N>&UL4$L! A0#%     @ PH)P4I>*NQS
M$P(   L              ( !D)$! %]R96QS+RYR96QS4$L! A0#%     @
MPH)P4N%;B)M<!0  M2\   \              ( !>9(! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( ,*"<%*L;5!7/ (  *\J   :              "
M 0*8 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,*"
M<%) :Q>Z  (  ,8I   3              "  7:: 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !0 %  YQ4  *>< 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>215</ContextCount>
  <ElementCount>430</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Investments in Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities</Role>
      <ShortName>Investments in Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure -  Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Investments in Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables</Role>
      <ShortName>Investments in Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaborations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables</Role>
      <ShortName>Collaborations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure -  Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - The Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails</Role>
      <ShortName>The Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Investments in Debt Securities - Summary of Classification of Debt Securities in Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails</Role>
      <ShortName>Investments in Debt Securities - Summary of Classification of Debt Securities in Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Investments in Debt Securities - Summary of Debt Securities by Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails</Role>
      <ShortName>Investments in Debt Securities - Summary of Debt Securities by Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Investments in Debt Securities - Summary of Debt Securities by Credit Quality Indicator (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails</Role>
      <ShortName>Investments in Debt Securities - Summary of Debt Securities by Credit Quality Indicator (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Investments in Debt Securities - Summary of Fair Value of Debt Securities by Major Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails</Role>
      <ShortName>Investments in Debt Securities - Summary of Fair Value of Debt Securities by Major Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Prepaid Expenses and Other Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net - Summary of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Intangible Assets, Net - Schedule of Expected Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Expected Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Summary of Components of Loss from Operations Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Loss from Operations Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Summary of Components of Expense for (Benefit) from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Expense for (Benefit) from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Summary of Components of Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails</Role>
      <ShortName>Income Taxes - Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Operating Leases - Summary of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Operating Leases - Summary of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails</Role>
      <ShortName>Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails</Role>
      <ShortName>Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Collaborations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails</Role>
      <ShortName>Collaborations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Collaborations - Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails</Role>
      <ShortName>Collaborations - Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails</Role>
      <ShortName>Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Employee Benefit Plans - Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Employee Benefit Plans - Summary of Key Weighted Average Assumptions used in Pricing Model on date of Grant for Options Granted to Employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of Key Weighted Average Assumptions used in Pricing Model on date of Grant for Options Granted to Employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Employee Benefit Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Employee Benefit Plans - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Employee Benefit Plans - Intrinsic Value of Stock Options Exercised and Vested RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails</Role>
      <ShortName>Employee Benefit Plans - Intrinsic Value of Stock Options Exercised and Vested RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Loss per Share - Summary of Basic and Diluted Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Loss per Share - Summary of Basic and Diluted Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrus-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrus-10k_20201231.htm">mrus-10k_20201231.htm</File>
    <File>mrus-20201231.xsd</File>
    <File>mrus-20201231_cal.xml</File>
    <File>mrus-20201231_def.xml</File>
    <File>mrus-20201231_lab.xml</File>
    <File>mrus-20201231_pre.xml</File>
    <File>mrus-ex1045_90.htm</File>
    <File>mrus-ex41_15.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gtqsgrqcdg4e000001.jpg</File>
    <File>gtqsgrqcdg4e000002.jpg</File>
    <File>gtqsgrqcdg4e000003.jpg</File>
    <File>gtqsgrqcdg4e000004.jpg</File>
    <File>gtqsgrqcdg4e000005.jpg</File>
    <File>gtqsgrqcdg4e000006.jpg</File>
    <File>gtqsgrqcdg4e000007.jpg</File>
    <File>gtqsgrqcdg4e000008.jpg</File>
    <File>gtqsgrqcdg4e000009.jpg</File>
    <File>gtqsgrqcdg4e000010.jpg</File>
    <File>gtqsgrqcdg4e000011.jpg</File>
    <File>gtqsgrqcdg4e000012.jpg</File>
    <File>gtqsgrqcdg4e000013.jpg</File>
    <File>gtqsgrqcdg4e000014.jpg</File>
    <File>gtqsgrqcdg4e000015.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrus-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "contextCount": 215,
   "dts": {
    "calculationLink": {
     "local": [
      "mrus-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrus-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrus-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrus-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrus-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrus-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 577,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 15,
    "http://www.merus.nl/20201231": 5,
    "http://xbrl.sec.gov/dei/2020-01-31": 8,
    "total": 28
   },
   "keyCustom": 54,
   "keyStandard": 376,
   "memberCustom": 43,
   "memberStandard": 29,
   "nsprefix": "mrus",
   "nsuri": "http://www.merus.nl/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Prepaid Expenses and Other Assets",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets",
     "shortName": "Prepaid Expenses and Other Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Property and Equipment, net",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Intangible Assets, Net",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Accrued Expenses",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Income Taxes",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Operating Leases",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders' Equity",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Collaborations",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure -  Employee Benefit Plans",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Loss per Share",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Related Party Transactions",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Subsequent Events",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Investments in Debt Securities (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables",
     "shortName": "Investments in Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Prepaid Expenses and Other Assets (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsTables",
     "shortName": "Prepaid Expenses and Other Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217EUR_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217EUR_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaborations (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables",
     "shortName": "Collaborations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure -  Employee Benefit Plans (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables",
     "shortName": "Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Loss per Share (Tables)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - The Company - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails",
     "shortName": "The Company - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalCashAndCashEquivalentRelatedText",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalCashAndCashEquivalentRelatedText",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapPropertyPlantAndEquipmentByTypeAxis_mrusLaboratoryEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Investments in Debt Securities - Summary of Classification of Debt Securities in Consolidated Balance Sheet (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails",
     "shortName": "Investments in Debt Securities - Summary of Classification of Debt Securities in Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapFinancialInstrumentAxis_us-gaapCashEquivalentsMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesHeldToMaturityPastDueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Investments in Debt Securities - Summary of Debt Securities by Maturity (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails",
     "shortName": "Investments in Debt Securities - Summary of Debt Securities by Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesHeldToMaturityPastDueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Investments in Debt Securities - Summary of Debt Securities by Credit Quality Indicator (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
     "shortName": "Investments in Debt Securities - Summary of Debt Securities by Credit Quality Indicator (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_srtCreditRatingStandardPoorsAxis_srtStandardPoorsAAARatingMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Investments in Debt Securities - Summary of Fair Value of Debt Securities by Major Security Type (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails",
     "shortName": "Investments in Debt Securities - Summary of Fair Value of Debt Securities by Major Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrus:PrepaidClinicalAndManufacturingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "mrus:PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrus:PrepaidClinicalAndManufacturingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndInvestmentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Prepaid Expenses and Other Assets - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails",
     "shortName": "Prepaid Expenses and Other Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndInvestmentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_srtStatementGeographicalAxis_countryNL_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_srtStatementGeographicalAxis_countryNL_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets, Net (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails",
     "shortName": "Intangible Assets, Net - Summary of Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Intangible Assets, Net - Schedule of Expected Amortization Expense (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Schedule of Expected Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrus:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrus:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Taxes - Summary of Components of Loss from Operations Before Income Tax Expense (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Summary of Components of Loss from Operations Before Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Summary of Components of Expense for (Benefit) from Income Taxes (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Components of Expense for (Benefit) from Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Summary of Components of Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "Income Taxes - Summary of Components of Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails",
     "shortName": "Income Taxes - Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeaseDescription",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Operating Leases - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "shortName": "Operating Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeaseDescription",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Operating Leases - Summary of Components of Lease Cost (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails",
     "shortName": "Operating Leases - Summary of Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails",
     "shortName": "Operating Leases - Schedule of Maturities of Operating Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails",
     "shortName": "Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "mrus:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mrus:DevelopmentMilestonesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Collaborations - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
     "shortName": "Collaborations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mrus:DevelopmentMilestonesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Collaborations - Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
     "shortName": "Collaborations - Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "mrus:Billings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
     "shortName": "Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "mrus:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapRetirementPlanNameAxis_mrusFourZeroOnePlanMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Employee Benefit Plans - Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails",
     "shortName": "Employee Benefit Plans - Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Employee Benefit Plans - Summary of Key Weighted Average Assumptions used in Pricing Model on date of Grant for Options Granted to Employees (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails",
     "shortName": "Employee Benefit Plans - Summary of Key Weighted Average Assumptions used in Pricing Model on date of Grant for Options Granted to Employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Employee Benefit Plans - Summary of Stock Option Activity (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails",
     "shortName": "Employee Benefit Plans - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Employee Benefit Plans - Summary of RSU Activity (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails",
     "shortName": "Employee Benefit Plans - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Employee Benefit Plans - Intrinsic Value of Stock Options Exercised and Vested RSUs (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails",
     "shortName": "Employee Benefit Plans - Intrinsic Value of Stock Options Exercised and Vested RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - The Company",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Loss per Share - Summary of Basic and Diluted Loss per Share (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails",
     "shortName": "Loss per Share - Summary of Basic and Diluted Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_srtOwnershipAxis_mrusMerusNVMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_mrusIncyteMember_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_mrusUnderwritersMember_20210121_20210121",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Investments in Debt Securities",
     "role": "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities",
     "shortName": "Investments in Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrus-10k_20201231.htm",
      "contextRef": "C_0001651311_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS",
        "terseLabel": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrus_AccruedGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued general and administrative expenses.",
        "label": "Accrued General And Administrative Expenses",
        "terseLabel": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_AdjustmentsToContractAssetsReceivables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to contract assets receivables.",
        "label": "Adjustments To Contract Assets Receivables",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "AdjustmentsToContractAssetsReceivables",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_AreaOfPropertySubjectToOrAvailableForOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The area of property under operating lease arrangements.",
        "label": "Area Of Property Subject To Or Available For Operating Lease",
        "terseLabel": "Area of property available for operating lease"
       }
      }
     },
     "localname": "AreaOfPropertySubjectToOrAvailableForOperatingLease",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "mrus_BettaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Betta collaboration and license agreement.",
        "label": "Betta Collaboration And License Agreement [Member]",
        "terseLabel": "Betta Collaboration and License Agreement"
       }
      }
     },
     "localname": "BettaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_Billings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Billings.",
        "label": "Billings",
        "terseLabel": "Billings"
       }
      }
     },
     "localname": "Billings",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreement and Share Subscription Agreement.",
        "label": "Collaboration And License Agreement And Share Subscription Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement and Share Subscription Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementAndShareSubscriptionAgreementMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_CollaborationAndSharePurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and share purchase agreements.",
        "label": "Collaboration And Share Purchase Agreements [Member]",
        "terseLabel": "Collaboration and Share Purchase Agreements"
       }
      }
     },
     "localname": "CollaborationAndSharePurchaseAgreementsMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_CollaborationRevenueRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue (related party).",
        "label": "Collaboration Revenue Related Party [Member]",
        "terseLabel": "Collaboration Revenue (Related Party) [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueRelatedPartyMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_CommercialSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial sales milestones.",
        "label": "Commercial Sales Milestones",
        "terseLabel": "Commercial sales milestones"
       }
      }
     },
     "localname": "CommercialSalesMilestones",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_ConsumerPriceIndex": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "consumer price index.",
        "label": "Consumer Price Index",
        "terseLabel": "Consumer price Index"
       }
      }
     },
     "localname": "ConsumerPriceIndex",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrus_ContingentMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent milestone payments receivable.",
        "label": "Contingent Milestone Payments Receivable",
        "terseLabel": "Contingent milestone payments receivable"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsReceivable",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_CorporatePaperNotesAndBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate paper notes and bonds.",
        "label": "Corporate Paper Notes And Bonds [Member]",
        "terseLabel": "Corporate paper and notes [member]"
       }
      }
     },
     "localname": "CorporatePaperNotesAndBondsMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of balance sheet classifications of debt securities measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities Held To Maturity Balance Sheet Classification Table [Text Block]",
        "terseLabel": "Summary of Classification of Debt Securities in Consolidated Balance Sheet"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityBalanceSheetClassificationTableTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_DeferredTaxAssetsLeaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease obligation.",
        "label": "Deferred Tax Assets Lease Obligation",
        "terseLabel": "Lease obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseObligation",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease right-of-use assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_DescriptionOfResearchAndDevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of research and development programs.",
        "label": "Description Of Research And Development Programs",
        "terseLabel": "Description of transaction price under fixed consideration"
       }
      }
     },
     "localname": "DescriptionOfResearchAndDevelopmentPrograms",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrus_DevelopmentMilestonesReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones received.",
        "label": "Development Milestones Received",
        "terseLabel": "Development milestones received"
       }
      }
     },
     "localname": "DevelopmentMilestonesReceived",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_ExpirationDateCarryForwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date carry forwards.",
        "label": "Expiration Date Carry Forwards",
        "terseLabel": "Expiry Year"
       }
      }
     },
     "localname": "ExpirationDateCarryForwards",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mrus_FinanceCostIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance cost incurred but not yet paid.",
        "label": "Finance Cost Incurred But Not Yet Paid",
        "terseLabel": "Non-cash financing costs"
       }
      }
     },
     "localname": "FinanceCostIncurredButNotYetPaid",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_ForeignCurrencyExchangeTranslation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency exchange translation.",
        "label": "Foreign Currency Exchange Translation",
        "terseLabel": "Foreign exchange"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeTranslation",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_ForeignExchangeGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange gain.",
        "label": "Foreign Exchange Gain",
        "negatedLabel": "Foreign exchange losses (gains)"
       }
      }
     },
     "localname": "ForeignExchangeGain",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_FourZeroOnePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four zero one plan.",
        "label": "Four Zero One Plan [Member]",
        "terseLabel": "401 (K) Plan"
       }
      }
     },
     "localname": "FourZeroOnePlanMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_FunctionalAndPresentationCurrencyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for functional and presentation currency.",
        "label": "Functional And Presentation Currency Policy [Text Block]",
        "terseLabel": "Functional and Presentation Currency"
       }
      }
     },
     "localname": "FunctionalAndPresentationCurrencyPolicyTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_FutureContingentDevelopmentAndRegulatoryMilestonesReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future contingent development and regulatory milestones receivable.",
        "label": "Future Contingent Development And Regulatory Milestones Receivable",
        "terseLabel": "Future contingent development and regulatory milestones receivable"
       }
      }
     },
     "localname": "FutureContingentDevelopmentAndRegulatoryMilestonesReceivable",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for going concern.",
        "label": "Going Concern Policy [Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_GrantOfRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant of restricted stock unit.",
        "label": "Grant Of Restricted Stock Unit",
        "terseLabel": "Grant of RSUs"
       }
      }
     },
     "localname": "GrantOfRestrictedStockUnit",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrus_GrantRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant revenue.",
        "label": "Grant Revenue [Member]",
        "terseLabel": "Grant Revenue [Member]"
       }
      }
     },
     "localname": "GrantRevenueMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in research and development expense",
        "label": "Increase Decrease In Research And Development Expense",
        "terseLabel": "Reduction in research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_IncyteCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte collaboration and license agreement.",
        "label": "Incyte Collaboration And License Agreement [Member]",
        "terseLabel": "Incyte Collaboration and License Agreement"
       }
      }
     },
     "localname": "IncyteCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_IncyteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte.",
        "label": "Incyte [Member]",
        "terseLabel": "Incyte"
       }
      }
     },
     "localname": "IncyteMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_KadansSciencePartnerXIIBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kadans Science Partner XII B.V.",
        "label": "Kadans Science Partner X I I B V [Member]",
        "terseLabel": "Kadans Science Partner XII BV"
       }
      }
     },
     "localname": "KadansSciencePartnerXIIBVMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_LesseeOperatingLeaseExtendedTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended term of contract.",
        "label": "Lessee Operating Lease Extended Term Of Contract",
        "terseLabel": "Operating lease, extended term of agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedTermOfContract",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrus_LesseeOperatingLeaseNumberOfRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease number of renewal term.",
        "label": "Lessee Operating Lease Number Of Renewal Term",
        "terseLabel": "Operating lease, number of renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerm",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrus_LesseeOperatingLeaseTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease termination term.",
        "label": "Lessee Operating Lease Termination Term",
        "terseLabel": "Operating lease, termination term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationTerm",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrus_LicenseAndPerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and performance.",
        "label": "License And Performance [Member]",
        "terseLabel": "License and Performance"
       }
      }
     },
     "localname": "LicenseAndPerformanceMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_LicenseAndRelatedActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and related activities.",
        "label": "License And Related Activities [Member]",
        "terseLabel": "License and Related Activities"
       }
      }
     },
     "localname": "LicenseAndRelatedActivitiesMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities current.",
        "label": "Marketable Securities Current [Member]",
        "terseLabel": "Current marketable securities [member]"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_MarketableSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities non current.",
        "label": "Marketable Securities Non Current [Member]",
        "terseLabel": "Non-current marketable securities [member]"
       }
      }
     },
     "localname": "MarketableSecuritiesNonCurrentMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merus NV.",
        "label": "Merus N V [Member]",
        "terseLabel": "Merus N V [Member]"
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_MerusUSIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merus US Inc.",
        "label": "Merus U S Inc [Member]",
        "terseLabel": "Merus US Inc"
       }
      }
     },
     "localname": "MerusUSIncMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_MilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable.",
        "label": "Milestone Payments Receivable",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "MilestonePaymentsReceivable",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_MilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone revenue.",
        "label": "Milestone Revenue",
        "terseLabel": "Milestone revenue"
       }
      }
     },
     "localname": "MilestoneRevenue",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_MiscellaneousIncomeAndGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10090.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous income and gains.",
        "label": "Miscellaneous Income And Gains",
        "terseLabel": "Miscellaneous income and gains"
       }
      }
     },
     "localname": "MiscellaneousIncomeAndGains",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_NonExecutiveDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive directors.",
        "label": "Non Executive Directors [Member]",
        "terseLabel": "Non-Executive Directors"
       }
      }
     },
     "localname": "NonExecutiveDirectorsMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_NonRefundableUpfrontPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront payments receivable.",
        "label": "Non Refundable Upfront Payments Receivable",
        "terseLabel": "Non-refundable upfront payment receivable"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentsReceivable",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_NonRefundableUpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payments received.",
        "label": "Non Refundable Upfront Payments Received",
        "terseLabel": "Non-refundable upfront payment received"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentsReceived",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_NumberOfBispecificAntibodies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of bispecific antibodies.",
        "label": "Number Of Bispecific Antibodies",
        "terseLabel": "Number of bispecific antibodies under collaboration and license agreement"
       }
      }
     },
     "localname": "NumberOfBispecificAntibodies",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrus_NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares pursuant to underwriters' option to purchase additional shares.",
        "label": "Number Of Common Shares Pursuant To Underwriters Option To Purchase Additional Shares",
        "terseLabel": "Number of common shares pursuant to underwriters' option to purchase additional shares"
       }
      }
     },
     "localname": "NumberOfCommonSharesPursuantToUnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrus_NumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones achieved.",
        "label": "Number Of Milestones Achieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "NumberOfMilestonesAchieved",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrus_NumberOfPerformanceObligation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligation.",
        "label": "Number Of Performance Obligation",
        "terseLabel": "Number of performance obligation"
       }
      }
     },
     "localname": "NumberOfPerformanceObligation",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrus_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office Building"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_OfficeEquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office equipment and furniture.",
        "label": "Office Equipment And Furniture [Member]",
        "terseLabel": "Office Equipment and Furniture"
       }
      }
     },
     "localname": "OfficeEquipmentAndFurnitureMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_OfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office furniture and equipment.",
        "label": "Office Furniture And Equipment [Member]",
        "terseLabel": "Office Furniture and Equipment"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_OnoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ono.",
        "label": "Ono [Member]",
        "terseLabel": "Ono"
       }
      }
     },
     "localname": "OnoMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_OperatingLeaseExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration term.",
        "label": "Operating Lease Expiration Term",
        "terseLabel": "Operating lease, expiration period"
       }
      }
     },
     "localname": "OperatingLeaseExpirationTerm",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrus_OperatingLeaseRentAdjustmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease rent adjustment description.",
        "label": "Operating Lease Rent Adjustment Description",
        "terseLabel": "Operating lease, rent adjustment description"
       }
      }
     },
     "localname": "OperatingLeaseRentAdjustmentDescription",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrus_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrus_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_OverTimePaymentForFullTimeEquivalentFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over time payment for full time equivalent funding.",
        "label": "Over Time Payment For Full Time Equivalent Funding",
        "terseLabel": "Over time payment for full time equivalent funding"
       }
      }
     },
     "localname": "OverTimePaymentForFullTimeEquivalentFunding",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_PaymentToCompensateResearchServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to compensate research services.",
        "label": "Payment To Compensate Research Services",
        "terseLabel": "Payment to compensate research services"
       }
      }
     },
     "localname": "PaymentToCompensateResearchServices",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_PendingAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending accounting pronouncements.",
        "label": "Pending Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Pending Accounting Pronouncements"
       }
      }
     },
     "localname": "PendingAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_PrepaidClinicalAndManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid clinical and manufacturing costs current.",
        "label": "Prepaid Clinical And Manufacturing Costs Current",
        "terseLabel": "Prepaid clinical and manufacturing costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndManufacturingCostsCurrent",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_PrepaidExpensesAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of prepaid expenses and other assets.",
        "label": "Prepaid Expenses And Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_PrepaidGeneralAndAdministrativeCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid general and administrative costs.",
        "label": "Prepaid General And Administrative Costs",
        "terseLabel": "Prepaid general and administrative costs"
       }
      }
     },
     "localname": "PrepaidGeneralAndAdministrativeCosts",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of property plant and equipment estimated useful lives.",
        "label": "Property Plant And Equipment Estimated Useful Lives Table [Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_ReimbursementRevenues": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement revenues.",
        "label": "Reimbursement Revenues",
        "terseLabel": "Reimbursement revenue"
       }
      }
     },
     "localname": "ReimbursementRevenues",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_RestrictedCashAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and other assets.",
        "label": "Restricted Cash And Other Assets",
        "terseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashAndOtherAssets",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_RevenueFromCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement.",
        "label": "Revenue From Collaborative Arrangement",
        "positiveVerboseLabel": "Collaborations, transaction price as revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangement",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_RevenueRelatedPerformanceObligationAmountAsRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue related performance obligation amount as revenue.",
        "label": "Revenue Related Performance Obligation Amount As Revenue",
        "terseLabel": "Revenue related performance obligation as revenue"
       }
      }
     },
     "localname": "RevenueRelatedPerformanceObligationAmountAsRevenue",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of weighted average remaining lease terms and discount rates.",
        "label": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table [Text Block]",
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrus_SecondBispecificAntibodyResearchProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second bispecific antibody research program.",
        "label": "Second Bispecific Antibody Research Program [Member]",
        "terseLabel": "Second Bispecific Antibody Research Program"
       }
      }
     },
     "localname": "SecondBispecificAntibodyResearchProgramMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_SecondONOResearchAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second ONO research and license agreement.",
        "label": "Second O N O Research And License Agreement [Member]",
        "terseLabel": "Second ONO Research and License Agreement"
       }
      }
     },
     "localname": "SecondONOResearchAndLicenseAgreementMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vesting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Period",
        "terseLabel": "Vesting period of RSUs granted share-based payments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriod",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrus_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual life of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Contractual Life Of Options",
        "terseLabel": "Contractual life of options (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLifeOfOptions",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrus_SimcereCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simcere collaboration and license agreement.",
        "label": "Simcere Collaboration And License Agreement [Member]",
        "terseLabel": "Simcere Collaboration and License Agreement"
       }
      }
     },
     "localname": "SimcereCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_StandardPoorsAAMinusToAAPlusRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standard poors AA minus to AA plus rating.",
        "label": "Standard Poors A A Minus To A A Plus Rating [Member]",
        "terseLabel": "AA- to AA+ [member]"
       }
      }
     },
     "localname": "StandardPoorsAAMinusToAAPlusRatingMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_StandardPoorsAMinusToAPlusRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standard poors A minus to A plus rating.",
        "label": "Standard Poors A Minus To A Plus Rating [Member]",
        "terseLabel": "A- to A+ [member]"
       }
      }
     },
     "localname": "StandardPoorsAMinusToAPlusRatingMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options exercised and stock options exercised and restricted stock units vested.",
        "label": "Stock Issued During Period Shares Stock Options Exercised And Stock Options Exercised And Restricted Stock Units Vested",
        "terseLabel": "Exercise of stock options and vesting of restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndStockOptionsExercisedAndRestrictedStockUnitsVested",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrus_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock options exercised and restricted stock units vested.",
        "label": "Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested",
        "terseLabel": "Exercise of stock options and vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrus_SubsequentAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsequent award.",
        "label": "Subsequent Award [Member]",
        "terseLabel": "Subsequent Award"
       }
      }
     },
     "localname": "SubsequentAwardMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TaxYear2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year 2024.",
        "label": "Tax Year2024 [Member]",
        "terseLabel": "Tax Year 2024"
       }
      }
     },
     "localname": "TaxYear2024Member",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TaxYear2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year 2025.",
        "label": "Tax Year2025 [Member]",
        "terseLabel": "Tax Year 2025"
       }
      }
     },
     "localname": "TaxYear2025Member",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TaxYear2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year 2026.",
        "label": "Tax Year2026 [Member]",
        "terseLabel": "Tax Year 2026"
       }
      }
     },
     "localname": "TaxYear2026Member",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TaxYear2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year 2027.",
        "label": "Tax Year2027 [Member]",
        "terseLabel": "Tax Year 2027"
       }
      }
     },
     "localname": "TaxYear2027Member",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TwoThousandSixteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen incentive award plan.",
        "label": "Two Thousand Sixteen Incentive Award Plan [Member]",
        "terseLabel": "2016 Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenIncentiveAwardPlanMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TwoThousandSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen plan.",
        "label": "Two Thousand Sixteen Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenPlanMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_TwoThousandTenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2010 Plan.",
        "label": "Two Thousand Ten Plan [Member]",
        "terseLabel": "2010 Plan"
       }
      }
     },
     "localname": "TwoThousandTenPlanMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_UnbilledReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled receivables.",
        "label": "Unbilled Receivables [Member]",
        "terseLabel": "Unbilled Receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters.",
        "label": "Underwriters [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrus_UpfrontPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "negatedLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.merus.nl/20201231",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r90",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CreditRatingStandardPoorsAxis": {
     "auth_ref": [
      "r163",
      "r188",
      "r189",
      "r218",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by Standard and Poor's rating.",
        "label": "Credit Rating Standard Poors [Axis]",
        "terseLabel": "Credit Rating, Standard &amp; Poor's"
       }
      }
     },
     "localname": "CreditRatingStandardPoorsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExternalCreditRatingStandardPoorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit-ratings as used by Standard &amp; Poor's. Contact Standard &amp; Poor's for a complete list of ratings and their definitions.",
        "label": "External Credit Rating Standard Poors [Member]",
        "terseLabel": "External Credit Rating, Standard &amp; Poor's"
       }
      }
     },
     "localname": "ExternalCreditRatingStandardPoorsMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r329",
      "r339",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r527",
      "r572",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r329",
      "r339",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r527",
      "r572",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r244",
      "r247",
      "r528",
      "r571",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r151",
      "r244",
      "r247",
      "r528",
      "r571",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r278",
      "r329",
      "r339",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r527",
      "r572",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r278",
      "r329",
      "r339",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r527",
      "r572",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Schedule Of Condensed Financial Statements Table [Text Block]",
        "terseLabel": "Summary of Company's Accompanying Consolidated Financial Statements Attributable to Transactions Arising From Collaboration Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r244",
      "r248",
      "r574",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StandardPoorsAAARatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AAA credit rating as defined by the external credit rating agency, Standard &amp; Poor's.",
        "label": "Standard Poors A A A Rating [Member]",
        "terseLabel": "AAA [member]"
       }
      }
     },
     "localname": "StandardPoorsAAARatingMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r244",
      "r248",
      "r574",
      "r599",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r216",
      "r334",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r155",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r16",
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r44",
      "r92",
      "r487",
      "r490"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable Related Parties Current",
        "terseLabel": "Accounts receivable (related party)"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r208"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r50",
      "r51",
      "r52",
      "r562",
      "r580",
      "r581"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r94",
      "r95",
      "r96",
      "r443",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashAndCashEquivalentRelatedText": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Additional Cash And Cash Equivalent Related Text",
        "terseLabel": "Cash and cash equivalents, maturities"
       }
      }
     },
     "localname": "AdditionalCashAndCashEquivalentRelatedText",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r341",
      "r343",
      "r383",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r343",
      "r373",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r74",
      "r194",
      "r200"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r87",
      "r134",
      "r143",
      "r149",
      "r182",
      "r438",
      "r444",
      "r454",
      "r545",
      "r561"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r46",
      "r87",
      "r182",
      "r438",
      "r444",
      "r454"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r344",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Non-cash purchases of property, equipment and intangibles"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Capital Lease Obligations Incurred",
        "terseLabel": "Non-cash lease obligations acquired from operating lease right-of-use assets"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r26",
      "r76"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r77",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r70",
      "r76",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r459"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect [Abstract]",
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents [member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r432",
      "r433",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r215",
      "r549",
      "r566"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for additional grants"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r250",
      "r255",
      "r340",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r57",
      "r62",
      "r437",
      "r447",
      "r552",
      "r568"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r195",
      "r198",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software Intangible Asset [Member]",
        "terseLabel": "Software Licenses [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r154",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r154",
      "r452",
      "r453",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r119",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r231",
      "r233",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "periodEndLabel": "Balance at December 31, 2020",
        "periodStartLabel": "Balance at January 1, 2020"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r231",
      "r232",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "periodEndLabel": "Balance at December 31, 2020",
        "periodStartLabel": "Balance at January 1, 2020"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized",
        "terseLabel": "Milestones"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r231",
      "r232",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r231",
      "r232",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Non-current balance at December 31, 2020"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized in the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditQualityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Quality Information [Abstract]"
       }
      }
     },
     "localname": "CreditQualityInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r411",
      "r418"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "U.S. federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r411",
      "r418",
      "r420"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense Benefit",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r411",
      "r418"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "U.S. state"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities.",
        "label": "Debt And Equity Securities Unrealized Gain Loss",
        "negatedLabel": "Amortization of discount on investments"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities Held To Maturity Credit Quality Indicator [Line Items]",
        "terseLabel": "Debt Securities Held To Maturity Credit Quality Indicator [Line Items]"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityCreditQualityIndicatorLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about credit quality indicator for investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities Held To Maturity Credit Quality Indicator [Table]",
        "terseLabel": "Debt Securities Held To Maturity Credit Quality Indicator [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityCreditQualityIndicatorTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of credit quality indicator for investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities Held To Maturity Credit Quality Indicator Table [Text Block]",
        "terseLabel": "Summary of Debt Securities by Credit Quality Indicator"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityCreditQualityIndicatorTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityNonaccrualLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities Held To Maturity Nonaccrual [Line Items]",
        "terseLabel": "Debt Securities Held To Maturity Nonaccrual [Line Items]"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityNonaccrualLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityNonaccrualTable": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity) on nonaccrual status.",
        "label": "Debt Securities Held To Maturity Nonaccrual [Table]",
        "terseLabel": "Debt Securities Held To Maturity Nonaccrual [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityNonaccrualTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityPastDueTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of aging analysis for investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities Held To Maturity Past Due Table [Text Block]",
        "terseLabel": "Summary of Debt Securities by Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityPastDueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r412",
      "r418"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "U.S. federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r74",
      "r88",
      "r412",
      "r418",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      },
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "terseLabel": "Deferred tax benefit",
        "totalLabel": "Total deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r12",
      "r13",
      "r401",
      "r546",
      "r560"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r412",
      "r418"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "U.S. state"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset Interest Carryforward",
        "terseLabel": "Excess interest carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Deferred tax asset valuation allowance",
        "terseLabel": "Deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance for tax benefit to be credited to shareholders' equity if tax benefit subsequently becomes realizable. Includes, but is not limited to, adjustment to opening balance of retained earnings for change in accounting principle or correction of error, gain (loss) in comprehensive income (loss) but excluded from net income (loss), deductible expenditure for income tax purposes reported as reduction of shareholders' equity, and deductible temporary difference existing at date of quasi-reorganization.",
        "label": "Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital",
        "terseLabel": "Deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Defined contribution plan, cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Employer matching contribution, percent of employees compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Percentage of employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r74",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r132"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization of property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of defined contribution pension and other postretirement plans.",
        "label": "Description Of Defined Contribution Pension And Other Postretirement Plans",
        "terseLabel": "Defined contribution plan , description"
       }
      }
     },
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r32",
      "r92",
      "r487"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Related Parties Current",
        "terseLabel": "Current portion of deferred revenue (related party)"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r39",
      "r92",
      "r487"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due To Related Parties Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion (related party)"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic And Diluted [Abstract]",
        "terseLabel": "Loss per share allocable to common stockholders:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "terseLabel": "Foreign exchange impact on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r395",
      "r422"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Netherlands statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r395",
      "r422"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r395",
      "r422"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate",
        "terseLabel": "Changes in tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r395",
      "r422"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r395",
      "r422"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfNetherlandsStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued personnel costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average remaining vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r113",
      "r183",
      "r222",
      "r229",
      "r377",
      "r378",
      "r379",
      "r414",
      "r415",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r175",
      "r179",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing any changes to a creditor's accounting policies or methodology from the prior period and management's rationale for the change.",
        "label": "Financing Receivable Allowance For Credit Losses Policy Or Methodology Change Policy [Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesPolicyOrMethodologyChangePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r199",
      "r202",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Future Amortization Expense Current And Five Succeeding Fiscal Years [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r199",
      "r530"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "terseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r199",
      "r529"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfExpectedAmortizationExpenseDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10080.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain Loss Before Tax",
        "terseLabel": "Foreign exchange (losses) gains"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r83",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill And Intangible Assets Intangible Assets Policy",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r167",
      "r169",
      "r548"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities",
        "terseLabel": "Balance",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held To Maturity Securities [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r171",
      "r177"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Accumulated Unrecognized Holding Gain",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r172",
      "r178"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Accumulated Unrecognized Holding Loss",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r174",
      "r556"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r173",
      "r555"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r170",
      "r176",
      "r548"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Fair Value",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r175",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities [Text Block]",
        "terseLabel": "Summary of Fair Value of Debt Securities by Major Security Type"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r74",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment Of Long Lived Assets To Be Disposed Of",
        "terseLabel": "Impairment charges of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r91",
      "r421"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r543",
      "r550",
      "r553",
      "r569"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r91",
      "r421"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Netherlands"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfLossFromOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r396",
      "r399",
      "r406",
      "r416",
      "r423",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r104",
      "r105",
      "r133",
      "r394",
      "r417",
      "r425",
      "r570"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfExpenseForBenefitFromIncomeTaxesDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r83",
      "r390",
      "r391",
      "r399",
      "r400",
      "r405",
      "r413",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets And Liabilities Net",
        "negatedLabel": "Operating lease right-of-use assets and lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Gross Excluding Goodwill [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Net Excluding Goodwill [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets Net Including Goodwill",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r65",
      "r131"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10070.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r544",
      "r558",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Investments in Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r480",
      "r482"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease cost included in operating expenses"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, options to extend description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease, term of agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r87",
      "r144",
      "r182",
      "r439",
      "r444",
      "r445",
      "r454"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r87",
      "r182",
      "r454",
      "r547",
      "r564"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r87",
      "r182",
      "r439",
      "r444",
      "r445",
      "r454"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licenses of Intellectual Property [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r36"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Minority Interest Ownership Percentage By Noncontrolling Owners",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r116",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r56",
      "r61",
      "r75",
      "r87",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r182",
      "r454",
      "r551",
      "r567"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number Of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r475",
      "r482"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease, estimated rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Total lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfMaturitiesOfOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Current portion of lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r470",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid to lessors included in operating cash outflows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r479",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r478",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining operating lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Netherlands Tax Loss Carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r37"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments To Acquire Intangible Assets",
        "negatedLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension And Other Postretirement Benefit Expense",
        "terseLabel": "Contributions to post-employment benefit plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r344",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityCurrent": {
     "auth_ref": [
      "r37",
      "r253",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable within one year of the balance sheet date.",
        "label": "Postemployment Benefits Liability Current",
        "terseLabel": "Executive settlement, cash compensation to be paid"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PostemploymentBenefitsPeriodExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period expense related to postemployment benefits.",
        "label": "Postemployment Benefits Period Expense",
        "terseLabel": "Executive settlement expense"
       }
      }
     },
     "localname": "PostemploymentBenefitsPeriodExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PostemploymentRetirementBenefitsMember": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special and contractual termination benefits provided in connection with termination of employment and payable upon retirement, but not payable from defined benefit plan. Excludes benefits payable upon termination from defined benefit pension and other postretirement plan, and postemployment benefits payable before retirement.",
        "label": "Postemployment Retirement Benefits [Member]",
        "terseLabel": "Postemployment Retirement Benefits"
       }
      }
     },
     "localname": "PostemploymentRetirementBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10290.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromCustomers": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.",
        "label": "Proceeds From Customers",
        "negatedLabel": "Cash receipts"
       }
      }
     },
     "localname": "ProceedsFromCustomers",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r72",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds From Income Tax Refunds",
        "terseLabel": "Income tax refunds received"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r376"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r56",
      "r69",
      "r87",
      "r97",
      "r104",
      "r105",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r182",
      "r437",
      "r441",
      "r442",
      "r446",
      "r447",
      "r454",
      "r553"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r83",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r207"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and Equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r209",
      "r565"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r83",
      "r209",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r303",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r303",
      "r486",
      "r487",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r303",
      "r486",
      "r490",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r484",
      "r485",
      "r487",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research And Development Arrangement [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r386",
      "r613"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r83",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash And Investments Noncurrent",
        "terseLabel": "Restricted cash held on account as collateral"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash And Investments Noncurrent [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r229",
      "r380",
      "r563",
      "r579",
      "r581"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated loss"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r183",
      "r377",
      "r378",
      "r379",
      "r414",
      "r415",
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r251",
      "r252",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r431",
      "r434"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer",
        "totalLabel": "Total collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r129",
      "r130",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r154",
      "r243",
      "r244",
      "r528"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10140.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r59",
      "r87",
      "r129",
      "r130",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r154",
      "r182",
      "r454",
      "r553"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale Of Stock Number Of Shares Issued In Transaction",
        "terseLabel": "Sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "positiveTerseLabel": "Issue price per share",
        "terseLabel": "Public offering price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario Plan [Member]",
        "terseLabel": "Scenario Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySAccompanyingConsolidatedFinancialStatementsAttributableToTransactionsArisingFromCollaborationArrangementsDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsSummaryOfCompanySCollaborationArrangementsEarnedInPeriodToBeBilledAndCollectedInNextPeriodDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]",
        "terseLabel": "Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Summary of Components of Expense for (Benefit) from Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Summary of Components of Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Summary of Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of Netherlands Statutory Income Tax Rate and Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r343",
      "r372",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense Classified in Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r195",
      "r198",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]",
        "terseLabel": "Summary of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Held To Maturity Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": {
     "auth_ref": [
      "r175",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Schedule Of Held To Maturity Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Summary of Components of Loss from Operations Before Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r89",
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.",
        "label": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Table [Text Block]",
        "terseLabel": "Intrinsic Value of Stock Options Exercised and Vested RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r344",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r351",
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Key Weighted Average Assumptions Used in Pricing Model on Date of Grant for Options Granted to Employees"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r41",
      "r85",
      "r114",
      "r115",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Expected Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1",
        "terseLabel": "Award vesting rights, required service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period of options granted share-based payments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r342",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "Description of RSUs granted to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of RSUs, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant-date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of RSUs, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant-date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of RSUs, Non-vested, Ending balance",
        "periodStartLabel": "Number of RSUs, Non-vested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant-date Fair Value, Non-vested, Ending balance",
        "periodStartLabel": "Weighted Average Grant-date Fair Value, Non-vested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of RSUs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value",
        "terseLabel": "Total fair value of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant-date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility of underlying stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfShareBasedCompensationExpenseClassifiedInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of common shares authorized for issuance for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Options, Forfeited or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options, Outstanding, Ending balance",
        "periodStartLabel": "Number of Options, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r342",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansIntrinsicValueOfStockOptionsExercisedAndVestedRsusDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Forfeited or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r83",
      "r344",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r367",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfKeyWeightedAverageAssumptionsUsedInPricingModelOnDateOfGrantForOptionsGrantedToEmployeesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r113",
      "r183",
      "r222",
      "r229",
      "r377",
      "r378",
      "r379",
      "r414",
      "r415",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r113",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Stock Compensation Plan [Member]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r222",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, net, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r222",
      "r229",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r222",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r87",
      "r165",
      "r182",
      "r454"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r466",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r466",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r466",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events Policy Policy [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r493",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary Of Operating Loss Carryforwards [Text Block]",
        "terseLabel": "Summary of Net Operating Loss Carryforwards for Dutch Income Tax Purposes"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURES:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetOperatingLossCarryforwardsForDutchIncomeTaxPurposesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r158",
      "r160",
      "r161",
      "r162",
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade And Other Accounts Receivable Policy",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r175",
      "r179",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfClassificationOfDebtSecuritiesInConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U S Government Corporations And Agencies Securities [Member]",
        "terseLabel": "U.S. government agency securities [member]"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r279",
      "r318",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. treasuries [member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfDebtSecuritiesByCreditQualityIndicatorDetails",
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureInvestmentsInDebtSecuritiesSummaryOfFairValueOfDebtSecuritiesByMajorSecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r389",
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Unrecognized tax benefits, tax related penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r121",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance, attributable to increase in net operating loss carryforward deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r476",
      "r482"
     ],
     "calculation": {
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureOperatingLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Basic and diluted",
        "verboseLabel": "Weighted average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShareDetails",
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merus.nl/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953659-111524"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921842-210448"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118644919&loc=SL5834089-161433"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5708775-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r614": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r615": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r616": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r617": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r618": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r619": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r620": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r621": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r622": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r623": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r624": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r625": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "i",
   "Publisher": "SEC",
   "Section": "3",
   "Subsection": "10"
  },
  "r626": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r627": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001564590-21-013584-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-013584-xbrl.zip
M4$L#!!0    ( ,*"<%+!(EMDLD8! )8= @ 6    9W1Q<V=R<6-D9S1E,# P
M,# Q+FIP9^Q]!50<7;9N0W )! \>W GN$"!X@. .(01M)+@'" &"!P^>X-:-
M-BX!@@=W=W=OM!_)/[_<^^Z;-[+FSMP[J5Y?5:V2?;Z]ZYR]]SE5706;@"T
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MV8#>+06@\KT*W!)GKG1UTB+,NE8<. V%[NS&^W!*^M4\9OX\QK--AC/3Z\H
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MG:A-ZWY(3T9CW(M6[B%+3L#41\S5:W=+/6=1>[JB&Y YHX.*$@3  #DDA<,
MUW3D=%6UPTZ;5*K=6$IB3.="X<CR=1U3+(]BR/A8!<>?#K,HV5A_?@\#E-UU
MW/58)=3I64DKA/F6:.OC^72MGN4RY!:_ 6:706NR.C#K*2;Z:QZHN?:,8&CE
MS%O4VF9MC5?:*_5\N>L8%PC3?[H7E:T'+S:9NTLUI"IQAD]-MW#.MJFUF;_Y
MP5 Z@$!C!N^L0)3N$,^0>#A@I:2B0,]VE!]D81PQAQ^"ATH<QA3Q-K.N%-(4
MVEWG1Q<I,+5,5:I9,S128UTE^GKT6N5^YE+\Z-CL(/K>A#+/=BU6Q"XD];YY
M!+)O*VJS@P"EEN2=QXK_U6.5UFLL!ME@3+N]Z2;*-KMXFUJOV?<Z+BY">RA?
MZ:BA3VAQMRCI/ 0,R0^:>?TE[713E&&49HA;Q_8E0@D"ADO1/KR;@Q&613Y^
M=T"UZ<T"LO"XHCT0<4::^7W\4Q&-('S<:(<CGFRD_.E"T=>5A^I<VW17>F\5
MZGDE"E\V*+?  #C6/,DKPS85FR_@W&@#^<&9MP]8[]WZ\<Z?]RH"%W>INNUX
MIY7?,@K::JR![V)B*=[&B/_,\*X4GB;R\[_DP1=UPG F7=F!L$[D'K7!)^02
M;^AG+!-<":;:WL4LAA0#[/774J*A"1W85@2\JI)P'W!W#6?M[XK=DZ1M3T<(
M\XC731N6+RF! 2+UM!=A "?-[BS505+PNY6;]<]^RT\YH.(#I\_AP%J+X4.3
M%JY5K.<F$LKKAI_M;3!'I!F7=:B_F\ 0DUH9XK?X=HAAR3Y0@_2!:DZ-NR*M
M8DT^=0MKO9CW<B3.;#T?%2T.+YG?E\++_I9P->5ANOH8-;DQ_-ERY*2S9!&F
M5F46&U:3=Z5=$QQ)Y2QRW(JD!0^)7N1O6,VZ>O-R:LM.S\T<4P1<-B>+-Y1]
M7%)'8!#U4WP!_=,()\\.02U;\JN=LS'[I[TC>=M2C:$Y4S/<!SI2I*#1$0=+
M3ZGB1/FPANF&,!C@H>6051IQ-238E:/YWJ:AV&(ZX:P;DR5K,2N-A1\EY1<1
MX/QE&/&WZH.S*)>K/6XHC9VF[O,D^5Y\S9C8V(R=?NQQYU[)CMIZ^*DQ<312
M1&K^A^!]PY%3(Q1+38DI7C?I^<>(9P_!2]\;DYXS*):#0D.WU-'<SITPP1&M
M.WW66'%$J7L*EQA'KO+4/-@MM.,LC78H_)V'>JA#*PD4W+]H%N=LG&%;(ZWX
M[2NSEF8:T2"U]V:.7J%' $AV6?8#%8,&&2";*30AGN%U)JVHNU!$1@@S]:>_
MO#^=3(T?_A'C R<B0##D<![G6FNTPL9VJ9M,$!7!)JP\J0,&")@$^PS0S=_>
M$@]/RG9LXUVEG4JYL5^S]3K>55H8X/Q@$ 9 +]>' 3XI-MU<<WLRGF$5J>UY
MCN(O-!W4\?1?(DS# /.M,G\\82=W0K14N69?7>OM76JU,RZV@6L' _A@4OSQ
MA++T%Y=MHNL-*H;H_Z$ GS^<0-[M[?^3T4]&/QG]9/23T4]&/QG]HQGMKD@V
M^<0F-[B$C<3]V6*-M'-GS@M,)'$KUX.)(E;%BU'^F$J(+;H TT]0JV" IL!(
M4]'FTQ#O?G< G.]C1F"SSQ_W00V2UF_@;6" _<7,2>42[Y?ICG-YQ8A_1E;K
M_V#K_F3TD]%/1C\9_63TD]%/1C\9_63TD]&?8_2+5$2]/QUD_",]M@"K?9FC
MK3WDC6;;HY0MD[U0\M#2>CZL]&V,4U5+7 I/E8&QS*?0+ELPF?ZR\O(Y\K<Y
M81@@JN,Y#/"FIGOCVA4&H([X?'OC&+<IN2@3I+9L+(6G@?W/?MO'3_QKPW.^
MA?T"7^OFK%BR6!@J!0-0%<  C:,;SNNCT,G=Y[?$: P9Y3QHUNE;TYM*.5VW
MH,98N&.^"!A@Q7Y$;![L4"M&!@-T+N?Y-.FO>CR'JBR.0+__2^+I7_-LQT_\
M^X'\_"#T5DH#!O N'-CN%WW@TUG0M _Q(',_?</KJ2X6^#:$H:A7XH>G4\O_
MX?8 7KW+31>DSECGVRG@R Z?(_XMBOUQ <-843PW9U'>N\JL\I?\\^ G_GV!
MW'!-=1<R-7SFK4X$C_O?&1TQ%5_M&@89>AN%IXUB+7[*"&'F>OZ+E]OZX?*>
M4'"Y[=_*D$G>7*XS9Q[.7T<(!EV=]FEE8P60DRF'!^"IJ#_Y%W@'ST_\ZP)N
MWP>E:47#Z'RJX7[]\2+A=4CA[976Y_%TK65SB"34@B$CY-O(?\[LA'YF=C_Q
M]^&ORNRRC&MD3_'@CME_S^P:2#H:$<?VA:5$QA+M:+L[)X609\%:M_C[83X;
MN/876M9 <9I(-C>K",6)UHPJL45#:,>M'Q]%',5!L9?)]T=V(KO3J_S$U//_
MG[LC[0"7V4KM9/@U, #:>;O8"6KU=1X,$."Y3'&),/-&W=,->93)Y?$&J!^J
MU<CQO>_4L2ISS3Q/! ,,T"T?94Y_$<U7*PV2LO5I:3B,O(&W%6/ZO1SR.;A3
M^=0P06;'WRBK_*&8LP.L O4=XT&]]#_P^4,Q5;[>JKDF]T-F_L#G]V)$ZN]M
MQ0D1.6FN_X'.[^7L+E#\VZB=91=T^UBE+^XWM;]F5/HLPA^ZWL"#OQ/[=>U/
MYXYH]E]3&K+=%:?Q7:O?5W\IF3AD$@9XA]XV?X+VPRB_K?Y"W$1%3^S SZWN
MUD_KNTE_7?N3TE;,YK?8[(0^ TS?K\9O:[_8*US*^JZ?CKBT?XFH_UVG7]=^
ML39''B@=^J3>X,XBA=\M\OOJ+Q>+![\<!D A#&W:P/]AT-]6?]&Y_=]=9Y]_
MV?KY;]HL?ZK]4^W_J6J+8=6_0/(INW,KYO\KG>6_8X! ]JW75Q(K^Z/._VOK
M[__49FO32 %MEE:Z2^74?/X-J^B_:K,\/+AJ1S"_^EE]?ZK][ZJV!M1S&;-5
M4./+PY6E7\1W%'O]/I2[TDAAX;#QACQBSNQ;<C U&9>!C8-B+MW@IFIH&([Q
MC[\:/]I4D/5XCJA@!+U, VL(_5C\_6/**LKG,F/9>;E7F=M/\#?^AI<B_!$J
MYT%C8 V.[_-_^DCY'W'/:(]OJ$"CZBK\I"#V;QX)52V>H]"5U[AJW7Y"^+=8
M)\2G!CKJ42HV<VW5\%>/A>';BRY<:@A6I[_V9H"S^#NOT_\/C"1[Z=FLU-[#
M)Y_0*BFV(J_:0:,*6*<R-\N:&X",$ 9 E@BC)98\(!\( U"HC7;G_FGY=Q?,
MQ'B[<3D"P8,!G+PMX!O^SCMT:*('EZ/=.3_F_U![_;4 WK1?:LA7P@#VC7&J
M/U[VQ%GLS&@#?F95\(1LJ^EL! :8T0W5A $BSR[1,HVX@MNUPBVE%!32LIFX
M9W MAF^GTJ]"97XY[%M&Z>49]<5D;DGNQ'_:$5G\4BPUZ-]V^Y.Q=60A@G*&
MS.V)R'7C'<8S7K'%1W<>/<U2YIJ&3^RXEYD\1+3A_:T+>4NZB<DM#DGZQ5JL
M3XND(PP@/%2Z\?.TO^TT'<A5$!%#;/]N/@Q0#4F4HC#\ZB.$9:Q<FGL#$3LG
MB/RY_<?VH@DKSEE]=]L")*XVX[' R#L/VG2 J[=H'[>NRQ%;8=T'(K;"S'+Z
M@]]GWE1FT?U'?[E1^BKW+L^8=[IA@ <%76;>'A8ZJ[;>W.5E;J.UO\0&+'E=
MR2%?)ET8H&/DU"%_ZI?EWU]RB$^M*(152FR60A=0_'<&?/C(>E&(0_Z/^3__
M:YA_ /$O/A_4-&.7K?[CA6?W77_U\UH0.R@,8/>I@.>(J&FY?S2ME^+'_?R4
M@7]VO/JOP"PI<\=['HI:=#DP" ,LG]_" W.1;P^QU 3G6\W%M7#WL++5"H//
MD8<:JP\#OB<-_TADV=6^B:T(/U>^JYD3/@5B^\15&BQBHQ3GX7J_O%KNPTEV
ME@@#?';QM;>R%E/JC\7?7^R/O%EU1.UF\/03VLG?>;N3X2ZSU&+Z^'W^CS76
M7PFXXG.230VFZ1])RX]KO^[\:TWU_"U)>11Z*WRCLS/XXZYL3>\__RM4_P4J
MN'V@-S" ;U(_")/B5LQG@:[VM<\^]BD7Z)KW/WC:[4BBGY[V;_&T8+Z.J;W<
MC&;SFX_=9<]6E;0$EE(T9H-38C4F)U7T._R]I*=V_6^R?6O"*\M.>C4%;Z"'
M%;6VIU><NU^F^[DOR';8+4GH9W88BH5KQ[QD/)=<AKFW.Q\9??2G<=]4%EQ_
M[X2I.X=IY09^E-I"+44^@"EFUG764[J!IXE4LQ3J33Z+%3O4R[3&K=;[4J=U
M.71#=* V/ MM)4[FW<K]V4V&.H/P$;E)*U=U+;Y/1ENW3F.U1=)R#TK*,G;5
M=!II#MD*\51S4H&TY4_X*H; &D&?,J/FOFS1DJ1"\(,6#>37U0=V]\ ?N<&^
MT4C,DFHC:@JET5M/V?)0*54MY]H8Z<#Z&?F;@B%64P8-U[(J= ;->GF%L2%*
M6XM2K],HQR#-2T ;YF<U(;@<U$[!'YA(&K3:R,EJ D[U/MK:S+Z]W1*I[E_6
MZOR6JEY+[B_U_':\3(^F-LDID.\A8B\MN";'L&=5S["5^70*U*N8F,O)S5!0
M11R76E2(=\[1OM]22*ZHI8R]B<4>F_0.Z=FRA:VCU$=':OF05]%9*HDT+_*0
MY'C2A*4R*QJU1UZP*?'N[4M]Y(U?2\777%8M@SC)[9F$IRQ*DE?T>!LIU\9E
MO-UCI#$LR(V2^FA :%'4Y265V?PHPD "P7Z$H'! O]F1,!FCX/!T)C>$I9F[
MRZ)HLEX\2T_^9?)S/U)GU9GA/1X@?\4D.^+(2\IZN32N"(;R^Z^,,JI]T*!=
M=G-/1^P^85:_(^/JQR^T=W[CG$= ICEH,X.[$G>1O*G8G&LFD9=4*RC(!!F]
M ;UCIEUM>0KZ8L:/,**9U)[J=<5J1Q77@+<6E^BJ1YB7$2+YWQ&6#;C'L)7I
M$ZFB.^8R;[LJ;K??."^,]S"K%S(66O5+I#$]"'FV;@$.O:(;O@)=#-[$6-Z,
M76^S[R3=#/KHYSA6:$G]LFGCEW.=?%Z-[_EOQ_:YA&PTE=F(U<ZG4DSRIL_:
M]47>G3+@[9#8-VA >*:8>ZYWG/F;3*-:++":P!1SQF]"IGR<FP3%RH#GXJ?=
MYD)23D:_"DE6WJM:ESE3?+,A6O-_$[MC43R+/,Z8LHL_^)N0/['@N?ITN<J5
MFE'+_IN0/[%H<J+XAZE2F#5%< _XNS"'D&VQDIVFZOGS48H)%Z,9NZNM7\5U
M#1J8GY$EG)/<7F9>W>^Y"H<!O%5^E2C(7'3;6G:[[#.O[F,\Z6/?M%_PJWGH
MI9S3?Q,EQ+['=W/ZJX%6-L#EOXL*,KUIAP$:\WXU4BK^V&^R?N7T)S/%9-3V
M_R;K5TZ_&,K!24OG=U&_<OJ3>DK_4NJ-*&1,%JQ0OW'&^F^YUO_SJ^UOJ:["
M+WM&2K3%[>B@(X'M@F/57I40P=)D2 Q5#A..OVSY'U+@AN5^@I"U:_,B XLI
M(66S[K*%A:@H_=+:PQ%!%L$Z*\WHEB\"P<87E>?[FI^F:F(+\NJT3RJ=Q1->
M9,XLQ6*W4K[%LC>T7V+UYFE"G3:<3G@?;VI<E^+7ZZ1+_[XBV1NGG3E<&N]C
M.YRFK:.DO_Q"02XS&0_^@^IW>HG?0JCNT1ZW,XN*X5B4]:[*Y.M5!$$E'=7,
M+*;TDBHT/ NO]!B>CG-EJ:2%=804FX,M78_<71(&OL$ L]*]!,;.GL1X&NB]
M=L^&5X_VV8T#+G==VA3-\W2M4 R'%NE41C[_.(; (D=^C2&Q)7Z*J\*99^WV
MT6%@'>92LJQN'P*_,>>KIJ&4EZNE7'F?P/T*668:#U\"R+KRK%<LBS[%W1ZW
M%[W)TF)=OKIX.00#E._.6Y]+HDC1@'<$%.*%.PR+BCB+4$Z1XJN#Q_6K*B##
M%:K&L5_!Y[ALIWT"^$J8GE\%"9J QN 9J=<)[!!BAC,_C2[O]V?YMI&2&1]I
MC)B_T:.'K4]5D\R37I"S!WXS^L+R[*.#)Q:(H:TA)&7$500II%]P+;XD./R$
MBO,UB2N^YKY!:=J8VXZST*L:]*-RT@#1DZ+VE? "9I(G:9L[II[;5YXYFE<'
M80 F9:B<DY%0]^U0U3%7>%U-QC>!.' OGU.XPTZ!B%P; V786Y0S,->2^OKM
M \3HARA(2\*<*:_,:K&P<*98:VAB(G+2V>OL&>>\<K+Q,4=G&\*0///C&?R:
MS80UF.VP-PD=WH-.46@^G&C86NK$3ND2.VD 4R6&!M_.Z--82S\Q&<OO6%(D
MUAE#& %-:?*CD41;W(78<%TF],(Z3Q*7M"W3$-JMG=>(YNPA%00O"@NF<3PP
M1W1*'!1<K%74UT>M66W&ECSSEH,#)4L70D+Z#8:*5SETC22Y_%+S)KEU@C@G
M!C-JZNK"9=U"4%Z.LN(@T?/N- EY,VLJFBA7Q;;RK"@P@==4W>^-A:+*$6X4
M78DX*C3%]%0T!IJ?2/>*GFL-GRR']E1_HK]:Q].)3-1=G6)FPL*Q&%=C>6RE
M>20[@ZBY,I8G\!"/>X NK?F_^@JL*M^LF+SN]_3X";[U+WVX@OA?1J$'?J2=
MLAZJ0^2Q<*KCMZ*YA7%*/Q;?A_6I;2>FE4A(O2W@+,""E\/M[:MSXVHE$5B+
M6 2R-\ /D,.@T*Q#JDV)K3$'DG6.M@ERH)1B0V)8(4,==_^+C/Q9*Q</)P[(
MZ?]A[[W#FFK7?.&H( H(TCM([Z! Z$64CO3>1:0D,2"]@XJTT 0$I$NO"5)#
M1WHO(?3>I4/H4C]?]YYYSWS[.^<ZLV?O^>:Z9OYX5J[\5M;*NM=ZRMU^]^I[
MZT!+(=J=:PSQLCZ:TX-O"RJ'[RATYY<#UPQ*_6 YPB5YTS.4;'6AK'2:2"#N
M6;"29WW<"+0OL6-H!F5#VUN3)_]D-5(T'+%H=8<UZH4^"",<0@,:V2E'TZR7
MO_QCW.DP)HDM$\LM#ATQE:]A"**P=O!K(VJ5\O!S:NZ&/8;R]HMSI4S!/Y)O
M.?+.*./1XO V%\COE%90/'O]^'%7K"212A]?Z'HQ9)X(A-J(G9'UO<65!YJ=
M,2!;Y \1W*1.;3.&[]0^*_DH.AW]QW1"7$0ZO.OE2J:B9J4>Y/)!M2O> %!(
MOA(PG%TWPK--"IQM>QLP5-.NEN@NG\3U<6HLT8&Z&[C-$8$*>POFN%3,4GL4
M*:4RFW)TZ_RW= 7R6M<3Z'H,SC3CH8;<;+_TH4X9^L07L2GJ?C7[@RJSCR_,
M18_S&"H]J957!WM\-F54N_8UH<U+B$];3676T!5[O9S >F8D,]_TU_W]^MS1
M%]^R8W5F5A%N6%E?U1"B"A50I5KO<N(HQX.'KK/<BC4:ISZ)!;$G./ICV<L$
M)M_-K!N!.KAX)_+L:FN2[#%KV?"]!A67UK1T99_?T2@AWQ?.KVKDJHTYV<^^
M-6&C*$JVY98TD.RWRLMOF1BL&9%4T-P>K5Z85.,%X\@'_A--H45IQE_VVD#4
M#< LZ@"Q6]U$-SDS.P-2F*/XQ))=A4+#JGT47!OO6M;S+_+:H[7#>$'BKV2G
MG:G3J(9_++&49?1\>VYFGY'-5K X6A4G[?JT=81HN)K_W@8UO"ET!5)M 8X.
MYFZ&DZ@)6W)4=[-^^\GGRFU!)[%1%>K,07A0]U(OQ)X5PP![%6S,-JRJ3\R"
MUU.Z86P,C1CVP""H<1XN7CN)YGFT*M6$Z9:/OGEE&VW=^Y'V$S:%P3>G.I$U
M6XM"50QY!\T'G[B(DX A)V[$:(EKG5E8#@AEFHO#=U9L\7!=Q*M-WZL!P50/
MDZEMG6>'0:,B'%Y6&I8(J6ZPJ>,Q+5!KZ!9K^\#S<GK-Z3!F)T4%_5;>UG3U
MT<)C4VUCP>%-*Z:U-X"W8X0?WR 0P*(K?1-/WF5/=QXGPB\8=8QYDU1[3D<J
M0;3'=L_33P2<)O-#8(W)1BN-[S4W@(_&XW?8>RF+'<C TBQ0\34QH2_DTR#Z
MEY]^D-X L+=$R*OBIUZ?JTT)(/##FWA=D^;2V0IR5*$TV"#2=R9SP=G'U*8C
MVXF='CK:& $[82+9[*<GF8_)=1B[Z:M+9,-+(U3#G]QY>P1,_PH:!HF3Y807
M4RVJY21DP+E"A>8"T6'A>H."F >7U+91%1=U,2TL5M7YW0655ZZ2!BS4;K$T
M2F2MY0)QW_?T*WG%/:\?@0YI;+Q=K6I@J_)N&U '&OO(>Y_."V_IK\0E?K;D
M=.9+$.U7Z%0=7BJG;IBNUPJXCD*^!:^6'--123X'\7T(>C!0^)W1-/S0C#!D
MA\_E!D!JLAD!X=UI7)K3M1(MCC!#'#<8#RR-*\9/D<4)Y#XFQ"DA<V3RC7;N
M&%O;:SO7O?V<_I3Y[2;7..Q2*F]B7?^4_!N+"!X3B4!48J$%\<2LVE(_F]U7
M]P@6UB\$V."SEBGO*,).VB>"U:X_=9UU_#_FT1Q*T%[7%9C->#AH!+)9BSPM
M$I4<VS9_,(QPJ7M5M4'V';?#FN$)4^G>$<UTTSVC>B[MM4GE>ZTI(_MG>=K"
M;B>:(!&M&;X1D)FTA1?=SNZ'RJM#[@XW'E=?^J&!E<200XDC^*QY![KUFNY"
M+^5> @LVZ.G/2*^DC"7N!PJ^S@K12R CMK[(L.]+M7#;%^*Y0=!:81'\<Q@-
MZH'"KK[DJ4+]?A9(\4++'((<V* F5H++8,]7%/B_CE&JRNF.5*#DJMY1SMXL
M6]=O>MDP9%WKT7VUXHA//4.!TT8MU>8V]2:>0*;QO?+R5$KB8Q-WL8O$2V8'
M:ZF&@:VB 7\_%+'_$QT/1NBQ \'FD.FCI"DQ&3>$*("S71_-GX.N4!C.'D*P
MUO3>$@LGZH9K (S,FG,WMYSMARK*8KXB!)LWY"K"[D%8;#WPY-'VYNY) ^RO
M;::4-OIE]/7"E@A2\K]RM9W=V>38WQF=#ZXT@ENC^:R5*9?DS.^J&8X4[R)\
M'/-F>2O2-#Y/)],2V%T8$*M&L\[ =/V)SL94\;)JQZ:$/LEYT5>.M"Z:X*D9
MXVVQD+< &3/#WUZOU338M%P\Q5!ON7UJ:!,,C%@*MW['<%T[@7:]4C0873S8
MMJDHUY0K$CCHK'J@VE Q,2RL5L!K[RJD)?_:Y1_%C7S@7SVO4J __T?8_>^?
M4U6:/'Q!G 9[A'" Z=_AM[S->?UC66^S[0;@C"D\^G>'^_7:+@(V=#>7?)N/
MOA+P+VGA+1YHO(3024)SD1^A%1<6PJKEE%&@\.4T\;$;0!N>:EC_PTX'/)4)
M28Y^\)F_^@?>N^W6%:'6AD';'0(/P$E:!F(SKS<EW"3WM(=^#/L08@G&Q-35
MO70;!.9+LN8Q8,D[LT!8NY\N:4M;;YGX25>D[:F$\BZ"*$E:8.4GH*;%>Q\(
M>>M1]["?#'KY[';';@_'ZJ];V=GS^V"56YC7:\GMLC"G]CQI=TIC&O%A$W*!
M4E'QCX[P9#)E'PX""ZZB"QCN&#.U<M6+"$A&6\6;BQ8:MZ_.E68TYQK;D4S'
M33?,,<8&;!G0]:W,\]9'\#\,JX,SJ-3%O1@+6>@+CJZXE32_/SL>B(@Q<H$8
M+J8]=O[()=O9($]?=4X?BUTQ!1R=!-PFDJ7C9GY>53MZ:7251?=QC+R[FG+%
MK*Y,JM!=/@_$#7X%,AX+<"^:G3D+\^T->JUKUWOK@Z/Q'-$([PU@D3>)EZ.+
MAS66$9<,]XD&$F:!LXDDZL^6SL#Z6/LE"P<KY1@XLDZ]+9ZRJO,\J2O@-#N<
M<(6S>^-K0:=N\LA&T;NSN.O"\8TK2%V2!AM%+ B:):&H8VZPS L^-+);0@[M
M!<<UOZJG'D@Z14#-<O#H4_/\NP3&KZM+#A",W>-^C]ZP^QB[5#,C@1E62\[2
M 5R]>3.3%<)G=RW#/TGHRA#R3!:OC;[6IC_"D:@=2N""AE:*4&95N$?>"WN"
M"Y-1.9R,OC19YO9D[*Y KW3[:X)N  ]=><W881T] Y[PZ;L*H5Z1RT([A&U#
M&_%#$\9GSMH1I%;>[S260!V\W!GJ8.U5;^8&(O[85:*XZ8J &8,XL#C;E_F'
M.PL0T7 -/JHGS25Z, UATEB06:NHE+SG'FP'<51"-@'>GU)UITBL&2:*P>9R
MT!I3;A=(;TO&\S915848QM^;\QB_)V6(.U>_WY&<XZ&^.HSE_9[\19M/1ZG/
M:P?@A0G5SM'6Q_8VN2S^1_9DTY!29?X@^U<1>$J6W[5&1H6'E>)(5]FM$O;#
MF?SQS(I,*VOO"PPT?A$CZ]\RN'Y@=G?%B)M.EO2GLR<+\;SQ*!)US"E)YNQ
MZR0ODE92$4Z,HV6$-#@UH*?R99IN17=R%^C'+=)>/=">6]/VV]1?-QI#Y-2>
MF8"'2VU(G@GX5:Z;T]T /K$V750V;QKKG5YRAT#)IQ12;4,^WTFYT^]^CN]
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M5'D,)]]ZB@GWJM#G=[<6O(TJM'_YQ$P^'59LC]!F7 P+Z9;Q_ H@'$:<J'2
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M\MZ]L]R?-F@^!)/ /H9-MM#!B.59Q&<:V>77AM<<&YBON(71 !S+]C>7%C>
M*#S_C$)SZ>&]^;8J\6-X<=E7P^X( QYQ/0:*V2USGDI"@F1'TK>NBE'QYUIT
MGH9KV[EUJ6D)N1L&TD2J$0H#G&,<2+_#"0.BA7[J<7-,RGDJO%#>"O]]/"L#
M'_?S-HVB]D4\")ZJQ(<5OJM"+ZMH TG"8K;0/-E74W3G,X_;8MXL#(_*5XCT
M_" ]IW3')5F2!&?ABM[!P&7"FP[OG:>OZM6KYFR*N\,61K]6Q-M]N<L5%B-6
MV B,-<*\B$<KYJG'[Z=D"OD_/D<;=PNP9EO39S4^NNW2\.C.!ZLP''2.&F*=
MG'.!<B^-S+O_8\6*3[_.V;)J4PWZ*"=HV B7Q?L#PC%<OZK!TIV_M0VIZDGM
MP!/QSEE9BDA=Q*EVW<;CN5R ^7Y$_UB^WRC+O1;F1Q?O.+^3IN/RV=0&ZZ#;
M>Q6BV;L4]YU-T@"EM97[9D>"WS%=/1/ZE.RKP%X/0OE1I@H,J9H#;WVL?$CB
M>RJ)?/M-)4<U40EW8%[-OJX,-$PS86?\W;=#>@&5%)>E;XT,\V7=Q=-MJ_#Z
MDF@-^9^%XT%\J_M705E6^78&(@8D2FX]C/CB1".PL&8O]1SLD^)3<B<%EG#H
MS\>$0MLQ=LE(CK*H@ H[8!3%['/7P^F]-VV*6.>C\&=D^R5M(5;HJ%BLR$)4
M'B 2U,@0;+A_7>=>2',_#?M327S!H; W;*@2#>2G]%@':T]U0Z"W#-IZ/\RK
M0+?<*T-AI]JJ)FEU^&DNG.RG06 5\*.(V_Q/'W..=GG)_G=-]=5%N'+ <Y^4
ME3(/9UQ/!5Q$F YW:(8Y.HV,:N6/#@NM%P_NY,M4C_A#9:\Z"LY/&'X.706J
M=Z22)5Y5XIQ21_W>Z>M->+DN]=\'YKI:/"YN^@UFF;Q[Z 9D,&^] 8@36NJ4
M-LE;W0!:GCO< "3GHLZ4H#> '\FHXVV9PZ\G9!(TI/HRERS"-X##_O4;P,>@
M^6O/AC\/+?V?0__#AU([7PUV%(U2 2_<3>_-9?[NT(KCWVX  P$3NML@E%'Z
MM*:_8_[_X+_Q0F^H@D2!3X4^#M5:H6@/24RX=1%)EA9WA>GON%S!Z!]&OAG;
M,]3_IO))7(G=_+0;R-[6[EG5DJ[K29$Q--P+^E$_VBDZ'!<I+U%G:%IXBLN1
M^:GE?Y-S1$#2ED2>QQ#*"X2+3YA7<+7V.+_OUQN!7FHLN5=6-0TSEWW@O).@
M. !!V17IV*C'N(\[X7%;VMJ2U::$C -&CK0TP7_DAC&N$)D[U=J&^$B4J#GG
M@@I\:6LD4D^6I8I0ZX7AQ7(+V6^I;:**-^<X@@U&M\?ZIJ57Y*'-14V9,%;N
MCX\R?YU!V?+_/5G^D7K$"?HCTQ^@]^NVZ?K/ >T+#?^B ?_%D?/O8)S(.XN;
MF"A+IKO>57,^EXEPN;)96N+0EC.D@73= -P/<V/!*S4LVP/QL'[I1\.WFD?@
MU;\4M@\YR-&*BQHLM]-//3_.M)J%C*(2W?E^/8J@?TV+T\<)J=>#+%8HU@7I
M*[[,^.P8:YQDGT%08$DW0W6P0D659PN)R4Y&:L^2:BE]_<_,SONP=C+5=\=9
MTO'.4)V5T"TI,EH=>7$'F+RKU,A:XDFOOV3S#_8D\5S/KWP:\MK)^NB=^=?C
MG[*\!-^K!^B6UOI^,FME]N*V2?V""'/1)@:PI-P:RZ=S5L$*R#?Y("HCFO,2
MRMN/RT7CG<\7ZUO?S12YZ2S?/MN0B5.=R*3]%B]%4R)62ZM5TH HE#':C/!9
M'E/V7SM<(&)GS/5]KBRWRS-/(/ _M5H+\'K9ERO'Y+?G[W?_H=V%WP 8=H[(
M%$K \YCK>5E=R,H3_\[T(JDDF599>5(#L:__!8H;_4W3_Y=<;*/CC*P;0.?>
M)=:X.N'5$GVN:U/0P <$^PR#2M[OV+ZOXS+>/UNE^0>.4AS^Y>F3TOV1"P)\
MF/XW:<IUC$PPG_0H931?B!M.$YGS4J[_(NT+VSV&59U+R3BF_13U/H!ALQBP
M;#BQ[[BDQ$JB0YIA/S<@J]MI2J\Z_L5'J5-]C58S;)[E6+,:"S:9!DKI+\57
MKY9^=,P)J8HJ0S@,*>X< -?]F$O5))J=IHPY\:@#35T+H?GY#9/W.=7Z>8DB
MYQ^6V._9A"D,RV]KW39^.K$Q5BDIN*QTW)EV?Y'\5.OMJP'/$LE]W+/0S%07
MM_([WO8D  WC#1=^[*UX<[9DPQ$6Y.UG9F/,[]'#G[/(7$@W=>.^7,B$HBWF
M9HRF-S)VF=R>OJ]=6$* +!ZR5X\'Q19L+/4X33O6 3LN'\O[AU#GKN+06U(Q
M[%!;$)=&+1F+[\^!"M]&B?"&ZMEVY<[K#-7K+*OZWLI OB=?.M&_93D@0*C2
M58NY+LJ>>09,?6C4S'@#,+0014AK=W:>S(,'.7)\>K:D>;YT?+Q#-J>[,V@<
M=R\WP2E5N9*3'4)-+Z($G,?Q+ A69V&(!Q,&)H76[J^XM9>]- Y0-J)8G&GT
ML/PR('+%+;.PYC?HF;)\AR'U@7>$&W7<9ONI8@%*GNS]V-]0PG[3I,#&?\0P
M*VZ9_\NB4^- NRGB99\,9<WN)ZE85#9?JDU:\F/=NVZK.L T[=RQ]P4O8IC%
M$4-0.H5HH=B-M[W<Y&[FR@@+M=&]W+/WO!\3",9:;K<(HH$6JA8T-P";UA6I
MX#CDZHQ8\3RNOQUAR/ - $09?@.PE=D\U\N?6E.''L!5Q>,Z*O,]>J#B:(.D
MX4=GM[SUCX.#77LA<3'+;<Z#E)OA64FKP%N%Z2$D-P!K2KDYV\M*6@/;S"A2
MO/FS%&!&U93_*(&S7(4Q;FI*ZE[- .0TJ;T3MHA^<ZP,M8H^605+Z5W*+G):
MUE6/YC95N1OV--UA62KR"+MX>K9)N(VFK#[TLQ#,!4ML\#O4RSM8+<7<QA>G
M%#7[CM&-#PF5,C^MF=@\W!P_$<Y2F6=(;XLI6)/Q6@-^N51>_)+1$&N<MLNT
M61SQ3@PX-\^ZM+'JTL1I@W?@0&N0?A8T;DK4[KZD$+&=%>VG:EY7WOZ"*D?/
MVM?AC#XX=_:JMH43$]&:\SQ_*\DOCDO14S0B?3=@+C5K;GI^X].,":=AR'<L
M/4)RT$/P%$\HI^YKB='##_=^P&UBULJ%H0=FU!13#?')]N6S+XB%UWW!_0UM
M[OJ803S[2-DXZ<SZL-8HUR4U;6Z:C?&>,M_>^(NKTCWS)E((OBHU@$P!0/J#
MC.Y^CM:@>3#-,IWQA<:H4/6./;U0O"\"QQ&VA9J8W&-?FU"'#/HQ_[P!. PW
M]B,'+A2[ZW(=C7$;)2[8B4$7PN=NA8[U6KA0=55]F9:IRN.]D!+H+A^]4K1
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M'. :!=Z=&*'_CNOZTO5O%.[_(9W\(T@G7&((1J3:H5)I21&M3O2PKH$"?K'
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M/%1<?,E U_;D8QK3.Z6[E(<S(_F*JL>\(ZFSM31I3+5/3"?CQOIAW8]N 6X
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MAJJD*F7!!@*W#DG>SR7PN!S2%&A9=!V!,YR+#:?,>8O1A2\F6I+"6LLK.P)
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MT :8Y6:WP*'@!5K=HEO[_F%9D<QA$O%$",].K^V=2R#4 9ZJ9>W,B;,J)58
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MH>7<3HM9&VN,@I2A0Q!+C4JH0@V#0*[W\38V5US8JJJ395]8QE?ZY@3;3&P
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M;RWR36J05$^VAWF0C$9!*^IJ;YXP6 '%27890\5%1D[,*C4N$B?^]:;^[^X
MX1A-)V(E<#R,DX\4.)=;/E%^]T+!HZW9.\JI2G.S++HNY=P^K@L:.PB7VCB\
M8SBQJ1%9%N>;>\(#21M>X)*\>2^]!.MM56&%54NVC4I!^OI ;L9ROKD'=E'L
M_"55!S7:M%MJ5='3IR)R72OQH:C%FGCE>Q(RGKN9PK2=M%V"-%;&4@[WOS52
M%Q;![;.A!(GB[Z^8>M+8MA%$U@0)1,4$^B_S>LJ@.\=PM6P @G%F\TD'0:F5
M-75[CB&LMZ[3^7N=+#.*57Q&;N#:C">VM'+'/C<\G=O)AI*8@\ZW,5X11ALK
MD9'E/2]G2RYSAY.LJ&16::6Z".=.R;)1M[/Z.DK1'V?1T*%)U"4VW:L*;&<:
M#9ROHW?R(DC:QDV+RP+]4G4'666%RK$&!(H 4X5V5F1R[MQE'BGZ+W-Y@]\W
M1DY%L11Y909%@XFLU#8;XE)THA7N3<T]>>CV;C2H!;&@0U_0'W'BY32*3\DO
M0;65R[.1FI$%&A]3@"1(N\U)*M\1*J8<W5@-+&3T,^RU1/K>UX_8%U8 V;R5
M>J\:#H<F+(0>QBH[:VQS;LVGFK=4Z)&6XO4ZDNT+ZQ"L16+=(5K7R=/&JLO=
M5:M66%:6.VZ(Z)NT+>IIMA 8" O55Y(^4G.HG&RRG_67L[?%BNII#D9 6;IZ
MJF<HS,\ VE&'JK%]9) %B&'?QVF:C< S0+W%:=!I&G0/RNKA-OT);3]P>*1>
M>YC@;1[=W#99\U&[B',W.^XPLWIO7>$@S(H$51DO]G M(.8-5J7E+H0K@IZ\
ME&T- CXHD$.]3(%)<4SXVKA]2;$-$@.!&-+2!@YDJ$J,/JY&2.MRSPXE;#Z#
MD+TC(7JB^@1PPDH@6]&S4G5[4-89N^V.\NPSA3'A"%(Y4\BW:397RJX3\9[8
M2?W0]BUZ8VRZT(=DC&,%'O?*FAT3R@A56J1H%S5TV%&%8+$GA3 H03,$,M^@
MI.2TQ*GF)E.?[?9(NGE;82L+*)UJPA(HG3;CXA!S!KBS#-V_8CW&C,JUW!7?
M0,=^=>O)-UE0H1$#!_ZZZHS>\9L*Z/@@?*A8NIL]4?AR*,DMP_%^V\:B7MZV
M?A]'6PO> *1])*@A=2/-%R'<X6R1\:+9,'K82HD+MCKWZ.U3:!DTPMDXFD(@
MUQ=!]F%L  "=4.F9DY^18?D4Q=PMMTDC&W0*+NP=,3R4TB(I373R;M7N\1B^
M3-YYL]1P B%D'G[@K/>R#'Q2<W>.= 9]-9][H$YABDG_4$7+$&-@+OJ=O12)
M=!9?[R*',#TD,HJKSH*#3D/+7"HD-&TS!X^V >Z1"V'KM98C!F;0IVA?UL;_
M. 4FI<%NT[N_>9KQ\8E87X!.66%YSPF!D?DK+\%EGQ&"??QKJ1-%]*J1^P+7
M/>@6NZ0D!ZS@#U[1:03VK,.K<\Q ]NL^>#-AS]F:Z)!XWC01FCW9%M$UK[3(
MOWJ]F/"PGT.%<GL0];(IHB<-PW/[N<.5!S+D@:!E.T?>LKV/"4X2_<!1:_JD
M.RS:LYNQN[CC1#M-,5B#EK%\%VLDU[IVPV>NC3!YK K6DS:[34BD]8E()+?7
M4S^;@_UZ?,[1_2O\E60&#@J$ XU) <^;!-^6^PCV\XC4WV8?OJJ%,ZOT*EO_
M#DV*M2-'P9<'9'/<HEMHGL(I/$>9S:L!R0.0,/JV;U84ICV9$]AF<*W09>F<
MVT'BW3P:A7[7UJ8"I;H:GH2\,CM5[IX,Q1,@3R&WUZ8LU:AL3W']'EMSU^N_
MY=WT'R5O_]Z<BXHGSG>4FRH"X0P<]-?;M6(3*QE@Z<V-^HQ7>(Q?"0MN\#2^
M7V4+"(IDO[D>]8B\7F=CW(NQRXV/S>_E]JQN-);_5#DV\W:YADZ+X,BH@LB&
MPMO<'=;R_NHM?]NW +4.97A6^@&.<D_%4WB:]\P373:6YP?:Q]@[F4Q[H97-
M>X2SLX_*W1_7P[UZ:88)K(@)2ZSW'&>#$O:RV<R_#.U4L;H;R/'.S]_'#-!)
M$L=.4A MXS3[-K'&5N%JK\>6G)'V+E3HH]I<S$3N)80?A*GOQ=LIR /I%U0D
MHT#)QX7!+,#*L32B:9'+DMD#$F7@"D)MUK4F#'.KFB)*[Z@$K4&S*[@A[ _3
M^'-:F/EYLY722-@-19WWX@I$!B]1?'987SPWY8@.N!J$Z6.9+>M#D9*L><NH
MA40NZP%5YHPLKLA."S?9V[D#NT"SS]D,W*9:L1](HME\ G(2S%E)D:YZ-=*L
M)V>  $<[Y?G^%WMFJ/)'-->=KNP,6N862N Y/S)Z3,7J?0OE'N<I*#F98[GF
M#A@N1 XTQI[TIP$5AF1FCJ]ITG=N!_!].4J9?T^FTN]_-^H189%YU^NA>/Q:
M8J1*B[Q6U#6F[^7"?B\:_A]ZW4]6T=*EMI,&,M,-X3]E9HC1FUXF7[58':I5
M',M,5Q@<ICC)*KI#'4\I1CDQJ4*CK;K-JIG$**_=+ATKDEN9TN&KL[8PFFTY
MZ*]U>8ZC%S\B9S)'K'8/!)^T^K;^Q15)FUN:Q4<**O*=<JV4&'\>!M3R;AIL
M&'JYYU+LQR-U8ULF3,Z;X8:5&Z$4?R-)3H_:@BU=;R[JU-?*8L[J/6E^MKS!
MMFTYI-X>?KHZZATS/]A 9Z]70A0750EA>8UU^8Y]FH&0.1GKP))BOLO:*T<:
M0MK8&BF]GG6/WEJ<LJO#<2U(09*$MM2A-GL[0.3LR1>LE_VJ>2)EU1$"T:&%
MH3=2#TN3UXR6A[(@ B_#&F\VW]$-4;5M>Z7D]'1I629,P]C:E>ZMH?:.3K)Z
M>C !$/Z TQ](L;7"WZ/L\L&#K"^ECQL)F72:TPWW5A*P5CVQ"V+TIB=*>GR=
M>%)"SNX%1B>&S!,A"8CN6,F(5A"K2<R","^RASM]U:1GEX!3NGV /&A6"_16
M;%J70):8L/6F):9S%G)S%Y&D#[6&LB@"%@"I,[EVOBJCI89K00+=;D#'R<0A
MXQP3:X[(A[F8XC[%/%?6$LX UTU@R+E\9*FO_E.*5/_TY76=#T#I9D4H]J7T
MA7@/XL.^=0OI/:5B5A=J]RDJS0Y8-G;=2F83SA4Z]02E%S<_88.B6),AY#9%
MQY^N%EMQ'6PQDS(R%PJ_2",Q:2Q[WF%%G69";5*,7IC9!B.NVKXYETA<V%T]
MA#T4@ICS"'#>&V6_SBOPX$GVK1?SMU!> (Q.H&(;Z?M?F?'_17Z9;(*;$/6C
M=Z]DTYXK35V]GZF%W3A6O) :$U-/!R\0/-J7V43DF16I3S6SM5YJHSKIRW*?
MR()4<,,-V;].8M;5[1B C4BTUQ.PPUV6G#=ZW&R*KJ=Q#%1]BV<X/0-P@@8*
M-N)[3CAMT[XX:C]_1VHP<MRO+([_DH0ND$M^HW(WUQO!?8CK8?>.R+-1)NSY
MQJ>\ YX=OYHJ<ZY@E0TNL#MQZ0 +4'"JIQ;-F5=@P4O!%A EKG\&>$"2,;%^
M?<S)8\_9\I9 4Z6CX3S/8)=<6Z$>"Z><<,V#D607?_5+552;I&%3TE9V004\
M%4FX]);NR]6)H6'B,MB2MZ>@^&:@.@?'R#F>7HNHRVQ>[>8TBAN-L-V%Z2!E
M5T.ISRK/3J5V<Z43X='/6ORU>J=X<J\OD:%O%/?<Y3S<3.V)G,ZQ"QV005/Q
M7J:V+MHJVXPIR1$X5TI*;^7GN29RKJX_Z:)%EC,9JGX=LF&)#9J4+9?3WYI:
M2 L1*#M)^T2YDIX4LSS'84)%/["](,@_I4N@JWT&>$%E4AA^DO78CB1I<AQ7
MAR%YJ*&D:?^ *3,@' ?L13PR?".%N/TI 9Y._;1LC,8'= ?MI8KM\X=Z\UKC
M'LLPC>XCU"AQ:4R+HK3F+4P/BO[S72GJ&$S:Q!;GXHS7OPS>8GJ&+8 A*WXC
M3(^<:>5?Z*'_W^-LK YLD\>]7JB= 7P$Y [4'<#H[?/-Y\;'2G%B]=Y8Z;_=
M'WE80E.G-Y:UN]$=9HK"!&./<N2HNV5O4W>CM)U#)$CR>GA<8(X.>2RLT1_F
MW<")8','HEHSQ8>A\M.PN&.&:321*7(E]U/>JN F?#@QCJO0,P1<\%H8N\H*
M6VN@@'%H==Y9>>Y0WL4X7?? H(&RWE^-+[6+;;J1J%J;<F>))4+">$'\DQ_(
M*4TASWM81DOB&D#8W%55B*R6L@Y^!M@K*IZYKG[W&5L# 6@M/:6]94]F_CJC
M#\\JE4HDE, ])B'8,'MU9,O<ZIDP$Q?-:CB2:#Z(;AM\A?A3] @)=ZQ_H!57
M,Y21VEA8>Z?-N?^]'0'%,B)S69]6H=Q[[MP&H64'MF.;?9L_>11[SYO'3T-+
MCY*A;RM0X39K?"),;C2"Q,C@?+_P3O\8?1.ZZM9XOF,PT;%5.LBJC8*WYR6/
M:A$3#>4]M'S$@P(JQ(S-N#X:3+H)[D;PW"98>16QS1FH0-(N.U$^OQ$3\\'P
MV#[]L<1Z>-@R>)>8&7DCC>)QP;?<"HZI5;-K;#PW32,[(VA;/)P60?#J=X4X
MP^![C_R=D3;=1N7ZY7#F8PD.@QM44G JJ42KBDP,A$$]]<TPY9(@Q<\645V\
ML\U?&,?*AEA4X([BWRMS3C 6;*Z.QB.C5E@IOAA+'N:-%=VON,^]CJ^M43.,
MH'^*4[JD4&FWH\J?KTH7L\]?C;V@#N*-L;W2++?%JP[I,)M?0VK::=AGM>Y=
M&IO"2]*;SW&A5T1QE]@'\&I)/ZG- ,3V,I<O,2MK%X$)^+I6W$39PW#W*"TC
M]S*CDYR#K6A[CU%]7LV;"$^VB FB,?&2R^0U@2/*4QL^OFPY*-1P72PX$R^+
MNMUO\7S7O[$"PHN+))?FNJ'S1& .H:3UL>;&X(KM99G-"@$;R*MHD7R)2ZQ1
MARVHB$9/?QT2]X=-GEQKQB8B=2[;NX@:6*"#:<:SR=P3^G3M@QL=$F(T0WK^
MK$8E33R=>.S6DU$]6U6VHK.!3NV<6MQ*-B]3Y&A;>,#T2!$"K8'1R5R9*9Y;
M"4>];><K'[NO"<D.W"$TF.6M)K%E@TB,@P[CQD#_:G_K!U%;\M.19!.+%\T3
MU82C=*]T#OS:BY2XJ-N3N@N5Y<QL6SZ%[0/[%BCC47:RX">XUZ,<.&'=F67V
M[P2,WJF]8M)()%=DZ=-?=<=/'QLZ-[&E_EW]]6<$Y?]H!&48-$W!VLY0KEQJ
MS2QW3ZCC6"3&CE@]3IDM@9__\6@,4;T*+)__#+#B&K<'%1#)6X,.GBS')Z8=
MLQ+,[T?LEOF(G ;9HCOF)7^A D\C?+;/31-[?.@Q]?QI7'O0#]0%IJ0+'!_4
MTJUS778!33.P+[*"MN\$2NZIT72L$^3T_EM*02O9(G%C-%KIMF> "W [J,'(
M&:#@L%]4G&90 RI2(5RL.'\&N(!?0#>6G@%,MA%O82+YG]%0)W?+A(XSP ^$
MKA^<GBM$J)'>"7KC:%0L[B=\T@]6R["9T"VUAZ>3?YQ<P"3PS:"H[9PCU?.^
M?KO\X SPF4-DX Q0E8[^4G'.,/H(D?B["*WGMH4.-.\,X X\?>.,;CS=!8O_
M+D34+Y2DXTO;IT''2V6PW\7@^(D@N7=E_IAFO\_^+P31_0D?M(+3L2>RGKGT
M%Z)4_X2G&2"+6X&.J_;^A2S0G_ B/WG.2O_]+MF<WZ4+#!7H3Y;5@;_?I]D_
M7$X07/P=ZJD"'PW?<\K>1&125%<2SZ.Q!=\IQD=;GQ-AK"5?8!=60M[%.>I?
M'[#Z>V%R)@S3_Z:2^+\UYN]*D.W[L4,\=M$/9Y\^V1_AN3\R["8+,4,(9  9
MYN<VF7)?2YNT8> 2."2R(T5V[^,98-ZS\\H02]30]^@\ LD?;T_(3#-U(7%H
M)R&:BU< .#'#/15Z.+'SXQ7# 9;R [?K_[\N+GR3=%>YS@ =6*FRUIR7'WR.
MQ^I2/5D4F0\#SDN? 03AK^\#_\F^7WA7Y;_KGC]55@U"GBM+0>K7[%TJ53TB
M)QLNPA>O@')QI>/G9X#MKPL_WRZMDLC^&,>D'V_Q.$A5CA_8?W;R9R?_22<7
M;F_,E',V:?L$BL[=T Z&>!QB5:B PN%,[_]'7[/.5]&LBR\I-V5#CE/C\63^
M/I3@'] %*>-Q7(!ZJK0UIXZ>'O!_>^3_&U\O5G<UW1C&DRVS&$N3(9%7.Q@N
M_RAWX9^GB^^)2E1%?N@@3UMA@C7JU[=__0^CW-/,>2MP[M^)\3CJ:TF[,)1.
M_P;90?Y9$Y?\EQK+N86>?%%E$\/FOS ZU]*^JY>LF]_K2W3^U9O>B\Q/RA?U
M)5Z3PIHWKY93OTDK' GA?B/AD#'3SW8&P+DW(7K[6^RMRL#!IKKD@!*AI7"J
M/B*6$+^"QT>LP9M\OG0^8F^/94J4\F]N8\2.LL9W61J6=UFP,_"'2M5R[B?4
MI[Q2EE<3/V)*3/[\FS\D?"TOP?$.$P7='D),_<#3('4TF?!I_XM/CQMJK^^F
M)H[5M5C#RA]3LCQV?K:W^>TJ)HR<(#T[ *I=VE5G/"Y34C7>WTP[>[(@7:Q7
M2H=H*V/M$)DTD=L;/]\;U?"[[OE;;NWC3I4%7-8N16%Z3\N4Y WVM#>V'2J_
M,E=[9M8@WS2<F+'DF*\!HD@L#)WU.2F03PV3J8Q2[$DLA:-DU3WRI/L@6K)1
M]JYDIHDE9P#*Y:@A<51DI VFY@S+(453/9&Z W%R(J*]!O:V72*RG>+6[$=1
M'DFM_I4=68E($SQ>$<=K(MP^G8IAEK46] YF7=J,)_=9^P*,PFKY%J^C'TH
M=A%94B@+GFB@$!(VN!2_DSJ%FFE(-EP)H/Q]E)(R=673AB@2D><<;DBBWO!9
MR/:JLK'O:1TSS4>B9(WUPF[%B(/C;Y8 Q8EQ_W;[I//'_T?^(G2AS5_O0?.O
MVQ\;[_!WTOZ]"C.^:W<#BBI@! FII_GC:%>.><6EKX]Y8;-1^BXL!$5:Y\:>
MT<G"L5'UR9YN>U1AVDGK.KZT V-B_,^?@GZ!["'/ !_=)YO9ZW94:%X6GZ\
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MB\Z7H#<PX8VCOI;4BU< :]1F5:FP7W)<0>XZ/>;5CE%$8L&N.V6'%M+<O-Z
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MUXSH+X16Z@8 T_[0R36\BIQIO<#?96HOW L%A\Z72:QH!25,1&]$I:D+JW7
M#&]@0,YY/\<@>5'4Z-S%.I6'-O-KI"(@#W)I34?F]U[@K4J5_.<W0OXZE6G5
MB=Q?"[N/R4CD\0;) ZO7'!3JP1NPU_%QAL(1F>?5RL-5/6*!2(=IG;L0RB:J
MDKMZIIWC\(VHB(VS9@IC!Z<(._H2VBY/N5.M?AL6/JWW!.TX5/$FLJ$)FSL@
M":@#WG6)&W#[I+Y'K6K,H>%LB(Z8XG,*;JBA^PM5*?Y](WZ_0<Z-.ELJ+6.J
MJV:42L-'#R\QT3,5I,[*%BF=5,I5(<E#[:9X"(QSII^J^$:&*(7*$31J1]RI
MC5BC8<JN_-/)!TU9M?::_;N%B^I&&04%]"<-^>H2F('0E,F"=>Y^9YYSR#0[
M\'O:UTG=3C;<]\,1KW3"7$I'"W7QZ9,(/[0W*RW(6X]K\FL*?,JIG$]9_LZ8
M2V7;2W!'! 4:NA'< PJ347W>'="5UEFFS:)NU\B]CY@\4YON&JFIN\:6";3D
MZZ++FCXK367,;JL=E"6TI?EQ:+5%7;:MGDCC) 9-F)(ZJ8V%1NM-SS)4E'67
MX2.E @7H?)T<3&U0M.?*&I<_<O>V&N1 ,LDR!Q/)H?A?0Q@6YNR*PXK:RN+F
MYA&B+26W1P=?*(L0,U8$4>47PR+S0"1 2?&(5$4!V*&;NV<<W.Z;DT0LHVDS
M5RWR/'T3FD$)T5H6/>$6<O><YLRX2UT9#&_QSE02WH[5XR%,")@W*IG9/K(\
M9K</"#;JJN[?2*"38$E,3/^I_+(,).13[^:X,8R+8P_9_B_%U_SFQ/KXFR)+
M;];M9DB.1>BKV3F6LH&*![GJKPC1J;!?AW1;@)R_,5/^NSY_1(@63_TZHWOW
M7ZM*:-;/G2&C\M9'\1_! O]_*3^]$[1*R-:6#R4_8 M4SI)+E*#BTTV52'I[
M:C#08C6K6JP\FNY'5H\'P2N:6;6U(8.&FQ0WNO9M:U/)M]8*;4WP49GT/FPE
M&XB^\ZA<E_S=#I+[H53:L7C!U2(,'KCPW85_3[9D]<G,#R<5BLBICN&N*%PH
M1K<G\F]P-*W0]XWV1-4O@WOL;09'8J6,#7YL45(M"<^(O%5U1]PQ8@_ULOX5
MU.D>8-*\,' /8+JB; <"R1UHS+0O!V0SOT0E@I#'X-KKDO< ?OA)[N]G$JLI
M'O2X U0[ ,76CGQ>X D&0T=_]T.BYG<Z[$<;O>=V>P_X< =M)LI$S\[]MSU(
M7O#=^7T1_.]W/5\K=U[(M=6'^J[7;_0*&:YI'(?P05^7F-CRHSWP3FG?C/-;
M>AM-R?1]+>NR+_>&^!X@](U43R^*T/),*)%0,?NVM.G$Z!Z0*7T/\ ;S_X7_
M+4X?%U=NF\*Q.S4;P9"3BLW^\#L/JA\GU'_#"U4OG=X].)^:6:[/$OVN7'=-
M.M"<]=>]_H+_RX,%__/!_H<'^^4K>?#0.EH&\3>$NI@B--O7'\H\"\I55]MH
MC=A9:5H=-)Q4%O<L?/./<Z(\YFJ(L;QP7-!ME#+2&UKT;^PZSFSVALGF;\DZ
M612N)WO@D]0=AL*$9LMLID*E\VA7!23H"L?V5QO&;8PCL1[@C2#KC)/GNAK-
MYPNJ[1M'3GOKN0F%I$D-:B\5R/:T=VX#-:[KRS*))@X8RI'V8!+Y@YQ\4T*A
M]MTD@4.Q.=7(Y-3X%7Y=3L/H_NQ.6)7X<Z0+1D+@8G(86T(^/E];2&$''?O3
M">K(OG4G6-[I*^[%IFMXJOL%L,7"TH:OESPJ-_@U:8)+D<OAB]$<2^7=F,5Y
MPO+!#3JY;E9%P[1$I(+FI%UVA*QQZY3+"P68N\:@(C#0M;/:VH8$4DP4^+6<
M^FF7(QNL9;";(+%K.UNF!HJ;(6ICQ/:E-/--<],T!/3B"4(C"E_I^U"9J E)
M3Y3\2R\@IR>>BW'0>]_@@+>/_'<$"QH7N#HN/9%N="V3X_J('U8U)31>]E@%
M7004+NK/#Y?MVF!]BRM^T?]."!6VKCE?R$-1C=@Y;>'E6!MK(WYK5,9'L-GR
MH%C?2D<RW8-/[HH(XG2'/67>=-16:DG>9B5&\;1K+>99+T?YT>#=.[\/)0[K
MX6(TIPH,Q!VO75[[6/3U.++H1G?AFX3+0%CZ^N2^819B_1#11OZ@+TR&?')W
MX5&D/,XFR<?93*R_WN.&ZF/)W]>K:3#2DK9RL.>.81+EP;\$><]BK/'FR!J:
M%0)4:VIKQH51?B/+\-_<3JLT2]J+ME[L.^>/,.?7\*UT6MMV:E$)BM7T1^?H
ME%P9++K%)8M##>.:?= KF*CMC1_]O+Z(R7;D,ZX].AO6:.,P"LX\,;#2A5CQ
MX_GS<E$%:-R!66*2T><&0SVAE-2>\]O=47Z"AO8C\"(Y:S=1CQ&YVQ:RMP9E
M4X$E5# -$9G90-XP_G!.<%);^MHLW=^10LW!WU7@>;?OVWM H),,L#O,S"S1
M&*' ^\FL[FQNW,^4Z$I)R^2#IV;BU:!BB/*1:U9IR\2/SW52@QO$+9D*=/J(
M:?2G[@J;2I#,Y0.S$!3*F!I_EIGQOB;O#O5DOK9I <*A:.[%]@R^2ID3.I]7
M"BVP=-4F>(9='HF%./2-\&Z$63/3@UU,JS3,9W/.?5TXQ$_W991JH(S8'AEI
MO#D=GC&"=9E&YH3PTPK"%>\)\<^/'E<2IBH]+)/T'+%[RK]([*.S<K%[(_QV
M/IOR_2?G5?8$[(H9F5P5!UECIQ6T0H^"K1P077#8;3=A\EC:EG/8H@WC,S/O
M6FJ*:%A+.W"RH/V(WM+>B9Q5(L)' 5394I]TV.F*P0 #BMA3FMD4VB*+[JJM
MYHCUN,6#JN'/,*(>%0OV)-1$E2%/PF.7) NO#+1KH>/GVK8*S/T4'3&./FP:
MM\8<YR--IB]:]DDS7W+B1>5$FQ?]@,1#!=Y)!7[CC3_/I\\M?7#.L:ZS$<04
MN Z9W*]DU%>^JS9)3)6FFN"@BJ!J;9RR?MN0D7L*$Y@QXOTHK=HV1&SV=^W)
M'\2]NX8G@J"H;5@@&Y7%D_5U?1-M2C,5I^VTII56,U!I*3%#1=(B#5F4-*GK
MA/\3C]S9)3,2!!PZ>?9AJ_?!Y(\7-.]SZ=]=IYUX7=7= YXO(1:VKNN2N7F<
MX[[U9W5RY*Z YB*]-&O'NJ*Q[# 5A@FQ^5?YP0(I7C;$TP6]D1!@*=YG3C=*
M5J>,8*@7LB7[C9M3DD4'%1Q\4OGJRK!%@)X2MF'Y/ODP;(U1<H)C)\W\UG__
M=]0S>1RX:KN_J3E%YS#,SOH0<T)JHOOL>Q=8@7-*C[3'#9>@:L(%A%W32*NM
MQNE(5\[228@O\[;![<OHIK[[]CW@&7H75E.MP9D[&?5A%!>Z)YE9/=9\SH3B
MFC.N(!W([Y5H7K@I'=G^*1NLWL7GW7::<[+PHX3'W^#I[NG*!)I1^Q4$S\R>
M4;KVL"IB>QD<KVFFB8U%DBE%U,0VK;Y&HSG1GZ:: Z9R.FN0,.#Z8ND9?GM&
M9F[];I.[+.P65(D02=;D?=AK,@1(]MCRFEH*WB9:1*Y=!'])6@ZV.#X_8[88
M-"DAL"06Z<G]9%Y!7;,!"9YO34N\)NS4J[KK)XB7#?=IHD>6V:!O>RVP&?9V
M J=?[!6-^T9__R-$@S=+P8_HSBK$?$Z[BBAJ%"ABTEBJC7I[EX"6^N,1UGL7
M+'&)?33'-.G,3+1W@G5UX9>XV[+:A$'_:X22?N6Z):[MQ^="_PA*F?\[R6[^
M8V<=O_)O9'[1M;S#_8](YQ^749)Z7!_I4&H)GB[27R&JL^)+&QCW]LN?W=XU
M+Y%CJ-CO3>J3<!1W2Y0_*Q>49+S0V.M:B\?K+U71J&5-(.5BU_YR50CTL>L\
MD<=N8V#V;I(\)LA=L?=;1A[O09>Z!YS1GI-6SWF\):WM7D<+JS,^R?>2M233
M6GPZBYN3B(<U"=N2*VKP:AWE/JZBW.UL1/YAY;?%T;P:H^A/^.AJXCM<DZ*\
M)5\NIN=&\& =F53&.::;WE<WMK3P4LM$97.NSW=PY90_V0!Y#XJ,?">H^1T%
M!N>Z\NKRM*U2@Q2)F-H=Q('&"49FOP8WA.[SZ!:M9##4O2KHSXX2/S-]K.XE
M[$5\SD.V:N'BG+8D0FKY2;PQ<=7& 0=.0HAIT!ZZ$F4CU; 00[2)O<>LI3W'
M8L%@&!;:0?W!+.5:(XLLV8O.U;B?DEDZKR"I@U8EJ3P3^*W/NQQ=XR$3 P$/
M"M,-%7=%_'(*F>B:\4>]-!U@3[[*TRFIC@>2;S.P7GYI-@PC,Q#75:997$;A
M+P=5#UV=#'BU8N@\9EH32OGBB;+.Z&UIZO&MNZJNJR&:!%4_N%4Y44^F"DFJ
M [E538].432AID%UAPQ+0IJ.923==OO 0[XCUI?T#<WICR+BMO-B\]520B$4
MGS@SC!V,@L<"I\ V@1J&;%'B_#8_WV=:\%LZR<YK^5R+^GT'XV?I=D/Z+&F%
MY*NN9MD4?%1C*\F=#</?4I\&'GIENS7\R(18N"_V^*$^)_26+H+NX_PXU8^O
MYK1&<!H3.O30UFQ[>G*[U#2@\C)'F!5F" Q>R'O3GS1[N#R]?>8\O3,^  \8
M5I[U"S\K\]%U5V[A5%6H!\N+6LY_(RJN=,"I7V'#\V>.<-2TZ"B2B"]$7>F9
M-Z\\Z%8I"7-WG:KP6*RU(5]"W9M26R</&QTCFCQT,%VI?**K/2.]J3<G'O^2
M5%@_U.8;BX<$.<L]P,VBF_,Y(="HY[E%SL)E_6O\XDVZF=UV61+E?+^O#UY$
MV%M-NQ[KBST<P%=P<ZL4/YK4H9[ M$%C!VKTJ02 H0B%3WO:93:ST2K&1%.A
MAN!%%B*6,@M>V@@4E8Q>A?3P+?MV;$*[D,X'GV1"2"/5!+FJ27 X&45VT$FF
M H[PRDG#-"9TMT)CNDZXTD)0V!8;SC(8A[:/^.N5OF=+,N"-RN3!_)O06%V(
MHSFFRJ@@1]Q)%@,M)SUKOAQ^7>6\LY:D5GT37)7IF8$V^)6*<8AGQAC]J-8!
M.37^-.20AC06HBJ)+5XZZM?*^\A[?&S='.='@XN(AA &8^JGI\0/"!5 .?".
MGWI:ELRWL_#OFCF,R>^S' <6?&/!J>4V"U,(O$$F$343Y?W'10(*3"M*5#)R
M:*O?IR5#']PMC5\).9*NT4U0^./W4(21DT2PR8. ;J9F_IRF6S)1-!*NX@/)
M;+:;A,?4KW(CT!4WM?1I8*^Y/%T+_:PH:IG%(H"?OT; BP8?JU;,&DG^;"V6
M=#2,%R45.^:LH0LFXWN\[<0YRO-3G0@"40PPM'#>60HQ8L&N(H,#5@9M7')[
M,@VE1%VQ%ROB"\F>R!*Z&(Z%=BMRE.%BA&X$\[QTUE02)]I9N5"8'CM9PG%/
M>^$II2EO(/CT[C8 XFF;?@]X/6APO=8^$#AA;?R8(@\%78GL8=D'+, 3P!82
MC32'B>[K"9O649YC>/C=L#N[^R;G<K\VE<&WR](VW&/<H+HYTYJZ-HDT#:0^
M@Y;>5E<VRVE--'V0%+GQ9,U#R[!\R^,JD^H&#>*G$:H;T0QA:UE<'"//5?JO
M8LW><9^&" 6Y+-+= V*0>F\*OVM4UW\8H&#N,2$FM.@KA)*#U2=9,S]'P!Q;
MP6I[6:F;=SC3.6.^!-UN;P],%M71CXFF*2-7Y-%N5&V NI/"*9AD8?"#1XA6
MX)Y&FV+\A7M+]BWA$R':D!M2N7M UG.[FS/:IND\7I5QJFH%H5?;Z 4^K8P?
M(8\.5W^:4DK'$O%<7<\%Q!F%(5&4&M[.Y.#S96.+-R?B=2)"!]9XMR5,>SYL
M=]X,[8=C^?CB:/:?XB;96Q4F-*IDFVG$8AH>A$#TBI;]Z=R[[']EOI4PT\H,
MIY7.*?VA0-1%7BK"/B;^>\[BAZ7XYXK;C)B]"-+W).\\A39_;FLE?D9"I^/W
M %[!+K_-W#OG!X[@P@NR>X  Z6GN/T'_ J+]Y3:=)/T3& 44*1%TO=UZ<*;N
M5^M7OY1!:G8/L&GG!52+:]YPW=A\'[^PNY@[_8-EY+_U=;)#]'+=LFJ;ON]S
MIZ5_20?0)*YZ@W$/R(S^B?LMQ\_/$]2%JDF_;]T#,OX)^R?LOPQ,\1(=5J(T
M;4(C:'SG8K"WM-^P^0Z'NN0>\'O "P[?S?DZ/S "5_XQX'/_6P%H-'_.7HT_
MYC,LW"[%>__[V)-\;,7?2Y[D3/3MF=_(!T9EM;O?RZ)/Z#U@5/)VZ^'Z?P<,
MU1]U=-(9,J=&4Y8R1/^+K*?_V>O8-K]HK,QGV^?L1LH88FF%W'].@%\T2C_^
M%,2?$V ,:8 VZ[<DHO^<)@#=?Z+^JZ-^*7R)JK\'LI1UU,1-[_;N.[1_J7&^
MO?HR]N"O2,M_^H_^Z3_Z&U]M@32[4L6VB9B!AC5*Y8_BPOB//C;W #_-6POL
M<=M?'#3-B;X3.!O+$L?QJF/,?T1&Y,J&FL3TQ.5R[V1_?)OW=PF<D;9O/%!!
MM&Q1)7CF)WE>*60Q$J<2%9XT[Y]]9I05)Y;X2P+*/W(PF!+,HH?X]^;9OJO]
M*4>MZ^0P>N=R$4*ZR#OK7#J((YV>E"DJ+T::JY$\EPG#O^$&-YEW#QZ9 ];#
M\I8NPB/VOJR"IPO- M.\D+ )YD5.V$&T^+C^V<&2RRHJ>+_[[^VJIRM_07UX
M(VS3[@:>+9@0D1?P!U/G,?]]S,??3*</M#._HR_4Z7^;4+]_9<Q9?IX ]</\
MW]$7O\MJ_\HY^L\&7_TV)"!_D,A9/&S]3Y9'0/G[=*B_W2:5O+J+C1P<,!5%
M_>!,A8Z.VO1U\99P_L]?)F$J/C^$A;:V$L=#EN@FL;.[4_CV _%_E5GV(,NE
MY+GVD 3K#+&3DI\MT^VQ4(;:GQ6RX2-&+%>AZ@E&9W)GV\O; \_JK.\!OR&D
M<^'W '[%32W54>(Z!OH(;#63C9;FKC;N3*\D__[ZGD+"D"?0FGM Y6KAH/P6
M=*83\^C*?='B8FE_C?2D[\XY:^[XY]K+]AT^;%.Y(^=TT>1W6**XOR![Y[O^
MB^-ZX:Z[UV]T_9+$[2**]#OIH@_=CW;2V]-?]_VKG<$<-/GVQ^ ]P$<U7GO*
MA%LV;.8&T\*#D\-.VZ?C1[;HKU;4'&L";X4RF"Y6?C9Z];/1R0YT.!>=TQ).
M1D8.EU^.)I(E_CJWQ&EL'-D;KSMU,O\U@THE0YQ)#*2('YSPW9209.I'8_MI
MUYWSGY(Q[*15Q.PG?%C&RFQY?AK-TE7X4RMX-*5EI9A=^Z^1QLJR-[*O;I<^
MW)7+5O^;:Y(7253?VP'7$,:>T3\?;OPWQB52G!2AE;5Q^VAGLIE0Z$\Q2_X)
MFN; \K,T\DL_0B]5V?NW+V-2^4=^V)W=%\%_YSVGT@7$]/J4WNBBPOET/)EN
MO=MO(.-!O9K%.BSQXZD:G1,1A%(+?W ))ORB6&T+/ U/^ \0&_[CRBCV>$O?
M V(>X).]/BMR)GUPY;LI7@U-&JH;Q3.SV8Q7N97!/_J.WR-<PHO^4>Q:(''T
M8OIS>@QGMR\RQ#HCNS5*FV[*4S==C9<S8T6>=VQ[Z"3U7=2[G\O":KG.]*T7
M26QI0=8%9>(\YE/;QC+2E\(7=OC;&';F<]S?TXM7LMA91H_-^BG>[:Y+V4LV
M%II<[C%:TN47% RU\3;5-T16.%MF9YK-8<EU,GH9Y3<<2S381U$<#4^2(2<9
MWG'8=2^2)&O70[SX&89+O\>N?7L5=1Z?XYZN)J_N+&]%';<^'F%&%O/NG(.&
MLB+6IE\&9DZSW.JF%M##5=.=JRMWD*[#W+F&SP^OTADDOZ@>I)>@,HP+*8%G
M7@G=2?Y0<CN1/.78QBIIE0Q13':*FO9V(XE?P6>/KJZ+"^W,?G'9OT=3K\_5
MQ)N'HU,0RYBUZ3.=&,(15D3.<.QP^RWDI82F6[G%K>@,9:UA-#=Z/+Q<D]Y9
M@RS3<^"&S5SG6 SJ,U-7-;%XMVGA1&0>4]BJ"KL%,7R'-C1.D->WA"XSS 9O
M7FLX9[YN;YHFJQFS8<AKE36Q)$]?7R5FTTJ32\N]%8V^47XM?9DQ^-S$+ C)
M1GC2&\%:$5ZQ$W.UN&)Q9KD1DZWZTC"&;1H:J:A<Y??24N1&QL&-AYOB'C"5
M5KI<^9WZTO@N)6M7_MCN-CJ-Z69?;6_]Y"V74NMU^C4\0E4ZC8^/3J(52HL>
M%Q)# V6*6+P'J-P\R2Z4+IQG^4H?P=K3V <$W@,"IT;2D>H:'I)]Y#,&(VS0
MN].R0NMN?H@@1K#J?8;&^ON+'< Z227RS;D2]X"5ASI6Y86]1B=##[Z\F$Y6
M.)Z'\WZL;H'EUS928>16#:9UCY6OQJ_(AL7JEC%,NI7Z4H@KAO(^4'I@.2)U
MV)&;Q 4)R'3=:%=-:X9S<%P%UE;$\LE4UY2]:3+<U6_(UQOU*NP5&"Y%#'2F
M9!55/-E<ORI^\M-ND+2%;(M^SE<N?5M4Z &:7&\17]7B%RH5-Z9'BBAN G+W
M[]%&^/*W@J\1Q)*BF0/X2U;#9*@^(+H>T/.K&X57C^G6'9H+'.F,5P#1-VB8
M#AL/;MHK:/*)V><55%LR+EAO3=_*K@RS2LVPUGD\=EO3E"Z[RC@;I41\[3Y_
M7H;.2CV"@FHO[^!9;;?_ M"^>,,\ND%GIPH_]&L8R<K6GI/U#"W03(Y"5[!L
MW)-)3#=+"EIE*S'@2%P/F-4#2$6.2#\LGK\5P; ZM:S:/F0_+J(MZ:3WH4N!
MD4^1KCB3(L(>RJ])=S'$(NIN:1ZK>DM.#<668@7)K#GSL'.+6Z'D+21>IT.I
M(N=4)D>R/ I;$_L?ESERD:-4NAP_>S]-.6$TL:@]+JR$Y]T+*[I*Q2$-O1:5
MR-8NSR./NIVR>RZ*M83IPD9+EU@OTD2,)L^HA;@@Y3\<]"VX"ULUFX0H%RQN
MCQH[.D'(;15HY9UZC.7;;UY$QALLH.* V?J06XW=RW_VJ,/6E:W]V5'J<-A0
MB[/Y'O L<<+RYWP32F+;K.?NSY9@4G(A;UUBJQ]K,4$DWF@M:0D$C=C']CGJ
MI)>ZC\CJ:=?M<\G'*V5@L='+L2(9W0,,W4ON 5VN:9FY=N8/YW(?&L;'I[GY
MOR3%7)1^,W0CQ;,;D<9CW#BYF2<W.4VJ<16=FUJ>AG">)Z'D+SZK5&S-!((T
MD_ (W)1CPB?ACTKHGQ_+2K$\7I2UFX,+GF]-L=4'J2@N*C:M("1#.2Q:0,6Z
M!6$.Y#"9YU_PS(2LSO3LNHVE&SY0E"KZO%:Q4;OMY!BV(/*6F?ZQN7I27,Y"
MU8V/<XB,,ZOT0Z!DW>QBRQR9NM=G-ANT&A[4'CRG :.82#(.\M!RT@/S]H%W
M',M87]C? S"QT;)> ?B/T)-W]5SCL_;"Y9>\!G3OU#_%U5@@7IQRMRJRPSE8
M\J^^%VH-P<I2I3ZNE^;4',\?%DN"BBTQ9^@#UN,D\ 03HYUCN+HF3_U)%X^A
M%=XR+\OSPT*CZWQ*7@/.YNEDJ4R&5!/4\K)4[0R.'2VY,'000([]R1 2&2(,
M)4M?MKA-5> +1?EXA42X8YB6DZ[)?H7?5S]GZ]?U<:9S=7(SC[9U+@EPPR$V
M1HN'2@VU$9(?H30\/9:.X@R2^Y0+X]NOUTR4Y=^)4 N\Z^:MYO7_2\/^Q7*L
M ON5: <H_2LH0.TO*^_W/B0*2XHY^XR2]-NJ^Z,23M:O!)*_UW$K7Q\W1$!^
M"!G@I-F,)J5+D]EZ:E;"@]V;^$=)Q+(64864=<:E6Q6L9:UH>WV.3KMQ"0Y2
MC-I\+F/7FKU<2P2%CDT/4EU>1"4*SJZ)='W\9-04R;IY]_*0L!]UN/Y9KF(A
M/VPV%W1'/\E!^7U_?S#'O.!IZ9KN_ +JC[Q//+SI[6C\FB6@5PLO-+;X'2@=
M)5B&62][>.O;5\Q@SCB<_:^P+/OFRP]U-S_V Q5?8GT+-<"[![A/1W^EGI8=
MG#7A29!>JI1Q!,OWI2BH*$=>\C9F'YM%NUA?:K8C'.26\=_*>1A/;E39WNJ5
M]1X#ML.=P@V8(U/V]8OU27WN 11:]P"XZ@]:&H3\ L&TPC/M<P$HJPXY5;&2
MO'W6RQ9YOSQ"+QM&FV3,XF^H<-L:>HUP,B+:SU0GE63 %)=[0!B]>2H2I"5(
MTPO ;&59;GN-JR,O3M',)4AT5:L\;4M>,T6Q9/^A@8Q(,U<3;,5:&-SV1IRB
MK#K%#"6OY\OYM6:>E3X'[*Q!/94QRTT4BR)D6R'/]I D;[S8 D)5W>#CFL3I
M.-]_::PR<][M/M)\S 1,.J"Q?H1 ]/F*?'G9B6B5E#E&2U\1LU@.=FSD>26F
M1CK2TKM27H:3#/7F/*97+N96QWN80=Y4-E:-Z?UIW).DV=*);BMF 9MUX#V:
MFHLQ>-5.,?S0AG)R_Q M"X\P:5IL$-T:;IKKUX<S>-=8>5+&1'05-R<Q;A;N
MNUNL%CKNL;F8PS=+)CV7M)\B^.@8LG_;X$J0BU_Q!NW.7#B(F/:IMW2E>ZU>
M)ERL^8;\958J^ "OJ(WDRFA+TJ-XGK&?$6-*\N;+M'FP7?J73,K)\L/]39/X
M1\X.R8?[0 ["-M4,&>_J#4]" O0(#A 3)F=LV9 Y#Y])#Y*G.X^2C[@[Q70Y
M3N7JH%>X6JPF=^<;U4G-5LF[8J$%[ PM1,^,!Y>+UXP+EK(V\?^W Z+<SY7>
M>JV15NOU"))#_:)0>RO:A2]A<R:'8_-X,*L0P?:MZ#W@M6QTOKW@B^/@C%S+
M^#G=7N?1S:8A^R1B'Y"6Q'%KA:&*C3S=+/%T4.FB51B9WK:3UMX6!=G&;2F3
M\G&-J+?UV2#79('R*3VYP^YTLM8QD9L^1G-[%6:V6M_IR^*2.^2ZAIIQRDGB
M1W+=&9]0ZWE7$A,KQG@X)U6_AR-''@3ML5CQ$G='L!+AYQM"0*)=F;31[ZK!
MZS:(-9F!DI>K/-O:R20"1^O]& O ^1AW$M.FA[5M9(KH%QP1Q_YO7DE\>3#W
MMECB1%,,&BD,H4MC<9_02J Q>*Z_+W#)=#6UX-6]*5KO+SFQ%J<M<K>'$:-H
M55AX=0^0>BF.F^C5_'-J1;MVFWB+-D=S<FG9,7G;13A%1$U2+VI8*.0JV<AL
MI+N?7,SG+EYY[B >36L:?A#PA!L8>Z%E6R6_9#8US*3[ .?7-J_<SI6J#E:L
MTZU,*EAA#1!2U?,+=IYU;B6AIGS=-OZ)")PJ3N&E!76TU6@=KQ5W\F6M:6^:
M>'SQJI^HRK2^N.?06#?<O?Y4LSY O)ZQX7-E2N?K")>-A/<(**V+FE[JCIJZ
M/.=4V9YQ4+Z'%FJ2+V30?5 3BGN!H,C%BEMW.U3U!_#? WAEN%S%?PZH9CX9
M.G#X5VA2E@/(R;)X?G[]8R*E+^"BHDY_KG*08HAVM205&8MCAHSR4H/U5GZ%
MXF@]P>V%[<2A3;;:2GPG"65(5WV-/)8$9\2'/@4ICLCC9W%ZO%VE=,4I)VB2
M,IUC7%<@?8CT,RVFCOBHS$0KFLZA 77R$F#V-M=E]?:%ROR K]9DO0 H98S?
M ZW9UR9N>!7_NVY5IYHO9SO;CVAY"%]>VCMRTKVTCJ/SN.U%)IS/#];C6I3Q
M&(%5&=).>?5<E=XN_+Q=:3:9D0)K1<W129WYBJ8KY3H;VT;)G9HQV3M[$LB[
MNBT$"Q4AQT].5K;-3"P>1M,\)X4U^U!UI_G6"L7;$ _4.]STR8 =(Y-"E=+C
MIR4H#J/.Z0"'0L$5TQSD=O3,?CI (6(KMW%)=A+\%G>3=5W6;]$C=;=V/^<!
M[JV5P>-[0%]VH1^<5_^084_(+RLY92$((:4\B\)&3:%H9^6#I2'Y[I=#)??7
M$5^)\:^_GQ\V9N%<)9W 5>I@[!LLNO/M2>0[6"O-5NO>ALL4QX\Q1NWHA'UL
M9;OZ>X#S4R+PR9&2^&BH2@/DV#75"0NN\Z$]\&A<(H5,8+<"VEY?57]Z2*EE
M_(@B'6+OND@S?<OE!3)=X7-/&BL29C>I?35FEG/\7!"RL@O$20TJLI<)Z'S(
M2]" LUA@944G?SL"1<>[\MQ0QN(M;VYV5E+DB#[&&+U@IX^0D.Y 1J2NC*):
M)MT1&EO:$+V2&! K:K2E>Z34$G?YA=-)ICM]R*7_HIN[6X^=9D3#(196=]JY
MS" H=6ZQ)RC^1/H!SP94UBNH =;=/07C?7O@ 47UA&>ZU]Y)'V3< W[:N1E"
M70U.]1DYEN--4@>F&&WH2FHJZXU>"L!K,B?=8_T0O[QA._/B3OHA;C4JRHRC
MA7!W)4SI'S<GBJWJ\%NJ J"[=&[P8[")\LV:0?II*2DJW"Y0V>F3W*I0)-I\
M&AK_XI23*T>+8KEHKJ6*#)P&M7' MHSTB3MB5&G"WXKWD\1Y@:D:/R9;M\T5
M%+:X*9(RC,*CW&$(:SH,OI;(8 JY@UTXL _:7SFV1!!(2\;M.3I=%)/5A&M4
M99[(2E7$5I#QZ;!,$@#+-7H&3((WULEB^U#*)^-UT3[^W#9QU>X!%?> ,=66
MG[L@&67Z/4 O+DI\^/U%97+ZT,$A!^B%H$5V,S2*AN(&W)M4HG35_"YSM2]<
M[6,^E>V8@I.N75>XH<>*#<K#O8\!WH/P<KY>G1>1A2'6>75!-INGN&P2S+WY
M'$^W?7,2M2GWQ_8J^=6SMR\9;-R*A;'Z[/NZUC1*A@F_4&H^86T.<.TM]SBY
M,NNQ>PSI'OA^R2H9SQ=1[PM)12MW;D-Z'R]X6)?RZ%6??H(C5=6/4@-,OJ9;
MX^5=RS0:"- YUK.8"CQ1/\G Q! YW+)-_MH$>E8![,Q\!5L;>P,J=3^@=/F>
M[]+/$;3L&M>K/GDV3L8NJ%OV.1/Y23*]WOX8MC2=DPN?1XMZ-K#($D+]DB0P
M7C&K"\H!@8YR9J.(S72^ZJA _H+ +L@OTI=U;W,L0.E9?:UVQSE!J#A=[D)9
MAVG)\CDR1WSAU/PF)XO<HXP))*@ (A[)6"&FTG"5?;Y5:+KS\JR<=X.?J<C=
M\ZH)5JZQJ/[(W>*":UU/P)S"S ;9Q?Y77O#_ML(.1 =_%G;-/*C.=N5^5%S^
MXG<VZ!"_TTKP!\+G9ITD1%&?X2.B2*KXD8G4;@(T*V0B_I\BEO"ORBLV.#EM
M3A[U(U="'++>0^F:^ZT])^I.-W9BDC<9V=+.-AJZQFB[[=83>9 ^<%S$%2O2
M!EK HD4W)TTCXXLY/4Q<XP<S8MF,89G.-U7OF#GE/1UG2X!]-OO+Z/&75]C]
M!KNX&FXE<7-S<86D="8:*=XC!6\5V%?J3M]68++'.9H+_,APR32TULBHU=-^
MS'DQW.C"O:O'V%SJDRP7+ 8)Q7W$[Z7FB5-ARPZ:U9]^._:Q 3Q0P%AN10)S
MGHC<!]V&1SX5*7R;U!9$<_ZQ&-I9-%OU]6/C-^/%:@X;\IE8_A<;P';:W0GL
M62V1!H2QK,-#^C@>X8^(VI$,BK+3;;;;L::Y5R13G9*XLL\UXY*AN2UVSG"-
MUA<[RHE:^IY+YG>F64CN=5]W37\:TS0W98IK=!.) 46F/$_:W!)U8/N)TDB$
M ?KIW_Q>I=<!"9,&(Y $AITV9T4<KA>0"M6OT]<;-[*JBD_X!D1$(N(_T("X
M]#/*SV2+E9836>G6+#LSK>B*]T=TJQWW=/T/GB<ZH98LHQ$21ZIEZ</V"UCD
MO3"E>(LY$HDB"]R=1L4)-WM\"[*RMY(JW]?JB=4._-#ND7>Y05%6^30'V2MO
M&MXOD2[JID/L(>[&ZFZX&T\G!L@!/TK<UZ25>)E-!9Y6&.A/3,B/Y6,TL]8-
M?"%=OL!660).[=N\29D3OZ#_5BW$*9@P_4PM1( *7N'O7OCL9%*/E]CY,NDB
M[]FZ&E6!E;TP("JX:4%351U2_TF8*-,,QA65RKZ@V86+P]9K]Y@6)@5XYVF.
M_<D^/DV&3M/O2T-8!'!C%GC,*T.76@OGH#Z7LCZ7>ALQD)_0X]2M6+P$4EK$
MK@6/=7P,H,^6IPI,RZ(#Z;F-@5XADYAD+12W20'BQ]0T+ID7)#>$7SOWXY/D
MU-3)Z\AK$!9MJF%^=17LC/VD+O"L;;AL?N:A:\EA[^3XN5G"9$.HE_.\SFP&
MA^56^_')/>!@VO2O;Q-??MI@HI,MDD>SS3+M[CZ6?QR=^QBN)O^?#0M^U77]
M?/?:;S;.-/2T'[^<F'%H^UH/DFV_@86BY5;J'#&02_^.)&^B&1*VKKG!$PG\
M&F>E\Z,@KX$V_/'' 8S^SU<JBE=R[^&"L.:W$@9,1)_@<G'DX4W$VCYJ:ZK%
MIRQ>W ?O=]-LF]V_;7N6Z%#S!XN F"2.7/;KZZ %I444ZU\?8B1*?1$ U>0$
M429^G AW,\=U^[8@S"_-6)YGI8SP*,(8*^9Y"-U52^+3@GD\COL8;,^;E@96
MD#_@[I T[F\1+Q3,/990 QO0FC1(2 I$.KO>H4Y60*28.!84^ [)WF"K52!9
M]R][:?-+(6:3%'EB*$=FL.M@/5$8>>)F6\_?IXV/BAM3PS1M]49X[P$=R?UE
MG-G9.RPSM:]%\&4=Y&#>Z![FE;T_M?EG_-\7WJ!(K.JU8O.?0,(OE%M'N)2/
M?&[<HV\,I"95AE,?,IM2D;4*'G[%=4/4I_L)G+ GY25_5QS]HXZY%_6GI-KE
M9P=V2?< F199OB_9<H&O8E4L=83"]BM7?_Y3#[RQH#B,%Q$!WK'(S4!T7CBT
MCA@K'I4EZ=/XO)\OI7MC0(_F4<QA@-J6N\+ I8:+$FY)>1+H.#7V+,>2\]G+
M]DM1U(FM#;=&+VY$+]F*T-.%'6B73D;0B<Z\1/HCUOAN9QU=7%>$MX.![O/P
MH!O8@XBI 1H>SC*.QQGCZYD"-;AWG-6!&87] UFBL0' 1QV>W3^F\M)Z*HFG
M6EXT&3^5M%J<;&&R*08I[3C*OAW$W$?A)9A_A(+\N=1IG-RDF(IRS1'1&RA4
MY\(GFV*NE=L@__'I[K#:I#>NKXO;I'.D!!]/GE*%MJP)RKY%L:I%@PS]<EWE
MPT7MJR0&LUUEZ36M65TD,@>!75F)H[(T@S [%[-&36#*U\>/8@/T!+!XZE$2
M-'JY2J\,SYDP9ZU*[8OJQ]E-GZYMY(ZWT% FKWBU:E>H3[L'&@+6C#DFE279
M("%[JUZ?#BJ7"R=OI0U+GDWA3.&C8 R:3#$ .R[9K(00!.([VGJL06ZF5*\U
M#<11Y!\5XC@1*$2O $%3\<K3J] &4D^.B(@I>=&.AEQM'UFQ2<P>;5R0K8J3
M7B*64_.\_@AG=>?,%>8*.L;LKB9N/T.7-AL1Z2*IG<P!=4Y\O%<B'O6> V]T
M  <5/'^*O5R!3YK"9[CIV3 0WD+!6?0:"FD&^J@P9U<\Y7XO4%J:D\5'-2NI
M&MYPY%OLXH?4TUPBZ5WU*:<$N]M5*IS("LQ<PHS$^W/ _^X5_M%T\CR5@]H.
MDZ86RBK\79XBV=_EF8O% 618FBDGS#ZV)-:?EV!_JV0SL4RQ)NC $7$8N-[:
M$G4C"P7R=?.P,H]80ETC5U(8IPXYK@H#783Q\2LJP+HCTZ2UD0>OM]ADQ;$I
M_H66ZA^48J(OO,+P2+WQN 67>6;@Z*'C-X=)S<IQ]6<GM;P)DU.IZP:8MS1>
M?DCE"T'-PSQ?7(3[OI0K/KGRW)4]RAAR>C?HP#VO%N44H!\@KEGGW9)W\_3T
M-%/]Z+03?G'I^<DSZ%-,-VN-_VHE96G_YUU?E&/NY@F;O+;:3\D6R_J:]6@@
MN$4NXN<[ZZ#.R^S%MEEYX:7=W!#,0+FIH&8/:_GR<G>[VP%Z$5NFX[Y_+L7>
M')XB%AA-CP::W<I6JQU'4_-(*CO=K<39Y=+1G2Y>]KI:R)DIDSER."_S0[H5
MC#IY=N M#*(=6<,FK(_5KQ4G@0T,OKO@LNR?/\DB\.;SGQZART!!:#9J/HZ<
MBZ*K/?*?EUZ>TSHG)"/^2DDXI/P)+BE.Q3F5LBK#DLQ*N\!= _%X#SG%%WY#
M!GBES[;*4G&5<[!HT<+G\30T3O3]YGFE?4ZH8N(\+>P"#.=>>&4PN0:[&[K&
M7FB)Z0@R[R5'.9T,T&N&+RE/\PMY.3?7%#7B_0 M4!>4 $WDBIHHW*I[MTFH
MVE*[JX^FULLL/K$E]A*7$([B&(@[;_%3N'$*12!M-%O1.-'M&9"7@S+-E^U0
M] UV8:"T,GT9?S'7O<;WZ#)G5<S,?"KC,BJ.QH%8V#'*?S]:_F# 3_J#M0F@
M^:<#\1%3E]#)X\9K3=QO-G9BU3 J\/4!@L=W;-,ZX)-9*X$4S(3F;;#J),&@
M(-XX?C@QZWR<HP*BL5]G:, ^/BZ.=D$P=26#8*=7H3GX72>JZN<*\Z]IUUM,
MG-'EV1"4(15+=PW]J8592U=>U\-J1.^3>T!KE3'[W#"9XB2IST*>*O,J(YM(
MW-SG3^2(N/EOWN8EV[QY2L(%\\+\O:_IC=,,B&CT'DEKX+V5$D;>H:L/[X3R
M8Y;%6HZ154H\[RMUP\%)MBAUL(VCC5%CWA)72=.H9DQ(<]L1+^Q GS$25/,1
M@M*%704BS]$'/^&?N;H'?$0YXU 71\D%.&,C=0?ES]'IOHO#YD$*D4D9&-F(
M#V'W4-#LN7Z[8$'G95O2@&/9)I#[.&WJ**D$6A#RW&]0*H$\2V?.'28U9)L=
M$_'2B@[$!^(PK0]ZJ\'S1E)5-NVXBEK'NZ_O6*,1RIC2;6]+@61H<,CA<0^X
M^&EGA3 QM(A'#CH$T ;=Y$=Z0H:#RK<CYK_$I8PH56U93N@ Y]^]3L)V#SF*
M[58SRRF3V^9I7AJ3Y2NJ9##.Q$4KXP4O>UM05ATK9)7AS<R)XD<N59&##]_[
MTUD$*O44!>04K:0[@9#6* E3DK1&*;0<5/&UYXL[!CB9%2.<X2"MLGQ@$\4;
M;6/^0F)Y\KNGXTP5^@<6E*<F?.F7@4XZ]=<XB99,J7;&J'8_UO5!(E$@[]>?
MEWJ+.ZX0/2_X)"?V]SLPRC8!GRZ*6N0+!YD"&9CV[P'PN1[.;T[3S<WI?%X0
M]<8@$Q3'1VC!"7,B8QY/.%B,"1VZ53+*9/-=;T>YCY32NW@G=B[!KN0B',BU
M3-@"A;<)-.U+=NMZ^^61Y7'6]1_?JC@%X>7AX(3;VR)!GT53' ^C>5;3,I!7
M>'0'W645WHJUQ"NE4><R U SV(9=+S+?CC':XA "=\T2H;0N0OE:C6/LZ4UR
M#3@OI3:O4CWR CJOQ<L&Z0F\,?I:\35CQ?)QN$4<$#T&D=_'\*(]TSN$3J@M
ME\Y'ZC?K@S>$&"VF)F[*:'X)4P//6&M5.4A]B]:C=0ZW__ 4\Z_Y\Z]B,.CB
MC]'R*RPNCQ5!((8?99$!J&2))&MP;7'VO?XXZ/SI"RD0"7=[0ZT/Y:K\1SPI
MF,(#4IH1[M)%RJ/S\XSUBN+\4EER<MQ("=GWFI_'-?=)186,,@[.^9>4ICF6
M,"UW"UZ@'?0O?+1<Z]!%:Z4=:5Z>2[=# 6KI=$WPLAB]] 0?;N6/SO@.7#;S
M'W9!Y7^,?MRS,83$;BHR.3[HZRAND5S>;1Y&5LQ$<.*ZF@_-1DE_66G>H5:U
M(,8Z\(@<J5R1MY.69W &E4K+>$_T/5"17-5CZKPA+!?J?(ZT)D_T59.<>7=4
M9\<B>V2G_[$E0G=X/K]4.WV?$V1OK^U>@=N1#*T/PX#9LLL6J-KO7T0]_)9V
MYDE#HZU5+'*B(G>:H0]7.SH,?U)L;LQPRX6J!\,8N'-)+Q&O= _1KYZ,2G6P
ML:TI8N8F3";MSI(Y!],FRCJ_&6_70\/MT3'=WP2S2^_O9TKE+&RP1N&47R&^
M[ER*U($1R$GBL=+J^[_TM,5,<5[+I:&-U;I&$E2@\2N/17U.MPJ0Q%'W.CR0
ML9SQK04E[@M:9&(?.IA%MOQGYWC/3%"!>T 7+^4GJ#<4:7TR%O59/(!TNLZ;
M8WFW[TWKI-V#&[&=&Z6H=Z^/]8:Q>"Y$U,J;6Z.HOJ2YK$? @W<65EY$-H?H
M-)6[IUWW[/9%=S9H5I\OICM<P]7%&4'-=1Q/<@=2-]L(88=VMZHNY?+F%(&.
M[T--2+)DSFBI<U2:B5[GE/W<AJ4-_[=%UXSL+!W?+@GK4ZR6$ZS,J7BUYN?&
M)(WF>]G^Z0 (+[8<LW*-?#SPE"P ?'24&O!E-5\%P67F"O_ZPQ@M=_*(#Q]5
MLZI194Z+".4@?[+<A$61,4,H)<"?I&G83;1QS(5^CY)Y5E69*K10]50L0N!9
M95V7JE8W01U$X]!X<UM^S/;5Q)H+J(*P3TZ3U[O;$_4E=X6;9D/0K'Q^1)'D
M(OUL42_8'/6I/TO4;+X?UM#W>X!$>&;+-#NS2Y%BVB?Z9EU8OJ<+F:7L$?E4
M!6/EWDJ8C0G*!]0?2)3Q#,-)Z2X/ZF);;M^# ]WCE-+Y?UJ*<B1O,TSGR70]
MS<%+,^H7OH.Q.I?SHPC1K*QT59E#G?87N+.OW5??<3UDZRNVA:0W?[?.8V'=
MOQF2U!D@>1LK;%#;([R;]J3%%>E$R68;O)&IGY&_ESBU]T->@\IE-)<6!/2=
M2SQ@!14>/8GFAX+U$^F(3%XJ>@Z,L=-%^BFC#8B]7TN[X'O^U'E7W1_I@9IQ
MOH,Y3X)]HTM@0$M:[0DO,YZD3F5]4AA.*7KWQ_:J"A3_=PH.P$3]ZQF]V<%'
MS@[@JY)72J7X@A&7N\(CZ>"=" ^&X<.@;UK?3=_-7*OQ,H5:9]>\U)>I/RE4
M=QJVM$B"<];#Q!U+ -:4:+XZ:7JD"FDB)]I=0YYQD"G:NF0.GIU*Y_&1XDEO
MR)M<2,:0O)V2GJB8FQAM.&\0U55(.9\*P%V]D=0>+GS!9T<NNE:8Q,O(7<A1
MQX2;,%X<70#C+M9*$1<7M\CH.3I)G/.$&$=/^JT]*_2#9HV4&0!<YOBC=F]+
M"T!\;N(202B5"X^=\T%:!.*Q.2J#8ZOY.CWBSH=7<4>5[79?-CD.^$7-) WH
M5T_+!J.KA\MU7YBI5)=9*<O:]%<LREJ8QIJX3V6XHTK*!/NP#FQ?CMH01>Y\
MS: W,<3&R03#@8=CM(:FE B0IH^"70>)3(;2W#V@^#1XQ*F'MB?3^Y! 7Z[=
M_DOIU2EP7!N(^+H-0I%L=%:.2!L=.^NW>1RO^X'*E0RP&7$L=OPRO5@5*CMZ
M/::434UKOW?XPV=C^-]:_M/<I)>AGAG<T<NUKHF^1]>P/V(ZKSM[&?\# :$/
M_G$4)8\HT_C<=2P_D5NP#GD^T&UK6/$A.)3+7(2K!$M7V9?T"M"V=_$5YU9#
MZL+ Y8,)CNC6ZGJR7Q$61]8V6,]>?(EXQ<HT!)+JMI@-W*2<-QX;/WJ\S$],
M5--_$D:49#S'D>=ML'R>/, +:8SGGHN?;KD@;"J_12[0$2>C;FJ,HS3<UG.[
M?7,MMTCX;KHZ;)JAYWT[R]M/.96N<E2,:KGCQ&H-S!W6<-:^4I2*E<W/))!4
MFY5RE!.'%VV%C^.XQ%7[*YX,^"BJ':F*U; '+TKS#V6U?/B&,G7T<QD*)@+.
MY?MW%N7YL;C7GP@,$X6]3=1 5,\N[?*Z)H$OX0Y?RK\P>DY8<RPPJ9%K+7;S
M$!&'Y'OX9I=M-PAR-]XA7DE;$H'6O\8FZT9<%(J76/:O/N=I$4+JLD\PIC?#
M!"M:^8Z*^+05%AKL0O63YNPJC3Y&FW-TN8>H0R;Y;3X+1,(&\27Z17MU0B3K
M%#'=>S9LI!]7EXEB-+S&4-[UI*B//7XDR;E$*X<7^N6+OB<*&58&%.R4D.N;
M+,"656L_I[#X;%^+0*![/@V"D"V;6Y"(OLO'"B"M+M^\!T2+WJU[C ;< ]9L
MX?> W<JS(C#4K#8Q'\NUQKU0%,P9>\Z-C0W&5!3A4V]^H=&K)G+!Q3*26RRJ
M;_B-&&U"I6W2I,6 5TA0Z:U#(K+#!H1?  "[=?(SM^ZV&?K\M/<=;?[CBEB,
M4BJSZ8@#%Q^)%VP*22N6TT0TB.%=1./A4_=%8A&/G$D7:K=/3Y,+0)73Y:^;
M8168*Q2Q8M;O#)>P.V[YQ\^V"YKC9+E3)PBEB6G$&?^?]MX"+,XF610>0A(2
M$D*".TD@N 1W"\&#R\!@"00=W)T$@EN X!9<9P@RN+L-!!C<@KN[#1?R97?O
M.??L?\Z>W?_LM_=^\SSU/M/=5=U=]7;WV]5=W06TAG>/4_JN@H+Q9AXOQL\M
M4)+)D/8X0??:6XCDLI^%=IT13MK? _<RLOO;"_D7WBY0XP@(_<[-O0FTQQ#$
MP&X_>S7ZU)<O[MN*-V 72).%%+=*3*N!.I:?#2=DSF^.A(LD)\")/&!9:ZT^
M/@M XKN:[U9U0&?#L=.L\;+FAA6^+SN>/<'7U5<V.4L*WX5D'^&P-5OR?Y7.
MP@H*3#%*U9E1'J;2^];1G*,D9D.&/6)Y*/38U*%<R3?P]IV[O+;:=E> W4WF
M<[]38,H)-E(<_M[S6WUO%OV48:2Y'+7,/(;TLO3W$'CZ1DR/:B\?4?77J6[7
MC%;^S2KQ-3#Y'.9%$!JRFGH?0O[@"M!Q%YUQZY;EN&9'YVZ8O\6&@9_,8$)7
M;05QA!XK#FH?+FFP!]V@Q68\\M!R-NG#<YK=Q?-XV-SV U)KK*5I\="])Y\H
MPCQ@0=E.V1K]EK.#]N?J\Q)OPR6#U8N.\T#MKRC'4VI<2'$0UL_1=/PR>8MY
M']%M\FODSDQ=^N[:G3QUSU]J3WFIGY-S03VG><H,+:T%R7,N33T,H2&X;310
M!5=6+!]D>)\\>Y1# +#G:%@ALN\)7ZO:Z/P&QQ9/'R6C5S4BE7.F)J1GM<T_
M"6J)KT40<0R,-9J=$R9QW=U6<^.;(U6:T4B1&%[89Z*077]*@)'\07%G)M8R
MX+RUS9,N$WH%Z)3P+]0.2%0>V**D&E"N6XIJ\6!$;%N >@_-GH;4B47S;^%L
MHSF%'NUI'&Q*QEG,,;@UO+R'-E E %;UEAPTJ(S[,,ZML[P#U6R(UVZ,GU>K
MD@VC?ZF([.17FF9:"N%@CZ0]:6_EW<P 8FEH=AJ1%C5&"-^+F02:I&K+N&8T
M7K\2"6&I"_K$DZ0KP//,]G-8]6S8*6#\6LW@0*HD56+?FU(Q*=$+I"F -_U'
M7J3_0;8T_QWX::*@A+BY=N\K^L'?N6WS;ZZ)_7MK]@\$E,)CXE55NHF?=XK^
M_$PMV_]VA7\>1[_6:H M2WBBEX2(PA5 3^P*(*"Y5YC48G"XK*84V%^WG"F/
M+?=2*M&C/+TQ?XQ=B68J[,L9T6Z(D6CE@,4TS^,---_VNW4QR)8@I$OYHLHV
M/T7V#)0)1RCU>:U95AG;K5,#XL:#RN:03 DL:%*&6WT@BZY8>;, 3N(F*A)5
MZ@J WBUV< 5H!Z]< 6 Q>T*U9$#$BXOVWHITW /@!3TC_N 5@#0=B1L=M'H%
M"!U$#H==XZ#]A@()P12I'&;J?W(O.%F3!/V8X\0H+;?WN^</#HC1+-^#VQ,6
M=;KG:95%/#"@;-[CXYIQCO0/81QK,J))_0>Q[ F4OB\ \TN"A^F:*:/AGGUJ
M%SF_F- E5$8)RJ7FR2]?<MUM40Q<#&TCQ:V\#,"_.+3L"MN0K%_.]U E'XM-
MG@G0!65.-J>5"Q4]OP(D0TX5_XS4(V_9(@B3J?03L_#\)=3T<RSFT[69J)^4
M_NZF,;:/ B=_%2EQ1*F[/U1/)U3"(E#_^&R(:>G_*%'%TU#/U>/989YV#R^]
M[9_R^E/->UJ.+D375:IC[;/3KL79?06H5O/\52O5(%D!1DHFJ)PX#V2G OU@
M7=P&1,%;$6CC+5GYO^V4H"S_TR]0@88(YF85E&4?'XW9:;V/U!IJ*X2N56&M
M[*SBJXV@IW"T?,#A7F^O=3' -7508XWBJ\[6AS.Z<7A:_^ S'GL(C![@_ZAN
M(RO-+W\]2S&0R*+R=BKQ>5*Z@)&-&$E7E$\^3W6E-^MEZKKO1CB[$F5W:G\_
MT\%(W=4HV58]\OHC@G,2"(\4KQC4#Y$T^@S %!Q:/5!27D=81!W4^26:NI@O
M^UZ(CT,@WKHB[. G/CA8]]:<(2$4+4IK("]0O:\%PU#CY4%@A6Y7U1F-;=70
MK6RC=/YQ)WMY])-X<#>8L- \4X'S%<_=?"F\ZH*3=ED$U&PQ= QE-+BF30##
M)0KG,OMS;5CRIS>88]+S216M5AYX@\SF-?(0.$=I $FQ 4$H<> !$9U*03R3
M@I+)$3>S7Y7Y9G!YV]K8W(PU!=,L H\[EZ%TO65W<W%0L^)C9H>;%;@R+2'!
MO%B5,D+;WV*>#23[>&U%S'G$SQ!1PP/5'JL+M^5G??F %:44F-DO)=W5*DT"
MY]MP1OID3Q>&)1]I:E!\3+6,\R,4R&OWMUOOO#!/G6RUV'ZHC+6%AOX27)&6
M(EA./4:OOI_?3=R'<1)^>.]@&<&XH!P[KR G/US&[OE$QM,E7,@7RM HM$X*
M1-V#E@620&'"N:4'>B\?9LJ_>@GNLZ=GE&CRH(Q4&X10UGCM^$00^/5\M=7Q
M$Z/I:I4C:4\PQ8_O"V%Z-^A9O,6^KA5 N@SP4EDF45OVGP .,!RLL$N.^5X6
MS]JVT4/24H3"!?O<[8T(/?.=O-\D]ZYO%&M/Q-:[WI;9M]B$ZTT+YL^3ZO1P
MQ@A\PAL(N!\G =]L=3''H9WXRBN[=<#=#2Y\+#IW#L8F]C3X9-Y7'GRT5$W%
MI_*9+111JE)N,T]LSQ^C63MLR2\]8][/;&'V3.^)?L,D?=Z@FZA@3K:\)Z8.
MZ+6RQ2I+,/"=F&:\Z3";2KQCY1(G)/^$3[U6W6XB:%UC8=+KR;&XP-K61_T<
MT_@-Y--KW=S?V15KJHU /],% X?G]%:Z11695-X,F*N.RL3R@&\B@4;WF)8,
MC7RXFA2_980KPCVN1LC9V#^1/;;Q")H7*&>2KVZ=-;=MV^-FFV_J4AO5&V/Y
M52>Y28<S?FK'L,B5WWIUA%=@*#N&X'*C8MR*OBC-CZ,;?"L+40F][GLB.?\(
MUQ&]H?:^:V;+D<KNE0*8B\)X*WDI%O*BIXI'"P="40#-M+R?\1(3D=^1*B@6
M@;D_X\EO4!3N5-%E_XS_5R5=^WE,3.@F3<5FFH*FX3H#WD#O3?H53SK!@3J_
MO:_W5W)^_DG_&0=(_K\G\=O/I=0>?)GPQHN\]M_O._J#]'^65..GS9+T2(Y*
M,'E7_F6F^S4*=K^"^\T?B7'@378"N&@__[C_*R8.W"PM%1Y%7?-*-T7SKO$B
M!U7N=_]2_C]);P_>W,L^(.,47 % JF+^;B3]MR3>G/6+BOOY5M0U$>AWKU'P
M:7[O@O^7)UV]N2%?]=S&A;S+VRU!'BT[$X#WRS6\ /\2ECM<Z]\<TT[Z=G?-
M[8-S?@+^>?I>WB]-7N&6F>Y66%=(T&7_J5*_\/TBSRHA.D[F8XE%&3$ 52MR
MY2)GM'Z*/(H1!_"3+EWO"F#GH5+Z+T:7F@0T/I70E4[^;?=>;5P ;5&\?T6(
M#D2#PADF<JI8ZH+9%1T(D$W_[J%B3N:]EYGV =OX@#R*6.+K1:[QU]N_/P(
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MZ0BM&/E-AN1*8;;Y_Y:32FD:Y&C*WM>S+ZY)NK_0^X]BA9;SD/9=BA)'+5>
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MET?A@YC'SDF+U>,GELUE(3ATJ#F]^*-J$J$;YAPI]R#KKU-[!Q[QK -K1*X
MS^%AY]<*[== ;YTK0(0[YGG^Q?IHZ.II(K-AT!$</%N/"6)7R'F8W^_N\_YD
MK6U08\=O O24Y(-(NX#IL;_0@D;1&?,>KJ[V-;%;RA;F\FM'^1XR.!$>Y)KT
MT35I,"_4JF;AH_K,8T9S>]W;4CD$7R2QZ:SAQNM7@#WZT4OL4_3T.<]3*N8K
M@)8/]U9*K$ \FYM06^2] \6+?*7B \S3.V+(%8CTB9O$KL&:Z\&_],(/=WV
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M4C(G_:OB1_FTH,#.FYLTFVZ&BJ5RWT5T>2S)[)QWX:I \<$GWHP^%>\ZGK,
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M.[W9[]B=1XPB;A/L^1- LP*E93$:N6P3_9JLQ8\?[L>PYJ)2I JLLSN1'4Q
M2N,G^RQJ[G4%HVA#<$['F+YH?+2=C:JH\9W?O.VLF*=/:JU(COZ.XVF,&<0U
M5/@<-J HP49>$M"QFOP$P;[<M&[+3KF8/O[25+,>?8IC(X;((Y_Q<^0VPUN@
MLAC)QHVK7Q^RC^SQ,F,S,P*#D5'A[?3J[0TC-B(+\A!92HJM5,6/VC <VE(N
M.6;;R#JNX;.0Z!@#OI!P+^O)1S $OZ'DP_<_PKU,ID'.R8:MTW>Y]./MJ;8X
MB E</'UG2TIJRL,OABIM+L*JK!5-!'&#I(LK/E(Q&-[&:Z^U8U=>>M>)C4Z.
MT4J6P)$88:E!P$UI1Y&I4+Y35FA)%[6+T?XE6U"G/]@%J'']YG1ZJ>A7! VK
MC?($FO'+_-O+R5T%5L>1?I?E#]%+8BE]CM,_=G 4B3$9"HJ!24+JO;?:TG$7
MEXH8!]LRF Y)#%-L9]V5UL0Q"N47N##P^KT$Z'_S2]P">6=8AO=X_%E72[78
MN^D3'1-8WR:]@,BFE$*!/^]';4:<2.-LG*&XGC4=W.BU.?J@ZR1JQ?-VD>X4
M935VH4=E,58C7/CF]C;-)E%^W ?7S6>?3UVGEZLR!KK2#"H&Z].&"33D8YGL
MPK,@B2DOU9ON"KTQA"I*;T!571.#=;"'S'>BD4\K0G'/BWP(<%,+G*S6''9.
M'67O3#K!F\)BY\ISLGLZCZQAH2Z#S2.ONI9&%!$+=:'O/E"2.^11^\"<,G29
M6[@>H*=$OTP'_"8H@<0WM#6\1HB"PO=5AJZ&4QWG0X\J9U\/VQ-88C0&I#<T
MD IS]/=+L*'=@^DS*_8_K1NLZZD(%",(%>817:-G:F]V@15T##AYS:F/G-PC
M@*8%2LN_JZ#:$K&U/$J0>LH8LAX\Q$@LKDTU;5S3_#2JG"00D194K>X K.R:
M.I%>F.FTS38M'LT/57K) N)5"Z[B".F*>U,L$Q/>L1C*.PPG%<<0-#QX\8IV
MB@3_D]V"N\/>LL7;]JU&DKM]'-FNL_1QEAD5Q4,&I?M23#EH'(,9BJU(*(?6
M%<!.+T46/CVG$J%FQ&P^BTDM&]V_323^^;%6&"CZN"G?/DUS==VFOP8=UP U
M?F4ELZ=]8[X(7N]+E2)35EJ%(#/RDIT3)PE?%;L"^"0[^,K0CY3&LWBM\)BN
MTJ3'^94$?,Q>B4\JL&4XZQFY\STO&G51$/:*^9ZNP*32#%A9NRUE#XYX.Z+]
M4[KB:9_$1/K%[_ &TLG\LRTP_X _X _X_Q>$KL;^%U!+ P04    " #"@G!2
M*,_E^LR*  !3UP  %@   &=T<7-G<G%C9&<T93 P,# P,BYJ<&?4>P585&NW
M_P:D2Y!!&I4&:89NI 7)&1J1GI%N$ $1A*%;A^Z<09"A,9!4NEL: 4D!$8D_
MGJ_.=[ZXY]SX/_=NGC4/,WO/GOVN=ZW?ZHN)BWG@JH:*N@J A84%W+_\ RZF
M 26   \/'P^7 !\?GY"0@(B$BI2$F)B$EO(:.14C'3,3(QT#PPU6/HX;MVZS
M,#!PBG'=%A 4$1%AYI"0$1>2YA,6$?IY$RQ"0D(28A(:4E(:H9L,-X7^\''Q
M%J @P'F(%X2#=0O IL#"H<"Z: .8 0 +%^N7 _CS@86-<P47#Y^ D(CX\@+,
M50 ;"P<'^PH.+NZ5*Y=G R_/ U<H<"EO"BK@7=.UPK_E1B44DI!+P*)8]0ZD
M-[C+*OS _0DA$?5U&EHZ-G8.3BYN$;"HF+B$I-(=9155-74-?0-#"-3(V,3:
MQM;.WL$1YN'IY>WCZ^<?^C0L_%E$)"(Q*3DE->WY"V1>?D%A47%):5GUJQI,
M;5U]0V/K^[;VCLZN[@]#PR.C8^,3DU,+BTO+*ZMKG]<W]O:_'AP>?3O^?O)S
M75@ #M9?CG^Z+HK+=6%?N8)S!?_GNK"P?7Y>0'$%]Z8@'J6"+KZ5V[5;0B$$
M5(H)N57O"%F$]79!#]P'B:A911;8]GXN[9>5_;Z%/?E/K>RO"_O;NJ8 $ARL
MR\W#H0#D@&\GG'G!1'^$;*H+N!KZ<&5?'3ZWRVI/Q$K+N>($Z]8F2<Z>3I7[
M.M1\OJDX;@+AS'@,;B=N<?D!TY3>;VG((?<^GZGF8+(U1]BD*-WL B^/(47?
M<.=_F4_8M$@J4)*FKJI8(L$7P2I5AB2>T,32C"1H)T:7YA Z%+ 2P37*A+0
M640,ASJ>P3!K$T)TJA,)9%V^5Z7%RZ*A TRXN>S55(R&K1L1^F$B6#(@DWT7
M=CQ7?VQXY&"SOIM/Q8QI\PN#AUA(8&>=]DDI1TY1VX\ER"'(4M^#*=UU<U0G
M09Y2U8^D(.SA8M&FA=5"H-UJ0,-35'PUQ<EXGG(@!9%P-Q76PPP2Y-,YQ>J'
MO%_U9[8CMM"0U7%=R:%&\ED/)+"I0"+$!2-VATC+F; VQMY,_?D45!X%^=PP
M$X";=OM!7>=SMZSD\6:$\!-XQ'%HN98]*-^T5DR@?TV>L7\J;XK,5Z1J1I5C
M%MPU^='/K[AM<+]= L7+1-PU&;W4 GB*Z$NW$V=K/-MZN3V=Y8#=2S7J^O[6
M,]>HI*%@1F6H:=>+VM#>NZSZ\F1Y"$[@UU3 BI6D+*1SUX:L!LO"27L*Y]DC
M [E?-JK!R4=CM#@SIG'9&WW-*,Y\>#2*Q'I3GJG[K,'Z I#A;I,,:UZCJ(5W
MU*1K>9^!DNWE3+8/&,7TZ^+IP][FD/5+T%)AL%Y81;N(3.Q8Q2_<$\&R0\B[
M"ZN9$0%>H.M3+!RTA8X)>.HYA)PEE-L<GV$Z\P,X)46O<&G!^-.YLW72 [A(
MKI!W9HBEPR"*>XZNNI8 LPGPY7-%#--9Y2V(=09B-'Y15'8$Z]KLG6<DH[?4
MT$)%]:0^!O5/MD#T,:.#GY$1OG+^,XO!8AM<'+$LX>*%L39)V\B.,:NF1+.W
MXCFDR2]8:?61B56>S[<?1'T[@QL7&=*R![/FE4?]PBUMLH4$>5P6<85$QVJ-
MJFB,+:QNH_8":))>#!8)F[D33U\H8M%JBM6 QNLT:$@],ICM5#"!'$TE9$@P
M<TGDD TP1"-,$)00*M)QAB&9$;>S)?EKNKJJ;@QO/$<R<0%>$,ZL,NU[.G?M
M6"%20%/YQHVA 2QE*IW_TV2P<SY?GJ)] 6P3[7V] +Y?-SP0*=S+6Z'2M7CW
M7%>9"O@CE%G>CG\:YR.G>P:?EH)&QGUGVGZ<?S* 7^F8O;?&/%0E;5OVL<BD
MP\JIXI2\K_:@__AKW+H1D^"HR+0:RP^8\]K*VFL'G,3P_O;K[XK(DUEXWI7P
M>CG!5=[$TG]W9=R51-0V9JZ,V!@U&'2"NC<2-C0KINB[Q>P48CEI-_Q743*O
MT]=4CF6-P&LGCZL6M9R]19/L!-J82+TE)_JB@[]%!'&7[FZ,L3UY</VX_VN.
MTMP%H#OD.1Z[OB?! "%MV)-%/YKV$WJC9/H8S/'#_-JQVFI=,QLE6\24#"=.
M_PY8CF*=\CF:[1U31^,T.:4F67"=CY#'S,ACT=I(I#K!]_+$$3:OW=IVZ:##
M$AQ%S4]7X="'#PM[>(>?P+@LVQKI"7=8V^Z<4!B<2H&777,C]XX-SYQE-/5K
MC9!WYT]T\%6]2BPV_&\%IGQE?]_8/'ZG=LRR33C"=)7RT0PT][.HF.@8J]K,
M%;D/+T^Y+@ 6\-J/"V H6$9)7?/IJP@SYG07,#OJ KB1GOV-U#CT3".0N[;R
ME[<GJPXX[U V(RKYW,:B8FI!F9Z)$\?H.>::G3:8D*](%D5=K+FBG5LBF\N:
M16:I2O;$4+1;=;#X!4#BF[@*5TS3L[N[F-<\O@-MVYLNR&Z26-JO@ NN6(3%
MA=0/2LCMIBEE*YVV [#CI+;K1XGU"+,'U4[D"+!O6WQWLG,&':92A?6-K56"
M>7;8#;4O+$2"\@S4*>5PI'?-_==IRV8V'N9V38NA3@7Y[>RL,E^-Z$ZPT'??
MHVQA)#9URH^A(E@P@F;=T@8DK3#MLBL\8\\,V:H.9]Q<YBE9W[%XOQ QX+@7
M+!=>?P%$UE9Q3-+PLXU? (HYQ*G?AJ<<J5?9WPE&C[;P&#4C.[9F][N*0>D<
MIT^<+H#-3+ZH2]Y,[WS3 CRZ%V6\-[86PIW1\IM0-$H:2J+RN7N?LWM^6)KE
M8>(GM1ZA.\^^CQ=N4G .L-.<$P'+CS@6I5[P7C)_^2,.PC[RD9(?[U[MRR3<
M1J+6H==JS"X,H^GR;&/Y]LL#.-3C[6[OCE*35I@Z7N3[/C.6G*BK3^=9M\BZ
MJ3KLG=#NUQ#"LJ?O1',!' [@EQEU#9GPB.E#8$7I%P"3.N0S\%O0KY3<>W/2
M($=W8/(UFR&H/&DOAY09+ZBSV6O4<H;8E]B> <HSWW_\+;;1";(X-_?)<XD'
M 7Q-WT1YGQ^I;=E\5U@*-:C,WQ--6U';MS**WH4KKIG4!12;WC#\:I1UXWSR
MQ2V[=*Z$D#A_8$>$]X'?%]:OEGRE)^/,Y<=IAJ:O2*[=?W4?4AQVY\D'%X'E
M+^#DU'6^$N+H10V@J3"H5>4&/.J%4&C6LT+(ZS%,P&8(**/%%SUV^ AU2SZ#
M_#:49:%^=.>=5=]7>:IMJSWSL/*[^_?)K2&GPHM."I.XRPV'E?+C.3$UCNY2
MT-2V)TPZUE18;RI]GYSX31'3"G066F/2HI3?3%W)8+8VVA%9,_A0!QY$=10<
M/1&\.7V00]PHBBG!YMVVZ0GV,*N+9!FU:[2/J>?M!)46.J:MZ3LR'LN.VALH
M/N7QP@L6E:;%*ZK*S3BM/T!OO5IF.)PVLJ"[ .(\3R 'V1OIZ_),6DL2%E)A
M%!F"TA#O%_:+ <^-MSZMX R,K47FJ?-;S\C%-NZ0*D;9O25?R"&[KCWJA1+:
MNO4FK3Q@7+D,_O4^#3,.Z,62B-&AFC?9I8R4"/*2RR9C-5#7^9PEL';<>PYE
M![^Y"KO>RN/X&G(R-L,B2967OB#EVWMPIU($*]U=6K>X*LM1('1BW#3W&*%D
M%[ZP/[OQ+?J6;J%ZB!FX"51C7H/E 1T#!_P8#V^U++2W-/'-FYO0=+T ;AZ!
MJQ8*H*/J5NOFJ4U$LLB<6$%Y)OA">21RPU+@=/[:":1&\NRX4?![-N=#HO)"
MQ81/,UN,<?ME"1= YR66M,C3R][8(SVKT26P?2]0D6ZUB-+@2)40RL\*1\,I
M;L<XU=L7>F<QA>G?>_1SY>3:(YA>V2/Q';;Y.FFZ+V!FBN_>O%7G@<T>9A=
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MEX2G%K)D*[.9/-K,?U3,2T$06(XN>"M3@M./.J5W9\53_\B?>ZNQ5U@-T2&
M38(8G9+A<L#B;.?]6_9 [T%J? ;) *"FFRB/]C'>,ZQ-81_C#J(+;9>]2>=4
M@\CG<(%]_];VFKW^31-'0"5[L&SDX"G4J:R$V\!^KO'&NV?XX/WB\$=:;M8^
M-'S+T &+ZWM71U!4+]^)YY"5(11Z>0&J![\6#[$C8I]K7$ 2M"2'7*YIUW-+
MU.IYS@$>VO$UI8,--+,N8=,\:W!=!=B2OSIM6MBL )+'&2K^3XK-_R;BSKP
M9D#NI9_.WEG(!ET MS9>AR>_%C'+0_!,"/^AM/%_0,*'IBQ^SCJ"#-#P1TH#
MN(E^Z=5&XP.JN2?0^$>&,<A1;W30F2?6 G=# _'Y&,]X,^["@ENM_'$G>(70
M26Q:M>OQ6<#:>X=)IW/;3BJ2@P!Z:Q<BM/HB6H]_EEG#Y,IO[?=_&XW3Q\>9
M>%%AM?L6O[\ 8*^0BFLAFY82QXG#7]+:A;.T JU0).L>>Z?@_0L@&K4B^:*5
MJ2A8F9]L,JK\\[AX;R#Y B_QE[&(=_TT.Q;7YH_9Z#(DE,9>I^V>+-VCI2(9
M49ZJ+]95QO[O9/3_*OJ)MV:_8"\T+OL"Z&JLS"WDC[E^*7E')*U_QHI_3UR$
M;[LOS<\KYT,UU KAFR2="P >A)&GIX+('=7], B"!PS@M8/2R I796?&$D57
M>@')?WZ?BHWF)'FR+;/5-PLE7L];N_PAPY:FQ7/^T1NUUA5YF<_1<7+,Q%^>
MYGX=6"OTFF(/H4Y.UZL)+[7S5^-6?EWG'*?\W)Q:58,KZM:;68GB(9H_F@[]
M X2%.W)K$3_ZP JQX"7WS-MG^'NL7W^A/RD5UMJ)R_N/FK1CRM)QL&U>WO8:
MJ>N%1O\+MOE_M0B]X#\I*AYFNP ,1K Z/[WE&+TJAG+JS&^%%J\;)UW>$"*'
M\J(X>R=/FSVQ>_(X.<CZ_?H)!$.%E4Z=1G6OGGRHAL(;S37RC\&W;K?0G::,
M>;U[0@JTWN+8]7)7CU-"I=WDF$WJ%;HGKW%QHK3.5-OB39]0WGL.Y0A8DDIL
MX]D[1*MLG*O/)/J/"BUGP5]G@;S$UR("R6)=KIEU^;F,E8DV2#&]03U836P$
M$>1?AZA,;2;%+9[!>AZS-=RU>F.R^KF7[*D1=[4JW&5)JN:&RQG<^V,'V]YJ
M]\EX&@XB_N[[W(K"L*B)(?%G(T?3EE<G>_!W_%#BZ ?/;<G@K:A#6JL;H:9C
M3#P-84]>B)^,W]Y%/71A4 S(:E)VEW1!+"1SIFH_Q@Q-S[6[Y^3VP9$Z;C.S
MZC)1(KK*Z@K_;74&"/*$!K]OHJ(\^YKQ'0)*C\.BO+E6)Q;_^)<6F-;9X[=\
MCQKD3#KJ]S('Q8WE3,9$V'MFC?*'33;8-D;ZZZ8O@,?-F:=0SS.;,]BU1=.,
MLPM@K,;(\=K6HO\%,+UU ;RY9_H\.Q\:%]2JZ9']YF1DT!>]14[YN$9:) 0:
M^04('4IM[AON@-)BJU\R0+WX.&_.##\I&V7+K1>95TKM167HR[=8KZ.S!GY0
M??L/&]22Y90'>D;C4J7'L>)"56]Z#\NB32>T"AL&:\HRM11=<O!QR_OMQKUH
M)[X[)1R6/!XMK6/'&-"FE\5I:)9D;V/NDOE#GZ,+2UL]LK(.BZT7(U.>S*B?
M#'F:X!HRKH#2K<L5O//A-LA!AC$MHU&I*&4JO3_N"Y?.PJY.H=?I03T;LKRQ
MTA$%:YM0&HF'FHFFF:%J91)@8HO6XM1*@8:]F&E!;&U9C/*IKN>LY2$JE>YN
M[WCD9M#49<C_J1BUS#M8WAFTP-K0_^D,9K"G-13$O*FU8'-O[%8 96.=DG8E
M9V@'%";_5?QD;#0[6M.Z-^FP)(4P;]3A54O>2]Y'6O:<0'?_&";W=;C;/L-J
MM1O<X\[P[4%U33V!_S4>/U?B!5 &"Q2R/-229VC^M ^*VS2_8^D)Y9<[#;,^
M&=>]/D,%;)C\H[UJ![@67X%)+8C!-Z=)9#9J,16J]O3LKA-+R 4^/F<O0K'4
M#V,CZU]A/6M2#\W&FO5L(6H%\S_&05[N7QOLP"ZZ]WB[*JKA [E:+(B*Z:M#
MNLI># N_UB -,B[.'&*!66FM>'CNL+2F3!-@\UW9O6:^C8F':R@ZAD6W[4B+
MH^VE65FYK.FF.95[11FM/]TNW%S1U(<$A=BJX:>:+^OYSFSRM6QAQDO52?*#
M:5:,LL&KEM@-@0_^/T8;5R8^_Y<06U&>%JRWHX,8)/08GJO?LFZ'B=WF#STL
MCV:H9=?7G=EP :?#Y7TRK.<:S.^UO[518I>C6^+'E&[3K-Y=K<ZR]TB$UV9=
M;_@HK6J=T[S'UK,<R@&* Y]6,Z26V5SBXI**H$2A;C7D19S^W=M:HHA!Y5M\
M[;UL?-R^O%,0@(A>C?)AF &RCC2Z^FS0%/D8H4V,<GE7K$SS ]/+7;17Y$Y<
M8&X=<F(0Y>CC[..)'I /]BQJJ7"6,.G^L)I1*R2">AQ@C/WAE.B 5%@_=I_M
MQO+EKAT4LG V#XN<*3I)/I*R4JB Z>M!5>+33;/RE>W6D4_,V^JE%VO*4\H9
M"6<N!4?I=S$IUOB.FM&)?O=;M'T;74[XK;*9@[)HO\RGLPE*IN,T20SW^MR,
M=*:ZW7^LT';W4@^"1[[L='& ZQ@>@ &B+]$&NCW323<0?>)OWY:>8@Z*!^4C
MLJY8=96)T<%$-2K!Q:HF]^\KN7D4]PFX/FG2HC?3+!DUKNZ<>\GGI&<@[6&L
MMK_^[6;R@O*=^0)$=(;QQOUEN]0J3W-#OAQ#CMMP6 /=JZJ!S$OC6O"[M;$B
MQA02^P&[O0K1XN=Z(Z*JDGN/#_W53)W&68;'Q.#[9*;Z?BZR,Z*P/B'%DF>J
MH=O9?"(1QO&@DSW=HH:+,[\O4V5B<;*@EPV$BFZ-'E0&Q$6Y6B&,I*K*/.Q2
MU<MB0QWN=+4/FS4]L !ULU%.<$9)AW)'N6KQ>A:_4HT6QZ:Y85:EBS?>^\3
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MRO:G+3I'LR#"2H;!)2WF]NN)LS<Y^SN91K>M\-/JIAHR]=]3F#4D7,7C8!W
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M_\)HR/A%=BL<C_] MC<")Y]D5?.0?8.- /E/#UG_U W_;:-&7RTEH>#:A!%
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MM;#VYGP(@7O;\U[*<>TE%J6Z,Y3O4OS+_\(\$'?FT3=X-_1CAM0.@<\[OIF
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M1>=\[O>IL7]-BHX<<67C\%)!QP;X4EM;H?F-QZ>?H0F,4F-6<_,PZ>^=]'*
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M1_)"P\6:H5IY@4?!%93L>ZOL_#F7D#FK(#5#Z?P*-M8<4P/>#F53&W"*_ZQ
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M.844)]S#@G#9;T_E/'^%N%)FCBWO?W?A.HU2YJVW'OTOAK:QG]%DY2&SFX<
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M60GVJ;?%>U.#H[F0G-F+]101.H,OW?+=3F^]Z'\<B8-@-^11VKL:81BHZ%3
M3#]%^.LF8PTO5]6O!0/3[YV\MU^P<U'"H''7+//NZ>H?3NC\L#"&#4IL.0:6
M=/,VAM$J=YNLZ@OV, V[#D4Z]FJKP;\JTF[)N7J38^D^JWU?#QMEZY<WGAFW
MR"HNQI,W>5*>Y]"; ^;@>_MW2_4? SD&\FB*<,])M&4> $FUCH\C$HM^/2WQ
M/[W7]#_#>]'8PN,?  ._GM?H=::\R<QZ )S/4*XLAZ[U7*N8J7C\PKW101U5
MV )*OC3SGMMHS1)__9UA3]=/#$ZD\8O?Z\/S2:$\BR,2\1ECG42!(>]:)@R#
MT_V8G,F510AD0;LMY[#RAWDS;R:TN9GGZ7;5 G.F?=&KTZ(Y!B#Y:I4XT2IH
MC$1_4<73=IW]:6DG^9ZI5)Z8[3*A!N]SR"!MY@.@/#=)NREA=CZ#/][)D&][
MD%'1PI;Q;5$N8T90=5F+0NZND)E5=7N0;7M#%%89;81AQT0+DU,)(FG%&S0F
M/D-RG*!Z$K!8OO!>@?!IWMU+D'"GL B?@:Y=3I"$RP- JWKR.9_I B-O[*HK
M>*02'OJY:,'[V5P4#XOE@D@%T?0YM4K_$O<-%:%0DG$>* -YBQR2'@@+7J(=
MCRFT?U3IYZ3D_1O _9R:A*GA/:($!^S7/ON2=!,./"-10L>M \(GW:XIJ_>\
M2U<TY*&S--;)F=WH#<O!T DSK]K#?*8H&_W*\X'2=G+'ED53Z*#Z@FJ/OVU?
M2O3K$-%1-ZKOXWY454^]7%8/0L5_"TMVTS?K^ZGD&IO>Q5#+8S2,BO]8$QC;
MYHW&AE4-!&@]Y[EZ %SOC020S@MFKP76""I&&\2NI:BQJVE9RCND!)-J+Y4[
MO*NN]SYDU%^53K)ZM)P[<X?)I6+Y(?M".&D_Y$<YDA&E@1=2F(-D'_A'JAYG
MV.>DG&75MJGW,'5RR<\/@!F-[$-7"M&*N2*&*1[' [=MG$O7/-Z8LBWDJK);
MRRRSA4A??_EG7]/0'A\<*9R[NLAKIC?S;9W'B=\8-S]&C!@46G%<8D\JYR^/
M^RHUG-07+UV"_>ZKUF5&V=@?3^[)#LV/-OH)6HUGV$6O'"(ZHH1'043]DFPU
M$_PJ#>_:H@5P&_2[_;H%-C)Q[/.G_*P2AGYN$K142H68(2JSN$)S!/C<1B_?
M.)/?/Y6Z<YL6+BZ*WQO529O@ON6'6_C7':HZ&G39=W&>7 [LI%R0<=,U?K(.
ME?/Z9FF@C@H,]9*"%=XR&K[VB4JVQ[2"*3B;8/30$@B%\D<ZXNU,)'Y]C3*
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MF8SCZ8C5K8*^66=RCK7N58!Q1D&5UMW&:!BVQL:)>+(Z//#"L7NGILCLCME
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M#>62M,R)9,8*$,G!.]#" 6N9*D8OA6>XVQ4/%U7X&JS;N>['X?VCC;Z,=:
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M[BQIU]#XHO1[,^>O-DJLY8-W^VMGV_S^+##G#-U/^2F$*B_0(@G &Q9\.P\
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M9LPV0IM*6,"DUWCLRDL<VHFF\%N^_.Z<M@3J)DAI.2:U>JN;6H[M59K.MI+
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MEO&LC1 +E:*A]4_]Y"4%\AZHE>L:Z"U-\2S8(YK)&DFOG$].=?J/[VSV VH
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MTQM'$.9,JI3!6GBW:Y+F,W$XJ2LH<S1G9%@8@9!C0:<@4VO](67[T8];R@J
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M>"UV@084XDQNWMP567J#E]:O+WO%3%5_=4ERN1)ZI@""GI_0G?8 +D=:=]'
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M(/4(]Q<R!!WM%7R7>CJ(QW<:TB.'+K22W\>1_4S +Z0UW1(S9\P:J*T^_O9
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M[6FUDN5S9'T_K:-L!Z;6G1IY%E1N@B%C:1S2-W(T2@"I*JY:W\>S@;[_' E
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M1Q@\JBD+.9A.^6:FK86=^SZ&RBM]F_NNR%.RM2"7'(%>]ENK%34O2/-"_)4
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M"; 0B5#X'FY_E NW<E 0O#GRZ2!%OQUS\Q-M:.1GXHF/@!]97W<)"]BZ[0(
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MF:_H95[O&Q 763,V/C(Z_B*%7T7\ ^?;#^N%;MJ '!#<,VV&^9LK @M?ABK
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M,YB1KY;L(,4:1$R3EO[Y ).5D9SMQUQ/=/6++\ZCHO*@O\--T$ UA.5WKIR
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M(^#*5'[I(=NS99Q P/B,@)[CJDO6]5O@!"W).#^C]?R6/,-'8K*X?4U#^E/
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M? 9TY.SL4H#1E\Y&@(G (-O[27*9W(D-JHS$^)$:UY8U89LLXX1$G%HL='>
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MV'V1.-C&?/GX%')U!EZUD&T%'S%NW@).F\'1QC#16T X-J+MQ29PB8H&[EL
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M>H('Z,ELR\VK%4-#73GQ@O8K,8=8!^CZ/7!-B]3+UP[5XSRDV_;@9*_ZV=;
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M^&-92ZB'0ZR<T[UYJP^L J[+^,:P%W/!O@@ ]D1'!Q>IH_JC,;G]5KH-AGD
MO.@G0AX;JMF( VR;?L3#@,[&-IF?AE<O(LA\Q:XFG1#)"]-D%/Z%-A>Y6624
M$RNW  TT\"+GS**[(J[8N B,!B68C.6;6 "C*@+4<!].PR7JLJO\ZMIR#G*U
M9$O!C5:$B"P/!$PLO6!,=)AJ;1-J=88ESVUW6-CHG2HP.6\!:^/H0\J82R&L
M36NA0E%(8LT&-P^5X.-.>(JM\A_??FH'M$0FF\_]\3:)>"#>5/N[3>_$$@C<
M4G6EVK\/<^N%;Q9:$<.%9GY?&!X"B>/%E?P[C.#_M4-D^;^V"Z?[7(SX:XRG
M!:=B:HA_]NQJ-'1U<,G("F.O6PL/DN8Y1:^?"*<P^_#BWT(4";]&< CKJ3Z/
MJ3,*GHQ]DX=*I_$CU%LYYJC5R8;D8"DC7(RV$Z1]"_@7I & 3UQOM^8;" ZM
M]Z3W.;2'[$ZYDD>[HZ8<$0?!:ZM/BE#:%XY(8ZK3#DE^%'M__WZ"^\[]H29]
MX2(.RA#(YR>M:2KJ;VDT2"R"]PC([G#?&VP1"?14!(#[UYG28O2#A<E;Y%Z-
MJ!E),+WMBOTU)UZ9#X0PP_68RZ7#M Z?GK)F60 "4O1FX<'#;$5YTOQ3PEQN
MD2_'GETQI:&?1(_B,E"X>5'%E.JU0B860C?GBPM?2^D5ZQ8%BVFD';P0.R]S
MT%#.,P/K2LH] @J0W@*@A&EV'7TNG*+<,PXTU"CHR,6SM,A,V-2!O8XVE373
MKMT"JDZK8Y%<S<TRF$(+>5DDAWM2\@OTR5&]:O=R4!_1JVCQK#:.<7?PA ([
M&ZTQD==[9?'?0N,"J,B+<44+$O2 7?3O5V28KBN:@$<O E"'.8*":5 WYC-"
MHL>J ,WM#.8'4P.%#TN>^ )QWE0'BI@.&+S+X>%9G"C-GRT<,/_J1.! (3[=
M^AR9SHPA>5PE)?SY;':9)1-!]N@0+V%1JU)%C!7;A*'>7.<S62^.)9#<*SG-
MIYEKSQQ&D-:J4;),-U4E-N3]6O*D]D0^7!G@<8[[9ON1[+"T/66=+_K)4J'Y
MQ/CGD2^03\FL=.0M*[P>S[JP$T9%_/3%6EP)@,0I*U(^QN-!/$VS^OIE"9^=
MEM ;2*$D11Y--3KU:'Q]YG3W#227A;BA^X$"C4/9TQSGWCJK6G^9T>AQAUHY
MZ[Z"5>DC2)V'JJ&Y8J^\*NKCWC +59O3IPA=+EDK*4Q50L]?F,CB'?9I,6Q;
MMTR 'Z&*3R!TF;MO4=]>\7R@^?M^B3KLO^Z7^%]U(&,,7IS$WHRJ3W/#O+A'
MJFR *R-ZYW+Z/Q<.+[Q^V:0)#"'%O(O0^?_*%<__\'%_P7$45,:Z^=:FSAR/
MQ_S>6/*_<K/YBZM-3O#%H0U4+Y^H">9:/9'/'PGTBW9DBE#M-S#5H8+&4Q_B
MR"[=V7(-_56\02W.LV\!'\;C_[BPL9-\EQY(^VC=ZP6XR[\0/%E^"Z#4U"6^
M!83;R"-> 0Q8 ?>_6J&F^D/-^>Y:#Q<KFP13PSXO(PI9W=!['[K _(V@/S](
M<M$OLIBF!V[SW*EV@,?N(!6K3"&+',M(I6ZZ-K;Q)_'FZY&9*TS*0AE/<?BI
MWR'E?(Q&=2',OVZ9#_/(;7_J7"+*77?$, QJ6VLU*6T'E.M8$O*2WA,RL@@*
MGRMJBR;JCHOC1])\-L'(H-@S]3#18#[_;2[GTW F5J)5I(7X.)E^BB6,#KF3
MUU84!73)V3F!Z-$E&55FF+E!NT_?>)>)UWK6XN48NVAI5K'6$AR?X$;+5OG3
M<06&!_>IJ*_<\R#*8:_/X'M!1<TY.6/&Z.'@]"+(T<!T\R2_A49Q!11(]3"
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MRJEL9R6YT4?('#,I3WH7[]>?,_:GJ.?M0E_#,]]]4J@]R1E"_CM.S1G2D>4
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M,S%IJ$HVZ(22=R@88+2"-D2%+.--L ]4CENCOE1Z+8%*#@_:IRC@(=NZ&;<
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M"X$YITV+2*[UE_H*A3O+UXP<HJ<57Y23][NM"[^\+7P%:+L?5]720)F3\QT
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M2XPVRP\V>@$EX$)R&NR*WA[I_DNG]:B$_GFUE,_YCA%)RCO,!'/BG :,<#[
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M*@I7)0P\I!Y&=(^X7RFJ1BCQ502.?[O>[EFGO]3M)#*(X4$5]@:-_\!4NM\
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M(5'HM/2XO(%PF^N:B\;DT1I2D%$RXL&QX&64C:1>QEE0.VQ)BA\%5E[SREA
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M%.<U47WH>AM6X07Q^-1/SQ<IN6>N.UT&1&L54D>JC>]<0[HW"*QE/K#5UB/
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MB3387_NB2646)T O=N]^>5(;6/ ,<RZ:I.']A.J!4S+M4?$*[$DQVVS,5P
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MJ_R3=>_^Y#7]OF5*P!K:+U?51Y[%0OE[WX3N3?#';_C. (6% SRV8AJG &!
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M[Y%!22V2]N5A?Z)65])B8S/<47CXRR;X72+T4MA-5Z1K'_2B4J">JKR-]V4
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MEJ7D,HV=W\7HJ-)M),:=XJ 04Q.]M^/YXOBWZ+"PH,<-7#67@_&:.<JVYUU
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MI?H"T<'\D]S4M O85_KH?4#WN7.]8W7;).M+$1$.QMNG7%A@![R?IILL?LN
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M(.2'#(E"1X34Q]T&%"U)$SU9UH]GRO8W)RK.[X265(\$AW.KGD;2]R+K[["
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MW;8'C&BV@(6<.JI:/C<-]'7 )<B_0N!_WQ1!8O[O\5V.Y7?++8Z!/<%1,J]
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M[/1\&VMB(\^!\#'CAVZ,J:C 80$(H<TP-X2VV13=A*JF<]0J,[;/TZ+W,JZ
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MT+7J0KW0W-*#+!!^(+PB8B(V'1OSUK)_/ *QFZ&K]ZY40OI9<0&>2J-8:?V
M"D60#WG@7WO Z"!VS:6C4Q10GF),K5M@_+T#]UO<&Q_\,BE-[MH_:QS#6:E;
M!*3#>-.@ME?[^[4$HC";82FZZ9G<=IEW]QZ=\NNL3JN[S8&>-$U(QVO9;;W=
MQD_<SSVC@-9R@!5J?B91S EE*>ZIWXG2G+.OIPQ"C#-:67B4@D<T9II>=6>
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MN/VW=(<CN5O$B.SO![1]R>_W2X3[S;9O&:)D(\=9%WEY-0VW,E215?NX4.*
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MQ5KSXIW0GF-:EE/JF^%]FP9RF9S6I]#HEP_]X&+X&N4JWGVWC-6T0\E@*=O
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MHWIMY84J[KFI*[[?WP_9"'!8ZQD.IT="&:JT[M_)N#_!D+YH=/].U/V)]+"
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MOGKM%QH6'A$9]?9==%)R2FI:>D9F5D$AHJBXI+2LO+:NOJ&QJ;FEM:>WKW\
M.3@T/#$Y-?UM9G9N?@&UOK&YM;VSN[=_[!<.@(OST\_O^D6!]>O4Z=.XIPF.
M_<(YY7@\@>(TWB4^?,K;*@2/K<]=YG].2'4G)#&_AHCEANH:]1.;[C,T5P0F
M6%''KIUX]L\Y]N)?\NQGQW[Q:Q@@P<7!)@^7 I $=F+\O8N#74_)%JFBA_W1
M3BU[=/'*&$ ]?E7#.U"(M[E*G..4[W:?P4:C4G/W4='Y0U38NF#RM_2=\^O)
M;4HKO-^D:,='5&"=M)(LLC^F#01'QH\:M 9S2Y961P"F, MI#"!F=!C(_&.>
MCH0.S!K&*89 3Z+5<=[_6%3@YWEF>Y"CAL.,]=X#_SUE?,?_*/_O5)[Y0Q[_
M]W+G$[G;3_<7_I _;?@GY7_CW.=_P;FP'V(,\%>=9SIQWN#?G9G"?V-FE'[(
M,< _LNZ?#>T?6,?WP[K/?Q#:WY7_;/U/2IE_S/NCT/UBG#4&^#]M_5^V[B^6
M7/#OBQ-_8]M?1^4/XTHQP!]-T(7];R>4/X$MTV^L_\>X_I?,3_DAAOU+XO\N
M*O\'H%;Y!R7Y-\;YGLBC_DVV%_Z![5/_0/X7"_;?%%CG'W22\:-H_A!W47]4
MM7\M\W_ *$I7_RJJ_T6^^S?CTEGN5\K_AXOB/\K__Z;<9'CQF9Y^44%R]O,X
M:25;=,5:3H8Z.56G)T';" H.CM^J]G8:6CW(:_=("_]XR9Y\"X+> AN45LMG
M9L"RE7:R>H)#/"*6W@4E^7$ _^K(-6U@X@ZN"TCL$IJ(4[3KGY:\('24->[X
M94B*#G>R]GKK<":S ;K*PHSI%EW_5Z^E"?X;L4B*B=2U]&U= VB)3)35E0^Y
M(S+%:X=F2)VG9W*IOKX@!1S\;!+V>Y"Q9OK\<0?:KC(.G 74U- &B6LQ<N7%
M@;2^;W=O)I!M^VU\L6T\-VCVVB%GQ-_0;X9UUS?KR\@[.,A8X^MAFJ=XFM]&
M'M[N?)%/)/W[@\F#AM(L-"?J,+*DT_#1%?X\.]H$<L4LND@X--5;F#++<CYZ
M_0MOT_#[XD0&G1</6T>/>GLRW.[VKU@E%K\A('16EAWP%+<7?,OVX4"=I("'
MZ$).%7N#J6K9]3WZ9_6FJ%R"&A?OX;G;1J./":V;BLQV9=6+HE0L,M1]1=@7
MI9C2R*0$BF:86'9?K.GZ*^"%?2: <!+-Y"]+7#(O%E8X2F#CRS_#GZ),4-BM
MRY,_=8G,S^KB$T+<])XRMMW7F5]JVY\6DGJ%(;JP<GWC"7*FMDS=JB+D6R/I
MEN9,-Y4I<#8TKW#H2N*KCCNQR@0I(/97@IM=$T&RRHZQMOJFQB@"M>*^2WY;
MT\:VO?A%8K ,GL0D[0?5]7TX8W/E/>;;DQK*_*Z@V)X4"MHKC[)$PW0EZ_+V
M\'@'RI7.$=%+E5&8>HSQ23%\+$2Q,4I,)!9[FQK?_-KO?F,RW%'S,GVV<4FG
M#;33SO^]1*].S &H?X0]<[)\!$XLA71H>=)5QW9[#VM3EHY>D_.I-OI3A)W4
M3\JHRPQ(S)ZNM^92R A%3UAZ7#3?4:L8>OU2WK8VK %PE::>1=.@$-'ABHSU
M-J\UY-I.W=(4R713*"^N#!WCXQ*:!)05 5=&ZAF:C[?*?>H['0H"VR*:+W^8
MV?7*'I6;&1%(8E;$IC_7[ZL8WU3S%K&-I3"^FE>%7R-2XM)HT=3M]#W/[$=O
MB!+(M9(J8^[N>MN5C)OTD7B7&[W@4FKP$'&_?,_,GYJ#GG@S@5PF(Y=M_1*$
M[WU"-.K=QXN+I'2=%]Y*!\2';^;6U:&YZ3I"VSDLQK39)>6!G@\H2&7U@?!0
M[;H,-$-FU',?&387G8J('E(/\!EU/H1$I]<KQ-!/09G?UA?C=YGA(CGRJ#&
MMV_6B%YBZ49E^B. $UHMP?-<@+>XV(;@P884HQ[U9(_;O7[3"H>2<\X<HYYI
M>6;59U?RBB0+)=^67GS\/($<G)10%-YVJFR%*P9EZG^Y*Y&3OX>B<1A8F+^P
MK*KT.!JE-M7^K&282FG:OK&NI]R5G%X(GLSG[]+N%;LU+T4GFA[\J'=5HN-5
M@9#U0#DWBYIH1$&KX5!(K&9'J(*U[:1N2^2M3O.=<6(NGG=,7V7;QCR%YW*8
M*:'50S3&_8PQZ:U<GW/%G.$KSA&I]\,W.<UPA^=IBY.%$]JM/YY%8?=2URNC
M1KBAT+P8M/@T!K## )S -Q,40GDAV\A0-VXO-VM,18SH(OI2]%J[+%I6ZV/Z
MGM]V^PWT[0^P"BF:N9Q & C=FG\#ST3L>7%EP6)3=&]%VSGYD*LL>-C\:U#/
M>C"@>LV%"HD<:5D8E>!/S*LI>7*V"$H"Y.L9'M\6P%G<U'PWN#OSS6Z[M$);
MDR#Y%!<>^M)"KV[%I\(]#N?:N'"<977-4#,8A27O%DU)V&=ZEQ5\A)C<U$Y1
M.'C8:N/,+$LTL%G.U9@C<7$!M!,"1X4GQ_$3YFGTV'-L<0F\DWQEXLF<.1XH
MVIW^B)#:/\FI7/S)1)*ZLD9^@\(4[QY.B[[T!#DE&"*:,F/,OO,^ W?('NXL
M\*JNP"M>)]UTLGEEB;19"EC6=Y_BI=4V?Y-T+X#,-3JJ;G37*%ZW"[^]J4$K
ML=0L\@L8TJ1S>3?M2H3:DO\&@WV>2'?\?443@^4+CGEO79'.3]&DH7840\#0
MU SSA!2CT4?N^X@:I^[GR[HMN_E,VQI%:EY!U4<N40W=P[G/T7XQAIWRWRII
MT^;.,SVNIK </WR !SB(PNH7%3('KD9<;OG4DENN:-EQBQ?Q+NKQJC[W9+OD
MO1?;S$N#O0XK69\&MCX&9IE[,/E="3.?3:3"Z59 \2H%S;:1TBH_ POVSNM\
M2\L^Z\0*NMERJG)2Z=2\J(>W6$G^I=*.NT9GVM;LD$+(*#FS^X%*;<^QM665
M5%EVZ"H1GRUGY6!@'I3R2&T2U=Z1G"V-ERS1R/#5Q%/4PK0!-2^L4MM,9!L$
MA2KUX6W'\7A^8A&<\A!]%[K2 PFZ+R()M],A#]X\T,.S^$+_3%7T0)E VG;*
M#+YU^P1AR=HHA,X#(A:9=*=.G75G>ZTB29JF*U+/O0:**BT*E[8]'K4NSVXE
MD+WVN,9"XB\M&8P!](LV8<R!JM;,0[6S'Z$^76QK;WNGSH.>IS2Q/\, 9Y;%
M).+HXQYO$RL'#\YX,N<>WO&7CCA;GP/N&]#:S?4]/9S!5(8!%I&L4V_A(_6@
MS.M,^I,B@GVWDYWNS\FO7V/32]]M .Q=R .6BF(Y[#3%GV?3=?KEV(6WM7KG
MOR%:U!=/'%E"22E>M_ GN#!3(:[P:4<TL.^\9FAC5\9>>!=^@V_]+?JR>LON
MM(<$@H.WQ1PIB"X_:G7U6[.B&)P'"7^X^\BO@.OK&UO]BJ\3%[N2-Q[J> IL
MB4O;+9J\\[PE_<SV4"/HEN]KBXCB>)UY-T,,</%U]9<\^JX8&3V=J0,9TL/]
M+H*D83>5DNA'8?="O$:C%\;U7\[/K)RZ ICZH:RHY"9FSY2[%[<(DS @#1/X
MBM=2VH4_5SXZ RQN6E&^!SFSK#L\7=4C=8[W%H2J6-LM>#O8V*IO88!7FK!A
M<D@ZD2.O"):[7=IM]JL#+O>L&I88G:XP#-/U\9H:62V1M?(($UKYIFBTV_K8
M.D>K%1]7+GY6BJG%T([7 O3L.ET.$G^,P_?.VNB#3Y$=^))GINF;RD<_]]:S
MK]^>_]!%4-2M2^#CYA2=8B-]_3&G]8;+ $\)BFRF3B>Z7:RNQ).*#MB*_CQ@
MKY:J@Z@5WZ5M<);#[A=@W>Q1Y]IS@YG4_8MTA^?'Z(5)4M"K;)ZBW+@&HGVW
M/^OKRT!M*L=KAOL1+BKOU3,(E>:U7(+KQ>^L["7W5G8E3'FS>8J'^FU(DCIM
MN[Y&=[HSI+8T:E$HHF2#4XK*A8H#6BX^-?$4%_5;)R9G6"C>,2_Q>-H,*T^K
MTE2J.!\9THX(;(NE Z(A/81MS9^ &^W/RL?KLRWX'?Q.RPTZX.?M3JE"];C[
MB?#"_38P +#[9 1<=@!*O!!UI8M *>U0S6]EPK"L1 N7*04),W4E72*^QD.K
M9?2DU (V\3YB6KMW\GXJ[C?V(G!/8OE:T)M:M/&;R\]H/&^YW'G&U6CY\9)Y
M%%+Q*(Z-(EB:K=A-$(6S8CG0L6=$F?_I&F$"68PFZJ6.QO0S_JL\(\X"7Y0:
M^2 #KV]=?O.90&=CE>%F%+C 7HP6UAC6:+".XX4N)Y^78BI*-L_.UG%> )CZ
M4_4M$J#=9A[G0F<>O"^]2=TAA\+5+(^6@T>KG(F=@F G#TD_TS^'&G7)D;FZ
M0Q1"S&=Y"T13C:*<WV(N@+S0&PW(P$;6O%"0T:93D6O[=0C_LQOZUDF[Z"/+
M@6&TR+O8KY0IFC=0S"H5\:JX,^LO/?.8-G&6=LJ7'(9=]>I/^XES\I+MOER,
M<WBR?EBXAXR;'PYOF0 )WWZ'?\L5U.FYY:J&=YB1JD'V$'8&V'3A:A&L?N5H
ML\"O _'GF1:+..UG&8:B7!\XNM@WH!8W32'%5"']3((#%38_H*(K54^@.$C=
M&O]*M*@_5/%4!S!=W-N<0&Z65,I[VJEK\26XO;(]+JUB&.!(\OLOC=E$#!"2
M!MN!-1;QP ;0U%'G#P-O8( *M&"F+;ID+8]>' /8[^7U#435\R2BX9)CV="=
M\_,:@K\T^ML/O/\KS7W>I=U/+Q2R[<3/:.8QX4/;/U[4UEY 6M.4$RH_\@-J
MUYKJ2'DU>A++(J&>'667M#! H,.^H]?2H61Z<W&/_.#=G1;Q3#'!3(B+?@1I
MA7Z:AG4[M&V2\?+]=Z33L.N7/<6":Y^>:[!Y87TPA5S4E+CT,#A3*^O#%05U
MP2JR86ZM+UH+]RR?C'/?03/YS+A"7V^9.(!&[SHDF,3[E:U5,F]UP>3GQ(0A
MY(<LE.?H**W[I54'E@46O]!Q&5?1:A+L@1I#)-Z9)@OF5^F^X:"HW85-#P@^
MB[5ME#PC)EB@Q*2XG<,<MENV!5\^I]1K(>A:X5NE6E#LG*7/UGV-6=GU@%3!
M*'"( [<$2>#;H^4]0<16$^BIR8LBLH 57B/]\-G5Z8H[E%R^1W51)<CU2+LU
M_8*MGNEKN,![)04?PBT\?-9/#<"-VH7XM9>)M;.&,,YO;L*5NHJ%J\[PPW8S
ML[-W'YL-=&90QA "1YP[/DN(+Q)K+:R3;W3C/! X7A/5UW:CK>U?N(T):ZJA
M+EU#WO=LS&#^C#XKGDU?[T(3MV, S>_;%KGU2KZYN+L:8:EL8-[C;%[SH<D/
M"%+C/;S<8]4A[)C;5"OTX?T9![Y,5M>,9*W\[F_='BVDDZ:X(9IV[+W7!,HN
M"F='ZBH3T*=8^#8@4T@X U"[_7!-O<K2 9KQ!WY7KXP</M(84;SU,%BWK$RX
M[FDR];MLL^TW"R\6>I5;FM:Z\"6J\#.B Y/'I>G.-0_I$;QZC0%>&BCM]Q._
MIZ3/3(S3TXC-.$@90*=:I(^9%1>//P4:G1-(,8"OP?H9 [C]_OL^&@=*16MT
MIFQ[@XT$57FO@/^E<_J9-:M@%Y_\Y/$A.<N=D&5K/V#J2J\8]^1(YFG;F^$V
M#BC=]->'M!B </"\D&VK^O5&(\DIU85A!AK'/(GXK.NC+I>RK"&A"X59^@L]
MKVHZ/YOA[,=ENSHF\)>Q:@"+>IW/*>OG1-ZK'1E\OD\%3YOC3BQZ5Q5LRT&?
MW_ZL8)[;]$8#-%ONFS#SU2DJG'DA4ZF#!Y/=G>^_E0#67<CW$)INI:F+>K>9
M'B^(+V:M%?G$I'WJE$AADE&5L$I5[;4[$D7J'VA_O#"FM"A%@V:1ZH84UU[H
MLV[$YPI?.\I[E=XK553R//GB^A=8A(M)%5M@#J26IDJJM12_LG\3F1_54M1O
MM+[OEN9):,<(&AC3-I:"EX8A!DQ\F3X,Y]1V<'RIL_U8A5L7Z4 S,*UO/@8Q
M#&7Z8 ^GZ2$>*/W0UQKY]$TXCLZ.%'+%_C9W'Q^+Y>FEFZM**(O")EL2U2"W
M_$-O[:ZEDK&]G>C/GC#[0//=H,Z'?3Q3]A\)S'$.,TXMZM2*,2E%OEMW6:;N
MW+W[BATW/1P686\A]-8.%[+=WQE5G+_)I2A:*X*KG_?YI>UF HDD&:RY%C9F
M-:LQ<"6L 5J*>S V68*((17M5#^X776A)4TV?;X-[I]7'$#P1>K<[@)AF%(Q
M%UUP?,$ Z6H,-H%#(^_+J =VWT+*4U/XX N'\+BKD6MF7O>@8/]IW?A*LU/D
M^.[>B++*3][Y'5*Y$+'@W0?&Z]:!4ZEJI3U+7TO#ELHW" ?7J5#J=DJ7.^NO
MM3O/!-;-".!LB@<?.O,>5/=4!C<>8(")2R4;MM^F9ZHXF^I%58<SH B"4V5Y
M-"-FP]/@GB.6$-G3]@G$D?/I&*"6LS['>3WH)G6-DSK? "M%0%-1UO->-M#!
M]?YOZ^7V4]2C3CI-,MUPF+-'Z/W;T]BFD>?+>33EX'KR:ES_2K3-<T,:@$$S
MG"TFG><C#WI8R)>MB@E93_< U.R#NDF%T[F[JJE ;).%$W83\/O*0U;MGJ+(
M!?YT<0LP98YP\.#WE1^8N!:U0"_R*9>?6_ASD:M)/^/96/L$4@.?B8%M90S@
M1!&]35L]-::T0[Z>=W4ML,HGT*:==>YI7%H5T:%L"N)!]=.'ZGX ZDCNQ>[
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M(^3QY!K?49(D+[J*^3'*]^BT[#<,@,R3&18G^";3/2?)"6S$?]BM0[]@6<<
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M?_9] \-.@.0TI>18UA@I!@@6P3;1$M>G[C.O@@Q>;A&;61AILTHY.@KHFO.
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MIO:;(]+O("N35@M3+7XUD7I[2V!NBQ@BHZHN>?<[BKA5U..QU5_S#@<#N*2
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ML6#W'4=7-Z!4U8;R+2/IU^IZK"1GD>VNNR IT%U.BOJNG;RG=(6@'/S"2/>
M?M#5]%VZ"04?-## 7_=JR0<IL6!M0^S9DAY0]8?Y&V,>+UE4RX<V+<K. P+B
M3;WQ47,\>5K9"@:71+[O*X5V/!":8C9(Z.UDU/W<P\Z I$'4TO6KZA_O>Z-T
M]C5/;&KRU!R!=D/_X?D$]KU%HA?6E+%T6UTHG.P(3=8:?#B05QLR)TG>NQQ
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MR,U]R.I:?_]W\;!1\*_QQ@<7$IM"WIC>3NPT?Y.#^MH8N:="A?)N8ISWI(Z
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MZ/D'0<[O^I0XGK4W"GVT1RG*O["X4QSVXL3;S8P(Y\*;0?'[UROKQT!II[%
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MB3.?ERN&<59H+OLJU.G<5THPN$>SO.O8^T*R:NX0]65O09&AR =%#A/GQ*Y
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M*7C[Y .58U#Q8,>MN$,?#?9WTL+!J\19*\[0>I+)P&CL-C9V]^^UX0%:]"$
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M =L]!BL8H2DU</:U1:.+ID*%4,V;Y7T"=ES%L6!8D:)EW/ 17[2V!9Q\8PC
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M+4G7--.F7NY+,9I<5&I^[Y=7*(1XJL5\O?5R"^YDA7?GK@8OK*.@)@>^<OC
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MOYK>@R$HNPE"*WW.[H=GLF#-T3[+>]_3>/=B(:O9 DGYD<(1:.3G;X/$D5'
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M.6XB\Y6EH61V#]-/5F\1W?5=NUC\66:J;V#]8ORW*O^ ?2R*$+_7P+G\;A=
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M:+?C?-E)B3W40ACARV<"2#HIJ6^2 R>R3BLGA=*)H?.X=ZGZ%^2)PCTGFK*
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MS2+$83K)&:(V./E9%6!HW36X#UA:'TDUC8IA,<V$!MRQP]27,VDK4;'R;$Z
M=4PU(WY3/^Z=Y^G'#3O"R)=6$6..%B_GU@Y><P&7EZ1W"6#$=9L0::W)*R01
M!O^JXA8?V+C59(P.#-P2I*X06%Z\:#14=#[F[4 9VZ$,;KLA<N_JIL0/1TX*
M2S6?D.:]8JR@HC8]LUI3:7?SR^60XNWSK8(W8F@[+8:CSCFM0N\R;3$RLOU
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M[HJ9Y*Y4 FUY*C^G4N4J4A2_,X=0^0[IQ5)T"3?:I=^()+,+1B'59B12O2X
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MF.2^P6<?+"N?"' SL!_6&O+6Z 023U]-,8;%\.%4G&526#1HV#SXEG0P%]-
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M[)(;V\S6O'D!^GY^6C8&\ [JI^GI&/!96NNO?$QD"/>)W%N(H?6*X@>D %]
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ME3%O>7>XRG#/&@V-_<J"_D>J)<0>_P8L':Z2V2Y@;JS) ::&=&ET%&SC:O%
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MH>*)*!FIJ6-MB+91\[^5-N;_?VGC?R%M#,_70#HRB55")$TV<*)K 9(7/#O
MR[X%Z/4-4DL@-PY6/AN+5++J8;FJ+KU:5_ 1X(>OCZ,DPMG6FZ&B[&!H>F(8
M.YD8]NOPGYU!UM?JIZJ4>_UL;+KD7VILRL]M; I-]#4EO*?0EV-5VV7Z)_')
M:OB02I>^7;_' FW;L13U2B9Q9%Y:9=;88:3')$0R<$'Z:?^=0_@UI&?CM-O\
M#CRO[$@&& !3FF%>DDP<6>5>C9Q^/7%D 6DL(JM8%<SR<T?<8$C:1Y?ML"A.
MJ6HV$L&'S8J+1>I:K[+(DZX$J\P',VWC#8/7&#:XG/=0N/TMJ*B<T!^HD;&
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M+@F\SK1$AJF/VKMW%FUXITI;WD='[&0R7/*C]",[21C2ET.E9_(3)UXNQ C
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M*D126B,''/;<K2]+'[1IZJMH@68G4"\-WN <9#VJHLE4:Z=4!5@[L< TH*J
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MSJ#>OQ!?^I_\#&^[&OM_4$L#!!0    ( ,*"<%):!C4CR2P! /AB 0 6
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MS_9_S^9&+W]]^-')F)L% E!H_ M\XGO,+JA/#B[7@[]4&(RUK>I5W0$J0'>
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M(=NP[ +RJ:O.]0EKS^;),*RL$WTHE$;TV*5]FT1"3V%Y#]P3]&1J+WM]$NK
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M+OO9%C?JLLAFI@[:U_"*:-[=S$>5_8V]WYAN_"[M*)BY.7]JA(# \B(FGD3
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M(/ZB-<6KQ.@.T'N]J-ST I="XS\,/*P]$,5;K)"MOQT_2#QXB;6-59#[X2%
M L#Y<]A5Y<_%,_3$4;+<AIR /.QQ""<@]P]^,N ^!9S2_*,B=U$Q_N&?/R19
M?U-H_P"72,5OA;4_/5"N+9(W<Y7MH*"9EX%MZ9\R]#>*@-O".O)J@IJOU1ZX
MNEJI2N"%J=5#=.C&GY$BH8Q?"G*3O+VY>'@858K.90TBT1;V\8[1ZL"<(/^'
M8*07S#TDIX"/8DUDW.13.! /M4T1+K>-=<UE6R+\YW:(-$]W_N9#(B&<6 #L
M;_="_\Z(')NZF^\/Q_$84F7.;]B LS\\L$3^ZLKJ_+-I?>3^A%I\X 0[@J;;
M?NP%H\UA;WO])=O0Y&W)_3@;NK<V' LM@A#N#5%1+QNU]"*Z)[D0;N)[$,YO
M_Q$\^+V(V;P#*'M67/OUWFX6+@;WYMUP(=LP.TQ7N1_8<__I:?_'45!J3U X
MK>3RQZH28RQ,SL^%]5*L[D;!!/CVR#V.<DG=M2TP[$F\V8;SWYQ=7E1(-[=D
M:*3DI[_LRL;SH<S@U5E5%TH3;6(@51/WJV\^E<XR85/M:T^.^[:J1P:S&]<W
MK2D5(HI\$M=3>2V)5JK)2(%XV]2ZAQ)<M9YN/5)P+IEYMXQ.<+M?5D;K&T['
MQQHC;O.Q!%:2R>K$X&+/];V,-OPCW&0L]B+FIN>48O+I%%ZKO<<:C9BJ0=Y8
M3)+QV'1_PH/TR=':M E^D49V?-EG)[]+CT':)E[I/5E*R]M<[=O1R1::4E72
MIER:/JF*TX(_^IASC)DB/2<L..L;WK^S:)?M #?IDGQ/7B7[#-Y[IM_WON18
M(:@8PS.6PF40#:+0,__T]ZB#3D-;!.$G:#^?<.1'4S7IH&3<?B>.."1*:4U,
M$5'-9+]1<P>@F%OLIX_.5ZL3?$[HHKBU$[-!65F.DKZ-]P33=/;3$)["G%\B
M*M 3T!-?#__DK^0#O@\^?\"*62_ED;<1F5#YSMLJ^'6H"RGQYK>(UZZN4LJ'
MK2E 9GKV58\N$BD1B* ZFB-$ZP+5&E?BD97"5[$J+\=A)S;C_-9?FBX$F1_%
M42<*!M.F\N&=#2]VOJ4V0"U8^T)B/O93!E0*;>2L&ZG3&0/GZO!!#;2AQ!U$
M<7I3XMT&C$)AMV1;M0JU*88$4HWO;MD<5BA %BY2P=++X:W#CB($SWO<Q,JY
MA*./<\'/"0V\!X-;'MM=I 6YR3[@>^R\4WP #,Y9M:N/LXQ 4\.$_;_<CC?6
M;;Z)G)C%0!EXNGE\^58?UU582><>>+B1#NYTZTSR\ELAKR6Y7^Q^MOGUKEF@
M3P%HNB/?U(QAK/XTP]Q039;_T45=.#VV]5#-[F#:WP=E57\5?/;Z#C"347D6
M$Y?=,.QZKM.BWMUO4VPX8V2@XLV'D-=OKGKF%QS[SO<R,YN2D8%6NJ]I=O6
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M;PO_YD3:/M!?_C&G$W2*G',0Z_HEO'):$?WT%$)W>GP'"/5%V"O'M*2\^I*
MS0]ZF\Y+VT)W!R#TI'\(EC1"0$\&W5D_/I;UQ-<RQ;$=J$E^!YN9YTXH;,P_
MX5RT=[5[>Y.K@!H<"$&D[P80KD0'DQM^86>6G+[\+NOC!SELT;T,E%\N2(F3
M%##7X77>]RC;W-]CLUU[]1D4F&V0?*.;M!YT?!6?WKWN!-49:$$$O@HN%DLV
MF!'XZG:C;MM;4E(N?%(E+[XHE-G_=+NGL2WR\B:B,=_Y$_HDN/>GQ3'YS@FL
M YY?OFN'E]\8FM"Z=:DYIFFPK@:] ]SO_22C-70'*+H1SM-!L/W 2)$2?!2?
M&"/-+E=XXH$B]E.8<3P3]"7;<T^EPR,X!0XOGGO]OG)355%/7Q3L8;'=4&U_
M<7*R92BO?'D',-3OT)ZON:UM_+5H:%@4LAQ!LP)?](OE;__)UB-/[&A_ANE$
M.Q-_>:]]-> 5XQH.-<'O=-UR,0[,SS^:4UEOZQ,)ZY4[UYU]10Z7E ]/VD]L
MKAC/R&Z;>A<K@FQ#%C$MET6#G<G!7A."O5)IDGF:XN8CRF;TH6F&P*X!PV&>
M\I&>%W1J!->N)@95M:+,2[-=UDQ'$^_F+Q")W?28+VNQEJ\F]2UILQVU=LTX
MX"MSJP%*Q7;ID1&UP!^V:ZZ/A_NR6H0@166H;KS8Y6HB[ICJ[M"R&#<ADWR_
MP,SGPAJHCH3Z!9T80% MCQQA:=GK\+=K<AJ]X^&L=10EC7S^C/YE8-''FMO(
M'G]_SF63[[0,(Z(,?MI4(<-)R_2AKD]&F';33Y2$K[@*C_-K0E9OC^4)2G"A
M#?=QR-"R#2*D:5M;JJJL*OFSD[_%;JB0-%)R:''6<(.HG]:FTV796+@!XC6A
M@.RW^-\6P(7Z[^6]]$>%;M 4[J>Y8GGA7MVTN1MB&B%:0P4MA&^KVRK0,A#.
M$N%_'5CA^H>SJ0W]QP;<?]3I^3\)_\L<M+^ '8OQCI 9AP9;?DF1MWPA<PA[
M(/IDZ5 !1Z\^(2',F#2Z^=E[:X2#UIK40%A]BZ_8+L,=P)_TZ]82QNQH/Y@E
M(^[-H9UE#%F"=FY2>A/]UZ6ISWY6/@6IP\LVX1 X?2C/1+-D!:A\)G;:Z".U
MYVWMQJ/>A 0=O!\!LH(+Y4T/LG,6SF"_&'PGBG-KU;\/1A<0M ^H(;?]\"$U
MC>:U&6]_1 9 \FLL+J:BS$S4 R657+I:_1@G3S@B3V=ER;8TYF?%WG62%)5F
M+TUE7;\XU*CSGJS9'$GV30<R>2^T1A)'YBGG)<;FCV1V#Q<8V@]O,9JP>FHJ
M[JBFN92.*YA";))';PB-FP_/2AC6RCYK7P_.1!8$/EVN($/YI"G'[<_T[+Y_
M/<(-7J=Y5-?,@8YN([0O<27CPZ978?0QU]#-D8#/S9*:3'CY,ZF-:0O'&DX9
M3N2VU'R6<I)DC!ROF"+I+?UC$W+F0O#^4T,MEG\=-.^1OB0=_T %X2)X4/!E
MB:3PSVD<#;HA_E<$R%,:L:J=_'=+0D.ZZ_E I12D2G9>TQ?(]_^^M':P;>3(
MD53WL6O6U_7\_\[DC!-'I\RP)!@D10!.2O[5-$IB$>L;*?@W>O\+BHKX."'I
M $.NQ"%ZLJ]LGJ\95.@?Q!$.^A=?][$K4=!;J6*Y^?VS_.>S8B6^N!R]-_9O
M[M$K;'1O^,J\OV@8_G4, 23^-^_T3<P*BTQRS;^T5$K(M+093_UO1G-Y_F]B
MEA%X!V",/RDR_#,6Y<'[$$#Z?[:@)R1+I)A_EK\O7/,6/_V\HE.UZ,U4'42U
M*;,J?ADX#!( [FF]HL<(:Q9;FH>2^AT%/]ZL.O=%K5/8U+H?)5QSC$[%0WXJ
MC:0G+G[?-L=4OK4OFQYN02Q7U@D\';0(WP=_F!0H1' (*OO<4NYRKR$J/-:5
MZ#@N=&A8*FRP/\0QN$M;^HA'F$NIK,4E *68T(,5#[:CN1\AAUUY?;>E@VI/
M='.";6!V4>[8O#_>-,=O@M?L'L$/L'R0SD3;]P@CK'^D_-C):=SG@4%EK#P;
M!R,K^BZL*MM6VO!:H]VFD(JJR9&L6+^)77:_1X"W@D^D;=[<$NP5J1<S-ROT
MR)!G=*:MY6HB-9D2VIIV[>VT6^/=WX 8S?PDZ2VC=%B5$1XXUJ6**:-?>\9&
M?1[WN)^;:1+P".D/!/M\W=KGV8R6[!/88VFL^ZQ$$<;=T:KJL=[4%ADDD237
M9")Q.JBO/(US!Q@4NJ6,M3=>.))PF;Q@XJV3OH18:N:/\5:*>9BGO/-ASC&V
M*?S/$$I+L_,<^?%])/+HEK/0Z9,ZL,*4;L49:^=W-D_Z.A*O(<)KH,'\Z-;3
M UW (\0]D<SB4Y:]3!_%"V9UH*&V)%O(,@BB_Y&A,LJ[N\\44"F/3?\;JOR5
M-2O!U;%;Q"5;%.&T>ZVP? [=9Q1;^Q)%J8;ML6/2O IM_DC_\&/\0/,BVD-K
M"'H>)&GW6DNXG*QO>*+;+*.S5>BAHE'7CY0';E(5M[4F2:$77]V!FH9FYHND
MSONU=*H6>]Z"2E5K8P9Q7G%^NO4?':'0W-8CH#4"6TV%:F1_I, ]F%!G0@FI
MJ[OXI,%E:-NW6(K*BI$6\SR\KO\LRJO.-:RN%(RNMP2)V]&=.NSN!UA\,U0;
M'2IY#2LB1H1<:O#7%^[0\F$F]L==$AAFW7LI-^",><L^UY12C_O)S>INEO,&
MF_SI]>26YL7+@QB'QV<_%22*2,&H86)#7.V<;<PED\GY=8BRPSM %ZUI_-)F
M^,VJ2[7R.7X28BK8O'AFVZL#/;#,_ND.\"C]N"TBB&9\_UIBJEZW7VI<4N
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MQI1EY2/94P=?R+IG,M\%)*".Y\3.;M;U"K%Q]CXL>_PPO^E)2II?6-BQNU:
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MP*C3?GB-1+(JEQAV0I)Q<)P36R!')^I]H[[3 C -GX9ZR\3[^NDEN:$<Z5D
MSYHC]_8W$86 .'MC3:3)H%920.6N$2) KL".E7!V&OU>D.)(?4VE< =E"BMW
M<&;)<%[ +H:Y&[<<#F>5!]WV[J$27DC5Q/]ZAZ]>X$[+-O<H0#.J?)?M!P3L
MWOI8M2G.#YWY+C_4T]AJ=+[M/,39<47? 7>517TZ8.K)-71KO$X*Q)]3?NYI
MK?H.9204RD\N=3S>Z*BG-#'2'4U-G,G.]91WZX=Y/'V"8=LCOG?5AV9)SH]
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ME^U04=</O@'!OH08[!BO_"DG![Y;CI[+,;T:JCL G$24FU&<.1P'56\VRF
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M\Z74VXGHMT@@ER?!=_%/S["T+]'P2_:)>K<2+IY%BYBZT8.5\Z^N9<+ZU>#
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M,&YQKNJGY_+8[L?4E?:PIVW&<Z.GET%1.@:VW?G#):&9A@F-/VHX#H#2>C$
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M6-1=C^((DF@W"O)RFPN:R<B+EQ957E/*1!%$SAA"0?8W?E7-Z&X?"\LA60N
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M^L%;T*P&0T0;B"Y-Y067+H1NZ#J3GY17:VF%DGHS?7KBG*+<P#)2VJ>$[R]
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MB566S>&K=?4)WOIVSB56XA\U*1U@T#(]IL7,; ON3('Q;\>8MY$S#X#SGP^
M9._-+Z(0RWPO,'+*'N%P0%+I]NGM=P<Q2(]H?Z)P9I7<?LE.C;9$Z*W<'QC/
MGSW\E430:\$TZ6;:H6BUC(KJLJJNKK$M6^+\\R(/V0[D3^6I@- :0;?<-;6Y
M/J&@=(2]+'.7O;PRQ)*LG=PK^IKID+ED"C;0M[P(-MS_[=J@-^Y9ST3.>#H>
M&^#?I3?TRG%NV,#4$45QT GH6^VQE<E<48RO_C/ -2L*,_C- %CA5.0UNHC
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MU79Y2>7< WL::>4B^)/-KUW!/%X2W81(&JX)?>.]#:H M\'2:VN^,7TO,(@
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M(4'_:55,UT:P-4F%J?R./?*:>@/FZA% #"E+D!PBJO)!'+S=-^1U]JI:?:_
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MC)-D,"I635_81D^<>]F_"&.<8-'A^J+(3S'FD7^>^.1I=!_%8823G.!5HM:
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M,S-GSLQU?=_U_;'_2_*3?>][K7MGW6L78PR:66\ OZ,#;@!W;@!#P:;#I5E
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MEXX=CP0'/\E_+P'7Z6;O<(%-*1=UVM/)V:MG,Q_BG _C<T^=/DR@-0#F];=
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MNP<G\Y75-1]IH"?'*DS+7?QIZ0FUQFULDQXI2K^@NP&$[%05EU+I._$A2Q-
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M.?,\^0W L^7:\_#Z.!?M=#7N_5#?,-6>HG PV6A'<K0IM7XJMOB=)C(CX:%
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MG;]_1I^$.U"F/*4;!:&BA'V!#3G;'FIK=]2:6K$SU==S'LI .I'TTE%W^7'
MBKV7@@$!46E91=E*(<Q#:>--25\B89_9AN[_=A$P>MW@9XNNAW+6(8L?"N=0
M>=CX!"E+LH4YP9(A[0^7 @52HO_QPD)%T]A(:00.8VY?&&*]T*G&+5X[FFMR
M0)W?-C0D:=6CYL![Z3K-IMC'ZI4LPS SJJ]-.S?]CU5AOY.6DM!$'P593<R
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MFZ8[G/::G^U_;':_ <@\06V8\/P83J@G_:P60KV]2-KQ0]/C;HH7N0$#0!-
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M[ZMKL7M-E9!K*0=3:+WYQQ9COCHV'WBJ+ILL=I$L-RM\YY#H7[<_PT?2@VX
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M8NU?(9UW6[@Q9L%%9R[*X]]EKM/<ZO?HHI26M#8R*(8]PAHQ4M0C9@.*;Z[
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MXX2[7>*V8^.EB-_5; *EHGBHQ74C=VVE$RH_MMF::9@7[,EM!C> Q+3Y2M'
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MF[B>E+#]""@-.%>]AT2WAGZ@)72W.F0Y%O"#'Q)!*CO.9_WC(2D:1LZ)R,F
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MBU)9(!<@:_W!PR?+D1'?:;TE>,. MBTIGI$MZW_81%3-1RJR^S-O1NQP@]9
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MY&YV?J^Y!1!V!Z",]\DM;$"Z\R99% A@S4A2XC1K>60VP8P1:/)"//UF7/3
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MS8%1JY06(:"J(S8XJH-4Z4T-!07.CD?I^LVYX\CT/ B>(5'W&ZO)="V4TB-
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M[I\.C\,J09MFOORH!-Y)P=JV(24_55\VO$K8X8/#88R/C&G"*%]X.Z/YHM?
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MX*GUC<&%S*R_9=&*N)>5<4>4UIP\*VBV]],:/I]!/@MC!.2!-1C;YS W'2>
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ML:/KN7Z'</$)'\JX*?)(D=E_C;="D?1#M+J1AQSZJK45Z\GTN>R;0C@D1F9
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M ^33' SC5VC0\#.M7UB7=4N)3D[;;.@VHQ+Q7C[UN&X2IMZ6FBU3'NFAC1V
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M;\?_YEV;"(I.W^.<Q/&@H">'#=< 3RC"UF/H"I@,;S^YN='TU>G;/(?(K]>
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MJ=.)U#H?OO$!S<YLGLRJ"2>8B*ZFX")C/UXFY:$LFZ$)O/4X)$8VUCJ.7*3
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M0X7W1M!'@*, X._!(=R#NVT%R   #@GNIQ_PIQ\</ (B$C(*ZATT=%B'BKL
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MSK?)KH]H+I\+'4X(7:XI():KZ)L'W'A(W )>:(*#V%<G$3<7N'",>/@3Y+=
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MVKW9RO>LDTE&OUK11I[0T:Y6G4'?$EUGS9#JFCDSAGH;[ 8#H\\E1^AH5$D
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MOJL[P8L[N\<0W9!9_5J8NG%VQ-A#M?GS9HQZ 9@Z7CSF%680O;-4B5*4OL;
M>^-<X%B#_GUZT< %[CC]4P68'[@U6U1VVRM[N%=QOA0ENAX?\4)R9"!^L+40
M9Z)X14M9*83KV#"E-75OLWSDXY7LH/$KR4\2.YW@YNI7S*=BE!(/,7"5C_'
M*EG/OM*3EAHM)#]4^.Q[PB9ORB,$ 15FAA8BHU1SSAU80'?L"TN;ZI.(&G)!
MM2L^BYW)Q9 O*T^QY 0K0O?T._L2-:/<520J%75F _B-<C?S*#&7IK$;T/=
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MBN;16' /01RU^%H+WK@G!Y1D>X<C89)-.ZDC95/'M=8E@G?-W<W)6M.#^Y,
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MJ&#D5=1-GR2Q;4OP@I66C$566?6"9!^^0)L;3[?.IY6U?AETY43B!D7GM+J
M_K<E=D.Y&=5],5L[#M9^!(6V8EQ53*^B[*IMC^,9DP:C8_N'8L.K1Y3H!^4/
MLOJXN)>5Q4PX G;F/ :4HY[3^8W3$"=.5[X51=6[7H^#6EBSCS98]K*G9,M9
M?;=Y0B1<9>K8ET%9#C[(YO!UK39.VMJJA'!5W$-URPIYN(X(>%_/M+X$1BLD
M>+MYSPGX.1YOOERO;DDXYM]2E;,X*'XMAJMNT/WO^GIF@=]N7FUD@2@L>+OA
MK1G"64>VVW7%8 S!DE+T$ZR /,Z=-G'ZH'VSU\/*1N"<2,R#PZU;0&N[Q=#-
MJVO+K?HKF5 39A]I<-%PKX6ME1-JXIV8Q14"E'4U$41CXN CCC777HZMEKVL
MGVK C#^QH4<_!0-0;;O?^+R$LJ*.KH1UC4._"8DLZ S<S-U(D6!M,YI6BD+!
M_L4]H8]%/3*;5RF?22-#"/W,VP;'$N3 &SN<_I1L._$$-5/#2&, *& !\HJV
MTDJK)!D7[Q!A '1M;JJ%O&5U@F^P U2,3*IA42-HX%]VOH&'NQ>4YMHOCJA2
MKH"2JFLQQNOH1Q64R.*MKMA.5U9;]8Q^"(T>XUXJQ$S?W%D]T.&NQ-;FB#I_
MW@G,/=6&)? 4^UE>(]R5D^,IC)_P:D^@_E:V'WW0B7*8QV.@P0$-W0Y14M=*
M3UL6.<8M5Q3NA.IT=Y7OST0M(%4K0)(0)K(S?.Z)CZ+Q8L6T)NB)BXRZC\0,
MJ;*U8H&U "?$Q7R\3).T&7V:*/&[S]WM#HDF*O<JWE)QU*T83/>!)(>C65(H
MDDB*%?<J,@5:JT*SF+C2.4>Q8L87)-]16>))"-,>#Z,>%)*::(5GU<!R0WZT
M3%:B:DW[*G:4ONU5SHJ\C6$I/M%7D_?D"#N4O JQ/"0B)U23KX9'2C=U-+8X
M2G'/#8^YTA658\>=\[+4#"%$<<9/%RLLU[54U LOUR?=KY?TZ#/]FR<F<(@5
MD918O#8#T./D\'!73K8<U=K$%>UD'&)1;!$=.2HXCS,UY$1@=+YCV48Z@#YT
MR6A37S+1?/\Q/KZI(*EUNN)(=7&#NSIWIC;A3NN2]XY0K;R#+J,1M[/CD%J@
MVN^12:OBQT+M"!&AT%\&(ZA^2\DY#L,-Y#L6C>S+7P5/I%Y[-!UPP,7_>,BR
M+/AC_>?WU[Q?GKT1XRX-^>#-9$A(<$,WDY&1S:G$7\:$8QO/QO-0NXF'8.DA
MM1Z)/$0+HFO3LNGJ/6SI69<^Y6BY&K<^%[]UFF<88Q<],!:B%9K/)Q"AE*PQ
MHJX=3\,_@$KY:(F(GE*$10")6?H7RD)'NV-4I3O$0OJF)NT.B2^M*0]"@XB!
M"76=ZQU$37$WH9F"J$G]C7MN.=3A8X))B8,5HT\^56B[/BO(^[R8V.S:S4'W
M6%-P;IY6XM0C.4FR5+PTK3GO,^[%(HY.@T27;<L ].1#D83'6YLX>7FMH[V$
M]H?WF)YO7?7S%F-!.+\><YIG!!^'*_SK3UE@(NNBHOOU,]Q4HO%AAPUBM.1G
M"B8ISGEOYOWIG1(7J@<.'&J6MO I6I69XJJZD;U!K<UOK4]Y2X)J5^(8'_3Q
M&*:LWP*A3O+M-:G8KF;:C8-(QYD!.G/BU[)V2-^FV$N-4ASTQ<X8YZ.;*QG1
MD'1][NT&;^=["G!DN,58A19-'0T<!"TU#"\='*,3IE,VLM'(/IL0.>@6]&_H
M!IE;X[\JI2_)1&NMW5-[[2P5+1^(,RU.1QFF;T'4SP V2-&A#@W=U>][UW__
M.%)B4<\7ALQ7_!W+_JH7/+< FKTGY]X!\0<WLNL5LGGUXVY3_6^CGA&<7M+?
ML!!V!8/9U1G*(0Z:+QFV$FD^W&AUM;EGQ_MQZ HASS0_\I)<J;P'3Z,*P V@
M];G.+HL?'<Q\,L-+\Q3\-+RD77C"[:+K;5,KA+:MB(=+EP<X LIYQ4_[E%VB
M!8@<TV6U:&!AX(WP'X_*_IDUK3\)Z*,J@QRPE @8#W3PFSZ]RQ;925%_V9;3
MTZ(8I.09+\2 7.A:LN R7DSU:4A5[SF/A79DXB&CO$;#6 G4X[R*]1&V,'U!
M"OH$2""<J*;D8[UY QAAU/$AJ $L)].I>H\@TO\))\QA4=MNA,8DCB!@M/$V
M@_E-28-')7$/*6OXH:-V<J&XR1%J*6R??.VG#GOJZ"$"I0[WT-QY#^@8N\5%
M\-:B6J/2)12ZW=]H=K1,&+RZCA2"TY0.:0QXP5HP<\'3V1I_'W5[D>WI$3':
MNF,)5I%<%?Y[-XGG6_3V$T/HJI,8TB%K2/+J:%*67PL6LA^;K[U% P L)$9<
MM=Q'/[%6CV_\'VCU!RW;E$>1';LZ+CG@NEM9":@.W#@N+(DS4BV=  9UZNYY
M:XEIY</74ZK?*NI"PAD[XE)G!&3-.NLR38[Q2$JII[VJT^Y0B]<H4<?."KBU
M,<6;V9 LM#TR"^OOJ8E CBNRV$^HH(G!PEGA0 K/II0<^/[=FT_N?\$U$%7Z
M:[8QA="L?>0C@3;=C.A@RZ\6Y3OAO(LMZI7&%6\O%V^!%!O- UV=B<K).O70
MB 4$B@;D!"HIFI8T@UT=Y<]?-O&-"@AJF(-TYHV:*J.S?#R(/O2&'CE=;69^
M:)DP7F6V]$F94Q6=QV0XDB 3+W9YG5=96MLV?,CZ=?!UU.;YR/V-!X.W0(]L
MQR#(RY,R^\U7ZUFUPLJ+!\FO1,)'V?@BGWT>\2C'QI?/[I,CSYM]5UE9% P.
MV[21VZNW[69BUNEGV7+';JY]K) )O%0:TV4@)B\<31IE58XJ&\1@S8W_2#,9
M:H379AG7/G$A$DK[%&]*E7Z;EWYM;Q&#EVBYUQ8;7WS@+*ZE>>R$O>Y;DI@@
M+1&AZLC<&RWV-7P[UG&$D@K!_F?546+LF'G83TO>A>N'J.*J$)D5[^.ZV3CD
M53E0W:NY(4^,2R!"'53  MH$FY[Y6M(*]*<Z-\+HHBKJ+VQ.] =N.+I&_<.A
M6A["0!ZL@_&?8>R8W9\5\!WAI@=_OWEP'5?BC1[,=Z;<C/WCESI+X$JR/#4S
M;@'K->X'H-:W)M@-KB3] 9P@[6B;QS&37SK0Y$##7Z3I,)WX^;N3IL7HS4TI
M\&V#V33FT"[XOD"9#>9#>(P1!3]+"I31]UWA[)TL[RPVC5*RM@;8MTM078Y]
MS$-+@_/A5=/H[M;;DCW8XD]WCQI:&!3#:W9/_V- ^*/\\TIA/XE.:BNC[E$)
MIK3A*RGF3DRGV!9/Q>&<QKTYUYBJF,E TE@(;K*8 X9,5":3[I:K-JLS0P?5
M@2S:G9<H2A9\"[5-2&=*BWJCE)$#D*)7A./AU=MZ(UEIQ?T)N7*J5)DD_99[
M!;RN]EW&?;LT3A=JO1(8,AA21!AT- ITTGO&.Y."Q?>6@T7$<)5H?N3LM-&/
MHAZ(#OK3'BF@/+C;O(ONM=:'R0C:Y/5X<*F#'D_FB;50&CMRNCKD@\*G$#VN
MXMRTO]-X?N/8$\3?/]710U;OA?0B68TGILX14("OLR)A\X";J24A;=D:<"L#
M0Z*CM[<5UFNEQ/'Q'Q'R%IQH36S_S&A^AQB<A7_, H%_;=+WM^0Q0?:_\S/)
M%HP7DXD<3T8@@L' "X %AO!_VR3_B::I P[FMQ#R7[&?$&L]Z81C)R>X<1I7
M?[Q/>?.\<#?MQM"').VLUDKO#A,31TW1-E2(18:<@'*/\XD?OYG%0@+3T#01
M5Y5]%O<^MM9*O52A8.I>8S>Z;:^#RWU1HA+E%"PAWI4K/C"S_Y5J3L+1MRW&
M8L,#8PMUN _%8&G@"(SK.M'3P@UU_I3)IU.)-3M'FE-^K.L]+#7\X,9K&P?#
MYPW5V#O0*3<IQ3[I)PXMW;8MUG;H7KVTI&AGKTLC]BB.UAXM3AJ[]O/]SJ*G
M2G!IF+N8KL'8]]>;K*O"A@266:9="VNS1RL@T0U0#-<O2NR)2XWX^_,)I;>
MD!)X336]4([9YH79^WE^;&4YNJV$GEB=>2?QX0?SQ=M73$-Y3[L,V<],4W.O
M-,J'*R>YPAD'7<EY.C9UG9%9=9C#^9E)V@KU)\0?J"Q_)A%S\M22G(>2'G-$
MKFD)11P)&%EF=P:+7F&W.=%L;-9HL B@<AY0?!*?*\1[Z1Z\6T^^3WTI'L<'
M6F77/.HA5<MP)((^'FJGWA; !F<46-2&5>8;D8P6!H2UB^!9U_0-_,IXWB6I
MHR_"7IRY4UY&(5-D[\%(*R6FFZB<2Q>U[#NR<8QIVO(BM&&TFYH/I]>NZA;
MXS@C@)1C<_&EQ"[C7\3.9-L.Z[X88B==?2V>;'CA=^2\)KB_4J/K)C7QI!2C
M+)G' >I!F@#:YSHXT?VXKCW6*'3M5&(C4-G$H_U>KUM84,>%4UEVF/&H1R48
MEQ A>FJT7;@EES+]J'A\*$KO<&2OT-"B6[\N+!*"XF\0L:LCW;/>!M+6F)P(
M%2,@O=XHCG >>U!G_#2*W=<+))>%4PO+I'$Q_L,?L?^#\J]+0_X1^2>XO>HN
M0UI3%<CC/53R0T&*?Y&B,.'!6B4.8VW7J]#*55:$*X[-;8H.)17M.N,8<?N$
M+<MC7#BY?IFRX47S;:NAQT9Q"#59Y4.OBM1,*JLDH88O7H,#1R=HX+,A?I7)
MUH,3S:7DCX-+\HN5!$59-UJC=0LQ\DDKVM+H-+%5#3$MY!V()K'R5@)E$=I;
MR&-"56+4.ECGW'MSQRL\WMOY$"_DJ5LL]&-MQ&N-G*I![:7020G%7K;,AYFZ
M<5&G<NV>@EQ[M1VB')>_;H7? O/(=6PSLMF=RYD&-7#;>@.8KB6OKYYZI4]W
M.?#<^RHN&#N;D^Z!;JT)\X:REC<ZJEKVS@(O>*-R8L++@K-S];./-(DEZ]DN
M5">^CM-D5AA8$K6F&/@/$]OV>2@@-E*/A,>G34TSSZA^OD@\7UA9D"D,HH[M
MX2NE2CS15>,+DY>+@TIUJ9.TN3F-^3M)4MG&]5/0MB_C]0:&)D-*MTQ4:443
MI+Z]'YUTQ>ID[W5LV=G#=+ SYRV"O"V+23T%->ZEI-KEC/-S*[Y?GH[*R45'
MV68:K+0)C!B=,CPV$Q7#52_PC,Q,9\4ORS5,&Q/3V7G[=N;%M0]\WME8:U7M
M\SA>[\3 L:J2"O0CQ<T+=?Y3/MHKFLU#&1T26-(2?-0@MNW$(?/!.;!VJKUZ
M?,:_YEJHM9&1]^'9FWY?D,82^1P=W&2JCDJ<^S2C;6W*IV)+M4J71)7*D\K[
MSZC<EI^2!Z(0=$!+SG#T&\;*\XT;5=E$:4,E4YT^=U#X\-;^QR^?_@/RK^*P
M_Y#\<\\KODM I$Y[OM4)Z,33,^KP;$P1YM*+#3[MBVM>F#QU;&:D)D8Q.9^L
ME"Q')DRVL*MZ#G$=38J^B0W6'9P@JCQ]=0'ML^Q@RZ9/UHM\13&\B)46=UY#
M6B&P&V]C014<C*H<3I_(S6V,?11'^MDPP<G#[<14_(-[2HVB!HF1@F>-@#QU
MLF2JG7=,.=SC["_E]5(2TT85'7G%-9*4E-EV-J>83G%8QJ5^$4H9/H]&=QI[
M#=OD^VX!FF(+=<O7Y]"J0#)V[8[)QV$F W!JY55W\NE8D(P)OAP75*#W4G'?
M+7^.,OV%PH?/@/BE,<4-?$V#(=D3Q?MP?I%@K>(QEW#[,=DC!#S,D7@'D8^]
M]>'B\T-)NLE=26ZQ 4KL2$H6<2$N#JA&< P\?%X@O1;QR&S-XH]X;BIDT$H'
MM:>QM%RZ@Q M=)8=E@//5G=UYL5MZ@N9;6:M4I\ISI#E!1+)U=Q5W?$YI7N)
M7^J2I30UY@S&.&?OZDLM6Y1I6?3<F5W%3O@P>5RL+!,/BT=OE6PP6S*GKC,L
M)-FJFVF>0#SD)H1]' %O7(Q#B#1?,KITZ>!.>4#3\/-'?&*G;WR$+HZS]Q;E
M&S\.62-]943$9C4GMRZH5S=7(4TCTHL!_F9I<0!9_B]7$#GC_UJB#9A<_7AP
M6B/_HW_]/BD1$^/?GVPUCJS,*[91@.ZL6%6:/Q#:Y586)I'%:Q5S8V^$IJB\
M<T(<7>.4F00OW"_)Q" "-LR++DG4T)NB=Z2F9<W_KLCU+[IF\0_+/_GN\9^D
MAGZ$U5*9'IZ;:WY7U\IL0\M^IATMN8QYVA)8I8TJ/DN0L)./-/85)=Y0#"@1
M%0/$K"_GE=?;9%3E+SC:FI8_I'B%:2')/PI50-"9QW1*=(_YZ">OX%L3 E)K
MJM&(2?99'G>&@')J2TW"9V3/D3ZVI.'"80?BAH2X;-G3LU7L<IPS,\09T?.'
M'-)L:W1_#G4T^()2 ? 6"O6[ICF*]$.S$TV"O#3V@"Q?MF 9KY6E <1R.U]9
MCH^*479J6X[K)4GL\.\0^MPK /,S;^H'!]+N?,9JO6P\4)KF1\VO?6A_#S[_
M,5M].X>S+4P\4^%HUG#)(U07$7U<P+&N[37=DI(C*IN&:OU_VOOJ@"BWK>]!
M4B1$&&F0$I!04D!I:6GI[A@!Z1 <0') $!!0<J0;$8;NKJ$9)*6[&4+RQ;>N
MGKKG?N_UG/.][_UC_3/S/'OMM?;>O[W6VFNOAVXB?F2K\-;@K#V]]53)GMJ&
M&^==PPDEM!9WG$P0WJL5O9L165X%7!2!A]DC$QXCPNK<".:<1HTC'\P5"&!U
M.8VHY,^\4O3[Z0>$4_^=KEP+D;:-,FTG4=>MI2(O1EO 3,5!3!*A^'H*T^AR
M+SN.S%_NU\-6GO<(Y,A[V3!UL5?6DA"%.,5>$7A =P?A:( HWGO@JV)Q"RH@
M>"&7NN:)T C8^59B 6_H=0#E*]ZY$'/4,.;M"T#V8P]L0 4H:W+<.T-D^0&!
M]$'I,7S4U 1D/V%!XZ^1]N4E2^NS50=<@)743!1I>P*71W0V?N "8T@ZZEGO
M>8V5U8CQ[K#I.4T3OK@&$^J=<;'2H,#8PX('9;)# *;Z:97^G]?)^1/##7ZF
MQC$0P-R2.'"CV:(X4NA-Y] (&ZDYL24G?N?L1Y]>_EGOFR%Z0IM/W%.".(LM
MMHS?-A<19),G^\"=>26O@31G;KR_P[_HS5\Q7546U,%0KD:],: )I^<Z>]]G
MVPI4Y,N-ZS[W6FTD9R;I:'.PC@;8C*]!]O)46C[<1]EK!1E2A(X0=9)*%T1)
M5=Z_R5)^NNQRN<K_GC7S@Z9Y3]T(*W?_>00O?HJOXHH(&;>Z1'BP4Z+H@:A+
M_ 6@<H(: ?/!3$>QM_R=UATSOJRV^( WW]UOT3O7YSMH]^;[WO\9^6DUI%]M
MW;1PH7EKF4O7\G4GG,MKA=S9><0;EI8C$,W35B_LD%2/*H(7X2K9M7KG@?HD
M%N86<T-V3EY@>SD.AMJ1X8/G?>@Y3)ATM!! ?U\:LRNK7H(MM?:ROR,9'^,3
M-##VGI[@7^YZY8B$\YWZZQXO-5TK63GHH]I8)*&FA<HZPQI*H5U&G'=5JI4P
M@;C0*?.(R7>55SRPB^?;$C92[NZ#UL*\LI$H>OFCFAU$H23[F*^M3!*V1N]L
MO)@*R,R0N]'Y5K"2#.!EO8Q[TN5W"#<:;V]SLCL<W >6O8]^97O[!9%]'.!S
MEGFE+\K)J)I01L7)I*W,IS;;1KZV'<*.''+QA&([DXF$/DS)L07(!:!+[,5+
M[NQ\S8JV^+*S39;$>LK !4F4=>$[@'6Z&'X-)UM2+]',$7+<YE*'JT;&1-3O
M'!OR*YR7"32Z)".">HAA5VS8X!XL-X2O2^K<J%\6]$"4$-^;:*5BQ&$NZ;N=
MU%RB+$'C_PUP8'V3KE6#]FT0$. !_'\MCR[VC-DZ+-?Y0(?8\(7);GBK-Q=,
M4#E)W.[I,TR\.9@IB0E;Q1L.P?$H!668^ZH[-ZR?),V^Q_;QPD.M%!8MH??&
M#^.S)-<S2=.VJ9LSW%,'G0/G3[.9]P\+PI4!*R,HE20]H'HS!G;2U],!TY!^
M47GN;C/E06OIXQD*@0#5UY*BF1H)GO=V[(=++@#K:YGP9KH%^K,9_5 !#?J4
MV?5>,4+55WV7:J#U_9GUQ(R/R@T@](F#5R$VV&3T6J7.5QVUM$MSZ7=AU3CJ
M/#-O7?.@4"?@PNP>TT L/7!T1 I[L9"-()\Q:)/B?!5=>55>S'EMIH/#!YFW
M2"/*",UHN5I^-I_ N)WO: 2:XU MT8M][SPGYF='#QH_*E*KKY 8GWPS(F-G
M3]G-POJ8E,240-?U3;Q]B<F*ML#E\C8O/V$'NYQF(0N=5=[0;3U(LLY+9P.&
MQ?R'A<?]@U!!C//>\Q&6W/%K5[6?F'%4]'3O)5NO+(#9>1W[)4'A[MJKYDD*
M<@D^RTQ76+1>S?D]EDKBHFEQ0I ]YMV)\91=YS=F2;J3F0-)^JP1JW VVITS
MP;2)"] >*BFRQ.F3A03F\+<M:(9X4ADPT> .VI_4)>K$:-F:<BJT!"\_P!;+
M#354PA1/TPRQ?!S:,!\5*24[6  6*S=-W.A@D.Y<@CG],IS_B=Z%M/O7<#I_
MC8;B<W?M62 ;(<4'RE<6 3B<L-%H-,-02$=5WVQT2'TKHU B+L"H7]UT8&N6
MCR O=5A!.)'6*LXO$(. NNH>-TK<Z(F;9JM>+ DP-T><H2 "/<T&-O^T(J5G
MBE)HDY]!N*YG9/*TY8%6N4QF&7.Y3Y(T'Q0GO3@(3]1D51[C4R;\6K20WXXZ
M$Q3+.-G1W0'W(]X4C$?\H;[Q@IOS24:A5:53I1^M#/T3?7^-?(#*6QE6.PJ6
MBJ(.ZB;Y8E'*-)/LMMN50X,SOOVSP?85THP5!=H\'"\)3MI=DAM+,BO\;5X?
M:YK%#!CPHKZ<=&Q(2X%9+UXM00K$DP_5> M02>$(XFH7J"J4\\9V.NY*NWPH
MR*) W%!W>4##;O9UJXOT_4&9HH9N/GL,)7H?9?*/ZW>N$/!4US5%7LT)F^^=
M,=<C4AX7BNZS)SEGK-7!Q5@4<S>K+\1E9!2"K1I<?\JCDR_$/'.YT!4TLQ:K
MB]$H"-KSK;1'^'>(*Q]/;H=E'2L&;3"JT\CY/W7%J$V"B++*T2*-(@QN:[((
MO;?-P9NCG:/6/BY\K"[/.6JPA54O'&T2++N2R'?[BS9;OP2PV_5[\TS=MLC#
MQL;W_244L %X+P :8</=]OB<!@I-:UJ%!?KN=I7TM[)),..@Q!1+]/N,-0+>
M3 VW(F3F>15$LZU;DN*!D\C@\M2/FSAWUMP<UJECW-H/@7O[NYW5&TU/>F63
M[E"4Q@30O^R.IEU74!PH]/'Q419\$Q/W,B\O3VS:\ EL8^&3JQA$T;5B?L[Z
M1+;RJ6\:;/9\(JRJ14J=^]/II )'&.$BSSA;F =H2DIC[-_!A25A_0>AB^^.
MG+8LI@JLK>$\7= ;H\H8!8UJOT.OX4!GQ;@5&+9PK(2F=Z>:#AZ=(5AN8.W5
M!/0)0J;[N-2_'/.F3X%PA5E>60R[9FT8!JD>4=2,0Z\@J.G"(9YQ7-'YY4H*
M?V;8@2@P'8!3CQ/EH^DZ-HJ6#L6D=N\555Z[ORCSHN-J/;57X&Z>^W8,O&Q%
M!'.LL""-G5V/\"&U06,)S7"A8;T+(=-:*ZYJL%@SU(5H%3#Q81?&>*(+28_U
M?^SU.5\Q1\LKHR62!R5V41=?=FFC@*QSQ5QU-XG" [*6>ND<KCI@M4/Q.'18
MVIOPL)#<JT/#W*5:N/#*>>K:U"\(E0]VA>_71*YIE#SW+ZUX9VI8%#TALP%)
MU0T/@UW+%61[562F\84TL(8OMXJ0WZ&EO6:V#M(W^F!L!9OA]3-3073'%S=W
MJD?B$B*L'7"Z'<BA&-73\Y$R'8)6:N\T.1,(^D:>6K;<Y>J,N>T0/=76+^*+
M0KE<>&_[<[CV\,UQY:Y;,Z:4N36E(\BN\N:(R9:7HV]1E09UXEME99?K&+'Q
MWZ.]</XTGM! NOF$>J!Z <8]5&C\87"\)^*MG=D\T_%(FEB2+I/??(Z/YI.)
MU=0/QTPIQ;P_[! 3J'X.OVL3=WNN7"@@7X6C,6J9"36X9L]IB:#=O]<F45X^
M$^LN@T%)UT+H#NFJ5<$&6_/',E;-\,Z(-_<:2',<;4AS[!66M T#Y,!,*26F
M)E:DP*5:QB/[]PIPAS";-%M(XM5C]?W2;/8$O%U]E$_[0'V9I%T3^[O@2GPC
M&9E\R!LZ!BNZ5WV>!'C16>GSWH^5%H#EA2J#L"=50JKL'5+;QR/"8M)&Y1!#
M=_4S)@>'83\C$A8)RD0BB /$2X+M.P,'39 E9FB1:]6NMXMD3 @VE!3=)G<!
MH"[C/[]<%U"TK\ZQW+5V&V<)JV3K=>&!LCE$'L6T0JH0K%/TI",MMDQ4]36)
M86@?>HUF]E!ULZ&*Q#0D5XT=:@/IJU#)O.62NV;BH0:VKZ+S)8=<0G\Q_^J@
M:R6M.38GR/51,<?XNWF22(5GS[$#VB3L[LFYO@Q30[=%\?&1=:P-JG3ZXFP\
M\.\!9'/K?V($^3L4<,G-//M(D7DC\PY($@*8653GZ"#T_8@'[;>=F5%=O@?*
MK1ZTV<+0>W;VUCDO8B9&1BZ]'W! Z\UUXIR=E_=9Z2U*,L.+$X\3]3?:5S"Z
M=V.I)RFP/T%(9D0BLM0H = K? ANK%0 #HKBKX#>GW@&F!/WJAWV\7(1A)
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MW]Y@2L*3^A_A/_#%Z+\!4$L#!!0    ( ,*"<%)JLXEA@2X! /=G 0 6
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M:NM:6MO:.SJ[NG\.#8^,CHU/3$XM+BVOK*ZM;VQN'1X=GYR>G5]<7OUA%QH
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M21K][NK+9-U9]RG:S(G2J,T(;^XB0-Z?XD6L-'V(AQ8=) VV-JUD(,HX":"
M86=[ ('VB?!5SF2@@*.1FL^!T1<:B4B]Z6Z,6-7PG[7R QBPF/DV1VM!V)1V
M<A%:L55&:F4L'P<[/IZAVH"P0,Y%?G$\3RZ[58\/'A1?[0"K,G,;WSOMY\>5
MJM%^Z/A&YI30+/X$N*/WL# <_V*\3<^F\A$U/]>Q)7\Q^&#=;[>"E6*'!9V4
M1N"TSXE8A26T$(,IKR?1!79;>;"O.5SI,L)-]G#&L=(Q0FW2ZI9O9&]1;SO
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M/6IH:LW^^ F3YE ;BD5S*B BZ+6%$&9?JGE^C>%>Z!6;)D#6N6J@Y._)AQ^
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M>(C=;H(KU)O7TM/3JZIEZ\%;"X736J ^^MDPH49/E.PY]$[HJOM*24Y<7*^
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M;F'P-7-*"$&HJ5F3&( _7/*Y&GD.DRP%YH7)X_\@,RIOK60]H$QD80E2X_V
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MF(YSRV*Y5N?[SR#A:;RB"\C=H)E"N>-Z2V#*54/7H>0Q<WRM!;PLMC,ZMC$
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M>H"-/P(V#UB?WF +X0?/E;OM:<A6X]^A;U6B9.WCR-YJ*3Q]7'6M?,+558^
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M"DWVMCWB7^H(EO '3NX\ NA[%=7."5]RSM;4)APRJQ3+;S!S[OUVJWZG0QH
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M]KA9]C@HS'XE*TRGH#.3022D)=W;?K+U[=]@;)-[P;@VM3\L/3R\IOI^_1%
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M.YJS;+$5(E0"W[D-;2>YCK+R*%\>)"2<TT>R'EO]Y >_7AD<GV,Z&=^V4X^
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MG]UA0QVVA<H*QQ>&*H)QC4B7!,;Y2]0ZR!>75L1<* 1[&^^[V73&['B0F64
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MN'AK@!DM,4E-T9G16#;_3?H9^K>B5@"5I 2YAY%!-^["8I\Z4W@.,;RXTZ3
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MNT7CR+XA7B1PAN4P>3V^M!D%!G5^U?&NUNUYAUF?M34CWV+%C)K7L%/:<7]
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M(MSQ<@7%4=.#Z:RE1>7G16!^A.(Y.>M3+E/%=/_(=IZ4)YS*\.6@&3][< <
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M73$O:V*LCM;X\L3NPJR-F^*VYN\I%H[V>5)CK[CY6G$;L]L:#R'-O)4*%-[
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MJ\L"BAH%:5N?P,_::VIR@D_3$+@2JGLWKY%]HS>"ECDU;74+ON<\V"B8/=+
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MG"*/>9X(" D) 3E$)9\_E> 3%'KZ-R98>'AXA 2$-$1$-$\?,3QZ^G^<,.T
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MM7L2HF<WX#&4+J):;I)@?I?E8);WN.3U2X/9$31WA$[3M.7TF2)U/;C^1-2
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M9SO@!A5B&Q&M$J&F;]'L[V1[#Y!TOQ*?&5ND7NXXJ#S)0.0>;&>Y=:$!\*3
M-4'&^.5[;"EFS>31[>%K9XLMX@8S[-0Q9/K!G43-6/I)>I+I5<\.M.2_$;^\
MBV50/;<0D3W!=VIVX0\%TL:XE%'G_1#/( 8)NBP$3BRG]P-EX#TQ1SR_Y#_L
M[\=,_% A=E_9ZE*Z9A#PF..PIEEO:!&#J3PQ(H]_^.VSL<VNQ&,3AMDH,,4
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MO00!!B!]KWX3TMGZ+-M/:N#VU\95XRL:WC86- 6D<PG.?T-(!8O% /"1"^&
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MB[/O?7@Q4KH+89V]MLTE:D'9/;_OJ1WL_=+\)JE0]LIVY?47%L+77@YG4*V
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M%]GAW*,2%:7&5+>V4%>+%N8Y(+Y3." 1OI!=4P"R%)8:V?IJXR466S1?<,'
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MHD"^8)-G\]L##!;-.-NKLHW6V"I2S6%TA-64=B"]LYC/36J[3#3NY.\45PV
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MI87T>EPW,5I=<Q'QZ0)MZ51S9-5TA!:@]O)*XV3[Q52JWS+1JM4WW0XZ8 I
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M21=)2E*7#+? %<:[*PK+&66JF168QXT[YL>>;FO?NK)>OM%;5L__"B#(D48
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M_T];5II. $'\ *6"JO=HZ84]6GZM7J0ZAD+IIIW&@ZQ>!@8F)QEF50T3WBM
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MPV 93''0JQR4ZA+3.<PN5>H>S*BHRIL5D*38G%,O$!=[-X0MAYZ78\"Y^AP
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ML*!N#4KL$:I3D5=2&8M4(U'(JIJ/+DV%%FKT'=#PY=B0Q-_JV&Z[[MGDA+\
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M& ];%8'HH;!-A#O=A (>VWT"<KS=#;2P03[2*3%H(3RF+UK;N>T3@;@=6G,
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MCGGK+DH=NJS81^_GQS8%560\ZO+^<0'P%M,%^>\,YOA43;.P^EM9KT$+8^>
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M(I<X]1FN1+B%"3<NM#61X/6YFMDL03AI^!QIU99KJ8&?>@)BUJY(PZ$%6K8
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M!5A<S98VNG$/KD$2'#H0@KL&#RZ-0W )$-PA$"0T%CS!W36X)[B[! C23?!
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M;<"/TAN#D^H&M27O&XH33GH\=*89<^.KJS"Q]B(5W#<P)?0G]?+Q;6W,:"L
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MAA51C6QTK58;+I7D@UQSMJ(DX!+Q4?7;C'%LV?[&#X(UH)'H)JE1X+U0^=+
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MV*N/+G"Z/FYW$=7CR>@?2>OK2UIF/ 5EVWOUT&"H3_D3O:K.?3:N[%]P">O
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M5<->OO D\,44,1;YEAGY'5@92:#BSF,O(M>S\82 YOG >JSHK-*J,_DW6.J
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MBP+SU;F#P#,I* F99=+]Y2:2*E\FRD-:$AME'R"(J70;F0WM*#\:%@;74%N
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M89K,[$/%2CIRK3+U(Y>G[F@Y.VYW=]';++)MHW+'['R?"_&6;9IM *Y["V
MR=P"*@U 9X],B_\.G%_"-^]ULO0GUU_'>=_[O(<=%,@YKB,)KAG]@:B[!;0%
M?:J;8C_Z6$;*K=A5I(\:R#XNQV.@1091^HEH1#^&_-/<$M+";"I<&I8'7-U)
M'527",B&LQ8*28:\\)."%;*-0&A#.U)W1WKC>?LV-6"^)V5E@^6PJ,O+6,^W
M 2Y29$LX,/=BKSI-Q!)45%C>L9_0L]+CRY>ZSV 57[MI.NE 0'$\"9^.')*.
M.9)Z-@H$[\4/K?'?>P1H88F<LT"*"_7D_9!W84R?2Q/#UO;9,F2[2&=FWOX8
MQ<>*,TR!LQ<=Q1&"9]QO 7C#Q88P)PPNOINA^79Z%J9TBT8\'/X@&)UN0Z@6
MY&U@2F+KR5;^25QD]DEO#&-*L3TAQT"UDQ"ROV"G!'7S="V.S4VYZ<3$(3?5
M2^X$C+,2H'Q2HY.RSZ>S6<L"F'RD&%4L8&%HOHW7V*-"K:Z'6K6K RC<WS>F
MFX7EE;#?7K5H3Y&4\6KU^0_5>L#Y>6DK\3A7LUSE7NK->74'=:?8J[Q8CR_C
M7#[&@\" (-,#PSLG7%MA9:]XG+.@;V32.F[5H+'H-(#?@ RV4-Q$&Z-]LE7E
M>7*MV39Y?/9CH\Y;Y>E^(#H<J- )UE]B@'9GTC76)BQ!^.\]7'\?? N8+=%(
M=4F +&>+T]%?M4V=&V#]H/\DN!X]B\.'$/Z>-1@Z:./5[Y2XI*G%V[7M;X]@
MM]LV4-33J.ZO'F#ZM+IONFKZR['R-R<R RM@<SY6%LVS.C#5U*0\_KEII_=#
M%O.ZH?=]K(F0OFN$PBD%*M<Y9!7>ZS3@S]],D-D>6[2 .LWP9CLO)XRC?FPO
M >8?D56(MIN=ZKJW]=T"9/GW?"[#V<7$"UL6SP8IF+^BK/,AO;Y"+*O7^J85
MZPF-624)56) 0=T<^KTB*6/-3[YXTQ]Z:\.O9P(**V!A:^":EVZU"1S\1MA=
MG\2AIETK;4B[K02?GT8R^"9(>*/W,P8^0=#Z<56?;+#Y!I1*9*^S#_$&FW[X
MB?'Y>XRJ_#6Y5Y/JGU[9</C"YIP[,H-.<?:E74EK)+=Z;B#;H"50U"EIB<E9
M3\K!*H;.I"BR1)2Y1R02$ 04!0:GE*^Y[GW%4:+2[&ZRE),[TXST_V<-TL3M
M7L=KH6DKT W+D4:ZM]H335%SJ@+:7T5*""19886]5Q^NDJ/X,6PL%#^\>2]%
M+1B&8&Z-6YL?MBX?Q'H_ .T3+C\4X'!=QVVVKO_84RC_6N<5-TP_>O8S''F:
M*;C[RUR0JE8@^EDV7HZ?Z&J&9)>/C^&<3&G-ZV\;"/[J_\&[0_Y_F@5C^2(4
MR13?NE=L"=,GENS1P)D?@BJ]DF7IV)6B;B'NB(O*)!7GU-@URJ2!AB:N&="K
M2<AL<2=EXP;%+VJJB-[7[*>?\A1\ I&:U'B<[\"C0J4?!MM>LSZJ\X'@A1(O
M?CRTU[X%E$M1TN('L/19MLF-(]6WO-]@X'&9+ZK$@N(%-<M:8^XE@RN6[7_T
M/U,B/U]KV5_=[BQR"VS\]/E^#SR+>WEDTC3+Q=K1$RETC2B!A[LVC CIQ,W#
MDZ=_,Y^@.FL57:DR3P(=AKNO&'/N"P,K,5,2G9-5JM>=F(5Q. 6,X[Y_F; M
M&O3=:" RDE@*4P1)"NM_1'/Z9YB"H(M=]K+-AO='O4TQC <56%HVYGGL+E+F
M70^WFD-[W$?#!2\%)9VO&3.(0AYPZH!Q18)-DN(+%KRT51M3]VX!A]PEFZ^5
MZ*!\%_HOFKZ(@-W-FJ4*D>/C3?GSYX!M#Q@:IXPT@4!KBT<Z [< .OUFRC43
M%:59=UJ\O>\8,5^J^QBY$W5'0>58HU.T\7M#>VU>;Z0>1@>;BEJDSG9SZ%U8
MM0F GRAJ/6D@ATN7MN+-\)O@]1+ @#KUW\<"+5X+;US?,$>V)+_R,;D0-XQD
MX1&_ WFVOP!YS5JNT#]CO-+?!-?AN!'(?^UB;0]B2VB%^:_.T:7:? YO0'E?
MHV\\A$_^<86YO_(^+ T:Z\NV>Q9#5MG_(4$&*1L5+GR2&5_LE688M#=-(U1H
M'EBTHE^F4 @#=0B\7\J5 ](L?US!GATPI80%EWFYZB9=+<G9I-0I8F[S0SJ*
MO-ZODU12MUZ$#CP1&V[&DQT;0ZT,;[8LARM,WP*JSE#BV;L<O4DG3RK53YBZ
MTO P#=D3'@]Z=7'087\W1!">>*2MF@AS'%J8\=+RO;5Z?U[Q&\V<_..WN'!%
M"-B8H3O(25PF?*L(*G'04RK:G81(+B9BIJ:4]N3K4.>GK"&03RIJRV#NG\(,
MKOD"@"_N>1:_K#TT<'0?Q7,@]#XUZL7LC[8BU.<;-".#<1R5L;,_O@-.\EYS
M!;T\_B$OO50Z2--J<10,(9S'^O>EOR*GN\*F599:P'5KRI>>2YN5;ZTU@BV1
M*8,%0+S&3E_($<P.\C2Y(_[?KC#;"K_!NCJT%PWL9[A-YKYV]PYSHL,!Y6UH
M7B+PI>5]D15-;R^RESCUS'0H-A&^$ULF;=)<[D*MMX"BT> 0T.<*!2A& [Q4
M4)^RE6_.VS])_!O<0=2?K2< 8[H2];TM\6)B5_*S"4<("'/NQ#/DW,!/6C"\
M=DJGWN5MC-&K9[AR?#_R"^:0]:+S%LX,B%,)2N:?Q^(5N!!ZV78?\_( .W32
MWVRZ5>Q%RHK);*M/U=P"HBAX]@3;'#S [XKGH_TZ6UK_&GGWOS[$O0WD46<1
MZT9<(=P3UU1$KP]I[/CFH@6Q<6?1"KQ16[)AUT_'C]S)W0NY.YO"%VJ0CC*M
M0,MF(Q\>R$NC[9K>7RWGZLNDG]!"X%A/D\4'#4):HCJ3*#(S<GM02U_9-FA^
M%WZX?9J-,\!"GHAJ$!2G!41[#LT,R7TZZNE/.PAG[HC;3 4L%VW6A][G8 \/
M!'FM-1L9P;:L/8*E)C<; MZ GY21G2V'+XF\=^\>!3HL1JV\.7L<*"[9<PO
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MU$)GU!C3P[BY3-]OH2_.2["G"L8#V5:8SLZ@813%[!W"TX84G(RDN:Y5$CI
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M/\%=-7U_"\"P";L%2+.!KF',R Z1/;> M]6RMX#LQ+8;.!&HTR#G%C"FO(Q
M8 (@N56@5?:Q.\^5P?D6 +I/>Y)D!SHC^)D2&BA05&8&4^&3O,(PN@4L=RC
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MT)=NWQ\(2(J4_*RW  ):3KP#95.Y@:QJGPR,I3ZK ;'CN9Y:H>!UEH(Z!>\
MX!CG) +^AZ*)2$X@W8^#Z&.YQW7,=6K^2OMI-8Z?[<^)#:8Q,X*.Q<Q3F^0
M-DQA-5X+(O;@DO8-? +HE4Y=JD160+8Q1(YQ"74#C=@G$E!@F__-?OV&9(:Y
M91Q0^M?T_NX857^[L&#\%+@NA26GY6BFKB0&;@X4S''1FW@:[TF'JKU  7#_
MT[7IF5:N40O*/A^^Z>S9HN)4W KD9RYR=+)HKC-8,1___/7QIY]4TB.];[_[
M+G%G8Z"GK)>FCHI,8&ORCGV<*2AY\)D/B?__20+;WRS-D^M,D15PX=4Q]H_Y
MU0\$D<<((\\:-P(>>@EPD>UHV*G/)7]P+G@Z"0Z1F9V"+F/")6?$#')CG@,3
MO$<$D;;<*M4G-IM.)(,9*0ZO:@:,!CV=6A/7FL0<3QKW'UD#^9WRJ?,#W/<$
M4F<RH"KMU3<-!C9O5(BU8[V(\S-6%@0862>4;257N**X7-:POM:6[DS,>CQF
M7W#GWY]=XAQWV_>R;6B)H$L[XG:J_0[JHD6U#Z"#JMUDG+SK08:G&:$=X]^P
ME<,67^ FV^9!C#84*,VMKB,9#_*VS95/XX^*BPU;LRXV$]5:%^>_][(FQ:TY
MLIEXDVHTQMI$KP:!78QG,C7@K#JW@$IYA'SS_,K;K<7SB.I+9,%=V2_%S!=/
M/RW0<6Y_V0_@&SM#.SVNM(C5.$K::C9:UP\_6PR854E6;XPU9Q3&G.N[5^7F
MR R7@:5XD^2QU>!_#7BV6*T&JUQATT WF5.RI/O(X(=BPX1&7@2.?[UG[V^5
M+ OQ$U[+8)(]J4BCR?&DXGJ\*BO :U+F"3Z=NRFGU\9=G.]8)UY!"(Q17*[&
MIA7+% Z!C3<"B('R4$AAQV[=("(>,UQQ5%( J)PPXUQB)6U_?SRSH0!6JCCC
MM '^TAQK8'D]4)Y:5]:DD+<H0D FK_BX.6Z%,WR_< %(&-QJ\T/I"+W2<!:T
M@>%]"S >5M,=I'VWVS2XY=>QVH3CW&O*,<5N.5T8-?@N_OLMH$;.R2M8!EK8
MM=+XUN=#]7S.H-_&9"LVJ%]N&K1T"Y@;]A7LMEL%W5_&")RO;F%I563A[#(]
M5R#1@;FN6T'-PGJZN]FA>$O3Y0IK"J%N_=&\#D^2M8.08]GZ$2B/DG LF%Y_
MKGJ8?D;&[W"M 0/F:XB8[M':-UIX!EP*28:7%N>W/NVRW?.YB%F[(36)2>V]
M8,&,3L1)8)Z$F^0Y^$1],USJOD1_]4Q0N#*]^;ZG,VEW-6HRFW^HO4#(8B:O
M?JU.<GL;:4Y]OXIW/FY?G3!?8GK>%NZNRM<KIN=0U+2<IU\<2%DPJ]H77%)K
M+?V=BR ,PV51].H\987!9A+PY]/+W9D,$V=I>@N%P'>B&\BFAZO#PF[EF#/C
M\@(/"Z@M-JYC#948ODW_UYW$WZ4'\%\1?0PH6J_^$C[)]WD(WTG=U7!>(?_B
M%*F>QV45V=%C Z*+%ZGJ-ZCE4R>TI'"3&BCG&\8,U'@F" /EZRZAT54C270X
M ^C%*G"WPM(*^.'1@QOIRF=1G2)4O-[%+Q[X;0N5Y\?0287GZ+@!M)7HX3WE
ML_&G;6_]Y)@"_1R+Q \_5#"\"P3T02D.6[EE7=?P<.ROALN;#C0^5O H/&[Q
MV>XR5-OLRQ)/=V0R7JL4CZE)6K;QTNF*=J2+U'B>?RFK/NF<)^'^!9;GR15$
M*%4[R0 L",^3$.H31KA[KKBGGPJ48D._\(9JQ\=.'\ZTDD^P;]@__!)AT)A1
M^WI2K;K*!FA'P--'7[2OZ^[)-)5FE[ S^G&EM1GF#*78V_-5HL&@9WHS[:H)
MEX>Z7\9LUM9':22Q"66Q*HZ*X_CS%MF).!5)-]7&RHC&*[;23LPL2+&OG?9)
MU^@4Y&KDJ.U!]EP;&5,;D[OL#C95C]^>*/CI#R;/U%U0'"S1+G0*UC_3GLU"
MM/AG/3%2P4!1"@Q_E>VK/^I#&UI+B^^GDZS97&,%UF?','[-';>I"]5KD^<*
M36RBF5O)H';3P/P&N0\9),,Y+Z=^23+NU$[.R*L_+5.D.?9L@%SY\U=Q.9;K
MV>_HOF )E1-0)%X0W+;8=-2:K^3T 0#%S=*$-DKB$=!4/-#>4"^#3U/QU1SQ
M\>CJ(L-"M8',\_3W-3HS5_)9=O,YM1%X19KRNRQNU!#'BL(4F%D':28%S-,C
M$KTMDV<X-B_8U&#%7T-YK)(KN5N/0,/C^>$2[_RNF1[Q?8]W3WSUGBZ1C!]Q
M!HPS1,NK;@OE@#<V%Y0X3;6W\="Y&V'EQ%-ZSLXH":%R\^WDE5(PZ.JZ:YYL
MJ51;2QU]%4V@?IE"[BY4O5H!2/&UA8S#Q8R,L?D6\%99187-(TFI0P8PPLIJ
MCY(LDU,V[Z]!"Y,L-(;%]2KY>Z;<_TR5-=":IUDK11W*-HC @AF:X$D!H^K!
MQNKJKX7W3?.,1E44JC[P-]VAS6KV_W7\U]]:J.VC"!X-9*/<@9E_CR52H?G!
MN-DW]E//[@&(S+$Q#7\CC/)/XQ#\;Y#?:,XSPZW#'1V+"ON\-,LN#.'#M2U%
M,*[IGTO[8Z<M@_9?*?]*^5?*[R-E^@]&\,YM^4.*+C]&GN]+MJ#7(A2 IK^=
M1OLH%<("W6(6*FJK+F_;_@@O621"TKX6F4=XQPW$'>P[_]B29*V3 ^@@1L"W
M@$S+T[P_'BL?ER*6_$.6HG\[5NKV[+[&'_-(_DO=O]3]2]W_*G6:A4;(6>PN
MAWI%V2@ I#<JOX,(@7_)/UR0;N?^#U!+ P04    " #"@G!2$KXBE,>/ 0 J
MZP$ %@   &=T<7-G<G%C9&<T93 P,# Q,"YJ<&?LNP54'-VV+MI @& A6' G
MN 1W.H(3((T'37 G. 1I@@=W$ER#-@1W"&[!W=VUT0::[DO^<^X^^YR[WQCO
MO7OONV><MZO'K*Y:]8W9:ZXUUYSSJZI&SB)7 4\5915D 2@H*( /#Q\ <@'P
M!O 8 P,3 _TQ)B8F%M9C;%QB/%P<'%QR0B)\8FH*6AIJ"BHJ.B9N%CH&3D8J
M*E9A-LX7O (" K0LHI(B?!+<_ )\?Y2@8&%AX>+@DN'AD?'14]'S_3_>D+\
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M%_2:Z)Y,,@HB[=7.6FT4.5Y^=6)N?5_O^IP<#?/-/)]DFY%,-86$:2[F:0^
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M4JX2S'+C3?WT@-6P2(AFR!(QR@[$4H$^>[ND)@XM@+S\5?Q;-2=B#:[<$B0
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MJ5)1-DHNY%&$4WF))?%#GV+B5^2$DC(O GYG<Y"J6"'31N$'H2MOC;%X3[J
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M&"R% A$;YY@:#-\5Z4/]]V49NG"E7-O5KZ=Z.J75OR"X8RV=D?(>5])^;;F
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MC5M1?.Q>#M_U7K Q+",L-N)@>-C9X>K/8XW7B<+<@YI%-CZX":^G!TS[%5<
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MG%<7RN,M>BOEM^%QCSNO]+U%<\[=Q&DYY-+V :#+\3\;:_L&?7)/Z]^?Z?8
M(-R;-.OX;5]K5=_^>3OSY=X]Z+;'X_O=V"D4.2M\^JC926%5Y/4WS6R&=0&E
MSPAQEV2L#7 ]&P5K)W)K(OC,(:UEJ#.J8)GP..J-0>MERB 'C^SR*+)_^YAA
MXFI>:V6\%9NK-M7@P*9=-GV9;3K\63.WAX-LO."4P602C;,5**D06EW?H$.&
M]@W&W=!/[:JE6*[701Q8;1W_3(<B[2<J4RF;/YSQB#8AMS>3$?4FZ+%!8(I$
MPEF/1+OJN3L4LP^(GK0Y)"N-;MDZH_%&9#JEC3A5!B;ZS&N@A$?Y/"(7J.P,
M5(825JT6+J=T/RVMMHGMN:D@<'3JD5MAMLC0>8X0*9&D?(@B!1B/K]0>S+Z_
M7@O?^7W+=)=IRI\K=OK^*$R'HDYRXM9&IN+KI3ROW%M;2-/Q5&!47\+CUDZ1
M1OCK >A$([*LM5.C=:GR<7)_&Y-KON-'[MUOS^'  1F'+=2*1MT=R@.=68T9
MEU)9M5./0AX/G*&BP2'I[>B-QO6CG+X_$IHTJ)"&T>]G%7);13*L"#B=:LD5
M>&C:G>X<_#Z4&IE)>?<#A?OTME"K,^Y5?H]X9J&4+>]>(W-*/13;)GR;MPUG
MQJB/.JVHC^ XK9"$5.AB-;?VR*[[H@Y6[AC'!QVPV)8I!5PT(.=5*Y5YUJ-+
M<XO/IIJCJK^?\P6!D0D;<BX]C':.;03<K:TMHNI^VF_=AM<Q?<3TBFIIFU/I
M<&T(?#L6(^KW&>&GJ@'6R*=G%;7X2_JY3=6+:JSNI+V'N0H"GXQ]>58/NM3T
MDNI(X\#W&@A#7W,0Y*)Z#YL2]T[S8B4[D*A?&8:(8M%YF-O!^.*R1;]'NHK9
MTM_CA;DIE"KMVM9#B2;P:.DQ(E/3TR<1!@+DVI$21M$A$&F67<T0%6DL-\Z5
MD=]I"O)-X1L<I4Q?,&AVTOT[<Z=/]_1&2(Q*>];?.S%B.TTGC*J@TH*1ZU7D
MSLMJ1)\[V)7L="I,)?5N;YCMI*="/C8^:XF)]"GE626R0.6J&$GBOQE%199R
MP_70J4'C<'MR:%(7Q6066P>XS(6/3)\2C6Z$/ U;3G.7H3E@!E$]2A?8$RON
MMY%?_,^ZKL-/R_\\X-[F^P#HZUV1G1A]6CKF,7B<F3B[K./-KQX7V=W%G9/#
MNA6H_[?$6B?UA91.$8P:OH)SDU4RBJ V-S?H+MR!?A#7B!Y>Z\/^R'>1"!"4
M;N1:)A)U-]F+YA&QI2"!3^PMM-^JC0N 65LG*XNU=XE"OMG-L5Y#B#_1X#Z#
MY3.W?T+3OQY%$3M/\,ZG:_FIIQF-,,0_J-@T26Y7_0P^>5Z6W<-3 PNSI-T]
M]H]2+!CVD5AI\M@'ZYB1L(<#&X>N[*^40P=%!2/=6%S"@^UX#A:'.-9C<-L6
MA K)]=IL=8SC31F<,;G>&A#5/#;'+F/ZU@H478JA2'1_O312%^+JUU"$GB>C
M85CR,J:W!9VU>RQ#<4(:-;E-HE(0BB-FSM*C;1P4^)S5J#O)R 1FWMXI=U)J
MMGQ-_2/@64UU^K$J8?.;W[ZH\K[[4;T97.$;_ VDO;9:7=?-M1.2YIA6H@/B
MGMP#A$R15["G]PTQCY(H3)<JLT!F4Q)G8.;K,EGPS9NFB:_L/Z5<1L_Y3"@=
MU/"Z;!TX1O/1BX2G%5<'9,Z1&Y6#''^)WS&#DBK'.,^0EARPU6]^.F+)^.8N
M6O]$_BDEN2U#US@:O]M*4A>AD#*8Q 7ZT .!,ZQ.OPI2JO?G^;T2X:6"2OU'
M\ZNJK]?G@B'%$IA_6F@%1;L56%4H1UUBSYWC;=2/ZOC_V'O+J#B[)6'T:1KH
MX GN)$!P"1H\#0D>W-VU@[LW(<$E2"!IK'&'X$X@. 2')L$MN#M!<GG/_6;F
MG)GSW35G[H^[UEW?C_K1O7L_3U7UWK7+=M7=+[^G_RLX]]A[SDJ7\J@DRGO?
MS#9/5?,NZ0#/.^'@FTCD3\/D5.7/7UH'[O&9L<V7IA\B[,OT")66^/<\-;'_
M=#EA9^<?LZN0X*(*S4N7_*L4TJ6"!5/8X)+12?9OQ#D=WEQ="BZ?#.8:!9)
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M7FTP\X/$JN;MDY>)B>-(XMR6D[4X(*M&7<]Z<<VD8C$XC@["HU4AP; Z):O
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M]P=PNF?%WHM_&Y4]MXJ[^=W]-Q*C@F &0?5_\>)%;=G7V;^);)5_'Q_[#R1
M*XLSJ,6]O['C_U=(YHJT(J^_=\X55=C???^W W#ECEEO5G+9= P:ON![#$'!
MA9U?LC!DK:E/W%OV:G37V3G-S;'C- ?]8FRQI;9 4U/L..=!_PL/6758_F%0
MR*^FSQ[I5L)B'8Z^W(TY'7?X"=N6*(^D08^WX#'9H@K9OS) 5=$ X%Y+3_['
M'*#_3M_5Z<-=OS.!\PJ+"7>[ PY*K>A/DV[&*LL/OB.*RT4^L&]S/C'[,L[Y
MIJ7R\S0".%%49#'E_(6$B*W4@ S=U(R"'4KGI3+=!3!">6W1I/@N[,EDAA55
M&4TEU"+%.N/2K.$80L9X5,T>^:9$W:*#5AO\P'OYU59[7;MRC>^.'U.=OK?7
M6QCTJLHY1%88JF(:(_NJ=L%Y^O6(>4Y?O!^E&[>[>>%K$^_P>T=5T8EX;)BI
MK5-K;)A*:ZLMA+NU;0?2ZOF!1FO_QRL53]-DQ"JO2L2$-7I)^ :6P(GC<(;/
M@O4#;$P,^3[\ZQ]6$U4;1H2[ 0=;-98&W$Z)LZG/6$+&;QL='JPRGAB1GH/9
MH00?&]8_$^Y3;/ +6AG&]Q7>C8^9WEN<BBRKD+1IBA4,P0GXUUXCV!Q=BW<Y
MG]$GPVW6.4[@N4H5+%0S!LL"U:PDVHG^V >RH7XI^UJSYOHEBVB3C@%5<.^]
M.2V@).C-CY*3'8S]N.'*UBT<DV0C-ETK]QRMX*-XR4"+EMDYC=$G@H]7Q"!A
M*R,^^Z-N\U>:0R?4:1,QLU?T8D?:''M)-_LO*(%JCL8J[\02+O8/XVW4_1XE
MJ45S[SF;FFW5Q-JA9=>\ #4(2G9Z_6"WU")8A*7;@"7/F8U87+C@LR VD.-&
MEH0UK_L<__O:?IF2S%(C@X<5P+<#)2XO?ZV8P*>GSF<H]T#*IT0D.K-M-AI5
ME^J83\+Q"8E5:O9PEDL&JX3*H#+KQWX[-;9O)4TAJ-UEV$U9BSJ!-7BD0#^^
M!T ?1<<M&V8755='5:$%A=8^Z%\ILH<&)$-5#N\%G\03)41+YT)5B457P]V/
M5(@82AQ@0?\ \3TX=>"%&7$)6T:_#Y3L=FVCFO@#U)S-&KQQ'N8SD87Y8M0$
MXF$1P@^YF0^1!.DW][HKG=27':<N'[)/XB6$<(F$_Y+WN?8'^"_UU. 2DN75
MG6#[#1HE5X]M.GSW%WNL25^NB!*AU(M1+=W'G:S U%<@J+<S6L?LB%TZ[)K8
MZ-6GXV$^PVFXF1J1_!P".&5\P<7JDC@D VJ?53RY0&(A2-Z8%>'5"<^KH?U<
M2?_\ (F%;ML.3'FB>H-\BXC%R1%U*=F/@J$X;KC.%6]0HD4VC%.I4<F?3[1B
M745&,1JX,C!F\#&D^?-EYB3Y+Y\LN$[9SI8+];"@A0WHQ-:@S"$*";9?E/'9
M0,U>S/1PCEFV%Y!(+D[-9Y;VUC?NY+F$CN3,""!\PY/ 'BV$/DY#0=:0&L%P
M9:3H.XHYP-4'IV'!J.P88GNH,4N,Y/(64P4'UA)OM?+$VLNHJR +Y]^9IL^I
M8CZ=O?WTD3EQO/ ]+\UW-AJ9@SW*>&DQ[,U3)<Q55=7>=TA<[QP"WL?&^;6U
M4?RQ/<\"S]D+X[XY2VF_$OZ@S?75S 6<DO+IJ!MPSI"/W32O7?[0"\:_+-UZ
M&'&Q ;=?TXOG;2U$2ZID;-^GV9YYA?F9PR*+/"L;_6R]O)/PD^>CZ3) ]= Q
MN:Z$OW%XU0AC\@N9;L=5C"0ZS,Y1_4GTI#E__,6CDTC :I! 0!7-[@'+8/UC
M[&2Y-:GRD@\BDR>OK,.\5^ ,":; B&_Y!<Y;JKR7S^(M^H6[==1:\;>!6.N.
MI\!Z$0N3X6E_"6>'T"8;^6C+=9B* K#I?NW,@'Y6HMY''Q%QP\:.YE_ZG(1D
MUF>"@\UO%!T53Z'9MM"Z(\/R"A:9,",026+H640A8XM&M])KKW.=J>#2*T#U
M?, 6W-=&;W$M#8LH;^Z=\$'TFRBLG^YH^ 7A-9UY=@,>@501"8.,II3?CV3$
M?G7[[F801@Y^*^)@$^N;7N_V@43$6A.#1J;_NUVT_A%XK"-^?F24L=H&HTD#
M$I'F@U35;"+5K)V 6^1_;@WX_P48NMW(C-_-"Y227O#5\/HXCN5#_RKO\%I>
M:T5/8M,L'M&/NI$DC7(Q(XX7"SWV>*]PSKC*#ZJ6?OSX]/'X*$A:5FQL%GJB
M,&LAV1B'+*T@\,Y1/!)OJ;9+0=.*&!#J0*?K@0O:EHHNDMJ14MZV18GWD4U$
MEWH+-,;?GS3_Q9K^>UB^8_T#].6_V+DWO/3WV<,N"S(OI3%!S".&H,4RP/EX
M7M;.AJIQK1"[]<>TQM(!9-"#%R8R&?1<UV$V.TY=W*X-Y_!-=8M^6U6C*>C^
MV T8\I5DBTJ0*J11 50!  R88NL7D)84C/"$LO?12MX\Z;'_!1"KDX(I'MOD
M*_UCWUB??_3'3J/^\6X%E$;VK8EC)1U=%_LVNR*68V"G^]?M<9[,\3:UP];V
M$$UUV"8G=T\5WA,'G6@N/BB%;R[#M>M6]511)DM[CUT4NXKS_JIHK)OZ84$P
M]%$?/J]0H;/\CO9G,-?>W.3K9DP7!!!GMR>50YN?,L1HX<CZ31W3!8K7__HP
ML ;,0&#_03$^@54Q9"(2B/(/[XQ&13/R@A>JQY+JQ5#O7,V\ 6S [_;[(TVF
M\Q*RYWX:MF!$UCH//S NU)]'Z/C:!I$(IA";Y$T8BC9517/HM"AC:@?U]1<)
M8JCJ)-A]>^9W B6MZ4<GPNL-F6FR9<(5 I/TA]=5+&R@RG^:B&&%G*A"Y)07
M)'>T\J %'C;RI1RV\H\168(%C#L=,RQHJ!Q_4D$MIYZ&P<%JZD8*<R63ML^Y
M3[5B11%%3DX;?20YYFT-2 +]0X=OAIN52\<0A4VJ48*>EME7DR\JT]6TOMN4
M2WN1_FZMG;17E]QG ;^DK=UH$YMQU$C[4GYO">C75\.;^W@A).N^"T6W>?R)
MB<<5"@#2]+;W<U--*77+$]TCW62WVC4KG8]#3OI0M7NI,%,<_4:XV_;'8 KV
MD%[S*_^-Q)E2),;KSQU(_&A%2J;=*8/4^;'T7) >%H\C12RKWBI.O;@MD" U
M7ZUZ%4&9,*?!F(2\LH_RJ4\,GUSR0F)Q[K5->5J:)8V0-!2J>9.CY=2%&W0]
M@OZ>_+DJC 1^I0B1D)+3AN8.1)^@4LQZ))&8^)ARP@6BI#UV$F89IY9'4&QG
M3#Y- 0X<8:S3,FKL@6D*BXE?PG=$4%KP"CU^A: XC*E\>]P'D31T-Z6.Q$]M
M5R\UYJJR%J(Z,I'?AJ83J,Y?Z+F^T+_2D/E<=@:STUPJ"3&^+?9.^QJJ_;C3
M#=E_PP+N%%/L*7J\EZ@[E56J8#5I:>XV9#/Z+^3M*%[THEHOEO5[2>,\N"1,
M/RXI.+=?3U??<$^1/-JS%-(C(P95K!9IW=QS+._RECWRD-J[BL,/L2?!GNOL
MK4R>;39HN=)H I8A4Z)J'H48%_QJWU$\85E/)*>F-'FVBJZ*5O&ER$+6LT<H
M-YAF-@-#SV<UV#,XP19-.,B]U:>XD7%MC.% F"E'S T!)+IFR.7:&-+4M/NL
MQQ2K&*J"5[P.QO-AR3C!6B-B8!G/0UL0I=+/^;0)X"K47@N]SJ4;%U/R7O?)
M35M2QP4GRBD;".=OX'4#3'NY2^J.C&MG!<'-A<@"L5&,2R[5+I X:Z+],ZEE
M16VCN0SI9B$:=OKQ@[VN:D]^$"K(3DIV8:7: T]7YMWC81BOG7_-:G+I3]P3
MP6<^2*S'":P"+%4^GA05;\;IY=Y8_'C6+.W]5D^\96PXZ%V(<<?RO#E[JX0
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MZ!\D@0M^4,0J^U>RKAE YRU.6).F<T&8,/G!Q$PK5^=>D'G4WJS$1%RFZ:I
M+VR&++PV@$RET<+AMLS&M3K\@N8=&O[<ZNQX,XUX^4(/4]LKQ00)CY<?\ "]
M?]&95I_?_\M$9N%L6\0_MRN7=FJM<-9(UU-@JXVJ2;XTT64/2A,0;PXJZ37;
M055S++JGRBI,L0@A@=X6,VE9QC<E0Z^]WCQ1>ID ^>YJB_:LQ7("!*P2E^/[
M3@@-LX!V)?<BHXMZ2!.S=N377T@3@WAE'EJFJ5=GI,;:\S6&,7UT2U,%QOX
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M@K6CO5"PF>[3*+!6O.R3]>PK3]YU30%SA0(05V(ES>5GP4](OH2/\<),["E
MQVKH5<00O@^AUE@.,1V<:O;4:':FLD6[;(K@J(O%9T_]Y.0:H*2?WN]*?%.K
M%5<&\+/T%N4QPUF?X3%-9+2HHJ4W]K@IFTAV\S_!^R!4L$^Q!25X0WY(H(!D
M9%JE<='N^T:HI(9>FM>.A RW)_CJY%U2CCT>C_XE83'>TA%[H>Z'.!=G>^*P
M?/G,Y2,2HZD!=\VB3 ;MK?@V[\_$?+NG'+D"@(*I.6^2DVTH5A:SJV#P="O/
M6-R +1BFDD[+^7D8-N ?5!!>J[XSF19Y&L/3TOBV]MX0[KZBG<I.YD'!A:G,
M#P?*?6EKJ]$B,ITIRHW']_(K%WK3=*27=T*>_822K84*&%8M:6JO,.,^<ANR
M,]+[;-Y)K>F9W._X#$"BB3X 0]A/M+JH9 #B8S)KN[\NDFI$V[2R\> ^R"_<
M]]6<U0!B:T"N=NBC0.!AZ2IY?Y&K%ZUWKE@:)1"%CDV,T*9^I*3UM &)A1O3
M8!'I8]7;RBL9/$+\K4,U@04MO\"+IBPMH1I4XU61*29;6)=3HOA$6'5.)^@(
MIRN\,E6(;EW<&380P9C@-XJF)NTN0O:^XDSZ6N';@I2K 3'(3;+ZV"'Z^S.Y
MTG3/M4&/+[08'E[%'*7G[C,\AB1=&9:[/[=MT=CNE]M_/Y9;HN_?IC5#O61=
M/%XTT_Y;%9(]6Y]I"]UG3[@ZG?<Q*!A!;-:P=L5SBQ>G1+S1ZVN(=FUU@=)^
M+C#$B1):?/Q+VA#[:Q<L[-"QBJGZV*C-?:5I<_V$*@_0]7^!E@.PG/&W;$1B
M0HQK@+'D$7MC'B7&Q&Y1)V)@SJ:H* >[P7I+S5G&5_U XZ_[SS/?H^@&]?1#
MFD?&LR,]I7BTNR)7&=V@%-=RAO%#CPV/[;\O@3_8E\OM0$&X*K5,&(H-JWGT
M,3^)@:BW$A^-=T25V7K:RU#%\Q]RT$<QG=6STA#=Z3/'1_11B4UEVQ=1,(LG
M&L.L&?@FM;S#G8SUQ* =8^+QG(F:S-IAB8 6ZZ+YP?/&65QE/">C[\DS'(*[
MS[K=#$_->'6IK>'DR3VO3#'M&Z(V>%81*#@]-8,E;4WYA\J!U7M;2/"CY_DQ
MO>.57Z0*Q0](E<&@V?L[#FW+Q"@?[_4F>3W'EB="8E\T[D50UUHCD;$%#3Z?
M07+96M7:(2S!2W FNO++];"+_MNM4:[5=B1^"V\;]FD)NVN'5&&IN,BM)11$
M4ESUA/84Y)0<QYRH1J[X$%.:;;#&84AH+CMZ P&X^4>-Z,?D'T^[F-I7S[5L
MV*/9J??_"&&@RP/$]RF#/I(F4SVC<@\3,!=Z9_.+Y,5@V@J<JMJ62IEEOI<A
M3_070^3+]FZ SCM21XJ Z2,-ST2\(F/4$S Y/]!%L?*Q32-$ 5.8N$=X!_IP
M?BZOM:2O"Q?[T(30'B^H1&%M#;.]0NYHOZ8N6>;!XH;9>$OPIVI2<7DD>GE4
M)\HR4_B]N;Y^OY=(+V4RXTGD_EY98*\E1 K"#PI9$?Z";M'JYI%3:DAQ0,4L
M5+H-L/]#N'9ZX.P?NV'9@J?^61']U;8GW@G7DN/9<<HUR7;[F8,G#VT&C'D7
MXV_9P0JU55,M!"7>04JA:T9S4CUZ!884C([R-_T5*H]ID72%2+98. $22<"8
MJ=&"NF&W6/9V'TSZNE YTABH^ZW.[7=@;<$1[^WCPQM]#L&)(9%!W)!!PYBL
M*MBX8*$P-M\ILCBCF&!2%2)J4Y%S*;;]T.#[ZX>@7_$GA)ALF9WSM'YXCPXJ
MDF)>JGX8D=A'9O#\UC&J 47C^IHG_UUV\@'9Y7L!!\F;IP5&C.K/_@#*Z;'H
M:A<F110DFP)A'DOWVH3Q?+^'6^ZLO%@!-P,W1\ F.'H:63/6(KUT'6X89&UP
MMS0@L?DF5F7-_D0%O^S('&LWE[#;QNIZBPS9[_A"S<CO,D@^4>'NNQ^Y4HJM
MW)6=^SS.Z[&]!1P<%F2L2MO#@(,RP,757M#DL('SAV%OC5[5AI@-#3MW5UWE
M94[O<U+SRRT\*P*R1VEB2_# =VZ_=3S^  ]40MO&SN-V_4Q$1>OW-@1LU Z'
M8XI;G/P*.OEZ!$N>K1$H !MW%,8U,[@H&4:T 4^X$IW\%\C0[VD'K=U2!_<=
MJ[KJX"?O [<?MY.8_W.=MZ#8WK-)(E7@=NVMT!.C[SWE6K ]B0F-&C^#6?<,
MR/580Q\_J,/;6NN(JVV!J:5![J+'XDLM\[KFXYO>N;<OV/*6:;0GY Z'O\*"
MV+K%R/CX<LZ>I(??XGF19CP:Y>!27YE6J(_4O"XMZ2OB%N/,MB?[=GZ@]-8@
M^.9-RRB$;SFFR>G;&EDYO1UG'AM=;%9#Z1\ 9T?PG.Y!;H/N^%Y6\*#DM)B[
MP*(])5=J\6Q>ZUF:1B?=O"PU=IC*(2HJCR/*HD 2;4"P07KY/>!](PB&QLE.
M9T_JJ!(.Q1?P/&683SR^Z+NH<'_92+Q*0=%M/G/Y$EK50J;]VZC%#=RHR_W2
MP/U_ZT3\;P)HXX[^<#&BEINDM_#ET^CSARS'G 76P/.+6(AX\7[E<JM%%R5)
MQ4Q>7=U4Z3H1](A0]=$'4-_6D*>[*H0LS]M-K_&(6'^A5>!KJ@/IH+<I8Z'8
MKUC95AO[#+JC@(VH,H_"5"4<6QIZJ:$3=HL*&N\*Z6RX<+HC-^& N9($I_A8
M(B%%_Q75I(N&MTIG6.<Y8<0ZT<)<GW5#$BY:+XUX0_G;2&"YQ2W+.\JPM3JV
M8V_V=?1^QH*VV7I&^Y+[CH92EOW,Q?ORTS)U*D69;[=ILPE22V]%XNQW-Y$$
M$B&=;0RH _[N(U!M[*QRP!^@D?%SF@7ZFF]D8H\(=X1'JT)_:78UZ;D.C@B9
M]>!# DB<[X$M$M])/>CA'\!J)M4/ARKJ+8^8>F)-@%"A&.=R<S/.=:N)IJW2
M[2A.U:-W$9C.$#"JJ>F_EO[Z.T +K0W@2LV9-Y9TO"#L^BR76$)YDHFY7<94
M>UM0LE7?J]/ZQ'5 $/IUGOH:<:;_MY*GJI!//Q<6O=G54:66X^7ER<<F(E/+
M0(F-,(1Y$A4:A[OP\!!_L%D^K[$1WY@%_E3OO5<7>!(L"9Q1( F>7SH$'EZZ
M;BBWC._GN"?H*?3EX!>DX<-(KV4F;N0]\$(CD/,&9)D>72<\6.0TSKPR;GO&
MW37X\$!-  +%  09'W45BK!T2_QK;E?6L4IYDC +I6RXN&BG5W,"J?65*_LF
M#,= 7*7S$=?4(#-DH4WE<.]N^A&?NYC.:";^S4N:[B]?/A]V[A/:@O'OAF&B
M6X\# 3&MP+!R6/-16X+8^U;)/CH>DF]6T!4X+OBMK?5:$!M@S@MA0O1)4JR-
M@K^5*5=Q*!['VC\4C/7A%W78@^+;X49CV@UW$]D*/)CK%<J6"@J%4UH.DV&^
MU?3(,\8DT%!BPSE"P<E^]?B-6V80JW]PFR#F@>P?[4"Q6P#1B? #-1:)6F;
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MX/*5]?YWOAO><_9-U_/4\"<<IST=KE,A9VDY6^';GTY8[:A0G%$;'9KT7A(
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MM\2&7?U<%\4?/_=YM2N?"V!.L;O@G^X.IK3( )8X=,[9K!4V*L:'FX&G6P^
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M))@%.KZJ9V#7L$4-N2IDHLQS/3)ZOZI*><.1\F:'8F2DV3='!X<Q08QHJZ1
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M&H=#:MY%1E),-G+.L:8V"8*-3[;-G$+'CH6*6FM\?2#%$.?;?M-H)UVT"X.
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M+1YY@+?* .(FX]6 HG.+/N[&UF57S ^XXTG8Q]S)G;$5KKR5)>N,%2%RA8.
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M:SG]WFZ'X$*GW2$!G)K4@K1S0:(G6[T->;KF5M])*5762ZV[.83^?N-+?5(
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MG^UO]M]F['&O[46GB.A<&\Z.+Z@1:]"BOB^19'W;S;EEEFQ0<'B& F"5^%R
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MY?(4BWHN"8@W.H=Q"GY^I[E1$E=#?6*=%.BOE> _J?4RW\K3@KLSF-6X+):
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MJ"[]#1B'_]X*%=7UZ=M]8'+UET,KS5H9$.0_L45BBQM*QE)]MS.[O%I[W<G
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M X7OPBZ.L^%+J89CD!'IAKIX7O!)PLCK>@NW-!C4L*_&J,K2>O<ZW$A -D7
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M\4CGPM%H,2=LU36I>D1C9*2A+;YRKQ6I]D _0M+N#@Z882[LOC2/NC2 EEU
MP^C=4Z8=F4CY@UQ1'+K(@U=1&^H!B@RW*W-5WPNI*M_W'8_/1M"\EQ:@;:0)
M@747^W9+%QWQS[/TX)ISNI!CM/C].E)G1@PV)MI!W5+W-A29GHJ]>[/,I.;W
MX*G'NX?WW465KU@UCFZJL3+M& :0WW5LMCRVZ#<:,/D8 K$-3MY?*OG4[X$(
M4?M,AR=Z8U'T:E%$,X1)2 P1US4^M,2@5 OOSY8FILG$MNF-IH_!KIQR5]8+
M%,;2CX=J[]!XC3S?$$VQ$X6&J;TIW%-;Z3FCM=-)]\#=YP3.ISE@93;@S8;
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M7>Z7Q]YH]5I$TPLD> +[K/<L@'F)K:ZL7VD-PU#BW=4"7IJ@"6=;/D:OD0N
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M*TZ+A==)NC:_3L,OT@P*L16#\N _H1F]8O+)L0>>TQ<V<+U,DC^/9M,*7DC
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M.N2V%>?>0E/8<GX_ J4ZWB3"WK',? &X6O].8L78I_,"@)8Y8SB_<P%(\;L
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M6J3',_>L;&MM%$LPH??)73&:4*^!UZHAZGO/T/J'UHUMV8X"P:9Y>@$R;"=
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M+H*!BXM+@$] 24A(R?>"Y@7??[C<_080XV#J/S+#Q&  /"#&P"3&N.L$T ,
M& \Q_E8 _[U@/,#$>O@(&P<7#_^^0_43P ,,3,P'6)@/'V)AW;?ZW+<#L(@?
MDKS@??WHJ;H9-H,#*9]?3"8.HW1Y&YG&V#$3_P='?UP\<@I**FIF%E8V=J"
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M^4TD3\,0ZR>H"&MX8 +J#L"?@X"BXD3O8_D"9$>PWYVC#70<9Y5XZ;DY6&$
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M!3C<+#($=(S/FZRI!!8SXK#+>&71AX%LI 3&R?MJ%@0LWEU_C#&6"SP>49N
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M]=IR?]-(MQIK$)II=F^\<^A3?^:/QS_V#%I>(*/-\JWY9G>LF0\&Q[[_D7Y
MX*ABP5:O$1::PTJI#>6O55_&!FWHU_U-<R6W33@WJFBN/\Y*<L E$5XB/1OF
M\%K98>P0!IR?1I\*]@Z4*J_> <(\$W8-!1"AO,#\/ORHZE94JR\T2W3FILH>
MM5PD:=[E:=%\!P@LX\H)=0V)&I:"TR6THR0G\P)^4_\B4*SEPQ*%GTR5/46]
M'3M$20K6)#$.>7Q)>8#UO!2"U[H"(1@"KQB&@Q/8!7<;R20K7G+0Z<NE'DTO
M>XQN4DT%LRK?]I"M$#TUM/IE;#0$,S):5'OQ*>&IR 8B&=I]O8.0<(VTS%F4
M=R/(_!8D09<%._[4;+M25#1$81*8J2;P8]/J1"QY/_=>\P0FBI1 #_C%'^+2
ML$I <\$\D4K &[UVZ/$",X>](RR* +8:]0E+<8-EQ7/[01[2(DMO%JDT??!"
M4[+_,*9W.WU9*6Y-$U<"VW'E"=7KGEQCI,\=@$$JZ0Y@%/@Q92/E5-C!9!J_
M@K>%B\T4MYL4@-7A=R:P%PX7N -\>SE$_&(H*X.Q1I:U:^2*["FZD6C#9K,F
M<:ZG?0_,?'/T2<C'H8OGRH%'^XK\#A#5VG&=($4*=[U 4RK??ETP*K=T%-V5
M/RMLI3C[\ZRC+_\;OA-!(:;?,*&%.T6W:PM599S,3-. CE]OY,_'.$/\W>DL
MT=T']AD[',SM35_[N-L!J#V#F/A"&#U/77OJ*O5COF5CB:$21_B1[^.K$YK&
M5_4H2KS*X\8W%=7'5;KA)%67-(V_MN%JB,BO$U(40Y] F_% V%[=IS*4R!T@
MAJ7G=ODXUV5 O:=.CDLU.4DA3:,P*_ =@!:0$RN0+!0E2Q#Q\O61:C&$=)?"
MTS38[HC3_)2;0;J_CA64X-3*7VL^Y*U]'&4OICR$]ZHM:ATSU7S':T9T=802
M[$L\K=-]NRFT>V,1I*&H?I">,*V/L@E\/IMO[7B;*2]E". _$^PR\JE<(XKH
MO)B.I.[_38*-DUTO.*NHHISH16=AJ5CJ:3<N#HV(+4;33S";-IR0@%X800.]
MB4OWDH$F>C8L.%0AN%O$HS.Z"'],[*"JNB"%R%[68S*_E>70Q'3*T:>J*6KI
MEKJ?EJ( &]O-*APWP@,+#=,7Y1=IT4K'H& 7'B*](?)L=SO:98Y$+C\3^773
M*W9'R,P;M'2S<KLIL:VW;GYSJA#_J_[&6O$'(*43*/W A7V([E,R5G-&\QD_
M66Z+D'"H_0D>*II@2M)%*B3\5@G2P-'7(@0IG$##KD>AU"M:VNC^)+_H%B"L
M*WRL8&=.<K>[MZ)TGVZVN#DUFVG9R5KG&[R?U_//P/'V5]3KHIU?)K.[<FQ,
M]$"/G _-'!W7C[,SD!K7<]<["V_[.VD[U\-6FK@0&B,=:/K:"8L)RX0U2NY2
M@."2NUI/8CI?^MHX!WO&+)VB*Q;Q1.UT=7&A(%-BD(BEHF/-[7J?+W6%_'JC
MO7!$$*94]9F%]^DZ$9&-% E"QH8\IG5V,/TS'UNOB5. L2RLNTJ963F-3[X>
M/[+W-[N EFHQ:9:8AI8EV^#Y[JE]1.L)USQDQAYN8/( H5JPYF%OQ\/5E.+"
ML?$UYS&Z-? 3RN+>K^SFT8T0I;:V=FL08]$<^T1<]">U8R^T+.8=P#CE:FHD
M#'K"9'2K>Q4&^Y>UQ?((7_ 97\<=H!$%W35#/;VG!W*Y][TTKZ=9NVGO@Z10
M0[&R'UL;XTT']+BDU1]R@C/9NE<(,=A!,]USB3DT2=V?^D2B)=;5F;.B,FZE
M?N.2*V)I&J2=J>G@ELL(&><RKED,_65E?JW$Z>\VM#9XY2+ZPIC<5DFV,XDP
M4*J0HWLE_?""PX==K^J#6HQD7QFLBE94H.3Q>-\C+'4_ RTEXCA3ZY^C=L5K
MT%GY[W^C+[?!MXZ@0=T"I#CZS2T'NGFZJ7)='A6\#]J+07]HUFQ;/F&%0\[;
MP,SH_6;(X"RD&:1V(K&\;HGRAB\?"I^6'JUNHT*N[6\=R=K_RDU%IXG?=J-=
M%E$2]\-)KW(?WZ5#[@"8]X1H;\/>1DC=1LS[(H[-:E,ZA_HJ6GVLE%-"5BBD
M5/$453Y"./S01\54 AD-.JZ>1[=2W &DLPE1RFX$-B;]M]'VQ\/1Y,$9<[-O
M '-?R\]9XPS.>B&3/>@=V+2&G89M&NE:-FG,L/L1^LV0,KH^>HN#9]6LQ^^]
M5*RDS;^KU!OQR\!NBM8E6E5=,BU(O0-$$D%W'-$8_I)N/9XMN9Y9^@RL[^V^
M.(6=13^U3KPN"SX\@$7J40Z/RR]*934U#!^J!?N*-PN/ME[XS*Z]XP/L08<;
M>$A0RF.;8WDUX\Q>17VCA<#N!<M6)6#7,._&O@I5-TELP?W.](#HF["&5'B^
M 3_)]_XV/D\"O,YCJ4CK F_I*5A#A.*%QP9;,1]_8XDKB/ ,]\R4L"E)N68-
M'E$,*]QP+H6L]J"BKB]O72&W.-,SM_O)^TXGK198=X ?Y[)A J)OM%DC_-2R
MPC8DGV2%L0'^'8H6%KEJ%G^G+25@7Q2;+M@ 6F7?_8V"R/]'3G4RTNP8ES+\
M4IU>D8S]'4'1,8$-#8+4]@P2D@H@/7\=O:((K+J/T3JM"3RS]YHJ'7RE%9#+
M!9"]L()L)Z.U?)+IK[9:$Y1E_Q-J-H($;/N_TK]C/WN'(4OZSS 2#I&B>5VX
MZVCC:A Y%#A_NQ4"33E?:TQFSYMH8%'7T+%,?GU<J/Q3O3K-\^2$6?0D+10;
M\9?PJ!&ZT%&TQ#)[+CM'^GCJ0UB!JH;.Q_;XYX>)L#0;4_Q:FXIE:^KJ+K^?
M%7!R^;UD)J2*!5>5X3G5TK$24^S:ZWHH;;W@3M6[0D4.%E;I%-OJ^E[W:V+[
MX^N3)XXD7/7GOP6[W<U_,^H<-T?EPG9UJ7W6,T^I641\U9H]@YISY$MW9JB=
M2]4_&9'3R@IW7 MX/HI\E/:TLE@&(Z4 1C6KW/AQ.#9^/2^49CL(33-O-?=]
M\LB>N;69WF4333^3O%MM#)S0G]BH:(J0X",@ANM:%<2GU@H$BK1YP9++.I[=
M/&+/14:=X#LZ,O9A0 R6CT<"'@>X7R91ETS==I0N#*IB[X*+LJ!5":%:S]/&
M16U-VV)VE]C+I^<.UL&:4+;G+UII9C3GPH!V^S$V[,+<Q9MQ;3&LD?2=II]]
M]C,\Q!^) %Q&JJW<XSJ$Z%@GT'V>.>\W:3T+2I+9&BN,_:39:VTO)7J]>2;7
MZ3]%=U$464]8L?K!(V:,5Z-QK='DU58E&!ZFMQ]'+I-K=PI=F*9*WUBU<\-I
M:AI7>L];B?5LAMP1@C!4)0Z.?8_@Y)BLRF*Q09B&XVY[G1H)2BB\LP$Y62K(
MKOX%.YX1Z[W75F,#6T2J*=\"ZT.1DX$/XNXZ<TLB3P^[,^57]=*YCJOH.,8#
M4RLI]?7X>HMB.7S#=*?7*ZH;:$8"4 P2[+ AZXONABB=Q>!7O-T<^)T@W*IF
M$_AA":N7J-%F@BY0;;O+DY;,SM%QJR7'B\WQQ%"FCQ.-]X;ET9&F$R7(Y9W3
M]0P,[FE1$PV3-;?*-0MY_W&JGRU!45&_7#KB^1'IEQ8.I#U1Z'G\I.F[V$=X
MI%G=."O;TXWBXF:6%@\KRLU(@ _DC0BTSC2VO)N:\=Z%Q4%U'-+YCK%,N!N"
MW%J\7"/,\?PJKV=4<JP'<N!?]'*"9 -=@QBIBJK4!Z\\/+&9/*ZN4Y<C)%[8
MK^WA'&RF9;C/._86Q>G3$2/!MJL^*F61>PM]M39!$80MM^#&K)!A=1WI-#95
M)0V#C#*0:>#%WEK90>L!.__65;IN(N]$GI.)GRQQ7'@#S2IUS&9BFPDDWYN[
MMA4A Y;7B,%78N+%::.B7!>]*'N5%=+7=2KO,$R<O)G8CO$5._>UEPW/YT_5
MGX#,TH%?X3$Z; 6>">4=[LJK35+D4\OO5*05_V2^BJ0T:8VN=A-0UV;O-XS!
M<_"O>G>O#IG_21S*C78?U']_NBNK^)\17_ZI1CO--9QVWTP+X\!@*NF>FM./
MO7N4^P_W2'8$61]6R]6=R(P\J.C%7? ,*_>Z ] Y^@"Y^-&2H!6YKYS__;KT
MGX+1'F6;&F.OB/\#-0H  .#E0ZY_UI)_09,I3#2;MS]LQ[.(($ MZRMO2KLG
M_M!6&G#&[=;1R%>O1(]KM29$%DN1U#PKZ^M#15GQYF]9<0VR7@//#)%O=5T1
M0U1H*M*7MS;5B0&YUJN!)8%-7D&4Q>9,.I&DQ@&*N_T7-3HUO#\.;-<"<?OT
M1ME&5DT,,SHK4*93XPH=C!^?=#Q'F%2_8TZH<B/\\CWC9\NI7U_AMWH+M]EL
ML?BKM=B=B9NP)TA+6?_UD>BWU?K\J5?*/7"##C\_63*N&JM80U+[*A]Q37IX
MXKNW7OS=N/21,M:K0]1= ?/PFM[U; _E&.1:-5NF4 TVZ;E5V-HT?AWULQ -
MO91",7^B566L)_/2O]I(Y*DC@,]_TP<JRK[XX[\[/'?- ]S%V8H6G6<(HB]1
M)%5O(^DB <IEXQ6^!,#&7AD6I/EDP WB[!I_U2;< 9K&_"%B/E'1,.N V\?]
M.&JN"K]9$463FHW5@?UE7L1&AC)N^#(.),I/?39<L.C;P[W<;<WT;-<4LDW"
MPK\"#=@?MRF\LGCQ]?GYH\0P0'?]<7J@&\]/[I^VC?7$?M#Q,GWK1#''SY55
M01C+ _>*J'"1]/#@@X>YU_V-]D]?\](N5O%GB.(#']&7:-XK.J<W=X ,V6 T
M)@RIDT9JG%F5OBENS*%:_KW/VMP6,\9_[$VAV@9[+;50DAM[XK9J5;+,U$:@
M'K0SK%F6PLP"3 4]CMJ!GN'\N@/\=KX#X)5+_31SPI.13&@JARW*ASQI?66S
M2&H<#-S_!&D7S8*,,MSS6HP)%+ K[Z?9^\'I1)V+_0ZLKB=&:&V[,.Z.!%>&
M]#G\_ C=)SV<EH4-]V/Y\0[0_B+#8\G^PKAF?YM.KV<S;#[KV]P?&LV%*'QW
MVRSBUR2RE#OY&1A76FZN0K4(CWOW4OTY//ODWKVZ2(/MOI$GZDR_O!)*1+31
M&Y?GJU]KEMK:'KUXN=!!,Y9>P!"$?2S(16K'%#M:8@F;A2-^[!]D^NEMA(QR
M0X"_=BI>R+_K[\ B_FYME;E7-U[3_=&$;FPU58WNIU4LYO=V,BSZ_JJ=K+1Y
M$L7/FDWCSK>OIXXX2[8M;O(4.HBOIGZL15%.B\2HDYIIR]U[@=+M@_Y+H,G]
MY$0MUQB\EEI*_VA6?C5Y_)JLBH. F,DAOSV+&X "*K&UOJIH;L_ORX+'+MX6
M*N-_JAOV[B!)'"EUT,W/?F\MV9'Q^YZ24=&,RCK@RPJ F3Z_[.]X/F%;PK6?
M\61>AH;W<2CU5] +3?57>B4>L-E=XBNWQ#'5YF\AS^C3-*N.I\/->5+L\^8Y
MOVX()_))I>J4D$Z S41@=:Y=.K43Q24LL6 OO0^Q,DG.K_!]5/2SON__JW]T
M\*XK\C:_[LG/N_U_#'F:C?[,U3$)I$_$UN+>WA-_4R29\M\%,LB*%H;KWS]'
MJCCG05X%PV_!&O]V9(7YUCDWAY;="O!/I/5?8MOEZ)E5.NUW61^GF_5QD<ER
ME,/XM]+];W-*^SOYI>;2B,/ -7QHI8$1W\AM'VDI1&QVRB6<EGRLU/Z0G*VG
M8.,6V],Q/&HM8IW9O>*<K)VGJXR@*O-MY3=6C$&NZ$WCA*!,<,$<\U#J *<J
M'Y6J=9TB1Q7;Y+>T.,XQ/:)U+A(NU3VUQ+V!]%EEQ68%S#+?6PZ6Y;6D(#N>
MP,*%WMP4FT:Y5ZPGF=)J'TD*< Z'I\.V!9>?[?C2XUXT9@RO V.\>\X*FB37
M#A@[>[?54BMA2_+/%%"$>'PV%]@:N"?+FJYA S,2KV%(SUEN05PJ1E<\O$P[
M"%[/5 NCNY>"2Y1A-E,$IFVH\GMZ(^><K*4.IP@W2_U[YD#'-MZDB*D(,[+G
MN(P)FJ;W@X'36<:;Q$E:LAT9%R^U",I1V (B5?MMJEQ.K)EEL@[D=P R;V'!
M]L[Q(?+30,O0KZ!<5P<5FM'BL3KW/Q]?BF)IQEN0N092Q\15&?>QE;Y'WG3L
MT>Y5S[-5^L0&23_V6/$\.]"1$%TGY.BB<[OPJG]YLCH:!:(690;_D<SA :><
MZ;(7>\N,"GAE@[DZE$5V?V5Z^S*4[-#QCS7)'=!&MITF%3NRZ]QZCF:RE'X7
M^ZZ6>)WVD(QP<8%<:,3!"=A#0E#)^YNLAZ?+GD!P.>8B](OJ(EK3')3 UC7P
M1E3U)3(M$A]"V>:P=E6%@8G+2+7\Y^P.0 W?ZW56#K%KX356PPIGLOM:Q-XK
M@7>^6R W%GX8 5?IUS1^^CC-&H. #P>DM"GAM!8)DAG/K:Y+5RBU8Y12G60]
MI^6(/";JY&)4&M69T&W^L4B%2]_P:>5L0QW/SKI*+"$;EZT%5J:NG=-2$]1S
M$-M?WE;I>RFR5G>%YG2WH9H33+0F4Z6:9OE]"]0R=)7M=PAKM'22M=AI>3[A
M_=IV&SZ##XS*SB;*WS.(%YBHI/F84^I??JY&9I7,O]\R^2),[?#ID"7RM%-E
M=?FQLH0\!0DJQ@<<?RS_U=:% Z/8W8]PL:MOB40F)F!818O1>>-"S@4HTB?-
MH>,Z9Q]116B@3IB7B]_OR>)1,K=V#@HR()SNXWQ/SB_7EI"Y\L5K1F-")A?>
M?ZE9V$/P7B#*(16/N0^<V3%G,LXU9B0!)6L2I.G"JJS #'@>6(XJ*BB?+A;D
M$C^XB"NN6?D8,^DCRTK%[!I,_3UN4TT#88&-]=6'7]F$<8V'=M;8?:G[8OC"
MS.SQ&$^OO,P(V2XU482S/0F57(I$+&60J;.%P]64F*.ZQ@O=@)3 H5V.9XH(
MN:2296/]6:4CP8).O^]?0:!<O6F7(JY';67VB[%D(LQ:Y;= :JLI1?'YS&S9
MCP-KDE)<&"Y9)\]87JTF\JD2U1HDR<YP"MX\;)K8.F5@I8D@/B=U;/8.'*$5
M7!@K5HXF@PLU;'B^J:5L] V7<:]4HGM._3QAZ2PBX0T340&-CLJ-NY;[TK1X
M?F6QR*#E@,C14JIY8<O@S^$Q[S(M5P$=G?HU+O&.&KA4-B.#N*U&OB&TO;S:
M-)2.=OR37FZ]-<U7A4CE]UYKL>%>9.S=XI6E6;]*O$VS3*R."N4]_6>E$'8X
M4C\DIE6B.^\ A,NF)5E&"A';-I7=KUAW905QA<$DNVT<"_L[>4?&*9>$=</[
MB+ -0:+0%II?]6!(E:) B*\9J47PUD.F%%=9)27@05JD4PL70LN$K*HV7>%M
MB],^P!6.%C@B0@[((1CY](R> L\C)PMN/6=8$7'HU]206[?[/3R_[;2;;W>,
M)#]-5(GGXXA<=:JQ@<R71UCY-$1O(R:G.FH[040[GCX)U5U]L68/[/3B?]&S
M'7)DCGJKW&N^A2&8$7;/DL;+CF.),39) P,L8->L<$&9+*D6]3\_AOD'6"Q#
M>LZT"_3=EA&W9 ";?R">&":7:(F-:RT#2Y0GY'>D\C\P7NZQ?\%5_Q':QO+O
M I1_)5]LQ!#(<,H:E&*N?4QG,&9Q_N4_6U5)<2U3_ZQ'LOY:O?%72D7]S,Y<
M5UXCC/D\CCQP^)&\8*:)Z H[ZG,R;05<)Y$G[RJ8AQ&P6+G4<$3GGJU^/)67
M?!%.]%,BDVFIGE:T1[!:R14*?)EKF@P52.P]L,KGS .'L[%XVSD3.!P9?8I9
M.Y"[7'N(#@5V7.A)K>*Y.9\/?<I82/7R#8HJUM*"&OJRNLAZW $B)5S<5B'$
M>O/%#LVI <[9UIR>SL5%(R3(\_UY_=J)C'!5TQ^,/K<MZZ(P2J'Z!CSM;"J1
M<TF=L),;2&AR4*/EP[Q@&)6@+GW3$L@5&GT',/EIO6Y/8F7R(D 5(5LE+>[_
MH,EH)1U;5-"D6[<<I!]86H.*ULPJV#5(:$G*4X9\008Q+:B5>'2UAGE;KQ4P
MI;RJ\'_&+*+S8P7:&9,<TC5@%Q170&EPJZ:9U33R%K%5F0L>@],!JZ-8XE>9
MHV';P^ ,Q&4H-THP4][K R/W^$.I][W=LL*/2K;>VG3!-NNGU4VTL2,DS-;X
MDJ@)OTF/OVPQ5^"MN^Q6N"Q3J[).'V>I>U=)]O#W#B%)0-CD"QU^US>3ZB9.
M:VJT-I:=]'^DGM4HEDZN+EX![@!*/V"L'XVV,ND^N4CQ-J5WM"=="HU46$T
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MU5I55E+"7&V:_$95*=K.*N*9[A^-PJP#<.7$3G'T8_ %FG$L:_+],YDO_6I
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MP#]&QNZJ;)P'FS\3M:_,I7NHZ.*9!RB[CH8@7;@W)ZG3"S5B$'S#+MO5(JQ
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MW'8X)^M!_C?VWCNLJ6]=%PTV%$2D=U!!>A'I-2("(D(H E(CH+10I'<B2%%
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M&7%^&46P8=WTTJP3NSC?D?"VO0Z\5NT>0*HYZ-CP27;*0@N[DM%98J<#2C&
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M'-.D+5ZNL\;8B'YN=Y4I49T3ET$"0#9QU(9)(5Z8'_/%8(<=F?/D\T:U3@=
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MV-DHF 2GYK]O/\]>GYP;/2_I?<*ZT]Q\^:C$!R]C2[F8UQQ_KK[(M[+X=B7
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MG^[#'U4#V","($C[S[-2O:--RVL<^4<ES_ZYEDDA.ISXV3WW?V+_S;]WZ9G
M*>=[VVA*G7U;8B29J3D;K1.&62Q12"HH:]88[:QL]#Z>>.7K9*MC=&/)3!2G
M>D;=KS@?>_J) \ZQ;'SH7N-1_J=L9NT!+V>'KLK?L57AUQF7N8L@LC!$^/=9
M>T.3J =W/<D>NJA7)4P.UU<$1JP)-T!L.()-VHXQZO=K-%$A%C'2)6:7#<V\
ME*M&X\289U59^79B]1V-MP4V,J"#P]D1?'^]A6D57CR8@Z,5J>>T9O3JH&&^
MM8PCUT/<O4:!+?AOF;+#%T_D%IJT764L-Q^6+T8$T))TF.'XT6:S:S:#)0G=
MW9,U?4ZV"(8A>=E0\31)<M,CT=(;);Z\Q@Z49CVRU9_R(8F:-@73*AY.G=PR
MUU28#6+R-SP%WN09JT"<OL>R6EWF+M-Y/$B9U !F.X[$N#J:M,FJ=.3DW[CQ
MR3,NU*7CUO7% VWLC,EP@_-56'B8_WUQ*?-7W*\_Q,=H9:S3'=$>5Y\(5"]=
MSV6/N^.\KM.:;V0BN2&XL^3\<DD?F%D0Y4C'\),E\"!N[ALT5)[*29%]<YKG
M0\F].M'. [4[77J&#H',6&60N@'%K8F3(E@OMZN"0'%VJ=8.8J7=Z/YD3SEZ
M/B9WT]4NT=C_MI%&&CH;:<))"@R54D$C/B(7I,XY-8,'^F2@?"YUL(W< "<Y
M.ZM;Y\UX]E&8]Y%)'_<T9*-+0"[OY:L5@[3=#+L?TQ*YJPUN,S6MJLMW(BI5
MZ(>;Q]?IFV[@J)/8WPXZ5G[;F=G'ZX_/3)M,&Y? &OAH^24+>7]=RL^.3KP%
M%Q7TOXN\D#*(UZ\<+LE"Q-_/5VEE/2J06"#?0-P/M1P[Q#HE*&YZ=(-S(4,J
M5>5@DV]]&:T+9"\G-=_<BK2_\]52A>\$#ZO,W:1GOA]A9%==,6.2/Q<M^HY_
MAW97X XQJ&[^S>"AE$4?6XG49-%-:=D]=\"P2G<JOR  D)Y8$7PP1R[7B*&R
M7;ZUKQ"=H>:H(\Q,D65&;>%*42W+J'YA7HKGZ[R4.B)J?/YS1EI!@7VBK$KJ
M'(I!=.;7^_NS&%,1G/# -98!SIUU)Y>UY=4LN?JK5;4;5?I^+%N.S_H%>F42
M(3Z&KK*']XJUQX+D0ND^+:4% F]Z!Z[K)W(G6'"X^*84+,;0MR\#*?.*:"G(
M*NDFY]LBZ.'P1[Y<"WK?_P-.=:GQ3SCW MZ$6><9SAX!+D_@K_XYR4U 1)?X
M@_H:F#$.^Y?J._'.9\9*PXE_P47^>92DL8.YX]&LY! !X&M(!C06A FP/1.1
M[-@E_]J)>8(,WS1G6 XE $*2EA/"@@J>$@!3A07GGU>57]\\S/,FQ?.5?9(M
M#;<2^"2D?"FT^P6)^IX*T$?@J!Y\)Z/>SQV^Y->.S[++,U88VVE[^RC#9^45
M +<I?J$ZHE^I4<\T[,VQ6\?ZWOSN4MJSO:6R:$YT?P)GZ2?;T[ID7U%6CBWS
MJ>^;GG62R5=#OUE*W]4NO$HU+C]0NK!&/6Q:M&96/$, W-Z8?I%NGE5H-%V+
M9\K3!Q;DM#'\M)N^>K2B4?<T6S!G'F&.I@]UQHBT&RZ@8^WW<X(:7\"%M;R9
MSG0-OYP::JINY_P>*"B6^"2EKSL=< $;CLYCNKR\7P1;FR?':J>383@7)E&5
MFM88NOW7"K>4=MH=P?YJ@^[$,5,-.;5JX;M->],E[BU_E>/]>AXSDPV/0P.1
MC_Z@?&^]9_C!4=-BF>D',MQ9Y9CHA!_>!B J9<Z ,'$;2S7.R]QYJ+YC_@&0
M6&9V PK\29$Z4OT<.FV$" B^H^AJ;X1_@+4<%^#CB7MA KL9$OU^X:"PNIIJ
M@\Y$NZEZ>-NZL2'!$AZJ(5>Q2*8N06Y;-3[*_$BH+=") #AV25DL;7!&@EF]
M#4W@8L\$,T,NLGZM"%/>R];\OE/'ZK ]_WNKBI+.%L\3H2Z>"DNSDO;WH*LT
M5T+W+#?C6=%K104;)X9BS32!%[G@K^Z;$7OR]Y<=.3L\1S1S>TRZ7Y66C-H0
M &/&XF5O)D/F2L_3V.BZO<.7A$.1C=8+SQH3$&.*<X4YTMV_^O0Q/.V@FUAK
M"V</]S>UTXRMC*?O.#FGLU$3POW'<K[K#?K+FBS-U16F$.I>5M?JL?UE83>L
M(1"Y$!5(CZ$XF^(:-NY?OUX9Y:3XS9#S7!7:1?[''F:MI\SZ+!&@>N5@74?V
M]N_VU77S"<X%1F(2L!;2J)^+L8=%L"[<@S^H339TXN>$F?%H1%2*ZEO'=DFB
MS%=2^G\[X? \Y47P#>[/2$[=WP$ )O&SX./+'E8N3K=N5CRT&>&D)6DE %K6
MT(875S+P%RE I)NW #X81  $]ODTX<0\%BZN9>%BL#H$P,TY+P) Z0>4$T]+
MLLF!KFV@(Q[R$ !-UC%8TWDR B SG@!8J#1W_M.IT%8I,P)@T)ZCBP (!?A1
MAOL'(/=HYR7R$CQ'GA>^#/ZZ5&>_/Q"V<",?+0P7PM4%FY)^Z(0I[<78'\G^
M!1 .**,_<*'%;7TEAB^?,C>C[X\B2#!%6*>=B$W?B(_%DX<&"H@&L@U%:0*@
M*X'R(B#_J"#PCK>QIE^S9%*ULE-N/F]-4"<XZ4K,<![U2L/\Q,1P[_YL0:G3
MRU,YW]G^*@(@_GT# 5!VEP#X:0#_V!#P@^<C$,F$;@^>MP_R>K8[&2VZ=\J\
MB&?%AF"3EBH:/02DRZEZ\G^\F:;<+QFX!J+/P!2U:R_4=4HT4Y!\7A9(W#1D
MQ#T(R!@P>)Y;G(OGZ&8V:+HMKYP).4X!1QU.OC+IF*'HJU\E.91 22P3N;!-
M,!Y$N3D>_7-! E57R/HYDW6BM"W70L4IT^VQ5RAN&A=RF-!0ZJIX?US>N.XS
M<5R-I:TQZW-[B]3;("$V[T9/1'LT834&0G$Z%K0,?1S)M.62.J%ZX_X:95M-
MMX7EA7+LJ39UC%793<*TC0ZBDZ]XE3H-]Z-:EZ-3KZY53Q>W7$YF>D&WV=ES
ME=^W9L$&.NHA'E5?%!ANMM3TX62:-"IGL,1]Q/N@M8Y+*_<@&I3[HAIS$B$.
MHGEIAQ :7@RF4#I6YKIU:R1VXN"'!X"R<P=XA]7XV^L >W#4G8#Z5J%9\U+*
M)3Z]P&V6\=V%4S$EA;4D%2@N<5T*$[C<%M[.+"PDA/\-?S0E]57L;B?&UQ#J
M5H2-!*'9RWYXQVM5F41Z)P\SSLK6,&U%K 4*/]!4;MZ7:8F$=2O(&K[!T+]<
MQ3J7,LZ9!L0B-@?L07.9%^"-%P&HBJ8W9]_FX850!QQY'#$JGLIO7/9QB;IZ
M6F_ $-J@LVR'8[/VE\EJ<RBY2[9O6LW\F%1.#6E(BDO]!CW:!A[*HA"L]F>O
M,VYM,\O52+8"C*XM2GZ6Z3,=R]>=$SK[G(8$X><OR!5O8N;@$?)RBCGBUM,0
MS98U2:#[C^Y2:THV[\YV-U,0DNW>Y.:@C)+$2-#:;9=.T+-U>88K$],,T<Z"
M"8@!F<\J\*R6@XCMP)O@*8[PZL'BBN_E]<4_7EZZM3P>4ELF5*4UW[1Z]O[$
M_0"R*X+E[/SI'7QVH#;FT)=8]@9?+;_RX(@CMMAOCP,;8X*AFT]:[)-D"?DI
M9Y/NV1(_2^G[>Z@'E<$FX=<H'Q9,KAIMJ!7:]4H&IZ*!MER;']]J&T\2CITC
M/[9D78R-[^,]/W;6%,'.X*^O[LX);P8R$ #O+&U3.K**<%Y5 5K-Q666E;;?
MH[X%/W)2@_E2AOI#/ JQE89H?"Z9LIOU3,X,3KT#^+54?:]$I,FVWLWNX3/.
MG[RK,B3O'"*2EI@4*;&AW[U_BE:/.[1ZJ@7>$CLENS>6%9 VT;^[,/%U+6W5
M<:QI,:=H5-[&M8FJ&"=B1=9U,]"Q-0,)WJ?P'%L%D[^2W?L@,<#8<\.D-LJ@
M[?@1"'2.:C1(,8A G%\L.>U[SCC7_'6FAJB2$$2ZL%% 4O!O$/!?)5P15>@E
MB7\178=$,L(,J/]WIVD9S/G1%U%KY"7V+4Q*S>K"=$]Q-TJA2QVU/IG8:V>H
MKH3D\J!P=/ C8'^#"3*IM82G<]IC[+BD6/.XF7M!\(&@[$$?[[QF[J!KE:YS
MP6$C(L?&R]ZII#0K!7#CH2HRB4/GY9G:IRH*+[U4K9&]89.OE;6D%<WM%E@>
M) & NRLIFU"<\B7)TZU@FG6_*!H2AX7D>_-3LJ&H;>%P,7!9<NU] /^GV67V
MHV?]GIN0N+WN0+A"8<3!G.$R3VA5@.XRJ#8%)$O*BV7;4FXA &CD@4MS*L7N
M4]]^%S2$L35UYW+X631*R?$+1&#4VD4HL ;KVTF&W)"*D\R0-^&'.2T+M/Y2
M2_49/Z=-&9UBGEHS6EWPQC26 [W<8'^G:;?+P9C.H 8QR?!"E*MM]2>_5?J#
M*"O/ #?S-VBI%F/*#^YSCS5--*H;O%=:DK59#:NQ _@G.X;X&N;]@:D1O))L
MQH5[=L1)7E-=DZA^X#9'*NY3&GEGDBCN>7QS];$G>K-Z4=""X<I;BI>8SC9'
MM59SF>$J#5M+;^'DRY6W JVB!=Y5(^!$.FD;F>R\>ENU_]KZYHF*"H;'9.0H
M(W):Y#B@I;^\CUJ.Y_GNYK-4UT_T)WY?AK4*=^"+Q(&.6I%G'LMC/+R#K%9_
M51OY^S/5 7O.I5JYA4_F0L-[.WL>;-=--DXHOAA&A0O@3P@ XTSL/ FF+(R$
MZ9K$(@'0:))1178/*Z8UG>GXF21H)%>@IAET/HY3@_0FG</%/*"?% 7VDPQ'
MW#GI/]9<YAJBGR,&\3+=QO$"U>$:UALAD$;VA&'M [O&\F[$FK\>L\@V]G'V
M.R'M*,KC=I_M09#4]CKY$\9"\\2W"OSYNQTN9LQ@'_$+O+I7[5!^._"#,:QJ
M&A&;U7X1S\3E_*&2CCV\T2O]"C:>(:J!Z.X5'X;Q]R<5-!T^*X'ZJ8N4U+8N
M_O="%%:HO@JEW5=U8#WH %*9 IN]7Z<[TZ"H^$Q429U96==I7YSX+-9Q[UUX
MT9J-VLSE6MHJ2GOGZ-&\W/25G461BU[N_5!^7>$1#C);)5!4/W>K?PU/0S$:
M*Z#!9.IH*<-81GN1<2\*-7T82EMC>9FJZ[1H@7]:)^*@DMHK?E_1 SM3: 8)
ME![Q%V7-=?3B7B7%)I>#5LW3WJ##F\LW*J8T<TQZ11(OSSZ,>?#-U<U<#Y,R
M'D"^9)Y6)N[@J/ZIEZ1#^75,3V-VYQ)#F'"5[='EHIGOU@_Z&;\5='+2I<GY
ML1S5UWJ([!AF5\0L@:CLP-=Q'! ["&T\U7F]K=$I4"_&%\F-S<?0@'[&&"$&
MD<P:;+./E:\JYI^-B7SR34.4SK.-[YCVY3:\"P<L+D9->"Q#J6U=_>^DOIFE
M7#?*5F&NUMJ^)8I]<: 1I\]^4KY=NWRU$CPQJ[RT0&N,;5ILG"^QSZ5_=#E+
MAG>N<\MH@=Q?Q0X)?5]2.,\QU_+[<72Q%_M5-T7VJO2%8Y_1^3=OC&R$WYVY
M&&DZNP"W3\D?,Q9[J7SO/ FT+SB/*W#>Q5O&-#)[[8ET;8XLY;<)F8\[6CT=
M7&+6I0[TCI0D;?+=Q9%CN$48L8''RUW[(MN?DRUY:M@@8LB%C^+2BE0SI_"W
M/%,[/;^C?K$U^RPWNG!<NQ,'*:.WIRJ@CZ$MS*_@6@E,T#5P"W_C%Y>VS'3B
M*43$5Q9_S6)EB?3D[,BTIZ+35E$)*B>7ZJ!A4-H]G&;QK&W*3N',0MM#,N'!
M@ K3SNWM".>C#GXIBJ_2*P&H,N1GAN.()K('4H<<NV,J@?L/ BP79D-USG]"
M<N!+ 90JM"]H_U[O$4DSL O($$7^L<QQ01B3>)\N56A-E$V^UG+*_@(Q"-"A
MYHC8/'MJ5#K?V <B',L\D6>763DPGUF.H<T/:9!2S%JMJKR8M-+G<6-/:/7G
M17N,3HAY][:1?!]UOF$;I_0;LO6,;*<T$IH!RM#IGN*9R#_%19LHC9?YTWGZ
M"R =144\'-,]=EK32T:CTRHC#F/""  JRD_4J.'=B>WI3\D7*)M@!6B:3^[O
M$RBEHC!*-FTWS</-SHOEBK>>U_P=?$(36D.UR1%BC&'K*TX</_E^/4XIV$>A
MB;G0U<TP +$>$*K+3Y$[9]+G85,Y<,7K@?K-0F8IW6)*%[ <MG4QL"S7GMI^
MGO9;@WW[^!W/!JCR?.-,VS#J@;?KF=E]#3#7ZY:<VC+:]\OY'QWN0,PT6I^?
MV.WO4L%Y%@B $J/-/H\Z$7,S3TM_06Q^";1%A2/,_\F>F)R/2T/R?+$<ZP6%
ME7<K7HMZ H^P)$H!%#0,03..T\$ O(MT*B$:MJMB_KUPE\UWLB>YV-9LU!E/
MFPF4QFA:79Q)S4"?RTGO&VL@79F4X&:_WY$8;.QIJU.X#V8/KXZ#'DU"^7O0
MX;C4ZBP"P)2;>&W(!TQ,I+\9AJ9UU?!)W RHDF25/US8UUW^9,=L+Z1$6.\X
M !&4F6#]0/-#S^W.U</B6>-\@PL'\$.WO'I6AF9GP*:Y<!VB;NQ++UW%=,6M
M$$PW;JL0BUQ,59!K80X83R9-HHOT\5/+L<+Q0Z>FA]?&1UZ>JS146.O$B)*M
M!VV9ERQ3T/DK(365->_0I]#?V)Y<*J+ZKF<FV)V#J3^QQ9P3XY042WJ+:.KS
MV, >G_4[ZW_H)'E.XIB_W?0NY0+WL1HRR5;+T4+2>5#&!QN"=>]E#5+D+DSA
MI]+R.-_YTGSS-1QE%QJ&5B)N+VQZ#B4^F&1LR>SF$N8M<%(?Q4.@8&\]@V]\
M! #?.I"D6$\7G?%!< 50W!Y/.J=BB;N'B&_)H-FK8@F;NEF,63QY(PW>,K/9
MWK-S@WQ'9=C"$P7[.K^&NOTZ*M5;5@S]L9%Q^^[XX5?NB[-P"C(:6)C8R):6
MZ\H/8A2AN:G6\WF/O7"JFT,9'/Z>B9Z_$Q,/&$C+R;LN5#P10J,(1F^_M@D:
ME*>R]AA7!Q97P5^ #RO"D:#'VDO"LDK,'V-F3>&)",O%Y5*?LXD;'FQ[08&"
M9O:^_9\4<YSVZS.I]KJLNSCA(&,M_ENTYT*X*<.U]8+UBH_+;"9/1OW!^?.V
MS$8C5I1,KV^4TU-,T&V"V=F^HZV#MUW[5N.@BQ(MV 6=T0;P$H6<P?O6^,E)
MGTC61\K!DS(KE"5>"RS;N_EH@^#RF5Y.WIBW3[ABDJ:S-4XT<$^_$P!^!(!3
M>@RZ%:_>\9$ ,.\U\W#-H+@7QQ&>(NB:PUE2%US\0,7#HQ&\),8/O43&FUWY
M=WFIT($1"1,G .@VBRP*;O@G?'XJ#Y]V%3#@I6;Q"%+5,;0E'?[.11+?;F7F
M7?GH9\VY0D>10]SA3!.P)T88N3[9-X1@PT*5,&P=]18W*^9F+[$ZG\K(2#,>
MY;01 )3N0#HS-1\?U@KSC@=P^KT*(C<TDVC\S>!RPW%-W4J!B9%*=W"\MQSL
M-;OL3AF6<NM] 87ZDQ.OUMT^#^[])BWITIZHQ=?#EQA?WU;[D>\IP!KS <&Z
M,7]WC.&%9RT,H?->HBJ5G-(WYBG6 KG#8@@?<XQ#EF61/NP6UECG\(OV-;11
MN;^[+;7G9*&!%'KH3*>RQ$U]4<>+@[7B:LX"Q1%WT*6I2^J"\SB-NF$=P4"3
MG17?\55:A[@=HNFGX5 @UNIR&_[6L+])GII5@>KJO;LY[@X/J6:9"RP6V81[
M6PU3F-)W(9#V&0$-81/V3KCQ] BL4<H@SGM;>#DMT_%GZ$ /Y'&D+:[EK(PS
M@_W6<!.2BIVI;6$**6D%[8M:+W$SY+B*$[E7:)+:^S+B2IRT]307P(HG6M-7
MB%;!;'ZQRD!,G*C6$1S#>L]'=MH\>T3AYPM@XY6RP-M8WR4\I-Y(Q,'8<X[?
M1+/"!'VI\5($>^DV?417*WHBI"KFQI1$=8)SN6AO/6M]AMM\A<1 :,HU6+%D
M06JJ!IPQMB1WJL$/8_)Q*4T61"L5_CX#+AAH8>H2#6VIWO"=?E15)WW!@LP(
M%Z<P7] K#WZY:_$X*/)B.XIZUA5"NNQ_G-^,V=QO7S.=ZZ_X1:KO#%XW3]/1
M='1^^Z+OBBN=C-G&+<IJ.W4WKO0%M),TPM"-H=F7&NO68ASX%4!!^TA1KEI&
MHDF%SC5)S.%#9\++/RNJPF=_FW7+?1-5&B JVPGF-RBGL#?-QPJ?_!>6.$+-
M!=%LHRG501Y<U4.K(>6B1K2^KPQK_=7&)"XX6C,<T;AKD ^S#(_$$KKZ?%1.
M.A4"]]03N[!O$E%/)D&)6(Y0&R]/9)U(MN[D!H+._WDCQNP3/K8(6?8J*/G-
M998.2G"@0#26B(CWP89GF@1 SE5''"-:LB!?.+<,]5;\FC>3Q:=PGCL',1T_
M\113YB;^VF-KB>.V(S06Z0])3CM]Y^Q,\'->HM#6@++\1?<%QATB6.]P^U4/
M"W&-BWP-N7]M.[WD;(PR1/%V4NL\_:B\OA>31D&F\]VG'303AW2_O$^TQR7
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M&7N?20:>$94>>=CPDD:JIMS3>L2H1?+RN3C_2Z360Y?ARD!J J!S(K)I:Y,
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M P0\+:U4QQ;1GAW*:E7FS&W2F!*?56V-[F7\*P/F=@C/SFT"P.[E9*0\$0W
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M;Z5@'#LR7X@YTCP,8@+N69<KRBZ8MN;8T;\MDO<RC/BIFL_RZ\[.0*/N& $
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M Q'--,PX(=:-8W:(W2::-K9^@2$ QDMCBGIKVX\VCFW*=<R!%TU+T-.S!@(
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MD<PK"/Z00O-OTV9/0^-9,9N&_CRTBG>P,*^RC0>,[A^R]U>^\.DG8S> EU6
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MB?.X#*_UKL1'<D $3CEA*<3W0W?BX0H^Z,R[XP^^-E>H YA%&LKJ;,1174\
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MJM"*4B2B5%KW-C2^\PO=H)>8ZV7[P16W<&];E)UU^:TTN1>>"U?2&\(5S(F
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MMU'1ZC7NPJFF,[H!WSYOP9MA7:TSS3&T'ZFDO.-BJ"Q\DO93J,$,M_>-/?-
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MDMU8ASP&T\\CR=+\I@1L1V07?*!-O,RE#M-1*WMO'GUJKM.29G!-]MUCCH\
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M2,^M:*QJ2][&:&*5^EC5CR:[-H" 7^4/']F!7"SHG4!)Q4^Z>JY82;8;9ZE
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M5I[6\UZ# X_9GL!7=W#>;6RFNEK\2W(S_8T@V>$A[4'T_V#OO<.:ZK+]\=A
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M^DA?[ZP?HGT7&();2D%2W>IK2M#I=@$=@F[KW)*8.+-]- RE?6%I,'ON^RG
M56) 8_@.7'[ G6J^[BQJD\DYGE)[;_>NJFYX9NJJ:^W!$'B\33JNK_Z*W2%-
M3EY8&FJ1-Q@4;=G9%HOU7Q.D=G?^-E)VY;*>D<%[7EZ/?DB.IQ 6KC3,MU<G
MUKHI8",[&M[('IG.#G-M+9O?Y&X60[P=L4JK"F7^@/I:4 ,-J&<H*Q4;6!DE
MZ+UHOJ3^6()TCX',+4\P_<3&P+5*(&_6+VQ:G"#GC-CO@,;J9Z7QV>7=(,^[
M"]BX,V+O8OVY1?_.M8#&"<EU6HMMJRQ[B>E#I7H9BX^LD@/+8XAB5/SX&P+M
M3.Q0,?%#%+[8P("LET2'5E.= @["@BO&7ULWV>)++!K3WX&"99CY;@;&<^I)
M3<JG8I:"K6U!6EY %T&J\!X#W#-:2$@#S!1*07);1Z_-^#XPZ366NU4,MUCK
M:IS_;5J1I'&:C6VT[CP@G1S .C*P&:MBSNK^+:81R5PN3?JHKA(=$>+=5:7#
M(=0)K*TZ!>R#ZA5X-,B[KI,H,9YW@0M@L^?QTJ[=9&,+B>=V@)F6>&$,8%@D
M)JO[*'G8O6HK"1%5J/+3>#H0BGH>+-2LY/'YKP>E_I_E]'^6T]_7WD>$B[";
MN)U\M<F0OW-4A.<W3M(1Y;U8)D5F_9:--]2T'S?Z<;F#]]-81E[C]!,-DO5T
MG:%'M!6X1^=(IUS'U(S%KT]C0<W7)$C$&O;>P V&MK\.6Z57>WDI,:X/3>25
M\AW%=?=1Z'1*%T]?,4L+;E[[F_L@_FNCUR?-^;?804&MC(]S<U+-2[<B!,'^
MM$U(QVC&SM6Y;<H,?]:1E7MK$QY^PU>TIV^IW6CD954#PV]A_>:-U$3)1#^]
MCD9>D;AA/_ SD]V5NH1:K5EUVZNB3(-E<0%9:[H'U64?<8ZAL*56^ZKE=6.V
M;$-#K'CKF=?W=S)V%O9X(%S9Z(B@C"&G'QPU4:%6SE)T$]7 8$D1>PZFQ2)=
MI3,<;R18V_9S\U"W<QLV;'W"5$3?!!24QDU_7M-\$G\%T\/8^?BKUX$HY[M3
M &59>LZ*FCGO6P/M4M-<ABG=_G@1F_=EJY(ZS+]$983^79LU_[IC\G]Y5IO_
MU/;/7+'R;S6)E&L0=XM1+L@SCZS+483^O4+5!L(-ZUO'&Z!'L-H 4N!WR^'U
M/FGK^0C^1.T2C<A='J]^W)C"G:PJ#KM7=SJ%#[Y-L_H6L,C?Z8R*5.!_9TR.
M49RK?K..;PK\DC)8,]'Y[IVSJ1I/7L;[2"T%!A*OOR6H'W<69AK]X2PK/_T9
M%/B2.T>U<ZH@G\GD^:E8%H9\!\4KXF!J@8+"0EE([.?:UE[J^VWE"B[Z]?'4
M\.P.R[O'38NR :.UQ1H7+,9 0^9Y3UXJ/DEI;"H354STS:@0P6U"S=6_S%9Y
MX#XEDXTI^B Y3*%[[S7B;Q[LP]V4]"Y)WGWS,E+)]0CQO'][3ZK<>^?*0YI.
M[)'!BF4Q6BFB]TMNUEJX_H^7)C'5;FP6R'3MV)WV PP6;!5KH4_(_J:EU2 -
MNEO0WPZ_3NFO'6FALB%-]=_U$[UHLY567!JWY#Q)_]AHLO],C*$(]%KM379H
MV_KY7NG& -N=POB6V9T[%HC]=6Z"M^4'K%:V^54V\O08[8H*LY"NNLQSUZ;,
M>8_[RA#7B=;/=$%MG]J0J"75VPY!D?6<+?[9]*_(0E 0GKV:Z77R[>0>SA@%
M_Z>CJTPQT9(HAD%HXTPI41>3%!$-R3X"@_J$09[&-B?88,_:HRT#Q ASUT3/
M!+F/VAN6[F;3\I$;F([F"S:?'\%+%$P9K!Z6V^M/U.0;/FHGF[ +C;#HQHJF
M38C[A.>*7#QT]2V6'KS; 11"1JM5+.(VQ 95>Y)ZO9!JO,VC0,O!K6BSAJ8S
M(QI?&6#&XO./M9MFF<O";O5?W!28WZTM6Z'I&:QSW0)S]9HKH15[CLBO&P9;
MYE5R''UQ8YX-K+]IQLI4=:7"A7.K*.:\BMZ'?$\F3%P(LG)!\DW_>_93@!X=
MI;"'PCNVBU:IH_ R.)U1:_'TE)$P[[<.31JYHQ&CMQ=KA3!#CZ,;S@NMV8DG
MY]V]#C@%8&X%;C,(Y&\-S@N6V9;@I.X-N"NC/&@:)[4UJ\^Z+-YXH%HQKX6U
M;9N@">9R<[O^Q3"UP_N!3I$AMQ?L*X:M!4B[=MA>HOQ&,,:VTO1%ER/>3PDC
M,,I&XRZ'[JUZP]0D,O3^Z<=KLU_VTZZWJ&YZ7OW!G2U:WX>:VH/20KH4T*46
M3KRIQ8@I/SF!6;EG> D,31.!JUHLSH53X$-?#$_L*]X =/=E2#J*JRP'?..3
M^0]_!IN'R>]/[B"N\LT3D<[#7#M%_5<+FP56[NIIP)<?B2XN'8,#7L3M:!T#
M([3'!,LHU,1&MFQMV+WI&4T=/O#R-GD*#DKK5E!E3+WO.F?]]EPP'$E#NCK#
M%SWHH=G%7TMNL#&)<%Y Q1%-:MQ^DSN=-Z_E[.4F\O-A L%Y7M^OT2OIB1P#
M^Y]ZKD5O_5QX4>M$WG;N=Z,D8![LJ L(;SY$\9NAA20?1O'<?;QE&C9IWD-<
M;1A:P3^JY>9Q0R]$#'3&C7KZ @B=W=A'!4$H$89&GBX6NK=&"'65OG!$,?S)
MA9$)QII3 ''GNHXB,.D$IH=]A \[!!.\)9%U^9'.11PM$ND=M.V7\BTT#6R[
MG<<$XG>-+O3IE#C6F)!2<?,S@/',WY+1N_OXQ'+<<7W%24UL@C KJ]:LRF/:
M'QJ,76\S9OG6+WO3<&7TEIPY<WLP2_&/^WW ,(_W\UV036G1+(.6% $ILQ%[
MMPOT9[+_(ZEZ_ONGGOA7VYA"%+FDORY1OY2NW3[76:L]WU%J.5NN3W(L)3:G
MA&9:K>5$E@Z;&/"V4MBGD[=A6YQ 5S!&#]!/O%!VWE3OP8%X<;O4Z9.\,;N*
MZ8]V(U1.BBIYBW'+%QZK^-9EB*U%Z*55;I-CZZ7V#*26*>SO@[C]"UNK%J]>
M?>NLG<L4M13X,^3E;QY&Y2)Q"#<W2R5W#8\WS9L4N1K)D:,HP1SQ%<Z# 3;Y
M#:8F'XQB'@'"BA#@3#>J%Y!LN7BCDL?(E"ZSWH?)84]7']H,BOD+U+/R#QY'
MW$0OAY2!:8SX;K>:J0)>.J1TUDWT.CB94FXRAK9[!8OK', 9XYM Y9(]U5UF
M[MMWK:S>/#\%Z!]\.I]VL;F9\6%8,_4]-:U8_NDQN='6H1:]5N;B-64%>NV[
M_Q:.\4\3427D;D0TYN+R3P'&Q= 5KEJW^8 F(_%F8^J*84%!VW<[]\UH=2\^
M,/G!="AU?+OL.MG&<E^L,+U'-NGY5SD0VZ8XUBL#J,&]^1L5BGS2K5/VZAHB
M"AP+LP:>7[F)MH5M>L-\'TV'>>J/YBP1KML&]]^V.8Q6PC<C@B2(<DCI\2F@
M/A%O.;22KKO5H,?+WB<.R7^.+J^RAJV,.DN40KDW%J*7S>>6\MVOCEAK?$"5
M1)L-NBFS<"J^(,>WUO%]D#O_FFG.B<W7F*5N^&V=U]9&QI>E-^6)KQ#PL[X3
MMCV"WYG4!+D<9IAX87CGD7U5D_J)7AJ.=DFZ71>X6HQ6T;!)75%9=;B!;U@L
M2KL3HPFQ;:S6\!,Y!129:[ZWBXE[*_%6=KE.=T":+L.,:?$ _KHX)']VOV:6
MO4(.J_6F\^N 8!ONI8N+ (Q 2H8VWF*1$$TB7U((7IM8#5*ZST%W"AC-*3O0
MN.QN/V!2_)+'O+\H*7)!0!Z*>5@]#9WW]"E<@^71.9B[GP(\#<S%;'#(4CS_
M7-CU1MX[0VD.(K/K7+$54IXB2I J1W F8LZW?M (O+35>VZ^I]D5V(Q@6(VW
M*5*6)EC)]8H+Z$<$#;848M<;<:*)!<49,XZ)U,Y>-3#G9"ZLPU=LVI'@EJZ9
M8.1+&_Y9$Y.IPVR(R?Q2P+QEE:#U4STXY_'0E.P!GNK2,378%%/> "RS+<."
M'0+1KP=6P-?<%;*G*X/@-$F7'3XT<>/-3P%732.>C[G?2]>K[G$X:+C'PSRO
M!%\T@@=[LIDE\U:&;V$X@W<$J^S.;=AAASVO8^V^0BQ.RB[JNH4L7=O=>CW3
MM+KZ2+9-?!QO_4WU_?T3>-/789$H@P>Y'#F?#*FZ22P[ZJDUR"V2.:?Y+*LW
M4'P2JT:'0;57L["PK]8/+7_@(Q^&O.]^L3PVENE0#KY0RY\]Q7<PN!8XW_3%
M*/GQ/C(0[TYD5S>B#8-YJZ%.IX#N/94[1:GAHG+1](![HTF_3<QDB7$CR(VR
M[8_AF+ZCXR.^HF?"#ACY6;67[FT]E2*(KDD>^A,9U^46>OT/'PNLJ]PK)GM>
M0AMAZ-E# <3V(5$D5"VJN^,'9/3O?P&.C/#D?F9#5\ 0*RR"2\#6"*S!Z.P>
M=?PN&TK_%(#.=Q<_Z8(?G_R2%)[!UO\44$5$!T7@AO4KWBUWG0)B3P'@>TO;
MK!INA1#DKGYYT<='._F%2LQG" S]#9CMYM&[2I8'JEH+.>H.R?<+9UO?&6!=
ME454'SE7.%%G*4T]6SX%P(QZ@^: 9-,KSN)765F&,A.>7YZ>N< 9Q!P#4K>N
M!_4WT07XWLB3-SUBY3P%4%$@H4=[I3_+4_C[88!XG+YGV78*NA!/) @/>^.)
M''-="<^+(#D%])<0S:HYR=%LLCDHNK^>^Q20HJHQ&H$U Q-7>%]F]KKQ$5%U
M;S<@]OA6H5CJ4FAC#=KVA$(23#@' T#8\"*"0:> Y<&A?:+RO]I\"MA=-<>-
MU?_Z*K;?=/N E?3? :^?U-> T"_+%;=TOP=6R/A!QG+5@#%A6:,\Z3L5G\HR
M:\8Y\$V\\M#&'B)H3"SNRH"!049^^>UXBW -"QQ*F<C&12-.W-J(_#H84/7/
MQP=TKP9+ZV5B536NNG[,()4R"2/1F^PG7[0B")HO$2@\0*KU0^R5]_TM X/S
M/;GI^8TB91C&5_:>LN>G57_)I_26&NP__[M;+Z"OO^,1>\ :\>]Y>RU#@Q:G
M<_+"I&'^%T6)!NMB,B?Z"^Y1UE:7P^0R4/ 9#$P!Z;\4)YDX%TYK@@]S"0^Y
M)?P+_3B$ S&"WN17:P;'>$>^LD#)5\,>]]AWSR4Q#L3+"%;N,;QQHLQ@D+F8
M";_3[V[DDGZ_O(:*O_J+M<S3.F[U$:O]Y^?+BP-86M^SZ7=FWGFPDFXLJIL8
M;Y86W#WU]P2P62J&RKU^JO102<7I?X\#^$^.X"#\4Z)"3H*NQ^_#]=#+^!!]
MTQ,WI9^?PPX\:'17%?GF=="G]T8/#@L"I561EI:0N>#WH_>'>3[0 $"W$OP4
MQ[=5*3'7+"P$1F4(P6@-K I>YQ0 %&>+2B?0(AB@?3UM"Q:$(M8VP0,=C26E
MN@%CLE, &3@8L;R$VA&!-H*0\*.C2GS8'XKQY.+;#ZMY&X#SO!@0'C_EJ1CQ
MJ^>M7]Y@&]<!?F8]5(!PXSD]>8CR*#&B?>!7S_-X)>/S2Y&>/@+?-W#(U0)U
MP$=:*!U8?=7XQL"84A&I=NEY@]:+]P0/%=SW\U9I8!:T8/!$[1BMQS)O1QX8
M'30)[?.!SO[Y.:O;V,>.MCARO5/ [.(O>9QO#B!6[I@2)7@\WG*)#?MH$['<
M@-A. ,[3_2RD\#./RY]+!?U[[R;]9:R&9M&1*[-[]"6G $07@3A6\NG0_J=]
M1"-)$#O6#?P36&@CM_4I0);J%. ^L!]X0+.1E](=D8WX=5\_2Q$%*!(G-3/E
MA #&P#]!?]4A\3_U28+[=<+1GX:837MB[8K+9'V'$^6QZY'-=;98/2*-E,J$
MOC6>O9@JI+@F?E8H9J+.L]RW*K9/MNZJH@WES]C<&_]%/D)IGY8YBU/ =6E@
MEB'50='#-SM]#V?%16LP,6H555@'CSM!\I-G.*Q(R"-I5)9K/7BP+LC9@+)C
M>'1+?^,.JU?X-H8A'6/9(OFFS3MCB$_P5G7M\,7PVVDONK_[] )Y EP4..MF
M9Z$[198J%1[QTR;?T)RH62S;XZK(Z&U !U#;B.$55DG=FKO1U3HD5.3N!Z5U
M YTZW21E@ZHP0:]KQMP8W9!Y-XX8O7I5A<JIJ"NZ4H$L]TFJV+R'E!SFZQY"
M#!R?SG:OS*2V-S-MBZK1J8ZBPF6T-<IK'W?<+FEEOB/3:HZSB<E>.9@U'2J8
M+PN0V)E_D Z4TXLS_ ]X:<\EC;FSORFX$P7P1I7DK._#92N+1J6%W*K<FQN0
MCQ;5W%B41"X;/C))$'64T?%7L";OE931Z@%1,=:;K?2R*6&](\I95&2RLQ/J
M@$R;_+8P.#N-K>3C["PJ^X2V#]8V+JHO9IX$) 5L$17W0P]>(_1>EH*>B29T
M])'Z;"\\^@OAJ@F;I7YX#,BH[U5:;9,&UB?'8-XF77D8^EW-,2Y9=M 4H+;T
MJ&T$@E^7T$I8L:74N>-4-#*@-XH[B+4GC?4@XR[')-2'%PLLO&@:UK46K:J.
M=A,:UE*X^7>G-OH[VC\B1[*N;"X21J,8J91CH2E_DT [1="Q!=42^@8%"OOP
MQ:%E[S4:B93*?(9G< NO!I_DW%_<Z"9-%K]@+/3!U4DD=M+<\7JQ<GUVP0\+
M,=>DRLKBJG!(!$9Q/%\'94P=0+A,$S*1$L#/&*]6&:C*_ @-:]/H'BL>,4-F
M5,?DQ82LT&OI".ZKL@C<Y#\9UL7$?!@4.Y-QKU-6[/&M$7>>A=<4BX2R#9VY
M4P!CK7SZFF2 ?TMRNJU$,,8(7]$[LAQC7$64M/%$ KLB_H8H510 -EK/H>C/
M$%N"CS/X<$_K__[]'_:O5:F01%=SJ(>*C]J?B@E%_?8:MC_?K2E5 MX8_9?:
M0EJ_E"&Z>H+F92?0"1)54[]-%X$0#)P71L^>D&P@ME=2!7J@)09$.^(B8MM+
M:1SV+^6)"B*P3VK%3P%R-8+'N-M$U=35!-V[7DQ4@6D?:D0)/;:G .F?<> 7
MV-[^L0)2\:^>FO[KWLYNC/T1-[U'PBP!HD!4D>3MOWGH;[JC^-_W!A^#[Q,6
M+*H(*RVRWTX!OP/C_']LC>G%&=\:*+N##^%7F7AOEQ15R57ZMT_#_"=3A-L6
M.*Y$N%ZBFOJ@U"<:-()HPQ>)I 3(7AF Z^X,J88:<D\YO[5&/$E8R_EJMN6U
M5M#X)S<<3_E7J&WFZNZL47T7Y*I#16HJA0@H*;L50=I>$VU9SMCZB!UO/HNN
MPG.>'/<=[P!;/\B0!^_.8@T)M(23Y9,C-I027@!*!O7<)> C,*DT#]-J#PE7
M@;X(Q/M3@*<2EDA@*5(:P;.UQ-EDQYN=Z\^!RYP"_/KF!;=GH+-1/YG?,CK^
M<!NX39QX)L >#V\?=-X!JWI\F'*X  T3(HA!9*5M$S9=F"D;)4[,S@V8_9ON
M9_L'(N_#&B73[+HC)+<][U5T,!(<SZR4@I)/ ;\&!/P5%H K \,RXE> (GZ%
MY0&KG\+[[5\!2O\UEG[2KUK&;K\%]!LL9U:>@9+9PE@O V(XY\[!MY2P0R;8
MR;E5.:$>Y^].S3_Q#Y@S,K0RRM,\Y.U#_-X(2282^S 7/Q+6SZLBB,Z-23FA
M9^AB+"%=FS=. 6<TH;_W:N9,)>'=K8YW^AS?]LW)O)I*X2A ;#%#)=-PX$#'
MW12!^8N$];?5-+\S]K KMXRT0AKD-\I#K^'ED;SJE(=GE-YJ$,J,0MIPI=+2
M=LH1VSX@#BQBK@,QRM]U"JBSH=G/L\>K8#W$9TKCU_A!>+.#;V[-*?DZ$4W"
M>V!:[I_%5HF?ZG>B.<94F4)KC0AO!7\/7K1Q=T /YYJ;U(9Y/((0RG1JM=#S
M_EIE-Y-3N* PYF'P@X46_@2I9FQ(MOA,^6?/#)W*6J=TX.SG=%PN7 AZ&7O^
MI*M. ;KI#SVPR!6HFR,46;C,REL L7G\"GX8U333$B4D[ JXRCTE\!:,JRRK
MX]#V%MZ 84X8$M*$.C&:;O)X>0XWXH T$G2^ F*?-CMP3!ZDL0XT^(X3 8\G
MQ[^#SC:H'JQK'.%\" 3RHS8"K8PXP8VM\XNT4C:TSU7F(_"3; GHB"9==M*<
M:#5J$B]7J8@KG'R*O"+KU0#_$A&XMWV$[3$:= =EZ*UI3FG8W0@6IYPD46[
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MN79^!'LDV8KY'L$/G2EL+6DVCIWH&9T:A_3UJ.';WAJ1S9*]>R$B_$R.+\A
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M3PQ383S++T,GF2C$4OI,8636WSK7VU,[6KU%(1.,;G"5.FZJ7['TF(J,.H1
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M>[.><E,7\](0Y5OOV)E&T5%.NY\2&GJ7*43FV\1]T#[P&;LH7'V1PP)J?]7
MFZ'KME!2A:QH"V^I4H7/%%*3DD,:")=*UY,&+<:V#0.)8!6[42#<6+#_%WWV
MS)_"#.)^42KNN)?"V9C  5L(\E[D<W"NJ6X@8]V$WIH;HS5^/DX\D<N?."@E
M#B<<)+EMKFMO"#N<*4*"S9V@A9GKU)[8^?,C".O9'P'*;R<8&_5R?-"'NZ$
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M^C*D%3.8]^(5W05H<Y4<H5@B[^:0MU<K:E3-=4=P_XR.74J[U0\H[D<E:N<
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M#Y4XEI/.?V.SG,K2T:\; HGL#)970U/5/6K#1J]9.!L8@4KCL(@P%K@?L.@
M[)@CQJ%0]KPY\;&>;QH$'H ",)D:(J0NF"N<XNC/,'ZB %6?48 +=I&T&*:9
MN>=)7_,FC"Z,^=Z1BY*V7A11YS[N;4GM)*0G]Y>?OK0-/_1&B^6;RB%MWU#Q
MMC%]9)Y@2#3TD4BJDB,6:AWD_Q[\JG7J\OL+R%8J:U5<RZTV<&A <K5$ZNR8
M:[N5;2PD\.720G;*PN](]<5$3*]VTKC3B.LM+_7X8=U$[]W.-I;Q[3H85D&)
MQ*9A_TO]GZ\.32(VE@TD+-;.5QBLW=FI#WOMF! <GN,@A.&U, H0L4I0):Z^
MWF@]??G(H@[]20\U89]D>&910/OZ;'>Z \NQJTK1<C5 C#AFZ_J/R(.?\=2)
M.+633<-#YE"S\2QY@ZT6:S>Z=IB38MU/,P;I Z,JX;6H!0,=Q8_#*76+ULW/
M\*+6 M;3C-"G-<TTOL@5%;^34@JP&GK]O_R@TM^ =A5P<[YTY*]0P0^,?W)U
MRO[*/]/Z.^^90XO>&+LAX[X7HR0@@YXI#G!+YH^$:O.&O_U.>(?M]*\AY1\!
M*MZ3L@L'%+Z$:1XD:-K\APJKOH:]U-.L9<:BZK+D1(H?2=1ET9]\DGO8+["+
M9(&KYQ_.AE]A^RGGNIJP<&0/MF)%Z=".L=7 >0"9].]FN"HM-+^$6_<=V-="
M$+0697#K.SPK#N=F7>P"=W=-WS(>3MHQQHBUF"=R#/%ZS7I]T/)1[//*["X@
M/K\:@<I5LGQC$PJ0E5A_;T0:%Y"<])CC-CN!] <<*0HO>[4V2;<;5C&?30M%
MQYH<O+%:!A6Z2F7ZCI *ZC;I3O:EP_W6W_IBY3BYD)6X#N ^8."M7QT2*-M8
MC:C/8OG.%3@ET#J(AQTGW3[8+,K6ZD4T?J;7AN=SSGV54N/F]B#CQDIW]UQ@
M/TTUR39W'S8__X8A$AN@?<"VJHP):NJ!AZQ?-GSVE[<O71[N<1C5$<_PP+X7
M *H7+J5/.XM_D1RP<9(&'9RXK7!#R^E>3+9UB7TU[OA)D#-B:RMJ;FL@T99-
M.2B=CE9VH?[3OM$G(RYRS="8O+LA;=@U)7&W= LV( 4IA[=WOO2N'^7PV6)E
M\'!^+1%G7Y";7*=<S4D=,,IA"O=SJ+*M)R-6[:1^Z_SHIK''HUXG86Z^Q^%)
MIUR._+H.:VFCWB",+,QI@Y/.07++/Y&-\J+2=W;]N+4]I !Z;L37>:2ZH4:S
MTVS'[M#^[;0A83N5'NMCX@I/D:F:+7L,'V,,>J!VP[VB#5\ AIU0P?+]TGL/
M7\3H(4%+ZEKI;^8__J,$\_XVL+C_MC6V#+-&1).C )<#[0GEW&%29\_F@+,\
MKVA;_S64_&?#?W'N[PI-_1DL_>!X#1NT:6WW-E#"53XLY6*)O0?=MJ(SBO7'
M:UD9+S?:S/(&H@Q&.[WL N_DL4AQ=1B!<6,U%-'^H3JLOF[1+<M%Z=I3IC[5
MNLF2R@#FMA9/:R/+=>11ZSGXVF:).&&UI#*D3Q1280&=.B[WC]ZD'XOK(U$L
MH Y6:::+3SA4-B%<7WT$[S.>>#:] 2-4>VG)I@&L4*&/;M%?XS2G5B,RW^G5
MP:EE#SK6MI?4;6);=F-8LBE' 8YM3.60D]&[G_M:T%9:Q/HD^6 .OT-6#:0A
MHNZNH1B7CD#1E*,C#5U=R:#<IG:TY1&_M671C?6A?FB)E<2A6&^]"<OT3OC8
MF^\.:TZ7B<FC[(49QF'DPY6>?R1>K)DP0V>C_4DM!;YY]#429H %%7ZK^$:$
M":3'D\+9Q;X@C;LCZ^I%:1[;NCNXXZ>IE4 L?2<2#DTDN+N 5.*C0QLQ;.:O
MYI8"0;WPQ,6>+$I(>=W]$Y][B)\ 9#$L+G/L)D\(K,8*6$NI/L9B)=@Y,:FS
MI#1'T[@%:0X!;1^+#WU+E>!=T_05>R26VT-*T1B6=XY1K'G7$<[.6G7,[)I@
MU'TDAHTQ26D5Q=$O^=([52/8SX%!+CEE.\AK<18]3>6_L?>687%V:;YO)01(
M($!P=X< P=U"\.!2H0HG!*D P1V2$*RPH F>X%)02.'NDA"\<'>GD%!!#WE[
M3I]]SNF>F9[I[ME[S_YP?^*BZJGG6FO=_]]M:]+.^/0\9'V;^L^!A$5@AA\C
M2OI'S5=52" CY-NK^[]V1JH"N"39WQY,411.BV/3=DED+)-(;UB55M>_/\),
MF5>,$]GL]Q(6?F.&"[>,:!7A<WU3I';J>293-:O@BMF^'_+R8V!%Z[BF5(7M
MYX;B!/<]^P7YD=7F6EDN-[J\(B]@%]D\QVCS.("C_\VF3V&I36>$:'@CV"&K
M2 P1M/%YY;W2_3S%U]>$J'X88<TDWZ B#3>Q'JWG3KGNJ&-H]K *OIP, O'O
M3PI#%M _[2O_$& %=X3^%#PHVOI3S/E/K2*&-X!K:5#)OP@P )@ ?0JJ-(#]
MH;_^I@H?2W3EM6+$#>!\=:$72=Z>^>O1KNS.YY(%LL#>\L ;@''J+ZIVM-ZM
M!J,-O7(EN3,S_$]/DEM#ZJ\RWEE.B+K<V:Q;'54[9Q2):Q"VA;/(4BY?&&)&
M9FCZK *_>OEV)LDP51)/BPVBV+Q)=?,YBBO%##_,90VD<&1]&?N;"SC$\]2]
M0$;XI$JJA5RW8/ESA]*AQN&8)'*HA]I,CP7=HZ@KWV <XVSJN1)#K>'K_--$
MPJ4,'Y9?\EJV/=CSU87MZD;3FVN.PZ:>4+A4];=.'S$:(*N1_MHXW3Q^$OFT
M;T7#L8#YV '/.E'7F^W%#7&X\2$\AL=1J,M$R3R>_5X\LO'E74T RX3W4DNH
MJ_VY5UV&&;OG'+9P.J6&K-MNC]Z7)9]ZNG3(LC_7SR7S]VL@)3$ U50I@2+:
MI5XIGW2QGF"MVGG ,W$*FZUI9:.X.\'Z(M_-^09 [+A:>2A]W*W"ZH':Q[.X
M)*Z $F#!MK&3N>-ZCDKS>R3 ]M=$S57RG_B3,,;>0GY</_1*F1_I]L>ZEL?[
M3D3#C<IP!FIY,S_8(_.5]E[H=OKUJ#0@]!<0XEVRA7Q"6<J[_(RVKQ1W>>"T
M.?MP'EQL=.]C;TXQ_@IINMG;6WBO^S.\VW1S4S@V$DN59OL]^PWOKDLE:X@
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M%(6A&:D4CZ]7=5^!$FTT.<OQ.? 5:V37>@@U?_KXBBSIGI0L7;P3V>>RU!L
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MT/DO:&W71<F[LAN?"RG_[F[/C1).A$XO485!WFS^A!D9E,GM0\8N=6#*69M
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M<D2*,^]0\RKH!E@I9WI]6\H)H*J0^)GNR9@R&3*]$:2'CC#*[)+%6FF)=68
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MTFH0D)8R@GIL2D U.U (JZG10(I-.&OUCG^+(;#G0ZE?&)@[55#H^/V8 MP
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MXNR89P73/)B2\[UJ.IO)4%)4RN$Y4"]'L6C;E6G!7RDZR'FKI$]'T@'0XQL
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M?")=/V$&TD>'A?3$0*I;"#\IUHLZ.*QZVP2P84?Z<Q>A=3+1<HA;?O\K6[.
M8V_S/W729M751H_,;22_[PYZK&4/2&H<76X):^[)YTW&"/CIU!2CF?BI]-(L
MCKLF5"-8C;-[G7+ N;K^0P8O*K&Q/A+Z=97&@^:D%.J6XC<B5FS)S-J'-[4M
MB]LH(31 O5>1QY8Y,5H ERMP8(R>1W)8=G=J8W'9=^NNW^)\VU.NW_XJ[O]'
M./^KVS^(T& E9ATIIO4D]F3M#DV"TU6V7_#!UZ0;(2T;K8$+!G46N49;29G6
M56$LLG,[P-L_FAXOW0!"X8Y1G=5RXN*2FG=*YF2?5X[L?2![ ].);C6HYP!Q
M8ZV3E2_1TAL[L^X5(8+0H5BYPY?\N;;F5R'C.C&&4ID_JCF^VI5)>W+:@PR2
M2EZ;-[VSCOS)5/Y:"F/I2F;56.$5;E!L[2K.UN976^JP(E(Y;0 M(/>?++%*
MM9:9-9L)ZX\$T_,]I+EAL"NGW9;)";/7/;%E!X.Y^B8I;/8HVU^JE;4;I=[%
M("N5^O2Z",FS2$O$GAOEZ97]\H+Z\P+7R!,,X2VZ1V@P:]2J9THVMP!-$;X2
MI-Z F;1P52];O(E ?40]G6NL[^RR:G -:$?ZE,.  F"N.Y'ABVM^^Q1_4X/T
M_PKVOVM2"_CI$HBBG]J=4*L)G%<_:SV!*XX=9(\B?I7FFA=!M61JX0^'2_)0
M/=&@=6W0W,M9UU%'B+W.1/*)>#FQAS:X<DB& NUTP:UT8=QW\>M7'VT#T%^G
M@ZCM[K,@'"B@D%M</7EV^I$V%'HK-W/*_A[D\#^;_6^*:E]AVSJ_4SPN97?(
MA7B>S25.K2^022D][<F>KAEDI#[TW_F*=EAJR[95E0H/WZ".5F8 IO]?[;UG
M0-1/DC \BH@DD:ADR6$($D8RB$B6G..(@(0A9Q 800F.9 04).<L.><, I)S
M&)",,$,<8!A>W-V[V]V[?6]WG^=NG[O]?Z@/T[^J[NGJZNZJZNIJKU?M4$K4
MR+[##6N-4Q(?Y]&F;4']3&WI((TW0)_(>,X[:[_W.-'^PSQ.OZT4?^<J$>6K
MBR15$_3A+K2(/0Q8 FWY/YPP'SGRWEMX,YOK.-D(:4NT6.1"ODN,Z^4F<&S<
MV!FMSHKY0W27JEC%:#,=RMM-XC;_SOMUZL3Z<UOV9]H:;VYCBY;'-C2(,I _
MR J$L6?]U=?*_J?!_SZ1,/=*U8]\-L)6[P$(:H_44@$V_,KHO XE.SYM&7\Y
MPDTM;">,TPP]/UY$D3Y1(>I Y!NK/)SOV3&U7"9D="1!I9CH[E*$TWNHN<XV
M?0<4D!'<&*W..],,%,EC$Q$M,F3/^"H:^(_66_\'ZL09L.%)4"'MW;Z2_5S]
M3(V)" $9#\)!/."@&SWLZ\XB#Y4X14G95Q:3$%/@]WT>>%EES+H'/@VD[OU1
M^F9)1_'[S5+.A!7_0JCX</IF[(+ALTY*'?Z[HJ<E26TI8M5(;9?.D<K[3E\4
M21&R^.H^M'[D&SY7@,[WW,<>HV[*N+Q[8_NAW<[/$==E=3SNV:.@0EPNA]0]
MG >W0R_FL,9<1S9+C+KI!"L1Q?6WM;C'<XD[F_2G'OJS[U"Y=DF6I:LY6C*L
M//W4BMY479Z(U,\HV)I"V'H0FQI]M<XVSB>W#2["G?_OV !+R5!))<VEQ;*9
MAGP6FECF=:"M9IXITJ??<VNY;@4I2.^;&B&6GL6:3&5/\HR7 ^-OG8J JE@L
MUH>,GWU)S*E/25X>Q!:DO?G@9@"0G<=O)R/-B>]W^0<^_2&.]7^=:^:_WDVC
MZU&880#AR_(L^TQ,[62,-!2<=)=.>)&Y^$9<5\S:7E*TAX"XR+GH";9&)+RD
M9V5B9P9%MV'VL._ >8_0A5^9'LT;9[]3TT^S<9FXXP^<?9R^#"EEVY@60@Y+
M:TDM]YQO&T-A&'#T:_AB,G9JH%T<$WA1CC9"- ;;NZ'O,@3IJ$EQO6 J.@+)
M:?G)]-+0(I/%/&A2:]\?A'AV3FI, +SEAQ\P)&HPP^RNFF$"=86DGN=QY*X8
MWJ4S2AD4V'/=SI<V4*RAV%P[6N;Y*4%#I# E.4XWOEOEI*#)4Q9<]D\W!]K$
M89[MU-.5E_+ZHSPT\OSS MCF80<<J>0.F1.-,IE;'D4L'Y4H P\#HFPDX(Z,
M"7-G<8X_,'.HFAP9J4$:C?U9'PN0#WTG]1V'QONOJ>5:&"V]MDP]BTK13$L4
ME0/O,0J6*DG#JH8-2Z$^@]DU;WF2AIY:/G^(4_S\"A!TBC$/NLQIEB5Z=]]1
M*I"!A$]2#TM*RTC(7_*[78GI(B2CG*&-6N65+]M85CE"I24QB]+?CCZ_^"(2
M9_.^5N68S=?&,)=OKL,[AN._G#9\*U*A5-B3 =ZW])XU=+<2AGR?& X21_TN
M 9ZXRO(2T1S*YT"_LE=GDO5A&++M-/-?7B70)OO; ]+?O<&5P!&L&D1-@55P
MI!--IJ.[)^A-.;(]S924.'</>4-GOS4_1)(92J1SA<XIT [ZE 8)*AQ)W,6W
M4'^0]TIRO;$'[A_$FE^H7&S*\:(XCGM^JLKM0;%MP^O0]8ZNOOK(/ U9\O?C
M?U]LG<:@N"[R,XL33"SV"8F&?BHBSL;4,V$C;(/RIR%BD ;YGM&IW^>>36U5
M'=\7RPKF#!@'V7];T-_?"?\%EQE>HF([=E:HB>VF7.>6-]SXR:6R[344"X-V
MO:W0'!)B/U/M1'/23R)2K&:I/3=,NF/AM6X+Y)5]K^*W'S]@M5I4.$^<RTA5
MQC%*L71&^(^;*)Q0)2\4\9=QD[G>$SDAGT29MXM"@WY24<MR[9_^<(UW[*['
M8S<$8HTO-\H@VCOTQR,R(:Z@N#&_]:#^C8-".BJ4JUG:XF6]379#PT_F(2/Z
M9(]*]<IINH8O&[!&VEROD@GS!H)R-@Y&FD=H2$(%2M:VAJ\)D^WI26 %)(LE
MD6(R39#%5PG8EG5TI"W")>"D$'P \,BWSGCS-[ZN#/B;G9AR#-JQK>1P2;&)
M;*04+&/TIZ)U=/NRYX]730(]S0PF^!T'<78J[)QO%VNA0?[TD($9]\*J8;97
MK]=K<NJTDD0@-2*<RNL^5L%'7D<J%/C/U"FU'21SJC8SRASV-I04@0]_ET3I
M;W:F%BS:4DSR):3HJ(M9)9+4)BGK&I8*(]>+.>J-A+^\PUIOV]'<Q@@EPF>7
M5,(.NY=%BJC#L?3JJB%GF:_8OM"UQ+EKYO:?93F]!!YV=:?DW%9U38'4(W@J
M^P0,C94/Z!MJI^Z?&(5?B'\6\K$'C1AXB6DE?C-AZ[U,$ 8UJ>I1"T2$B%MY
M94[$Q05K!TKD0_I7QH\O\51B"LM+J^4W3.XFK<X9A"I7\M6XW #U<?(;%JNI
M/LB38,D4$^4LKLZT\0A(_TPM44,P4=!52(N;^^N5AK^#!?^#3P?_8_@O%66.
MDATJ@;+VO#[![=5F1J_W;BJW%49:H(]F,Z>1JIQ[G4-*?/8ID%5".<?[J&X)
MT>GX]_0O>DI!/T4I$BBBLZ1M2-Z0R_E7K;?@B8N.*K)6N=6]DF*0K-LQK3.<
M@%JZ/>KH:AB/WV7_2SE&_S+D-!1P6+U(\V1]0ZNAYDQ>^4KQ"V-$UI1($:I_
MM%70B?XQV/:',L2?O;9UL2SVZ&9U..NQ#U-B#BN?;]E$\NVJU4\9K-0WFLX=
M?NKKSLI5K"AVUG#M$(L,N)5DRB%,BD,-'*"O>5N4MC4%PY]F!&%])5?-,OOU
M@L&$9P%&CBX:;D3+)V-'HGRY3EX%[")@R6(PQ_IRE _L;V9%!:Z(O1M+B\I8
MY7UK/&$K6/=YR^Q10=:$L+6'C!%B>/8$_X.CF&3C>OV=K B%B947O3[$X$?>
MD0T>)PL[B4?TMU!K@KV+<YIQ8>!6->$2KY<BR5D^^F&%,QV)\;DE:O:$[?;Q
M(.<]X)?Q1M+<1<MT,,?PJ8]6.G(Q1&BAOF=<!]6HDC5XZC!V6/)IHOK;08$9
M,T:81J(GZ#B9X5N\PV[F11Q+:M@QMTBGW@@%5LE>U2;QMJX64?P*T[&9SM[1
M3U[UI^5%W"G;<A!W ^45/>&U=U] .;L:8XW@G"5 C@9IRC>(CPB)S@+U;:UY
M/:(\K[O\S^,%=B6>#+[\B;P=P"KM(7T%N)DYTP[&9YO3R44KI!3*.OEX1KYA
MX$WG]*$H*1\P+&M1-TM6?4T*&])>HQV$FY+.)))IWKS3^W!TG"J(+"A.3O^-
MQ"#(,GR(0M8Q?1 @^8^V#/];K,3_$/Y+8]MN*S-VD"ILX&4R3P6B8">.5%X+
MW PL:?*S@*VPL*D,7R7D@Y$CN9KW9>)7 /:3(JEW&!H.@L2N?M\#^EC)X)K<
MO:[!+W&IE8DYS5:96U1N/J:?L;.4 +* U<E2#=D7[BR6?].I@R8)H*_H4MZP
M?(R16[PP>L1ULM9$K6OJO"AX22T\#K>U=;TR2$2A.]M+:\GUZT2CFGEV_NTG
M!U!W[Q*Z?:-)<5FI6-N2,M(P7J66+!3G"G)R53.Z;L-&?,K5,L=P^AG)G3CG
M)9K)A"")JE<T51!?0Z:8D4:\4%T_Z9H:DR99#X^3[[/=3,&/8&)X\9GQ7FE/
M#^H+(GY,:GW)KAM3#3/+TF"1E>A\/)*0*"M+JPCJWEDBMA/\.6+HCW%(Y5C6
MNSN&2N@6$E;C,V-#>=VL6S/@IB@ZRENV8AF4<O=.SFE",O9WN#TV'TI(DR@<
MK )-BLMP)7Z,'^4_?^-L^B'-]W%E!5 R;=&MR7FVP:O(WBRD+^(6\2KUTS!M
M4==\)"UQEWJ'F(:>W_!G]&?/W8,YSQQ@,R*AX[# L*H[C0[D6,LWZ!-R<CMA
MP[O%_(.'ZRFV-2.7+3D99\0;//6.K+T>,.CCJJUMSY=!1,I$R\1"?\N;HC-_
MLOGTRRZXU#ZQ:9FL]69'67\%P=,+^? ^Q$[G/5?:]M3,<;:.9MZ**X .UQ?H
M]:9U7#B;EW]"O&E=P=EBPW8@KC>,K,HUX/ET=_H*L*-Y!6C76<F3F_GYRGG)
M"[2[=N]8'8H7_M-^:?]IR';E:XKJ*$P3KJ_V"/Q^XM$4S7 NIY3K6VW&2:N
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M;#E<D!(%5\]!ARW0.QU0.!V2-VOI="830WP%(/51^=53D6THNY\1T36?-/;
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M1Y1F6:8])RJ2$::?\S<Q-#5E$RP&K.\]]K2^3,G*_B'I$-G?DBG^?X&CX\_
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M3)Q&2:X *82>5=C)11ZZSD;/'D7G::#P4DI<UN-Z8>5?-63)6?[AEO__\YZ
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M1R+N12X^AWN2;7I@\LFRZN_RKT4/=T63O@Q49-,!^EI,QB3_>V$,35&G8(Z
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M;*E)XK4K)ZH.1KWT* :"UNV-?= AHL%#<.Q6X/GXN;BH)M)3"=,-DV>_KR"
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MH&JO&?Y>8.=-JU&^$B*Y#Z)U#F:O=@V28F1Z^D)#L>S/IEG=4+0!VGY4&E5
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MXK+ZG'KDOJPFVJNY#MV/Y_T*>#'2FS& K7LSR<%T!@8!6E,ZZHJNIGOAIOT
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M4QZ<%\LV5R<,&1#@J"LW9'CQG5>N?"N)T:WB Q R(LAL_BV3]/%_GJ$I#".
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M&TS2OF6W2("2/A7>I'.VY.D:,,EA44_9VX["<P0^QLA6A(P"AHKWU,=GO<X
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MVJ@VVFT80?Y:RPG11YR!I?GY 5._U,3*YO%4'F<K0"N]=@8P/RN.\U"AQNK
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MO<DD?^!\/[VKEJ<B4S?7-L<$DIGN<H[2^"&RYQT0]J\D]B*M)MQ>S<FS!D4
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M)&;$,=+"A_+M;F.=#(UI*2<MDS(7]'S8-;.WF!C_;RC$ 4:'KPT%/G8@X-X
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MX'1+TX*,N]OH8OL.WY$HS4G@GD>IO>W;4@,.4<0@9@U(KS1QL%$XB$2TXYE
MJ]CCQK8 WHP86Y <XN;"Z-2(N]V*I;RGO(8?B3,#69=@CX+>N#5"$-)"+ FQ
M--E[>@%B<_(%Z"CEUEHM4MB+(1[Z&HPCZKIR8.Z.FR.%]J.O+ L&5_J1)C?
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M^>,U]@(;R7D&N7.M39 AY$,C9AP5]%>XY=[XL=1V'"UBAO/0=O+_.9J9&*W
M\VQ72#C.BY/+_@L9#L%?[\U:#SH^#P*6?6H]F9UJT-X$60 8T(6L#YOHIC:L
MC-U4#3+-\HWU+GGX,T24#,]NJTPW,+U%+D$C[:WNIYJ/B< W_ Q@]\GJQ$W5
MS[#F+X1 A2%U<I\/GHP*GR.KO7<=#QX:!!K8B0)].;_:%!^P$]9H>:CSG6'N
MUM4GM<.V_5J^ Q9 N7BPB'.&]SDT!0R0I_E I&+T_]";XK=PZ!SLLXFH43R]
M7(K=4I+A:NUU3PLO?WC+C@Q=Z@GW\= X+#&..;F7T^NXNO)__8![%D@&(E%
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M N5Q82L1ZC*<+XRVG>SV"*C(1_0%@M?_O+4G=8^=O<#81K]X>@GEAHF8<G;
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MBWXH\3P-CJL\-#,_7R7UID_CA.*<%AM"!6M5#_<M&4+(*$NDE6*==P2O8=A
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MV&OU9$/U2Y8NC'=DO?A4-0E:52!.2X*GJSX;J[U'89=%)L<18]I$-9<TN]2
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M= BG?(>4^KD^U%,:X1QE/KWYR*1:RNX550\!.>49$,R"RCAFVH;O;, Q#W^
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M_]3DV@721[M4@&_<_!P9++#KN&HKR'AI4=#^M5&>HS-V@D!NR26Z(/LBTV?
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M4 ^8)N2A2=H!WC[D^_5\)"%8)V2OH"PH7Z'(SJ-][6+HWC7=&2W3B/66WT'
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MT%?L'SXCAN39G9 6E"5@60SED;=^;66\Z,6DL$OO^],H_03J\)W#+:M,-F>
M/P.._Y26*/V8)[&\/-]H!80W)'08[2N!#IY!=+XW6- 9?FUT1U*1ZU$9K/N.
MP(SM[\.E,[[O(.C&II2L\8G4^(O"16&.&X>EDR'K,T*;*]4),CS1.<^]+T4
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M&"?G*2,\V*,9C/7[ $ON3A$OM>._*>Z03.HZRF'Q;!_[,/=2UOH'(EPAR<H
M]@%8&#Z0 O^',7R&$PS+<ARJ^OA"D^5+AA_=6FL6FM!$,YSLV%-L@P,J./%<
MFJ8JXPHC&+]/U/,OF MG0.MC0@S\8XUN7XR DBVY2RM<.B2/)^/YM?AUV6T%
MQSNW)ZKL_RR>Y?Q.:$I9,(;]R+PN2;SZG14YL+*\-MMD$ #V^I,M?$@Z R[B
M;\R83QMU4&K(M1QWT7?$#C?'(231!&..S$ ACF+Q07PD 7^Z*N>/-M <0DBO
M'#YBPS%:>JKLPXRYAM,Y3[Z_4&C;@D+^[&+CLF3(A@%J$XL>C_5NG^1$CYB
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MJ4@9^#?'8=&U$AKQ?S\_3K](AF"TNB<]"/)3\K)XU2QB!$O5.SFW2/SMZ4D
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M&W7Z_C8+" (5,9X!Y!BMB@X;3)S#O'Q<[G=M4!/@QX8R.0,V9XAW5R2MH[;
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MRXW7G.8%%55&]^70.Z]O!ON5X\5VTEE:F)-#-[=K'&VBZ,$'RQP<+8M4!6?
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MN]*EJ,O?A8*\CR>R?771:>D"Z,HD]",-CF_-V)5CJ.6YQ*I/]"%T=[WG]2.
MG_YS/>S<(XW\OKRG"2^L%!:+PV(UWSN;EZ,#VT9@EAW-#H-3SJY[]<?,.]\R
M;*WW-!I]3CW& @!&-CZBOUC8BG ,<W>6'RK23]!!B*N\AH)']XX";^':EH7R
MF&IEGTRX[&>'(0+E -!^'*C-8YYWYZ(+0K<O7==NE%>&J^TCSL-2+#A@_F?
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MW/B[U9[_+?];_EST/ N.@L5=VD$"1^5=OGF%V&04*?3(Q"I-N:(:XN%MA0H
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MGM%LRE)$LS9M))2N+@H [-K04744JHP5&R+J<7?[5U&WBM@]2L%'\MY)Z2F
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M^L1/_Q20F;8#FIRC:J5:;6&6X9\7,(><E:Y'^TFG@%LJ?Z#E390@^:8YZ*_
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M-4DB"^Q^MB/8QF0Y#3H\*O6Y?.-W46O:#FJ*OZ%[U^&]</BS9:(RS=KLN5-
M(F2$6HL+0UZGH_)4SH&V)YL^^RF$5!9IC#0;6_9X\H7?P-H.W".API(N=W6P
M?+16UTV.A,8!%&)0BQ4.IX"]/1 U5&:2XC._0Z@1"_<CN=KG\#Y;@!8ANOZG
M;V23QPB&#Z#L9O9>J7*NYW+5KJ>+N&GQ@S@;-.?CV%JIIJG2&ND(.K;TW>)Z
M?&ZA[T'KI*RG4#]#TB#&D8!T)V[I#%(X56Q'+V,>/6><D;RU.E6_%2)3CS\N
M*;P3\)YF:8X9K)+GE"%;4XT-[>%^FY -V1NG^%=%#X\8!@/;'9I%)@OG0O6%
M(]H%R:_>U-O>Z#DR;=I@;LD>Z5;GIU;0#*^;[]A#&9US(I/?6=C<%:^" 7]2
MY,A.^>0DG208+D7_3WJZ33TJR9RJ-)*/)=]\.1@;^47'M=LTO\6*8W*6K"DW
M]3C>GNEASD[0;""8L#9&Y:,\"&>%P(Z%?EWC?TW47S>WJF#G-?\5=T:<A:'/
MJ9+?*#JU,>T@H&SFR$#ZD$8!<)E/LICBA>X9K^ [!=2S@[YE7HRY2];._(W@
MMZLS>]68(K=Q)8 Z-H"DKU$-$!U[C1Q9*LQ]HK_;76(]V+2H&T*M@853SM(Y
M<>?A*:!XB](/\%> ,Y'^K!A\=ZBZ\&!F/A%C?E!W>+Q066K$X8"+?1/Z?9#A
M^\1]971XRG;SC> ^YY*+9&\\ BN.^'X*>#*.['EN=O&1=X#,]&W!DK"?"92.
MOYV_O4MDR!Q?N_(<?5-2/=:Y^U6]JD7>TX218EI4,X"CA;DC#1U5'UYEJVJI
M=_AV1F7KEU"D*D<6:H^A']21A!K4%-W3\HSU!V7A3]X9YU2-'/@4F!]$R5>
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MIX +!-P"RWYX%Y$T37&*':$J.=45QY2U&3ILO;>9@8450&1/ >\X7$\!-*>
M22?7>9=/MF#!_2"7C-?I2@OO%*5I2]I. 3'#ZQH_5Z;Z($]^_Q.>)'C8 ANO
M&0*JXW][ZP^50-<K0(RSY5/>0IN[!5^^RZO>##JSBG/@J?C*W%5Y<K I* P@
M2FXCQ!0=Q>6]GYOL]OFY$[VG0(O8[^WT17UDW][DC8C-<#>M,*1MG6L9>GJ2
MH<1U*YQOO0.!;NN)1Y-\MX=Q2R$'(78NNS2K*':J=!M>G[-U6 &RKQW(?3*R
M6WR][:R,<M8XI"(K_NC97KI"!T3G6^@6(WW?"8YQ=DJ\!![2\9>\)BD$>;AR
M'8)<(D[T?VX0 J\WN"V8>: 9XNP,KVI++G7WFY-M"'Y-0+*9BF!SUL.)>>OQ
M6G2LJN)J$YO \(Q7A\"+N^9DCE. !%7AH.E;YH7/U@27 FL2#TX[5FIR\:,)
M%NYSR134-7!X80+5T#3\@V)TQB7?VZC8,Q-R&UA+VJ%JJX*V%'8SV72K2'+5
M80&"9HYJ5_L* ,TFH_.P3P,D[XX2CM',X4F/OXO7X&,KX]LK/RCJ/Y*>Z<V.
MO7A4V04_[X.+"I!>50L0^:0_Z&''?GXZG373F"&++$7@#K@^F)\V>STU0>%7
MQ#C6<VS/WQDKWK@SO6!L%G"GZYD(--=7X>^:MV$!IT:34;.I3EW!*8!EEB,(
MK8*@?*6KJ2-M12J71!BO5>^O U<3BL?AS?,P*^(IH(,+$=/:]JCQ:E%2^H6+
M,BED BWY.CL]_5T[A(:/')9IQH!#=/_'.7]IFMG+Y"[$T>@4+.*UN4_6R]RN
M2R.4*Z1XVW&8'DDXV^+^,NUM19K"LRP[T*^J']E2,5LPDT<.UT^\VO_>)%)Q
M;*%I8=@4?#G^-;)#=W9QD.$+Y3XI;"ZL0KFQ=,HL7$?'*;CR+(58C;3B*DZN
MY=4]^_B*;@D4IM >TZ- !3JD7D^OOSNP;FG7\HG%A#@\Y2H*[O&.>/W61YG&
M M_4 2/)[:;9YK(E>WP^>G7TLA&.?35":518B$ARY=-;#- 2[O=7TQ*Q(=6;
M^2NTK'/K_JEQYS^R5G&?I[Y/<PTJR@6P5:"OH5>?>6\PO#D%O"P+H7.AX/SQ
MO(H4Z9'%!_S.UZ%G'2(B'J)@E+\NI3-8%'O@^*:+_T\-%(0X.C8GKJT>=6;L
MXYX',ZV,Y1(+C&),R5%?UW@=R_0%$^A@^J0=O7+_BRP#5TSM?]'1: DV,;J*
M_2";L(YV,0EV=]9JZA*V(O=N'H<->N0KWM:3[4T/FLOUA#)A>TX!S"E<?M5_
M"?IJFZM3I?)4*;+=7;^BF[>'^LK9;R$"6\Y<GQ%^KD,?:82")/J_?M$0IU1?
M"OGPU0,4)?"^B6.S@E7_R7/3:?[IV-T2%;*9!P[%52QO!JY*K.;>_5,'C:YB
M^X+4'E;I?IO (_)"I#:3S9QT"HA&X;F)%77OGO?47*5;<S>#L)#"-@Y"Y3UG
MK!P[,\N>6]\8 "Z? O@:M.H:!$3BZ%PL!@OU-!F;J94K;'A]&-YH7_E<U+F;
M7=\6;F1>I$7%0B3&Y9>=6>[+N3+=K)EI+N[%=W6 R/<V7XV4%,%9:G#JXN$E
M7$1<U-Y A%HU>^]SR( 2,$'OHP2L&'F3E!JZ=_(T1\##U#=Q^1)-P['Q>>@4
M?7,5^H4_Q[3$HU>)JR'PL'E6/<< ]K(D=1F^<[B;I.\2J',/GM(^?O4(R\*)
M9/^H?ABQ=U:3_Y7Y+?_W2/DT#"7$!?I;Q25MI4Q4A_]1"S?-SE;+.4_29FVM
MWLG?SP%Y]>BX[_WSK4#]F_4!P.G56:'ABD_?7%X7#O/GJGO!]^Q,AO_N6:#$
M]L^G0#<K 3Z\;1*>9), ?CV(A1N9>9D*$"_.]:G5.SRF K=X?"4Q+UZ.>XWW
M"-=?X!9FO9M+=M(?^IS1^NL&?UUR)AL&*Z8K2J[G8&SW"4GWEQF$7),!T=RF
M33K.7=TMT:HG=J+]D HNLME^@>X-RRIVQL.RG@8FSCXN9>WTM&>G=FW55#I^
M-+_SM#O'I^R^8D!>C16+TP&*I<$09?-UJOOUQ_A6AMJ2[(K^J[VZY3Q5BK**
MP7I/5OMAHY2;N4[G!->E\\3KF0';6VQ(0QS8C%#JD.^ EZ5S%P6UP;N5@C(J
M=0V'*DXD%>0[QV_ 3A)A*W2_L*JH'HW:4P 2)0[7)[81@%TAN\OQVV.+90E+
M_+K:\&I2.55_#'?6W 26 U@<5,WS0^[#QGNN;X(5CP89^*WW3P%1*&ZNQQ9V
M%M)5>T( F4&L$N*V\Z,V'AP/ATM*]V*@NG@L+&>U3A63<W=I8JJ+&;,9W?"S
M./<I+9OQ70#R #\06[8RRRY@LQ$3LR*^/0_P!"VK0%N-6!TUFJ*WP&;?;BU%
M"8KJK2%*7M02O8*\O>3S1EXX!/WZ:]K.0[*X4ZHMD"7=S'Q-2\1H 1UY9EA"
MP;I""L\OC^0L*C($=;P1@9+BHQ8$^8IV^T%JF\W\JMNL_I?]\R;7C#\4;PP_
MUOQ@:HD)469AHJP[JW(G""TR Q8I,IF6#BC&>(P;:.LCW+!F#_@'RM+P!!2&
M-/"W]G;!;X(<W>94=K$=D^5T+M>BVU&,]D8!"I^,8C8 BQ#U?L!KB]YEBYP/
MG?AT&)HZ>*\?[^3__<%E84AX8]SCJV%T (_O L51^>O&C)XLKS(4WP*_TO4I
M+[F232:FW)<RH!I])Y^34UC=WR8>=ZSO.>XK#Q5R&5('+#QX:KI2IS[FK&BX
MA)>Q:HQ=XDS'SN[2S%L)#@W$>+1R)TC"W39EL*2#,*MVS$5G >F#9U/M$K'6
MZ3C/;P@[O;%\_9+"[+0[Z@\G"96<$O&7HQZ?,PG4_$JWC*&G//W4.L6=9EI@
MHS ERH<6_Y9'@0SN@03(I :#K]-EYJW'"[,W2;&P&CA95WM4:F?38P7^H%:L
M4DZVZ.\+]ND[I9DKW,8,H11[XLQ>2F,^^=U/.EG3S=QFX18^ZA,K*W*_VS?$
M2QEA>::7HSW&]_8[95:8-@AU85EI*AXO@OEL2R\1C2**-K$C/!^9?U[T?AFH
M".;T++)H+E/]8360(LE27W*/9,6T?@!E;;!#U,5]^K!T\^E"E1]L="TZ&OCX
M:GP@<_<H4B[;L9K6KY<Q-P'%<48 T X%7C@92^#/KGBGJ6EQ8!/QZ$P]O7(G
MFO;<?N=5 OKL6X0+W;TY;;^Q/(*WSU9_TG6OW.V+0[6Y[X2A(_IUH[CF>0#B
M(%BVN)C*YJBHQ6\CW47W;9[TS+4-Q3]-%I$Y=EIG<,J7LNO]Y5.2N[LAV7NO
M6G7?ZZR%?8]/OFW%L*(T>U)LJ,'S27TF?I=F!QVN(OCI3,]Y'17-%#27=S^E
MU;!366D2D<VM&RRRB^:2>C\=19?KZS'+-[1<;Y!?&MD7<;79&ABPUCFU/UFT
M*68F]B*X4)JN%R) 'I\S&[30U[.T#09?4^E BNI:1=5%7=6:D7+U/?A\LTT
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MU'#Y(DL5&OT3K*[_\]L*FTORYEF]?"0SX"V;PC<_/6I*^#U7VV/WUU$AZA3
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M3S8L*IPY<2H0[*U/'LFV0-S0??O4ZJY(_\>UB4*KD"FY7[4++ -<O^\\I&L
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M>&V_KYO]]H0AV(/N$E_%O;(4[=V\FN3U6(VF0[:HW9J9+(20<.9E+(2BX]Q
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M-/-_/&B?Z0VU5*%WXD'RM2XAG8\I_Y29+)1C8:17  M!Z+KB)Q;HLP\*U+J
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M("<ITJLA"K&S?8_%".'K3:),!@QKX6I,V>$G/('LCI6+)2==&G9[Q[^4TEX
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MJM8ZS\_64$CRNYEZQ@BW4LK_[C<30.A5Q1GR9<^$<W&\ZEY4<%,[KH8C0<E
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M*?RDH%]91N[MXF&=,MOR&HX;X <LNIV"O'.MCV!D*X^7I)LWXZKU))&!J]#
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M@@6:-P-=XQ7+FW0+C@>>">ONR-U=K+$E=7-\L77B2I86 WQX^;5<3?Q,F7)
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M,X!>^$YN"Y1BL>&ILG'J.6,-4,1G_0L4PRQ&7_%<:/3*KC/&:@R;^SX21S5
M/9J4#P?WH&G<LP*$/&$B];]]! IIZ@@/V(H7=&7 $0N"K<;[6E0D>X!['1Q#
M(^"*[EFYL]9"!I1EG]-TVW./M%R NS$X54['1"9.ON81/Z!,W,]I NU5=^QG
M**#@+;C%2\MZD*4]D9"O\:UE:PFK:PAS&/NR@XW5I-/+IR[Q6W0GD5S7+<M!
M=&:GZR1OL-S*_2&XNE"RP?:%!YL-P@\@U*J]2WT6*+:9P*L;*-OBCHJ61S5V
MR>^1XSKM%C81$FFWGKXGL8PEP+M\N8$%%TVPR2,Q^M$?N\)=.@V82DG_VM+M
MFPVE/+U,WPJ\ZCU RADRN>UW?=6<S?JH<GOI D_\UJ!3?+DX37UT\G;)D&U/
M\S6_4*&2J&@7;X.(?[)F"7'<\.89@(#AX-)"/K[*E+4F6M8(N(^JZL,'^:75
MF;)- A&3-_R1JI\;+Y5 Z5+3RB??>$+;DQ!-X9MT_4)^#<;A\J_,%UV;HW]2
M(JOS@;)KZVIWV@&&*6]TR\;ROGAPG7HR.I/L^]-!9H) N]Z?&P&&UX6@^_D\
MFWC)"CV\-'6V=BQTAZ%D<X?/20,+RCOIFY!IJ@,M6N 1I^;GP"F#.85(INK7
M'YV:8S;_V [\#T"^[EL/!?]-6 A=*/$1044L_P]:?/[#3MUQQTA5W"'LNB_)
MN9,E-J$!9X'7P% WGP@/[R5LKIN789Y=')B(J?*"%MB"-X#UPDS<&F#;X;]R
M8:*KC;WNR95SXJ18^-09H)DN:;A:[^?;(!M*\PF*BXPQ*^6A,#>#5^BTA[DK
M6XKX\0<=)Y;@JB&1'213,(T+Q#1[PN+V0= %20\36B &5;UY 2L]UZR)=J6+
M61KGTUD1Z8X+?(VCL/SEW$O3WEB2$$K<%F[82("%+X6+^9YO:R@"]!^CO$!9
MNG+Y/[V3TNZIZ?F_JL?RJ:(.V/*U-@D7>MG.@.8Q&-W,OS$D!#[-O-3TZJ<[
M994!>+Y6H."GY*RUDC(Y; 2><CD>V6GKBG"5);FD@<"A;>=.[^./G& 233_U
MZI/LE_B*Q3$DE77&[9FK/H^VU59O"PE;:!:-=MJ\]KL=43U7::12UM"_\W!<
M&9,;? :XLLK1;"ZBQ]#Z RT/P^@>P3HYV.R'; 1;+;5'V^=2:/7:"\JBP&"P
MU$(C7-W&M-,X;/_-&AX()6W]%9U>_<7(9BQ@>^&(^703#M2$<+W[,<41JS)4
MULDG+%QC$HID)XH<-F3*U(SUKB;3<=]_5K9)U_I+D40]7/U8:J0\+./ _(IP
MB@4M+0>RBD&Y#24F@"V>P8S?80\23#*^KVN2F")_H'P9ZV(Z9&OC/*X5/Z>"
M$. BSC%B,A2K*A3:WH^!Q;;9DF?":E5R?\J&7O#MW,N$Q30K+'M6G6</U!+_
MOQ7:&>S%6<TL,FQKI*MVZE4=^2-QN19?N2T<@6 )DP?M]B\39TMS%F-F.7S\
M?'60W9=N'QQQ$!]^+$0+S\ >MRE3_.PZB"CSY]%*[7. I+%RSF]=4J154E6+
M596J@/>$4T*X4Y<=I]MM#S[?\"JV(:O"\\V!?3+@_7/FC)O-RGPC+=8N7_&6
MH=U#(N@,Q9K6*=8;<&CI(YU'GK(C%U=OS[DDYSVY',E,C+\(3!YL48A7F%16
M5G-*J/FYNB=<,]Y-Q(;_YG3D&,Y:7<E8"R+:)M.MW;Y<3/&A["K%&,>/NC@/
M*2;[> *DSNYM500?1RY:@F2ZROV<'WF.* <RWO F5O265!6S*?;QZOY,G],O
M#*GL&"C.6W;QN8LURK'X^M0O@%Z =J/];O2&Y1G@ W1>%@G%3$)CY.8,CFZ5
MA^/VH0NJV-OX5Z$<^#KTD?IIJA#=@_2""XC-&]BO2U+)@JD#S@ROA*+T1]3]
M#Y[?KZ9[2#3/2+S-GY&I/?4"3SV2N;NY$.UQ?\950+)?5;\ZM(XZ**:CCT)5
MRX?J#!!.UH [/A<P\M5I#T9_H?H675T%$H>? 3H<7YT!X.U'FFNE,A<56>$Y
MP2/?MH!?4>4*M'Q)#,A5=O5O7^]5VVO/FE*3"8SOLMM*%J3GZTR/Z17K>'Z:
M-^212!R)7U;D<]*.<9_! ,<#DLVJR"<E>EZ<Y)6X22I\=FFST7!,O-H!6P5R
M2$2[VM_F7..[(4.7OD0*H'V>K2IE^>2_=1D#15O:-YQP=<>.N03;[QJ/U5&V
M@,?<H'+>$K*,)A)$ZB+H4$M]\=OZ+%7#:16<X11?@]HCO"%@IW=J/ MZ5[2"
MU/-?#KN4(A"SBOHJVRMTT%Y/<1+;D](W4V5[>NQ<C*V&2B88ED/VDA.6[+?#
MJ^B+=9/3/834]<H!/'8/YP(7VE71;Z/G.AG=G+G'68+K59SJ+CD#" R?J[\9
M1(O/'9+7Y0B;;G:JV33AMLJWG\Z!G>.@9X![0*;#4(LS0#)0T$L-7WU'#;N$
MP3'_KLGDD[3<MK#<ZJ2$9M[[12%?GF?Y<> *,Z-I]U:>L#K8)V:!-1;TKJ?*
M^3E'HJ>FL\G2<97W:<.O;V_95Z="17'UTUNOUR]T3$R+[O4VV$K^+(83$@]"
MCH<JZ+WT AD-("^%"OWNI!A+9B3E12=G&EIP.FE48PX_XZ&XD3A"2GEO_/$9
M@$4SY7S=823.]?P$]R$33._WJL+0GU4%IP8X%"POWL^7-G"NU;]N9]\I^FPJ
M_+RU)![06A>H61LB_?;] [O&38PO:)WN-.6VZJO\L+Q1UI&&W5YNS'[!B+!"
M_-I2Z'5MQ]TGY^4:= J,2C/P9>A6P)B;K8CL3O-]X%12YG#HA$NA&IQDIO+S
MX_)V%!?\)K75QFO[F#NLGFCO?R_@8$P$?;-DO+.]]+E<P:\>%:V(]/.386B8
M-CDL5"Z@N(,-/>&:67'FK3A^*4UL9O=<U%%MK=P8-$KK<;N9XKIY 3O$V--U
MN-_!-0I*MZ;&^_F"=%">()$T(&_,^00<D&3K$O+MZQ,LB(26X9GF!Y*TR[D'
M;#KV! IV^1\&J7^MOZ"K_J4#XG^/TN<1J,L.117A);4^R>O5;""P2>_V4T?;
MA3?<_KX_,V:@1S0%T GQ'A0TV%G[;1@7>\OBP>["'3SUAJ4>AXJOPI9&^63S
M6\%9CE4'M[QDRJ&EVJJ$%KJ@,\#WB93)A_B+Z[I*2NHSTO1EA?,AA4[IH764
M\L$R0RP5+W>)8FTW!1QUKU<6KL2#VJ[8VA3>UX+M?99,:O:M$20$T=GN_&!N
M4DM7_FS*=IO6ZQYW02V[$XK.PKTBH:QPAYYVUGB,JJH\T,0R)B8\2^1VEI[;
M4@L2.Z05$BS[$YY [$1VN@8J0'-L(740/HS+Z^Y,L<P?7MQI[Q)BZJKN*KM,
M\9>"^;/&AAU6"_']C8:N8A&(0#"<=UVSJU^^R//J/5-*D7FQIYUM#Y.OQK:B
MQLSB3)TSM;B"I*EZ2J.P[;IOLS#)/X8WE\]+[,*J,I: 'UO9)VZ3A%1UH@%W
M$[;Z^U#O'X?-UTX>1#/YD\??6?K4SDDBO?K=SC+EX'$<X051.0-,\_D$C31Q
M.VE$@J>:D(/!.N/?K:2OJ@:52E$AY;3_"Y.O\[4Y@.? A4'%718\#N^4^I'G
M"LM8!)F6*YZC8F@I_CG,IN/325_QK88D&]"]V22/U6GE8>LS0#%\C#HT<(Q(
MKVH_-Y%3SF=]54K.(3_^*R-;Y?"[,$&8S1>Y#I=/_B<8&X3!-0P:Q%^AN9ZA
MUWXSQ.<T:'T%55DNJH26'5JHJ_TB0PZ)4H8:;2I1K4J!/8I"AL+Y^AQGU0=;
M?W5GNI+JOD\]Y-O=_'K4UM:?!1S;"Q7:;1>JQL376C/&4D+3P2FS9P!SE%GF
M78MM)3<:WIO>W[P^2 N!,I1O% W8ET\MW2WJOZTI-"IZ^RA61.C*UOK[YQ<E
MQ$D)("2B E"Y\!ZP3.6$4R- H7BFV[-8WL2:%%OYNQ$J:P4<1[-AR=-*P^>]
M7#)VP6RUGWK+>"(C/+PY]5LK3=Y-=Z2,:8H+SH39>:A9>A15M- T]U3[4(,2
M0:*/*NS&RB18N,9N"5P6Q*&6 O=:*RMN\^0^ZW@6/4PZXZ\]'!WB@6?:4KZ?
MY!&3-:/4A:L<SYY2S%PQ,&.?G3^*5>XT'O^IF7 &R+=-RSXW4?Q=N!%?6M&S
M^^AG%:Z4]  9^.CU*=F?DLUT_Y%F^&^T3$J#=G"*'R80#CB1OT$VAGNF?2!1
M8,MHV>_W<2D!6W_WKSG#KGXW3WLGVQ-"0BI,P/U\&HM-UF%F!)U3S5NU*X^>
M]^_EPEBC]%/B[L1]C]K58W+TB#[950'WLRZ#%5S\<$_[+*&[_?NP-XIZ##>C
MHJHI?D/O'[/\_OTLE3)H\E\$ >])'XKW\S;\U@, O7BV]@]"V<OM7:AD7)WT
M']V- @[D]_C<6A6(K=2_%[:X**<&;&*Y[ECF"<H&>?&+Z<,0DQ__6H A;=M6
M"H? L1ZK30<SL/5Y@RG9[#L7*B!!V+R=[ ^/3THPM*:45*N4(L/];S,0"YV0
M7Z%<R:CI-J$2&=H?3Y\^$*?;AQ)9\&L*.<6"?2KM\UXZ?F2T$+!NM[7DO<;]
MH[F99N7=-;^OMC<>]99MS"6F@!NQ>@>R^YN4+S,0WM2/92)>=@7@F>M'%*0'
MZ?.3DZ2H5)ZDYZW2A6;%FAVZ#GV_P=PMG$BD/<817*9\HY/5PWI'@=7XD1^U
MH:B=IUH5O1-(L%YX:YS M49]U?TF-G>V4V)=#QV'^-[I;.L'SPS1K;IVDG5V
M9;-]VF]<EQJ!,TJ/_+6^OH;S2;/(TY9Q-Q52MF7NJK[KJ__TGTUMY#?__P&\
MM&&>]B> @USJI?1<*&1E>O?4]@P O23&)=_E?M%>KVG#@[.*==BQO0H>K*XJ
MI=54BVZOY][F"(1G?KS&/Z9#RR+,9O9<Q%'_R[DZMR%L$]W"'TMG%D<R!K[X
M+LIH\(F0&:)8X^Z]K$U;'O:U,L$S #G$Y]YV8KQT(NI)*#_[-#M]GF\GWX9:
M]Z68?#D65I46!&OBI0NUQS/\29=#?\DZ*U3*G@R;O3-^GW-U4\NU.B![&Z)E
M+2!OP57+;8.MJKY+_U&8PE++P^8J@LM@88 95K6N_&9$C!-#D;'<SU88F.JE
MI^>T6Q=8_D+L+M9L:+8O*8L]&6;)NYC8UGXO28F(#R,D%FZ:9E'T4TNB^.6M
M7P"AX_AY&^A\E1;TYWWETRL@R4<;<Z'W0HU#)=)#.#\T4JT^R+L05GH&8-:9
MQLU.=R6D$3C6K7X\@M3EWYULQAMX-:CY#*9)46DN7&+(*<B?@WNGGOI;]0C.
M]7+P4<9RUL'9US3_%?L7>-?%6^*M>&28?MZ18Y%UI1Q.1*M2),QG)U7VM/=6
M9D$>/?,*XN(SDH10I <!4_]3)>9"^52:A7'E^K,"G?J-C7T0_A8#ZUY]\&Y^
MZ=CXQ%R_/^OXD,,2==\RG7?"E.6/]?1[-I]T<WX9@D3EU-_(\P]_G>R+8S"1
M<GJN27O1-5N-TU\E#T"<2E6.>*FQ:94VS!4_9=?&CRDOLFQ5'P8?6?U<Z:2<
M@%[Y,F.^H#;X><VA?V:<:/;;6F#2/+W!D\)O/@=K()"Q\?44*^9*<A82%D>S
MJN?<7BHBME27I]K7I7LB!))J7*$B:,>L\F,P<<YW.?OD5S+W2[/]U0N!7% 6
M3H=@FPZ$UA37&2!26?T,4.@"B]^Q_90L,&S%!YPD?6#(CWQ%54SB>K\ZYTV,
M7.:-0C7>7Q-AQ_*UOLI;,4F]/1\%,RK5>I3+'?@KT- ;^_YUM:#@E^7020FW
MW?#< [A.,R[I,(R/_MIEG%10TR1/YVWZ)ARZ8EQ'TL*:H?:F7Q#?6![)2QUU
M_1\-B] /H0+K2+P&-L:V<*T,>.FKXX(._*8$W!Y+NA,JJ8M<P'X0^U[:\,60
M]'IS(CH74_UQ)1ZB6UXY!C#D-W3=U%?-L33W<A<636?% ,PJY_S;=?<*A>#L
M2;QSK..8E4,&E46-]*'R%$B21N8PJ (C<O';>%H;IZ:IU$0+0'BQ2.93E*SJ
MH_6X)=M?JDU(>!PTI^)4POBN=WH(.A'3IGPH3WB4')<UN>/8Y!S%N6Z*HNIN
MB4=;AMH+I#M1ZUK@PK+&-[.>2HZQPCQUZ#UYQ\F-O&57+=O/9Z\<J*5L,W5:
MB>?W995G[NA ?SSOAMTG\SR6G:$WCIAI/RS6NT/T F!(]"%\%UE* (IY-F/\
M]@H8>NX0G/1 FB<F8FMOYFI_C([!P+E5<%8#K@+'M'O>ETP(1)&$K*!RX R0
MDFGE+!KRUU 6^SN4)?R/4%::>2*(NS/3X$OQBN/WS):&\^DNY]%1X7QPB[G-
M'R&:'-X]\T_D 2@30M'Y_N#?.])?D)WOG6O3SA5LOT\#H,D6T'[Q)=B?[\9[
M##!CG=.U5PS&AL8-N+HG)F(CB1:?+4,0A0^P@LKC)XJ=A+QU"+VB7WC._X,:
MZ/?_9?8*$-@2'Q:7:0X"@:LT2]1;@D#"@5E S:KIH"<ZO;]T4%7?7MUO"=))
M8]X2IXNK>96SVD\;Q42BKW1(DTR_+03N&+WYHD7:QQ=9%S[3EI$YL:(V9B%T
M#15]J9C8M,D0(;H[A?"FGSW]AK3^.M>,[KS?1G5D9ZI$HJK7[E>K8SW[#<XX
MU38[+/%"S.E<PYT+U+O/6/%.@1"BGO6) 14=V+;6Z^I*)H_0*=L;Z_X.)+0'
MU$F.KN[&A;HR, L:%US&RA"]PCC[/1=_UES&]!K;VVX6)Y+O;*SA8OW>%MQ)
MMH]YB#V/-3639KC A[KXD6V^^6>U=KPW6B_,O# *X)A*[]<XM=),2#RVX#?8
M2H<MW&@K)3-!W/IEL^N8-+K?J[/EI[JJ+S3RF%M%F=7%+IWVLLO'#,%^V(,M
MBD_74Y@"4T!^6)_GE9=&CX?N/+^:(C\\?,*6-X9)&9NBJPL8TV:^H7BW.\;P
M,A%N9'K*81D'-;"#9=;<A35\MJFES,)^V%OG*YP+UQQEJ'YWY8[)'$.^7\VV
M]5)P/2?69^-0WOOYG/-+^G>1T?WWZS:;?.C. 'Y0A2A@G%3O9$^6YV?9F40<
M*/9$6L,@5.P.:2HYQ\L-2RND++>KXX2,_ .&!WDW_K]X1:GQY.=J G+O,!]F
MIK]_;DMICK,2DG,K2)7>O1WS@@(\5H[DQ;B$F5NEAKT0-'UQ)8\1&"E>_&D*
ML4O94&?]:KDC35NN<1D2SSNSGIQT>U5>X5M49)(JF? E%1XYT8?1$U(0,D61
MX+OF/#WM %"D6_ZL69RG"XK,K=LL^_H]^F0#HZ#J<@1U5(WW!;5BE"5=^>;G
M30/Y0:UV\VS*2=PQZ9P8FUN]>&"\DS[3(&Q. *1*R8LDCZ!@2E+.QHCQH-9I
MNINJZ5:$?)X>Y*?MWB0DS5 :K]LCMDZCSCJA]H5\O&H[[@U.'WZJJWT?6DHN
M.:F-D!::W'#0IT#M&S#(96+O[YP!UJK5;NETZ?*FFJRSU\<CR_*Y;BL%-"M7
MRG+-ZG*>]]^A0TYN8ZT.U'3<\@XTK+<K1V?U)R*CC^@..9>EJ,HUAV\U269^
MIW ]N> @@1<LY(D?;UO?ID&K/K$P@"C<#F$_&"VKY,#H)^6LK.3J?#+YJM7X
MO,>Z#"5^<N^KM-'3ZMI=0*.MX!)U*$@3/WLB9[W'6P8:2>X6ZG'I=*S)1+#9
M8U$Q*D.\57L=DRSQ%@)WHX$;K0:PM^/@?*H0^@8*7;TXW]7#C\_E>@Q# )Y.
MW\NWU@Z2U;**W1?:0]BEGZX@*Y<+Z@N5#BMG.Q=>_@[J_X]:9R?:O'>:16HO
M:S[=_''DKQ"E4X1P""J\M _KCOGH]J=R%621G0<HH+A^!FC?*#X#&,@<D2+R
M1RT%/G(765X>LG'UBIO4!06LE7?7K.L9HUY+TY>$>!6YIH 9&%VRO4/>\7^/
M"9=-S_B@QRP5<UAUQZR-QU+>[(<4=?!LK[P>2[, NF(CE]=^X>I^-K6KD;P\
MYUI/"EX^J>'45QD?J&?\1.-1"T H"K+$O[U8-=:TFN5TK-:Z0%P9BNAU!8LV
M?/9RS982R\@AL^;=>B7"FXR 5U=IO^3@CQ(TG\U@'Z8>'<3HBY64)(Y:V-5G
M^KC=;.[RW8!TB6AG8RK',MLR\F0NR*L_NR]X=%GP3J%)4<G6DC_7P:LM"9DI
M5T,M/%\+-@6,C/=6\M0*[7%5L38#'C(-TRVX+1LM42N-U4"J0%E+3%/BD;%;
MS?*(\FT1 9ZCM_R?YJX_&T+6?3P&%0T9<[LZWW5;TXG&@N+=7)5&1%Y2PWJ_
MA;71N[7XO W3.H3W-?\ .]=^A)0<1N]S/>SH1R+RWF)FV<>"UGT"OID+2@P^
MVZQ5YJ\DKP!+Q[ UR?+'F=*#,+J4*Y3=LP;WCRC&)?PBVP])K-"5K>1VJ;*1
MJC(O,J@7P46V6.UH.Y<C<625O:"[L+Q#W60-"SSTL4>QFF?):7E27;S51S;5
M51+V[-]2(/%^JH:EH+(H39D1:4[.0<V7_SJ,INL9'\7152U",/303#G7\11T
MGP'^G( HGVQK-\_&[@\L96[WH_<DSH.?.GRSY_H@F<7WKM/YNQK3YZ-I\J*L
MS=<@@EWRG3^;D86LE>5A4PK/FTV2QMWF"=%T8AT/[7OPEQDWZK.S,,](Z81L
M1LU-PW\,N,E]>&[FG\]/\4>O)75>63L/J!F_[6'Z>0D)WN_A:+_;F\^U70,7
M"#GTGZ0ON4P5[YYZ">LJYB]P4+)"LT[=I!OII(--0-4$[13Z#LHQ;'Y6:.NZ
MMM(V@P[:!V^&M7>/N";X&$E1:=#Z__U=L4^A@OGW?[ 5DV.8XUR.3'O;POB-
M>A3E@KB<:9^I0!/MR% ^Y]W)($"$5>_4H[YMYEX1OFW3RUMUOVZK+9=\,%5:
M:ZV;FSAGML;V*K9DJ/7F!!\\Q=W\'C-3V0OCR13YQ6E)[+>;06Y1K=^N$U40
M\XDWZ[UKH?/#M<9^?ISA.?[0SXPUY/$@)G*8[OO&*$V)Z.6@!ZG_T$3]54GD
MZ?^7!(WWVY]1,/^]5]+?MQL10HFJ"&BMN-""V#VI#&C3,[;%2JXN'7#2W-HN
MKU7O3Q.ZHR69;?% MFWR[ESV?,8X%J*;.BL"KT2519!53-IJ-R->;NIK,+5R
MB:&07-Q-U9II^;R2;Y^3V%9H[9CSGP$H3]2^3^B.F_-;\6C>BWNZ?P; #-J)
M-,]^+3<UG:5/XI;S7-^6B\OTS&*NU+T$H[CB)16N5/[,HIH_TSV_P)/)>TB$
M&>JVE&DOQC<P,\37^75:W5J2:[=C59)F<ZQFTY>1=FC3EN,VJ.:[X9WQ'!8[
MQNSM @[5S U@L<#/J:*!6L@V5^VZJYJ02W3*/LW<)<S B>C67+/870W^:B^'
M/J%>P:GV77C6@Z@[7P4C.!\TJ@A2X5 W+3S'BD"KS$325  2(_7RPJ,+!E T
M"5ZZ$$0VR\#2#@Z=[++ M2;5^>5I&)N_%!3;6P!>7PQLMCWBJ!8_=; ]O9:?
M5\B[=1@@XIWZP]0D?B3ZITZBN_3-*$0G[0D$V6;?#U:-:9HA/';_I36D"<8.
MH]9^8Q">^N&'F%&\Z"A#L02(T@7$EU,H4E2_#</G>AO&AP;5I1%]:WSBJ+<0
M/P%+!+HL'Q+)?.MX<O6 6BTX;%XB6ZPC[@/GBS;937WCV4F@9G&QP/5JPU#X
M39E8^LL+5;T>W@XI-Z#S^L'X^IDSP$#K#3\.-MKOZ#B^.3=^K0'>4/FFE?E:
M/1$6=I+1@8#^.3T&YN.,E9?W7K*^)U&S=%HNL+BSDT]+MU@L]@7U^5IA,OJ6
MN^'7,:+UZ$U=_<#\5:'7N,GFE=4N=+;;+?( P5\>(Q1!4RQEU>6512557+P.
MFRZ2C:WN'KJ3(A\T9]7Z?NTL?=V'Y1@NZ2=FDWZM'[,V[F]YB^ <=1)+U_EY
M\2HKLOVJZ<5 NZ=:N)0P$=%,H#ONR^,Y['WASR?YGX9\[JP*A=AW%ZS";[X7
MTY41\59TH7-MWKRVDL=OL0(,GTM8%(>]>IO>X+9QTM"/)QK.!NM(3V6SY7AI
M(1#&-,%9 B)7S<X 1+H'Z5Z2LT"+2VOHTAKR=G+5FW?$]M<C+2J> .Z7^0/V
M7FI*Y(4   ?4US---I4&C_1.UV(#O^"?ZQY]$!'/J<^I=HV0&KI[T>::QX'_
M+YC#M?OTPKU:XQ(9IZ\9H$((OB_$L\,\1\;V1=-G@ N3(7B-<8W9=R*OJ"#6
M]?&T,UO%OK;SCB[)5Y#,UKL9DW*366\A]*W)C"-LR$+D5:>?95N97Y]>O0XX
MW(<?E(I(G@'N$]ZL4WO+117_.Y57"JM6DP2K?C9N!<3 5W#>47P+GXNO7 UE
M,5P2VQ_58*#'OZB [G="8_1AQAP/LMJOY+1U /OX($@?9D7(0O@^RR(#9!#3
MRP?1ALX8*SXWF#QB2=$')E"7>2LE\IW6<DT,$O#6]7R=9_-\33YVOQ^CQ?2:
MJ7"HCK U(,_G <AP\D;RY,<\$C3%?[FZIG)>JH\)/V[/_+WXP[!G\3V2U5KB
M;8=#=E"#A2U7=5'4S%)G!]=8<:# L^J)Q>^KCIU=_ W9;]O_D7*=3Q'(("25
M.@P2_TB^F/ -^+K?_P"8_CY)\V_S!10(7WX^H9>0EQ&^]H\[,<!@M]\6QK24
M//RW3F85(L+_[F?LX0XR_M9-]^'2;_N0\!4<X?>MIEX^>;[- GD'JH#(_CIF
MZ SA<88Z;NI-NK<W]=XZ \BGZ,?O$%.Y"IBFLY[.8/3#SP4:W_Z-+?\SW?4V
MQ./B3/T4<@7R0]2.NXE<4P##2[A__0H.]!'KVH8K#-@7=1EK;Q;P2+3V6#/U
M2R1>&1BN+.2./:+([.OIWI;]>*G^*P4<A]RB\'=6O*6G\ ;].,I;635"I$9L
M]<, B.\,0 9I@>XQKQK$G0%F(<5;!D&;)\K7N@V604)O)%ZH"FPO#7W08+KW
M+._W587Y\H5^QZ:\1FWRD4%H%1)(KCZ;6^@O_GZYE[J]L*6!HCZ=2U+/G=W@
MGBTY20=WHO7D?G[U8:@3[,*BL+9_;^\0?/M:@;0TV>E<V,?@?%VAG\N8O\X2
M-AHL3V#P5 P[ RC']GS SAOF,KQD"'4[_&>\>B)3=?V+BI#J_WEFZ[_=@%';
M_:'KM2Q9H?D'H4K0*-3(\W?&IP^)ND[L4%9G@!F&\&9,O9[T=K/D7:]D"H\M
M1>"/^+ZT@@2FH@XZ&D8WE@W2PX;K)X_TS 30(E:FB)&-C@CIDAB:N9(0UWP"
M1'"3R\U>4Z*IK!YGG*RJB6!,ZG,OR%I#;K"ON4S1E925#7(95Y30S HV.;RG
M_(""6>+JX.$FZ-N/24SUU[POO:FM'ZIE26^_P57"-THN%2S,V)P,89$;M-FO
M&4$Y#[;K>.IW"%-J#^>SGB;RQ2XL=CIX<O6] PW ^6JD4;9<LY42,V\#NVG'
ME-_H1V9::'J8?KFI,][BST*&4+E@F1+TGNX>P/ J)?$V+.<,,%(XH#Z0GCL2
M"S+%!3TM-<Y)_^-E^Y_C/>?SGGQ;EA=!._["U&%$XN"Y0A&Y61WZ&@6+LF #
MGI4NF>"P9YNMNLP+Q90Y:8BQ0>WX5[BR;HZ#S._\\][]CQ5'3X%*F?G"5$DC
M?9[@;9^4-+U@".RX:^.7IA?3S3W(9U7*GNXBU58GNN0X8U?RD@FPY*./SP*<
M+N[!WS4*22<)!*(L'J6Z7]P,,+FXY9:YMH% I$R$F*PZ[N0S5,V;$?["A/<&
M44CO%@8E-P_VMB657WR1H+O=J_YV@8WJ]7S:;7;-K:63,+%[9P!W(+SPXE ]
MFX'6*KJR"7D+;97Y@X,L:$\&FY9^Y>T-MMZ%Y@==+V\R\PN9H*5T^=0/GIN_
MM1"L4YI.[757#O7RSM0?%TNXU67Z<8&,H9:AX"I>P^6XO9[9/'C<7,&"=ODP
MRGIN15\4REHZW2^2:ALET:/NA1"+R:+QTY/^/H)6^#:[K1F:-GR %0.Z^6BQ
M.9A*O^!/TS=8T7XVA2UMY^@N_E VR1>.:_]55"#NAV/[FI$SV>]IQ69^X5MS
M&)$H9IQ:(D<#0#1 I T*%7*T5VW(A3%9Z).^<=&7B:_\<?S\T8@^_HUS8NUW
M.RAIX]9ALYLS\'@!@E(NFG0W)CLL[O648W9F]H:$;^D\&*Z5_,JTC9]<#KB?
M%UQZ=VL8,9>&EF**(95)7%=YIIP>M"A\(<]2=:K;K-N(1U+,S57W@^9RFO 3
MR]7V)+E,MW \I=:"4$SE6'W;"RAW:$VU,4:O+X%A3].RVF^[5\S=29>T-QHO
M\ZD!TW(&6':N>T.'S'5^'-*52*5C#GS6(K[#;4# 9!J84,\VQ4DP^@RPWYIG
M>0:XKA^"U+FU/+USJ?0, %<XR=M7'6R8)WMW!M"-/=)8=<)?6B9[^W##J#R\
M)UD]]%EHCQVPIUQ1E:E]B+I*NOS)^SN,0A[HK GP#]?;,?:WY./ZT+34B[AL
MOU\5VV6Q&$<R'87KESXQ.>%F$=M/$Z/*"T*WMA-@C&^D6.54A)XXBU[95#IU
MQ T9?[[_(C)58XV$:I,0D=X6#N,T/"W_;K+O@_C36/8A&.]3E@+CWC^U$-<G
MY+T> /'^,X#^U[\-IPG_5Y_]C']CMW^1"HH[ ^#V&LX#$<?>TLKFB];3A^<^
MQCXIR-CL"D+@^:NY\7GL >!3?A_K)__\>R#R^0+]<TY<:5K9\N*[$TX4]SXP
MU(<>,2:[OM'5 CMA0=:Q5]D&ZM_5HSP&S]BR)$Y.Q#Y(V>G_>?QG(,S_C#Q$
M%)PRY0[)I%N34^^=)5T&*\?@\2;C/^DP#S)1,\@F:T;?G<Q&ADM_&\3Z&?MY
M5AKYR+ILV>1);X[XUW<_[K-N0$*V8E"AV87!3I./E]PAWH.,#O/WNGV<UQS'
M=";F^C\^MQ_R\ UJ'A*Y9Y1M69VY^MWZX.1"LA;]Y2<O<"B;QPNZ<_.5Y6<
M?Q+;B*!+\;)WH-#G_6@^XQ^D[-MM,-9&WG0D@,RY;5"3I%FN IXX-K^>^AUO
M^3.&$3%>,\2778#EU$G2=E:\K>[-L]9R+R+=!J0Z% Y&XG=C':RSN8W#?%71
M99[BMP3\"U ;1OG&W2SW7AHD,(7:N<9G?^8S")IBBFVI %HXP--N@FAUDR'+
MW.18%XIK%F:HAW06)HZ/AL2G(OO5(%T^_XA=N>51DG63_7;_E9#.[SV/TB4
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M]V6=D<0'^=FHK,R(GGJ0J1&SH[3U)^VV<YNT$;OMY9B%+G\+?[(-!9X?!^W
M-;7^_;;6P3O%'JY=K*\LHLH)UXSBB >R)_K6/7:]^@M.-'1'=D=PMBWZ8$%5
MH;NK=6%W6B181YP*IG[K=]/.3TT#W AML-@P*K]?Q;+T]#DBU;#@ FVJ"!4I
M*@F:.)S"*!T?CZS!CTUT!AN[5:BK*($DVOFZKMB++<3HD;>D5I"\F=NS'FC=
M])46QW@8#",C6@19E1H3^6+HFK$_J (BZ(QPD4AR&",S6!D<J6EV!_(.7P,L
M"RZ1Q_!#49!IN#D+'5O!=AO_LH_(/G4;0W(0Y"[N1;':?+XXF]F.L<C^SVN
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M>C.<(TK?%$"*I_X]QSA::>,:0#")292@ -7!ONN0U*6G$C&S+KP6*J _,2L
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MTXC9OD>]EJNVNF35L+H92!";3HPQ:FRN?^5U7$&@?=;![2:IW!65JN5CKDL
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M&':(&/-M5?RZPM((M:E-QP?;YWY5(@IQ]0CZB6I?)\F"#,SN%/2P9SD_+B6
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MQ^O[SKG=[TJ/TW?T&V\SOA^U:X]:8ZXUUS>_.>?:W,_?KP*>*,D#Y0%(2$@
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M-'P4J3K8%?KP?,RV#EA!%Y[2R7?3+CZR7K:Z[NKP:!E?*'3_1)B_#*SW68-
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MC_1UN0M)HSV'@K[FC7'OG[))%R9O.0"I2.?B*=<4K8RH:# $0@)1H,U/LT2
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ML,B*ZI7SOIJU%]59#020=:FK/(59@C;=PH*'9M5,SF&3OS/Z'2TZHY4L<UB
M;B-/:4BO3XFQ#X?]LZWGY?RJ#XD7/_';HH8R/]/('\'//&(\TLXNE^M&GJ#2
MY6KU%0Q]\)]76Y/Y:L0OMBA\2A+2B7-_%,_L=X#!1[E)J)D_4&F*;0C4]CH
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M57,Y"UA[4X[38+>413M"-EJ-5_BYEW"-%4 E<X5KH*,'-$G#WBR"8L$N''<
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M5>_!S,==?5]$WJG8)5F5V&%1WF]/OK\V4#MKL;U A=]>$1Y'&&-[*=[RV^#
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M6#MG:=X]W4:,;6FR>19_#)[X#ZK(3VZ2R\#0:\E".=<2J\NDU+<_525Y$;(
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M*FP?>[$@B4.=9CX[4QBK3]#)\3XN6GR*9V392"5Y\R>6&/TA3CG^9N_FQ/W
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M6G]YZ["C;XR;JV#!"HCW)DEAYGK<9=5R3PQ[6AFVS'(5:6*H(C5-IIRV_M
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M??O7?_>/CX]'8=GJF0'[!@"TS_S^@'DAG6\C@&O89;C";\/TD5MSB%\UGLW
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M52R1'I&#RM\R,^&H,Y]?K5JOGVS L?&HA>@K#PVKE^LGR=CBEW<?@2(AYY^
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M[-OI?.+XF[;EO:]JB%!FTZLA^X5&A(9M.RAJF^ZMZ=B7WIDY<"+3W1VDF H
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MC2?6>,;N &,V6P0P^SN&9YI/;+QL]LC/*4;5,(AH$S%*A9F,_9H9:HLSH4Z
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M]@$4Z%9H^W]!K\GZ=0A];W3.0&&OA\X76)'JH/%ZFS6&W4'JW<H1*!Q:Z_R
M=0GP&M-W3&Y?%^KOO.5^ X383=+I=MOB773)<9LQ:=LLQ<47U[88F[;?PKJ!
M,M(6X]M85++LR[RQ44 ;)E?53N?NPWQ:8'S*A@+O'C*M4:[:-DP:B;_=05Q:
MIURU9=CT:M#K[J%7L>2JHN-;X]D,[/OA@*DUT%N1;_T\\_L#. P"XZUK>ED#
M+7YS;?99@HGWS_Y]SX]#T[/OF?K"5DCW&3"EI<VG &IQUE<5U +')P%;ZPVK
MQV_QPI\LC!ROFYFF9P;LFQDR6YV+KP@H&>#UC;=5MM_MN"5S3*H<NK+=V8]=
MW]?-NJ\PJ+ZONW=?DV/7]W5S[^L6Z$+ZOA;^ONZBOM=R7B*F=;[5W;8Q@&N^
MM"X\UUQEN_%<TW-MXRC,;5FRN6&;[JWF3XN\MYK+Z7NK^>UFW%MMHUSWO9W5
M_+!-]U;S6VVKU/=V\^YM8?EM&$3W3N2RF\ZE9SM/CAV;;G()KWVO^<*L.'*>
MV+D3,"OR@Y$2X-K0N1%7=;$79(:) :\^YR*6F'T*:FFNNG&W4S-2?3LU[RSF
M[=1&Y4+<\6TU3FT;M=&R0"&HC98H-+79 6JC99M"& *U;*,-@3M ;;1L4PAJ
MHV4;36UV@-IHV6:$<,CR@1D,#0 [NY0[_9<3]=(%I0A]:P[QY_#;$.>\Z>0.
M(Y??BMLA^SN&YVF5VNFBS;J+( ]S['K)6"ZVDHOG6J+2-$Z[KC2-TS1N)^2X
M::3J#I2$P+$B9M,U>/"<*+QK/6AY*)]63 574:G%+O'SE>/Z]O)%C>L;3->7
M9=1+>6WS"?XS-FWVYY0CU/"6;-'EV$ZA,=E=_BDKV\\[Y]5<3:650BU[,9?;
M2N'2L_P^:T5PD7'Y/WPKU;92!L/,P.HUX+ZS)^;Z WRR^8)(LE4!0E-@D>$?
MKT%#"RY+P[(MD$LV%\N*+C+,@&7?F<<"TP6P-NR^XSDA=?UY8KM*S6:"AZ9G
M2\2T7:%H!<6THM.T95O4Q33-_L#UAXR1 G SP)\56KBIB+ET0ZV<:"+X5JX\
MK+0/6R&0<^,9]:Y@Z28Q^ )@]A8(!KN(V447*.:VJVX%C5VXO7,':>(;O$^;
M3+R6X#]:N+@W2CJ6*^Z]"0&VEW@4 !.VGGQHI-D>;?&-_&/CI>#B8L(FR:UW
M+'("4AM01AM%HUL_C!@I ?A$^NPWYK$. ':;V%$^)%+$F@T6FD$M"<.V@&)M
M*H9M%@W+1"E=^''PWRSP;SRV;;IW_JY%Y$_NOC5M4C,Y[M!>1H@"'Z[,%Z<?
M][/A:[N%5Y@#D,!D[RM^S$!E<0%C&G/70O.VCH,6$W,VBUN^0Q[;#B0JMABV
M039)+>ZO \^TP62%!0YNGCT6A#UGD/#:*X:9OW^.7H%9V[[3&)>>-8S4&,G-
M1?@YV]VK.W\_GJ/$FCDA,4OFC+;4%KPJY-QD:JR1<[TRQ8032%#MS'==L^T'
M/!#%LW\X%H:P-KH!([X(7U$P"Z8368%#X2C)CPM+/*N=;")V+R4'Z_VW2T'T
M!9SNRFDWI8S53I9/NV>Q16W&Y=&W:,-OT?(MA<NPUHW<U!FL=2-O+-OFHF^O
MOKV;PP,WZ6Z]">&5'QW;,8-AR\3B1V0!26[E@V>SX#EP(A:$F8M2KR5_;.I%
MR=VU0-/Q?2_NDA2Y6, XUM?G\?^,O+&%6*^1?7N0?53-J:_ 1/6ZFJ.)^<[C
M]P8K(*MG%[]^<EX^!RSTX\!B(7Y%W_28:=-^?_UD.T_P+_PU,,)HZ *Z@@ *
M/Y;;?A3Y_<_G?MQVF5&OU \'T9>!:=N.UY4_UN"KOAET'4]^4TV_B?P!?<3%
ME!T/4?MS]9<O'5A>^9DYW5[TN>V[]A?^3>C\FWW>A\?WOO[G?]2.JE]^_33X
MJBZ+AC%=I^M]!JD8T%6=9S]W(:_-G$Y<.X+'Z6/'[#ON\/,]8%-H7+-GX\[O
MFYYX%%?RV?.#ONGRP2.4XSOP!7SK,?[4DQDX0!\_&^+!O:\/UY?WS7.C==^X
M;[:,F3?V=I"N:F.MYMG#W>7])>RJ<7UN-/]Q]GOC^GO3.+NYNKILM2YOKE>V
MVZG;(TA4)23>NMN_S+ 'R!_Y7LDXKYQ5C'KU\.!TAAUF;U3+=QW;J+WQ-HF/
M+NM$GP\ &N)S0.# +_*@E5RN5T$EX"KV_"YPK>,:GRP3VR]N[JZ,7X%\PD/7
M<1](KT5BS 6*,?"_/<,SD=_;S &R:<5]P?/V#$&2[UAG1.C)B0BL5<M_$)%.
M9_GZ:S@P/0G!G'/:^PI8B,]\U<@X#S(N$/66BGD?KLS@)]_"C<<^2I(#O%ON
MA!\Q'L07E%)_C4SDVORL?]L#U+28ZP*&6'#$R6=QY/0YR_PMM$0-0O99_O'%
M>';LJ =4%,# 9R#Y(;*-)YH;4,T?),/PAP\JM>-?OCSW0+@LX]RX]>? '.S-
M=P@J6%NLZS/CX=)H#?MP KGT?8%H,W[QUK2.251G/Y?J-#PO-MT[-O"#:"[J
M8^!*S.BW/0>6!LH*8+GOMDW7]:.V_X+7Z/3XX.C+&'U*B<^OGR([!S'><.(+
M ]\<\D'>B:OW?4]NM7%]_=#X8=PU;V_N[HW;A[O60^/ZWKB_,4 FN@?!A]_6
MVKYQ<V?4#C_8'XV;"^/^]Z:AR$R)O-0XNX>?Q2NG^P<)(.$_ ?X';_-7*:PO
MGYFN0)BZ\ ,CZC&CXX26Z1I#9@8&Z#C,GL)AZWFX?DLJ4).K1V]&]L\VEM&"
M=WNV.<3%,&_OZSFS2#'D![-?*QGX[CCR+T7"F>,,%DAH %LU<]',13"76JY(
MBX,ZZ'M:%H,YT SFZ_U=X[IUB9QD64S&6"*7R2@&E<.#K"90YE^MD<Q)[A,E
MN&QP4YK1"?P^A]&Z_FM$_EPLI58O.$\Y\_M])T33K''A .. 2XU&V%?N@=#8
M)M&F>H8V-<DHBZ/SP>=3N>%S>?_X^'A_"MG12O4.6'BNFG</+>.Z\F=E26;+
MV4T%"SRF#\T7TXKHMAA^Q[AC72H#ZT6&&1KA@%GH<;(-QS.<*#3.>F8 ^_NH
M[9IO,26] 1W6NG[!Z]\JT?,]?C;CR/_R#NF>0VU$P#^4C[_G$JIHA9^SQX!?
MK$T#O@?Y8S)[JX^S-RSX' Q$>!C5?3[S8R\*AF>^_7;-EZ1P9G?-8!#X3Q8?
M$;7?:P824N":GAWFJ;PY<OA.'N.U'QF- ?J1\0ZID/DD\+QPV+X>+D08:X#@
M[2->&?^* R>T'8J!!+:T (9;Y-T[ZMTE( 1=TW/^39\_%O4^K0=1+BMWE5;%
M$-5E@RW'C$L1\\.K]QO7?N7C1A"1==#:R>SR8)Q=-FP[8&$H_OGA>*PVGUKX
M3]-EK@E*ZE']S3;?+0/ST40P8[:ZZ?ZW,YA;&/FZ?WAR8)Q=C<)XBG!T.'$9
M9_#G37#O/WOSK>$A"IC5BW;KG*=+H,>3@<R%Q/>)G$+2Q"FTM*FES44+$0)5
MT> Q"$#Z<@:F:S#9I!J^!H[+0BUY98 &Y-M ^ITG@<SO'MB4D-"UP#JUPOWG
M?YS4:\=?0B-B+AOTX!W#(R-VR0"\=6.TN1AFP$P@MS;[O"ISZUKEC!.5]R!/
M;\#^YY<L_M=^S=@?<]A/X7FGZKS84<N]Q0-YBU.A?KAOG)Q4WQ NH,VJVW'%
M6\!L B=R8)* ;CL+F&T,XB",T?@>^08\@4J?\,G6/[0_(K]"QV3#BL9N^OM,
MS..&WP*%=^3RVX-MY[?W3N222X:95L^P7#,,YY%':FL CXI%,Z_S9-O/,3#Q
M+FRYH8H'(WV83V;>%!S=>EIS+;R_1&K8B]7#_#C#]XSGG@/?I QJ%IU2C<9K
MF];/;@#*O(V4WP\^_\<%_>^+"MC)(689/Y?@F,-:O4VT<3Z):]4ZO]@N3_Y8
MG="LQLU\FP1\'G4#QQMBP8BP-'M^R.Y!RO/[CF>ZB-TQ,T =VS\Z^%*M5$\Q
M)HP#,!-_."K/OT9A7KDA*R21L\8HSD,_7]O="IE_H738:L96+D0$SD/G(VM7
M=P^MMYE$=QKQ5LG1"X5X^_MY++4I6#[* >^,%8&1I-4>/0C79FB;?QM46,#
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MUQ[]EKT,F!6-?CMP36_T.^P7A*$!$1O]Q<H;V($;Y8U]&P&6L?'I O]?.:M
MP+/^P,V9LLU<ASV-?<W"R.GG/ Y090#QG(F9[>1LWX_P.$Q7?N\'ZIH<+V;*
M+X!(AL>ZO'42(!!\#IDX*OB9(UKHP,4Q P/@'3!J (AQ?&X$A]+M :9'\,&=
M=OH""\7HSWY@ S9=O/K\3%A;@F<L-[89%47'?D\N+#<B 5P=,X!=!BB$&7X<
M&(@DH1'YA@TGX?H#"A&Q_'Z?!6CP 6K 'PM\.[8B1'/;L6$LV#B"#$Z*1NK0
M4[[7]>DC'Q?7;8'43]<P GK@CKV%L^&;9MMQ,;0?%N*W"43X2Q_^H ^PYA@P
MR ^&ACF M3PE0R7CQQ$?02PE;\'XO;HU DT)9L&V6(XH%P^4,$:2$0?XC64.
M^-(<$3T31I@CW1WRT?C%X^&><*,#DI4E:$'4=,VV4('"G!=,ZLJ%N\"K#J]Y
M@%1$O1@BE85D"/;1X:@&6T;PQ.'T$PECS.IVF&<EL(!+TRO1?PWV=^P \))V
M+8[W!->-$(-'I.(0'"?H:-IXI>%*T++Z:3(%X+C1B0%(L)BDGR7''7, 2.?2
M3K$#)M9(KFPTVYK&"V;E)K[G#@U!J!)0X0]M8"&VX2)%A2?@/3HPP"2$<A9;
MX U!8Q7L$8< EU<>:2<QUD8PB!TB>XR,9YB*DULX1KA%G0Z,0Y.UX]!!Q"LI
M;UJ9YJ5!VKPT/>R*<4]$; ILP@&(H7SK9BB(JH&HRO]^!6H"0&%,.(BH;QI>
MW&\#'8;7?WK^,U]=[/&_ R?\"9N(/8L'8B=7U@S#N#](@<AIN=/'.4W$95-4
M1N#T$S<!]!.V9K/0"IPVPSELQGE$*,$_P\$C^XE<>%VP'6R\9USPV23KP06)
MGY?8:5:=C;DA>P8(L!FVL,D7]QL("_%T!#4)" @++P(D55"-D$F@EX)/)2[W
M 6R?>P[(;T!\D>NWF;S;<-A &?^FOHP=!SX1S\B\0[>>#7W!^9#%![[+I4@N
MWI$D$0AZ$+UVR^!JJ80%YLG0!+JG*GVPG,"*^S  ; RE@8[+:-T.ISU39D+"
M(;9K6CVD);1;W[*0@^-- [8)B"3I!8F4ANT K0D,E.A0!(!==0*_+ZZ8(&A2
MP)DN=E^! (BU24I(S3@E8KPM#.S/=Y_P>>8].8'OX1L5PC4\27G%QP^4]@3C
M _D5RP(D103 ?SE'="(#[@CN>^##56R[M$B5&<+CX@1(_IL^8\5HOEAL$.&Y
M!<B.X4W4"D"N<4&0P>%=\YFV:/M\6F#'-$?<AB< ?O& $]$ !GAR0FS].57G
M2*5(1'4'1!ZX_T0$80VF."XNC<$! \R<M#QU*8M-($90.YY1-)(B\C,LIV+\
MA<>"FL,K1SJ?5@8@ ,RS$ ,XR(@>FQUF],R@[9-(!."@6T#RR8SSMCA)-^K'
M#<FD1*HI(DC#(M#43O?W2P2O/J;IV"6I-&0?+8D0:S%BK9DS(IP_P5 9^B!W
M:/7!55+BM]I:CN:WM:PG-DLX+8R[R]8?QD6#:BR]UUQ5&,/RC2+3(>52N!J(
M3PQ4E' R>YLL L%%N37A2EZ6#/2]&;5&99I<,X-L8?PSY7BHZW1B9 YP-4-'
M2%NP@ DK10KF">T%5RN8%VIWJ.T"06""\PV29(A)0W%96&IM*>B$-LU)F.OZ
MS_#(Y\59-<FX/'+5;.=)#LSO&7HRN%>$/ ,&D#F S6][U3W#8JX;#DP+5I5\
M%NX5^BQ]./1&F9310<@^RS^^&,)#5:T*O\M4[S5_^*!R>/#+%Y!C(E;&N1$_
MGP-S,-%O0^M_E4K,= 7$!3/CR)_].K@,D_O+ D[I9 NOO\OALU_9WR\"?*;X
MBO_GR)[_Y[N N9?CLIV)EBG.89KPVYBKD3:RKDT)_^_8WF:<'A$'Z.#1E]<=
MR=MZ<S*PFW"ZN9B0#_TL>]W[^A=*?4\H9Y*Q!)0L !JH7!9J]!Z+#!>$=5@A
M$'.+GF*#1$4&T9I;5I G2ELP_DV#31JI(Z0R-$.'C!$YYK)Q9?9P 4%S*X6@
M$NNBHN3M'O-U:]Y7[%/3O$_S/LW[BL3[3.[A0RL<M_2""L,=W\,2?P+-1Z 3
M#6!#9(L<COOCD"&*9Z5/*11.-G@%F5[J,C-"TV4E8<=$RUG?_,G00(8V/L="
M*Q*^@)9,X*8,CCHF0Y7BTDC4*^[.X%8SLCMR,U,86Y;\^<D1;D'-8#6#W?Y3
MTPQ6,UC-8 O"8#$B0_IGT(2*C@X,)C*0"$84CI&$.@"OXZYSSNI4'_EE![5-
M=/G%'M%8]"V:Z+.A^"\Y EDS/<:D]1\550M55OX.1B&11PAY;IM44 N8,T7M
MN"8P>^"CL44>(88B@4=<UZ,O^G[ 9" (*JYF@#Y(X*YV$'=EU ^YL8#E=P.3
MQSL);CP6+6.P#DP>A9HC:XZ\_:>F.;+FR)HC%X$CHR?/CR-+1-* XI@JLL(%
M2+%-9N".Z;AJW(J,E$F"?!.%$SYBC'*0KR'CDVH87#SV7#(+=CL(.T/Q"@D0
M25@Z?G=QWB@9S:M&&E:,&KH9F"*R!$XW&_ :1SV?APYHKJNY[O:?FN:ZFNMJ
MKEL4KIME<R(>?"P; Y5'9*.,!]6ZS.M&/5!,*9P20WKBON312L!M[ E^C&2W
M)'VSR$BY)U;5M?TP(LT4/;<!IC<PKOQ2)+:P<<,4I#X#FZ8,(I>TY53SEJ9P
MGBFAZKZC62]<V9V82Z(9L6;$VW]JFA%K1JP9<1$8\0TE6$1.V[>'"ALB5DG.
MVQ!X(@;VFO83"T)6HHRET.%*)7)$3[$G8WPM&G(9NGI39RZQ4\K=#"C87TV,
M%&R>#-IDN<Z,07DT//D9<UYLGCLYRF,%-\W;!T7KBQ#;9+*2X5!*0F+Y1@,Y
MY8&UX4V1*C<R <^J'I]!)(NFGFS,JW1<)K,>$H>W:[:9*^WLPKU.,D5J?5<"
MJF5:L!HP)G*(4>@![9]1>D2ZN7&8RFT:6J98@$RQ)84]:G,6]M"B5+&158M2
M6I32HM3\HM0\1S[]7&<3M&:,#N#-NM!-S[P Z*(4/P:P2ED6(,]'@-%Q$V0@
M-?<J&09D._Q\??>]-LO*C%D>ZL243S[P0X<$E2CN4_9[FIT<P']*_'NGRV #
M!OS7[\._,J4X+ZR!0^(U$(RGF(D]BG0O,YAE#VPF:*@[D.FKXV$0B@ I@AOH
M^S>611!)SVVF)CP+J=R5=1>8K0U(VH"T_:>FI1XM]6BIIP@&I+\8%13A/I;\
MY#?^.U4<<0(;^'@PFA+N)$U*HY2MBQSLKIF4NZ"*)J85I7S6#[JF)YPJ9.PY
MN[M!DPPM@%PKW,W"RLFP801SB@(^(R($B1^B/INZ5%DO0T1TB'1R,PB&AJBS
MY03)XC IW8[I-0R29$Q66T+[%3-M+%:<QES*JB="U!$ERO+\8"3A!3D5U/+,
M7K+Z69(4D0@/2L2IBR:^H*]E!BTS[,*I:9E!RPQ:9BB"S'#.Y0)D4#+/$#@Z
M?+1D83T>.8ELG.<Q<'X9AY&25BCJ>@W,, +&:CDV^7!*6)>%HAK_/>8D$K59
M\AU%3TQ&32;U7=6X#%&4$"?BA:"0>Y-K!Y=)"VHSYAG/@9_4^QS7SX65X(F!
M:*1C/33;W8%3TVQ7LUW-=HO =N]YH,* 1=S4W.$%15T>6S$ 1N5['G.QM!LI
MOA;HH)CU0!470R;M[J"L R,.AA-R$!FQ6!BZAPF./]DP'7F2UAO">.(EV/%S
M1G/53%(SR>T_-<TD-9/43+((3/*O3 'H'@" 2H<*KHFU<=!!"UJIC=]C%5UA
MP$:>2&9M2D7HR*JA]!X:L-4V&#Q6SXB8U?-@_JXP%B=5<BBU7DY"36AXT68J
M%&=&Q'+I&1XG"<LJ4;UBLA"[J#I3DX20O/#X.BG*8\D&-"I?UF@/"P "UE6-
M/5Y9F(H6M--&)B@5].$$M<-9,^B=.#7-H#6#U@RZ" P:,Q9D:CWW&H>RNXW2
MZPF8723MK:B_NMB+(N;A^<#>X2'I(L4O@'%'9C#,,.1\]=:TV=\Q3P!\_Q2\
M(D].5RHG#&-4R<V( M[2 +JD!U,TNLG<ME1HSI:^7RZ+P'ZZV LO,F(A9MB@
MIEL1>NCY-,^\4<@HH]=*N>;Y.W9JFN=KGJ]Y?E%X/GMQ>#D>*]/]D*<()BW7
MA%LY4PQ6E)QS'0O-V-QS:[HA-?W)O!FGVOL8XT]X,R;4)6T\LVLA?N[(W\P@
MP!X[:4.P; A9:4* E@[IUMQV%T]-<UO-;36W+0*W13_QV<V?E^?EVBGHH)[-
M,$.+>EXFW?$\'W1#8%J![YE/3A!C1EF8A#VIT=\I/\M1)-4@\'DBM>=M*:LY
MZ"(SX(O4(7 CDN[K<R;=OZ\)W')[,<ZX"+47X[R0?RN8;QMW]\;E0AKIK6'Y
MAF/_MG=YW[QZK#U^>VA=7C=;K;VOO"5BQ?B6FMX6O#UE#T=3\&(Q8,QG\OE0
M?2,6W "_>7)@K'?M@(OC2P3-')!8("7ZB^NU9L)0820@18;O(=_I<E<WJKC"
M+\R=V\#M3>'\%I'3:%DV!RR.'"NL&*B?#YP!P]PFWB?:=<N\5)_1BV$?1A\K
MYX4#9F$YF_R4)5A6EWGD>K=YR^2)MO,AMBZ.<+.9]'*IJ\MA8)O NE#Z(&5\
MR&ORB*G;<!ZX.]M'U9[K[A=F&TT PD(.<@W:\U$3!X# "KHLJAA-4RT$E!V%
M]Q@-N?AABE?*R;9[S'RBH %X<F!2?^9G!T!DRO:B+IXS?Z!B7"'(!JB89E>*
M0./]BOMMZC0<R?XZ4BQKJY"V460:A3R*511)@&.3E(8J*\8<8%=@-&_0TKGL
M9</K+D7MX>"\TF*"$6V'#D3&QROG$K .HP9Z.'QH?',LUP>4"W\-X\&XX']R
M^,L71)]RCR-[K0X7!<XN(B3E_(AD>KB"QP<H_,>#K[28^V )(Y>PX;;_C%X2
M%:%<! MVNVVC8P7@)/$+[@QSZ9N9@(_0P:^YBZ64-GW'BT6GVXD]BU>HQ/[Q
M5L"8:"I-2RB'L'9&=HERVT2YW Q#+%F)O09YO:RAJ((0>\[?,8:+N,R*77GN
M VH]&"8(0X>8N( PE\'%-NRBIWR(ABO*T\"84=/HPK(]E0;()N.XXHIQ$0?X
M6PF5!8F\:$*3""V0J[1A."'+=&']LVYZ\9[PXI@&TEH6$8WI,PP,<L(^IP,6
M;W>>:CJA@Z  C/'C$"N)NKY%?<0#AI74,%B(SL@.DBH:=-(4'!OQXA)A##SN
M291-[?OH^/RW+(TF"F6@FEP[_A*"WM6//:HR/L#287@J0)I-"ERZY[8NLGM^
MPK-%E.0-OW!#6/GMI^.ZC*^ \ L.W<:CE@4^WB>1<+/.UO%9Y(AY[,I@_8'K
M(T?!&^L'D5+@!:5M.QL41A0$O\ [G"5%G*^F)*5B &^'NYCD!2<C7K$K?Z'7
M +""J5S'-(#21 IWY2%C@*J2/"J<3V1XY;"\-+;-,@>\OF!'I1]9?HQ3=9$*
M";Z,NP]'=JXR7)SU[/=]R:EM0(! EN-53DH%<397>H!.A)FH.RV&/ SBM#.+
M:@$)Q'7[1HO(^B*/)KL1)H,%$A:B\*F\HREE:)O* 3,1B0F'V3#ZK3(L-0J2
M8VJG0]6C'9(_^[[-%.I-?"]CG,H:I7BGB,K[5([J%M+!AU":]I:"*Y*NHLA"
M.9B")-G<D4>TA/>'=%65IB3Z+<O:F2DR?#:NSGXTRK7ZB?'AW\SSK3B*_PV4
MMOTQ:=.<IH=& 3,3 A[ZKF,+EL@I6<\,VO#.-8NIG@,0G9KQ 2MN?2028_!Z
M6>%__L?AZ1<Q[>')/-/P-W&C_.V#PY+<))<5,^Y)CN>7GC4$TG;F!P/Q?6F>
M*2LP@%&OUFLEZ2*%(_ \0:$I?MBS5/U25'<7R;H/'DF1K8@N'LXKP'TZURJD
MH.J$G,SR=BM)\=3LMA$^PO<+JAU001Q1CC!@0=\!/><;BR+3N,5Z&*9%% *K
MJIWY%>-'9%>,#_3[1R*J+R#&A3PT2L9TRTW@-L]ZCF?2\,# KAB:QGE.5$AJ
M,;Q?ID>, /$\3*1EI+"E!(_-C#ZM*L%YNC/JDRIQ&BU 3QE<1-,[?#+#A2<"
M4OR7=3671L;?.93!1\D5SE3M*=%6E%X!DTJMF/83->D#T/8) 7,.8I',@0S>
MT\CXYAOQ "U;$4IAW:$VY$T 4-<W*5LSPE 6ZF!EPL4VN3=M-H->KEW.X:H&
MD=]$#8R& RX168CJ 3?Z)>$KH3PKG Z$8K(S9%@L? _;\:+P\T*/,\^7L0NA
M'CE@VACWXBI"/18!'QWJL8VA'AMU<Y8<ZC'QA,9Y/H$":_$XUI?185IJ83PI
M%*-DV4>[D)".[*SQ9%22*AD9?2O5!S): *I/0G'*ZB4SU>T5WB^%%2YJD3,K
MA1@:@_8GVHBJ!I('A7]->1V4!D)C R)3&*N8ZO?FW7YB*B8C;_V+:?P$$NGQ
M()V42:MF8SX^S0@JFF_+\L_D=2 =&G]#TPAL0 U='?'C3%BX7+/,0Q$]*4>?
MIMFX81L-38!-9+0&I.[VQG<G.F2"],%?R=O5V'H,W[(H):<34)N,B$I8C'FX
M$H./')4$G(KQW^H!4U03U74*>PA?5<MR>:(1'3RBO1,&\2!*#)8263_@'O"O
MLJR/S2$5DC9)V^4EK=R(/Q9&Z!X@*]28[9_4[QLK\MNPX'JU=DH:8\ PB)G9
MO,8F,T[36MFD\^<=@H4.K.<>EJZR"=X.-BG)8#>>-ATC^B((^9E#RB/7;7F-
M$&? O05"P1]1^S$>FKRB'K-2&P2@0),JBS1X&M<M[P]N?&@V;C\JCA)^O4)2
M5=/ZWZ5T$NG2X%I8R(4[. AFAHQ/Q2%(7<R5$#'QB13G$%3TOGB.\K(#;K]-
M:YD.L-RH1S P4\?T;0\GJ7VJJS2IG!0_5VX^AT4IMX;ZZ[25P?##6:A;R4#K
MN=''OG<\+([PVTHJI84,0^6PY$N [6CA:-&00YN5[CXZ:Z<S@@= A\(<"H]>
M1\QP:W/K1D[14CC+B*[0"(G$J$ [X/'Y2@A^[/59E&R -^6A!844.Y]:\MJ,
M.M[ P^C+DHD!W+S+4_<\X[]B>! V6.7&OH=*JV)<^#Y?\SFVJ&_8?< CTEP0
M-3Y<G#<^PCTSR4J?A<!-,, T>GKMG$SD9FH6ALN$-)\;E9&2<).+\5^F%Z/%
MAIO+1(?>9((+K%MW'P!+SXP(L,E.G<L&L_<;  &#T0HR#(<;(!-"GR&2PD+)
M3:9=/ M./]#A89N!7?8[90N9)8?JL+*.+D(;):J]*8;RK:8&K?$6%1GJ6Z+Q
MCIH8MT+C7?JFIFN\KTZ_TQIOO< :[PCYG5D!GJI-)DZ_RA39<.*<X\ILQH=H
M*@*7C64)FM\O[C[]N/M^R ..3)OERQ99=]]-*NJ."?>==$8'BS!T?443L#'X
M#(1HP!C2>G ,&"X5BVJ'I=23*&1L[K;$I8<HHF*(&KZ,_JO Z2M^E404)\E2
MK(]/B:%Q29?E9($FU>DW&ACU@3IHR[=DN-:9'/5&VLQQ6<9WD*D"'Z=&\1)^
M/A-:4VO81S$_[E>,AHCTI/6 S 924P>_:8'ZROI<24,)-%G&,V;)"+F3":5Z
M?S^5YZ@,<4UL!9UT;FA\.(17JU6CCPJ1B\H8_ AZDDFQ&PZ5HF!TA%@SPA_$
MKN+OY0J!2<#H\(K+'K?C4YWD5+QKA%)GE_O@.E]FZ7X;U*4GONPVJ%BHF4:^
MRX-VN<_=\\7BL;(S]PN_@)K(&R)8),/;W&00,.XOQL+-',7J_%6<B9$VYX0]
MU#(B0P!@3 C=ZEZ-^[I7XV;SLH5)@;LL [S"!C/4U,$>+$^@/U-@K8_&#[0>
M#8WHV0=JQ7X"1VOF-]8C:MDEFE]FH0\\I<M$G!>06;L,?Y0]!MJZ-)[)),>0
M\Q8GY,1+L+\1SB=IJS]@7IE: 9>X[Y63I==-1)/W[]EO> M9!E)H#SDQPQ!F
MA)6(X.16*PH%QG)*/?,-$X1O61196B6/&4O:?*]&+3[BY?A\7#D%4K2P  M-
M>0M&039?_]8>9^UQ7COOW0G]^^!PH?HW1N'.&GMK?.#?D=<+G2%2B98J-]>T
MYPK0E:M G5P-YP=U*X@=[*##<WQX*>,!=:.)A,S2,^-0JLXT'G#'CN.2BP2S
MA<IIMI":)9;OXGGR<57P-?=-A^A^Y06+>7WBP&'D<2?8G)W7]H\-L^M[E#^9
MNB=()D =G-L&4B<C.:XP^ECUT2F!Q_& SI@[Q<Q_43.^5UQC/=/M)'ZQ98H?
M1Y6CXWSQXTW)^UK\*!@1G5O\* 1XM/2AI0\M?:Q*^GB+@KR<]<OTE3E&GSA6
M;B#>:]N:)$IA6E"^*$7Y.&F2UX0DI*P4Y?#,)<KR2'H+LS1Y!TWSN2(612%E
MTH_27&Y OG((F._R,"TWYNED& ;RX;IU]N/L(Y=3$O^&=$0TSN[*UV>7Y>;-
MW?T9B(9P;7@("'H:4@$%-GS%4_?-P+A7JC)P;P0:TI-"'+A#-3AL)"D(?108
MQL9C96 =2MI2SVE39E8T#'P,Z3=^.IY)UBSZ!01!V(!#V; &;6LLY^B%>1C%
MU8E$?C!F4+IA1D@C^QBE!3A!&$G3&_?X3,@7:\E3T^*8%L>T.*;%,2V.:7'L
M%7$"HXJY2YH'(CBAY9,3B(H995L"*\F=#F?!(K5?%3F ]_%X[*GR7)BDVM(H
M.:4AU(?7)6MQ4JB$_(HT;G+E\^AE7QB,R(4E.E@HR<B;E2VL%#YZQ8JF!.\F
M3Z 3D4+>>7XPI0U0='E%RJQH-\)H<I"I<HN7XJ2R0PCAA9K+/:6:2 )Q,^1G
M _^*I&V9MZ*\G=9!0.&8M_*2"(R1P*F\RNV-):/I.L8/AQ=3 6%2)(E^2+[^
M6#):3A\ PD:RXHWO0 (&Q@?QZT<NA),\OG 93<? ;C+ST%*7EKJTU+4K4E>+
ML9^R# "FPF0Z8[Q!4*DDDDI:O22<-@>5-P&(NTXD13_+'.#BRTDAK%'Q+R/;
MF'R2OOGB]+&(&HX Z!8S^>2&23ZY)4[$)DV>>2>*0V(JGX>)E5AW#0&8E%TW
M$8>C(8D[Y(ZC<"4>:>6/'H#BY%0$C$204"0%L@8)0^DK0C4O;RDZO"WE!'+@
ME#%;/?O!3R%8D2R8RH^BLTQ6UE*J[""QLJ6G58C3B%4B27?S<&HQM7=2;,1"
M?*G1]_7B>BIFI#A)-:#PE*0S^>;Z9E1J/?,K):KE5 *DMU'.Q^Q19@96;[PZ
M5*8*X#A^2KD>,WTM@?M^')&#6]9=D06F)"K0I*"(\HPZ V-X;<0H'A;(ZT1E
ML"]-R<QK-)0L.>UOE*Q>-A-2M1A9IQ3# 7 K:,?MQ$EI15G :(P>JC4 VP"1
MCA.E<?>*\@RPA'<M%I;&BD^E385EN45R_D=.>@DR%V@\TW!Y:L1;ZRAM=ESY
MP0:U(]B4ZOU4D&FSB#FZD$0@U*T? .5Q';_(%2S7<UG^4DM(\HBDE"%D:_#E
ME7TKR30<61]Z"I.;K:(?3YY)*VMQXT88]P&$ (60**I*A--X-TG:/R_FF-=S
M(+\Z_:X1!M9O>]WH[[ ;_&W9W0-&:D.M\J]!=\^(G CWM ?<*\)_,F:&XWIU
M\/)%W)/]_2/X@&1NA0!9<N>5A=#;^7K[K(/>"O_W)18W]]5V%)J$C8)*A=$0
MPT+)G\%+F)J&!\NP7#-4BOLIAG$*%$#9FD1 D*EY6\VQ(O,8X2D*S8?#,.)U
M,$U0]:R?0A5/2O?PBD&![$3"NRG@Y(ZRSJ1#!0\,2<-8J70]2\H2FM1&(<E=
MS"R!UX]A+V9_ ' S/M0^@LAJ#J@^"ST(FFW)D.27Y&3>#1O)JJB&1-_V0>;O
M.##_?5H&G_)F*5&&"+S5HX+B5E*77-8PHL8B9XV[Y%WXR.-HTS)'?'RN2O"B
MOOQ+RN1,XF[3C!Q9,,GRDVI!%+0+\.TQZ^< LU9%?251)/A#_2.6?40FD.X\
M]0I(]:K,.ZH3UX 9*>@$U'E?Y' .C0^-\[.SCZ7D5_6%S'-GY_A8W_=\- =\
M DTLX#E5F>=*!BPIQNH^HLO A^L_/O)(FNQCZ$7).F($3-3'1#UD^)8?8QIM
MD\6^OZA^$5>L4FQ[0H\,\-VD>X/:O $>&^*U&5*-E(1A)T4M$_SC,,;TJ0RF
MJ;<"MZJ4=B*, (T-*3[VQQ/GEI2RQAHWZOKYM0 !;D 5=$:Z.RRN'<.J>D2M
M2:Q3<(#*%9EP=4)A3Y"UX'BL$@-=&A751+-GU ((C0[T.&4ZBT:#QD5*<7C-
M'^;U^&!X<Z@["-X)5ZTGG-.-!\NF)YU24&$6%7JP_:*".9C)KJKYCL<;,G@&
M&HD%:I ]O?K%AV.@X> V=3IE&H9^JGTQDGL+DW,046";*%_EA&$LEY@T3Q9K
MXN'S9C]9JZ!_%>,L;4Z37K(P1M"%^=05J&3Y7MD9]EIQT'0;NY$TH3$OI*XH
M:*?UX@Y<F!@MBP0(%F"(&LG.,JNS0U6]/)S$BWIA28Z+S3<L7NI?R.<$ B(G
M/QVZ3RY5$0N'GAU0:5U8O-E!"=["O-) M(SBXU'Q77B-LAOHTG<4!N'Z6*),
M $QF5R#8^"%+CB'[3G'#$3Z@ H3XH"!K&0/1?%8SI7A74LJ,-P%*K7(^5L8;
M3^C ( K:*+\U*MHOM 7,F/MP(^T!J=\&648CO>G%;I>S'FJ,&BU<*\Q$&JFT
M#I>9RN:+;G)<1.RZ?IL:*GPW/EQVOU-OACXO%&<:_RR'/7- /3QXY$=2>#-I
MS8;9X+S0.^K68\UILC\K'6HP\RD4I2!%A&K'Z5)?&+A3SZ(YW&B;-^$8$:4\
MTVXW/B^[B;,11%"-#U@WZ20OZ8*L*-D)S"XW*5Q@Z=$LQ^#/\A>3_EJRTX['
M W?YX$GS!)+^T-$C?A!Y6B*72\YF6 %(+D"HG7_3"C]<6!_3N4.162;Z5LDT
M+#3R$BU,.)4 5T88HCI]F6-7&P?"P9:$#RX+'"*%Z?G@)B481IC1@KIE[G+K
MVL-MM17/0TG?:9G)97"O[G<U)K/Z#":SP_UZ:C*KGU0GF,P6#*4M86V77KX'
MD=.V/.*?4C/X,2U3+$F:<8_N^YYP#CH):1VAG8(GED9&49G3V,2<4:)$"\HV
M>:ES^[3QN$?>?91HN'0$EC*6C$0I5N>\L#)D')8+H\A*6*+C(9FW<?%"5A[=
M&2V3>M!-VEIH!":9"^A1?,SR2?^0DC?R".5YR1/[YD_<,ZIH8T+T8GC)MJ$V
M(DJ&A>>KMQ_ZC7;XD7@UGN"4&Y$@"$=$<17HVU>E##0L.F$B,,%CH#DF%T0D
MP">.:=GKDB.9D$Q&Q!9Z#I1Y5%##<0DF,7\FS34560R @])_>Y@GQ4A,3+"+
M+WT0^!28XZ &[+K";,!=/B.08:GB3&91,C-P*T-(E=JSG9"I@Q_7Y\8Z@DK-
MTQ1%O<GN)QLKCD]-^G\;]5>79_!C< #6%.11SJ:EA .-"WW+;&"^':KCRES)
MT\-/]]X;[I.)'.(Q'<9M8F4H=E>G]5!4:AL+W"HW= \YGMK].6T1+;I[BNJ;
M_21?E,)OIO:()M-/2>T(M6$Q# F128WR/1-)$ NP++S%:Z $HG6UC,92W>F:
MK8]'/$C;XN9%**JAKDKLFC3QYSDXN2\MZ?>G=D?+=H%]7^<RG5*\'3'ZHZ>C
MDUMT<HM.;MFRCF;?4)V1?31!BP*Y@G=@PA035 _3[E7MI/>3:$*C_#8PH]XS
MR5S41(F;-T:;.AG4H8A7U["X:W-,AQZ.]V&9!H5[;A?B!OY,&$S.]+0L#_>A
M=#(*4UT.]I%(69GV7!7C=^P4$_G"L:RHZ(FO6-USNETLTCY@4H_E;W/O-DH<
MYZA*4JX(GL)"DX&3V(YGC$ 2JKFT%YABG8IS6&P,J^2!R,UM#IE@C#3C"!TI
MHHZ<#:C//3QDOR /!>G'+GKQ \6?+XQZ::B3%3C<K='ASF6<2?3^6A!J+SR\
M?GI=W3*Q/BWY; T!UY*/EGRTY+.UDD\3XVMY3.A8#&-B,&X/I35=*0N+?.Y3
M-G!U:H"JJ"T&/\PFU/S%!081%SFE=7E.V/"B>>>T=8:X89#E&'4A6.7,:AB$
MC!D6021GY_MI$&W&R<$CJF44, \B$2?)2P"/B4-"HC2S&8;<M<##U29-->J"
MX<'<,N4R9"X/GX/A1H-D9\T*W$%Q878CX&[*"V^#CQ88=D!@*/C5V3")04F
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MJAP=_Z)%NJWE3%JDTR*=%NFV5J1;:94@8I4RW"*)!!$%[(3Y:WDRIA#",(T
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MS*))!4,*CI)E0B;?JVF'-*V^8CXP4B/@6!+RJ$R6BFO*2<U43Z1B-#!PG\=
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ML9$NNE\L5C%N/.'-#V!L-A(T7N+T@;JYTK)DO]]0D&Z^7KF7M'T>OL$;ZX8
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MFU3(IP%/ F\JH>3&:94SSV%H]OE#0GZVUC=X)Q,!T.">$6FP)]$,^"-)B:_
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MY&.T9G%#T>9P<>Q^]$H5@GG%?.Y24\^>'"S.^T H#J*B'$2K@^G1$>HR;9C
MF&+H'/@E P6I&8CJV0?"M;8RP]@J4MI6#9= 'AT<'5*)LX*%Y'?T\=<OCQ%%
M0PQ4KS'-\J%"@<\LA6O*$W0/@YASN*+B9>!:KLD!]B^Y[PK=<37$_*(8?$+%
M!;3YMP:/':$]#P&A,$)[1FC/".UY(-">7[+J*#IV'#=OO3IY41$:0+*[.XL7
M)[LC]N?&V)^W"6*&CPZXY5=1P(9/-1XD<1\*0A"7"QM-JN@3!Y%FDZIG'NS@
MC[N1CS7BMDUXVRP9Q%79SE-B-6#SAB(:8N$<%V"JS&'?F>]08BO'R/N#$<^S
M<IIG; VZ//V[8LH-AX[/3MX='43_E5<-/N.,&M)29OZ4V=O(+(09T,ODY5G*
MX(2D48XWZI^C:X)3HBI+4[/(D&A?V$B3NLQAF;,YMM(@KT6:\N;<^23GMK;J
M5R!2X-_7KI(QJ2[*(</(M>-U@5BM?3PR_#L,E-$Y*(+=NTY"6YFH#P<;"9;6
M+-JIF7 9SV%T],,NE9YB.%F]/R&"*5QH0( )0]]_])R^_S:IIA?1H\-8#M^C
MYQU<0.!Q2:0 3V&P\$JMDBQ*B32;Y\31X1$_"_Y8TN$II/S V:L>D$049T54
MM#@K6D*)I07+Q[_SB\OK32]YPGCY$"[/?@>!!Z1S#44)LQ#=CB#_7>^.]J:L
M/@X%#;.VP6X<19Y8K).)V)B#)VC]&<@3M[H^2D37C(-#QZ]<R45W9X9\+PK"
MVK**1\\\VJKC "BL0[(5>-A1I MMF;##[SSZ=RF-N #7O9Q>9 NLBEY%.V]^
M.:'*7K@>\$_SE,DJFLU;F&D]E;1&G3=M=+&:5'FJ3+,[K]^<_;*[JVVZJ-A8
MQ<0$7(Y9WC!USPX*.9!Q)JU_\G[WWZ/!;/^_1_]G*/L&-^OH,;MM_Y<.^:,G
M^X=_B_[/\X._G;R)CH[VC_:>'.P?_%_9%8GO<7CODD$^)^^C><)MT0Z?[S_B
MA\71TQX$ F3O^VA'/TL8K2?[L(C((7ND7Q1&H*,C_=;9R]YWGM-WGCS?![^7
MO[3/:HW_>^S(E]S=EFL=NUN'%%>RP).,8#*R5O#-LY<QW(P@/@BW#'2,V\?3
M]W#2\*/,K49WZ8&!'![=&<CA6Z()>F;<MQF'"O?$G50+--R/3C0(%8.W75$;
MTTY"/,PR2O0D,&TH"K.<)T4O!N/0D:$IA-P%T:Q%'H:A",T50LHH1J,<4]*V
ME<RL?6/&?D\L3=_<EK41:;)G3; 7U=Z\K(UIJ_L)JIB(#&T_R TF*Z<>1-ZA
M>B@D!H@Y0:9*% Q\6Z'0!)U>:[;#!B#%6NY@05W <F0.#K>7J8*?_!#M_..\
M>A)]BE[]_/K]2!7\5:Z66WMF">Y"_3^'-?AN28-YQ5V7;L^=9^/403B:A$(^
MU.ZUU'M/75)Z;7/F&;(?9GL5&B]@PL,+]@R9P\]*\ >_;)?S+/5DN4_X*#-"
MYUIJW1T\[[O[$9U^XCC\_=</2OS*U*$\*#;( PY:%E8@&2L!$HB.PR?T*'ZT
M:0S=+WK1@CT]T:[@]T1\#/$W;GP=B(\C'LZ59U*2UX.L0;T5#@%$SL!$UD?E
M@@2'Q9Y+NW'(SX$9%-\6P1/.DG,L%<$?*.>/, D<*(EOV7FDZ]A,2.O7V(^:
MGRAY%[@EY?Q2FH8:BEK>;C[]>A2'NA71*]BGA@6D;D Y/ :S:=BQ:.!4<LP"
ME$=>-]V">GHK\1.3J[B4G+QBP/);4CBW8FW@"[:WZ4?.L_NE+#9RGKD;FV8+
M:OG%*+(62_F]># L9W3YJ!$/1QXP:M)**1H(J#W?"65Q/$$+OVD1'3@QP@&#
M%2$;#Q&3L59@&(W[&C43EK=+1,F3]72)@2A4G5&]GIJ&U7E2E'F*P12''D+/
M(QA,![^@T\MT9"922+3K=(/=6]T[>.CHOKC?Z&?(*^$=<7V3YRKQ; ;=C4OA
M.!3GT0=RQ Z'[*G<#@\.HH9.5 !$DN_+.^EM=C7>%,1PA"'2V//,RR#\ZO-6
M<9MR;8:[9K3#;^)XQP&%0=Q /2/RI@>&4Z\U-)Q]VL,&SK)IHC_M5SF6HRM&
M7% 2$=2..&Z_;]PMNE#:J5FC3]:FA*EW/>MDD?4.IY_( R2DNQ>#^(KE&8?;
ME&<<'9GRC&>WVD_N0>(B&'OU[1/_]Q<7<3_69P1&C,"($1C1 T:<D7?W@;R[
M$??P^0$M#U*=9&CS!WE-QUQ'K"A[\V22S6-.M[.!P0GEV#Q%X?^N1<T2GQ#W
MX<XA6I3*GZJ<2ORS(EV6>4%A"<G%<Q,>3-1+?;I$8[3W#)+4,8R>PP_V,;4$
M4[*0( \\-.Z,0Z0"O20O]6)2H.CA$TH''VI478 2M$++LJ:%D$Y*5!J3+TR'
M/9<G0;]0UQ,''&4U?,!A2]VN")1\.Y ' 5A_!L>BPKEB8))X(01+?K9:(+M"
MN]#T=A)B$S!%F2T;Q3)@PCOPU0*Z _ J'CWRNTA%DX<R%>YH'>T\@:\>(%-"
M',U@:O1'S,,.H3YLHR#.)P@* 49%?0P=G,-B$58Z%<IFRSRPL>%F-[,+D\<3
M590R>.R/P^U**$J+*2GII9/RT5Q'C,A0 ,J&<V,=F+(LP":J"*2LZ$.=7P7P
MHO"VG-,.[V5U"??I/*.P,S:73=(]^,=>D4T_N@("K8*I^21A=+"LLS4W4U=R
MW06G;$TLZ ]_8[)+3WZ(MZ>#D'#U!KH+7RNA\YVGRA]_1WP WUGN[/&3:.?D
MY>&C9]&GZ/3EWC\.[W'VS*[20S4_'DL>YTZZ9G[8HSJ5K#A/SCE&UU ^BSKI
M<4A0T(V(P4E!'UWL27^Y0Z0;@^/!B2DZ,1I-Y2';5(LD-F)M()&IH+S4JO'L
MTT72UJZS!,4R\V*6SZGI!>B<#YKR233=AEF*1 .TCI=GGNFL3+.*W,8M%_FT
M*K/B,J_*@NEY=-BN"-?TY4JXE <F!,--\ZG YZC?.PYCWM9"<(5V!UT<>.$'
MS:DAA(.O45Z;W!O&K-,_DJEF065>G%'"H<H<7 G\"I]R^'=YE.\"5@=SVX]>
M9+PP@VNP+N+.$57J>\%6 *I&=E0D58MXQ7^V><5EV3@&36Y>M[I!VSAW/@8;
ME@6](S\6.!PJSN:$5QUP^9*VY^5.SDNT'VQ!$.E4M/)\V1[/><S#;! RC4MT
M$B6?:X4-QV%/8"^NFAZ/TOF\G##H,2,T*"4/,=8V$>^6=^E-,5W!0T[*:JF_
MW^'?[6JK5-C71=[4XJMX@ T_$81/-84SHG!-N&C,NP56=:?W-M;Z=9MZXP%W
MCL6=B-$EF.>XTOO1;[0X=!M@2M[^MJL2<WMB6#=,_]?4>K'"MY'4E>GWINXO
M#SB)TD'R$BUT.=^_%40*<M9@(P_-SLO2XVW[@C<H24+O-0$&= #[EGCWKEW2
M24+V/3UQ7)B8_(%"X[KRQ(MD/G.UB6,.>LQ!?Z4<-!Q3*>LP)@$K0&?VQ %N
M P[I!X?,4/H$U(RQ[^R)6(Y!Q9Y\RJ6"@*V:GA9_D(VC[L4@OF*>[FB;[E6/
MO[=NC=^(E(6SY^:^#F-&?,<YPD4)%!S!U$GEN7+ZC?:2;MNYGH6QY\4!_2A&
MJ;<]<O0 I/_3;775?>B$CT^^HP#/0Q53C[804T^/'ALQ=72K3?8>))Q@I%D8
M:19&-,&()OC^T031""?X3!H%*3OC5.G4=KX+THM!&K[#$.CRX!BL$2HS\2R[
M*?,9J"OV8%?R-\ULQM$UM2]A;E4JX-(-D(1R\@>#E%WD2R?&P\8"1AK#3+QI
MJG+P33JPWF8-DL$ (_B=_$0BRR*2TNP3[&IAY]*%+G22K\0LVA93J4^2(AG.
MA;CJ'[L'NN(/)P#UU;**1\^Y-"GZ%$WWWK[Z,"85OVF\'[9CN$CO+K8E[I?+
MT5&@^#,>AFOE4(<Q3TO."E,V5A93[I<9I8ALKZ@V%UE) VJ_%D3">>NQ1'P6
M?7&;PV,D=5U.<T\M4F4H81.A1.41N/(332 >,5<WUY2A/)ZN*RE[C5F6.+*;
M$:R12P/ZH<&W>=6$CP6C%[QXW0(P&5C81=J6I^U'9Q15-P-HFQPS '6$99=[
MMNZL@0D4A*'29(T=K*6:I6I.#:ZXG?0IR4E)1'_]]6"UX*I"I4AD6NZ9'*.;
MOC\TO;RBKG]PD'"$7-JAI:4VZ$."O8Y\?1"_!.Y =DN1FC^/.&%@I$\4$OU1
M+QOX LQBLG?@"5-JLP3:.SHI]Z-_-.E^M$-_W]TVD\9/RVME$\G1Q5=IXK&%
MVZ04=2K]]-K)!=@03$&52=:ND[1SRV#XQ.E; 8\F0R-YR!T.+1PN?@%KB7Y5
M8?Q6LF*G58D<_W YP_ DT:1,L;(65QO^CHSF.'F_*P798RAR?L\X-4ZVDG^[
M83@@P\SG@'W+-IO'<\05E P\PW_=7DYNS5WY"M0$WV$F[F$+EE.;E",LKDL=
MP[FFPKD 8!R2>B@T^ YZPHG#0VCF?A>X8-BA8Z.#_S'L_N;;OCD=Q%9)(G92
M+'W> GXY<\-=.Y "60.(+RSMV"O=QAKZUV838?$.]X^,Y2^$,6:^;ARC:S;2
M+\8=JD=$+CANW/"F$.+\[F>,-:(S#9NRD4F7$R\.22JI6*_L?"2/0UJ<Y[7@
MC;7=1+)J7DH[D0>6-GEZL[3)@\EBN)/SQEV'#__Y)GKOS@4=OB#6)7/!*.&/
MCUAH1EO%Q.!S_]_0!P<>Z(;U7N_E\111=)WA3;,U5$[?]9Z8P+]2K<#<Z,<'
M,;\-F;/'6V3.'AV8!/_A,^V3)JNV_ME//O_9(WB@WY&+NN%T38VZ/3]'BL+
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MII?FSO3'W>7Y(G%)8\FZA\Z#&ZG*=QO>BG8FNV:("I_R0=,F^9AQ4R(#?Q
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M23^V+>O!PRMNT"-U"&9ON%.,-V-$A7#[:6X1VS.Y":LD6*#ND5%#"+>&&^>
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M8OS?474;?SD8D1(L2D-)"FM*$\>\_LB$T_P/K-6B+^(;7'2)HAL$P2I=04Q
M,-D?_'[TBU:%,1K[D[#P=9JA-53/#YY&)3VA9EB=NI 6!_@]8E]MIRYC.MA8
MQKC8IM9AH&O%=PYM>CI"F^YN').5R&\R@0/OR9)6(O=O'; @11=ME<[YKCOS
M.ZC_V&@S.#$"#CCE?O&"7I751[SQ<&UM^?>(+-J"Y)]LMG@8IVVTCD512R7@
M(*2?>[?-,"O*=9J>59W2MD%3H[XRN:)F7EALX<PYNZ,]S%L'5K!QO-06ST&U
M0X(='/3AD0Y98Y(T6@=KVG;$AO,8-/?AT1X^U11'!S7:22&X86J2P AL/MH:
M$-5J4G@@H9 M!T%/%WM.&K%*$;V"_,S$2>/ZJ;@GZA>EC-41<'::]G(T.=L+
M>FAS; 7_00MV(VQXK\U5UK'#K!GFFPX&5CR=7"DF%H]#0R2VVI@7OE9OPSN#
MCDF[[OD5OA#BN.%MI( C2+18*CC@QSENJU)2.PF(W/OP4$D3=!XLB0)[]A".
M@A%-#&,T,8-9DC3GAM\<9>1+L,3&IPE'D_A HACD4"=_@@-#\CG$*ER-?LA@
M7=*0L^! 65(J[YL R44,> (&N51\$YS@BL.E%)0743C6EE^+C$3!Y0T=6KH%
M"1$ID\.")S^G)^S1$X8('ZJV,#*,&@3/'#6]>44%M\L%V,U+7(F58M,F2>UK
M02[+.8C+I'(M+#2H:E9,.ZWV6@V(JRY^M]R1WRO4(@5!+;*ZT3M"!?\47^/G
MC6=Y;;B&!&%>JQ>@I(D"5V"B I)$(,,UU&E#GU;%GBAJ,&PU*V8"LACBKZ1\
M* F0WSR.SAD3I'+,+($">\P<91F%/06F5Z .50Y_J5MA]Y.5O;([RSOCCOW(
M3I&$"H)QPU,6%#GW859KD6+DG28]\A;<.+R**NQ]@)TYX79/V#(J3\Z+DCJZ
M?M7Y7=>ZX,_4E>!WC?-L1BO:^B^)523%@*]I%_PO_PM%/-SSJA1/*TK=CI-[
MQV3$JTZ[U#XZ0^&70?TIXA_] 8HEVM$A3YVZPQ9\EI-XVDX<<>%"7)!F"&JN
MI6G1$'D;2,%__>NC'WXZH="V,I Y22.M\CRVRJ>-!-862:O7)EL/9V.K;;@-
M4#A4P8!*T;OI-QF8XR3PG8G-!*_T$5=\!+8J0[DL5L%V V<47BY?#9)ML<M<
M87RIK))S!.VMP_[$PC?7S;PB!Q1U8!3M __48*NODK*$M*Z['Y$T806RX8^(
M@[-&B'$]O[:<<&#:WC3B,G',$#)X1+&S=M3L:C17&"(%Y8/M8VR5N6%<:)N+
MLLK_V[!<.,A;TMW4A'*3NCO@ CH<<"P.34)NTY/#@YV/NWX>KEA$G4.=T\[I
M6VS5Z9*$G6N/GN705=$C)87->/.YT&6#F(!EH5;;N(+P5HW,C-UGOC5-N<KM
MX9U&;H*Z]L0N_9ZE_@%=[JF D:1P=\?GVZFF0N^?C\E4]@8*6[T?$5JH&<J!
MI,@X$&^16P&)5V.*X%T,X%T1';?G+7H,N'E/8ZQ=>^SQ^N)E)-+5NY?=LWSZ
M0_4L/;077A'Q6:Y7C:!@_LNJQB&S"+F>2!VIS^-0&1I2TT''IB&:N8^.\G!=
M[<*:PZ!B2+0; :(PYD.O[NV^+T,2Q]#B8P*Z -GP+!W87!/ST#@4'CBM;7/H
MG8&]-OHGF6-ZYMR#;K@&SM=C<'C&6AP&\Y8,/IU8Y>2QFQ<L=^UCKY\PV1AR
M14Q!Y2=VJR3%-_BR'EE5()O7K9'60G&)RM 0??XR6)].R\?K]B HNJJEF4&3
MDS67N6WUY;^]^;%*==>1]!TLRYSH^S:MBVQ"6RMMR4=#=.![S@4%A[:I.!WL
MCM":9(Y9B1$+>7&)]M.Y8G3YI;'IJX62%,S!<B4[0U^2G<*IASR)_N0H<??
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M5+.=+#\ZK'BT*J-RFK+''$R:%/T^/F<H1ZXUZ3>8\T%+#KT=MW,QV1 H7:V
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MG 57.C,0S93>&ET78("6+#?#UH"W5MIM=3YA-#2<CC6AQ:8SA>D@/^!0IHF
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MD#4 JYSXEF<<,':1*>[(Q@0%6:T#$ SL@AD4C<6#T5(XEPOAV/.LYV$XRT5
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M3IO+>#!X6WJG+ELJ':(BX8"$F7'<"3:TJ+F8@A+;1!&9%P[0S=2E".A#VM&
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M'1[H5(N@;;7P9=*6PY/^C*:\%Z[K&.>7EH<;,^)IYM,L-='L@!U"8QY M0R
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MVH[,F(K(=PQKTV]SAK4B;P.P)FFUN:&*[&KMKN)&1P[-7",9VX9X3)(/LC=
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MZA_IEA:P\5+=$=)KZ2.Y$7,_((FP0./XI?.^*)>:TLOCR^MFG5>Z568)HFI
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M%&89[67P4/4$$$6RD(N<Y9NO[^-3D!8"QT?A,,Z69$1F2;0WM7LXE@*)GQI
MHX=K-H 7586JQ@"^P.7;8_82?KUN$'D("KA21>"SD6KZKO+KNK%X8B_I#SW*
M9<M,:FK'!5V83N[AA*0Q=],F+?=L51FY DC6TR<@T<^E.B'B>6-&]]*U!0]+
M4A1>?3&0G*HD/\VY3^$?B58'K_[0S3%&/!A6'T*=#J9K<!(LE&'@,!Q++V"
M\.Q$$'26>B[(7,KW]+T7]'\)V%Q ]ALU!I*\0*@LN%.3Q, *B!!;>Z21.J=
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MW.W@F1X(>_X:__M;M>QL7,7.8N\!83U3&6+#8+ZSM;1.T$?17S?%O!"I1WZ
MV89B%'(@9DL61,[&&XO(;?Z6BP?L?.[RO7@4].DF:FH8JP4X_U9JP.SZALP2
M#N/8G9*BTKG$/SRY%/WZK7.[(F(/GT5_)IM&>*L*Y@-W><=VD7%4L80A^[IW
M9*-6;E4(N!$=;%H\9-2BB6"/3458:Q'0,!/T2<:"17*(["Q(\GE=OS6I!4+Q
MUN([1<N.W[[MW!8?VO8\#4RP)1$M!$K9%N9TG&JMR^P'IP*P84*7ZX).-Y[9
M[Y9X(=<[JV(;ZC41:?IPCP.R=' _W3)V.6B>VKKB39JWI$I9_XFB<K.AFB,3
MEE3"O/?!')G5P7Z(#\;8">3#04/PNBP2)9?97^H;:..9!(?%=JTV0D@6%%MK
M?H#8GR2WO<E-YFO0]^^:DZ%8$B-9Q#H];-.3,,TXO.X%BC@'L(W9DJ>M1<-M
M"GZ$2I2[OY\W7</6#%RGJAZN EOB?IGEX-H3E= G760V:5"I&:8&)B0=!/I]
MQVI"GF(63K[.8?C0Y)H^HU/B&@MLV-'QK;&F>;T?^XLV">\.^HB=ZH]8KIVS
M9H0,><UD>=XG]TF Q[ @VY9;T%X_?7R?__K$(>9J+MQ?^[8S[)ZBDM@W'WR6
M2Z[B\EN1:UA:?0G<O0U] BRHFMZ\MVU%KG-5!P=/MA0V@L;-W]>$G8GGJ2*;
M;2 29F4ABIFW7J(6Z=^1%ARSZP8AYS5.,I\A_IX2X7&\BI\*-WFO9ZR5QUUF
M_V!+.M+G[?B+#K3O"GMM%FQ$;][Z$]&W(@%9;SG]^L&T)6!YV,>LCU)0/7X-
M[>O<?/\0FPR+")Y$'8%;AM (&]<E/]_?'ODX=([73;X-G@VK;9D-F4>S3'6]
M_!G+KLS/OPXS>!#@6N9;VA@'KB<_B<[#4GX\7C(X,)/SCO>6KHW,5+0%M8OG
M=W1L3SR:\.8]>Z0LO$?W -TQWUN<QO=AA?C,NJSG=+,'W_7S-<P;*C18:I2.
M!SU_LRC/J8OU9R0%ZQL.EV=^HZO!N>S%VR!K?N$%>>G61:O]QAKK#:EQLQ/2
MI9Z-N3$K'H$*U&5#WYO$ :OLKWG5PXO]^.$L>_3@T0,="JT6!V#9->-OE-6Q
M3,%W%6F>A008'WTBMXX.P,P>>ALB+NC\6/K(+_8;.<=KT+Z:108U;[*X:"SX
MBYB"'%Z5-9MB9U[6T^]YES_ZZOMOLS<<>\!+']=^ZV17> //W#TN47GPU9O'
M5_S3PZ_NVT:=NT6^)4.\D" Z)KY6$Y0'OQS[O&@&90(?:A3T)H>'P.%K5@^Y
M'X(N'@E]]3P>?8X7O)#)M.3E#YL"-G6XJSJ8G8P^@E.F^75-MCB]--.O(Z6]
M='FI7TC>+D>(6U(FM#-K+^QAP4O.IB$SMB ]P1;:O_JZRR_DBYG Y@*\O'X)
MZ.5KJ?>0>'X%>YN&4T(CD>*2M)@/[F.0K-F#ZF2] @]+%1*J/^1-GA\GN\>Z
M)>?J$S@9#EFX8K>S=';$$+^HV\Z2PZKF2?/=]QN*MP2]ED>=9.&.[M4H#V[?
ML*Q=R_DPGVU1)]1LK273%V=;.J:VSC[;GKSTV_10+"6X#D/,)\;3Z)FN_<'C
M=Z[&FAU]N+BD&+QX*7!&0_@BU'GN$!K(%ZZ7BB'3GW3YO>#>T""4URC:&>W]
MRVR8*%.OJT4"WT.\1^^E^2)KJ#I\L7@SK;/1\E=L>R8;A5.\K@K;,=_04F8O
MDCI4BP!E][YY\1*Q'];\9MBE-:OTDU6L8A7A5BP* 8C@C)!\(CV'5IV<-4EM
M@LUZ&:;4]L,LVYC+B9V0<Y2UIL.0E\=&KXM$JS^8^2&1E X'*9QJF3>((KV.
M,L!1D1>$MFGFN+M.I P*<Q'9I9'2D!8;%4"1*'W'J:"A\AF6Q@WQ&/0\C^JB
M$;/C0'V?>?7%H]^M^N)T/O)4BC'>UZX-ZCKJ68J/!6G-H]6N?\PG9B<V'C;,
MN*]KGT031@I1#G.Y[_ 5L#!:1" .N5X_XD.$%$KT1D]0;3?*Y>0NDS.]Q#/5
MB6 5JJEN_[*W;F\W2.R@H!E7[UNR8C'B\<&84%?6TKW7>=G[V/@1DBD>/7+E
M72;.9VOE0QRY$G\HRH($6T<'>,VN=<DA&3C</D2QDA!+FEV_?5%^:>C?-)'&
M^\^_LB<Q[=Y/K,#:EDD*Y2FD1^N%MV7YPA=7QS!+S"A-,D-<HQ(]!F]9Y#WM
M@]GH&>2_<:348N(ZE'RY)9>"MKTX[WPO;!NN=T7*@&VQLJC>IB8I!APJ5[^]
M)&>$+2+=PG_A)/!":N#40'H5[.^KM=2)1/V=9%KLV;-8-[GF)>BM/)!.ZC_Z
M;E,WQ<^Y1<%EP[-U'_\I^4I)\Z"#R4<*-%"&P+VD7^DT:18^Q([A%M!^J&1G
M5[3/EDV_9M\XQ!$YW9*\B\64=#T)3 QLQ<%WF(5F(9#P9? 'HA>(X4C&)/_B
M.BK[65F!D+W:ERCY&5XUY)ER4%Y*B9=<W$M.2)//R[W=$!4#:ZT3G2O)-HW.
MK;E,6]= $/C%6(55]AZVY<$.=_29A\L>?_>/YT\N'GY)NJ#BK@4]>19UJ6J$
MD!=U0V[9=='TK7C<(Z=R-,<?!&[D22'SUK@+OY7:COY@ZB+97[]E)=2IB^7G
M<4CIP<,O9]!H=&NA,8+A.F"=+._F5Y&.$11H=L."6DMBS6QI^X;TIDCN'WI2
MU+/L\8:F%UZ59,P<?F7/PD*WM% X29L&=?KPH? Z.HKE<IC[BT3Z,%ID01WZ
MQ!=<NQ_"93_@42IAL^^:=5[9.;SWPU^^NP_) \?6B43Q8V,/S+8LR98Z6W(Y
M3S>ZI3>YM@RM.*SG4ZLR]Z@;]560D?//7WE#4B;^4JO)K!O.1@NH;1*NF&7M
MQI5HHZ*=QM7 &7=CRJS\J\]%)7#M)&=&I#IHL:EK6N"R5H:A>2Z1#TV?KW/,
M+IM0+/<]P.[<<6=219900P[84DJA.*O"*\]BD[7Q!A&)7=^T/0PD^M.:K$5+
M@UQS!(T.O85G9U(X*>B^-5//^?J#=.&YU^,QN["L(I[H'GPL.55^PDONGI!U
M??Q$<W<^_B[/UUJK?&TUX.EKI,[D[Q8]?EZU7='UG02B= /Q4T-Q5<9_Z;)7
MQ8]OVT)NZ&%5TN__49=OV[7[F83*QA6(^68OR-)T?7;OU?-_O+A_B1H;TJ\Y
M0FJS;%NW/@D4H1O#9!EM6?%;PEI$ ORQJBM,VTP1?\S:UA>D=6_I>L,*T=<.
MZU[8Y/&6;UH?/U)LE>:S7A<D])!$G!W_/E[IO'%'/F[$N--DN#@('>\X3,)A
M&\RM?7^UR8V'7UBH_0:Q8!A#)$?9B2#SO,(6QE?YR=M'[4)1PE>S+R$*1M_W
M?=>XQ::;'7P!I*<K2:,@+2U!N39?.7&FTNW 8@^:D!<5)RSD+! #(U.C6H9L
M*[OF7-D,B\TBNURE01^B!Q\6'M=H,E!452D>JY=A!]*.*U]$WK-4)TU+IZS2
MJ1&1TP;0;IFF> *L. <#&A\B!VQ9E7?";18E<=DR:U&U+6.,IL#D311=5F_J
M1D?L)TE'&Z9VY(2EYT(7 _9O@2J)/1GQ4)/?OYZ1K%A<SI)-/)"*= HK7YA_
M*?W?\M]G/F,?7H6;>2JZNTXIV^)ZV>% Z<K'^7;>%$ORG%_DES/)#<E!"Y+<
M%TV-+\J*<VRW+P;GT<:D/N^D)X]GV3,'JWI$^L>Q60O]BSR@2R Q_6\3WT[R
M.+2^9%3&U5(^A^\+9_D3"ZXRE5/6%.U;S)8_ 72!W^TW_-P:%9"H*]M?:.P"
MKCJ= BX:N/%ESFO1NLZ:+F)9S'/7:* 70?K.-(ZJ9X[\<K'T3[MT(W#(@K,(
M-5<"&>6?*[DHHHMJKQHN=-=*G8 $-\S9QW&'05NS??IE]HVO\HAC>JG=?F@$
MA=F8!X6CI6KA&U60_C(Q6C?^_C[4N-C&3SM[SMA2OSH,_Q],]^Q0ITMA4)C*
M.K)V6S*+7GW7WE?+N6B6%PC.[<4!+[AZAHS8&X>2H'9@("3:&:E?&/5:K-1X
MOUAK0,.MW H/J2!EWWK9<-R)IQ9[:#1]J&V!,3NOE]A_Y)XM.>['LGR.Z(JU
M"2;=J%+&*>7H-"-\4.%-PCE)>[*T.G@9153H?'!2'Q(,Q3PZVL4&I[YK]H-4
ME_CX6MPW1/#B=;%O"^./+4]X#IUVW$OW%]J0\1<KZ6B#D%[Q >"^11N#2AQK
M&BZ0*]8KM6I?:G@/!V=;BLNFDEG!OV4^AO=T*-.7'/7(VATNU.B$A V"?<F_
M)P6ZAWOUM"RROQ5<Q4+S2B8C3;^+FS5Y7%(AR0:_5C&$-BX_G"A:,]82/:B;
MP^$X?C;XU6FW'!+Q3>&XD45]JJ"@ P[0K6/'..*@DM7L'4YDO&-^=E6]H$'\
MW&_S^2Q[\?AO5Q<//_V"WR[_^.33Z!^/2*"_J!M7<PHUMX[X0S? -\?+\6;K
MIVR=.!!J/;7]%I935$&F1RN:CL$,'.XA#K#?Y3S-=+(NQA8UUA3+@$)@GL!!
M@E\\"#R>;3/);' GKE\@!4_E8Z@)$(/"8(W*Q?FH R_E%/*#>-,<>NGB1Q4K
MD4UE6UON?J24N W5'%$Y9L34&]0G?1MI(78<.^?;FVT'7AZTX)^1UOMAI.3X
M(%HW;GI(O*XT\XPL%5D#WK5+$IV+3OH64'ND_Q+=X."8TUXKI>N*)G>&#NN*
MBSS34'2+-F%X.@B2A#XIMNBL.K*ZX*NV=570F8HDY>!#)"0C@!.TRIQ4\N6C
M?K.#(B.1_3OH]KC2-+D45]Q%.%@?J:3F.J=!ZFJ1U$\-OAX/#P+%Q\/,L:KG
MJ,7A&JEMO90L'QQ;5 F'0,'@F6'F9?:BE!AWR :,^EO,H*0^&17YA;9AA_9E
M')R]ZWCQY&POFK[H9,G-I\Y07^7T8'5CL,G^Y;;5DO,>;!+.,,[4MEC^V+>=
M'.(MZJ3P*O6CMJ2T=/N(9N?XF6XK\;8N^IWUI4$<88<--YC:X^V._@2EWT"7
M:3=#U,OR&V\V;:V6N=+%T776HULS],FX0N;,"<(TJ&_S/D;&,I!^PWD5EM3N
M0\,4^7C"%/G]QA%GB_2$R(8*$BBWGBV8.T5[X#8<$3*'5LY*(DQ17E&UN%93
MH&+M:*X*.NI.R2EO]?TY+0N8(!U/#)AN@G2<(!TG2,<3A'0,@1V2N4[(0LG)
M:NIK*SU*PL^(16H11U=8!)9^]!V]H[[!A*M^QAMP$MV3Z)Y$]^F*[F%T&DVI
M'#C@#A=QEP5'[##.,LGE\]U=DUR>Y/(DE\]*+H>@1L&U"6PX<Y5YRDT4WZ/!
MV*2&76\W4#"/39S\G>F1)@%_OMMT$O"3@)\$_"D*>%21M)KVV83FI,9)%JD%
M_$*$/Q]AV!R/8&L73OSD&M#+R(9R'[\4PQP:\9K1@P*P.T3V<WU&W?ARN@&4
MSN0*?##[?=(4DZ:8-,4):@HNH>:T9]+J+?$9J28;JWY1)#HM6!W47(\4GQ0H
MX5K7@J(<M:18Q<'&Q>UZAP^(U=!\;VW@IC<",FZH8K'N;L98GU3'^1Z 275,
MJF-2'2>H.F**/8,-&8(8^ K?65)SK+5L7+(6%[3-8DR"8X_*#/ALK+QS6-1I
M_^86 ;PN%-[-K.HX1CT.A<:".:;=LJ'I;*0!EJZ0%'14\.M[)&.,WH H'$W;
M\"L4[$3+"KG,M.N7^QB7V$._T9!J\+1YBA?IYG"H\09F' HBN:K^?EPE'2E=
M#&;=*.Z+O9KG*0W7\0CH;3M2X9,Z/6>A,*G329U.ZO3DU6D3-;1QIVDHK5<'
MZ=F3*UP&9*):$'SRAB6JL4&,%T2-* )?365%W9. /^-M.@GX2<!/ O[D!?QJ
ME@IY7]PZLZ[5-C3I"H1:U);+F9ND:3QMPDP[Q]7/X9P+8W:$YM9=8'ALR_IF
M6=_ /U/42(\G'0H&6EK&G72%)G!P_ U ;F&B-R'CF=3(&1^&28U,:F12(R>H
M1@;1*L.:B7+[$0TFAYUNP) VAV.P8 "8<>*:]V]I8T((A7%IB\5;8PB+()<:
M(ZG W!7^-\R4UKCT8C36@J=!4.*-/+>D97<9IG#7!DC_2;.<[_F8-,ND62;-
M<H*:I7&KOF48SU\38&(YOEBXG282V%49U@\4 ?@I6SM0K.TVQ11W.N?-.8GU
M2:Q/8OT$Q?KQQ,(AF%MLW8_CNLVRK^ES\^PE$S/- L2; 54J)6=@9E.$N.^J
MVE^3+W*%DD]!W$)J8@A'ID1F!M1FT.81ZE]P7V;"QU<:$+3  P;L&O-NE/]W
M)P0)<96;L7[RK<___N3" 9.40V=R+RNJ;-)49WG>)DTU::I)4YVBIN)\M&8W
M2 :7=;5FE#8&6A.PQJ8!?9366!U28"[V<]3],C_X7C&5I8:J89J_ <V3\9/@
M8B"#J&"G.R;9?I8[=)+MDVR?9/L)RO8C/>?L&@"TDDM05TI@HPGK.+T,(1[
M[(N %J_"'K\1&J_+NXGN<T38'3()>\KI7<, ^@P:S@#45D4]+^H!A2X'\BKV
M89C*#RG]Q=L(_120K^7>F!7=&)?M"*5(!,-X"UP[*6'VVQ:YM($J;50&+F!?
M[X!B:]0CT+@U!Y57>]'U<IUBI=,U?;7*KVL)2S+SM\":^O'5?<?(G)Z'3*"A
MZ>U+^D1'WWCM$B14\"&Q$\I%=W:W846:@?(.XK*[Y=&.<TF.,9H)N[ 3ZH7*
M0,PCM[;5@:,$7)<P F;% #RWPPZ,FPN/YTTO615+Q[PKKS'+QIUI--/S7BK+
M<;N1SRA:M])_!8X^F&&R-Y=]DY ^VFS.QCFQ$MZKVPBR#LE-BH266;C$#FEZ
M8KI#Q06>18:@A1;JR#H<"B \4F@)0;"AZ<Y<\8.[_*VK?OE8E'C)+U<'_O=X
M5G\O'L'W$&6_5&Z]8CO\E:(NZ]9Y$D/!@Y3"#LB;P%'P'1VH*T/3?^SKGWX3
MD/0_@E#QJBQO(0G@0R:QK("8#ZAX0&,KF\8X/8*?.^;MC(-=1<O(V-6ZV^R-
M$-15+0@VN:.D51T<9(6O DYU+LXO269FZ3N ";B5^2 !^#Z";\[5< '?7$09
MJ9$!/4D2DU2Z5?42+;+)R-W<E .MD3(DJ.+HA6$(.-=S_C0/FQVGM+0J6I'A
M&?L?F:_T 3$[J#NZKHQ;S/.Z%]AB'EX'(/%SIKEYXR=0&GAI$KD):VP6 \VJ
M"''FJ:GVMVZ<\64,)"K1#&_[MJ/U)[N!R7V=MRQ8K^MVOQNCJ,6%TQ=@LX'5
M;08^%@$W%\X2'-@-;68PV/IC:#0KM-+AO*D29D6!>LU]MJ>3K8(?)(*=AM$+
M-C'XM.$)1A$5:_3+[%E>E+W24=2+12\;BA[*X.M+J0,=:<764R]63V2#')V>
M4>GSSF//9RVU-S ':@M$[X5.:,8??QED?_1@FF^^)VN%GN00M$2-SX+Y!MM-
M?1/5'"V-FX\_#:9IOMC#(L&DTR4[;& RAL6JKM<->N@\O^GQ61*LK'+D$Z+V
M] \,"_^3"0O_]\3"5S_-3,I#5XYV0<\,/$K>NQ+VVICEOG7=G'QYJ;A87H.L
MYE#@61\L7<@E>78J('P51T$/#9V(%?F$))OI:$,9PP97#[3>BF]G9QLPGR0Z
M"MKZ=A9@SJGG,I!*=E,D-4@"0U"M^C+VZ,]75:9\*_A(D_KBX Y7)>'R4&HA
MZ=."TW&KZ@1AD=)$J0VEQ9YL5@L0Q\'[;F&?F0WH9^AIL<O+D7FM*GVY ;/O
M\^'ZTECE]H>?#]AK>"@C]#7O>M"C+T4)CPGD0)YVS*X8Y)C3G/BQ&5)&DV7-
MJ_>V(L5RLW%"TC8.*RYN^]RM\60QK<%1)$[0''H06FE=P6@5S)4 B*O7LT/J
MHKV"T,ABXY8]6(>+E=F1D?$AKU:>*F\4>P9<MK41+6$&2ME?>88]JYRUPL)Y
M@/TEC#8(+H8H^Y0#.;U([I0#F7(@4P[D=',@!9=AK=1_8SJS'(%;*YCB< %7
MT(:XMD0^2/\SNQX\*4]X.0:VJ-D!OI,$ND)NB4(PF ]Z<7".*[>N%>N7'PK]
M> WJZ<B8!#T;.=B" "RDQ8%U,[Q[*N(]WP,PJ8Y)=4RJXZQ4!X.ODU O1&)Z
M]X'^Z"$=&8P=(6A(Z4D^G^\NF^3S))\G^7Q&\MFU$)1%NPD1O%W#9'3+NI64
MD 5S) XSGO"8H- _F(TXB?!)A$\B_ 1%N)1::;$B,,8S%,5UQ6IO ?"VGU_L
MZEU?YA%=M"98ND8NJ[5PB^WM4/EB,.:APXTUA@;]?0V4L,3SRW;UC22-\V&$
M!Y6QKD,(!_BS1<O)P#()U5@^;5(4Y[O=)T4Q*8I)49R@HBA9,I/PKT(6FVL'
M40Z& 'HC17^KA-QT,N$_F/TU2>9),D^2^00E<Q1XX2(K+W^M>L9BX,+JT/5-
MQ5&77=WB^\EN9TM<"ETN^MTDI,]WJTU">A+2DY ^02&=D$"CYOZZD"I0H2.U
M)H6NIANYJZ>I!86Z[CN)ATQIS#/?89-LGF3S))M/4#87U34ZU];HLZ-!UE5;
M<T>)UM4?)22(2\7=3XP*L.0:QK;ULIPN8M(9#:I;2PGZ6ZWA!'T%KD&S=<M=
MWKY%_6B+H!7Z,\9UY6C@Q36Z+ 5=U-._16'V08T_]Q",%^]/&N9\S\FD828-
M,VF8$]0P(NA(5-^,%JY/,O=\=\XD<R>9.\G<$Y2YP=+NZM(U^;PH@;?FK>T%
M<\4(ETO/V"0I,G0MS,7'""4!$ ;&L@6D[HPQ%Z35-.DS]:'W8J7 'N_UDE7!
M("P*B>0KVQ'<SQF415T/YFRF(?15U$*U<7E)7@3#@4X:YGS/R:1A)@TS:9@3
MU#!1XK6>MZX!VE&V=7E%@UWU$2K.W%5N5723$#[?K30)X4D(3T+X!(7PL1XD
M#W)X@,K'"$]B91M7L&$: A5GRK2>_9:;A/4DK"=A?7["NJC:KNAZ9;!JW'5!
M(YW7>;/,[CU_]?5]9F;L-L6BS1Z3N"[H6R. N+S+&%(&(?5)>I_O'IRD]R2]
M)^E]@M(;H6N2OLWR I'H/=HM7=XLF$N!/D_H$R#5M2>4Z\_W4LL2V>$*\2GT
M#;#%?1@]*_,;P6FLLZUSG?*HV^-[V.[S$H4Z9K7WK6*\",SX%B4MS2P C4]Z
MX'QW\Z0')CTPZ8$3U .+#=@(6?(>$>NS;%>33#>8^'5?+(5=8Y+'Y[NK)GD\
MR>-)'I^@/*9W]F O$_83,") ]%8=V,6J3E@"&3U_6$K.;:"H?YDZ]3^D[38)
MZDE03X+Z! 4UBOA()G,=8LU43EJ4R-)Y5$#G)4=3YJZL;V)\=*:@R9OE)*C/
M>+M-@GH2U).@/D%!'44XA'#:0%*8R':1[YQGG>YHRAP:+)=D/4<(B>CZW(+S
M\!A58%5G3.*)ZN_27=,EDR@_WPTYB?))E$^B_ 1%.2<L,TE8&FGYHLR+;<$<
MZBO$3(2 :+X_*JL/XR/ 96F+I>=V3:C/A>F<:UKD+3_VE;ZZ .'IRG&DQC?Y
M&^4J*P#</"F!L]S*DQ*8E,"D!$Y0"<S[%ME'%;]-OQ-A+'CA'H5K[>H+Y"V%
M9UB510SR<I,WPOM&SZB;HMURI4F5=WU#-RR+-F_I3VT,"T-Z9_.OGOP L-/M
M=YN:'[DJZWHI:F)5-/B;VY$RV:*R$<B,_;PL%M; 2=J)7(S*9U._OWQ]R>^M
MJPO^>5U?NZ:"#@O#EJ[2EI35PKZU9&09X,:XKKZ\FXHY1];AYR!]7A;X[!D6
MQ2\W]_HNH>>AL1]_]X_G3RX>?IDQ< ]-O0#U5 L0P0H:?5F\=65!:[;TJ/>T
M#K0QF8B]7VP"=#[G6)J(4E>HT;&YC.26?PR4Q#-:DEW=*#LQ;E:\SD()A@V@
MAXV)<7+>R^P'IXW,86 VAA$0_:(-A+@#/ER:E9[VH4[.\U=?MV/5MJW9.U&I
M+G^N0/SSG!AOL&]0UF\&!Z\^_DG>Y=DKJ>\-E;ST/O[#:^G<?E'3%-9L*7W-
M-<!PN<,;F")8'O?LR95P/]*S=@Q(G5V%-FH;\M.G5]D+QZST:J;=PZ\??9X]
M_7[PAUW9M]ESLI%H[F?9WPJWV( SLJ//F65_KYL;VBDL"&#Y?7O? S(=:>2^
MS%YCV-%O9*]MT;@MGY3KPK2%[ 5;&?Q3F<KSK.IYD/0]*ZFVBX535$ZM$\[#
M&^X 9MDD*P^DZ.\LS>-F=7M !&E%J\^,G!CK:NPU]<XUN1=$ >HD63$LR)$5
MNWT^(\&M$1J>RL(&%.W[35W2"O85[1W7.E<9 %?1MKV\R).]PYIWC* %"1UF
MDX0#?4?72#N_]G**QNB9^SW/EDV/LQVB1HE(UH^PV1@2ND=J?.%P@F.U_?#1
MB4O;3S[5[]DT]D&[?.TNYB1&WU[D*_J>/^<E'9CV3]E'[Z=2_L"O.K3E_IAQ
MY$N2 @5O/A#61LJ])".)]_J2SBRGBLA>\H6WY,-6O1LYF9?9<T:B&*6!Y\M5
M"?%)F@U%$7Z55_L1?OJC8'7Z4#)B%@IRRK*CO>4F(Y#/-GFSA=I@%8AK-5]&
MWT@6D>,C:;A\C;MV%<XTGTP,4D03$XZ-C OZD5M'\ )[H?+&TRS%1@0>%F9I
MH*:'@0%^E#<C!.ZCA4AID<);UC?5D<\&**PKZYWGQ?&=+?1_#"J(7_[HZATI
M0]IQPQGQ'8PV(VU>6@&>399-$FFDB#=GL)KZJ6)7T"?5J*2FL<NW0%X77.I-
M[YRS>M87\F_H&+]U'<TE)"YVVK+F7"?);A+S/)78>3!_EU*P(J;#C1/T<FP7
M]Q,I-69H;G"2_,?Q#O)?/K)O\*VD"O*B&9V<=]T_V!1&"8U=R+=X-T)8BYAL
MB+>QUW:Q67VFYO-5?'+JQ:)O&NRJ=GPJ&*.&; GL&Y@=A2?3#@<]8=,>'*UM
M.*AFU(BMS<8ZRY_2Y0"WF4'/,GU4D%2\WX4]O$DEU\&QQ.AY+\-PV-)JEWM[
M,C^-9EXEV6C+\%%9=7G&2_UX.$=]BY,;#/8Q<S&8;]_/#FUJE=5LO$6-'>-V
M',(>#S__BM9AS6927$"<V'^F]$(AL;P'/D;$[ ZCJV6)(68F;>#4-X[=Z!'7
MIA&_1^&62//PY"2NS@W<YQ&]*OZ.G[C!+C_8C <3S5/;]I@Q=ZMJ%%E+=Y"Z
MIPF2X]G1=]805G$AX X],P4MV[W%-R]>WD^-^[!*T11?9L_Z!K_<DNR>020W
M."9TH#SE_1A\(5-^5FVO$P.V3Z>!$FG+,7]$/^M@YNA*4@*E\TH@7S=.!RH+
M6 @9'3<#R7HMV1BZ5J LN[$LMH7LVU79LS+$[7JKMA#1X' RL*/9?UXZ@>VJ
M1K"YQ/<>WPKX&\]+Y'&-?9Z9#$4X0[Q:D6-E"_7-X\$Z769O:E6)["2-HH>Q
MYXN!P&F1Q4"\(<4+6PW=.1G=S-\4.XV /F:U20,*I4;L+37>2!+JUH2 #^MM
MXMG]Y!:]=Q'U9<%=S1>;PEVSX]K36 -6,2\FI#6=#P$T_K_LO6N3V]:U+?I7
M6.?6OM>N@CJ6'>=YZE1U9#EQSM:V2[*W/X,DV$0$ @P>W:)__9UC/M::"P2Z
M6W84-[51E8K5W20>:\TUWW,,R4Z82[4U?XJK)OG!W!6D TBB/=O@F;5ZX%BR
MX4G.L6S>4-,'BECSL6Q"2 %P\4>R_YI!P.U-,PTL(CLY6O:X^"Z<\+J#/J+_
MJ4.!U8JOVNU+\0?UG>W98U1Y%K;;0Q7U3:Z5+;HDDH7VR"%Q"*%A)+N[@K:
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M 1602)NC+6)>&44ZFC[2_B ;L'T\T#-,"HQBC";9J2?Z"'B!OCNW61) <"<
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MH>P8FH7GD?F2#V;3[YU!M/>96^[3)<][)8.'1=P6 Y<8#6EF]VDZ<XL?P*V
M@.R*NX)=YD.#H5Q!J'0-I9V@K=[)Q&C1]5G81)^E.;;EIF ZZX \0 JVO8F8
M!P8D(-^_:0$O'G9; 'QO>/13S@2=0"R9 :@K9LL1>&<1?. <([L=O?]44ZU
M7@A=JO1N;1M:#;R2!T,(=*HZ21^'.$'M771E,#Q: PI0 9-H+]HD-GX:P;4Q
MD#':@YN&L6\V14TBTMB\GP.F8=4UPJ=*T68^*.;&KS&(_G7>]:OO6_(]=$I&
M5C7J"'[M%#Z[F8#PG[F.'A$%][NG"(B,(N^!@;/E9++ UYL,X#:)<FJ+VY*6
MP'D,IN8O65O9"#'#8_%A!K["W *?[TY2Z%Q)C=-!619Y?X:WS\?V4/1TBQQ
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ME:_F%B"7LH$-BOBW';$2IJ/T;$%T SPFZHZ=/B;RX&'[!)WT:O6CF#+W,%/
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MXRNN74#IQ<=(0ZE#87K&IV&2AU5S^O(')H.1]+G#&!U%DIY-(HDJ';<[- 4
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M*#9L":0J;"7>+-1W0_'ZQ;ZLMFU1A]&Y\YA8Z0>Y^YP'^?.Z'CBXLW[O5V_
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MI+'J$&W?@W[V7-A,B#+M'V/4[$24NKP^9]8-0J0C>H\2H)72R099&*^3GBQ
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MAWV6KRG*"#VO=7<L6[P'O4^]*8\5-,8+P%T%&#3ARE/L/\@X4D<V.M5NAD,
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M8OL:-E5<@CF21B[5U,K46U(L>*L9=D>(FK-;_DQ\8OQ1@O]<YMWDFI*B\'+
M::@MNS9=PP$CMXX;9G-"B,Q_8=SAKHA+%YO L3V%%-RG&QTJDB303PW2\8*!
M+%85<W 3F< =4W1PFH>DX.K4F0BX:^2;7'C8T[9#9R&,]=Y#/FBW#XL26X29
MV891:?"\R6PB?VE9YJ:]H6?\R5''LJN7<CU;UCXQ,WITK?3'C)B.5UM!2-BR
M'G-VLWUS!GR\#C.Y99<43G$*_+#JKO%74TF5<E'*FYZB4R!]&NGF\UYE13WF
M&<-^R5KHQX"%TC95N0M K3MI@@/0GM4?H$:X?1OIZ!K.WLTI2T?_])A9/Y@>
ME?&9RZ5#+BJDHK,)R-#DS%58/M+B*]*>DU<C^0)8!CJWTF$ZI=9\234F=6PK
M@YJ!"OG(VFM^_\'::YY*0\VOF=.H3U/'/SC8B9/BC6,:'JAQ<GJE>%=VUF.A
MIPQ?XT,2?N/F)].C,N[$A6,QX23$S/+]/D'H["7+%/Y^>L QL1"9*RYS=.7:
M4.$NVJR[IBIZYH?LNN1Q>?R,WK1N#KB9>"KV 421M!137;Q_,@@8'Y'\#\3I
M>?P)N R@GJ>Q/@M0S_\ H)XG?G0^,%+//7Y\J J-G.@L>M"9H,0E#C<K_!#=
M[@?Z[F1(L.#\7[!4+@I]4>B+0G^*"GT^$DE3'0Q2D>^0V>.<:XB3U3L/%3/]
M._GFMT5=*LH0(GYA[S)(GD)XX-F>[ JAH)4K=>AW@9'9VET6CI=+%N!%]R^Z
M?]']3U'W:UGFGT.Y>5LD=7.KSRR*]X*E9U&\B^)=%.]35+RQ2,DMV:6,/1Y1
M9<8<U['I2L/"5>I@Q1<0AUP(E6)];-'2%RQJBY9>M/2BI9^BE@Z3L*.,AWC'
MC'G#S0?G'#C"%-*TBTZ^3,%:=/*BDQ>=_!1U,D_0LCK.MQAARV\*H4Y#P^5-
MN<'L:2DSIQ\O9<>;O;3Y![CY3J"3&6]:(.=] W[F!O;04UF&9LE)2/DX!7-
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MQM./>,OBB[N%375.H9/BN.[52:D^>6>4X-*\!XZ,BEI0UJ:6XI*5X8^:=9)
MD,%+IA<^@#;B&)\'>'8T$Y=(_7U-9!QSGB;NRPT\CHUF5SS]A,1_P&%AYM_6
MN0&3C_+RU<2C)-0H?+7S^-2_"SYM%Q)5%,X^, T9U9G%"1C:,)SL7BFBM;F\
MCES*M)*->1:JQH+D.G=%7%LE!8LH6V>;X7V%J=CH?#\,#TL#_,D0716OI3P_
MLOGI/RSSTQ_N.5QZ?%(@%9K1+-==Q")=%\XWB3FJ&;01^ <.Z=/"Z6CZMT,
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MB^)'<>J+_L'D3[GZ_UDJ+J99Q#\Q4MX2]A[EVGQ^T<*'Q>[(X?#,.^9PCGJ
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MX?31YY]]]L?5)W_Y[L4WUY\:J"F4C;KKZS7X:>7'0$^;]_N[7'A2;$<\+4#
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M]PW)K,U?7WWWL;6'/%_:0S[<<R2RB2#!FI-'BD;)R)W./S_;+3DW>7]NVK4
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MT[!/2,J%O89%>HK ?N#4D8.X9'LP6)_OZE_(B?'*<^66:"8-#W3/5*$)[,D
M7[J.WL=@XZKW2^[<K+UPQK"U=VP8UV5$*&;J4G,,U<PM-I6-WE9GB"5$ELPQ
M;PF,=*T)-,FH=.A%:4[+^S'V1:O3P<0]YOW[H;@O^6*_1QFZC'.XMLLG]A8
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MHAB;]++4)U*J%$\1A4]1Q:#TIIH,?2*=-I_'X]_1V<&CZJD(,K^:PX%<)S_
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M.*_G]+K3UL6LM#QD>R[H0Y'2'=EL8\P3$1]>#4X.PAP7$K#@]$V(( I1C:R
M#^F/GNR@_Y6OW(L HC8<!_)H]<S)5SV05J615R*(8$V%"TNU0),GS9U)E^.]
M/IH<VY[7LR?K6@)MR-"0[< (0$>%3Q(2;I 4!27OV$O3B,01(Y4]='Z=4\87
MCA5RUWNFU%]0T0]34F1E'K@E#%!A%+$A4&8]-09!PD=#!BOQI)S-<"5V$M1"
M6454N(?>0;0DPR-'L*J]-^D_JAE7R@W%ON,0%4'[,E)T)4S&#?N)2K<0$9X)
MPS2J%3D]F61OFYYW>=OS*(?U8P\ #'6L7@Q#Z[PIOOXK0/^#+HIQ,R]M=)-"
MQ-'IXW,I>*&_@KI$9C#VG9Y]AY"9)T^X'$ONR=03&'!#(Q5C15G,Y4CPQZJN
M1>JAD42'@+4BL!?#MB(O.42X[1A&4R<D,XO&W7H&M'VW*/)FJURL'Y79Z^GO
M$53<;AL_#9? I4;*OU9@910EUEJ;G!FBD7&488&I]D? 0IK>%VDY./'-V142
MGFM7UTJ,)J0D\E3\O-SN->' 1A&--I=E?</14E,;:N0J#][U@U;X:"@/G_:A
MK&[AKQO7@Z.A MDS$Q$I$:EZLF&.=0[F&5_@38[E&(RD8](YA&X02V,JI81=
M:74(<O>7&'^D*I>Q.8,7@EV1175($KVNLA6OAA KD8&##TX\<D'-3C+NKI/G
M8H^B&DN/6IM&?M.RA?,#8C>UC*9Z/6BRBNY<."J5A!GMD)Z5LRU2&6IMUA"T
MF2@4IE",9B,GN8:9J4\4652$OKHK2'#)L;9W)NU[MP-SK&]=RD2E6@6WJ#EQ
M&LQ,!2@&U<F9+7+BE ZZWF/G";1V.=E)!U&S4'=WJ?&T\X&#%#^Z!F=MA7';
MRM]",@'!?L2Z9OS9-WHE] JF'%2!1'/HAZ85.'TT3#^EWZUQV[BV9=Q+8%/"
M2U_<B 40V.)&%E5)F6.ZM[$7>(),!HN68G]:FR)B6.H9B9SZ5(9@ZIC"!L48
M9"JV+ZPUPB7^AQ$3EQ2N;P,<V:/(C$;GP319L!V/?-WD!=]'WD9%EGE#;@4"
MJ$,RQ#Q$!-C%$>VZ##:\V.WI (_MG(><M6X'V@#>SKD%1*!EI3C8=;7-%[GQ
M.>+2U3MN()=:U@+L8B_,YKAJQF_J@.'$2+YLY%G(BR[6&YCH105GOK848R='
M=! -Z-'4<+'HQ,$*:=6CIS,/?*4A9YR*HC&5MNA\Y1C1C@YH8%_FXUUF<D>]
M\@Z. CTQW'0C%<"KJX0AX('0_T11K)RC0QA:7K74B[MI:Y J[588QC7!*PS\
MWCV7H[Q'E_$.YH+1TI:*&UB!]="K=IFNZT7&ABV6C#F*!>9J<JR(C&'E@K>J
M5\5W?86CKOT **%(]R^==MF'A QWESC$;0"BHYCM,/I"9!4(1(&C>@ABG!V%
M4M:9ACE^=VS(V@,X,H/OM('!R/>P$!N3R]S!HW>YM(/"D145U6@+D -N,RS7
M@8NDPLLO.,W]>ISC2_F=>PEMMQ)AQ&K<1,>H\=!:Z^@5M%<>?'78P9IBWHJ(
M>P@8,4Q4V!P/^52 P;E+G7>$5ZH9C44&0^S4(%%P9!#&71;6>%T4#$9%942[
M8VR8VFVRVG@_IZ)*KCE $$G%./:%XQQ]PE7H50%KW&$SB;B7-$..V1"2.KPZ
MV[NNS9?<J 6E61*1#Z,7VG$L;(GQ6W+8P#PHJ@/)BN."@5EGI5]%E6PH1%IR
M]TQBZ]6JNSQR%@B=KVRU4[;F$<K.L4%%9K$EA_!!.T_A'6Z*B>-ETM>@-6@[
M\3CZP304@X(T$FLYY[=- E/HVAN6D$N^6:^Y7@M=DQT?Q4A3<'"=ULV6RC5Q
MVG.OI=TACY>MP$W(J:\NP3Y,6N\..)3]:$[TW%(,R_$R49!Q@ NW2XPX8ZJ1
M'E]72ZX+AZWVS7-"XPPU"%G[LH;G%D>6Y)Q5,)W7'2SFP?L\=,&B-AE<$KPD
MA!K:J=;5N^/ZQ0F2U=]!#"RS7H#:A/P9U"T6;-7'(5(5HN)+_R G=.XP?V9]
MLN<.\W.'^;G#_!EVF,?.V F8\UQ(CZW3,.1.SJ"E-)$PB&@8FX&82L3\IU=_
M<0F+C[7T"L+5C!W5'O_Q[]]\-S@#=S27OW!XV[?WA+?-*N_,+NZL\F:5-ZN\
MGZWR[K/EQ_?U-(5XRF<4 ,?DAK8*5>JS,(M(NG$ZHI+V4%FN* 1PS_7H'G-O
MRE8Y#J3?F@)M]7%:J05J5;5&&*B6\N.RZ!JIW*L=J.)-[LODHY #L]]+25V#
MS0PCN$',GG /=3VKK3.[?+/:FM76K+;.T%/S66>.EX_7W@K_,PIKS=QVC;1S
M9)!\<>BEMG=Y0VB$?<TD6$.%$]/\V7BA\N!+ SC/G,/?\R/VV31Z-E94\2A
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ML*DX(%Q2'R9<QZMINUE;X#^M!+*7Y,N<D"8>+>RWRN"$J[AI*#&)#6!(\3K
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M-FS(\^]U'O#/!X7+:W!_87)I&1^,-+W@XL&W5#QXN;6#4A]#0L:#V\ @:O)
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MV$'\R./'!@O PY:D&4K2C&I$/#XU(-)T1] -A-'WK]I1"DPY;A*N5G88#7C
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MT2/^ ;=;)$J#6XE?7E6WY:8F.3P8.KH,7_20,*6AEUI\*,:'WY@)+)'SC*<
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MXEX?A:HZI/$+9+.RM!!JK^!Z"JT#NP"^N!SX(9]XRD_CY^2!84R]W8528,Y
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M]?9Z<&G5VZMETZV6V]JRZJV6N+'JS>+&JC>KWJQZ>TKG7^M@:<=<6_56RW9
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M[PAN  9!8\38G02Z$%%RE250I<)F"A+P3EA"KP:?!Y%,5T:*IM%NRE::GO^
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M47P>LK$KB-J%7P [)+D1 :ACA!J:0EO)RH#+)<:1-WGB@9(+_A%4QGL B<S
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M@%92!B\M;/FN,CV%/("/1(@HD70 %#A0PPW?_A?<@R8#&@XQF?<)0$UK$4'
M\#UR(>Z[FZ=!A*%^LO0.+\Y$%'@V5C79IEGN$^5I(P\8+>\ACA(T3GK5.@6_
MSD6XEDS6$I^D;HF"U9LDD1N_*1Y!>"([*12:\98K(K "!)+R@3PH-R-3+TJ:
M$AU0H@*>JTTID&28RD#J]]#R%S&!XIG*;T525=\BB1K&N7#@D(:E)*B\2A@^
M$<A[?)S/4R\)NF@@A2F_PW4(# *;=*(HIR@A4A$N^1APZK2:F[^[TB1" ^1K
MC, ^H 6VFI+?,!,&5 N//8178AD8"9%C38"7F@!76CI_9!@UBZ-2T$:2!L!F
M%++(G2U_\6=):V@^B3" 8$3I;BGI*U,00$Y@FJ:I(4= H0[+SB-RZI/B*DCJ
M<X)@PO.$12F7S0@9!B#P_ #_@J5YY++J4)X7QJF,<]#'^P,-]"W9^)B!] :L
M]".]_B@,G"\!LAI0[6\@%E!(PSI;%+W<;3::.DRG-$.QVDA8&Q/K+#VE!ZN,
M[S9)=(L8(3VXU3XP8X\RRYCF/;#S _+3C& >HAGA5=!%24]6V/BE2+80L(#4
MD+-4>$6 JQCN'+"PA\N!E6Z30"9;O4LT21RL=1IN/TWSX4B0E38D43YQ*?+O
MDAC=(@K8>*#1$_3$4D5W*DN;<4%4%0(7XZ!E(8O*%K5^.*X(=FEB#E1DK+A)
M:QJ*R#)DH3S,A+HF&U 9$ IXB4YEI#'P:R*2P9HK5CCM>RGWA0 L#$#@Y146
MFYA\%9Q%10^(82!.LG'5[GKP8SE/G,Y/%"-\,+7[[F& >6A9C*RY$3)35"S]
MLM'<<$!CAUB3!!O2GV6U$WTNK>4=R[/XO:QW(D$X2OD[]<=[1Y:P->7A#%-S
M!K[3+(BGC .?F9E^2EG6RM8TOHJ)0U,BL":G(F?H:2'S 29V-VHP6:W=;NPL
M-EEM;<X3_S=6Y!R5Y#=FH9<^ZV:=3Q.W FQ]$6$I_[4,07MMFJ(.V++L817#
MFB*B7N/_+&*L EE%;%DV6@@QL^9HKG5\JX9XL@9!?1"A0UWM.H2Z6LU'3?U8
M[V 8YBNL?JH=6NHG]Q[%3E8P6L&XHGC%_*T5C+5#2_T$HY5[*R+WK%C#YN0!
M-EE8P58[Q-1'L*T3@*W JCO:?K2RJG8XJ5'T="8OB8#JVK!)30_V7&.-4J/R
MO[7A@C<G6+\?YRF.>EO:F9SSIHNOLY*H!P[63B+5 .8+!!\M8]3J#.['X^D5
MJY>:8LZJE1K@P*H5JU8LDJQ:>3V86W.ULIR#M1\4SWH&Z-?F= &<QTW=UGDJ
MI\3H$07%U,C:'33U0FJ_-EBI[S%M:W7T1EU/6%OOLVK>[!VX!\U6[7"S;MSQ
MZ$"O50M6+:PR&JQ:J"-6WNQNN<WM_=KA9MVXPZH%JQ;6DO"M6J@C5MZT=MW]
MG:6=;6FYPZH%JQ;6F?!KB@:K&S8^M/=JAY9UXXZJTXT?F/OYKK7,KPGV.O<C
M9]3[3G?LO)&)H+=X%HZ<]/ST3-"J%8#4!D?KG:2V:+!*_'X'S]W>WZT=:M:-
M0VI8]F]5@R7\M46#50W@WVV[K;UV[5!C.:0>:+#ZP5+_VJ+!Z@=P'=H[[N[.
MHTL&+(M8WV%%(5Y3H;1NA%]3-%C=L/%AL]6T0:5E(^$9LD.V,^@YLT/Z5'G;
M';2J6L.FKE\W&JSRWOBP=>#N/'[ NN60U\TA5C]8ZE]?-%C]L/%A;]MM;STZ
M,60YY'5SB-4/EOK7%PU6/VQ\>+.U[>ZUK()8-AYLTY 52FM)^#5%@]4-&Q\V
MMVW7T+)Q4)47^BECW9##MWYP^["-E_;YH['VW5%6XL6%G[H[ZZFTWR #@O$J
M830/G&7X/0!:9WJD6T<G;9S)_<P<](C[:;5'54Q<M<7E$(1H (#]#!*UH1'K
M\\UNPMG-)NO!?MZQ\(Z-TPWGIV? XV.Q]J1-_HPG'*AU+W$=Y9F!/_^$RZK-
MXDHC#&F5-5N@F3BMU<+J!BBXP,D&W!ESEC@\P@ST)^[Q89<G0B1OM=RZK5F<
MZUNK)=4-1$'D@5"NH>3XH;7;.'#@56$01S5;6]U@Q5+'BX=X I?O9/$L-G5J
MR:%XP&RMEE0W$(V2 &P@>%/-UE4W. $3,"?A:1YF3MRKV>*<N&8+*AME"8B(
M8)2E\$?(,I(B-5LO'BD6LFZ,JZZ?/F!)@B?*#L$KJ9T=^28?]1+XS1FQ,2W0
M1:W*TPQN@K]9Y"/7@+KP!O3!Y[<\C$=X*?P0#+MYDHJ=O:W;UFJV'I^3+56S
M57&_9@NJ&]I^:-76T'0GO><XSYQ>&-^9DMJXAG\;\2BMGR^+<B5CW^JWL)JM
M1WIC-5N5E2#W2I!V8Z^V(J1F"T)94+,EU3$PB9*^9DN:5CS9@"<."*UXR!TK
MNU93=K4;[9J*KH9:ST.2?90<JT^V[T2/[9N3[9O(<=4YM3=U0E757$)GH60!
M1N<=Z3/!!3^T=PHEZBP6TC0?UCIP'1TK<\K1(+I?O0I7':EM!)&0:N B#^FJ
M(<OR),C&>)?/NYEX1<H]_!;W1AN')?5R4&3P;8*.LC3!XRC%^WYH[S6:>BMQ
MKY?"Z[KCJ56,<G"ZX6^Z:93@0[*QZ_#_Y('POU%7!E'&HG[0#<5EX*ULJ4<W
M5IDSCG7SXOV<L0KYX(4[-!_''5O;WX\[9#A04J7'N2\9),X3HDY@CR!-<]B:
M),JMW4:K@N!5=BDE:E>/HL??PD+%,T?(-^"Z\L0+4DWDV\],Y.;AB@^EDL>2
MQ"&2PRF+F @-KC!QGP'BX^[?'(F82&2(NT*Z1I*0,>04_D:">(.?7?$M4LLM
M"T7<$<49;/&&4W&04PC5MT!.2,@IZ_%^SA+?.>5)GO[7O_;;K;WW#NL&(=(<
M7.'!^H(HYX*$^S%%1F*@PR024888Z"8*A@ E(FLO3HF./39" 8>_2_Z$!8.D
MCP0[I@/@I0'0!D]2>DZ71[P79.)78>>F&;M1US1665*= ;B<.Z[X$. H,(=P
MT@++K<(L $DJ?"%X1A@Y3N 1"KR$%2%GQH =%KH**P U?%>*KH* O+@8B"".
M?+P<_IL"7H0>;3C$/'CS)!VA5 ES'T76*$X11T)-XK(H3NT,>.@[=T$V4-N!
ME0416"E9+G0T_08V;IP$@"+X56M]'WP;A -H6Z#( 5R3#1(.9@& <@!H/ZTB
M7[TB$,I#%&/PQ!$#;>Z6+@*)*;1"RF]AFW!-W@65"W<EHUB9#P0N(-P_&I<-
MYPJE9PZP$0N>7F8?+LAX,KU2AV5"K,L+02!G(4FA>9!%_!+PX.XNBV[$<N8!
M$>2['V2.B#^F#A#;&%FRR[,[SB.G0P_H=#JN<S<(0EY"DZ F9P"$#3HI(:_R
ME@\"#TT=>GJ W!)X\.;R>QZF$VK&?7E2\% %?P%5A_%8\!?S!@'0"K%B$>75
M@IC4:B]/4#PI60S2K9^PX4,E5+WT)G(,8KWC>7$>T:;/8V 59",DJ",@0^"%
MU388D1!8L<&1WF""3 S_]/(0^,+GJ9<$7>%M?8V!G=L4>X&[#X$-\1QQXIQC
MS:67&7PQ-$6E[_ PY7= )L1Q*!@Z493#M1<@0Q/0D)%S#.MR6LW-WQM.)W7\
M(/7".#7?ZM)](/+![B1A9>@+>%)JOA6%.0( 915Q<A_T*8@\M#T]CX]PP>;>
M@7R]8(1\GZ \ HX0%@8]D)0ZZ%Z':[0C$3"0I\.1E)I=RHSD(![ALEM:!<A$
M\*!Z/> 56CD;XNOP#;AEL3/\OG(+] */C.R()%H$, "F E\%P29L9[3"<Y"6
M?@!O 0,AZ$=!#P@WRF"?TJ,$&!;K;CA_<9"-(3$UK8\6$(?@@^)+$.IYFI*)
M[_OP$K*' =-#-&,\Q1855$/R%3.X"9<O%=LG6H)[@R%NF@E@$A[A8\+&\#3
M(KZB  ,JY( 0+)/#M%6\K/!RQ2^$*@-3TF!+Q3L1+($'-X,:S+7Q2(H'X!KR
M;\[?N=\7\([1I 1-%@AEG#W<QGJ !'NDO_L WKY &@0K]0*L&R * N8*BZK+
M@K()9X(M \VMQ$ML- K'2@U5"39II^-WB81/4L"GX:! +)5YE.HJ@"S&P#N*
ME!0=IQY0)1(G['MLOA:8&>U*G\01MFK0$]5=^D=<-6P,#3KX3:V+F!=]C03\
M=F7JY"D@"@C3E6(5WP(RE9P#$&U@38+5EVB/VEB\6CN;O3^TAGUP.:)",%5N
M!EZBWEFVRY)<@(E_\P;X4/V8E TK%V, 4C@X_1Q4":"HX5SF($HD&]+E(#Z8
M%*,!HHM$H$8=\7<*I$#[*%9-Y21"D>1)F0 F +3:_M1\NLW&(Y3:X5B["<P!
MDL-$O5+D093Q,.1"MZA (($OG<5Y1+<"R3X'/*'7:] CB7@@1I2_+-'O"TBS
M W( F2+Z0E?#^W"7B'RP+L.@+Z6\(D0347]Q[:F5WD98YPF^=*SI7;(5> RA
M\LCU4N2S@7 BX7L*\P*<\U0:%_,7!XY4#DKB"(SD"?#W./I)&*N- B!*!\%#
M\84"\,K->L#[6)C&Z. $J,>)0TH>:VHR">A[DH0]DTTH#F'>@E(C]E0V;<9[
M5]G7Z3@W?*S-'XUR(7(52) !*O2!T!MC)312$9T'>HO]"KBJ!\2W2([!D )$
M,S&9<&F" .C!IZ>'2D&G6!0S&Z,\V^QB^!6#(9G^Y.B0D$ C6F0"D;@8L41)
M(8;%FB"-9SR2D1 9_<2*'2]3J0,!'W@7951I6S,J\XQP<F'X&1(]1Z!E# 3+
M&!Q^4@B*G4V#=!;-5FCGJXD[!PR,.;"*M=T& FY"\P#\ P0LA8DB:7(OY+@T
MT!T!X#!$DBOT+SQD9"A^DY-53MJ 2C7NE9@YB;QQQN=H8[GU?_"A:35UH2.3
MIMJ>AA7@"W5T7W@\ZJ4C<!\BTIL@<?S<PUP!6-F^0$):) WDXY2QX0I*E+%Y
MY)9(QOHEC#5S,3+1?V/@UB5C1V40[LA!(5P5R80)_.(FY^0D')V. (D+O)O$
MW^B-@.\?VHT=%:=WT?*05A$MC#PO6A0\'&1*I$T3AZ1'* )]KZSU<>]%6A]K
MY=Q,UP<L8Q676>S=;'XD@CX$80["@$D_:U[5P,))]MJT5U\A,XG"3I&KH(T+
M3>29&Z=4A0R(].'1TJ[@0PHH"CE3&*/*:L20M-!J0J#0G9L4-^ZQ(,%^^ER:
M9QA6D"\@?2"N=2:O12/3U''XU%Q(+[Q JLG8YZ&IO#!V'D?AF!+L2MU,79^3
MY0BJ6-VJ@A"%8M*!CX3W0AET0"$D@T.FPBW\.!&'2>XP]R0N03D9I#>;/0RJ
MHX$.^H<"T*"/;F,47J$L$T"-1@DDF>+*!KQXALIK@CD,4CA %/4*E) Y+3^)
M&S^&S+MQ+KU!3 E_D1P=)0$ED0D(B%,):( "48-&NRG&-V>(<;%(YOR:A^'F
M7SBHH/HUE++%!>/#<*44P!^ ^Q G(@R%68P^UYXY\ Z9=3/AC7XB8ML(W.&M
M\ K\#]H27?)Z<X0R6%"5OL\0-"->5T!-)Y=0O8$YADZ'8>&4':29)#[+SEZ%
MJIRK07G'0)^WA1E6,!$F@F9)CQ>UYUP*;TS%E%M;8*CZTH$$ZW7 F2]M4 PE
MMIOO*VK13-4BU8!S)@CX3[53J0/H(:WW,Z,+JX);)B(#XJG<WY2<-UM63ZJ!
MA<R[.\#1#ZU68V]',7M!.5+F3E&4%,N:&;4H !KR^8@3! G[+"KL^?MLVL6$
MIVG<%GW,^( 7!A1('"SYWMI&&04TP9)P/+6IUH^3)KH_4V_(G>C;O]<>6HW]
M;5)!ZM:6V][9=[>V6Y4:9=;#A$:Y,QR*LFA1ULLB=D:$-0' &;CYS1#,$[P+
M+ KA>@VX4/@I:BTL/0 G4(HE'79%'0X"I\@X:2.DR)I3(F20Q'D??'0,(*DB
M1I\TS]D$1(MGX75B+3U$GU"-JYNG^$P%-(<BQ/+40%.%Q;R\@"PO:3U*22Q6
M1:03D#GY]O(Y(@<O;1J=K@>JSV7)&F7RTQPS7H',65*%*%71B"I1(!\MV8Q4
MFLB68DQ 9$;NC_AH>3E!V:4LGIG,Q+0O59\(>U-M209 NPHR8)C%<"^NCR(N
MQ!FR-DCN56^U*%J@:K ;E?@I U-97DS'D&9O$*,D( V'S..YR'/*4 DY+D&$
MV6L"XHPPU^K6.UQPC'24JAV2.(IQ<P*!*QP"QC@>,Q/;B&;0(RH_E-#>L2[
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MN+.Y1%&X,/\^C=DWR<TS[[@<X.C_\]!SWA3AR.(L,CIMLE!G5PQ8:5+/:X)
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M:)T0]04JD3<QM 7+:^9R89G)L ZE&U.R35;HN\5W8#IF"%;'(,R)6GUY)8\
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M?W[/QM&7VW#F!T]8_S\S.WR X\/Q\W#\%AS_=<<_'USUA]=7@^MG")!LV]G
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MPQQS"P4,%# 0RJ. @3">%* H;QO DWD! Q4,P I@!;"2J8RZW94M?# :  H
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M]2=3QWO@G VFCTQ=88;@<,'I%K?0%X.^&.2'M\\/UPY."IT<1L&)!J(H;QL
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M&DIK**T!3[*14;U>/]!K[4:WV)<< U8 *R1L [ 2R4CLDW,JUQ=4(  4  H
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MY"(V\*?S3T+3#YI^D/W>6D8XK8QR&LII !1T_0!5@"KT; .HLCBMC FL !0
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MU^L'>JW=Z-8 8X QP-B^)0882R4\36QD &  , #8OB4& $L)8(=:]U!K L0
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M2S[U_)!Y-^Q4_'3*HY6R2WYK!\(AN,4N9B/'-EG/-$5P$ KUL1/;G_SC4'Z
MH%#C^4?M43;L\9G6B7=B*ZE5NYT51O+"))(VLU8DDB)[,]\05#OBR7Z.[9 ?
M2#^2$OGI&]/5>U=?2G+'6_ZL=7ARH*^3/5#/W9=A_OIK[TS ?/]Z^'N_?S7<
MP-F//#?JQC)"X=A?#<=P3<Z&8\[#  X-A\[%H>O[<NBU-$G FY]"M>O!1?^R
M=W4J?GM]-/AV<9G6M8>A^&<BUAQ(8A],>?P' 3-<BQUYDZG/Q]P-[#O.SKP
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M5(4[1?(*HQ*7=N\NC(J@>HLVA_]R\<Y&,)9FV]$U_0N9Z@IF==(%&7 S'5V
MFTN@*G!S3O=]:;7$M>)[)N=W\AF/%X<M92^T)EBY$.:9P<U@A'L@Z-\\'H_*
MWC)Q@1)-R6H#Z 4MAI[0$)I+=N*5>\4C? S>F4N=00M#M])M9'=6 F67D@,
M^!'\"#V!'W?+CZ]<"+X&/V;1EE#7*EH=_$C.AJBT):A[GF$PY;(SR+UE_'[*
MW8 'G^DE;1&NX'"5NFI QR5=W<!%2*@!! 'K5U<-( BZNE'>15"<W;D2+GG
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M[F)S04,#ZQ>(U.87@HH"U=!1Q"/5Z!2H1JNG&I:N-A?)ID 0C\)XELI- '@
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MC7J]4^]IM4JSTP+34K-,HL /N@7=$M 3Z+:0:MN<;A,CP#:BV^V(L2YG;-=
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MV(GBY:.E</F2_V=F!T+\0^[?V2:/=\.7W/1NW>A=HHWQ_OJ(,;FC4+9,%&;
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M;NL(!K,P" U7ZBO7QKR70=CI^<E;P=>O@AI:-;W2;687=F7#%LFP:R57 '+
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M-?OC_J0YGMK])G!LV^R9YG0\LR_5<=%M&=_B^5S>DC/';*3G;*B#WNP9FA3
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M9T/Q ;#/9D[CG2;G\"FX$?)V:*FC*]^!J$H'4L8HS4R1 LWB+>(H62W?*D9
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M+X3%;^3O>J:<EV6NYHBO9R4Y3UJ5 90$(=:.B!L41\0)17#CV1E+_E?!/V)
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MG,]N O6]NY/A;Q;XMAD^(*^.NYWN&VT"(UJ6)VK#F>?5+ 3(^M"" /D*2$6
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MZ*KA"5@)6#6@$P'K19)M=V#=NO_9C67%\]C%;$'TLEK^O8=^UO^"BRK0"P-
M9X)>&GZJ/5OJJO4); EL-: 3@>U%DFU7L.VWM[[%;@9;#/@1V!+87I;6)[ E
ML-6 3@2V%TFVW<%VZYLMAJ-Y-)I\QX2PES23O+XA\N^M;RTC"I@9@@R?+_>-
MC!W-CKWVBD@+,@B#ANR5W3SQG5.$N+]_NQ-:,_.\2DR50:/=KZYO)FF(Z]80
MA(_$_?4E ^'C/OBX]?2(XT:J]T#0#$P20NK&B)KJ"$)(XO[ZDH$0<A^/]]8W
MR..&EP^\8QXOQ$Q:X[JU!F$F<7]]R4"8N0]F;GVKK"1*?%3W:W5S"4E5:!8I
MIF+J@R+%]_XC"SP42-G].--=5[]L"K)B*(FEMF0@*V8?WWCW-+'CWQ(]>NL'
M"]GL.;SQ[!O4JO#X:JV:2:,ST&=8$VD.O34'X29Q?WW)0+BY#VYN/;WXV#'E
MXR K56MIS[.:JA,"4^+^^I*!P'0?5_K6E]!CAY\)3$F=:$4& E/B_MJ2@<!T
M'S#=^F9:45R:7+ND0O2I;-9CT*8V9%$BR8R%N6"!87HV_#$Z^]"/\XYITX8\
MFB:$/3/>H);=7S0EU63K(2%D1^WFX>\=-3(^#^(P4<Y?43=_1K4,9M,[OZ(F
M,-U18S(::Y/:I^7D%&WX4Y^)3X3*FJIZ0N6+(16A\K%0>7SFN/MAN)T!9\+E
MB^!0PF6B!>'RM9"*<'D[\KW</>RP]77Y2#%\ N9Z:9A7A,DZD$%314^8?#&D
M(DP^5B; UG?EPS(!R)5-R*QCZ?JF5 #;CZ<N,[JM"I&ZTVN-]*;,G1^9[KE2
M93;83<>@QL4)B2YI2\^.$]E$O%H:5A<[&*822I+1E0M0]"M(&SC(5AIV&[WN
M2)L,R76VTEJ=7RO5<5X8($C6AQ8$R03)!,E'@>3)27(&G@\M5#?EA$#Y>H&
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MY$R<PLPZKCB+S??V#ZAG;NS4-OTRV$B_;A2$GKJI9$+/BR$5H>>QT+,PC.T
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M7V8&QJ^P+-MXSRPVGP*L]#J-,PO4:8)#>E!@^\A0O?%%0T(1U.A#B 1JNCI
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M$/+_U9<,9(;L8X84^K6MFB$?I>[+^OR/=N]NM,=M\OCKQE6Z2CSA'7%_?<E
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M+0F;SX7-_;5#R';&YJO)>"!L)C?'%9"%3*9ZTH),ICK0DDRFJR PV1K:TX9
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M3B!P*9N7&,;3D/T[!AQS43%;_KV'ZI9_>,H\-G/@XT]^[-JHC>%@; >UN.W
M9_$K<&;((/P0X?>6N7"PW"W"HC>V%\MN:A+!PG<Q  <+0U#^4\?C^RVR-/[#
M@F.T[_S;='&W8FV[JNANSJQL%=-$%1^WT*I8;T4,\U;$4"\KXEEN4VAKPV4)
ML?G!Y(;%LD1$F&"P[ZUO+6/&T"IQ#?@98#KBTN7/&>>O11R B8+,_L^<*99R
M0Z\X-?A;/(=37'Z9I;W1X)6W&:$,[V#?[X #?NRFF!F0>8'7MB"6".AX,;-O
MHG0Q?UI>]&?GQ=N[S($\F/9S:D*<Q_LX H$KV;\X8)/K6ZX0V%\+!VPB-)Y,
M_"[R=6B\Y,CGQR&:7*]>K]JOW*:%7\F%"U60/4FU>&!1:54+M2?N);^\:,.F
MF>OBS0-VD?PL[S3\YQQC___LO>F2V\C1+GPK"!W[?#,1)(?[(MF*:&T^\IF1
M%%*/_?F7 P2*37C0 (VEI7ZO_F16%4" (-D$EV8"R#\S:BX@4$]6/EFYOC3C
MR'^E3S5PHG#-52A>)O]X9:B3SZ2KFV(6HHO7B_-/NYWA@7T*=I[H+=BT(CC'
MD3Z[E^>^:^\\G4T/40K':H#W2N;^!<1Z[7RGR37SG6B@L=7_"7>"1M!?7P E
M77\3]<:="6^B0@P_/1.#N;)I$-3XR9&$E=!FJ?CJ"4#/X4RC 0"5K)Y#27>G
MZ[V^L9!=5NYH.,WU I94+.VW=V QR_WT01N2>RQ:;2"#VOD"E_?MFQ].^&^\
M'KR"K Z&[O W:=YO,7Y?X[M;+4I2_:6D:5!? :':UNN 7<M!S>M"-,H98\?#
MQ#'+K#-J5(A9[O8ZG$\U'UW&W!^T>OVB\YV>M'+G=EJSU+1M5E\$=IM>L^<Q
MO49[3:_1N4RO"TZW8=.+9UPT%@9E7K'U5,YZ*F107,IZ&IW#>NKUNBWX33)M
M8%@I5,RU55\$=II/H^[SF$_CO>;3F#U7Y+8HC65OO*:D 0.;3\>83X7<ETN9
M3^-SF$^S46LT/M^X7-8)Q*RG\\1D#TB]:4:%VVZ3JO<\)M5DKTDUH>*1(I$4
M1$9JJ/I'>$939: :'9RVQ?9:.7NM4$AR*7MM<@Y[;3!I#?O%>J.KIVQQSR;"
M+K!]1EP#VQ3(V4[7;M&TQ3)J(!1471_<-*))^57<-^+\9E6AAO4HL^JTQ*KQ
MN%6BH\1SJ7YN*D&RJ42V J^R;24.+@C%^L?RF[I0Y?N[MZX^AI/.&UU[7')'
M?_ST(;>EVZ&P<%M_AVT2"B^[ISV_6,D;>SM*H ^IQSYM00H#?G<L2#H6YXOP
M3!=;Y=QX]D<L)A)A=&-902SLYUTT4_VHX>B;P%K?57)S1B!<K,3&0G%0@")8
MF8_W(-YR-=>UL+H2OORR%4;[';-L[W_ _89/->_8V<?AU/63A;^AJJB>"^%E
MZ_!UMPOL[X+VAEQ*64B=+J*N.X8/J$89B1C*+BKIE=;HX#IOA<?T<@@5 ();
MR10O"[5F3Q2];^@X6D7OV=5:.*Y\Q/3Y A'%@1<F .2*V7$)?S/#T+26<2@B
MP.$_<>"$MB,1#;%H^[N U3?3KV<* Q5*B&$<R98EKG/O1 I!62>./1K"4$(P
M?Y3?EG(*B!E?Q8/P8F%\$\&#8PGCIX]?O_W<VG(_LM=#'"W]0';3PJ87ENN'
M +3LH 'OJ@X:J\#!OWWLE#$YXLZR!8_'_.8H+[/P%>PM8,5!H#I22($$60.!
M4,T>TB7Y^@WU#'[)QUO80&"AWTM_M;.=G7=%8?K3@F+Y%1Y=B+7MB2U"+M5J
M '[^WS:6ZX]&@[YICJ;M;K_?;0_'DV%[/NV-VH/NK&MU1=^R>Y,2AIQLJ;)M
M V;+%\ONR&.WWZQCI*MIJ.4T=FB31'<4'V[;PQ +Z(T+G6:WB=([D(G 6:%4
M[N^Y,TUZ[DQ5L.XW$<3PF)U_= Q7+2*V;+'\ #MKP3Y>"M/^;VP&H$)"O9]
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M;.\:QB9ZV'SMLLK^GN0L&7?1'+9:!?X/N=O@_O8$PN(H"/][GPV"C?/MPVX
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MXA(8?X\]@?<Q S+"T3D)L%\^PP\\^'_(*XJBZ.!WI<T&RQH(D&*EZV^"J&/
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M][BJT,USH^V9G+-JMK6?Q9N4>F_2Y=OOI?J*QWWI48(_?E.]0<MYH;X)-".
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MP!7W^_;\4.VYED:..HVJ?AO[N[,\6^HNJ(>W2\<S-PX4CJR(5E,$UXE-R4$
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MT<H,8 WK';S_X =P,<\0/ZREZ=T=W0CY/,A(R^@9<*FUP73)W*)]V/ ,;"I
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M[P8*,# O'L.+O6OP8JE \SI3:W2^(#(K@WHK Z9&&C"PM^3Z(+!3M3PM]J]
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MK9(Y</[<C.%@PJ9 )42;C0&&@HT!-@;8&+B<,3"KE#%0)FOCL)$]K>ZTR^9
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M^4%XL3 "8?EW'OR,;41+,S*^FZ'A>)8;V_"*XQFV6(@@@'\'^@OPF6@IC+F
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MP'5@ZXK<.: P($9RDMP".8,F@!]1VNG-X_HCFK1N<'O(__P#'A<D7QJ_X1>
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MNIA$#\Q087>4XRA_8SM<OLA)(BBX-RA;FA_:_4$IW\9IMY_U>\%/+H/D-U?
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M\HE.<Y7OUD+;W5#':*%W4HZDP!WIXOT*SP>W!\!)+?(['+=">/CSZNK7TBR
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MW5?99RV(Z_=;O?ZA2'_C3.K%PW?2#;A6\9PT\B<UA;=#=84;>K3%2?(,'UU
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M;5]QW"OG/*J.A/4(V0-"6ON,MCQ,F"CGTBLQT;N*EW05Z6(%XC\K(/;0]7A
M_U?J&<>$;7U&&YXFH#0^*YI?["0M([7I),;ML;/SP=)T7B@\KX-*2Q8F9#0X
MBIJ;4,H'57L4['!2-=O,\MRUQR --E["09P;[KGQL46/^1=$N.RL7B./LM\V
M3#@RG)+-;XVE<L!?\MC14HB",EE0)(S"H_<Z+X>WN&MO/!X?UP-@*)5VP5E3
MW@9\G>DRQ\WPE0!G"=L2L1!O(L#E#W+WP-H!6%-B><RB#HTWXT4P\4BX(Y:M
M/ER$',(W]%+R*0X(K)N72R*_$9TK:(BV_3=H@J#N#KT<!/,B ?84H5 JE>K5
MH/UH;9^(5BKM<;EWAW=%EH1S8@N**/B]I7@A[ ;[2+LXNR9\32@KYY:;.KJD
M=0F=9!-"D>!-#Z6=H+3%<K]971,DZJ\?[!?W+^PYA!//7D02P>HEYGPC>OD+
MYK8O INK,+ >TXJ3D*\]PQIN_ZV8(*1[4[_*JT >0'EC"L+SG# RDI+BJ'-5
M(E&/NIW?B&OM:-K4-R&EG&<NO3W7.YP7,[U^K0Y%EYY?N^VP%2,3&,H)9@T8
MJE?V0(&@O1X9NR,CS0?')SLIG,3/$XT7#EU%&90V4-F.LPD[Y9RS#CM*MCEK
M'?XJ$"-%@AY-WPA-IR\'IU,CGLJ9ZOWCZ;0'U,Z ^A>AJT?8KGH2!"LR)2X6
M$L=T<\)=.(D%?.#M'LAP;.>KMF_&!+1R*ML M$04%,N"4F%BK$EQ9)HG$4BF
M=GI'MI?KK=N_9-F.A0$O[\NIZ<IKL?O0>8](R%\1T1H%+:J;$&"\OJ(W^TN9
M/;?.P6PS@]=&Y2_A?M77ZVXHP\RBV$F_R^@/@X#311C /0=S3[T=>,BI+^K#
M7E6NN2$71*NH=G-L?7L930 N)YU+ "ZL\H3PD6?SD:I-_HW&5)_L8YB"7-$(
M!5[N5F84*X5 J[P,2-6K'S=['S>5&+K&G!%[Q":$4\^>>Q?D@CJ."+S@BQ_B
M!QP0&K%[\AQ$%#N,B[W+8,)].;/> O<U\(SDA1>:(GD YQ<$14+''S>)Q08B
M$#RA[)&]EZN.6H<#K9F8L%5.N5?<BM0'!R\+A>S*"[C7Z$(LR&P8R43,.B!Q
M?#XD>5\?'(DZB64S5YK$@,F721Z</(JZ]$E>P-0675];+A-@RYG_2L"J5W:
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M4W))M;7EL^UMJE7.;<N7I)1[%<DKN?A-/$U,6)Z6L[AI.\1K0/L:#\Y5HU]
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M=2.>7ZU_60<]MY.;$H$>8Y<V=1QM1]I:"K/0>K[U]8@0MH.+\S&Q"&+9!7>
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MMKK*2JYGE7[QN3%.:>^F*@I5V#<O:\D=6PU(\]W/&#.:3K 3$,>-301Y02<
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MVT[T*IAA1\PK+0^SWA[=Y ,0*@]=!:%6LE *EPS<.00R*)6!J(53[D:71JL
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MA#UOBB;4E:16 UFU?@8-3:C6)68E7(*LT2EY^DMA6+%B\JG+PB!UT#<,7+0
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MF*X )G;YYGFY=FG+N3---_L4.[\RY&6),ZT05)_>?&=JM3:0[ZKFE-M_R3=
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M[%B '+2ZS>=-H6P'D[=QZC:'-T6J'1S>QJG;'$ZE8E+YQ0X6[R"EZ85067,
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M%O!G %U'3L1CM/(\?Y(E9>G)DNYLCNC&K_;,%>Z**"NN:A<[SGYONM+?&_
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MO7YR%E3.74,NZ<%=/;V:^?LA+\IKE[KWU]GC/D1$?;K% -.<%=W=TJ/E>5+
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MDSA"JW3S/DH/VRBFH.DC;1A8]M17?N6J)=/PO9T&AI>7KP(?Q$(!=I1I)ZL
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MB5ALG)#ER#;1FN6/BK)H9#$LVL,P_>7=EV#+X<((5%6BL*;5 B=%Q%5YKD>
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M""?GB-3<62!^2/,]C)-M C5.$8T(,+1WG\!/VK5':<!*U@G2Y*AI;2#!Z,^
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MD6;+U9!T[]=QOF%G0NB5S%&YZ1U29"GQ>!1<XQ8-G[-FB+5O$:6(]!+1$C.
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M4SC92818^7U4@/\G2@]1]@K>O0'4@&$L]Y4XPSHV#)F?*FY$S2E% B448%B
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M 6\&[V3!0&%PE+HN!=[3;:A?YXW#16*,Y29!;?@IS+HJT\/3Y=4]\A'%-',
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M<_CF7^U_BUFD\_4\Y+IH^^8:>Y9G8\M]\[B;Z?][<^/9[][,7/?- _LL>/.
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M9C[4-LH>TB@2,X@,3=<54RE$0.%QI,R,'6^/5)GIPE$S,Y$-AEJ9(<H1&JL
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ME!^[(R%J*8H 1/45-9(1,X,K."-26488>R-EQ 5QZ2*20LB\L 53]G'_LJ'
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M30^?IQ Y/?.B6BQ"K'$ZBV=@6N\W'#Y?1$%(J#QLL5VAE+7&V;:85S4-/:&
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M*PABA<Y.L*1B53/8U$RWXV:Z"M=J+&%VXAV*)0[V6.+NU( HIB#&$H8GCJF
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MA$MCLYO6C-^;QQ+T*G@R"/!XCR<00UQTBF"8%_UC<>) U"IIM@3&XMV1@4W
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M%5_,]"YT$RE(Y$(B.=AF7GSDC%M0/"S/*C53[^D5YFHCK+.U.35[>W<2#T^
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M*]5//=/'O49#3,=4S_1QKY&Y6LB8E=$8G@=ERBA-SR7S,+ N8>NX<=Y7?\,
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M?W,?Z#HGN=L>/+>V@D /O+.T%0F!54VDISG(2*E2$I(68*8EB4<5YRTUY+T
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M/[GV<ZU9_VOR&F/T#=O\K?*M4FFNP4-X5)2U(K.EEE;% K7H,53&%&)E%H7
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MO>P;,\XO.$J5HX5&R=?.A9.:MNH+QP0)1<OEE>>1R4O_%<("")")*Y'A3?Q
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MY8<B,43O,P&YATF!+AKCV#B!?_MPO!'3'"/H*/,:;DZF'42C :U*MH<PGXY
MO6*?1K:.E17\$"9Y+$@2$WA8(T4T1:P"T>MGF4Y)3I])P1WI@1B6!-NHG 0K
M&.^5!"="]",8)B$N%"9289A9DJ1 ?5CT N K<;8Q2G5N"Z$;@EF7I"HN$,>,
M 5EY)5@=#U3LPD"R1H(P8<TLI)N%Z1>L8[]DL>FZPK0J3.M6\"]NGSGX&INO
M5A@P'I*Z^5CF"-,VOOIL96)V<JR$CD6&5$1R*-&V- N4DU;B;,GRI/QD^9AE
MXH^(601NY8Q;.J^11-KFXOJ4_"=HG9NX*Q(E,+IB8),5EV,UT^<1Z!A41CQ8
M.)(X7E1.6(HQX3I!:X8R*Y%4$'-=Q--<JG1JI 8E^ED=C>)84*-1/VI]GA\+
M2IZGZN4&2&VM65G#@:I6&'@?W^7 M!,1[WPYV#D@[^B@IF"N;[D5K ^#MZ((
M+II*,*'.N3]Z"I_!^9VR\24E<M!FYC)P[B=S;SI98<HWCF2IF&$W1>-F</Y=
M.EEML31F!N9;G\Z>1_:/@=^L#__\W]_+U;/N^/#LY.-L['6[?73RZ:)SVOW7
M9>W1^],9=]O^4]\X;%Y^KL\N6H,PWY//G^;?]JKU4ASTGX,DA]S' 0I^Y%DL
M0)*>B_@4]'IL]TM3M &4]TO3G\9[5Q?&>ZL5':WH=KO1.O]78D5_O6K6GML7
M-S?MK[=GZZ@952L.DC%>9NB]6JG&MJSP"J<10S@XKL(@A(4[\_%:CP5/Z.,@
M.F#=(X>P*!>JRT*?Z PUJ8A,7[O2QUJU6=*JY6JY%(=U1>C,@P-(&YYK#B/O
M[@)/X45;&)*VN_#GL@]02RJU27;//Y\]UYKUOYZ]'S-*MN%EI]=W9XVG8!V+
MK#A8RV5IQ!8<X$1IL?4VU5XNXCDKM]@91W5,2[#* UXD.0KC(]: Z'-"7M)L
MQ"C4(L(?(D&81Q'D/DR^\+BT,;GO\?J8BZ@WCFD\2IJHBU1*>43VL'%P8G2B
M6)D;DWO!*Z.;L"JE@Y>AKY4R?"E T8LNX,Z04MP,N(A7%TOC&[@?A>))JP^(
MR[4E$KC[HMZ>PXE<DD5'. E1-IY\<>.$ZG.;BTE!5+I+3KU@\I15167Q!!IQ
M.J_3.$>L2Z/0\T,Q&1/,87*[*/&Q$T_D3!\X)VFB#TZCFRY<FO%B'"'J.2_]
M^;*64ECXU?1S<1#'CRO0YF9Q*8S0DC%""L4*^@,XJB \2Q?!58Z.B^-\7 D(
M;8=H48SM(?.0@=FK2?HX'KB6,1[+Z6/$'CV^>L^G2&:2O(BHH(2:2FH?^3JQ
M,KI@ [M6$.&MZ)J)EN_*%88K*&Z5B)\*+1?1U&'3L)\R:N5H(TZHNK?%YM*K
M5E%1L,\)6,E28)9UFS"B'6^&7869V8\24VD;EA],+WQ(8QSBIW!K!M9U7#0%
M>@ZV H9F$532X^>F.64W,Z$V:X3(8C%86(:1:1'RK7P*;BI.32./8<6B"&S7
M)X@LAQI%F(DS^M*/QC4!I]#[?1T.;I,,9!&4=+W0QX7EYO58Q-,)E,N;-'-]
MD,29?N!<J(?8UA.U43E)_!R(VA;O,UF6;*O]^?#QR1G7JG[8_O&U_-RXO#BM
M_VZ=-;]DN*$O/D:NT?/+R_/[+O3K\<]U'-:+D@21D--W"466[U2TA>=PT:R?
M[5U#KQ+RHH"17Q3R8N>L;:_TSM #RT0BQ6UO'8FL%P7$=<JQDI'_:-6HX^+3
M\=.BCHM/M8HZKJ$66[72F%QO\L<Z_'@XZT>\L[6.)5<4:-?<\8'U. J#O% #
MS9VMB#>H?I")4U++)7.Y]&P:Q6HE8T'@;U7XK3SC-[QOBA(Q<=\Z<L[J12%^
M.[4>&57C]?*R7-X*'%G [):&RFY1V2TJN^67W,U>M;L4!:)YBBCE%:HVZMK7
M@[N4V]FD)Y62WO+_5]YC16%%U/ CCP4\"<4E]@E[K&RFE.V3=<*0MD]]';9/
M49"-W0B[=ZJO\;3 MZJ !]C09X8QL =/'PVBVN<1R%%Q)V6**8IB<QVB6!3\
M7]>V1!T(0:\PPAA6V[&&")&ENN#P/:8'WO*H+!E*&/(5U\@T$>;Q2.I=2$0(
MWE*L$3_!/UM?D!Y7K8M93HY:UKFVC]1 W^I'\'/6D5AZ'6KK8/>O%P6T!8MJ
M)5Z?3%%?X?W3"_K<=<TD#2]G%,G+&GU!HJ8CB1F2I=;W*\VS>I:/5^R)]<8Z
MEF]1T&+=@Z\+$:]-YI@PK1LB,%IWM*\.T?J(E'+/$N@@0< B,S8L![?4<>FG
M Z)]UT8'A2QK-0H]S,+WI\W$D@:#(8 N/61.9D,.AY*(%[P=.HL'G\\@7Z8[
M5"OL]<?LH@!2NE\; A:X_'K!(J<@MB&1CA%-O%@=:7$J:><,F<)@E9QY2!A6
MTNY&NL5Q?1?0K/$V\\%G[8CU+#LM^G$M!^VB8$FZS\P(Z:#]!8G"ECN5S!U<
M(<28*#\)M:>ZL:6(/6ON-/!@P^03R'ZC)WR0%6D$L1OT@%)M4(<C'EY\(0[_
M$3Z5VH5I][T]@9REPK5]SQWRLN<(:,5_15JCXVHV,J? 9%O(?K(_Y 1L<3)3
M5/?<Y0.IV4A79U+"2K2/B"[@>$^7@E>+-&EL-><86T=K6**-HD!8NEA)F0-8
M*.4L)T>2*#Q>/J@>9/H558!\+;9.HRC CTA0DUF D:&<*;<O/W3I"CN<P#%Z
MJT:Q969RJDR9N!Y7+M<G^"X3M<K33FBD](0'B=RKY$UP'!#)6I2TR)^=(*^D
MW6E$BP6?K/]@<7H79;.*K!.1NY%@+H;KADG&&,R$[+GF.$YKT1_ TO,#(DVE
M*K4^L_DOM)4) NOHUQ'6GC42U6,\Z9RDM!13IB=$_1"]YGNI> A29&.A=CU=
M'S?*S%3K?+5U7A1@BL@[W&B>6#+W<87DSU2&=XG6(,]X1V/2MI.4RT2*%Z<7
M39$N"P,Q_A:S.D,_^1NF/I6T"<[T-,T?X_W9;I;Q5ZV>H@3>N\]@Q>$10CMC
M.0-V:74%T7]+$2U,]#T2T7NDJU!"NDU"6I2X_-EI>[40A/">WA&1HG:&<3\T
MO$\Q_[MM#BTG4<2&NY9\7F,3/W%:7-RV6>!NL8AE>&P:LU#=Z+%I3?Z62'(]
MZORK8PV'Z_#I%"7^3?6"5@#?@6D:8A@J.EQR'A.LG6%;0V$/EU)D"'2]]#^:
MEOX YTF+"ETPS(7EUP^9;8G1%,QJ$<6TX ,RP4K%FN")Z@41@Q'J=JKY+8[4
MA'OQE6]SJG3.8:5<KM>;ZTAC:!0E5GQF.0D0%)RD;.N1>7CN6LJP$ <W) N8
MJI:\WQOO3U50[NDDYK XD$4]\5;)GB$IIV1P./;=R "#9H:>I"DTW-#SF63G
M":+J)3#ILE!;FGF$\_9,5'>V=0?Y#^$9^"/5SPNSRC_SEB78L?HAMD=4!4*J
M]Z2C"@Z/EA<5+XD>AL:;X-Y*];_'>*=P8/0D^YC[:A,-'4FAS;19\CEEI+T<
MF2Q@<L@AK6Z5(*(21-:4(%*P+6^>\J!GS=CL:%\K"K+C#+:0)]3Y-R#%[C+&
MW$(H)+'?B;BUH?NBN&IGH#L/]+>@2B1B6]JVX%I>=0SO:!NTR7GQSYQ&:*KP
M0DG6FX-.\.B#8Y![DK]YFD47OYUN!=4:X]Q$\D[=0Y@S7K1(C_^]R$7_6.2B
M_U/N@;=S#Q0%V"*7Y_)&9D+DZ0&\NK'AP:X&O_D!&%&6CP&S5# Q8GA% A98
M':8H#.<D*&H'_'24L38)KS)[@2)!F8^UZ^@ZQZ7Z>91Z0(X)"PO5(1OJ)!O8
M%&S19'W+L?@Q3XQW-%!ITBX)7\QZ;$0R)F*#S$%C-%'NCX-N'(:4<8\6R"UI
MAT?=#E&'C&QY4DQ:!>F:Q%.&=!IU*?&9H/(,?!'W#!)*2 !SL*!SWX53;039
M@5<.7?Q%\NN-\!HLRV0Q/\E*3A;S5*UB^:<!#;=0%_K"MI[7_139;8P-A0]/
MKO<CH2RG9GU6MS4;^\"MJC%&K?#A6)(I-9@4_$5)',4'"MVA/FVQXLMP6AW.
M<5HUUD';<5@4F!'GX8^#E-J=;B\5GYK)JRO)+CG<@FJ5(J2;\'CT4EDZGI/<
MBJOA-,X/X<B1:06P"OI(4DE.6^[-LCSM+J+S1C+,*0IJ/&"#44*LWJBW0 F$
MPU&*+U>^#C0)?1;-$W79,^J?I]P'HJ K[1"\0'Q4)2X^"A&#M:@FGAR9>>]/
MZ5Q5TV=RU59GK]K#6<0C>%]]SGWK2, Z+ I6"[9Q@VE7^G>&9D4>61$KC8-*
MINY4EOS4TOARV?UV>7']>2K#,/IA'2[GPZ( E,[NNZN%!E&S@XJ780_RNNX3
M#)R;Z6PXLMTQ8WAGY>B#3U:<],H2U&_2;-4GG;^B;+BO4>5T'78_M.7I.0-T
M,>/3M ZVP=0][0^X-1U'67K*+_HRACE(9)30&WU.>4_Y)6@^8R,RFRT8K*?<
MU+COI1[!K69Z$,$.HX[\*X3+F%?BK/(XUO+X<=^5\\ -8ST(/*L7"E+IB6:G
M!SY"',;Y5X9N(X,_WMW3$9 9CH2%#>.*KF3](38U,IX;N($8' [_E]OR9$<2
M&0:)086MW0DBTW[V4&8[_7F#H;E2(O A,X2BQ/%KS.1! A^1X38&IF$]/U \
MD$X5,^5H[K'.<9.=$AD4!I94>F3<BD):*CC)4:T#2GS *O;. YAQ,)]*(<>9
M+-4F6!9'DU;'+>LWJO7*8;W27,L9HRC8-Q .[79)0H]8.WO" 8E/,5P?C@0Z
M%=LA/X 18@7E.(9'APT\-PL5@.K(?,3T.%D^0Q8N2U:P2<7/3D+S@0529<='
M>?9LX&/_/7^V80WCJL7&SE?I]P-:-30PTNWBBPZBIM)Q6:*WH<<<UK>HF!!W
M)V'('0\4H"(,YN]++GXQ-K[O&I8>'3QH?Z/]2X;UY6Y&C@S2)GZR4]-".J$S
MU#)/'"V:<QP)1U/H%QS;VF&YWFC5UW+L* JR\!SD\0=CH^4J]OR$TT;MH*%(
M<1>4^E/7^)][>!0(<652LI._36Y[B=^F&4#AR]I1N5:N'+76<E8I"HR1>$<N
M>;UH=#.MQ#RR]O2*\\N;%0(GY+B/TBK(U-^G?9D>H./V9W(LFAUW.'%DPE]&
M&/+7#18&B#'CJ1I3'%YGI^W(8I\U@+):#??\B] 'Y8%IU8K6.3@[N$WM9F@.
M:(UF2;CC0\>P;.V4\JPP%-0\>E=IONMV.SQY!*N-8E('KZ4#N[8ULD4/9C8(
M!N"=P.'-O";Q+!%J_>(]@-9+5!+J@@'N#JE^^/X7T*1Q$9]D[9I=(1!?NIU3
M,4M[/"3%@Q;1=,!K'K UB2D912WV*<H4>3QEX;$4B0>/<Y%%XB;:RDVP!ZS.
MYF"+$.B!Z%F+X(O"SRD^< LK]A3#\3BJE%.*44Y4LVRB^525R0UX=K8?4%DU
MM.4&O'D)I.^L,?_9>DWM("F[:8XKMUE9QTY0%$PPR6<JN2POF\'5*IL!P2'C
MS4#N _-ZF80UIS+TWA-=PX2N-5F@6S;7Z(3KO],Z"[RD-%O]^UH=?RWC_RHE
M[;",_ZN429$U83R)+2)2?O'>\"MB&(\4?E'A%[>"X'J>2JN6R[5WK?J[;H=F
M>1$MV U-3[?9\T(HOSKH%.-%S?;[QR_:_>V=UFH>:FW'8<]:M<2_.*R(+P[%
M%XVC^ IL,7W9:LDO%VD4-,G<TRXZ'[5_'6D/H878<8?Y'^AYNPOY[O8FHRGM
M>".XU)_(YJ,BT[*0;@0*(+P\K+FA/J9@ +>SN3<O?L8438^RJ5(VU1P>Z>94
M")Q\4;6CHWIU/<[HHB2FK('Q<_VFUNW->BVMZ?XM8&1)4A#MSQ!:&8P3QRT.
M(*2XU!/'YT0'\>BNZ"1ID1^;UZ*E,Z8/IS_TP.,Q%BOQBB,ZNJ@QXC9YU'^=
M:Z_[/+!Z5H"\QN3KUQ;*%YUF>.1F7RHR\"\Q+FWA8T>K8/?V7^T]K5JNU*.?
MH0O1+>>1(J7>_R[">W#)-0S$;300\H9X8T#M+Y^8G$7M1/<M0SNQ7)F0E_$R
MO@N@0G])(U.8N*0T\]MJYCFL9LUUL)H=%B5]XCQR#''F03"D<Q82J)0/Z@>9
M;F05$YA+K]F<Q9,,O[7FA,F:4V&RQ'USW$2M.8B_UAS$7VNJU!@ZZ\J59N6H
MO!;/4U%R)<Z33MJV9+1<P1"!C8/SBNEVB9=\B3_V&2PX_,,/B$V-TFX=0AIC
M0,#%#2SV%I<(<N_"ID<[FQ_V$(]"G"1$ON#V2Y*=81C:@27?DW)!RRLBDLZ2
M)' @,/!P:/GT1$R##VP..&+/"'_V>:5R/4$'\0AM9I(MM:1]!Q,*&U_2;/9@
M^;:X IN,#+Q>#!Q&E[_^G"8+I<X],5$U!U^%^<649T#H)^S)KFB]R1!BQ0>E
M%WI,#XFJ;=9PI#WN'EA 9(O1S_R3K2&'W-ZOOG:W6"N_1FL=%25AX6/G]'8A
M)J#I(&5 .0(#IC_"PAOH%(["5'Y:-;A 861@6&'QHPD,:QD7FOPJCH/!W#FN
M!B./Z/\_0SK:B*@=S1,:Q+N_[6DFS*E%L+YM9N)^E5 6!5?_T1W"-P]CK?L,
MIVP?(]OCY3.$7\%V,2^5-TK(C8_ZE-1+6%8.FQ-D&+[(O8F08W-8/&8C6DN2
M83OQI@E^BCEP6&*UD"=86#YT )6)T#%]=TFF':./O^_:MOL4)?'A.]4VL-J*
M*PK8_^+Z=!5+%22*RNL^2,/1@5$WD0-,>#,XWH+<\/$J.&U'G& 6S)CNS;I:
M3Z6.178?@>)EBID;!DCOPH.7!W<'J<PRL7R9UH%#*MG ]QAL\GEB0AHE$^6F
M3B:1;:_H9YF3<\KWM*8\YJT?5Q_/&W_\%M3;[:/.Q[.3SGF_=Q3\&-8NIDS/
M^-J3DZ/.Q?GBUW[ZF''MJY9M4:#@%R!*0\3G+ ,&7V9Z?DXYKO5.?:K =J5R
M4%%4ERNL\SD^UM94*D9:D#Y?O#"!%Q_?<.T6!<4MUZZ[#(I[F2'_:6OWA>E4
MZ_&GFIQ%P6R#_ N3;S4?*7I&*7@62E8G"7S%8TU?6)CHV--'9.+%=)QIWLZA
M)0W8$H9]68E[!@7')W^T!R/]X,#<FTD.SXB[LT0'-+H2IM_J(\%-Q&CX\LUX
M!C/V$O6-X(39I[2E\7 $,CV=A[3 0U.'/1@2WD8*9!I[%+6..!OQQ1+_-U&7
MO..:/%V,.YZE04[0Y-W.V>T>!JHQ2OH@#6]>,$0 Q,]N>=2X6JX(5VPR?)JX
M0X9,,\WZ) *9=P%;+/'./KIV\5R<.D7 !;QD'#9-G!W^TJ/QUGFV%G\W\;K
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M*)5JZO*2I&^B84/]DE(@DXK@# FA;%UP]D>[^*3HQ*Z-J+4X*N(\Q^^Y XM
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M=\+Q1192K1O=Q0.Z#..I-P9C!]0E!01E0;;Q,/RR>54EPJZ<?SLVME-<:.O
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M2.8E TE=:M+5@DFE+2<4RBU,R:LP7,)>ZA4NUA\%HZ'HLN*O2E(/VZ9GW%Q
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MK.5R<=VN19=2!IX]*I#X#T:UJ_Y!-HV)$.@S(G/@)5=H<CY4$.#61 )XRY"
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MQ$L*#UE]<_A]RBTC.-;K>I9&,9;MHU?J%VZ>Q4-7):T:O$0I5=A08V.%&$/
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M(7!\%6^5@ GY5=0U'C[-S8AI%#$40#B(OY*H&@S&"M8:!?Z@1,1U0/B.\'N
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MZD:J-8933^ ^K][!=-P[%5T@NX&M\[(";YX023P&#6^FS.$M^8"ISD,@I$1
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MUQD?IL6(5PP'71"\!6UI'G&G&0D#D9@.5)@_W083LA0$XIDJ^5G]J Z'_:K
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M9\8F8X1O$[LY)M LP_P')5; O2ZS/46^[^]1X(4C;R@Z34E.FSW27"0Q?<J
M<G_$";547A'!8N,(B23H"O8WY+UP1UH#!2#"D,2$MY,4YOX]$*T Z8G([25N
M#:K%JI,E%K-S[VO(%C"[K6RTD,$E>43D9\$8M0[/,7O-$X_SQ#P ?0K0GHR
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MC /_@M9+AS=S%P"MI<0M?VQSY#+7(/6SD*\-4I%D%+E1)\=0]BM(YY4=\F,
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M1:6?MM=WORQ::X IP[K?9/.<%DUT8_Y\5_GS*_@0V?.NJ?J*$C0_W;R%&9%
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M0+:IWT5?9BBV?^;=X'%'/N:NF<7@_P).1F1"$W37O \1? PH2!NX18F-'D7
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M!:E<&,V@[#CU%7) T/TGJX_%PC)=,T6M;>93_C<2"TXHJ#"G&0FM!ZY(JD+
M"C&EB:"FU :\A5%$M3*]:6V!F^'&N7.-"E!'H:Z/G?N0WI/)3$=9#RY_H*.K
M%_[P5A+<P94_(I_C$L/'D+V4_.6.9<N*H64?Y+Z'D7BG9N,!39P),Y;<,SR
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MP@*D[O0B3]$)YH'92$X#7FWB\B;.3,ZMNJ_2@BHX(VHZ8+.-EYN4UO$5!\/
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M&4LT>M:9C<\(C8$:C6,?4=(Z?4BH37)UXP4CQ7&Y$"D3Q^3@Y.I]&IC'*;
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M$0\[G1-:6PT[LUWQYF$:L8:SS.N$/^NO<E?O&!QK$\+?+A"S3B;L]X&EE?T
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MG.R?5IR3LX.3P^[9)?Y]\.GLHOM_7^!?\)7S":[_<G9R>?*UZQSN?]P_[E[
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M)7YQAQ7M-?NNZ9L4I@L49H2]:S),4EUK)-26>:R)XZDL:\7I@0V)API&B-%
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M1['N[<Z,E,*_UR&ZG-F6+(*8S:- Q_V)#SQG00CKI[C!P>JC)I02+;[72-&
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M:;O@','+W,!M8EW].)A'"0HN=87S&6R=<+"V(.)SV&QYS#W53!C18NZIEE&
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M7Z7G45I0U4G\J1I9R\_^G ?2O1Y,+V;/)AX*ZGQP[4FCH_&V1NJE,K3F"$=
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M].?1$_?Q7'<_J:W_1&6)^S2O2_GT;C15200KB^)465J%U7%=@E"@;53JB;&
M_CJ):H!.&5WH&*4%O)_P)"[HHGGZ^8=XJK*)CL[B"K]FQ%,V D8$;R>/(Y@W
MBO/9#$:P4U5J.X3WJPC 4TVCD4[S>63@\<C6,SBE!0X2@WB@3!:9#(&H:/8X
MS^#CS&03&I&&BF)5X&'A?'.=TL_>@6 ,C2<6%65^92R,1[O&@519F3C5]#<
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M-((+TSP 4]+:,NDH.C-$#9%1T4D2!^:+2Q:FF=\-L##B!>Q';T#I2.>X!F9
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MS:6R# W<FR)MG!N8=H%Z(8QGS8=H!A"9>DL7NKG@5W*K-QK&0JMR&)TU5BR
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MGRI?,SIZ[[5*PK@^MHK.B7U6)"YL5H%QCQS_X30[B3CD,+N, OHIYP %8N8
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M:0 -4]2<U"@>J95%@ZFJL;@$;(07RY7PD5)4$=4,]2ML3&[LA6[XJ-"_IHZ
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M>IN"FN?M@II<.Q?EO^!0FJ9N/>>RLK0FG$I$;:+)EW%%=8Y=TPQ>J0DJ"SI
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M='%S9W)Q8V1G-&4P,# P,#4N:G!G4$L! A0#%     @ PH)P4L:6R'$F:P
M7J\  !8              ( !;=8% &=T<7-G<G%C9&<T93 P,# P-BYJ<&=0
M2P$"% ,4    " #"@G!2:K.)88$N 0#W9P$ %@              @ ''008
M9W1Q<V=R<6-D9S1E,# P,# W+FIP9U!+ 0(4 Q0    ( ,*"<%+)^,;*QO@
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MO4H3 &UR=7,M,C R,#$R,S$N>'-D4$L! A0#%     @ PH)P4M;BE1,I$P
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@>#0Q7S$U+FAT;5!+!08     %P 7  @&   =,A8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
